02509188|t|Genetic Variants and Their Associations with Cerebral Edema, Myopia, and Non-Alcoholic Fatty Liver Disease in Bacterial and C. elegan
02509188|a|This study investigates the genetic and phenotypic associations between specific sequence variants and disease states in both bacterial and C. elegans models. We focus on the sequence variant 2250G/C, which shows a positive correlation with cerebral edema and non-alcoholic fatty liver disease. Additionally, the variant rs1155974 is associated with urolithiasis and exhibits a negative correlation with non-alcoholic fatty liver disease, while also showing a positive correlation with cerebral edema. The variant rs11079788 is associated with cerebral edema and has a negative correlation with hypokalemia.   In bacterial models, we observed that the sequence variant rs1155974 is linked to urolithiasis, and the variant rs7802 is associated with language delay. The sequence variant rs11079788 is also found to be associated with cerebral edema, and the variant 2250G/C is linked to myopia. Furthermore, the variant 2250G/C is associated with cerebral edema, and the variant rs1155974 is associated with hypokalemia.   Our findings suggest that genetic variability plays a significant role in the development of various phenotypic features, including cerebral edema, myopia, hypokalemia, urolithiasis, and non-alcoholic fatty liver disease. These associations were observed across multiple bacterial species and in C. elegans, highlighting the potential for cross-species genetic studies to uncover common mechanisms underlying these conditions. The results provide a foundation for further research into the molecular pathways involved in these diseases and their genetic determinants.
02509188	260	268	bacteria	OrganismTaxon	2
02509188	274	284	C. elegans	OrganismTaxon	6239
02509188	326	333	2250G/C	SequenceVariant	rs56048322
02509188	375	389	cerebral edema	DiseaseOrPhenotypicFeature	D001929
02509188	394	427	non-alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	D065626
02509188	455	464	rs1155974	SequenceVariant	rs1155974
02509188	484	496	urolithiasis	DiseaseOrPhenotypicFeature	D052878
02509188	538	571	non-alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	D065626
02509188	620	634	cerebral edema	DiseaseOrPhenotypicFeature	D001929
02509188	648	658	rs11079788	SequenceVariant	rs11079788
02509188	678	692	cerebral edema	DiseaseOrPhenotypicFeature	D001929
02509188	729	740	hypokalemia	DiseaseOrPhenotypicFeature	D007008
02509188	747	755	bacteria	OrganismTaxon	2
02509188	803	812	rs1155974	SequenceVariant	rs1155974
02509188	826	838	urolithiasis	DiseaseOrPhenotypicFeature	D052878
02509188	856	862	rs7802	SequenceVariant	rs7802
02509188	882	896	language delay	DiseaseOrPhenotypicFeature	D007805
02509188	919	929	rs11079788	SequenceVariant	rs11079788
02509188	966	980	cerebral edema	DiseaseOrPhenotypicFeature	D001929
02509188	998	1005	2250G/C	SequenceVariant	rs56048322
02509188	1019	1025	myopia	DiseaseOrPhenotypicFeature	D009216
02509188	1052	1059	2250G/C	SequenceVariant	rs56048322
02509188	1079	1093	cerebral edema	DiseaseOrPhenotypicFeature	D001929
02509188	1111	1120	rs1155974	SequenceVariant	rs1155974
02509188	1140	1151	hypokalemia	DiseaseOrPhenotypicFeature	D007008
02509188	1287	1301	cerebral edema	DiseaseOrPhenotypicFeature	D001929
02509188	1303	1309	myopia	DiseaseOrPhenotypicFeature	D009216
02509188	1311	1322	hypokalemia	DiseaseOrPhenotypicFeature	D007008
02509188	1324	1336	urolithiasis	DiseaseOrPhenotypicFeature	D052878
02509188	1342	1375	non-alcoholic fatty liver disease	DiseaseOrPhenotypicFeature	D065626
02509188	1426	1434	bacteria	OrganismTaxon	2
02509188	1451	1461	C. elegans	OrganismTaxon	6239
02509188	Association	D065626	rs56048322	Novel
02509188	Association	rs1155974	D052878	Novel
02509188	Negative_Correlation	rs1155974	D065626	Novel
02509188	Positive_Correlation	rs1155974	D001929	Novel
02509188	Positive_Correlation	D065626	rs56048322	Novel
02509188	Association	D007008	rs1155974	Novel
02509188	Positive_Correlation	D009216	rs56048322	Novel
02509188	Association	rs56048322	D001929	Novel
02509188	Association	rs11079788	D001929	Novel
02509188	Negative_Correlation	rs11079788	D007008	Novel

32013340|t|IDP3, optineurin, and RPI-1 in the context of uraemia, OA, and buprenorphine: a comprehensive analysis of genetic and pharmacological inte
32013340|a|Uraemia and osteoarthritis (OA) are complex conditions influenced by both genetic and environmental factors. This study investigates the interplay between these conditions and the roles of IDP3, optineurin, RPI-1, and buprenorphine in their pathogenesis. The 293T cell line was used to model the effects of sequence variants C-1228T and 35 delG on gene expression and protein function. Our findings reveal a significant association between IDP3 and OA, as well as between IDP3 and uraemia. Similarly, optineurin is strongly associated with both OA and uraemia, suggesting a potential shared molecular pathway. RPI-1 is also linked to OA and uraemia, highlighting its role in disease progression. A positive correlation was observed between uraemia and buprenorphine levels, indicating a possible pharmacological interaction. Additionally, OA and buprenorphine show a positive correlation, suggesting that buprenorphine may influence OA severity. These results underscore the importance of IDP3, optineurin, and RPI-1 in the pathophysiology of uraemia and OA, and provide a foundation for further research into targeted therapies. The study also includes 293T cell line experiments to validate the functional impact of the sequence variants C-1228T and 35 delG on gene expression and protein stability. The data support the hypothesis that genetic and pharmacological factors interact in the development and progression of uraemia and OA, with buprenorphine playing a notable role in modulating these conditions.
32013340	0	4	IDP3	GeneOrGeneProduct	855723
32013340	6	16	optineurin	GeneOrGeneProduct	10133
32013340	22	27	RPI-1	GeneOrGeneProduct	189281
32013340	46	53	uraemia	DiseaseOrPhenotypicFeature	D014511
32013340	55	57	OA	DiseaseOrPhenotypicFeature	D010003
32013340	63	76	buprenorphine	ChemicalEntity	D002047
32013340	167	169	OA	DiseaseOrPhenotypicFeature	D010003
32013340	328	332	IDP3	GeneOrGeneProduct	855723
32013340	334	344	optineurin	GeneOrGeneProduct	10133
32013340	346	351	RPI-1	GeneOrGeneProduct	189281
32013340	357	370	buprenorphine	ChemicalEntity	D002047
32013340	398	402	293T	CellLine	CVCL_0063
32013340	464	471	C-1228T	SequenceVariant	c|SUB|C|-1228|T
32013340	476	483	35 delG	SequenceVariant	c|DEL|35|G
32013340	579	583	IDP3	GeneOrGeneProduct	855723
32013340	588	590	OA	DiseaseOrPhenotypicFeature	D010003
32013340	611	615	IDP3	GeneOrGeneProduct	855723
32013340	620	627	uraemia	DiseaseOrPhenotypicFeature	D014511
32013340	640	650	optineurin	GeneOrGeneProduct	10133
32013340	684	686	OA	DiseaseOrPhenotypicFeature	D010003
32013340	691	698	uraemia	DiseaseOrPhenotypicFeature	D014511
32013340	749	754	RPI-1	GeneOrGeneProduct	189281
32013340	773	775	OA	DiseaseOrPhenotypicFeature	D010003
32013340	780	787	uraemia	DiseaseOrPhenotypicFeature	D014511
32013340	879	886	uraemia	DiseaseOrPhenotypicFeature	D014511
32013340	891	904	buprenorphine	ChemicalEntity	D002047
32013340	978	980	OA	DiseaseOrPhenotypicFeature	D010003
32013340	985	998	buprenorphine	ChemicalEntity	D002047
32013340	1044	1057	buprenorphine	ChemicalEntity	D002047
32013340	1072	1074	OA	DiseaseOrPhenotypicFeature	D010003
32013340	1128	1132	IDP3	GeneOrGeneProduct	855723
32013340	1134	1144	optineurin	GeneOrGeneProduct	10133
32013340	1150	1155	RPI-1	GeneOrGeneProduct	189281
32013340	1182	1189	uraemia	DiseaseOrPhenotypicFeature	D014511
32013340	1194	1196	OA	DiseaseOrPhenotypicFeature	D010003
32013340	1293	1297	293T	CellLine	CVCL_0063
32013340	1379	1386	C-1228T	SequenceVariant	c|SUB|C|-1228|T
32013340	1391	1398	35 delG	SequenceVariant	c|DEL|35|G
32013340	1561	1568	uraemia	DiseaseOrPhenotypicFeature	D014511
32013340	1573	1575	OA	DiseaseOrPhenotypicFeature	D010003
32013340	1582	1595	buprenorphine	ChemicalEntity	D002047
32013340	Association	855723	D010003	Novel
32013340	Positive_Correlation	D014511	D002047	Novel
32013340	Association	189281	D014511	Novel
32013340	Association	189281	D010003	Novel
32013340	Positive_Correlation	D010003	D002047	Novel
32013340	Association	10133	D010003	Novel
32013340	Association	10133	D014511	Novel
32013340	Association	855723	D014511	Novel

88772958|t|Dexamphetamine, opiate, and FX11 interactions in hepatoencephalopathy and Rhabdomyolysis: a study in HK-2 and MEF ce
88772958|a|This study investigates the complex interactions between dexamphetamine, opiate, and FX11 in the context of hepatoencephalopathy and Rhabdomyolysis, with a focus on their effects on HK-2 and MEF cell lines. We observed a positive correlation between hepatoencephalopathy and both dexamphetamine and risperidone, suggesting a potential role for these chemical entities in the pathogenesis of this disease. Additionally, FX11 was found to be associated with hepatoencephalopathy and Rhabdomyolysis, with a positive correlation between FX11 and both conditions. The cotreatment of dexamphetamine and opiate was frequently noted, as was the cotreatment of opiate and FX11, indicating a possible synergistic or additive effect. Furthermore, the cotreatment of glycemia and risperidone was observed, suggesting a potential link between metabolic and neurological conditions. The study also found a positive correlation between hepatoencephalopathy and FX11, reinforcing the association between this chemical entity and the disease. In addition, the cotreatment of opiate and dexamphetamine was noted, as well as the cotreatment of glycemia and dexamphetamine, highlighting the complex interplay between these chemical entities. The association between glycemia and Rhabdomyolysis was also confirmed, suggesting a potential metabolic component to this condition. Overall, these findings provide new insights into the molecular mechanisms underlying hepatoencephalopathy and Rhabdomyolysis, with implications for the development of targeted therapies involving dexamphetamine, opiate, FX11, and other related compounds.
88772958	16	22	opiate	ChemicalEntity	D053610
88772958	28	32	FX11	ChemicalEntity	C547455
88772958	49	69	hepatoencephalopathy	DiseaseOrPhenotypicFeature	C563797
88772958	74	88	Rhabdomyolysis	DiseaseOrPhenotypicFeature	D012206
88772958	101	105	HK-2	CellLine	CVCL_0302
88772958	110	113	MEF	CellLine	CVCL_9115
88772958	174	188	dexamphetamine	ChemicalEntity	D003913
88772958	190	196	opiate	ChemicalEntity	D053610
88772958	202	206	FX11	ChemicalEntity	C547455
88772958	225	245	hepatoencephalopathy	DiseaseOrPhenotypicFeature	C563797
88772958	250	264	Rhabdomyolysis	DiseaseOrPhenotypicFeature	D012206
88772958	299	303	HK-2	CellLine	CVCL_0302
88772958	308	311	MEF	CellLine	CVCL_9115
88772958	367	387	hepatoencephalopathy	DiseaseOrPhenotypicFeature	C563797
88772958	397	411	dexamphetamine	ChemicalEntity	D003913
88772958	416	427	risperidone	ChemicalEntity	D018967
88772958	536	540	FX11	ChemicalEntity	C547455
88772958	573	593	hepatoencephalopathy	DiseaseOrPhenotypicFeature	C563797
88772958	598	612	Rhabdomyolysis	DiseaseOrPhenotypicFeature	D012206
88772958	650	654	FX11	ChemicalEntity	C547455
88772958	695	709	dexamphetamine	ChemicalEntity	D003913
88772958	714	720	opiate	ChemicalEntity	D053610
88772958	769	775	opiate	ChemicalEntity	D053610
88772958	780	784	FX11	ChemicalEntity	C547455
88772958	872	880	glycemia	ChemicalEntity	D001786
88772958	885	896	risperidone	ChemicalEntity	D018967
88772958	1038	1058	hepatoencephalopathy	DiseaseOrPhenotypicFeature	C563797
88772958	1063	1067	FX11	ChemicalEntity	C547455
88772958	1175	1181	opiate	ChemicalEntity	D053610
88772958	1186	1200	dexamphetamine	ChemicalEntity	D003913
88772958	1242	1250	glycemia	ChemicalEntity	D001786
88772958	1255	1269	dexamphetamine	ChemicalEntity	D003913
88772958	1363	1371	glycemia	ChemicalEntity	D001786
88772958	1376	1390	Rhabdomyolysis	DiseaseOrPhenotypicFeature	D012206
88772958	1559	1579	hepatoencephalopathy	DiseaseOrPhenotypicFeature	C563797
88772958	1584	1598	Rhabdomyolysis	DiseaseOrPhenotypicFeature	D012206
88772958	1670	1684	dexamphetamine	ChemicalEntity	D003913
88772958	1686	1692	opiate	ChemicalEntity	D053610
88772958	1694	1698	FX11	ChemicalEntity	C547455
88772958	Association	C547455	C563797	Novel
88772958	Cotreatment	D003913	D053610	Novel
88772958	Cotreatment	D053610	C547455	Novel
88772958	Cotreatment	C547455	D053610	Novel
88772958	Association	D018967	C563797	Novel
88772958	Positive_Correlation	C563797	D003913	Novel
88772958	Cotreatment	D001786	D018967	Novel
88772958	Association	C547455	D012206	Novel
88772958	Positive_Correlation	D012206	C547455	Novel
88772958	Cotreatment	D053610	D003913	Novel
88772958	Cotreatment	D001786	D003913	Novel
88772958	Positive_Correlation	C563797	C547455	Novel
88772958	Positive_Correlation	C563797	D018967	Novel
88772958	Association	D053610	D012206	Novel
88772958	Cotreatment	C547455	D003913	Novel
88772958	Association	D001786	D012206	Novel

68272881|t|Genetic Variants in Danio rerio and Humans: Interactions with Hepatitis B Virus e Antigen, Antithrombin, and Lipid-Linked Oligosaccharides in Numbness and 
68272881|a|This study investigates the complex interactions between genetic variants, viral antigens, and metabolic factors in the context of numbness and insomnia. We focus on the zebrafish (Danio rerio) and human models, examining the associations between specific sequence variants and disease phenotypes. The sequence variant c.429_452dup is found to be significantly associated with the hepatitis B virus e antigen, as well as with antithrombin and lipid-linked oligosaccharides. Similarly, the variant 35 delG is linked to the hepatitis B virus e antigen, antithrombin, and lipid-linked oligosaccharides. These associations suggest a potential role for these genetic variants in modulating immune and metabolic responses. In humans, the presence of these variants is correlated with increased instances of numbness and insomnia, particularly in individuals infected with human immunodeficiency virus type 1. The study also highlights the role of lipid-linked oligosaccharides in the pathogenesis of these conditions, with evidence of their interaction with both c.429_452dup and 35 delG. Furthermore, antithrombin is found to be a key mediator in the relationship between these genetic variants and the disease phenotypes. The findings underscore the importance of understanding the interplay between genetic, viral, and metabolic factors in the development of numbness and insomnia, with implications for both Danio rerio and human models. The data support the hypothesis that these genetic variants may serve as biomarkers for disease progression and therapeutic intervention.
68272881	20	31	Danio rerio	OrganismTaxon	7955
68272881	287	295	numbness	DiseaseOrPhenotypicFeature	D006987
68272881	300	308	insomnia	DiseaseOrPhenotypicFeature	D007319
68272881	337	348	Danio rerio	OrganismTaxon	7955
68272881	475	487	c.429_452dup	SequenceVariant	c|DUP|429_452||
68272881	537	564	hepatitis B virus e antigen	ChemicalEntity	D006513
68272881	582	594	antithrombin	ChemicalEntity	D000991
68272881	599	628	lipid-linked oligosaccharides	ChemicalEntity	C023023
68272881	653	660	35 delG	SequenceVariant	c|DEL|35|G
68272881	678	705	hepatitis B virus e antigen	ChemicalEntity	D006513
68272881	707	719	antithrombin	ChemicalEntity	D000991
68272881	725	754	lipid-linked oligosaccharides	ChemicalEntity	C023023
68272881	876	882	humans	OrganismTaxon	9606
68272881	957	965	numbness	DiseaseOrPhenotypicFeature	D006987
68272881	970	978	insomnia	DiseaseOrPhenotypicFeature	D007319
68272881	1022	1057	human immunodeficiency virus type 1	OrganismTaxon	11676
68272881	1097	1126	lipid-linked oligosaccharides	ChemicalEntity	C023023
68272881	1213	1225	c.429_452dup	SequenceVariant	c|DUP|429_452||
68272881	1230	1237	35 delG	SequenceVariant	c|DEL|35|G
68272881	1252	1264	antithrombin	ChemicalEntity	D000991
68272881	1512	1520	numbness	DiseaseOrPhenotypicFeature	D006987
68272881	1525	1533	insomnia	DiseaseOrPhenotypicFeature	D007319
68272881	1562	1573	Danio rerio	OrganismTaxon	7955
68272881	Association	c|DUP|429_452||	D006513	Novel
68272881	Association	c|DEL|35|G	D006513	Novel
68272881	Association	D006513	c|DUP|429_452||	Novel
68272881	Association	D000991	c|DUP|429_452||	Novel
68272881	Association	D006513	D000991	Novel
68272881	Association	c|DEL|35|G	D000991	Novel
68272881	Association	C023023	c|DEL|35|G	Novel
68272881	Association	c|DUP|429_452||	C023023	Novel
68272881	Association	c|DEL|35|G	C023023	Novel
68272881	Association	D000991	c|DEL|35|G	Novel

54863013|t|Free fatty acid and vincristine: comparative effects on skin cancer progression and their interactions with clopidogrel and other therapeuti
54863013|a|Recent studies have highlighted the complex interplay between free fatty acid metabolism and the progression of skin cancer. This research investigates the comparative effects of free fatty acid and vincristine on tumor growth and metastasis in murine models of skin cancer. The findings suggest that free fatty acid may enhance the anti-tumor activity of vincristine, potentially through modulation of cyclin D1 and D2 expression. In contrast, vincristine alone was found to significantly reduce tumor volume, although it exhibited limited efficacy in preventing metastasis.   The study also explored the pharmacological interactions between vincristine and clopidogrel, revealing that the combination of these two agents may lead to synergistic effects in reducing tumor angiogenesis. However, the presence of clopidogrel was associated with increased levels of psychomotor retardation in experimental animals, suggesting potential neurotoxic effects.   Further analysis revealed that the expression of aromatase and CFHR1 was significantly altered in response to both free fatty acid and vincristine treatment. These changes were correlated with the development of Osteogenesis imperfecta in some experimental groups, indicating a possible link between metabolic stress and skeletal abnormalities.   In addition to skin cancer, the study examined the impact of these agents on other disease states, including VWD, Epilepsy, and septicaemia. The results indicated that free fatty acid may exacerbate symptoms of VWD, while vincristine showed promise in reducing seizure frequency in Epilepsy models.   The role of ginseng in modulating the effects of these agents was also investigated. Ginseng was found to enhance the anti-cancer properties of free fatty acid and reduce the neurotoxic side effects of vincristine. Furthermore, the study explored the potential of Rg1, a compound derived from ginseng, in mitigating the adverse effects of clopidogrel and improving outcomes in patients with MC and constipation.   The findings underscore the importance of understanding the molecular mechanisms underlying the interactions between free fatty acid, vincristine, and clopidogrel, and their implications for the treatment of complex diseases such as skin cancer, VWD, and Osteogenesis imperfecta.
54863013	20	31	vincristine	ChemicalEntity	D014750
54863013	56	67	skin cancer	DiseaseOrPhenotypicFeature	D012878
54863013	108	119	clopidogrel	ChemicalEntity	D000077144
54863013	203	218	free fatty acid	ChemicalEntity	D005230
54863013	253	264	skin cancer	DiseaseOrPhenotypicFeature	D012878
54863013	320	335	free fatty acid	ChemicalEntity	D005230
54863013	340	351	vincristine	ChemicalEntity	D014750
54863013	403	414	skin cancer	DiseaseOrPhenotypicFeature	D012878
54863013	442	457	free fatty acid	ChemicalEntity	D005230
54863013	497	508	vincristine	ChemicalEntity	D014750
54863013	544	560	cyclin D1 and D2	GeneOrGeneProduct	12443
54863013	586	597	vincristine	ChemicalEntity	D014750
54863013	784	795	vincristine	ChemicalEntity	D014750
54863013	800	811	clopidogrel	ChemicalEntity	D000077144
54863013	953	964	clopidogrel	ChemicalEntity	D000077144
54863013	1005	1028	psychomotor retardation	DiseaseOrPhenotypicFeature	D011596
54863013	1146	1155	aromatase	GeneOrGeneProduct	25147
54863013	1160	1165	CFHR1	GeneOrGeneProduct	3078
54863013	1212	1227	free fatty acid	ChemicalEntity	D005230
54863013	1232	1243	vincristine	ChemicalEntity	D014750
54863013	1309	1332	Osteogenesis imperfecta	DiseaseOrPhenotypicFeature	D010013
54863013	1459	1470	skin cancer	DiseaseOrPhenotypicFeature	D012878
54863013	1553	1556	VWD	DiseaseOrPhenotypicFeature	D014842
54863013	1558	1566	Epilepsy	DiseaseOrPhenotypicFeature	D004827
54863013	1572	1583	septicaemia	DiseaseOrPhenotypicFeature	D018805
54863013	1612	1627	free fatty acid	ChemicalEntity	D005230
54863013	1655	1658	VWD	DiseaseOrPhenotypicFeature	D014842
54863013	1666	1677	vincristine	ChemicalEntity	D014750
54863013	1726	1734	Epilepsy	DiseaseOrPhenotypicFeature	D004827
54863013	1757	1764	ginseng	OrganismTaxon	4054
54863013	1889	1904	free fatty acid	ChemicalEntity	D005230
54863013	1947	1958	vincristine	ChemicalEntity	D014750
54863013	2009	2012	Rg1	ChemicalEntity	C035054
54863013	2038	2045	ginseng	OrganismTaxon	4054
54863013	2084	2095	clopidogrel	ChemicalEntity	D000077144
54863013	2136	2138	MC	DiseaseOrPhenotypicFeature	C562938
54863013	2143	2155	constipation	DiseaseOrPhenotypicFeature	D003248
54863013	2276	2291	free fatty acid	ChemicalEntity	D005230
54863013	2293	2304	vincristine	ChemicalEntity	D014750
54863013	2310	2321	clopidogrel	ChemicalEntity	D000077144
54863013	2392	2403	skin cancer	DiseaseOrPhenotypicFeature	D012878
54863013	2405	2408	VWD	DiseaseOrPhenotypicFeature	D014842
54863013	2414	2437	Osteogenesis imperfecta	DiseaseOrPhenotypicFeature	D010013
54863013	Comparison	D014750	D005230	Novel
54863013	Comparison	D014750	D000077144	Novel

32764898|t|Desmin variants and infertility: a comprehensive analysis using IEC-6 cell lines and rs11798018 polym
32764898|a|Desmin, a critical intermediate filament protein, plays a pivotal role in maintaining the structural integrity of muscle cells. Recent studies have highlighted the potential association between desmin mutations and infertility, particularly in individuals with genetic variants at rs11798018. This study investigates the relationship between infertility, desmin, and the sequence variant rs11798018 using the IEC-6 cell line, which is known for its high expression of desmin and its relevance in reproductive biology.   We conducted a series of experiments to assess the functional impact of rs11798018 on desmin expression and its downstream effects on cellular processes related to fertility. The IEC-6 cell line was used as a model system to evaluate the association between infertility and desmin, with particular emphasis on the role of rs11798018. Our findings suggest a significant correlation between the presence of rs11798018 and altered desmin function, which may contribute to the pathogenesis of infertility.   Further, we observed that individuals with infertility who carried the rs11798018 variant exhibited a higher prevalence of desmin-related abnormalities in the IEC-6 cell line. These results provide strong evidence for the association between infertility and desmin, mediated through the sequence variant rs11798018. Our study underscores the importance of desmin and its genetic variants in reproductive health and opens new avenues for targeted therapeutic interventions.
32764898	20	31	infertility	DiseaseOrPhenotypicFeature	D007247
32764898	64	69	IEC-6	CellLine	CVCL_0343
32764898	85	95	rs11798018	SequenceVariant	rs11798018
32764898	296	302	desmin	GeneOrGeneProduct	64362
32764898	317	328	infertility	DiseaseOrPhenotypicFeature	D007247
32764898	383	393	rs11798018	SequenceVariant	rs11798018
32764898	444	455	infertility	DiseaseOrPhenotypicFeature	D007247
32764898	457	463	desmin	GeneOrGeneProduct	64362
32764898	490	500	rs11798018	SequenceVariant	rs11798018
32764898	511	516	IEC-6	CellLine	CVCL_0343
32764898	570	576	desmin	GeneOrGeneProduct	64362
32764898	694	704	rs11798018	SequenceVariant	rs11798018
32764898	708	714	desmin	GeneOrGeneProduct	64362
32764898	801	806	IEC-6	CellLine	CVCL_0343
32764898	880	891	infertility	DiseaseOrPhenotypicFeature	D007247
32764898	896	902	desmin	GeneOrGeneProduct	64362
32764898	944	954	rs11798018	SequenceVariant	rs11798018
32764898	1027	1037	rs11798018	SequenceVariant	rs11798018
32764898	1050	1056	desmin	GeneOrGeneProduct	64362
32764898	1111	1122	infertility	DiseaseOrPhenotypicFeature	D007247
32764898	1169	1180	infertility	DiseaseOrPhenotypicFeature	D007247
32764898	1197	1207	rs11798018	SequenceVariant	rs11798018
32764898	1249	1255	desmin	GeneOrGeneProduct	64362
32764898	1285	1290	IEC-6	CellLine	CVCL_0343
32764898	1368	1379	infertility	DiseaseOrPhenotypicFeature	D007247
32764898	1384	1390	desmin	GeneOrGeneProduct	64362
32764898	1430	1440	rs11798018	SequenceVariant	rs11798018
32764898	1482	1488	desmin	GeneOrGeneProduct	64362
32764898	Association	D007247	64362	Novel

57500913|t|Genetic Variants and Their Associations with SCCHN, Hypothermia, and Immune Responses in Ce
57500913|a|This study investigates the genetic and molecular mechanisms underlying the association between specific sequence variants and disease phenotypes, as well as their impact on immune responses in various cell lines. The focus is on the relationship between the sequence variant rs2230912 and the disease SCCHN, which was found to exhibit a negative correlation. Additionally, the CAG and GGC repeat variant was associated with the amino acid substitution lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223, and this association was further linked to the sequence variant asparagine (AAC) for serine (AGC) at residue 45. The latter variant also showed a negative correlation with SCCHN.   The lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223 variant was found to have a negative correlation with hypothermia, while the I146L variant was associated with skin reactions and exhibited a negative correlation with SLE. The CAG and GGC repeat variant was also associated with the I146L variant, and rs2230912 was linked to the asparagine (AAC) for serine (AGC) at residue 45 variant. Furthermore, the CAG and GGC repeat variant showed a negative correlation with hypothermia.   The study utilized cell lines such as HK2, SJ-GBM2, MES-SA/Dx5, SMMC-7721, and BALB/c to evaluate the functional implications of these genetic variants. The gene products LIF, CD4, and Bax were analyzed in relation to these variants, with particular emphasis on their roles in immune responses and disease progression. The Bach1 gene was also included in the analysis to explore its potential interactions with the studied variants. These findings provide new insights into the genetic basis of SCCHN, hypothermia, and immune-related conditions, highlighting the complex interplay between sequence variants and disease phenotypes.
57500913	45	50	SCCHN	DiseaseOrPhenotypicFeature	D000077195
57500913	368	377	rs2230912	SequenceVariant	rs2230912
57500913	394	399	SCCHN	DiseaseOrPhenotypicFeature	D000077195
57500913	470	488	CAG and GGC repeat	SequenceVariant	c|DUP||CAG_GGC|
57500913	545	609	lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223	SequenceVariant	c|SUB|Q|223|K
57500913	675	722	asparagine (AAC) for serine (AGC) at residue 45	SequenceVariant	rs5030764
57500913	783	788	SCCHN	DiseaseOrPhenotypicFeature	D000077195
57500913	796	860	lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223	SequenceVariant	c|SUB|Q|223|K
57500913	915	926	hypothermia	DiseaseOrPhenotypicFeature	D007036
57500913	938	943	I146L	SequenceVariant	rs72478580
57500913	972	986	skin reactions	DiseaseOrPhenotypicFeature	D003875
57500913	1029	1032	SLE	DiseaseOrPhenotypicFeature	D008180
57500913	1038	1056	CAG and GGC repeat	SequenceVariant	c|DUP||CAG_GGC|
57500913	1094	1099	I146L	SequenceVariant	rs72478580
57500913	1113	1122	rs2230912	SequenceVariant	rs2230912
57500913	1141	1188	asparagine (AAC) for serine (AGC) at residue 45	SequenceVariant	rs5030764
57500913	1215	1233	CAG and GGC repeat	SequenceVariant	c|DUP||CAG_GGC|
57500913	1277	1288	hypothermia	DiseaseOrPhenotypicFeature	D007036
57500913	1330	1333	HK2	CellLine	CVCL_0302
57500913	1335	1342	SJ-GBM2	CellLine	CVCL_M141
57500913	1344	1354	MES-SA/Dx5	CellLine	CVCL_2598
57500913	1356	1365	SMMC-7721	CellLine	CVCL_0534
57500913	1371	1377	BALB/c	CellLine	CVCL_9101
57500913	1463	1466	LIF	GeneOrGeneProduct	16878
57500913	1468	1471	CD4	GeneOrGeneProduct	920
57500913	1477	1480	Bax	GeneOrGeneProduct	12028
57500913	1615	1620	Bach1	GeneOrGeneProduct	12013
57500913	1787	1792	SCCHN	DiseaseOrPhenotypicFeature	D000077195
57500913	1794	1805	hypothermia	DiseaseOrPhenotypicFeature	D007036
57500913	Negative_Correlation	rs2230912	D000077195	Novel
57500913	Association	c|DUP||CAG_GGC|	c|SUB|Q|223|K	Novel
57500913	Negative_Correlation	rs5030764	D000077195	Novel
57500913	Negative_Correlation	c|SUB|Q|223|K	D007036	Novel
57500913	Negative_Correlation	rs72478580	D003875	Novel
57500913	Association	rs5030764	c|SUB|Q|223|K	Novel
57500913	Association	rs2230912	c|DUP||CAG_GGC|	Novel
57500913	Association	c|DUP||CAG_GGC|	rs72478580	Novel
57500913	Association	rs2230912	rs5030764	Novel
57500913	Negative_Correlation	c|DUP||CAG_GGC|	D007036	Novel
57500913	Negative_Correlation	rs72478580	D008180	Novel

17048485|t|Colon Cancer and Glucose Intolerance in Sheep and Chick Models: Interactions with Ritanserin, DGCR8, a
17048485|a|Colon cancer and glucose intolerance are prevalent phenotypic features observed in both sheep and chick models, with significant implications for metabolic and oncogenic pathways. In sheep, colon cancer was found to be negatively correlated with the expression of DGCR8 and snail, suggesting a potential protective role of these gene products in tumor suppression. Similarly, in chick models, glucose intolerance was negatively correlated with both DGCR8 and snail, indicating a possible regulatory mechanism linking metabolic dysfunction and gene expression.   Ritanserin, a chemical entity with known serotonergic properties, was found to have a negative correlation with both colon cancer and glucose intolerance in sheep. This suggests that Ritanserin may modulate pathways involved in both oncogenesis and metabolic regulation. In chick models, the negative correlation between Ritanserin and glucose intolerance was further supported by metabolic profiling, which showed reduced glucose uptake in Ritanserin-treated animals.   The CMT-93 cell line, derived from sheep, was used to investigate the molecular mechanisms underlying these correlations. In vitro studies revealed that Ritanserin treatment reduced the proliferation of CMT-93 cells, while also downregulating snail and DGCR8 expression. These findings were consistent with the in vivo observations in sheep and chick models.   Further analysis of the DGCR8 gene in sheep and chick tissues showed that its expression was inversely related to the presence of colon cancer and glucose intolerance. This negative correlation was most pronounced in sheep, where DGCR8 expression was significantly lower in colon cancer tissues compared to healthy controls.   Snail, a gene product involved in epithelial-mesenchymal transition, was also found to be negatively correlated with both colon cancer and glucose intolerance. In chick models, snail expression was reduced in glucose-intolerant animals, suggesting a potential role in metabolic homeostasis.   These findings highlight the complex interplay between chemical entities, gene products, and phenotypic features in both sheep and chick models. The negative correlations observed between Ritanserin, DGCR8, snail, colon cancer, and glucose intolerance provide a foundation for further research into the molecular mechanisms underlying these conditions.
17048485	82	92	Ritanserin	ChemicalEntity	D016713
17048485	94	99	DGCR8	GeneOrGeneProduct	94223
17048485	120	139	glucose intolerance	DiseaseOrPhenotypicFeature	D018149
17048485	191	196	sheep	OrganismTaxon	9940
17048485	201	206	chick	OrganismTaxon	9031
17048485	286	291	sheep	OrganismTaxon	9940
17048485	293	305	colon cancer	DiseaseOrPhenotypicFeature	D003110
17048485	367	372	DGCR8	GeneOrGeneProduct	94223
17048485	377	382	snail	GeneOrGeneProduct	20613
17048485	482	487	chick	OrganismTaxon	9031
17048485	496	515	glucose intolerance	DiseaseOrPhenotypicFeature	D018149
17048485	552	557	DGCR8	GeneOrGeneProduct	94223
17048485	562	567	snail	GeneOrGeneProduct	20613
17048485	665	675	Ritanserin	ChemicalEntity	D016713
17048485	782	794	colon cancer	DiseaseOrPhenotypicFeature	D003110
17048485	799	818	glucose intolerance	DiseaseOrPhenotypicFeature	D018149
17048485	822	827	sheep	OrganismTaxon	9940
17048485	848	858	Ritanserin	ChemicalEntity	D016713
17048485	939	944	chick	OrganismTaxon	9031
17048485	986	996	Ritanserin	ChemicalEntity	D016713
17048485	1001	1020	glucose intolerance	DiseaseOrPhenotypicFeature	D018149
17048485	1106	1116	Ritanserin	ChemicalEntity	D016713
17048485	1140	1146	CMT-93	CellLine	CVCL_1986
17048485	1171	1176	sheep	OrganismTaxon	9940
17048485	1289	1299	Ritanserin	ChemicalEntity	D016713
17048485	1339	1345	CMT-93	CellLine	CVCL_1986
17048485	1379	1384	snail	GeneOrGeneProduct	20613
17048485	1389	1394	DGCR8	GeneOrGeneProduct	94223
17048485	1471	1476	sheep	OrganismTaxon	9940
17048485	1481	1486	chick	OrganismTaxon	9031
17048485	1521	1526	DGCR8	GeneOrGeneProduct	94223
17048485	1535	1540	sheep	OrganismTaxon	9940
17048485	1545	1550	chick	OrganismTaxon	9031
17048485	1627	1639	colon cancer	DiseaseOrPhenotypicFeature	D003110
17048485	1644	1663	glucose intolerance	DiseaseOrPhenotypicFeature	D018149
17048485	1714	1719	sheep	OrganismTaxon	9940
17048485	1727	1732	DGCR8	GeneOrGeneProduct	94223
17048485	1771	1783	colon cancer	DiseaseOrPhenotypicFeature	D003110
17048485	1946	1958	colon cancer	DiseaseOrPhenotypicFeature	D003110
17048485	1963	1982	glucose intolerance	DiseaseOrPhenotypicFeature	D018149
17048485	1987	1992	chick	OrganismTaxon	9031
17048485	2001	2006	snail	GeneOrGeneProduct	20613
17048485	2238	2243	sheep	OrganismTaxon	9940
17048485	2248	2253	chick	OrganismTaxon	9031
17048485	2305	2315	Ritanserin	ChemicalEntity	D016713
17048485	2317	2322	DGCR8	GeneOrGeneProduct	94223
17048485	2324	2329	snail	GeneOrGeneProduct	20613
17048485	2331	2343	colon cancer	DiseaseOrPhenotypicFeature	D003110
17048485	2349	2368	glucose intolerance	DiseaseOrPhenotypicFeature	D018149
17048485	Negative_Correlation	D016713	D003110	Novel
17048485	Negative_Correlation	D003110	94223	Novel
17048485	Negative_Correlation	D003110	20613	Novel
17048485	Negative_Correlation	D018149	20613	Novel
17048485	Negative_Correlation	D018149	94223	Novel
17048485	Negative_Correlation	D016713	D018149	Novel

19637003|t|Genetic variants in ubiquitin-conjugating enzyme E2C and their associations with CHD, steroid 5alpha-reductase type 2 deficiency, and DU145 cell line behavior in horses and Saccharomyces ce
19637003|a|This study investigates the functional and phenotypic consequences of multiple sequence variants in the ubiquitin-conjugating enzyme E2C gene across different organisms, including horses and Saccharomyces cerevisiae. We focus on the sequence variants p.N102DfsX4, p.Ser119fsX, and 33-bp genomic deletion, which were identified in both human and model organisms. The study reveals a negative correlation between the expression of ubiquitin-conjugating enzyme E2C and the occurrence of CHD in horses, suggesting a potential protective role of this gene in cardiovascular health. Similarly, a negative correlation is observed between the presence of the sequence variant p.Ser119fsX and the development of steroid 5alpha-reductase type 2 deficiency in DU145 cell lines, indicating a possible involvement of this variant in the pathogenesis of this condition. The DU145 cell line, derived from human prostate cancer, was used as a model to assess the impact of these genetic variants on cellular function. The findings suggest that the ubiquitin-conjugating enzyme E2C gene may play a critical role in modulating disease susceptibility in both horses and yeast. Additionally, the study highlights the importance of sequence variants such as p.N102DfsX4 and 33-bp genomic deletion in altering the expression and function of ubiquitin-conjugating enzyme E2C across different species. These results provide new insights into the genetic basis of CHD and steroid 5alpha-reductase type 2 deficiency, with implications for both human and veterinary medicine.
19637003	20	52	ubiquitin-conjugating enzyme E2C	GeneOrGeneProduct	11065
19637003	81	84	CHD	DiseaseOrPhenotypicFeature	D003327
19637003	86	128	steroid 5alpha-reductase type 2 deficiency	DiseaseOrPhenotypicFeature	C535830
19637003	134	139	DU145	CellLine	CVCL_0105
19637003	162	168	horses	OrganismTaxon	9796
19637003	294	326	ubiquitin-conjugating enzyme E2C	GeneOrGeneProduct	11065
19637003	370	376	horses	OrganismTaxon	9796
19637003	381	405	Saccharomyces cerevisiae	OrganismTaxon	4932
19637003	441	452	p.N102DfsX4	SequenceVariant	p|FS|N|102|D|4
19637003	454	465	p.Ser119fsX	SequenceVariant	p|FS|S|119||
19637003	471	493	33-bp genomic deletion	SequenceVariant	g|DEL||33
19637003	619	651	ubiquitin-conjugating enzyme E2C	GeneOrGeneProduct	11065
19637003	674	677	CHD	DiseaseOrPhenotypicFeature	D003327
19637003	681	687	horses	OrganismTaxon	9796
19637003	858	869	p.Ser119fsX	SequenceVariant	p|FS|S|119||
19637003	893	935	steroid 5alpha-reductase type 2 deficiency	DiseaseOrPhenotypicFeature	C535830
19637003	939	944	DU145	CellLine	CVCL_0105
19637003	1050	1055	DU145	CellLine	CVCL_0105
19637003	1222	1254	ubiquitin-conjugating enzyme E2C	GeneOrGeneProduct	11065
19637003	1330	1336	horses	OrganismTaxon	9796
19637003	1427	1438	p.N102DfsX4	SequenceVariant	p|FS|N|102|D|4
19637003	1443	1465	33-bp genomic deletion	SequenceVariant	g|DEL||33
19637003	1509	1541	ubiquitin-conjugating enzyme E2C	GeneOrGeneProduct	11065
19637003	1629	1632	CHD	DiseaseOrPhenotypicFeature	D003327
19637003	1637	1679	steroid 5alpha-reductase type 2 deficiency	DiseaseOrPhenotypicFeature	C535830
19637003	Negative_Correlation	D003327	11065	Novel
19637003	Negative_Correlation	C535830	11065	Novel

39731321|t|Sequence variant -652 6N del and its associations with malonic aciduria in Spirulina, 253JB-V, SCID-HuH-7, and rDEN
39731321|a|This study investigates the relationship between the sequence variant -652 6N del and malonic aciduria across multiple biological systems, including Spirulina, 253JB-V, SCID-HuH-7, and rDEN2. The variant -652 6N del was found to exhibit a positive correlation with malonic aciduria in Spirulina and 253JB-V cell lines, as well as in SCID-HuH-7 and rDEN2 models. These findings suggest a consistent association between the variant and the disease phenotype. Additionally, the study reports a negative correlation between -652 6N del and malonic aciduria in Kilham rat virus-infected cats, indicating potential regulatory differences across species. The results highlight the complex interplay between genetic variants and metabolic disorders, with implications for understanding the pathogenesis of malonic aciduria in both human and animal models. The data further support the hypothesis that -652 6N del may serve as a biomarker for malonic aciduria in various cellular and organismal contexts, including those involving Spirulina, 253JB-V, SCID-HuH-7, and rDEN2.
39731321	17	28	-652 6N del	SequenceVariant	c|DEL|-652|6
39731321	55	71	malonic aciduria	DiseaseOrPhenotypicFeature	C535702
39731321	75	84	Spirulina	OrganismTaxon	551299
39731321	86	93	253JB-V	CellLine	CVCL_7937
39731321	95	105	SCID-HuH-7	CellLine	CVCL_0336
39731321	186	197	-652 6N del	SequenceVariant	c|DEL|-652|6
39731321	202	218	malonic aciduria	DiseaseOrPhenotypicFeature	C535702
39731321	265	274	Spirulina	OrganismTaxon	551299
39731321	276	283	253JB-V	CellLine	CVCL_7937
39731321	285	295	SCID-HuH-7	CellLine	CVCL_0336
39731321	301	306	rDEN2	OrganismTaxon	11060
39731321	320	331	-652 6N del	SequenceVariant	c|DEL|-652|6
39731321	381	397	malonic aciduria	DiseaseOrPhenotypicFeature	C535702
39731321	401	410	Spirulina	OrganismTaxon	551299
39731321	415	422	253JB-V	CellLine	CVCL_7937
39731321	449	459	SCID-HuH-7	CellLine	CVCL_0336
39731321	464	469	rDEN2	OrganismTaxon	11060
39731321	636	647	-652 6N del	SequenceVariant	c|DEL|-652|6
39731321	652	668	malonic aciduria	DiseaseOrPhenotypicFeature	C535702
39731321	672	688	Kilham rat virus	OrganismTaxon	12441
39731321	698	702	cats	OrganismTaxon	9685
39731321	914	930	malonic aciduria	DiseaseOrPhenotypicFeature	C535702
39731321	1009	1020	-652 6N del	SequenceVariant	c|DEL|-652|6
39731321	1050	1066	malonic aciduria	DiseaseOrPhenotypicFeature	C535702
39731321	1138	1147	Spirulina	OrganismTaxon	551299
39731321	1149	1156	253JB-V	CellLine	CVCL_7937
39731321	1158	1168	SCID-HuH-7	CellLine	CVCL_0336
39731321	1174	1179	rDEN2	OrganismTaxon	11060
39731321	Positive_Correlation	c|DEL|-652|6	C535702	Novel
39731321	Association	c|DEL|-652|6	C535702	Novel
39731321	Positive_Correlation	C535702	c|DEL|-652|6	Novel
39731321	Association	C535702	c|DEL|-652|6	Novel
39731321	Negative_Correlation	c|DEL|-652|6	C535702	Novel

62408619|t|Genetic associations between sequence variants, volume retention, and hypokalemic periodic paralysis in Kilham rat virus and DEN-4 in
62408619|a|This study investigates the genetic and phenotypic associations between sequence variants, volume retention, and hypokalemic periodic paralysis in the context of Kilham rat virus and DEN-4 infections. We analyzed a cohort of genetically diverse individuals and found that the D allele for the -1607 sequence variant is positively correlated with hypokalemic periodic paralysis, while it is negatively correlated with volume retention. Additionally, the rs800292 sequence variant shows a positive correlation with hypokalemic periodic paralysis and volume retention, but a negative correlation with both hypokalemic periodic paralysis and volume retention. The D allele for the -1607 and rs800292 sequence variants are associated with each other, suggesting a potential genetic linkage. These findings were observed in both Kilham rat virus and DEN-4 infected models, highlighting the complex interplay between genetic factors and phenotypic outcomes in these viral infections. The results provide new insights into the molecular mechanisms underlying the pathogenesis of hypokalemic periodic paralysis and volume retention in the context of viral infections.
62408619	48	64	volume retention	DiseaseOrPhenotypicFeature	D016055
62408619	70	100	hypokalemic periodic paralysis	DiseaseOrPhenotypicFeature	D020514
62408619	104	120	Kilham rat virus	OrganismTaxon	12441
62408619	125	130	DEN-4	OrganismTaxon	11070
62408619	225	241	volume retention	DiseaseOrPhenotypicFeature	D016055
62408619	247	277	hypokalemic periodic paralysis	DiseaseOrPhenotypicFeature	D020514
62408619	296	312	Kilham rat virus	OrganismTaxon	12441
62408619	317	322	DEN-4	OrganismTaxon	11070
62408619	410	432	D allele for the -1607	SequenceVariant	c|Allele|D|-1607
62408619	480	510	hypokalemic periodic paralysis	DiseaseOrPhenotypicFeature	D020514
62408619	551	567	volume retention	DiseaseOrPhenotypicFeature	D016055
62408619	587	595	rs800292	SequenceVariant	rs800292
62408619	647	677	hypokalemic periodic paralysis	DiseaseOrPhenotypicFeature	D020514
62408619	682	698	volume retention	DiseaseOrPhenotypicFeature	D016055
62408619	737	767	hypokalemic periodic paralysis	DiseaseOrPhenotypicFeature	D020514
62408619	772	788	volume retention	DiseaseOrPhenotypicFeature	D016055
62408619	794	816	D allele for the -1607	SequenceVariant	c|Allele|D|-1607
62408619	821	829	rs800292	SequenceVariant	rs800292
62408619	957	973	Kilham rat virus	OrganismTaxon	12441
62408619	978	983	DEN-4	OrganismTaxon	11070
62408619	1205	1235	hypokalemic periodic paralysis	DiseaseOrPhenotypicFeature	D020514
62408619	1240	1256	volume retention	DiseaseOrPhenotypicFeature	D016055
62408619	Positive_Correlation	D020514	c|Allele|D|-1607	Novel
62408619	Positive_Correlation	D020514	rs800292	Novel
62408619	Positive_Correlation	D016055	rs800292	Novel
62408619	Association	c|Allele|D|-1607	rs800292	Novel
62408619	Negative_Correlation	c|Allele|D|-1607	D016055	Novel
62408619	Positive_Correlation	D016055	c|Allele|D|-1607	Novel
62408619	Negative_Correlation	rs800292	D020514	Novel
62408619	Negative_Correlation	rs800292	D016055	Novel
62408619	Negative_Correlation	c|Allele|D|-1607	D020514	Novel
62408619	Association	rs800292	c|Allele|D|-1607	Novel

27592627|t|Genetic and pharmacological interactions of JAG1, NOTCH1, and Star-PAP in the context of arterial dysfunction and ventricular septa
27592627|a|This study investigates the genetic and pharmacological interactions between the gene JAG1, the gene NOTCH1, and the gene Star-PAP in relation to arterial dysfunction and ventricular septal defect. We focus on the molecular mechanisms underlying these associations, particularly in the context of mutations in the gene JAG1 and the sequence variant c.689C>G. The study also explores the role of the sequence variant c.892C>T and the sequence variant 217_218insC in modulating the expression and function of JAG1.   Our findings reveal a significant association between the gene NOTCH1 and the chemical entity valdecoxib, as well as between NOTCH1 and platinum. These associations are further supported by the observed interaction between NOTCH1 and Coenzyme Q10. Additionally, the gene Star-PAP is found to be associated with platinum, highlighting a potential pharmacological link between this gene and the metal-based drug.   The gene Id3 is also found to be associated with platinum, suggesting a broader role for platinum in modulating the expression of multiple genes involved in vascular development and function. Furthermore, the gene JAG1 is associated with Coenzyme Q10, indicating a possible regulatory role of this coenzyme in the function of JAG1.   The study also examines the impact of the sequence variant rs5393 and the sequence variant C262T on the expression of the gene STL1, which is further associated with valdecoxib. These findings suggest that genetic variability in STL1 may influence the response to valdecoxib, a nonsteroidal anti-inflammatory drug.   In addition, the study identifies the sequence variant IVS3 + 18C > T as a potential modifier of the expression of the gene JAG1, which is linked to the phenotypic feature of ventricular septal defect. The presence of multiple sequence variants in JAG1, including c.689C>G, c.892C>T, and 217_218insC, underscores the genetic complexity of this gene in the context of cardiovascular development.   The chemical entity GFC75 is also examined in relation to arterial dysfunction, with preliminary evidence suggesting a potential therapeutic role in modulating vascular function. Overall, this study provides a comprehensive analysis of the genetic and pharmacological interactions between key genes and chemical entities in the context of arterial dysfunction and ventricular septal defect, with implications for personalized medicine and targeted therapies.
27592627	44	48	JAG1	GeneOrGeneProduct	182
27592627	50	56	NOTCH1	GeneOrGeneProduct	4851
27592627	62	70	Star-PAP	GeneOrGeneProduct	64852
27592627	89	109	arterial dysfunction	DiseaseOrPhenotypicFeature	D018754
27592627	218	222	JAG1	GeneOrGeneProduct	182
27592627	233	239	NOTCH1	GeneOrGeneProduct	4851
27592627	254	262	Star-PAP	GeneOrGeneProduct	64852
27592627	278	298	arterial dysfunction	DiseaseOrPhenotypicFeature	D018754
27592627	303	328	ventricular septal defect	DiseaseOrPhenotypicFeature	D006345
27592627	451	455	JAG1	GeneOrGeneProduct	182
27592627	481	489	c.689C>G	SequenceVariant	c|SUB|C|689|G
27592627	548	556	c.892C>T	SequenceVariant	c|SUB|C|892|T
27592627	582	593	217_218insC	SequenceVariant	c|INS|217_218|C
27592627	639	643	JAG1	GeneOrGeneProduct	182
27592627	710	716	NOTCH1	GeneOrGeneProduct	4851
27592627	741	751	valdecoxib	ChemicalEntity	C406224
27592627	772	778	NOTCH1	GeneOrGeneProduct	4851
27592627	783	791	platinum	ChemicalEntity	D010984
27592627	870	876	NOTCH1	GeneOrGeneProduct	4851
27592627	881	893	Coenzyme Q10	ChemicalEntity	C024989
27592627	918	926	Star-PAP	GeneOrGeneProduct	64852
27592627	958	966	platinum	ChemicalEntity	D010984
27592627	1069	1072	Id3	GeneOrGeneProduct	15903
27592627	1109	1117	platinum	ChemicalEntity	D010984
27592627	1149	1157	platinum	ChemicalEntity	D010984
27592627	1274	1278	JAG1	GeneOrGeneProduct	182
27592627	1298	1310	Coenzyme Q10	ChemicalEntity	C024989
27592627	1386	1390	JAG1	GeneOrGeneProduct	182
27592627	1453	1459	rs5393	SequenceVariant	rs5393
27592627	1485	1490	C262T	SequenceVariant	c|SUB|C|262|T
27592627	1521	1525	STL1	GeneOrGeneProduct	369068
27592627	1560	1570	valdecoxib	ChemicalEntity	C406224
27592627	1623	1627	STL1	GeneOrGeneProduct	369068
27592627	1658	1668	valdecoxib	ChemicalEntity	C406224
27592627	1766	1780	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
27592627	1835	1839	JAG1	GeneOrGeneProduct	182
27592627	1886	1911	ventricular septal defect	DiseaseOrPhenotypicFeature	D006345
27592627	1959	1963	JAG1	GeneOrGeneProduct	182
27592627	1975	1983	c.689C>G	SequenceVariant	c|SUB|C|689|G
27592627	1985	1993	c.892C>T	SequenceVariant	c|SUB|C|892|T
27592627	1999	2010	217_218insC	SequenceVariant	c|INS|217_218|C
27592627	2128	2133	GFC75	ChemicalEntity	C573355
27592627	2166	2186	arterial dysfunction	DiseaseOrPhenotypicFeature	D018754
27592627	2447	2467	arterial dysfunction	DiseaseOrPhenotypicFeature	D018754
27592627	2472	2497	ventricular septal defect	DiseaseOrPhenotypicFeature	D006345
27592627	Association	4851	C406224	Novel
27592627	Association	4851	D010984	Novel
27592627	Association	369068	C406224	Novel
27592627	Association	182	C024989	Novel
27592627	Association	4851	C024989	Novel
27592627	Association	64852	D010984	Novel
27592627	Association	15903	D010984	Novel

08159870|t|Genetic and pharmacological associations between non-autoimmune hyperthyroidism, p.Ser119fsX, ACh, and stomach cancer in PATIENTS and ce
08159870|a|This study investigates the complex interplay between genetic variants, pharmacological agents, and disease phenotypes in PATIENTS and cell lines. We focus on the association between the sequence variant p.Ser119fsX and the disease SCCs, as well as its correlation with stomach cancer. The variant p.Ser119fsX was found to be associated with SCCs in multiple PATIENTS and cell lines, including HEK293 and Hs578T. However, the relationship between p.Ser119fsX and SCCs was also found to be negative in some contexts, suggesting a nuanced genetic influence.   In addition, we observed a positive correlation between non-autoimmune hyperthyroidism and ACh, which was further supported by the association between ACh and stomach cancer. The chemical entity ACh was found to be positively correlated with stomach cancer in PATIENTS, and this relationship was also evident in the cell lines HEK293 and Hs578T. Furthermore, the association between ACh and stomach cancer was reinforced by the presence of bupivacaine, which was found to be associated with stomach cancer in multiple PATIENTS and cell lines.   The chemical entity bupivacaine was also found to be associated with non-autoimmune hyperthyroidism, suggesting a potential pharmacological link between these two conditions. Additionally, the sequence variant p.Ser119fsX was found to be associated with non-autoimmune hyperthyroidism, indicating a possible genetic connection.   The study also included multiple instances of the cell line 253JB-V, which was used to validate the observed associations. The results highlight the importance of considering both genetic and pharmacological factors in understanding the pathogenesis of diseases such as SCCs and stomach cancer, as well as their interactions with conditions like non-autoimmune hyperthyroidism.
08159870	49	79	non-autoimmune hyperthyroidism	DiseaseOrPhenotypicFeature	C563786
08159870	81	92	p.Ser119fsX	SequenceVariant	p|FS|S|119||
08159870	94	97	ACh	ChemicalEntity	D000109
08159870	103	117	stomach cancer	DiseaseOrPhenotypicFeature	D013274
08159870	121	129	PATIENTS	OrganismTaxon	9606
08159870	259	267	PATIENTS	OrganismTaxon	9606
08159870	341	352	p.Ser119fsX	SequenceVariant	p|FS|S|119||
08159870	369	373	SCCs	DiseaseOrPhenotypicFeature	D002294
08159870	407	421	stomach cancer	DiseaseOrPhenotypicFeature	D013274
08159870	435	446	p.Ser119fsX	SequenceVariant	p|FS|S|119||
08159870	479	483	SCCs	DiseaseOrPhenotypicFeature	D002294
08159870	496	504	PATIENTS	OrganismTaxon	9606
08159870	531	537	HEK293	CellLine	CVCL_0045
08159870	542	548	Hs578T	CellLine	CVCL_0332
08159870	584	595	p.Ser119fsX	SequenceVariant	p|FS|S|119||
08159870	600	604	SCCs	DiseaseOrPhenotypicFeature	D002294
08159870	751	781	non-autoimmune hyperthyroidism	DiseaseOrPhenotypicFeature	C563786
08159870	786	789	ACh	ChemicalEntity	D000109
08159870	846	849	ACh	ChemicalEntity	D000109
08159870	854	868	stomach cancer	DiseaseOrPhenotypicFeature	D013274
08159870	890	893	ACh	ChemicalEntity	D000109
08159870	937	951	stomach cancer	DiseaseOrPhenotypicFeature	D013274
08159870	955	963	PATIENTS	OrganismTaxon	9606
08159870	1022	1028	HEK293	CellLine	CVCL_0045
08159870	1033	1039	Hs578T	CellLine	CVCL_0332
08159870	1078	1081	ACh	ChemicalEntity	D000109
08159870	1086	1100	stomach cancer	DiseaseOrPhenotypicFeature	D013274
08159870	1135	1146	bupivacaine	ChemicalEntity	D002045
08159870	1186	1200	stomach cancer	DiseaseOrPhenotypicFeature	D013274
08159870	1213	1221	PATIENTS	OrganismTaxon	9606
08159870	1260	1271	bupivacaine	ChemicalEntity	D002045
08159870	1309	1339	non-autoimmune hyperthyroidism	DiseaseOrPhenotypicFeature	C563786
08159870	1450	1461	p.Ser119fsX	SequenceVariant	p|FS|S|119||
08159870	1494	1524	non-autoimmune hyperthyroidism	DiseaseOrPhenotypicFeature	C563786
08159870	1630	1637	253JB-V	CellLine	CVCL_7937
08159870	1840	1844	SCCs	DiseaseOrPhenotypicFeature	D002294
08159870	1849	1863	stomach cancer	DiseaseOrPhenotypicFeature	D013274
08159870	1916	1946	non-autoimmune hyperthyroidism	DiseaseOrPhenotypicFeature	C563786
08159870	Association	p|FS|S|119||	D002294	Novel
08159870	Positive_Correlation	D013274	D000109	Novel
08159870	Negative_Correlation	p|FS|S|119||	D002294	Novel
08159870	Association	D002045	D013274	Novel
08159870	Positive_Correlation	C563786	D000109	Novel
08159870	Association	D000109	D013274	Novel
08159870	Negative_Correlation	p|FS|S|119||	D013274	Novel
08159870	Positive_Correlation	p|FS|S|119||	D013274	Novel
08159870	Association	D002045	C563786	Novel
08159870	Association	C563786	p|FS|S|119||	Novel

22059634|t|Ezetimibe and Basal Cell Carcinomas: A Study on Kilham Rat Virus Infection and Its Modulation by E
22059634|a|Basal Cell Carcinomas (BCCs) have been increasingly associated with Kilham rat virus (KRV) infection, particularly in experimental models. This study investigates the relationship between Ezetimibe, a cholesterol absorption inhibitor, and the development of BCCs in KRV-infected rats. The findings suggest a negative correlation between Ezetimibe treatment and the incidence of BCCs in KRV-infected animals.   In a series of experiments, 11 groups of rats were infected with Kilham rat virus, and 27 of these groups were treated with Ezetimibe at varying dosages. The results showed that Ezetimibe significantly reduced the occurrence of Basal Cell Carcinomas compared to untreated controls. The negative correlation between Ezetimibe and BCCs was further supported by histopathological analysis and molecular profiling.   Ezetimibe was found to modulate the expression of key genes involved in the pathogenesis of BCCs, including those related to cell proliferation and immune response. These findings provide evidence that Ezetimibe may have a protective effect against BCCs in the context of KRV infection. The study highlights the potential therapeutic role of Ezetimibe in preventing or mitigating the development of Basal Cell Carcinomas in viral-induced models.   The data also emphasize the importance of understanding the interplay between viral infections, chemical entities like Ezetimibe, and the development of phenotypic features such as Basal Cell Carcinomas. This research contributes to the growing body of evidence linking Ezetimibe with a negative correlation to BCCs, particularly in the presence of Kilham rat virus.
22059634	0	9	Ezetimibe	ChemicalEntity	D000069438
22059634	14	35	Basal Cell Carcinomas	DiseaseOrPhenotypicFeature	D002280
22059634	99	120	Basal Cell Carcinomas	DiseaseOrPhenotypicFeature	D002280
22059634	167	183	Kilham rat virus	OrganismTaxon	12441
22059634	287	296	Ezetimibe	ChemicalEntity	D000069438
22059634	436	445	Ezetimibe	ChemicalEntity	D000069438
22059634	574	590	Kilham rat virus	OrganismTaxon	12441
22059634	633	642	Ezetimibe	ChemicalEntity	D000069438
22059634	687	696	Ezetimibe	ChemicalEntity	D000069438
22059634	737	758	Basal Cell Carcinomas	DiseaseOrPhenotypicFeature	D002280
22059634	824	833	Ezetimibe	ChemicalEntity	D000069438
22059634	922	931	Ezetimibe	ChemicalEntity	D000069438
22059634	1124	1133	Ezetimibe	ChemicalEntity	D000069438
22059634	1264	1273	Ezetimibe	ChemicalEntity	D000069438
22059634	1321	1342	Basal Cell Carcinomas	DiseaseOrPhenotypicFeature	D002280
22059634	1489	1498	Ezetimibe	ChemicalEntity	D000069438
22059634	1551	1572	Basal Cell Carcinomas	DiseaseOrPhenotypicFeature	D002280
22059634	1640	1649	Ezetimibe	ChemicalEntity	D000069438
22059634	1719	1735	Kilham rat virus	OrganismTaxon	12441
22059634	Association	D000069438	D002280	Novel
22059634	Negative_Correlation	D002280	D000069438	Novel

08607839|t|Glucocorticoids and their complex interactions with precancerous conditions, hyperkeratosis, and developmental malformations in guinea-pigs a
08607839|a|This study investigates the multifaceted role of glucocorticoids in the context of precancerous conditions, hyperkeratosis, and developmental malformations in guinea-pigs and DEN-2. The research focuses on the intricate relationships between these factors, particularly in the context of CMT-93 and Capan1 cell lines.   Our findings reveal a negative correlation between glucocorticoids and precancerous conditions, suggesting that glucocorticoids may have a protective effect against the development of precancerous features. However, we also observed a positive correlation between glucocorticoids and precancerous conditions, indicating a complex interplay that may depend on the specific cellular context, such as the CMT-93 cell line.   In addition, we found a negative correlation between glucocorticoids and hyperkeratosis, which is counterbalanced by a positive correlation between glucocorticoids and hyperkeratosis in the Capan1 cell line. This suggests that the effect of glucocorticoids on hyperkeratosis may vary depending on the cell type and the presence of other factors.   The study also highlights a negative correlation between glucocorticoids and cardiovascular, craniofacial, and thymic malformations, while simultaneously showing an association between these malformations and glucocorticoids. This dual relationship indicates that glucocorticoids may have both protective and harmful effects on developmental processes, depending on the specific conditions and the organism involved.   The research was conducted in guinea-pigs and DEN-2, with a notable presence of dogs in the experimental design. The results underscore the importance of considering the organism taxon and cell line when evaluating the effects of glucocorticoids on various disease states. The repeated mentions of CMT-93, Capan1, and the disease features reflect the extensive analysis required to understand the complex interactions between glucocorticoids and these conditions.
08607839	52	64	precancerous	DiseaseOrPhenotypicFeature	D011230
08607839	77	91	hyperkeratosis	DiseaseOrPhenotypicFeature	D017488
08607839	128	139	guinea-pigs	OrganismTaxon	10141
08607839	191	206	glucocorticoids	ChemicalEntity	D005938
08607839	225	237	precancerous	DiseaseOrPhenotypicFeature	D011230
08607839	250	264	hyperkeratosis	DiseaseOrPhenotypicFeature	D017488
08607839	301	312	guinea-pigs	OrganismTaxon	10141
08607839	317	322	DEN-2	OrganismTaxon	11060
08607839	430	436	CMT-93	CellLine	CVCL_1986
08607839	441	447	Capan1	CellLine	CVCL_0237
08607839	513	528	glucocorticoids	ChemicalEntity	D005938
08607839	533	545	precancerous	DiseaseOrPhenotypicFeature	D011230
08607839	574	589	glucocorticoids	ChemicalEntity	D005938
08607839	646	658	precancerous	DiseaseOrPhenotypicFeature	D011230
08607839	726	741	glucocorticoids	ChemicalEntity	D005938
08607839	746	758	precancerous	DiseaseOrPhenotypicFeature	D011230
08607839	864	870	CMT-93	CellLine	CVCL_1986
08607839	937	952	glucocorticoids	ChemicalEntity	D005938
08607839	957	971	hyperkeratosis	DiseaseOrPhenotypicFeature	D017488
08607839	1032	1047	glucocorticoids	ChemicalEntity	D005938
08607839	1052	1066	hyperkeratosis	DiseaseOrPhenotypicFeature	D017488
08607839	1074	1080	Capan1	CellLine	CVCL_0237
08607839	1125	1140	glucocorticoids	ChemicalEntity	D005938
08607839	1144	1158	hyperkeratosis	DiseaseOrPhenotypicFeature	D017488
08607839	1289	1304	glucocorticoids	ChemicalEntity	D005938
08607839	1309	1363	cardiovascular, craniofacial, and thymic malformations	DiseaseOrPhenotypicFeature	D018376
08607839	1441	1456	glucocorticoids	ChemicalEntity	D005938
08607839	1496	1511	glucocorticoids	ChemicalEntity	D005938
08607839	1681	1692	guinea-pigs	OrganismTaxon	10141
08607839	1697	1702	DEN-2	OrganismTaxon	11060
08607839	1731	1735	dogs	OrganismTaxon	9615
08607839	1881	1896	glucocorticoids	ChemicalEntity	D005938
08607839	1949	1955	CMT-93	CellLine	CVCL_1986
08607839	1957	1963	Capan1	CellLine	CVCL_0237
08607839	2077	2092	glucocorticoids	ChemicalEntity	D005938
08607839	Negative_Correlation	D011230	D005938	Novel
08607839	Association	D005938	D017488	Novel
08607839	Positive_Correlation	D018376	D005938	Novel
08607839	Negative_Correlation	D005938	D018376	Novel
08607839	Negative_Correlation	D005938	D017488	Novel
08607839	Association	D018376	D005938	Novel
08607839	Association	D005938	D018376	Novel
08607839	Association	D017488	D005938	Novel
08607839	Negative_Correlation	D018376	D005938	Novel
08607839	Negative_Correlation	D005938	D011230	Novel
08607839	Negative_Correlation	D017488	D005938	Novel
08607839	Positive_Correlation	D017488	D005938	Novel
08607839	Positive_Correlation	D011230	D005938	Novel
08607839	Association	D011230	D005938	Novel
08607839	Association	D005938	D011230	Novel

89692614|t|Genetic and pharmacological interactions in cancer therapy: insights from HCT116 and Capan1 ce
89692614|a|Recent studies have highlighted the complex interplay between genetic variants, drug interactions, and therapeutic outcomes in cancer treatment. This research investigates the effects of sequence variants and chemical entities on cellular responses in the HCT116 and Capan1 cell lines. A significant positive correlation was observed between Terfenadine and the sequence variant N673S, suggesting a potential role in modulating drug efficacy. Additionally, a drug interaction was identified between Methadone and Terfenadine, which may have implications for clinical dosing strategies.   The positive correlation between atorvastatin and the sequence variant G->A indicates a possible mechanism by which this statin may influence gene expression. An association was found between doxorubicin and COMT inhibitors, suggesting that these agents may act synergistically in certain cellular contexts. Furthermore, Terfenadine was found to be associated with Methadone, reinforcing the need for careful monitoring of drug combinations in patients.   A negative correlation was observed between HBsAg and Methadone, which may have therapeutic relevance in the treatment of hepatitis B. A drug interaction was also identified between HBsAg and doxorubicin, highlighting potential adverse effects in patients co-infected with hepatitis B and undergoing chemotherapy.   The positive correlation between COMT inhibitors and the sequence variant arginine84 to glutamine suggests a possible functional link between these agents and genetic polymorphisms. Conversely, a negative correlation was found between arginine84 to glutamine and COMT inhibitors, indicating a complex regulatory network.   In addition, the sequence variant 125-126insAA was found to be present in multiple instances, and the variant G1681A was associated with doxorubicin, further supporting the role of genetic variability in drug response. These findings underscore the importance of integrating genetic and pharmacological data to optimize therapeutic strategies in cancer treatment.
89692614	74	80	HCT116	CellLine	CVCL_0291
89692614	85	91	Capan1	CellLine	CVCL_0237
89692614	351	357	HCT116	CellLine	CVCL_0291
89692614	362	368	Capan1	CellLine	CVCL_0237
89692614	437	448	Terfenadine	ChemicalEntity	D016593
89692614	474	479	N673S	SequenceVariant	rs3917815
89692614	594	603	Methadone	ChemicalEntity	D008691
89692614	608	619	Terfenadine	ChemicalEntity	D016593
89692614	716	728	atorvastatin	ChemicalEntity	D000069059
89692614	754	758	G->A	SequenceVariant	rs368698783
89692614	875	886	doxorubicin	ChemicalEntity	D004317
89692614	891	906	COMT inhibitors	ChemicalEntity	D065098
89692614	1004	1015	Terfenadine	ChemicalEntity	D016593
89692614	1048	1057	Methadone	ChemicalEntity	D008691
89692614	1183	1188	HBsAg	ChemicalEntity	D006514
89692614	1193	1202	Methadone	ChemicalEntity	D008691
89692614	1321	1326	HBsAg	ChemicalEntity	D006514
89692614	1331	1342	doxorubicin	ChemicalEntity	D004317
89692614	1488	1503	COMT inhibitors	ChemicalEntity	D065098
89692614	1529	1552	arginine84 to glutamine	SequenceVariant	rs74315458
89692614	1690	1713	arginine84 to glutamine	SequenceVariant	rs74315458
89692614	1718	1733	COMT inhibitors	ChemicalEntity	D065098
89692614	1812	1824	125-126insAA	SequenceVariant	|INS|125_126|AA
89692614	1888	1894	G1681A	SequenceVariant	rs113994095
89692614	1915	1926	doxorubicin	ChemicalEntity	D004317
89692614	Positive_Correlation	D016593	rs3917815	Novel
89692614	Drug_Interaction	D008691	D016593	Novel
89692614	Positive_Correlation	D000069059	rs368698783	Novel
89692614	Association	D004317	D065098	Novel
89692614	Association	D016593	D008691	Novel
89692614	Negative_Correlation	D006514	D008691	Novel
89692614	Drug_Interaction	D006514	D004317	Novel
89692614	Positive_Correlation	D065098	rs74315458	Novel
89692614	Positive_Correlation	D004317	rs368698783	Novel
89692614	Negative_Correlation	rs74315458	D065098	Novel

92322596|t|D541E variant in HOOK3 modulates RagC interactions and expression in Capan1 cells and C.
92322596|a|The D541E variant in the HOOK3 gene has been shown to modulate interactions with the RagC protein in both Capan1 cells and C. elegans. This study investigates the molecular mechanisms underlying the association between the D541E variant and the expression levels of HOOK3 and RagC. In Capan1 cells, the D541E variant was found to associate with both HOOK3 and RagC, suggesting a potential role in the regulation of these proteins. Furthermore, the D541E variant exhibited a positive correlation with HOOK3 expression and a negative correlation with RagC expression in C. elegans. These findings were corroborated by in vitro binding assays, which demonstrated a direct interaction between HOOK3 and RagC, as well as a positive correlation between their expression levels. The D541E variant also showed a negative correlation with RagC in Capan1 cells, indicating a complex regulatory network involving these proteins. Additionally, the association between D541E and RagC was further supported by genetic and functional studies in C. elegans. These results highlight the importance of the D541E variant in modulating the expression and interactions of HOOK3 and RagC, with implications for understanding their roles in cellular processes and disease mechanisms.
92322596	0	5	D541E	SequenceVariant	rs627928
92322596	17	22	HOOK3	GeneOrGeneProduct	84376
92322596	33	37	RagC	GeneOrGeneProduct	298514
92322596	69	75	Capan1	CellLine	CVCL_0237
92322596	93	98	D541E	SequenceVariant	rs627928
92322596	114	119	HOOK3	GeneOrGeneProduct	84376
92322596	174	178	RagC	GeneOrGeneProduct	298514
92322596	195	201	Capan1	CellLine	CVCL_0237
92322596	212	222	C. elegans	OrganismTaxon	6239
92322596	312	317	D541E	SequenceVariant	rs627928
92322596	355	360	HOOK3	GeneOrGeneProduct	84376
92322596	365	369	RagC	GeneOrGeneProduct	298514
92322596	374	380	Capan1	CellLine	CVCL_0237
92322596	392	397	D541E	SequenceVariant	rs627928
92322596	439	444	HOOK3	GeneOrGeneProduct	84376
92322596	449	453	RagC	GeneOrGeneProduct	298514
92322596	537	542	D541E	SequenceVariant	rs627928
92322596	589	594	HOOK3	GeneOrGeneProduct	84376
92322596	638	642	RagC	GeneOrGeneProduct	298514
92322596	657	667	C. elegans	OrganismTaxon	6239
92322596	778	783	HOOK3	GeneOrGeneProduct	84376
92322596	788	792	RagC	GeneOrGeneProduct	298514
92322596	865	870	D541E	SequenceVariant	rs627928
92322596	919	923	RagC	GeneOrGeneProduct	298514
92322596	927	933	Capan1	CellLine	CVCL_0237
92322596	1045	1050	D541E	SequenceVariant	rs627928
92322596	1055	1059	RagC	GeneOrGeneProduct	298514
92322596	1119	1129	C. elegans	OrganismTaxon	6239
92322596	1177	1182	D541E	SequenceVariant	rs627928
92322596	1240	1245	HOOK3	GeneOrGeneProduct	84376
92322596	1250	1254	RagC	GeneOrGeneProduct	298514
92322596	Bind	298514	84376	Novel
92322596	Bind	84376	298514	Novel
92322596	Positive_Correlation	298514	84376	Novel
92322596	Negative_Correlation	298514	84376	Novel
92322596	Positive_Correlation	84376	298514	Novel
92322596	Association	rs627928	298514	Novel
92322596	Negative_Correlation	84376	298514	Novel
92322596	Association	298514	84376	Novel
92322596	Association	rs627928	84376	Novel
92322596	Association	84376	298514	Novel

32962313|t|Drosophila, 253JB-V, and 293T cell lines in the study of Platonia insignis Mart and Rhodiola rosea: implications for sheep and rabbi
32962313|a|This study explores the interactions between the fruit fly *Drosophila*, the human cell line 253JB-V, and the human cell line 293T in the context of plant-derived compounds from *Platonia insignis Mart* and *Rhodiola rosea*. The research aims to elucidate the molecular mechanisms underlying the biological effects of these compounds in both in vitro and in vivo models. The 253JB-V cell line, derived from human bladder cancer, was used to assess the cytotoxic and proliferative responses to extracts from *Platonia insignis Mart*. Similarly, the 293T cell line, a human embryonic kidney cell line, was employed to evaluate the expression of key signaling pathways modulated by *Rhodiola rosea* extracts. The study also included the PA-1 cell line, a human bladder cancer cell line, to compare the effects of these plant extracts across different cell types. In addition to cell culture experiments, the study incorporated animal models, including sheep and rabbit, to investigate the systemic effects of these compounds. The sheep model was used to assess the pharmacokinetics and tissue distribution of the compounds, while the rabbit model provided insights into immune responses and inflammatory markers. The results suggest that *Platonia insignis Mart* and *Rhodiola rosea* have distinct biological activities that may be modulated by the cellular context, as evidenced by the differential responses observed in the various cell lines and animal models. The findings highlight the potential of these plant-derived compounds as therapeutic agents and underscore the importance of using diverse biological systems to fully understand their mechanisms of action. The repeated use of the organism taxon *Drosophila* and the cell lines 253JB-V, 293T, and PA-1, along with the organism taxa *sheep*, *rabbit*, *Platonia insignis Mart*, and *Rhodiola rosea*, reflects the comprehensive approach taken in this study to evaluate the biological relevance of these compounds.
32962313	0	10	Drosophila	OrganismTaxon	7227
32962313	12	19	253JB-V	CellLine	CVCL_7937
32962313	25	29	293T	CellLine	CVCL_0063
32962313	57	79	Platonia insignis Mart	OrganismTaxon	198787
32962313	84	98	Rhodiola rosea	OrganismTaxon	203015
32962313	117	122	sheep	OrganismTaxon	9940
32962313	193	203	Drosophila	OrganismTaxon	7227
32962313	226	233	253JB-V	CellLine	CVCL_7937
32962313	259	263	293T	CellLine	CVCL_0063
32962313	312	334	Platonia insignis Mart	OrganismTaxon	198787
32962313	341	355	Rhodiola rosea	OrganismTaxon	203015
32962313	508	515	253JB-V	CellLine	CVCL_7937
32962313	641	663	Platonia insignis Mart	OrganismTaxon	198787
32962313	681	685	293T	CellLine	CVCL_0063
32962313	813	827	Rhodiola rosea	OrganismTaxon	203015
32962313	867	871	PA-1	CellLine	CVCL_0479
32962313	1082	1087	sheep	OrganismTaxon	9940
32962313	1092	1098	rabbit	OrganismTaxon	9986
32962313	1160	1165	sheep	OrganismTaxon	9940
32962313	1264	1270	rabbit	OrganismTaxon	9986
32962313	1369	1391	Platonia insignis Mart	OrganismTaxon	198787
32962313	1398	1412	Rhodiola rosea	OrganismTaxon	203015
32962313	1840	1850	Drosophila	OrganismTaxon	7227
32962313	1871	1878	253JB-V	CellLine	CVCL_7937
32962313	1880	1884	293T	CellLine	CVCL_0063
32962313	1890	1894	PA-1	CellLine	CVCL_0479
32962313	1926	1931	sheep	OrganismTaxon	9940
32962313	1935	1941	rabbit	OrganismTaxon	9986
32962313	1945	1967	Platonia insignis Mart	OrganismTaxon	198787
32962313	1975	1989	Rhodiola rosea	OrganismTaxon	203015

91226412|t|Interactions between human immunodeficiency virus, raptor, and environmental agents: implications for hearing impairment and cardiac arr
91226412|a|This study investigates the complex interactions between human immunodeficiency virus (HIV), the gene product raptor, and various environmental agents, including diclofenac, sugars, agar, and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), with a focus on their roles in hearing impairment and cardiac arrhythmias. The research reveals a negative correlation between TCDD and cardiac arrhythmias, suggesting that TCDD may have protective effects against arrhythmogenic conditions. Additionally, there is a positive correlation between TCDD and raptor, indicating that TCDD may modulate raptor activity in cellular pathways. The conversion between sugars and TCDD is observed, suggesting a metabolic link between these two entities. A comparison between sugars and TCDD further highlights their distinct yet interconnected roles in cellular processes. The conversion between agar and sugars is also noted, implying a structural or functional relationship between these two substances.   Diclofenac is found to convert into TCDD, and a comparison between diclofenac and TCDD reveals their differing impacts on biological systems. The conversion between sugars and diclofenac suggests a potential metabolic pathway involving these compounds. Furthermore, a positive correlation between sugars and raptor is identified, reinforcing the role of raptor in metabolic regulation. The negative correlation between hearing impairment and agar suggests that agar may have a protective effect against hearing loss. The study also includes three instances of human immunodeficiency virus (HIV) and three instances of HIV type 1, emphasizing the role of these viral entities in the observed interactions. The findings provide new insights into the molecular mechanisms underlying these complex relationships and their implications for human health.
91226412	21	49	human immunodeficiency virus	OrganismTaxon	12721
91226412	51	57	raptor	GeneOrGeneProduct	287871
91226412	102	120	hearing impairment	DiseaseOrPhenotypicFeature	D034381
91226412	194	222	human immunodeficiency virus	OrganismTaxon	12721
91226412	247	253	raptor	GeneOrGeneProduct	287871
91226412	299	309	diclofenac	ChemicalEntity	D004008
91226412	311	317	sugars	ChemicalEntity	D000073893
91226412	319	323	agar	ChemicalEntity	D000362
91226412	329	364	2,3,7,8-tetrachlorodibenzo-p-dioxin	ChemicalEntity	D000072317
91226412	404	422	hearing impairment	DiseaseOrPhenotypicFeature	D034381
91226412	427	446	cardiac arrhythmias	DiseaseOrPhenotypicFeature	D001145
91226412	509	528	cardiac arrhythmias	DiseaseOrPhenotypicFeature	D001145
91226412	677	683	raptor	GeneOrGeneProduct	287871
91226412	719	725	raptor	GeneOrGeneProduct	287871
91226412	780	786	sugars	ChemicalEntity	D000073893
91226412	886	892	sugars	ChemicalEntity	D000073893
91226412	1007	1011	agar	ChemicalEntity	D000362
91226412	1016	1022	sugars	ChemicalEntity	D000073893
91226412	1186	1196	diclofenac	ChemicalEntity	D004008
91226412	1284	1290	sugars	ChemicalEntity	D000073893
91226412	1295	1305	diclofenac	ChemicalEntity	D004008
91226412	1416	1422	sugars	ChemicalEntity	D000073893
91226412	1427	1433	raptor	GeneOrGeneProduct	287871
91226412	1473	1479	raptor	GeneOrGeneProduct	287871
91226412	1538	1556	hearing impairment	DiseaseOrPhenotypicFeature	D034381
91226412	1561	1565	agar	ChemicalEntity	D000362
91226412	1580	1584	agar	ChemicalEntity	D000362
91226412	1679	1707	human immunodeficiency virus	OrganismTaxon	12721
91226412	Negative_Correlation	D001145	D000072317	Novel
91226412	Association	287871	D000072317	Novel
91226412	Conversion	D000073893	D000072317	Novel
91226412	Positive_Correlation	D000072317	287871	Novel
91226412	Negative_Correlation	D034381	D000362	Novel
91226412	Comparison	D000073893	D000072317	Novel
91226412	Conversion	D000362	D000073893	Novel
91226412	Conversion	D004008	D000072317	Novel
91226412	Comparison	D004008	D000072317	Novel
91226412	Conversion	D000073893	D004008	Novel
91226412	Positive_Correlation	D000073893	287871	Novel

88548012|t|DAPT and clodronate modulate dopamine receptor and transforming growth factor beta1 in the context of malformations, cerebral ischemia, and precancerous co
88548012|a|Recent studies have highlighted the complex interplay between chemical entities, genetic variants, and disease phenotypes in the pathogenesis of congenital malformations and neurological disorders. This research explores the associations between DAPT, clodronate, and various genetic elements in the context of malformations, cerebral ischemia, and precancerous conditions. DAPT, a gamma-secretase inhibitor, was found to have a negative correlation with OPHN1, suggesting a potential role in neurodevelopmental processes. Additionally, DAPT showed a positive correlation with the -107C/T variant, indicating a possible regulatory interaction.   Clodronate, a bisphosphonate, was positively correlated with both selenocysteine and Lys198Asn, suggesting a role in modulating cellular responses to oxidative stress and structural integrity. The positive correlation between clodronate and selenocysteine was further supported by its positive correlation with Lys198Asn, which is associated with transforming growth factor beta1. This suggests a potential pathway involving clodronate in the regulation of fibrotic and inflammatory responses.  The sequence variant M200V was found to be associated with both the dopamine receptor and FGF receptor 2, indicating a possible role in signal transduction pathways. The variant c.1239 +1G>A was associated with the dopamine receptor and transforming growth factor beta1, reinforcing the role of this variant in modulating cellular signaling. Furthermore, the variant R58fs was associated with the dopamine receptor, highlighting its potential involvement in neurodevelopmental processes.  The sequence variant -107C/T was associated with OPHN1 and transforming growth factor beta1, suggesting a dual role in both neuronal and fibrotic processes. The variant 'arginine residue for the proline residue at position 158' was associated with the Sulfonylurea Receptor, indicating a potential role in ion channel function.   The disease phenotypes of cerebral ischemia and precancerous conditions were positively correlated with M200V and c.1239 +1G>A, respectively, suggesting a potential role for these genetic variants in disease progression. The positive correlation between selenocysteine and DAPT, as well as between selenocysteine and clodronate, further supports the involvement of these chemical entities in modulating genetic expression and disease outcomes.   Overall, this study provides evidence for the complex interactions between chemical entities, genetic variants, and disease phenotypes, offering new insights into the molecular mechanisms underlying malformations, cerebral ischemia, and precancerous conditions.
88548012	0	4	DAPT	ChemicalEntity	C419410
88548012	9	19	clodronate	ChemicalEntity	D004002
88548012	29	46	dopamine receptor	GeneOrGeneProduct	24316
88548012	51	83	transforming growth factor beta1	GeneOrGeneProduct	59086
88548012	102	115	malformations	DiseaseOrPhenotypicFeature	D000013
88548012	117	134	cerebral ischemia	DiseaseOrPhenotypicFeature	D002545
88548012	140	152	precancerous	DiseaseOrPhenotypicFeature	D011230
88548012	312	325	malformations	DiseaseOrPhenotypicFeature	D000013
88548012	402	406	DAPT	ChemicalEntity	C419410
88548012	408	418	clodronate	ChemicalEntity	D004002
88548012	467	480	malformations	DiseaseOrPhenotypicFeature	D000013
88548012	482	499	cerebral ischemia	DiseaseOrPhenotypicFeature	D002545
88548012	505	517	precancerous	DiseaseOrPhenotypicFeature	D011230
88548012	530	534	DAPT	ChemicalEntity	C419410
88548012	611	616	OPHN1	GeneOrGeneProduct	4983
88548012	693	697	DAPT	ChemicalEntity	C419410
88548012	737	744	-107C/T	SequenceVariant	c|SUB|C|-107|T
88548012	868	882	selenocysteine	ChemicalEntity	D017279
88548012	887	896	Lys198Asn	SequenceVariant	rs5370
88548012	1028	1038	clodronate	ChemicalEntity	D004002
88548012	1043	1057	selenocysteine	ChemicalEntity	D017279
88548012	1113	1122	Lys198Asn	SequenceVariant	rs5370
88548012	1149	1181	transforming growth factor beta1	GeneOrGeneProduct	59086
88548012	1227	1237	clodronate	ChemicalEntity	D004002
88548012	1318	1323	M200V	SequenceVariant	rs2227914
88548012	1365	1382	dopamine receptor	GeneOrGeneProduct	24316
88548012	1387	1401	FGF receptor 2	GeneOrGeneProduct	14183
88548012	1475	1487	c.1239 +1G>A	SequenceVariant	c|SUB|G|1239+1|A
88548012	1512	1529	dopamine receptor	GeneOrGeneProduct	24316
88548012	1534	1566	transforming growth factor beta1	GeneOrGeneProduct	59086
88548012	1664	1669	R58fs	SequenceVariant	p|FS|R|58||
88548012	1694	1711	dopamine receptor	GeneOrGeneProduct	24316
88548012	1807	1814	-107C/T	SequenceVariant	c|SUB|C|-107|T
88548012	1835	1840	OPHN1	GeneOrGeneProduct	4983
88548012	1845	1877	transforming growth factor beta1	GeneOrGeneProduct	59086
88548012	1956	2012	arginine residue for the proline residue at position 158	SequenceVariant	p|SUB|R|158|P
88548012	2038	2059	Sulfonylurea Receptor	GeneOrGeneProduct	6833
88548012	2142	2159	cerebral ischemia	DiseaseOrPhenotypicFeature	D002545
88548012	2164	2176	precancerous	DiseaseOrPhenotypicFeature	D011230
88548012	2220	2225	M200V	SequenceVariant	rs2227914
88548012	2230	2242	c.1239 +1G>A	SequenceVariant	c|SUB|G|1239+1|A
88548012	2370	2384	selenocysteine	ChemicalEntity	D017279
88548012	2389	2393	DAPT	ChemicalEntity	C419410
88548012	2414	2428	selenocysteine	ChemicalEntity	D017279
88548012	2433	2443	clodronate	ChemicalEntity	D004002
88548012	2761	2774	malformations	DiseaseOrPhenotypicFeature	D000013
88548012	2776	2793	cerebral ischemia	DiseaseOrPhenotypicFeature	D002545
88548012	2799	2811	precancerous	DiseaseOrPhenotypicFeature	D011230
88548012	Association	rs2227914	24316	Novel
88548012	Negative_Correlation	C419410	4983	Novel
88548012	Association	c|SUB|C|-107|T	59086	Novel
88548012	Positive_Correlation	D004002	D017279	Novel
88548012	Positive_Correlation	D006333	rs5370	Novel
88548012	Negative_Correlation	D017279	14183	Novel
88548012	Association	c|SUB|G|1239+1|A	24316	Novel
88548012	Positive_Correlation	D017279	rs5370	Novel
88548012	Positive_Correlation	D006333	p|SUB|R|158|P	Novel
88548012	Positive_Correlation	D011230	c|SUB|G|1239+1|A	Novel
88548012	Association	rs5370	59086	Novel
88548012	Association	rs2227914	14183	Novel
88548012	Association	c|SUB|G|1239+1|A	59086	Novel
88548012	Association	p|SUB|R|158|P	6833	Novel
88548012	Positive_Correlation	D017279	C419410	Novel
88548012	Association	p|FS|R|58||	24316	Novel
88548012	Positive_Correlation	D004002	rs5370	Novel
88548012	Positive_Correlation	D002545	rs2227914	Novel
88548012	Association	c|SUB|C|-107|T	4983	Novel
88548012	Positive_Correlation	C419410	c|SUB|C|-107|T	Novel
88548012	Positive_Correlation	D017279	D004002	Novel

26199894|t|A30P and p.Asp46_Gln48delinsGlu: associations with unilateral ureteric obstruction and interactions with RAB28, PTPN22, a
26199894|a|Unilateral ureteric obstruction has been linked to multiple genetic and molecular factors, including the sequence variants A30P and p.Asp46_Gln48delinsGlu. This study investigates the complex interplay between these genetic elements and their associations with unilateral ureteric obstruction, as well as their interactions with other key molecular players such as RAB28, PTPN22, and Foxp3.   The findings reveal a strong positive correlation between unilateral ureteric obstruction and both A30P and p.Asp46_Gln48delinsGlu, suggesting that these sequence variants may contribute to the pathogenesis of the condition. Additionally, the association between unilateral ureteric obstruction and p.Asp46_Gln48delinsGlu is further supported by functional studies showing altered cellular responses in models expressing this variant.   Interestingly, the study also identifies a negative correlation between RAB28 and Foxp3, as well as between PTPN22 and Foxp3, indicating potential regulatory interactions among these genes. Furthermore, a negative correlation is observed between RAB28 and PTPN22, and between Foxp3 and PTPN22, suggesting a complex network of gene interactions that may influence disease progression.   The role of chemical entities such as flutamide, vitamin E, aspartate, and prostaglandins is also explored, with some evidence suggesting that these compounds may modulate the effects of the genetic variants on unilateral ureteric obstruction. For instance, flutamide and vitamin E are found to have a protective effect in certain cellular models, while aspartate and prostaglandins show variable associations depending on the context of the genetic background.   These results highlight the multifactorial nature of unilateral ureteric obstruction and underscore the importance of considering both genetic and environmental factors in understanding its etiology. The study provides a foundation for future research into targeted therapies and personalized treatment strategies for patients with this condition.
26199894	0	4	A30P	SequenceVariant	p|SUB|A|30|P
26199894	9	31	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
26199894	51	82	unilateral ureteric obstruction	DiseaseOrPhenotypicFeature	D014517
26199894	105	110	RAB28	GeneOrGeneProduct	9364
26199894	112	118	PTPN22	GeneOrGeneProduct	26191
26199894	245	249	A30P	SequenceVariant	p|SUB|A|30|P
26199894	254	276	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
26199894	383	414	unilateral ureteric obstruction	DiseaseOrPhenotypicFeature	D014517
26199894	487	492	RAB28	GeneOrGeneProduct	9364
26199894	494	500	PTPN22	GeneOrGeneProduct	26191
26199894	506	511	Foxp3	GeneOrGeneProduct	20371
26199894	573	604	unilateral ureteric obstruction	DiseaseOrPhenotypicFeature	D014517
26199894	614	618	A30P	SequenceVariant	p|SUB|A|30|P
26199894	623	645	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
26199894	778	809	unilateral ureteric obstruction	DiseaseOrPhenotypicFeature	D014517
26199894	814	836	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
26199894	1024	1029	RAB28	GeneOrGeneProduct	9364
26199894	1034	1039	Foxp3	GeneOrGeneProduct	20371
26199894	1060	1066	PTPN22	GeneOrGeneProduct	26191
26199894	1071	1076	Foxp3	GeneOrGeneProduct	20371
26199894	1198	1203	RAB28	GeneOrGeneProduct	9364
26199894	1208	1214	PTPN22	GeneOrGeneProduct	26191
26199894	1228	1233	Foxp3	GeneOrGeneProduct	20371
26199894	1238	1244	PTPN22	GeneOrGeneProduct	26191
26199894	1376	1385	flutamide	ChemicalEntity	D005485
26199894	1387	1396	vitamin E	ChemicalEntity	D014810
26199894	1398	1407	aspartate	ChemicalEntity	D001224
26199894	1413	1427	prostaglandins	ChemicalEntity	D011453
26199894	1549	1580	unilateral ureteric obstruction	DiseaseOrPhenotypicFeature	D014517
26199894	1596	1605	flutamide	ChemicalEntity	D005485
26199894	1610	1619	vitamin E	ChemicalEntity	D014810
26199894	1692	1701	aspartate	ChemicalEntity	D001224
26199894	1706	1720	prostaglandins	ChemicalEntity	D011453
26199894	1855	1886	unilateral ureteric obstruction	DiseaseOrPhenotypicFeature	D014517
26199894	Association	D014517	p|INDEL|46_48|Glu	Novel
26199894	Negative_Correlation	9364	20371	Novel
26199894	Negative_Correlation	26191	20371	Novel
26199894	Negative_Correlation	9364	26191	Novel
26199894	Negative_Correlation	20371	9364	Novel
26199894	Association	p|INDEL|46_48|Glu	D014517	Novel
26199894	Association	p|SUB|A|30|P	D014517	Novel
26199894	Negative_Correlation	26191	9364	Novel
26199894	Positive_Correlation	D014517	p|SUB|A|30|P	Novel
26199894	Positive_Correlation	D014517	p|INDEL|46_48|Glu	Novel
26199894	Negative_Correlation	20371	26191	Novel
26199894	Association	D014517	p|SUB|A|30|P	Novel

61148382|t|Dynein, MyD88, and 5-HT2: Multifaceted associations with non-melanoma skin cancers, anemia, bone deformities, and Coronary Heart
61148382|a|This study explores the complex interplay between dynein, MyD88, and 5-HT2 in the context of various diseases and phenotypic features. We demonstrate a positive correlation between dynein and anemia, suggesting a potential role for dynein in the pathophysiology of anemia. Additionally, we find a positive correlation between dynein and bone deformities, indicating a possible involvement of dynein in skeletal development and maintenance. The association between non-melanoma skin cancers and dynein is further supported by our findings, highlighting a potential link between dynein dysfunction and skin cancer progression.   We also report a positive correlation between anemia and 5-HT2, as well as a positive correlation between anemia and MyD88, suggesting that these gene products may be involved in the same biological pathways that contribute to anemia. Furthermore, we observe a positive correlation between 5-HT2 and anemia, reinforcing the association between these two entities. The study also reveals a positive correlation between apical ballooning syndrome and 5-HT2, indicating a potential role for 5-HT2 in cardiac dysfunction.   In addition, we find a positive correlation between Coronary Heart Disease and 5-HT2, as well as an association between Coronary Heart Disease and dynein. These findings suggest that dynein and 5-HT2 may be involved in the pathogenesis of cardiovascular diseases. The association between VLCAD-deficient and dynein is also noted, along with a positive correlation between VLCAD-deficient and 5-HT2, indicating a possible interaction between these gene products in metabolic disorders.   Moreover, we observe a positive correlation between bone deformities and RUNX2, and a positive correlation between agitation and RUNX2, suggesting that RUNX2 may play a role in both skeletal development and neurological conditions. Finally, we find a positive correlation between agitation and dynein, further expanding the network of interactions involving dynein. These results provide new insights into the molecular mechanisms underlying these diseases and highlight the importance of these gene products in their pathogenesis.
61148382	8	13	MyD88	GeneOrGeneProduct	301059
61148382	19	24	5-HT2	GeneOrGeneProduct	29595
61148382	57	82	non-melanoma skin cancers	DiseaseOrPhenotypicFeature	D012878
61148382	84	90	anemia	DiseaseOrPhenotypicFeature	D000740
61148382	92	108	bone deformities	DiseaseOrPhenotypicFeature	D001847
61148382	179	185	dynein	GeneOrGeneProduct	172041
61148382	187	192	MyD88	GeneOrGeneProduct	301059
61148382	198	203	5-HT2	GeneOrGeneProduct	29595
61148382	310	316	dynein	GeneOrGeneProduct	172041
61148382	321	327	anemia	DiseaseOrPhenotypicFeature	D000740
61148382	361	367	dynein	GeneOrGeneProduct	172041
61148382	394	400	anemia	DiseaseOrPhenotypicFeature	D000740
61148382	455	461	dynein	GeneOrGeneProduct	172041
61148382	466	482	bone deformities	DiseaseOrPhenotypicFeature	D001847
61148382	521	527	dynein	GeneOrGeneProduct	172041
61148382	593	618	non-melanoma skin cancers	DiseaseOrPhenotypicFeature	D012878
61148382	623	629	dynein	GeneOrGeneProduct	172041
61148382	706	712	dynein	GeneOrGeneProduct	172041
61148382	802	808	anemia	DiseaseOrPhenotypicFeature	D000740
61148382	813	818	5-HT2	GeneOrGeneProduct	29595
61148382	862	868	anemia	DiseaseOrPhenotypicFeature	D000740
61148382	873	878	MyD88	GeneOrGeneProduct	301059
61148382	983	989	anemia	DiseaseOrPhenotypicFeature	D000740
61148382	1046	1051	5-HT2	GeneOrGeneProduct	29595
61148382	1056	1062	anemia	DiseaseOrPhenotypicFeature	D000740
61148382	1174	1200	apical ballooning syndrome	DiseaseOrPhenotypicFeature	D054549
61148382	1205	1210	5-HT2	GeneOrGeneProduct	29595
61148382	1244	1249	5-HT2	GeneOrGeneProduct	29595
61148382	1328	1350	Coronary Heart Disease	DiseaseOrPhenotypicFeature	D003324
61148382	1355	1360	5-HT2	GeneOrGeneProduct	29595
61148382	1396	1418	Coronary Heart Disease	DiseaseOrPhenotypicFeature	D003324
61148382	1423	1429	dynein	GeneOrGeneProduct	172041
61148382	1459	1465	dynein	GeneOrGeneProduct	172041
61148382	1470	1475	5-HT2	GeneOrGeneProduct	29595
61148382	1564	1579	VLCAD-deficient	DiseaseOrPhenotypicFeature	C536353
61148382	1584	1590	dynein	GeneOrGeneProduct	172041
61148382	1648	1663	VLCAD-deficient	DiseaseOrPhenotypicFeature	C536353
61148382	1668	1673	5-HT2	GeneOrGeneProduct	29595
61148382	1815	1831	bone deformities	DiseaseOrPhenotypicFeature	D001847
61148382	1836	1841	RUNX2	GeneOrGeneProduct	860
61148382	1878	1887	agitation	DiseaseOrPhenotypicFeature	D011595
61148382	1892	1897	RUNX2	GeneOrGeneProduct	860
61148382	1915	1920	RUNX2	GeneOrGeneProduct	860
61148382	2043	2052	agitation	DiseaseOrPhenotypicFeature	D011595
61148382	2057	2063	dynein	GeneOrGeneProduct	172041
61148382	2121	2127	dynein	GeneOrGeneProduct	172041
61148382	Association	D000740	29595	Novel
61148382	Positive_Correlation	D000740	29595	Novel
61148382	Positive_Correlation	172041	D000740	Novel
61148382	Positive_Correlation	D011595	860	Novel
61148382	Association	D012878	172041	Novel
61148382	Positive_Correlation	D000740	301059	Novel
61148382	Positive_Correlation	172041	D001847	Novel
61148382	Positive_Correlation	C536353	172041	Novel
61148382	Positive_Correlation	D001847	860	Novel
61148382	Association	D011595	860	Novel
61148382	Positive_Correlation	D011595	172041	Novel
61148382	Positive_Correlation	D054549	29595	Novel
61148382	Positive_Correlation	301059	C536353	Novel
61148382	Positive_Correlation	D054549	860	Novel
61148382	Association	D003324	29595	Novel
61148382	Association	C536353	29595	Novel
61148382	Positive_Correlation	29595	D000740	Novel
61148382	Positive_Correlation	D003324	29595	Novel
61148382	Bind	172041	29595	Novel
61148382	Positive_Correlation	D012878	29595	Novel
61148382	Association	D003324	172041	Novel

07738174|t|Genetic and functional analysis of Drosophila and human models in radiculopathy, nephronophthisis with liver fibrosis, and cataract-microcornea 
07738174|a|This study investigates the genetic and functional relationships between specific sequence variants, gene products, and disease phenotypes in both Drosophila and human models. We focus on the association between the adenine 474 deletion and radiculopathy, as well as its role in nephronophthisis with liver fibrosis. Additionally, we explore the impact of the A53T sequence variant on nephronophthisis with liver fibrosis and cataract-microcornea syndrome. The gene 4E-BP1 is found to be associated with both nephronophthisis with liver fibrosis and radiculopathy, highlighting its potential role in these conditions. The CRB1 gene is linked to cataract-microcornea syndrome and nephronophthisis with liver fibrosis, suggesting a broader involvement in these phenotypes. The Brat gene product is associated with radiculopathy, cataract-microcornea syndrome, and nephronophthisis with liver fibrosis, indicating its multifaceted role in disease pathogenesis. The alanine for valine at position 88 sequence variant is implicated in both radiculopathy and nephronophthisis with liver fibrosis. Furthermore, the adenine 474 deletion is also associated with cataract-microcornea syndrome, and the A53T variant is linked to radiculopathy. These findings are supported by experiments using the hRPTEC cell line and MEF cell lines, as well as the Drosophila model. The study also includes the use of Rhodiola rosea in assessing potential therapeutic interventions. These results provide a comprehensive understanding of the genetic underpinnings of these diseases and their potential therapeutic targets.
07738174	35	45	Drosophila	OrganismTaxon	7227
07738174	66	79	radiculopathy	DiseaseOrPhenotypicFeature	D011843
07738174	81	117	nephronophthisis with liver fibrosis	DiseaseOrPhenotypicFeature	OMIM:613550
07738174	292	302	Drosophila	OrganismTaxon	7227
07738174	361	381	adenine 474 deletion	SequenceVariant	rs587777017
07738174	386	399	radiculopathy	DiseaseOrPhenotypicFeature	D011843
07738174	424	460	nephronophthisis with liver fibrosis	DiseaseOrPhenotypicFeature	OMIM:613550
07738174	505	509	A53T	SequenceVariant	p|SUB|A|53|T
07738174	530	566	nephronophthisis with liver fibrosis	DiseaseOrPhenotypicFeature	OMIM:613550
07738174	571	600	cataract-microcornea syndrome	DiseaseOrPhenotypicFeature	C538287
07738174	611	617	4E-BP1	GeneOrGeneProduct	116636
07738174	654	690	nephronophthisis with liver fibrosis	DiseaseOrPhenotypicFeature	OMIM:613550
07738174	695	708	radiculopathy	DiseaseOrPhenotypicFeature	D011843
07738174	767	771	CRB1	GeneOrGeneProduct	23418
07738174	790	819	cataract-microcornea syndrome	DiseaseOrPhenotypicFeature	C538287
07738174	824	860	nephronophthisis with liver fibrosis	DiseaseOrPhenotypicFeature	OMIM:613550
07738174	920	924	Brat	GeneOrGeneProduct	35197
07738174	957	970	radiculopathy	DiseaseOrPhenotypicFeature	D011843
07738174	972	1001	cataract-microcornea syndrome	DiseaseOrPhenotypicFeature	C538287
07738174	1007	1043	nephronophthisis with liver fibrosis	DiseaseOrPhenotypicFeature	OMIM:613550
07738174	1107	1140	alanine for valine at position 88	SequenceVariant	p|SUB|A|88|V
07738174	1180	1193	radiculopathy	DiseaseOrPhenotypicFeature	D011843
07738174	1198	1234	nephronophthisis with liver fibrosis	DiseaseOrPhenotypicFeature	OMIM:613550
07738174	1253	1273	adenine 474 deletion	SequenceVariant	rs587777017
07738174	1298	1327	cataract-microcornea syndrome	DiseaseOrPhenotypicFeature	C538287
07738174	1337	1341	A53T	SequenceVariant	p|SUB|A|53|T
07738174	1363	1376	radiculopathy	DiseaseOrPhenotypicFeature	D011843
07738174	1432	1438	hRPTEC	CellLine	CVCL_K278
07738174	1453	1456	MEF	CellLine	CVCL_9115
07738174	1484	1494	Drosophila	OrganismTaxon	7227
07738174	1537	1551	Rhodiola rosea	OrganismTaxon	203015
07738174	Association	23418	C538287	Novel
07738174	Association	rs587777017	D011843	Novel
07738174	Association	35197	D011843	Novel
07738174	Association	35197	C538287	Novel
07738174	Association	35197	OMIM:613550	Novel
07738174	Association	116636	OMIM:613550	Novel
07738174	Association	p|SUB|A|53|T	OMIM:613550	Novel
07738174	Association	p|SUB|A|53|T	D011843	Novel
07738174	Association	rs587777017	OMIM:613550	Novel
07738174	Association	p|SUB|A|88|V	D011843	Novel
07738174	Association	p|SUB|A|53|T	C538287	Novel
07738174	Association	23418	OMIM:613550	Novel
07738174	Association	p|SUB|A|88|V	C538287	Novel
07738174	Association	23418	D011843	Novel
07738174	Association	116636	D011843	Novel
07738174	Association	rs587777017	C538287	Novel
07738174	Association	116636	C538287	Novel
07738174	Association	p|SUB|A|88|V	OMIM:613550	Novel

27816699|t|Exploring the Interplay Between Fat, ADP, and NELARABINE in the Context of Cystic Fibrosis, AVSDs, and Attention-Deficit/Hyperactivity 
27816699|a|This study investigates the complex interactions between fat, ADP, and nelarabine in the context of various disease states, including cystic fibrosis, AVSDs, and attention-deficit/hyperactivity disorder. The research highlights the drug interaction between fat and nelarabine, as well as the drug interaction between ADP and nelarabine, which is further compared with the effects of efavirenz. The association between cystic fibrosis and L180M is explored, along with the link between cystic fibrosis and A6V, which is also associated with fat. The sequence variant Ile/Val is found to be associated with both efavirenz and ADP, and it is also linked to diarrhea and AVSDs. The comparison between ADP and nelarabine is central to understanding their roles in cellular processes, while the comparison between ADP and fat reveals distinct metabolic pathways. The drug interaction between nelarabine and fat is further supported by the association between Ile/Val and fat. The study also examines the association between AVSDs and L180M, as well as the association between AVSDs and Ile/Val. The comparison between efavirenz and ADP, along with the comparison between efavirenz and nelarabine, provides insights into the pharmacological profiles of these compounds. The association between L180M and efavirenz, as well as the association between L180M and ADP, underscores the role of these sequence variants in disease mechanisms. Additionally, the association between diarrhea and Ile/Val, and between diarrhea and L180M, further expands the understanding of these genetic and metabolic interactions. The findings suggest that the interplay between fat, ADP, and nelarabine is critical in the pathophysiology of multiple conditions, including cystic fibrosis, AVSDs, and attention-deficit/hyperactivity disorder, with significant implications for therapeutic strategies.
27816699	37	40	ADP	ChemicalEntity	D000244
27816699	92	97	AVSDs	DiseaseOrPhenotypicFeature	C562831
27816699	193	196	fat	ChemicalEntity	D004041
27816699	198	201	ADP	ChemicalEntity	D000244
27816699	207	217	nelarabine	ChemicalEntity	C104457
27816699	270	285	cystic fibrosis	DiseaseOrPhenotypicFeature	D003550
27816699	287	292	AVSDs	DiseaseOrPhenotypicFeature	C562831
27816699	298	338	attention-deficit/hyperactivity disorder	DiseaseOrPhenotypicFeature	D001289
27816699	393	396	fat	ChemicalEntity	D004041
27816699	401	411	nelarabine	ChemicalEntity	C104457
27816699	453	456	ADP	ChemicalEntity	D000244
27816699	461	471	nelarabine	ChemicalEntity	C104457
27816699	519	528	efavirenz	ChemicalEntity	C098320
27816699	554	569	cystic fibrosis	DiseaseOrPhenotypicFeature	D003550
27816699	574	579	L180M	SequenceVariant	p|SUB|L|180|M
27816699	621	636	cystic fibrosis	DiseaseOrPhenotypicFeature	D003550
27816699	641	644	A6V	SequenceVariant	rs199922907
27816699	676	679	fat	ChemicalEntity	D004041
27816699	702	709	Ile/Val	SequenceVariant	rs1048943
27816699	746	755	efavirenz	ChemicalEntity	C098320
27816699	760	763	ADP	ChemicalEntity	D000244
27816699	790	798	diarrhea	DiseaseOrPhenotypicFeature	D003967
27816699	803	808	AVSDs	DiseaseOrPhenotypicFeature	C562831
27816699	833	836	ADP	ChemicalEntity	D000244
27816699	841	851	nelarabine	ChemicalEntity	C104457
27816699	944	947	ADP	ChemicalEntity	D000244
27816699	952	955	fat	ChemicalEntity	D004041
27816699	1022	1032	nelarabine	ChemicalEntity	C104457
27816699	1037	1040	fat	ChemicalEntity	D004041
27816699	1089	1096	Ile/Val	SequenceVariant	rs1048943
27816699	1101	1104	fat	ChemicalEntity	D004041
27816699	1154	1159	AVSDs	DiseaseOrPhenotypicFeature	C562831
27816699	1164	1169	L180M	SequenceVariant	p|SUB|L|180|M
27816699	1206	1211	AVSDs	DiseaseOrPhenotypicFeature	C562831
27816699	1216	1223	Ile/Val	SequenceVariant	rs1048943
27816699	1248	1257	efavirenz	ChemicalEntity	C098320
27816699	1262	1265	ADP	ChemicalEntity	D000244
27816699	1301	1310	efavirenz	ChemicalEntity	C098320
27816699	1315	1325	nelarabine	ChemicalEntity	C104457
27816699	1423	1428	L180M	SequenceVariant	p|SUB|L|180|M
27816699	1433	1442	efavirenz	ChemicalEntity	C098320
27816699	1479	1484	L180M	SequenceVariant	p|SUB|L|180|M
27816699	1489	1492	ADP	ChemicalEntity	D000244
27816699	1603	1611	diarrhea	DiseaseOrPhenotypicFeature	D003967
27816699	1616	1623	Ile/Val	SequenceVariant	rs1048943
27816699	1637	1645	diarrhea	DiseaseOrPhenotypicFeature	D003967
27816699	1650	1655	L180M	SequenceVariant	p|SUB|L|180|M
27816699	1784	1787	fat	ChemicalEntity	D004041
27816699	1789	1792	ADP	ChemicalEntity	D000244
27816699	1798	1808	nelarabine	ChemicalEntity	C104457
27816699	1878	1893	cystic fibrosis	DiseaseOrPhenotypicFeature	D003550
27816699	1895	1900	AVSDs	DiseaseOrPhenotypicFeature	C562831
27816699	1906	1946	attention-deficit/hyperactivity disorder	DiseaseOrPhenotypicFeature	D001289
27816699	Comparison	D000244	C104457	Novel
27816699	Drug_Interaction	D004041	C104457	Novel
27816699	Comparison	C104457	C098320	Novel
27816699	Association	D009503	rs199922907	Novel
27816699	Association	D003550	rs199922907	Novel
27816699	Association	rs199922907	D004041	Novel
27816699	Association	rs1048943	C098320	Novel
27816699	Association	D003550	p|SUB|L|180|M	Novel
27816699	Comparison	C104457	D000244	Novel
27816699	Association	D001289	p|SUB|L|180|M	Novel
27816699	Association	rs1048943	D000244	Novel
27816699	Drug_Interaction	D004041	D000244	Novel
27816699	Association	rs199922907	C104457	Novel
27816699	Association	D003550	rs1048943	Novel
27816699	Association	rs1048943	D004041	Novel
27816699	Association	C562831	p|SUB|L|180|M	Novel
27816699	Association	C562831	rs1048943	Novel
27816699	Comparison	C098320	D000244	Novel
27816699	Drug_Interaction	C104457	C098320	Novel
27816699	Association	p|SUB|L|180|M	C098320	Novel
27816699	Drug_Interaction	D000244	C104457	Novel
27816699	Drug_Interaction	C104457	D004041	Novel
27816699	Association	p|SUB|L|180|M	D000244	Novel
27816699	Comparison	C098320	C104457	Novel
27816699	Comparison	D000244	D004041	Novel
27816699	Association	D003967	rs1048943	Novel
27816699	Association	D003967	p|SUB|L|180|M	Novel

71363342|t|miR-192 and NVP interactions in guinea pigs: implications for 5 nucleotide deletion and cell line r
71363342|a|This study investigates the molecular interactions between miR-192 and the chemical entity NVP in the context of a 5 nucleotide deletion in guinea pigs. We focused on the effects of this genetic variant on the expression and function of miR-192, particularly in relation to NVP treatment. The negative correlation between miR-192 and NVP was observed in multiple experimental models, including the cell lines Ba/F3, MCF7/AdrR, and KU7. The 5 nucleotide deletion was found to modulate the expression levels of miR-192, which in turn influenced the cellular response to NVP. These findings were validated in both guinea pig and guinea pigs models, highlighting the importance of genetic background in determining the pharmacological outcomes of NVP. The study also demonstrated that the presence of the 5 nucleotide deletion significantly altered the sensitivity of Ba/F3 and MCF7/AdrR cells to NVP, suggesting a potential mechanism for differential drug responses. These results provide new insights into the interplay between miR-192, NVP, and genetic variants in cellular systems, with implications for personalized medicine approaches in guinea pig models.
71363342	0	7	miR-192	GeneOrGeneProduct	387187
71363342	12	15	NVP	ChemicalEntity	D019829
71363342	32	42	guinea pig	OrganismTaxon	10141
71363342	32	43	guinea pigs	OrganismTaxon	10141
71363342	62	83	5 nucleotide deletion	SequenceVariant	c|DEL||5
71363342	159	166	miR-192	GeneOrGeneProduct	387187
71363342	191	194	NVP	ChemicalEntity	D019829
71363342	215	236	5 nucleotide deletion	SequenceVariant	c|DEL||5
71363342	240	250	guinea pig	OrganismTaxon	10141
71363342	240	251	guinea pigs	OrganismTaxon	10141
71363342	337	344	miR-192	GeneOrGeneProduct	387187
71363342	374	377	NVP	ChemicalEntity	D019829
71363342	422	429	miR-192	GeneOrGeneProduct	387187
71363342	434	437	NVP	ChemicalEntity	D019829
71363342	509	514	Ba/F3	CellLine	CVCL_0161
71363342	516	525	MCF7/AdrR	CellLine	 CVCL_1452
71363342	531	534	KU7	CellLine	CVCL_4714
71363342	540	561	5 nucleotide deletion	SequenceVariant	c|DEL||5
71363342	609	616	miR-192	GeneOrGeneProduct	387187
71363342	668	671	NVP	ChemicalEntity	D019829
71363342	711	721	guinea pig	OrganismTaxon	10141
71363342	726	736	guinea pig	OrganismTaxon	10141
71363342	726	737	guinea pigs	OrganismTaxon	10141
71363342	843	846	NVP	ChemicalEntity	D019829
71363342	901	922	5 nucleotide deletion	SequenceVariant	c|DEL||5
71363342	964	969	Ba/F3	CellLine	CVCL_0161
71363342	974	983	MCF7/AdrR	CellLine	 CVCL_1452
71363342	993	996	NVP	ChemicalEntity	D019829
71363342	1126	1133	miR-192	GeneOrGeneProduct	387187
71363342	1135	1138	NVP	ChemicalEntity	D019829
71363342	1240	1250	guinea pig	OrganismTaxon	10141
71363342	Association	c|DEL||5	D019829	Novel
71363342	Negative_Correlation	387187	D019829	Novel

20168609|t|Genetic and pharmacological interactions in neuromuscular function and metabolic d
20168609|a|This study investigates the complex interplay between genetic variants, pharmacological agents, and metabolic phenotypes in the context of neuromuscular block, immunodeficiency, and impaired glucose tolerance. A key focus is the positive correlation between neuromuscular block and the sequence variant c.1239 +1G>A, which was observed in a cohort of patients with neuromuscular disorders. Additionally, the sequence variant C282Y was found to be positively correlated with neuromuscular block, suggesting a potential role in modulating neuromuscular function.   The relationship between immunodeficiency and glycine (Gly) with arginine (Arg) was also explored, revealing a significant positive correlation. This finding may have implications for the treatment of immunodeficiency syndromes. Furthermore, the study found a positive correlation between immunodeficiency and xanthine oxidase, indicating a possible involvement of this enzyme in immune regulation.   A comparison between antibiotic and Ca2+ was conducted, highlighting the potential for antibiotic-induced changes in calcium homeostasis. Similarly, a comparison between xanthine oxidase and cytochalasin B was made, with evidence suggesting a functional interaction between these two entities. The study also found a positive correlation between impaired glucose tolerance and xanthine oxidase, which may point to a role for this enzyme in glucose metabolism.   The relationship between cytochalasin B and Ca2+ was further examined, revealing a significant comparison in their effects on cellular processes. Additionally, the positive correlation between diarrhea and antibiotic was confirmed, underscoring the role of antibiotics in gastrointestinal disturbances.   The study also included multiple instances of the sequence variant 46delS, which was associated with various phenotypes, and the sequence variant rs4704559, which was found in multiple genetic analyses. The chemical entities Ca2+ and potassium were frequently mentioned, with their roles in neuromuscular and metabolic functions being emphasized.   In conclusion, this research provides a comprehensive overview of the genetic and pharmacological factors influencing neuromuscular block, immunodeficiency, and metabolic disorders, offering new insights into the molecular mechanisms underlying these conditions.
20168609	222	241	neuromuscular block	DiseaseOrPhenotypicFeature	D055191
20168609	243	259	immunodeficiency	DiseaseOrPhenotypicFeature	D007153
20168609	265	291	impaired glucose tolerance	DiseaseOrPhenotypicFeature	D018149
20168609	341	360	neuromuscular block	DiseaseOrPhenotypicFeature	D055191
20168609	386	398	c.1239 +1G>A	SequenceVariant	c|SUB|G|1239+1|A
20168609	508	513	C282Y	SequenceVariant	rs1800562
20168609	557	576	neuromuscular block	DiseaseOrPhenotypicFeature	D055191
20168609	671	687	immunodeficiency	DiseaseOrPhenotypicFeature	D007153
20168609	692	725	glycine (Gly) with arginine (Arg)	SequenceVariant	rs351855
20168609	847	863	immunodeficiency	DiseaseOrPhenotypicFeature	D007153
20168609	935	951	immunodeficiency	DiseaseOrPhenotypicFeature	D007153
20168609	956	972	xanthine oxidase	ChemicalEntity	D014969
20168609	1068	1078	antibiotic	ChemicalEntity	D000900
20168609	1083	1087	Ca2+	ChemicalEntity	D000069285
20168609	1134	1144	antibiotic	ChemicalEntity	D000900
20168609	1217	1233	xanthine oxidase	ChemicalEntity	D014969
20168609	1238	1252	cytochalasin B	ChemicalEntity	D003571
20168609	1393	1419	impaired glucose tolerance	DiseaseOrPhenotypicFeature	D018149
20168609	1424	1440	xanthine oxidase	ChemicalEntity	D014969
20168609	1534	1548	cytochalasin B	ChemicalEntity	D003571
20168609	1553	1557	Ca2+	ChemicalEntity	D000069285
20168609	1702	1710	diarrhea	DiseaseOrPhenotypicFeature	D003967
20168609	1715	1725	antibiotic	ChemicalEntity	D000900
20168609	1766	1776	antibiotic	ChemicalEntity	D000900
20168609	1881	1887	46delS	SequenceVariant	|DEL|46|S
20168609	1960	1969	rs4704559	SequenceVariant	rs4704559
20168609	2039	2043	Ca2+	ChemicalEntity	D000069285
20168609	2048	2057	potassium	ChemicalEntity	D011188
20168609	2281	2300	neuromuscular block	DiseaseOrPhenotypicFeature	D055191
20168609	2302	2318	immunodeficiency	DiseaseOrPhenotypicFeature	D007153
20168609	Positive_Correlation	D055191	rs1800562	Novel
20168609	Comparison	D000900	D000069285	Novel
20168609	Positive_Correlation	D007153	rs351855	Novel
20168609	Comparison	D014969	D003571	Novel
20168609	Positive_Correlation	D055191	c|SUB|G|1239+1|A	Novel
20168609	Positive_Correlation	D018149	D014969	Novel
20168609	Comparison	D003571	D000069285	Novel
20168609	Positive_Correlation	D003967	D000900	Novel
20168609	Positive_Correlation	D007153	D014969	Novel

53607905|t|Genetic variants in Toxorynchites mosquitoes and their associations with Alpers' syndrome and C4-2B cell line r
53607905|a|This study investigates the genetic and phenotypic associations between sequence variants in Toxorynchites mosquitoes and the development of Alpers' syndrome, with a focus on the impact of these variants on the behavior of C4-2B and BALB/c cell lines. We identified a significant positive correlation between the sequence variant p.A365E and the occurrence of Alpers' syndrome, as well as a negative correlation between p.A365E and Alpers' syndrome in certain experimental conditions. These findings suggest a complex interplay between genetic factors and disease manifestation. Additionally, we observed a strong association between p.A365E and the sequence variant G/C, which was further linked to a positive correlation with Alpers' syndrome. The presence of G/C was found to be associated with both p.A365E and Alpers' syndrome, indicating a potential genetic pathway that may contribute to the pathogenesis of the disease. Our results were validated using multiple cell lines, including C4-2B, BALB/c, and SNU-C2A, which were exposed to varying concentrations of the sequence variants. The data suggest that the interaction between p.A365E and G/C may play a critical role in the progression of Alpers' syndrome, and further studies are warranted to explore the molecular mechanisms underlying these associations. The findings also highlight the importance of considering genetic variability in Toxorynchites mosquitoes when studying the etiology of Alpers' syndrome and its cellular responses.
53607905	20	44	Toxorynchites mosquitoes	OrganismTaxon	2498889
53607905	73	89	Alpers' syndrome	DiseaseOrPhenotypicFeature	D002549
53607905	94	99	C4-2B	CellLine	CVCL_4784
53607905	205	229	Toxorynchites mosquitoes	OrganismTaxon	2498889
53607905	253	269	Alpers' syndrome	DiseaseOrPhenotypicFeature	D002549
53607905	335	340	C4-2B	CellLine	CVCL_4784
53607905	345	351	BALB/c	CellLine	CVCL_9101
53607905	442	449	p.A365E	SequenceVariant	p|SUB|A|365|E
53607905	472	488	Alpers' syndrome	DiseaseOrPhenotypicFeature	D002549
53607905	532	539	p.A365E	SequenceVariant	p|SUB|A|365|E
53607905	544	560	Alpers' syndrome	DiseaseOrPhenotypicFeature	D002549
53607905	746	753	p.A365E	SequenceVariant	p|SUB|A|365|E
53607905	779	782	G/C	SequenceVariant	g|SUB|G||C
53607905	840	856	Alpers' syndrome	DiseaseOrPhenotypicFeature	D002549
53607905	874	877	G/C	SequenceVariant	g|SUB|G||C
53607905	915	922	p.A365E	SequenceVariant	p|SUB|A|365|E
53607905	927	943	Alpers' syndrome	DiseaseOrPhenotypicFeature	D002549
53607905	1104	1109	C4-2B	CellLine	CVCL_4784
53607905	1111	1117	BALB/c	CellLine	CVCL_9101
53607905	1123	1130	SNU-C2A	CellLine	CVCL_1709
53607905	1249	1256	p.A365E	SequenceVariant	p|SUB|A|365|E
53607905	1261	1264	G/C	SequenceVariant	g|SUB|G||C
53607905	1312	1328	Alpers' syndrome	DiseaseOrPhenotypicFeature	D002549
53607905	1512	1536	Toxorynchites mosquitoes	OrganismTaxon	2498889
53607905	1567	1583	Alpers' syndrome	DiseaseOrPhenotypicFeature	D002549
53607905	Positive_Correlation	p|SUB|A|365|E	D002549	Novel
53607905	Association	p|SUB|A|365|E	g|SUB|G||C	Novel
53607905	Negative_Correlation	p|SUB|A|365|E	D002549	Novel
53607905	Positive_Correlation	g|SUB|G||C	D002549	Novel
53607905	Association	D002549	p|SUB|A|365|E	Novel
53607905	Association	g|SUB|G||C	p|SUB|A|365|E	Novel

48508876|t|Cardiogenic shock and sequence variants in Danio rerio: a multi-organism study on oxygen dynamics and olanzapine
48508876|a|Cardiogenic shock is a critical condition that has been increasingly linked to various sequence variants across multiple organisms. This study investigates the relationship between cardiogenic shock and several sequence variants, including H194Q, p.Thr26, Val539Asp, K294E, and G7958, in the context of Danio rerio and other organisms. The findings reveal a positive correlation between cardiogenic shock and each of these sequence variants, suggesting a potential molecular mechanism underlying the pathophysiology of the condition.   In Danio rerio, the presence of Val539Asp was associated with altered oxygen metabolism, which may contribute to the development of cardiogenic shock. Similarly, the sequence variant H194Q showed a strong positive correlation with cardiogenic shock, particularly in the presence of reduced oxygen availability. The variant p.Thr26 was also found to be significantly correlated with the onset of cardiogenic shock, especially in environments with fluctuating oxygen levels.   The study further examined the impact of olanzapine on these sequence variants and their association with cardiogenic shock. Olanzapine was found to modulate the expression of certain variants, potentially influencing the severity of cardiogenic shock. Additionally, the sequence variant K294E was linked to increased susceptibility to cardiogenic shock, particularly in Spirulina-exposed organisms.   The variant G7958 was also found to be positively correlated with cardiogenic shock, with its effects being more pronounced in West Nile virus-infected individuals. The study highlights the complex interplay between genetic variants, environmental factors, and physiological responses in the context of cardiogenic shock. These findings provide a foundation for further research into the molecular mechanisms underlying cardiogenic shock and its potential therapeutic targets.
48508876	43	54	Danio rerio	OrganismTaxon	7955
48508876	82	88	oxygen	ChemicalEntity	D010100
48508876	102	112	olanzapine	ChemicalEntity	C076029
48508876	294	311	cardiogenic shock	DiseaseOrPhenotypicFeature	D012770
48508876	353	358	H194Q	SequenceVariant	rs74315522
48508876	360	367	p.Thr26	SequenceVariant	p|Allele|T|26
48508876	369	378	Val539Asp	SequenceVariant	p|SUB|V|539|D
48508876	380	385	K294E	SequenceVariant	rs143544690
48508876	391	396	G7958	SequenceVariant	c|Aelle|G|7958
48508876	416	427	Danio rerio	OrganismTaxon	7955
48508876	500	517	cardiogenic shock	DiseaseOrPhenotypicFeature	D012770
48508876	652	663	Danio rerio	OrganismTaxon	7955
48508876	681	690	Val539Asp	SequenceVariant	p|SUB|V|539|D
48508876	719	725	oxygen	ChemicalEntity	D010100
48508876	781	798	cardiogenic shock	DiseaseOrPhenotypicFeature	D012770
48508876	832	837	H194Q	SequenceVariant	rs74315522
48508876	880	897	cardiogenic shock	DiseaseOrPhenotypicFeature	D012770
48508876	939	945	oxygen	ChemicalEntity	D010100
48508876	972	979	p.Thr26	SequenceVariant	p|Allele|T|26
48508876	1044	1061	cardiogenic shock	DiseaseOrPhenotypicFeature	D012770
48508876	1107	1113	oxygen	ChemicalEntity	D010100
48508876	1165	1175	olanzapine	ChemicalEntity	C076029
48508876	1230	1247	cardiogenic shock	DiseaseOrPhenotypicFeature	D012770
48508876	1358	1375	cardiogenic shock	DiseaseOrPhenotypicFeature	D012770
48508876	1412	1417	K294E	SequenceVariant	rs143544690
48508876	1460	1477	cardiogenic shock	DiseaseOrPhenotypicFeature	D012770
48508876	1495	1504	Spirulina	OrganismTaxon	551299
48508876	1538	1543	G7958	SequenceVariant	c|Aelle|G|7958
48508876	1592	1609	cardiogenic shock	DiseaseOrPhenotypicFeature	D012770
48508876	1653	1668	West Nile virus	OrganismTaxon	11082
48508876	1829	1846	cardiogenic shock	DiseaseOrPhenotypicFeature	D012770
48508876	1946	1963	cardiogenic shock	DiseaseOrPhenotypicFeature	D012770
48508876	Positive_Correlation	D012770	rs74315522	Novel
48508876	Positive_Correlation	D012770	p|Allele|T|26	Novel
48508876	Positive_Correlation	D012770	p|SUB|V|539|D	Novel
48508876	Positive_Correlation	D012770	rs143544690	Novel
48508876	Positive_Correlation	D012770	c|Aelle|G|7958	Novel

26265060|t|Genetic Variants in C. elegans and Human Cell Lines: Associations with Neurodevelopmental Disorders and Viral In
26265060|a|This study investigates the genetic and phenotypic associations between specific sequence variants, cell lines, and disease states in both human and model organisms. We focus on the impact of sequence variants such as p.W826S, c.1146+25insA, G158R, S140G, R462Q, and D299G on the development of neurodevelopmental disorders including unipolar depression, bipolar I disorder, IRIDA, and JBTS. Additionally, we explore the role of these variants in the context of viral infections, particularly West Nile virus and mouse mammary tumor virus, using cell lines such as DUCaP, HEK293, and COS-7.   Our findings reveal a significant association between the sequence variant D299G and both bipolar I disorder and unipolar depression, suggesting a potential genetic link between these conditions. Furthermore, the variant R462Q is associated with S140G, as well as with bipolar I disorder and unipolar depression, indicating a possible functional interaction between these variants. The variant c.1146+25insA is strongly linked to IRIDA, while G158R is also associated with IRIDA, highlighting the importance of these variants in the pathogenesis of this rare disorder.   In addition, the sequence variant p.W826S is found to be associated with both S140G and R462Q, suggesting a complex network of genetic interactions. The study also demonstrates that the variant D299G is associated with JBTS, further expanding the genetic basis of this condition.   To validate these associations, we used the DUCaP cell line, which is known for its relevance in studying neurodevelopmental processes, and the HEK293 and COS-7 cell lines, which are widely used in virology and molecular biology. The use of C. elegans as a model organism allowed us to explore the functional consequences of these variants in a simpler genetic background, with multiple instances of C. elegans used to ensure robustness of the results.   The study also includes multiple instances of West Nile virus and mouse mammary tumor virus, with the latter being associated with the DUCaP cell line. The presence of Daucus carota in the study highlights the potential for cross-species comparisons in genetic research. Overall, this work provides a comprehensive analysis of the genetic and phenotypic relationships between sequence variants, cell lines, and disease states, offering new insights into the molecular mechanisms underlying these conditions.
26265060	20	30	C. elegans	OrganismTaxon	6239
26265060	331	338	p.W826S	SequenceVariant	p|SUB|W|826|S
26265060	340	353	c.1146+25insA	SequenceVariant	c|INS|1146+25|A
26265060	355	360	G158R	SequenceVariant	p|SUB|G|158|R
26265060	362	367	S140G	SequenceVariant	p|SUB|S|140|G
26265060	369	374	R462Q	SequenceVariant	rs486907
26265060	380	385	D299G	SequenceVariant	rs4986790
26265060	447	466	unipolar depression	DiseaseOrPhenotypicFeature	D003866
26265060	468	486	bipolar I disorder	DiseaseOrPhenotypicFeature	D001714
26265060	488	493	IRIDA	DiseaseOrPhenotypicFeature	C562385
26265060	499	503	JBTS	DiseaseOrPhenotypicFeature	C536293
26265060	606	621	West Nile virus	OrganismTaxon	11082
26265060	626	651	mouse mammary tumor virus	OrganismTaxon	11757
26265060	678	683	DUCaP	CellLine	CVCL_2025
26265060	685	691	HEK293	CellLine	CVCL_0045
26265060	697	702	COS-7	CellLine	CVCL_0224
26265060	781	786	D299G	SequenceVariant	rs4986790
26265060	796	814	bipolar I disorder	DiseaseOrPhenotypicFeature	D001714
26265060	819	838	unipolar depression	DiseaseOrPhenotypicFeature	D003866
26265060	927	932	R462Q	SequenceVariant	rs486907
26265060	952	957	S140G	SequenceVariant	p|SUB|S|140|G
26265060	975	993	bipolar I disorder	DiseaseOrPhenotypicFeature	D001714
26265060	998	1017	unipolar depression	DiseaseOrPhenotypicFeature	D003866
26265060	1100	1113	c.1146+25insA	SequenceVariant	c|INS|1146+25|A
26265060	1136	1141	IRIDA	DiseaseOrPhenotypicFeature	C562385
26265060	1149	1154	G158R	SequenceVariant	p|SUB|G|158|R
26265060	1179	1184	IRIDA	DiseaseOrPhenotypicFeature	C562385
26265060	1311	1318	p.W826S	SequenceVariant	p|SUB|W|826|S
26265060	1355	1360	S140G	SequenceVariant	p|SUB|S|140|G
26265060	1365	1370	R462Q	SequenceVariant	rs486907
26265060	1471	1476	D299G	SequenceVariant	rs4986790
26265060	1496	1500	JBTS	DiseaseOrPhenotypicFeature	C536293
26265060	1603	1608	DUCaP	CellLine	CVCL_2025
26265060	1703	1709	HEK293	CellLine	CVCL_0045
26265060	1714	1719	COS-7	CellLine	CVCL_0224
26265060	1800	1810	C. elegans	OrganismTaxon	6239
26265060	1959	1969	C. elegans	OrganismTaxon	6239
26265060	2060	2075	West Nile virus	OrganismTaxon	11082
26265060	2080	2105	mouse mammary tumor virus	OrganismTaxon	11757
26265060	2149	2154	DUCaP	CellLine	CVCL_2025
26265060	2182	2195	Daucus carota	OrganismTaxon	4039
26265060	Association	D001714	rs4986790	Novel
26265060	Association	D003866	rs4986790	Novel
26265060	Association	rs486907	p|SUB|S|140|G	Novel
26265060	Association	D001714	rs486907	Novel
26265060	Association	C562385	c|INS|1146+25|A	Novel
26265060	Association	rs486907	rs4986790	Novel
26265060	Association	C562385	p|SUB|G|158|R	Novel
26265060	Association	p|SUB|W|826|S	p|SUB|S|140|G	Novel
26265060	Association	p|SUB|W|826|S	rs486907	Novel
26265060	Association	D003866	rs486907	Novel
26265060	Association	C536293	rs4986790	Novel
26265060	Association	D003866	p|SUB|G|158|R	Novel

15046495|t|TRK, NPM, and copper/zinc superoxide dismutase: genetic and pharmacological interactions with learning and memory impairment, cerebellar ataxia, and sequence 
15046495|a|This study investigates the complex genetic and pharmacological interactions between the gene products TRK, NPM, and copper/zinc superoxide dismutase (Cu/Zn SOD) in relation to learning and memory impairment, cerebellar ataxia, and multiple sequence variants. We demonstrate that the sequence variant rs6410 is significantly associated with learning and memory impairment, as well as with TRK, and that rs6410 also shows a strong correlation with learning and memory impairment. Additionally, the sequence variant c.695T>A is found to be associated with both learning and memory impairment and cerebellar ataxia, highlighting its potential role in neurodevelopmental disorders. The gene product TRK is strongly linked to learning and memory impairment, while NPM is associated with cerebellar ataxia. Notably, the sequence variant R47W is also associated with learning and memory impairment, and cerebellar ataxia is linked to R47W. The negative correlation between C5L2 and both NPM and Cu/Zn SOD suggests a regulatory relationship between these gene products. Furthermore, the chemical entity 3,4-methylenedioxymethamphetamine (MDMA) is shown to have a significant association with learning and memory impairment, indicating a potential pharmacological impact on cognitive function. The negative correlation between Cu/Zn SOD and atropine sulphate suggests a possible antagonistic interaction between this enzyme and the chemical entity. Finally, the gene product C5L2 is found to have a negative correlation with Cu/Zn SOD, reinforcing the complex interplay between these molecular entities in neurological processes. These findings provide a comprehensive framework for understanding the genetic and pharmacological underpinnings of learning and memory impairment and cerebellar ataxia.
15046495	0	3	TRK	GeneOrGeneProduct	4914
15046495	5	8	NPM	GeneOrGeneProduct	4869
15046495	14	46	copper/zinc superoxide dismutase	GeneOrGeneProduct	6647
15046495	94	124	learning and memory impairment	DiseaseOrPhenotypicFeature	D007859
15046495	126	143	cerebellar ataxia	DiseaseOrPhenotypicFeature	D002524
15046495	262	265	TRK	GeneOrGeneProduct	4914
15046495	267	270	NPM	GeneOrGeneProduct	4869
15046495	276	308	copper/zinc superoxide dismutase	GeneOrGeneProduct	6647
15046495	336	366	learning and memory impairment	DiseaseOrPhenotypicFeature	D007859
15046495	368	385	cerebellar ataxia	DiseaseOrPhenotypicFeature	D002524
15046495	460	466	rs6410	SequenceVariant	rs6410
15046495	500	530	learning and memory impairment	DiseaseOrPhenotypicFeature	D007859
15046495	548	551	TRK	GeneOrGeneProduct	4914
15046495	562	568	rs6410	SequenceVariant	rs6410
15046495	606	636	learning and memory impairment	DiseaseOrPhenotypicFeature	D007859
15046495	673	681	c.695T>A	SequenceVariant	c|SUB|T|695|A
15046495	718	748	learning and memory impairment	DiseaseOrPhenotypicFeature	D007859
15046495	753	770	cerebellar ataxia	DiseaseOrPhenotypicFeature	D002524
15046495	854	857	TRK	GeneOrGeneProduct	4914
15046495	880	910	learning and memory impairment	DiseaseOrPhenotypicFeature	D007859
15046495	918	921	NPM	GeneOrGeneProduct	4869
15046495	941	958	cerebellar ataxia	DiseaseOrPhenotypicFeature	D002524
15046495	990	994	R47W	SequenceVariant	rs121917720
15046495	1019	1049	learning and memory impairment	DiseaseOrPhenotypicFeature	D007859
15046495	1055	1072	cerebellar ataxia	DiseaseOrPhenotypicFeature	D002524
15046495	1086	1090	R47W	SequenceVariant	rs121917720
15046495	1125	1129	C5L2	GeneOrGeneProduct	27202
15046495	1139	1142	NPM	GeneOrGeneProduct	4869
15046495	1254	1287	3,4-methylenedioxymethamphetamine	ChemicalEntity	D018817
15046495	1343	1373	learning and memory impairment	DiseaseOrPhenotypicFeature	D007859
15046495	1491	1508	atropine sulphate	ChemicalEntity	D001285
15046495	1625	1629	C5L2	GeneOrGeneProduct	27202
15046495	1896	1926	learning and memory impairment	DiseaseOrPhenotypicFeature	D007859
15046495	1931	1948	cerebellar ataxia	DiseaseOrPhenotypicFeature	D002524
15046495	Negative_Correlation	27202	6647	Novel
15046495	Association	c|SUB|T|695|A	D007859	Novel
15046495	Association	4914	D007859	Novel
15046495	Association	4869	D002524	Novel
15046495	Association	D007859	c|SUB|T|695|A	Novel
15046495	Negative_Correlation	27202	4869	Novel
15046495	Association	rs121917720	D007859	Novel
15046495	Association	c|SUB|T|695|A	D002524	Novel
15046495	Negative_Correlation	6647	D001285	Novel
15046495	Association	c|SUB|T|695|A	4914	Novel
15046495	Association	D002524	rs121917720	Novel
15046495	Association	D018817	D007859	Novel
15046495	Association	6647	D002524	Novel
15046495	Association	rs6410	4914	Novel
15046495	Association	rs6410	D007859	Novel
15046495	Association	D007859	rs6410	Novel
15046495	Association	6647	D007859	Novel

23765268|t|BPH and vascular endothelial growth factor receptor 2: interactions with SUM159PT, cannabis, and naproxen in rhesus monkeys and C.
23765268|a|This study investigates the complex interplay between benign prostatic hyperplasia (BPH), vascular endothelial growth factor receptor 2 (VEGFR2), and the SUM159PT cell line in the context of cannabis and naproxen exposure. Using rhesus monkeys and C. elegans as model organisms, we explored the molecular mechanisms underlying these interactions. Our findings reveal a negative correlation between cannabis and BPH, as well as between BPH and cannabis, suggesting that cannabis may have a protective effect against the development of BPH. Similarly, we observed a negative correlation between naproxen and BPH, and between BPH and naproxen, indicating that naproxen may also play a role in mitigating BPH progression. These effects were further modulated by the expression levels of vascular endothelial growth factor receptor 2 (VEGFR2), which was found to be significantly upregulated in SUM159PT cells exposed to cannabis. Additionally, the gene products IKKalpha/beta, DKFZP434I216, TXN2, and P-selectin were identified as key regulators in the signaling pathways influenced by these compounds. The study highlights the potential therapeutic applications of cannabis and naproxen in managing BPH, with implications for future research in both human and model organism systems. The results also underscore the importance of VEGFR2 and other gene products in mediating the biological responses to these chemical entities.
23765268	0	3	BPH	DiseaseOrPhenotypicFeature	D011470
23765268	8	53	vascular endothelial growth factor receptor 2	GeneOrGeneProduct	25589
23765268	73	81	SUM159PT	CellLine	CVCL_5423
23765268	83	91	cannabis	ChemicalEntity	D002188
23765268	97	105	naproxen	ChemicalEntity	D009288
23765268	109	123	rhesus monkeys	OrganismTaxon	9544
23765268	215	218	BPH	DiseaseOrPhenotypicFeature	D011470
23765268	221	266	vascular endothelial growth factor receptor 2	GeneOrGeneProduct	25589
23765268	285	293	SUM159PT	CellLine	CVCL_5423
23765268	322	330	cannabis	ChemicalEntity	D002188
23765268	335	343	naproxen	ChemicalEntity	D009288
23765268	360	374	rhesus monkeys	OrganismTaxon	9544
23765268	379	389	C. elegans	OrganismTaxon	6239
23765268	529	537	cannabis	ChemicalEntity	D002188
23765268	542	545	BPH	DiseaseOrPhenotypicFeature	D011470
23765268	566	569	BPH	DiseaseOrPhenotypicFeature	D011470
23765268	574	582	cannabis	ChemicalEntity	D002188
23765268	600	608	cannabis	ChemicalEntity	D002188
23765268	665	668	BPH	DiseaseOrPhenotypicFeature	D011470
23765268	724	732	naproxen	ChemicalEntity	D009288
23765268	737	740	BPH	DiseaseOrPhenotypicFeature	D011470
23765268	754	757	BPH	DiseaseOrPhenotypicFeature	D011470
23765268	762	770	naproxen	ChemicalEntity	D009288
23765268	788	796	naproxen	ChemicalEntity	D009288
23765268	832	835	BPH	DiseaseOrPhenotypicFeature	D011470
23765268	914	959	vascular endothelial growth factor receptor 2	GeneOrGeneProduct	25589
23765268	1021	1029	SUM159PT	CellLine	CVCL_5423
23765268	1047	1055	cannabis	ChemicalEntity	D002188
23765268	1089	1102	IKKalpha/beta	GeneOrGeneProduct	309361
23765268	1104	1116	DKFZP434I216	GeneOrGeneProduct	25894
23765268	1118	1122	TXN2	GeneOrGeneProduct	25828
23765268	1128	1138	P-selectin	GeneOrGeneProduct	6403
23765268	1293	1301	cannabis	ChemicalEntity	D002188
23765268	1306	1314	naproxen	ChemicalEntity	D009288
23765268	1327	1330	BPH	DiseaseOrPhenotypicFeature	D011470
23765268	Negative_Correlation	D002188	D011470	Novel
23765268	Negative_Correlation	D011470	D002188	Novel
23765268	Negative_Correlation	D009288	D011470	Novel
23765268	Negative_Correlation	D011470	D009288	Novel

83627895|t|Cidea and SDHA: complex interactions in HIV-1-seropositive individuals and their associations with Basal Cell Carcinomas and plantar ker
83627895|a|In this study, we investigate the intricate relationships between the gene products Cidea and SDHA in the context of HIV-1-seropositive human immunodeficiency virus type 1 patients and their associations with Basal Cell Carcinomas and plantar keratoderma. Our findings reveal a positive correlation between Cidea and Basal Cell Carcinomas, while a negative correlation is observed between Cidea and Basal Cell Carcinomas, indicating a complex regulatory network. Additionally, we find a negative correlation between Cidea and SDHA, and a positive correlation between SDHA and Basal Cell Carcinomas. The association between SDHA and plantar keratoderma is further supported by our data. Notably, HIV-1-seropositive individuals show a positive correlation with SDHA, suggesting a potential role of SDHA in the pathogenesis of HIV-1-seropositive conditions. Furthermore, we demonstrate a bind between SDHA and Cidea, as well as a bind between Cidea and SDHA, highlighting their direct molecular interactions. These results provide new insights into the molecular mechanisms underlying the interplay between these genes and their associations with disease states in HIV-1-seropositive human immunodeficiency virus type 1 patients. The HK2 cell line was used as a model system to validate these findings, and the results were consistent across multiple experimental conditions. The repeated observations of these relationships across different biological contexts reinforce the significance of Cidea and SDHA in the pathophysiology of Basal Cell Carcinomas, plantar keratoderma, and HIV-1-seropositive conditions.
83627895	0	5	Cidea	GeneOrGeneProduct	1149
83627895	10	14	SDHA	GeneOrGeneProduct	6389
83627895	40	58	HIV-1-seropositive	DiseaseOrPhenotypicFeature	D006679
83627895	99	120	Basal Cell Carcinomas	DiseaseOrPhenotypicFeature	D002280
83627895	221	226	Cidea	GeneOrGeneProduct	1149
83627895	231	235	SDHA	GeneOrGeneProduct	6389
83627895	254	272	HIV-1-seropositive	DiseaseOrPhenotypicFeature	D006679
83627895	273	308	human immunodeficiency virus type 1	OrganismTaxon	11676
83627895	346	367	Basal Cell Carcinomas	DiseaseOrPhenotypicFeature	D002280
83627895	372	391	plantar keratoderma	DiseaseOrPhenotypicFeature	D017499
83627895	444	449	Cidea	GeneOrGeneProduct	1149
83627895	454	475	Basal Cell Carcinomas	DiseaseOrPhenotypicFeature	D002280
83627895	526	531	Cidea	GeneOrGeneProduct	1149
83627895	536	557	Basal Cell Carcinomas	DiseaseOrPhenotypicFeature	D002280
83627895	653	658	Cidea	GeneOrGeneProduct	1149
83627895	663	667	SDHA	GeneOrGeneProduct	6389
83627895	704	708	SDHA	GeneOrGeneProduct	6389
83627895	713	734	Basal Cell Carcinomas	DiseaseOrPhenotypicFeature	D002280
83627895	760	764	SDHA	GeneOrGeneProduct	6389
83627895	769	788	plantar keratoderma	DiseaseOrPhenotypicFeature	D017499
83627895	832	850	HIV-1-seropositive	DiseaseOrPhenotypicFeature	D006679
83627895	896	900	SDHA	GeneOrGeneProduct	6389
83627895	933	937	SDHA	GeneOrGeneProduct	6389
83627895	961	979	HIV-1-seropositive	DiseaseOrPhenotypicFeature	D006679
83627895	1035	1039	SDHA	GeneOrGeneProduct	6389
83627895	1044	1049	Cidea	GeneOrGeneProduct	1149
83627895	1077	1082	Cidea	GeneOrGeneProduct	1149
83627895	1087	1091	SDHA	GeneOrGeneProduct	6389
83627895	1299	1317	HIV-1-seropositive	DiseaseOrPhenotypicFeature	D006679
83627895	1318	1353	human immunodeficiency virus type 1	OrganismTaxon	11676
83627895	1368	1371	HK2	CellLine	CVCL_0302
83627895	1626	1631	Cidea	GeneOrGeneProduct	1149
83627895	1636	1640	SDHA	GeneOrGeneProduct	6389
83627895	1667	1688	Basal Cell Carcinomas	DiseaseOrPhenotypicFeature	D002280
83627895	1690	1709	plantar keratoderma	DiseaseOrPhenotypicFeature	D017499
83627895	1715	1733	HIV-1-seropositive	DiseaseOrPhenotypicFeature	D006679
83627895	Negative_Correlation	6389	D002280	Novel
83627895	Positive_Correlation	1149	D002280	Novel
83627895	Association	6389	D017499	Novel
83627895	Positive_Correlation	D006679	6389	Novel
83627895	Negative_Correlation	D002280	1149	Novel
83627895	Association	D006679	6389	Novel
83627895	Negative_Correlation	1149	D002280	Novel
83627895	Negative_Correlation	1149	6389	Novel
83627895	Association	1149	D002280	Novel
83627895	Bind	6389	1149	Novel
83627895	Bind	1149	6389	Novel

65500192|t|Small-GTPases and T3: Multifaceted roles in coronary heart disease, calcification of ascending aorta, and insomnia across bovine and canin
65500192|a|Recent studies have highlighted the complex interplay between small-GTPases, thyroid hormone T3, and various disease states, including coronary heart disease and calcification of ascending aorta. This research explores the molecular mechanisms underlying these associations in both bovine and canine models. The findings reveal a significant association between small-GTPases and coronary heart disease, suggesting that these proteins may play a critical role in the pathogenesis of this condition. Additionally, T3 has been shown to be linked to calcification of ascending aorta, indicating a potential regulatory role in vascular calcification processes. Furthermore, T3 is associated with insomnia, highlighting its involvement in neuroendocrine regulation. The study also demonstrates that small-GTPases are connected to insomnia, suggesting a broader role in both cardiovascular and neurological functions. These results were observed across multiple cell lines, including MCF7/AdrR, Capan1, and SF188, which were used to model the disease states in bovine and canine systems. The data provide strong evidence for the multifaceted roles of small-GTPases and T3 in the development of coronary heart disease, calcification of ascending aorta, and insomnia, with implications for therapeutic interventions in both human and veterinary medicine.
65500192	18	20	T3	ChemicalEntity	D014284
65500192	44	66	coronary heart disease	DiseaseOrPhenotypicFeature	D003327
65500192	68	100	calcification of ascending aorta	DiseaseOrPhenotypicFeature	D001018
65500192	106	114	insomnia	DiseaseOrPhenotypicFeature	D007319
65500192	122	128	bovine	OrganismTaxon	9913
65500192	201	214	small-GTPases	GeneOrGeneProduct	363875
65500192	232	234	T3	ChemicalEntity	D014284
65500192	274	296	coronary heart disease	DiseaseOrPhenotypicFeature	D003327
65500192	301	333	calcification of ascending aorta	DiseaseOrPhenotypicFeature	D001018
65500192	421	427	bovine	OrganismTaxon	9913
65500192	501	514	small-GTPases	GeneOrGeneProduct	363875
65500192	519	541	coronary heart disease	DiseaseOrPhenotypicFeature	D003327
65500192	652	654	T3	ChemicalEntity	D014284
65500192	686	718	calcification of ascending aorta	DiseaseOrPhenotypicFeature	D001018
65500192	809	811	T3	ChemicalEntity	D014284
65500192	831	839	insomnia	DiseaseOrPhenotypicFeature	D007319
65500192	933	946	small-GTPases	GeneOrGeneProduct	363875
65500192	964	972	insomnia	DiseaseOrPhenotypicFeature	D007319
65500192	1117	1126	MCF7/AdrR	CellLine	 CVCL_1452
65500192	1128	1134	Capan1	CellLine	CVCL_0237
65500192	1140	1145	SF188	CellLine	CVCL_6948
65500192	1194	1200	bovine	OrganismTaxon	9913
65500192	1284	1297	small-GTPases	GeneOrGeneProduct	363875
65500192	1302	1304	T3	ChemicalEntity	D014284
65500192	1327	1349	coronary heart disease	DiseaseOrPhenotypicFeature	D003327
65500192	1351	1383	calcification of ascending aorta	DiseaseOrPhenotypicFeature	D001018
65500192	1389	1397	insomnia	DiseaseOrPhenotypicFeature	D007319
65500192	Association	D003327	363875	Novel
65500192	Association	D014284	D001018	Novel
65500192	Association	D014284	D003327	Novel
65500192	Association	D001018	363875	Novel
65500192	Association	D007319	363875	Novel
65500192	Association	D014284	D007319	Novel

63480617|t|Ile462Val variant in melanocortin receptor type 4: associations with tumor development and progression
63480617|a|A recent study has investigated the role of the Ile462Val sequence variant in the melanocortin receptor type 4 (MC4R) gene in dogs, with a focus on its potential association with tumor development and progression. The study involved a large cohort of 130 dogs, including 90 with various types of tumors and 40 healthy controls. The Ile462Val variant was found to be significantly more prevalent in tumor-bearing dogs compared to healthy controls, with 9 instances of the variant detected in tumor cases versus 3 in healthy dogs. This suggests a positive correlation between the Ile462Val variant and the occurrence of tumors in dogs. Further analysis revealed that the variant was associated with increased tumor size and aggressiveness, with 6 instances of the variant linked to malignant tumors and 3 to benign tumors. The study also examined the interaction between the Ile462Val variant and the chemical entity 2,4-diene-VPA, which was found to modulate the expression of the MC4R gene. The 2,4-diene-VPA was administered to 12 dogs with the Ile462Val variant, and the results showed a significant increase in tumor markers, with 13 instances of elevated markers observed. The findings support the hypothesis that the Ile462Val variant in the melanocortin receptor type 4 gene is associated with tumor development and progression in dogs, and that the chemical entity 2,4-diene-VPA may play a role in this process. The study highlights the importance of understanding the genetic and chemical factors that contribute to tumor biology in dogs, with implications for both veterinary and human medicine.
63480617	0	9	Ile462Val	SequenceVariant	rs1048943
63480617	21	49	melanocortin receptor type 4	GeneOrGeneProduct	4160
63480617	151	160	Ile462Val	SequenceVariant	rs1048943
63480617	185	213	melanocortin receptor type 4	GeneOrGeneProduct	4160
63480617	229	233	dogs	OrganismTaxon	9615
63480617	358	362	dogs	OrganismTaxon	9615
63480617	435	444	Ile462Val	SequenceVariant	rs1048943
63480617	515	519	dogs	OrganismTaxon	9615
63480617	626	630	dogs	OrganismTaxon	9615
63480617	681	690	Ile462Val	SequenceVariant	rs1048943
63480617	731	735	dogs	OrganismTaxon	9615
63480617	976	985	Ile462Val	SequenceVariant	rs1048943
63480617	1018	1031	2,4-diene-VPA	ChemicalEntity	C556631
63480617	1098	1111	2,4-diene-VPA	ChemicalEntity	C556631
63480617	1135	1139	dogs	OrganismTaxon	9615
63480617	1149	1158	Ile462Val	SequenceVariant	rs1048943
63480617	1325	1334	Ile462Val	SequenceVariant	rs1048943
63480617	1350	1378	melanocortin receptor type 4	GeneOrGeneProduct	4160
63480617	1440	1444	dogs	OrganismTaxon	9615
63480617	1475	1488	2,4-diene-VPA	ChemicalEntity	C556631
63480617	1644	1648	dogs	OrganismTaxon	9615
63480617	Association	rs1048943	D009369	Novel
63480617	Positive_Correlation	rs1048943	D009369	Novel

31237107|t|Genetic Variants and Functional Relationships in matriptase-2, IL-7, PDH, and Related Pat
31237107|a|This study investigates the functional and genetic relationships between matriptase-2, IL-7, PDH, and several disease phenotypes, including bipolar I disorder, Fanconi syndrome, and Autoimmune Diabetes. We identified multiple sequence variants associated with these genes and explored their potential roles in disease pathogenesis. Notably, matriptase-2 was found to have a negative correlation with both glucagon and snail, and was also associated with bipolar I disorder. In contrast, IL-7 showed a complex relationship with multiple factors, including a positive association with paralysis, Fanconi syndrome, and type I collagen, while also exhibiting a negative correlation with matriptase-2. The sequence variant p.R491C was found to be associated with both IL-7 and type I collagen, suggesting a potential functional link. Additionally, the variant rs2073416 was associated with IL-7, and c.14_15insC was linked to PDH. PDH was associated with bipolar I disorder, Fanconi syndrome, and type I collagen, with a negative correlation observed between PDH and type I collagen. The variant c.342delA was also associated with IL-7, and the variant N221D was found to be linked to glucagon. The sequence variant Pro75Ala was associated with glucagon, and snail was found to be associated with both Autoimmune Diabetes and glucagon. These findings highlight the complex interplay between genetic variants and their functional consequences in various disease contexts.
31237107	49	61	matriptase-2	GeneOrGeneProduct	164656
31237107	63	67	IL-7	GeneOrGeneProduct	25647
31237107	69	72	PDH	GeneOrGeneProduct	54704
31237107	163	175	matriptase-2	GeneOrGeneProduct	164656
31237107	177	181	IL-7	GeneOrGeneProduct	25647
31237107	183	186	PDH	GeneOrGeneProduct	54704
31237107	230	248	bipolar I disorder	DiseaseOrPhenotypicFeature	D001714
31237107	250	266	Fanconi syndrome	DiseaseOrPhenotypicFeature	D005198
31237107	272	291	Autoimmune Diabetes	DiseaseOrPhenotypicFeature	D003922
31237107	431	443	matriptase-2	GeneOrGeneProduct	164656
31237107	495	503	glucagon	GeneOrGeneProduct	2641
31237107	508	513	snail	GeneOrGeneProduct	20613
31237107	544	562	bipolar I disorder	DiseaseOrPhenotypicFeature	D001714
31237107	577	581	IL-7	GeneOrGeneProduct	25647
31237107	673	682	paralysis	DiseaseOrPhenotypicFeature	D010243
31237107	684	700	Fanconi syndrome	DiseaseOrPhenotypicFeature	D005198
31237107	706	721	type I collagen	GeneOrGeneProduct	1278
31237107	773	785	matriptase-2	GeneOrGeneProduct	164656
31237107	808	815	p.R491C	SequenceVariant	rs759977194
31237107	853	857	IL-7	GeneOrGeneProduct	25647
31237107	862	877	type I collagen	GeneOrGeneProduct	1278
31237107	945	954	rs2073416	SequenceVariant	rs2073416
31237107	975	979	IL-7	GeneOrGeneProduct	25647
31237107	985	996	c.14_15insC	SequenceVariant	rs11399890
31237107	1011	1014	PDH	GeneOrGeneProduct	54704
31237107	1016	1019	PDH	GeneOrGeneProduct	54704
31237107	1040	1058	bipolar I disorder	DiseaseOrPhenotypicFeature	D001714
31237107	1060	1076	Fanconi syndrome	DiseaseOrPhenotypicFeature	D005198
31237107	1082	1097	type I collagen	GeneOrGeneProduct	1278
31237107	1144	1147	PDH	GeneOrGeneProduct	54704
31237107	1152	1167	type I collagen	GeneOrGeneProduct	1278
31237107	1181	1190	c.342delA	SequenceVariant	c|DEL|342|A
31237107	1216	1220	IL-7	GeneOrGeneProduct	25647
31237107	1238	1243	N221D	SequenceVariant	rs6232
31237107	1270	1278	glucagon	GeneOrGeneProduct	2641
31237107	1301	1309	Pro75Ala	SequenceVariant	rs74805019
31237107	1330	1338	glucagon	GeneOrGeneProduct	2641
31237107	1344	1349	snail	GeneOrGeneProduct	20613
31237107	1387	1406	Autoimmune Diabetes	DiseaseOrPhenotypicFeature	D003922
31237107	1411	1419	glucagon	GeneOrGeneProduct	2641
31237107	Negative_Correlation	164656	2641	Novel
31237107	Association	25647	D010243	Novel
31237107	Association	rs759977194	25647	Novel
31237107	Association	54704	D001714	Novel
31237107	Association	25647	164656	Novel
31237107	Association	25647	2641	Novel
31237107	Negative_Correlation	1278	54704	Novel
31237107	Association	54704	2641	Novel
31237107	Association	54704	1278	Novel
31237107	Negative_Correlation	164656	20613	Novel
31237107	Association	1278	25647	Novel
31237107	Association	rs74805019	2641	Novel
31237107	Association	20613	D003922	Novel
31237107	Association	164656	D001714	Novel
31237107	Negative_Correlation	25647	164656	Novel
31237107	Association	rs2073416	25647	Novel
31237107	Association	rs759977194	1278	Novel
31237107	Association	rs11399890	54704	Novel
31237107	Association	20613	25647	Novel
31237107	Association	25647	D005198	Novel
31237107	Association	c|DEL|342|A	25647	Novel
31237107	Association	20613	2641	Novel

43445304|t|Nhe 1 expression in Capan1 and C4-2B cells: interactions with hepatitis B virus, DEN-4, and Saccharomyces ce
43445304|a|This study investigates the expression and functional role of Nhe 1 in Capan1 and C4-2B cell lines, with a focus on its interactions with hepatitis B virus, DEN-4, and Saccharomyces cerevisiae. Nhe 1, a key enzyme involved in pH regulation, was found to be significantly upregulated in both Capan1 and C4-2B cells under various stress conditions. The expression levels of Nhe 1 were correlated with the presence of hepatitis B virus in C4-2B cells, suggesting a potential role in viral replication or host cell adaptation. In Capan1 cells, Nhe 1 expression was also linked to the presence of DEN-4, a flavivirus, indicating possible cross-talk between viral infection and cellular pH homeostasis.   Further analysis revealed that Saccharomyces cerevisiae, a model organism, exhibited a unique response to Nhe 1 activity, with altered growth patterns observed in yeast cultures co-cultured with Capan1 cells. The study also included experiments using MCF7/AdrR, PC-3, and SJ-GBM2 cell lines to assess the broader implications of Nhe 1 in different cellular contexts. Rabbit-derived cell lines were used to evaluate the impact of Nhe 1 on immune responses, with results showing a significant modulation of cytokine production.   The findings suggest that Nhe 1 plays a critical role in mediating interactions between host cells and various pathogens, including hepatitis B virus, DEN-4, and yeast. These results highlight the importance of Nhe 1 in cellular stress responses and its potential as a therapeutic target in diseases involving viral infections and microbial interactions.
43445304	0	5	Nhe 1	GeneOrGeneProduct	6548
43445304	20	26	Capan1	CellLine	CVCL_0237
43445304	31	36	C4-2B	CellLine	CVCL_4784
43445304	62	79	hepatitis B virus	OrganismTaxon	10407
43445304	81	86	DEN-4	OrganismTaxon	11070
43445304	171	176	Nhe 1	GeneOrGeneProduct	6548
43445304	180	186	Capan1	CellLine	CVCL_0237
43445304	191	196	C4-2B	CellLine	CVCL_4784
43445304	247	264	hepatitis B virus	OrganismTaxon	10407
43445304	266	271	DEN-4	OrganismTaxon	11070
43445304	277	301	Saccharomyces cerevisiae	OrganismTaxon	4932
43445304	303	308	Nhe 1	GeneOrGeneProduct	6548
43445304	400	406	Capan1	CellLine	CVCL_0237
43445304	411	416	C4-2B	CellLine	CVCL_4784
43445304	481	486	Nhe 1	GeneOrGeneProduct	6548
43445304	524	541	hepatitis B virus	OrganismTaxon	10407
43445304	545	550	C4-2B	CellLine	CVCL_4784
43445304	635	641	Capan1	CellLine	CVCL_0237
43445304	649	654	Nhe 1	GeneOrGeneProduct	6548
43445304	701	706	DEN-4	OrganismTaxon	11070
43445304	839	863	Saccharomyces cerevisiae	OrganismTaxon	4932
43445304	914	919	Nhe 1	GeneOrGeneProduct	6548
43445304	971	976	yeast	OrganismTaxon	4932
43445304	1003	1009	Capan1	CellLine	CVCL_0237
43445304	1059	1068	MCF7/AdrR	CellLine	 CVCL_1452
43445304	1070	1074	PC-3	CellLine	CVCL_0035
43445304	1080	1087	SJ-GBM2	CellLine	CVCL_M141
43445304	1137	1142	Nhe 1	GeneOrGeneProduct	6548
43445304	1237	1242	Nhe 1	GeneOrGeneProduct	6548
43445304	1362	1367	Nhe 1	GeneOrGeneProduct	6548
43445304	1468	1485	hepatitis B virus	OrganismTaxon	10407
43445304	1487	1492	DEN-4	OrganismTaxon	11070
43445304	1498	1503	yeast	OrganismTaxon	4932
43445304	1547	1552	Nhe 1	GeneOrGeneProduct	6548

70438299|t|Sequence variants H194Q and -1240 L/S modulate nitric oxide and mannose metabolism in Platonia insignis Mart, guinea pig, and Drosophila models of inferior colliculus lesions and pituitary
70438299|a|This study investigates the molecular mechanisms underlying the interplay between sequence variants H194Q and -1240 L/S, and their effects on nitric oxide and mannose metabolism in three model organisms: Platonia insignis Mart, guinea pig, and Drosophila. The research focuses on the association of these genetic variants with inferior colliculus lesions and pituitary adenoma, two phenotypic features linked to metabolic dysregulation.   Our findings reveal a positive correlation between H194Q and both nitric oxide and mannose levels, suggesting that this variant may play a role in modulating metabolic pathways involving these chemical entities. Similarly, the -1240 L/S variant shows a positive correlation with both nitric oxide and mannose, indicating a potential regulatory role in the conversion between these two molecules.   The study also demonstrates a bidirectional conversion between nitric oxide and mannose, with evidence of a positive correlation between these two chemical entities. This suggests a dynamic metabolic network where nitric oxide and mannose may influence each other in a feedback loop.   In Platonia insignis Mart, guinea pig, and Drosophila models, the presence of H194Q and -1240 L/S variants is associated with altered metabolic profiles, particularly in the context of inferior colliculus lesions and pituitary adenoma. These findings highlight the importance of genetic variability in shaping metabolic responses and provide a foundation for further research into the molecular mechanisms underlying these conditions.   The results underscore the complex interplay between genetic variants, metabolic pathways, and phenotypic outcomes, offering new insights into the role of nitric oxide and mannose in disease pathogenesis across different species.
70438299	18	23	H194Q	SequenceVariant	rs74315522
70438299	28	37	-1240 L/S	SequenceVariant	p|SUB|L|-1240|S
70438299	47	59	nitric oxide	ChemicalEntity	D009569
70438299	64	71	mannose	ChemicalEntity	D008358
70438299	86	108	Platonia insignis Mart	OrganismTaxon	198787
70438299	110	120	guinea pig	OrganismTaxon	10141
70438299	126	136	Drosophila	OrganismTaxon	7227
70438299	147	174	inferior colliculus lesions	DiseaseOrPhenotypicFeature	D001927
70438299	289	294	H194Q	SequenceVariant	rs74315522
70438299	299	308	-1240 L/S	SequenceVariant	p|SUB|L|-1240|S
70438299	331	343	nitric oxide	ChemicalEntity	D009569
70438299	348	355	mannose	ChemicalEntity	D008358
70438299	393	415	Platonia insignis Mart	OrganismTaxon	198787
70438299	417	427	guinea pig	OrganismTaxon	10141
70438299	433	443	Drosophila	OrganismTaxon	7227
70438299	516	543	inferior colliculus lesions	DiseaseOrPhenotypicFeature	D001927
70438299	548	565	pituitary adenoma	DiseaseOrPhenotypicFeature	D010911
70438299	679	684	H194Q	SequenceVariant	rs74315522
70438299	694	706	nitric oxide	ChemicalEntity	D009569
70438299	711	718	mannose	ChemicalEntity	D008358
70438299	855	864	-1240 L/S	SequenceVariant	p|SUB|L|-1240|S
70438299	912	924	nitric oxide	ChemicalEntity	D009569
70438299	929	936	mannose	ChemicalEntity	D008358
70438299	1089	1101	nitric oxide	ChemicalEntity	D009569
70438299	1106	1113	mannose	ChemicalEntity	D008358
70438299	1240	1252	nitric oxide	ChemicalEntity	D009569
70438299	1257	1264	mannose	ChemicalEntity	D008358
70438299	1315	1337	Platonia insignis Mart	OrganismTaxon	198787
70438299	1339	1349	guinea pig	OrganismTaxon	10141
70438299	1355	1365	Drosophila	OrganismTaxon	7227
70438299	1390	1395	H194Q	SequenceVariant	rs74315522
70438299	1400	1409	-1240 L/S	SequenceVariant	p|SUB|L|-1240|S
70438299	1497	1524	inferior colliculus lesions	DiseaseOrPhenotypicFeature	D001927
70438299	1529	1546	pituitary adenoma	DiseaseOrPhenotypicFeature	D010911
70438299	1904	1916	nitric oxide	ChemicalEntity	D009569
70438299	1921	1928	mannose	ChemicalEntity	D008358
70438299	Conversion	D008358	D009569	Novel
70438299	Conversion	D009569	D008358	Novel
70438299	Positive_Correlation	p|SUB|L|-1240|S	D008358	Novel
70438299	Positive_Correlation	rs74315522	D008358	Novel
70438299	Positive_Correlation	rs74315522	D009569	Novel
70438299	Positive_Correlation	D008358	D009569	Novel
70438299	Positive_Correlation	D009569	D008358	Novel
70438299	Positive_Correlation	p|SUB|L|-1240|S	D009569	Novel

84579076|t|I238M variant in Cidec and regulator of G-protein signaling 4: associations with visual hallucinations and their modulation in MCF7/AdrR and Ba/F3 ce
84579076|a|Recent studies have highlighted the complex interplay between genetic variants, cellular responses, and phenotypic outcomes in the context of neurological disorders. This study investigates the role of the I238M variant in the gene Cidec and its interaction with the regulator of G-protein signaling 4 (RGS4) in relation to visual hallucinations. The I238M variant was identified in multiple independent cohorts, including the MCF7/AdrR and Ba/F3 cell lines, where it showed differential expression patterns. Notably, the I238M variant in Cidec was found to be negatively correlated with the occurrence of visual hallucinations, suggesting a potential protective role. Similarly, the expression levels of RGS4 were inversely associated with the presence of visual hallucinations, indicating a negative correlation between RGS4 and this phenotypic feature. These findings were further supported by in vitro experiments using the MCF7/AdrR and Ba/F3 cell lines, where modulation of Cidec and RGS4 expression led to changes in the frequency of visual hallucinations. The results suggest that the I238M variant in Cidec and the expression levels of RGS4 may serve as important biomarkers for the development of therapeutic strategies targeting visual hallucinations. The study also underscores the importance of cell line-specific responses in understanding the functional consequences of genetic variants.
84579076	0	5	I238M	SequenceVariant	rs34242818
84579076	17	22	Cidec	GeneOrGeneProduct	63924
84579076	27	61	regulator of G-protein signaling 4	GeneOrGeneProduct	5999
84579076	81	102	visual hallucinations	DiseaseOrPhenotypicFeature	D006212
84579076	127	136	MCF7/AdrR	CellLine	 CVCL_1452
84579076	141	146	Ba/F3	CellLine	CVCL_0161
84579076	356	361	I238M	SequenceVariant	rs34242818
84579076	382	387	Cidec	GeneOrGeneProduct	63924
84579076	417	451	regulator of G-protein signaling 4	GeneOrGeneProduct	5999
84579076	474	495	visual hallucinations	DiseaseOrPhenotypicFeature	D006212
84579076	501	506	I238M	SequenceVariant	rs34242818
84579076	577	586	MCF7/AdrR	CellLine	 CVCL_1452
84579076	591	596	Ba/F3	CellLine	CVCL_0161
84579076	672	677	I238M	SequenceVariant	rs34242818
84579076	689	694	Cidec	GeneOrGeneProduct	63924
84579076	756	777	visual hallucinations	DiseaseOrPhenotypicFeature	D006212
84579076	907	928	visual hallucinations	DiseaseOrPhenotypicFeature	D006212
84579076	1078	1087	MCF7/AdrR	CellLine	 CVCL_1452
84579076	1092	1097	Ba/F3	CellLine	CVCL_0161
84579076	1130	1135	Cidec	GeneOrGeneProduct	63924
84579076	1191	1212	visual hallucinations	DiseaseOrPhenotypicFeature	D006212
84579076	1243	1248	I238M	SequenceVariant	rs34242818
84579076	1260	1265	Cidec	GeneOrGeneProduct	63924
84579076	1390	1411	visual hallucinations	DiseaseOrPhenotypicFeature	D006212
84579076	Negative_Correlation	D006212	5999	Novel
84579076	Negative_Correlation	63924	D006212	Novel

11436696|t|Genetic Variants and Functional Interactions of tPA and Estrogen Receptor in Bovine and Guinea Pi
11436696|a|This study investigates the functional and genetic interactions between tissue plasminogen activator (tPA) and estrogen receptor (ER) in bovine and guinea pig models, with a focus on sequence variants and their associations with cellular responses in hRPTEC and CD18/HPAF cell lines. We identified multiple sequence variants, including +25 G->A, T2734, p.P230R, and Arginine (R) to Glycine (G) mutation at position 76, and evaluated their impact on tPA and ER expression and activity.   Our findings reveal a negative correlation between tPA and estrogen receptor in bovine tissues, while a positive correlation is observed in guinea-pigs. The association between +25 G->A and tPA is significant in hRPTEC cells, and this variant also shows a link with estrogen receptor in CD18/HPAF cell lines. Similarly, T2734 is associated with both tPA and estrogen receptor, with a positive correlation noted in guinea-pigs. The Arginine (R) to Glycine (G) mutation at position 76 is strongly associated with tPA and also shows a direct interaction with estrogen receptor, suggesting a potential mechanism for their functional coupling.   The p.P230R variant is found to be associated with both tPA and estrogen receptor, with evidence of a binding interaction between these two proteins. Furthermore, the study demonstrates a direct bind between tPA and estrogen receptor in both bovine and guinea pig models, supporting their functional relationship. These results highlight the complex interplay between genetic variants and the expression/activity of tPA and estrogen receptor, with implications for understanding their roles in cellular processes and disease mechanisms.
11436696	48	51	tPA	GeneOrGeneProduct	5327
11436696	200	203	tPA	GeneOrGeneProduct	5327
11436696	209	226	estrogen receptor	GeneOrGeneProduct	2099
11436696	235	241	bovine	OrganismTaxon	9913
11436696	246	256	guinea pig	OrganismTaxon	10141
11436696	349	355	hRPTEC	CellLine	CVCL_K278
11436696	360	369	CD18/HPAF	CellLine	CVCL_0313
11436696	434	442	+25 G->A	SequenceVariant	rs368698783
11436696	444	449	T2734	SequenceVariant	c|Aelle|T|2734
11436696	451	458	p.P230R	SequenceVariant	p|SUB|P|230|R
11436696	464	515	Arginine (R) to Glycine (G) mutation at position 76	SequenceVariant	p|SUB|R|76|G
11436696	547	550	tPA	GeneOrGeneProduct	5327
11436696	636	639	tPA	GeneOrGeneProduct	5327
11436696	644	661	estrogen receptor	GeneOrGeneProduct	2099
11436696	665	671	bovine	OrganismTaxon	9913
11436696	725	736	guinea-pigs	OrganismTaxon	10141
11436696	762	770	+25 G->A	SequenceVariant	rs368698783
11436696	775	778	tPA	GeneOrGeneProduct	5327
11436696	797	803	hRPTEC	CellLine	CVCL_K278
11436696	851	868	estrogen receptor	GeneOrGeneProduct	2099
11436696	872	881	CD18/HPAF	CellLine	CVCL_0313
11436696	905	910	T2734	SequenceVariant	c|Aelle|T|2734
11436696	935	938	tPA	GeneOrGeneProduct	5327
11436696	943	960	estrogen receptor	GeneOrGeneProduct	2099
11436696	999	1010	guinea-pigs	OrganismTaxon	10141
11436696	1016	1067	Arginine (R) to Glycine (G) mutation at position 76	SequenceVariant	p|SUB|R|76|G
11436696	1096	1099	tPA	GeneOrGeneProduct	5327
11436696	1141	1158	estrogen receptor	GeneOrGeneProduct	2099
11436696	1230	1237	p.P230R	SequenceVariant	p|SUB|P|230|R
11436696	1282	1285	tPA	GeneOrGeneProduct	5327
11436696	1290	1307	estrogen receptor	GeneOrGeneProduct	2099
11436696	1434	1437	tPA	GeneOrGeneProduct	5327
11436696	1442	1459	estrogen receptor	GeneOrGeneProduct	2099
11436696	1468	1474	bovine	OrganismTaxon	9913
11436696	1479	1489	guinea pig	OrganismTaxon	10141
11436696	1642	1645	tPA	GeneOrGeneProduct	5327
11436696	1650	1667	estrogen receptor	GeneOrGeneProduct	2099
11436696	Negative_Correlation	5327	2099	Novel
11436696	Association	rs368698783	5327	Novel
11436696	Association	2099	5327	Novel
11436696	Positive_Correlation	2099	5327	Novel
11436696	Association	p|SUB|R|76|G	5327	Novel
11436696	Association	p|SUB|P|230|R	5327	Novel
11436696	Association	p|SUB|R|76|G	2099	Novel
11436696	Association	p|SUB|P|230|R	2099	Novel
11436696	Association	5327	2099	Novel
11436696	Association	c|Aelle|T|2734	5327	Novel
11436696	Positive_Correlation	5327	2099	Novel
11436696	Bind	5327	2099	Novel
11436696	Association	c|Aelle|T|2734	2099	Novel
11436696	Bind	2099	5327	Novel
11436696	Association	rs368698783	2099	Novel
11436696	Negative_Correlation	2099	5327	Novel

73569394|t|Genetic Variants and Their Associations in Drosophila, Dogs, and Mouse Mammary Tumor Virus: A Multispeci
73569394|a|This study explores the genetic associations between several sequence variants and their potential roles in different organisms, including Drosophila, dogs, and mouse mammary tumor virus. The research focuses on the sequence variants c.1627A>T, V274I, (CCTTT)14, and rs1155794, and their interrelationships across multiple species.   In Drosophila, the sequence variant c.1627A>T was found to be associated with V274I, suggesting a potential functional link between these two variants. Additionally, (CCTTT)14 was shown to be associated with both c.1627A>T and rs1155794, indicating a possible regulatory or structural interaction. The variant rs1155794 was also found to be associated with c.1627A>T, reinforcing the complex network of genetic interactions.   In dogs, the sequence variant V274I was linked to both rs1155794 and (CCTTT)14, suggesting a shared genetic pathway or functional mechanism. The variant (CCTTT)14 was further associated with V274I, highlighting its potential role in modulating the expression or function of these variants.   The mouse mammary tumor virus exhibited multiple associations, including the link between (CCTTT)14 and rs1155794, as well as between rs1155794 and V274I. These findings suggest that these sequence variants may play a role in viral replication or host interaction.   Bacteria were also included in the study, with the sequence variant rs1155794 being associated with (CCTTT)14, indicating potential horizontal gene transfer or co-evolutionary relationships. The variant c.1627A>T was found to be associated with (CCTTT)14, further supporting the idea of a complex genetic network across species.   Overall, this study provides evidence for a web of genetic associations between the sequence variants c.1627A>T, V274I, (CCTTT)14, and rs1155794 across multiple organisms, including Drosophila, dogs, mouse mammary tumor virus, and bacteria. These findings have implications for understanding the functional and evolutionary roles of these genetic variants in diverse biological contexts.
73569394	43	53	Drosophila	OrganismTaxon	7227
73569394	244	254	Drosophila	OrganismTaxon	7227
73569394	256	260	dogs	OrganismTaxon	9615
73569394	266	291	mouse mammary tumor virus	OrganismTaxon	11757
73569394	339	348	c.1627A>T	SequenceVariant	c|SUB|A|1627|T
73569394	350	355	V274I	SequenceVariant	rs2235371
73569394	357	366	(CCTTT)14	SequenceVariant	c|DUP||CCTTT|14
73569394	372	381	rs1155794	SequenceVariant	rs1155794
73569394	442	452	Drosophila	OrganismTaxon	7227
73569394	475	484	c.1627A>T	SequenceVariant	c|SUB|A|1627|T
73569394	517	522	V274I	SequenceVariant	rs2235371
73569394	605	614	(CCTTT)14	SequenceVariant	c|DUP||CCTTT|14
73569394	652	661	c.1627A>T	SequenceVariant	c|SUB|A|1627|T
73569394	666	675	rs1155794	SequenceVariant	rs1155794
73569394	749	758	rs1155794	SequenceVariant	rs1155794
73569394	796	805	c.1627A>T	SequenceVariant	c|SUB|A|1627|T
73569394	869	873	dogs	OrganismTaxon	9615
73569394	896	901	V274I	SequenceVariant	rs2235371
73569394	921	930	rs1155794	SequenceVariant	rs1155794
73569394	935	944	(CCTTT)14	SequenceVariant	c|DUP||CCTTT|14
73569394	1019	1028	(CCTTT)14	SequenceVariant	c|DUP||CCTTT|14
73569394	1057	1062	V274I	SequenceVariant	rs2235371
73569394	1162	1187	mouse mammary tumor virus	OrganismTaxon	11757
73569394	1248	1257	(CCTTT)14	SequenceVariant	c|DUP||CCTTT|14
73569394	1262	1271	rs1155794	SequenceVariant	rs1155794
73569394	1292	1301	rs1155794	SequenceVariant	rs1155794
73569394	1306	1311	V274I	SequenceVariant	rs2235371
73569394	1493	1502	rs1155794	SequenceVariant	rs1155794
73569394	1525	1534	(CCTTT)14	SequenceVariant	c|DUP||CCTTT|14
73569394	1628	1637	c.1627A>T	SequenceVariant	c|SUB|A|1627|T
73569394	1670	1679	(CCTTT)14	SequenceVariant	c|DUP||CCTTT|14
73569394	1858	1867	c.1627A>T	SequenceVariant	c|SUB|A|1627|T
73569394	1869	1874	V274I	SequenceVariant	rs2235371
73569394	1876	1885	(CCTTT)14	SequenceVariant	c|DUP||CCTTT|14
73569394	1891	1900	rs1155794	SequenceVariant	rs1155794
73569394	1938	1948	Drosophila	OrganismTaxon	7227
73569394	1950	1954	dogs	OrganismTaxon	9615
73569394	1956	1981	mouse mammary tumor virus	OrganismTaxon	11757
73569394	1987	1995	bacteria	OrganismTaxon	2
73569394	Association	c|SUB|A|1627|T	rs2235371	Novel
73569394	Association	c|DUP||CCTTT|14	c|SUB|A|1627|T	Novel
73569394	Association	c|DUP||CCTTT|14	rs1155794	Novel
73569394	Association	c|SUB|A|1627|T	rs1155794	Novel
73569394	Association	rs1155794	c|SUB|A|1627|T	Novel
73569394	Association	c|DUP||CCTTT|14	rs2235371	Novel
73569394	Association	rs1155794	c|DUP||CCTTT|14	Novel
73569394	Association	rs2235371	rs1155794	Novel
73569394	Association	rs2235371	c|DUP||CCTTT|14	Novel
73569394	Association	c|SUB|A|1627|T	c|DUP||CCTTT|14	Novel
73569394	Association	rs1155794	rs2235371	Novel
73569394	Association	rs2235371	c|SUB|A|1627|T	Novel

55445766|t|C-peptide interactions with prolactin receptor and desmin in rabbit and sheep ce
55445766|a|This study investigates the molecular interactions between C-peptide, prolactin receptor, desmin, and Src in rabbit and sheep cell lines. We demonstrate that C-peptide binds directly to the prolactin receptor, forming a stable complex that modulates downstream signaling pathways. Additionally, C-peptide exhibits a strong association with desmin, suggesting a potential role in cytoskeletal organization. The interaction between C-peptide and Src is further supported by biochemical assays, indicating a possible role in kinase activation.   The prolactin receptor also shows a significant association with desmin, and this relationship is reinforced by co-localization studies in both rabbit and sheep cell lines. Src is found to associate with both desmin and the prolactin receptor, suggesting a potential regulatory role in these interactions. Notably, the desmin-Src association is further validated through immunoprecipitation experiments, highlighting the importance of Src in desmin-mediated signaling.   Our findings provide evidence for a complex network involving C-peptide, prolactin receptor, desmin, and Src, with implications for cellular signaling and structural dynamics in rabbit and sheep models. These results contribute to a better understanding of the molecular mechanisms underlying these interactions in different species.
55445766	0	9	C-peptide	ChemicalEntity	D002096
55445766	28	46	prolactin receptor	GeneOrGeneProduct	5618
55445766	51	57	desmin	GeneOrGeneProduct	64362
55445766	61	67	rabbit	OrganismTaxon	9986
55445766	72	77	sheep	OrganismTaxon	9940
55445766	140	149	C-peptide	ChemicalEntity	D002096
55445766	151	169	prolactin receptor	GeneOrGeneProduct	5618
55445766	171	177	desmin	GeneOrGeneProduct	64362
55445766	183	186	Src	GeneOrGeneProduct	6714
55445766	190	196	rabbit	OrganismTaxon	9986
55445766	201	206	sheep	OrganismTaxon	9940
55445766	239	248	C-peptide	ChemicalEntity	D002096
55445766	271	289	prolactin receptor	GeneOrGeneProduct	5618
55445766	376	385	C-peptide	ChemicalEntity	D002096
55445766	421	427	desmin	GeneOrGeneProduct	64362
55445766	511	520	C-peptide	ChemicalEntity	D002096
55445766	525	528	Src	GeneOrGeneProduct	6714
55445766	628	646	prolactin receptor	GeneOrGeneProduct	5618
55445766	689	695	desmin	GeneOrGeneProduct	64362
55445766	768	774	rabbit	OrganismTaxon	9986
55445766	779	784	sheep	OrganismTaxon	9940
55445766	797	800	Src	GeneOrGeneProduct	6714
55445766	833	839	desmin	GeneOrGeneProduct	64362
55445766	848	866	prolactin receptor	GeneOrGeneProduct	5618
55445766	943	949	desmin	GeneOrGeneProduct	64362
55445766	950	953	Src	GeneOrGeneProduct	6714
55445766	1059	1062	Src	GeneOrGeneProduct	6714
55445766	1066	1072	desmin	GeneOrGeneProduct	64362
55445766	1157	1166	C-peptide	ChemicalEntity	D002096
55445766	1168	1186	prolactin receptor	GeneOrGeneProduct	5618
55445766	1188	1194	desmin	GeneOrGeneProduct	64362
55445766	1200	1203	Src	GeneOrGeneProduct	6714
55445766	1273	1279	rabbit	OrganismTaxon	9986
55445766	1284	1289	sheep	OrganismTaxon	9940
55445766	Association	D002096	5618	Novel
55445766	Association	5618	64362	Novel
55445766	Association	D002096	6714	Novel
55445766	Association	64362	6714	Novel
55445766	Bind	D002096	64362	Novel
55445766	Bind	D002096	5618	Novel
55445766	Association	6714	64362	Novel
55445766	Bind	D002096	6714	Novel
55445766	Association	6714	5618	Novel
55445766	Association	D002096	64362	Novel
55445766	Association	64362	5618	Novel
55445766	Association	5618	6714	Novel

17246485|t|Folic Acid, Suxamethonium, and Genetic Variants in the Context of Malaria Infection, Darier's Disease, and West Ni
17246485|a|This study explores the complex interplay between folic acid, suxamethonium, and genetic variants in the context of malaria infection, Darier's disease, and West Nile virus. We investigate the association between folic acid and suxamethonium, revealing a significant correlation that suggests a potential synergistic or antagonistic relationship. Additionally, we find that folic acid is associated with malaria infection, which is further linked to Na+/ K+ ATPase, indicating a possible role for this enzyme in the pathophysiology of the disease.   The study also examines the negative correlation between folic acid and Darier's disease, which is counterbalanced by a positive correlation between folic acid and Darier's disease, highlighting the complexity of this relationship. Furthermore, we observe a positive correlation between suxamethonium and both L180M and p.W290L, suggesting that these sequence variants may be influenced by the presence of suxamethonium.   In the context of West Nile virus, we find that the virus is associated with multiple instances of malaria infection, indicating a possible interaction between these two pathogens. The study also highlights the role of bacteria in the immune response to these conditions, with folic acid playing a central role in modulating this response.   Our findings suggest that folic acid is a key player in the interplay between genetic variants, chemical entities, and infectious diseases. The association between folic acid and Na+/ K+ ATPase is further supported by the negative correlation between Na+/ K+ ATPase and malaria infection, reinforcing the importance of this enzyme in the immune response.   The results of this study provide new insights into the molecular mechanisms underlying these conditions and may have implications for the development of targeted therapies and interventions.
17246485	165	175	folic acid	ChemicalEntity	D005492
17246485	177	190	suxamethonium	ChemicalEntity	D013390
17246485	231	248	malaria infection	DiseaseOrPhenotypicFeature	D008288
17246485	250	266	Darier's disease	DiseaseOrPhenotypicFeature	D007644
17246485	272	287	West Nile virus	OrganismTaxon	11082
17246485	328	338	folic acid	ChemicalEntity	D005492
17246485	343	356	suxamethonium	ChemicalEntity	D013390
17246485	489	499	folic acid	ChemicalEntity	D005492
17246485	519	536	malaria infection	DiseaseOrPhenotypicFeature	D008288
17246485	565	579	Na+/ K+ ATPase	ChemicalEntity	D000254
17246485	722	732	folic acid	ChemicalEntity	D005492
17246485	737	753	Darier's disease	DiseaseOrPhenotypicFeature	D007644
17246485	814	824	folic acid	ChemicalEntity	D005492
17246485	829	845	Darier's disease	DiseaseOrPhenotypicFeature	D007644
17246485	952	965	suxamethonium	ChemicalEntity	D013390
17246485	975	980	L180M	SequenceVariant	p|SUB|L|180|M
17246485	985	992	p.W290L	SequenceVariant	rs267607117
17246485	1071	1084	suxamethonium	ChemicalEntity	D013390
17246485	1106	1121	West Nile virus	OrganismTaxon	11082
17246485	1187	1204	malaria infection	DiseaseOrPhenotypicFeature	D008288
17246485	1307	1315	bacteria	OrganismTaxon	2
17246485	1365	1375	folic acid	ChemicalEntity	D005492
17246485	1456	1466	folic acid	ChemicalEntity	D005492
17246485	1594	1604	folic acid	ChemicalEntity	D005492
17246485	1609	1623	Na+/ K+ ATPase	ChemicalEntity	D000254
17246485	1681	1695	Na+/ K+ ATPase	ChemicalEntity	D000254
17246485	1700	1717	malaria infection	DiseaseOrPhenotypicFeature	D008288
17246485	Association	D005492	D013390	Novel
17246485	Association	D008288	D005492	Novel
17246485	Positive_Correlation	D013390	rs267607117	Novel
17246485	Comparison	D005492	D013390	Novel
17246485	Association	D007644	D005492	Novel
17246485	Negative_Correlation	D000254	D008288	Novel
17246485	Negative_Correlation	D005492	D007644	Novel
17246485	Association	D005492	D008288	Novel
17246485	Association	D000254	D008288	Novel
17246485	Association	D005492	D007644	Novel
17246485	Association	D008288	D000254	Novel
17246485	Association	D005492	D000254	Novel
17246485	Positive_Correlation	D013390	p|SUB|L|180|M	Novel
17246485	Positive_Correlation	rs267607117	D007644	Novel

08351758|t|HPV, penicillin, and language delay: genetic and pharmacological interactions with rs10954213 and CDG 
08351758|a|This study investigates the complex interplay between human papillomavirus (HPV), penicillin, language delay, and the genetic variant rs10954213 in the context of congenital disorders of glycosylation (CDG) in sheep. Our findings reveal a negative correlation between language delay and penicillin, suggesting that penicillin administration may exacerbate or contribute to language delay in certain populations. Conversely, lithium exhibits a positive correlation with penicillin, indicating a potential synergistic effect in modulating biological pathways. The sequence variant rs10954213 shows a positive correlation with language delay, while also displaying a negative correlation with both penicillin and CDG. These results suggest that rs10954213 may play a dual role in influencing language development and metabolic processes. Additionally, CDG is associated with rs10954213, and there is a negative correlation between CDG and lithium, implying that lithium may have a protective effect against CDG. Furthermore, dopamine D2 receptor antagonists demonstrate a positive correlation with penicillin, highlighting potential therapeutic applications in managing conditions involving both neurochemical and pharmacological interactions. These findings underscore the intricate relationships between genetic variants, pharmacological agents, and phenotypic outcomes in both human and animal models.
08351758	0	3	HPV	OrganismTaxon	10566
08351758	5	15	penicillin	ChemicalEntity	D010406
08351758	21	35	language delay	DiseaseOrPhenotypicFeature	D007805
08351758	83	93	rs10954213	SequenceVariant	rs10954213
08351758	98	101	CDG	DiseaseOrPhenotypicFeature	D018981
08351758	179	182	HPV	OrganismTaxon	10566
08351758	185	195	penicillin	ChemicalEntity	D010406
08351758	197	211	language delay	DiseaseOrPhenotypicFeature	D007805
08351758	237	247	rs10954213	SequenceVariant	rs10954213
08351758	305	308	CDG	DiseaseOrPhenotypicFeature	D018981
08351758	313	318	sheep	OrganismTaxon	9940
08351758	371	385	language delay	DiseaseOrPhenotypicFeature	D007805
08351758	390	400	penicillin	ChemicalEntity	D010406
08351758	418	428	penicillin	ChemicalEntity	D010406
08351758	476	490	language delay	DiseaseOrPhenotypicFeature	D007805
08351758	527	534	lithium	ChemicalEntity	D008094
08351758	572	582	penicillin	ChemicalEntity	D010406
08351758	682	692	rs10954213	SequenceVariant	rs10954213
08351758	727	741	language delay	DiseaseOrPhenotypicFeature	D007805
08351758	798	808	penicillin	ChemicalEntity	D010406
08351758	813	816	CDG	DiseaseOrPhenotypicFeature	D018981
08351758	845	855	rs10954213	SequenceVariant	rs10954213
08351758	952	955	CDG	DiseaseOrPhenotypicFeature	D018981
08351758	975	985	rs10954213	SequenceVariant	rs10954213
08351758	1031	1034	CDG	DiseaseOrPhenotypicFeature	D018981
08351758	1039	1046	lithium	ChemicalEntity	D008094
08351758	1062	1069	lithium	ChemicalEntity	D008094
08351758	1107	1110	CDG	DiseaseOrPhenotypicFeature	D018981
08351758	1125	1157	dopamine D2 receptor antagonists	ChemicalEntity	D065127
08351758	1198	1208	penicillin	ChemicalEntity	D010406
08351758	Negative_Correlation	D007805	D010406	Novel
08351758	Positive_Correlation	D008094	D010406	Novel
08351758	Negative_Correlation	rs10954213	D007805	Novel
08351758	Positive_Correlation	D007805	rs10954213	Novel
08351758	Association	D018981	rs10954213	Novel
08351758	Negative_Correlation	D018981	D010406	Novel
08351758	Negative_Correlation	rs10954213	D010406	Novel
08351758	Negative_Correlation	rs10954213	D018981	Novel
08351758	Negative_Correlation	D018981	D008094	Novel
08351758	Positive_Correlation	D065127	D010406	Novel

12971911|t|Genetic variants and cellular models in the pathogenesis of autoimmune diabetes and related ph
12971911|a|This study investigates the molecular mechanisms underlying the development of autoimmune diabetes and associated phenotypes, using a combination of genetic variants and cellular models. We focus on the sequence variants A/G transition -1,071 bp, R266W, p.R428C, and G145R, and their associations with various disease states. The A/G transition -1,071 bp variant shows a positive correlation with both retinopathy of prematurity and radiculopathy, suggesting a potential role in neurodevelopmental and inflammatory pathways. Additionally, the G145R variant is associated with p.R428C, indicating a possible functional interaction between these two sequence variants.   We examined the effects of these genetic variants in multiple cell lines, including DUCaP, SNU-C2A, SCID-HuH-7, 293T, and Mz-ChA-1. The results suggest that the A/G transition -1,071 bp variant may contribute to the pathogenesis of autoimmune diabetes by modulating immune responses. Furthermore, the association between asparagine deficit and the A/G transition -1,071 bp variant supports a potential metabolic link between genetic variation and disease progression.   The study also highlights the role of radiculopathy in the context of autoimmune diabetes, with a positive correlation observed between radiculopathy and both the A/G transition -1,071 bp variant and the G145R variant. These findings suggest that genetic factors may influence the development of both neurological and autoimmune features.   In addition to autoimmune diabetes, the study explores the relationship between genetic variants and other phenotypes, including cone-rod dystrophy, Nephronophthisis, and tumorigenesis. The findings provide a framework for understanding the complex interplay between genetic variation, cellular function, and disease manifestation in multiple systems.
12971911	60	79	autoimmune diabetes	DiseaseOrPhenotypicFeature	D003922
12971911	174	193	autoimmune diabetes	DiseaseOrPhenotypicFeature	D003922
12971911	316	340	A/G transition -1,071 bp	SequenceVariant	c|SUB|A|-1071|G
12971911	342	347	R266W	SequenceVariant	p|SUB|R|266|W
12971911	349	356	p.R428C	SequenceVariant	rs750700202
12971911	362	367	G145R	SequenceVariant	p|SUB|G|145|R
12971911	425	449	A/G transition -1,071 bp	SequenceVariant	c|SUB|A|-1071|G
12971911	497	523	retinopathy of prematurity	DiseaseOrPhenotypicFeature	D012178
12971911	528	541	radiculopathy	DiseaseOrPhenotypicFeature	D011843
12971911	638	643	G145R	SequenceVariant	p|SUB|G|145|R
12971911	671	678	p.R428C	SequenceVariant	rs750700202
12971911	848	853	DUCaP	CellLine	CVCL_2025
12971911	855	862	SNU-C2A	CellLine	CVCL_1709
12971911	864	874	SCID-HuH-7	CellLine	CVCL_0336
12971911	876	880	293T	CellLine	CVCL_0063
12971911	886	894	Mz-ChA-1	CellLine	CVCL_6932
12971911	925	949	A/G transition -1,071 bp	SequenceVariant	c|SUB|A|-1071|G
12971911	996	1015	autoimmune diabetes	DiseaseOrPhenotypicFeature	D003922
12971911	1085	1103	asparagine deficit	DiseaseOrPhenotypicFeature	OMIM:615574
12971911	1112	1136	A/G transition -1,071 bp	SequenceVariant	c|SUB|A|-1071|G
12971911	1272	1285	radiculopathy	DiseaseOrPhenotypicFeature	D011843
12971911	1304	1323	autoimmune diabetes	DiseaseOrPhenotypicFeature	D003922
12971911	1370	1383	radiculopathy	DiseaseOrPhenotypicFeature	D011843
12971911	1397	1421	A/G transition -1,071 bp	SequenceVariant	c|SUB|A|-1071|G
12971911	1438	1443	G145R	SequenceVariant	p|SUB|G|145|R
12971911	1590	1609	autoimmune diabetes	DiseaseOrPhenotypicFeature	D003922
12971911	1704	1722	cone-rod dystrophy	DiseaseOrPhenotypicFeature	D000071700
12971911	1724	1740	Nephronophthisis	DiseaseOrPhenotypicFeature	C537699
12971911	1746	1759	tumorigenesis	DiseaseOrPhenotypicFeature	D009369
12971911	Positive_Correlation	OMIM:615574	c|SUB|A|-1071|G	Novel
12971911	Association	p|SUB|G|145|R	rs750700202	Novel
12971911	Positive_Correlation	D011843	c|SUB|A|-1071|G	Novel
12971911	Positive_Correlation	D011843	p|SUB|G|145|R	Novel

97666082|t|Nonsteroidal antiinflammatory drugs and Kilham rat virus: interactions with transferrin receptor 2, MLYCD, and GLUT8 in bovine and C. elegans models of hypotensive ph
97666082|a|Recent studies have revealed complex interactions between nonsteroidal antiinflammatory drugs (NSAIDs), Kilham rat virus, and the gene product transferrin receptor 2 (TfR2) in the context of hypotensive phenotypes. These interactions are further modulated by the expression of MLYCD and GLUT8, which are critical in maintaining cellular homeostasis. In bovine models, the association between NSAIDs and TfR2 has been consistently observed, with evidence suggesting a direct interaction between these two entities. Similarly, the association between NSAIDs and MLYCD has been demonstrated, highlighting a potential role for MLYCD in mediating the effects of NSAIDs on vascular function.   In C. elegans, the gene product GLUT8 has been found to exhibit a negative correlation with TfR2, suggesting a regulatory relationship between these two proteins. This negative correlation is further supported by the negative correlation between GLUT8 and MLYCD, indicating a complex network of interactions among these gene products. Additionally, the association between MLYCD and GLUT8 has been confirmed through both binding assays and functional studies, reinforcing the idea of a direct interaction between these two proteins.   The hypotensive phenotype has been shown to be associated with both TfR2 and GLUT8, with a positive correlation between GLUT8 and hypotensive states. However, this association is counterbalanced by a negative correlation between TfR2 and hypotensive phenotypes, suggesting that TfR2 may act as a protective factor against hypotension. The negative correlation between MLYCD and GLUT8 further complicates the regulatory landscape, as it implies that the expression of these two proteins may be mutually exclusive in certain contexts.   Amiodarone has also been found to interact with GLUT8, with evidence of a direct association between the two. This interaction may have implications for the treatment of hypotensive conditions, as amiodarone is known to affect vascular tone. Overall, these findings underscore the intricate relationships between NSAIDs, Kilham rat virus, TfR2, MLYCD, and GLUT8 in the context of hypotensive phenotypes, with significant implications for both bovine and C. elegans models.
97666082	40	56	Kilham rat virus	OrganismTaxon	12441
97666082	76	98	transferrin receptor 2	GeneOrGeneProduct	7036
97666082	100	105	MLYCD	GeneOrGeneProduct	23417
97666082	111	116	GLUT8	GeneOrGeneProduct	56017
97666082	120	126	bovine	OrganismTaxon	9913
97666082	131	141	C. elegans	OrganismTaxon	6239
97666082	152	163	hypotensive	DiseaseOrPhenotypicFeature	D007022
97666082	225	260	nonsteroidal antiinflammatory drugs	ChemicalEntity	D000894
97666082	271	287	Kilham rat virus	OrganismTaxon	12441
97666082	310	332	transferrin receptor 2	GeneOrGeneProduct	7036
97666082	358	369	hypotensive	DiseaseOrPhenotypicFeature	D007022
97666082	444	449	MLYCD	GeneOrGeneProduct	23417
97666082	454	459	GLUT8	GeneOrGeneProduct	56017
97666082	520	526	bovine	OrganismTaxon	9913
97666082	727	732	MLYCD	GeneOrGeneProduct	23417
97666082	790	795	MLYCD	GeneOrGeneProduct	23417
97666082	858	868	C. elegans	OrganismTaxon	6239
97666082	887	892	GLUT8	GeneOrGeneProduct	56017
97666082	1101	1106	GLUT8	GeneOrGeneProduct	56017
97666082	1111	1116	MLYCD	GeneOrGeneProduct	23417
97666082	1228	1233	MLYCD	GeneOrGeneProduct	23417
97666082	1238	1243	GLUT8	GeneOrGeneProduct	56017
97666082	1394	1405	hypotensive	DiseaseOrPhenotypicFeature	D007022
97666082	1467	1472	GLUT8	GeneOrGeneProduct	56017
97666082	1510	1515	GLUT8	GeneOrGeneProduct	56017
97666082	1520	1531	hypotensive	DiseaseOrPhenotypicFeature	D007022
97666082	1628	1639	hypotensive	DiseaseOrPhenotypicFeature	D007022
97666082	1758	1763	MLYCD	GeneOrGeneProduct	23417
97666082	1768	1773	GLUT8	GeneOrGeneProduct	56017
97666082	1973	1978	GLUT8	GeneOrGeneProduct	56017
97666082	2095	2106	hypotensive	DiseaseOrPhenotypicFeature	D007022
97666082	2122	2132	amiodarone	ChemicalEntity	D000638
97666082	2246	2262	Kilham rat virus	OrganismTaxon	12441
97666082	2270	2275	MLYCD	GeneOrGeneProduct	23417
97666082	2281	2286	GLUT8	GeneOrGeneProduct	56017
97666082	2305	2316	hypotensive	DiseaseOrPhenotypicFeature	D007022
97666082	2368	2374	bovine	OrganismTaxon	9913
97666082	2379	2389	C. elegans	OrganismTaxon	6239
97666082	Negative_Correlation	D007022	7036	Novel
97666082	Association	23417	56017	Novel
97666082	Bind	23417	56017	Novel
97666082	Negative_Correlation	7036	56017	Novel
97666082	Negative_Correlation	23417	56017	Novel
97666082	Negative_Correlation	56017	7036	Novel
97666082	Association	D007022	56017	Novel
97666082	Negative_Correlation	7036	23417	Novel
97666082	Association	D007022	D000894	Novel
97666082	Association	D000894	7036	Novel
97666082	Association	7036	56017	Novel
97666082	Association	D000894	23417	Novel
97666082	Association	D000638	56017	Novel
97666082	Bind	7036	56017	Novel
97666082	Negative_Correlation	56017	23417	Novel
97666082	Positive_Correlation	56017	D007022	Novel
97666082	Association	7036	23417	Novel
97666082	Negative_Correlation	D007022	56017	Novel

28783924|t|AAS and ESA: interactions with tissue injury and chronic periodontitis in the context of genetic sequence 
28783924|a|This study investigates the complex interplay between the chemical entities AAS and ESA, and their associations with tissue injury and chronic periodontitis, in the context of multiple sequence variants. AAS was found to have a negative correlation with both tissue injury and chronic periodontitis, suggesting a protective role in these conditions. In contrast, ESA exhibited a negative correlation with tissue injury, indicating a potential therapeutic benefit in mitigating tissue damage. However, ESA also showed a negative correlation with chronic periodontitis, which may imply a dual effect on different pathological processes. Notably, a drug interaction was observed between AAS and ESA, with both AAS and ESA showing a drug interaction with each other, suggesting that their combined use may require careful monitoring. The study also identified the sequence variant c.1052delA, which was associated with the insertion/deletion (long allele-L/short allele-S) of 43 bp, and the amino acid substitution of arginine by glutamine at amino acid position 714. These variants were found to be present in multiple individuals, highlighting their potential role in modulating the effects of AAS and ESA on tissue injury and chronic periodontitis. The findings underscore the importance of considering genetic variability when evaluating the therapeutic potential and side effects of AAS and ESA in clinical settings.
28783924	0	3	AAS	ChemicalEntity	D045165
28783924	8	11	ESA	ChemicalEntity	D006397
28783924	31	44	tissue injury	DiseaseOrPhenotypicFeature	D017695
28783924	49	70	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
28783924	183	186	AAS	ChemicalEntity	D045165
28783924	191	194	ESA	ChemicalEntity	D006397
28783924	224	237	tissue injury	DiseaseOrPhenotypicFeature	D017695
28783924	242	263	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
28783924	311	314	AAS	ChemicalEntity	D045165
28783924	366	379	tissue injury	DiseaseOrPhenotypicFeature	D017695
28783924	384	405	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
28783924	470	473	ESA	ChemicalEntity	D006397
28783924	512	525	tissue injury	DiseaseOrPhenotypicFeature	D017695
28783924	608	611	ESA	ChemicalEntity	D006397
28783924	652	673	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
28783924	791	794	AAS	ChemicalEntity	D045165
28783924	799	802	ESA	ChemicalEntity	D006397
28783924	814	817	AAS	ChemicalEntity	D045165
28783924	822	825	ESA	ChemicalEntity	D006397
28783924	984	994	c.1052delA	SequenceVariant	rs137853893
28783924	1026	1084	insertion/deletion (long allele-L/short allele-S) of 43 bp	SequenceVariant	c|INDEL||43
28783924	1121	1169	arginine by glutamine at amino acid position 714	SequenceVariant	c|SUB|R|714|Q
28783924	1299	1302	AAS	ChemicalEntity	D045165
28783924	1307	1310	ESA	ChemicalEntity	D006397
28783924	1314	1327	tissue injury	DiseaseOrPhenotypicFeature	D017695
28783924	1332	1353	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
28783924	1491	1494	AAS	ChemicalEntity	D045165
28783924	1499	1502	ESA	ChemicalEntity	D006397
28783924	Negative_Correlation	D045165	D055113	Novel
28783924	Negative_Correlation	D006397	D017695	Novel
28783924	Drug_Interaction	D045165	D006397	Novel
28783924	Drug_Interaction	D006397	D045165	Novel
28783924	Negative_Correlation	D006397	D055113	Novel
28783924	Negative_Correlation	D045165	D017695	Novel

45093810|t|D542A Mutation in C. elegans and Its Multifaceted Implications in Neurological Disorders, Ovarian Malignancies, and Drug Me
45093810|a|This study investigates the multifaceted biological and pharmacological implications of the D542A sequence variant in C. elegans, with a focus on its associations with neurological phenotypes, ovarian malignancies, and drug metabolism. The D542A mutation was found to be strongly associated with abnormal movements, bradykinesia, and LCA, suggesting a potential role in neurodegenerative processes. Additionally, the mutation showed a significant link with ovarian epithelial malignancy, indicating possible oncogenic or tumor-suppressive effects in this context.   The D542A variant was also associated with primary microcephaly, highlighting its potential involvement in developmental pathways. In parallel, the study explored the conversion and comparison between Methadone and metrifonate, revealing a complex interplay between these two chemical entities. The findings suggest that Methadone and metrifonate may have overlapping or distinct pharmacological profiles, with implications for their use in therapeutic settings.   The study further examined the effects of Methadone and metrifonate on C. elegans, with particular attention to their interactions with the D542A mutation. The results indicate that the mutation may influence the metabolic pathways of these drugs, potentially altering their efficacy or toxicity. The research also included the use of H446 and MCF7/AdrR cell lines to model the effects of the D542A mutation in human-derived systems, providing insights into its broader biological relevance.   The study underscores the importance of understanding the molecular mechanisms underlying the D542A mutation and its interactions with various disease states and chemical entities. These findings have significant implications for the development of targeted therapies and the management of neurological and oncological conditions in both C. elegans and human models.
45093810	0	5	D542A	SequenceVariant	p|SUB|D|542|A
45093810	18	28	C. elegans	OrganismTaxon	6239
45093810	216	221	D542A	SequenceVariant	p|SUB|D|542|A
45093810	242	252	C. elegans	OrganismTaxon	6239
45093810	364	369	D542A	SequenceVariant	p|SUB|D|542|A
45093810	420	438	abnormal movements	DiseaseOrPhenotypicFeature	D009069
45093810	440	452	bradykinesia	DiseaseOrPhenotypicFeature	D018476
45093810	458	461	LCA	DiseaseOrPhenotypicFeature	D057130
45093810	581	610	ovarian epithelial malignancy	DiseaseOrPhenotypicFeature	D002277
45093810	694	699	D542A	SequenceVariant	p|SUB|D|542|A
45093810	733	753	primary microcephaly	DiseaseOrPhenotypicFeature	D008831
45093810	891	900	Methadone	ChemicalEntity	D008691
45093810	905	916	metrifonate	ChemicalEntity	D014236
45093810	1011	1020	Methadone	ChemicalEntity	D008691
45093810	1025	1036	metrifonate	ChemicalEntity	D014236
45093810	1197	1206	Methadone	ChemicalEntity	D008691
45093810	1211	1222	metrifonate	ChemicalEntity	D014236
45093810	1226	1236	C. elegans	OrganismTaxon	6239
45093810	1295	1300	D542A	SequenceVariant	p|SUB|D|542|A
45093810	1490	1494	H446	CellLine	CVCL_1562
45093810	1499	1508	MCF7/AdrR	CellLine	 CVCL_1452
45093810	1548	1553	D542A	SequenceVariant	p|SUB|D|542|A
45093810	1743	1748	D542A	SequenceVariant	p|SUB|D|542|A
45093810	1987	1997	C. elegans	OrganismTaxon	6239
45093810	Conversion	D008691	D014236	Novel
45093810	Association	D009069	p|SUB|D|542|A	Novel
45093810	Association	p|SUB|D|542|A	D018476	Novel
45093810	Association	p|SUB|D|542|A	D057130	Novel
45093810	Association	D002277	p|SUB|D|542|A	Novel
45093810	Conversion	D014236	D008691	Novel
45093810	Association	D008831	p|SUB|D|542|A	Novel
45093810	Association	p|SUB|D|542|A	C538237	Novel
45093810	Association	p|SUB|D|542|A	D008831	Novel
45093810	Comparison	D014236	D008691	Novel
45093810	Association	p|SUB|D|542|A	D002277	Novel
45093810	Comparison	D008691	D014236	Novel
45093810	Association	p|SUB|D|542|A	D009069	Novel

00960940|t|Ginsenoside Re and I280S: Interactions, conversions, and correlations across multiple organisms and ce
00960940|a|Ginsenoside Re, a bioactive compound derived from ginseng, has been shown to exhibit complex interactions with the sequence variant I280S across various biological contexts. This study investigates the molecular and functional relationships between ginsenoside Re and I280S, as well as their interactions with Terfenadine, in multiple cell lines and organisms. The research was conducted using the human cell lines SNU-C5, HEK, CD18/HPAF, and Ba/F3, as well as the model organisms man, ginseng, Mangifera indica Linn, and E. coli.   The findings reveal a significant association between I280S and ginsenoside Re, with both positive and negative correlations observed in different experimental conditions. Notably, a positive correlation between I280S and ginsenoside Re was detected in SNU-C5 and HEK cell lines, while a negative correlation was observed in CD18/HPAF and Ba/F3. These results suggest that the relationship between I280S and ginsenoside Re is context-dependent and may involve complex regulatory mechanisms.  Further, the study demonstrates a conversion between ginsenoside Re and Terfenadine, with evidence of mutual conversion in both directions. This conversion was most prominent in HEK and CD18/HPAF cell lines, and the association between Terfenadine and I280S was confirmed through biochemical assays. A positive correlation between Terfenadine and ginsenoside Re was observed in SNU-C5 and HEK, while a negative correlation was noted in Ba/F3 and CD18/HPAF.   The comparison between Terfenadine and ginsenoside Re revealed distinct pharmacological profiles, with Terfenadine showing greater affinity for certain receptors in man and ginseng. Additionally, the study highlights the importance of the sequence variant I280S in modulating the interactions between Terfenadine and ginsenoside Re, with both positive and negative correlations observed across different organisms and cell lines.   These findings provide a comprehensive understanding of the molecular interactions and functional relationships between ginsenoside Re, I280S, and Terfenadine, offering new insights into their potential therapeutic applications and biological roles in diverse systems.
00960940	19	24	I280S	SequenceVariant	p|SUB|I|280|S
00960940	153	160	ginseng	OrganismTaxon	4054
00960940	235	240	I280S	SequenceVariant	p|SUB|I|280|S
00960940	352	366	ginsenoside Re	ChemicalEntity	C049864
00960940	371	376	I280S	SequenceVariant	p|SUB|I|280|S
00960940	413	424	Terfenadine	ChemicalEntity	D016593
00960940	503	506	man	OrganismTaxon	9606
00960940	518	524	SNU-C5	CellLine	CVCL_5112
00960940	526	529	HEK	CellLine	CVCL_M624
00960940	531	540	CD18/HPAF	CellLine	CVCL_0313
00960940	546	551	Ba/F3	CellLine	CVCL_0161
00960940	584	587	man	OrganismTaxon	9606
00960940	589	596	ginseng	OrganismTaxon	4054
00960940	598	619	Mangifera indica Linn	OrganismTaxon	29780
00960940	625	632	E. coli	OrganismTaxon	562
00960940	690	695	I280S	SequenceVariant	p|SUB|I|280|S
00960940	700	714	ginsenoside Re	ChemicalEntity	C049864
00960940	848	853	I280S	SequenceVariant	p|SUB|I|280|S
00960940	858	872	ginsenoside Re	ChemicalEntity	C049864
00960940	889	895	SNU-C5	CellLine	CVCL_5112
00960940	900	903	HEK	CellLine	CVCL_M624
00960940	961	970	CD18/HPAF	CellLine	CVCL_0313
00960940	975	980	Ba/F3	CellLine	CVCL_0161
00960940	1034	1039	I280S	SequenceVariant	p|SUB|I|280|S
00960940	1044	1058	ginsenoside Re	ChemicalEntity	C049864
00960940	1181	1195	ginsenoside Re	ChemicalEntity	C049864
00960940	1200	1211	Terfenadine	ChemicalEntity	D016593
00960940	1306	1309	HEK	CellLine	CVCL_M624
00960940	1314	1323	CD18/HPAF	CellLine	CVCL_0313
00960940	1364	1375	Terfenadine	ChemicalEntity	D016593
00960940	1380	1385	I280S	SequenceVariant	p|SUB|I|280|S
00960940	1459	1470	Terfenadine	ChemicalEntity	D016593
00960940	1475	1489	ginsenoside Re	ChemicalEntity	C049864
00960940	1506	1512	SNU-C5	CellLine	CVCL_5112
00960940	1517	1520	HEK	CellLine	CVCL_M624
00960940	1564	1569	Ba/F3	CellLine	CVCL_0161
00960940	1574	1583	CD18/HPAF	CellLine	CVCL_0313
00960940	1610	1621	Terfenadine	ChemicalEntity	D016593
00960940	1626	1640	ginsenoside Re	ChemicalEntity	C049864
00960940	1690	1701	Terfenadine	ChemicalEntity	D016593
00960940	1752	1755	man	OrganismTaxon	9606
00960940	1760	1767	ginseng	OrganismTaxon	4054
00960940	1843	1848	I280S	SequenceVariant	p|SUB|I|280|S
00960940	1888	1899	Terfenadine	ChemicalEntity	D016593
00960940	1904	1918	ginsenoside Re	ChemicalEntity	C049864
00960940	2139	2153	ginsenoside Re	ChemicalEntity	C049864
00960940	2155	2160	I280S	SequenceVariant	p|SUB|I|280|S
00960940	2166	2177	Terfenadine	ChemicalEntity	D016593
00960940	Association	p|SUB|I|280|S	C049864	Novel
00960940	Conversion	C049864	D016593	Novel
00960940	Association	p|SUB|I|280|S	D016593	Novel
00960940	Conversion	D016593	C049864	Novel
00960940	Association	D016593	p|SUB|I|280|S	Novel
00960940	Comparison	C049864	D016593	Novel
00960940	Positive_Correlation	p|SUB|I|280|S	D016593	Novel
00960940	Negative_Correlation	p|SUB|I|280|S	D016593	Novel
00960940	Negative_Correlation	p|SUB|I|280|S	C049864	Novel
00960940	Comparison	D016593	C049864	Novel
00960940	Positive_Correlation	D016593	C049864	Novel
00960940	Positive_Correlation	C049864	D016593	Novel
00960940	Association	C049864	p|SUB|I|280|S	Novel
00960940	Positive_Correlation	p|SUB|I|280|S	C049864	Novel

51251131|t|Genetic Variants and Their Functional Associations in Platonia insignis Mart, Zebrafish, and Other O
51251131|a|This study investigates the functional and genetic associations of multiple sequence variants across various organisms, including Platonia insignis Mart, zebrafish, and others. We focus on the interactions between specific sequence variants and their potential roles in biological processes. The sequence variant p.W290L is associated with IVS3 + 18C > T, which in turn is linked to Gln27Glu. Additionally, p.T286M is functionally connected to both E359K and G-->A, while also showing an association with IVS3 + 18C > T. The 8 nucleotide deletion is found to be related to Gln27Glu, p.T286M, and G-->A, highlighting its potential role in genetic regulation. Furthermore, E359K is associated with both IVS3 + 18C > T and Gln27Glu, reinforcing the complex network of interactions among these variants. The study also includes the organism taxon HBV, West Nile virus, HPV, rat, Spirulina, and cats, with the zebrafish (Danio rerio) and Platonia insignis Mart being central to the experimental design. The findings suggest that these genetic variants may play a significant role in the biological functions of these organisms, and further research is warranted to explore their implications in health and disease.
51251131	54	76	Platonia insignis Mart	OrganismTaxon	198787
51251131	231	253	Platonia insignis Mart	OrganismTaxon	198787
51251131	255	264	zebrafish	OrganismTaxon	7955
51251131	414	421	p.W290L	SequenceVariant	rs267607117
51251131	441	455	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
51251131	484	492	Gln27Glu	SequenceVariant	p|SUB|Q|27|E
51251131	508	515	p.T286M	SequenceVariant	rs193302860
51251131	550	555	E359K	SequenceVariant	rs368489876
51251131	560	565	G-->A	SequenceVariant	c|SUB|G||A
51251131	606	620	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
51251131	626	647	8 nucleotide deletion	SequenceVariant	c|DEL||8
51251131	674	682	Gln27Glu	SequenceVariant	p|SUB|Q|27|E
51251131	684	691	p.T286M	SequenceVariant	rs193302860
51251131	697	702	G-->A	SequenceVariant	c|SUB|G||A
51251131	772	777	E359K	SequenceVariant	rs368489876
51251131	802	816	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
51251131	821	829	Gln27Glu	SequenceVariant	p|SUB|Q|27|E
51251131	944	947	HBV	OrganismTaxon	10407
51251131	949	964	West Nile virus	OrganismTaxon	11082
51251131	966	969	HPV	OrganismTaxon	10566
51251131	971	974	rat	OrganismTaxon	10116
51251131	976	985	Spirulina	OrganismTaxon	551299
51251131	991	995	cats	OrganismTaxon	9685
51251131	1006	1015	zebrafish	OrganismTaxon	7955
51251131	1017	1028	Danio rerio	OrganismTaxon	7955
51251131	1034	1056	Platonia insignis Mart	OrganismTaxon	198787
51251131	Association	rs267607117	c|SUB|C|IVS3+18|T	Novel
51251131	Association	c|SUB|C|IVS3+18|T	p|SUB|Q|27|E	Novel
51251131	Association	rs193302860	rs368489876	Novel
51251131	Association	p|SUB|Q|27|E	rs193302860	Novel
51251131	Association	rs193302860	c|SUB|G||A	Novel
51251131	Association	c|DEL||8	p|SUB|Q|27|E	Novel
51251131	Association	c|DEL||8	rs193302860	Novel
51251131	Association	c|SUB|G||A	p|SUB|Q|27|E	Novel
51251131	Association	c|DEL||8	c|SUB|G||A	Novel
51251131	Association	rs368489876	c|SUB|C|IVS3+18|T	Novel
51251131	Association	rs368489876	p|SUB|Q|27|E	Novel
51251131	Association	c|SUB|C|IVS3+18|T	rs193302860	Novel
51251131	Association	rs193302860	c|SUB|C|IVS3+18|T	Novel
51251131	Association	p|SUB|Q|27|E	rs368489876	Novel
51251131	Association	c|SUB|C|IVS3+18|T	c|DEL||8	Novel
51251131	Association	p|SUB|Q|27|E	c|SUB|G||A	Novel

70401499|t|Genetic and pharmacological modulation of TACC1 and CXCL5 in bovine and bacterial systems: implications for cytoskeletal dynamics and immune 
70401499|a|This study investigates the genetic and pharmacological modulation of TACC1 and CXCL5 in bovine and bacterial systems, with a focus on their roles in cytoskeletal dynamics and immune response. Using the HL-7702 cell line, we demonstrate that the four-basepair deletion in the TACC1 gene is associated with altered expression of CXCL5, a chemokine critical for immune cell recruitment. This association is further supported by the finding that the sequence variant rs204890 is also linked to the four-basepair deletion, suggesting a potential regulatory mechanism. Additionally, the sequence variant glycine (Gly) with arginine (Arg) is found to be associated with the four-basepair deletion, highlighting the complexity of genetic interactions in this pathway.   In parallel, we explore the pharmacological effects of cytochalasin B and 5-Aza-2'-deoxy-cytidine on the expression of Vps24 and CXCL5. Our results show that 5-Aza-2'-deoxy-cytidine binds to Vps24 and also binds to CXCL5, indicating a potential role for DNA methylation in regulating these genes. Furthermore, we observe a negative correlation between glutamine and Ritanserin, suggesting a possible interaction between amino acid metabolism and serotonergic signaling.   The study also includes experiments with Toxorynchites mosquitoes and bacteria, where the presence of bovine-derived factors influences the expression of Vps24 and CXCL5. These findings underscore the importance of cross-species interactions in modulating gene expression and cellular function. Overall, this work provides new insights into the genetic and pharmacological regulation of TACC1 and CXCL5, with potential applications in understanding immune responses and cytoskeletal dynamics in both mammalian and microbial systems.
70401499	42	47	TACC1	GeneOrGeneProduct	6867
70401499	52	57	CXCL5	GeneOrGeneProduct	6374
70401499	61	67	bovine	OrganismTaxon	9913
70401499	72	80	bacteria	OrganismTaxon	2
70401499	212	217	TACC1	GeneOrGeneProduct	6867
70401499	222	227	CXCL5	GeneOrGeneProduct	6374
70401499	231	237	bovine	OrganismTaxon	9913
70401499	242	250	bacteria	OrganismTaxon	2
70401499	345	352	HL-7702	CellLine	CVCL_6926
70401499	388	410	four-basepair deletion	SequenceVariant	c|DEL||4
70401499	418	423	TACC1	GeneOrGeneProduct	6867
70401499	470	475	CXCL5	GeneOrGeneProduct	6374
70401499	606	614	rs204890	SequenceVariant	rs204890
70401499	637	659	four-basepair deletion	SequenceVariant	c|DEL||4
70401499	741	774	glycine (Gly) with arginine (Arg)	SequenceVariant	rs351855
70401499	810	832	four-basepair deletion	SequenceVariant	c|DEL||4
70401499	960	974	cytochalasin B	ChemicalEntity	D003571
70401499	979	1002	5-Aza-2'-deoxy-cytidine	ChemicalEntity	D000077209
70401499	1024	1029	Vps24	GeneOrGeneProduct	51652
70401499	1034	1039	CXCL5	GeneOrGeneProduct	6374
70401499	1063	1086	5-Aza-2'-deoxy-cytidine	ChemicalEntity	D000077209
70401499	1096	1101	Vps24	GeneOrGeneProduct	51652
70401499	1120	1125	CXCL5	GeneOrGeneProduct	6374
70401499	1257	1266	glutamine	ChemicalEntity	D018698
70401499	1271	1281	Ritanserin	ChemicalEntity	D016713
70401499	1418	1442	Toxorynchites mosquitoes	OrganismTaxon	2498889
70401499	1447	1455	bacteria	OrganismTaxon	2
70401499	1479	1485	bovine	OrganismTaxon	9913
70401499	1531	1536	Vps24	GeneOrGeneProduct	51652
70401499	1541	1546	CXCL5	GeneOrGeneProduct	6374
70401499	1764	1769	TACC1	GeneOrGeneProduct	6867
70401499	1774	1779	CXCL5	GeneOrGeneProduct	6374
70401499	Association	c|DEL||4	6374	Novel
70401499	Bind	596	D018698	Novel
70401499	Association	c|DEL||4	rs204890	Novel
70401499	Bind	D000077209	51652	Novel
70401499	Negative_Correlation	D018698	D016713	Novel
70401499	Bind	D000077209	6374	Novel
70401499	Association	rs204890	51652	Novel
70401499	Association	rs351855	c|DEL||4	Novel

14473811|t|Alpha-ENaC and IL-5 interactions in KU7 and C57BL/6J cell lines: implications for hepatorenal syndrome, colon carcinoma, and steroid 5alpha-reductase deficienc
14473811|a|This study investigates the molecular interactions between alpha-ENaC and IL-5 in the context of KU7 and C57BL/6J cell lines, with a focus on their potential roles in hepatorenal syndrome, colon carcinoma, and steroid 5alpha-reductase deficiency type 2. Using a combination of biochemical assays and functional genomics, we demonstrate a significant association between alpha-ENaC and IL-5, suggesting a potential regulatory mechanism in cellular signaling pathways. The findings are further supported by the observation that IL-5 expression is modulated in response to Ca2+ influx, which is positively correlated with OXC levels. Additionally, we report a positive correlation between OXC and triglyceride accumulation, highlighting the metabolic implications of these interactions.   Our analysis also reveals a negative correlation between Giant cell tumor of bone and escitalopram, as well as between Giant cell tumor of bone and Antithrombin. These results suggest that escitalopram and Antithrombin may have protective roles against the progression of Giant cell tumor of bone. Furthermore, we observe a negative correlation between steroid 5alpha-reductase deficiency type 2 and Antithrombin, indicating a potential regulatory relationship in the context of androgen metabolism.   The study also explores the role of Let-7b in modulating these interactions, with evidence suggesting its involvement in the regulation of alpha-ENaC and IL-5 expression. The findings provide new insights into the complex interplay between genetic, metabolic, and pathological factors in diseases such as hepatorenal syndrome, colon carcinoma, and steroid 5alpha-reductase deficiency type 2. These results have important implications for the development of targeted therapies and the understanding of disease mechanisms in these conditions.
14473811	15	19	IL-5	GeneOrGeneProduct	3567
14473811	36	39	KU7	CellLine	CVCL_4714
14473811	44	52	C57BL/6J	CellLine	CVCL_5U84
14473811	82	102	hepatorenal syndrome	DiseaseOrPhenotypicFeature	D006530
14473811	104	119	colon carcinoma	DiseaseOrPhenotypicFeature	D015179
14473811	219	229	alpha-ENaC	GeneOrGeneProduct	25122
14473811	234	238	IL-5	GeneOrGeneProduct	3567
14473811	257	260	KU7	CellLine	CVCL_4714
14473811	265	273	C57BL/6J	CellLine	CVCL_5U84
14473811	327	347	hepatorenal syndrome	DiseaseOrPhenotypicFeature	D006530
14473811	349	364	colon carcinoma	DiseaseOrPhenotypicFeature	D015179
14473811	370	412	steroid 5alpha-reductase deficiency type 2	DiseaseOrPhenotypicFeature	C535830
14473811	530	540	alpha-ENaC	GeneOrGeneProduct	25122
14473811	545	549	IL-5	GeneOrGeneProduct	3567
14473811	686	690	IL-5	GeneOrGeneProduct	3567
14473811	730	734	Ca2+	ChemicalEntity	D002118
14473811	779	782	OXC	ChemicalEntity	C036006
14473811	846	849	OXC	ChemicalEntity	C036006
14473811	854	866	triglyceride	ChemicalEntity	D014280
14473811	1003	1027	Giant cell tumor of bone	DiseaseOrPhenotypicFeature	D018212
14473811	1032	1044	escitalopram	ChemicalEntity	D015283
14473811	1065	1089	Giant cell tumor of bone	DiseaseOrPhenotypicFeature	D018212
14473811	1094	1106	Antithrombin	ChemicalEntity	D000991
14473811	1135	1147	escitalopram	ChemicalEntity	D015283
14473811	1152	1164	Antithrombin	ChemicalEntity	D000991
14473811	1218	1242	Giant cell tumor of bone	DiseaseOrPhenotypicFeature	D018212
14473811	1299	1341	steroid 5alpha-reductase deficiency type 2	DiseaseOrPhenotypicFeature	C535830
14473811	1346	1358	Antithrombin	ChemicalEntity	D000991
14473811	1484	1490	Let-7b	GeneOrGeneProduct	387245
14473811	1587	1597	alpha-ENaC	GeneOrGeneProduct	25122
14473811	1602	1606	IL-5	GeneOrGeneProduct	3567
14473811	1753	1773	hepatorenal syndrome	DiseaseOrPhenotypicFeature	D006530
14473811	1775	1790	colon carcinoma	DiseaseOrPhenotypicFeature	D015179
14473811	1796	1838	steroid 5alpha-reductase deficiency type 2	DiseaseOrPhenotypicFeature	C535830
14473811	Negative_Correlation	D018212	D015283	Novel
14473811	Negative_Correlation	D018212	D000991	Novel
14473811	Negative_Correlation	C535830	D000991	Novel
14473811	Association	25122	3567	Novel
14473811	Positive_Correlation	C036006	D014280	Novel
14473811	Positive_Correlation	D002118	C036006	Novel

04249540|t|BMP-2 and PTPN11 interactions in neurodegenerative diseases: implications for neuropathic pain, metachromatic leukodystrophy, and CN
04249540|a|Recent studies have highlighted the critical role of BMP-2 in modulating neurodegenerative processes, particularly in the context of neuropathic pain and metachromatic leukodystrophy. This research explores the molecular interactions between BMP-2 and key proteins such as PTPN11, alpha-syn, and the glucocorticoid receptor, with implications for disease mechanisms in both human and model organisms. In horses, BMP-2 has been shown to bind to PTPN11, suggesting a potential role in the regulation of inflammatory responses associated with metachromatic leukodystrophy. Similarly, in Drosophila, the association between BMP-2 and PTPN11 is further supported by functional studies demonstrating their cooperative effects in neuronal development.   The interaction between BMP-2 and alpha-syn is particularly relevant in the context of neuropathic pain and CNS injury, where these proteins are implicated in the pathogenesis of neurodegenerative conditions. In human immunodeficiency virus-infected individuals, the binding of BMP-2 to alpha-syn has been linked to altered pain signaling pathways. Furthermore, the association between the glucocorticoid receptor and BMP-2 is evident in both Drosophila and human models, with evidence of a direct bind between these two proteins. This interaction is also reinforced by the association between the glucocorticoid receptor and PTPN11, which is further supported by the bind between PTPN11 and the glucocorticoid receptor.   In women, the interplay between the glucocorticoid receptor and alpha-syn has been associated with the development of neuropathic pain, while the presence of type 1 diabetes in some patients suggests a broader role for these proteins in metabolic and neurodegenerative disorders. The repeated occurrence of metachromatic leukodystrophy in both horses and Drosophila underscores the evolutionary conservation of these molecular interactions. Additionally, the presence of Daucus carota in some experimental models highlights the potential for cross-species comparisons in understanding the functional roles of BMP-2, PTPN11, and alpha-syn in disease pathogenesis.
04249540	0	5	BMP-2	GeneOrGeneProduct	12156
04249540	10	16	PTPN11	GeneOrGeneProduct	5781
04249540	78	94	neuropathic pain	DiseaseOrPhenotypicFeature	D009437
04249540	96	124	metachromatic leukodystrophy	DiseaseOrPhenotypicFeature	D007966
04249540	186	191	BMP-2	GeneOrGeneProduct	12156
04249540	266	282	neuropathic pain	DiseaseOrPhenotypicFeature	D009437
04249540	287	315	metachromatic leukodystrophy	DiseaseOrPhenotypicFeature	D007966
04249540	375	380	BMP-2	GeneOrGeneProduct	12156
04249540	406	412	PTPN11	GeneOrGeneProduct	5781
04249540	414	423	alpha-syn	GeneOrGeneProduct	6622
04249540	433	456	glucocorticoid receptor	GeneOrGeneProduct	2908
04249540	537	543	horses	OrganismTaxon	9796
04249540	545	550	BMP-2	GeneOrGeneProduct	12156
04249540	577	583	PTPN11	GeneOrGeneProduct	5781
04249540	673	701	metachromatic leukodystrophy	DiseaseOrPhenotypicFeature	D007966
04249540	717	727	Drosophila	OrganismTaxon	7227
04249540	753	758	BMP-2	GeneOrGeneProduct	12156
04249540	763	769	PTPN11	GeneOrGeneProduct	5781
04249540	904	909	BMP-2	GeneOrGeneProduct	12156
04249540	914	923	alpha-syn	GeneOrGeneProduct	6622
04249540	967	983	neuropathic pain	DiseaseOrPhenotypicFeature	D009437
04249540	988	998	CNS injury	DiseaseOrPhenotypicFeature	D002493
04249540	1092	1120	human immunodeficiency virus	OrganismTaxon	12721
04249540	1158	1163	BMP-2	GeneOrGeneProduct	12156
04249540	1167	1176	alpha-syn	GeneOrGeneProduct	6622
04249540	1270	1293	glucocorticoid receptor	GeneOrGeneProduct	2908
04249540	1298	1303	BMP-2	GeneOrGeneProduct	12156
04249540	1323	1333	Drosophila	OrganismTaxon	7227
04249540	1478	1501	glucocorticoid receptor	GeneOrGeneProduct	2908
04249540	1506	1512	PTPN11	GeneOrGeneProduct	5781
04249540	1561	1567	PTPN11	GeneOrGeneProduct	5781
04249540	1576	1599	glucocorticoid receptor	GeneOrGeneProduct	2908
04249540	1606	1611	women	OrganismTaxon	9606
04249540	1639	1662	glucocorticoid receptor	GeneOrGeneProduct	2908
04249540	1667	1676	alpha-syn	GeneOrGeneProduct	6622
04249540	1721	1737	neuropathic pain	DiseaseOrPhenotypicFeature	D009437
04249540	1761	1776	type 1 diabetes	DiseaseOrPhenotypicFeature	D003922
04249540	1910	1938	metachromatic leukodystrophy	DiseaseOrPhenotypicFeature	D007966
04249540	1947	1953	horses	OrganismTaxon	9796
04249540	1958	1968	Drosophila	OrganismTaxon	7227
04249540	2074	2087	Daucus carota	OrganismTaxon	4039
04249540	2212	2217	BMP-2	GeneOrGeneProduct	12156
04249540	2219	2225	PTPN11	GeneOrGeneProduct	5781
04249540	2231	2240	alpha-syn	GeneOrGeneProduct	6622
04249540	Association	12156	6622	Novel
04249540	Bind	12156	5781	Novel
04249540	Bind	12156	6622	Novel
04249540	Association	5781	2908	Novel
04249540	Bind	2908	5781	Novel
04249540	Association	2908	12156	Novel
04249540	Bind	6622	12156	Novel
04249540	Bind	12156	2908	Novel
04249540	Bind	5781	6622	Novel
04249540	Association	2908	6622	Novel

32321990|t|Proinsulin Dynamics and Immune Modulation in Drosophila and Human Ce
32321990|a|This study explores the intricate interplay between proinsulin, antioxidant molecules, and immune-related gene products in both Drosophila and human cell lines. We demonstrate a conversion between proinsulin and the chemical entity Ro4368554, suggesting a potential metabolic pathway that may be relevant in cellular stress responses. Additionally, we observe a bidirectional conversion between antioxidant and proinsulin, highlighting the role of antioxidants in modulating proinsulin processing.   In parallel, we investigate the relationship between the gene product TGF-beta and the gene product CD86. Our findings reveal a binding interaction between TGF-beta and CD86, which is further supported by a negative correlation between TGF-beta and CD86 expression levels. This negative correlation is also observed in the reverse direction, indicating a complex regulatory network involving these two key molecules.   The study also includes the analysis of Drosophila as a model organism to understand the broader implications of these interactions. We find that the Drosophila model exhibits similar patterns of TGF-beta and CD86 expression, suggesting evolutionary conservation of these pathways. Furthermore, the human cell lines MCF7/AdrR and CD18/HPAF show distinct responses to the chemical entity Ro4368554, with notable differences in the conversion dynamics between Ro4368554 and antioxidant.   Our results provide a comprehensive framework for understanding the molecular mechanisms underlying proinsulin metabolism and immune signaling, with potential applications in both basic research and therapeutic development.
32321990	45	55	Drosophila	OrganismTaxon	7227
32321990	121	131	proinsulin	ChemicalEntity	D011384
32321990	133	144	antioxidant	ChemicalEntity	D000975
32321990	197	207	Drosophila	OrganismTaxon	7227
32321990	266	276	proinsulin	ChemicalEntity	D011384
32321990	301	310	Ro4368554	ChemicalEntity	C507242
32321990	464	475	antioxidant	ChemicalEntity	D000975
32321990	480	490	proinsulin	ChemicalEntity	D011384
32321990	517	528	antioxidant	ChemicalEntity	D000975
32321990	544	554	proinsulin	ChemicalEntity	D011384
32321990	639	647	TGF-beta	GeneOrGeneProduct	7040
32321990	669	673	CD86	GeneOrGeneProduct	12524
32321990	725	733	TGF-beta	GeneOrGeneProduct	7040
32321990	738	742	CD86	GeneOrGeneProduct	12524
32321990	805	813	TGF-beta	GeneOrGeneProduct	7040
32321990	818	822	CD86	GeneOrGeneProduct	12524
32321990	1028	1038	Drosophila	OrganismTaxon	7227
32321990	1138	1148	Drosophila	OrganismTaxon	7227
32321990	1184	1192	TGF-beta	GeneOrGeneProduct	7040
32321990	1197	1201	CD86	GeneOrGeneProduct	12524
32321990	1304	1313	MCF7/AdrR	CellLine	 CVCL_1452
32321990	1318	1327	CD18/HPAF	CellLine	CVCL_0313
32321990	1375	1384	Ro4368554	ChemicalEntity	C507242
32321990	1446	1455	Ro4368554	ChemicalEntity	C507242
32321990	1460	1471	antioxidant	ChemicalEntity	D000975
32321990	1575	1585	proinsulin	ChemicalEntity	D011384
32321990	Conversion	D011384	C507242	Novel
32321990	Comparison	D011384	D000975	Novel
32321990	Conversion	D000975	D011384	Novel
32321990	Bind	7040	12524	Novel
32321990	Negative_Correlation	7040	12524	Novel
32321990	Negative_Correlation	12524	7040	Novel
32321990	Conversion	C507242	D000975	Novel

77784426|t|Genetic and pharmacological interactions of HIV 1/2, HPVs, and bovine organisms with melatonin, fentanyl, and GABA(A) r
77784426|a|This study investigates the complex genetic and pharmacological interactions between HIV 1/2, HPVs, and bovine organisms, with a focus on the roles of glutathione-S-transferase P1, hGR, p65, and GABA(A) receptors. We report that glutathione-S-transferase P1 binds to GABA(A) receptors, suggesting a potential functional interaction in modulating neuronal activity. Additionally, we find a positive correlation between glutathione-S-transferase P1 and fentanyl, indicating a possible pharmacological synergy.   The sequence variant p.Ser119fsX is associated with apomorphine, while the p.G159R variant shows a negative correlation with apomorphine. These findings suggest that apomorphine may influence the expression or function of these variants. Furthermore, apomorphine exhibits a negative correlation with both GABA(A) receptors and glutathione-S-transferase P1, highlighting its potential role in modulating these pathways.   The sequence variant rs2230912 is associated with apomorphine and also with melatonin, indicating a possible shared regulatory mechanism. Similarly, the variant Delta30-4995 is associated with apomorphine, reinforcing the idea of a genetic link between these molecules. The association between dup33bp and melatonin suggests a potential role for this variant in melatonin regulation, while the association between G-->C substitution at position 135 and fentanyl indicates a possible functional interaction.   Notably, the G-->C substitution at position 135 also shows a negative correlation with DFG, suggesting a complex interplay between these genetic elements. The sequence variant rs2230912 is further associated with melatonin, reinforcing its potential role in melatonin regulation.   In addition, the p65 protein binds to hGR, indicating a potential functional interaction in transcriptional regulation. These findings collectively suggest that genetic and pharmacological factors play a significant role in modulating the interactions between HIV 1/2, HPVs, and bovine organisms with melatonin, fentanyl, and GABA(A) receptors, with implications for therapeutic strategies targeting these pathways.
77784426	44	51	HIV 1/2	OrganismTaxon	11676
77784426	53	57	HPVs	OrganismTaxon	10566
77784426	63	69	bovine	OrganismTaxon	9913
77784426	85	94	melatonin	ChemicalEntity	D008550
77784426	96	104	fentanyl	ChemicalEntity	D005283
77784426	205	212	HIV 1/2	OrganismTaxon	11676
77784426	214	218	HPVs	OrganismTaxon	10566
77784426	224	230	bovine	OrganismTaxon	9913
77784426	271	299	glutathione-S-transferase P1	GeneOrGeneProduct	2950
77784426	301	304	hGR	GeneOrGeneProduct	2908
77784426	306	309	p65	GeneOrGeneProduct	5970
77784426	315	332	GABA(A) receptors	GeneOrGeneProduct	29705
77784426	349	377	glutathione-S-transferase P1	GeneOrGeneProduct	2950
77784426	387	404	GABA(A) receptors	GeneOrGeneProduct	29705
77784426	538	566	glutathione-S-transferase P1	GeneOrGeneProduct	2950
77784426	571	579	fentanyl	ChemicalEntity	D005283
77784426	651	662	p.Ser119fsX	SequenceVariant	p|FS|S|119||
77784426	682	693	apomorphine	ChemicalEntity	D001058
77784426	705	712	p.G159R	SequenceVariant	rs760654579
77784426	755	766	apomorphine	ChemicalEntity	D001058
77784426	796	807	apomorphine	ChemicalEntity	D001058
77784426	881	892	apomorphine	ChemicalEntity	D001058
77784426	935	952	GABA(A) receptors	GeneOrGeneProduct	29705
77784426	957	985	glutathione-S-transferase P1	GeneOrGeneProduct	2950
77784426	1072	1081	rs2230912	SequenceVariant	rs2230912
77784426	1101	1112	apomorphine	ChemicalEntity	D001058
77784426	1127	1136	melatonin	ChemicalEntity	D008550
77784426	1212	1224	Delta30-4995	SequenceVariant	c|DEL|4995|30
77784426	1244	1255	apomorphine	ChemicalEntity	D001058
77784426	1345	1352	dup33bp	SequenceVariant	c|DUP||33|
77784426	1357	1366	melatonin	ChemicalEntity	D008550
77784426	1413	1422	melatonin	ChemicalEntity	D008550
77784426	1465	1499	G-->C substitution at position 135	SequenceVariant	g|SUB|G|135|C
77784426	1504	1512	fentanyl	ChemicalEntity	D005283
77784426	1573	1607	G-->C substitution at position 135	SequenceVariant	g|SUB|G|135|C
77784426	1647	1650	DFG	ChemicalEntity	C553185
77784426	1736	1745	rs2230912	SequenceVariant	rs2230912
77784426	1773	1782	melatonin	ChemicalEntity	D008550
77784426	1818	1827	melatonin	ChemicalEntity	D008550
77784426	1859	1862	p65	GeneOrGeneProduct	5970
77784426	1880	1883	hGR	GeneOrGeneProduct	2908
77784426	2102	2109	HIV 1/2	OrganismTaxon	11676
77784426	2111	2115	HPVs	OrganismTaxon	10566
77784426	2121	2127	bovine	OrganismTaxon	9913
77784426	2143	2152	melatonin	ChemicalEntity	D008550
77784426	2154	2162	fentanyl	ChemicalEntity	D005283
77784426	2168	2185	GABA(A) receptors	GeneOrGeneProduct	29705
77784426	Bind	2950	29705	Novel
77784426	Negative_Correlation	rs760654579	D001058	Novel
77784426	Association	p|FS|S|119||	D001058	Novel
77784426	Positive_Correlation	2950	D005283	Novel
77784426	Association	c|DUP||33|	D008550	Novel
77784426	Negative_Correlation	D001058	29705	Novel
77784426	Negative_Correlation	D001058	2950	Novel
77784426	Association	rs2230912	D001058	Novel
77784426	Association	c|DEL|4995|30	D001058	Novel
77784426	Association	D008550	D005283	Novel
77784426	Negative_Correlation	g|SUB|G|135|C	C553185	Novel
77784426	Association	rs2230912	D008550	Novel
77784426	Association	g|SUB|G|135|C	D005283	Novel
77784426	Bind	5970	2908	Novel

51516875|t|G12D and G196S sequence variants in tobacco, ginseng, and Drosophila: functional and evolutionary implications in SNU-C2A cell lin
51516875|a|Recent studies have explored the functional and evolutionary significance of sequence variants such as G12D and G196S across diverse organisms, including tobacco, ginseng, and Drosophila. These variants have been extensively analyzed in the context of the SNU-C2A cell line, which serves as a model system for understanding gene regulation and cellular responses. The G12D variant has been shown to associate with altered signaling pathways in tobacco, while the G196S variant has been linked to changes in metabolic processes in ginseng. Notably, there is a bidirectional association between G12D and G196S, suggesting a potential functional interplay between these variants. In Drosophila, both variants have been implicated in developmental processes, with G12D showing a stronger correlation with cell proliferation and G196S with stress response mechanisms. The SNU-C2A cell line has been used to validate these associations, revealing that the presence of G12D enhances the expression of G196S, and vice versa. These findings highlight the importance of these sequence variants in shaping phenotypic outcomes across different species and provide a foundation for further research into their roles in biological systems. The repeated occurrence of G12D and G196S in tobacco, ginseng, and Drosophila, along with their association in the SNU-C2A cell line, underscores their potential as key genetic markers in evolutionary and functional studies.
51516875	0	4	G12D	SequenceVariant	rs121913529
51516875	9	14	G196S	SequenceVariant	rs121434250
51516875	36	43	tobacco	OrganismTaxon	4097
51516875	45	52	ginseng	OrganismTaxon	4054
51516875	58	68	Drosophila	OrganismTaxon	7227
51516875	114	121	SNU-C2A	CellLine	CVCL_1709
51516875	234	238	G12D	SequenceVariant	rs121913529
51516875	243	248	G196S	SequenceVariant	rs121434250
51516875	285	292	tobacco	OrganismTaxon	4097
51516875	294	301	ginseng	OrganismTaxon	4054
51516875	307	317	Drosophila	OrganismTaxon	7227
51516875	387	394	SNU-C2A	CellLine	CVCL_1709
51516875	499	503	G12D	SequenceVariant	rs121913529
51516875	575	582	tobacco	OrganismTaxon	4097
51516875	594	599	G196S	SequenceVariant	rs121434250
51516875	661	668	ginseng	OrganismTaxon	4054
51516875	724	728	G12D	SequenceVariant	rs121913529
51516875	733	738	G196S	SequenceVariant	rs121434250
51516875	811	821	Drosophila	OrganismTaxon	7227
51516875	891	895	G12D	SequenceVariant	rs121913529
51516875	955	960	G196S	SequenceVariant	rs121434250
51516875	998	1005	SNU-C2A	CellLine	CVCL_1709
51516875	1093	1097	G12D	SequenceVariant	rs121913529
51516875	1125	1130	G196S	SequenceVariant	rs121434250
51516875	1384	1388	G12D	SequenceVariant	rs121913529
51516875	1393	1398	G196S	SequenceVariant	rs121434250
51516875	1402	1409	tobacco	OrganismTaxon	4097
51516875	1411	1418	ginseng	OrganismTaxon	4054
51516875	1424	1434	Drosophila	OrganismTaxon	7227
51516875	1472	1479	SNU-C2A	CellLine	CVCL_1709
51516875	Association	rs121913529	rs121434250	Novel
51516875	Association	rs121434250	rs121913529	Novel

61838071|t|Lactic acidosis, sequence variants, and chemical interactions in diverse cell lines and diseas
61838071|a|This study investigates the complex interplay between lactic acidosis, sequence variants, and chemical entities in various cell lines and disease conditions. We examined the effects of sequence variants such as del418T, 714C, p.Q298X, R211H, -107C/T, and p.Val204Asp on cellular function in hRPTEC, MCF-7, HeLa, and CA3 cell lines. The gene CGI-58 and its interactions with mTOR and angiotensin-converting enzyme were also explored. Chemical entities including sodium, lactose, ethosuximide, naproxen, NDP-MSH, and Thromboxane were analyzed for their roles in modulating these biological processes.   Our findings reveal significant negative correlations between lactic acidosis and NDP-MSH, Thromboxane, and ethosuximide, suggesting a potential regulatory role of these chemical entities in the pathophysiology of lactic acidosis. Similarly, lactic acidosis showed a negative correlation with lactose, indicating possible metabolic interactions. The negative correlation between lactic acidosis and Thromboxane further supports the involvement of Thromboxane in the progression of lactic acidosis.   Naproxen exhibited multiple negative correlations, including with lactose, sodium, Thromboxane, and NDP-MSH, suggesting its potential as a modulator in these pathways. Ethosuximide was found to have negative correlations with lactose, sodium, and Thromboxane, highlighting its possible role in metabolic regulation. Breast cancer was negatively correlated with naproxen, lactose, and NDP-MSH, indicating potential therapeutic implications.   The study also identified negative correlations between sodium and lactose, sodium and ethosuximide, and sodium and Thromboxane, suggesting a complex interplay between these chemical entities. Additionally, the negative correlation between Thromboxane and NDP-MSH, as well as between Thromboxane and ethosuximide, underscores the need for further investigation into their regulatory mechanisms.   These results provide a comprehensive framework for understanding the molecular and chemical interactions underlying lactic acidosis, breast cancer, and related conditions, offering new insights into potential therapeutic strategies.
61838071	149	164	lactic acidosis	DiseaseOrPhenotypicFeature	D000140
61838071	306	313	del418T	SequenceVariant	c|DEL|418|T
61838071	315	319	714C	SequenceVariant	rs34242818
61838071	321	328	p.Q298X	SequenceVariant	p|SUB|Q|298|X
61838071	330	335	R211H	SequenceVariant	p|SUB|R|211|H
61838071	337	344	-107C/T	SequenceVariant	c|SUB|C|-107|T
61838071	350	361	p.Val204Asp	SequenceVariant	p|SUB|V|204|D
61838071	386	392	hRPTEC	CellLine	CVCL_K278
61838071	394	399	MCF-7	CellLine	CVCL_0031
61838071	401	405	HeLa	CellLine	CVCL_0030
61838071	411	414	CA3	CellLine	CVCL_JW73
61838071	436	442	CGI-58	GeneOrGeneProduct	51099
61838071	469	473	mTOR	GeneOrGeneProduct	56717
61838071	478	507	angiotensin-converting enzyme	GeneOrGeneProduct	1636
61838071	556	562	sodium	ChemicalEntity	D012964
61838071	564	571	lactose	ChemicalEntity	D007785
61838071	573	585	ethosuximide	ChemicalEntity	D005013
61838071	587	595	naproxen	ChemicalEntity	D009288
61838071	597	604	NDP-MSH	ChemicalEntity	C027756
61838071	610	621	Thromboxane	ChemicalEntity	D013931
61838071	758	773	lactic acidosis	DiseaseOrPhenotypicFeature	D000140
61838071	778	785	NDP-MSH	ChemicalEntity	C027756
61838071	787	798	Thromboxane	ChemicalEntity	D013931
61838071	804	816	ethosuximide	ChemicalEntity	D005013
61838071	910	925	lactic acidosis	DiseaseOrPhenotypicFeature	D000140
61838071	938	953	lactic acidosis	DiseaseOrPhenotypicFeature	D000140
61838071	989	996	lactose	ChemicalEntity	D007785
61838071	1075	1090	lactic acidosis	DiseaseOrPhenotypicFeature	D000140
61838071	1095	1106	Thromboxane	ChemicalEntity	D013931
61838071	1143	1154	Thromboxane	ChemicalEntity	D013931
61838071	1177	1192	lactic acidosis	DiseaseOrPhenotypicFeature	D000140
61838071	1262	1269	lactose	ChemicalEntity	D007785
61838071	1271	1277	sodium	ChemicalEntity	D012964
61838071	1279	1290	Thromboxane	ChemicalEntity	D013931
61838071	1296	1303	NDP-MSH	ChemicalEntity	C027756
61838071	1422	1429	lactose	ChemicalEntity	D007785
61838071	1431	1437	sodium	ChemicalEntity	D012964
61838071	1443	1454	Thromboxane	ChemicalEntity	D013931
61838071	1512	1525	Breast cancer	DiseaseOrPhenotypicFeature	D001943
61838071	1557	1565	naproxen	ChemicalEntity	D009288
61838071	1567	1574	lactose	ChemicalEntity	D007785
61838071	1580	1587	NDP-MSH	ChemicalEntity	C027756
61838071	1694	1700	sodium	ChemicalEntity	D012964
61838071	1705	1712	lactose	ChemicalEntity	D007785
61838071	1714	1720	sodium	ChemicalEntity	D012964
61838071	1725	1737	ethosuximide	ChemicalEntity	D005013
61838071	1743	1749	sodium	ChemicalEntity	D012964
61838071	1754	1765	Thromboxane	ChemicalEntity	D013931
61838071	1878	1889	Thromboxane	ChemicalEntity	D013931
61838071	1894	1901	NDP-MSH	ChemicalEntity	C027756
61838071	1922	1933	Thromboxane	ChemicalEntity	D013931
61838071	1938	1950	ethosuximide	ChemicalEntity	D005013
61838071	2152	2167	lactic acidosis	DiseaseOrPhenotypicFeature	D000140
61838071	Negative_Correlation	D007785	D013931	Novel
61838071	Negative_Correlation	D009288	D007785	Novel
61838071	Negative_Correlation	D009288	D013931	Novel
61838071	Negative_Correlation	D001943	D009288	Novel
61838071	Negative_Correlation	D000140	C027756	Novel
61838071	Negative_Correlation	D009288	D012964	Novel
61838071	Negative_Correlation	D012964	D007785	Novel
61838071	Negative_Correlation	D000140	D013931	Novel
61838071	Negative_Correlation	D001943	D005013	Novel
61838071	Negative_Correlation	D007785	D005013	Novel
61838071	Negative_Correlation	D009288	C027756	Novel
61838071	Negative_Correlation	C027756	D013931	Novel
61838071	Negative_Correlation	D007785	D009288	Novel
61838071	Negative_Correlation	D000140	D005013	Novel
61838071	Negative_Correlation	D012964	D005013	Novel
61838071	Negative_Correlation	C027756	D007785	Novel
61838071	Negative_Correlation	D001943	D007785	Novel
61838071	Negative_Correlation	D005013	D009288	Novel
61838071	Negative_Correlation	D012964	D009288	Novel
61838071	Negative_Correlation	D001943	C027756	Novel
61838071	Negative_Correlation	D001943	D012964	Novel
61838071	Negative_Correlation	D005013	D007785	Novel
61838071	Negative_Correlation	D013931	D012964	Novel
61838071	Negative_Correlation	D005013	D013931	Novel
61838071	Negative_Correlation	C027756	D005013	Novel
61838071	Negative_Correlation	D007785	D012964	Novel
61838071	Negative_Correlation	D013931	C027756	Novel
61838071	Negative_Correlation	D013931	D005013	Novel
61838071	Negative_Correlation	C027756	D012964	Novel
61838071	Negative_Correlation	D009288	D005013	Novel

97278709|t|Cardiovascular toxicity in West Nile virus and dengue virus type 2 infections: interactions with antithrombin and insulin in chick, guinea pigs, and Mangifera ind
97278709|a|Cardiovascular toxicity has been observed in both West Nile virus (WNV) and dengue virus type 2 (DEN-2) infections, with significant implications for host response mechanisms. This study investigates the interplay between cardiovascular toxicity and key biochemical factors such as antithrombin and insulin in various model organisms, including chick, guinea pigs, and Mangifera indica Linn.   Our findings reveal a complex relationship between antithrombin and insulin, with evidence of both association and negative correlation with cardiovascular toxicity. Specifically, antithrombin levels were found to be inversely correlated with the severity of cardiovascular toxicity in WNV-infected guinea pigs, while insulin levels showed a similar negative correlation in DEN-2-infected chick models.   Interestingly, the association between antithrombin and insulin was also observed in both WNV and DEN-2 infections, suggesting a potential regulatory mechanism that may influence the development of cardiovascular toxicity. In Mangifera indica Linn, the presence of both antithrombin and insulin was linked to a reduced incidence of cardiovascular toxicity, further supporting the hypothesis of a protective role for these molecules.  These results highlight the importance of understanding the biochemical interactions between antithrombin, insulin, and cardiovascular toxicity in the context of viral infections. The study also underscores the value of using diverse model organisms, including chick, guinea pigs, and Mangifera indica Linn, to elucidate the mechanisms underlying these complex relationships.
97278709	27	42	West Nile virus	OrganismTaxon	11082
97278709	47	66	dengue virus type 2	OrganismTaxon	11060
97278709	97	109	antithrombin	ChemicalEntity	D000991
97278709	114	121	insulin	ChemicalEntity	D007328
97278709	125	130	chick	OrganismTaxon	9031
97278709	132	143	guinea pigs	OrganismTaxon	10141
97278709	213	228	West Nile virus	OrganismTaxon	11082
97278709	239	258	dengue virus type 2	OrganismTaxon	11060
97278709	260	265	DEN-2	OrganismTaxon	11060
97278709	385	408	cardiovascular toxicity	DiseaseOrPhenotypicFeature	D002318
97278709	445	457	antithrombin	ChemicalEntity	D000991
97278709	462	469	insulin	ChemicalEntity	D007328
97278709	508	513	chick	OrganismTaxon	9031
97278709	515	526	guinea pigs	OrganismTaxon	10141
97278709	532	553	Mangifera indica Linn	OrganismTaxon	29780
97278709	608	620	antithrombin	ChemicalEntity	D000991
97278709	625	632	insulin	ChemicalEntity	D007328
97278709	698	721	cardiovascular toxicity	DiseaseOrPhenotypicFeature	D002318
97278709	737	749	antithrombin	ChemicalEntity	D000991
97278709	816	839	cardiovascular toxicity	DiseaseOrPhenotypicFeature	D002318
97278709	856	867	guinea pigs	OrganismTaxon	10141
97278709	875	882	insulin	ChemicalEntity	D007328
97278709	931	936	DEN-2	OrganismTaxon	11060
97278709	946	951	chick	OrganismTaxon	9031
97278709	1001	1013	antithrombin	ChemicalEntity	D000991
97278709	1018	1025	insulin	ChemicalEntity	D007328
97278709	1060	1065	DEN-2	OrganismTaxon	11060
97278709	1160	1183	cardiovascular toxicity	DiseaseOrPhenotypicFeature	D002318
97278709	1188	1209	Mangifera indica Linn	OrganismTaxon	29780
97278709	1232	1244	antithrombin	ChemicalEntity	D000991
97278709	1249	1256	insulin	ChemicalEntity	D007328
97278709	1294	1317	cardiovascular toxicity	DiseaseOrPhenotypicFeature	D002318
97278709	1489	1501	antithrombin	ChemicalEntity	D000991
97278709	1503	1510	insulin	ChemicalEntity	D007328
97278709	1516	1539	cardiovascular toxicity	DiseaseOrPhenotypicFeature	D002318
97278709	1657	1662	chick	OrganismTaxon	9031
97278709	1664	1675	guinea pigs	OrganismTaxon	10141
97278709	1681	1702	Mangifera indica Linn	OrganismTaxon	29780
97278709	Association	D000991	D007328	Novel
97278709	Association	D002318	D000991	Novel
97278709	Association	D002318	D007328	Novel
97278709	Association	D007328	D000991	Novel
97278709	Negative_Correlation	D007328	D002318	Novel
97278709	Negative_Correlation	D000991	D002318	Novel

98561942|t|Selenoprotein N interactions with lipid-linked oligosaccharides and L-364,718 in horses and Rhodio
98561942|a|Selenoprotein N, a critical component of the endoplasmic reticulum-associated degradation pathway, has been shown to interact with lipid-linked oligosaccharides and L-364,718 in both horses and Rhodiola rosea. These interactions are essential for the proper folding and secretion of glycoproteins, as well as for the modulation of cellular stress responses. In horses, selenoprotein N binds to lipid-linked oligosaccharides, facilitating the transfer of these molecules to nascent polypeptide chains during glycosylation. This process is crucial for the maturation of secretory proteins and the maintenance of cellular homeostasis. Additionally, selenoprotein N exhibits a high-affinity binding to L-364,718, a synthetic compound known to modulate the activity of various signaling pathways. In Rhodiola rosea, the interaction between selenoprotein N and lipid-linked oligosaccharides is further enhanced, suggesting a potential role in the plant's adaptive response to environmental stress. The binding of selenoprotein N to L-364,718 in both organisms provides evidence for its involvement in the regulation of metabolic and immune functions. These findings highlight the importance of selenoprotein N in the context of lipid-linked oligosaccharides and L-364,718, with implications for both animal and plant biology.
98561942	34	63	lipid-linked oligosaccharides	ChemicalEntity	C023023
98561942	68	77	L-364,718	ChemicalEntity	D020109
98561942	81	87	horses	OrganismTaxon	9796
98561942	230	259	lipid-linked oligosaccharides	ChemicalEntity	C023023
98561942	264	273	L-364,718	ChemicalEntity	D020109
98561942	282	288	horses	OrganismTaxon	9796
98561942	293	307	Rhodiola rosea	OrganismTaxon	203015
98561942	460	466	horses	OrganismTaxon	9796
98561942	468	483	selenoprotein N	GeneOrGeneProduct	57190
98561942	493	522	lipid-linked oligosaccharides	ChemicalEntity	C023023
98561942	745	760	selenoprotein N	GeneOrGeneProduct	57190
98561942	797	806	L-364,718	ChemicalEntity	D020109
98561942	894	908	Rhodiola rosea	OrganismTaxon	203015
98561942	934	949	selenoprotein N	GeneOrGeneProduct	57190
98561942	954	983	lipid-linked oligosaccharides	ChemicalEntity	C023023
98561942	1106	1121	selenoprotein N	GeneOrGeneProduct	57190
98561942	1125	1134	L-364,718	ChemicalEntity	D020109
98561942	1287	1302	selenoprotein N	GeneOrGeneProduct	57190
98561942	1321	1350	lipid-linked oligosaccharides	ChemicalEntity	C023023
98561942	1355	1364	L-364,718	ChemicalEntity	D020109
98561942	Bind	57190	C023023	Novel
98561942	Bind	57190	D020109	Novel

50923803|t|p53 Mutations and Sequence Variants in Yeast and Aedes Mosquitoes: Functional and Structural Impl
50923803|a|Recent studies have highlighted the critical role of the tumor suppressor protein p53 in maintaining genomic stability across diverse organisms, including yeast and Aedes mosquitoes. This research explores the functional and structural implications of several sequence variants in the p53 gene across these species. The deletion (TGAG) variant was found to significantly disrupt the DNA-binding activity of p53 in yeast, leading to increased genomic instability and reduced cell viability. In Aedes mosquitoes, the same deletion (TGAG) was associated with altered p53 expression patterns, suggesting a potential role in vector biology and disease transmission.    The p.Q298X variant was shown to result in a truncated p53 protein in both yeast and Aedes mosquitoes, leading to loss of function and impaired response to DNA damage. This variant was more prevalent in Aedes mosquitoes, where it correlated with increased susceptibility to viral infections. The c.855 +1G>C variant was found to cause splicing defects in the p53 gene, resulting in the production of non-functional transcripts in yeast. In Aedes mosquitoes, this variant was associated with reduced p53 activity and increased viral replication.    The c.1092 +1G>A variant was linked to altered splicing and reduced p53 expression in yeast, while in Aedes mosquitoes, it was associated with increased resistance to certain viral strains. The p.G821S variant was found to alter the conformation of the p53 protein, leading to reduced DNA-binding affinity in yeast. In Aedes mosquitoes, this variant was associated with enhanced survival under stress conditions, suggesting a potential adaptive advantage.    These findings underscore the importance of p53 in maintaining cellular homeostasis and its susceptibility to sequence variants that can modulate its function. The study also highlights the evolutionary conservation of p53 function across yeast and Aedes mosquitoes, despite the vast differences in their biological contexts. Further research is needed to fully understand the implications of these variants in both model organisms and disease-related contexts.
50923803	0	3	p53	GeneOrGeneProduct	7157
50923803	180	183	p53	GeneOrGeneProduct	7157
50923803	253	258	yeast	OrganismTaxon	4932
50923803	263	279	Aedes mosquitoes	OrganismTaxon	1245352
50923803	383	386	p53	GeneOrGeneProduct	7157
50923803	418	433	deletion (TGAG)	SequenceVariant	c|DEL||TGAG
50923803	505	508	p53	GeneOrGeneProduct	7157
50923803	512	517	yeast	OrganismTaxon	4932
50923803	591	607	Aedes mosquitoes	OrganismTaxon	1245352
50923803	618	633	deletion (TGAG)	SequenceVariant	c|DEL||TGAG
50923803	662	665	p53	GeneOrGeneProduct	7157
50923803	766	773	p.Q298X	SequenceVariant	p|SUB|Q|298|X
50923803	817	820	p53	GeneOrGeneProduct	7157
50923803	837	842	yeast	OrganismTaxon	4932
50923803	847	863	Aedes mosquitoes	OrganismTaxon	1245352
50923803	965	981	Aedes mosquitoes	OrganismTaxon	1245352
50923803	1058	1069	c.855 +1G>C	SequenceVariant	c|SUB|C|855+1|C
50923803	1121	1124	p53	GeneOrGeneProduct	7157
50923803	1192	1197	yeast	OrganismTaxon	4932
50923803	1202	1218	Aedes mosquitoes	OrganismTaxon	1245352
50923803	1261	1264	p53	GeneOrGeneProduct	7157
50923803	1314	1326	c.1092 +1G>A	SequenceVariant	c|SUB|G|1092+1|A
50923803	1378	1381	p53	GeneOrGeneProduct	7157
50923803	1396	1401	yeast	OrganismTaxon	4932
50923803	1412	1428	Aedes mosquitoes	OrganismTaxon	1245352
50923803	1504	1511	p.G821S	SequenceVariant	rs267607116
50923803	1563	1566	p53	GeneOrGeneProduct	7157
50923803	1619	1624	yeast	OrganismTaxon	4932
50923803	1629	1645	Aedes mosquitoes	OrganismTaxon	1245352
50923803	1813	1816	p53	GeneOrGeneProduct	7157
50923803	1988	1991	p53	GeneOrGeneProduct	7157
50923803	2008	2013	yeast	OrganismTaxon	4932
50923803	2018	2034	Aedes mosquitoes	OrganismTaxon	1245352
50923803	Association	c|DEL||TGAG	7157	Novel
50923803	Association	p|SUB|Q|298|X	7157	Novel
50923803	Association	c|SUB|C|855+1|C	7157	Novel
50923803	Association	c|SUB|G|1092+1|A	7157	Novel
50923803	Association	rs267607116	7157	Novel

19032355|t|Salt-mediated interactions of C3 and low-density lipoprotein receptor in brain lymphomas and Meningococcal disease: insights from Toxorynchites mosquitoes and bovin
19032355|a|Recent studies have revealed complex interactions between salt, C3, and the low-density lipoprotein receptor (LDLR) in both physiological and pathological contexts. A negative correlation between salt and C3 was observed in Rats, suggesting that increased salt intake may suppress C3 activity. Similarly, a negative correlation between salt and LDLR was found, indicating that salt may influence lipid metabolism through this receptor. Notably, a bind between C3 and LDLR was confirmed, highlighting a potential regulatory mechanism in immune responses.    In addition, a negative correlation between LDLR and C3 was identified, which may have implications for the pathogenesis of brain lymphomas. A positive correlation between brain lymphomas and C3 was also noted, suggesting that C3 may play a role in tumor progression. Furthermore, a bind between LDLR and C3 was observed, reinforcing the idea of a functional relationship between these molecules.    The gene Liver kinase B1 (LKB1) was found to be associated with Meningococcal disease, and a negative correlation between LKB1 and C3 was identified, indicating potential antagonistic interactions. A positive correlation between LKB1 and brain lymphomas was also observed, suggesting a possible role for LKB1 in oncogenesis. A bind between LKB1 and LDLR was confirmed, and a bind between LKB1 and PI3K was also established, highlighting the involvement of LKB1 in multiple signaling pathways.    The PI3K pathway was further implicated through a bind between PI3K and LDLR, and a negative correlation between salt and PI3K was noted, suggesting that salt may modulate this pathway. These findings were supported by studies in Toxorynchites mosquitoes and bovine models, which provided additional evidence for the role of these molecules in disease processes. The results underscore the importance of salt, C3, LDLR, and LKB1 in the development of brain lymphomas and Meningococcal disease, with potential applications in therapeutic interventions.
19032355	30	32	C3	GeneOrGeneProduct	718
19032355	37	69	low-density lipoprotein receptor	GeneOrGeneProduct	3949
19032355	73	88	brain lymphomas	DiseaseOrPhenotypicFeature	D016543
19032355	93	114	Meningococcal disease	DiseaseOrPhenotypicFeature	D008589
19032355	130	154	Toxorynchites mosquitoes	OrganismTaxon	2498889
19032355	223	227	salt	ChemicalEntity	D012492
19032355	229	231	C3	GeneOrGeneProduct	718
19032355	241	273	low-density lipoprotein receptor	GeneOrGeneProduct	3949
19032355	361	365	salt	ChemicalEntity	D012492
19032355	370	372	C3	GeneOrGeneProduct	718
19032355	389	393	Rats	OrganismTaxon	10116
19032355	421	425	salt	ChemicalEntity	D012492
19032355	446	448	C3	GeneOrGeneProduct	718
19032355	501	505	salt	ChemicalEntity	D012492
19032355	542	546	salt	ChemicalEntity	D012492
19032355	625	627	C3	GeneOrGeneProduct	718
19032355	775	777	C3	GeneOrGeneProduct	718
19032355	846	861	brain lymphomas	DiseaseOrPhenotypicFeature	D016543
19032355	894	909	brain lymphomas	DiseaseOrPhenotypicFeature	D016543
19032355	914	916	C3	GeneOrGeneProduct	718
19032355	949	951	C3	GeneOrGeneProduct	718
19032355	1027	1029	C3	GeneOrGeneProduct	718
19032355	1131	1146	Liver kinase B1	GeneOrGeneProduct	20869
19032355	1186	1207	Meningococcal disease	DiseaseOrPhenotypicFeature	D008589
19032355	1253	1255	C3	GeneOrGeneProduct	718
19032355	1360	1375	brain lymphomas	DiseaseOrPhenotypicFeature	D016543
19032355	1519	1523	PI3K	GeneOrGeneProduct	5291
19032355	1622	1626	PI3K	GeneOrGeneProduct	5291
19032355	1681	1685	PI3K	GeneOrGeneProduct	5291
19032355	1731	1735	salt	ChemicalEntity	D012492
19032355	1740	1744	PI3K	GeneOrGeneProduct	5291
19032355	1772	1776	salt	ChemicalEntity	D012492
19032355	1848	1872	Toxorynchites mosquitoes	OrganismTaxon	2498889
19032355	1877	1883	bovine	OrganismTaxon	9913
19032355	2022	2026	salt	ChemicalEntity	D012492
19032355	2028	2030	C3	GeneOrGeneProduct	718
19032355	2069	2084	brain lymphomas	DiseaseOrPhenotypicFeature	D016543
19032355	2089	2110	Meningococcal disease	DiseaseOrPhenotypicFeature	D008589
19032355	Negative_Correlation	718	D012492	Novel
19032355	Association	20869	D008589	Novel
19032355	Bind	5291	20869	Novel
19032355	Negative_Correlation	D012492	718	Novel
19032355	Bind	718	3949	Novel
19032355	Negative_Correlation	3949	D012492	Novel
19032355	Bind	3949	20869	Novel
19032355	Bind	718	5291	Novel
19032355	Positive_Correlation	D016543	718	Novel
19032355	Association	20869	D016543	Novel
19032355	Negative_Correlation	20869	718	Novel
19032355	Bind	5291	3949	Novel
19032355	Negative_Correlation	3949	20869	Novel
19032355	Negative_Correlation	D012492	5291	Novel
19032355	Bind	718	20869	Novel
19032355	Positive_Correlation	3949	D016543	Novel

55617191|t|Alprazolam, Buprenorphine, and Genetic Variants: Interactions with Weight Loss and Hypertrophic Cardiomyopathy in CD18/HPAF and SNU-C5 Ce
55617191|a|This study investigates the complex interactions between the benzodiazepine alprazolam, the opioid buprenorphine, and the genetic variant rs1441817 in the context of weight loss and hypertrophic cardiomyopathy. Using the CD18/HPAF and SNU-C5 cell lines, we explored how these factors influence each other and contribute to disease phenotypes. Our findings reveal a negative correlation between alprazolam and buprenorphine, suggesting that these two drugs may have opposing effects on cellular pathways. Additionally, we observed a positive correlation between rs1441817 and both weight loss and hypertrophic cardiomyopathy, indicating that this genetic variant may play a significant role in the development of these conditions. The study also highlights the importance of considering the interplay between chemical entities and genetic factors in understanding disease mechanisms. Multiple instances of alprazolam, buprenorphine, rs1441817, weight loss, and hypertrophic cardiomyopathy were included to ensure the robustness of the observed relationships. These results provide new insights into the molecular basis of these conditions and their potential therapeutic implications.
55617191	114	123	CD18/HPAF	CellLine	CVCL_0313
55617191	128	134	SNU-C5	CellLine	CVCL_5112
55617191	214	224	alprazolam	ChemicalEntity	D000525
55617191	237	250	buprenorphine	ChemicalEntity	D002047
55617191	276	285	rs1441817	SequenceVariant	rs1441817
55617191	304	315	weight loss	DiseaseOrPhenotypicFeature	D015431
55617191	320	347	hypertrophic cardiomyopathy	DiseaseOrPhenotypicFeature	D002312
55617191	359	368	CD18/HPAF	CellLine	CVCL_0313
55617191	373	379	SNU-C5	CellLine	CVCL_5112
55617191	532	542	alprazolam	ChemicalEntity	D000525
55617191	547	560	buprenorphine	ChemicalEntity	D002047
55617191	699	708	rs1441817	SequenceVariant	rs1441817
55617191	718	729	weight loss	DiseaseOrPhenotypicFeature	D015431
55617191	734	761	hypertrophic cardiomyopathy	DiseaseOrPhenotypicFeature	D002312
55617191	1043	1053	alprazolam	ChemicalEntity	D000525
55617191	1055	1068	buprenorphine	ChemicalEntity	D002047
55617191	1070	1079	rs1441817	SequenceVariant	rs1441817
55617191	1081	1092	weight loss	DiseaseOrPhenotypicFeature	D015431
55617191	1098	1125	hypertrophic cardiomyopathy	DiseaseOrPhenotypicFeature	D002312
55617191	Negative_Correlation	D000525	D002047	Novel
55617191	Positive_Correlation	rs1441817	D015431	Novel
55617191	Positive_Correlation	rs1441817	D002312	Novel
55617191	Negative_Correlation	D002047	D000525	Novel

21697781|t|Bisphosphonate, free fatty acids, and dopamine D2 receptor antagonists: multi-cellular and multi-phenotypic interactions in rhabdomyolysis and related co
21697781|a|This study investigates the complex interplay between bisphosphonate, free fatty acids, dopamine D2 receptor antagonists, and other chemical entities in the context of rhabdomyolysis and related phenotypic features. Using a combination of in vitro and in vivo models, we examined the effects of these compounds on LNCaP, KU7, COS-7, HCT116, and DUCaP cell lines. Our findings reveal a negative correlation between bisphosphonate and free fatty acids, as well as a negative correlation between bisphosphonate and bleomycin. Additionally, we observed a positive correlation between dopamine D2 receptor antagonists and anterior segment malformations, and a negative correlation between dopamine D2 receptor antagonists and free fatty acids.   The relationship between free fatty acids and hypothermic was found to be positive, while the correlation between hypothermic and dopamine D2 receptor antagonists was also positive. Nitric oxide showed a positive correlation with hypothermic, microphthalmia, and anterior segment malformations, and a positive correlation with skin pigmentation. Furthermore, Nitric oxide was found to be in comparison with free fatty acids, suggesting a complex regulatory mechanism.   Bleomycin was associated with free fatty acids and microphthalmia, with a positive correlation between bleomycin and microphthalmia. The study also highlights the role of free fatty acids in the pathogenesis of rhabdomyolysis, with multiple instances of this condition observed across different cell lines. The results suggest that the interactions between these chemical entities and phenotypic features are not only significant but also context-dependent, requiring further investigation to fully understand their biological implications.
21697781	16	32	free fatty acids	ChemicalEntity	D005230
21697781	38	70	dopamine D2 receptor antagonists	ChemicalEntity	D065127
21697781	124	138	rhabdomyolysis	DiseaseOrPhenotypicFeature	D012206
21697781	208	222	bisphosphonate	ChemicalEntity	D004164
21697781	224	240	free fatty acids	ChemicalEntity	D005230
21697781	242	274	dopamine D2 receptor antagonists	ChemicalEntity	D065127
21697781	322	336	rhabdomyolysis	DiseaseOrPhenotypicFeature	D012206
21697781	468	473	LNCaP	CellLine	CVCL_0395
21697781	475	478	KU7	CellLine	CVCL_4714
21697781	480	485	COS-7	CellLine	CVCL_0224
21697781	487	493	HCT116	CellLine	CVCL_0291
21697781	499	504	DUCaP	CellLine	CVCL_2025
21697781	568	582	bisphosphonate	ChemicalEntity	D004164
21697781	587	603	free fatty acids	ChemicalEntity	D005230
21697781	647	661	bisphosphonate	ChemicalEntity	D004164
21697781	666	675	bleomycin	ChemicalEntity	D001761
21697781	734	766	dopamine D2 receptor antagonists	ChemicalEntity	D065127
21697781	771	801	anterior segment malformations	DiseaseOrPhenotypicFeature	C537775
21697781	838	870	dopamine D2 receptor antagonists	ChemicalEntity	D065127
21697781	875	891	free fatty acids	ChemicalEntity	D005230
21697781	920	936	free fatty acids	ChemicalEntity	D005230
21697781	941	952	hypothermic	DiseaseOrPhenotypicFeature	D007035
21697781	1009	1020	hypothermic	DiseaseOrPhenotypicFeature	D007035
21697781	1025	1057	dopamine D2 receptor antagonists	ChemicalEntity	D065127
21697781	1077	1089	Nitric oxide	ChemicalEntity	D009569
21697781	1125	1136	hypothermic	DiseaseOrPhenotypicFeature	D007035
21697781	1138	1152	microphthalmia	DiseaseOrPhenotypicFeature	D008850
21697781	1158	1188	anterior segment malformations	DiseaseOrPhenotypicFeature	C537775
21697781	1222	1239	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
21697781	1254	1266	Nitric oxide	ChemicalEntity	D009569
21697781	1302	1318	free fatty acids	ChemicalEntity	D005230
21697781	1395	1411	free fatty acids	ChemicalEntity	D005230
21697781	1416	1430	microphthalmia	DiseaseOrPhenotypicFeature	D008850
21697781	1468	1477	bleomycin	ChemicalEntity	D001761
21697781	1482	1496	microphthalmia	DiseaseOrPhenotypicFeature	D008850
21697781	1536	1552	free fatty acids	ChemicalEntity	D005230
21697781	1576	1590	rhabdomyolysis	DiseaseOrPhenotypicFeature	D012206
21697781	Positive_Correlation	D005230	D007035	Novel
21697781	Negative_Correlation	D065127	D005230	Novel
21697781	Association	D001761	D005230	Novel
21697781	Comparison	D009569	D005230	Novel
21697781	Positive_Correlation	D001761	D008850	Novel
21697781	Positive_Correlation	D007035	D009569	Novel
21697781	Positive_Correlation	D009569	D008850	Novel
21697781	Positive_Correlation	D009569	C537775	Novel
21697781	Negative_Correlation	D005230	D004164	Novel
21697781	Positive_Correlation	D065127	C537775	Novel
21697781	Negative_Correlation	D004164	D001761	Novel
21697781	Negative_Correlation	D004164	D005230	Novel
21697781	Positive_Correlation	D010859	D009569	Novel
21697781	Positive_Correlation	D007035	D065127	Novel
21697781	Positive_Correlation	D008850	D005230	Novel
21697781	Association	D005230	D001761	Novel

69184532|t|Interactions between desmin and tenascin-C in Kilham rat virus-infected RAW 264.7 cells and their implications in dengue virus type 2 and Drosophil
69184532|a|This study investigates the molecular interactions between desmin and tenascin-C in the context of Kilham rat virus (KRV) infection and their potential role in disease progression. Using RAW 264.7 cells, we demonstrate a positive correlation between desmin and tenascin-C expression, as well as an association between the two proteins. Furthermore, we observe a bind between desmin and tenascin-C, suggesting a direct physical interaction. However, we also report a negative correlation between desmin and tenascin-C in certain experimental conditions, indicating a complex regulatory mechanism. These findings are further supported by in vitro studies using GT1-1 and SJ-GBM2 cell lines, where the relationship between desmin and tenascin-C is consistently observed.   To explore the broader implications of these interactions, we extended our analysis to Drosophila melanogaster, where we found that desmin-like and tenascin-C-like proteins exhibit similar binding patterns. Additionally, we examined the role of these proteins in sheep and rat models, noting that desmin and tenascin-C expression is significantly altered in response to KRV infection. Notably, dengue virus type 2 (DENV-2) infection also modulates the expression of both proteins, suggesting a potential cross-talk between viral infections and the host's cytoskeletal network.   Our results highlight the importance of desmin and tenascin-C in cellular responses to viral infections and provide a foundation for further studies on their functional roles in both mammalian and invertebrate systems. The consistent presence of these proteins across multiple cell lines and organisms underscores their evolutionary conservation and functional significance.
69184532	21	27	desmin	GeneOrGeneProduct	64362
69184532	32	42	tenascin-C	GeneOrGeneProduct	3371
69184532	46	62	Kilham rat virus	OrganismTaxon	12441
69184532	53	56	rat	OrganismTaxon	10116
69184532	72	81	RAW 264.7	CellLine	CVCL_0493
69184532	114	133	dengue virus type 2	OrganismTaxon	11060
69184532	207	213	desmin	GeneOrGeneProduct	64362
69184532	218	228	tenascin-C	GeneOrGeneProduct	3371
69184532	247	263	Kilham rat virus	OrganismTaxon	12441
69184532	254	257	rat	OrganismTaxon	10116
69184532	335	344	RAW 264.7	CellLine	CVCL_0493
69184532	362	365	rat	OrganismTaxon	10116
69184532	398	404	desmin	GeneOrGeneProduct	64362
69184532	409	419	tenascin-C	GeneOrGeneProduct	3371
69184532	523	529	desmin	GeneOrGeneProduct	64362
69184532	534	544	tenascin-C	GeneOrGeneProduct	3371
69184532	643	649	desmin	GeneOrGeneProduct	64362
69184532	654	664	tenascin-C	GeneOrGeneProduct	3371
69184532	807	812	GT1-1	CellLine	CVCL_6236
69184532	817	824	SJ-GBM2	CellLine	CVCL_M141
69184532	868	874	desmin	GeneOrGeneProduct	64362
69184532	879	889	tenascin-C	GeneOrGeneProduct	3371
69184532	1005	1015	Drosophila	OrganismTaxon	7227
69184532	1050	1056	desmin	GeneOrGeneProduct	64362
69184532	1066	1076	tenascin-C	GeneOrGeneProduct	3371
69184532	1181	1186	sheep	OrganismTaxon	9940
69184532	1191	1194	rat	OrganismTaxon	10116
69184532	1215	1221	desmin	GeneOrGeneProduct	64362
69184532	1226	1236	tenascin-C	GeneOrGeneProduct	3371
69184532	1312	1331	dengue virus type 2	OrganismTaxon	11060
69184532	1537	1543	desmin	GeneOrGeneProduct	64362
69184532	1548	1558	tenascin-C	GeneOrGeneProduct	3371
69184532	1702	1705	rat	OrganismTaxon	10116
69184532	Positive_Correlation	64362	3371	Novel
69184532	Positive_Correlation	3371	64362	Novel
69184532	Association	64362	3371	Novel
69184532	Bind	3371	64362	Novel
69184532	Negative_Correlation	3371	64362	Novel
69184532	Negative_Correlation	64362	3371	Novel
69184532	Association	3371	64362	Novel
69184532	Bind	64362	3371	Novel

02720786|t|Joubert syndrome (JBTS) type 6, prednisolone, and genetic variants in Ishikawa and HK2 cell lines: a rat mod
02720786|a|Joubert syndrome (JBTS) type 6 is a rare genetic disorder characterized by cerebellar vermis hypoplasia and other developmental anomalies. This study investigates the molecular mechanisms underlying JBTS type 6 in a rat model, with a focus on the interplay between genetic variants, cell lines, and the therapeutic agent prednisolone. The research highlights the complex relationships between JBTS type 6 and multiple sequence variants, including the 457_458insG and single base pair deletion.   In this study, we observed a positive correlation between JBTS type 6 and the 457_458insG variant, as well as a positive correlation between JBTS type 6 and the single base pair deletion. These findings suggest that these sequence variants may play a role in the pathogenesis of JBTS type 6. Furthermore, we found an association between JBTS type 6 and prednisolone, indicating that prednisolone may have a therapeutic role in managing the symptoms of JBTS type 6.   Interestingly, the study also revealed a negative correlation between 457_458insG and prednisolone, suggesting that the presence of this variant may reduce the efficacy of prednisolone treatment. Similarly, a negative correlation was observed between single base pair deletion and prednisolone, indicating that this variant may also interfere with the therapeutic effects of prednisolone. Additionally, there was an association between the single base pair deletion and 457_458insG, suggesting that these variants may co-occur or influence each other in the context of JBTS type 6.  The experiments were conducted using Ishikawa and HK2 cell lines, which are commonly used in cancer and renal research. The rat model was used to simulate the in vivo environment and to assess the effects of prednisolone on the expression of JBTS type 6-related genes. The results of this study provide new insights into the genetic and molecular basis of JBTS type 6 and its potential treatment with prednisolone. These findings may have important implications for the development of targeted therapies for JBTS type 6 and other related disorders.
02720786	0	30	Joubert syndrome (JBTS) type 6	DiseaseOrPhenotypicFeature	C537689
02720786	32	44	prednisolone	ChemicalEntity	D011239
02720786	70	78	Ishikawa	CellLine	CVCL_2529
02720786	83	86	HK2	CellLine	CVCL_0302
02720786	101	104	rat	OrganismTaxon	10116
02720786	109	139	Joubert syndrome (JBTS) type 6	DiseaseOrPhenotypicFeature	C537689
02720786	325	328	rat	OrganismTaxon	10116
02720786	430	442	prednisolone	ChemicalEntity	D011239
02720786	560	571	457_458insG	SequenceVariant	c|INS|457_458|G
02720786	576	601	single base pair deletion	SequenceVariant	rs137853893
02720786	683	694	457_458insG	SequenceVariant	c|INS|457_458|G
02720786	766	791	single base pair deletion	SequenceVariant	rs137853893
02720786	958	970	prednisolone	ChemicalEntity	D011239
02720786	988	1000	prednisolone	ChemicalEntity	D011239
02720786	1142	1153	457_458insG	SequenceVariant	c|INS|457_458|G
02720786	1158	1170	prednisolone	ChemicalEntity	D011239
02720786	1244	1256	prednisolone	ChemicalEntity	D011239
02720786	1323	1348	single base pair deletion	SequenceVariant	rs137853893
02720786	1353	1365	prednisolone	ChemicalEntity	D011239
02720786	1447	1459	prednisolone	ChemicalEntity	D011239
02720786	1512	1537	single base pair deletion	SequenceVariant	rs137853893
02720786	1542	1553	457_458insG	SequenceVariant	c|INS|457_458|G
02720786	1692	1700	Ishikawa	CellLine	CVCL_2529
02720786	1705	1708	HK2	CellLine	CVCL_0302
02720786	1779	1782	rat	OrganismTaxon	10116
02720786	1863	1875	prednisolone	ChemicalEntity	D011239
02720786	2056	2068	prednisolone	ChemicalEntity	D011239
02720786	Negative_Correlation	c|INS|457_458|G	D011239	Novel
02720786	Positive_Correlation	C537689	c|INS|457_458|G	Novel
02720786	Association	C537689	D011239	Novel
02720786	Association	D011239	C537689	Novel
02720786	Positive_Correlation	C537689	rs137853893	Novel
02720786	Association	rs137853893	c|INS|457_458|G	Novel
02720786	Negative_Correlation	rs137853893	D011239	Novel
02720786	Negative_Correlation	C537689	D011239	Novel
02720786	Association	c|INS|457_458|G	rs137853893	Novel

57700854|t|SOX2 and the sequence variant c.357-3C>G in relation to unipolar recurrent major depression in SMMC-77
57700854|a|This study investigates the molecular mechanisms underlying the association between the transcription factor SOX2 and the pathogenesis of unipolar recurrent major depression in the context of the SMMC-7721 cell line. We focused on the sequence variants C61G and c.357-3C>G, which have been previously implicated in neurodevelopmental processes and psychiatric disorders. Using a combination of transcriptomic and functional assays, we assessed the impact of these variants on SOX2 expression and downstream signaling pathways in SMMC-7721 cells. Our results demonstrate a negative correlation between SOX2 expression levels and the manifestation of unipolar recurrent major depression, as evidenced by reduced SOX2 activity in cells expressing the C61G variant. Furthermore, the c.357-3C>G variant was found to modulate the stability of the SOX2 transcript, thereby contributing to the observed phenotypic effects. These findings suggest that alterations in SOX2 regulation may play a critical role in the development of unipolar recurrent major depression, with implications for the design of targeted therapeutic strategies. The SMMC-7721 cell line served as a robust model for studying the interplay between genetic variants and disease phenotypes, with multiple instances of the disease or phenotypic feature 'unipolar recurrent major depression' and the gene 'SOX2' being consistently observed across experimental conditions.
57700854	0	4	SOX2	GeneOrGeneProduct	20674
57700854	30	40	c.357-3C>G	SequenceVariant	c|SUB|C|357-3|G
57700854	56	91	unipolar recurrent major depression	DiseaseOrPhenotypicFeature	D003865
57700854	212	216	SOX2	GeneOrGeneProduct	20674
57700854	241	276	unipolar recurrent major depression	DiseaseOrPhenotypicFeature	D003865
57700854	299	308	SMMC-7721	CellLine	CVCL_0534
57700854	356	360	C61G	SequenceVariant	rs28897672
57700854	365	375	c.357-3C>G	SequenceVariant	c|SUB|C|357-3|G
57700854	579	583	SOX2	GeneOrGeneProduct	20674
57700854	632	641	SMMC-7721	CellLine	CVCL_0534
57700854	704	708	SOX2	GeneOrGeneProduct	20674
57700854	752	787	unipolar recurrent major depression	DiseaseOrPhenotypicFeature	D003865
57700854	813	817	SOX2	GeneOrGeneProduct	20674
57700854	851	855	C61G	SequenceVariant	rs28897672
57700854	882	892	c.357-3C>G	SequenceVariant	c|SUB|C|357-3|G
57700854	944	948	SOX2	GeneOrGeneProduct	20674
57700854	1061	1065	SOX2	GeneOrGeneProduct	20674
57700854	1124	1159	unipolar recurrent major depression	DiseaseOrPhenotypicFeature	D003865
57700854	1234	1243	SMMC-7721	CellLine	CVCL_0534
57700854	1417	1452	unipolar recurrent major depression	DiseaseOrPhenotypicFeature	D003865
57700854	1468	1472	SOX2	GeneOrGeneProduct	20674
57700854	Negative_Correlation	20674	D003865	Novel

04655047|t|CA3 Cell Line and Genetic Variants in Enzymatic Complex I-Deficiency, Non-Syndromic Autosomal Recessive Deafness, and Postoperative Nausea and 
04655047|a|The CA3 cell line has been extensively used to study the molecular mechanisms underlying enzymatic complex I-deficiency, non-syndromic autosomal recessive deafness, and postoperative nausea and vomiting. Recent studies have highlighted the role of sequence variants such as c.429_452dup, G1359A, and p.Ala88Val in modulating these conditions. The CA3 cell line was employed to investigate the functional consequences of these genetic alterations in the context of enzymatic complex I-deficiency and non-syndromic autosomal recessive deafness.   The c.429_452dup variant was found to be positively correlated with non-syndromic autosomal recessive deafness, suggesting a potential pathogenic role in the development of this condition. In contrast, the same variant showed a negative correlation with hyperlipemia, indicating a complex interplay between genetic factors and metabolic outcomes.   The G1359A variant exhibited a positive correlation with postoperative nausea and vomiting, which was further supported by in vitro experiments using the CA3 cell line. This finding suggests that G1359A may contribute to the pathophysiology of postoperative nausea and vomiting.   Interestingly, the p.Ala88Val variant showed a positive correlation with Pneumonitis, while also displaying a negative correlation with postoperative nausea and vomiting. These opposing effects highlight the pleiotropic nature of this sequence variant and its potential role in multiple disease processes.   The CA3 cell line was also used to assess the impact of these genetic variants on the expression and function of key proteins involved in enzymatic complex I-deficiency. The results suggest that the CA3 cell line is a valuable model for studying the molecular basis of these conditions and for identifying potential therapeutic targets.   Overall, the study provides important insights into the genetic and molecular mechanisms underlying enzymatic complex I-deficiency, non-syndromic autosomal recessive deafness, and postoperative nausea and vomiting, with the CA3 cell line serving as a critical tool for these investigations.
04655047	0	3	CA3	CellLine	CVCL_JW73
04655047	148	151	CA3	CellLine	CVCL_JW73
04655047	265	307	non-syndromic autosomal recessive deafness	DiseaseOrPhenotypicFeature	C567134
04655047	313	346	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
04655047	418	430	c.429_452dup	SequenceVariant	c|DUP|429_452||
04655047	432	438	G1359A	SequenceVariant	rs1049353
04655047	444	454	p.Ala88Val	SequenceVariant	p|SUB|A|88|V
04655047	491	494	CA3	CellLine	CVCL_JW73
04655047	643	685	non-syndromic autosomal recessive deafness	DiseaseOrPhenotypicFeature	C567134
04655047	693	705	c.429_452dup	SequenceVariant	c|DUP|429_452||
04655047	757	799	non-syndromic autosomal recessive deafness	DiseaseOrPhenotypicFeature	C567134
04655047	943	955	hyperlipemia	DiseaseOrPhenotypicFeature	D006949
04655047	1042	1048	G1359A	SequenceVariant	rs1049353
04655047	1095	1128	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
04655047	1192	1195	CA3	CellLine	CVCL_JW73
04655047	1234	1240	G1359A	SequenceVariant	rs1049353
04655047	1282	1315	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
04655047	1338	1348	p.Ala88Val	SequenceVariant	p|SUB|A|88|V
04655047	1392	1403	Pneumonitis	DiseaseOrPhenotypicFeature	D011014
04655047	1455	1488	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
04655047	1631	1634	CA3	CellLine	CVCL_JW73
04655047	1826	1829	CA3	CellLine	CVCL_JW73
04655047	2098	2140	non-syndromic autosomal recessive deafness	DiseaseOrPhenotypicFeature	C567134
04655047	2146	2179	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
04655047	2190	2193	CA3	CellLine	CVCL_JW73
04655047	Negative_Correlation	p|SUB|A|88|V	D020250	Novel
04655047	Positive_Correlation	rs1049353	D020250	Novel
04655047	Positive_Correlation	p|SUB|A|88|V	D011014	Novel
04655047	Positive_Correlation	c|DUP|429_452||	C567134	Novel
04655047	Negative_Correlation	c|DUP|429_452||	D006949	Novel

08757629|t|FABP3 and C-1228T: dual roles in the pathogenesis of diabetic nephropathy i
08757629|a|Diabetic nephropathy is a progressive complication of diabetes that significantly impacts renal function. Recent studies in horses have highlighted the potential involvement of the fatty acid-binding protein 3 (FABP3) and the sequence variant C-1228T in the development of this condition. This study investigates the complex relationships between FABP3, C-1228T, and diabetic nephropathy in horses.   Our findings reveal a positive correlation between the C-1228T variant and diabetic nephropathy, suggesting that this sequence variant may contribute to the pathophysiology of the disease. However, a negative correlation was also observed between C-1228T and diabetic nephropathy in certain subgroups, indicating potential regulatory mechanisms that modulate this relationship.   Furthermore, the association between FABP3 and diabetic nephropathy was confirmed, with both positive and negative correlations observed depending on the context. These results suggest that FABP3 may act as a modulator in the progression of diabetic nephropathy, with its expression influenced by the C-1228T variant.   The dual roles of C-1228T and FABP3 in the development of diabetic nephropathy in horses underscore the complexity of genetic and molecular interactions in this disease. These findings provide a foundation for further research into the genetic basis of diabetic nephropathy and its management in equine populations.
08757629	0	5	FABP3	GeneOrGeneProduct	2170
08757629	10	17	C-1228T	SequenceVariant	c|SUB|C|-1228|T
08757629	53	73	diabetic nephropathy	DiseaseOrPhenotypicFeature	D003928
08757629	200	206	horses	OrganismTaxon	9796
08757629	287	292	FABP3	GeneOrGeneProduct	2170
08757629	319	326	C-1228T	SequenceVariant	c|SUB|C|-1228|T
08757629	423	428	FABP3	GeneOrGeneProduct	2170
08757629	430	437	C-1228T	SequenceVariant	c|SUB|C|-1228|T
08757629	443	463	diabetic nephropathy	DiseaseOrPhenotypicFeature	D003928
08757629	467	473	horses	OrganismTaxon	9796
08757629	532	539	C-1228T	SequenceVariant	c|SUB|C|-1228|T
08757629	552	572	diabetic nephropathy	DiseaseOrPhenotypicFeature	D003928
08757629	724	731	C-1228T	SequenceVariant	c|SUB|C|-1228|T
08757629	736	756	diabetic nephropathy	DiseaseOrPhenotypicFeature	D003928
08757629	894	899	FABP3	GeneOrGeneProduct	2170
08757629	904	924	diabetic nephropathy	DiseaseOrPhenotypicFeature	D003928
08757629	1047	1052	FABP3	GeneOrGeneProduct	2170
08757629	1098	1118	diabetic nephropathy	DiseaseOrPhenotypicFeature	D003928
08757629	1158	1165	C-1228T	SequenceVariant	c|SUB|C|-1228|T
08757629	1195	1202	C-1228T	SequenceVariant	c|SUB|C|-1228|T
08757629	1207	1212	FABP3	GeneOrGeneProduct	2170
08757629	1235	1255	diabetic nephropathy	DiseaseOrPhenotypicFeature	D003928
08757629	1259	1265	horses	OrganismTaxon	9796
08757629	1430	1450	diabetic nephropathy	DiseaseOrPhenotypicFeature	D003928
08757629	Positive_Correlation	D003928	c|SUB|C|-1228|T	Novel
08757629	Negative_Correlation	c|SUB|C|-1228|T	D003928	Novel
08757629	Association	D003928	2170	Novel
08757629	Negative_Correlation	D003928	2170	Novel
08757629	Association	D003928	c|SUB|C|-1228|T	Novel
08757629	Association	c|SUB|C|-1228|T	D003928	Novel
08757629	Positive_Correlation	c|SUB|C|-1228|T	D003928	Novel
08757629	Association	2170	D003928	Novel

35996901|t|TNF-a and snail interactions in diverse cellular and organismal contexts: from zebrafish to human ce
35996901|a|This study explores the complex interactions between TNF-a and snail across multiple biological systems, including zebrafish and various human cell lines. The findings reveal a multifaceted relationship between TNF-a and snail, encompassing both binding and correlation dynamics. In zebrafish models, TNF-a was found to bind to snail, suggesting a direct molecular interaction that may influence developmental processes. Additionally, a negative correlation between TNF-a and snail was observed in zebrafish, indicating potential regulatory mechanisms. In contrast, a positive correlation between TNF-a and snail was noted in the KU7 cell line, highlighting context-dependent interactions.   In the PC-3 cell line, an association between TNF-a and snail was identified, further supporting the notion of functional interplay. The MCF7/AdrR cell line showed a positive correlation between TNF-a and snail, while the C4-2B cell line exhibited a negative correlation. These findings were corroborated by additional studies in the PA-1, RAW 264.7, and COS-7 cell lines, where both binding and correlation events were documented. The HEK cell line also demonstrated an association between TNF-a and snail, reinforcing the broad relevance of these interactions.   Interestingly, the Kilham rat virus was found to modulate the expression of snail in the presence of TNF-a, suggesting a potential viral influence on the TNF-a-snail axis. In Drosophila, the relationship between TNF-a and snail was further explored, revealing a binding interaction that may have evolutionary implications. The hepatitis B virus was also implicated in the regulation of TNF-a and snail, with evidence of both positive and negative correlations observed in multiple cell lines.   These results collectively underscore the importance of TNF-a and snail in diverse biological contexts, from zebrafish to human cell lines, and highlight the need for further investigation into the molecular mechanisms underlying their interactions.
35996901	0	5	TNF-a	GeneOrGeneProduct	7124
35996901	10	15	snail	GeneOrGeneProduct	20613
35996901	154	159	TNF-a	GeneOrGeneProduct	7124
35996901	164	169	snail	GeneOrGeneProduct	20613
35996901	312	317	TNF-a	GeneOrGeneProduct	7124
35996901	322	327	snail	GeneOrGeneProduct	20613
35996901	402	407	TNF-a	GeneOrGeneProduct	7124
35996901	429	434	snail	GeneOrGeneProduct	20613
35996901	567	572	TNF-a	GeneOrGeneProduct	7124
35996901	577	582	snail	GeneOrGeneProduct	20613
35996901	698	703	TNF-a	GeneOrGeneProduct	7124
35996901	708	713	snail	GeneOrGeneProduct	20613
35996901	731	734	KU7	CellLine	CVCL_4714
35996901	800	804	PC-3	CellLine	CVCL_0035
35996901	839	844	TNF-a	GeneOrGeneProduct	7124
35996901	849	854	snail	GeneOrGeneProduct	20613
35996901	930	939	MCF7/AdrR	CellLine	 CVCL_1452
35996901	988	993	TNF-a	GeneOrGeneProduct	7124
35996901	998	1003	snail	GeneOrGeneProduct	20613
35996901	1015	1020	C4-2B	CellLine	CVCL_4784
35996901	1127	1131	PA-1	CellLine	CVCL_0479
35996901	1133	1142	RAW 264.7	CellLine	CVCL_0493
35996901	1148	1153	COS-7	CellLine	CVCL_0224
35996901	1229	1232	HEK	CellLine	CVCL_M624
35996901	1284	1289	TNF-a	GeneOrGeneProduct	7124
35996901	1294	1299	snail	GeneOrGeneProduct	20613
35996901	1377	1393	Kilham rat virus	OrganismTaxon	12441
35996901	1434	1439	snail	GeneOrGeneProduct	20613
35996901	1459	1464	TNF-a	GeneOrGeneProduct	7124
35996901	1512	1517	TNF-a	GeneOrGeneProduct	7124
35996901	1518	1523	snail	GeneOrGeneProduct	20613
35996901	1533	1543	Drosophila	OrganismTaxon	7227
35996901	1570	1575	TNF-a	GeneOrGeneProduct	7124
35996901	1580	1585	snail	GeneOrGeneProduct	20613
35996901	1685	1702	hepatitis B virus	OrganismTaxon	10407
35996901	1744	1749	TNF-a	GeneOrGeneProduct	7124
35996901	1754	1759	snail	GeneOrGeneProduct	20613
35996901	1909	1914	TNF-a	GeneOrGeneProduct	7124
35996901	1919	1924	snail	GeneOrGeneProduct	20613
35996901	Bind	20613	7124	Novel
35996901	Negative_Correlation	20613	7124	Novel
35996901	Positive_Correlation	20613	7124	Novel
35996901	Association	7124	20613	Novel
35996901	Association	20613	7124	Novel
35996901	Positive_Correlation	7124	20613	Novel
35996901	Bind	7124	20613	Novel
35996901	Negative_Correlation	7124	20613	Novel

74203191|t|P29S and IVS3 + 18C > T variants in bovine TSPO and their associations with deterioration of learning and short-term memory in MEF ce
74203191|a|This study investigates the functional and phenotypic consequences of sequence variants in the bovine TSPO gene and their interactions with other genetic elements in MEF cell lines. We focused on the P29S variant and the IVS3 + 18C > T splice site mutation, both of which were found to be significantly associated with each other in multiple independent experiments. The P29S variant was also found to be positively correlated with deterioration of learning and short-term memory, a phenotypic feature observed in bovine models. Similarly, the IVS3 + 18C > T variant showed a positive correlation with both the P29S variant and deterioration of learning and short-term memory. These findings suggest that the IVS3 + 18C > T mutation may act as a modifier of the P29S variant's effects on cognitive function. Additionally, the gene product HSL was found to have a positive correlation with deterioration of learning and short-term memory, indicating a potential role for HSL in the pathophysiology of this phenotypic feature. The results highlight the complex interplay between genetic variants and phenotypic outcomes in bovine models, with implications for understanding similar mechanisms in human neurodegenerative disorders.
74203191	0	4	P29S	SequenceVariant	rs2075789
74203191	9	23	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
74203191	36	42	bovine	OrganismTaxon	9913
74203191	43	47	TSPO	GeneOrGeneProduct	12257
74203191	76	123	deterioration of learning and short-term memory	DiseaseOrPhenotypicFeature	D007859
74203191	127	130	MEF	CellLine	CVCL_9115
74203191	229	235	bovine	OrganismTaxon	9913
74203191	236	240	TSPO	GeneOrGeneProduct	12257
74203191	300	303	MEF	CellLine	CVCL_9115
74203191	334	338	P29S	SequenceVariant	rs2075789
74203191	355	369	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
74203191	505	509	P29S	SequenceVariant	rs2075789
74203191	566	613	deterioration of learning and short-term memory	DiseaseOrPhenotypicFeature	D007859
74203191	648	654	bovine	OrganismTaxon	9913
74203191	678	692	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
74203191	745	749	P29S	SequenceVariant	rs2075789
74203191	762	809	deterioration of learning and short-term memory	DiseaseOrPhenotypicFeature	D007859
74203191	843	857	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
74203191	896	900	P29S	SequenceVariant	rs2075789
74203191	973	976	HSL	GeneOrGeneProduct	3991
74203191	1023	1070	deterioration of learning and short-term memory	DiseaseOrPhenotypicFeature	D007859
74203191	1104	1107	HSL	GeneOrGeneProduct	3991
74203191	1255	1261	bovine	OrganismTaxon	9913
74203191	Association	rs2075789	c|SUB|C|IVS3+18|T	Novel
74203191	Positive_Correlation	12257	D007859	Novel
74203191	Association	c|SUB|C|IVS3+18|T	rs2075789	Novel
74203191	Positive_Correlation	c|SUB|C|IVS3+18|T	D007859	Novel
74203191	Positive_Correlation	3991	D007859	Novel
74203191	Positive_Correlation	rs2075789	D007859	Novel

28918972|t|CE and A118D: interactions with Capan1 cells, VWD, ADCA, and caffeine in the context of oral stereotypies and Peters
28918972|a|This study investigates the molecular and cellular interactions between the chemical entity CE, the sequence variant A118D, and the cell line Capan1 in relation to the disease or phenotypic features VWD, ADCA, and oral stereotypies. The research highlights the association between oral stereotypies and caffeine, as well as the link between caffeine and ADCA, suggesting a potential role for caffeine in modulating ADCA-related phenotypes. Additionally, the study demonstrates a significant association between CE and VWD, indicating that CE may influence the pathogenesis of VWD. The sequence variant A118D is found to be present in multiple instances across the Capan1 cell line, suggesting a possible functional role in cellular processes related to these diseases. Notably, the presence of Peters anomaly is also observed in some cases, further complicating the interplay between these genetic and phenotypic elements. The findings underscore the complex relationships between chemical entities, sequence variants, and disease states, providing a foundation for future therapeutic strategies targeting these interactions.
28918972	0	2	CE	ChemicalEntity	C105934
28918972	7	12	A118D	SequenceVariant	p|SUB|A|118|D
28918972	32	38	Capan1	CellLine	CVCL_0237
28918972	46	49	VWD	DiseaseOrPhenotypicFeature	D014842
28918972	51	55	ADCA	DiseaseOrPhenotypicFeature	OMIM:604121
28918972	61	69	caffeine	ChemicalEntity	D002110
28918972	88	105	oral stereotypies	DiseaseOrPhenotypicFeature	D009062
28918972	209	211	CE	ChemicalEntity	C105934
28918972	234	239	A118D	SequenceVariant	p|SUB|A|118|D
28918972	259	265	Capan1	CellLine	CVCL_0237
28918972	316	319	VWD	DiseaseOrPhenotypicFeature	D014842
28918972	321	325	ADCA	DiseaseOrPhenotypicFeature	OMIM:604121
28918972	331	348	oral stereotypies	DiseaseOrPhenotypicFeature	D009062
28918972	398	415	oral stereotypies	DiseaseOrPhenotypicFeature	D009062
28918972	420	428	caffeine	ChemicalEntity	D002110
28918972	458	466	caffeine	ChemicalEntity	D002110
28918972	471	475	ADCA	DiseaseOrPhenotypicFeature	OMIM:604121
28918972	509	517	caffeine	ChemicalEntity	D002110
28918972	532	536	ADCA	DiseaseOrPhenotypicFeature	OMIM:604121
28918972	628	630	CE	ChemicalEntity	C105934
28918972	635	638	VWD	DiseaseOrPhenotypicFeature	D014842
28918972	656	658	CE	ChemicalEntity	C105934
28918972	693	696	VWD	DiseaseOrPhenotypicFeature	D014842
28918972	719	724	A118D	SequenceVariant	p|SUB|A|118|D
28918972	781	787	Capan1	CellLine	CVCL_0237
28918972	911	925	Peters anomaly	DiseaseOrPhenotypicFeature	C537884
28918972	Association	D009062	D002110	Novel
28918972	Association	D002110	OMIM:604121	Novel
28918972	Association	C105934	D014842	Novel

47599118|t|Dystrophin, neuregulin-1 (NRG-1) beta, and protein kinase A: associations with LCA, vomiting, and craniofacial syndromes in diverse cellular and viral 
47599118|a|This study investigates the complex interactions between dystrophin, neuregulin-1 (NRG-1) beta, and protein kinase A in relation to LCA, vomiting, and craniofacial syndromes across multiple cellular and viral systems. Using the SJ-GBM2 cell line, we observed a positive correlation between dystrophin and LCA, as well as between dystrophin and Let-96. The association between dystrophin and Let-96 was further supported by the presence of the Leu269Phe sequence variant, which showed a positive correlation with vomiting.   In the context of the 253JB-V cell line, we found that protein kinase A exhibited a positive correlation with both vomiting and craniofacial syndromes. This correlation was also observed in the SNU-C2A and H446 cell lines, where protein kinase A was associated with dystrophin and showed a positive correlation with LCA. The dup33bp sequence variant was found to be positively correlated with both vomiting and LCA, suggesting a potential role in the pathogenesis of these conditions.  The neuregulin-1 (NRG-1) beta gene product demonstrated a strong positive correlation with LCA, particularly in the SJ-GBM2 and Ba/F3 cell lines. Additionally, the presence of the dup33bp variant in the SJ-GBM2 cell line was associated with LCA, reinforcing the link between sequence variants and disease phenotypes.   In the context of the human immunodeficiency virus, we observed that the Leu269Phe variant was associated with increased vomiting, while the presence of the dup33bp variant in the SJ-GBM2 cell line was linked to LCA. The study also included the ginseng and Spirulina organisms, which were found to influence the expression of dystrophin and neuregulin-1 (NRG-1) beta in the SJ-GBM2 and hRPTEC cell lines, respectively.  The findings suggest that the interplay between dystrophin, neuregulin-1 (NRG-1) beta, and protein kinase A is critical in the development of LCA, vomiting, and craniofacial syndromes. These associations were further supported by the presence of multiple sequence variants, including Leu269Phe and dup33bp, which were found to be positively correlated with these phenotypic features. The study also highlights the role of the SJ-GBM2 and 253JB-V cell lines in understanding the molecular mechanisms underlying these conditions.
47599118	12	37	neuregulin-1 (NRG-1) beta	GeneOrGeneProduct	3084
47599118	43	59	protein kinase A	GeneOrGeneProduct	5566
47599118	79	82	LCA	DiseaseOrPhenotypicFeature	D057130
47599118	84	92	vomiting	DiseaseOrPhenotypicFeature	D014839
47599118	98	120	craniofacial syndromes	DiseaseOrPhenotypicFeature	D019465
47599118	209	219	dystrophin	GeneOrGeneProduct	24907
47599118	221	246	neuregulin-1 (NRG-1) beta	GeneOrGeneProduct	3084
47599118	252	268	protein kinase A	GeneOrGeneProduct	5566
47599118	284	287	LCA	DiseaseOrPhenotypicFeature	D057130
47599118	289	297	vomiting	DiseaseOrPhenotypicFeature	D014839
47599118	303	325	craniofacial syndromes	DiseaseOrPhenotypicFeature	D019465
47599118	380	387	SJ-GBM2	CellLine	CVCL_M141
47599118	442	452	dystrophin	GeneOrGeneProduct	24907
47599118	457	460	LCA	DiseaseOrPhenotypicFeature	D057130
47599118	481	491	dystrophin	GeneOrGeneProduct	24907
47599118	496	502	Let-96	GeneOrGeneProduct	-
47599118	528	538	dystrophin	GeneOrGeneProduct	24907
47599118	543	549	Let-96	GeneOrGeneProduct	-
47599118	595	604	Leu269Phe	SequenceVariant	rs199852470
47599118	664	672	vomiting	DiseaseOrPhenotypicFeature	D014839
47599118	698	705	253JB-V	CellLine	CVCL_7937
47599118	731	747	protein kinase A	GeneOrGeneProduct	5566
47599118	791	799	vomiting	DiseaseOrPhenotypicFeature	D014839
47599118	804	826	craniofacial syndromes	DiseaseOrPhenotypicFeature	D019465
47599118	870	877	SNU-C2A	CellLine	CVCL_1709
47599118	882	886	H446	CellLine	CVCL_1562
47599118	905	921	protein kinase A	GeneOrGeneProduct	5566
47599118	942	952	dystrophin	GeneOrGeneProduct	24907
47599118	992	995	LCA	DiseaseOrPhenotypicFeature	D057130
47599118	1001	1008	dup33bp	SequenceVariant	c|DUP||33|
47599118	1074	1082	vomiting	DiseaseOrPhenotypicFeature	D014839
47599118	1087	1090	LCA	DiseaseOrPhenotypicFeature	D057130
47599118	1166	1191	neuregulin-1 (NRG-1) beta	GeneOrGeneProduct	3084
47599118	1253	1256	LCA	DiseaseOrPhenotypicFeature	D057130
47599118	1278	1285	SJ-GBM2	CellLine	CVCL_M141
47599118	1290	1295	Ba/F3	CellLine	CVCL_0161
47599118	1342	1349	dup33bp	SequenceVariant	c|DUP||33|
47599118	1365	1372	SJ-GBM2	CellLine	CVCL_M141
47599118	1403	1406	LCA	DiseaseOrPhenotypicFeature	D057130
47599118	1503	1531	human immunodeficiency virus	OrganismTaxon	12721
47599118	1554	1563	Leu269Phe	SequenceVariant	rs199852470
47599118	1602	1610	vomiting	DiseaseOrPhenotypicFeature	D014839
47599118	1638	1645	dup33bp	SequenceVariant	c|DUP||33|
47599118	1661	1668	SJ-GBM2	CellLine	CVCL_M141
47599118	1693	1696	LCA	DiseaseOrPhenotypicFeature	D057130
47599118	1726	1733	ginseng	OrganismTaxon	4054
47599118	1738	1747	Spirulina	OrganismTaxon	551299
47599118	1807	1817	dystrophin	GeneOrGeneProduct	24907
47599118	1822	1847	neuregulin-1 (NRG-1) beta	GeneOrGeneProduct	3084
47599118	1855	1862	SJ-GBM2	CellLine	CVCL_M141
47599118	1867	1873	hRPTEC	CellLine	CVCL_K278
47599118	1949	1959	dystrophin	GeneOrGeneProduct	24907
47599118	1961	1986	neuregulin-1 (NRG-1) beta	GeneOrGeneProduct	3084
47599118	1992	2008	protein kinase A	GeneOrGeneProduct	5566
47599118	2043	2046	LCA	DiseaseOrPhenotypicFeature	D057130
47599118	2048	2056	vomiting	DiseaseOrPhenotypicFeature	D014839
47599118	2062	2084	craniofacial syndromes	DiseaseOrPhenotypicFeature	D019465
47599118	2185	2194	Leu269Phe	SequenceVariant	rs199852470
47599118	2199	2206	dup33bp	SequenceVariant	c|DUP||33|
47599118	2327	2334	SJ-GBM2	CellLine	CVCL_M141
47599118	2339	2346	253JB-V	CellLine	CVCL_7937
47599118	Positive_Correlation	D014839	5566	Novel
47599118	Positive_Correlation	-	D019465	Novel
47599118	Positive_Correlation	5566	D014839	Novel
47599118	Positive_Correlation	D057130	5566	Novel
47599118	Positive_Correlation	c|DUP||33|	D014839	Novel
47599118	Positive_Correlation	3084	D057130	Novel
47599118	Positive_Correlation	24907	D057130	Novel
47599118	Association	5566	24907	Novel
47599118	Positive_Correlation	D057130	3084	Novel
47599118	Positive_Correlation	rs199852470	D014839	Novel
47599118	Positive_Correlation	D019465	5566	Novel
47599118	Positive_Correlation	D003550	-	Novel
47599118	Positive_Correlation	5566	D019465	Novel
47599118	Positive_Correlation	c|DUP||33|	D057130	Novel
47599118	Association	24907	-	Novel
47599118	Positive_Correlation	D019465	-	Novel

21440466|t|OATP1B1, del(1)(p31.2p32.3), and rs757229: genetic interactions in DU145 and MH134 cell lines with hepatitis B virus and 
21440466|a|This study investigates the genetic interactions between the OATP1B1 gene, the sequence variant del(1)(p31.2p32.3), and the single nucleotide polymorphism rs757229 in the context of DU145 and MH134 cell lines. The research focuses on the potential roles of these genetic elements in modulating cellular responses to hepatitis B virus and bacteria.   OATP1B1, a key transporter involved in drug and xenobiotic uptake, was found to exhibit altered expression patterns in DU145 and MH134 cell lines harboring the del(1)(p31.2p32.3) sequence variant. This variant, which spans a large genomic region, was associated with significant changes in OATP1B1 function, as evidenced by reduced transport activity and altered protein localization.   Further analysis revealed a strong association between rs757229 and both del(1)(p31.2p32.3) and OATP1B1. The rs757229 variant, located in a regulatory region of the OATP1B1 gene, was shown to influence the expression levels of OATP1B1 in both DU145 and MH134 cell lines. This association was confirmed through multiple independent experiments, including quantitative PCR and Western blot analysis.   In addition, the presence of del(1)(p31.2p32.3) was found to modulate the effect of rs757229 on OATP1B1 expression, suggesting a complex interplay between these genetic elements. These findings were further supported by in vitro studies using DU145 and MH134 cell lines infected with hepatitis B virus and bacteria, where the genetic variants were shown to influence the susceptibility and response to these pathogens.   The study highlights the importance of understanding the genetic architecture of OATP1B1 and its interactions with sequence variants in the context of cellular responses to infectious agents. These results have implications for personalized medicine and the development of targeted therapies for diseases involving OATP1B1 dysfunction.
21440466	0	7	OATP1B1	GeneOrGeneProduct	10599
21440466	9	27	del(1)(p31.2p32.3)	SequenceVariant	c|DEL|p31.2_p32.3|
21440466	33	41	rs757229	SequenceVariant	rs757229
21440466	67	72	DU145	CellLine	CVCL_0105
21440466	77	82	MH134	CellLine	CVCL_8111
21440466	99	116	hepatitis B virus	OrganismTaxon	10407
21440466	183	190	OATP1B1	GeneOrGeneProduct	10599
21440466	218	236	del(1)(p31.2p32.3)	SequenceVariant	c|DEL|p31.2_p32.3|
21440466	277	285	rs757229	SequenceVariant	rs757229
21440466	304	309	DU145	CellLine	CVCL_0105
21440466	314	319	MH134	CellLine	CVCL_8111
21440466	438	455	hepatitis B virus	OrganismTaxon	10407
21440466	460	468	bacteria	OrganismTaxon	2
21440466	472	479	OATP1B1	GeneOrGeneProduct	10599
21440466	591	596	DU145	CellLine	CVCL_0105
21440466	601	606	MH134	CellLine	CVCL_8111
21440466	632	650	del(1)(p31.2p32.3)	SequenceVariant	c|DEL|p31.2_p32.3|
21440466	762	769	OATP1B1	GeneOrGeneProduct	10599
21440466	914	922	rs757229	SequenceVariant	rs757229
21440466	932	950	del(1)(p31.2p32.3)	SequenceVariant	c|DEL|p31.2_p32.3|
21440466	955	962	OATP1B1	GeneOrGeneProduct	10599
21440466	968	976	rs757229	SequenceVariant	rs757229
21440466	1024	1031	OATP1B1	GeneOrGeneProduct	10599
21440466	1086	1093	OATP1B1	GeneOrGeneProduct	10599
21440466	1102	1107	DU145	CellLine	CVCL_0105
21440466	1112	1117	MH134	CellLine	CVCL_8111
21440466	1288	1306	del(1)(p31.2p32.3)	SequenceVariant	c|DEL|p31.2_p32.3|
21440466	1343	1351	rs757229	SequenceVariant	rs757229
21440466	1355	1362	OATP1B1	GeneOrGeneProduct	10599
21440466	1502	1507	DU145	CellLine	CVCL_0105
21440466	1512	1517	MH134	CellLine	CVCL_8111
21440466	1543	1560	hepatitis B virus	OrganismTaxon	10407
21440466	1565	1573	bacteria	OrganismTaxon	2
21440466	1761	1768	OATP1B1	GeneOrGeneProduct	10599
21440466	1995	2002	OATP1B1	GeneOrGeneProduct	10599
21440466	Association	rs757229	c|DEL|p31.2_p32.3|	Novel
21440466	Association	c|DEL|p31.2_p32.3|	rs757229	Novel
21440466	Association	rs757229	10599	Novel
21440466	Association	c|DEL|p31.2_p32.3|	10599	Novel

78207855|t|HOMER1 and laminin interactions in MC3T3-E1 and Ba/F3 cell lines: implications for neurotransmitter signaling and platinum-based drug r
78207855|a|This study investigates the molecular interactions between HOMER1 and laminin in the context of multiple cell lines, including MC3T3-E1, Ba/F3, and Hs578T, and explores their functional relevance in neurotransmitter signaling and responses to platinum-based compounds. We demonstrate that HOMER1 binds directly to laminin, a finding supported by biochemical assays and confirmed in multiple cell lines. This interaction is further reinforced by the association of HOMER1 with neurotransmitters, suggesting a potential role in synaptic plasticity and neuronal function.   Our results also reveal that HOMER1 interacts with Simvastatinezetimibe, a compound known for its cholesterol-lowering properties, indicating a possible pharmacological relevance. Additionally, we show that HOMER1 associates with platinum, a metal commonly used in cancer chemotherapy, raising questions about its potential involvement in drug resistance mechanisms.   The study further explores the relationship between MutS and platinum, demonstrating that MutS binds to platinum and is associated with neurotransmitters, suggesting a possible link between DNA repair mechanisms and neuronal signaling. MutS also binds to laminin, and this interaction is further supported by the association of MutS with Simvastatinezetimibe. Notably, MutS binds to HOMER1, reinforcing the interconnectedness of these proteins in cellular processes.   In addition to these interactions, laminin is shown to bind to MutS and associate with Simvastatinezetimibe, highlighting the complex network of molecular interactions involving these proteins. The study also identifies the sequence variant Delta695-725 and the mutation c.592C-->T, which may contribute to the observed functional differences in these interactions.   These findings provide new insights into the molecular mechanisms underlying the interactions between HOMER1, laminin, MutS, and various chemical entities, with potential implications for understanding disease pathogenesis and developing targeted therapeutic strategies.
78207855	0	6	HOMER1	GeneOrGeneProduct	9456
78207855	11	18	laminin	GeneOrGeneProduct	16777
78207855	35	43	MC3T3-E1	CellLine	CVCL_0409
78207855	48	53	Ba/F3	CellLine	CVCL_0161
78207855	114	122	platinum	ChemicalEntity	D010984
78207855	195	201	HOMER1	GeneOrGeneProduct	9456
78207855	206	213	laminin	GeneOrGeneProduct	16777
78207855	263	271	MC3T3-E1	CellLine	CVCL_0409
78207855	273	278	Ba/F3	CellLine	CVCL_0161
78207855	284	290	Hs578T	CellLine	CVCL_0332
78207855	379	387	platinum	ChemicalEntity	D010984
78207855	425	431	HOMER1	GeneOrGeneProduct	9456
78207855	450	457	laminin	GeneOrGeneProduct	16777
78207855	600	606	HOMER1	GeneOrGeneProduct	9456
78207855	612	629	neurotransmitters	ChemicalEntity	D018377
78207855	736	742	HOMER1	GeneOrGeneProduct	9456
78207855	758	778	Simvastatinezetimibe	ChemicalEntity	D000069499
78207855	914	920	HOMER1	GeneOrGeneProduct	9456
78207855	937	945	platinum	ChemicalEntity	D010984
78207855	1128	1132	MutS	GeneOrGeneProduct	850545
78207855	1137	1145	platinum	ChemicalEntity	D010984
78207855	1166	1170	MutS	GeneOrGeneProduct	850545
78207855	1180	1188	platinum	ChemicalEntity	D010984
78207855	1212	1229	neurotransmitters	ChemicalEntity	D018377
78207855	1312	1316	MutS	GeneOrGeneProduct	850545
78207855	1331	1338	laminin	GeneOrGeneProduct	16777
78207855	1404	1408	MutS	GeneOrGeneProduct	850545
78207855	1414	1434	Simvastatinezetimibe	ChemicalEntity	D000069499
78207855	1445	1449	MutS	GeneOrGeneProduct	850545
78207855	1459	1465	HOMER1	GeneOrGeneProduct	9456
78207855	1580	1587	laminin	GeneOrGeneProduct	16777
78207855	1608	1612	MutS	GeneOrGeneProduct	850545
78207855	1632	1652	Simvastatinezetimibe	ChemicalEntity	D000069499
78207855	1786	1798	Delta695-725	SequenceVariant	p|DEL|695-725|
78207855	1816	1826	c.592C-->T	SequenceVariant	c|SUB|C|592|T
78207855	2015	2021	HOMER1	GeneOrGeneProduct	9456
78207855	2023	2030	laminin	GeneOrGeneProduct	16777
78207855	2032	2036	MutS	GeneOrGeneProduct	850545
78207855	Bind	16777	9456	Novel
78207855	Association	9456	D018377	Novel
78207855	Association	9456	D000069499	Novel
78207855	Association	850545	D010984	Novel
78207855	Bind	850545	16777	Novel
78207855	Association	16777	D010984	Novel
78207855	Bind	850545	9456	Novel
78207855	Bind	9456	16777	Novel
78207855	Association	9456	D010984	Novel
78207855	Association	850545	D018377	Novel
78207855	Bind	9456	850545	Novel
78207855	Association	16777	D000069499	Novel
78207855	Association	850545	D000069499	Novel
78207855	Bind	16777	850545	Novel
78207855	Association	16777	D018377	Novel

85642325|t|Testosterone, Disrupted in Schizophrenia 1, and GCD type III: A Multifaceted Analysis of Genetic, Cellular, and Pathophysiological Inte
85642325|a|This study explores the complex interplay between testosterone, Disrupted in Schizophrenia 1 (DISC1), and GCD type III, with a focus on their genetic, cellular, and pathophysiological relationships. We investigated the association between flutamide and DISC1, revealing a significant interaction that may influence neurodevelopmental processes. Additionally, we found that LPA2 binds to both calcium and prednisolone, suggesting a role in intracellular signaling pathways. The sequence variant rs2073163 was associated with rs2738751, highlighting potential genetic interactions that may contribute to disease susceptibility.   Bladder dysfunction was found to be associated with both p.R34X and paired box homeotic gene 6 (PAX6), while also showing a negative correlation with calcium. The negative correlation between glomerulosclerosis and flutamide suggests a protective effect of flutamide in renal disease. Furthermore, the negative correlation between NAFLD and bisphosphonate indicates that bisphosphonate treatment may not be beneficial in patients with non-alcoholic fatty liver disease.   We also observed a positive correlation between EXT2 and p27, and a negative correlation between p27 and EXT2, suggesting a complex regulatory network. The negative correlation between liver disease and testosterone implies that testosterone may play a role in the progression of hepatic pathology. Additionally, liver disease was found to be associated with p.R34X and rs2073163, reinforcing the genetic underpinnings of hepatic dysfunction.   The association between NAFLD and DISC1, as well as between NAFLD and LPA2, suggests a potential role for these genes in the pathogenesis of metabolic disorders. The positive correlation between DISC1 and EXT2, along with the negative correlation between DISC1 and PAX6, indicates a complex genetic architecture.   In cellular studies, we examined the effects of Testosterone on the GT1-1 and HEK293 cell lines, finding that Testosterone interacts with EXT2 and influences gene expression. The negative correlation between liver disease and prednisolone suggests that prednisolone may not be an effective treatment for certain hepatic conditions.   The association between GCD type III and p27, along with the negative correlation between GCD type III and prednisolone, highlights the potential involvement of these genes in neurodevelopmental and renal pathologies. Finally, the negative correlation between PAX6 and LPA2, as well as between PAX6 and DISC1, underscores the importance of these interactions in maintaining cellular homeostasis. These findings provide a comprehensive framework for understanding the molecular mechanisms underlying these conditions.
85642325	0	12	Testosterone	ChemicalEntity	D013739
85642325	14	42	Disrupted in Schizophrenia 1	GeneOrGeneProduct	27185
85642325	48	60	GCD type III	DiseaseOrPhenotypicFeature	C535476
85642325	200	228	Disrupted in Schizophrenia 1	GeneOrGeneProduct	27185
85642325	242	254	GCD type III	DiseaseOrPhenotypicFeature	C535476
85642325	375	384	flutamide	ChemicalEntity	D005485
85642325	509	513	LPA2	GeneOrGeneProduct	53978
85642325	528	535	calcium	ChemicalEntity	D002118
85642325	540	552	prednisolone	ChemicalEntity	D011239
85642325	630	639	rs2073163	SequenceVariant	rs2073163
85642325	660	669	rs2738751	SequenceVariant	rs2738751
85642325	821	827	p.R34X	SequenceVariant	rs121908073
85642325	832	858	paired box homeotic gene 6	GeneOrGeneProduct	5080
85642325	914	921	calcium	ChemicalEntity	D002118
85642325	956	974	glomerulosclerosis	DiseaseOrPhenotypicFeature	D005921
85642325	979	988	flutamide	ChemicalEntity	D005485
85642325	1021	1030	flutamide	ChemicalEntity	D005485
85642325	1095	1100	NAFLD	DiseaseOrPhenotypicFeature	D065626
85642325	1105	1119	bisphosphonate	ChemicalEntity	D004164
85642325	1135	1149	bisphosphonate	ChemicalEntity	D004164
85642325	1219	1232	liver disease	DiseaseOrPhenotypicFeature	D008107
85642325	1284	1288	EXT2	GeneOrGeneProduct	2132
85642325	1293	1296	p27	GeneOrGeneProduct	1027
85642325	1333	1336	p27	GeneOrGeneProduct	1027
85642325	1341	1345	EXT2	GeneOrGeneProduct	2132
85642325	1421	1434	liver disease	DiseaseOrPhenotypicFeature	D008107
85642325	1549	1562	liver disease	DiseaseOrPhenotypicFeature	D008107
85642325	1595	1601	p.R34X	SequenceVariant	rs121908073
85642325	1606	1615	rs2073163	SequenceVariant	rs2073163
85642325	1705	1710	NAFLD	DiseaseOrPhenotypicFeature	D065626
85642325	1741	1746	NAFLD	DiseaseOrPhenotypicFeature	D065626
85642325	1751	1755	LPA2	GeneOrGeneProduct	53978
85642325	1886	1890	EXT2	GeneOrGeneProduct	2132
85642325	2044	2056	Testosterone	ChemicalEntity	D013739
85642325	2064	2069	GT1-1	CellLine	CVCL_6236
85642325	2074	2080	HEK293	CellLine	CVCL_0045
85642325	2106	2118	Testosterone	ChemicalEntity	D013739
85642325	2134	2138	EXT2	GeneOrGeneProduct	2132
85642325	2204	2217	liver disease	DiseaseOrPhenotypicFeature	D008107
85642325	2222	2234	prednisolone	ChemicalEntity	D011239
85642325	2249	2261	prednisolone	ChemicalEntity	D011239
85642325	2354	2366	GCD type III	DiseaseOrPhenotypicFeature	C535476
85642325	2371	2374	p27	GeneOrGeneProduct	1027
85642325	2420	2432	GCD type III	DiseaseOrPhenotypicFeature	C535476
85642325	2437	2449	prednisolone	ChemicalEntity	D011239
85642325	2599	2603	LPA2	GeneOrGeneProduct	53978
85642325	Association	D005485	27185	Novel
85642325	Bind	53978	D002118	Novel
85642325	Association	rs2073163	rs2738751	Novel
85642325	Association	D001745	rs121908073	Novel
85642325	Negative_Correlation	D005921	D005485	Novel
85642325	Negative_Correlation	D065626	D004164	Novel
85642325	Negative_Correlation	27185	2132	Novel
85642325	Association	D065626	27185	Novel
85642325	Bind	53978	D011239	Novel
85642325	Association	rs121908073	rs2073163	Novel
85642325	Association	D002118	27185	Novel
85642325	Association	D001745	5080	Novel
85642325	Positive_Correlation	2132	1027	Novel
85642325	Negative_Correlation	D008107	D013739	Novel
85642325	Positive_Correlation	27185	2132	Novel
85642325	Association	D011239	5080	Novel
85642325	Association	D008107	27185	Novel
85642325	Association	D001745	rs2073163	Novel
85642325	Association	C535476	1027	Novel
85642325	Negative_Correlation	1027	2132	Novel
85642325	Negative_Correlation	5080	53978	Novel
85642325	Negative_Correlation	5080	27185	Novel
85642325	Negative_Correlation	D001745	D002118	Novel
85642325	Bind	1027	D005485	Novel
85642325	Association	D001745	2132	Novel
85642325	Positive_Correlation	5080	53978	Novel
85642325	Association	D013739	2132	Novel
85642325	Association	D008107	rs121908073	Novel
85642325	Negative_Correlation	5080	1027	Novel
85642325	Association	D065626	rs121908073	Novel
85642325	Negative_Correlation	D008107	D011239	Novel
85642325	Association	D065626	53978	Novel
85642325	Positive_Correlation	53978	27185	Novel
85642325	Negative_Correlation	2132	5080	Novel
85642325	Positive_Correlation	53978	5080	Novel
85642325	Bind	5080	D002118	Novel
85642325	Association	D008107	rs2073163	Novel
85642325	Association	D005921	rs2073163	Novel
85642325	Negative_Correlation	C535476	D011239	Novel

55976278|t|S140G variant of Dihydrofolate reductase and its interactions with valproate and fluvastatin in IEC-6 ce
55976278|a|This study investigates the functional and molecular interactions between the S140G variant of Dihydrofolate reductase (DHFR) and the pharmacological agents valproate and fluvastatin in the context of the IEC-6 cell line. The S140G variant, a known polymorphism in the DHFR gene, was found to exhibit altered enzymatic activity and altered sensitivity to both valproate and fluvastatin. The study revealed a negative correlation between the S140G variant of DHFR and valproate, as well as a negative correlation between DHFR and fluvastatin. These findings suggest that the S140G variant may modulate the pharmacological response to these agents. Additionally, a negative correlation was observed between fluvastatin and valproate, indicating potential competitive interactions or shared metabolic pathways. However, an association was also noted between valproate and fluvastatin, suggesting that their effects may be partially synergistic in certain cellular contexts. The IEC-6 cell line was used as a model system to assess these interactions, and the results were consistent across multiple experimental replicates. The presence of the S140G variant was confirmed in all tested samples, and its impact on drug response was further validated through biochemical assays and gene expression profiling. These findings provide important insights into the molecular mechanisms underlying drug interactions and may have implications for personalized medicine approaches in the treatment of metabolic and neurological disorders.
55976278	0	5	S140G	SequenceVariant	p|SUB|S|140|G
55976278	17	40	Dihydrofolate reductase	GeneOrGeneProduct	1719
55976278	67	76	valproate	ChemicalEntity	D014635
55976278	81	92	fluvastatin	ChemicalEntity	C065180
55976278	96	101	IEC-6	CellLine	CVCL_0343
55976278	183	188	S140G	SequenceVariant	p|SUB|S|140|G
55976278	200	223	Dihydrofolate reductase	GeneOrGeneProduct	1719
55976278	262	271	valproate	ChemicalEntity	D014635
55976278	276	287	fluvastatin	ChemicalEntity	C065180
55976278	310	315	IEC-6	CellLine	CVCL_0343
55976278	331	336	S140G	SequenceVariant	p|SUB|S|140|G
55976278	465	474	valproate	ChemicalEntity	D014635
55976278	479	490	fluvastatin	ChemicalEntity	C065180
55976278	546	551	S140G	SequenceVariant	p|SUB|S|140|G
55976278	572	581	valproate	ChemicalEntity	D014635
55976278	634	645	fluvastatin	ChemicalEntity	C065180
55976278	679	684	S140G	SequenceVariant	p|SUB|S|140|G
55976278	810	821	fluvastatin	ChemicalEntity	C065180
55976278	826	835	valproate	ChemicalEntity	D014635
55976278	960	969	valproate	ChemicalEntity	D014635
55976278	974	985	fluvastatin	ChemicalEntity	C065180
55976278	1080	1085	IEC-6	CellLine	CVCL_0343
55976278	1246	1251	S140G	SequenceVariant	p|SUB|S|140|G
55976278	Negative_Correlation	D014635	C065180	Novel
55976278	Negative_Correlation	C065180	D014635	Novel
55976278	Negative_Correlation	1719	D014635	Novel
55976278	Association	C065180	D014635	Novel
55976278	Negative_Correlation	1719	C065180	Novel
55976278	Association	D014635	C065180	Novel

42989529|t|Ouabain, lactate, and p120-catenin interactions in the context of Liver metastases, calcification of ascending aorta, and 
42989529|a|This study investigates the complex interplay between ouabain, lactate, and p120-catenin in the context of Liver metastases, calcification of ascending aorta, and polyuria. Our findings reveal a positive correlation between lactate and myogenic factor 5, suggesting a potential regulatory role of lactate in myogenic differentiation. Additionally, we observe a positive correlation between cholinergic and JAG1, highlighting the involvement of cholinergic signaling in the regulation of JAG1 expression. The study also demonstrates a positive correlation between TARBP2 and serine-threonine liver kinase B1, as well as between serine-threonine liver kinase B1 and JAG1, indicating a potential signaling cascade involving these proteins.   A drug interaction between lactate and paraffin is further explored, with evidence suggesting that paraffin may modulate lactate metabolism in certain pathological conditions. The presence of multiple instances of ouabain and p120-catenin underscores their potential roles in the progression of Liver metastases and the associated phenotypic features. Furthermore, the study identifies a link between ouabain and the development of calcification of ascending aorta, which may be mediated through interactions with beta-adrenergic receptors.   The occurrence of polyuria in the context of these molecular interactions suggests a possible involvement of the renin-angiotensin system and other regulatory pathways. The study also notes the presence of anthracyclines and fever in the patient cohort, which may be related to the underlying pathophysiology of the disease. Notably, Lenz microphthalmia syndrome and ASPS are identified as rare but significant phenotypic features associated with the observed molecular interactions. The role of scopolamine and cholinergic signaling in these conditions is further emphasized, with implications for therapeutic strategies targeting these pathways. Finally, the study highlights the importance of myogenic factor 5 and TARBP2 in the context of these complex interactions, providing new insights into the molecular mechanisms underlying these diseases.
42989529	9	16	lactate	ChemicalEntity	D019344
42989529	22	34	p120-catenin	GeneOrGeneProduct	1500
42989529	66	82	Liver metastases	DiseaseOrPhenotypicFeature	D008113
42989529	84	116	calcification of ascending aorta	DiseaseOrPhenotypicFeature	D001018
42989529	177	184	ouabain	ChemicalEntity	D010042
42989529	186	193	lactate	ChemicalEntity	D019344
42989529	199	211	p120-catenin	GeneOrGeneProduct	1500
42989529	230	246	Liver metastases	DiseaseOrPhenotypicFeature	D008113
42989529	248	280	calcification of ascending aorta	DiseaseOrPhenotypicFeature	D001018
42989529	286	294	polyuria	DiseaseOrPhenotypicFeature	D011141
42989529	347	354	lactate	ChemicalEntity	D019344
42989529	359	376	myogenic factor 5	GeneOrGeneProduct	4617
42989529	420	427	lactate	ChemicalEntity	D019344
42989529	513	524	cholinergic	ChemicalEntity	D018678
42989529	529	533	JAG1	GeneOrGeneProduct	182
42989529	567	578	cholinergic	ChemicalEntity	D018678
42989529	610	614	JAG1	GeneOrGeneProduct	182
42989529	686	692	TARBP2	GeneOrGeneProduct	21357
42989529	697	729	serine-threonine liver kinase B1	GeneOrGeneProduct	6794
42989529	750	782	serine-threonine liver kinase B1	GeneOrGeneProduct	6794
42989529	787	791	JAG1	GeneOrGeneProduct	182
42989529	889	896	lactate	ChemicalEntity	D019344
42989529	901	909	paraffin	ChemicalEntity	D010232
42989529	961	969	paraffin	ChemicalEntity	D010232
42989529	983	990	lactate	ChemicalEntity	D019344
42989529	1076	1083	ouabain	ChemicalEntity	D010042
42989529	1088	1100	p120-catenin	GeneOrGeneProduct	1500
42989529	1157	1173	Liver metastases	DiseaseOrPhenotypicFeature	D008113
42989529	1263	1270	ouabain	ChemicalEntity	D010042
42989529	1294	1326	calcification of ascending aorta	DiseaseOrPhenotypicFeature	D001018
42989529	1376	1401	beta-adrenergic receptors	GeneOrGeneProduct	153
42989529	1423	1431	polyuria	DiseaseOrPhenotypicFeature	D011141
42989529	1611	1625	anthracyclines	ChemicalEntity	D018943
42989529	1630	1635	fever	DiseaseOrPhenotypicFeature	D005334
42989529	1739	1767	Lenz microphthalmia syndrome	DiseaseOrPhenotypicFeature	C537464
42989529	1772	1776	ASPS	DiseaseOrPhenotypicFeature	C565789
42989529	1901	1912	scopolamine	ChemicalEntity	D012601
42989529	1917	1928	cholinergic	ChemicalEntity	D018678
42989529	2101	2118	myogenic factor 5	GeneOrGeneProduct	4617
42989529	2123	2129	TARBP2	GeneOrGeneProduct	21357
42989529	Positive_Correlation	D019344	4617	Novel
42989529	Positive_Correlation	D018678	182	Novel
42989529	Positive_Correlation	21357	6794	Novel
42989529	Positive_Correlation	6794	182	Novel
42989529	Drug_Interaction	D019344	D010232	Novel

04840414|t|C57BL/6J and MEF cell lines in the study of psychomotor retardation and the impact of sequence variants IVS51 + 1G-->A, c.1475G>A, a
04840414|a|This study investigates the role of sequence variants IVS51 + 1G-->A, c.1475G>A, and 55M/L in the development of psychomotor retardation using the C57BL/6J and MEF cell lines. The C57BL/6J cell line, a widely used model in behavioral and neurodevelopmental research, was employed to assess the functional consequences of these genetic alterations. The MEF cell line, derived from mouse embryos, was also utilized to evaluate the effects of these variants in a different cellular context. The sequence variant IVS51 + 1G-->A was found to be significantly associated with psychomotor retardation in both C57BL/6J and MEF cell lines. Additionally, the variant c.1475G>A was observed to modulate the expression of key genes involved in neural development, while the variant 55M/L showed a distinct pattern of expression in the C57BL/6J cell line. These findings suggest that the sequence variants IVS51 + 1G-->A, c.1475G>A, and 55M/L may contribute to the pathogenesis of psychomotor retardation through distinct molecular mechanisms. The C57BL/6J and MEF cell lines provided valuable insights into the cellular and molecular basis of these associations, highlighting the importance of genetic variability in neurodevelopmental disorders.
04840414	0	8	C57BL/6J	CellLine	CVCL_5U84
04840414	13	16	MEF	CellLine	CVCL_9115
04840414	44	67	psychomotor retardation	DiseaseOrPhenotypicFeature	D011596
04840414	104	118	IVS51 + 1G-->A	SequenceVariant	c|SUB|G|IVS51+1|A
04840414	120	129	c.1475G>A	SequenceVariant	c|SUB|G|1475|A
04840414	187	201	IVS51 + 1G-->A	SequenceVariant	c|SUB|G|IVS51+1|A
04840414	203	212	c.1475G>A	SequenceVariant	c|SUB|G|1475|A
04840414	218	223	55M/L	SequenceVariant	p|SUB|M|55|L
04840414	246	269	psychomotor retardation	DiseaseOrPhenotypicFeature	D011596
04840414	280	288	C57BL/6J	CellLine	CVCL_5U84
04840414	293	296	MEF	CellLine	CVCL_9115
04840414	313	321	C57BL/6J	CellLine	CVCL_5U84
04840414	485	488	MEF	CellLine	CVCL_9115
04840414	642	656	IVS51 + 1G-->A	SequenceVariant	c|SUB|G|IVS51+1|A
04840414	703	726	psychomotor retardation	DiseaseOrPhenotypicFeature	D011596
04840414	735	743	C57BL/6J	CellLine	CVCL_5U84
04840414	748	751	MEF	CellLine	CVCL_9115
04840414	790	799	c.1475G>A	SequenceVariant	c|SUB|G|1475|A
04840414	903	908	55M/L	SequenceVariant	p|SUB|M|55|L
04840414	956	964	C57BL/6J	CellLine	CVCL_5U84
04840414	1026	1040	IVS51 + 1G-->A	SequenceVariant	c|SUB|G|IVS51+1|A
04840414	1042	1051	c.1475G>A	SequenceVariant	c|SUB|G|1475|A
04840414	1057	1062	55M/L	SequenceVariant	p|SUB|M|55|L
04840414	1101	1124	psychomotor retardation	DiseaseOrPhenotypicFeature	D011596
04840414	1168	1176	C57BL/6J	CellLine	CVCL_5U84
04840414	1181	1184	MEF	CellLine	CVCL_9115

04033964|t|PGE(2) and Anemia: Interactions in MC3T3-E1, DU145, and CMT-93 cell lines with ginseng-derived c
04033964|a|This study investigates the complex interactions between the prostaglandin E2 (PGE(2)) and Anemia in the context of various cell lines and ginseng-derived compounds. The research focuses on three distinct cell lines: MC3T3-E1, DU145, and CMT-93, each of which exhibits unique responses to PGE(2) and Anemia. The findings reveal a positive correlation between PGE(2) and Anemia, suggesting that PGE(2) may play a role in the pathophysiology of Anemia. Additionally, the study demonstrates an association between PGE(2) and Anemia, further supporting the hypothesis that PGE(2) could be a therapeutic target for Anemia treatment. The role of ginseng, a well-known medicinal plant, is also explored, with multiple instances of ginseng being used to modulate the effects of PGE(2) on Anemia. The results indicate that ginseng may enhance the positive correlation between PGE(2) and Anemia, potentially through its anti-inflammatory and immunomodulatory properties. The study includes multiple instances of MC3T3-E1, DU145, and CMT-93 cell lines, as well as repeated mentions of PGE(2) and Anemia, to ensure robust statistical analysis. The data collected from these experiments provide strong evidence for the existence of a positive correlation between PGE(2) and Anemia, as well as an association between the two, which could have significant implications for the development of new therapeutic strategies for Anemia.
04033964	0	6	PGE(2)	ChemicalEntity	D015232
04033964	11	17	Anemia	DiseaseOrPhenotypicFeature	D000740
04033964	35	43	MC3T3-E1	CellLine	CVCL_0409
04033964	45	50	DU145	CellLine	CVCL_0105
04033964	56	62	CMT-93	CellLine	CVCL_1986
04033964	79	86	ginseng	OrganismTaxon	4054
04033964	176	182	PGE(2)	ChemicalEntity	D015232
04033964	188	194	Anemia	DiseaseOrPhenotypicFeature	D000740
04033964	236	243	ginseng	OrganismTaxon	4054
04033964	314	322	MC3T3-E1	CellLine	CVCL_0409
04033964	324	329	DU145	CellLine	CVCL_0105
04033964	335	341	CMT-93	CellLine	CVCL_1986
04033964	386	392	PGE(2)	ChemicalEntity	D015232
04033964	397	403	Anemia	DiseaseOrPhenotypicFeature	D000740
04033964	456	462	PGE(2)	ChemicalEntity	D015232
04033964	467	473	Anemia	DiseaseOrPhenotypicFeature	D000740
04033964	491	497	PGE(2)	ChemicalEntity	D015232
04033964	540	546	Anemia	DiseaseOrPhenotypicFeature	D000740
04033964	608	614	PGE(2)	ChemicalEntity	D015232
04033964	619	625	Anemia	DiseaseOrPhenotypicFeature	D000740
04033964	666	672	PGE(2)	ChemicalEntity	D015232
04033964	707	713	Anemia	DiseaseOrPhenotypicFeature	D000740
04033964	737	744	ginseng	OrganismTaxon	4054
04033964	821	828	ginseng	OrganismTaxon	4054
04033964	867	873	PGE(2)	ChemicalEntity	D015232
04033964	877	883	Anemia	DiseaseOrPhenotypicFeature	D000740
04033964	911	918	ginseng	OrganismTaxon	4054
04033964	964	970	PGE(2)	ChemicalEntity	D015232
04033964	975	981	Anemia	DiseaseOrPhenotypicFeature	D000740
04033964	1099	1107	MC3T3-E1	CellLine	CVCL_0409
04033964	1109	1114	DU145	CellLine	CVCL_0105
04033964	1120	1126	CMT-93	CellLine	CVCL_1986
04033964	1171	1177	PGE(2)	ChemicalEntity	D015232
04033964	1182	1188	Anemia	DiseaseOrPhenotypicFeature	D000740
04033964	1347	1353	PGE(2)	ChemicalEntity	D015232
04033964	1358	1364	Anemia	DiseaseOrPhenotypicFeature	D000740
04033964	1505	1511	Anemia	DiseaseOrPhenotypicFeature	D000740
04033964	Positive_Correlation	D000740	D015232	Novel
04033964	Positive_Correlation	D015232	D000740	Novel
04033964	Association	D015232	D000740	Novel

98583780|t|Genetic and pharmacological interactions in liver failure and joint abnormalities: a study of cell lines, sequence variants, and chemical 
98583780|a|This study investigates the complex interplay between genetic sequence variants, chemical entities, and disease phenotypes in the context of liver failure and joint abnormalities. Using the CA3 cell line, we explored the effects of melanotan II, Terfenadine, and agar on cellular responses, while also examining the impact of sequence variants such as -652 6N ins/del, 55M/L, G12D, and c.643T>C. The HEK cell line was employed to assess the role of fura-2 and oxygen in intracellular calcium dynamics and oxidative stress.    Our findings reveal a negative correlation between liver failure and Terfenadine, suggesting that Terfenadine may have protective effects in this condition. Conversely, liver failure is positively correlated with G12D, 55M/L, and c.643T>C, indicating that these sequence variants may contribute to the pathogenesis of liver failure. Notably, the -652 6N ins/del variant shows a strong positive correlation with liver failure, highlighting its potential as a biomarker.    In contrast, joint abnormalities are negatively correlated with fura-2 and melanotan II, suggesting that these chemical entities may have inhibitory effects on the development of joint abnormalities. Additionally, joint abnormalities are negatively correlated with agar and oxygen, indicating that these factors may exacerbate the condition. However, there is a positive correlation between joint abnormalities and 55M/L, suggesting that this sequence variant may play a protective role.    The study also demonstrates a negative correlation between liver failure and melanotan II and oxygen, implying that these chemical entities may have a mitigating effect on liver failure. Overall, the results underscore the importance of genetic and pharmacological factors in the development and progression of liver failure and joint abnormalities, with implications for targeted therapeutic strategies.
98583780	44	57	liver failure	DiseaseOrPhenotypicFeature	D017093
98583780	62	81	joint abnormalities	DiseaseOrPhenotypicFeature	D007592
98583780	280	293	liver failure	DiseaseOrPhenotypicFeature	D017093
98583780	298	317	joint abnormalities	DiseaseOrPhenotypicFeature	D007592
98583780	329	332	CA3	CellLine	CVCL_JW73
98583780	371	383	melanotan II	ChemicalEntity	C079282
98583780	385	396	Terfenadine	ChemicalEntity	D016593
98583780	402	406	agar	ChemicalEntity	D000362
98583780	491	506	-652 6N ins/del	SequenceVariant	c|INDEL|-652|6
98583780	508	513	55M/L	SequenceVariant	p|SUB|M|55|L
98583780	515	519	G12D	SequenceVariant	rs121913529
98583780	525	533	c.643T>C	SequenceVariant	c|SUB|T|643|C
98583780	539	542	HEK	CellLine	CVCL_M624
98583780	588	594	fura-2	ChemicalEntity	D016257
98583780	599	605	oxygen	ChemicalEntity	D010100
98583780	716	729	liver failure	DiseaseOrPhenotypicFeature	D017093
98583780	734	745	Terfenadine	ChemicalEntity	D016593
98583780	763	774	Terfenadine	ChemicalEntity	D016593
98583780	834	847	liver failure	DiseaseOrPhenotypicFeature	D017093
98583780	878	882	G12D	SequenceVariant	rs121913529
98583780	884	889	55M/L	SequenceVariant	p|SUB|M|55|L
98583780	895	903	c.643T>C	SequenceVariant	c|SUB|T|643|C
98583780	983	996	liver failure	DiseaseOrPhenotypicFeature	D017093
98583780	1011	1026	-652 6N ins/del	SequenceVariant	c|INDEL|-652|6
98583780	1076	1089	liver failure	DiseaseOrPhenotypicFeature	D017093
98583780	1150	1169	joint abnormalities	DiseaseOrPhenotypicFeature	D007592
98583780	1201	1207	fura-2	ChemicalEntity	D016257
98583780	1212	1224	melanotan II	ChemicalEntity	C079282
98583780	1316	1335	joint abnormalities	DiseaseOrPhenotypicFeature	D007592
98583780	1351	1370	joint abnormalities	DiseaseOrPhenotypicFeature	D007592
98583780	1402	1406	agar	ChemicalEntity	D000362
98583780	1411	1417	oxygen	ChemicalEntity	D010100
98583780	1528	1547	joint abnormalities	DiseaseOrPhenotypicFeature	D007592
98583780	1552	1557	55M/L	SequenceVariant	p|SUB|M|55|L
98583780	1687	1700	liver failure	DiseaseOrPhenotypicFeature	D017093
98583780	1705	1717	melanotan II	ChemicalEntity	C079282
98583780	1722	1728	oxygen	ChemicalEntity	D010100
98583780	1800	1813	liver failure	DiseaseOrPhenotypicFeature	D017093
98583780	1939	1952	liver failure	DiseaseOrPhenotypicFeature	D017093
98583780	1957	1976	joint abnormalities	DiseaseOrPhenotypicFeature	D007592
98583780	Negative_Correlation	D007592	D016257	Novel
98583780	Negative_Correlation	D017093	D016593	Novel
98583780	Positive_Correlation	D017093	rs121913529	Novel
98583780	Positive_Correlation	D017093	p|SUB|M|55|L	Novel
98583780	Positive_Correlation	D007592	p|SUB|M|55|L	Novel
98583780	Positive_Correlation	D017093	c|SUB|T|643|C	Novel
98583780	Negative_Correlation	D007592	C079282	Novel
98583780	Negative_Correlation	D017093	C079282	Novel
98583780	Negative_Correlation	D007592	D000362	Novel
98583780	Negative_Correlation	D017093	D010100	Novel
98583780	Negative_Correlation	D007592	D010100	Novel
98583780	Positive_Correlation	D017093	c|INDEL|-652|6	Novel

36611535|t|Genetic and functional analysis of Ubiquitin carboxyl-terminal esterase L1 in MCF7/AdrR and BALB/c cell lines: interactions with IFNAR 
36611535|a|This study investigates the functional and genetic interactions between Ubiquitin carboxyl-terminal esterase L1 (UCHL1), IFNAR, and IL-4 in the context of MCF7/AdrR and BALB/c cell lines. We demonstrate a positive correlation between UCHL1 and IFNAR, as well as a positive correlation between UCHL1 and IL-4. Notably, we also observe a negative correlation between IFNAR and IL-4, suggesting a complex regulatory network. The sequence variant rs2844580 is significantly associated with UCHL1 expression in MCF7/AdrR cells, while the variant Ile326Ile is linked to IFNAR activity in BALB/c cells. Additionally, the sequence variant 'alanine for proline at amino acid 286' is found to modulate the binding affinity of UCHL1 to IFNAR, supporting a direct bind relationship between these two molecules. The nine-nucleotide deletion starting at position 1952 is associated with reduced IL-4 production in BALB/c cells. Furthermore, we show that IL-4 binds to UCHL1, reinforcing the interplay between these factors. These findings highlight the critical role of UCHL1 in modulating immune responses through its interactions with IFNAR and IL-4 in both MCF7/AdrR and BALB/c cell lines.
36611535	35	74	Ubiquitin carboxyl-terminal esterase L1	GeneOrGeneProduct	7345
36611535	78	87	MCF7/AdrR	CellLine	 CVCL_1452
36611535	92	98	BALB/c	CellLine	CVCL_9101
36611535	129	134	IFNAR	GeneOrGeneProduct	288264
36611535	208	247	Ubiquitin carboxyl-terminal esterase L1	GeneOrGeneProduct	7345
36611535	257	262	IFNAR	GeneOrGeneProduct	288264
36611535	268	272	IL-4	GeneOrGeneProduct	16189
36611535	291	300	MCF7/AdrR	CellLine	 CVCL_1452
36611535	305	311	BALB/c	CellLine	CVCL_9101
36611535	380	385	IFNAR	GeneOrGeneProduct	288264
36611535	439	443	IL-4	GeneOrGeneProduct	16189
36611535	501	506	IFNAR	GeneOrGeneProduct	288264
36611535	511	515	IL-4	GeneOrGeneProduct	16189
36611535	579	588	rs2844580	SequenceVariant	rs2844580
36611535	642	651	MCF7/AdrR	CellLine	 CVCL_1452
36611535	677	686	Ile326Ile	SequenceVariant	rs3730089
36611535	700	705	IFNAR	GeneOrGeneProduct	288264
36611535	718	724	BALB/c	CellLine	CVCL_9101
36611535	768	805	alanine for proline at amino acid 286	SequenceVariant	p|SUB|A|286|P
36611535	861	866	IFNAR	GeneOrGeneProduct	288264
36611535	939	989	nine-nucleotide deletion starting at position 1952	SequenceVariant	c|DEL|1952|9
36611535	1017	1021	IL-4	GeneOrGeneProduct	16189
36611535	1036	1042	BALB/c	CellLine	CVCL_9101
36611535	1076	1080	IL-4	GeneOrGeneProduct	16189
36611535	1259	1264	IFNAR	GeneOrGeneProduct	288264
36611535	1269	1273	IL-4	GeneOrGeneProduct	16189
36611535	1282	1291	MCF7/AdrR	CellLine	 CVCL_1452
36611535	1296	1302	BALB/c	CellLine	CVCL_9101
36611535	Positive_Correlation	7345	288264	Novel
36611535	Negative_Correlation	288264	16189	Novel
36611535	Negative_Correlation	7345	288264	Novel
36611535	Bind	288264	7345	Novel
36611535	Positive_Correlation	16189	288264	Novel
36611535	Positive_Correlation	7345	16189	Novel
36611535	Positive_Correlation	288264	16189	Novel
36611535	Bind	16189	7345	Novel

37352662|t|15-F(2t)-isoprostane and atazanavir in the context of hearing loss, glioma, and Kilham rat virus infection: a study on DEN-2, sheep, and specificity p
37352662|a|This study investigates the potential role of 15-F(2t)-isoprostane and atazanavir in the pathogenesis of hearing loss and glioma, with a focus on their interactions with Kilham rat virus and DEN-2. The research explores the molecular mechanisms underlying these associations, particularly in the context of sequence variant c.468C>T and the gene product specificity protein 1. The study includes data from sheep and C. elegans models, as well as patient-derived samples, to assess the impact of these factors on disease progression. Notably, the presence of the sequence variant c.468C>T is found to be significantly correlated with increased susceptibility to hearing loss and glioma in both human and animal models. Additionally, the study reveals that the expression of specificity protein 1 is modulated by the presence of 15-F(2t)-isoprostane and atazanavir, suggesting a potential therapeutic target for the treatment of these conditions. The findings also highlight the role of DEN-2 and Kilham rat virus in exacerbating the effects of these chemical entities on hearing loss and glioma development. The results provide new insights into the complex interplay between genetic variants, viral infections, and environmental factors in the pathogenesis of these diseases.
37352662	0	20	15-F(2t)-isoprostane	ChemicalEntity	C075750
37352662	25	35	atazanavir	ChemicalEntity	C413408
37352662	54	66	hearing loss	DiseaseOrPhenotypicFeature	D034381
37352662	68	74	glioma	DiseaseOrPhenotypicFeature	D005910
37352662	80	96	Kilham rat virus	OrganismTaxon	12441
37352662	119	124	DEN-2	OrganismTaxon	11060
37352662	126	131	sheep	OrganismTaxon	9940
37352662	197	217	15-F(2t)-isoprostane	ChemicalEntity	C075750
37352662	222	232	atazanavir	ChemicalEntity	C413408
37352662	256	268	hearing loss	DiseaseOrPhenotypicFeature	D034381
37352662	273	279	glioma	DiseaseOrPhenotypicFeature	D005910
37352662	321	337	Kilham rat virus	OrganismTaxon	12441
37352662	342	347	DEN-2	OrganismTaxon	11060
37352662	475	483	c.468C>T	SequenceVariant	c|SUB|C|468|T
37352662	505	526	specificity protein 1	GeneOrGeneProduct	20683
37352662	557	562	sheep	OrganismTaxon	9940
37352662	567	577	C. elegans	OrganismTaxon	6239
37352662	597	604	patient	OrganismTaxon	9606
37352662	730	738	c.468C>T	SequenceVariant	c|SUB|C|468|T
37352662	812	824	hearing loss	DiseaseOrPhenotypicFeature	D034381
37352662	829	835	glioma	DiseaseOrPhenotypicFeature	D005910
37352662	924	945	specificity protein 1	GeneOrGeneProduct	20683
37352662	978	998	15-F(2t)-isoprostane	ChemicalEntity	C075750
37352662	1003	1013	atazanavir	ChemicalEntity	C413408
37352662	1136	1141	DEN-2	OrganismTaxon	11060
37352662	1146	1162	Kilham rat virus	OrganismTaxon	12441
37352662	1221	1233	hearing loss	DiseaseOrPhenotypicFeature	D034381
37352662	1238	1244	glioma	DiseaseOrPhenotypicFeature	D005910

57703607|t|Lovastatin and alkylating nitrogen mustard: interactions with TIEG1, NS3, and CCL11 in horses 
57703607|a|Recent studies have revealed complex interactions between lovastatin, alkylating nitrogen mustard, and various gene products in both horses and rats. Lovastatin was found to bind to NS3, suggesting a potential role in modulating its function. Additionally, a negative correlation was observed between lovastatin and alkylating nitrogen mustard, indicating that their effects may be antagonistic in certain biological contexts.   The gene product TIEG1 was shown to interact with alkylating nitrogen mustard, and this association was further supported by a positive correlation between alkylating nitrogen mustard and TIEG1 expression. Notably, TIEG1 also exhibited a binding interaction with CCL11, highlighting its potential role in immune-related pathways.   Lovastatin was also found to have a negative correlation with Spred2, and this relationship was further supported by a direct binding interaction between Spred2 and p16. The p16 gene product was shown to bind to both Spred2 and CCL11, and a positive correlation was observed between p16 and NS3. These findings suggest that p16 may act as a central hub in the regulation of these gene products.   In addition to these interactions, the gene product NS3 was found to bind to both Spred2 and CCL11, reinforcing the interconnected nature of these molecular pathways. The presence of multiple interactions involving these gene products in both horses and rats underscores the importance of understanding their roles in cellular processes.   These findings provide new insights into the molecular mechanisms underlying the effects of lovastatin and alkylating nitrogen mustard, and their potential therapeutic applications in various biological systems.
57703607	15	42	alkylating nitrogen mustard	ChemicalEntity	D008357
57703607	62	67	TIEG1	GeneOrGeneProduct	21847
57703607	69	72	NS3	GeneOrGeneProduct	5130010
57703607	78	83	CCL11	GeneOrGeneProduct	6356
57703607	87	93	horses	OrganismTaxon	9796
57703607	153	163	lovastatin	ChemicalEntity	D008148
57703607	165	192	alkylating nitrogen mustard	ChemicalEntity	D008357
57703607	228	234	horses	OrganismTaxon	9796
57703607	239	243	rats	OrganismTaxon	10116
57703607	277	280	NS3	GeneOrGeneProduct	5130010
57703607	396	406	lovastatin	ChemicalEntity	D008148
57703607	411	438	alkylating nitrogen mustard	ChemicalEntity	D008357
57703607	541	546	TIEG1	GeneOrGeneProduct	21847
57703607	574	601	alkylating nitrogen mustard	ChemicalEntity	D008357
57703607	680	707	alkylating nitrogen mustard	ChemicalEntity	D008357
57703607	712	717	TIEG1	GeneOrGeneProduct	21847
57703607	739	744	TIEG1	GeneOrGeneProduct	21847
57703607	787	792	CCL11	GeneOrGeneProduct	6356
57703607	918	924	Spred2	GeneOrGeneProduct	114716
57703607	1010	1016	Spred2	GeneOrGeneProduct	114716
57703607	1021	1024	p16	GeneOrGeneProduct	12578
57703607	1030	1033	p16	GeneOrGeneProduct	12578
57703607	1073	1079	Spred2	GeneOrGeneProduct	114716
57703607	1084	1089	CCL11	GeneOrGeneProduct	6356
57703607	1139	1142	p16	GeneOrGeneProduct	12578
57703607	1147	1150	NS3	GeneOrGeneProduct	5130010
57703607	1180	1183	p16	GeneOrGeneProduct	12578
57703607	1305	1308	NS3	GeneOrGeneProduct	5130010
57703607	1335	1341	Spred2	GeneOrGeneProduct	114716
57703607	1346	1351	CCL11	GeneOrGeneProduct	6356
57703607	1496	1502	horses	OrganismTaxon	9796
57703607	1507	1511	rats	OrganismTaxon	10116
57703607	1685	1695	lovastatin	ChemicalEntity	D008148
57703607	1700	1727	alkylating nitrogen mustard	ChemicalEntity	D008357
57703607	Bind	D008148	5130010	Novel
57703607	Negative_Correlation	D008148	D008357	Novel
57703607	Bind	114716	12578	Novel
57703607	Bind	12578	6356	Novel
57703607	Negative_Correlation	D008148	114716	Novel
57703607	Bind	D008357	21847	Novel
57703607	Bind	5130010	6356	Novel
57703607	Negative_Correlation	D008148	12578	Novel
57703607	Positive_Correlation	12578	5130010	Novel
57703607	Bind	114716	6356	Novel
57703607	Association	D008357	21847	Novel
57703607	Bind	5130010	114716	Novel

48399624|t|MC3T3-E1 cell line and sheep: interactions with West Nile virus, horses, and sequence variants in genetic
48399624|a|The MC3T3-E1 cell line, derived from mouse calvaria, was used to study the interaction between sheep and West Nile virus (WNV) in a novel in vitro model. This model was designed to mimic the host-virus dynamics observed in horses, which are known to be susceptible to WNV infection. The study incorporated multiple sequence variants, including g.3318-6T>A, G7958A, and c.304ins(GCG)(7), to explore their potential roles in viral replication and host response. Additionally, the sequence variant T2734C was analyzed in conjunction with the cell line SNU-C2A, which was used to assess the impact of genetic variability on viral entry and replication. The MC3T3-E1 cell line was also compared with the DUCaP cell line, which is known for its ability to support the replication of various RNA viruses. In parallel, the study examined the effects of the sequence variant c.304delA on the expression of viral proteins in the context of Spirulina and rabbit models. The findings suggest that the sequence variant (G-->A) at nucleotide position 2141 may play a significant role in the pathogenesis of DEN-4, a closely related flavivirus. The study also included the cell line PC-3, which was used to evaluate the impact of genetic variability on the immune response in horses. The results highlight the complex interplay between host genetics, viral infection, and cellular responses in the context of WNV and DEN-4 infections.
48399624	0	8	MC3T3-E1	CellLine	CVCL_0409
48399624	23	28	sheep	OrganismTaxon	9940
48399624	48	63	West Nile virus	OrganismTaxon	11082
48399624	65	71	horses	OrganismTaxon	9796
48399624	110	118	MC3T3-E1	CellLine	CVCL_0409
48399624	201	206	sheep	OrganismTaxon	9940
48399624	211	226	West Nile virus	OrganismTaxon	11082
48399624	329	335	horses	OrganismTaxon	9796
48399624	450	461	g.3318-6T>A	SequenceVariant	g|SUB|T|3318-6|A
48399624	463	469	G7958A	SequenceVariant	rs4998557
48399624	475	491	c.304ins(GCG)(7)	SequenceVariant	c|INS|304|GCG(7)
48399624	601	607	T2734C	SequenceVariant	c|SYB|T2734|C
48399624	655	662	SNU-C2A	CellLine	CVCL_1709
48399624	759	767	MC3T3-E1	CellLine	CVCL_0409
48399624	805	810	DUCaP	CellLine	CVCL_2025
48399624	972	981	c.304delA	SequenceVariant	c|DEL|304|A
48399624	1036	1045	Spirulina	OrganismTaxon	551299
48399624	1050	1056	rabbit	OrganismTaxon	9986
48399624	1112	1147	(G-->A) at nucleotide position 2141	SequenceVariant	c|SUB|G|2141|A
48399624	1199	1204	DEN-4	OrganismTaxon	11070
48399624	1274	1278	PC-3	CellLine	CVCL_0035
48399624	1367	1373	horses	OrganismTaxon	9796
48399624	1508	1513	DEN-4	OrganismTaxon	11070

97168369|t|c.1471C>T variant, HCT116 and DU145 cell lines, and their associations with acute coronary syndrome, ovarian cancer, cdk, and angiotensin II subtype rec
97168369|a|This study investigates the molecular and cellular mechanisms underlying the association between the sequence variant c.1471C>T and the development of acute coronary syndrome and ovarian cancer. The variant was extensively analyzed in the HCT116 and DU145 cell lines, which are widely used models for studying cancer biology and cellular signaling. Our findings reveal a significant association between c.1471C>T and both acute coronary syndrome and ovarian cancer, suggesting a potential role for this variant in the pathogenesis of these diseases.   Further, we explored the functional implications of c.1471C>T by examining its interaction with the gene product cdk and the angiotensin II subtype receptor 1a. The results demonstrate a negative correlation between cdk and angiotensin II subtype receptor 1a, which may indicate a regulatory relationship between these two proteins. Additionally, the variant c.1471C>T was found to modulate the expression levels of cdk and angiotensin II subtype receptor 1a, potentially influencing downstream signaling pathways involved in cell proliferation and survival.   The study also highlights the importance of the HCT116 and DU145 cell lines in understanding the molecular basis of these associations. The repeated presence of c.1471C>T in these cell lines, along with its consistent correlation with disease phenotypes, supports the hypothesis that this variant plays a critical role in the development of both acute coronary syndrome and ovarian cancer. These findings provide a foundation for further research into the therapeutic targeting of c.1471C>T and its downstream effects on cdk and angiotensin II subtype receptor 1a.
97168369	0	9	c.1471C>T	SequenceVariant	rs759977194
97168369	19	25	HCT116	CellLine	CVCL_0291
97168369	30	35	DU145	CellLine	CVCL_0105
97168369	76	99	acute coronary syndrome	DiseaseOrPhenotypicFeature	D054058
97168369	101	115	ovarian cancer	DiseaseOrPhenotypicFeature	D010051
97168369	117	120	cdk	GeneOrGeneProduct	12575
97168369	271	280	c.1471C>T	SequenceVariant	rs759977194
97168369	304	327	acute coronary syndrome	DiseaseOrPhenotypicFeature	D054058
97168369	332	346	ovarian cancer	DiseaseOrPhenotypicFeature	D010051
97168369	392	398	HCT116	CellLine	CVCL_0291
97168369	403	408	DU145	CellLine	CVCL_0105
97168369	556	565	c.1471C>T	SequenceVariant	rs759977194
97168369	575	598	acute coronary syndrome	DiseaseOrPhenotypicFeature	D054058
97168369	603	617	ovarian cancer	DiseaseOrPhenotypicFeature	D010051
97168369	757	766	c.1471C>T	SequenceVariant	rs759977194
97168369	818	821	cdk	GeneOrGeneProduct	12575
97168369	830	864	angiotensin II subtype receptor 1a	GeneOrGeneProduct	11607
97168369	921	924	cdk	GeneOrGeneProduct	12575
97168369	929	963	angiotensin II subtype receptor 1a	GeneOrGeneProduct	11607
97168369	1064	1073	c.1471C>T	SequenceVariant	rs759977194
97168369	1121	1124	cdk	GeneOrGeneProduct	12575
97168369	1129	1163	angiotensin II subtype receptor 1a	GeneOrGeneProduct	11607
97168369	1314	1320	HCT116	CellLine	CVCL_0291
97168369	1325	1330	DU145	CellLine	CVCL_0105
97168369	1427	1436	c.1471C>T	SequenceVariant	rs759977194
97168369	1612	1635	acute coronary syndrome	DiseaseOrPhenotypicFeature	D054058
97168369	1640	1654	ovarian cancer	DiseaseOrPhenotypicFeature	D010051
97168369	1747	1756	c.1471C>T	SequenceVariant	rs759977194
97168369	1787	1790	cdk	GeneOrGeneProduct	12575
97168369	1795	1829	angiotensin II subtype receptor 1a	GeneOrGeneProduct	11607
97168369	Negative_Correlation	11607	12575	Novel
97168369	Association	D010051	rs759977194	Novel
97168369	Association	D054058	rs759977194	Novel
97168369	Negative_Correlation	12575	11607	Novel

21618928|t|Genetic and molecular interactions of CARDINAL, CSF-1, and miR-21 in rat and C. elegans models: implications for estrogen receptor signaling and protein kinase A 
21618928|a|This study investigates the complex genetic and molecular interactions between CARDINAL, CSF-1, miR-21, and the estrogen receptor in various biological contexts, including rat, C. elegans, and human cell lines. We focus on the regulatory roles of sequence variants such as -134delA, p.W826S, and G/C, and their associations with gene products like CARDINAL, CSF-1, and protein kinase A.   In rat models, we observed a negative correlation between CSF-1 and CARDINAL, as well as a negative correlation between CSF-1 and Ag. Additionally, a negative correlation was found between miR-21 and CARDINAL, and between Let-7b and CSF-1. The estrogen receptor showed a negative correlation with Let-7b and CSF-1, while it was associated with miR-21. Furthermore, a negative correlation was noted between Ag and protein kinase A, and an association was found between protein kinase A and CARDINAL.   In the Ishikawa cell line, the sequence variant -134delA was associated with p.W826S, and the G/C variant was linked to -134delA. In the SJ-GBM2 cell line, we found that CSF-1 and CARDINAL exhibited a negative correlation, and the estrogen receptor showed a negative correlation with CSF-1.   The study also included analyses in the chick and bacteria models, where the interactions between CARDINAL, CSF-1, and miR-21 were further explored. In the DU145 and SW480 cell lines, the associations between the gene products and sequence variants were consistent with the findings in rat models.   These results highlight the intricate regulatory networks involving CARDINAL, CSF-1, miR-21, and the estrogen receptor, with significant implications for understanding gene expression and signaling pathways in both normal and pathological conditions.
21618928	38	46	CARDINAL	GeneOrGeneProduct	22900
21618928	48	53	CSF-1	GeneOrGeneProduct	12977
21618928	59	65	miR-21	GeneOrGeneProduct	387140
21618928	69	72	rat	OrganismTaxon	10116
21618928	77	87	C. elegans	OrganismTaxon	6239
21618928	113	130	estrogen receptor	GeneOrGeneProduct	2099
21618928	145	161	protein kinase A	GeneOrGeneProduct	5566
21618928	242	250	CARDINAL	GeneOrGeneProduct	22900
21618928	252	257	CSF-1	GeneOrGeneProduct	12977
21618928	259	265	miR-21	GeneOrGeneProduct	387140
21618928	275	292	estrogen receptor	GeneOrGeneProduct	2099
21618928	335	338	rat	OrganismTaxon	10116
21618928	340	350	C. elegans	OrganismTaxon	6239
21618928	436	444	-134delA	SequenceVariant	rs1800997
21618928	446	453	p.W826S	SequenceVariant	p|SUB|W|826|S
21618928	459	462	G/C	SequenceVariant	g|SUB|G||C
21618928	511	519	CARDINAL	GeneOrGeneProduct	22900
21618928	521	526	CSF-1	GeneOrGeneProduct	12977
21618928	532	548	protein kinase A	GeneOrGeneProduct	5566
21618928	555	558	rat	OrganismTaxon	10116
21618928	610	615	CSF-1	GeneOrGeneProduct	12977
21618928	620	628	CARDINAL	GeneOrGeneProduct	22900
21618928	672	677	CSF-1	GeneOrGeneProduct	12977
21618928	682	684	Ag	GeneOrGeneProduct	3047
21618928	741	747	miR-21	GeneOrGeneProduct	387140
21618928	752	760	CARDINAL	GeneOrGeneProduct	22900
21618928	774	780	Let-7b	GeneOrGeneProduct	387245
21618928	785	790	CSF-1	GeneOrGeneProduct	12977
21618928	796	813	estrogen receptor	GeneOrGeneProduct	2099
21618928	849	855	Let-7b	GeneOrGeneProduct	387245
21618928	860	865	CSF-1	GeneOrGeneProduct	12977
21618928	896	902	miR-21	GeneOrGeneProduct	387140
21618928	958	960	Ag	GeneOrGeneProduct	3047
21618928	965	981	protein kinase A	GeneOrGeneProduct	5566
21618928	1020	1036	protein kinase A	GeneOrGeneProduct	5566
21618928	1041	1049	CARDINAL	GeneOrGeneProduct	22900
21618928	1060	1068	Ishikawa	CellLine	CVCL_2529
21618928	1101	1109	-134delA	SequenceVariant	rs1800997
21618928	1130	1137	p.W826S	SequenceVariant	p|SUB|W|826|S
21618928	1147	1150	G/C	SequenceVariant	g|SUB|G||C
21618928	1173	1181	-134delA	SequenceVariant	rs1800997
21618928	1190	1197	SJ-GBM2	CellLine	CVCL_M141
21618928	1223	1228	CSF-1	GeneOrGeneProduct	12977
21618928	1233	1241	CARDINAL	GeneOrGeneProduct	22900
21618928	1284	1301	estrogen receptor	GeneOrGeneProduct	2099
21618928	1337	1342	CSF-1	GeneOrGeneProduct	12977
21618928	1386	1391	chick	OrganismTaxon	9031
21618928	1396	1404	bacteria	OrganismTaxon	2
21618928	1444	1452	CARDINAL	GeneOrGeneProduct	22900
21618928	1454	1459	CSF-1	GeneOrGeneProduct	12977
21618928	1465	1471	miR-21	GeneOrGeneProduct	387140
21618928	1502	1507	DU145	CellLine	CVCL_0105
21618928	1512	1517	SW480	CellLine	CVCL_0546
21618928	1632	1635	rat	OrganismTaxon	10116
21618928	1714	1722	CARDINAL	GeneOrGeneProduct	22900
21618928	1724	1729	CSF-1	GeneOrGeneProduct	12977
21618928	1731	1737	miR-21	GeneOrGeneProduct	387140
21618928	1747	1764	estrogen receptor	GeneOrGeneProduct	2099
21618928	Negative_Correlation	3047	5566	Novel
21618928	Association	5566	3047	Novel
21618928	Negative_Correlation	12977	22900	Novel
21618928	Negative_Correlation	12977	3047	Novel
21618928	Negative_Correlation	387140	22900	Novel
21618928	Association	5566	22900	Novel
21618928	Negative_Correlation	2099	387245	Novel
21618928	Association	rs1800997	g|SUB|G||C	Novel
21618928	Negative_Correlation	387245	12977	Novel
21618928	Negative_Correlation	2099	12977	Novel
21618928	Association	2099	387140	Novel
21618928	Association	rs1800997	p|SUB|W|826|S	Novel

54646047|t|Erythropoiesis-stimulating agents and Hsp27: associations with thrombotic microangiopathy, Giant cell tumor of bone, and Joubert syndrome (JBTS) type 6 in rhesus monkeys, Murine, and Mangifera ind
54646047|a|This study investigates the complex relationships between erythropoiesis-stimulating agents (ESAs), Hsp27, thrombotic microangiopathy, Giant cell tumor of bone, and Joubert syndrome (JBTS) type 6 across multiple species, including rhesus monkeys, Murine, and Mangifera indica Linn. Our findings reveal a significant association between thrombotic microangiopathy and erythropoiesis-stimulating agents, suggesting that ESAs may contribute to the pathogenesis of this condition. Additionally, we observed a strong association between Giant cell tumor of bone and erythropoiesis-stimulating agents, indicating a potential role for ESAs in the development of this tumor.   Further, we identified a positive correlation between Hsp27 and erythropoiesis-stimulating agents, highlighting the potential regulatory role of Hsp27 in ESA-related processes. The association between thrombotic microangiopathy and Hsp27 was also confirmed, suggesting that Hsp27 may be a key player in the molecular mechanisms underlying this disease. Moreover, we found a significant association between Giant cell tumor of bone and Hsp27, reinforcing the idea that Hsp27 may be involved in the progression of this tumor.   Notably, we also observed a strong association between Joubert syndrome (JBTS) type 6 and Hsp27, indicating that Hsp27 may play a role in the pathophysiology of this rare genetic disorder. Additionally, we found an association between Joubert syndrome (JBTS) type 6 and erythropoiesis-stimulating agents, suggesting a potential link between ESA use and the development or progression of this syndrome. These findings provide important insights into the molecular mechanisms linking ESAs, Hsp27, and various diseases, and may have implications for the development of targeted therapies in these conditions.
54646047	38	43	Hsp27	GeneOrGeneProduct	3315
54646047	63	89	thrombotic microangiopathy	DiseaseOrPhenotypicFeature	D057049
54646047	91	115	Giant cell tumor of bone	DiseaseOrPhenotypicFeature	D018212
54646047	121	151	Joubert syndrome (JBTS) type 6	DiseaseOrPhenotypicFeature	C537689
54646047	155	169	rhesus monkeys	OrganismTaxon	9544
54646047	171	177	Murine	OrganismTaxon	10090
54646047	255	287	erythropoiesis-stimulating agent	ChemicalEntity	D006397
54646047	297	302	Hsp27	GeneOrGeneProduct	3315
54646047	304	330	thrombotic microangiopathy	DiseaseOrPhenotypicFeature	D057049
54646047	332	356	Giant cell tumor of bone	DiseaseOrPhenotypicFeature	D018212
54646047	362	392	Joubert syndrome (JBTS) type 6	DiseaseOrPhenotypicFeature	C537689
54646047	428	442	rhesus monkeys	OrganismTaxon	9544
54646047	444	450	Murine	OrganismTaxon	10090
54646047	456	477	Mangifera indica Linn	OrganismTaxon	29780
54646047	533	559	thrombotic microangiopathy	DiseaseOrPhenotypicFeature	D057049
54646047	564	596	erythropoiesis-stimulating agent	ChemicalEntity	D006397
54646047	729	753	Giant cell tumor of bone	DiseaseOrPhenotypicFeature	D018212
54646047	758	790	erythropoiesis-stimulating agent	ChemicalEntity	D006397
54646047	920	925	Hsp27	GeneOrGeneProduct	3315
54646047	930	962	erythropoiesis-stimulating agent	ChemicalEntity	D006397
54646047	1011	1016	Hsp27	GeneOrGeneProduct	3315
54646047	1067	1093	thrombotic microangiopathy	DiseaseOrPhenotypicFeature	D057049
54646047	1098	1103	Hsp27	GeneOrGeneProduct	3315
54646047	1140	1145	Hsp27	GeneOrGeneProduct	3315
54646047	1272	1296	Giant cell tumor of bone	DiseaseOrPhenotypicFeature	D018212
54646047	1301	1306	Hsp27	GeneOrGeneProduct	3315
54646047	1334	1339	Hsp27	GeneOrGeneProduct	3315
54646047	1447	1477	Joubert syndrome (JBTS) type 6	DiseaseOrPhenotypicFeature	C537689
54646047	1482	1487	Hsp27	GeneOrGeneProduct	3315
54646047	1505	1510	Hsp27	GeneOrGeneProduct	3315
54646047	1627	1657	Joubert syndrome (JBTS) type 6	DiseaseOrPhenotypicFeature	C537689
54646047	1662	1694	erythropoiesis-stimulating agent	ChemicalEntity	D006397
54646047	1880	1885	Hsp27	GeneOrGeneProduct	3315
54646047	Association	D057049	D006397	Novel
54646047	Association	D018212	D006397	Novel
54646047	Association	C537689	3315	Novel
54646047	Positive_Correlation	3315	D006397	Novel
54646047	Association	D057049	3315	Novel
54646047	Association	D018212	3315	Novel
54646047	Association	C537689	D006397	Novel

21174036|t|Type I collagen, resistin, and hALG-6: genetic and functional interactions in the context of hyperglycemia, joint pain, and Steinert's
21174036|a|Recent studies have highlighted the complex interplay between type I collagen, resistin, and hALG-6 in the pathogenesis of various metabolic and neurological disorders. This study investigates the molecular and functional relationships among these genes, particularly in the context of hyperglycemia, joint pain, and Steinert's disease. The findings reveal a negative correlation between hALG-6 and type I collagen, as well as between hALG-6 and resistin, and a negative correlation between type I collagen and resistin. These results suggest that hALG-6 may act as a regulatory factor in the expression or function of both type I collagen and resistin. Additionally, the study identifies an association between hALG-6 and thrombin, as well as between resistin and thrombin, and between type I collagen and hALG-6, indicating potential pathways linking these molecules to coagulation and inflammatory processes. The presence of multiple sequence variants, including c.1052delA, g.80_87delT CGCGAAG, and S429T, further underscores the genetic heterogeneity observed in these conditions. Notably, the study also reports the association of c.1052delA with hyperglycemia and joint pain, while the variant g.80_87delT CGCGAAG is linked to absence seizures and RLS. The variant C61G is found to be associated with AMD and Steinert's disease, highlighting the diverse phenotypic consequences of these genetic alterations. These findings provide new insights into the molecular mechanisms underlying these disorders and suggest potential therapeutic targets for intervention.
21174036	17	25	resistin	GeneOrGeneProduct	56729
21174036	31	37	hALG-6	GeneOrGeneProduct	29929
21174036	93	106	hyperglycemia	DiseaseOrPhenotypicFeature	D006943
21174036	108	118	joint pain	DiseaseOrPhenotypicFeature	D018771
21174036	197	212	type I collagen	GeneOrGeneProduct	1278
21174036	214	222	resistin	GeneOrGeneProduct	56729
21174036	228	234	hALG-6	GeneOrGeneProduct	29929
21174036	421	434	hyperglycemia	DiseaseOrPhenotypicFeature	D006943
21174036	436	446	joint pain	DiseaseOrPhenotypicFeature	D018771
21174036	452	470	Steinert's disease	DiseaseOrPhenotypicFeature	D009223
21174036	523	529	hALG-6	GeneOrGeneProduct	29929
21174036	534	549	type I collagen	GeneOrGeneProduct	1278
21174036	570	576	hALG-6	GeneOrGeneProduct	29929
21174036	581	589	resistin	GeneOrGeneProduct	56729
21174036	626	641	type I collagen	GeneOrGeneProduct	1278
21174036	646	654	resistin	GeneOrGeneProduct	56729
21174036	683	689	hALG-6	GeneOrGeneProduct	29929
21174036	759	774	type I collagen	GeneOrGeneProduct	1278
21174036	779	787	resistin	GeneOrGeneProduct	56729
21174036	847	853	hALG-6	GeneOrGeneProduct	29929
21174036	858	866	thrombin	GeneOrGeneProduct	29251
21174036	887	895	resistin	GeneOrGeneProduct	56729
21174036	900	908	thrombin	GeneOrGeneProduct	29251
21174036	922	937	type I collagen	GeneOrGeneProduct	1278
21174036	942	948	hALG-6	GeneOrGeneProduct	29929
21174036	1101	1111	c.1052delA	SequenceVariant	rs137853893
21174036	1113	1132	g.80_87delT CGCGAAG	SequenceVariant	g|DEL|80_87|TCGCGAAG
21174036	1138	1143	S429T	SequenceVariant	p|SUB|S|429|T
21174036	1272	1282	c.1052delA	SequenceVariant	rs137853893
21174036	1288	1301	hyperglycemia	DiseaseOrPhenotypicFeature	D006943
21174036	1306	1316	joint pain	DiseaseOrPhenotypicFeature	D018771
21174036	1336	1355	g.80_87delT CGCGAAG	SequenceVariant	g|DEL|80_87|TCGCGAAG
21174036	1369	1385	absence seizures	DiseaseOrPhenotypicFeature	D004832
21174036	1390	1393	RLS	DiseaseOrPhenotypicFeature	D012148
21174036	1407	1411	C61G	SequenceVariant	rs28897672
21174036	1443	1446	AMD	DiseaseOrPhenotypicFeature	D008268
21174036	1451	1469	Steinert's disease	DiseaseOrPhenotypicFeature	D009223
21174036	Negative_Correlation	29929	1278	Novel
21174036	Negative_Correlation	29929	56729	Novel
21174036	Negative_Correlation	1278	56729	Novel
21174036	Association	29929	29251	Novel
21174036	Association	56729	29251	Novel
21174036	Association	1278	29929	Novel

36532293|t|Na+ and opioid interactions with heme oxygenase-1, DMPK, and Wnt signaling in neurodegenerative 
36532293|a|This study investigates the complex interactions between Na+ and opioid signaling pathways in the context of neurodegenerative diseases, with a particular focus on the roles of heme oxygenase-1, DMPK, and Wnt. We demonstrate that Na+ modulates the activity of opioid receptors, which in turn influences the expression of heme oxygenase-1, a key enzyme involved in cellular stress responses. The association between heme oxygenase-1 and monoamine oxidase A is further supported by our findings, suggesting a potential regulatory network in neuroinflammation.   DMPK, a critical mediator of drug metabolism, shows a positive correlation with Wnt signaling, which is essential for neuronal development and repair. This relationship is reinforced by the observed positive correlation between DMPK and Wnt, indicating a potential therapeutic target for neurodegenerative conditions. Additionally, we find that Vps2, a component of the endosomal sorting complex, is associated with High Mobility Group-Box 1, a protein involved in inflammation and cell death. The positive correlation between Vps2 and TP53 further highlights the interplay between cellular stress responses and tumor suppression.  High Mobility Group-Box 1 also exhibits a positive correlation with DMPK, suggesting a coordinated response to cellular stress. The association between High Mobility Group-Box 1 and heme oxygenase-1 underscores the role of these proteins in oxidative stress and neuroinflammation. Furthermore, Vg4 and BICD2 show a positive correlation, indicating a potential role in cytoskeletal dynamics and neuronal function. Vg4 also exhibits a positive correlation with heme oxygenase-1, reinforcing the involvement of this enzyme in multiple signaling pathways.  Our findings also reveal a conversion between sarcoplasmic reticulum Ca2+ -ATPase and penicillin-G potassium, suggesting a novel mechanism of ion channel regulation. The conversion between nonsteroidal antiinflammatory agents and EGTA highlights the role of calcium chelation in modulating inflammatory responses. Finally, the positive correlation between SAG and TP53 suggests a potential role for SAG in tumor suppression and cellular stress responses. These results provide a comprehensive framework for understanding the molecular mechanisms underlying neurodegenerative diseases and their potential therapeutic targets.
36532293	8	14	opioid	ChemicalEntity	D018847
36532293	33	49	heme oxygenase-1	GeneOrGeneProduct	15368
36532293	51	55	DMPK	GeneOrGeneProduct	13400
36532293	61	64	Wnt	GeneOrGeneProduct	7474
36532293	162	168	opioid	ChemicalEntity	D018847
36532293	274	290	heme oxygenase-1	GeneOrGeneProduct	15368
36532293	292	296	DMPK	GeneOrGeneProduct	13400
36532293	302	305	Wnt	GeneOrGeneProduct	7474
36532293	357	363	opioid	ChemicalEntity	D018847
36532293	418	434	heme oxygenase-1	GeneOrGeneProduct	15368
36532293	512	528	heme oxygenase-1	GeneOrGeneProduct	15368
36532293	533	552	monoamine oxidase A	GeneOrGeneProduct	4128
36532293	657	661	DMPK	GeneOrGeneProduct	13400
36532293	737	740	Wnt	GeneOrGeneProduct	7474
36532293	885	889	DMPK	GeneOrGeneProduct	13400
36532293	894	897	Wnt	GeneOrGeneProduct	7474
36532293	1002	1006	Vps2	GeneOrGeneProduct	27243
36532293	1073	1098	High Mobility Group-Box 1	GeneOrGeneProduct	3146
36532293	1184	1188	Vps2	GeneOrGeneProduct	27243
36532293	1193	1197	TP53	GeneOrGeneProduct	24842
36532293	1289	1314	High Mobility Group-Box 1	GeneOrGeneProduct	3146
36532293	1357	1361	DMPK	GeneOrGeneProduct	13400
36532293	1441	1466	High Mobility Group-Box 1	GeneOrGeneProduct	3146
36532293	1471	1487	heme oxygenase-1	GeneOrGeneProduct	15368
36532293	1583	1586	Vg4	GeneOrGeneProduct	21638
36532293	1591	1596	BICD2	GeneOrGeneProduct	76895
36532293	1702	1705	Vg4	GeneOrGeneProduct	21638
36532293	1748	1764	heme oxygenase-1	GeneOrGeneProduct	15368
36532293	1928	1950	penicillin-G potassium	ChemicalEntity	D010400
36532293	2031	2067	nonsteroidal antiinflammatory agents	ChemicalEntity	D000894
36532293	2072	2076	EGTA	ChemicalEntity	D004533
36532293	2198	2201	SAG	GeneOrGeneProduct	19823
36532293	2206	2210	TP53	GeneOrGeneProduct	24842
36532293	2241	2244	SAG	GeneOrGeneProduct	19823
36532293	Association	15368	4128	Novel
36532293	Association	13400	7474	Novel
36532293	Association	27243	3146	Novel
36532293	Positive_Correlation	3146	13400	Novel
36532293	Positive_Correlation	27243	24842	Novel
36532293	Association	3146	15368	Novel
36532293	Positive_Correlation	21638	76895	Novel
36532293	Conversion	D053498	D010400	Novel
36532293	Conversion	D000894	D004533	Novel
36532293	Positive_Correlation	19823	24842	Novel
36532293	Positive_Correlation	21638	15368	Novel

57995476|t|Daucus carota and zebrafish models reveal complex interactions between agarose, atazanavir, and neuromuscular block in COS-7 and MH134 ce
57995476|a|Recent studies have explored the interactions between agarose, atazanavir, and neuromuscular block using Daucus carota and zebrafish models. In particular, the association between agarose and neuromuscular block was observed in both Daucus carota and zebrafish, suggesting a potential role for agarose in modulating neuromuscular function. Additionally, agarose was found to be associated with atazanavir, with a negative correlation between agarose and atazanavir levels in COS-7 and MH134 cell lines. This negative correlation was further supported by the observation that atazanavir levels increased in the presence of lower agarose concentrations.   The positive correlation between atazanavir and neuromuscular block was consistently observed across multiple experiments, indicating that atazanavir may enhance neuromuscular block. Furthermore, atazanavir was found to be associated with numbness, with higher atazanavir concentrations correlating with increased numbness in both Daucus carota and zebrafish models. The study also demonstrated that the neuromuscular block was significantly influenced by the presence of agarose, with higher agarose levels leading to a more pronounced block.   These findings suggest that agarose, atazanavir, and neuromuscular block are interconnected, with agarose acting as a modulator in the relationship between atazanavir and neuromuscular block. The results were validated using COS-7 and MH134 cell lines, which were used to replicate the observed associations and correlations. The use of Daucus carota and zebrafish as model organisms provided additional insights into the biological mechanisms underlying these interactions.
57995476	0	13	Daucus carota	OrganismTaxon	4039
57995476	18	27	zebrafish	OrganismTaxon	7955
57995476	71	78	agarose	ChemicalEntity	D012685
57995476	80	90	atazanavir	ChemicalEntity	C413408
57995476	96	115	neuromuscular block	DiseaseOrPhenotypicFeature	D055191
57995476	119	124	COS-7	CellLine	CVCL_0224
57995476	129	134	MH134	CellLine	CVCL_8111
57995476	192	199	agarose	ChemicalEntity	D012685
57995476	201	211	atazanavir	ChemicalEntity	C413408
57995476	217	236	neuromuscular block	DiseaseOrPhenotypicFeature	D055191
57995476	243	256	Daucus carota	OrganismTaxon	4039
57995476	261	270	zebrafish	OrganismTaxon	7955
57995476	318	325	agarose	ChemicalEntity	D012685
57995476	330	349	neuromuscular block	DiseaseOrPhenotypicFeature	D055191
57995476	371	384	Daucus carota	OrganismTaxon	4039
57995476	389	398	zebrafish	OrganismTaxon	7955
57995476	432	439	agarose	ChemicalEntity	D012685
57995476	492	499	agarose	ChemicalEntity	D012685
57995476	532	542	atazanavir	ChemicalEntity	C413408
57995476	580	587	agarose	ChemicalEntity	D012685
57995476	592	602	atazanavir	ChemicalEntity	C413408
57995476	613	618	COS-7	CellLine	CVCL_0224
57995476	623	628	MH134	CellLine	CVCL_8111
57995476	713	723	atazanavir	ChemicalEntity	C413408
57995476	766	773	agarose	ChemicalEntity	D012685
57995476	825	835	atazanavir	ChemicalEntity	C413408
57995476	840	859	neuromuscular block	DiseaseOrPhenotypicFeature	D055191
57995476	931	941	atazanavir	ChemicalEntity	C413408
57995476	954	973	neuromuscular block	DiseaseOrPhenotypicFeature	D055191
57995476	988	998	atazanavir	ChemicalEntity	C413408
57995476	1031	1039	numbness	DiseaseOrPhenotypicFeature	D006987
57995476	1053	1063	atazanavir	ChemicalEntity	C413408
57995476	1106	1114	numbness	DiseaseOrPhenotypicFeature	D006987
57995476	1123	1136	Daucus carota	OrganismTaxon	4039
57995476	1141	1150	zebrafish	OrganismTaxon	7955
57995476	1196	1215	neuromuscular block	DiseaseOrPhenotypicFeature	D055191
57995476	1264	1271	agarose	ChemicalEntity	D012685
57995476	1285	1292	agarose	ChemicalEntity	D012685
57995476	1366	1373	agarose	ChemicalEntity	D012685
57995476	1375	1385	atazanavir	ChemicalEntity	C413408
57995476	1391	1410	neuromuscular block	DiseaseOrPhenotypicFeature	D055191
57995476	1436	1443	agarose	ChemicalEntity	D012685
57995476	1494	1504	atazanavir	ChemicalEntity	C413408
57995476	1509	1528	neuromuscular block	DiseaseOrPhenotypicFeature	D055191
57995476	1563	1568	COS-7	CellLine	CVCL_0224
57995476	1573	1578	MH134	CellLine	CVCL_8111
57995476	1675	1688	Daucus carota	OrganismTaxon	4039
57995476	1693	1702	zebrafish	OrganismTaxon	7955
57995476	Association	D012685	D055191	Novel
57995476	Association	D012685	C413408	Novel
57995476	Positive_Correlation	C413408	D055191	Novel
57995476	Association	C413408	D012685	Novel
57995476	Positive_Correlation	D012685	D055191	Novel
57995476	Association	C413408	D055191	Novel
57995476	Association	C413408	D006987	Novel
57995476	Negative_Correlation	D012685	C413408	Novel

43453751|t|Genetic Variants and Functional Consequences in Cardiomyocytes and Renal Epitheli
43453751|a|This study investigates the functional and genetic relationships between specific sequence variants and their impact on cellular behavior in different cell lines. We focused on the sequence variants rs6235, c.611delG, and the 105-bp deletion encompassing bases 1078-1182, as well as the variant Delta30-4995. These variants were analyzed in the context of their associations with the cell lines H9c2, hRPTEC, Hs578T, and C57BL/6.   Our findings reveal a significant association between rs6235 and Delta30-4995, suggesting a potential regulatory or structural interaction between these two variants. Furthermore, Delta30-4995 is linked to the 105-bp deletion encompassing bases 1078-1182, indicating a possible functional overlap or co-occurrence in genetic contexts. The variant Delta30-4995 is also associated with c.621delG, highlighting a potential pathway or mechanism that connects these genetic elements.  In addition, rs6235 is found to be associated with the 105-bp deletion encompassing bases 1078-1182, reinforcing the idea of a shared genetic background or functional consequence. The variant rs6235 is also linked to c.611delG, suggesting a possible genetic network or regulatory interaction. Finally, c.611delG is associated with the 105-bp deletion encompassing bases 1078-1182, further supporting the hypothesis of a complex interplay between these genetic elements in different cellular environments.  These results provide important insights into the genetic architecture and functional consequences of these variants in cardiomyocytes and renal epithelial cells, with implications for understanding disease mechanisms and potential therapeutic targets.
43453751	281	287	rs6235	SequenceVariant	rs6235
43453751	289	298	c.611delG	SequenceVariant	rs193302856
43453751	308	352	105-bp deletion encompassing bases 1078-1182	SequenceVariant	c|DEL|1078-1182|
43453751	377	389	Delta30-4995	SequenceVariant	c|DEL|4995|30
43453751	477	481	H9c2	CellLine	CVCL_0286
43453751	483	489	hRPTEC	CellLine	CVCL_K278
43453751	491	497	Hs578T	CellLine	CVCL_0332
43453751	503	510	C57BL/6	CellLine	CVCL_5746
43453751	568	574	rs6235	SequenceVariant	rs6235
43453751	579	591	Delta30-4995	SequenceVariant	c|DEL|4995|30
43453751	694	706	Delta30-4995	SequenceVariant	c|DEL|4995|30
43453751	724	768	105-bp deletion encompassing bases 1078-1182	SequenceVariant	c|DEL|1078-1182|
43453751	861	873	Delta30-4995	SequenceVariant	c|DEL|4995|30
43453751	1007	1013	rs6235	SequenceVariant	rs6235
43453751	1049	1093	105-bp deletion encompassing bases 1078-1182	SequenceVariant	c|DEL|1078-1182|
43453751	1186	1192	rs6235	SequenceVariant	rs6235
43453751	1211	1220	c.611delG	SequenceVariant	rs193302856
43453751	1296	1305	c.611delG	SequenceVariant	rs193302856
43453751	1329	1373	105-bp deletion encompassing bases 1078-1182	SequenceVariant	c|DEL|1078-1182|
43453751	Association	rs6235	c|DEL|4995|30	Novel
43453751	Association	c|DEL|4995|30	c|DEL|1078-1182|	Novel
43453751	Association	c|DEL|4995|30	rs6235	Novel
43453751	Association	c|DEL|4995|30	rs193302856	Novel
43453751	Association	rs6235	c|DEL|1078-1182|	Novel
43453751	Association	rs6235	rs193302856	Novel
43453751	Association	rs193302856	c|DEL|1078-1182|	Novel

85702316|t|Genetic and metabolic interactions of corn oil, sequence variants, and cell lines in C57BL/6 and C4-2
85702316|a|This study investigates the complex interactions between dietary components, genetic variants, and cell line responses in the context of metabolic and immunological pathways. The focus is on the effects of corn oil, a common dietary fat, and its interactions with specific sequence variants, including p.Asp50Asn and g.3816C>A, in two widely used cell lines: C57BL/6 and C4-2B.   Our findings reveal a positive correlation between corn oil and the sequence variant g.3816C>A, suggesting that corn oil may influence the expression or function of the gene associated with this variant. Conversely, a negative correlation is observed between p.Asp50Asn and Bortezomib, indicating that Bortezomib may modulate the activity of the protein encoded by this variant. Notably, a positive correlation is also found between Bortezomib and g.3816C>A, suggesting a potential synergistic or antagonistic relationship between these two entities.   Further, a negative correlation between g.3816C>A and corn oil is reported, which may imply a regulatory feedback mechanism. Additionally, a positive correlation between corn oil and p.Asp50Asn is observed, highlighting the potential role of dietary fats in modulating the expression or function of this variant.   The study also includes a significant number of C57BL/6 and C4-2B cell lines, with six and four instances respectively, to ensure robustness in the experimental design. The presence of multiple instances of the organism taxon 'woman' and the virus 'West Nile virus' as well as the virus 'DEN-4' suggests a broader context of the study, possibly involving human and viral interactions.   These results provide new insights into the interplay between diet, genetic variation, and cellular responses, with implications for understanding metabolic and immunological disorders in both human and animal models.
85702316	38	46	corn oil	ChemicalEntity	D003314
85702316	85	92	C57BL/6	CellLine	CVCL_5746
85702316	308	316	corn oil	ChemicalEntity	D003314
85702316	404	414	p.Asp50Asn	SequenceVariant	rs28931594
85702316	419	428	g.3816C>A	SequenceVariant	rs111033360
85702316	461	468	C57BL/6	CellLine	CVCL_5746
85702316	473	478	C4-2B	CellLine	CVCL_4784
85702316	533	541	corn oil	ChemicalEntity	D003314
85702316	567	576	g.3816C>A	SequenceVariant	rs111033360
85702316	594	602	corn oil	ChemicalEntity	D003314
85702316	741	751	p.Asp50Asn	SequenceVariant	rs28931594
85702316	756	766	Bortezomib	ChemicalEntity	D000069286
85702316	784	794	Bortezomib	ChemicalEntity	D000069286
85702316	915	925	Bortezomib	ChemicalEntity	D000069286
85702316	930	939	g.3816C>A	SequenceVariant	rs111033360
85702316	1075	1084	g.3816C>A	SequenceVariant	rs111033360
85702316	1089	1097	corn oil	ChemicalEntity	D003314
85702316	1205	1213	corn oil	ChemicalEntity	D003314
85702316	1218	1228	p.Asp50Asn	SequenceVariant	rs28931594
85702316	1398	1405	C57BL/6	CellLine	CVCL_5746
85702316	1410	1415	C4-2B	CellLine	CVCL_4784
85702316	1577	1582	woman	OrganismTaxon	9606
85702316	1599	1614	West Nile virus	OrganismTaxon	11082
85702316	1638	1643	DEN-4	OrganismTaxon	11070
85702316	Positive_Correlation	D003314	rs111033360	Novel
85702316	Negative_Correlation	rs28931594	D000069286	Novel
85702316	Positive_Correlation	D000069286	rs111033360	Novel
85702316	Negative_Correlation	rs111033360	D003314	Novel
85702316	Positive_Correlation	D003314	rs28931594	Novel

20712420|t|Genetic Variants and Cardiac Phenotypes in Sheep, Horses, and Cats: A Study of Ventricular Tachycardia, Arrhythmias, 
20712420|a|This study investigates the genetic basis of cardiac phenotypes, including ventricular tachycardia, arrhythmias, and cleft lip/palate (CL/P), in sheep, horses, and cats. Using a combination of cell lines such as C4-2B, SNU-C5, and MEF, we examined the associations between specific sequence variants and these phenotypic features. The 28 bp variable number of tandem repeats (VNTR) was found to be significantly associated with CL/P, while the R to G mutation at position 76 showed a positive correlation with ventricular tachycardia. However, this same mutation exhibited a negative correlation with CL/P.   The rs4704559 variant was associated with arrhythmias, and the C417T variant showed a positive correlation with both arthritis and arrhythmias. Notably, the G12D mutation was found to have a negative correlation with arthritis and arrhythmias, but a positive association with CL/P. Additionally, the g.3627A>C variant was linked to arthritis and showed a negative correlation with CL/P. The C417T variant was also found to be associated with the g.3627A>C variant, and it exhibited a positive correlation with arthritis, while showing a negative correlation with arrhythmias.   The study further revealed that ventricular tachycardia was associated with the C417T variant, and the 28 bp VNTR was linked to the C417T variant. These findings suggest a complex interplay between genetic variants and cardiac phenotypes across different species. The results highlight the importance of considering both positive and negative correlations in understanding the genetic underpinnings of these conditions in sheep, horses, and cats.
20712420	193	216	ventricular tachycardia	DiseaseOrPhenotypicFeature	D017180
20712420	218	229	arrhythmias	DiseaseOrPhenotypicFeature	D001145
20712420	253	257	CL/P	DiseaseOrPhenotypicFeature	D002971
20712420	263	268	sheep	OrganismTaxon	9940
20712420	270	276	horses	OrganismTaxon	9796
20712420	282	286	cats	OrganismTaxon	9685
20712420	330	335	C4-2B	CellLine	CVCL_4784
20712420	337	343	SNU-C5	CellLine	CVCL_5112
20712420	349	352	MEF	CellLine	CVCL_9115
20712420	453	492	28 bp variable number of tandem repeats	SequenceVariant	c|DUP||28
20712420	546	550	CL/P	DiseaseOrPhenotypicFeature	D002971
20712420	562	592	R to G mutation at position 76	SequenceVariant	p|SUB|R|76|G
20712420	628	651	ventricular tachycardia	DiseaseOrPhenotypicFeature	D017180
20712420	719	723	CL/P	DiseaseOrPhenotypicFeature	D002971
20712420	731	740	rs4704559	SequenceVariant	rs4704559
20712420	769	780	arrhythmias	DiseaseOrPhenotypicFeature	D001145
20712420	790	795	C417T	SequenceVariant	rs121909210
20712420	844	853	arthritis	DiseaseOrPhenotypicFeature	D001168
20712420	858	869	arrhythmias	DiseaseOrPhenotypicFeature	D001145
20712420	884	888	G12D	SequenceVariant	p|SUB|G|12|D
20712420	944	953	arthritis	DiseaseOrPhenotypicFeature	D001168
20712420	958	969	arrhythmias	DiseaseOrPhenotypicFeature	D001145
20712420	1003	1007	CL/P	DiseaseOrPhenotypicFeature	D002971
20712420	1027	1036	g.3627A>C	SequenceVariant	g|SUB|A|3627|C
20712420	1059	1068	arthritis	DiseaseOrPhenotypicFeature	D001168
20712420	1108	1112	CL/P	DiseaseOrPhenotypicFeature	D002971
20712420	1118	1123	C417T	SequenceVariant	rs121909210
20712420	1173	1182	g.3627A>C	SequenceVariant	g|SUB|A|3627|C
20712420	1237	1246	arthritis	DiseaseOrPhenotypicFeature	D001168
20712420	1290	1301	arrhythmias	DiseaseOrPhenotypicFeature	D001145
20712420	1337	1360	ventricular tachycardia	DiseaseOrPhenotypicFeature	D017180
20712420	1385	1390	C417T	SequenceVariant	rs121909210
20712420	1437	1442	C417T	SequenceVariant	rs121909210
20712420	1727	1732	sheep	OrganismTaxon	9940
20712420	1734	1740	horses	OrganismTaxon	9796
20712420	1746	1750	cats	OrganismTaxon	9685
20712420	Positive_Correlation	D017180	p|SUB|R|76|G	Novel
20712420	Positive_Correlation	D001145	rs4704559	Novel
20712420	Association	c|DUP||28	D002971	Novel
20712420	Negative_Correlation	p|SUB|G|12|D	D001168	Novel
20712420	Negative_Correlation	p|SUB|G|12|D	D001145	Novel
20712420	Association	p|SUB|G|12|D	D002971	Novel
20712420	Negative_Correlation	p|SUB|R|76|G	D002971	Novel
20712420	Association	D017180	rs4704559	Novel
20712420	Negative_Correlation	g|SUB|A|3627|C	D002971	Novel
20712420	Association	D001145	c|DUP||28	Novel
20712420	Association	rs121909210	g|SUB|A|3627|C	Novel
20712420	Association	D001145	p|SUB|G|12|D	Novel
20712420	Association	D002971	g|SUB|A|3627|C	Novel
20712420	Positive_Correlation	D001145	rs121909210	Novel
20712420	Association	p|SUB|G|12|D	c|DUP||28	Novel
20712420	Association	D001168	c|DUP||28	Novel
20712420	Association	c|DUP||28	rs121909210	Novel
20712420	Positive_Correlation	rs121909210	D001168	Novel
20712420	Negative_Correlation	rs121909210	D001145	Novel
20712420	Association	D017180	rs121909210	Novel
20712420	Positive_Correlation	g|SUB|A|3627|C	D001168	Novel
20712420	Association	rs121909210	D001145	Novel

75669791|t|P120T variant in SW480 cells and its impact on West Nile virus and rDEN2 rep
75669791|a|The P120T variant has been extensively studied in the context of its effects on the replication of West Nile virus and rDEN2. In this study, we investigated the role of the P120T variant in SW480 cells, a commonly used cell line for virological research. The P120T variant was found to significantly alter the replication dynamics of both West Nile virus and rDEN2. Multiple experiments were conducted using SW480 cells expressing the P120T variant, and the results consistently showed a reduction in viral load compared to cells expressing the wild-type sequence. The P120T variant was also found to influence the interaction between the viral proteins and host cell factors, which may explain the observed changes in replication efficiency. The study included 6 instances of the P120T variant, 7 instances of the SW480 cell line, 13 instances of the organism taxon West Nile virus, and 4 instances of the organism taxon rDEN2. These findings suggest that the P120T variant may serve as a potential therapeutic target for controlling infections caused by these viruses. Further research is needed to fully understand the molecular mechanisms underlying the effects of the P120T variant on viral replication.
75669791	0	5	P120T	SequenceVariant	c|SUB|P|120|T
75669791	17	22	SW480	CellLine	CVCL_0546
75669791	47	62	West Nile virus	OrganismTaxon	11082
75669791	67	72	rDEN2	OrganismTaxon	11060
75669791	81	86	P120T	SequenceVariant	c|SUB|P|120|T
75669791	176	191	West Nile virus	OrganismTaxon	11082
75669791	196	201	rDEN2	OrganismTaxon	11060
75669791	250	255	P120T	SequenceVariant	c|SUB|P|120|T
75669791	267	272	SW480	CellLine	CVCL_0546
75669791	336	341	P120T	SequenceVariant	c|SUB|P|120|T
75669791	416	431	West Nile virus	OrganismTaxon	11082
75669791	436	441	rDEN2	OrganismTaxon	11060
75669791	485	490	SW480	CellLine	CVCL_0546
75669791	512	517	P120T	SequenceVariant	c|SUB|P|120|T
75669791	646	651	P120T	SequenceVariant	c|SUB|P|120|T
75669791	858	863	P120T	SequenceVariant	c|SUB|P|120|T
75669791	892	897	SW480	CellLine	CVCL_0546
75669791	944	959	West Nile virus	OrganismTaxon	11082
75669791	999	1004	rDEN2	OrganismTaxon	11060
75669791	1038	1043	P120T	SequenceVariant	c|SUB|P|120|T
75669791	1250	1255	P120T	SequenceVariant	c|SUB|P|120|T

75424989|t|Genetic and molecular interactions in cats, rats, and rhesus monkeys: insights into insulin regulation, sequence variants, and gene product asso
75424989|a|This study investigates the molecular and genetic interactions among various organisms, including cats, rats, and rhesus monkeys, with a focus on insulin regulation, sequence variants, and gene product associations. We examined the effects of the sequence variant 46delS on insulin levels in rats and found a significant association between this variant and altered insulin expression. Additionally, we explored the binding interactions between the gene product NPM and nitric oxide synthase, as well as between NPM and cytochrome P450 (CYP) 1A2. These interactions were further supported by the binding of cytochrome P450 (CYP) 1A2 to nitric oxide synthase and the mutual binding between NPM and cytochrome P450 (CYP) 1A2. The gene product MSH5 was found to bind to both VEGFR2 and nitric oxide synthase, and it also interacts with NPM, forming a complex network of molecular interactions. Furthermore, the chemical entity 15-F(2t)-isoprostane was shown to bind to cytochrome P450 (CYP) 1A2, highlighting its role in metabolic pathways. In cats, we observed the presence of the sequence variant p.R34X, which may influence the expression of key genes involved in metabolic processes. The study also included the organism taxon Saccharomyces cerevisiae as a model system to understand the broader implications of these interactions. Our findings provide new insights into the molecular mechanisms underlying insulin regulation and the role of sequence variants in gene expression across different species, including human immunodeficiency virus and DEN-4.
75424989	38	42	cats	OrganismTaxon	9685
75424989	54	68	rhesus monkeys	OrganismTaxon	9544
75424989	84	91	insulin	ChemicalEntity	D007328
75424989	243	247	cats	OrganismTaxon	9685
75424989	259	273	rhesus monkeys	OrganismTaxon	9544
75424989	291	298	insulin	ChemicalEntity	D007328
75424989	409	415	46delS	SequenceVariant	|DEL|46|S
75424989	419	426	insulin	ChemicalEntity	D007328
75424989	511	518	insulin	ChemicalEntity	D007328
75424989	607	610	NPM	GeneOrGeneProduct	4869
75424989	615	636	nitric oxide synthase	GeneOrGeneProduct	18125
75424989	657	660	NPM	GeneOrGeneProduct	4869
75424989	665	690	cytochrome P450 (CYP) 1A2	GeneOrGeneProduct	1544
75424989	752	777	cytochrome P450 (CYP) 1A2	GeneOrGeneProduct	1544
75424989	781	802	nitric oxide synthase	GeneOrGeneProduct	18125
75424989	834	837	NPM	GeneOrGeneProduct	4869
75424989	842	867	cytochrome P450 (CYP) 1A2	GeneOrGeneProduct	1544
75424989	886	890	MSH5	GeneOrGeneProduct	4439
75424989	917	923	VEGFR2	GeneOrGeneProduct	3791
75424989	928	949	nitric oxide synthase	GeneOrGeneProduct	18125
75424989	978	981	NPM	GeneOrGeneProduct	4869
75424989	1069	1089	15-F(2t)-isoprostane	ChemicalEntity	C075750
75424989	1111	1136	cytochrome P450 (CYP) 1A2	GeneOrGeneProduct	1544
75424989	1186	1190	cats	OrganismTaxon	9685
75424989	1241	1247	p.R34X	SequenceVariant	rs121908073
75424989	1373	1397	Saccharomyces cerevisiae	OrganismTaxon	4932
75424989	1553	1560	insulin	ChemicalEntity	D007328
75424989	1661	1689	human immunodeficiency virus	OrganismTaxon	12721
75424989	1694	1699	DEN-4	OrganismTaxon	11070
75424989	Bind	4869	18125	Novel
75424989	Bind	4439	3791	Novel
75424989	Bind	4439	18125	Novel
75424989	Bind	18125	1544	Novel
75424989	Bind	4869	1544	Novel
75424989	Bind	1544	4869	Novel
75424989	Bind	18125	3791	Novel
75424989	Association	|DEL|46|S	D007328	Novel
75424989	Bind	4439	4869	Novel
75424989	Bind	C075750	1544	Novel

60310876|t|Hemochromatosis, lipid peroxide, and luminal interactions in dogs, DEN-4, yeast, and HPV: a comprehensive analysis of gene-disease and chemical-organism relat
60310876|a|This study investigates the complex interplay between hemochromatosis, lipid peroxide, and luminal in the context of multiple organisms, including dogs, DEN-4, yeast, and HPV. We report a significant association between hemochromatosis and lipid peroxide, with evidence of a positive correlation between lipid peroxide and hemochromatosis. Additionally, lipid peroxide is found to be associated with Aniridia, and a positive correlation is observed between lipid peroxide and Aniridia.   The gene IL-12p70 is shown to bind to lipid peroxide, and this interaction is further supported by the cotreatment and drug interaction between lipid peroxide and luminal. Luminal is also associated with Aniridia, and there is a comparison between lipid peroxide and luminal in terms of their biological roles and effects.   The ghrelin receptor is found to bind both lipid peroxide and luminal, and it is also associated with hemochromatosis. Furthermore, the hypoxia inducible factor-1a binds to lipid peroxide and is associated with hemochromatosis.   Cysteine proteases are associated with hemochromatosis and Aniridia, and they also bind to luminal. The TCF1 gene is found to be involved in the regulation of these interactions, particularly in the context of hemochromatosis.   The study also explores the role of lipid peroxide in the context of different organisms, including dogs, DEN-4, yeast, and HPV, highlighting the broad relevance of these interactions across species. These findings provide a foundation for understanding the molecular mechanisms underlying these diseases and their potential therapeutic targets.
60310876	17	31	lipid peroxide	ChemicalEntity	D008054
60310876	37	44	luminal	ChemicalEntity	D010634
60310876	61	65	dogs	OrganismTaxon	9615
60310876	67	72	DEN-4	OrganismTaxon	11070
60310876	74	79	yeast	OrganismTaxon	4932
60310876	85	88	HPV	OrganismTaxon	10566
60310876	213	228	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
60310876	230	244	lipid peroxide	ChemicalEntity	D008054
60310876	250	257	luminal	ChemicalEntity	D010634
60310876	306	310	dogs	OrganismTaxon	9615
60310876	312	317	DEN-4	OrganismTaxon	11070
60310876	319	324	yeast	OrganismTaxon	4932
60310876	330	333	HPV	OrganismTaxon	10566
60310876	379	394	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
60310876	399	413	lipid peroxide	ChemicalEntity	D008054
60310876	463	477	lipid peroxide	ChemicalEntity	D008054
60310876	482	497	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
60310876	513	527	lipid peroxide	ChemicalEntity	D008054
60310876	559	567	Aniridia	DiseaseOrPhenotypicFeature	D015783
60310876	616	630	lipid peroxide	ChemicalEntity	D008054
60310876	635	643	Aniridia	DiseaseOrPhenotypicFeature	D015783
60310876	656	664	IL-12p70	GeneOrGeneProduct	16185
60310876	685	699	lipid peroxide	ChemicalEntity	D008054
60310876	791	805	lipid peroxide	ChemicalEntity	D008054
60310876	810	817	luminal	ChemicalEntity	D010634
60310876	851	859	Aniridia	DiseaseOrPhenotypicFeature	D015783
60310876	895	909	lipid peroxide	ChemicalEntity	D008054
60310876	914	921	luminal	ChemicalEntity	D010634
60310876	976	992	ghrelin receptor	GeneOrGeneProduct	208188
60310876	1015	1029	lipid peroxide	ChemicalEntity	D008054
60310876	1034	1041	luminal	ChemicalEntity	D010634
60310876	1074	1089	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
60310876	1108	1135	hypoxia inducible factor-1a	GeneOrGeneProduct	15251
60310876	1145	1159	lipid peroxide	ChemicalEntity	D008054
60310876	1183	1198	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
60310876	1241	1256	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
60310876	1261	1269	Aniridia	DiseaseOrPhenotypicFeature	D015783
60310876	1293	1300	luminal	ChemicalEntity	D010634
60310876	1306	1310	TCF1	GeneOrGeneProduct	6927
60310876	1412	1427	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
60310876	1467	1481	lipid peroxide	ChemicalEntity	D008054
60310876	1531	1535	dogs	OrganismTaxon	9615
60310876	1537	1542	DEN-4	OrganismTaxon	11070
60310876	1544	1549	yeast	OrganismTaxon	4932
60310876	1555	1558	HPV	OrganismTaxon	10566
60310876	Comparison	D008054	D010634	Novel
60310876	Bind	16185	D008054	Novel
60310876	Association	15251	D006432	Novel
60310876	Cotreatment	D008054	D010634	Novel
60310876	Drug_Interaction	D008054	D010634	Novel
60310876	Bind	208188	D008054	Novel
60310876	Bind	208188	D010634	Novel
60310876	Association	1508	D006432	Novel
60310876	Association	16185	D006432	Novel
60310876	Association	D010634	D015783	Novel
60310876	Association	D008054	D006432	Novel
60310876	Association	D006432	D008054	Novel
60310876	Positive_Correlation	D008054	D015783	Novel
60310876	Positive_Correlation	D008054	D006432	Novel
60310876	Bind	1508	D010634	Novel
60310876	Association	1508	D015783	Novel
60310876	Bind	15251	D008054	Novel
60310876	Association	208188	D006432	Novel

65819680|t|Nitric Oxide Synthase and C-to-T substitution at -31: interactions with infection in C. elegans
65819680|a|Nitric Oxide Synthase (NOS) plays a critical role in immune responses and cellular signaling, particularly in the context of infection. This study investigates the relationship between NOS expression, the C-to-T substitution at -31, and infection in both C. elegans and HIV. Our findings reveal a negative correlation between infection and Nitric Oxide Synthase, suggesting that NOS may act as a suppressor of infectious processes. In contrast, the C-to-T substitution at -31 is associated with increased susceptibility to infection, indicating a potential genetic risk factor. These effects were observed in both C. elegans and HIV models, highlighting the conserved role of these genetic elements in infection dynamics. The C-to-T substitution at -31 was found to modulate the expression of Nitric Oxide Synthase, thereby influencing the host's ability to combat infection. In C. elegans, the presence of the C-to-T substitution at -31 correlated with higher rates of infection, while in HIV-infected individuals, the same variant was linked to more severe disease progression. These results provide evidence for the complex interplay between genetic variation, NOS activity, and infection outcomes. Further studies are needed to elucidate the molecular mechanisms underlying these associations and their implications for therapeutic interventions.
65819680	0	21	Nitric Oxide Synthase	GeneOrGeneProduct	4843
65819680	26	52	C-to-T substitution at -31	SequenceVariant	rs1143627
65819680	72	81	infection	DiseaseOrPhenotypicFeature	D007239
65819680	85	95	C. elegans	OrganismTaxon	6239
65819680	96	117	Nitric Oxide Synthase	GeneOrGeneProduct	4843
65819680	221	230	infection	DiseaseOrPhenotypicFeature	D007239
65819680	301	327	C-to-T substitution at -31	SequenceVariant	rs1143627
65819680	333	342	infection	DiseaseOrPhenotypicFeature	D007239
65819680	351	361	C. elegans	OrganismTaxon	6239
65819680	366	369	HIV	OrganismTaxon	11676
65819680	422	431	infection	DiseaseOrPhenotypicFeature	D007239
65819680	436	457	Nitric Oxide Synthase	GeneOrGeneProduct	4843
65819680	545	571	C-to-T substitution at -31	SequenceVariant	rs1143627
65819680	619	628	infection	DiseaseOrPhenotypicFeature	D007239
65819680	710	720	C. elegans	OrganismTaxon	6239
65819680	725	728	HIV	OrganismTaxon	11676
65819680	798	807	infection	DiseaseOrPhenotypicFeature	D007239
65819680	822	848	C-to-T substitution at -31	SequenceVariant	rs1143627
65819680	889	910	Nitric Oxide Synthase	GeneOrGeneProduct	4843
65819680	961	970	infection	DiseaseOrPhenotypicFeature	D007239
65819680	975	985	C. elegans	OrganismTaxon	6239
65819680	1007	1033	C-to-T substitution at -31	SequenceVariant	rs1143627
65819680	1066	1075	infection	DiseaseOrPhenotypicFeature	D007239
65819680	1086	1089	HIV	OrganismTaxon	11676
65819680	1278	1287	infection	DiseaseOrPhenotypicFeature	D007239
65819680	Negative_Correlation	D007239	4843	Novel
65819680	Association	D007239	rs1143627	Novel

96438512|t|Genetic Variants and Functional Interactions of Rap1/Rac1 GTPase with IL1A in HIV-Infec
96438512|a|This study investigates the genetic and functional relationships between sequence variants and the expression of Rap1/Rac1 GTPase and IL1A in HIV-infected cats. We analyzed 111G, C-1228T, and c.1138G>A variants in a cohort of HIV-infected cats, focusing on their potential impact on the expression and activity of Rap1/Rac1 GTPase and IL1A. The results reveal a complex interplay between these genetic variants and the biological functions of the genes. Specifically, the 111G variant was found to be associated with both positive and negative correlations between Rap1/Rac1 GTPase and IL1A, depending on the context of the infection. Similarly, the C-1228T variant showed a significant association with the expression levels of IL1A, which in turn influenced the activity of Rap1/Rac1 GTPase. The c.1138G>A variant was linked to a negative correlation between Rap1/Rac1 GTPase and IL1A, suggesting a regulatory role in the immune response. These findings highlight the importance of genetic variability in shaping the immune response to HIV in cats. The study also demonstrates that the interactions between Rap1/Rac1 GTPase and IL1A are not uniform and can vary based on the specific genetic background and environmental factors. Overall, the data provide new insights into the molecular mechanisms underlying the immune response to HIV in feline models.
96438512	48	64	Rap1/Rac1 GTPase	GeneOrGeneProduct	5879
96438512	70	74	IL1A	GeneOrGeneProduct	3552
96438512	78	81	HIV	OrganismTaxon	11676
96438512	201	217	Rap1/Rac1 GTPase	GeneOrGeneProduct	5879
96438512	222	226	IL1A	GeneOrGeneProduct	3552
96438512	230	233	HIV	OrganismTaxon	11676
96438512	243	247	cats	OrganismTaxon	9685
96438512	261	265	111G	SequenceVariant	c|Allele|G|111
96438512	267	274	C-1228T	SequenceVariant	c|SUB|C|-1228|T
96438512	280	289	c.1138G>A	SequenceVariant	rs28931614
96438512	314	317	HIV	OrganismTaxon	11676
96438512	327	331	cats	OrganismTaxon	9685
96438512	402	418	Rap1/Rac1 GTPase	GeneOrGeneProduct	5879
96438512	423	427	IL1A	GeneOrGeneProduct	3552
96438512	560	564	111G	SequenceVariant	c|Allele|G|111
96438512	653	669	Rap1/Rac1 GTPase	GeneOrGeneProduct	5879
96438512	674	678	IL1A	GeneOrGeneProduct	3552
96438512	738	745	C-1228T	SequenceVariant	c|SUB|C|-1228|T
96438512	817	821	IL1A	GeneOrGeneProduct	3552
96438512	864	880	Rap1/Rac1 GTPase	GeneOrGeneProduct	5879
96438512	886	895	c.1138G>A	SequenceVariant	rs28931614
96438512	949	965	Rap1/Rac1 GTPase	GeneOrGeneProduct	5879
96438512	970	974	IL1A	GeneOrGeneProduct	3552
96438512	1126	1129	HIV	OrganismTaxon	11676
96438512	1133	1137	cats	OrganismTaxon	9685
96438512	1197	1213	Rap1/Rac1 GTPase	GeneOrGeneProduct	5879
96438512	1218	1222	IL1A	GeneOrGeneProduct	3552
96438512	1423	1426	HIV	OrganismTaxon	11676
96438512	Negative_Correlation	3552	5879	Novel
96438512	Association	3552	5879	Novel
96438512	Association	5879	3552	Novel
96438512	Negative_Correlation	5879	3552	Novel

03892175|t|Allopurinol, NDUFS3, and Mitogen-Activated Protein Kinases: Interactions with Developmental Delay and Amino Acid Variants in Human Papillo
03892175|a|Recent studies have highlighted the complex interplay between genetic variants, chemical entities, and disease phenotypes in the context of Human Papilloma Virus (HPV) infection. This research explores the associations between the sequence variant 'lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223', the gene product NDUFS3, the chemical entity Allopurinol, and the disease feature developmental delay. The findings suggest a significant association between developmental delay and the amino acid variant 'lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223', as well as between developmental delay and the sequence variant C262.   The study also reveals a positive correlation between the gene product mitogen-activated protein kinases and Allopurinol, while simultaneously showing a negative correlation between mitogen-activated protein kinases and Allopurinol. This apparent contradiction is explained by the context-dependent modulation of these pathways in response to HPV infection. Furthermore, the gene product NDUFS3 exhibits a negative correlation with Allopurinol, yet a positive correlation with developmental delay, suggesting a dual role in both metabolic and developmental processes.  The presence of multiple instances of the gene product NDUFS3 and the sequence variant C262 underscores the importance of these elements in the pathophysiology of developmental delay. The repeated mention of Allopurinol in relation to both NDUFS3 and mitogen-activated protein kinases highlights its potential as a therapeutic target in conditions involving these genetic and biochemical pathways. Overall, the data support a multifaceted relationship between genetic variants, chemical entities, and disease phenotypes in the context of Human Papilloma Virus infection.
03892175	0	11	Allopurinol	ChemicalEntity	D000493
03892175	13	19	NDUFS3	GeneOrGeneProduct	4722
03892175	388	452	lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223	SequenceVariant	c|SUB|Q|223|K
03892175	472	478	NDUFS3	GeneOrGeneProduct	4722
03892175	500	511	Allopurinol	ChemicalEntity	D000493
03892175	537	556	developmental delay	DiseaseOrPhenotypicFeature	D002658
03892175	613	632	developmental delay	DiseaseOrPhenotypicFeature	D002658
03892175	661	725	lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223	SequenceVariant	c|SUB|Q|223|K
03892175	747	766	developmental delay	DiseaseOrPhenotypicFeature	D002658
03892175	792	796	C262	SequenceVariant	c|Aelle|C|262
03892175	871	904	mitogen-activated protein kinases	GeneOrGeneProduct	26413
03892175	909	920	Allopurinol	ChemicalEntity	D000493
03892175	982	1015	mitogen-activated protein kinases	GeneOrGeneProduct	26413
03892175	1020	1031	Allopurinol	ChemicalEntity	D000493
03892175	1188	1194	NDUFS3	GeneOrGeneProduct	4722
03892175	1232	1243	Allopurinol	ChemicalEntity	D000493
03892175	1277	1296	developmental delay	DiseaseOrPhenotypicFeature	D002658
03892175	1424	1430	NDUFS3	GeneOrGeneProduct	4722
03892175	1456	1460	C262	SequenceVariant	c|Aelle|C|262
03892175	1532	1551	developmental delay	DiseaseOrPhenotypicFeature	D002658
03892175	1577	1588	Allopurinol	ChemicalEntity	D000493
03892175	1609	1615	NDUFS3	GeneOrGeneProduct	4722
03892175	1620	1653	mitogen-activated protein kinases	GeneOrGeneProduct	26413
03892175	Positive_Correlation	26413	D000493	Novel
03892175	Association	D002658	c|SUB|Q|223|K	Novel
03892175	Negative_Correlation	4722	D000493	Novel
03892175	Negative_Correlation	26413	D000493	Novel
03892175	Positive_Correlation	4722	D000493	Novel
03892175	Association	D002658	c|Aelle|C|262	Novel

21872453|t|HBV and hCG interactions in the context of cerebral microbleeds and cerebral edema: a study on scabicide
21872453|a|This study investigates the complex interactions between the hepatitis B virus (HBV), human chorionic gonadotropin (hCG), and scabicide in the context of cerebral microbleeds and cerebral edema. The research highlights the conversion between hCG and scabicide, suggesting a biochemical pathway that may influence neurological outcomes. Furthermore, the study reveals a negative correlation between scabicide levels and the occurrence of cerebral microbleeds, indicating a potential protective role of scabicide in preventing these vascular events. Similarly, a negative correlation is observed between hCG and cerebral edema, suggesting that hCG may have a neuroprotective effect in reducing brain swelling. The findings also support a negative correlation between hCG and cerebral microbleeds, reinforcing the idea that hCG may modulate the risk of these neurological complications. Additionally, the conversion between scabicide and hCG is further validated, providing a mechanistic link between these two chemical entities. The study also includes an analysis of the West Nile virus, which was found to have no significant interaction with the other variables in this context. These results contribute to a better understanding of the interplay between HBV, hCG, scabicide, cerebral microbleeds, and cerebral edema, offering new insights into potential therapeutic strategies for neurological disorders.
21872453	0	3	HBV	OrganismTaxon	10407
21872453	8	11	hCG	ChemicalEntity	D006063
21872453	68	82	cerebral edema	DiseaseOrPhenotypicFeature	D001929
21872453	95	104	scabicide	ChemicalEntity	D056810
21872453	185	188	HBV	OrganismTaxon	10407
21872453	221	224	hCG	ChemicalEntity	D006063
21872453	231	240	scabicide	ChemicalEntity	D056810
21872453	284	298	cerebral edema	DiseaseOrPhenotypicFeature	D001929
21872453	347	350	hCG	ChemicalEntity	D006063
21872453	355	364	scabicide	ChemicalEntity	D056810
21872453	503	512	scabicide	ChemicalEntity	D056810
21872453	606	615	scabicide	ChemicalEntity	D056810
21872453	707	710	hCG	ChemicalEntity	D006063
21872453	715	729	cerebral edema	DiseaseOrPhenotypicFeature	D001929
21872453	747	750	hCG	ChemicalEntity	D006063
21872453	870	873	hCG	ChemicalEntity	D006063
21872453	926	929	hCG	ChemicalEntity	D006063
21872453	1026	1035	scabicide	ChemicalEntity	D056810
21872453	1040	1043	hCG	ChemicalEntity	D006063
21872453	1175	1190	West Nile virus	OrganismTaxon	11082
21872453	1361	1364	HBV	OrganismTaxon	10407
21872453	1366	1369	hCG	ChemicalEntity	D006063
21872453	1371	1380	scabicide	ChemicalEntity	D056810
21872453	1408	1422	cerebral edema	DiseaseOrPhenotypicFeature	D001929
21872453	Conversion	D006063	D056810	Novel
21872453	Negative_Correlation	D056810	D002543	Novel
21872453	Negative_Correlation	D006063	D001929	Novel
21872453	Conversion	D056810	D006063	Novel
21872453	Negative_Correlation	D056810	D001929	Novel
21872453	Negative_Correlation	D006063	D002543	Novel

37166570|t|CYP1B1: multifaceted associations with diabetes mellitus, mucolipidosis III gamma, and IBD across bovine and Mangifera indica Lin
37166570|a|The enzyme CYP1B1 has been implicated in a variety of physiological and pathological processes, including metabolic regulation, inflammation, and lysosomal storage disorders. This study investigates the complex relationships between CYP1B1 and several disease states, including diabetes mellitus, mucolipidosis III gamma, and inflammatory bowel disease (IBD), across multiple biological models. Using a combination of in vitro and in vivo approaches, we examined the expression and functional roles of CYP1B1 in bovine and Mangifera indica Linn tissues, as well as in human-derived cell lines such as SNU-C5, HCT116, H9c2, Mz-ChA-1, Ishikawa, SUM159PT, and others.    Our findings reveal a positive correlation between CYP1B1 and diabetes mellitus, with evidence suggesting that CYP1B1 may play a role in modulating glucose homeostasis. However, a negative correlation was also observed, indicating potential context-dependent effects. Similarly, CYP1B1 showed both positive and negative correlations with mucolipidosis III gamma, highlighting the complexity of its involvement in lysosomal storage disorders. Notably, a strong positive correlation was found between CYP1B1 and IBD, suggesting a potential role in inflammatory processes. However, a negative correlation was also observed, indicating that the relationship between CYP1B1 and IBD may be influenced by multiple factors.    These results underscore the multifaceted nature of CYP1B1's interactions with various disease states. The study also demonstrates the utility of using diverse biological models, including bovine and Mangifera indica Linn, to better understand the functional roles of CYP1B1 in different physiological contexts. Further research is warranted to elucidate the mechanisms underlying these associations and to explore potential therapeutic applications.
37166570	0	6	CYP1B1	GeneOrGeneProduct	1545
37166570	39	56	diabetes mellitus	DiseaseOrPhenotypicFeature	D003920
37166570	58	81	mucolipidosis III gamma	DiseaseOrPhenotypicFeature	C565367
37166570	87	90	IBD	DiseaseOrPhenotypicFeature	D015212
37166570	98	104	bovine	OrganismTaxon	9913
37166570	141	147	CYP1B1	GeneOrGeneProduct	1545
37166570	363	369	CYP1B1	GeneOrGeneProduct	1545
37166570	408	425	diabetes mellitus	DiseaseOrPhenotypicFeature	D003920
37166570	427	450	mucolipidosis III gamma	DiseaseOrPhenotypicFeature	C565367
37166570	484	487	IBD	DiseaseOrPhenotypicFeature	D015212
37166570	632	638	CYP1B1	GeneOrGeneProduct	1545
37166570	642	648	bovine	OrganismTaxon	9913
37166570	653	674	Mangifera indica Linn	OrganismTaxon	29780
37166570	731	737	SNU-C5	CellLine	CVCL_5112
37166570	739	745	HCT116	CellLine	CVCL_0291
37166570	747	751	H9c2	CellLine	CVCL_0286
37166570	753	761	Mz-ChA-1	CellLine	CVCL_6932
37166570	763	771	Ishikawa	CellLine	CVCL_2529
37166570	773	781	SUM159PT	CellLine	CVCL_5423
37166570	849	855	CYP1B1	GeneOrGeneProduct	1545
37166570	860	877	diabetes mellitus	DiseaseOrPhenotypicFeature	D003920
37166570	909	915	CYP1B1	GeneOrGeneProduct	1545
37166570	1077	1083	CYP1B1	GeneOrGeneProduct	1545
37166570	1136	1159	mucolipidosis III gamma	DiseaseOrPhenotypicFeature	C565367
37166570	1297	1303	CYP1B1	GeneOrGeneProduct	1545
37166570	1308	1311	IBD	DiseaseOrPhenotypicFeature	D015212
37166570	1460	1466	CYP1B1	GeneOrGeneProduct	1545
37166570	1471	1474	IBD	DiseaseOrPhenotypicFeature	D015212
37166570	1569	1575	CYP1B1	GeneOrGeneProduct	1545
37166570	1706	1712	bovine	OrganismTaxon	9913
37166570	1717	1738	Mangifera indica Linn	OrganismTaxon	29780
37166570	1785	1791	CYP1B1	GeneOrGeneProduct	1545
37166570	Association	D015212	1545	Novel
37166570	Association	D003920	1545	Novel
37166570	Association	C565367	1545	Novel
37166570	Negative_Correlation	1545	D003920	Novel
37166570	Association	1545	D003920	Novel
37166570	Positive_Correlation	D015212	1545	Novel
37166570	Positive_Correlation	C565367	1545	Novel
37166570	Positive_Correlation	1545	D003920	Novel
37166570	Positive_Correlation	1545	C565367	Novel
37166570	Negative_Correlation	1545	C565367	Novel
37166570	Positive_Correlation	D003920	1545	Novel
37166570	Negative_Correlation	1545	D015212	Novel
37166570	Association	1545	D015212	Novel
37166570	Association	1545	C565367	Novel
37166570	Positive_Correlation	1545	D015212	Novel

91004293|t|Multifaceted interactions between carbachol, bromocriptine, and epipodophyllotoxin in MC3T3-E1, Mz-ChA-1, and HL-7702 cell lines with implications for Amphetamine and G1103R 
91004293|a|This study investigates the complex interactions between carbachol, bromocriptine, and epipodophyllotoxin in three distinct cell lines: MC3T3-E1, Mz-ChA-1, and HL-7702. Our findings reveal a positive correlation between carbachol and bromocriptine, as well as between bromocriptine and epipodophyllotoxin. Additionally, epipodophyllotoxin demonstrates a positive correlation with both bromocriptine and dexamphetamine, while Amphetamine shows a positive correlation with dexamphetamine, epipodophyllotoxin, and bromocriptine. These results suggest a potential pharmacological synergy among these compounds in modulating cellular responses.   Further, we explored the association between the sequence variant G1103R and both epipodophyllotoxin and bromocriptine, indicating a possible functional link between this variant and the observed interactions. The variant Ile326Ile was also examined, though its role in these interactions remains less clear. The study utilized multiple concentrations of carbachol, bromocriptine, and epipodophyllotoxin across the three cell lines, with Amphetamine and dexamphetamine serving as key modulators in the observed correlations.   These findings highlight the importance of understanding the interplay between chemical entities and genetic variants in cellular signaling pathways, particularly in the context of neuropharmacology and cellular response mechanisms. The results provide a foundation for future research into the therapeutic potential of these compounds and their variants in disease models involving MC3T3-E1, Mz-ChA-1, and HL-7702 cell lines.
91004293	34	43	carbachol	ChemicalEntity	D002217
91004293	45	58	bromocriptine	ChemicalEntity	D001971
91004293	64	82	epipodophyllotoxin	ChemicalEntity	D011034
91004293	86	94	MC3T3-E1	CellLine	CVCL_0409
91004293	96	104	Mz-ChA-1	CellLine	CVCL_6932
91004293	110	117	HL-7702	CellLine	CVCL_6926
91004293	151	162	Amphetamine	ChemicalEntity	D000661
91004293	167	173	G1103R	SequenceVariant	rs62636275
91004293	232	241	carbachol	ChemicalEntity	D002217
91004293	243	256	bromocriptine	ChemicalEntity	D001971
91004293	262	280	epipodophyllotoxin	ChemicalEntity	D011034
91004293	311	319	MC3T3-E1	CellLine	CVCL_0409
91004293	321	329	Mz-ChA-1	CellLine	CVCL_6932
91004293	335	342	HL-7702	CellLine	CVCL_6926
91004293	395	404	carbachol	ChemicalEntity	D002217
91004293	409	422	bromocriptine	ChemicalEntity	D001971
91004293	443	456	bromocriptine	ChemicalEntity	D001971
91004293	461	479	epipodophyllotoxin	ChemicalEntity	D011034
91004293	495	513	epipodophyllotoxin	ChemicalEntity	D011034
91004293	560	573	bromocriptine	ChemicalEntity	D001971
91004293	578	592	dexamphetamine	ChemicalEntity	D003913
91004293	600	611	Amphetamine	ChemicalEntity	D000661
91004293	646	660	dexamphetamine	ChemicalEntity	D003913
91004293	662	680	epipodophyllotoxin	ChemicalEntity	D011034
91004293	686	699	bromocriptine	ChemicalEntity	D001971
91004293	883	889	G1103R	SequenceVariant	rs62636275
91004293	899	917	epipodophyllotoxin	ChemicalEntity	D011034
91004293	922	935	bromocriptine	ChemicalEntity	D001971
91004293	1039	1048	Ile326Ile	SequenceVariant	rs3730089
91004293	1172	1181	carbachol	ChemicalEntity	D002217
91004293	1183	1196	bromocriptine	ChemicalEntity	D001971
91004293	1202	1220	epipodophyllotoxin	ChemicalEntity	D011034
91004293	1255	1266	Amphetamine	ChemicalEntity	D000661
91004293	1271	1285	dexamphetamine	ChemicalEntity	D003913
91004293	1727	1735	MC3T3-E1	CellLine	CVCL_0409
91004293	1737	1745	Mz-ChA-1	CellLine	CVCL_6932
91004293	1751	1758	HL-7702	CellLine	CVCL_6926
91004293	Positive_Correlation	D011034	D003913	Novel
91004293	Positive_Correlation	D000661	D003913	Novel
91004293	Positive_Correlation	D002217	D001971	Novel
91004293	Positive_Correlation	D001971	D011034	Novel
91004293	Positive_Correlation	D000661	D011034	Novel
91004293	Positive_Correlation	D000661	D001971	Novel
91004293	Association	rs62636275	D011034	Novel
91004293	Positive_Correlation	D011034	D001971	Novel
91004293	Association	rs62636275	D001971	Novel

19769112|t|Genetic and pharmacological interactions of erythropoiesis-stimulating agents with rs4828037, mangiferin, and joint abnormalities in mitral valve prolapse and cell lin
19769112|a|This study investigates the complex interplay between erythropoiesis-stimulating agents (ESAs), genetic variants, and disease phenotypes in the context of mitral valve prolapse and joint abnormalities. We focus on the association between rs4828037 and mangiferin, as well as the negative correlation between Glu873Stop and mitral valve prolapse. The role of ESAs in modulating these interactions is explored using multiple cell lines, including SJ-GBM2, Ba/F3, and MH134.   Our findings reveal that mangiferin significantly modulates the expression of genes associated with rs4828037, suggesting a potential pharmacological synergy. Furthermore, we observed that the presence of Glu873Stop is inversely correlated with the severity of mitral valve prolapse, indicating a possible protective effect. In contrast, the administration of erythropoiesis-stimulating agents was found to exacerbate joint abnormalities in patients with mitral valve prolapse, highlighting the need for careful monitoring in clinical settings.  To validate these findings, we conducted experiments using the cell lines SJ-GBM2, Ba/F3, and MH134, which exhibited distinct responses to ESAs and mangiferin. The results suggest that the interaction between these agents and genetic variants may influence disease progression and therapeutic outcomes. Additionally, the repeated presence of NT-proBNP in our data underscores its role as a biomarker in these conditions.   Overall, this study provides a comprehensive framework for understanding the molecular and pharmacological mechanisms underlying the interactions between ESAs, genetic variants, and disease phenotypes, with implications for personalized medicine and targeted therapies.
19769112	44	76	erythropoiesis-stimulating agent	ChemicalEntity	D006397
19769112	83	92	rs4828037	SequenceVariant	rs4828037
19769112	94	104	mangiferin	ChemicalEntity	C013592
19769112	110	129	joint abnormalities	DiseaseOrPhenotypicFeature	D007592
19769112	133	154	mitral valve prolapse	DiseaseOrPhenotypicFeature	D008945
19769112	222	254	erythropoiesis-stimulating agent	ChemicalEntity	D006397
19769112	323	344	mitral valve prolapse	DiseaseOrPhenotypicFeature	D008945
19769112	349	368	joint abnormalities	DiseaseOrPhenotypicFeature	D007592
19769112	406	415	rs4828037	SequenceVariant	rs4828037
19769112	420	430	mangiferin	ChemicalEntity	C013592
19769112	476	486	Glu873Stop	SequenceVariant	rs121918047
19769112	491	512	mitral valve prolapse	DiseaseOrPhenotypicFeature	D008945
19769112	613	620	SJ-GBM2	CellLine	CVCL_M141
19769112	622	627	Ba/F3	CellLine	CVCL_0161
19769112	633	638	MH134	CellLine	CVCL_8111
19769112	667	677	mangiferin	ChemicalEntity	C013592
19769112	742	751	rs4828037	SequenceVariant	rs4828037
19769112	847	857	Glu873Stop	SequenceVariant	rs121918047
19769112	903	924	mitral valve prolapse	DiseaseOrPhenotypicFeature	D008945
19769112	1002	1034	erythropoiesis-stimulating agent	ChemicalEntity	D006397
19769112	1060	1079	joint abnormalities	DiseaseOrPhenotypicFeature	D007592
19769112	1097	1118	mitral valve prolapse	DiseaseOrPhenotypicFeature	D008945
19769112	1262	1269	SJ-GBM2	CellLine	CVCL_M141
19769112	1271	1276	Ba/F3	CellLine	CVCL_0161
19769112	1282	1287	MH134	CellLine	CVCL_8111
19769112	1336	1346	mangiferin	ChemicalEntity	C013592
19769112	1530	1539	NT-proBNP	ChemicalEntity	C109794
19769112	Negative_Correlation	rs121918047	D008945	Novel
19769112	Association	rs4828037	C013592	Novel

15862656|t|Genetic Variants and Cellular Responses in Horses and Mice: A Study on Sequence Mutations and Cell Line 
15862656|a|This study investigates the genetic and cellular responses of horses and mice to a series of sequence variants and their associations with specific cell lines. The research focuses on the impact of mutations such as 217_218insC, Lys198Asn, R to G mutation at position 76, c.1052delA, and deletion (10-12Mb) on the behavior of cell lines including H9c2, 253JB-V, MES-SA/Dx5, PA-1, and others.   The findings reveal a significant association between the sequence variant 217_218insC and both Lys198Asn and deletion (10-12Mb), suggesting a potential functional link between these genetic changes. Additionally, the deletion (10-12Mb) is found to be associated with c.1052delA, indicating a possible cascade of genetic events. The study also demonstrates that 217_218insC is linked to c.1052delA, further supporting the hypothesis of interconnected genetic alterations.   In the context of horses, the presence of these sequence variants is correlated with altered cellular responses in H9c2 and 253JB-V cell lines, while in mice, similar patterns are observed in MES-SA/Dx5 and PA-1 cell lines. The R to G mutation at position 76 is found to be associated with Lys198Asn, highlighting the complexity of genetic interactions.   These results provide new insights into the molecular mechanisms underlying genetic variability in horses and mice, and their implications for cellular function and disease susceptibility. The study underscores the importance of understanding the interplay between sequence variants and cell line behavior in both model organisms and potential translational applications.
15862656	54	58	Mice	OrganismTaxon	10090
15862656	167	173	horses	OrganismTaxon	9796
15862656	321	332	217_218insC	SequenceVariant	c|INS|217_218|C
15862656	334	343	Lys198Asn	SequenceVariant	rs5370
15862656	345	375	R to G mutation at position 76	SequenceVariant	p|SUB|R|76|G
15862656	377	387	c.1052delA	SequenceVariant	rs137853893
15862656	393	411	deletion (10-12Mb)	SequenceVariant	c|DEL||10-12MB
15862656	452	456	H9c2	CellLine	CVCL_0286
15862656	458	465	253JB-V	CellLine	CVCL_7937
15862656	467	477	MES-SA/Dx5	CellLine	CVCL_2598
15862656	479	483	PA-1	CellLine	CVCL_0479
15862656	574	585	217_218insC	SequenceVariant	c|INS|217_218|C
15862656	595	604	Lys198Asn	SequenceVariant	rs5370
15862656	609	627	deletion (10-12Mb)	SequenceVariant	c|DEL||10-12MB
15862656	717	735	deletion (10-12Mb)	SequenceVariant	c|DEL||10-12MB
15862656	767	777	c.1052delA	SequenceVariant	rs137853893
15862656	861	872	217_218insC	SequenceVariant	c|INS|217_218|C
15862656	886	896	c.1052delA	SequenceVariant	rs137853893
15862656	991	997	horses	OrganismTaxon	9796
15862656	1088	1092	H9c2	CellLine	CVCL_0286
15862656	1097	1104	253JB-V	CellLine	CVCL_7937
15862656	1165	1175	MES-SA/Dx5	CellLine	CVCL_2598
15862656	1180	1184	PA-1	CellLine	CVCL_0479
15862656	1201	1231	R to G mutation at position 76	SequenceVariant	p|SUB|R|76|G
15862656	1263	1272	Lys198Asn	SequenceVariant	rs5370
15862656	1428	1434	horses	OrganismTaxon	9796
15862656	Association	rs5370	c|INS|217_218|C	Novel
15862656	Association	c|DEL||10-12MB	c|INS|217_218|C	Novel
15862656	Association	rs137853893	c|DEL||10-12MB	Novel
15862656	Association	c|DEL||10-12MB	rs137853893	Novel
15862656	Association	c|INS|217_218|C	rs137853893	Novel
15862656	Association	c|INS|217_218|C	c|DEL||10-12MB	Novel
15862656	Association	p|SUB|R|76|G	rs5370	Novel

85947125|t|Yohimbine, Carbachol, and Lithium Interactions in Neurotransmitter Modulation and Cellular Response 
85947125|a|This study investigates the complex interactions among yohimbine, carbachol, lithium, and other chemical entities in modulating neurotransmitter activity and cellular responses. We observed a negative correlation between lithium and yohimbine, suggesting that their combined effects may counteract each other in neural signaling pathways. Additionally, a negative correlation was found between yohimbine and acetic acid, indicating potential competitive interactions in metabolic or synaptic processes.   The relationship between yohimbine and lithium was further explored, revealing a consistent negative correlation, which may have implications for the treatment of mood disorders. Conversion between yohimbine and lithium was also noted, suggesting a dynamic interplay in cellular mechanisms.   In the context of cellular imaging, a conversion between cerulenin and propidium iodide was observed, along with a negative correlation between cerulenin and propidium iodide. This suggests that cerulenin may influence the uptake or binding of propidium iodide in cell membranes. Furthermore, a negative correlation between cerulenin and yohimbine was identified, indicating possible antagonistic effects in intracellular signaling.   The interaction between propidium iodide and carbachol was examined, revealing both a conversion and a negative correlation, which may reflect the role of carbachol in modulating membrane permeability. A negative correlation between propidium iodide and lithium was also noted, suggesting that lithium may interfere with the cellular uptake of propidium iodide.   Additionally, a negative correlation between cerulenin and carbachol was observed, and a conversion between cerulenin and carbachol was documented, highlighting the complex interplay between these compounds in cellular processes. Finally, a conversion between acetic acid and yohimbine was identified, suggesting a potential metabolic pathway or regulatory mechanism linking these two entities.   These findings provide new insights into the biochemical and pharmacological relationships among these compounds and their potential applications in neuropharmacology and cellular biology.
85947125	156	165	yohimbine	ChemicalEntity	D015016
85947125	167	176	carbachol	ChemicalEntity	D002217
85947125	178	185	lithium	ChemicalEntity	D008094
85947125	322	329	lithium	ChemicalEntity	D008094
85947125	334	343	yohimbine	ChemicalEntity	D015016
85947125	495	504	yohimbine	ChemicalEntity	D015016
85947125	509	520	acetic acid	ChemicalEntity	D019342
85947125	631	640	yohimbine	ChemicalEntity	D015016
85947125	645	652	lithium	ChemicalEntity	D008094
85947125	804	813	yohimbine	ChemicalEntity	D015016
85947125	818	825	lithium	ChemicalEntity	D008094
85947125	956	965	cerulenin	ChemicalEntity	D002569
85947125	970	986	propidium iodide	ChemicalEntity	D011419
85947125	1043	1052	cerulenin	ChemicalEntity	D002569
85947125	1057	1073	propidium iodide	ChemicalEntity	D011419
85947125	1094	1103	cerulenin	ChemicalEntity	D002569
85947125	1143	1159	propidium iodide	ChemicalEntity	D011419
85947125	1223	1232	cerulenin	ChemicalEntity	D002569
85947125	1237	1246	yohimbine	ChemicalEntity	D015016
85947125	1358	1374	propidium iodide	ChemicalEntity	D011419
85947125	1379	1388	carbachol	ChemicalEntity	D002217
85947125	1489	1498	carbachol	ChemicalEntity	D002217
85947125	1567	1583	propidium iodide	ChemicalEntity	D011419
85947125	1588	1595	lithium	ChemicalEntity	D008094
85947125	1628	1635	lithium	ChemicalEntity	D008094
85947125	1678	1694	propidium iodide	ChemicalEntity	D011419
85947125	1743	1752	cerulenin	ChemicalEntity	D002569
85947125	1757	1766	carbachol	ChemicalEntity	D002217
85947125	1806	1815	cerulenin	ChemicalEntity	D002569
85947125	1820	1829	carbachol	ChemicalEntity	D002217
85947125	1958	1969	acetic acid	ChemicalEntity	D019342
85947125	1974	1983	yohimbine	ChemicalEntity	D015016
85947125	Negative_Correlation	D008094	D015016	Novel
85947125	Conversion	D002569	D011419	Novel
85947125	Negative_Correlation	D011419	D002569	Novel
85947125	Negative_Correlation	D002569	D015016	Novel
85947125	Negative_Correlation	D019342	D011419	Novel
85947125	Negative_Correlation	D002569	D011419	Novel
85947125	Negative_Correlation	D015016	D008094	Novel
85947125	Conversion	D011419	D002217	Novel
85947125	Negative_Correlation	D015016	D019342	Novel
85947125	Negative_Correlation	D011419	D002217	Novel
85947125	Conversion	D002569	D002217	Novel
85947125	Negative_Correlation	D011419	D008094	Novel
85947125	Negative_Correlation	D002569	D002217	Novel
85947125	Conversion	D019342	D015016	Novel
85947125	Conversion	D015016	D008094	Novel

41834816|t|Cidea and Mad2 interactions in PC-3 and SUM159PT cells: implications for abnormal glucose homeostasis, acute renal failure, and 
41834816|a|This study investigates the molecular interactions between Cidea and Mad2 in the context of PC-3, SUM159PT, and RAW 264.7 cell lines, with a focus on their roles in abnormal glucose homeostasis, acute renal failure, and glycemia. Our findings reveal a positive correlation between Cidea and Mad2, suggesting a potential regulatory mechanism in cellular responses to metabolic stress. Additionally, we observed a negative correlation between Cidea and glycemia, indicating a possible inverse relationship in metabolic regulation.   The study also explores the interplay between Cidea and dopaminergic drugs, revealing a positive correlation between Cidea and dopaminergic drugs, while a negative correlation was found between dopaminergic drugs and resistin. These results suggest that Cidea may act as a mediator in the dopaminergic signaling pathway. Furthermore, a positive correlation was identified between resistin and propidium iodide, while a negative correlation was observed between propidium iodide and resistin, highlighting complex regulatory networks involving these molecules.  In the context of renal function, we found a negative correlation between creatinine and IRS-1, as well as between creatinine and Cidea, suggesting that these genes may be involved in the pathophysiology of acute renal failure. A negative correlation was also noted between IRS-1 and Arsenic, and between IRS-1 and nelarabine, indicating potential toxicological interactions.   The study further demonstrates a positive correlation between resistin and glycemia, and a negative correlation between glycemia and Mad2, underscoring the role of these molecules in glucose homeostasis. Additionally, a negative correlation was found between nelarabine and Cidea, as well as between nelarabine and IRS-1, suggesting that nelarabine may have inhibitory effects on these genes.   Overall, our findings provide new insights into the molecular mechanisms underlying abnormal glucose homeostasis, acute renal failure, and the interactions between various chemical entities and gene products in different cell lines.
41834816	0	5	Cidea	GeneOrGeneProduct	1149
41834816	10	14	Mad2	GeneOrGeneProduct	56150
41834816	31	35	PC-3	CellLine	CVCL_0035
41834816	40	48	SUM159PT	CellLine	CVCL_5423
41834816	73	101	abnormal glucose homeostasis	DiseaseOrPhenotypicFeature	D044882
41834816	188	193	Cidea	GeneOrGeneProduct	1149
41834816	198	202	Mad2	GeneOrGeneProduct	56150
41834816	221	225	PC-3	CellLine	CVCL_0035
41834816	227	235	SUM159PT	CellLine	CVCL_5423
41834816	241	250	RAW 264.7	CellLine	CVCL_0493
41834816	294	322	abnormal glucose homeostasis	DiseaseOrPhenotypicFeature	D044882
41834816	349	357	glycemia	ChemicalEntity	D001786
41834816	410	415	Cidea	GeneOrGeneProduct	1149
41834816	420	424	Mad2	GeneOrGeneProduct	56150
41834816	570	575	Cidea	GeneOrGeneProduct	1149
41834816	580	588	glycemia	ChemicalEntity	D001786
41834816	706	711	Cidea	GeneOrGeneProduct	1149
41834816	716	733	dopaminergic drug	ChemicalEntity	D004298
41834816	777	782	Cidea	GeneOrGeneProduct	1149
41834816	787	804	dopaminergic drug	ChemicalEntity	D004298
41834816	854	871	dopaminergic drug	ChemicalEntity	D004298
41834816	877	885	resistin	GeneOrGeneProduct	56729
41834816	914	919	Cidea	GeneOrGeneProduct	1149
41834816	1040	1048	resistin	GeneOrGeneProduct	56729
41834816	1053	1069	propidium iodide	ChemicalEntity	D011419
41834816	1121	1137	propidium iodide	ChemicalEntity	D011419
41834816	1142	1150	resistin	GeneOrGeneProduct	56729
41834816	1295	1305	creatinine	ChemicalEntity	D003404
41834816	1310	1315	IRS-1	GeneOrGeneProduct	3667
41834816	1336	1346	creatinine	ChemicalEntity	D003404
41834816	1351	1356	Cidea	GeneOrGeneProduct	1149
41834816	1495	1500	IRS-1	GeneOrGeneProduct	3667
41834816	1505	1512	Arsenic	ChemicalEntity	D001151
41834816	1526	1531	IRS-1	GeneOrGeneProduct	3667
41834816	1536	1546	nelarabine	ChemicalEntity	C104457
41834816	1661	1669	resistin	GeneOrGeneProduct	56729
41834816	1674	1682	glycemia	ChemicalEntity	D001786
41834816	1719	1727	glycemia	ChemicalEntity	D001786
41834816	1732	1736	Mad2	GeneOrGeneProduct	56150
41834816	1858	1868	nelarabine	ChemicalEntity	C104457
41834816	1873	1878	Cidea	GeneOrGeneProduct	1149
41834816	1899	1909	nelarabine	ChemicalEntity	C104457
41834816	1914	1919	IRS-1	GeneOrGeneProduct	3667
41834816	1937	1947	nelarabine	ChemicalEntity	C104457
41834816	2078	2106	abnormal glucose homeostasis	DiseaseOrPhenotypicFeature	D044882
41834816	Negative_Correlation	D004298	1149	Novel
41834816	Positive_Correlation	56729	D011419	Novel
41834816	Positive_Correlation	1149	56150	Novel
41834816	Positive_Correlation	3667	D001151	Novel
41834816	Positive_Correlation	1149	D004298	Novel
41834816	Negative_Correlation	D011419	56729	Novel
41834816	Negative_Correlation	D001151	3667	Novel
41834816	Negative_Correlation	D011419	3667	Novel
41834816	Negative_Correlation	D001786	1149	Novel
41834816	Negative_Correlation	D003404	3667	Novel
41834816	Negative_Correlation	C104457	1149	Novel
41834816	Positive_Correlation	56729	C104457	Novel
41834816	Negative_Correlation	D003404	1149	Novel
41834816	Negative_Correlation	C104457	3667	Novel
41834816	Positive_Correlation	1149	D011419	Novel
41834816	Positive_Correlation	56729	D001786	Novel
41834816	Negative_Correlation	D004298	56729	Novel
41834816	Negative_Correlation	D001786	56150	Novel

50904890|t|Genetic Variants in RagA-D and Their Associations with Disease in Platonia insignis Mart, Dogs, and West Ni
50904890|a|This study investigates the associations between specific sequence variants and the gene product RagA-D across multiple organisms, including Platonia insignis Mart, dogs, and West Nile virus. The research focuses on the functional and phenotypic implications of genetic variability in these species.   We identified several sequence variants, including R462Q, H194Q, rs2738751, rs1800734, and TGAG deletion, all of which were found to be associated with RagA-D. These associations were observed in both in vitro and in vivo models, suggesting a potential role for these variants in modulating the expression or function of RagA-D.   In Platonia insignis Mart, the variant rs2738751 was found to be significantly correlated with altered RagA-D activity, which may contribute to the organism's immune response. Similarly, in dogs, the variant H194Q showed a strong association with RagA-D expression levels, potentially influencing disease susceptibility.   The variant rs1800734 was linked to RagA-D in both dogs and West Nile virus, indicating a possible evolutionary conservation of this genetic element. The TGAG deletion was found to be associated with reduced RagA-D function in Platonia insignis Mart, while the R462Q variant was linked to increased expression in dogs.   These findings highlight the importance of genetic variability in the regulation of RagA-D across different species and suggest that these variants may serve as potential biomarkers for disease risk and therapeutic targets. Further studies are needed to elucidate the precise mechanisms underlying these associations.
50904890	20	26	RagA-D	GeneOrGeneProduct	117043
50904890	66	88	Platonia insignis Mart	OrganismTaxon	198787
50904890	205	211	RagA-D	GeneOrGeneProduct	117043
50904890	249	271	Platonia insignis Mart	OrganismTaxon	198787
50904890	273	277	dogs	OrganismTaxon	9615
50904890	283	298	West Nile virus	OrganismTaxon	11082
50904890	461	466	R462Q	SequenceVariant	rs486907
50904890	468	473	H194Q	SequenceVariant	rs74315522
50904890	475	484	rs2738751	SequenceVariant	rs2738751
50904890	486	495	rs1800734	SequenceVariant	rs1800734
50904890	501	514	TGAG deletion	SequenceVariant	c|DEL||TGAG
50904890	562	568	RagA-D	GeneOrGeneProduct	117043
50904890	731	737	RagA-D	GeneOrGeneProduct	117043
50904890	744	766	Platonia insignis Mart	OrganismTaxon	198787
50904890	780	789	rs2738751	SequenceVariant	rs2738751
50904890	844	850	RagA-D	GeneOrGeneProduct	117043
50904890	931	935	dogs	OrganismTaxon	9615
50904890	949	954	H194Q	SequenceVariant	rs74315522
50904890	988	994	RagA-D	GeneOrGeneProduct	117043
50904890	1076	1085	rs1800734	SequenceVariant	rs1800734
50904890	1100	1106	RagA-D	GeneOrGeneProduct	117043
50904890	1115	1119	dogs	OrganismTaxon	9615
50904890	1124	1139	West Nile virus	OrganismTaxon	11082
50904890	1218	1231	TGAG deletion	SequenceVariant	c|DEL||TGAG
50904890	1272	1278	RagA-D	GeneOrGeneProduct	117043
50904890	1291	1313	Platonia insignis Mart	OrganismTaxon	198787
50904890	1325	1330	R462Q	SequenceVariant	rs486907
50904890	1377	1381	dogs	OrganismTaxon	9615
50904890	1469	1475	RagA-D	GeneOrGeneProduct	117043
50904890	Association	rs2738751	117043	Novel
50904890	Association	rs74315522	117043	Novel
50904890	Association	rs1800734	117043	Novel
50904890	Association	c|DEL||TGAG	117043	Novel
50904890	Association	rs486907	117043	Novel

05948861|t|Ishikawa cell line responses to 4-diphenylacetoxy-N-methylpiperidine-methiodide in S. cerevisiae: implications for maturity-onset diabetes and asparagine
05948861|a|This study investigates the effects of 4-diphenylacetoxy-N-methylpiperidine-methiodide on Ishikawa cells and S. cerevisiae, with a focus on its potential role in maturity-onset diabetes and asparagine deficit. The Ishikawa cell line, known for its relevance in endometrial cancer research, was exposed to varying concentrations of 4-diphenylacetoxy-N-methylpiperidine-methiodide, and its metabolic responses were analyzed. The results showed a positive correlation between 4-diphenylacetoxy-N-methylpiperidine-methiodide and maturity-onset diabetes, suggesting a possible mechanism by which this chemical entity may influence glucose metabolism. Additionally, the study found a positive correlation between 4-diphenylacetoxy-N-methylpiperidine-methiodide and asparagine deficit, indicating a potential link between the chemical and amino acid metabolism.   To further explore these findings, the sequence variant M 235 was examined in relation to 4-diphenylacetoxy-N-methylpiperidine-methiodide. The data revealed a positive correlation between M 235 and 4-diphenylacetoxy-N-methylpiperidine-methiodide, suggesting that this genetic variant may modulate the cellular response to the chemical. The study also included HEK293 cells as a control, demonstrating that the observed effects were specific to the Ishikawa cell line.   The findings were further validated using S. cerevisiae as a model organism, where the same chemical and genetic variant were tested. The results from S. cerevisiae supported the observed correlations in human cell lines, reinforcing the hypothesis that 4-diphenylacetoxy-N-methylpiperidine-methiodide may play a role in the pathogenesis of maturity-onset diabetes and asparagine deficit. These results provide a foundation for future studies aimed at understanding the molecular mechanisms underlying these conditions.
05948861	0	8	Ishikawa	CellLine	CVCL_2529
05948861	32	79	4-diphenylacetoxy-N-methylpiperidine-methiodide	ChemicalEntity	C042375
05948861	83	96	S. cerevisiae	OrganismTaxon	4932
05948861	115	138	maturity-onset diabetes	DiseaseOrPhenotypicFeature	D003924
05948861	193	240	4-diphenylacetoxy-N-methylpiperidine-methiodide	ChemicalEntity	C042375
05948861	244	252	Ishikawa	CellLine	CVCL_2529
05948861	263	276	S. cerevisiae	OrganismTaxon	4932
05948861	316	339	maturity-onset diabetes	DiseaseOrPhenotypicFeature	D003924
05948861	344	362	asparagine deficit	DiseaseOrPhenotypicFeature	OMIM:615574
05948861	368	376	Ishikawa	CellLine	CVCL_2529
05948861	485	532	4-diphenylacetoxy-N-methylpiperidine-methiodide	ChemicalEntity	C042375
05948861	627	674	4-diphenylacetoxy-N-methylpiperidine-methiodide	ChemicalEntity	C042375
05948861	679	702	maturity-onset diabetes	DiseaseOrPhenotypicFeature	D003924
05948861	861	908	4-diphenylacetoxy-N-methylpiperidine-methiodide	ChemicalEntity	C042375
05948861	913	931	asparagine deficit	DiseaseOrPhenotypicFeature	OMIM:615574
05948861	1067	1072	M 235	SequenceVariant	p|Allele|M|235
05948861	1101	1148	4-diphenylacetoxy-N-methylpiperidine-methiodide	ChemicalEntity	C042375
05948861	1199	1204	M 235	SequenceVariant	p|Allele|M|235
05948861	1209	1256	4-diphenylacetoxy-N-methylpiperidine-methiodide	ChemicalEntity	C042375
05948861	1371	1377	HEK293	CellLine	CVCL_0045
05948861	1459	1467	Ishikawa	CellLine	CVCL_2529
05948861	1523	1536	S. cerevisiae	OrganismTaxon	4932
05948861	1632	1645	S. cerevisiae	OrganismTaxon	4932
05948861	1735	1782	4-diphenylacetoxy-N-methylpiperidine-methiodide	ChemicalEntity	C042375
05948861	1822	1845	maturity-onset diabetes	DiseaseOrPhenotypicFeature	D003924
05948861	1850	1868	asparagine deficit	DiseaseOrPhenotypicFeature	OMIM:615574
05948861	Positive_Correlation	C042375	D003924	Novel
05948861	Positive_Correlation	p|Allele|M|235	C042375	Novel
05948861	Positive_Correlation	C042375	OMIM:615574	Novel

59264136|t|Platonia insignis Mart and homogentisic acid metabolism: insights from DCP gene expression in LNCaP and Mz-ChA-1 ce
59264136|a|Platonia insignis Mart, a species of the genus Platonia, has been studied for its potential role in the metabolism of homogentisic acid, a compound with implications in various metabolic pathways. This study investigates the expression of the DCP gene, which is involved in the regulation of homogentisic acid metabolism, in two distinct cell lines: LNCaP and Mz-ChA-1. The research highlights the differential expression of DCP in these cell lines and its potential impact on homogentisic acid processing.   The study was conducted using RNA extracted from both LNCaP and Mz-ChA-1 cell lines, which are commonly used in cancer research. The DCP gene was amplified and sequenced to confirm its presence and expression levels. Homogentisic acid levels were measured in the culture media of these cell lines, and the results showed a significant correlation between DCP expression and homogentisic acid concentration.   Further analysis revealed that Platonia insignis Mart, when introduced into the culture environment, influenced the metabolic activity of these cell lines. The presence of Platonia insignis Mart was associated with increased homogentisic acid metabolism, suggesting a potential role for this organism in modulating the metabolic pathways of these cell lines.   The findings suggest that the interaction between Platonia insignis Mart and the DCP gene may have implications for the metabolism of homogentisic acid in both in vitro and potentially in vivo settings. This study provides a foundation for further research into the role of Platonia insignis Mart in metabolic regulation and its potential therapeutic applications.
59264136	0	22	Platonia insignis Mart	OrganismTaxon	198787
59264136	27	44	homogentisic acid	ChemicalEntity	D006713
59264136	71	74	DCP	GeneOrGeneProduct	2147
59264136	94	99	LNCaP	CellLine	CVCL_0395
59264136	104	112	Mz-ChA-1	CellLine	CVCL_6932
59264136	116	138	Platonia insignis Mart	OrganismTaxon	198787
59264136	234	251	homogentisic acid	ChemicalEntity	D006713
59264136	359	362	DCP	GeneOrGeneProduct	2147
59264136	408	425	homogentisic acid	ChemicalEntity	D006713
59264136	466	471	LNCaP	CellLine	CVCL_0395
59264136	476	484	Mz-ChA-1	CellLine	CVCL_6932
59264136	541	544	DCP	GeneOrGeneProduct	2147
59264136	593	610	homogentisic acid	ChemicalEntity	D006713
59264136	679	684	LNCaP	CellLine	CVCL_0395
59264136	689	697	Mz-ChA-1	CellLine	CVCL_6932
59264136	758	761	DCP	GeneOrGeneProduct	2147
59264136	980	983	DCP	GeneOrGeneProduct	2147
59264136	999	1016	homogentisic acid	ChemicalEntity	D006713
59264136	1065	1087	Platonia insignis Mart	OrganismTaxon	198787
59264136	1206	1228	Platonia insignis Mart	OrganismTaxon	198787
59264136	1259	1276	homogentisic acid	ChemicalEntity	D006713
59264136	1445	1467	Platonia insignis Mart	OrganismTaxon	198787
59264136	1476	1479	DCP	GeneOrGeneProduct	2147
59264136	1529	1546	homogentisic acid	ChemicalEntity	D006713
59264136	1669	1691	Platonia insignis Mart	OrganismTaxon	198787

48289655|t|Phenylephrine, Warfarin, and the Adrenoleukodystrophy Gene: Interactions in Chick and Horse Models Using hRPTEC and RAW 264.7 Ce
48289655|a|This study investigates the complex interactions between phenylephrine, warfarin, and the Adrenoleukodystrophy gene across multiple biological systems, including chick and horse models, and utilizing hRPTEC and RAW 264.7 cell lines. The research highlights the dual nature of phenylephrine's relationship with the Adrenoleukodystrophy gene, revealing both positive and negative correlations. In chick models, phenylephrine was found to positively correlate with the expression of the Adrenoleukodystrophy gene, while in horse models, a negative correlation was observed. These findings suggest that the impact of phenylephrine on the Adrenoleukodystrophy gene may vary depending on the organism and cellular context.   Warfarin's interactions with the Adrenoleukodystrophy gene were also explored, showing both positive and negative correlations. In chick models, warfarin exhibited a positive correlation with the gene, whereas in horse models, a negative correlation was noted. This variability underscores the need for species-specific analysis when studying gene-drug interactions.   The study also examined the cotreatment of phenylephrine and warfarin, revealing that their combined use in chick and horse models led to distinct biological outcomes. In particular, the cotreatment of phenylephrine and warfarin in hRPTEC and RAW 264.7 cell lines demonstrated a synergistic effect on the Adrenoleukodystrophy gene, with phenylephrine enhancing the gene's expression while warfarin suppressed it. These findings suggest that the interplay between these two chemicals may have therapeutic implications in certain contexts.   The results of this study provide a comprehensive understanding of the molecular mechanisms underlying the interactions between phenylephrine, warfarin, and the Adrenoleukodystrophy gene, offering valuable insights for future research and clinical applications.
48289655	105	111	hRPTEC	CellLine	CVCL_K278
48289655	116	125	RAW 264.7	CellLine	CVCL_0493
48289655	186	199	phenylephrine	ChemicalEntity	D010656
48289655	201	209	warfarin	ChemicalEntity	D014859
48289655	219	244	Adrenoleukodystrophy gene	GeneOrGeneProduct	215
48289655	291	296	chick	OrganismTaxon	9031
48289655	329	335	hRPTEC	CellLine	CVCL_K278
48289655	340	349	RAW 264.7	CellLine	CVCL_0493
48289655	405	418	phenylephrine	ChemicalEntity	D010656
48289655	443	468	Adrenoleukodystrophy gene	GeneOrGeneProduct	215
48289655	524	529	chick	OrganismTaxon	9031
48289655	538	551	phenylephrine	ChemicalEntity	D010656
48289655	613	638	Adrenoleukodystrophy gene	GeneOrGeneProduct	215
48289655	742	755	phenylephrine	ChemicalEntity	D010656
48289655	763	788	Adrenoleukodystrophy gene	GeneOrGeneProduct	215
48289655	881	906	Adrenoleukodystrophy gene	GeneOrGeneProduct	215
48289655	979	984	chick	OrganismTaxon	9031
48289655	993	1001	warfarin	ChemicalEntity	D014859
48289655	1260	1273	phenylephrine	ChemicalEntity	D010656
48289655	1278	1286	warfarin	ChemicalEntity	D014859
48289655	1325	1330	chick	OrganismTaxon	9031
48289655	1419	1432	phenylephrine	ChemicalEntity	D010656
48289655	1437	1445	warfarin	ChemicalEntity	D014859
48289655	1449	1455	hRPTEC	CellLine	CVCL_K278
48289655	1460	1469	RAW 264.7	CellLine	CVCL_0493
48289655	1522	1547	Adrenoleukodystrophy gene	GeneOrGeneProduct	215
48289655	1554	1567	phenylephrine	ChemicalEntity	D010656
48289655	1606	1614	warfarin	ChemicalEntity	D014859
48289655	1885	1898	phenylephrine	ChemicalEntity	D010656
48289655	1900	1908	warfarin	ChemicalEntity	D014859
48289655	1918	1943	Adrenoleukodystrophy gene	GeneOrGeneProduct	215
48289655	Negative_Correlation	D010656	215	Novel
48289655	Cotreatment	D010656	D014859	Novel
48289655	Positive_Correlation	D010656	215	Novel
48289655	Negative_Correlation	D014859	215	Novel
48289655	Positive_Correlation	D014859	215	Novel
48289655	Cotreatment	D014859	D010656	Novel

66037118|t|Hodgkin lymphoma, malignant hyperthermia, and recessive osteogenesis imperfecta: interactions with CAA, 30delG, and salvianolic acid A in bovine and DEN-
66037118|a|Recent studies have explored the complex interplay between genetic variants, chemical entities, and disease phenotypes in both human and animal models. This research focuses on the associations between Hodgkin lymphoma, malignant hyperthermia, and recessive osteogenesis imperfecta, and their relationships with the chemical entities CAA and salvianolic acid A, as well as the sequence variant 30delG. In bovine models, the presence of 30delG was found to have a negative correlation with recessive osteogenesis imperfecta, suggesting a potential protective role against the disease. Conversely, 30delG showed a positive correlation with malignant hyperthermia, indicating a possible exacerbating effect. The association between 30delG and salvianolic acid A was also observed, with salvianolic acid A potentially modulating the expression or function of the variant. Furthermore, CAA was found to be associated with both Hodgkin lymphoma and malignant hyperthermia, highlighting its potential role in disease pathogenesis. In DEN-2 models, the repeated exposure to the organism taxon DEN-2 was linked to the development of Hodgkin lymphoma, while the presence of the rabbit model provided additional insights into the pharmacological effects of salvianolic acid A. These findings underscore the importance of understanding the molecular mechanisms underlying these associations and their implications for therapeutic interventions in both human and animal health.
66037118	0	16	Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
66037118	18	40	malignant hyperthermia	DiseaseOrPhenotypicFeature	D008305
66037118	46	79	recessive osteogenesis imperfecta	DiseaseOrPhenotypicFeature	D010013
66037118	99	102	CAA	ChemicalEntity	C004656
66037118	104	110	30delG	SequenceVariant	c|DEL|30|G
66037118	116	134	salvianolic acid A	ChemicalEntity	C066201
66037118	138	144	bovine	OrganismTaxon	9913
66037118	356	372	Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
66037118	374	396	malignant hyperthermia	DiseaseOrPhenotypicFeature	D008305
66037118	402	435	recessive osteogenesis imperfecta	DiseaseOrPhenotypicFeature	D010013
66037118	488	491	CAA	ChemicalEntity	C004656
66037118	496	514	salvianolic acid A	ChemicalEntity	C066201
66037118	548	554	30delG	SequenceVariant	c|DEL|30|G
66037118	559	565	bovine	OrganismTaxon	9913
66037118	590	596	30delG	SequenceVariant	c|DEL|30|G
66037118	643	676	recessive osteogenesis imperfecta	DiseaseOrPhenotypicFeature	D010013
66037118	750	756	30delG	SequenceVariant	c|DEL|30|G
66037118	792	814	malignant hyperthermia	DiseaseOrPhenotypicFeature	D008305
66037118	883	889	30delG	SequenceVariant	c|DEL|30|G
66037118	894	912	salvianolic acid A	ChemicalEntity	C066201
66037118	937	955	salvianolic acid A	ChemicalEntity	C066201
66037118	1035	1038	CAA	ChemicalEntity	C004656
66037118	1076	1092	Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
66037118	1097	1119	malignant hyperthermia	DiseaseOrPhenotypicFeature	D008305
66037118	1181	1186	DEN-2	OrganismTaxon	11060
66037118	1239	1244	DEN-2	OrganismTaxon	11060
66037118	1278	1294	Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
66037118	1322	1328	rabbit	OrganismTaxon	9986
66037118	1400	1418	salvianolic acid A	ChemicalEntity	C066201
66037118	Association	D006689	C004656	Novel
66037118	Negative_Correlation	c|DEL|30|G	D010013	Novel
66037118	Association	c|DEL|30|G	C066201	Novel
66037118	Positive_Correlation	c|DEL|30|G	D008305	Novel
66037118	Association	D008305	C004656	Novel
66037118	Association	C004656	D008305	Novel
66037118	Association	C004656	D006689	Novel

88850734|t|c.429_452dup in HCT116 cells and its interaction with etomidate: a mechanistic and pharmacologic
88850734|a|The sequence variant c.429_452dup in the HCT116 cell line has been shown to exhibit a positive correlation with the chemical entity etomidate. This relationship was observed in multiple experimental conditions, including in vitro assays and pharmacological studies. The HCT116 cell line, which is frequently used in cancer research, was found to respond differently to etomidate when the c.429_452dup variant was present. Specifically, the presence of c.429_452dup in HCT116 cells was associated with increased sensitivity to etomidate, suggesting a potential mechanism by which this sequence variant may modulate the pharmacological effects of etomidate.   Further analysis revealed a positive correlation between etomidate and c.429_452dup in the HCT116 cell line, indicating that the variant may influence the binding affinity or metabolic processing of etomidate. This was supported by biochemical assays showing enhanced etomidate uptake in HCT116 cells harboring the c.429_452dup variant. Additionally, the variant was found to alter the expression levels of genes involved in etomidate metabolism, further reinforcing the positive correlation between the sequence variant and the chemical entity.   The study also included multiple instances of the HCT116 cell line and the sequence variant c.429_452dup, as well as repeated mentions of etomidate, to ensure the robustness of the findings. These results suggest that the c.429_452dup variant may play a significant role in the pharmacological response to etomidate in HCT116 cells, and further research is warranted to explore its implications in broader biological contexts.
88850734	0	12	c.429_452dup	SequenceVariant	c|DUP|429_452||
88850734	16	22	HCT116	CellLine	CVCL_0291
88850734	54	63	etomidate	ChemicalEntity	D005045
88850734	118	130	c.429_452dup	SequenceVariant	c|DUP|429_452||
88850734	138	144	HCT116	CellLine	CVCL_0291
88850734	229	238	etomidate	ChemicalEntity	D005045
88850734	367	373	HCT116	CellLine	CVCL_0291
88850734	466	475	etomidate	ChemicalEntity	D005045
88850734	485	497	c.429_452dup	SequenceVariant	c|DUP|429_452||
88850734	549	561	c.429_452dup	SequenceVariant	c|DUP|429_452||
88850734	565	571	HCT116	CellLine	CVCL_0291
88850734	623	632	etomidate	ChemicalEntity	D005045
88850734	742	751	etomidate	ChemicalEntity	D005045
88850734	812	821	etomidate	ChemicalEntity	D005045
88850734	826	838	c.429_452dup	SequenceVariant	c|DUP|429_452||
88850734	846	852	HCT116	CellLine	CVCL_0291
88850734	954	963	etomidate	ChemicalEntity	D005045
88850734	1023	1032	etomidate	ChemicalEntity	D005045
88850734	1043	1049	HCT116	CellLine	CVCL_0291
88850734	1070	1082	c.429_452dup	SequenceVariant	c|DUP|429_452||
88850734	1180	1189	etomidate	ChemicalEntity	D005045
88850734	1353	1359	HCT116	CellLine	CVCL_0291
88850734	1395	1407	c.429_452dup	SequenceVariant	c|DUP|429_452||
88850734	1441	1450	etomidate	ChemicalEntity	D005045
88850734	1525	1537	c.429_452dup	SequenceVariant	c|DUP|429_452||
88850734	1609	1618	etomidate	ChemicalEntity	D005045
88850734	1622	1628	HCT116	CellLine	CVCL_0291
88850734	Positive_Correlation	c|DUP|429_452||	D005045	Novel
88850734	Positive_Correlation	D005045	c|DUP|429_452||	Novel

34050345|t|miR-483-3p, CCL4, and their interactions with osteomyelitis, NMS, skin reactions, and peters anomaly in Drosophila, ginseng, and human immunodeficiency viru
34050345|a|This study explores the complex interactions between miR-483-3p, CCL4, and various disease phenotypes including osteomyelitis, NMS, skin reactions, and peters anomaly across multiple biological systems. Using Drosophila as a model organism, we investigate the regulatory relationships between miR-483-3p and CCL4, and their associations with disease states. Our findings reveal a positive correlation between miR-483-3p and osteomyelitis, while a negative correlation is observed between miR-483-3p and osteomyelitis in certain contexts. Additionally, miR-483-3p shows a positive correlation with skin reactions and peters anomaly, and a negative correlation with peters anomaly in some cases.   CCL4 is associated with osteomyelitis, NMS, and skin reactions, with both positive and negative correlations observed. Notably, CCL4 exhibits a positive correlation with NMS and a negative correlation with NMS in different experimental conditions. The relationship between CCL4 and peters anomaly is complex, with both positive and negative correlations reported. Furthermore, CCL4 is associated with miR-483-3p, and there is evidence of a bind between CCL4 and miR-483-3p.   The study also examines the role of ginseng in modulating these interactions, suggesting potential therapeutic applications. In human immunodeficiency virus models, the interplay between miR-483-3p, CCL4, and disease phenotypes is further explored, highlighting the importance of these molecular interactions in disease progression. Overall, this research provides a comprehensive understanding of the regulatory networks involving miR-483-3p and CCL4 in the context of multiple diseases and organisms.
34050345	0	10	miR-483-3p	GeneOrGeneProduct	723874
34050345	12	16	CCL4	GeneOrGeneProduct	6351
34050345	46	59	osteomyelitis	DiseaseOrPhenotypicFeature	D010019
34050345	61	64	NMS	DiseaseOrPhenotypicFeature	D009459
34050345	66	80	skin reactions	DiseaseOrPhenotypicFeature	D003875
34050345	86	100	peters anomaly	DiseaseOrPhenotypicFeature	C537884
34050345	104	114	Drosophila	OrganismTaxon	7227
34050345	116	123	ginseng	OrganismTaxon	4054
34050345	210	220	miR-483-3p	GeneOrGeneProduct	723874
34050345	222	226	CCL4	GeneOrGeneProduct	6351
34050345	269	282	osteomyelitis	DiseaseOrPhenotypicFeature	D010019
34050345	284	287	NMS	DiseaseOrPhenotypicFeature	D009459
34050345	289	303	skin reactions	DiseaseOrPhenotypicFeature	D003875
34050345	309	323	peters anomaly	DiseaseOrPhenotypicFeature	C537884
34050345	366	376	Drosophila	OrganismTaxon	7227
34050345	450	460	miR-483-3p	GeneOrGeneProduct	723874
34050345	465	469	CCL4	GeneOrGeneProduct	6351
34050345	566	576	miR-483-3p	GeneOrGeneProduct	723874
34050345	581	594	osteomyelitis	DiseaseOrPhenotypicFeature	D010019
34050345	645	655	miR-483-3p	GeneOrGeneProduct	723874
34050345	660	673	osteomyelitis	DiseaseOrPhenotypicFeature	D010019
34050345	709	719	miR-483-3p	GeneOrGeneProduct	723874
34050345	754	768	skin reactions	DiseaseOrPhenotypicFeature	D003875
34050345	773	787	peters anomaly	DiseaseOrPhenotypicFeature	C537884
34050345	821	835	peters anomaly	DiseaseOrPhenotypicFeature	C537884
34050345	853	857	CCL4	GeneOrGeneProduct	6351
34050345	877	890	osteomyelitis	DiseaseOrPhenotypicFeature	D010019
34050345	892	895	NMS	DiseaseOrPhenotypicFeature	D009459
34050345	901	915	skin reactions	DiseaseOrPhenotypicFeature	D003875
34050345	981	985	CCL4	GeneOrGeneProduct	6351
34050345	1023	1026	NMS	DiseaseOrPhenotypicFeature	D009459
34050345	1059	1062	NMS	DiseaseOrPhenotypicFeature	D009459
34050345	1126	1130	CCL4	GeneOrGeneProduct	6351
34050345	1135	1149	peters anomaly	DiseaseOrPhenotypicFeature	C537884
34050345	1230	1234	CCL4	GeneOrGeneProduct	6351
34050345	1254	1264	miR-483-3p	GeneOrGeneProduct	723874
34050345	1306	1310	CCL4	GeneOrGeneProduct	6351
34050345	1315	1325	miR-483-3p	GeneOrGeneProduct	723874
34050345	1365	1372	ginseng	OrganismTaxon	4054
34050345	1457	1485	human immunodeficiency virus	OrganismTaxon	12721
34050345	1516	1526	miR-483-3p	GeneOrGeneProduct	723874
34050345	1528	1532	CCL4	GeneOrGeneProduct	6351
34050345	1761	1771	miR-483-3p	GeneOrGeneProduct	723874
34050345	1776	1780	CCL4	GeneOrGeneProduct	6351
34050345	Positive_Correlation	723874	D010019	Novel
34050345	Association	6351	D009459	Novel
34050345	Negative_Correlation	723874	D010019	Novel
34050345	Association	6351	D010019	Novel
34050345	Association	D009459	6351	Novel
34050345	Positive_Correlation	723874	D003875	Novel
34050345	Association	D009459	723874	Novel
34050345	Association	6351	723874	Novel
34050345	Negative_Correlation	723874	C537884	Novel
34050345	Negative_Correlation	6351	C537884	Novel
34050345	Negative_Correlation	D009459	6351	Novel
34050345	Association	723874	D003875	Novel
34050345	Positive_Correlation	C537884	6351	Novel
34050345	Association	723874	C537884	Novel
34050345	Positive_Correlation	D003875	723874	Novel
34050345	Positive_Correlation	6351	D010019	Novel
34050345	Association	D003875	6351	Novel
34050345	Negative_Correlation	723874	6351	Novel
34050345	Negative_Correlation	6351	D009459	Novel
34050345	Association	D010019	723874	Novel
34050345	Association	6351	C537884	Novel
34050345	Negative_Correlation	C537884	6351	Novel
34050345	Association	D010019	6351	Novel
34050345	Positive_Correlation	D003875	6351	Novel
34050345	Positive_Correlation	6351	D003875	Novel
34050345	Association	C537884	6351	Novel
34050345	Positive_Correlation	D009459	6351	Novel
34050345	Negative_Correlation	6351	D010019	Novel
34050345	Positive_Correlation	723874	C537884	Novel
34050345	Positive_Correlation	6351	C537884	Novel
34050345	Bind	6351	723874	Novel
34050345	Association	723874	6351	Novel
34050345	Negative_Correlation	D010019	723874	Novel
34050345	Association	6351	D003875	Novel
34050345	Positive_Correlation	6351	D009459	Novel
34050345	Positive_Correlation	723874	D009459	Novel
34050345	Negative_Correlation	D010019	6351	Novel

26926887|t|Mineralocorticoid and Testosterone Modulation of Laminin and BCL2-Interacting Killer: Effects of Sequence Variants and Cotreatment with DMSO
26926887|a|This study investigates the interplay between mineralocorticoid receptor signaling, testosterone levels, and the expression of laminin and BCL2-interacting killer in response to genetic sequence variants and chemical cotreatment. We examined the effects of the sequence variants T3801C, V876E, and p.A384D on the expression of laminin and BCL2-interacting killer in cultured cells. The results showed that the T3801C variant significantly increased laminin expression, while the V876E variant led to a decrease in BCL2-interacting killer levels. The p.A384D variant was found to have a moderate effect on both proteins.   To assess the impact of chemical cotreatment, we evaluated the combined effects of DMSO and EFV on the expression of these proteins. The cotreatment of DMSO and EFV was found to enhance the expression of laminin and BCL2-interacting killer, suggesting a potential synergistic effect. Furthermore, a positive correlation was observed between BCL2-interacting killer levels and DMSO concentration, indicating that DMSO may play a role in modulating the expression of this gene product.   Testosterone was also found to influence the expression of laminin, with higher levels associated with increased laminin production. The study also included multiple instances of mineralocorticoid and DMSO, highlighting their roles in the regulation of these proteins. These findings provide new insights into the molecular mechanisms underlying the interactions between mineralocorticoids, testosterone, and the expression of laminin and BCL2-interacting killer, with implications for therapeutic strategies involving sequence variants and chemical cotreatment.
26926887	22	34	Testosterone	ChemicalEntity	D013739
26926887	136	140	DMSO	ChemicalEntity	D004121
26926887	187	204	mineralocorticoid	ChemicalEntity	D008901
26926887	268	275	laminin	GeneOrGeneProduct	16777
26926887	280	303	BCL2-interacting killer	GeneOrGeneProduct	638
26926887	420	426	T3801C	SequenceVariant	g|SUB|T|3801|C
26926887	428	433	V876E	SequenceVariant	rs267606698
26926887	439	446	p.A384D	SequenceVariant	p|SUB|A|384|D
26926887	468	475	laminin	GeneOrGeneProduct	16777
26926887	480	503	BCL2-interacting killer	GeneOrGeneProduct	638
26926887	551	557	T3801C	SequenceVariant	g|SUB|T|3801|C
26926887	590	597	laminin	GeneOrGeneProduct	16777
26926887	620	625	V876E	SequenceVariant	rs267606698
26926887	655	678	BCL2-interacting killer	GeneOrGeneProduct	638
26926887	691	698	p.A384D	SequenceVariant	p|SUB|A|384|D
26926887	846	850	DMSO	ChemicalEntity	D004121
26926887	855	858	EFV	ChemicalEntity	C098320
26926887	915	919	DMSO	ChemicalEntity	D004121
26926887	924	927	EFV	ChemicalEntity	C098320
26926887	967	974	laminin	GeneOrGeneProduct	16777
26926887	979	1002	BCL2-interacting killer	GeneOrGeneProduct	638
26926887	1104	1127	BCL2-interacting killer	GeneOrGeneProduct	638
26926887	1139	1143	DMSO	ChemicalEntity	D004121
26926887	1175	1179	DMSO	ChemicalEntity	D004121
26926887	1249	1261	Testosterone	ChemicalEntity	D013739
26926887	1308	1315	laminin	GeneOrGeneProduct	16777
26926887	1362	1369	laminin	GeneOrGeneProduct	16777
26926887	1428	1445	mineralocorticoid	ChemicalEntity	D008901
26926887	1450	1454	DMSO	ChemicalEntity	D004121
26926887	1620	1637	mineralocorticoid	ChemicalEntity	D008901
26926887	1676	1683	laminin	GeneOrGeneProduct	16777
26926887	1688	1711	BCL2-interacting killer	GeneOrGeneProduct	638
26926887	Cotreatment	D004121	C098320	Novel
26926887	Positive_Correlation	638	D004121	Novel

31615680|t|Hyperventilation and Sal-induced changes in rabbit physiology: implications for Leber congenital amaurosis and the role of nevirapine and S-1 in Spirulina and do
31615680|a|Hyperventilation, a common respiratory response, has been observed in rabbits under various experimental conditions. This study investigates the effects of Sal, a novel chemical entity, on hyperventilation patterns in rabbits, with particular attention to its potential role in modulating respiratory physiology. The findings suggest that Sal may influence hyperventilation through mechanisms involving the 2172_2173insCCCC sequence variant, which has been previously associated with altered gene expression in rabbits.    In addition to its effects on hyperventilation, Sal was found to interact with nevirapine, a well-known antiretroviral drug, in a manner that may have implications for the treatment of urticaria. The study also explores the potential therapeutic use of S-1, another chemical entity, in conjunction with Spirulina, a cyanobacterial organism, in the context of Leber congenital amaurosis. The results indicate that Spirulina may have protective effects against the progression of this inherited retinal disease, particularly in rabbit models.    Furthermore, the study examines the impact of nevirapine on hyperventilation in dogs, revealing a complex interplay between the drug and the respiratory system. The presence of the 2172_2173insCCCC sequence variant in dogs was found to modulate the response to nevirapine, suggesting a genetic basis for variability in drug efficacy. The findings highlight the importance of considering genetic factors when evaluating the effects of chemical entities like Sal and nevirapine on respiratory and ocular conditions.
31615680	21	24	Sal	ChemicalEntity	C009172
31615680	44	50	rabbit	OrganismTaxon	9986
31615680	80	106	Leber congenital amaurosis	DiseaseOrPhenotypicFeature	D057130
31615680	123	133	nevirapine	ChemicalEntity	D019829
31615680	138	141	S-1	ChemicalEntity	C079198
31615680	145	154	Spirulina	OrganismTaxon	551299
31615680	232	238	rabbit	OrganismTaxon	9986
31615680	318	321	Sal	ChemicalEntity	C009172
31615680	351	367	hyperventilation	DiseaseOrPhenotypicFeature	D006985
31615680	380	386	rabbit	OrganismTaxon	9986
31615680	501	504	Sal	ChemicalEntity	C009172
31615680	519	535	hyperventilation	DiseaseOrPhenotypicFeature	D006985
31615680	569	585	2172_2173insCCCC	SequenceVariant	c|INS|2172_2173|CCCC
31615680	673	679	rabbit	OrganismTaxon	9986
31615680	715	731	hyperventilation	DiseaseOrPhenotypicFeature	D006985
31615680	733	736	Sal	ChemicalEntity	C009172
31615680	764	774	nevirapine	ChemicalEntity	D019829
31615680	870	879	urticaria	DiseaseOrPhenotypicFeature	D014581
31615680	938	941	S-1	ChemicalEntity	C079198
31615680	988	997	Spirulina	OrganismTaxon	551299
31615680	1044	1070	Leber congenital amaurosis	DiseaseOrPhenotypicFeature	D057130
31615680	1098	1107	Spirulina	OrganismTaxon	551299
31615680	1211	1217	rabbit	OrganismTaxon	9986
31615680	1275	1285	nevirapine	ChemicalEntity	D019829
31615680	1289	1305	hyperventilation	DiseaseOrPhenotypicFeature	D006985
31615680	1309	1313	dogs	OrganismTaxon	9615
31615680	1410	1426	2172_2173insCCCC	SequenceVariant	c|INS|2172_2173|CCCC
31615680	1447	1451	dogs	OrganismTaxon	9615
31615680	1490	1500	nevirapine	ChemicalEntity	D019829
31615680	1686	1689	Sal	ChemicalEntity	C009172
31615680	1694	1704	nevirapine	ChemicalEntity	D019829

09292849|t|Modulation of N-methyl-D-aspartate receptor 1 and UP III expression in SNU-C5 and MCF-7 cells by DAPT and c
09292849|a|This study investigates the effects of DAPT and carbachol on the expression of N-methyl-D-aspartate receptor 1 and UP III in the cell lines SNU-C5 and MCF-7. DAPT, a gamma-secretase inhibitor, was found to significantly modulate the expression levels of N-methyl-D-aspartate receptor 1 in both SNU-C5 and MCF-7 cells. Similarly, carbachol, an acetylcholine analog, was shown to influence the expression of UP III in these cell lines. Notably, the drug interaction between carbachol and DAPT was observed to enhance the regulatory effects on N-methyl-D-aspartate receptor 1 in SNU-C5 cells. Conversely, the drug interaction between DAPT and carbachol was found to suppress UP III expression in MCF-7 cells. These findings suggest that the combined use of DAPT and carbachol may have synergistic or antagonistic effects on the expression of these genes in different cell contexts. Further studies are required to elucidate the molecular mechanisms underlying these interactions and their potential therapeutic implications.
09292849	14	45	N-methyl-D-aspartate receptor 1	GeneOrGeneProduct	14810
09292849	50	56	UP III	GeneOrGeneProduct	22270
09292849	71	77	SNU-C5	CellLine	CVCL_5112
09292849	82	87	MCF-7	CellLine	CVCL_0031
09292849	97	101	DAPT	ChemicalEntity	C419410
09292849	147	151	DAPT	ChemicalEntity	C419410
09292849	156	165	carbachol	ChemicalEntity	D002217
09292849	187	218	N-methyl-D-aspartate receptor 1	GeneOrGeneProduct	14810
09292849	223	229	UP III	GeneOrGeneProduct	22270
09292849	248	254	SNU-C5	CellLine	CVCL_5112
09292849	259	264	MCF-7	CellLine	CVCL_0031
09292849	266	270	DAPT	ChemicalEntity	C419410
09292849	362	393	N-methyl-D-aspartate receptor 1	GeneOrGeneProduct	14810
09292849	402	408	SNU-C5	CellLine	CVCL_5112
09292849	413	418	MCF-7	CellLine	CVCL_0031
09292849	437	446	carbachol	ChemicalEntity	D002217
09292849	514	520	UP III	GeneOrGeneProduct	22270
09292849	580	589	carbachol	ChemicalEntity	D002217
09292849	594	598	DAPT	ChemicalEntity	C419410
09292849	649	680	N-methyl-D-aspartate receptor 1	GeneOrGeneProduct	14810
09292849	684	690	SNU-C5	CellLine	CVCL_5112
09292849	739	743	DAPT	ChemicalEntity	C419410
09292849	748	757	carbachol	ChemicalEntity	D002217
09292849	780	786	UP III	GeneOrGeneProduct	22270
09292849	801	806	MCF-7	CellLine	CVCL_0031
09292849	862	866	DAPT	ChemicalEntity	C419410
09292849	871	880	carbachol	ChemicalEntity	D002217
09292849	Drug_Interaction	D002217	C419410	Novel
09292849	Drug_Interaction	C419410	D002217	Novel

48960896|t|Genetic and functional interactions of ubiquitin carboxyl-terminal esterase L1 with sequence variants in Rhodiola rosea and Capan1 ce
48960896|a|This study investigates the functional and genetic interactions between the ubiquitin carboxyl-terminal esterase L1 (UCHL1) gene and several sequence variants, including G12D, p.Val37Ile, and CAG repeat, in the context of Rhodiola rosea, Capan1 cell lines, and mouse mammary tumor virus. The research highlights the complex associations between these genetic elements and their potential roles in cellular processes.   The study demonstrates a significant association between the G12D sequence variant and the UCHL1 gene, suggesting a possible functional link that may influence protein stability and enzymatic activity. Furthermore, the CAG repeat variant is found to be closely associated with both G12D and p.Val37Ile, indicating a potential regulatory or structural interaction between these variants. The p.Val37Ile variant is also shown to have a strong association with UCHL1, reinforcing the idea of a shared genetic pathway or functional overlap.  In the Capan1 cell line, the presence of G12D and CAG repeat variants is linked to altered expression levels of UCHL1, suggesting a possible role in tumor progression. The study also reveals that the CAG repeat variant is associated with p.Val37Ile, further supporting the hypothesis of a network of genetic interactions involving these variants.   The findings are further validated in guinea-pigs and Escherichia coli models, where the associations between G12D, CAG repeat, and p.Val37Ile are consistently observed. The repeated associations between G12D and itself, as well as between p.Val37Ile and CAG repeat, suggest a potential feedback mechanism or self-regulatory loop within the genetic network.   These results provide a comprehensive framework for understanding the genetic and functional relationships between UCHL1 and the sequence variants, with implications for both basic research and potential therapeutic applications in diseases involving these genetic elements.
48960896	39	78	ubiquitin carboxyl-terminal esterase L1	GeneOrGeneProduct	7345
48960896	105	119	Rhodiola rosea	OrganismTaxon	203015
48960896	124	130	Capan1	CellLine	CVCL_0237
48960896	210	249	ubiquitin carboxyl-terminal esterase L1	GeneOrGeneProduct	7345
48960896	304	308	G12D	SequenceVariant	p|SUB|G|12|D
48960896	304	308	G12D	SequenceVariant	rs121913529
48960896	310	320	p.Val37Ile	SequenceVariant	rs72474224
48960896	326	336	CAG repeat	SequenceVariant	c|DUP||CAG|
48960896	356	370	Rhodiola rosea	OrganismTaxon	203015
48960896	372	378	Capan1	CellLine	CVCL_0237
48960896	395	420	mouse mammary tumor virus	OrganismTaxon	11757
48960896	614	618	G12D	SequenceVariant	p|SUB|G|12|D
48960896	614	618	G12D	SequenceVariant	rs121913529
48960896	772	782	CAG repeat	SequenceVariant	c|DUP||CAG|
48960896	835	839	G12D	SequenceVariant	p|SUB|G|12|D
48960896	835	839	G12D	SequenceVariant	rs121913529
48960896	844	854	p.Val37Ile	SequenceVariant	rs72474224
48960896	944	954	p.Val37Ile	SequenceVariant	rs72474224
48960896	1098	1104	Capan1	CellLine	CVCL_0237
48960896	1132	1136	G12D	SequenceVariant	p|SUB|G|12|D
48960896	1132	1136	G12D	SequenceVariant	rs121913529
48960896	1141	1151	CAG repeat	SequenceVariant	c|DUP||CAG|
48960896	1291	1301	CAG repeat	SequenceVariant	c|DUP||CAG|
48960896	1329	1339	p.Val37Ile	SequenceVariant	rs72474224
48960896	1478	1489	guinea-pigs	OrganismTaxon	10141
48960896	1494	1510	Escherichia coli	OrganismTaxon	562
48960896	1550	1554	G12D	SequenceVariant	p|SUB|G|12|D
48960896	1550	1554	G12D	SequenceVariant	rs121913529
48960896	1556	1566	CAG repeat	SequenceVariant	c|DUP||CAG|
48960896	1572	1582	p.Val37Ile	SequenceVariant	rs72474224
48960896	1644	1648	G12D	SequenceVariant	p|SUB|G|12|D
48960896	1644	1648	G12D	SequenceVariant	rs121913529
48960896	1680	1690	p.Val37Ile	SequenceVariant	rs72474224
48960896	1695	1705	CAG repeat	SequenceVariant	c|DUP||CAG|
48960896	Association	c|DUP||CAG|	p|SUB|G|12|D	Novel
48960896	Association	rs121913529	7345	Novel
48960896	Association	rs121913529	c|DUP||CAG|	Novel
48960896	Association	rs121913529	rs72474224	Novel
48960896	Association	rs72474224	p|SUB|G|12|D	Novel
48960896	Association	c|DUP||CAG|	rs121913529	Novel
48960896	Association	rs72474224	7345	Novel
48960896	Association	c|DUP||CAG|	rs72474224	Novel
48960896	Association	rs72474224	rs121913529	Novel
48960896	Association	p|SUB|G|12|D	rs72474224	Novel
48960896	Association	c|DUP||CAG|	7345	Novel
48960896	Association	p|SUB|G|12|D	c|DUP||CAG|	Novel
48960896	Association	p|SUB|G|12|D	rs121913529	Novel
48960896	Association	rs72474224	c|DUP||CAG|	Novel

39101544|t|HK2 and diabetes insipidus: a zebrafish model reveals sequence variant-associated phenotypic correlations and functional impl
39101544|a|In this study, we investigate the relationship between the gene HK2 and the disease diabetes insipidus using a zebrafish model. Our findings reveal a positive correlation between HK2 expression and the manifestation of diabetes insipidus in zebrafish, as well as a direct association between HK2 and the phenotypic features of diabetes insipidus. We observed that the sequence variant Y329fs is significantly enriched in zebrafish models exhibiting diabetes insipidus, suggesting a potential functional role in disease pathogenesis. Additionally, the sequence variant 55M/L was found to be associated with altered HK2 function, further supporting the link between HK2 and diabetes insipidus. Our results were validated across multiple zebrafish strains, including Danio rerio, and were consistent across 13 different zebrafish taxon groups. The study also included analysis of Escherichia coli and horses as control organisms, highlighting the specificity of the observed associations. The repeated occurrence of diabetes insipidus in the experimental groups, along with the consistent presence of HK2 and the sequence variants Y329fs and 55M/L, provides strong evidence for the role of HK2 in the development of diabetes insipidus. These findings have important implications for understanding the molecular mechanisms underlying diabetes insipidus and may inform future therapeutic strategies targeting HK2.
39101544	0	3	HK2	GeneOrGeneProduct	25059
39101544	8	26	diabetes insipidus	DiseaseOrPhenotypicFeature	D003919
39101544	30	39	zebrafish	OrganismTaxon	7955
39101544	190	193	HK2	GeneOrGeneProduct	25059
39101544	210	228	diabetes insipidus	DiseaseOrPhenotypicFeature	D003919
39101544	237	246	zebrafish	OrganismTaxon	7955
39101544	305	308	HK2	GeneOrGeneProduct	25059
39101544	345	363	diabetes insipidus	DiseaseOrPhenotypicFeature	D003919
39101544	367	376	zebrafish	OrganismTaxon	7955
39101544	418	421	HK2	GeneOrGeneProduct	25059
39101544	453	471	diabetes insipidus	DiseaseOrPhenotypicFeature	D003919
39101544	511	517	Y329fs	SequenceVariant	p|FS|Y|329||
39101544	547	556	zebrafish	OrganismTaxon	7955
39101544	575	593	diabetes insipidus	DiseaseOrPhenotypicFeature	D003919
39101544	694	699	55M/L	SequenceVariant	p|SUB|M|55|L
39101544	740	743	HK2	GeneOrGeneProduct	25059
39101544	790	793	HK2	GeneOrGeneProduct	25059
39101544	798	816	diabetes insipidus	DiseaseOrPhenotypicFeature	D003919
39101544	861	870	zebrafish	OrganismTaxon	7955
39101544	890	901	Danio rerio	OrganismTaxon	7955
39101544	943	952	zebrafish	OrganismTaxon	7955
39101544	1003	1019	Escherichia coli	OrganismTaxon	562
39101544	1024	1030	horses	OrganismTaxon	9796
39101544	1139	1157	diabetes insipidus	DiseaseOrPhenotypicFeature	D003919
39101544	1224	1227	HK2	GeneOrGeneProduct	25059
39101544	1254	1260	Y329fs	SequenceVariant	p|FS|Y|329||
39101544	1265	1270	55M/L	SequenceVariant	p|SUB|M|55|L
39101544	1313	1316	HK2	GeneOrGeneProduct	25059
39101544	1339	1357	diabetes insipidus	DiseaseOrPhenotypicFeature	D003919
39101544	1456	1474	diabetes insipidus	DiseaseOrPhenotypicFeature	D003919
39101544	1530	1533	HK2	GeneOrGeneProduct	25059
39101544	Positive_Correlation	D003919	25059	Novel
39101544	Association	25059	D003919	Novel

25639631|t|ETS2 and its interactions with insulin, enflurane, and diclofenac in the context of HBV mono-infected individuals and cerebellar hy
25639631|a|This study investigates the complex interactions between the transcription factor ETS2 and various chemical entities, including insulin, enflurane, and diclofenac, in the context of HBV mono-infected individuals and cerebellar hypoplasia. We also explore the genetic associations between sequence variants and phenotypic features. Our findings reveal a negative correlation between ETS2 and insulin, as well as between ETS2 and enflurane, suggesting that ETS2 may modulate the metabolic and pharmacological responses to these agents. Additionally, we observe a negative correlation between ETS2 and diclofenac, further supporting the role of ETS2 in drug metabolism and response.   The study also reports a drug interaction between enflurane and diclofenac, which may have implications for anesthetic and anti-inflammatory therapies. Furthermore, we find a drug interaction between enflurane and insulin, as well as between diclofenac and insulin, indicating potential synergistic or antagonistic effects in metabolic pathways. These interactions are further supported by the drug interaction between insulin and enflurane, and between insulin and diclofenac, highlighting the need for careful monitoring in clinical settings involving these agents.  Genetically, we identify an association between the sequence variant 1284A>C and the nine nucleotide insertion, suggesting a potential functional link between these variants. This association is further reinforced by the co-occurrence of these genetic elements in the context of HBV mono-infected individuals and cerebellar hypoplasia. The presence of cerebellar hypoplasia and AF (atrial fibrillation) in some of the HBV mono-infected individuals adds complexity to the phenotypic landscape, suggesting that these conditions may be influenced by both genetic and environmental factors.  Our results provide a comprehensive view of the interplay between ETS2, chemical entities, and genetic variants in the context of HBV mono-infection and related phenotypes, offering new insights into the molecular mechanisms underlying these conditions.
25639631	0	4	ETS2	GeneOrGeneProduct	2114
25639631	31	38	insulin	ChemicalEntity	D007328
25639631	40	49	enflurane	ChemicalEntity	D004737
25639631	55	65	diclofenac	ChemicalEntity	D004008
25639631	84	101	HBV mono-infected	DiseaseOrPhenotypicFeature	D006509
25639631	214	218	ETS2	GeneOrGeneProduct	2114
25639631	260	267	insulin	ChemicalEntity	D007328
25639631	269	278	enflurane	ChemicalEntity	D004737
25639631	284	294	diclofenac	ChemicalEntity	D004008
25639631	314	331	HBV mono-infected	DiseaseOrPhenotypicFeature	D006509
25639631	348	369	cerebellar hypoplasia	DiseaseOrPhenotypicFeature	C562568
25639631	514	518	ETS2	GeneOrGeneProduct	2114
25639631	523	530	insulin	ChemicalEntity	D007328
25639631	551	555	ETS2	GeneOrGeneProduct	2114
25639631	560	569	enflurane	ChemicalEntity	D004737
25639631	587	591	ETS2	GeneOrGeneProduct	2114
25639631	722	726	ETS2	GeneOrGeneProduct	2114
25639631	731	741	diclofenac	ChemicalEntity	D004008
25639631	774	778	ETS2	GeneOrGeneProduct	2114
25639631	864	873	enflurane	ChemicalEntity	D004737
25639631	878	888	diclofenac	ChemicalEntity	D004008
25639631	1014	1023	enflurane	ChemicalEntity	D004737
25639631	1028	1035	insulin	ChemicalEntity	D007328
25639631	1056	1066	diclofenac	ChemicalEntity	D004008
25639631	1071	1078	insulin	ChemicalEntity	D007328
25639631	1233	1240	insulin	ChemicalEntity	D007328
25639631	1245	1254	enflurane	ChemicalEntity	D004737
25639631	1268	1275	insulin	ChemicalEntity	D007328
25639631	1280	1290	diclofenac	ChemicalEntity	D004008
25639631	1452	1459	1284A>C	SequenceVariant	c|SUB|A|1284|C
25639631	1468	1493	nine nucleotide insertion	SequenceVariant	c|INS||9
25639631	1662	1679	HBV mono-infected	DiseaseOrPhenotypicFeature	D006509
25639631	1696	1717	cerebellar hypoplasia	DiseaseOrPhenotypicFeature	C562568
25639631	1735	1756	cerebellar hypoplasia	DiseaseOrPhenotypicFeature	C562568
25639631	1761	1763	AF	DiseaseOrPhenotypicFeature	D001281
25639631	1801	1818	HBV mono-infected	DiseaseOrPhenotypicFeature	D006509
25639631	2037	2041	ETS2	GeneOrGeneProduct	2114
25639631	Negative_Correlation	2114	D007328	Novel
25639631	Negative_Correlation	2114	D004737	Novel
25639631	Drug_Interaction	D004737	D004008	Novel
25639631	Association	c|INS||9	c|SUB|A|1284|C	Novel
25639631	Drug_Interaction	D004008	D004737	Novel
25639631	Drug_Interaction	D004737	D007328	Novel
25639631	Drug_Interaction	D004008	D007328	Novel
25639631	Association	c|SUB|A|1284|C	c|INS||9	Novel
25639631	Drug_Interaction	D007328	D004008	Novel
25639631	Negative_Correlation	2114	D004008	Novel
25639631	Drug_Interaction	D007328	D004737	Novel

65515976|t|Functional interactions and regulatory networks involving CARD8, Bax, and glial fibrillary acidic protein in diverse ce
65515976|a|This study investigates the functional interactions and regulatory networks involving CARD8, Bax, and glial fibrillary acidic protein (GFAP) across multiple cell lines. Using a combination of biochemical assays and molecular profiling, we demonstrate that CARD8 binds to both Bax and GFAP, suggesting a potential role for CARD8 in modulating apoptotic pathways. Additionally, we observe a negative correlation between CARD8 and Bax, which may indicate a regulatory relationship in cellular stress responses.   Our findings also reveal a significant association between Bax and GFAP, with Bax showing a direct binding interaction with GFAP. Furthermore, we establish a negative correlation between the IGF-1 receptor and GFAP, and a binding interaction between GFAP and the IGF-1 receptor. These results suggest that GFAP may act as a central hub in a regulatory network involving CARD8, Bax, and the IGF-1 receptor.   The study was conducted using a panel of cell lines including MCF-7, SMMC-7721, Ba/F3, hRPTEC, SNU-C5, MES-SA/Dx5, SNU-C2A, IEC-6, KU7, and SW480. Genetic variants such as p.R34X, P163S, P163S, R227Q, (CCTTT)13, p.N102DfsX4, p.D815A, Arg389Gly, del642T, c.742_744delTAC, and R211H were analyzed for their potential impact on these interactions. The results highlight the complex interplay between these proteins and their variants in different cellular contexts, providing new insights into the molecular mechanisms underlying cellular regulation and disease.
65515976	58	63	CARD8	GeneOrGeneProduct	22900
65515976	65	68	Bax	GeneOrGeneProduct	24887
65515976	74	105	glial fibrillary acidic protein	GeneOrGeneProduct	24387
65515976	206	211	CARD8	GeneOrGeneProduct	22900
65515976	213	216	Bax	GeneOrGeneProduct	24887
65515976	222	253	glial fibrillary acidic protein	GeneOrGeneProduct	24387
65515976	376	381	CARD8	GeneOrGeneProduct	22900
65515976	396	399	Bax	GeneOrGeneProduct	24887
65515976	442	447	CARD8	GeneOrGeneProduct	22900
65515976	538	543	CARD8	GeneOrGeneProduct	22900
65515976	548	551	Bax	GeneOrGeneProduct	24887
65515976	689	692	Bax	GeneOrGeneProduct	24887
65515976	708	711	Bax	GeneOrGeneProduct	24887
65515976	821	835	IGF-1 receptor	GeneOrGeneProduct	16001
65515976	893	907	IGF-1 receptor	GeneOrGeneProduct	16001
65515976	1000	1005	CARD8	GeneOrGeneProduct	22900
65515976	1007	1010	Bax	GeneOrGeneProduct	24887
65515976	1020	1034	IGF-1 receptor	GeneOrGeneProduct	16001
65515976	1100	1105	MCF-7	CellLine	CVCL_0031
65515976	1107	1116	SMMC-7721	CellLine	CVCL_0534
65515976	1118	1123	Ba/F3	CellLine	CVCL_0161
65515976	1125	1131	hRPTEC	CellLine	CVCL_K278
65515976	1133	1139	SNU-C5	CellLine	CVCL_5112
65515976	1141	1151	MES-SA/Dx5	CellLine	CVCL_2598
65515976	1153	1160	SNU-C2A	CellLine	CVCL_1709
65515976	1162	1167	IEC-6	CellLine	CVCL_0343
65515976	1169	1172	KU7	CellLine	CVCL_4714
65515976	1178	1183	SW480	CellLine	CVCL_0546
65515976	1210	1216	p.R34X	SequenceVariant	rs121908073
65515976	1218	1223	P163S	SequenceVariant	rs387906769
65515976	1225	1230	P163S	SequenceVariant	rs387906769
65515976	1232	1237	R227Q	SequenceVariant	rs9332964
65515976	1239	1248	(CCTTT)13	SequenceVariant	c|DUP||CCTTT|13
65515976	1250	1261	p.N102DfsX4	SequenceVariant	p|FS|N|102|D|4
65515976	1263	1270	p.D815A	SequenceVariant	p|SUB|D|815|A
65515976	1272	1281	Arg389Gly	SequenceVariant	p|SUB|R|389|G
65515976	1283	1290	del642T	SequenceVariant	c|DEL|642|T
65515976	1292	1307	c.742_744delTAC	SequenceVariant	rs267606574
65515976	1313	1318	R211H	SequenceVariant	p|SUB|R|211|H
65515976	Bind	22900	24387	Novel
65515976	Negative_Correlation	24387	16001	Novel
65515976	Association	24887	24387	Novel
65515976	Negative_Correlation	16001	24387	Novel
65515976	Bind	24387	16001	Novel
65515976	Bind	22900	24887	Novel
65515976	Negative_Correlation	22900	24887	Novel
65515976	Association	24887	22900	Novel

18108513|t|Genetic and pharmacological modulation of cell line responses to chemical entities and sequence 
18108513|a|This study investigates the interplay between genetic sequence variants, chemical entities, and their effects on cellular responses in multiple cell lines. We focused on the cell lines HK-2, CD18/HPAF, Ishikawa, and SNU-C5, and examined their interactions with the chemical entities agar, alpha-methyl-para-tyrosine, 5-Aza-2'-deoxy-cytidine, MK-801, and the sequence variants rs729302, rs10942891, 111G, and the arginine residue for the proline residue at position 158.   Our findings reveal a significant association between the sequence variant rs10942891 and the chemical entity agar, suggesting a potential regulatory role of this variant in agar metabolism or response. Additionally, we observed a positive correlation between the chemical entity 5-Aza-2'-deoxy-cytidine and the sequence variant rs729302, indicating that 5-Aza-2'-deoxy-cytidine may influence the expression or stability of rs729302.   Furthermore, the arginine residue for the proline residue at position 158 was found to be associated with agar, highlighting a possible structural or functional interaction between this sequence variant and the chemical entity. These results provide new insights into the molecular mechanisms underlying the interactions between genetic variants, chemical entities, and cellular responses in different cell lines. The study underscores the importance of considering both genetic and pharmacological factors in understanding cellular behavior and response to external stimuli.
18108513	282	286	HK-2	CellLine	CVCL_0302
18108513	288	297	CD18/HPAF	CellLine	CVCL_0313
18108513	299	307	Ishikawa	CellLine	CVCL_2529
18108513	313	319	SNU-C5	CellLine	CVCL_5112
18108513	380	384	agar	ChemicalEntity	D000362
18108513	386	412	alpha-methyl-para-tyrosine	ChemicalEntity	D019805
18108513	414	437	5-Aza-2'-deoxy-cytidine	ChemicalEntity	D000077209
18108513	439	445	MK-801	ChemicalEntity	D016291
18108513	473	481	rs729302	SequenceVariant	rs729302
18108513	483	493	rs10942891	SequenceVariant	rs10942891
18108513	495	499	111G	SequenceVariant	c|Allele|G|111
18108513	509	565	arginine residue for the proline residue at position 158	SequenceVariant	p|SUB|R|158|P
18108513	644	654	rs10942891	SequenceVariant	rs10942891
18108513	679	683	agar	ChemicalEntity	D000362
18108513	743	747	agar	ChemicalEntity	D000362
18108513	849	872	5-Aza-2'-deoxy-cytidine	ChemicalEntity	D000077209
18108513	898	906	rs729302	SequenceVariant	rs729302
18108513	924	947	5-Aza-2'-deoxy-cytidine	ChemicalEntity	D000077209
18108513	993	1001	rs729302	SequenceVariant	rs729302
18108513	1022	1078	arginine residue for the proline residue at position 158	SequenceVariant	p|SUB|R|158|P
18108513	1111	1115	agar	ChemicalEntity	D000362
18108513	Association	rs10942891	D000362	Novel
18108513	Positive_Correlation	D000077209	rs729302	Novel
18108513	Association	p|SUB|R|158|P	D000362	Novel

31358628|t|Myogenic factor 5 and its interactions with anesthetics, Fentanyl, and sequence variants in cell lines and gene re
31358628|a|Myogenic factor 5 (Myo5) plays a critical role in muscle development and has been implicated in various cellular processes. This study investigates the interactions between Myo5 and anesthetics, particularly Fentanyl, in different cell lines and their impact on gene expression and sequence variant stability. We focused on the cell lines SF188, RAW 264.7, and HEK, which were exposed to varying concentrations of Fentanyl and other anesthetics. Our findings reveal a significant bind and association between Fentanyl and Myo5, suggesting a potential mechanism by which anesthetics may modulate myogenic gene expression. Additionally, we observed that the sequence variant R211H in Myo5 is more prevalent in RAW 264.7 cells compared to SF188 and HEK, indicating possible functional differences in these cell types. The study also explored the effects of dopamine D2 receptor antagonists on Myo5 expression, with notable changes observed in HEK cells. Furthermore, we examined the interaction between Myo5 and other genes such as PQBP1, SLC2A2, and PARK2, finding that PQBP1 exhibits a strong bind and association with Fentanyl, which may have implications for neurodevelopmental disorders. These results highlight the complex interplay between Myo5, anesthetics, and sequence variants in cellular function and disease pathogenesis.
31358628	44	55	anesthetics	ChemicalEntity	D000777
31358628	57	65	Fentanyl	ChemicalEntity	D005283
31358628	297	308	anesthetics	ChemicalEntity	D000777
31358628	323	331	Fentanyl	ChemicalEntity	D005283
31358628	454	459	SF188	CellLine	CVCL_6948
31358628	461	470	RAW 264.7	CellLine	CVCL_0493
31358628	476	479	HEK	CellLine	CVCL_M624
31358628	529	537	Fentanyl	ChemicalEntity	D005283
31358628	548	559	anesthetics	ChemicalEntity	D000777
31358628	624	632	Fentanyl	ChemicalEntity	D005283
31358628	685	696	anesthetics	ChemicalEntity	D000777
31358628	788	793	R211H	SequenceVariant	p|SUB|R|211|H
31358628	823	832	RAW 264.7	CellLine	CVCL_0493
31358628	851	856	SF188	CellLine	CVCL_6948
31358628	861	864	HEK	CellLine	CVCL_M624
31358628	969	1001	dopamine D2 receptor antagonists	ChemicalEntity	D065127
31358628	1055	1058	HEK	CellLine	CVCL_M624
31358628	1144	1149	PQBP1	GeneOrGeneProduct	10084
31358628	1151	1157	SLC2A2	GeneOrGeneProduct	6514
31358628	1163	1168	PARK2	GeneOrGeneProduct	5071
31358628	1183	1188	PQBP1	GeneOrGeneProduct	10084
31358628	1233	1241	Fentanyl	ChemicalEntity	D005283
31358628	1365	1376	anesthetics	ChemicalEntity	D000777
31358628	Bind	10084	D005283	Novel
31358628	Association	D005283	10084	Novel

99668364|t|CD79a, CD44, and VEGF receptor 2 interactions in Aedes mosquitoes and human cell lines: implications for tumor progression and immune 
99668364|a|This study investigates the molecular interactions between CD79a, CD44, and VEGF receptor 2 in both Aedes mosquitoes and human cell lines, with a focus on their roles in tumor progression and immune response. Using a combination of immunoprecipitation, co-localization assays, and gene expression profiling, we demonstrate a positive correlation between CD79a and VEGF receptor 2 in SJ-GBM2 and MH134 cell lines. This correlation is further supported by the observation that both proteins are co-expressed in the same cellular compartments in Aedes mosquitoes.   We also report an association between CD44 and glutamate NMDA receptor in SNU-C5 and SUM159PT cell lines, which is consistent with their shared involvement in cell adhesion and signaling pathways. Additionally, we find that VEGF receptor 2 interacts with IkB kinaseb in SJ-GBM2 and IEC-6 cell lines, suggesting a potential regulatory role in inflammatory responses. The binding of IkB kinaseb to CD44 is confirmed in Ba/F3 and HeLa cell lines, highlighting a possible mechanism for modulating immune cell activation.  Furthermore, the glutamate NMDA receptor is shown to bind CD44 in MH134 and SUM159PT cell lines, reinforcing the idea of a complex network of interactions between these proteins. A positive correlation between glutamate NMDA receptor and CD79a is observed in SJ-GBM2 and IEC-6 cell lines, which may have implications for the regulation of B-cell signaling.   Interestingly, the study also includes data from Mangifera indica Linn, where the expression of CD79a and VEGF receptor 2 is found to be upregulated in response to environmental stressors, suggesting a potential role in plant defense mechanisms. In mouse models, the association between IkB kinaseb and VEGF receptor 2 is further validated, indicating a conserved pathway across species. These findings provide new insights into the functional roles of these proteins in both human and non-human systems.
99668364	0	5	CD79a	GeneOrGeneProduct	12518
99668364	7	11	CD44	GeneOrGeneProduct	960
99668364	17	32	VEGF receptor 2	GeneOrGeneProduct	16542
99668364	49	65	Aedes mosquitoes	OrganismTaxon	1245352
99668364	194	199	CD79a	GeneOrGeneProduct	12518
99668364	201	205	CD44	GeneOrGeneProduct	960
99668364	211	226	VEGF receptor 2	GeneOrGeneProduct	16542
99668364	235	251	Aedes mosquitoes	OrganismTaxon	1245352
99668364	489	494	CD79a	GeneOrGeneProduct	12518
99668364	499	514	VEGF receptor 2	GeneOrGeneProduct	16542
99668364	518	525	SJ-GBM2	CellLine	CVCL_M141
99668364	530	535	MH134	CellLine	CVCL_8111
99668364	678	694	Aedes mosquitoes	OrganismTaxon	1245352
99668364	736	740	CD44	GeneOrGeneProduct	960
99668364	745	768	glutamate NMDA receptor	GeneOrGeneProduct	24408
99668364	772	778	SNU-C5	CellLine	CVCL_5112
99668364	783	791	SUM159PT	CellLine	CVCL_5423
99668364	922	937	VEGF receptor 2	GeneOrGeneProduct	16542
99668364	953	964	IkB kinaseb	GeneOrGeneProduct	3551
99668364	968	975	SJ-GBM2	CellLine	CVCL_M141
99668364	980	985	IEC-6	CellLine	CVCL_0343
99668364	1079	1090	IkB kinaseb	GeneOrGeneProduct	3551
99668364	1094	1098	CD44	GeneOrGeneProduct	960
99668364	1115	1120	Ba/F3	CellLine	CVCL_0161
99668364	1125	1129	HeLa	CellLine	CVCL_0030
99668364	1233	1256	glutamate NMDA receptor	GeneOrGeneProduct	24408
99668364	1274	1278	CD44	GeneOrGeneProduct	960
99668364	1282	1287	MH134	CellLine	CVCL_8111
99668364	1292	1300	SUM159PT	CellLine	CVCL_5423
99668364	1426	1449	glutamate NMDA receptor	GeneOrGeneProduct	24408
99668364	1454	1459	CD79a	GeneOrGeneProduct	12518
99668364	1475	1482	SJ-GBM2	CellLine	CVCL_M141
99668364	1487	1492	IEC-6	CellLine	CVCL_0343
99668364	1624	1645	Mangifera indica Linn	OrganismTaxon	29780
99668364	1671	1676	CD79a	GeneOrGeneProduct	12518
99668364	1681	1696	VEGF receptor 2	GeneOrGeneProduct	16542
99668364	1824	1829	mouse	OrganismTaxon	10090
99668364	1862	1873	IkB kinaseb	GeneOrGeneProduct	3551
99668364	1878	1893	VEGF receptor 2	GeneOrGeneProduct	16542
99668364	Positive_Correlation	12518	16542	Novel
99668364	Association	960	24408	Novel
99668364	Association	16542	3551	Novel
99668364	Bind	3551	960	Novel
99668364	Bind	24408	960	Novel
99668364	Association	3551	16542	Novel
99668364	Positive_Correlation	24408	12518	Novel

17645986|t|Genetic Variants in Daucus carota and Mangifera indica Linn: Functional and Structural Implications in Viral and Cellular 
17645986|a|This study investigates the functional and structural implications of multiple sequence variants in the context of Daucus carota, Mangifera indica Linn, and West Nile virus. The focus is on the interplay between genetic variability and biological function, particularly in relation to cellular responses and viral interactions. The sequence variants c.1092 +1G>A, c.689C>G, and L351A are examined in detail, with particular emphasis on their associations with Q126R and other variants.   The c.1092 +1G>A variant is found to be associated with Q126R, as well as with L351A, suggesting a potential functional link between these genetic elements. Similarly, the c.689C>G variant is associated with both L351A and Q126R, indicating a complex network of interactions. The L351A variant is further linked to Q126R and c.1092 +1G>A, reinforcing the idea of a coordinated genetic response. These associations are explored in the context of C57BL/6J and BALB/c cell lines, which are used to model the biological effects of these variants.  The study also examines the role of Daucus carota and Mangifera indica Linn in modulating these genetic interactions, suggesting that plant-derived compounds may influence the expression or function of these variants. The West Nile virus is used as a model to assess the impact of these genetic changes on viral replication and host response.   The findings highlight the importance of understanding the interplay between genetic variants and their biological consequences, particularly in the context of cellular and viral systems. The results provide a foundation for further research into the functional significance of these sequence variants in both plant and animal models.
17645986	20	33	Daucus carota	OrganismTaxon	4039
17645986	38	59	Mangifera indica Linn	OrganismTaxon	29780
17645986	238	251	Daucus carota	OrganismTaxon	4039
17645986	253	274	Mangifera indica Linn	OrganismTaxon	29780
17645986	280	295	West Nile virus	OrganismTaxon	11082
17645986	473	485	c.1092 +1G>A	SequenceVariant	c|SUB|G|1092+1|A
17645986	487	495	c.689C>G	SequenceVariant	c|SUB|C|689|G
17645986	501	506	L351A	SequenceVariant	p|SUB|L|351|A
17645986	583	588	Q126R	SequenceVariant	rs368386747
17645986	615	627	c.1092 +1G>A	SequenceVariant	c|SUB|G|1092+1|A
17645986	667	672	Q126R	SequenceVariant	rs368386747
17645986	690	695	L351A	SequenceVariant	p|SUB|L|351|A
17645986	783	791	c.689C>G	SequenceVariant	c|SUB|C|689|G
17645986	824	829	L351A	SequenceVariant	p|SUB|L|351|A
17645986	834	839	Q126R	SequenceVariant	rs368386747
17645986	891	896	L351A	SequenceVariant	p|SUB|L|351|A
17645986	926	931	Q126R	SequenceVariant	rs368386747
17645986	936	948	c.1092 +1G>A	SequenceVariant	c|SUB|G|1092+1|A
17645986	1056	1064	C57BL/6J	CellLine	CVCL_5U84
17645986	1069	1075	BALB/c	CellLine	CVCL_9101
17645986	1191	1204	Daucus carota	OrganismTaxon	4039
17645986	1209	1230	Mangifera indica Linn	OrganismTaxon	29780
17645986	1377	1392	West Nile virus	OrganismTaxon	11082
17645986	Association	c|SUB|C|689|G	p|SUB|L|351|A	Novel
17645986	Association	c|SUB|G|1092+1|A	rs368386747	Novel
17645986	Association	rs368386747	c|SUB|G|1092+1|A	Novel
17645986	Association	rs368386747	c|SUB|C|689|G	Novel
17645986	Association	c|SUB|C|689|G	c|SUB|G|1092+1|A	Novel
17645986	Association	p|SUB|L|351|A	rs368386747	Novel
17645986	Association	p|SUB|L|351|A	c|SUB|G|1092+1|A	Novel
17645986	Association	c|SUB|G|1092+1|A	p|SUB|L|351|A	Novel
17645986	Association	rs368386747	p|SUB|L|351|A	Novel

68594276|t|Dibucaine, 5-Aza-2'-deoxy-cytidine, and Arsenic: Interactions with Cell Lines, Genes, and Viruses in Comparative and Functional
68594276|a|This study investigates the molecular and cellular interactions of dibucaine, 5-Aza-2'-deoxy-cytidine, and arsenic with various cell lines and genes, with a focus on their effects on gene expression, protein binding, and functional outcomes. Using BALB/c and DU145 cell lines, we demonstrate a comparison between dibucaine and 5-Aza-2'-deoxy-cytidine, revealing distinct regulatory effects on the erbB4 gene. The association between 5-Aza-2'-deoxy-cytidine and erbB4 is further supported by its positive correlation with erbB4 expression, as well as its positive correlation with PLAU.   Arsenic exhibits a positive correlation with both PLAU and p16, and it binds to p16 and erbB4, suggesting a potential role in modulating these genes. The comparison between arsenic and midazolam reveals distinct effects on p16, with midazolam also binding to p16 and showing a positive correlation with p27. Additionally, midazolam and bombesin are compared, with bombesin binding to p16 and showing a positive correlation with both p27 and erbB4. The association between bombesin and NFkappaB is further supported by its binding to NFkappaB and a positive correlation with NFkappaB and midazolam.  The study also explores the interactions of Topiramate with multiple targets, including NFkappaB, F4/80, and p27, with Topiramate showing a positive correlation with FBXW11 and a comparison with Ca+2 ATPase. Ca+2 ATPase binds to both p16 and erbB4, and it shows a positive correlation with erbB4 and p27. The comparison between Topiramate and dibucaine highlights distinct pharmacological profiles, while the comparison between Topiramate and Ca+2 ATPase reveals functional differences in their interactions with cellular components.  The study further examines the role of thyroid hormone receptor a1 in these interactions, with a positive correlation between thyroid hormone receptor a1 and 5-Aza-2'-deoxy-cytidine. The involvement of various cell lines, including HEK, HCT116, and SNU-C5, as well as the organism taxons such as West Nile virus, cats, hepatitis B virus, and rhesus monkeys, underscores the broad applicability of these findings. The study also includes the analysis of Daucus carota and its potential interactions with the studied compounds, highlighting the diverse biological contexts in which these molecular interactions occur.
68594276	11	34	5-Aza-2'-deoxy-cytidine	ChemicalEntity	D000077209
68594276	40	47	Arsenic	ChemicalEntity	D001151
68594276	195	204	dibucaine	ChemicalEntity	D003992
68594276	206	229	5-Aza-2'-deoxy-cytidine	ChemicalEntity	D000077209
68594276	376	382	BALB/c	CellLine	CVCL_9101
68594276	387	392	DU145	CellLine	CVCL_0105
68594276	441	450	dibucaine	ChemicalEntity	D003992
68594276	455	478	5-Aza-2'-deoxy-cytidine	ChemicalEntity	D000077209
68594276	525	530	erbB4	GeneOrGeneProduct	13869
68594276	561	584	5-Aza-2'-deoxy-cytidine	ChemicalEntity	D000077209
68594276	589	594	erbB4	GeneOrGeneProduct	13869
68594276	649	654	erbB4	GeneOrGeneProduct	13869
68594276	708	712	PLAU	GeneOrGeneProduct	5328
68594276	716	723	Arsenic	ChemicalEntity	D001151
68594276	766	770	PLAU	GeneOrGeneProduct	5328
68594276	775	778	p16	GeneOrGeneProduct	12578
68594276	796	799	p16	GeneOrGeneProduct	12578
68594276	804	809	erbB4	GeneOrGeneProduct	13869
68594276	901	910	midazolam	ChemicalEntity	D008874
68594276	939	942	p16	GeneOrGeneProduct	12578
68594276	949	958	midazolam	ChemicalEntity	D008874
68594276	975	978	p16	GeneOrGeneProduct	12578
68594276	1019	1022	p27	GeneOrGeneProduct	12576
68594276	1038	1047	midazolam	ChemicalEntity	D008874
68594276	1052	1060	bombesin	ChemicalEntity	D001839
68594276	1080	1088	bombesin	ChemicalEntity	D001839
68594276	1100	1103	p16	GeneOrGeneProduct	12578
68594276	1149	1152	p27	GeneOrGeneProduct	12576
68594276	1157	1162	erbB4	GeneOrGeneProduct	13869
68594276	1188	1196	bombesin	ChemicalEntity	D001839
68594276	1201	1209	NFkappaB	GeneOrGeneProduct	18033
68594276	1249	1257	NFkappaB	GeneOrGeneProduct	18033
68594276	1290	1298	NFkappaB	GeneOrGeneProduct	18033
68594276	1303	1312	midazolam	ChemicalEntity	D008874
68594276	1359	1369	Topiramate	ChemicalEntity	D000077236
68594276	1403	1411	NFkappaB	GeneOrGeneProduct	18033
68594276	1413	1418	F4/80	GeneOrGeneProduct	13733
68594276	1424	1427	p27	GeneOrGeneProduct	12576
68594276	1434	1444	Topiramate	ChemicalEntity	D000077236
68594276	1481	1487	FBXW11	GeneOrGeneProduct	23291
68594276	1510	1521	Ca+2 ATPase	ChemicalEntity	D000252
68594276	1523	1534	Ca+2 ATPase	ChemicalEntity	D000252
68594276	1549	1552	p16	GeneOrGeneProduct	12578
68594276	1557	1562	erbB4	GeneOrGeneProduct	13869
68594276	1605	1610	erbB4	GeneOrGeneProduct	13869
68594276	1615	1618	p27	GeneOrGeneProduct	12576
68594276	1643	1653	Topiramate	ChemicalEntity	D000077236
68594276	1658	1667	dibucaine	ChemicalEntity	D003992
68594276	1743	1753	Topiramate	ChemicalEntity	D000077236
68594276	1758	1769	Ca+2 ATPase	ChemicalEntity	D000252
68594276	1889	1916	thyroid hormone receptor a1	GeneOrGeneProduct	7067
68594276	1976	2003	thyroid hormone receptor a1	GeneOrGeneProduct	7067
68594276	2008	2031	5-Aza-2'-deoxy-cytidine	ChemicalEntity	D000077209
68594276	2082	2085	HEK	CellLine	CVCL_M624
68594276	2087	2093	HCT116	CellLine	CVCL_0291
68594276	2099	2105	SNU-C5	CellLine	CVCL_5112
68594276	2146	2161	West Nile virus	OrganismTaxon	11082
68594276	2163	2167	cats	OrganismTaxon	9685
68594276	2169	2186	hepatitis B virus	OrganismTaxon	10407
68594276	2192	2206	rhesus monkeys	OrganismTaxon	9544
68594276	2303	2316	Daucus carota	OrganismTaxon	4039
68594276	Association	D000077209	13869	Novel
68594276	Bind	D008874	12578	Novel
68594276	Positive_Correlation	5328	D001151	Novel
68594276	Comparison	D003992	D000077209	Novel
68594276	Positive_Correlation	12576	D001839	Novel
68594276	Comparison	D008874	D001839	Novel
68594276	Bind	D001839	12578	Novel
68594276	Positive_Correlation	12578	D001839	Novel
68594276	Bind	D001151	13869	Novel
68594276	Association	D000252	13869	Novel
68594276	Bind	D000077236	18033	Novel
68594276	Positive_Correlation	5328	D000077209	Novel
68594276	Association	D001839	18033	Novel
68594276	Bind	D000077236	13733	Novel
68594276	Comparison	D003992	D000077236	Novel
68594276	Comparison	D001151	D008874	Novel
68594276	Positive_Correlation	18033	D008874	Novel
68594276	Comparison	D000077236	D000252	Novel
68594276	Bind	D000252	12578	Novel
68594276	Bind	D000077236	12576	Novel
68594276	Positive_Correlation	13869	D001839	Novel
68594276	Positive_Correlation	13869	D000252	Novel
68594276	Positive_Correlation	23291	D000077236	Novel
68594276	Positive_Correlation	12576	D000252	Novel
68594276	Association	D001151	12578	Novel

37436088|t|PKCalpha, HRH4, and aryl hydrocarbon receptor interacting protein: complex interactions in hyperalgesia and X-linked adrenoleukod
37436088|a|This study investigates the intricate molecular relationships between PKCalpha, HRH4, and aryl hydrocarbon receptor interacting protein (AhRIP) in the context of hyperalgesia and X-linked adrenoleukodystrophy (X-ALD). Our findings reveal a negative correlation between AhRIP and HRH4, suggesting a regulatory antagonism between these two proteins. Conversely, there is a positive correlation between AhRIP and PKCalpha, indicating a potential functional synergy. PKCalpha is further associated with hyperalgesia, highlighting its role in pain signaling pathways. HRH4 is also positively correlated with X-ALD, suggesting a possible involvement in the pathogenesis of this X-linked disorder. Notably, PKCalpha exhibits a negative correlation with AhRIP, and HRH4 shows a negative correlation with both PKCalpha and hyperalgesia. Additionally, PKCalpha is positively correlated with X-ALD, reinforcing its role in the disease. These results collectively suggest a complex network of interactions among PKCalpha, HRH4, and AhRIP that may contribute to the development of hyperalgesia and X-ALD. Further research is needed to elucidate the precise mechanisms underlying these associations.
37436088	0	8	PKCalpha	GeneOrGeneProduct	5578
37436088	10	14	HRH4	GeneOrGeneProduct	59340
37436088	20	65	aryl hydrocarbon receptor interacting protein	GeneOrGeneProduct	9049
37436088	91	103	hyperalgesia	DiseaseOrPhenotypicFeature	D006930
37436088	200	208	PKCalpha	GeneOrGeneProduct	5578
37436088	210	214	HRH4	GeneOrGeneProduct	59340
37436088	220	265	aryl hydrocarbon receptor interacting protein	GeneOrGeneProduct	9049
37436088	292	304	hyperalgesia	DiseaseOrPhenotypicFeature	D006930
37436088	309	338	X-linked adrenoleukodystrophy	DiseaseOrPhenotypicFeature	D000326
37436088	409	413	HRH4	GeneOrGeneProduct	59340
37436088	540	548	PKCalpha	GeneOrGeneProduct	5578
37436088	593	601	PKCalpha	GeneOrGeneProduct	5578
37436088	629	641	hyperalgesia	DiseaseOrPhenotypicFeature	D006930
37436088	693	697	HRH4	GeneOrGeneProduct	59340
37436088	830	838	PKCalpha	GeneOrGeneProduct	5578
37436088	887	891	HRH4	GeneOrGeneProduct	59340
37436088	931	939	PKCalpha	GeneOrGeneProduct	5578
37436088	944	956	hyperalgesia	DiseaseOrPhenotypicFeature	D006930
37436088	972	980	PKCalpha	GeneOrGeneProduct	5578
37436088	1130	1138	PKCalpha	GeneOrGeneProduct	5578
37436088	1140	1144	HRH4	GeneOrGeneProduct	59340
37436088	1198	1210	hyperalgesia	DiseaseOrPhenotypicFeature	D006930
37436088	Negative_Correlation	9049	59340	Novel
37436088	Association	9049	5578	Novel
37436088	Association	5578	D006930	Novel
37436088	Association	59340	9049	Novel
37436088	Positive_Correlation	59340	D000326	Novel
37436088	Positive_Correlation	5578	59340	Novel
37436088	Positive_Correlation	D006930	5578	Novel
37436088	Negative_Correlation	59340	D006930	Novel
37436088	Negative_Correlation	5578	9049	Novel
37436088	Negative_Correlation	59340	5578	Novel
37436088	Positive_Correlation	5578	D000326	Novel
37436088	Negative_Correlation	D006930	5578	Novel

51971020|t|X-box binding protein, HEK, and hRPTEC: interactions with lower extremity weakness, OPMD, and telaprevir in the context of alcohol, 5-HT(6) receptor antagonists, and Hyp
51971020|a|This study investigates the complex interplay between the X-box binding protein (XBP), HEK cell lines, hRPTEC cell lines, and C4-2B cell lines in relation to lower extremity weakness, OPMD, and Hypotension. The research also explores the effects of alcohol, telaprevir, and 5-HT(6) receptor antagonists on these conditions.   We found a significant association between X-box binding protein and lower extremity weakness, as well as between X-box binding protein and thrombotic microangiopathy. Additionally, X-box binding protein was linked to Hypotension, suggesting a potential role in vascular regulation. The study also revealed a positive correlation between lower extremity weakness and telaprevir, as well as between OPMD and telaprevir, indicating that telaprevir may have therapeutic potential in these conditions.   FasL was found to be associated with both OPMD and lower extremity weakness, and it also showed a connection with Hypotension. Glucagon was linked to OPMD and lower extremity weakness, highlighting its possible involvement in the pathophysiology of these disorders.   The comparison between alcohol and 5-HT(6) receptor antagonists revealed distinct effects on cellular responses, with 5-HT(6) receptor antagonists showing a positive correlation with thrombotic microangiopathy. Furthermore, alcohol was found to have a positive correlation with OPMD, suggesting a potential role in disease progression.   The study also compared alcohol and telaprevir, finding that both substances influence the same pathways, though with different mechanisms. The association between IL-4 and both OPMD and thrombotic microangiopathy suggests a role for this cytokine in inflammatory processes.   Overall, the findings underscore the importance of X-box binding protein, FasL, and glucagon in the development and progression of lower extremity weakness, OPMD, and Hypotension, while also highlighting the potential therapeutic value of telaprevir and 5-HT(6) receptor antagonists in these conditions.
51971020	0	21	X-box binding protein	GeneOrGeneProduct	22433
51971020	23	26	HEK	CellLine	CVCL_M624
51971020	32	38	hRPTEC	CellLine	CVCL_K278
51971020	58	82	lower extremity weakness	DiseaseOrPhenotypicFeature	D020335
51971020	84	88	OPMD	DiseaseOrPhenotypicFeature	D039141
51971020	94	104	telaprevir	ChemicalEntity	C486464
51971020	123	130	alcohol	ChemicalEntity	D000431
51971020	132	160	5-HT(6) receptor antagonists	ChemicalEntity	D012702
51971020	228	249	X-box binding protein	GeneOrGeneProduct	22433
51971020	257	260	HEK	CellLine	CVCL_M624
51971020	273	279	hRPTEC	CellLine	CVCL_K278
51971020	296	301	C4-2B	CellLine	CVCL_4784
51971020	328	352	lower extremity weakness	DiseaseOrPhenotypicFeature	D020335
51971020	354	358	OPMD	DiseaseOrPhenotypicFeature	D039141
51971020	364	375	Hypotension	DiseaseOrPhenotypicFeature	D007022
51971020	419	426	alcohol	ChemicalEntity	D000431
51971020	428	438	telaprevir	ChemicalEntity	C486464
51971020	444	472	5-HT(6) receptor antagonists	ChemicalEntity	D012702
51971020	539	560	X-box binding protein	GeneOrGeneProduct	22433
51971020	565	589	lower extremity weakness	DiseaseOrPhenotypicFeature	D020335
51971020	610	631	X-box binding protein	GeneOrGeneProduct	22433
51971020	636	662	thrombotic microangiopathy	DiseaseOrPhenotypicFeature	D057049
51971020	678	699	X-box binding protein	GeneOrGeneProduct	22433
51971020	714	725	Hypotension	DiseaseOrPhenotypicFeature	D007022
51971020	834	858	lower extremity weakness	DiseaseOrPhenotypicFeature	D020335
51971020	863	873	telaprevir	ChemicalEntity	C486464
51971020	894	898	OPMD	DiseaseOrPhenotypicFeature	D039141
51971020	903	913	telaprevir	ChemicalEntity	C486464
51971020	931	941	telaprevir	ChemicalEntity	C486464
51971020	996	1000	FasL	GeneOrGeneProduct	14103
51971020	1038	1042	OPMD	DiseaseOrPhenotypicFeature	D039141
51971020	1047	1071	lower extremity weakness	DiseaseOrPhenotypicFeature	D020335
51971020	1110	1121	Hypotension	DiseaseOrPhenotypicFeature	D007022
51971020	1146	1150	OPMD	DiseaseOrPhenotypicFeature	D039141
51971020	1155	1179	lower extremity weakness	DiseaseOrPhenotypicFeature	D020335
51971020	1287	1294	alcohol	ChemicalEntity	D000431
51971020	1299	1327	5-HT(6) receptor antagonists	ChemicalEntity	D012702
51971020	1382	1410	5-HT(6) receptor antagonists	ChemicalEntity	D012702
51971020	1447	1473	thrombotic microangiopathy	DiseaseOrPhenotypicFeature	D057049
51971020	1488	1495	alcohol	ChemicalEntity	D000431
51971020	1542	1546	OPMD	DiseaseOrPhenotypicFeature	D039141
51971020	1626	1633	alcohol	ChemicalEntity	D000431
51971020	1638	1648	telaprevir	ChemicalEntity	C486464
51971020	1766	1770	IL-4	GeneOrGeneProduct	16189
51971020	1780	1784	OPMD	DiseaseOrPhenotypicFeature	D039141
51971020	1789	1815	thrombotic microangiopathy	DiseaseOrPhenotypicFeature	D057049
51971020	1930	1951	X-box binding protein	GeneOrGeneProduct	22433
51971020	1953	1957	FasL	GeneOrGeneProduct	14103
51971020	1963	1971	glucagon	GeneOrGeneProduct	14526
51971020	2010	2034	lower extremity weakness	DiseaseOrPhenotypicFeature	D020335
51971020	2036	2040	OPMD	DiseaseOrPhenotypicFeature	D039141
51971020	2046	2057	Hypotension	DiseaseOrPhenotypicFeature	D007022
51971020	2118	2128	telaprevir	ChemicalEntity	C486464
51971020	2133	2161	5-HT(6) receptor antagonists	ChemicalEntity	D012702
51971020	Comparison	D012702	D000431	Novel
51971020	Association	14526	D039141	Novel
51971020	Association	22433	D020335	Novel
51971020	Association	14103	D039141	Novel
51971020	Association	22433	D057049	Novel
51971020	Association	14103	D020335	Novel
51971020	Positive_Correlation	D039141	C486464	Novel
51971020	Positive_Correlation	D057049	D012702	Novel
51971020	Positive_Correlation	D007022	C486464	Novel
51971020	Association	16189	D057049	Novel
51971020	Association	16189	D039141	Novel
51971020	Association	22433	D007022	Novel
51971020	Comparison	D000431	D012702	Novel
51971020	Positive_Correlation	D020335	C486464	Novel
51971020	Positive_Correlation	D039141	D000431	Novel
51971020	Comparison	D000431	C486464	Novel
51971020	Association	14103	D007022	Novel
51971020	Association	14526	D020335	Novel

13668493|t|Genetic and pharmacological interactions of LpA, Bortezomib, and Diazinon in autoimmune diseases and neuron
13668493|a|Recent studies have revealed complex interactions between genetic variants and chemical entities in the context of autoimmune diseases and neuronal death. A key focus has been on the sequence variant c.429_452dup, which shows a positive correlation with headache disorder and is associated with the chemical entity LpA. Additionally, the sequence variant L490R exhibits a positive correlation with headache disorder and is linked to autoimmune diseases. The sequence variant A53T is positively correlated with both autoimmune diseases and headache disorder, and also shows a positive correlation with Bortezomib and Diazinon.   The chemical entity LpA is associated with Bortezomib, Diazinon, and salt, and exhibits positive correlations with L490R, c.429_452dup, and A53T. Bortezomib is also associated with salt and shows positive correlations with LpA and c.429_452dup. Diazinon is associated with LpA and shows a positive correlation with A53T.   In a study involving Saccharomyces cerevisiae, the effects of these genetic and chemical interactions were further explored. The chemical entity Diazinon was found to have a positive correlation with A53T, while salt showed a positive correlation with A53T. The organism taxon dogs was used as a model to study the impact of these interactions on neuronal death.   These findings highlight the intricate relationships between genetic variants and chemical entities in the context of autoimmune diseases, headache disorders, and neuronal death, suggesting potential therapeutic targets and areas for further research.
13668493	44	47	LpA	ChemicalEntity	D008050
13668493	49	59	Bortezomib	ChemicalEntity	D000069286
13668493	65	73	Diazinon	ChemicalEntity	D003976
13668493	77	96	autoimmune diseases	DiseaseOrPhenotypicFeature	D001327
13668493	223	242	autoimmune diseases	DiseaseOrPhenotypicFeature	D001327
13668493	247	261	neuronal death	DiseaseOrPhenotypicFeature	D009410
13668493	308	320	c.429_452dup	SequenceVariant	c|DUP|429_452||
13668493	362	379	headache disorder	DiseaseOrPhenotypicFeature	D020773
13668493	423	426	LpA	ChemicalEntity	D008050
13668493	463	468	L490R	SequenceVariant	rs80338886
13668493	506	523	headache disorder	DiseaseOrPhenotypicFeature	D020773
13668493	541	560	autoimmune diseases	DiseaseOrPhenotypicFeature	D001327
13668493	583	587	A53T	SequenceVariant	p|SUB|A|53|T
13668493	623	642	autoimmune diseases	DiseaseOrPhenotypicFeature	D001327
13668493	647	664	headache disorder	DiseaseOrPhenotypicFeature	D020773
13668493	709	719	Bortezomib	ChemicalEntity	D000069286
13668493	724	732	Diazinon	ChemicalEntity	D003976
13668493	756	759	LpA	ChemicalEntity	D008050
13668493	779	789	Bortezomib	ChemicalEntity	D000069286
13668493	791	799	Diazinon	ChemicalEntity	D003976
13668493	805	809	salt	ChemicalEntity	D012492
13668493	851	856	L490R	SequenceVariant	rs80338886
13668493	858	870	c.429_452dup	SequenceVariant	c|DUP|429_452||
13668493	876	880	A53T	SequenceVariant	p|SUB|A|53|T
13668493	882	892	Bortezomib	ChemicalEntity	D000069286
13668493	917	921	salt	ChemicalEntity	D012492
13668493	959	962	LpA	ChemicalEntity	D008050
13668493	967	979	c.429_452dup	SequenceVariant	c|DUP|429_452||
13668493	981	989	Diazinon	ChemicalEntity	D003976
13668493	1009	1012	LpA	ChemicalEntity	D008050
13668493	1051	1055	A53T	SequenceVariant	p|SUB|A|53|T
13668493	1080	1104	Saccharomyces cerevisiae	OrganismTaxon	4932
13668493	1204	1212	Diazinon	ChemicalEntity	D003976
13668493	1259	1263	A53T	SequenceVariant	p|SUB|A|53|T
13668493	1271	1275	salt	ChemicalEntity	D012492
13668493	1311	1315	A53T	SequenceVariant	p|SUB|A|53|T
13668493	1336	1340	dogs	OrganismTaxon	9615
13668493	1406	1420	neuronal death	DiseaseOrPhenotypicFeature	D009410
13668493	1542	1561	autoimmune diseases	DiseaseOrPhenotypicFeature	D001327
13668493	1563	1580	headache disorder	DiseaseOrPhenotypicFeature	D020773
13668493	1587	1601	neuronal death	DiseaseOrPhenotypicFeature	D009410
13668493	Association	D008050	D000069286	Novel
13668493	Positive_Correlation	D003976	p|SUB|A|53|T	Novel
13668493	Positive_Correlation	D020773	c|DUP|429_452||	Novel
13668493	Association	D012492	D000069286	Novel
13668493	Positive_Correlation	D000069286	p|SUB|A|53|T	Novel
13668493	Association	D003976	D008050	Novel
13668493	Positive_Correlation	D020773	rs80338886	Novel
13668493	Association	D000069286	D008050	Novel
13668493	Positive_Correlation	D001327	p|SUB|A|53|T	Novel
13668493	Positive_Correlation	D008050	rs80338886	Novel
13668493	Positive_Correlation	D008050	c|DUP|429_452||	Novel
13668493	Association	D008050	D003976	Novel
13668493	Positive_Correlation	D000069286	c|DUP|429_452||	Novel
13668493	Positive_Correlation	D012492	p|SUB|A|53|T	Novel
13668493	Association	D008050	D012492	Novel
13668493	Positive_Correlation	D001327	rs80338886	Novel
13668493	Positive_Correlation	D020773	p|SUB|A|53|T	Novel

54581851|t|Genetic variants in Rhodiola rosea and their associations with actin expression, BMP-2 levels, and nitroglycerin response in PC
54581851|a|Recent studies have highlighted the potential of Rhodiola rosea as a therapeutic agent for modulating cellular responses in cancer and inflammatory conditions. This study investigates the impact of multiple genetic variants on the expression of actin, BMP-2, and IDO in the PC-3 cell line, with a focus on the interplay between these factors and the effects of nitroglycerin. The sequence variant p.V657_G726 was found to exhibit a positive correlation with nitroglycerin-induced changes in cellular function, suggesting a potential role in modulating nitroglycerin sensitivity. Similarly, the sequence variant -107C/T showed a positive correlation with nitroglycerin, indicating a possible mechanism by which this polymorphism influences nitroglycerin response. In contrast, nitroglycerin was found to have a negative correlation with BMP-2 and IDO expression, as well as with actin levels, suggesting that nitroglycerin may inhibit the expression of these key proteins. The sequence variant g.2839T>G was also positively correlated with nitroglycerin, further supporting the hypothesis that genetic variability in this region may influence nitroglycerin's biological effects. These findings were observed across multiple PC-3 cell line experiments, with Rhodiola rosea being used as a source of genetic material to assess the impact of these variants. The results provide new insights into the molecular mechanisms underlying the interactions between genetic variants, nitroglycerin, and key cellular proteins such as actin, BMP-2, and IDO in the context of Rhodiola rosea. The study also underscores the importance of considering genetic variability in the development of personalized therapeutic strategies involving nitroglycerin and other pharmacological agents.
54581851	20	34	Rhodiola rosea	OrganismTaxon	203015
54581851	63	68	actin	GeneOrGeneProduct	60
54581851	81	86	BMP-2	GeneOrGeneProduct	12156
54581851	99	112	nitroglycerin	ChemicalEntity	D005996
54581851	177	191	Rhodiola rosea	OrganismTaxon	203015
54581851	373	378	actin	GeneOrGeneProduct	60
54581851	380	385	BMP-2	GeneOrGeneProduct	12156
54581851	391	394	IDO	GeneOrGeneProduct	3620
54581851	402	406	PC-3	CellLine	CVCL_0035
54581851	489	502	nitroglycerin	ChemicalEntity	D005996
54581851	525	536	p.V657_G726	SequenceVariant	p|DEL|657_726|
54581851	586	599	nitroglycerin	ChemicalEntity	D005996
54581851	680	693	nitroglycerin	ChemicalEntity	D005996
54581851	739	746	-107C/T	SequenceVariant	c|SUB|C|-107|T
54581851	782	795	nitroglycerin	ChemicalEntity	D005996
54581851	867	880	nitroglycerin	ChemicalEntity	D005996
54581851	904	917	nitroglycerin	ChemicalEntity	D005996
54581851	964	969	BMP-2	GeneOrGeneProduct	12156
54581851	974	977	IDO	GeneOrGeneProduct	3620
54581851	1006	1011	actin	GeneOrGeneProduct	60
54581851	1036	1049	nitroglycerin	ChemicalEntity	D005996
54581851	1121	1130	g.2839T>G	SequenceVariant	g|SUB|T|2839|G
54581851	1167	1180	nitroglycerin	ChemicalEntity	D005996
54581851	1270	1283	nitroglycerin	ChemicalEntity	D005996
54581851	1351	1355	PC-3	CellLine	CVCL_0035
54581851	1384	1398	Rhodiola rosea	OrganismTaxon	203015
54581851	1599	1612	nitroglycerin	ChemicalEntity	D005996
54581851	1648	1653	actin	GeneOrGeneProduct	60
54581851	1655	1660	BMP-2	GeneOrGeneProduct	12156
54581851	1666	1669	IDO	GeneOrGeneProduct	3620
54581851	1688	1702	Rhodiola rosea	OrganismTaxon	203015
54581851	1849	1862	nitroglycerin	ChemicalEntity	D005996
54581851	Negative_Correlation	D005996	12156	Novel
54581851	Positive_Correlation	p|DEL|657_726|	D005996	Novel
54581851	Positive_Correlation	c|SUB|C|-107|T	D005996	Novel
54581851	Negative_Correlation	D005996	3620	Novel
54581851	Negative_Correlation	D005996	60	Novel
54581851	Positive_Correlation	g|SUB|T|2839|G	D005996	Novel

44812007|t|Thromboxane and SSRI Modulation of Oligodontia Phenotype in S. cerevisiae and Their Interactions with HEY2 and CXCR-1 in Ishikawa and H9c2 Ce
44812007|a|Recent studies have revealed a significant positive correlation between the oligodontia phenotype and the presence of thromboxane in both S. cerevisiae and human cell lines. This correlation suggests that thromboxane may play a critical role in the development of the oligodontia phenotype, possibly through its effects on cellular signaling pathways. Similarly, a positive correlation has been observed between the oligodontia phenotype and the use of selective serotonin reuptake inhibitors (SSRIs), indicating that these drugs may influence the expression or activity of genes associated with tooth development.    Further investigation into the molecular mechanisms underlying these associations has led to the identification of a binding interaction between chemokine receptor 1 (CXCR-1) and HEY2 in Ishikawa cells. This interaction is further supported by a reciprocal binding relationship between HEY2 and CXCR-1, suggesting a potential regulatory loop that may modulate cellular responses to thromboxane and SSRI. These findings were validated using H9c2 cell lines, where the expression levels of HEY2 and CXCR-1 were found to be significantly altered in the presence of thromboxane and SSRI.    The study also highlights the importance of S. cerevisiae as a model organism for understanding the broader implications of these interactions, as the observed correlations between thromboxane, SSRI, and the oligodontia phenotype were consistent across multiple experimental conditions. These results provide a foundation for future research into the therapeutic potential of targeting these pathways in the treatment of developmental disorders associated with the oligodontia phenotype.
44812007	0	11	Thromboxane	ChemicalEntity	D013931
44812007	16	20	SSRI	ChemicalEntity	D017367
44812007	60	73	S. cerevisiae	OrganismTaxon	4932
44812007	102	106	HEY2	GeneOrGeneProduct	23493
44812007	121	129	Ishikawa	CellLine	CVCL_2529
44812007	134	138	H9c2	CellLine	CVCL_0286
44812007	218	239	oligodontia phenotype	DiseaseOrPhenotypicFeature	C538049
44812007	280	293	S. cerevisiae	OrganismTaxon	4932
44812007	410	431	oligodontia phenotype	DiseaseOrPhenotypicFeature	C538049
44812007	558	579	oligodontia phenotype	DiseaseOrPhenotypicFeature	C538049
44812007	636	640	SSRI	ChemicalEntity	D017367
44812007	939	943	HEY2	GeneOrGeneProduct	23493
44812007	947	955	Ishikawa	CellLine	CVCL_2529
44812007	1046	1050	HEY2	GeneOrGeneProduct	23493
44812007	1158	1162	SSRI	ChemicalEntity	D017367
44812007	1200	1204	H9c2	CellLine	CVCL_0286
44812007	1248	1252	HEY2	GeneOrGeneProduct	23493
44812007	1338	1342	SSRI	ChemicalEntity	D017367
44812007	1391	1404	S. cerevisiae	OrganismTaxon	4932
44812007	1541	1545	SSRI	ChemicalEntity	D017367
44812007	1555	1576	oligodontia phenotype	DiseaseOrPhenotypicFeature	C538049
44812007	1812	1833	oligodontia phenotype	DiseaseOrPhenotypicFeature	C538049
44812007	Positive_Correlation	C538049	D013931	Novel
44812007	Positive_Correlation	C538049	D017367	Novel
44812007	Bind	3577	23493	Novel
44812007	Bind	23493	3577	Novel

14150358|t|Neopterin, VEGF Receptor 2, and Malonic Aciduria: Multifaceted Associations with Developmental Defects and
14150358|a|Neopterin, a pteridine derivative, has been implicated in various pathological conditions, including malonic aciduria and developmental defects. This study explores the complex interplay between neopterin, VEGF receptor 2, and their associations with malonic aciduria, developmental defects, and gliomas. Using a combination of in vitro and in vivo models, we demonstrate that neopterin binds directly to VEGF receptor 2, suggesting a potential mechanism for its involvement in angiogenic processes. Furthermore, we observe a positive correlation between neopterin levels and both malonic aciduria and developmental defects, indicating a possible role for neopterin in metabolic and developmental pathways. The SCID-HuH-7 cell line was used to model the effects of neopterin on VEGF receptor 2 activity, revealing that neopterin enhances the expression and activation of VEGF receptor 2. Additionally, we find that VEGF receptor 2 is positively correlated with malonic aciduria, developmental defects, and gliomas, suggesting a broader role for this receptor in disease progression. Notably, the HL-7702 cell line exhibited a significant increase in VEGF receptor 2 expression in the presence of neopterin, further supporting the hypothesis of a direct interaction. Our findings highlight the importance of neopterin and VEGF receptor 2 in the pathogenesis of malonic aciduria, developmental defects, and gliomas, and suggest that targeting these molecules may offer therapeutic opportunities in these conditions.
14150358	208	224	malonic aciduria	DiseaseOrPhenotypicFeature	C535702
14150358	229	250	developmental defects	DiseaseOrPhenotypicFeature	D003147
14150358	302	311	neopterin	ChemicalEntity	D019798
14150358	313	328	VEGF receptor 2	GeneOrGeneProduct	3791
14150358	358	374	malonic aciduria	DiseaseOrPhenotypicFeature	C535702
14150358	376	397	developmental defects	DiseaseOrPhenotypicFeature	D003147
14150358	403	410	gliomas	DiseaseOrPhenotypicFeature	D005910
14150358	484	493	neopterin	ChemicalEntity	D019798
14150358	512	527	VEGF receptor 2	GeneOrGeneProduct	3791
14150358	662	671	neopterin	ChemicalEntity	D019798
14150358	688	704	malonic aciduria	DiseaseOrPhenotypicFeature	C535702
14150358	709	730	developmental defects	DiseaseOrPhenotypicFeature	D003147
14150358	763	772	neopterin	ChemicalEntity	D019798
14150358	818	828	SCID-HuH-7	CellLine	CVCL_0336
14150358	872	881	neopterin	ChemicalEntity	D019798
14150358	885	900	VEGF receptor 2	GeneOrGeneProduct	3791
14150358	926	935	neopterin	ChemicalEntity	D019798
14150358	978	993	VEGF receptor 2	GeneOrGeneProduct	3791
14150358	1022	1037	VEGF receptor 2	GeneOrGeneProduct	3791
14150358	1068	1084	malonic aciduria	DiseaseOrPhenotypicFeature	C535702
14150358	1086	1107	developmental defects	DiseaseOrPhenotypicFeature	D003147
14150358	1113	1120	gliomas	DiseaseOrPhenotypicFeature	D005910
14150358	1203	1210	HL-7702	CellLine	CVCL_6926
14150358	1257	1272	VEGF receptor 2	GeneOrGeneProduct	3791
14150358	1303	1312	neopterin	ChemicalEntity	D019798
14150358	1414	1423	neopterin	ChemicalEntity	D019798
14150358	1428	1443	VEGF receptor 2	GeneOrGeneProduct	3791
14150358	1467	1483	malonic aciduria	DiseaseOrPhenotypicFeature	C535702
14150358	1485	1506	developmental defects	DiseaseOrPhenotypicFeature	D003147
14150358	1512	1519	gliomas	DiseaseOrPhenotypicFeature	D005910
14150358	Bind	D019798	3791	Novel
14150358	Association	3791	D019798	Novel
14150358	Positive_Correlation	D019798	D003147	Novel
14150358	Positive_Correlation	D019798	C535702	Novel
14150358	Positive_Correlation	D005910	3791	Novel
14150358	Positive_Correlation	D019798	D005910	Novel
14150358	Positive_Correlation	C535702	3791	Novel
14150358	Positive_Correlation	D003147	3791	Novel
14150358	Positive_Correlation	3791	C535702	Novel
14150358	Positive_Correlation	3791	D005910	Novel
14150358	Positive_Correlation	3791	D003147	Novel

79716670|t|Genetic and pharmacological associations between sequence variants, phosphatidylethanolamine, and disease phenotypes in neurodegenerative and metabolic d
79716670|a|This study investigates the complex interplay between genetic variants, phosphatidylethanolamine metabolism, and disease phenotypes in a cohort of patients with neurodegenerative and metabolic disorders. We identified several sequence variants, including c.2113_2114delGG, (CCTTT)14, and p.R428C, which were found to be significantly associated with various disease features. Notably, the variant arginine to tryptophan at codon 198 showed a positive correlation with both GI adverse experiences and neurologic deterioration, suggesting a potential role in gastrointestinal and neurological pathophysiology. Additionally, the variant c.2113_2114delGG was positively correlated with GI adverse experiences, neurologic deterioration, and metachromatic leukodystrophy, indicating its involvement in multiple disease pathways.   Phosphatidylethanolamine was found to have a complex relationship with disease phenotypes. It was associated with GI adverse experiences and neurologic deterioration, but also showed a negative correlation with fatigue and hypothermic states. This suggests that phosphatidylethanolamine may have both protective and detrimental effects depending on the context. Furthermore, bisphosphonates were associated with fatigue and hypothermic states, but showed a negative correlation with phosphatidylethanolamine and metachromatic leukodystrophy, indicating potential therapeutic and toxic interactions.   The study also revealed that hypothermic states were positively correlated with the variant (CCTTT)14 and c.2113_2114delGG, while showing a negative correlation with bisphosphonates. These findings highlight the intricate relationships between genetic variants, metabolic substrates, and disease phenotypes, providing a foundation for future targeted therapies and personalized medicine approaches in neurodegenerative and metabolic disorders.
79716670	68	92	phosphatidylethanolamine	ChemicalEntity	D010714
79716670	226	250	phosphatidylethanolamine	ChemicalEntity	D010714
79716670	409	425	c.2113_2114delGG	SequenceVariant	c|DEL|2113_2114|GG
79716670	427	436	(CCTTT)14	SequenceVariant	c|DUP||CCTTT|14
79716670	442	449	p.R428C	SequenceVariant	rs750700202
79716670	551	586	arginine to tryptophan at codon 198	SequenceVariant	p|SUB|R|198|W
79716670	627	649	GI adverse experiences	DiseaseOrPhenotypicFeature	D005767
79716670	654	678	neurologic deterioration	DiseaseOrPhenotypicFeature	D009422
79716670	788	804	c.2113_2114delGG	SequenceVariant	c|DEL|2113_2114|GG
79716670	836	858	GI adverse experiences	DiseaseOrPhenotypicFeature	D005767
79716670	860	884	neurologic deterioration	DiseaseOrPhenotypicFeature	D009422
79716670	890	918	metachromatic leukodystrophy	DiseaseOrPhenotypicFeature	D007966
79716670	1093	1115	GI adverse experiences	DiseaseOrPhenotypicFeature	D005767
79716670	1120	1144	neurologic deterioration	DiseaseOrPhenotypicFeature	D009422
79716670	1190	1197	fatigue	DiseaseOrPhenotypicFeature	D005221
79716670	1202	1213	hypothermic	DiseaseOrPhenotypicFeature	D007035
79716670	1241	1265	phosphatidylethanolamine	ChemicalEntity	D010714
79716670	1354	1369	bisphosphonates	ChemicalEntity	D004164
79716670	1391	1398	fatigue	DiseaseOrPhenotypicFeature	D005221
79716670	1403	1414	hypothermic	DiseaseOrPhenotypicFeature	D007035
79716670	1462	1486	phosphatidylethanolamine	ChemicalEntity	D010714
79716670	1491	1519	metachromatic leukodystrophy	DiseaseOrPhenotypicFeature	D007966
79716670	1609	1620	hypothermic	DiseaseOrPhenotypicFeature	D007035
79716670	1672	1681	(CCTTT)14	SequenceVariant	c|DUP||CCTTT|14
79716670	1686	1702	c.2113_2114delGG	SequenceVariant	c|DEL|2113_2114|GG
79716670	1746	1761	bisphosphonates	ChemicalEntity	D004164
79716670	Positive_Correlation	D005767	p|SUB|R|198|W	Novel
79716670	Association	D005221	D004164	Novel
79716670	Negative_Correlation	D007966	D004164	Novel
79716670	Association	D005767	D010714	Novel
79716670	Association	D005767	D004164	Novel
79716670	Positive_Correlation	D005221	c|DEL|2113_2114|GG	Novel
79716670	Association	D007035	D004164	Novel
79716670	Negative_Correlation	D007035	D010714	Novel
79716670	Negative_Correlation	D005221	D010714	Novel
79716670	Positive_Correlation	D007035	p|SUB|R|198|W	Novel
79716670	Positive_Correlation	D009422	p|SUB|R|198|W	Novel
79716670	Association	D009422	D010714	Novel
79716670	Positive_Correlation	D005767	c|DEL|2113_2114|GG	Novel
79716670	Positive_Correlation	D009422	c|DEL|2113_2114|GG	Novel
79716670	Positive_Correlation	D007966	c|DEL|2113_2114|GG	Novel
79716670	Association	D005221	D010714	Novel
79716670	Positive_Correlation	D005767	rs750700202	Novel
79716670	Negative_Correlation	D009422	D010714	Novel
79716670	Positive_Correlation	D005767	c|DUP||CCTTT|14	Novel
79716670	Negative_Correlation	D007035	D004164	Novel
79716670	Positive_Correlation	D009422	c|DUP||CCTTT|14	Novel
79716670	Negative_Correlation	D005221	D004164	Novel
79716670	Association	D009422	D004164	Novel
79716670	Negative_Correlation	D010714	D004164	Novel
79716670	Association	D007966	D010714	Novel
79716670	Positive_Correlation	D007035	c|DEL|2113_2114|GG	Novel
79716670	Negative_Correlation	D004164	D010714	Novel
79716670	Positive_Correlation	D007966	c|DUP||CCTTT|14	Novel
79716670	Negative_Correlation	D005767	D010714	Novel

31327559|t|Annexin V, GLUT5, and abnormal involuntary motor movements in the context of recessive skeletal dysplasia and their associations with Mz-ChA-1 and HL-7702 ce
31327559|a|Recent studies have highlighted the complex interplay between genetic factors and phenotypic features in the pathogenesis of neurological and skeletal disorders. This study investigates the associations between abnormal involuntary motor movements, recessive skeletal dysplasia, and the expression of Annexin V and GLUT5 in various cell lines, including Mz-ChA-1, HL-7702, and C57BL/6J.   Abnormal involuntary motor movements were found to be significantly associated with elevated levels of Annexin V in Mz-ChA-1 and HL-7702 cell lines, suggesting a potential role for Annexin V in the pathophysiology of these movements. However, a negative correlation was observed between Annexin V and abnormal involuntary motor movements in C57BL/6J cells, indicating cell-type-specific regulatory mechanisms.   Recessive skeletal dysplasia was associated with reduced expression of GLUT5 in both Mz-ChA-1 and HL-7702 cell lines, and a negative correlation was identified between GLUT5 and recessive skeletal dysplasia. Furthermore, Annexin V was found to be negatively correlated with recessive skeletal dysplasia in all three cell lines, suggesting a possible antagonistic relationship between Annexin V and the genetic basis of this condition.   Interestingly, abnormal involuntary motor movements were also associated with GLUT5 expression, with a negative correlation observed between GLUT5 and abnormal involuntary motor movements in HL-7702 cells. This suggests a complex network of interactions among these phenotypic features and their molecular determinants.   These findings provide new insights into the molecular mechanisms underlying abnormal involuntary motor movements, recessive skeletal dysplasia, and the roles of Annexin V and GLUT5 in these conditions. The use of multiple cell lines, including Mz-ChA-1, HL-7702, and C57BL/6J, allowed for a comprehensive analysis of these associations across different genetic and cellular contexts.
31327559	0	9	Annexin V	GeneOrGeneProduct	308
31327559	11	16	GLUT5	GeneOrGeneProduct	56485
31327559	22	58	abnormal involuntary motor movements	DiseaseOrPhenotypicFeature	D004409
31327559	77	105	recessive skeletal dysplasia	DiseaseOrPhenotypicFeature	D010009
31327559	134	142	Mz-ChA-1	CellLine	CVCL_6932
31327559	147	154	HL-7702	CellLine	CVCL_6926
31327559	369	405	abnormal involuntary motor movements	DiseaseOrPhenotypicFeature	D004409
31327559	407	435	recessive skeletal dysplasia	DiseaseOrPhenotypicFeature	D010009
31327559	459	468	Annexin V	GeneOrGeneProduct	308
31327559	473	478	GLUT5	GeneOrGeneProduct	56485
31327559	512	520	Mz-ChA-1	CellLine	CVCL_6932
31327559	522	529	HL-7702	CellLine	CVCL_6926
31327559	535	543	C57BL/6J	CellLine	CVCL_5U84
31327559	650	659	Annexin V	GeneOrGeneProduct	308
31327559	663	671	Mz-ChA-1	CellLine	CVCL_6932
31327559	676	683	HL-7702	CellLine	CVCL_6926
31327559	728	737	Annexin V	GeneOrGeneProduct	308
31327559	834	843	Annexin V	GeneOrGeneProduct	308
31327559	848	884	abnormal involuntary motor movements	DiseaseOrPhenotypicFeature	D004409
31327559	888	896	C57BL/6J	CellLine	CVCL_5U84
31327559	1030	1035	GLUT5	GeneOrGeneProduct	56485
31327559	1044	1052	Mz-ChA-1	CellLine	CVCL_6932
31327559	1057	1064	HL-7702	CellLine	CVCL_6926
31327559	1127	1132	GLUT5	GeneOrGeneProduct	56485
31327559	1137	1165	recessive skeletal dysplasia	DiseaseOrPhenotypicFeature	D010009
31327559	1180	1189	Annexin V	GeneOrGeneProduct	308
31327559	1233	1261	recessive skeletal dysplasia	DiseaseOrPhenotypicFeature	D010009
31327559	1343	1352	Annexin V	GeneOrGeneProduct	308
31327559	1411	1447	abnormal involuntary motor movements	DiseaseOrPhenotypicFeature	D004409
31327559	1474	1479	GLUT5	GeneOrGeneProduct	56485
31327559	1537	1542	GLUT5	GeneOrGeneProduct	56485
31327559	1547	1583	abnormal involuntary motor movements	DiseaseOrPhenotypicFeature	D004409
31327559	1587	1594	HL-7702	CellLine	CVCL_6926
31327559	1795	1831	abnormal involuntary motor movements	DiseaseOrPhenotypicFeature	D004409
31327559	1833	1861	recessive skeletal dysplasia	DiseaseOrPhenotypicFeature	D010009
31327559	1880	1889	Annexin V	GeneOrGeneProduct	308
31327559	1894	1899	GLUT5	GeneOrGeneProduct	56485
31327559	1963	1971	Mz-ChA-1	CellLine	CVCL_6932
31327559	1973	1980	HL-7702	CellLine	CVCL_6926
31327559	1986	1994	C57BL/6J	CellLine	CVCL_5U84
31327559	Association	D010009	56485	Novel
31327559	Negative_Correlation	56485	D010009	Novel
31327559	Association	D004409	308	Novel
31327559	Negative_Correlation	308	D010009	Novel
31327559	Negative_Correlation	308	D004409	Novel
31327559	Association	D004409	56485	Novel
31327559	Association	D010009	308	Novel
31327559	Negative_Correlation	56485	D004409	Novel

24153441|t|Shh and BIK interactions in memory impairment: effects of LY294002, ergometrine, and M235T variants on cellular and phenotypic 
24153441|a|This study investigates the complex interplay between the Hedgehog signaling pathway and the BIK protein in the context of memory impairment. We examined the effects of the Shh gene and its variants, particularly the M235T sequence variant, on cellular responses in the MH134 and CA3 cell lines. Our findings reveal a negative correlation between BIK and Shh, suggesting that increased BIK expression may suppress Shh activity. Conversely, a positive correlation was observed between Shh and LY294002, indicating that LY294002 may enhance Shh signaling. Additionally, we found a positive correlation between memory impairment and both Shh and BIK, highlighting the potential role of these factors in cognitive decline. The M235T variant was consistently associated with altered Shh expression in the CA3 cell line, and its presence correlated with increased memory impairment in both MEF and CA3 cell lines. Furthermore, a positive correlation was observed between BIK and ergometrine, suggesting that ergometrine may modulate BIK activity. The study also demonstrated a positive correlation between BIK and LY294002, reinforcing the idea that these two factors may act synergistically in cellular processes. Overall, our results provide new insights into the molecular mechanisms underlying memory impairment and the potential therapeutic implications of targeting Shh, BIK, and related chemical entities such as LY294002 and ergometrine.
24153441	0	3	Shh	GeneOrGeneProduct	20423
24153441	8	11	BIK	GeneOrGeneProduct	638
24153441	28	45	memory impairment	DiseaseOrPhenotypicFeature	D008569
24153441	58	66	LY294002	ChemicalEntity	C085911
24153441	68	79	ergometrine	ChemicalEntity	D004874
24153441	85	90	M235T	SequenceVariant	rs699
24153441	221	224	BIK	GeneOrGeneProduct	638
24153441	251	268	memory impairment	DiseaseOrPhenotypicFeature	D008569
24153441	301	304	Shh	GeneOrGeneProduct	20423
24153441	345	350	M235T	SequenceVariant	rs699
24153441	398	403	MH134	CellLine	CVCL_8111
24153441	408	411	CA3	CellLine	CVCL_JW73
24153441	475	478	BIK	GeneOrGeneProduct	638
24153441	483	486	Shh	GeneOrGeneProduct	20423
24153441	514	517	BIK	GeneOrGeneProduct	638
24153441	542	545	Shh	GeneOrGeneProduct	20423
24153441	612	615	Shh	GeneOrGeneProduct	20423
24153441	620	628	LY294002	ChemicalEntity	C085911
24153441	646	654	LY294002	ChemicalEntity	C085911
24153441	667	670	Shh	GeneOrGeneProduct	20423
24153441	736	753	memory impairment	DiseaseOrPhenotypicFeature	D008569
24153441	763	766	Shh	GeneOrGeneProduct	20423
24153441	771	774	BIK	GeneOrGeneProduct	638
24153441	851	856	M235T	SequenceVariant	rs699
24153441	906	909	Shh	GeneOrGeneProduct	20423
24153441	928	931	CA3	CellLine	CVCL_JW73
24153441	986	1003	memory impairment	DiseaseOrPhenotypicFeature	D008569
24153441	1012	1015	MEF	CellLine	CVCL_9115
24153441	1020	1023	CA3	CellLine	CVCL_JW73
24153441	1093	1096	BIK	GeneOrGeneProduct	638
24153441	1101	1112	ergometrine	ChemicalEntity	D004874
24153441	1130	1141	ergometrine	ChemicalEntity	D004874
24153441	1155	1158	BIK	GeneOrGeneProduct	638
24153441	1228	1231	BIK	GeneOrGeneProduct	638
24153441	1236	1244	LY294002	ChemicalEntity	C085911
24153441	1420	1437	memory impairment	DiseaseOrPhenotypicFeature	D008569
24153441	1494	1497	Shh	GeneOrGeneProduct	20423
24153441	1499	1502	BIK	GeneOrGeneProduct	638
24153441	1542	1550	LY294002	ChemicalEntity	C085911
24153441	1555	1566	ergometrine	ChemicalEntity	D004874
24153441	Negative_Correlation	638	20423	Novel
24153441	Positive_Correlation	D008569	638	Novel
24153441	Positive_Correlation	20423	C085911	Novel
24153441	Positive_Correlation	D008569	20423	Novel
24153441	Positive_Correlation	638	D004874	Novel
24153441	Positive_Correlation	638	C085911	Novel
24153441	Negative_Correlation	20423	638	Novel
24153441	Positive_Correlation	20423	D004874	Novel

47503056|t|Re and manganese superoxide dismutase interactions in SUM159PT and hRPTEC cells: implications for Mitochondrial Dysfunction and craniofacial s
47503056|a|This study investigates the molecular interactions between Re and manganese superoxide dismutase (MnSOD) in the context of Mitochondrial Dysfunction and their potential role in craniofacial syndromes. Using the SUM159PT and hRPTEC cell lines, we demonstrate that Re modulates the expression and activity of MnSOD, a key enzyme in mitochondrial antioxidant defense. Our findings reveal a bidirectional association between MnSOD and Re, with Re acting as both a regulator and a target of MnSOD activity.   Further, we explore the interplay between MnSOD and the gene product IL1RN, showing that IL1RN influences MnSOD expression and activity in both SUM159PT and hRPTEC cells. This association is reciprocal, with MnSOD also affecting IL1RN levels and signaling pathways. Additionally, we identify a significant correlation between IL1RN and desmin, a cytoskeletal protein, in the SUM159PT cell line. Desmin expression is further linked to MnSOD, suggesting a complex network of interactions involving these proteins.  Our results highlight the role of Re in modulating MnSOD and IL1RN, which in turn influence desmin expression and mitochondrial function. These findings are particularly relevant in the context of Mitochondrial Dysfunction and craniofacial syndromes, where disruptions in these pathways may contribute to disease pathogenesis. The study also underscores the importance of the SUM159PT and hRPTEC cell lines in modeling these interactions, providing a valuable resource for future research on the molecular mechanisms underlying these conditions.
47503056	0	2	Re	ChemicalEntity	C049864
47503056	7	37	manganese superoxide dismutase	GeneOrGeneProduct	6648
47503056	54	62	SUM159PT	CellLine	CVCL_5423
47503056	67	73	hRPTEC	CellLine	CVCL_K278
47503056	98	123	Mitochondrial Dysfunction	DiseaseOrPhenotypicFeature	D028361
47503056	202	204	Re	ChemicalEntity	C049864
47503056	209	239	manganese superoxide dismutase	GeneOrGeneProduct	6648
47503056	266	291	Mitochondrial Dysfunction	DiseaseOrPhenotypicFeature	D028361
47503056	320	342	craniofacial syndromes	DiseaseOrPhenotypicFeature	D019465
47503056	354	362	SUM159PT	CellLine	CVCL_5423
47503056	367	373	hRPTEC	CellLine	CVCL_K278
47503056	406	408	Re	ChemicalEntity	C049864
47503056	574	576	Re	ChemicalEntity	C049864
47503056	583	585	Re	ChemicalEntity	C049864
47503056	716	721	IL1RN	GeneOrGeneProduct	3557
47503056	736	741	IL1RN	GeneOrGeneProduct	3557
47503056	791	799	SUM159PT	CellLine	CVCL_5423
47503056	804	810	hRPTEC	CellLine	CVCL_K278
47503056	876	881	IL1RN	GeneOrGeneProduct	3557
47503056	973	978	IL1RN	GeneOrGeneProduct	3557
47503056	983	989	desmin	GeneOrGeneProduct	64362
47503056	1022	1030	SUM159PT	CellLine	CVCL_5423
47503056	1194	1196	Re	ChemicalEntity	C049864
47503056	1221	1226	IL1RN	GeneOrGeneProduct	3557
47503056	1252	1258	desmin	GeneOrGeneProduct	64362
47503056	1357	1382	Mitochondrial Dysfunction	DiseaseOrPhenotypicFeature	D028361
47503056	1387	1409	craniofacial syndromes	DiseaseOrPhenotypicFeature	D019465
47503056	1536	1544	SUM159PT	CellLine	CVCL_5423
47503056	1549	1555	hRPTEC	CellLine	CVCL_K278
47503056	Association	64362	3557	Novel
47503056	Association	3557	64362	Novel
47503056	Association	6648	64362	Novel
47503056	Association	64362	6648	Novel
47503056	Association	6648	3557	Novel
47503056	Association	3557	6648	Novel

14644091|t|Sequence variants and their associations with bone tumor and blindness in LNCaP and C57BL/6 cell lines across Rats and DEN-4 o
14644091|a|This study investigates the genetic and phenotypic associations between specific sequence variants and the development of bone tumor and blindness in multiple cell lines and organisms. We focused on the sequence variant 'G to C at codon 158' and 'IVS3 + 18C > T', examining their roles in disease progression and cellular behavior. The study was conducted using LNCaP and C57BL/6 cell lines derived from Rats and DEN-4 organisms.   Our findings reveal a positive correlation between 'G to C at codon 158' and the occurrence of bone tumor in Rats, as well as a negative correlation between the same variant and bone tumor in DEN-4 organisms. This suggests that the variant may have context-dependent effects on tumor development. Additionally, we observed a positive correlation between 'G to C at codon 158' and blindness in C57BL/6 cell lines, indicating a potential role in neurodegenerative processes.   The variant 'IVS3 + 18C > T' showed a positive correlation with bone tumor in both Rats and DEN-4 organisms, suggesting a consistent genetic risk factor across these models. Furthermore, the presence of multiple instances of 'bone tumor' and 'blindness' in the data highlights the importance of these phenotypic features in understanding the molecular mechanisms underlying these conditions.   The study also emphasizes the utility of using multiple cell lines and organisms to dissect the complex interactions between genetic variants and phenotypic outcomes. These results provide a foundation for further research into the molecular pathways involved in bone tumor and blindness, with potential implications for therapeutic strategies.
14644091	46	56	bone tumor	DiseaseOrPhenotypicFeature	D001859
14644091	61	70	blindness	DiseaseOrPhenotypicFeature	D001766
14644091	74	79	LNCaP	CellLine	CVCL_0395
14644091	84	91	C57BL/6	CellLine	CVCL_5746
14644091	110	114	Rats	OrganismTaxon	10116
14644091	119	124	DEN-4	OrganismTaxon	11070
14644091	249	259	bone tumor	DiseaseOrPhenotypicFeature	D001859
14644091	264	273	blindness	DiseaseOrPhenotypicFeature	D001766
14644091	348	367	G to C at codon 158	SequenceVariant	c|SUB|G|CODON158|C
14644091	374	388	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
14644091	489	494	LNCaP	CellLine	CVCL_0395
14644091	499	506	C57BL/6	CellLine	CVCL_5746
14644091	531	535	Rats	OrganismTaxon	10116
14644091	540	545	DEN-4	OrganismTaxon	11070
14644091	611	630	G to C at codon 158	SequenceVariant	c|SUB|G|CODON158|C
14644091	654	664	bone tumor	DiseaseOrPhenotypicFeature	D001859
14644091	668	672	Rats	OrganismTaxon	10116
14644091	737	747	bone tumor	DiseaseOrPhenotypicFeature	D001859
14644091	751	756	DEN-4	OrganismTaxon	11070
14644091	914	933	G to C at codon 158	SequenceVariant	c|SUB|G|CODON158|C
14644091	939	948	blindness	DiseaseOrPhenotypicFeature	D001766
14644091	952	959	C57BL/6	CellLine	CVCL_5746
14644091	1047	1061	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
14644091	1098	1108	bone tumor	DiseaseOrPhenotypicFeature	D001859
14644091	1117	1121	Rats	OrganismTaxon	10116
14644091	1126	1131	DEN-4	OrganismTaxon	11070
14644091	1260	1270	bone tumor	DiseaseOrPhenotypicFeature	D001859
14644091	1277	1286	blindness	DiseaseOrPhenotypicFeature	D001766
14644091	1691	1701	bone tumor	DiseaseOrPhenotypicFeature	D001859
14644091	1706	1715	blindness	DiseaseOrPhenotypicFeature	D001766
14644091	Positive_Correlation	c|SUB|G|CODON158|C	D001859	Novel
14644091	Positive_Correlation	c|SUB|C|IVS3+18|T	D001859	Novel
14644091	Negative_Correlation	c|SUB|G|CODON158|C	D001859	Novel
14644091	Positive_Correlation	c|SUB|G|CODON158|C	D001766	Novel

17128285|t|Genetic and molecular interactions in glioblastoma cell lines: associations between sequence variants, gene products, and functional outcomes
17128285|a|This study investigates the molecular and genetic interactions in two glioblastoma cell lines, SJ-GBM2 and CD18/HPAF, derived from rats. We focus on the functional relationships between sequence variants and gene products, particularly in the context of tumor progression and cellular signaling. The sequence variant 3472delC was found to be associated with the sequence variant P686fs, suggesting a potential genetic linkage. Additionally, the variant 3472delC was associated with the gene product Haptoglobin, indicating a possible regulatory or functional interaction. The sequence variant P686fs was also associated with the M(3)-muscarinic acetylcholine receptor, highlighting its role in modulating receptor function.   The gene product Haptoglobin showed a positive correlation with the M(3)-muscarinic acetylcholine receptor, suggesting a potential functional synergy. Haptoglobin was also found to bind to both S6K1 and FABP7, indicating its involvement in multiple signaling pathways. FABP7 exhibited a positive correlation with the M(3)-muscarinic acetylcholine receptor and also showed a negative correlation with S6K1, suggesting a complex regulatory network. Furthermore, S6K1 was found to bind to both FABP7 and the M(3)-muscarinic acetylcholine receptor, reinforcing its role as a central hub in these interactions.   The negative correlation between S6K1 and FABP7, along with the negative correlation between the M(3)-muscarinic acetylcholine receptor and S6K1, suggests a potential antagonistic relationship among these gene products. These findings provide new insights into the molecular mechanisms underlying glioblastoma progression and highlight the importance of genetic and molecular interactions in tumor biology. The results also emphasize the need for further studies to elucidate the precise functional roles of these gene products and sequence variants in rat models of glioblastoma.
17128285	237	244	SJ-GBM2	CellLine	CVCL_M141
17128285	249	258	CD18/HPAF	CellLine	CVCL_0313
17128285	273	277	rats	OrganismTaxon	10116
17128285	459	467	3472delC	SequenceVariant	c|DEL|3472|C
17128285	521	527	P686fs	SequenceVariant	p|FS|P|686||
17128285	595	603	3472delC	SequenceVariant	c|DEL|3472|C
17128285	641	652	Haptoglobin	GeneOrGeneProduct	3240
17128285	735	741	P686fs	SequenceVariant	p|FS|P|686||
17128285	771	809	M(3)-muscarinic acetylcholine receptor	GeneOrGeneProduct	100379235
17128285	885	896	Haptoglobin	GeneOrGeneProduct	3240
17128285	936	974	M(3)-muscarinic acetylcholine receptor	GeneOrGeneProduct	100379235
17128285	1019	1030	Haptoglobin	GeneOrGeneProduct	3240
17128285	1062	1066	S6K1	GeneOrGeneProduct	83840
17128285	1071	1076	FABP7	GeneOrGeneProduct	2173
17128285	1137	1142	FABP7	GeneOrGeneProduct	2173
17128285	1185	1223	M(3)-muscarinic acetylcholine receptor	GeneOrGeneProduct	100379235
17128285	1268	1272	S6K1	GeneOrGeneProduct	83840
17128285	1328	1332	S6K1	GeneOrGeneProduct	83840
17128285	1359	1364	FABP7	GeneOrGeneProduct	2173
17128285	1373	1411	M(3)-muscarinic acetylcholine receptor	GeneOrGeneProduct	100379235
17128285	1509	1513	S6K1	GeneOrGeneProduct	83840
17128285	1518	1523	FABP7	GeneOrGeneProduct	2173
17128285	1573	1611	M(3)-muscarinic acetylcholine receptor	GeneOrGeneProduct	100379235
17128285	1616	1620	S6K1	GeneOrGeneProduct	83840
17128285	Positive_Correlation	3240	100379235	Novel
17128285	Bind	3240	83840	Novel
17128285	Bind	2173	3240	Novel
17128285	Association	c|DEL|3472|C	p|FS|P|686||	Novel
17128285	Association	p|FS|P|686||	c|DEL|3472|C	Novel
17128285	Positive_Correlation	2173	100379235	Novel
17128285	Bind	83840	2173	Novel
17128285	Bind	83840	3240	Novel
17128285	Association	c|DEL|3472|C	100379235	Novel
17128285	Bind	83840	100379235	Novel
17128285	Positive_Correlation	100379235	2173	Novel
17128285	Negative_Correlation	83840	2173	Novel
17128285	Negative_Correlation	100379235	83840	Novel
17128285	Association	p|FS|P|686||	100379235	Novel
17128285	Association	c|DEL|3472|C	3240	Novel
17128285	Bind	3240	2173	Novel

51490125|t|Genetic and metabolic interactions in Rats, Mangifera indica Linn, and West Nile virus: implications for autosomal recessive (DFNB) deafness, mitochondrial respiratory dysfunction, and hemochr
51490125|a|This study explores the complex interplay between genetic variants, metabolic factors, and disease phenotypes in Rats, Mangifera indica Linn, and West Nile virus. We investigated the role of the sequence variant c.1475G>A in Rats and its association with autosomal recessive (DFNB) deafness, while also examining the impact of the sequence variant Arg16Gly and cytosine insertion on mitochondrial respiratory dysfunction. The gene product IL-15 was found to be significantly upregulated in Rats with hemochromatosis, suggesting a potential role in disease progression.   In parallel, we analyzed the effects of aspirin and asparagine on the expression of the gene LIF in Rats, revealing a negative correlation between hemochromatosis and both aspirin and asparagine. This finding was further supported by in vitro experiments showing that aspirin treatment reduced the expression of LIF in Rats with hemochromatosis. Additionally, the sequence variant rs1155974 was identified as a potential modifier of the disease phenotype in Rats with autosomal recessive (DFNB) deafness.  The study also examined the impact of Mangifera indica Linn on the progression of interstitial fibrosis in Rats, with asparagine supplementation showing a protective effect against fibrotic changes. Furthermore, the sequence variant cytosine insertion was found to be associated with increased susceptibility to mitochondrial respiratory dysfunction in Mangifera indica Linn.   West Nile virus was found to interact with the sequence variant c.1475G>A in Rats, leading to exacerbated symptoms of autosomal recessive (DFNB) deafness. The gene product LIF was also implicated in the pathogenesis of hemochromatosis in Rats infected with West Nile virus.   Overall, this research highlights the intricate relationships between genetic variants, metabolic factors, and disease phenotypes, providing new insights into the molecular mechanisms underlying autosomal recessive (DFNB) deafness, mitochondrial respiratory dysfunction, and hemochromatosis.
51490125	38	42	Rats	OrganismTaxon	10116
51490125	44	65	Mangifera indica Linn	OrganismTaxon	29780
51490125	71	86	West Nile virus	OrganismTaxon	11082
51490125	105	140	autosomal recessive (DFNB) deafness	DiseaseOrPhenotypicFeature	C564609
51490125	142	179	mitochondrial respiratory dysfunction	DiseaseOrPhenotypicFeature	D028361
51490125	306	310	Rats	OrganismTaxon	10116
51490125	312	333	Mangifera indica Linn	OrganismTaxon	29780
51490125	339	354	West Nile virus	OrganismTaxon	11082
51490125	405	414	c.1475G>A	SequenceVariant	c|SUB|G|1475|A
51490125	418	422	Rats	OrganismTaxon	10116
51490125	448	483	autosomal recessive (DFNB) deafness	DiseaseOrPhenotypicFeature	C564609
51490125	541	549	Arg16Gly	SequenceVariant	p|SUB|R|16|G
51490125	554	572	cytosine insertion	SequenceVariant	c|INS||C
51490125	576	613	mitochondrial respiratory dysfunction	DiseaseOrPhenotypicFeature	D028361
51490125	632	637	IL-15	GeneOrGeneProduct	3600
51490125	683	687	Rats	OrganismTaxon	10116
51490125	693	708	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
51490125	804	811	aspirin	ChemicalEntity	D001241
51490125	816	826	asparagine	ChemicalEntity	D001216
51490125	857	860	LIF	GeneOrGeneProduct	3976
51490125	864	868	Rats	OrganismTaxon	10116
51490125	911	926	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
51490125	936	943	aspirin	ChemicalEntity	D001241
51490125	948	958	asparagine	ChemicalEntity	D001216
51490125	1032	1039	aspirin	ChemicalEntity	D001241
51490125	1076	1079	LIF	GeneOrGeneProduct	3976
51490125	1083	1087	Rats	OrganismTaxon	10116
51490125	1093	1108	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
51490125	1145	1154	rs1155974	SequenceVariant	rs1155974
51490125	1222	1226	Rats	OrganismTaxon	10116
51490125	1232	1267	autosomal recessive (DFNB) deafness	DiseaseOrPhenotypicFeature	C564609
51490125	1308	1329	Mangifera indica Linn	OrganismTaxon	29780
51490125	1352	1373	interstitial fibrosis	DiseaseOrPhenotypicFeature	D005355
51490125	1377	1381	Rats	OrganismTaxon	10116
51490125	1388	1398	asparagine	ChemicalEntity	D001216
51490125	1503	1521	cytosine insertion	SequenceVariant	c|INS||C
51490125	1582	1619	mitochondrial respiratory dysfunction	DiseaseOrPhenotypicFeature	D028361
51490125	1623	1644	Mangifera indica Linn	OrganismTaxon	29780
51490125	1648	1663	West Nile virus	OrganismTaxon	11082
51490125	1712	1721	c.1475G>A	SequenceVariant	c|SUB|G|1475|A
51490125	1725	1729	Rats	OrganismTaxon	10116
51490125	1766	1801	autosomal recessive (DFNB) deafness	DiseaseOrPhenotypicFeature	C564609
51490125	1820	1823	LIF	GeneOrGeneProduct	3976
51490125	1867	1882	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
51490125	1886	1890	Rats	OrganismTaxon	10116
51490125	1905	1920	West Nile virus	OrganismTaxon	11082
51490125	2119	2154	autosomal recessive (DFNB) deafness	DiseaseOrPhenotypicFeature	C564609
51490125	2156	2193	mitochondrial respiratory dysfunction	DiseaseOrPhenotypicFeature	D028361
51490125	2199	2214	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
51490125	Negative_Correlation	D006432	D001216	Novel
51490125	Negative_Correlation	D006432	D001241	Novel

95246062|t|Kilham rat virus and the role of -1240 L/S and EPZ015666 in modulating aspartate levels and nephritis pro
95246062|a|Kilham rat virus (KRV) has been implicated in the development of experimental nephritis, and recent studies have highlighted the potential role of genetic variants and chemical entities in modulating disease outcomes. This study investigates the association between the sequence variant -1240 L/S and the chemical entity aspartate, as well as the interaction between -1240 L/S and the small molecule EPZ015666 in the context of KRV-induced nephritis.   Using a combination of in vitro and in vivo models, we demonstrate that the -1240 L/S variant significantly alters the expression of genes involved in aspartate metabolism, leading to increased intracellular aspartate levels. This effect is further amplified in the presence of EPZ015666, a potent inhibitor of the histone methyltransferase EZH2, which is known to regulate inflammatory pathways. Our findings suggest that the -1240 L/S variant may serve as a modifier of aspartate homeostasis, thereby influencing the progression of nephritis in KRV-infected animals.  Additionally, we observed that EPZ015666 treatment in KRV-infected mice with the -1240 L/S variant resulted in a significant reduction in renal inflammation and fibrosis compared to controls. These results provide evidence for the association between -1240 L/S and aspartate, as well as between -1240 L/S and EPZ015666, and highlight the potential therapeutic value of targeting these interactions in the treatment of KRV-related nephritis. The study also underscores the importance of considering genetic and chemical factors in the pathogenesis of viral-induced renal diseases.
95246062	0	16	Kilham rat virus	OrganismTaxon	12441
95246062	33	42	-1240 L/S	SequenceVariant	p|SUB|L|-1240|S
95246062	47	56	EPZ015666	ChemicalEntity	C000599896
95246062	71	80	aspartate	ChemicalEntity	D001224
95246062	92	101	nephritis	DiseaseOrPhenotypicFeature	D009393
95246062	106	122	Kilham rat virus	OrganismTaxon	12441
95246062	184	193	nephritis	DiseaseOrPhenotypicFeature	D009393
95246062	393	402	-1240 L/S	SequenceVariant	p|SUB|L|-1240|S
95246062	427	436	aspartate	ChemicalEntity	D001224
95246062	473	482	-1240 L/S	SequenceVariant	p|SUB|L|-1240|S
95246062	506	515	EPZ015666	ChemicalEntity	C000599896
95246062	546	555	nephritis	DiseaseOrPhenotypicFeature	D009393
95246062	635	644	-1240 L/S	SequenceVariant	p|SUB|L|-1240|S
95246062	710	719	aspartate	ChemicalEntity	D001224
95246062	767	776	aspartate	ChemicalEntity	D001224
95246062	837	846	EPZ015666	ChemicalEntity	C000599896
95246062	986	995	-1240 L/S	SequenceVariant	p|SUB|L|-1240|S
95246062	1031	1040	aspartate	ChemicalEntity	D001224
95246062	1093	1102	nephritis	DiseaseOrPhenotypicFeature	D009393
95246062	1160	1169	EPZ015666	ChemicalEntity	C000599896
95246062	1210	1219	-1240 L/S	SequenceVariant	p|SUB|L|-1240|S
95246062	1380	1389	-1240 L/S	SequenceVariant	p|SUB|L|-1240|S
95246062	1394	1403	aspartate	ChemicalEntity	D001224
95246062	1424	1433	-1240 L/S	SequenceVariant	p|SUB|L|-1240|S
95246062	1438	1447	EPZ015666	ChemicalEntity	C000599896
95246062	1559	1568	nephritis	DiseaseOrPhenotypicFeature	D009393
95246062	Association	p|SUB|L|-1240|S	D001224	Novel
95246062	Association	p|SUB|L|-1240|S	C000599896	Novel

09006198|t|Neurological and metabolic associations in cats: correlations between neopterin, fat, and antiepileptic drugs in gastric cancer and inherited bleeding 
09006198|a|A recent study investigated the complex interplay between metabolic and neurological factors in cats, focusing on the associations between neopterin, fat, and antiepileptic drugs in the context of gastric cancer and inherited bleeding disorder. The research revealed a positive correlation between Topiramate and fat, suggesting that Topiramate may influence lipid metabolism in feline models. Additionally, a significant positive correlation was observed between neopterin and 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester, indicating a potential role for neopterin in oxidative stress pathways. Furthermore, the study found a positive correlation between 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester and neopterin, reinforcing the involvement of these molecules in inflammatory and metabolic processes.   In the context of treatment, the study reported a cotreatment between antiepileptic drugs and azithromycin, highlighting the potential for combined therapeutic strategies in managing neurological and infectious conditions. Additionally, a cotreatment between fat and azithromycin was noted, suggesting that dietary and pharmacological interventions may be synergistic in certain feline pathologies. The findings also indicated that gastric cancer and inherited bleeding disorder may be associated with altered metabolic profiles, including changes in neopterin and fat levels. Notably, the study also identified a link between hypersensitivity and rigid spine muscular dystrophy, as well as precordial pain, further emphasizing the complexity of disease interactions in cats.
09006198	43	47	cats	OrganismTaxon	9685
09006198	70	79	neopterin	ChemicalEntity	D019798
09006198	81	84	fat	ChemicalEntity	D004041
09006198	90	108	antiepileptic drug	ChemicalEntity	D000927
09006198	113	127	gastric cancer	DiseaseOrPhenotypicFeature	D013274
09006198	248	252	cats	OrganismTaxon	9685
09006198	291	300	neopterin	ChemicalEntity	D019798
09006198	302	305	fat	ChemicalEntity	D004041
09006198	311	329	antiepileptic drug	ChemicalEntity	D000927
09006198	349	363	gastric cancer	DiseaseOrPhenotypicFeature	D013274
09006198	368	395	inherited bleeding disorder	DiseaseOrPhenotypicFeature	D025861
09006198	450	460	Topiramate	ChemicalEntity	D000077236
09006198	465	468	fat	ChemicalEntity	D004041
09006198	486	496	Topiramate	ChemicalEntity	D000077236
09006198	616	625	neopterin	ChemicalEntity	D019798
09006198	630	709	5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester	ChemicalEntity	-
09006198	743	752	neopterin	ChemicalEntity	D019798
09006198	843	922	5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester	ChemicalEntity	-
09006198	927	936	neopterin	ChemicalEntity	D019798
09006198	1098	1116	antiepileptic drug	ChemicalEntity	D000927
09006198	1122	1134	azithromycin	ChemicalEntity	D017963
09006198	1287	1290	fat	ChemicalEntity	D004041
09006198	1295	1307	azithromycin	ChemicalEntity	D017963
09006198	1460	1474	gastric cancer	DiseaseOrPhenotypicFeature	D013274
09006198	1479	1506	inherited bleeding disorder	DiseaseOrPhenotypicFeature	D025861
09006198	1579	1588	neopterin	ChemicalEntity	D019798
09006198	1593	1596	fat	ChemicalEntity	D004041
09006198	1655	1671	hypersensitivity	DiseaseOrPhenotypicFeature	D004342
09006198	1676	1706	rigid spine muscular dystrophy	DiseaseOrPhenotypicFeature	C535683
09006198	1719	1734	precordial pain	DiseaseOrPhenotypicFeature	D002637
09006198	1798	1802	cats	OrganismTaxon	9685
09006198	Positive_Correlation	D000077236	D004041	Novel
09006198	Positive_Correlation	-	D019798	Novel
09006198	Positive_Correlation	D019798	-	Novel
09006198	Cotreatment	D000927	D017963	Novel
09006198	Cotreatment	D004041	D017963	Novel

36858706|t|Genetic Variants and Their Associations with Inflammatory Disease and Status Epilepticus in Horses and Ce
36858706|a|This study investigates the genetic associations between specific sequence variants and inflammatory disease, as well as the relationship between these variants and the occurrence of status epilepticus in horses. We focused on the sequence variants rs2230912, rs12910509, and g.3455_3460del, and their potential interactions with inflammatory disease and status epilepticus. The study also examined the effects of these variants in various cell lines, including 293T and DU145, and their potential role in modulating disease outcomes.   Our findings reveal a significant association between rs2230912 and rs12910509, suggesting a possible genetic linkage between these two variants. Additionally, we observed a strong association between g.3455_3460del and rs12910509, indicating that this deletion may influence the expression or function of the gene associated with rs12910509. Furthermore, the study demonstrates a bidirectional relationship between rs2230912 and g.3455_3460del, with each variant influencing the other in a complex genetic network.   In horses, the presence of these variants was correlated with an increased incidence of status epilepticus and inflammatory disease. The 293T and DU145 cell lines were used to model these associations in vitro, and the results suggest that these variants may play a role in the pathogenesis of these conditions. The study also highlights the importance of considering multiple sequence variants in understanding the genetic basis of inflammatory disease and status epilepticus in both human and animal models.   Overall, this research provides new insights into the genetic mechanisms underlying inflammatory disease and status epilepticus, with implications for both human and veterinary medicine. The findings underscore the need for further studies to explore the functional consequences of these variants in different biological contexts.
36858706	194	214	inflammatory disease	DiseaseOrPhenotypicFeature	D007249
36858706	311	317	horses	OrganismTaxon	9796
36858706	355	364	rs2230912	SequenceVariant	rs2230912
36858706	366	376	rs12910509	SequenceVariant	rs12910509
36858706	382	396	g.3455_3460del	SequenceVariant	g|DEL|3455_3460|
36858706	436	456	inflammatory disease	DiseaseOrPhenotypicFeature	D007249
36858706	568	572	293T	CellLine	CVCL_0063
36858706	577	582	DU145	CellLine	CVCL_0105
36858706	697	706	rs2230912	SequenceVariant	rs2230912
36858706	711	721	rs12910509	SequenceVariant	rs12910509
36858706	844	858	g.3455_3460del	SequenceVariant	g|DEL|3455_3460|
36858706	863	873	rs12910509	SequenceVariant	rs12910509
36858706	974	984	rs12910509	SequenceVariant	rs12910509
36858706	1059	1068	rs2230912	SequenceVariant	rs2230912
36858706	1073	1087	g.3455_3460del	SequenceVariant	g|DEL|3455_3460|
36858706	1164	1170	horses	OrganismTaxon	9796
36858706	1272	1292	inflammatory disease	DiseaseOrPhenotypicFeature	D007249
36858706	1298	1302	293T	CellLine	CVCL_0063
36858706	1307	1312	DU145	CellLine	CVCL_0105
36858706	1594	1614	inflammatory disease	DiseaseOrPhenotypicFeature	D007249
36858706	1757	1777	inflammatory disease	DiseaseOrPhenotypicFeature	D007249
36858706	Association	rs2230912	rs12910509	Novel
36858706	Association	g|DEL|3455_3460|	rs12910509	Novel
36858706	Association	rs2230912	g|DEL|3455_3460|	Novel
36858706	Association	g|DEL|3455_3460|	rs2230912	Novel
36858706	Association	rs12910509	rs2230912	Novel
36858706	Association	rs12910509	g|DEL|3455_3460|	Novel

29968520|t|GC and Glutathione-S-transferase P1 interactions in Mangifera indica Linn and Escherichia coli: a study of sequence variants and cellular r
29968520|a|This study investigates the molecular interactions between the chemical entity GC and the gene product Glutathione-S-transferase P1 in the context of sequence variants and cellular responses across different organisms. Using the cell lines hRPTEC and Mz-ChA-1, we observed a negative correlation between GC and Glutathione-S-transferase P1, as well as a negative correlation between Glutathione-S-transferase P1 and GC. These findings were further supported by evidence of a binding interaction between GC and Glutathione-S-transferase P1. The sequence variant g.80_87delT CGCGAAG was found to be associated with altered expression levels of Glutathione-S-transferase P1 in both hRPTEC and Mz-ChA-1 cells. Additionally, the sequence variant Glu873Stop was identified in Mangifera indica Linn, suggesting a potential role in modulating the enzymatic activity of Glutathione-S-transferase P1. The organism taxon Mangifera indica Linn was used as a model system to study the functional consequences of these sequence variants, while Escherichia coli served as a control for bacterial expression studies. Our results highlight the complex interplay between GC, Glutathione-S-transferase P1, and sequence variants in different cellular and organismal contexts.
29968520	0	2	GC	ChemicalEntity	D005938
29968520	7	35	Glutathione-S-transferase P1	GeneOrGeneProduct	2950
29968520	52	73	Mangifera indica Linn	OrganismTaxon	29780
29968520	78	94	Escherichia coli	OrganismTaxon	562
29968520	219	221	GC	ChemicalEntity	D005938
29968520	243	271	Glutathione-S-transferase P1	GeneOrGeneProduct	2950
29968520	380	386	hRPTEC	CellLine	CVCL_K278
29968520	391	399	Mz-ChA-1	CellLine	CVCL_6932
29968520	444	446	GC	ChemicalEntity	D005938
29968520	451	479	Glutathione-S-transferase P1	GeneOrGeneProduct	2950
29968520	523	551	Glutathione-S-transferase P1	GeneOrGeneProduct	2950
29968520	556	558	GC	ChemicalEntity	D005938
29968520	643	645	GC	ChemicalEntity	D005938
29968520	650	678	Glutathione-S-transferase P1	GeneOrGeneProduct	2950
29968520	701	720	g.80_87delT CGCGAAG	SequenceVariant	g|DEL|80_87|TCGCGAAG
29968520	714	716	GC	ChemicalEntity	D005938
29968520	782	810	Glutathione-S-transferase P1	GeneOrGeneProduct	2950
29968520	819	825	hRPTEC	CellLine	CVCL_K278
29968520	830	838	Mz-ChA-1	CellLine	CVCL_6932
29968520	881	891	Glu873Stop	SequenceVariant	rs121918047
29968520	910	931	Mangifera indica Linn	OrganismTaxon	29780
29968520	1001	1029	Glutathione-S-transferase P1	GeneOrGeneProduct	2950
29968520	1050	1071	Mangifera indica Linn	OrganismTaxon	29780
29968520	1170	1186	Escherichia coli	OrganismTaxon	562
29968520	1293	1295	GC	ChemicalEntity	D005938
29968520	1297	1325	Glutathione-S-transferase P1	GeneOrGeneProduct	2950
29968520	Negative_Correlation	2950	D005938	Novel
29968520	Negative_Correlation	D005938	2950	Novel
29968520	Bind	D005938	2950	Novel

27355172|t|ATP and creatinine dynamics in SNU-C5 cells with sequence variants and their implications for impaired intellectual development and chronic allograft nep
27355172|a|This study investigates the molecular mechanisms underlying the interplay between ATP levels, creatinine metabolism, and genetic variants in SNU-C5 cells, with a focus on their association with impaired intellectual development and chronic allograft nephropathy. We demonstrate a positive correlation between the sequence variant 457_458insG and ATP levels, suggesting that this insertion may enhance cellular energy availability. Conversely, the stop codon for glutamine at codon 298 shows a negative correlation with ATP, indicating a potential disruption in energy homeostasis. Additionally, the sequence variant p.E947stop is negatively correlated with LY294002, a known inhibitor of the phosphatidylinositol 3-kinase pathway, implying a possible role in modulating signaling pathways. The T>G variant is found to have a negative correlation with ATP, further supporting the hypothesis that certain sequence changes may alter metabolic pathways.   We also observe a positive correlation between the stop codon for glutamine at codon 298 and creatinine levels, suggesting a potential link between this variant and renal function. The negative correlation between LY294002 and creatinine indicates that inhibition of the phosphatidylinositol 3-kinase pathway may influence creatinine clearance. Our findings are further supported by the presence of multiple instances of the RB1 gene, which is implicated in both impaired intellectual development and chronic allograft nephropathy. The repeated occurrence of the sequence variant T>G across multiple samples highlights its potential role in disease progression.   These results provide a framework for understanding how genetic variants, such as the stop codon for glutamine at codon 298 and 457_458insG, may influence metabolic and developmental outcomes in SNU-C5 cells, with implications for the management of conditions like impaired intellectual development and chronic allograft nephropathy.
27355172	0	3	ATP	ChemicalEntity	D000255
27355172	8	18	creatinine	ChemicalEntity	D003404
27355172	31	37	SNU-C5	CellLine	CVCL_5112
27355172	94	127	impaired intellectual development	DiseaseOrPhenotypicFeature	D008607
27355172	236	239	ATP	ChemicalEntity	D000255
27355172	248	258	creatinine	ChemicalEntity	D003404
27355172	295	301	SNU-C5	CellLine	CVCL_5112
27355172	348	381	impaired intellectual development	DiseaseOrPhenotypicFeature	D008607
27355172	386	415	chronic allograft nephropathy	DiseaseOrPhenotypicFeature	D051436
27355172	484	495	457_458insG	SequenceVariant	c|INS|457_458|G
27355172	500	503	ATP	ChemicalEntity	D000255
27355172	601	638	stop codon for glutamine at codon 298	SequenceVariant	p|SUB|Q|298|X
27355172	673	676	ATP	ChemicalEntity	D000255
27355172	770	780	p.E947stop	SequenceVariant	p|SUB|E|947|X
27355172	811	819	LY294002	ChemicalEntity	C085911
27355172	948	951	T>G	SequenceVariant	rs11891426
27355172	1005	1008	ATP	ChemicalEntity	D000255
27355172	1157	1194	stop codon for glutamine at codon 298	SequenceVariant	p|SUB|Q|298|X
27355172	1199	1209	creatinine	ChemicalEntity	D003404
27355172	1320	1328	LY294002	ChemicalEntity	C085911
27355172	1333	1343	creatinine	ChemicalEntity	D003404
27355172	1429	1439	creatinine	ChemicalEntity	D003404
27355172	1531	1534	RB1	GeneOrGeneProduct	5925
27355172	1569	1602	impaired intellectual development	DiseaseOrPhenotypicFeature	D008607
27355172	1607	1636	chronic allograft nephropathy	DiseaseOrPhenotypicFeature	D051436
27355172	1686	1689	T>G	SequenceVariant	rs11891426
27355172	1856	1893	stop codon for glutamine at codon 298	SequenceVariant	p|SUB|Q|298|X
27355172	1898	1909	457_458insG	SequenceVariant	c|INS|457_458|G
27355172	1965	1971	SNU-C5	CellLine	CVCL_5112
27355172	2035	2068	impaired intellectual development	DiseaseOrPhenotypicFeature	D008607
27355172	2073	2102	chronic allograft nephropathy	DiseaseOrPhenotypicFeature	D051436
27355172	Positive_Correlation	c|INS|457_458|G	D000255	Novel
27355172	Negative_Correlation	p|SUB|Q|298|X	D000255	Novel
27355172	Negative_Correlation	C085911	D003404	Novel
27355172	Negative_Correlation	p|SUB|E|947|X	C085911	Novel
27355172	Positive_Correlation	p|SUB|Q|298|X	D003404	Novel
27355172	Negative_Correlation	rs11891426	D000255	Novel

30001660|t|Uterine Sarcoma and Mitral Valve Prolapse: Interactions with Sarcoplasmic Reticulum Ca2+ -ATPase, Isoproterenol, and Antithrombot
30001660|a|Recent studies have revealed complex interactions between uterine sarcoma, mitral valve prolapse, and beta-cell dysfunction, with significant roles played by sarcoplasmic reticulum Ca2+ -ATPase, isoproterenol, and antithrombotic drugs. This study investigates the molecular and functional relationships among these entities, focusing on the associations and correlations observed in HCT116 cell lines and in response to sequence variants such as Ile(146)-->Leu, 192RR, and rs7535263.   Uterine sarcoma was found to be associated with sarcoplasmic reticulum Ca2+ -ATPase, with both positive and negative correlations observed depending on the context of cotreatment with antithrombotic drugs. The association between uterine sarcoma and sarcoplasmic reticulum Ca2+ -ATPase was further supported by the presence of the Ile(146)-->Leu variant in HCT116 cells. Additionally, the negative correlation between sarcoplasmic reticulum Ca2+ -ATPase and uterine sarcoma was evident in the presence of the 192RR variant, which modulated the expression of the enzyme in response to isoproterenol.  Mitral valve prolapse was found to be associated with antithrombotic drugs, with a negative correlation observed when these drugs were cotreated with sarcoplasmic reticulum Ca2+ -ATPase. The association between mitral valve prolapse and isoproterenol was also significant, with both positive and negative correlations noted depending on the presence of the rs7535263 variant. Furthermore, the association between mitral valve prolapse and sarcoplasmic reticulum Ca2+ -ATPase was confirmed through functional assays in HCT116 cell lines.  Beta-cell dysfunction was strongly associated with isoproterenol, with a negative correlation observed between isoproterenol and beta-cell dysfunction. The association between beta-cell dysfunction and antithrombotic drugs was also significant, with a negative correlation noted in the presence of the Ile(146)-->Leu variant. Additionally, the association between beta-cell dysfunction and sarcoplasmic reticulum Ca2+ -ATPase was supported by the presence of the 192RR variant, which modulated the enzyme's activity in response to isoproterenol.  The cotreatment of antithrombotic drugs with isoproterenol was found to have a significant impact on the expression of sarcoplasmic reticulum Ca2+ -ATPase, with both positive and negative effects observed depending on the genetic background of the HCT116 cell lines. These findings highlight the complex interplay between these entities and their potential implications for therapeutic strategies in the treatment of uterine sarcoma, mitral valve prolapse, and beta-cell dysfunction.
30001660	188	203	uterine sarcoma	DiseaseOrPhenotypicFeature	D014594
30001660	205	226	mitral valve prolapse	DiseaseOrPhenotypicFeature	D008945
30001660	232	253	beta-cell dysfunction	DiseaseOrPhenotypicFeature	-
30001660	325	338	isoproterenol	ChemicalEntity	D007545
30001660	344	364	antithrombotic drugs	ChemicalEntity	D005343
30001660	513	519	HCT116	CellLine	CVCL_0291
30001660	576	590	Ile(146)-->Leu	SequenceVariant	rs72478580
30001660	592	597	192RR	SequenceVariant	p|Allele|R|192
30001660	603	612	rs7535263	SequenceVariant	rs7535263
30001660	800	820	antithrombotic drugs	ChemicalEntity	D005343
30001660	846	861	uterine sarcoma	DiseaseOrPhenotypicFeature	D014594
30001660	947	961	Ile(146)-->Leu	SequenceVariant	rs72478580
30001660	973	979	HCT116	CellLine	CVCL_0291
30001660	1074	1089	uterine sarcoma	DiseaseOrPhenotypicFeature	D014594
30001660	1125	1130	192RR	SequenceVariant	p|Allele|R|192
30001660	1200	1213	isoproterenol	ChemicalEntity	D007545
30001660	1270	1290	antithrombotic drugs	ChemicalEntity	D005343
30001660	1427	1448	mitral valve prolapse	DiseaseOrPhenotypicFeature	D008945
30001660	1453	1466	isoproterenol	ChemicalEntity	D007545
30001660	1573	1582	rs7535263	SequenceVariant	rs7535263
30001660	1629	1650	mitral valve prolapse	DiseaseOrPhenotypicFeature	D008945
30001660	1734	1740	HCT116	CellLine	CVCL_0291
30001660	1805	1818	isoproterenol	ChemicalEntity	D007545
30001660	1865	1878	isoproterenol	ChemicalEntity	D007545
30001660	1883	1904	beta-cell dysfunction	DiseaseOrPhenotypicFeature	-
30001660	1930	1951	beta-cell dysfunction	DiseaseOrPhenotypicFeature	-
30001660	1956	1976	antithrombotic drugs	ChemicalEntity	D005343
30001660	2056	2070	Ile(146)-->Leu	SequenceVariant	rs72478580
30001660	2118	2139	beta-cell dysfunction	DiseaseOrPhenotypicFeature	-
30001660	2217	2222	192RR	SequenceVariant	p|Allele|R|192
30001660	2285	2298	isoproterenol	ChemicalEntity	D007545
30001660	2320	2340	antithrombotic drugs	ChemicalEntity	D005343
30001660	2346	2359	isoproterenol	ChemicalEntity	D007545
30001660	2549	2555	HCT116	CellLine	CVCL_0291
30001660	2718	2733	uterine sarcoma	DiseaseOrPhenotypicFeature	D014594
30001660	2735	2756	mitral valve prolapse	DiseaseOrPhenotypicFeature	D008945
30001660	2762	2783	beta-cell dysfunction	DiseaseOrPhenotypicFeature	-
30001660	Association	D014594	D053498	Novel
30001660	Association	D005343	D008945	Novel
30001660	Association	-	D007545	Novel
30001660	Cotreatment	D005343	D053498	Novel
30001660	Negative_Correlation	D007545	D014594	Novel
30001660	Association	D005343	D014594	Novel
30001660	Association	D053498	-	Novel
30001660	Association	D007545	-	Novel
30001660	Negative_Correlation	D005343	D008945	Novel
30001660	Association	-	D005343	Novel
30001660	Cotreatment	D005343	D007545	Novel
30001660	Negative_Correlation	D053498	D014594	Novel
30001660	Association	D053498	D014594	Novel
30001660	Association	D008945	D005343	Novel
30001660	Association	D008945	D053498	Novel
30001660	Association	D007545	D014594	Novel
30001660	Negative_Correlation	D005343	-	Novel
30001660	Negative_Correlation	D007545	-	Novel
30001660	Association	D008945	D007545	Novel
30001660	Negative_Correlation	D007545	D008945	Novel
30001660	Association	D007545	D008945	Novel

50416894|t|Genetic Variants in IL1RN and Tuba8: Associations with Infertility, TdP, and Aedes Mosquito Infection in HeLa and GT1-1 Ce
50416894|a|Recent studies have highlighted the complex interplay between genetic variants and phenotypic outcomes in Aedes mosquitoes, particularly in the context of infertility and cardiac arrhythmias such as TdP. This research explores the associations between specific sequence variants and gene products in HeLa and GT1-1 cell lines, with a focus on IL1RN, Tuba8, and their interactions.   The deletion of valine 624, valine 625 in IL1RN is strongly associated with infertility and TdP, as well as with the sequence variant rs1800587. This variant also shows a significant correlation with V311fs, a frameshift mutation that contributes to the pathogenesis of infertility and TdP. The rs1800587 variant is further linked to infertility, reinforcing its role in reproductive health.   In addition, the deletion of valine 624, valine 625 is found to bind directly to Tuba8, suggesting a functional interaction that may influence cellular processes in Aedes mosquitoes. The V311fs variant is also associated with TdP, indicating a potential role in cardiac dysfunction.   These findings were validated using HeLa and GT1-1 cell lines, which were exposed to Aedes mosquitoes to study the effects of these genetic variants on cellular behavior. The results provide evidence for the complex genetic architecture underlying infertility, TdP, and the interactions between IL1RN, Tuba8, and various sequence variants. This work underscores the importance of genetic studies in understanding the molecular mechanisms of disease and infection in vector-borne systems.
50416894	20	25	IL1RN	GeneOrGeneProduct	3557
50416894	30	35	Tuba8	GeneOrGeneProduct	53857
50416894	68	71	TdP	DiseaseOrPhenotypicFeature	D016171
50416894	105	109	HeLa	CellLine	CVCL_0030
50416894	114	119	GT1-1	CellLine	CVCL_6236
50416894	229	245	Aedes mosquitoes	OrganismTaxon	1245352
50416894	278	289	infertility	DiseaseOrPhenotypicFeature	D007247
50416894	322	325	TdP	DiseaseOrPhenotypicFeature	D016171
50416894	423	427	HeLa	CellLine	CVCL_0030
50416894	432	437	GT1-1	CellLine	CVCL_6236
50416894	466	471	IL1RN	GeneOrGeneProduct	3557
50416894	473	478	Tuba8	GeneOrGeneProduct	53857
50416894	510	544	deletion of valine 624, valine 625	SequenceVariant	p|DEL|624_625|VV
50416894	548	553	IL1RN	GeneOrGeneProduct	3557
50416894	582	593	infertility	DiseaseOrPhenotypicFeature	D007247
50416894	598	601	TdP	DiseaseOrPhenotypicFeature	D016171
50416894	640	649	rs1800587	SequenceVariant	rs1800587
50416894	706	712	V311fs	SequenceVariant	p|FS|V|311||
50416894	776	787	infertility	DiseaseOrPhenotypicFeature	D007247
50416894	792	795	TdP	DiseaseOrPhenotypicFeature	D016171
50416894	801	810	rs1800587	SequenceVariant	rs1800587
50416894	840	851	infertility	DiseaseOrPhenotypicFeature	D007247
50416894	917	951	deletion of valine 624, valine 625	SequenceVariant	p|DEL|624_625|VV
50416894	981	986	Tuba8	GeneOrGeneProduct	53857
50416894	1065	1081	Aedes mosquitoes	OrganismTaxon	1245352
50416894	1087	1093	V311fs	SequenceVariant	p|FS|V|311||
50416894	1126	1129	TdP	DiseaseOrPhenotypicFeature	D016171
50416894	1221	1225	HeLa	CellLine	CVCL_0030
50416894	1230	1235	GT1-1	CellLine	CVCL_6236
50416894	1270	1286	Aedes mosquitoes	OrganismTaxon	1245352
50416894	1433	1444	infertility	DiseaseOrPhenotypicFeature	D007247
50416894	1446	1449	TdP	DiseaseOrPhenotypicFeature	D016171
50416894	1480	1485	IL1RN	GeneOrGeneProduct	3557
50416894	1487	1492	Tuba8	GeneOrGeneProduct	53857
50416894	Bind	3557	53857	Novel
50416894	Association	p|FS|V|311||	rs1800587	Novel
50416894	Association	p|DEL|624_625|VV	p|FS|V|311||	Novel
50416894	Association	p|DEL|624_625|VV	D016171	Novel
50416894	Association	rs1800587	D007247	Novel
50416894	Association	p|DEL|624_625|VV	rs1800587	Novel
50416894	Association	p|FS|V|311||	D016171	Novel
50416894	Association	p|FS|V|311||	D007247	Novel
50416894	Association	rs1800587	p|DEL|624_625|VV	Novel
50416894	Association	p|DEL|624_625|VV	D007247	Novel

85674964|t|Genetic Variants and Their Impact on Chronic Liver Inflammation, Developmental Delay, and Hearing Impairment in Human and Zebrafis
85674964|a|This study investigates the complex interplay between genetic variants and their associations with chronic liver inflammation, developmental delay, and hearing impairment in both human and zebrafish models. We focus on two specific sequence variants: the replacement of the (GCG)6(GCA)3GCG sequence with (GCG)6(GCA)(GCG)4(GCA)3GCG, and the deletion of 92 nucleotides spanning -19/+73. These variants were analyzed in multiple cell lines, including HEK, HEK293, 293T, PA-1, LbetaT2, C4-2B, KU7, and C57BL/6, to assess their functional and phenotypic consequences.  Our findings reveal a negative correlation between the (GCG)6(GCA)3GCG sequence replacement and chronic liver inflammation, suggesting that this variant may have a protective role against liver inflammation. Conversely, a positive correlation was observed between this variant and hypokalemia, indicating a potential role in electrolyte homeostasis. Additionally, the same variant was associated with hearing impairment and developmental delay, with both positive and negative correlations observed, highlighting the complexity of its effects. Notably, the variant was also linked to a disorder of amino acid metabolism, with conflicting associations that require further investigation.  The deletion of 92 nucleotides (-19/+73) showed a positive correlation with chronic liver inflammation, supporting its involvement in inflammatory processes. This variant was also positively correlated with hypokalemia and developmental delay, while exhibiting a negative correlation with joint pain. Furthermore, the deletion was associated with a disorder of amino acid metabolism and hearing impairment, with some associations being negative. These results suggest that this deletion may have broad implications across multiple physiological systems.  In zebrafish models, the effects of these variants were studied to understand their broader biological relevance. The study underscores the importance of genetic variants in modulating disease phenotypes and highlights the need for further research to elucidate the molecular mechanisms underlying these associations. Overall, this work provides a comprehensive analysis of the relationships between specific genetic variants and a range of phenotypic features, offering insights into potential therapeutic targets and diagnostic markers.
85674964	230	256	chronic liver inflammation	DiseaseOrPhenotypicFeature	D007249
85674964	258	277	developmental delay	DiseaseOrPhenotypicFeature	D002658
85674964	283	301	hearing impairment	DiseaseOrPhenotypicFeature	D034381
85674964	579	582	HEK	CellLine	CVCL_M624
85674964	584	587	HEK	CellLine	CVCL_M624
85674964	584	590	HEK293	CellLine	CVCL_0045
85674964	592	596	293T	CellLine	CVCL_0063
85674964	598	602	PA-1	CellLine	CVCL_0479
85674964	604	611	LbetaT2	CellLine	CVCL_0398
85674964	613	618	C4-2B	CellLine	CVCL_4784
85674964	620	623	KU7	CellLine	CVCL_4714
85674964	629	636	C57BL/6	CellLine	CVCL_5746
85674964	791	817	chronic liver inflammation	DiseaseOrPhenotypicFeature	D007249
85674964	976	987	hypokalemia	DiseaseOrPhenotypicFeature	D007008
85674964	1096	1114	hearing impairment	DiseaseOrPhenotypicFeature	D034381
85674964	1119	1138	developmental delay	DiseaseOrPhenotypicFeature	D002658
85674964	1281	1314	disorder of amino acid metabolism	DiseaseOrPhenotypicFeature	D000592
85674964	1459	1485	chronic liver inflammation	DiseaseOrPhenotypicFeature	D007249
85674964	1590	1601	hypokalemia	DiseaseOrPhenotypicFeature	D007008
85674964	1606	1625	developmental delay	DiseaseOrPhenotypicFeature	D002658
85674964	1672	1682	joint pain	DiseaseOrPhenotypicFeature	D018771
85674964	1732	1765	disorder of amino acid metabolism	DiseaseOrPhenotypicFeature	D000592
85674964	1770	1788	hearing impairment	DiseaseOrPhenotypicFeature	D034381
85674964	Negative_Correlation	c|DEL|-19_+73|92	D007249	Novel
85674964	Association	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	D007008	Novel
85674964	Association	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	D034381	Novel
85674964	Negative_Correlation	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	D000592	Novel
85674964	Association	D034381	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	Novel
85674964	Association	D007249	c|DEL|-19_+73|92	Novel
85674964	Association	D007249	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	Novel
85674964	Positive_Correlation	D007008	c|DEL|-19_+73|92	Novel
85674964	Positive_Correlation	D007008	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	Novel
85674964	Positive_Correlation	c|DEL|-19_+73|92	D000592	Novel
85674964	Association	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	D002658	Novel
85674964	Negative_Correlation	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	D002658	Novel
85674964	Positive_Correlation	D002658	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	Novel
85674964	Negative_Correlation	c|DEL|-19_+73|92	D018771	Novel
85674964	Association	c|DEL|-19_+73|92	D002658	Novel
85674964	Positive_Correlation	c|DEL|-19_+73|92	D007249	Novel
85674964	Positive_Correlation	D002658	c|DEL|-19_+73|92	Novel
85674964	Positive_Correlation	D018771	c|DEL|-19_+73|92	Novel
85674964	Positive_Correlation	c|DEL|-19_+73|92	D018771	Novel
85674964	Positive_Correlation	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	D034381	Novel
85674964	Association	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	D000592	Novel
85674964	Positive_Correlation	D007249	c|DEL|-19_+73|92	Novel
85674964	Negative_Correlation	c|DEL|-19_+73|92	D000592	Novel
85674964	Association	D034381	c|DEL|-19_+73|92	Novel
85674964	Association	D002658	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	Novel
85674964	Positive_Correlation	D034381	c|DEL|-19_+73|92	Novel
85674964	Association	D007008	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	Novel
85674964	Positive_Correlation	D000592	c|DEL|-19_+73|92	Novel
85674964	Association	D002658	c|DEL|-19_+73|92	Novel
85674964	Negative_Correlation	c|DEL|-19_+73|92	D034381	Novel
85674964	Association	D018771	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	Novel

67429052|t|Reactive oxygen species and chloroacetaldehyde interactions in horses, mice, and yeast: implications for oxidative stress and cell line r
67429052|a|This study investigates the complex interactions between reactive oxygen species (ROS) and chloroacetaldehyde (CAA) in various biological systems, including horses, mice, and yeast. The research focuses on the positive correlation and association between ROS and CAA, as well as the reciprocal relationship between CAA and ROS. These interactions were examined across multiple cell lines, including Mz-ChA-1, PC-3, Ba/F3, CA3, and H9c2, to understand their role in oxidative stress and cellular responses.   In horses, the presence of ROS was found to be positively correlated with CAA levels, suggesting a potential regulatory mechanism in metabolic pathways. Similarly, in mice, the association between ROS and CAA was confirmed through biochemical assays, with both entities showing increased concentrations under oxidative stress conditions. Yeast models were used to further explore the relationship, revealing that CAA can modulate ROS production, thereby influencing cellular redox balance.  The Mz-ChA-1 cell line exhibited a strong positive correlation between ROS and CAA, while the PC-3 and Ba/F3 lines showed varying degrees of association. The CA3 and H9c2 cell lines were particularly responsive to changes in CAA levels, with ROS levels fluctuating in direct proportion to CAA concentrations. These findings highlight the importance of understanding the interplay between ROS and CAA in both physiological and pathological contexts, with potential applications in disease prevention and therapeutic strategies.
67429052	63	69	horses	OrganismTaxon	9796
67429052	81	86	yeast	OrganismTaxon	4932
67429052	195	218	reactive oxygen species	ChemicalEntity	D017382
67429052	295	301	horses	OrganismTaxon	9796
67429052	313	318	yeast	OrganismTaxon	4932
67429052	537	545	Mz-ChA-1	CellLine	CVCL_6932
67429052	547	551	PC-3	CellLine	CVCL_0035
67429052	553	558	Ba/F3	CellLine	CVCL_0161
67429052	560	563	CA3	CellLine	CVCL_JW73
67429052	569	573	H9c2	CellLine	CVCL_0286
67429052	649	655	horses	OrganismTaxon	9796
67429052	1141	1149	Mz-ChA-1	CellLine	CVCL_6932
67429052	1231	1235	PC-3	CellLine	CVCL_0035
67429052	1240	1245	Ba/F3	CellLine	CVCL_0161
67429052	1295	1298	CA3	CellLine	CVCL_JW73
67429052	1303	1307	H9c2	CellLine	CVCL_0286
67429052	Positive_Correlation	D017382	C004656	Novel
67429052	Association	D017382	C004656	Novel
67429052	Positive_Correlation	C004656	D017382	Novel
67429052	Association	C004656	D017382	Novel

70350798|t|TS and 17alpha-hydroxylase deficiency: interactions with SW480, BALB/c, Hs578T, and Capan1 cell lines in the context of SAD, akinesia, and juvenile p
70350798|a|This study investigates the complex interplay between TS and 17alpha-hydroxylase deficiency, with a focus on their associations with various cell lines and disease phenotypes. The research highlights the role of SW480, BALB/c, Hs578T, and Capan1 cell lines in modulating the expression and function of TS and 17alpha-hydroxylase deficiency. The findings suggest a positive correlation between anabolic androgenic steroid and 17alpha-hydroxylase deficiency, as well as a positive correlation between anabolic androgenic steroid and akinesia. These correlations were observed across multiple experimental conditions involving SW480 and Hs578T cell lines. Additionally, the study reveals a negative correlation between Cisplatin and SRL, which was most pronounced in BALB/c and Capan1 cell lines. The results also indicate that leucovorin and corticosteroid may play a modulatory role in these interactions, particularly in the context of juvenile polyposis and SAD. The data further suggest that TS may contribute to the pathogenesis of akinesia and juvenile polyposis, with implications for therapeutic strategies targeting these conditions. The study underscores the importance of understanding the molecular mechanisms underlying these associations to develop targeted interventions.
70350798	0	2	TS	DiseaseOrPhenotypicFeature	D054549
70350798	7	37	17alpha-hydroxylase deficiency	DiseaseOrPhenotypicFeature	C538237
70350798	57	62	SW480	CellLine	CVCL_0546
70350798	64	70	BALB/c	CellLine	CVCL_9101
70350798	72	78	Hs578T	CellLine	CVCL_0332
70350798	84	90	Capan1	CellLine	CVCL_0237
70350798	120	123	SAD	DiseaseOrPhenotypicFeature	D016574
70350798	125	133	akinesia	DiseaseOrPhenotypicFeature	D004409
70350798	204	206	TS	DiseaseOrPhenotypicFeature	D054549
70350798	211	241	17alpha-hydroxylase deficiency	DiseaseOrPhenotypicFeature	C538237
70350798	362	367	SW480	CellLine	CVCL_0546
70350798	369	375	BALB/c	CellLine	CVCL_9101
70350798	377	383	Hs578T	CellLine	CVCL_0332
70350798	389	395	Capan1	CellLine	CVCL_0237
70350798	452	454	TS	DiseaseOrPhenotypicFeature	D054549
70350798	459	489	17alpha-hydroxylase deficiency	DiseaseOrPhenotypicFeature	C538237
70350798	543	570	anabolic androgenic steroid	ChemicalEntity	D045165
70350798	575	605	17alpha-hydroxylase deficiency	DiseaseOrPhenotypicFeature	C538237
70350798	649	676	anabolic androgenic steroid	ChemicalEntity	D045165
70350798	681	689	akinesia	DiseaseOrPhenotypicFeature	D004409
70350798	774	779	SW480	CellLine	CVCL_0546
70350798	784	790	Hs578T	CellLine	CVCL_0332
70350798	866	875	Cisplatin	ChemicalEntity	D002945
70350798	880	883	SRL	ChemicalEntity	D020123
70350798	914	920	BALB/c	CellLine	CVCL_9101
70350798	925	931	Capan1	CellLine	CVCL_0237
70350798	975	985	leucovorin	ChemicalEntity	D002955
70350798	990	1004	corticosteroid	ChemicalEntity	D000305
70350798	1086	1104	juvenile polyposis	DiseaseOrPhenotypicFeature	C537702
70350798	1109	1112	SAD	DiseaseOrPhenotypicFeature	D016574
70350798	1144	1146	TS	DiseaseOrPhenotypicFeature	D054549
70350798	1185	1193	akinesia	DiseaseOrPhenotypicFeature	D004409
70350798	1198	1216	juvenile polyposis	DiseaseOrPhenotypicFeature	C537702
70350798	Positive_Correlation	D045165	C538237	Novel
70350798	Positive_Correlation	D045165	D004409	Novel
70350798	Negative_Correlation	D002945	D020123	Novel

99672225|t|Pirenzepine, GSH, and E-cadherin interactions in thrombocytopenia and hyperthyroidism: a study in Platonia insignis Mart and human immunodeficien
99672225|a|Recent studies have explored the complex interactions between pirenzepine, GSH, and E-cadherin in the context of thrombocytopenia and hyperthyroidism. In Platonia insignis Mart, a plant species known for its unique biochemical profile, researchers have observed a significant association between pirenzepine and GSH, as well as a positive correlation between pirenzepine and E-cadherin. These findings suggest that pirenzepine may modulate the redox state of the cell through its interaction with GSH, which in turn influences the expression and function of E-cadherin, a critical component of cell-cell adhesion.   In addition, the study found that GSH is associated with both voltage-gated calcium channels and beta-adrenergic receptors, with evidence of a bind between GSH and beta-adrenergic receptor. This interaction is further supported by a positive correlation between GSH and voltage-gated calcium channels, indicating a potential role for GSH in modulating calcium influx and downstream signaling pathways. The carbohydrate was found to bind to both the beta-adrenergic receptor and E-cadherin, suggesting that carbohydrate metabolism may influence these receptor functions. Furthermore, a positive correlation was observed between r-aminobutyric acid and E-cadherin, and a bind between carbohydrate and r-aminobutyric acid was also noted, highlighting the interconnected nature of these molecular interactions.  The study also examined the effects of these interactions in the context of hyperthyroidism and thrombocytopenia, with multiple instances of these conditions observed in both Platonia insignis Mart and human immunodeficiency virus. The sequence variant 326Ile was found to be associated with E-cadherin, while the variant I280S was linked to beta-adrenergic receptor function. Additionally, the sequence variant rs1329428 was identified as a potential modifier of GSH levels, further emphasizing the genetic complexity of these interactions.  The findings suggest that the interplay between pirenzepine, GSH, and E-cadherin may play a critical role in the pathophysiology of thrombocytopenia and hyperthyroidism, with implications for therapeutic strategies targeting these molecular pathways. The study also highlights the importance of considering the role of carbohydrate and r-aminobutyric acid in modulating these interactions, particularly in the context of disease states such as hyperthyroidism and thrombocytopenia.
99672225	13	16	GSH	ChemicalEntity	D005978
99672225	22	32	E-cadherin	GeneOrGeneProduct	12550
99672225	49	65	thrombocytopenia	DiseaseOrPhenotypicFeature	D013921
99672225	70	85	hyperthyroidism	DiseaseOrPhenotypicFeature	D006980
99672225	98	120	Platonia insignis Mart	OrganismTaxon	198787
99672225	208	219	pirenzepine	ChemicalEntity	D010890
99672225	221	224	GSH	ChemicalEntity	D005978
99672225	230	240	E-cadherin	GeneOrGeneProduct	12550
99672225	259	275	thrombocytopenia	DiseaseOrPhenotypicFeature	D013921
99672225	280	295	hyperthyroidism	DiseaseOrPhenotypicFeature	D006980
99672225	300	322	Platonia insignis Mart	OrganismTaxon	198787
99672225	442	453	pirenzepine	ChemicalEntity	D010890
99672225	458	461	GSH	ChemicalEntity	D005978
99672225	505	516	pirenzepine	ChemicalEntity	D010890
99672225	521	531	E-cadherin	GeneOrGeneProduct	12550
99672225	561	572	pirenzepine	ChemicalEntity	D010890
99672225	643	646	GSH	ChemicalEntity	D005978
99672225	704	714	E-cadherin	GeneOrGeneProduct	12550
99672225	796	799	GSH	ChemicalEntity	D005978
99672225	824	854	voltage-gated calcium channels	GeneOrGeneProduct	783
99672225	859	883	beta-adrenergic receptor	GeneOrGeneProduct	11554
99672225	918	921	GSH	ChemicalEntity	D005978
99672225	926	950	beta-adrenergic receptor	GeneOrGeneProduct	11554
99672225	1024	1027	GSH	ChemicalEntity	D005978
99672225	1032	1062	voltage-gated calcium channels	GeneOrGeneProduct	783
99672225	1096	1099	GSH	ChemicalEntity	D005978
99672225	1168	1180	carbohydrate	ChemicalEntity	D002241
99672225	1211	1235	beta-adrenergic receptor	GeneOrGeneProduct	11554
99672225	1240	1250	E-cadherin	GeneOrGeneProduct	12550
99672225	1268	1280	carbohydrate	ChemicalEntity	D002241
99672225	1389	1408	r-aminobutyric acid	ChemicalEntity	D005680
99672225	1413	1423	E-cadherin	GeneOrGeneProduct	12550
99672225	1444	1456	carbohydrate	ChemicalEntity	D002241
99672225	1461	1480	r-aminobutyric acid	ChemicalEntity	D005680
99672225	1646	1661	hyperthyroidism	DiseaseOrPhenotypicFeature	D006980
99672225	1666	1682	thrombocytopenia	DiseaseOrPhenotypicFeature	D013921
99672225	1745	1767	Platonia insignis Mart	OrganismTaxon	198787
99672225	1772	1800	human immunodeficiency virus	OrganismTaxon	12721
99672225	1823	1829	326Ile	SequenceVariant	rs3730089
99672225	1862	1872	E-cadherin	GeneOrGeneProduct	12550
99672225	1892	1897	I280S	SequenceVariant	p|SUB|I|280|S
99672225	1912	1936	beta-adrenergic receptor	GeneOrGeneProduct	11554
99672225	1982	1991	rs1329428	SequenceVariant	rs1329428
99672225	2034	2037	GSH	ChemicalEntity	D005978
99672225	2161	2172	pirenzepine	ChemicalEntity	D010890
99672225	2174	2177	GSH	ChemicalEntity	D005978
99672225	2183	2193	E-cadherin	GeneOrGeneProduct	12550
99672225	2245	2261	thrombocytopenia	DiseaseOrPhenotypicFeature	D013921
99672225	2266	2281	hyperthyroidism	DiseaseOrPhenotypicFeature	D006980
99672225	2432	2444	carbohydrate	ChemicalEntity	D002241
99672225	2449	2468	r-aminobutyric acid	ChemicalEntity	D005680
99672225	2557	2572	hyperthyroidism	DiseaseOrPhenotypicFeature	D006980
99672225	2577	2593	thrombocytopenia	DiseaseOrPhenotypicFeature	D013921
99672225	Association	D005978	D010890	Novel
99672225	Bind	D002241	11554	Novel
99672225	Positive_Correlation	D005680	12550	Novel
99672225	Association	D005978	783	Novel
99672225	Association	D002241	D005680	Novel
99672225	Bind	D005978	11554	Novel
99672225	Positive_Correlation	D005978	783	Novel
99672225	Bind	D002241	12550	Novel
99672225	Association	D010890	D005978	Novel
99672225	Positive_Correlation	D010890	12550	Novel
99672225	Bind	D005978	783	Novel
99672225	Association	D005978	12550	Novel
99672225	Association	D010890	D005680	Novel

03531438|t|Sorafenib and dexamphetamine interactions in rectal cancers and their associations with COX-1, APO, and hyper
03531438|a|This study investigates the pharmacological interactions between Sorafenib and dexamphetamine in the context of rectal cancers and their associations with COX-1, APO, and hyperactivity. We demonstrate a drug interaction between dexamphetamine and Sorafenib, which may influence their therapeutic efficacy and side effect profiles. Our findings reveal a negative correlation between rectal cancers and COX-1, while a positive correlation is observed between rectal cancers and COX-1, suggesting a complex regulatory mechanism. Additionally, we report a negative correlation between Malignant peripheral nerve sheath tumors and COX-1, and a positive correlation between hyperactivity and COX-1. The binding of dexamphetamine to COX-1 is confirmed through molecular docking studies, highlighting its potential role in modulating COX-1 activity. Furthermore, we establish an association between Sorafenib and APO, indicating a possible mechanism by which Sorafenib exerts its anti-cancer effects. The study also includes in vitro experiments using the HK2 and SMMC-7721 cell lines to validate these findings. The BALB/c cell line was used as a control to ensure the specificity of the observed effects. These results provide new insights into the molecular mechanisms underlying the interactions between these compounds and their potential therapeutic applications in cancer and neurological disorders.
03531438	0	9	Sorafenib	ChemicalEntity	D000077157
03531438	14	28	dexamphetamine	ChemicalEntity	D003913
03531438	45	59	rectal cancers	DiseaseOrPhenotypicFeature	D012004
03531438	88	93	COX-1	GeneOrGeneProduct	4512
03531438	95	98	APO	GeneOrGeneProduct	84909
03531438	175	184	Sorafenib	ChemicalEntity	D000077157
03531438	189	203	dexamphetamine	ChemicalEntity	D003913
03531438	222	236	rectal cancers	DiseaseOrPhenotypicFeature	D012004
03531438	265	270	COX-1	GeneOrGeneProduct	4512
03531438	272	275	APO	GeneOrGeneProduct	84909
03531438	281	294	hyperactivity	DiseaseOrPhenotypicFeature	D006948
03531438	338	352	dexamphetamine	ChemicalEntity	D003913
03531438	357	366	Sorafenib	ChemicalEntity	D000077157
03531438	492	506	rectal cancers	DiseaseOrPhenotypicFeature	D012004
03531438	511	516	COX-1	GeneOrGeneProduct	4512
03531438	567	581	rectal cancers	DiseaseOrPhenotypicFeature	D012004
03531438	586	591	COX-1	GeneOrGeneProduct	4512
03531438	691	731	Malignant peripheral nerve sheath tumors	DiseaseOrPhenotypicFeature	D018319
03531438	736	741	COX-1	GeneOrGeneProduct	4512
03531438	778	791	hyperactivity	DiseaseOrPhenotypicFeature	D006948
03531438	796	801	COX-1	GeneOrGeneProduct	4512
03531438	818	832	dexamphetamine	ChemicalEntity	D003913
03531438	836	841	COX-1	GeneOrGeneProduct	4512
03531438	936	941	COX-1	GeneOrGeneProduct	4512
03531438	1001	1010	Sorafenib	ChemicalEntity	D000077157
03531438	1015	1018	APO	GeneOrGeneProduct	84909
03531438	1061	1070	Sorafenib	ChemicalEntity	D000077157
03531438	1158	1161	HK2	CellLine	CVCL_0302
03531438	1166	1175	SMMC-7721	CellLine	CVCL_0534
03531438	1219	1225	BALB/c	CellLine	CVCL_9101
03531438	Drug_Interaction	D003913	D000077157	Novel
03531438	Negative_Correlation	D012004	4512	Novel
03531438	Negative_Correlation	D018319	4512	Novel
03531438	Bind	D003913	4512	Novel
03531438	Association	D000077157	84909	Novel
03531438	Positive_Correlation	D012004	4512	Novel
03531438	Positive_Correlation	D006948	4512	Novel

88144195|t|HK2 and H446 cell lines in the context of non-syndromic deafness, liver toxicity, and inpatient care: a study on yeast and West Nile virus inte
88144195|a|This study investigates the role of the HK2 and H446 cell lines in the pathogenesis of non-syndromic deafness and liver toxicity, with a focus on their interactions with inpatient care settings. The research explores how these cell lines respond to environmental stressors, including exposure to yeast and West Nile virus. The findings suggest that HK2 cells exhibit a unique susceptibility to yeast-induced inflammation, which may contribute to the development of non-syndromic deafness. In contrast, H446 cells show a higher resistance to yeast infection, but are more prone to liver toxicity under inpatient conditions. The study also highlights the importance of inpatient monitoring in patients with non-syndromic deafness, as they are at increased risk of complications related to liver toxicity. Additionally, the presence of West Nile virus in inpatient environments is linked to a higher incidence of liver toxicity, particularly in patients with pre-existing conditions. The research underscores the need for further studies on the interplay between cell lines, yeast, and viral infections in the context of inpatient care and their impact on disease progression.
88144195	0	3	HK2	CellLine	CVCL_0302
88144195	8	12	H446	CellLine	CVCL_1562
88144195	42	64	non-syndromic deafness	DiseaseOrPhenotypicFeature	D003638
88144195	66	80	liver toxicity	DiseaseOrPhenotypicFeature	D056486
88144195	86	95	inpatient	OrganismTaxon	9606
88144195	113	118	yeast	OrganismTaxon	4932
88144195	123	138	West Nile virus	OrganismTaxon	11082
88144195	184	187	HK2	CellLine	CVCL_0302
88144195	192	196	H446	CellLine	CVCL_1562
88144195	231	253	non-syndromic deafness	DiseaseOrPhenotypicFeature	D003638
88144195	258	272	liver toxicity	DiseaseOrPhenotypicFeature	D056486
88144195	314	323	inpatient	OrganismTaxon	9606
88144195	440	445	yeast	OrganismTaxon	4932
88144195	450	465	West Nile virus	OrganismTaxon	11082
88144195	493	496	HK2	CellLine	CVCL_0302
88144195	538	543	yeast	OrganismTaxon	4932
88144195	609	631	non-syndromic deafness	DiseaseOrPhenotypicFeature	D003638
88144195	646	650	H446	CellLine	CVCL_1562
88144195	685	690	yeast	OrganismTaxon	4932
88144195	724	738	liver toxicity	DiseaseOrPhenotypicFeature	D056486
88144195	745	754	inpatient	OrganismTaxon	9606
88144195	811	820	inpatient	OrganismTaxon	9606
88144195	849	871	non-syndromic deafness	DiseaseOrPhenotypicFeature	D003638
88144195	931	945	liver toxicity	DiseaseOrPhenotypicFeature	D056486
88144195	977	992	West Nile virus	OrganismTaxon	11082
88144195	996	1005	inpatient	OrganismTaxon	9606
88144195	1054	1068	liver toxicity	DiseaseOrPhenotypicFeature	D056486
88144195	1216	1221	yeast	OrganismTaxon	4932
88144195	1262	1271	inpatient	OrganismTaxon	9606

89782379|t|Erysipelas, cataracts, and uterine sarcoma: genetic associations with Bax, Akt, and sequence variants in a multi-phenoty
89782379|a|A comprehensive study was conducted to investigate the genetic and molecular mechanisms underlying erysipelas, cataracts, and uterine sarcoma. The research focused on the interplay between specific sequence variants and gene products, including the role of Bax, Akt, and c-Kit in disease pathogenesis. The study revealed a positive correlation between erysipelas and the sequence variant codon 787 CAG/CAA, suggesting a potential genetic link in the development of this inflammatory skin condition. Additionally, an association was found between cataracts and the sequence variant rs2070197, highlighting its possible involvement in ocular disease progression.   The study also demonstrated a positive correlation between the gene product C4A and Akt, indicating a potential regulatory relationship that may influence immune responses and cellular signaling. Furthermore, the association between erysipelas and the sequence variant G86R was confirmed, as was the positive correlation between uterine sarcoma and G86R, suggesting a shared genetic basis for these two distinct conditions.   The sequence variant p.Arg284Pro was found to be associated with the gene product Bax, pointing to its role in apoptosis regulation. The study also included multiple instances of the gene product Akt, which was implicated in various cellular processes, including cell survival and proliferation. The gene product c-Kit was found to be present in multiple instances, suggesting its involvement in multiple disease pathways.   The findings underscore the complex genetic architecture of these conditions and provide a foundation for future research into targeted therapeutic strategies. The study also included instances of palmoplantar keratoderma, acanthosis, and MKS, further emphasizing the need for a multi-phenotype approach in understanding the genetic basis of complex diseases.
89782379	12	21	cataracts	DiseaseOrPhenotypicFeature	D002386
89782379	27	42	uterine sarcoma	DiseaseOrPhenotypicFeature	D014594
89782379	70	73	Bax	GeneOrGeneProduct	24887
89782379	75	78	Akt	GeneOrGeneProduct	24185
89782379	220	230	erysipelas	DiseaseOrPhenotypicFeature	D004886
89782379	232	241	cataracts	DiseaseOrPhenotypicFeature	D002386
89782379	247	262	uterine sarcoma	DiseaseOrPhenotypicFeature	D014594
89782379	378	381	Bax	GeneOrGeneProduct	24887
89782379	383	386	Akt	GeneOrGeneProduct	24185
89782379	392	397	c-Kit	GeneOrGeneProduct	16590
89782379	473	483	erysipelas	DiseaseOrPhenotypicFeature	D004886
89782379	509	526	codon 787 CAG/CAA	SequenceVariant	p|SUB|Q|787|Q
89782379	667	676	cataracts	DiseaseOrPhenotypicFeature	D002386
89782379	702	711	rs2070197	SequenceVariant	rs2070197
89782379	860	863	C4A	GeneOrGeneProduct	720
89782379	868	871	Akt	GeneOrGeneProduct	24185
89782379	1017	1027	erysipelas	DiseaseOrPhenotypicFeature	D004886
89782379	1053	1057	G86R	SequenceVariant	rs28937888
89782379	1113	1128	uterine sarcoma	DiseaseOrPhenotypicFeature	D014594
89782379	1133	1137	G86R	SequenceVariant	rs28937888
89782379	1231	1242	p.Arg284Pro	SequenceVariant	rs1114167891
89782379	1292	1295	Bax	GeneOrGeneProduct	24887
89782379	1406	1409	Akt	GeneOrGeneProduct	24185
89782379	1523	1528	c-Kit	GeneOrGeneProduct	16590
89782379	1832	1856	palmoplantar keratoderma	DiseaseOrPhenotypicFeature	D007645
89782379	1858	1868	acanthosis	DiseaseOrPhenotypicFeature	D000052
89782379	1874	1877	MKS	DiseaseOrPhenotypicFeature	C536133
89782379	Positive_Correlation	D004886	p|SUB|Q|787|Q	Novel
89782379	Association	D002386	rs2070197	Novel
89782379	Positive_Correlation	720	24185	Novel
89782379	Association	D004886	rs28937888	Novel
89782379	Positive_Correlation	D014594	rs28937888	Novel
89782379	Association	rs1114167891	24887	Novel

24994744|t|Palmoplantar erythrokeratoderma, YC1, and melatonin: complex interactions with midazolam, Nijmegen breakage syndrome, and proteinuria in human immunodeficiency virus and Mangifera ind
24994744|a|Recent studies have revealed intricate relationships between palmoplantar erythrokeratoderma, YC1, and melatonin in both human immunodeficiency virus (HIV) and Mangifera indica Linn. This research explores the positive correlation between midazolam and palmoplantar erythrokeratoderma, suggesting that midazolam may modulate the expression or activity of this phenotypic feature. Additionally, a strong association between Nijmegen breakage syndrome and YC1 was observed, indicating a potential role for YC1 in the pathogenesis of this disease. The positive correlation between Nijmegen breakage syndrome and midazolam further supports the hypothesis that midazolam may influence the progression or severity of this condition.   Melatonin was found to have a positive correlation with Nijmegen breakage syndrome, and an association between Nijmegen breakage syndrome and melatonin was confirmed. These findings suggest that melatonin may play a protective or regulatory role in the context of Nijmegen breakage syndrome. Furthermore, a positive correlation between proteinuria and midazolam was identified, indicating that midazolam may contribute to the development or exacerbation of proteinuria.   The cotreatment of melatonin and midazolam was associated with improved outcomes in patients with palmoplantar erythrokeratoderma, and an association between midazolam and melatonin was consistently observed. Additionally, a positive correlation between melatonin and palmoplantar erythrokeratoderma was noted, suggesting that melatonin may have therapeutic potential in managing this condition.   The association between proteinuria and melatonin was also confirmed, with a positive correlation between proteinuria and melatonin reinforcing the idea that melatonin may help mitigate the effects of proteinuria. Finally, a positive correlation between midazolam and melatonin was observed, highlighting the potential for these two chemical entities to work synergistically in the treatment of various conditions. These findings provide a comprehensive understanding of the complex interactions between palmoplantar erythrokeratoderma, YC1, midazolam, melatonin, Nijmegen breakage syndrome, and proteinuria in both HIV and Mangifera indica Linn.
24994744	33	36	YC1	GeneOrGeneProduct	56878
24994744	42	51	melatonin	ChemicalEntity	D008550
24994744	79	88	midazolam	ChemicalEntity	D008874
24994744	90	116	Nijmegen breakage syndrome	DiseaseOrPhenotypicFeature	D049932
24994744	122	133	proteinuria	DiseaseOrPhenotypicFeature	D011507
24994744	137	165	human immunodeficiency virus	OrganismTaxon	12721
24994744	245	276	palmoplantar erythrokeratoderma	DiseaseOrPhenotypicFeature	C563781
24994744	278	281	YC1	GeneOrGeneProduct	56878
24994744	287	296	melatonin	ChemicalEntity	D008550
24994744	305	333	human immunodeficiency virus	OrganismTaxon	12721
24994744	344	365	Mangifera indica Linn	OrganismTaxon	29780
24994744	423	432	midazolam	ChemicalEntity	D008874
24994744	437	468	palmoplantar erythrokeratoderma	DiseaseOrPhenotypicFeature	C563781
24994744	486	495	midazolam	ChemicalEntity	D008874
24994744	607	633	Nijmegen breakage syndrome	DiseaseOrPhenotypicFeature	D049932
24994744	638	641	YC1	GeneOrGeneProduct	56878
24994744	688	691	YC1	GeneOrGeneProduct	56878
24994744	762	788	Nijmegen breakage syndrome	DiseaseOrPhenotypicFeature	D049932
24994744	793	802	midazolam	ChemicalEntity	D008874
24994744	840	849	midazolam	ChemicalEntity	D008874
24994744	969	995	Nijmegen breakage syndrome	DiseaseOrPhenotypicFeature	D049932
24994744	1024	1050	Nijmegen breakage syndrome	DiseaseOrPhenotypicFeature	D049932
24994744	1055	1064	melatonin	ChemicalEntity	D008550
24994744	1108	1117	melatonin	ChemicalEntity	D008550
24994744	1177	1203	Nijmegen breakage syndrome	DiseaseOrPhenotypicFeature	D049932
24994744	1249	1260	proteinuria	DiseaseOrPhenotypicFeature	D011507
24994744	1265	1274	midazolam	ChemicalEntity	D008874
24994744	1307	1316	midazolam	ChemicalEntity	D008874
24994744	1370	1381	proteinuria	DiseaseOrPhenotypicFeature	D011507
24994744	1404	1413	melatonin	ChemicalEntity	D008550
24994744	1418	1427	midazolam	ChemicalEntity	D008874
24994744	1483	1514	palmoplantar erythrokeratoderma	DiseaseOrPhenotypicFeature	C563781
24994744	1543	1552	midazolam	ChemicalEntity	D008874
24994744	1557	1566	melatonin	ChemicalEntity	D008550
24994744	1639	1648	melatonin	ChemicalEntity	D008550
24994744	1653	1684	palmoplantar erythrokeratoderma	DiseaseOrPhenotypicFeature	C563781
24994744	1712	1721	melatonin	ChemicalEntity	D008550
24994744	1807	1818	proteinuria	DiseaseOrPhenotypicFeature	D011507
24994744	1823	1832	melatonin	ChemicalEntity	D008550
24994744	1889	1900	proteinuria	DiseaseOrPhenotypicFeature	D011507
24994744	1905	1914	melatonin	ChemicalEntity	D008550
24994744	1941	1950	melatonin	ChemicalEntity	D008550
24994744	1984	1995	proteinuria	DiseaseOrPhenotypicFeature	D011507
24994744	2037	2046	midazolam	ChemicalEntity	D008874
24994744	2051	2060	melatonin	ChemicalEntity	D008550
24994744	2287	2318	palmoplantar erythrokeratoderma	DiseaseOrPhenotypicFeature	C563781
24994744	2320	2323	YC1	GeneOrGeneProduct	56878
24994744	2325	2334	midazolam	ChemicalEntity	D008874
24994744	2336	2345	melatonin	ChemicalEntity	D008550
24994744	2347	2373	Nijmegen breakage syndrome	DiseaseOrPhenotypicFeature	D049932
24994744	2379	2390	proteinuria	DiseaseOrPhenotypicFeature	D011507
24994744	2407	2428	Mangifera indica Linn	OrganismTaxon	29780
24994744	Positive_Correlation	D008874	C563781	Novel
24994744	Association	D049932	56878	Novel
24994744	Positive_Correlation	D049932	D008874	Novel
24994744	Positive_Correlation	D049932	D008550	Novel
24994744	Association	D049932	D008550	Novel
24994744	Positive_Correlation	D011507	D008874	Novel
24994744	Cotreatment	D008550	D008874	Novel
24994744	Association	D008874	D008550	Novel
24994744	Association	D008550	D008874	Novel
24994744	Association	D008874	56878	Novel
24994744	Positive_Correlation	D008550	D049932	Novel
24994744	Association	D011507	D008550	Novel
24994744	Positive_Correlation	D011507	D008550	Novel
24994744	Positive_Correlation	D008874	D008550	Novel
24994744	Positive_Correlation	D008550	C563781	Novel

59668493|t|Salvianolic Acid A and Its Interactions with RAD51, MHC, and A6V in Yeast Models of Autosomal Dominant Developmental Disorder of 
59668493|a|Salvianolic acid A (SAA) has been shown to interact with multiple biological entities, including the gene products RAD51 and MHC, as well as the sequence variant A6V, in yeast models. This study explores the complex relationships between SAA and these molecular components, with a focus on their potential roles in the pathogenesis of autosomal dominant developmental disorder of the iris (ADDDI).   Our findings reveal a bind between RAD51 and SAA, suggesting a direct molecular interaction that may influence DNA repair processes. Additionally, SAA exhibits both positive and negative correlations with MHC, indicating a dual role in modulating immune responses. A positive correlation between SAA and RAD51 further supports the hypothesis that SAA may enhance the function of RAD51 in maintaining genomic stability.   The sequence variant A6V shows a positive correlation with SAA, and an association between A6V and SAA is observed, suggesting that SAA may influence the expression or activity of A6V. Furthermore, an association between MHC and RAD51 is noted, highlighting potential crosstalk between these two gene products.   Notably, SAA also demonstrates a negative correlation with ADDDI, implying that its presence may mitigate the severity of this developmental disorder. This is supported by the observation that SAA binds to MHC, potentially modulating immune pathways involved in the disease.   These results underscore the multifaceted interactions of SAA with various molecular entities in yeast, providing a foundation for further research into its therapeutic potential in the context of ADDDI and other related conditions.
59668493	45	50	RAD51	GeneOrGeneProduct	5888
59668493	52	55	MHC	GeneOrGeneProduct	3123
59668493	61	64	A6V	SequenceVariant	rs199922907
59668493	245	250	RAD51	GeneOrGeneProduct	5888
59668493	255	258	MHC	GeneOrGeneProduct	3123
59668493	292	295	A6V	SequenceVariant	rs199922907
59668493	300	305	yeast	OrganismTaxon	4932
59668493	465	518	autosomal dominant developmental disorder of the iris	DiseaseOrPhenotypicFeature	D007499
59668493	565	570	RAD51	GeneOrGeneProduct	5888
59668493	735	738	MHC	GeneOrGeneProduct	3123
59668493	834	839	RAD51	GeneOrGeneProduct	5888
59668493	909	914	RAD51	GeneOrGeneProduct	5888
59668493	972	975	A6V	SequenceVariant	rs199922907
59668493	1042	1045	A6V	SequenceVariant	rs199922907
59668493	1131	1134	A6V	SequenceVariant	rs199922907
59668493	1172	1175	MHC	GeneOrGeneProduct	3123
59668493	1180	1185	RAD51	GeneOrGeneProduct	5888
59668493	1470	1473	MHC	GeneOrGeneProduct	3123
59668493	1638	1643	yeast	OrganismTaxon	4932
59668493	Bind	5888	C066201	Novel
59668493	Negative_Correlation	C066201	3123	Novel
59668493	Positive_Correlation	C066201	3123	Novel
59668493	Positive_Correlation	rs199922907	C066201	Novel
59668493	Association	C066201	rs199922907	Novel
59668493	Association	5888	3123	Novel
59668493	Negative_Correlation	D007499	C066201	Novel
59668493	Bind	3123	C066201	Novel
59668493	Positive_Correlation	C066201	5888	Novel
59668493	Negative_Correlation	C066201	5888	Novel
59668493	Association	3123	5888	Novel

63605793|t|Genetic Variants in P2RX7 and NOS Modulate Carcinogenesis and Interstitial Nephritis: A Multifactorial Analysis Involving hCG, Dopaminergic Drugs, and Camp
63605793|a|Recent studies have highlighted the complex interplay between genetic variants and disease susceptibility, particularly in the context of carcinogenesis and interstitial nephritis. This study investigates the association between specific sequence variants and disease outcomes, with a focus on the role of P2RX7 and NOS in modulating these conditions. The sequence variant c.1627A>T was found to be significantly associated with carcinogenesis, as evidenced by its presence in multiple tumor samples and its correlation with increased proliferation rates. Similarly, the variant p.A1369S was linked to both carcinogenesis and Anemia, suggesting a dual role in oncogenic processes and hematological disorders. The variant R266W also showed a strong association with carcinogenesis, further supporting the hypothesis that these genetic changes contribute to tumor development.   In addition to these variants, the study examined the impact of del 92 nucleotide -19/+73 on gene expression and found that it may influence the stability of the P2RX7 transcript. The chemical entity hCG was found to modulate the expression of NOS, which in turn affects the progression of carcinogenesis. The use of dopaminergic drugs and camptothecin was associated with altered NOS activity, suggesting potential therapeutic applications in cancer treatment.   The gene product ghrelin was found to interact with the sequence variant G7958, which was present in three independent cohorts. The chemical entity EPZ015666 was shown to enhance the expression of RP1, which may have implications for the regulation of cell cycle progression. The gene product chordin-like was found to be upregulated in the presence of the sequence variant G7958, indicating a possible role in developmental pathways.   The study also explored the association between the gene product MLH1 and the disease phenotypic feature basal cell carcinomas, finding a significant correlation. The gene product IL-23 was linked to breast diseases, suggesting a potential role in the immune response to tumor formation. The sequence variant p.A1369S was also found to be associated with interstitial nephritis, highlighting the pleiotropic effects of genetic changes.   Overall, this study provides a comprehensive analysis of the genetic and molecular mechanisms underlying carcinogenesis and related phenotypes, offering new insights into the potential therapeutic targets for these conditions.
63605793	20	25	P2RX7	GeneOrGeneProduct	5027
63605793	30	33	NOS	GeneOrGeneProduct	24598
63605793	122	125	hCG	ChemicalEntity	D006063
63605793	294	308	carcinogenesis	DiseaseOrPhenotypicFeature	D063646
63605793	313	335	interstitial nephritis	DiseaseOrPhenotypicFeature	D009395
63605793	462	467	P2RX7	GeneOrGeneProduct	5027
63605793	472	475	NOS	GeneOrGeneProduct	24598
63605793	529	538	c.1627A>T	SequenceVariant	c|SUB|A|1627|T
63605793	585	599	carcinogenesis	DiseaseOrPhenotypicFeature	D063646
63605793	735	743	p.A1369S	SequenceVariant	rs757110
63605793	763	777	carcinogenesis	DiseaseOrPhenotypicFeature	D063646
63605793	782	788	Anemia	DiseaseOrPhenotypicFeature	D000740
63605793	877	882	R266W	SequenceVariant	p|SUB|R|266|W
63605793	921	935	carcinogenesis	DiseaseOrPhenotypicFeature	D063646
63605793	1097	1122	del 92 nucleotide -19/+73	SequenceVariant	c|DEL|-19_+73|92
63605793	1195	1200	P2RX7	GeneOrGeneProduct	5027
63605793	1233	1236	hCG	ChemicalEntity	D006063
63605793	1277	1280	NOS	GeneOrGeneProduct	24598
63605793	1323	1337	carcinogenesis	DiseaseOrPhenotypicFeature	D063646
63605793	1350	1367	dopaminergic drug	ChemicalEntity	D004298
63605793	1373	1385	camptothecin	ChemicalEntity	D002166
63605793	1414	1417	NOS	GeneOrGeneProduct	24598
63605793	1514	1521	ghrelin	GeneOrGeneProduct	58991
63605793	1570	1575	G7958	SequenceVariant	c|Aelle|G|7958
63605793	1645	1654	EPZ015666	ChemicalEntity	C000599896
63605793	1694	1697	RP1	GeneOrGeneProduct	6101
63605793	1790	1802	chordin-like	GeneOrGeneProduct	563085
63605793	1871	1876	G7958	SequenceVariant	c|Aelle|G|7958
63605793	1999	2003	MLH1	GeneOrGeneProduct	4292
63605793	2039	2060	basal cell carcinomas	DiseaseOrPhenotypicFeature	D002280
63605793	2114	2119	IL-23	GeneOrGeneProduct	83430
63605793	2134	2149	breast diseases	DiseaseOrPhenotypicFeature	D001941
63605793	2243	2251	p.A1369S	SequenceVariant	rs757110
63605793	2289	2311	interstitial nephritis	DiseaseOrPhenotypicFeature	D009395
63605793	2477	2491	carcinogenesis	DiseaseOrPhenotypicFeature	D063646
63605793	Association	c|SUB|A|1627|T	D063646	Novel
63605793	Association	rs757110	D063646	Novel
63605793	Association	p|SUB|R|266|W	D063646	Novel
63605793	Association	rs757110	D000740	Novel

89056085|t|Role of manganese superoxide dismutase and the c.2444A>C sequence variant in memory deficiency and hypersensitivity in Murin
89056085|a|In this study, we investigate the role of manganese superoxide dismutase (MnSOD) and the sequence variant c.2444A>C in the development of memory deficiency and hypersensitivity in Murine models. Our findings reveal a positive correlation between MnSOD expression and memory deficiency in H446 cell lines, suggesting that MnSOD may play a critical role in the pathophysiology of memory-related phenotypes. Additionally, we observe a positive correlation between MnSOD and hypersensitivity, indicating a potential involvement of MnSOD in immune-mediated responses. The c.2444A>C sequence variant is strongly associated with MnSOD, with multiple instances of this variant detected in Murine populations. This association is further supported by the consistent presence of c.2444A>C in H446 cell lines, which exhibit altered MnSOD activity. Our results highlight the importance of MnSOD and its sequence variants in the regulation of memory deficiency and hypersensitivity, providing a foundation for future studies on the molecular mechanisms underlying these phenotypic features in Murine models. The data also suggest that the c.2444A>C variant may serve as a biomarker for MnSOD-related disorders, with implications for both basic research and therapeutic development.
89056085	8	38	manganese superoxide dismutase	GeneOrGeneProduct	6648
89056085	47	56	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
89056085	77	94	memory deficiency	DiseaseOrPhenotypicFeature	D008569
89056085	99	115	hypersensitivity	DiseaseOrPhenotypicFeature	D004342
89056085	167	197	manganese superoxide dismutase	GeneOrGeneProduct	6648
89056085	231	240	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
89056085	263	280	memory deficiency	DiseaseOrPhenotypicFeature	D008569
89056085	285	301	hypersensitivity	DiseaseOrPhenotypicFeature	D004342
89056085	305	311	Murine	OrganismTaxon	10090
89056085	392	409	memory deficiency	DiseaseOrPhenotypicFeature	D008569
89056085	413	417	H446	CellLine	CVCL_1562
89056085	596	612	hypersensitivity	DiseaseOrPhenotypicFeature	D004342
89056085	692	701	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
89056085	806	812	Murine	OrganismTaxon	10090
89056085	894	903	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
89056085	907	911	H446	CellLine	CVCL_1562
89056085	1055	1072	memory deficiency	DiseaseOrPhenotypicFeature	D008569
89056085	1077	1093	hypersensitivity	DiseaseOrPhenotypicFeature	D004342
89056085	1205	1211	Murine	OrganismTaxon	10090
89056085	1251	1260	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
89056085	Positive_Correlation	6648	D008569	Novel
89056085	Positive_Correlation	6648	D004342	Novel
89056085	Association	c|SUB|A|2444|C	6648	Novel

08736328|t|Celecoxib, Ifosfamide, and d-fructose interactions in Toxorynchites mosquitoes: implications for liver toxicity and penicillin 
08736328|a|Recent studies have explored the complex interactions between the chemical entities Celecoxib, Ifosfamide, d-fructose, and penicillin in the context of liver toxicity and their effects on Toxorynchites mosquitoes. Celecoxib has been shown to exhibit a significant association with Ifosfamide, suggesting a potential synergistic or antagonistic relationship in metabolic pathways. This association is further supported by the observed positive correlation between d-fructose and Celecoxib, which may indicate a shared regulatory mechanism in energy metabolism.   The relationship between d-fructose and liver toxicity is well-documented, with evidence of a positive correlation between d-fructose levels and the occurrence of liver toxicity. This is further reinforced by the association between d-fructose and penicillin, suggesting that d-fructose may modulate the pharmacokinetics or toxicity profile of penicillin. Notably, penicillin has been linked to liver toxicity in Toxorynchites mosquitoes, highlighting the need for careful monitoring of these interactions in experimental models.  Ifosfamide has been found to have a significant association with both d-fructose and penicillin, indicating a potential role in the metabolic processing of these compounds. Additionally, the negative correlation between catalase and liver toxicity suggests that catalase activity may serve as a protective factor against the development of liver toxicity. This finding is particularly relevant in the context of Toxorynchites mosquitoes, where catalase expression may influence the organism's response to toxicants.  These findings underscore the importance of understanding the interplay between chemical entities, gene products, and disease phenotypes in Toxorynchites mosquitoes. The observed relationships provide a foundation for further research into the molecular mechanisms underlying liver toxicity and the potential therapeutic or toxicological implications of these interactions.
08736328	0	9	Celecoxib	ChemicalEntity	C105934
08736328	11	21	Ifosfamide	ChemicalEntity	D007069
08736328	27	37	d-fructose	ChemicalEntity	D005632
08736328	54	78	Toxorynchites mosquitoes	OrganismTaxon	2498889
08736328	97	111	liver toxicity	DiseaseOrPhenotypicFeature	D056486
08736328	116	126	penicillin	ChemicalEntity	D010406
08736328	212	221	Celecoxib	ChemicalEntity	C105934
08736328	223	233	Ifosfamide	ChemicalEntity	D007069
08736328	235	245	d-fructose	ChemicalEntity	D005632
08736328	251	261	penicillin	ChemicalEntity	D010406
08736328	280	294	liver toxicity	DiseaseOrPhenotypicFeature	D056486
08736328	316	340	Toxorynchites mosquitoes	OrganismTaxon	2498889
08736328	342	351	Celecoxib	ChemicalEntity	C105934
08736328	409	419	Ifosfamide	ChemicalEntity	D007069
08736328	591	601	d-fructose	ChemicalEntity	D005632
08736328	606	615	Celecoxib	ChemicalEntity	C105934
08736328	715	725	d-fructose	ChemicalEntity	D005632
08736328	730	744	liver toxicity	DiseaseOrPhenotypicFeature	D056486
08736328	813	823	d-fructose	ChemicalEntity	D005632
08736328	853	867	liver toxicity	DiseaseOrPhenotypicFeature	D056486
08736328	923	933	d-fructose	ChemicalEntity	D005632
08736328	938	948	penicillin	ChemicalEntity	D010406
08736328	966	976	d-fructose	ChemicalEntity	D005632
08736328	1034	1044	penicillin	ChemicalEntity	D010406
08736328	1055	1065	penicillin	ChemicalEntity	D010406
08736328	1085	1099	liver toxicity	DiseaseOrPhenotypicFeature	D056486
08736328	1103	1127	Toxorynchites mosquitoes	OrganismTaxon	2498889
08736328	1221	1231	Ifosfamide	ChemicalEntity	D007069
08736328	1291	1301	d-fructose	ChemicalEntity	D005632
08736328	1306	1316	penicillin	ChemicalEntity	D010406
08736328	1441	1449	catalase	GeneOrGeneProduct	24248
08736328	1454	1468	liver toxicity	DiseaseOrPhenotypicFeature	D056486
08736328	1483	1491	catalase	GeneOrGeneProduct	24248
08736328	1561	1575	liver toxicity	DiseaseOrPhenotypicFeature	D056486
08736328	1633	1657	Toxorynchites mosquitoes	OrganismTaxon	2498889
08736328	1665	1673	catalase	GeneOrGeneProduct	24248
08736328	1878	1902	Toxorynchites mosquitoes	OrganismTaxon	2498889
08736328	2014	2028	liver toxicity	DiseaseOrPhenotypicFeature	D056486
08736328	Association	C105934	D007069	Novel
08736328	Association	D010406	D056486	Novel
08736328	Association	D007069	D005632	Novel
08736328	Negative_Correlation	D056486	24248	Novel
08736328	Association	D007069	D010406	Novel
08736328	Association	D005632	C105934	Novel
08736328	Positive_Correlation	D005632	D056486	Novel
08736328	Association	D005632	D010406	Novel

96671274|t|IL-1beta and PCNA interactions in Aedes mosquitoes: implications for toxicities, radiculopathy, and loss of appetite in Mangifera indica Linn and tobacco-associated co
96671274|a|Recent studies have explored the complex interactions between the inflammatory cytokine IL-1beta and the proliferative marker PCNA in Aedes mosquitoes, with implications for disease progression in both human and plant systems. This research highlights a positive correlation between IL-1beta and PCNA expression in Aedes mosquitoes, suggesting a potential role for these molecules in modulating immune responses and tissue repair. Furthermore, a direct bind between IL-1beta and PCNA was observed, reinforcing their functional relationship.   In parallel, the study found a negative correlation between loss of appetite and both IL-1beta and PCNA, indicating that elevated levels of these molecules may be associated with reduced food intake. Similarly, toxicities were found to be negatively correlated with both IL-1beta and PCNA, suggesting that these proteins may act as protective factors against toxic effects. Radiculopathy was also negatively correlated with both IL-1beta and PCNA, implying that their downregulation may contribute to the development of nerve-related pathologies.  The research further extended to the plant species Mangifera indica Linn and tobacco, where the presence of IL-1beta and PCNA was linked to the manifestation of toxicities and loss of appetite in these organisms. The findings suggest that the interplay between IL-1beta and PCNA may be a critical factor in the pathogenesis of multiple phenotypic features, including toxicities, radiculopathy, and loss of appetite, across different biological systems. These results provide a foundation for further investigations into the molecular mechanisms underlying these conditions in both human and plant models.
96671274	0	8	IL-1beta	GeneOrGeneProduct	16176
96671274	13	17	PCNA	GeneOrGeneProduct	25737
96671274	34	50	Aedes mosquitoes	OrganismTaxon	1245352
96671274	69	79	toxicities	DiseaseOrPhenotypicFeature	D064420
96671274	81	94	radiculopathy	DiseaseOrPhenotypicFeature	D011843
96671274	100	116	loss of appetite	DiseaseOrPhenotypicFeature	D001068
96671274	120	141	Mangifera indica Linn	OrganismTaxon	29780
96671274	146	153	tobacco	OrganismTaxon	4097
96671274	256	264	IL-1beta	GeneOrGeneProduct	16176
96671274	294	298	PCNA	GeneOrGeneProduct	25737
96671274	302	318	Aedes mosquitoes	OrganismTaxon	1245352
96671274	451	459	IL-1beta	GeneOrGeneProduct	16176
96671274	464	468	PCNA	GeneOrGeneProduct	25737
96671274	483	499	Aedes mosquitoes	OrganismTaxon	1245352
96671274	634	642	IL-1beta	GeneOrGeneProduct	16176
96671274	647	651	PCNA	GeneOrGeneProduct	25737
96671274	771	787	loss of appetite	DiseaseOrPhenotypicFeature	D001068
96671274	797	805	IL-1beta	GeneOrGeneProduct	16176
96671274	810	814	PCNA	GeneOrGeneProduct	25737
96671274	922	932	toxicities	DiseaseOrPhenotypicFeature	D064420
96671274	982	990	IL-1beta	GeneOrGeneProduct	16176
96671274	995	999	PCNA	GeneOrGeneProduct	25737
96671274	1140	1148	IL-1beta	GeneOrGeneProduct	16176
96671274	1153	1157	PCNA	GeneOrGeneProduct	25737
96671274	1310	1331	Mangifera indica Linn	OrganismTaxon	29780
96671274	1336	1343	tobacco	OrganismTaxon	4097
96671274	1367	1375	IL-1beta	GeneOrGeneProduct	16176
96671274	1380	1384	PCNA	GeneOrGeneProduct	25737
96671274	1420	1430	toxicities	DiseaseOrPhenotypicFeature	D064420
96671274	1435	1451	loss of appetite	DiseaseOrPhenotypicFeature	D001068
96671274	1520	1528	IL-1beta	GeneOrGeneProduct	16176
96671274	1533	1537	PCNA	GeneOrGeneProduct	25737
96671274	1626	1636	toxicities	DiseaseOrPhenotypicFeature	D064420
96671274	1638	1651	radiculopathy	DiseaseOrPhenotypicFeature	D011843
96671274	1657	1673	loss of appetite	DiseaseOrPhenotypicFeature	D001068
96671274	Positive_Correlation	16176	25737	Novel
96671274	Negative_Correlation	D001068	25737	Novel
96671274	Negative_Correlation	D001068	16176	Novel
96671274	Negative_Correlation	D064420	16176	Novel
96671274	Negative_Correlation	D064420	25737	Novel
96671274	Negative_Correlation	D011843	16176	Novel
96671274	Bind	16176	25737	Novel
96671274	Positive_Correlation	25737	16176	Novel
96671274	Negative_Correlation	D011843	25737	Novel
96671274	Bind	25737	16176	Novel

98770743|t|DEN-2, 28 bp variable number of tandem repeats, and p17: associations with VSD, infection, and primary Hodgkin 
98770743|a|This study investigates the complex interplay between the DEN-2 virus, the 28 bp variable number of tandem repeats (VNTR), the p17 gene product, and their associations with VSD, infection, and primary Hodgkin lymphoma. DEN-2, a flavivirus known for its role in dengue fever, was found to exhibit a strong association with the 28 bp VNTR, which is a sequence variant commonly observed in viral genomes. This association was consistent across multiple isolates and was further supported by phylogenetic analysis. The 28 bp VNTR was also linked to VSD, a congenital heart defect, suggesting a potential role for this sequence variant in developmental pathways.   The p17 gene product, a structural component of the DEN-2 virion, showed a negative correlation with both primary Hodgkin lymphoma and VSD. This negative correlation was observed in multiple cohorts, including patients with primary Hodgkin lymphoma and individuals with VSD. Additionally, p17 was found to have a negative correlation with infection, particularly in the context of DEN-2 and other viral infections. These findings suggest that p17 may play a regulatory role in immune responses and disease progression.  Infection, particularly by DEN-2, was strongly associated with the 28 bp VNTR, indicating that this sequence variant may influence viral replication or pathogenicity. The study also highlights the potential for the 28 bp VNTR to serve as a biomarker for both viral infection and certain congenital conditions. Overall, the data support a complex network of interactions between DEN-2, the 28 bp VNTR, p17, VSD, and primary Hodgkin lymphoma, with implications for both virology and clinical medicine.
98770743	0	5	DEN-2	OrganismTaxon	11060
98770743	7	46	28 bp variable number of tandem repeats	SequenceVariant	c|DUP||28
98770743	52	55	p17	GeneOrGeneProduct	155348
98770743	75	78	VSD	DiseaseOrPhenotypicFeature	D006345
98770743	80	89	infection	DiseaseOrPhenotypicFeature	D007239
98770743	170	175	DEN-2	OrganismTaxon	11060
98770743	187	226	28 bp variable number of tandem repeats	SequenceVariant	c|DUP||28
98770743	239	242	p17	GeneOrGeneProduct	155348
98770743	285	288	VSD	DiseaseOrPhenotypicFeature	D006345
98770743	290	299	infection	DiseaseOrPhenotypicFeature	D007239
98770743	305	329	primary Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
98770743	331	336	DEN-2	OrganismTaxon	11060
98770743	657	660	VSD	DiseaseOrPhenotypicFeature	D006345
98770743	776	779	p17	GeneOrGeneProduct	155348
98770743	824	829	DEN-2	OrganismTaxon	11060
98770743	878	902	primary Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
98770743	907	910	VSD	DiseaseOrPhenotypicFeature	D006345
98770743	996	1020	primary Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
98770743	1042	1045	VSD	DiseaseOrPhenotypicFeature	D006345
98770743	1061	1064	p17	GeneOrGeneProduct	155348
98770743	1111	1120	infection	DiseaseOrPhenotypicFeature	D007239
98770743	1153	1158	DEN-2	OrganismTaxon	11060
98770743	1175	1184	infection	DiseaseOrPhenotypicFeature	D007239
98770743	1215	1218	p17	GeneOrGeneProduct	155348
98770743	1319	1324	DEN-2	OrganismTaxon	11060
98770743	1557	1566	infection	DiseaseOrPhenotypicFeature	D007239
98770743	1670	1675	DEN-2	OrganismTaxon	11060
98770743	1693	1696	p17	GeneOrGeneProduct	155348
98770743	1698	1701	VSD	DiseaseOrPhenotypicFeature	D006345
98770743	1707	1731	primary Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
98770743	Association	D006689	c|DUP||28	Novel
98770743	Negative_Correlation	155348	D006689	Novel
98770743	Negative_Correlation	155348	D006345	Novel
98770743	Association	D006345	c|DUP||28	Novel
98770743	Association	D007239	c|DUP||28	Novel
98770743	Negative_Correlation	155348	D007239	Novel

40036193|t|Regulation of renal and tumor cell functions by Cdkn2a, IL-1, and other genes in diverse ce
40036193|a|This study investigates the molecular interactions and regulatory networks involving the tumor suppressor gene Cdkn2a and its associations with multiple genes in various cell lines. Using a combination of biochemical assays and transcriptomic profiling, we demonstrate that Cdkn2a binds to both NR2F1 and renin, suggesting a role in modulating cell cycle control and hormone secretion. Additionally, we observe a negative correlation between IL-1 and Prl, which may indicate a regulatory feedback mechanism in inflammatory and endocrine responses.   The gene Cdkn2a also shows a positive correlation with synaptophysin, suggesting potential involvement in neuronal function or tumor progression. Furthermore, we find that CXCL1 is associated with both Nix and renin, highlighting its role in immune signaling and cellular metabolism. A direct interaction between Never in mitosis gene A (NIMA)-related kinase 2 and MLH1 is identified, which may contribute to DNA repair and genomic stability.   In the context of cell lines, we observe that Cdkn2a exhibits a negative correlation with CXCL1, suggesting a complex regulatory network. The gene Prl is found to bind to MLYCD, potentially influencing lipid metabolism. Our findings are validated across multiple cell lines, including hRPTEC, SJ-GBM2, BALB/c, H446, Ishikawa, SNU-C5, CD18/HPAF, and KU7, underscoring the broad relevance of these interactions in both normal and pathological conditions.
40036193	48	54	Cdkn2a	GeneOrGeneProduct	12578
40036193	56	60	IL-1	GeneOrGeneProduct	111343
40036193	203	209	Cdkn2a	GeneOrGeneProduct	12578
40036193	366	372	Cdkn2a	GeneOrGeneProduct	12578
40036193	387	392	NR2F1	GeneOrGeneProduct	7025
40036193	397	402	renin	GeneOrGeneProduct	19701
40036193	534	538	IL-1	GeneOrGeneProduct	111343
40036193	543	546	Prl	GeneOrGeneProduct	5617
40036193	651	657	Cdkn2a	GeneOrGeneProduct	12578
40036193	697	710	synaptophysin	GeneOrGeneProduct	20977
40036193	814	819	CXCL1	GeneOrGeneProduct	14825
40036193	844	847	Nix	GeneOrGeneProduct	12177
40036193	852	857	renin	GeneOrGeneProduct	19701
40036193	955	1002	Never in mitosis gene A (NIMA)-related kinase 2	GeneOrGeneProduct	4751
40036193	1007	1011	MLH1	GeneOrGeneProduct	4292
40036193	1133	1139	Cdkn2a	GeneOrGeneProduct	12578
40036193	1177	1182	CXCL1	GeneOrGeneProduct	14825
40036193	1234	1237	Prl	GeneOrGeneProduct	5617
40036193	1258	1263	MLYCD	GeneOrGeneProduct	23417
40036193	1372	1378	hRPTEC	CellLine	CVCL_K278
40036193	1380	1387	SJ-GBM2	CellLine	CVCL_M141
40036193	1389	1395	BALB/c	CellLine	CVCL_9101
40036193	1397	1401	H446	CellLine	CVCL_1562
40036193	1403	1411	Ishikawa	CellLine	CVCL_2529
40036193	1413	1419	SNU-C5	CellLine	CVCL_5112
40036193	1421	1430	CD18/HPAF	CellLine	CVCL_0313
40036193	1436	1439	KU7	CellLine	CVCL_4714
40036193	Bind	12578	7025	Novel
40036193	Negative_Correlation	111343	5617	Novel
40036193	Bind	12578	19701	Novel
40036193	Association	14825	12177	Novel
40036193	Positive_Correlation	20977	12578	Novel
40036193	Bind	4751	4292	Novel
40036193	Negative_Correlation	12578	14825	Novel
40036193	Bind	5617	23417	Novel
40036193	Association	14825	19701	Novel

25111134|t|Genetic and molecular mechanisms linking urticaria, skin carcinogenesis, and immune-related phenotypes through glycoprotein, CD28, and a/b-tubulin inte
25111134|a|Urticaria, a common skin condition, has been increasingly linked to genetic and molecular pathways involving immune regulators and structural proteins. This study investigates the molecular mechanisms underlying urticaria and its association with skin carcinogenesis, hypoalbuminemia, and other phenotypic features. We report that the glycoprotein CD28 binds to the gene product CD28, and this interaction is associated with the development of urticaria. Additionally, the sequence variant Arg389Gly in the glycoprotein gene is significantly associated with skin carcinogenesis, suggesting a potential role in tumor progression. The sequence variant 28 bp variable number of tandem repeats is also linked to urticaria, highlighting the importance of genetic variability in immune responses.   The chemical entity hCG is associated with skin carcinogenesis, and its effects are compared with those of L-364,718, a compound that binds to a/b-tubulin. This binding is further supported by the association between L-364,718 and the glycoprotein, indicating a potential therapeutic target. The gene product a/b-tubulin is also associated with urticaria, and it binds to CD28, reinforcing the role of the tubulin-CD28 axis in immune-mediated diseases.   The sequence variant rs1800872 shows a positive correlation with skin carcinogenesis, and the gene product CCL2 is associated with urticaria, suggesting a role in inflammatory processes. The gene product IgA is linked to hypoalbuminemia and also to skin carcinogenesis, indicating a broader involvement in immune and metabolic pathways. The gene product AT2R binds to the glycoprotein and is associated with skin carcinogenesis, further linking the renin-angiotensin system to tumor biology.   These findings provide a comprehensive view of the molecular and genetic interactions that contribute to the pathogenesis of urticaria and its association with skin carcinogenesis, offering new insights into potential therapeutic strategies.
25111134	41	50	urticaria	DiseaseOrPhenotypicFeature	D014581
25111134	52	71	skin carcinogenesis	DiseaseOrPhenotypicFeature	D012878
25111134	111	123	glycoprotein	GeneOrGeneProduct	11820
25111134	125	129	CD28	GeneOrGeneProduct	940
25111134	135	146	a/b-tubulin	GeneOrGeneProduct	22142
25111134	364	373	urticaria	DiseaseOrPhenotypicFeature	D014581
25111134	399	418	skin carcinogenesis	DiseaseOrPhenotypicFeature	D012878
25111134	420	435	hypoalbuminemia	DiseaseOrPhenotypicFeature	D034141
25111134	487	499	glycoprotein	GeneOrGeneProduct	11820
25111134	500	504	CD28	GeneOrGeneProduct	940
25111134	531	535	CD28	GeneOrGeneProduct	940
25111134	596	605	urticaria	DiseaseOrPhenotypicFeature	D014581
25111134	642	651	Arg389Gly	SequenceVariant	p|SUB|R|389|G
25111134	659	671	glycoprotein	GeneOrGeneProduct	11820
25111134	710	729	skin carcinogenesis	DiseaseOrPhenotypicFeature	D012878
25111134	802	841	28 bp variable number of tandem repeats	SequenceVariant	c|DUP||28
25111134	860	869	urticaria	DiseaseOrPhenotypicFeature	D014581
25111134	965	968	hCG	ChemicalEntity	D006063
25111134	988	1007	skin carcinogenesis	DiseaseOrPhenotypicFeature	D012878
25111134	1052	1061	L-364,718	ChemicalEntity	D020109
25111134	1088	1099	a/b-tubulin	GeneOrGeneProduct	22142
25111134	1162	1171	L-364,718	ChemicalEntity	D020109
25111134	1180	1192	glycoprotein	GeneOrGeneProduct	11820
25111134	1254	1265	a/b-tubulin	GeneOrGeneProduct	22142
25111134	1290	1299	urticaria	DiseaseOrPhenotypicFeature	D014581
25111134	1317	1321	CD28	GeneOrGeneProduct	940
25111134	1359	1363	CD28	GeneOrGeneProduct	940
25111134	1421	1430	rs1800872	SequenceVariant	rs1800872
25111134	1465	1484	skin carcinogenesis	DiseaseOrPhenotypicFeature	D012878
25111134	1507	1511	CCL2	GeneOrGeneProduct	24770
25111134	1531	1540	urticaria	DiseaseOrPhenotypicFeature	D014581
25111134	1604	1607	IgA	GeneOrGeneProduct	3493
25111134	1621	1636	hypoalbuminemia	DiseaseOrPhenotypicFeature	D034141
25111134	1649	1668	skin carcinogenesis	DiseaseOrPhenotypicFeature	D012878
25111134	1754	1758	AT2R	GeneOrGeneProduct	24182
25111134	1772	1784	glycoprotein	GeneOrGeneProduct	11820
25111134	1808	1827	skin carcinogenesis	DiseaseOrPhenotypicFeature	D012878
25111134	2019	2028	urticaria	DiseaseOrPhenotypicFeature	D014581
25111134	2054	2073	skin carcinogenesis	DiseaseOrPhenotypicFeature	D012878
25111134	Bind	11820	940	Novel
25111134	Association	940	D014581	Novel
25111134	Association	D012878	D006063	Novel
25111134	Association	24770	D014581	Novel
25111134	Association	c|DUP||28	D014581	Novel
25111134	Comparison	D020109	D006063	Novel
25111134	Association	11820	D012878	Novel
25111134	Association	p|SUB|R|389|G	D012878	Novel
25111134	Association	22142	D014581	Novel
25111134	Positive_Correlation	rs1800872	D012878	Novel
25111134	Bind	940	24770	Novel
25111134	Bind	22142	D020109	Novel
25111134	Bind	24182	11820	Novel
25111134	Association	D020109	11820	Novel
25111134	Association	3493	D034141	Novel
25111134	Association	D012878	D005907	Novel
25111134	Association	24182	D012878	Novel
25111134	Association	3493	D012878	Novel
25111134	Bind	940	22142	Novel

86330965|t|Genetic and pharmacological interactions in the context of hydronephrosis and cell line responses to therapeuti
86330965|a|This study investigates the complex interplay between genetic variants, pharmacological agents, and disease phenotypes in the context of hydronephrosis and cellular responses. A key focus is the sequence variant g.3318-15C>T, which was found to be associated with butyrylthiocholine metabolism in multiple experimental models. The variant p.G705RfsX16 was also observed to co-occur with butyrylthiocholine in several cell lines, including LbetaT2 and Mz-ChA-1. These findings suggest a potential molecular mechanism linking genetic variability to altered drug metabolism.   The study also examined the effects of various chemical entities on cellular function. Propranolol was found to have a positive correlation with disulfiram, while a negative correlation was observed between Propranolol and ristocetin. Additionally, antiepileptic drugs showed a positive correlation with Propranolol, but a negative correlation with ristocetin. These results highlight the complex pharmacological interactions between these agents.   Hydronephrosis was a recurring phenotype across multiple experimental conditions, with 9 instances of the disease observed in both in vivo and in vitro models. Notably, a negative correlation was found between hydronephrosis and NaCl, suggesting a potential protective role of NaCl in the context of this condition. Furthermore, a positive correlation was observed between NaCl and ristocetin, indicating a possible synergistic effect in certain cellular environments.   The cell lines BALB/c, LbetaT2, and Mz-ChA-1 were used extensively in the study. These lines were exposed to various chemical entities, including alkylating agents, which were found to have a negative correlation with butyrylthiocholine. This suggests that alkylating agents may interfere with the metabolism of butyrylthiocholine. Additionally, a cotreatment between butyrylthiocholine and alkylating agents was observed, indicating a potential therapeutic strategy for certain conditions.   The study also explored the relationship between elbow dislocation and various chemical entities. A negative correlation was found between elbow dislocation and NaCl, as well as between elbow dislocation and Propranolol. These findings suggest that NaCl and Propranolol may have protective effects in the context of elbow dislocation.   Overall, the study provides a comprehensive analysis of the interactions between genetic variants, chemical entities, and disease phenotypes, offering new insights into the molecular and pharmacological mechanisms underlying hydronephrosis and related conditions.
86330965	59	73	hydronephrosis	DiseaseOrPhenotypicFeature	D006869
86330965	249	263	hydronephrosis	DiseaseOrPhenotypicFeature	D006869
86330965	324	336	g.3318-15C>T	SequenceVariant	g|SUB|C|3318-15|T
86330965	376	394	butyrylthiocholine	ChemicalEntity	D002092
86330965	451	463	p.G705RfsX16	SequenceVariant	p|FS|G|705|R|16
86330965	499	517	butyrylthiocholine	ChemicalEntity	D002092
86330965	551	558	LbetaT2	CellLine	CVCL_0398
86330965	563	571	Mz-ChA-1	CellLine	CVCL_6932
86330965	773	784	Propranolol	ChemicalEntity	D011433
86330965	831	841	disulfiram	ChemicalEntity	D004221
86330965	893	904	Propranolol	ChemicalEntity	D011433
86330965	909	919	ristocetin	ChemicalEntity	D012310
86330965	935	953	antiepileptic drug	ChemicalEntity	D000927
86330965	990	1001	Propranolol	ChemicalEntity	D011433
86330965	1035	1045	ristocetin	ChemicalEntity	D012310
86330965	1346	1360	hydronephrosis	DiseaseOrPhenotypicFeature	D006869
86330965	1365	1369	NaCl	ChemicalEntity	D012965
86330965	1413	1417	NaCl	ChemicalEntity	D012965
86330965	1509	1513	NaCl	ChemicalEntity	D012965
86330965	1518	1528	ristocetin	ChemicalEntity	D012310
86330965	1622	1628	BALB/c	CellLine	CVCL_9101
86330965	1630	1637	LbetaT2	CellLine	CVCL_0398
86330965	1643	1651	Mz-ChA-1	CellLine	CVCL_6932
86330965	1753	1769	alkylating agent	ChemicalEntity	D000477
86330965	1825	1843	butyrylthiocholine	ChemicalEntity	D002092
86330965	1864	1880	alkylating agent	ChemicalEntity	D000477
86330965	1919	1937	butyrylthiocholine	ChemicalEntity	D002092
86330965	1975	1993	butyrylthiocholine	ChemicalEntity	D002092
86330965	1998	2014	alkylating agent	ChemicalEntity	D000477
86330965	2149	2166	elbow dislocation	DiseaseOrPhenotypicFeature	D004204
86330965	2239	2256	elbow dislocation	DiseaseOrPhenotypicFeature	D004204
86330965	2261	2265	NaCl	ChemicalEntity	D012965
86330965	2286	2303	elbow dislocation	DiseaseOrPhenotypicFeature	D004204
86330965	2308	2319	Propranolol	ChemicalEntity	D011433
86330965	2349	2353	NaCl	ChemicalEntity	D012965
86330965	2358	2369	Propranolol	ChemicalEntity	D011433
86330965	2416	2433	elbow dislocation	DiseaseOrPhenotypicFeature	D004204
86330965	2662	2676	hydronephrosis	DiseaseOrPhenotypicFeature	D006869
86330965	Positive_Correlation	D000927	D011433	Novel
86330965	Negative_Correlation	D004204	D012965	Novel
86330965	Negative_Correlation	D011433	D012310	Novel
86330965	Positive_Correlation	D004221	D011433	Novel
86330965	Negative_Correlation	D000477	D002092	Novel
86330965	Association	g|SUB|C|3318-15|T	D002092	Novel
86330965	Cotreatment	D002092	D000477	Novel
86330965	Cotreatment	D000927	D004221	Novel
86330965	Negative_Correlation	D004204	D011433	Novel
86330965	Positive_Correlation	D012965	D012310	Novel
86330965	Negative_Correlation	D000927	D011433	Novel
86330965	Positive_Correlation	D012310	D000927	Novel
86330965	Negative_Correlation	D002092	D000927	Novel

14378641|t|OPG, c-Kit, and Lactoferrin: Interactions with tremors, bradykinesia, uremia, and the effects of isoflurane, yohimbine, LiCl, and f
14378641|a|This study investigates the complex interactions between the gene OPG, the gene c-Kit, and the gene Lactoferrin, and their associations with tremors, bradykinesia, and uremia. We also explore the effects of the chemical entities isoflurane, yohimbine, LiCl, and flutamide on these biological processes. Our findings reveal a positive correlation between isoflurane and IL-5, suggesting a potential role for isoflurane in modulating immune responses. Additionally, we observe an association between OCT4A and c-Kit, highlighting a possible regulatory relationship between these two genes. A negative correlation between yohimbine and OPG is noted, indicating that yohimbine may inhibit OPG expression. The association between DFF-45 and Lactoferrin, as well as the mutual association between Lactoferrin and DFF-45, suggests a coordinated regulatory network involving these genes.   We also report a drug interaction between isoflurane and LiCl, which may have implications for anesthetic and therapeutic strategies. The positive correlation between LiCl and IL-5, along with the positive correlation between LiCl and DFF-45, supports the idea that LiCl may influence multiple pathways. Furthermore, the positive correlation between flutamide and OPG, as well as the positive correlation between flutamide and IL-5, indicates that flutamide may have a stimulatory effect on these genes. However, a negative correlation between flutamide and Lactoferrin suggests a more complex regulatory mechanism.   The association between OPG and c-Kit, as well as the association between Lactoferrin and c-Kit, underscores the importance of c-Kit in linking these genes. Additionally, a positive correlation between isoflurane and c-Kit is observed, suggesting that isoflurane may enhance c-Kit activity. The negative correlation between isoflurane and uremia implies that isoflurane may have protective effects against uremia. Finally, the conversion between flutamide and LiCl is reported, indicating a potential metabolic or pharmacological relationship between these two chemical entities. These findings provide new insights into the molecular mechanisms underlying tremors, bradykinesia, and uremia, and their interactions with genetic and chemical factors.
14378641	0	3	OPG	GeneOrGeneProduct	4982
14378641	5	10	c-Kit	GeneOrGeneProduct	16590
14378641	16	27	Lactoferrin	GeneOrGeneProduct	17002
14378641	47	54	tremors	DiseaseOrPhenotypicFeature	D014202
14378641	56	68	bradykinesia	DiseaseOrPhenotypicFeature	D018476
14378641	70	76	uremia	DiseaseOrPhenotypicFeature	D014511
14378641	97	107	isoflurane	ChemicalEntity	D007530
14378641	109	118	yohimbine	ChemicalEntity	D015016
14378641	120	124	LiCl	ChemicalEntity	D018021
14378641	198	201	OPG	GeneOrGeneProduct	4982
14378641	212	217	c-Kit	GeneOrGeneProduct	16590
14378641	232	243	Lactoferrin	GeneOrGeneProduct	17002
14378641	273	280	tremors	DiseaseOrPhenotypicFeature	D014202
14378641	282	294	bradykinesia	DiseaseOrPhenotypicFeature	D018476
14378641	300	306	uremia	DiseaseOrPhenotypicFeature	D014511
14378641	361	371	isoflurane	ChemicalEntity	D007530
14378641	373	382	yohimbine	ChemicalEntity	D015016
14378641	384	388	LiCl	ChemicalEntity	D018021
14378641	394	403	flutamide	ChemicalEntity	D005485
14378641	486	496	isoflurane	ChemicalEntity	D007530
14378641	501	505	IL-5	GeneOrGeneProduct	3567
14378641	539	549	isoflurane	ChemicalEntity	D007530
14378641	630	635	OCT4A	GeneOrGeneProduct	5460
14378641	640	645	c-Kit	GeneOrGeneProduct	16590
14378641	751	760	yohimbine	ChemicalEntity	D015016
14378641	765	768	OPG	GeneOrGeneProduct	4982
14378641	795	804	yohimbine	ChemicalEntity	D015016
14378641	817	820	OPG	GeneOrGeneProduct	4982
14378641	857	863	DFF-45	GeneOrGeneProduct	1676
14378641	868	879	Lactoferrin	GeneOrGeneProduct	17002
14378641	923	934	Lactoferrin	GeneOrGeneProduct	17002
14378641	939	945	DFF-45	GeneOrGeneProduct	1676
14378641	1056	1066	isoflurane	ChemicalEntity	D007530
14378641	1071	1075	LiCl	ChemicalEntity	D018021
14378641	1181	1185	LiCl	ChemicalEntity	D018021
14378641	1190	1194	IL-5	GeneOrGeneProduct	3567
14378641	1240	1244	LiCl	ChemicalEntity	D018021
14378641	1249	1255	DFF-45	GeneOrGeneProduct	1676
14378641	1280	1284	LiCl	ChemicalEntity	D018021
14378641	1364	1373	flutamide	ChemicalEntity	D005485
14378641	1378	1381	OPG	GeneOrGeneProduct	4982
14378641	1427	1436	flutamide	ChemicalEntity	D005485
14378641	1441	1445	IL-5	GeneOrGeneProduct	3567
14378641	1462	1471	flutamide	ChemicalEntity	D005485
14378641	1558	1567	flutamide	ChemicalEntity	D005485
14378641	1572	1583	Lactoferrin	GeneOrGeneProduct	17002
14378641	1656	1659	OPG	GeneOrGeneProduct	4982
14378641	1664	1669	c-Kit	GeneOrGeneProduct	16590
14378641	1706	1717	Lactoferrin	GeneOrGeneProduct	17002
14378641	1722	1727	c-Kit	GeneOrGeneProduct	16590
14378641	1759	1764	c-Kit	GeneOrGeneProduct	16590
14378641	1834	1844	isoflurane	ChemicalEntity	D007530
14378641	1849	1854	c-Kit	GeneOrGeneProduct	16590
14378641	1884	1894	isoflurane	ChemicalEntity	D007530
14378641	1907	1912	c-Kit	GeneOrGeneProduct	16590
14378641	1956	1966	isoflurane	ChemicalEntity	D007530
14378641	1971	1977	uremia	DiseaseOrPhenotypicFeature	D014511
14378641	1991	2001	isoflurane	ChemicalEntity	D007530
14378641	2038	2044	uremia	DiseaseOrPhenotypicFeature	D014511
14378641	2078	2087	flutamide	ChemicalEntity	D005485
14378641	2092	2096	LiCl	ChemicalEntity	D018021
14378641	2289	2296	tremors	DiseaseOrPhenotypicFeature	D014202
14378641	2298	2310	bradykinesia	DiseaseOrPhenotypicFeature	D018476
14378641	2316	2322	uremia	DiseaseOrPhenotypicFeature	D014511
14378641	Positive_Correlation	D007530	3567	Novel
14378641	Association	5460	16590	Novel
14378641	Negative_Correlation	D015016	4982	Novel
14378641	Association	1676	17002	Novel
14378641	Association	17002	1676	Novel
14378641	Drug_Interaction	D007530	D018021	Novel
14378641	Association	3567	16590	Novel
14378641	Conversion	D005485	D018021	Novel
14378641	Negative_Correlation	D007530	D014511	Novel
14378641	Positive_Correlation	D005485	4982	Novel
14378641	Positive_Correlation	D018021	3567	Novel
14378641	Drug_Interaction	D018021	D005485	Novel
14378641	Positive_Correlation	D018021	1676	Novel
14378641	Positive_Correlation	D005485	3567	Novel
14378641	Association	4982	16590	Novel
14378641	Association	17002	16590	Novel
14378641	Positive_Correlation	D007530	16590	Novel
14378641	Negative_Correlation	D005485	17002	Novel

81014275|t|Genetic and molecular interactions of g.3503C>T, ROCK, cyclin D1, and brain-derived neurotrophic factor in HIV 1/2-infected GT1-1, RAW 264.7, and PA
81014275|a|This study investigates the molecular and genetic interactions between the sequence variant g.3503C>T, the gene products ROCK, cyclin D1, and brain-derived neurotrophic factor (BDNF) in the context of HIV 1/2 infection and their effects on GT1-1, RAW 264.7, and PA-1 cell lines. The research highlights the complex regulatory network involving these factors across multiple organisms, including HIV 1/2, Spirulina, and Drosophila.   The findings reveal a positive correlation between BDNF and SCD1, as well as a negative correlation between BDNF and SCD1, suggesting a dynamic interplay between these two genes. Additionally, a negative correlation is observed between SCD1 and ROCK, while a positive correlation is noted between ROCK and SCD1. The study also reports a negative correlation between ROCK and cyclin D1, and a positive correlation between cyclin D1 and SCD1. Notably, there is a negative correlation between cyclin D1 and BDNF, and a positive correlation between BDNF and ROCK. These relationships are further supported by an association between g.3503C>T and both ROCK and SCD1, indicating a potential regulatory role of this variant in modulating these gene products.  The study further demonstrates a bind between ROCK and cyclin D1, reinforcing the functional interaction between these two proteins. The results suggest that the genetic variant g.3503C>T may influence the expression or activity of ROCK and SCD1, which in turn affect the levels of cyclin D1 and BDNF. These findings are consistent across multiple cell lines, including GT1-1, RAW 264.7, and PA-1, and are also observed in the context of HIV 1/2 infection. The research also extends to other organisms, such as Spirulina and Drosophila, where similar interactions are observed, suggesting a conserved regulatory mechanism. The study underscores the importance of these molecular interactions in understanding the pathophysiology of HIV 1/2 infection and their potential therapeutic implications.
81014275	38	47	g.3503C>T	SequenceVariant	g|SUB|C|3503|T
81014275	49	53	ROCK	GeneOrGeneProduct	6093
81014275	55	64	cyclin D1	GeneOrGeneProduct	595
81014275	70	103	brain-derived neurotrophic factor	GeneOrGeneProduct	24225
81014275	107	114	HIV 1/2	OrganismTaxon	11676
81014275	124	129	GT1-1	CellLine	CVCL_6236
81014275	131	140	RAW 264.7	CellLine	CVCL_0493
81014275	241	250	g.3503C>T	SequenceVariant	g|SUB|C|3503|T
81014275	270	274	ROCK	GeneOrGeneProduct	6093
81014275	276	285	cyclin D1	GeneOrGeneProduct	595
81014275	291	324	brain-derived neurotrophic factor	GeneOrGeneProduct	24225
81014275	350	357	HIV 1/2	OrganismTaxon	11676
81014275	389	394	GT1-1	CellLine	CVCL_6236
81014275	396	405	RAW 264.7	CellLine	CVCL_0493
81014275	411	415	PA-1	CellLine	CVCL_0479
81014275	544	551	HIV 1/2	OrganismTaxon	11676
81014275	553	562	Spirulina	OrganismTaxon	551299
81014275	568	578	Drosophila	OrganismTaxon	7227
81014275	642	646	SCD1	GeneOrGeneProduct	6319
81014275	699	703	SCD1	GeneOrGeneProduct	6319
81014275	818	822	SCD1	GeneOrGeneProduct	6319
81014275	827	831	ROCK	GeneOrGeneProduct	6093
81014275	879	883	ROCK	GeneOrGeneProduct	6093
81014275	888	892	SCD1	GeneOrGeneProduct	6319
81014275	948	952	ROCK	GeneOrGeneProduct	6093
81014275	957	966	cyclin D1	GeneOrGeneProduct	595
81014275	1003	1012	cyclin D1	GeneOrGeneProduct	595
81014275	1017	1021	SCD1	GeneOrGeneProduct	6319
81014275	1072	1081	cyclin D1	GeneOrGeneProduct	595
81014275	1136	1140	ROCK	GeneOrGeneProduct	6093
81014275	1210	1219	g.3503C>T	SequenceVariant	g|SUB|C|3503|T
81014275	1229	1233	ROCK	GeneOrGeneProduct	6093
81014275	1238	1242	SCD1	GeneOrGeneProduct	6319
81014275	1381	1385	ROCK	GeneOrGeneProduct	6093
81014275	1390	1399	cyclin D1	GeneOrGeneProduct	595
81014275	1513	1522	g.3503C>T	SequenceVariant	g|SUB|C|3503|T
81014275	1567	1571	ROCK	GeneOrGeneProduct	6093
81014275	1576	1580	SCD1	GeneOrGeneProduct	6319
81014275	1617	1626	cyclin D1	GeneOrGeneProduct	595
81014275	1705	1710	GT1-1	CellLine	CVCL_6236
81014275	1712	1721	RAW 264.7	CellLine	CVCL_0493
81014275	1727	1731	PA-1	CellLine	CVCL_0479
81014275	1773	1780	HIV 1/2	OrganismTaxon	11676
81014275	1846	1855	Spirulina	OrganismTaxon	551299
81014275	1860	1870	Drosophila	OrganismTaxon	7227
81014275	2067	2074	HIV 1/2	OrganismTaxon	11676
81014275	Positive_Correlation	24225	6319	Novel
81014275	Negative_Correlation	24225	6319	Novel
81014275	Negative_Correlation	6319	6093	Novel
81014275	Negative_Correlation	6093	595	Novel
81014275	Association	g|SUB|C|3503|T	6093	Novel
81014275	Association	24225	595	Novel
81014275	Positive_Correlation	595	6319	Novel
81014275	Negative_Correlation	6319	595	Novel
81014275	Association	595	24225	Novel
81014275	Negative_Correlation	595	24225	Novel
81014275	Positive_Correlation	6093	6319	Novel
81014275	Positive_Correlation	6093	24225	Novel
81014275	Positive_Correlation	24225	6093	Novel
81014275	Negative_Correlation	595	6093	Novel
81014275	Negative_Correlation	6093	24225	Novel
81014275	Association	g|SUB|C|3503|T	6319	Novel
81014275	Bind	6093	595	Novel
81014275	Association	595	6319	Novel
81014275	Association	6093	6319	Novel

93753443|t|Evaluation of neurotoxic effects of bovine-derived compounds in guinea-pigs and inpatient populations using LNCaP, Hs578T, H9c2, CD18/HPAF, and RAW 264.7 ce
93753443|a|This study investigates the neurotoxic potential of compounds derived from bovine sources in both in vivo and in vitro models. The research focuses on the impact of these compounds on neurotoxic outcomes in guinea-pigs and inpatient populations, with particular emphasis on the effects observed in neurodegenerative conditions such as Pneumonitis and myopia. The study employs a range of cell lines, including LNCaP, Hs578T, H9c2, CD18/HPAF, and RAW 264.7, to model the cellular responses to these compounds.   In addition to neurotoxic effects, the study also explores the potential role of these compounds in the development of non-melanoma skin cancers and vasovagal syncope. The research includes a comprehensive analysis of the interactions between bovine-derived compounds and the immune system, as well as their effects on the respiratory and ocular systems.   The findings suggest that certain bovine-derived compounds may contribute to the pathogenesis of Pneumonitis and myopia, while others may have protective effects against neurotoxicity. The study also highlights the importance of inpatient monitoring in identifying early signs of neurotoxicity and the need for further research into the long-term effects of these compounds in both human and animal models.   The results are particularly relevant for the development of safer therapeutic agents and for understanding the mechanisms underlying neurotoxicity in bovine-derived products. The study also includes data from Toxorynchites mosquitoes and Aedes mosquitoes, which were used to assess the potential for vector-borne transmission of neurotoxic compounds. The findings underscore the complex interplay between environmental factors, organism taxon-specific responses, and cellular mechanisms in the context of neurotoxicity.
93753443	14	24	neurotoxic	DiseaseOrPhenotypicFeature	D020258
93753443	36	42	bovine	OrganismTaxon	9913
93753443	64	75	guinea-pigs	OrganismTaxon	10141
93753443	80	89	inpatient	OrganismTaxon	9606
93753443	108	113	LNCaP	CellLine	CVCL_0395
93753443	115	121	Hs578T	CellLine	CVCL_0332
93753443	123	127	H9c2	CellLine	CVCL_0286
93753443	129	138	CD18/HPAF	CellLine	CVCL_0313
93753443	144	153	RAW 264.7	CellLine	CVCL_0493
93753443	185	195	neurotoxic	DiseaseOrPhenotypicFeature	D020258
93753443	232	238	bovine	OrganismTaxon	9913
93753443	341	351	neurotoxic	DiseaseOrPhenotypicFeature	D020258
93753443	364	375	guinea-pigs	OrganismTaxon	10141
93753443	380	389	inpatient	OrganismTaxon	9606
93753443	492	503	Pneumonitis	DiseaseOrPhenotypicFeature	D011014
93753443	508	514	myopia	DiseaseOrPhenotypicFeature	D009216
93753443	567	572	LNCaP	CellLine	CVCL_0395
93753443	574	580	Hs578T	CellLine	CVCL_0332
93753443	582	586	H9c2	CellLine	CVCL_0286
93753443	588	597	CD18/HPAF	CellLine	CVCL_0313
93753443	603	612	RAW 264.7	CellLine	CVCL_0493
93753443	683	693	neurotoxic	DiseaseOrPhenotypicFeature	D020258
93753443	787	812	non-melanoma skin cancers	DiseaseOrPhenotypicFeature	D012878
93753443	817	834	vasovagal syncope	DiseaseOrPhenotypicFeature	D019462
93753443	911	917	bovine	OrganismTaxon	9913
93753443	1059	1065	bovine	OrganismTaxon	9913
93753443	1122	1133	Pneumonitis	DiseaseOrPhenotypicFeature	D011014
93753443	1138	1144	myopia	DiseaseOrPhenotypicFeature	D009216
93753443	1195	1205	neurotoxic	DiseaseOrPhenotypicFeature	D020258
93753443	1254	1263	inpatient	OrganismTaxon	9606
93753443	1305	1315	neurotoxic	DiseaseOrPhenotypicFeature	D020258
93753443	1568	1578	neurotoxic	DiseaseOrPhenotypicFeature	D020258
93753443	1585	1591	bovine	OrganismTaxon	9913
93753443	1644	1668	Toxorynchites mosquitoes	OrganismTaxon	2498889
93753443	1673	1689	Aedes mosquitoes	OrganismTaxon	1245352
93753443	1764	1774	neurotoxic	DiseaseOrPhenotypicFeature	D020258
93753443	1940	1950	neurotoxic	DiseaseOrPhenotypicFeature	D020258

41367841|t|Modulation of small GTPases by genetic variants and dietary factors in diverse biological
41367841|a|This study investigates the complex interactions between genetic variants, dietary components, and biological processes in multiple organisms and cell lines. We focus on the modulation of small GTPases, a family of key regulators of intracellular signaling, by various genetic and environmental factors. In cats, we observed a negative correlation between the sequence variant 1123T-->G and small GTPases, as well as a positive correlation between alpha-fetoprotein and small GTPases. The sequence variant Y355X was found to be associated with both small GTPases and alpha-fetoprotein, suggesting a potential functional link. Additionally, the sequence variant p.G705RfsX16 showed a strong association with small GTPases and alpha-fetoprotein, indicating a possible role in regulating these proteins.   In the context of human cell lines, the cell line IEC-6 demonstrated a negative correlation between tacrolimus and small GTPases, as well as a negative correlation between tacrolimus and alpha-fetoprotein. Similarly, ezetimibe was found to have a negative correlation with both small GTPases and alpha-fetoprotein, while organochloride showed a negative correlation with both targets. The cell line HeLa exhibited a negative correlation between organochloride and small GTPases, and the cell line MCF-7 showed a negative correlation between ezetimibe and small GTPases.   In tobacco, the sequence variant Y355X was associated with small GTPases, and the sequence variant 1123T-->G was associated with both small GTPases and alpha-fetoprotein. The chemical entity corn oil was found to have a negative correlation with small GTPases, while the chemical entity ezetimibe showed a negative correlation with alpha-fetoprotein. The chemical entity tacrolimus was also found to have a negative correlation with alpha-fetoprotein, and the chemical entity organochloride showed a negative correlation with both small GTPases and alpha-fetoprotein.   These findings highlight the intricate relationships between genetic variants, chemical entities, and biological processes across different organisms and cell lines, providing a foundation for further research into the molecular mechanisms underlying these interactions.
41367841	14	27	small GTPases	GeneOrGeneProduct	363875
41367841	278	291	small GTPases	GeneOrGeneProduct	363875
41367841	397	401	cats	OrganismTaxon	9685
41367841	467	476	1123T-->G	SequenceVariant	g|SUB|T|1123|G
41367841	481	494	small GTPases	GeneOrGeneProduct	363875
41367841	538	555	alpha-fetoprotein	GeneOrGeneProduct	174
41367841	560	573	small GTPases	GeneOrGeneProduct	363875
41367841	596	601	Y355X	SequenceVariant	p|SUB|Y|355|X
41367841	639	652	small GTPases	GeneOrGeneProduct	363875
41367841	657	674	alpha-fetoprotein	GeneOrGeneProduct	174
41367841	751	763	p.G705RfsX16	SequenceVariant	p|FS|G|705|R|16
41367841	797	810	small GTPases	GeneOrGeneProduct	363875
41367841	815	832	alpha-fetoprotein	GeneOrGeneProduct	174
41367841	943	948	IEC-6	CellLine	CVCL_0343
41367841	993	1003	tacrolimus	ChemicalEntity	D016559
41367841	1008	1021	small GTPases	GeneOrGeneProduct	363875
41367841	1065	1075	tacrolimus	ChemicalEntity	D016559
41367841	1080	1097	alpha-fetoprotein	GeneOrGeneProduct	174
41367841	1110	1119	ezetimibe	ChemicalEntity	D000069438
41367841	1171	1184	small GTPases	GeneOrGeneProduct	363875
41367841	1189	1206	alpha-fetoprotein	GeneOrGeneProduct	174
41367841	1214	1228	organochloride	ChemicalEntity	D006843
41367841	1292	1296	HeLa	CellLine	CVCL_0030
41367841	1338	1352	organochloride	ChemicalEntity	D006843
41367841	1357	1370	small GTPases	GeneOrGeneProduct	363875
41367841	1390	1395	MCF-7	CellLine	CVCL_0031
41367841	1434	1443	ezetimibe	ChemicalEntity	D000069438
41367841	1448	1461	small GTPases	GeneOrGeneProduct	363875
41367841	1468	1475	tobacco	OrganismTaxon	4097
41367841	1498	1503	Y355X	SequenceVariant	p|SUB|Y|355|X
41367841	1524	1537	small GTPases	GeneOrGeneProduct	363875
41367841	1564	1573	1123T-->G	SequenceVariant	g|SUB|T|1123|G
41367841	1599	1612	small GTPases	GeneOrGeneProduct	363875
41367841	1617	1634	alpha-fetoprotein	GeneOrGeneProduct	174
41367841	1656	1664	corn oil	ChemicalEntity	D003314
41367841	1711	1724	small GTPases	GeneOrGeneProduct	363875
41367841	1752	1761	ezetimibe	ChemicalEntity	D000069438
41367841	1797	1814	alpha-fetoprotein	GeneOrGeneProduct	174
41367841	1836	1846	tacrolimus	ChemicalEntity	D016559
41367841	1898	1915	alpha-fetoprotein	GeneOrGeneProduct	174
41367841	1941	1955	organochloride	ChemicalEntity	D006843
41367841	1996	2009	small GTPases	GeneOrGeneProduct	363875
41367841	2014	2031	alpha-fetoprotein	GeneOrGeneProduct	174
41367841	Negative_Correlation	D003314	363875	Novel
41367841	Positive_Correlation	174	363875	Novel
41367841	Association	g|SUB|T|1123|G	174	Novel
41367841	Association	p|FS|G|705|R|16	174	Novel
41367841	Negative_Correlation	D016559	363875	Novel
41367841	Association	g|SUB|T|1123|G	363875	Novel
41367841	Association	p|SUB|Y|355|X	363875	Novel
41367841	Negative_Correlation	D000069438	174	Novel
41367841	Association	p|FS|G|705|R|16	363875	Novel
41367841	Association	p|SUB|Y|355|X	174	Novel
41367841	Negative_Correlation	D016559	174	Novel
41367841	Negative_Correlation	D006843	174	Novel
41367841	Negative_Correlation	D006843	363875	Novel
41367841	Positive_Correlation	363875	174	Novel
41367841	Negative_Correlation	D000069438	363875	Novel

82210129|t|Genetic variants in Mangifera indica Linn and their associations with dystonia, AN, glucocorticoid resistance, and EH in MES-SA/Dx5 and HEK ce
82210129|a|This study investigates the genetic and phenotypic associations of specific sequence variants and disease features in the context of Mangifera indica Linn and its impact on cellular responses in MES-SA/Dx5 and HEK cell lines. We focused on the sequence variant 521T>C and its potential role in modulating disease phenotypes such as dystonia, AN, glucocorticoid resistance, and EH. Our findings reveal a positive correlation between 521T>C and dystonia, as well as between 521T>C and glucocorticoid resistance. Additionally, we observed a significant positive correlation between 521T>C and EH.   Further, we examined the sequence variant 'deletion of valine 624, valine 625' and found a strong positive correlation with AN. Notably, there is an association between the deletion of valine 624, valine 625 and the 521T>C variant, suggesting a potential genetic interaction. These results were validated using MES-SA/Dx5 and HEK cell lines, which were used to model the cellular mechanisms underlying these associations. The study highlights the complex interplay between genetic variants and disease phenotypes in Mangifera indica Linn, providing a foundation for further research into the molecular pathways involved in these conditions.
82210129	20	41	Mangifera indica Linn	OrganismTaxon	29780
82210129	80	82	AN	DiseaseOrPhenotypicFeature	D015783
82210129	84	109	glucocorticoid resistance	DiseaseOrPhenotypicFeature	C564221
82210129	115	117	EH	DiseaseOrPhenotypicFeature	D000075222
82210129	121	131	MES-SA/Dx5	CellLine	CVCL_2598
82210129	136	139	HEK	CellLine	CVCL_M624
82210129	276	297	Mangifera indica Linn	OrganismTaxon	29780
82210129	338	348	MES-SA/Dx5	CellLine	CVCL_2598
82210129	353	356	HEK	CellLine	CVCL_M624
82210129	404	410	521T>C	SequenceVariant	c|SUB|T|521|C
82210129	485	487	AN	DiseaseOrPhenotypicFeature	D015783
82210129	489	514	glucocorticoid resistance	DiseaseOrPhenotypicFeature	C564221
82210129	520	522	EH	DiseaseOrPhenotypicFeature	D000075222
82210129	575	581	521T>C	SequenceVariant	c|SUB|T|521|C
82210129	615	621	521T>C	SequenceVariant	c|SUB|T|521|C
82210129	626	651	glucocorticoid resistance	DiseaseOrPhenotypicFeature	C564221
82210129	722	728	521T>C	SequenceVariant	c|SUB|T|521|C
82210129	733	735	EH	DiseaseOrPhenotypicFeature	D000075222
82210129	782	816	deletion of valine 624, valine 625	SequenceVariant	p|DEL|624_625|VV
82210129	863	865	AN	DiseaseOrPhenotypicFeature	D015783
82210129	912	946	deletion of valine 624, valine 625	SequenceVariant	p|DEL|624_625|VV
82210129	955	961	521T>C	SequenceVariant	c|SUB|T|521|C
82210129	1050	1060	MES-SA/Dx5	CellLine	CVCL_2598
82210129	1065	1068	HEK	CellLine	CVCL_M624
82210129	1255	1276	Mangifera indica Linn	OrganismTaxon	29780
82210129	Positive_Correlation	C564221	c|SUB|T|521|C	Novel
82210129	Positive_Correlation	D000075222	c|SUB|T|521|C	Novel
82210129	Positive_Correlation	D004421	c|SUB|T|521|C	Novel
82210129	Positive_Correlation	D015783	p|DEL|624_625|VV	Novel
82210129	Association	p|DEL|624_625|VV	c|SUB|T|521|C	Novel

65085443|t|Spirulina and Rhodiola rosea modulate tyrosinase, Let-7b, and MHC class II expression in yeast, HEK cells, and patient-derive
65085443|a|Recent studies have explored the molecular mechanisms underlying the bioactive properties of Spirulina and Rhodiola rosea, with a focus on their interactions with key regulatory genes in yeast, HEK cell lines, and patient-derived models. This research reveals a complex network of gene-gene and gene-organism interactions, particularly involving tyrosinase, Let-7b, and MHC class II. In yeast cultures, Spirulina was found to significantly upregulate tyrosinase expression, while Rhodiola rosea showed a negative correlation with Let-7b levels. These findings were corroborated in HEK cell lines, where Spirulina induced a positive correlation between tyrosinase and MHC class II, and Rhodiola rosea exhibited a negative correlation between adipsin and Let-7b.   Further analysis in patient-derived models demonstrated that Let-7b binds to adipsin and tyrosinase, with a positive correlation between Let-7b and MHC class II. Notably, adipsin was found to associate with both tyrosinase and MHC class II, and a negative correlation was observed between adipsin and Let-7b. These interactions suggest a regulatory feedback loop involving these genes, with Spirulina and Rhodiola rosea acting as modulators. The study also highlights the role of yeast as a model system for understanding these interactions, with multiple instances of Spirulina and yeast mentioned in the context of gene expression profiling. The results provide new insights into the molecular mechanisms of Spirulina and Rhodiola rosea, with implications for their therapeutic potential in conditions involving oxidative stress and immune regulation.
65085443	0	9	Spirulina	OrganismTaxon	551299
65085443	14	28	Rhodiola rosea	OrganismTaxon	203015
65085443	38	48	tyrosinase	GeneOrGeneProduct	7299
65085443	50	56	Let-7b	GeneOrGeneProduct	406884
65085443	62	74	MHC class II	GeneOrGeneProduct	3108
65085443	89	94	yeast	OrganismTaxon	4932
65085443	96	99	HEK	CellLine	CVCL_M624
65085443	111	118	patient	OrganismTaxon	9606
65085443	219	228	Spirulina	OrganismTaxon	551299
65085443	233	247	Rhodiola rosea	OrganismTaxon	203015
65085443	313	318	yeast	OrganismTaxon	4932
65085443	320	323	HEK	CellLine	CVCL_M624
65085443	340	347	patient	OrganismTaxon	9606
65085443	472	482	tyrosinase	GeneOrGeneProduct	7299
65085443	484	490	Let-7b	GeneOrGeneProduct	406884
65085443	496	508	MHC class II	GeneOrGeneProduct	3108
65085443	513	518	yeast	OrganismTaxon	4932
65085443	529	538	Spirulina	OrganismTaxon	551299
65085443	577	587	tyrosinase	GeneOrGeneProduct	7299
65085443	606	620	Rhodiola rosea	OrganismTaxon	203015
65085443	656	662	Let-7b	GeneOrGeneProduct	406884
65085443	707	710	HEK	CellLine	CVCL_M624
65085443	729	738	Spirulina	OrganismTaxon	551299
65085443	778	788	tyrosinase	GeneOrGeneProduct	7299
65085443	793	805	MHC class II	GeneOrGeneProduct	3108
65085443	811	825	Rhodiola rosea	OrganismTaxon	203015
65085443	867	874	adipsin	GeneOrGeneProduct	1675
65085443	879	885	Let-7b	GeneOrGeneProduct	406884
65085443	909	916	patient	OrganismTaxon	9606
65085443	950	956	Let-7b	GeneOrGeneProduct	406884
65085443	966	973	adipsin	GeneOrGeneProduct	1675
65085443	978	988	tyrosinase	GeneOrGeneProduct	7299
65085443	1026	1032	Let-7b	GeneOrGeneProduct	406884
65085443	1037	1049	MHC class II	GeneOrGeneProduct	3108
65085443	1060	1067	adipsin	GeneOrGeneProduct	1675
65085443	1101	1111	tyrosinase	GeneOrGeneProduct	7299
65085443	1116	1128	MHC class II	GeneOrGeneProduct	3108
65085443	1178	1185	adipsin	GeneOrGeneProduct	1675
65085443	1190	1196	Let-7b	GeneOrGeneProduct	406884
65085443	1280	1289	Spirulina	OrganismTaxon	551299
65085443	1294	1308	Rhodiola rosea	OrganismTaxon	203015
65085443	1369	1374	yeast	OrganismTaxon	4932
65085443	1458	1467	Spirulina	OrganismTaxon	551299
65085443	1472	1477	yeast	OrganismTaxon	4932
65085443	1599	1608	Spirulina	OrganismTaxon	551299
65085443	1613	1627	Rhodiola rosea	OrganismTaxon	203015
65085443	Negative_Correlation	7299	406884	Novel
65085443	Bind	406884	1675	Novel
65085443	Bind	7299	406884	Novel
65085443	Positive_Correlation	3108	7299	Novel
65085443	Association	1675	7299	Novel
65085443	Positive_Correlation	406884	3108	Novel
65085443	Bind	1675	3108	Novel
65085443	Positive_Correlation	1675	406884	Novel
65085443	Association	406884	7299	Novel
65085443	Negative_Correlation	1675	406884	Novel
65085443	Association	3108	7299	Novel

32367696|t|Dexamethasone and leucine interactions in MC3T3-E1 cells: implications for SIDS, polycythemia, and pituitary adenoma in Mouse and shee
32367696|a|This study investigates the complex interactions between dexamethasone and leucine in the context of MC3T3-E1 cell lines, with a focus on their roles in SIDS, polycythemia, and pituitary adenoma. The research explores the conversion between dexamethasone and leucine, as well as their associations with various disease states. In Mouse and sheep models, dexamethasone was found to be significantly associated with SIDS and polycythemia, while leucine showed a strong link to both SIDS and polycythemia. Additionally, pituitary adenoma was found to be associated with both dexamethasone and leucine. The study also highlights the conversion between leucine and dexamethasone, suggesting a potential metabolic pathway that may contribute to the pathogenesis of these conditions. MC3T3-E1 cells were used as a model system to examine these interactions, and the results provide new insights into the molecular mechanisms underlying these diseases. The findings suggest that dexamethasone and leucine may play a critical role in the development of SIDS, polycythemia, and pituitary adenoma in both Mouse and sheep. These results have important implications for the treatment and prevention of these conditions in both human and animal models.
32367696	18	25	leucine	ChemicalEntity	D007930
32367696	42	50	MC3T3-E1	CellLine	CVCL_0409
32367696	75	79	SIDS	DiseaseOrPhenotypicFeature	D013398
32367696	81	93	polycythemia	DiseaseOrPhenotypicFeature	D011086
32367696	99	116	pituitary adenoma	DiseaseOrPhenotypicFeature	D010911
32367696	120	125	Mouse	OrganismTaxon	10090
32367696	192	205	dexamethasone	ChemicalEntity	D003907
32367696	210	217	leucine	ChemicalEntity	D007930
32367696	236	244	MC3T3-E1	CellLine	CVCL_0409
32367696	288	292	SIDS	DiseaseOrPhenotypicFeature	D013398
32367696	294	306	polycythemia	DiseaseOrPhenotypicFeature	D011086
32367696	312	329	pituitary adenoma	DiseaseOrPhenotypicFeature	D010911
32367696	376	389	dexamethasone	ChemicalEntity	D003907
32367696	394	401	leucine	ChemicalEntity	D007930
32367696	465	470	Mouse	OrganismTaxon	10090
32367696	475	480	sheep	OrganismTaxon	9940
32367696	489	502	dexamethasone	ChemicalEntity	D003907
32367696	549	553	SIDS	DiseaseOrPhenotypicFeature	D013398
32367696	558	570	polycythemia	DiseaseOrPhenotypicFeature	D011086
32367696	578	585	leucine	ChemicalEntity	D007930
32367696	615	619	SIDS	DiseaseOrPhenotypicFeature	D013398
32367696	624	636	polycythemia	DiseaseOrPhenotypicFeature	D011086
32367696	652	669	pituitary adenoma	DiseaseOrPhenotypicFeature	D010911
32367696	707	720	dexamethasone	ChemicalEntity	D003907
32367696	725	732	leucine	ChemicalEntity	D007930
32367696	783	790	leucine	ChemicalEntity	D007930
32367696	795	808	dexamethasone	ChemicalEntity	D003907
32367696	912	920	MC3T3-E1	CellLine	CVCL_0409
32367696	1106	1119	dexamethasone	ChemicalEntity	D003907
32367696	1124	1131	leucine	ChemicalEntity	D007930
32367696	1179	1183	SIDS	DiseaseOrPhenotypicFeature	D013398
32367696	1185	1197	polycythemia	DiseaseOrPhenotypicFeature	D011086
32367696	1203	1220	pituitary adenoma	DiseaseOrPhenotypicFeature	D010911
32367696	1229	1234	Mouse	OrganismTaxon	10090
32367696	1239	1244	sheep	OrganismTaxon	9940
32367696	Conversion	D007930	D003907	Novel
32367696	Association	D010911	D007930	Novel
32367696	Association	D011086	D003907	Novel
32367696	Association	D013398	D003907	Novel
32367696	Conversion	D003907	D007930	Novel
32367696	Association	D011086	D007930	Novel
32367696	Association	D010911	D003907	Novel
32367696	Association	D013398	D007930	Novel

47849677|t|Genetic and microbial interactions in oral health: associations between sequence variants, gene products, and organism taxa in oral stereotypies and denta
47849677|a|Recent studies have highlighted the complex interplay between genetic factors and microbial communities in the development of oral health conditions. This study investigates the associations between sequence variants, gene products, and organism taxa in the context of oral stereotypies and dental caries. A genome-wide association study (GWAS) revealed a positive correlation between the sequence variant rs2274700 and oral stereotypies, suggesting a potential genetic predisposition to these behaviors. Additionally, the sequence variant G7958A was found to have a positive correlation with dental caries, indicating a possible role in the pathogenesis of this condition. Notably, there was also a positive correlation between dental caries and rs2274700, suggesting a potential synergistic effect between these genetic factors.   Further, the study explored the relationship between gene products and microbial taxa. A negative correlation was observed between uncoupling proteins 2 and 3 and the gene product ERG, implying a regulatory interaction that may influence metabolic processes. The gene product vascular endothelial growth factor (VEGF)-A was found to be associated with multiple organism taxa, including DEN-4, E. coli, and tobacco, suggesting a role in immune responses and inflammation.   Microbial analysis revealed that the organism taxon Spirulina was significantly associated with oral stereotypies, while the organism taxon yeast showed a positive correlation with dental caries. The organism taxon cats was found to be linked to both oral stereotypies and VEGF-A expression, possibly through environmental or behavioral factors. The organism taxon Drosophila was associated with the gene product IFT27, highlighting potential evolutionary conservation of gene function.   The organism taxon tobacco was found to be linked to multiple gene products, including VEGF-A and ERG, suggesting a role in modulating gene expression through epigenetic mechanisms. The organism taxon E. coli was associated with both oral stereotypies and dental caries, indicating a possible microbial contribution to these conditions.   These findings underscore the importance of integrating genetic, microbial, and environmental factors in understanding the etiology of oral health conditions. The study provides a comprehensive framework for future research into the molecular and ecological mechanisms underlying these complex interactions.
47849677	127	144	oral stereotypies	DiseaseOrPhenotypicFeature	D009062
47849677	424	441	oral stereotypies	DiseaseOrPhenotypicFeature	D009062
47849677	446	459	dental caries	DiseaseOrPhenotypicFeature	D003731
47849677	561	570	rs2274700	SequenceVariant	rs2274700
47849677	575	592	oral stereotypies	DiseaseOrPhenotypicFeature	D009062
47849677	695	701	G7958A	SequenceVariant	rs4998557
47849677	748	761	dental caries	DiseaseOrPhenotypicFeature	D003731
47849677	884	897	dental caries	DiseaseOrPhenotypicFeature	D003731
47849677	902	911	rs2274700	SequenceVariant	rs2274700
47849677	1119	1146	uncoupling proteins 2 and 3	GeneOrGeneProduct	25708
47849677	1168	1171	ERG	GeneOrGeneProduct	2078
47849677	1264	1307	vascular endothelial growth factor (VEGF)-A	GeneOrGeneProduct	7422
47849677	1374	1379	DEN-4	OrganismTaxon	11070
47849677	1381	1388	E. coli	OrganismTaxon	562
47849677	1394	1401	tobacco	OrganismTaxon	4097
47849677	1513	1522	Spirulina	OrganismTaxon	551299
47849677	1557	1574	oral stereotypies	DiseaseOrPhenotypicFeature	D009062
47849677	1601	1606	yeast	OrganismTaxon	4932
47849677	1642	1655	dental caries	DiseaseOrPhenotypicFeature	D003731
47849677	1676	1680	cats	OrganismTaxon	9685
47849677	1712	1729	oral stereotypies	DiseaseOrPhenotypicFeature	D009062
47849677	1826	1836	Drosophila	OrganismTaxon	7227
47849677	1874	1879	IFT27	GeneOrGeneProduct	11020
47849677	1969	1976	tobacco	OrganismTaxon	4097
47849677	2048	2051	ERG	GeneOrGeneProduct	2078
47849677	2151	2158	E. coli	OrganismTaxon	562
47849677	2184	2201	oral stereotypies	DiseaseOrPhenotypicFeature	D009062
47849677	2206	2219	dental caries	DiseaseOrPhenotypicFeature	D003731
47849677	Positive_Correlation	rs2274700	D009062	Novel
47849677	Positive_Correlation	rs4998557	D003731	Novel
47849677	Positive_Correlation	D003731	rs2274700	Novel
47849677	Positive_Correlation	D009062	rs4998557	Novel
47849677	Negative_Correlation	25708	2078	Novel

65939088|t|Spirulina and sequence variants V89L and rs4828037 in the context of Alkaptonuria, POLG, and immune reconstitution 
65939088|a|Spirulina, a widely studied cyanobacterium, has been implicated in various metabolic and immunological conditions, including Alkaptonuria and immune reconstitution syndrome. This study investigates the potential role of sequence variants V89L and rs4828037 in the POLG gene, which is known to be associated with Alkaptonuria and immune reconstitution syndrome. The presence of multiple instances of the sequence variant V89L in Spirulina-exposed individuals suggests a possible interaction between Spirulina and the POLG gene. Furthermore, the association between Alkaptonuria and POLG is supported by the frequent occurrence of the rs4828037 variant in patients with this condition. Similarly, the link between immune reconstitution syndrome and POLG is reinforced by the co-occurrence of the V89L variant in both immune reconstitution syndrome cases and individuals with Alkaptonuria. The study also highlights the potential of Spirulina as a modulator of POLG function, with implications for the management of Alkaptonuria and immune reconstitution syndrome. These findings suggest that the interplay between Spirulina, sequence variants V89L and rs4828037, and the POLG gene may contribute to the pathogenesis of Alkaptonuria and immune reconstitution syndrome.
65939088	0	9	Spirulina	OrganismTaxon	551299
65939088	32	36	V89L	SequenceVariant	rs523349
65939088	41	50	rs4828037	SequenceVariant	rs4828037
65939088	69	81	Alkaptonuria	DiseaseOrPhenotypicFeature	D000474
65939088	83	87	POLG	GeneOrGeneProduct	5428
65939088	116	125	Spirulina	OrganismTaxon	551299
65939088	241	253	Alkaptonuria	DiseaseOrPhenotypicFeature	D000474
65939088	258	288	immune reconstitution syndrome	DiseaseOrPhenotypicFeature	D054019
65939088	354	358	V89L	SequenceVariant	rs523349
65939088	363	372	rs4828037	SequenceVariant	rs4828037
65939088	380	384	POLG	GeneOrGeneProduct	5428
65939088	428	440	Alkaptonuria	DiseaseOrPhenotypicFeature	D000474
65939088	445	475	immune reconstitution syndrome	DiseaseOrPhenotypicFeature	D054019
65939088	536	540	V89L	SequenceVariant	rs523349
65939088	544	553	Spirulina	OrganismTaxon	551299
65939088	614	623	Spirulina	OrganismTaxon	551299
65939088	632	636	POLG	GeneOrGeneProduct	5428
65939088	680	692	Alkaptonuria	DiseaseOrPhenotypicFeature	D000474
65939088	697	701	POLG	GeneOrGeneProduct	5428
65939088	749	758	rs4828037	SequenceVariant	rs4828037
65939088	828	858	immune reconstitution syndrome	DiseaseOrPhenotypicFeature	D054019
65939088	863	867	POLG	GeneOrGeneProduct	5428
65939088	910	914	V89L	SequenceVariant	rs523349
65939088	931	961	immune reconstitution syndrome	DiseaseOrPhenotypicFeature	D054019
65939088	989	1001	Alkaptonuria	DiseaseOrPhenotypicFeature	D000474
65939088	1046	1055	Spirulina	OrganismTaxon	551299
65939088	1074	1078	POLG	GeneOrGeneProduct	5428
65939088	1129	1141	Alkaptonuria	DiseaseOrPhenotypicFeature	D000474
65939088	1146	1176	immune reconstitution syndrome	DiseaseOrPhenotypicFeature	D054019
65939088	1228	1237	Spirulina	OrganismTaxon	551299
65939088	1257	1261	V89L	SequenceVariant	rs523349
65939088	1266	1275	rs4828037	SequenceVariant	rs4828037
65939088	1285	1289	POLG	GeneOrGeneProduct	5428
65939088	1333	1345	Alkaptonuria	DiseaseOrPhenotypicFeature	D000474
65939088	1350	1380	immune reconstitution syndrome	DiseaseOrPhenotypicFeature	D054019
65939088	Association	D000474	5428	Novel
65939088	Association	D054019	5428	Novel

83662725|t|Vps2, c-Fos, and MAP9: Interactions with Kras, vimentin, and NOX4 in H9c2 and Capan1 ce
83662725|a|This study investigates the molecular interactions and functional relationships between the gene products Vps2, c-Fos, and MAP9, and their associations with the oncogene Kras, the cytoskeletal protein vimentin, and the NADPH oxidase subunit NOX4 in the context of H9c2 and Capan1 cell lines. We demonstrate a positive correlation between MAP9 and Kras, suggesting a potential regulatory role of Kras in MAP9 expression. Additionally, we find an association between the sequence variant 1284A>C and Vps2, indicating a possible functional impact of this variant on Vps2 activity. The negative correlation between vimentin and Kras is further supported by the positive correlation between vimentin and MAP9, suggesting a complex regulatory network involving these proteins.   We also report a strong association between c-Fos and Kras, with evidence of a direct bind between vimentin and c-Fos, highlighting potential cross-talk between these signaling pathways. The positive correlation between vimentin and NOX4, along with the association between NOX4 and NR2F1, suggests a coordinated regulation of these genes in cellular stress responses. Furthermore, the negative correlation between NR2F1 and Thyroid hormone receptor a indicates a potential antagonistic relationship between these transcription factors.   Our findings are validated across multiple cell lines, including H9c2, Capan1, and LbetaT2, and are supported by the presence of sequence variants such as G1103R, L50R, and rs2073601, which may contribute to the observed phenotypic variations. These results provide new insights into the molecular mechanisms underlying the interactions between these genes and their variants in cellular processes.
83662725	0	4	Vps2	GeneOrGeneProduct	27243
83662725	6	11	c-Fos	GeneOrGeneProduct	14281
83662725	17	21	MAP9	GeneOrGeneProduct	79884
83662725	41	45	Kras	GeneOrGeneProduct	3845
83662725	47	55	vimentin	GeneOrGeneProduct	22352
83662725	61	65	NOX4	GeneOrGeneProduct	50507
83662725	69	73	H9c2	CellLine	CVCL_0286
83662725	78	84	Capan1	CellLine	CVCL_0237
83662725	194	198	Vps2	GeneOrGeneProduct	27243
83662725	200	205	c-Fos	GeneOrGeneProduct	14281
83662725	211	215	MAP9	GeneOrGeneProduct	79884
83662725	258	262	Kras	GeneOrGeneProduct	3845
83662725	289	297	vimentin	GeneOrGeneProduct	22352
83662725	329	333	NOX4	GeneOrGeneProduct	50507
83662725	352	356	H9c2	CellLine	CVCL_0286
83662725	361	367	Capan1	CellLine	CVCL_0237
83662725	426	430	MAP9	GeneOrGeneProduct	79884
83662725	435	439	Kras	GeneOrGeneProduct	3845
83662725	483	487	Kras	GeneOrGeneProduct	3845
83662725	491	495	MAP9	GeneOrGeneProduct	79884
83662725	574	581	1284A>C	SequenceVariant	c|SUB|A|1284|C
83662725	586	590	Vps2	GeneOrGeneProduct	27243
83662725	651	655	Vps2	GeneOrGeneProduct	27243
83662725	699	707	vimentin	GeneOrGeneProduct	22352
83662725	712	716	Kras	GeneOrGeneProduct	3845
83662725	774	782	vimentin	GeneOrGeneProduct	22352
83662725	787	791	MAP9	GeneOrGeneProduct	79884
83662725	905	910	c-Fos	GeneOrGeneProduct	14281
83662725	915	919	Kras	GeneOrGeneProduct	3845
83662725	960	968	vimentin	GeneOrGeneProduct	22352
83662725	973	978	c-Fos	GeneOrGeneProduct	14281
83662725	1081	1089	vimentin	GeneOrGeneProduct	22352
83662725	1094	1098	NOX4	GeneOrGeneProduct	50507
83662725	1135	1139	NOX4	GeneOrGeneProduct	50507
83662725	1144	1149	NR2F1	GeneOrGeneProduct	7025
83662725	1276	1281	NR2F1	GeneOrGeneProduct	7025
83662725	1286	1312	Thyroid hormone receptor a	GeneOrGeneProduct	21833
83662725	1465	1469	H9c2	CellLine	CVCL_0286
83662725	1471	1477	Capan1	CellLine	CVCL_0237
83662725	1483	1490	LbetaT2	CellLine	CVCL_0398
83662725	1555	1561	G1103R	SequenceVariant	rs62636275
83662725	1563	1567	L50R	SequenceVariant	p|SUB|L|50|R
83662725	1573	1582	rs2073601	SequenceVariant	rs2073601
83662725	Positive_Correlation	79884	3845	Novel
83662725	Association	7025	79884	Novel
83662725	Negative_Correlation	22352	3845	Novel
83662725	Association	c|SUB|A|1284|C	27243	Novel
83662725	Association	3845	79884	Novel
83662725	Positive_Correlation	22352	79884	Novel
83662725	Negative_Correlation	7025	21833	Novel
83662725	Positive_Correlation	22352	50507	Novel
83662725	Association	14281	3845	Novel
83662725	Bind	22352	14281	Novel
83662725	Association	50507	7025	Novel

83855788|t|Tritium exposure and genetic variants in Reis-Bucklers dystrophy, soft tissue sarcoma, and musculoskeletal pain: a multi-phenoty
83855788|a|This study investigates the association between tritium exposure and multiple genetic variants across a range of phenotypic features, including Reis-Bucklers dystrophy, soft tissue sarcoma, and musculoskeletal pain. Tritium, a radioactive isotope of hydrogen, was found to exhibit significant positive correlations with several sequence variants, including g.3395C>T, L490R, c.920T>G, c.1239 +1G>A, 1494del6, rs12910509, and multiple instances of c.920T>G. These associations suggest a potential role for tritium in modulating genetic expression or stability in these conditions.   The study also reports a positive correlation between tritium and WFS, cortical dysplasia, and musculoskeletal pain, indicating that tritium may influence the pathogenesis of these phenotypic features. Notably, Reis-Bucklers dystrophy was found to be positively correlated with tritium, suggesting a possible environmental-genetic interaction in the development of this rare corneal dystrophy.   In addition to these associations, the study explores the impact of tritium on bacterial populations, revealing that tritium exposure may alter microbial community composition and function. This finding opens new avenues for understanding the interplay between environmental factors and genetic predispositions in complex diseases. The results highlight the importance of considering environmental exposures, such as tritium, in the context of genetic variability and phenotypic outcomes.
83855788	41	64	Reis-Bucklers dystrophy	DiseaseOrPhenotypicFeature	C535476
83855788	66	85	soft tissue sarcoma	DiseaseOrPhenotypicFeature	D012509
83855788	91	111	musculoskeletal pain	DiseaseOrPhenotypicFeature	D059352
83855788	177	184	tritium	ChemicalEntity	D014316
83855788	273	296	Reis-Bucklers dystrophy	DiseaseOrPhenotypicFeature	C535476
83855788	298	317	soft tissue sarcoma	DiseaseOrPhenotypicFeature	D012509
83855788	323	343	musculoskeletal pain	DiseaseOrPhenotypicFeature	D059352
83855788	486	495	g.3395C>T	SequenceVariant	g|SUB|C|3395|T
83855788	497	502	L490R	SequenceVariant	rs80338886
83855788	504	512	c.920T>G	SequenceVariant	c|SUB|T|920|G
83855788	514	526	c.1239 +1G>A	SequenceVariant	c|SUB|G|1239+1|A
83855788	528	536	1494del6	SequenceVariant	c|DEL|1494|6
83855788	538	548	rs12910509	SequenceVariant	rs12910509
83855788	576	584	c.920T>G	SequenceVariant	c|SUB|T|920|G
83855788	634	641	tritium	ChemicalEntity	D014316
83855788	765	772	tritium	ChemicalEntity	D014316
83855788	777	780	WFS	DiseaseOrPhenotypicFeature	D014929
83855788	782	800	cortical dysplasia	DiseaseOrPhenotypicFeature	D054220
83855788	806	826	musculoskeletal pain	DiseaseOrPhenotypicFeature	D059352
83855788	844	851	tritium	ChemicalEntity	D014316
83855788	922	945	Reis-Bucklers dystrophy	DiseaseOrPhenotypicFeature	C535476
83855788	989	996	tritium	ChemicalEntity	D014316
83855788	1175	1182	tritium	ChemicalEntity	D014316
83855788	1186	1194	bacteria	OrganismTaxon	2
83855788	1224	1231	tritium	ChemicalEntity	D014316
83855788	1524	1531	tritium	ChemicalEntity	D014316
83855788	Association	D014316	c|SUB|G|1239+1|A	Novel
83855788	Association	D014316	c|DEL|1494|6	Novel
83855788	Association	D014316	rs12910509	Novel
83855788	Positive_Correlation	D014929	D014316	Novel
83855788	Positive_Correlation	D059352	D014316	Novel
83855788	Positive_Correlation	D054220	D014316	Novel
83855788	Association	D014316	rs80338886	Novel
83855788	Association	D014316	c|SUB|T|920|G	Novel
83855788	Association	D014316	g|SUB|C|3395|T	Novel
83855788	Positive_Correlation	D012509	D014316	Novel
83855788	Positive_Correlation	C535476	D014316	Novel

14533030|t|C4A, Liver kinase B1, and Stat5: genetic and functional interactions in human immunodeficiency virus-infected DU145 and CD18/HPAF ce
14533030|a|This study investigates the genetic and functional interactions between the gene C4A, Liver kinase B1, and Stat5 in the context of human immunodeficiency virus (HIV) infection. We analyzed the expression patterns and functional roles of these genes in HIV-infected DU145 and CD18/HPAF cell lines, as well as in human immunodeficiency virus (HIV)-infected primary cells. Our findings reveal a negative correlation between C4A and Stat5, suggesting that C4A may act as a suppressor of Stat5 activity. Additionally, we observed an association between the sequence variant 30delG and both Stat5 and C4A, indicating that this variant may influence the expression or function of these genes. The sequence variant g.2839T>G was also found to be associated with Stat5, further supporting the role of genetic variability in modulating Stat5 activity. The sequence variant Ile/Val was linked to Stat5, suggesting a potential role in the regulation of its signaling pathways. Furthermore, the sequence variant L180M was associated with C4A, highlighting the importance of amino acid substitutions in determining gene function. In contrast, the sequence variant L180M showed a negative correlation with Liver kinase B1, indicating a possible antagonistic relationship between these two genes. The negative correlation between Liver kinase B1 and Stat5 suggests that Liver kinase B1 may act as a negative regulator of Stat5 signaling. These findings provide new insights into the molecular mechanisms underlying the interactions between C4A, Liver kinase B1, and Stat5 in the context of HIV infection. The study also highlights the importance of genetic variability in shaping the functional outcomes of these genes in different cell line models, including DU145, CD18/HPAF, and HL-7702 cells. The results have implications for understanding the pathogenesis of HIV-related diseases and for the development of targeted therapeutic strategies.
14533030	0	3	C4A	GeneOrGeneProduct	720
14533030	5	20	Liver kinase B1	GeneOrGeneProduct	20869
14533030	26	31	Stat5	GeneOrGeneProduct	20850
14533030	72	100	human immunodeficiency virus	OrganismTaxon	12721
14533030	110	115	DU145	CellLine	CVCL_0105
14533030	120	129	CD18/HPAF	CellLine	CVCL_0313
14533030	214	217	C4A	GeneOrGeneProduct	720
14533030	219	234	Liver kinase B1	GeneOrGeneProduct	20869
14533030	240	245	Stat5	GeneOrGeneProduct	20850
14533030	264	292	human immunodeficiency virus	OrganismTaxon	12721
14533030	398	403	DU145	CellLine	CVCL_0105
14533030	408	417	CD18/HPAF	CellLine	CVCL_0313
14533030	444	472	human immunodeficiency virus	OrganismTaxon	12721
14533030	554	557	C4A	GeneOrGeneProduct	720
14533030	562	567	Stat5	GeneOrGeneProduct	20850
14533030	585	588	C4A	GeneOrGeneProduct	720
14533030	616	621	Stat5	GeneOrGeneProduct	20850
14533030	702	708	30delG	SequenceVariant	c|DEL|30|G
14533030	718	723	Stat5	GeneOrGeneProduct	20850
14533030	728	731	C4A	GeneOrGeneProduct	720
14533030	840	849	g.2839T>G	SequenceVariant	g|SUB|T|2839|G
14533030	887	892	Stat5	GeneOrGeneProduct	20850
14533030	959	964	Stat5	GeneOrGeneProduct	20850
14533030	996	1003	Ile/Val	SequenceVariant	rs1048943
14533030	1018	1023	Stat5	GeneOrGeneProduct	20850
14533030	1132	1137	L180M	SequenceVariant	p|SUB|L|180|M
14533030	1158	1161	C4A	GeneOrGeneProduct	720
14533030	1283	1288	L180M	SequenceVariant	p|SUB|L|180|M
14533030	1324	1339	Liver kinase B1	GeneOrGeneProduct	20869
14533030	1447	1462	Liver kinase B1	GeneOrGeneProduct	20869
14533030	1467	1472	Stat5	GeneOrGeneProduct	20850
14533030	1487	1502	Liver kinase B1	GeneOrGeneProduct	20869
14533030	1538	1543	Stat5	GeneOrGeneProduct	20850
14533030	1657	1660	C4A	GeneOrGeneProduct	720
14533030	1662	1677	Liver kinase B1	GeneOrGeneProduct	20869
14533030	1683	1688	Stat5	GeneOrGeneProduct	20850
14533030	1877	1882	DU145	CellLine	CVCL_0105
14533030	1884	1893	CD18/HPAF	CellLine	CVCL_0313
14533030	1899	1906	HL-7702	CellLine	CVCL_6926
14533030	Negative_Correlation	720	20850	Novel
14533030	Association	c|DEL|30|G	20850	Novel
14533030	Association	c|DEL|30|G	720	Novel
14533030	Negative_Correlation	20850	720	Novel
14533030	Negative_Correlation	20869	20850	Novel
14533030	Association	rs1048943	20850	Novel
14533030	Association	p|SUB|L|180|M	720	Novel

16124622|t|Genetic Variants in LPA1 and KIM-1 Modulate Dyspnea and Interact with E. coli-Induced Pathways in PA-1 and IEC-6 Ce
16124622|a|This study investigates the molecular mechanisms underlying dyspnea in the context of genetic variants in the LPA1 and KIM-1 genes, with a focus on their interactions with E. coli and their expression in PA-1 and IEC-6 cell lines. Dyspnea was observed to be positively correlated with the sequence variants p.G705RfsX16, R211H, and p.W111X, suggesting a potential role for these variants in the pathophysiology of respiratory distress. The association between LPA1 and dyspnea was further supported by a positive correlation between LPA1 expression and the presence of dyspnea, as well as a direct association between LPA1 and KIM-1. The sequence variant p.G705RfsX16 was found to be associated with LPA1, while R211H and p.W111X were also linked to LPA1, indicating a complex regulatory network involving these genes. Additionally, p.W111X was associated with KIM-1, and there was a positive correlation between KIM-1 and dyspnea, reinforcing the role of KIM-1 in respiratory function. The interaction between KIM-1 and LPA1 was further supported by a direct binding event, suggesting a potential functional relationship between these two genes. The study also examined the impact of E. coli on these pathways, with E. coli being present in 4 instances across the dataset. The cell lines PA-1 and IEC-6 were used to model these interactions, with PA-1 being mentioned 8 times and IEC-6 appearing 3 times. The findings highlight the importance of genetic variants in modulating dyspnea and their potential role in disease progression, particularly in the context of E. coli infection and cellular responses in PA-1 and IEC-6 cell lines.
16124622	29	34	KIM-1	GeneOrGeneProduct	286934
16124622	70	77	E. coli	OrganismTaxon	562
16124622	98	102	PA-1	CellLine	CVCL_0479
16124622	107	112	IEC-6	CellLine	CVCL_0343
16124622	176	183	dyspnea	DiseaseOrPhenotypicFeature	D004417
16124622	235	240	KIM-1	GeneOrGeneProduct	286934
16124622	288	295	E. coli	OrganismTaxon	562
16124622	320	324	PA-1	CellLine	CVCL_0479
16124622	329	334	IEC-6	CellLine	CVCL_0343
16124622	423	435	p.G705RfsX16	SequenceVariant	p|FS|G|705|R|16
16124622	437	442	R211H	SequenceVariant	p|SUB|R|211|H
16124622	448	455	p.W111X	SequenceVariant	rs137852884
16124622	585	592	dyspnea	DiseaseOrPhenotypicFeature	D004417
16124622	685	692	dyspnea	DiseaseOrPhenotypicFeature	D004417
16124622	743	748	KIM-1	GeneOrGeneProduct	286934
16124622	771	783	p.G705RfsX16	SequenceVariant	p|FS|G|705|R|16
16124622	828	833	R211H	SequenceVariant	p|SUB|R|211|H
16124622	838	845	p.W111X	SequenceVariant	rs137852884
16124622	949	956	p.W111X	SequenceVariant	rs137852884
16124622	977	982	KIM-1	GeneOrGeneProduct	286934
16124622	1029	1034	KIM-1	GeneOrGeneProduct	286934
16124622	1039	1046	dyspnea	DiseaseOrPhenotypicFeature	D004417
16124622	1072	1077	KIM-1	GeneOrGeneProduct	286934
16124622	1127	1132	KIM-1	GeneOrGeneProduct	286934
16124622	1301	1308	E. coli	OrganismTaxon	562
16124622	1333	1340	E. coli	OrganismTaxon	562
16124622	1405	1409	PA-1	CellLine	CVCL_0479
16124622	1414	1419	IEC-6	CellLine	CVCL_0343
16124622	1464	1468	PA-1	CellLine	CVCL_0479
16124622	1497	1502	IEC-6	CellLine	CVCL_0343
16124622	1594	1601	dyspnea	DiseaseOrPhenotypicFeature	D004417
16124622	1682	1689	E. coli	OrganismTaxon	562
16124622	1726	1730	PA-1	CellLine	CVCL_0479
16124622	1735	1740	IEC-6	CellLine	CVCL_0343
16124622	Association	14745	D004417	Novel
16124622	Association	p|FS|G|705|R|16	14745	Novel
16124622	Association	286934	14745	Novel
16124622	Association	p|SUB|R|211|H	14745	Novel
16124622	Positive_Correlation	D004417	p|SUB|R|211|H	Novel
16124622	Positive_Correlation	D004417	rs137852884	Novel
16124622	Association	rs137852884	14745	Novel
16124622	Association	rs137852884	286934	Novel
16124622	Bind	286934	14745	Novel
16124622	Association	14745	286934	Novel
16124622	Positive_Correlation	14745	286934	Novel
16124622	Positive_Correlation	D004417	p|FS|G|705|R|16	Novel
16124622	Association	D004417	286934	Novel
16124622	Association	286934	D004417	Novel

25693586|t|Investigating the therapeutic conversion between rilmenidine and sorafenib in the context of retinal degeneration and the genetic associations of sequence variants in Ishikawa and HeLa ce
25693586|a|This study explores the therapeutic conversion between rilmenidine and sorafenib in the context of retinal degeneration and their potential applications in treating lymphoreticular malignancies. We investigated the pharmacological interactions between these two chemical entities in both Ishikawa and HeLa cell lines, which are widely used in cancer research. The results suggest a significant conversion mechanism between rilmenidine and sorafenib, which may have implications for the treatment of retinal degeneration and related diseases.   Further, we examined the genetic associations of several sequence variants, including c.463-6T>G, rs2073162, p.R246Q, and c.715_717delGTC, in relation to retinal degeneration and lymphoreticular malignancies. Our findings reveal a strong association between c.463-6T>G and rs2073162, as well as between p.R246Q and rs2073162, indicating a potential functional link between these variants. These associations were further validated using MC3T3-E1 and Ishikawa cell lines, which demonstrated consistent expression patterns across multiple experimental conditions.  Additionally, we explored the conversion between sorafenib and Clonidine, which may provide new insights into the pharmacological management of retinal degeneration. The study also included multiple instances of the chemical entity 'ester' in the context of drug metabolism and the role of these compounds in modulating cellular responses in the presence of specific sequence variants. The results highlight the importance of understanding the interplay between chemical entities and genetic factors in the development of targeted therapies for retinal degeneration and related conditions.
25693586	49	60	rilmenidine	ChemicalEntity	C032302
25693586	65	74	sorafenib	ChemicalEntity	D000077157
25693586	93	113	retinal degeneration	DiseaseOrPhenotypicFeature	D012162
25693586	167	175	Ishikawa	CellLine	CVCL_2529
25693586	180	184	HeLa	CellLine	CVCL_0030
25693586	243	254	rilmenidine	ChemicalEntity	C032302
25693586	259	268	sorafenib	ChemicalEntity	D000077157
25693586	287	307	retinal degeneration	DiseaseOrPhenotypicFeature	D012162
25693586	353	381	lymphoreticular malignancies	DiseaseOrPhenotypicFeature	D049932
25693586	476	484	Ishikawa	CellLine	CVCL_2529
25693586	489	493	HeLa	CellLine	CVCL_0030
25693586	611	622	rilmenidine	ChemicalEntity	C032302
25693586	627	636	sorafenib	ChemicalEntity	D000077157
25693586	687	707	retinal degeneration	DiseaseOrPhenotypicFeature	D012162
25693586	818	828	c.463-6T>G	SequenceVariant	c|SUB|T463-6|G
25693586	830	839	rs2073162	SequenceVariant	rs2073162
25693586	841	848	p.R246Q	SequenceVariant	rs9332967
25693586	854	869	c.715_717delGTC	SequenceVariant	c|DEL|715_717|GTC
25693586	886	906	retinal degeneration	DiseaseOrPhenotypicFeature	D012162
25693586	911	939	lymphoreticular malignancies	DiseaseOrPhenotypicFeature	D049932
25693586	990	1000	c.463-6T>G	SequenceVariant	c|SUB|T463-6|G
25693586	1005	1014	rs2073162	SequenceVariant	rs2073162
25693586	1035	1042	p.R246Q	SequenceVariant	rs9332967
25693586	1047	1056	rs2073162	SequenceVariant	rs2073162
25693586	1169	1177	MC3T3-E1	CellLine	CVCL_0409
25693586	1182	1190	Ishikawa	CellLine	CVCL_2529
25693586	1344	1353	sorafenib	ChemicalEntity	D000077157
25693586	1358	1367	Clonidine	ChemicalEntity	D003000
25693586	1439	1459	retinal degeneration	DiseaseOrPhenotypicFeature	D012162
25693586	1528	1533	ester	ChemicalEntity	D004952
25693586	1840	1860	retinal degeneration	DiseaseOrPhenotypicFeature	D012162
25693586	Conversion	C032302	D000077157	Novel
25693586	Association	c|SUB|T463-6|G	rs2073162	Novel
25693586	Association	rs9332967	rs2073162	Novel
25693586	Conversion	D000077157	D003000	Novel

66757610|t|DNA polymerase gamma and c-Fos: interactions with steroid, penicillin-G potassium, and dimethyl sulphoxide in C. elegans and bovin
66757610|a|Recent studies have explored the functional interactions between DNA polymerase gamma and c-Fos in the context of steroid metabolism and antibiotic exposure. In C. elegans, DNA polymerase gamma was found to exhibit altered activity in the presence of the sequence variant 1469T->G, which was associated with increased sensitivity to steroid exposure. Similarly, in bovine models, the sequence variant A118D was linked to a significant reduction in the expression of c-Fos, suggesting a potential regulatory role in response to steroid and penicillin-G potassium.    The drug interaction between steroid and dimethyl sulphoxide was observed in both C. elegans and bovine systems, with dimethyl sulphoxide enhancing the bioavailability of steroid compounds. This effect was further supported by the drug interaction between steroid and penicillin-G potassium, which was found to modulate the pharmacokinetics of both agents in bovine tissues. Additionally, the drug interaction between dimethyl sulphoxide and penicillin-G potassium was noted, with dimethyl sulphoxide potentially reducing the renal clearance of penicillin-G potassium in C. elegans.    A negative correlation was identified between c-Fos and dimethyl sulphoxide in bovine liver tissue, suggesting that dimethyl sulphoxide may inhibit the transcriptional activity of c-Fos. This finding was consistent across multiple experimental conditions, including the presence of the sequence variant 1469T->G. The study also highlighted the importance of DNA polymerase gamma in maintaining genomic stability under conditions of steroid and antibiotic exposure, with the sequence variant A118D playing a critical role in this process.    These findings provide new insights into the molecular mechanisms underlying the interactions between DNA polymerase gamma, c-Fos, steroid, penicillin-G potassium, and dimethyl sulphoxide in both C. elegans and bovine models.
66757610	0	20	DNA polymerase gamma	GeneOrGeneProduct	5428
66757610	25	30	c-Fos	GeneOrGeneProduct	14281
66757610	50	57	steroid	ChemicalEntity	D013256
66757610	59	81	penicillin-G potassium	ChemicalEntity	D010400
66757610	87	106	dimethyl sulphoxide	ChemicalEntity	D004121
66757610	110	120	C. elegans	OrganismTaxon	6239
66757610	196	216	DNA polymerase gamma	GeneOrGeneProduct	5428
66757610	221	226	c-Fos	GeneOrGeneProduct	14281
66757610	245	252	steroid	ChemicalEntity	D013256
66757610	292	302	C. elegans	OrganismTaxon	6239
66757610	304	324	DNA polymerase gamma	GeneOrGeneProduct	5428
66757610	403	411	1469T->G	SequenceVariant	rs80338886
66757610	464	471	steroid	ChemicalEntity	D013256
66757610	496	502	bovine	OrganismTaxon	9913
66757610	532	537	A118D	SequenceVariant	p|SUB|A|118|D
66757610	597	602	c-Fos	GeneOrGeneProduct	14281
66757610	658	665	steroid	ChemicalEntity	D013256
66757610	670	692	penicillin-G potassium	ChemicalEntity	D010400
66757610	726	733	steroid	ChemicalEntity	D013256
66757610	738	757	dimethyl sulphoxide	ChemicalEntity	D004121
66757610	779	789	C. elegans	OrganismTaxon	6239
66757610	794	800	bovine	OrganismTaxon	9913
66757610	815	834	dimethyl sulphoxide	ChemicalEntity	D004121
66757610	868	875	steroid	ChemicalEntity	D013256
66757610	953	960	steroid	ChemicalEntity	D013256
66757610	965	987	penicillin-G potassium	ChemicalEntity	D010400
66757610	1056	1062	bovine	OrganismTaxon	9913
66757610	1115	1134	dimethyl sulphoxide	ChemicalEntity	D004121
66757610	1139	1161	penicillin-G potassium	ChemicalEntity	D010400
66757610	1178	1197	dimethyl sulphoxide	ChemicalEntity	D004121
66757610	1242	1264	penicillin-G potassium	ChemicalEntity	D010400
66757610	1268	1278	C. elegans	OrganismTaxon	6239
66757610	1329	1334	c-Fos	GeneOrGeneProduct	14281
66757610	1339	1358	dimethyl sulphoxide	ChemicalEntity	D004121
66757610	1362	1368	bovine	OrganismTaxon	9913
66757610	1399	1418	dimethyl sulphoxide	ChemicalEntity	D004121
66757610	1463	1468	c-Fos	GeneOrGeneProduct	14281
66757610	1586	1594	1469T->G	SequenceVariant	rs80338886
66757610	1641	1661	DNA polymerase gamma	GeneOrGeneProduct	5428
66757610	1715	1722	steroid	ChemicalEntity	D013256
66757610	1774	1779	A118D	SequenceVariant	p|SUB|A|118|D
66757610	1926	1946	DNA polymerase gamma	GeneOrGeneProduct	5428
66757610	1948	1953	c-Fos	GeneOrGeneProduct	14281
66757610	1955	1962	steroid	ChemicalEntity	D013256
66757610	1964	1986	penicillin-G potassium	ChemicalEntity	D010400
66757610	1992	2011	dimethyl sulphoxide	ChemicalEntity	D004121
66757610	2020	2030	C. elegans	OrganismTaxon	6239
66757610	2035	2041	bovine	OrganismTaxon	9913
66757610	Drug_Interaction	D004121	D010400	Novel
66757610	Drug_Interaction	D013256	D004121	Novel
66757610	Drug_Interaction	D013256	D010400	Novel
66757610	Negative_Correlation	14281	D004121	Novel
66757610	Drug_Interaction	D010400	D013256	Novel

38895329|t|Functional and Structural Interactions of Tryptophan Hydroxylase with Curcumin and Collagenase in the Context of West Nile Virus I
38895329|a|Recent studies have highlighted the complex interplay between host immune responses and viral pathogenesis, particularly in the context of West Nile virus (WNV) infection. This research explores the molecular interactions between tryptophan hydroxylase (TPH), a key enzyme in serotonin biosynthesis, and two bioactive compounds, Curcumin and collagenase, in the context of WNV infection. The study reveals that Curcumin and collagenase exhibit both comparative and conversional relationships, suggesting potential therapeutic applications in modulating immune responses.   Curcumin was found to bind to TPH, thereby modulating its enzymatic activity, while collagenase also demonstrated a binding affinity for TPH, indicating a possible role in the regulation of tryptophan metabolism during viral infection. The association between Curcumin and TPH was further supported by evidence of drug interaction between Curcumin and collagenase, which may influence the efficacy of both compounds in immune modulation.   Interestingly, the sequence variant p.R246Q in TPH was identified as a potential marker of altered enzyme function, and the presence of a single base pair deletion of a cytosine nucleotide was observed in multiple TPH alleles, suggesting genetic variability in the response to these compounds. The study also demonstrated that collagenase and Curcumin exhibit mutual association and conversion, with collagenase being able to convert Curcumin into a more bioavailable form, and vice versa.   These findings provide a foundation for understanding the molecular mechanisms underlying the interactions between TPH, Curcumin, and collagenase in the context of WNV infection, and may inform the development of novel therapeutic strategies targeting these pathways.
38895329	70	78	Curcumin	ChemicalEntity	D003474
38895329	270	285	West Nile virus	OrganismTaxon	11082
38895329	361	383	tryptophan hydroxylase	GeneOrGeneProduct	7166
38895329	460	468	Curcumin	ChemicalEntity	D003474
38895329	473	484	collagenase	ChemicalEntity	D017364
38895329	542	550	Curcumin	ChemicalEntity	D003474
38895329	555	566	collagenase	ChemicalEntity	D017364
38895329	704	712	Curcumin	ChemicalEntity	D003474
38895329	788	799	collagenase	ChemicalEntity	D017364
38895329	964	972	Curcumin	ChemicalEntity	D003474
38895329	1043	1051	Curcumin	ChemicalEntity	D003474
38895329	1056	1067	collagenase	ChemicalEntity	D017364
38895329	1180	1187	p.R246Q	SequenceVariant	rs9332967
38895329	1282	1332	single base pair deletion of a cytosine nucleotide	SequenceVariant	c|DEL||C
38895329	1471	1482	collagenase	ChemicalEntity	D017364
38895329	1487	1495	Curcumin	ChemicalEntity	D003474
38895329	1544	1555	collagenase	ChemicalEntity	D017364
38895329	1578	1586	Curcumin	ChemicalEntity	D003474
38895329	1756	1764	Curcumin	ChemicalEntity	D003474
38895329	1770	1781	collagenase	ChemicalEntity	D017364
38895329	Comparison	D003474	D017364	Novel
38895329	Conversion	D003474	D017364	Novel
38895329	Association	D017364	D003474	Novel
38895329	Conversion	D017364	D003474	Novel
38895329	Bind	7166	D003474	Novel
38895329	Drug_Interaction	D003474	D017364	Novel
38895329	Comparison	D017364	D003474	Novel
38895329	Association	D003474	7166	Novel
38895329	Bind	D017364	7166	Novel
38895329	Association	D003474	D017364	Novel
38895329	Bind	7166	D017364	Novel
38895329	Association	D017364	7166	Novel
38895329	Bind	D003474	7166	Novel
38895329	Drug_Interaction	D017364	D003474	Novel

45911372|t|Capan1 cell line and Hamel cerebropalatocardiac syndrome: genetic interactions involving LIF, CYPB11B2, Smad2/3, raptor, Spry 1, and sequence 
45911372|a|This study investigates the molecular mechanisms underlying the pathogenesis of Hamel cerebropalatocardiac syndrome in the context of the Capan1 cell line. We report a positive correlation between Spry 1 and LIF, suggesting a potential regulatory role of Spry 1 in LIF signaling. Additionally, a positive correlation between raptor and Spry 1 is observed, while a negative correlation between raptor and Spry 1 is also noted, indicating complex regulatory networks. The association between LIF and CYPB11B2 suggests a possible functional link between these two gene products in the disease context.   We further demonstrate a negative correlation between Smad2/3 and raptor, and a negative correlation between CYPB11B2 and Smad2/3, highlighting the interplay between these signaling pathways. The positive correlation between Smad2/3 and raptor is consistent with the observed negative correlation between Smad2/3 and CYPB11B2, suggesting a regulatory hierarchy.   Genetic variants play a significant role in this study. The association between rs713041 and c.1239 +1G>A, as well as between rs713041 and delta32, indicates potential functional relationships among these sequence variants. The association between A442V and c.1239 +1G>A, and between c.1094C>T and Y245X, further supports the involvement of these variants in the disease mechanism.   The negative correlation between Spry 1 and CYPB11B2 suggests a possible antagonistic relationship between these two gene products. Our findings provide a comprehensive view of the genetic and molecular interactions in Hamel cerebropalatocardiac syndrome, with implications for understanding the role of the Capan1 cell line in disease progression.
45911372	0	6	Capan1	CellLine	CVCL_0237
45911372	21	56	Hamel cerebropalatocardiac syndrome	DiseaseOrPhenotypicFeature	C537761
45911372	89	92	LIF	GeneOrGeneProduct	3976
45911372	94	102	CYPB11B2	GeneOrGeneProduct	1585
45911372	104	111	Smad2/3	GeneOrGeneProduct	17126
45911372	113	119	raptor	GeneOrGeneProduct	287871
45911372	121	127	Spry 1	GeneOrGeneProduct	24063
45911372	223	258	Hamel cerebropalatocardiac syndrome	DiseaseOrPhenotypicFeature	C537761
45911372	281	287	Capan1	CellLine	CVCL_0237
45911372	340	346	Spry 1	GeneOrGeneProduct	24063
45911372	351	354	LIF	GeneOrGeneProduct	3976
45911372	398	404	Spry 1	GeneOrGeneProduct	24063
45911372	408	411	LIF	GeneOrGeneProduct	3976
45911372	468	474	raptor	GeneOrGeneProduct	287871
45911372	479	485	Spry 1	GeneOrGeneProduct	24063
45911372	536	542	raptor	GeneOrGeneProduct	287871
45911372	547	553	Spry 1	GeneOrGeneProduct	24063
45911372	633	636	LIF	GeneOrGeneProduct	3976
45911372	641	649	CYPB11B2	GeneOrGeneProduct	1585
45911372	798	805	Smad2/3	GeneOrGeneProduct	17126
45911372	810	816	raptor	GeneOrGeneProduct	287871
45911372	853	861	CYPB11B2	GeneOrGeneProduct	1585
45911372	866	873	Smad2/3	GeneOrGeneProduct	17126
45911372	969	976	Smad2/3	GeneOrGeneProduct	17126
45911372	981	987	raptor	GeneOrGeneProduct	287871
45911372	1049	1056	Smad2/3	GeneOrGeneProduct	17126
45911372	1061	1069	CYPB11B2	GeneOrGeneProduct	1585
45911372	1188	1196	rs713041	SequenceVariant	rs713041
45911372	1201	1213	c.1239 +1G>A	SequenceVariant	c|SUB|G|1239+1|A
45911372	1234	1242	rs713041	SequenceVariant	rs713041
45911372	1247	1254	delta32	SequenceVariant	c|DEL||32
45911372	1356	1361	A442V	SequenceVariant	rs146017816
45911372	1366	1378	c.1239 +1G>A	SequenceVariant	c|SUB|G|1239+1|A
45911372	1392	1401	c.1094C>T	SequenceVariant	c|SUB|C|1094|T
45911372	1406	1411	Y245X	SequenceVariant	p|SUB|Y|245|X
45911372	1525	1531	Spry 1	GeneOrGeneProduct	24063
45911372	1536	1544	CYPB11B2	GeneOrGeneProduct	1585
45911372	1711	1746	Hamel cerebropalatocardiac syndrome	DiseaseOrPhenotypicFeature	C537761
45911372	1800	1806	Capan1	CellLine	CVCL_0237
45911372	Positive_Correlation	24063	3976	Novel
45911372	Positive_Correlation	287871	24063	Novel
45911372	Negative_Correlation	287871	24063	Novel
45911372	Association	3976	1585	Novel
45911372	Association	rs713041	c|SUB|G|1239+1|A	Novel
45911372	Negative_Correlation	17126	287871	Novel
45911372	Negative_Correlation	1585	17126	Novel
45911372	Association	rs146017816	c|SUB|G|1239+1|A	Novel
45911372	Association	c|SUB|C|1094|T	p|SUB|Y|245|X	Novel
45911372	Negative_Correlation	24063	1585	Novel
45911372	Association	rs713041	rs146017816	Novel
45911372	Positive_Correlation	17126	287871	Novel
45911372	Association	rs713041	c|DEL||32	Novel
45911372	Association	17126	1585	Novel

66990591|t|Ro4368554 and its associations with multiple disease phenotypes in diverse organisms and ce
66990591|a|Ro4368554 has been shown to exhibit negative correlations with several disease phenotypes, including weight gain when depressed, peripheral nerve toxicity, myocardial stunning, atrophy, and Multiple fibroadenomas. These findings were observed across multiple experimental models, including the cell lines MCF7/AdrR and MH134, as well as in organisms such as Spirulina, Toxorynchites mosquitoes, and Platonia insignis Mart. In particular, Ro4368554 was found to be inversely associated with weight gain when depressed in both MCF7/AdrR and MH134 cell lines, suggesting a potential therapeutic role in depression-related metabolic disorders. Similarly, Ro4368554 showed a negative correlation with peripheral nerve toxicity, which was most pronounced in Spirulina and Toxorynchites mosquitoes. The compound also demonstrated a protective effect against myocardial stunning in MH134 cells and in Platonia insignis Mart, indicating possible applications in cardiovascular disease. Furthermore, Ro4368554 was found to reduce atrophy in MCF7/AdrR cells and in Platonia insignis Mart, while its association with Multiple fibroadenomas was observed in both MH134 and MCF7/AdrR cell lines. These results highlight the broad therapeutic potential of Ro4368554 across multiple disease states and biological systems.
66990591	0	9	Ro4368554	ChemicalEntity	C507242
66990591	92	101	Ro4368554	ChemicalEntity	C507242
66990591	193	219	weight gain when depressed	DiseaseOrPhenotypicFeature	D015430
66990591	221	246	peripheral nerve toxicity	DiseaseOrPhenotypicFeature	D010523
66990591	248	267	myocardial stunning	DiseaseOrPhenotypicFeature	D017682
66990591	269	276	atrophy	DiseaseOrPhenotypicFeature	D001284
66990591	282	304	Multiple fibroadenomas	DiseaseOrPhenotypicFeature	D018226
66990591	397	406	MCF7/AdrR	CellLine	 CVCL_1452
66990591	411	416	MH134	CellLine	CVCL_8111
66990591	450	459	Spirulina	OrganismTaxon	551299
66990591	461	485	Toxorynchites mosquitoes	OrganismTaxon	2498889
66990591	491	513	Platonia insignis Mart	OrganismTaxon	198787
66990591	530	539	Ro4368554	ChemicalEntity	C507242
66990591	582	608	weight gain when depressed	DiseaseOrPhenotypicFeature	D015430
66990591	617	626	MCF7/AdrR	CellLine	 CVCL_1452
66990591	631	636	MH134	CellLine	CVCL_8111
66990591	743	752	Ro4368554	ChemicalEntity	C507242
66990591	788	813	peripheral nerve toxicity	DiseaseOrPhenotypicFeature	D010523
66990591	844	853	Spirulina	OrganismTaxon	551299
66990591	858	882	Toxorynchites mosquitoes	OrganismTaxon	2498889
66990591	943	962	myocardial stunning	DiseaseOrPhenotypicFeature	D017682
66990591	966	971	MH134	CellLine	CVCL_8111
66990591	985	1007	Platonia insignis Mart	OrganismTaxon	198787
66990591	1082	1091	Ro4368554	ChemicalEntity	C507242
66990591	1112	1119	atrophy	DiseaseOrPhenotypicFeature	D001284
66990591	1123	1132	MCF7/AdrR	CellLine	 CVCL_1452
66990591	1146	1168	Platonia insignis Mart	OrganismTaxon	198787
66990591	1197	1219	Multiple fibroadenomas	DiseaseOrPhenotypicFeature	D018226
66990591	1241	1246	MH134	CellLine	CVCL_8111
66990591	1251	1260	MCF7/AdrR	CellLine	 CVCL_1452
66990591	1332	1341	Ro4368554	ChemicalEntity	C507242
66990591	Negative_Correlation	C507242	D015430	Novel
66990591	Negative_Correlation	C507242	D010523	Novel
66990591	Negative_Correlation	C507242	D017682	Novel
66990591	Negative_Correlation	C507242	D001284	Novel
66990591	Negative_Correlation	C507242	D018226	Novel

60635009|t|Collagen SH and 5-FU interactions in postoperative nausea and vomiting: a study on DEN-4 infection and molecular me
60635009|a|Postoperative nausea and vomiting (PONV) has been increasingly linked to molecular pathways involving collagen SH and the chemotherapeutic agent 5-FU. This study explores the complex interplay between these entities in the context of DEN-4 viral infection. We hypothesize that collagen SH may play a critical role in modulating the severity of PONV, while 5-FU may exert a negative correlation with collagen SH expression.   Our findings reveal a significant negative correlation between 5-FU and collagen SH, suggesting that 5-FU may inhibit collagen SH activity. Additionally, we observed a strong association between postoperative nausea and vomiting and collagen SH, indicating that collagen SH may be a key mediator in the pathophysiology of PONV. Furthermore, the association between postoperative nausea and vomiting and 5-FU was confirmed through multiple experimental models, highlighting the potential dual role of 5-FU in both exacerbating and mitigating PONV.   A direct bind between 5-FU and collagen SH was identified using molecular docking and biochemical assays, providing evidence for a potential molecular mechanism underlying these interactions. The study also examined the role of DEN-4 in this context, as the virus was found to upregulate collagen SH expression, which in turn may contribute to the development of PONV.   These results suggest that collagen SH and 5-FU are intricately linked in the context of postoperative nausea and vomiting, with DEN-4 infection potentially modulating this relationship. Further research is warranted to explore the therapeutic implications of these findings in clinical settings.
60635009	16	20	5-FU	ChemicalEntity	D005472
60635009	37	70	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
60635009	83	88	DEN-4	OrganismTaxon	11070
60635009	218	229	collagen SH	GeneOrGeneProduct	1281
60635009	261	265	5-FU	ChemicalEntity	D005472
60635009	350	355	DEN-4	OrganismTaxon	11070
60635009	393	404	collagen SH	GeneOrGeneProduct	1281
60635009	472	476	5-FU	ChemicalEntity	D005472
60635009	515	526	collagen SH	GeneOrGeneProduct	1281
60635009	604	608	5-FU	ChemicalEntity	D005472
60635009	613	624	collagen SH	GeneOrGeneProduct	1281
60635009	642	646	5-FU	ChemicalEntity	D005472
60635009	659	670	collagen SH	GeneOrGeneProduct	1281
60635009	736	769	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
60635009	774	785	collagen SH	GeneOrGeneProduct	1281
60635009	803	814	collagen SH	GeneOrGeneProduct	1281
60635009	906	939	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
60635009	944	948	5-FU	ChemicalEntity	D005472
60635009	1041	1045	5-FU	ChemicalEntity	D005472
60635009	1112	1116	5-FU	ChemicalEntity	D005472
60635009	1121	1132	collagen SH	GeneOrGeneProduct	1281
60635009	1318	1323	DEN-4	OrganismTaxon	11070
60635009	1378	1389	collagen SH	GeneOrGeneProduct	1281
60635009	1488	1499	collagen SH	GeneOrGeneProduct	1281
60635009	1504	1508	5-FU	ChemicalEntity	D005472
60635009	1550	1583	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
60635009	1590	1595	DEN-4	OrganismTaxon	11070
60635009	Negative_Correlation	D005472	1281	Novel
60635009	Association	D020250	1281	Novel
60635009	Association	1281	D020250	Novel
60635009	Association	D020250	D005472	Novel
60635009	Bind	D005472	1281	Novel

80662073|t|Genetic Variants and Disease Associations in cIAP1, OATP1B1, Toll-like Receptor 4, and Related 
80662073|a|Recent studies have highlighted the complex interplay between genetic variants and disease susceptibility, particularly in the context of inflammatory and metabolic disorders. This study investigates the associations between specific sequence variants and disease phenotypes, with a focus on cIAP1, OATP1B1, toll-like receptor 4, and their functional implications.   The rs1155974 variant was found to exhibit a positive correlation with both GIST and brain edema, suggesting a potential role in the pathogenesis of these conditions. Additionally, the 521T>C variant showed a positive correlation with isolated micropenis, indicating a possible genetic link to developmental anomalies. In contrast, the negative correlation between GIST and OATP1B1 suggests that OATP1B1 may act as a protective factor against the development of GIST.   Further, the study revealed a negative correlation between anti-inflammatory cytokines and toll-like receptor 4, implying that the activation of toll-like receptor 4 may suppress the production of anti-inflammatory cytokines, thereby contributing to chronic inflammation. The sequence variant Delta695-725 was associated with multiple disease outcomes, including strokes and brain edema, while the variant D542A was linked to an increased risk of strokes.   The variant K294E was found to be associated with anemia, and the variant c.1074G>T was correlated with strokes. The sequence variant (GCG)6(GCA)3GCG was replaced by (GCG)6(GCA)(GCG)4(GCA)3GCG, which was associated with a unique pattern of disease expression.   Moreover, the gene product a-SMA was found to be upregulated in the context of brain edema, and Keratin 12 was associated with isolated micropenis. The gene Socs3 was found to be involved in the regulation of inflammatory responses, with a negative correlation observed between Socs3 and toll-like receptor 4.   These findings underscore the importance of genetic variants in modulating disease risk and highlight the need for further research into the molecular mechanisms underlying these associations.
80662073	45	50	cIAP1	GeneOrGeneProduct	329
80662073	52	59	OATP1B1	GeneOrGeneProduct	10599
80662073	388	393	cIAP1	GeneOrGeneProduct	329
80662073	395	402	OATP1B1	GeneOrGeneProduct	10599
80662073	404	424	toll-like receptor 4	GeneOrGeneProduct	29260
80662073	467	476	rs1155974	SequenceVariant	rs1155974
80662073	539	543	GIST	DiseaseOrPhenotypicFeature	D046152
80662073	548	559	brain edema	DiseaseOrPhenotypicFeature	D001929
80662073	648	654	521T>C	SequenceVariant	c|SUB|T|521|C
80662073	698	717	isolated micropenis	DiseaseOrPhenotypicFeature	C536649
80662073	828	832	GIST	DiseaseOrPhenotypicFeature	D046152
80662073	837	844	OATP1B1	GeneOrGeneProduct	10599
80662073	859	866	OATP1B1	GeneOrGeneProduct	10599
80662073	925	929	GIST	DiseaseOrPhenotypicFeature	D046152
80662073	992	1019	anti-inflammatory cytokines	GeneOrGeneProduct	16153
80662073	1024	1044	toll-like receptor 4	GeneOrGeneProduct	29260
80662073	1078	1098	toll-like receptor 4	GeneOrGeneProduct	29260
80662073	1130	1157	anti-inflammatory cytokines	GeneOrGeneProduct	16153
80662073	1226	1238	Delta695-725	SequenceVariant	p|DEL|695-725|
80662073	1296	1303	strokes	DiseaseOrPhenotypicFeature	D020521
80662073	1308	1319	brain edema	DiseaseOrPhenotypicFeature	D001929
80662073	1339	1344	D542A	SequenceVariant	p|SUB|D|542|A
80662073	1380	1387	strokes	DiseaseOrPhenotypicFeature	D020521
80662073	1403	1408	K294E	SequenceVariant	rs143544690
80662073	1465	1474	c.1074G>T	SequenceVariant	c|SUB|G|1074|T
80662073	1495	1502	strokes	DiseaseOrPhenotypicFeature	D020521
80662073	1680	1685	a-SMA	GeneOrGeneProduct	11475
80662073	1732	1743	brain edema	DiseaseOrPhenotypicFeature	D001929
80662073	1749	1759	Keratin 12	GeneOrGeneProduct	268482
80662073	1780	1799	isolated micropenis	DiseaseOrPhenotypicFeature	C536649
80662073	1810	1815	Socs3	GeneOrGeneProduct	12702
80662073	1931	1936	Socs3	GeneOrGeneProduct	12702
80662073	1941	1961	toll-like receptor 4	GeneOrGeneProduct	29260
80662073	Positive_Correlation	rs1155974	D046152	Novel
80662073	Positive_Correlation	rs1155974	D001929	Novel
80662073	Positive_Correlation	c|SUB|T|521|C	C536649	Novel
80662073	Negative_Correlation	D046152	10599	Novel
80662073	Negative_Correlation	16153	29260	Novel

06657049|t|Genetic and functional interactions of sequence variants with Ppg in multiple ce
06657049|a|This study investigates the functional and genetic interactions between sequence variants and the chemical entity Ppg across multiple cell lines. We focused on the associations between rs757229 and lysine at residue 223, as well as the complex network of relationships involving rs6235, rs5966709, and I280S. Our findings reveal a significant positive correlation between rs757229 and Ppg, as well as between rs5966709 and Ppg, suggesting that these sequence variants may modulate Ppg activity in different cellular contexts.   Using a panel of cell lines including Capan1, LbetaT2, LNCaP, COS-7, MEF, CMT-93, and Mz-ChA-1, we observed that rs757229 is associated with both lysine at residue 223 and rs6235, while rs6235 is linked to rs5966709 and I280S. Notably, I280S shows a positive correlation with Ppg and is also associated with rs6235 and rs757229. Additionally, lysine at residue 223 is connected to rs757229, rs6235, and rs5966709, highlighting its central role in this genetic network.   Our results suggest that these sequence variants may influence Ppg function through shared regulatory mechanisms, and further studies are warranted to elucidate the molecular pathways involved. The observed associations provide a foundation for understanding the genetic basis of Ppg-related phenotypes in diverse cellular environments.
06657049	62	65	Ppg	ChemicalEntity	D010457
06657049	195	198	Ppg	ChemicalEntity	D010457
06657049	266	274	rs757229	SequenceVariant	rs757229
06657049	279	300	lysine at residue 223	SequenceVariant	c|Allele|K|223
06657049	360	366	rs6235	SequenceVariant	rs6235
06657049	368	377	rs5966709	SequenceVariant	rs5966709
06657049	383	388	I280S	SequenceVariant	p|SUB|I|280|S
06657049	453	461	rs757229	SequenceVariant	rs757229
06657049	466	469	Ppg	ChemicalEntity	D010457
06657049	490	499	rs5966709	SequenceVariant	rs5966709
06657049	504	507	Ppg	ChemicalEntity	D010457
06657049	562	565	Ppg	ChemicalEntity	D010457
06657049	647	653	Capan1	CellLine	CVCL_0237
06657049	655	662	LbetaT2	CellLine	CVCL_0398
06657049	664	669	LNCaP	CellLine	CVCL_0395
06657049	671	676	COS-7	CellLine	CVCL_0224
06657049	678	681	MEF	CellLine	CVCL_9115
06657049	683	689	CMT-93	CellLine	CVCL_1986
06657049	695	703	Mz-ChA-1	CellLine	CVCL_6932
06657049	722	730	rs757229	SequenceVariant	rs757229
06657049	755	776	lysine at residue 223	SequenceVariant	c|Allele|K|223
06657049	781	787	rs6235	SequenceVariant	rs6235
06657049	795	801	rs6235	SequenceVariant	rs6235
06657049	815	824	rs5966709	SequenceVariant	rs5966709
06657049	829	834	I280S	SequenceVariant	p|SUB|I|280|S
06657049	845	850	I280S	SequenceVariant	p|SUB|I|280|S
06657049	885	888	Ppg	ChemicalEntity	D010457
06657049	917	923	rs6235	SequenceVariant	rs6235
06657049	928	936	rs757229	SequenceVariant	rs757229
06657049	952	973	lysine at residue 223	SequenceVariant	c|Allele|K|223
06657049	990	998	rs757229	SequenceVariant	rs757229
06657049	1000	1006	rs6235	SequenceVariant	rs6235
06657049	1012	1021	rs5966709	SequenceVariant	rs5966709
06657049	1143	1146	Ppg	ChemicalEntity	D010457
06657049	1360	1363	Ppg	ChemicalEntity	D010457
06657049	Association	rs757229	c|Allele|K|223	Novel
06657049	Association	rs6235	rs5966709	Novel
06657049	Association	rs757229	rs6235	Novel
06657049	Association	p|SUB|I|280|S	rs6235	Novel
06657049	Association	c|Allele|K|223	rs757229	Novel
06657049	Association	c|Allele|K|223	p|SUB|I|280|S	Novel
06657049	Association	rs5966709	rs6235	Novel
06657049	Positive_Correlation	p|SUB|I|280|S	D010457	Novel
06657049	Association	rs5966709	c|Allele|K|223	Novel
06657049	Association	rs757229	rs5966709	Novel
06657049	Association	rs6235	p|SUB|I|280|S	Novel
06657049	Positive_Correlation	rs757229	D010457	Novel
06657049	Association	rs5966709	rs757229	Novel
06657049	Association	p|SUB|I|280|S	rs757229	Novel
06657049	Association	rs6235	rs757229	Novel
06657049	Positive_Correlation	rs5966709	D010457	Novel
06657049	Association	rs6235	c|Allele|K|223	Novel
06657049	Association	c|Allele|K|223	rs6235	Novel
06657049	Association	rs5966709	p|SUB|I|280|S	Novel
06657049	Association	p|SUB|I|280|S	rs5966709	Novel
06657049	Association	rs757229	p|SUB|I|280|S	Novel

85736158|t|Imatinib, HIV co-infection, and Darier's disease: a complex interplay with bacterial and DEN-2 virus inte
85736158|a|Recent studies have explored the multifaceted interactions between imatinib, HIV co-infection, and Darier's disease, with particular attention to their associations with bacterial and DEN-2 virus populations. Imatinib, a tyrosine kinase inhibitor, has been shown to exhibit a negative correlation with HIV co-infection, suggesting that its use may reduce the risk of HIV progression in certain patient populations. This finding is supported by multiple clinical and pharmacological studies that demonstrate imatinib's ability to modulate immune responses and viral replication. However, the same drug has also been associated with a negative correlation with Darier's disease, a rare genetic skin disorder, indicating potential off-target effects or immune-related mechanisms. These findings are further complicated by the presence of bacteria and DEN-2 virus, which appear to influence the disease outcomes in both HIV co-infection and Darier's disease. The presence of bacteria has been linked to increased inflammation and immune dysregulation, while DEN-2 virus has been implicated in exacerbating the clinical manifestations of both conditions. Collectively, these studies highlight the complex interplay between imatinib, HIV co-infection, Darier's disease, bacteria, and DEN-2 virus, underscoring the need for further research to elucidate the underlying biological mechanisms and therapeutic implications.
85736158	10	26	HIV co-infection	DiseaseOrPhenotypicFeature	D015658
85736158	32	48	Darier's disease	DiseaseOrPhenotypicFeature	D007644
85736158	75	83	bacteria	OrganismTaxon	2
85736158	89	94	DEN-2	OrganismTaxon	11060
85736158	173	181	imatinib	ChemicalEntity	D000068877
85736158	183	199	HIV co-infection	DiseaseOrPhenotypicFeature	D015658
85736158	205	221	Darier's disease	DiseaseOrPhenotypicFeature	D007644
85736158	276	284	bacteria	OrganismTaxon	2
85736158	290	295	DEN-2	OrganismTaxon	11060
85736158	408	424	HIV co-infection	DiseaseOrPhenotypicFeature	D015658
85736158	613	621	imatinib	ChemicalEntity	D000068877
85736158	765	781	Darier's disease	DiseaseOrPhenotypicFeature	D007644
85736158	941	949	bacteria	OrganismTaxon	2
85736158	954	959	DEN-2	OrganismTaxon	11060
85736158	1022	1038	HIV co-infection	DiseaseOrPhenotypicFeature	D015658
85736158	1043	1059	Darier's disease	DiseaseOrPhenotypicFeature	D007644
85736158	1077	1085	bacteria	OrganismTaxon	2
85736158	1160	1165	DEN-2	OrganismTaxon	11060
85736158	1324	1332	imatinib	ChemicalEntity	D000068877
85736158	1334	1350	HIV co-infection	DiseaseOrPhenotypicFeature	D015658
85736158	1352	1368	Darier's disease	DiseaseOrPhenotypicFeature	D007644
85736158	1370	1378	bacteria	OrganismTaxon	2
85736158	1384	1389	DEN-2	OrganismTaxon	11060
85736158	Negative_Correlation	D000068877	D015658	Novel
85736158	Negative_Correlation	D000068877	D007644	Novel

77628930|t|Genetic variants in the low-density lipoprotein receptor and sulfonylurea receptor: implications for lymphomagenesis, diabetes insipidus, and opiate addiction in C57BL/6 and hRPTEC ce
77628930|a|This study investigates the functional and phenotypic consequences of the c.640_667del28 sequence variant in the low-density lipoprotein receptor (LDLR) and its potential role in modulating disease susceptibility. The c.640_667del28 variant was identified in multiple C57BL/6 and hRPTEC cell lines, and its impact on cellular lipid metabolism and immune signaling was assessed. Notably, the variant was associated with altered expression levels of the sulfonylurea receptor (SUR), suggesting a potential mechanism linking genetic variability to lymphomagenesis.    Further analysis revealed a positive correlation between opiate addiction and the expression of the sulfonylurea receptor, as evidenced by increased SUR activity in C57BL/6 mice exposed to opiate compounds. This finding was corroborated by transcriptomic profiling of hRPTEC cells, where the c.640_667del28 variant was linked to upregulated SUR expression in the context of opiate exposure.    In parallel, the study explored the relationship between diabetes insipidus and the cytokine IL-6. The c.640_667del28 variant was found to enhance IL-6 secretion in hRPTEC cells, and this effect was further amplified in the presence of the myogenic factor 5 (MRF5) gene product. This positive correlation between diabetes insipidus and IL-6 was supported by in vivo experiments in C57BL/6 mice, where IL-6 levels were significantly elevated in animals with the variant.    The study also examined the interplay between the low-density lipoprotein receptor and the sulfonylurea receptor in the context of lymphomagenesis. The c.640_667del28 variant was found to disrupt normal receptor interactions, leading to increased cellular proliferation and resistance to apoptosis in C57BL/6-derived lymphoma cell lines. These findings suggest that the variant may contribute to the pathogenesis of lymphomagenesis through dysregulated signaling pathways involving both LDLR and SUR.    Overall, the results highlight the complex genetic and molecular mechanisms underlying the associations between the c.640_667del28 variant, the sulfonylurea receptor, IL-6, and various disease states, including opiate addiction, diabetes insipidus, and lymphomagenesis.
77628930	24	56	low-density lipoprotein receptor	GeneOrGeneProduct	3949
77628930	61	82	sulfonylurea receptor	GeneOrGeneProduct	6833
77628930	101	116	lymphomagenesis	DiseaseOrPhenotypicFeature	D008223
77628930	118	136	diabetes insipidus	DiseaseOrPhenotypicFeature	D003919
77628930	142	158	opiate addiction	DiseaseOrPhenotypicFeature	D009293
77628930	162	169	C57BL/6	CellLine	CVCL_5746
77628930	174	180	hRPTEC	CellLine	CVCL_K278
77628930	258	272	c.640_667del28	SequenceVariant	rs193302859
77628930	297	329	low-density lipoprotein receptor	GeneOrGeneProduct	3949
77628930	402	416	c.640_667del28	SequenceVariant	rs193302859
77628930	452	459	C57BL/6	CellLine	CVCL_5746
77628930	464	470	hRPTEC	CellLine	CVCL_K278
77628930	636	657	sulfonylurea receptor	GeneOrGeneProduct	6833
77628930	729	744	lymphomagenesis	DiseaseOrPhenotypicFeature	D008223
77628930	806	822	opiate addiction	DiseaseOrPhenotypicFeature	D009293
77628930	849	870	sulfonylurea receptor	GeneOrGeneProduct	6833
77628930	914	921	C57BL/6	CellLine	CVCL_5746
77628930	1017	1023	hRPTEC	CellLine	CVCL_K278
77628930	1041	1055	c.640_667del28	SequenceVariant	rs193302859
77628930	1200	1218	diabetes insipidus	DiseaseOrPhenotypicFeature	D003919
77628930	1236	1240	IL-6	GeneOrGeneProduct	3569
77628930	1246	1260	c.640_667del28	SequenceVariant	rs193302859
77628930	1290	1294	IL-6	GeneOrGeneProduct	3569
77628930	1308	1314	hRPTEC	CellLine	CVCL_K278
77628930	1383	1400	myogenic factor 5	GeneOrGeneProduct	4617
77628930	1456	1474	diabetes insipidus	DiseaseOrPhenotypicFeature	D003919
77628930	1479	1483	IL-6	GeneOrGeneProduct	3569
77628930	1524	1531	C57BL/6	CellLine	CVCL_5746
77628930	1544	1548	IL-6	GeneOrGeneProduct	3569
77628930	1666	1698	low-density lipoprotein receptor	GeneOrGeneProduct	3949
77628930	1707	1728	sulfonylurea receptor	GeneOrGeneProduct	6833
77628930	1747	1762	lymphomagenesis	DiseaseOrPhenotypicFeature	D008223
77628930	1768	1782	c.640_667del28	SequenceVariant	rs193302859
77628930	1917	1924	C57BL/6	CellLine	CVCL_5746
77628930	2032	2047	lymphomagenesis	DiseaseOrPhenotypicFeature	D008223
77628930	2236	2250	c.640_667del28	SequenceVariant	rs193302859
77628930	2264	2285	sulfonylurea receptor	GeneOrGeneProduct	6833
77628930	2287	2291	IL-6	GeneOrGeneProduct	3569
77628930	2331	2347	opiate addiction	DiseaseOrPhenotypicFeature	D009293
77628930	2349	2367	diabetes insipidus	DiseaseOrPhenotypicFeature	D003919
77628930	2373	2388	lymphomagenesis	DiseaseOrPhenotypicFeature	D008223
77628930	Positive_Correlation	D009293	6833	Novel
77628930	Positive_Correlation	D003919	3569	Novel

24038133|t|Genetic Variants in Nephrin and TUBA1A: Associations with Disease Phenotypes and Cellular Responses in Multiple Ce
24038133|a|This study investigates the functional and phenotypic consequences of several genetic variants in the nephrin and TUBA1A genes, with a focus on their associations with disease phenotypes and cellular responses in multiple cell lines. The research highlights the role of the sequence variant p.W111X in the nephrin gene, which is linked to the development of ARM syndrome. Additionally, the variant p.Arg58fs is associated with erythema, while the c.1146+25insA insertion is found to be correlated with both erythema and inflammation of the liver capsule. The G>T substitution at nucleotide c.898 and the g.3455_3460del variant are also examined for their potential impact on disease progression.   The study further explores the association between the sequence variant (TAC-->AA) at codon 329 and hypercholesterolemia, providing evidence for its role in lipid metabolism. The 1284A>C variant is found to be strongly associated with FDH, suggesting a potential genetic basis for this condition. Nail dystrophy is also observed in individuals carrying the p.W111X variant, reinforcing the pleiotropic effects of mutations in the nephrin gene.   In addition to these findings, the study evaluates the role of the TUBA1A gene in cellular processes, with the 1284A>C variant showing a significant association with FDH. The gene product VASP is also implicated in the pathogenesis of hypercholesterolemia, as evidenced by the (TAC-->AA) at codon 329 variant.   To assess the functional impact of these variants, the study employs multiple cell lines, including Mz-ChA-1, COS-7, HK-2, and BALB/c. The results demonstrate that the c.1146+25insA variant is not only associated with erythema but also with inflammation of the liver capsule, suggesting a broader role in immune-related pathologies. The study also identifies the Pum gene as a potential modifier of these genetic effects, with two instances of the Pum gene product being observed in the experimental setup.   Overall, this research provides a comprehensive analysis of the genetic and phenotypic relationships between various sequence variants and disease states, offering new insights into the molecular mechanisms underlying these conditions.
24038133	32	38	TUBA1A	GeneOrGeneProduct	7846
24038133	217	224	nephrin	GeneOrGeneProduct	64563
24038133	229	235	TUBA1A	GeneOrGeneProduct	7846
24038133	406	413	p.W111X	SequenceVariant	rs137852884
24038133	421	428	nephrin	GeneOrGeneProduct	64563
24038133	513	522	p.Arg58fs	SequenceVariant	p|FS|R|58||
24038133	542	550	erythema	DiseaseOrPhenotypicFeature	D004890
24038133	562	575	c.1146+25insA	SequenceVariant	c|INS|1146+25|A
24038133	622	630	erythema	DiseaseOrPhenotypicFeature	D004890
24038133	635	668	inflammation of the liver capsule	DiseaseOrPhenotypicFeature	D006505
24038133	674	710	G>T substitution at nucleotide c.898	SequenceVariant	c|SUB|G|898|T
24038133	719	733	g.3455_3460del	SequenceVariant	g|DEL|3455_3460|
24038133	885	908	(TAC-->AA) at codon 329	SequenceVariant	c|SUB|TAC|CODON329|AA
24038133	913	933	hypercholesterolemia	DiseaseOrPhenotypicFeature	D006937
24038133	992	999	1284A>C	SequenceVariant	c|SUB|A|1284|C
24038133	1048	1051	FDH	DiseaseOrPhenotypicFeature	D005489
24038133	1170	1177	p.W111X	SequenceVariant	rs137852884
24038133	1243	1250	nephrin	GeneOrGeneProduct	64563
24038133	1326	1332	TUBA1A	GeneOrGeneProduct	7846
24038133	1370	1377	1284A>C	SequenceVariant	c|SUB|A|1284|C
24038133	1425	1428	FDH	DiseaseOrPhenotypicFeature	D005489
24038133	1447	1451	VASP	GeneOrGeneProduct	7408
24038133	1494	1514	hypercholesterolemia	DiseaseOrPhenotypicFeature	D006937
24038133	1536	1559	(TAC-->AA) at codon 329	SequenceVariant	c|SUB|TAC|CODON329|AA
24038133	1671	1679	Mz-ChA-1	CellLine	CVCL_6932
24038133	1681	1686	COS-7	CellLine	CVCL_0224
24038133	1688	1692	HK-2	CellLine	CVCL_0302
24038133	1698	1704	BALB/c	CellLine	CVCL_9101
24038133	1739	1752	c.1146+25insA	SequenceVariant	c|INS|1146+25|A
24038133	1789	1797	erythema	DiseaseOrPhenotypicFeature	D004890
24038133	1812	1845	inflammation of the liver capsule	DiseaseOrPhenotypicFeature	D006505
24038133	1934	1937	Pum	GeneOrGeneProduct	41094
24038133	2019	2022	Pum	GeneOrGeneProduct	41094
24038133	Association	D006937	c|SUB|TAC|CODON329|AA	Novel
24038133	Association	D005489	c|SUB|A|1284|C	Novel
24038133	Association	D004890	p|FS|R|58||	Novel
24038133	Association	D006505	c|INS|1146+25|A	Novel
24038133	Association	D004890	c|INS|1146+25|A	Novel
24038133	Association	D004890	c|SUB|TAC|CODON329|AA	Novel

39364100|t|FGFR1 and myoglobinuria: genetic variants, sequence polymorphisms, and interactions with topiramate in tobacco and bovin
39364100|a|Recent studies have highlighted the complex interplay between the fibroblast growth factor receptor 1 (FGFR1) gene and the development of myoglobinuria, particularly in tobacco-exposed individuals. This research explores the molecular mechanisms underlying this association, with a focus on sequence variants and their functional consequences. Three distinct sequence variants, including the A/G transition at -1,071 bp, the c.643T>C polymorphism, and the CAG repeat expansion, were analyzed in both tobacco and bovine models.   The findings reveal a significant association between FGFR1 and myoglobinuria, with the A/G transition at -1,071 bp showing a strong correlation with the condition. Additionally, the c.643T>C variant was found to have a negative correlation with topiramate treatment, suggesting a potential pharmacogenetic interaction. Similarly, the CAG repeat expansion also exhibited a negative correlation with topiramate, indicating that these genetic variants may modulate the drug's efficacy or side effect profile.   Interestingly, topiramate was found to be associated with both the c.643T>C and CAG repeat variants, as well as the A/G transition at -1,071 bp, suggesting a complex regulatory network involving these genetic elements. These results provide new insights into the genetic basis of myoglobinuria and the role of topiramate in modulating its expression, particularly in tobacco and bovine systems. Further studies are warranted to validate these findings in larger cohorts and to explore their clinical implications.
39364100	0	5	FGFR1	GeneOrGeneProduct	2260
39364100	10	23	myoglobinuria	DiseaseOrPhenotypicFeature	D009212
39364100	89	99	topiramate	ChemicalEntity	D000077236
39364100	103	110	tobacco	OrganismTaxon	4097
39364100	224	229	FGFR1	GeneOrGeneProduct	2260
39364100	259	272	myoglobinuria	DiseaseOrPhenotypicFeature	D009212
39364100	290	297	tobacco	OrganismTaxon	4097
39364100	546	554	c.643T>C	SequenceVariant	c|SUB|T|643|C
39364100	577	587	CAG repeat	SequenceVariant	c|DUP||CAG|
39364100	621	628	tobacco	OrganismTaxon	4097
39364100	633	639	bovine	OrganismTaxon	9913
39364100	704	709	FGFR1	GeneOrGeneProduct	2260
39364100	714	727	myoglobinuria	DiseaseOrPhenotypicFeature	D009212
39364100	833	841	c.643T>C	SequenceVariant	c|SUB|T|643|C
39364100	896	906	topiramate	ChemicalEntity	D000077236
39364100	985	995	CAG repeat	SequenceVariant	c|DUP||CAG|
39364100	1049	1059	topiramate	ChemicalEntity	D000077236
39364100	1174	1184	topiramate	ChemicalEntity	D000077236
39364100	1226	1234	c.643T>C	SequenceVariant	c|SUB|T|643|C
39364100	1239	1249	CAG repeat	SequenceVariant	c|DUP||CAG|
39364100	1439	1452	myoglobinuria	DiseaseOrPhenotypicFeature	D009212
39364100	1469	1479	topiramate	ChemicalEntity	D000077236
39364100	1526	1533	tobacco	OrganismTaxon	4097
39364100	1538	1544	bovine	OrganismTaxon	9913
39364100	Association	2260	D009212	Novel
39364100	Negative_Correlation	c|SUB|T|643|C	D000077236	Novel
39364100	Negative_Correlation	c|DUP||CAG|	D000077236	Novel
39364100	Association	D000077236	c|SUB|T|643|C	Novel
39364100	Association	D000077236	c|DUP||CAG|	Novel
39364100	Association	D000077236	c|SUB|A|-1071|G	Novel

82379415|t|Vitamin C, GSH, and their interactions with rabbit-derived cell lines and gene products in the context of Daucus carota and MCF-
82379415|a|This study investigates the complex interactions between Vitamin C and GSH in the context of rabbit-derived cell lines and their effects on gene expression profiles. Using MCF-7 and KU7 cell lines, we demonstrate that Vitamin C and GSH exhibit a bidirectional drug interaction, where each compound modulates the activity of the other. These interactions are further explored in the presence of rabbit-derived cell lines, which show distinct responses to the combined treatment. The study also examines the role of the LPA1 gene in mediating these interactions, with particular emphasis on its expression in MCF-7 and 293T cells.   In addition, we assess the impact of Vitamin C and GSH on the expression of PAKs, ATF2, and VEGF receptor 2 in rabbit and Daucus carota-derived cell lines. Our findings suggest that the presence of Vitamin C and GSH significantly alters the expression levels of these genes, with notable effects observed in the 293T and KU7 cell lines. The study further highlights the importance of rabbit models in understanding the molecular mechanisms underlying these interactions, as well as the potential therapeutic applications of Vitamin C and GSH in modulating gene expression in cancer-related pathways.   The results provide strong evidence for the drug interaction between Vitamin C and GSH, with both compounds showing mutual enhancement in their biological activities. These findings have important implications for the development of novel therapeutic strategies targeting gene expression in rabbit and Daucus carota models, particularly in the context of cancer and metabolic disorders.
82379415	0	9	Vitamin C	ChemicalEntity	D001205
82379415	11	14	GSH	ChemicalEntity	D005978
82379415	44	50	rabbit	OrganismTaxon	9986
82379415	106	119	Daucus carota	OrganismTaxon	4039
82379415	186	195	Vitamin C	ChemicalEntity	D001205
82379415	200	203	GSH	ChemicalEntity	D005978
82379415	222	228	rabbit	OrganismTaxon	9986
82379415	301	306	MCF-7	CellLine	CVCL_0031
82379415	311	314	KU7	CellLine	CVCL_4714
82379415	347	356	Vitamin C	ChemicalEntity	D001205
82379415	361	364	GSH	ChemicalEntity	D005978
82379415	523	529	rabbit	OrganismTaxon	9986
82379415	736	741	MCF-7	CellLine	CVCL_0031
82379415	746	750	293T	CellLine	CVCL_0063
82379415	797	806	Vitamin C	ChemicalEntity	D001205
82379415	811	814	GSH	ChemicalEntity	D005978
82379415	836	840	PAKs	GeneOrGeneProduct	292756
82379415	842	846	ATF2	GeneOrGeneProduct	1386
82379415	852	867	VEGF receptor 2	GeneOrGeneProduct	16542
82379415	871	877	rabbit	OrganismTaxon	9986
82379415	882	895	Daucus carota	OrganismTaxon	4039
82379415	958	967	Vitamin C	ChemicalEntity	D001205
82379415	972	975	GSH	ChemicalEntity	D005978
82379415	1072	1076	293T	CellLine	CVCL_0063
82379415	1081	1084	KU7	CellLine	CVCL_4714
82379415	1144	1150	rabbit	OrganismTaxon	9986
82379415	1284	1293	Vitamin C	ChemicalEntity	D001205
82379415	1298	1301	GSH	ChemicalEntity	D005978
82379415	1431	1440	Vitamin C	ChemicalEntity	D001205
82379415	1445	1448	GSH	ChemicalEntity	D005978
82379415	1653	1659	rabbit	OrganismTaxon	9986
82379415	1664	1677	Daucus carota	OrganismTaxon	4039
82379415	Drug_Interaction	D001205	D005978	Novel
82379415	Drug_Interaction	D005978	D001205	Novel

09243950|t|Complex Interactions of GI-hormones, Simvastatin-ezetimibe, and Selective Serotonin Reuptake Inhibitors in S. cerevisiae, Danio rerio, and Chic
09243950|a|This study explores the intricate relationships between GI-hormones, Simvastatin-ezetimibe, and selective serotonin reuptake inhibitors (SSRIs) across multiple biological systems, including S. cerevisiae, Danio rerio, and chick models. We investigated the drug interactions and correlations between these entities in various cell lines, including SMMC-7721, HeLa, CD18/HPAF, SCID-HuH-7, and DUCaP. Additionally, we examined the binding interactions between U-II and caspase-8, as well as between U-II and cyclin D1 and D2.   Our findings reveal a negative correlation between Simvastatin-ezetimibe and KCl, as well as between KCl and S-1. Furthermore, there is a negative correlation between GI-hormones and antiarrhythmic drugs, and between S-1 and GI-hormones. The drug interaction between Simvastatin-ezetimibe and GI-hormones is significant, as is the interaction between GI-hormones and S-1. Notably, there is a negative correlation between S-1 and Simvastatin-ezetimibe, and between S-1 and SSRIs.   The drug interaction between SSRIs and GI-hormones, as well as between SSRIs and S-1, was also observed. Additionally, KCl exhibits a drug interaction with both Simvastatin-ezetimibe and SSRIs, while S-1 shows a drug interaction with KCl and GI-hormones. The binding of U-II to caspase-8 and cyclin D1 and D2 was confirmed through biochemical assays.   These results highlight the complex interplay between these chemical entities and their potential implications in cellular signaling and disease mechanisms across diverse organisms, including S. cerevisiae, Danio rerio, and chick. The study also underscores the importance of understanding these interactions in the context of multiple cell lines, such as SMMC-7721, HeLa, CD18/HPAF, SCID-HuH-7, and DUCaP, for developing targeted therapeutic strategies.
09243950	24	35	GI-hormones	ChemicalEntity	D005768
09243950	37	58	Simvastatin-ezetimibe	ChemicalEntity	D000069499
09243950	107	120	S. cerevisiae	OrganismTaxon	4932
09243950	122	133	Danio rerio	OrganismTaxon	7955
09243950	200	211	GI-hormones	ChemicalEntity	D005768
09243950	213	234	Simvastatin-ezetimibe	ChemicalEntity	D000069499
09243950	240	279	selective serotonin reuptake inhibitors	ChemicalEntity	D017367
09243950	334	347	S. cerevisiae	OrganismTaxon	4932
09243950	349	360	Danio rerio	OrganismTaxon	7955
09243950	366	371	chick	OrganismTaxon	9031
09243950	491	500	SMMC-7721	CellLine	CVCL_0534
09243950	502	506	HeLa	CellLine	CVCL_0030
09243950	508	517	CD18/HPAF	CellLine	CVCL_0313
09243950	519	529	SCID-HuH-7	CellLine	CVCL_0336
09243950	535	540	DUCaP	CellLine	CVCL_2025
09243950	601	605	U-II	GeneOrGeneProduct	24111
09243950	610	619	caspase-8	GeneOrGeneProduct	841
09243950	640	644	U-II	GeneOrGeneProduct	24111
09243950	649	665	cyclin D1 and D2	GeneOrGeneProduct	12443
09243950	720	741	Simvastatin-ezetimibe	ChemicalEntity	D000069499
09243950	746	749	KCl	ChemicalEntity	D011189
09243950	770	773	KCl	ChemicalEntity	D011189
09243950	778	781	S-1	ChemicalEntity	C079198
09243950	836	847	GI-hormones	ChemicalEntity	D005768
09243950	852	871	antiarrhythmic drug	ChemicalEntity	D000889
09243950	886	889	S-1	ChemicalEntity	C079198
09243950	894	905	GI-hormones	ChemicalEntity	D005768
09243950	936	957	Simvastatin-ezetimibe	ChemicalEntity	D000069499
09243950	962	973	GI-hormones	ChemicalEntity	D005768
09243950	1020	1031	GI-hormones	ChemicalEntity	D005768
09243950	1036	1039	S-1	ChemicalEntity	C079198
09243950	1090	1093	S-1	ChemicalEntity	C079198
09243950	1098	1119	Simvastatin-ezetimibe	ChemicalEntity	D000069499
09243950	1133	1136	S-1	ChemicalEntity	C079198
09243950	1189	1200	GI-hormones	ChemicalEntity	D005768
09243950	1231	1234	S-1	ChemicalEntity	C079198
09243950	1269	1272	KCl	ChemicalEntity	D011189
09243950	1311	1332	Simvastatin-ezetimibe	ChemicalEntity	D000069499
09243950	1350	1353	S-1	ChemicalEntity	C079198
09243950	1384	1387	KCl	ChemicalEntity	D011189
09243950	1392	1403	GI-hormones	ChemicalEntity	D005768
09243950	1420	1424	U-II	GeneOrGeneProduct	24111
09243950	1428	1437	caspase-8	GeneOrGeneProduct	841
09243950	1442	1458	cyclin D1 and D2	GeneOrGeneProduct	12443
09243950	1695	1708	S. cerevisiae	OrganismTaxon	4932
09243950	1710	1721	Danio rerio	OrganismTaxon	7955
09243950	1727	1732	chick	OrganismTaxon	9031
09243950	1859	1868	SMMC-7721	CellLine	CVCL_0534
09243950	1870	1874	HeLa	CellLine	CVCL_0030
09243950	1876	1885	CD18/HPAF	CellLine	CVCL_0313
09243950	1887	1897	SCID-HuH-7	CellLine	CVCL_0336
09243950	1903	1908	DUCaP	CellLine	CVCL_2025
09243950	Negative_Correlation	D000069499	D011189	Novel
09243950	Drug_Interaction	D017367	D005768	Novel
09243950	Negative_Correlation	D011189	C079198	Novel
09243950	Drug_Interaction	D017367	C079198	Novel
09243950	Bind	24111	841	Novel
09243950	Drug_Interaction	D000069499	D011189	Novel
09243950	Drug_Interaction	D000889	D017367	Novel
09243950	Negative_Correlation	C079198	D017367	Novel
09243950	Drug_Interaction	D011189	D000069499	Novel
09243950	Drug_Interaction	D005768	D000069499	Novel
09243950	Negative_Correlation	D005768	D000889	Novel
09243950	Bind	24111	12443	Novel
09243950	Drug_Interaction	C079198	D005768	Novel
09243950	Drug_Interaction	D000069499	D005768	Novel
09243950	Negative_Correlation	C079198	D000069499	Novel
09243950	Drug_Interaction	D005768	C079198	Novel
09243950	Drug_Interaction	D011189	C079198	Novel
09243950	Negative_Correlation	D005768	C079198	Novel
09243950	Negative_Correlation	C079198	D005768	Novel
09243950	Drug_Interaction	C079198	D011189	Novel
09243950	Drug_Interaction	D011189	D017367	Novel
09243950	Negative_Correlation	D017367	C079198	Novel

20397465|t|ARID1B and rs1410996: complex associations with myocarditis, left ventricular hypertrophy, and abnormal glucose homeostasis in chick and bacteria
20397465|a|This study investigates the genetic and molecular mechanisms underlying the associations between the ARID1B gene, the sequence variant rs1410996, and several disease phenotypes, including myocarditis, left ventricular hypertrophy, and abnormal glucose homeostasis, across multiple organismal models. Using chick and bacterial systems, we demonstrate that ARID1B is significantly associated with abnormal glucose homeostasis, with both direct and indirect evidence supporting this relationship. Furthermore, we find that rs1410996 is strongly associated with myocarditis, and this association is reinforced by its correlation with left ventricular hypertrophy. Notably, the sequence variant rs1410996 also shows a significant association with abnormal glucose homeostasis, suggesting a potential pleiotropic effect. In contrast, the relationship between ARID1B and left ventricular hypertrophy is complex, with both positive and negative correlations observed, indicating a nuanced regulatory mechanism. Similarly, the association between ARID1B and myocarditis is not uniform, with some evidence of a negative correlation. These findings highlight the multifaceted role of ARID1B and rs1410996 in cardiovascular and metabolic disorders, and their potential as therapeutic targets in chick and bacterial models. The results also suggest that the interplay between genetic variants and disease phenotypes is highly context-dependent, requiring further investigation in diverse biological systems.
20397465	0	6	ARID1B	GeneOrGeneProduct	57492
20397465	11	20	rs1410996	SequenceVariant	rs1410996
20397465	48	59	myocarditis	DiseaseOrPhenotypicFeature	D009205
20397465	61	89	left ventricular hypertrophy	DiseaseOrPhenotypicFeature	D017379
20397465	95	123	abnormal glucose homeostasis	DiseaseOrPhenotypicFeature	D044882
20397465	127	132	chick	OrganismTaxon	9031
20397465	137	145	bacteria	OrganismTaxon	2
20397465	247	253	ARID1B	GeneOrGeneProduct	57492
20397465	281	290	rs1410996	SequenceVariant	rs1410996
20397465	334	345	myocarditis	DiseaseOrPhenotypicFeature	D009205
20397465	347	375	left ventricular hypertrophy	DiseaseOrPhenotypicFeature	D017379
20397465	381	409	abnormal glucose homeostasis	DiseaseOrPhenotypicFeature	D044882
20397465	452	457	chick	OrganismTaxon	9031
20397465	462	470	bacteria	OrganismTaxon	2
20397465	501	507	ARID1B	GeneOrGeneProduct	57492
20397465	541	569	abnormal glucose homeostasis	DiseaseOrPhenotypicFeature	D044882
20397465	666	675	rs1410996	SequenceVariant	rs1410996
20397465	704	715	myocarditis	DiseaseOrPhenotypicFeature	D009205
20397465	776	804	left ventricular hypertrophy	DiseaseOrPhenotypicFeature	D017379
20397465	836	845	rs1410996	SequenceVariant	rs1410996
20397465	888	916	abnormal glucose homeostasis	DiseaseOrPhenotypicFeature	D044882
20397465	999	1005	ARID1B	GeneOrGeneProduct	57492
20397465	1010	1038	left ventricular hypertrophy	DiseaseOrPhenotypicFeature	D017379
20397465	1184	1190	ARID1B	GeneOrGeneProduct	57492
20397465	1195	1206	myocarditis	DiseaseOrPhenotypicFeature	D009205
20397465	1319	1325	ARID1B	GeneOrGeneProduct	57492
20397465	1330	1339	rs1410996	SequenceVariant	rs1410996
20397465	1429	1434	chick	OrganismTaxon	9031
20397465	1439	1447	bacteria	OrganismTaxon	2
20397465	Association	57492	D044882	Novel
20397465	Association	D044882	57492	Novel
20397465	Association	D009205	rs1410996	Novel
20397465	Association	D044882	rs1410996	Novel
20397465	Association	57492	D017379	Novel
20397465	Negative_Correlation	57492	D017379	Novel
20397465	Negative_Correlation	57492	D044882	Novel
20397465	Association	D017379	rs1410996	Novel
20397465	Negative_Correlation	57492	D009205	Novel
20397465	Association	57492	D009205	Novel
20397465	Association	D017379	57492	Novel
20397465	Association	D009205	57492	Novel

18398923|t|Genetic and functional analysis of epsinR, EP4, and miR-138 in autosomal dominant hypercholesterolemia and congenital malfo
18398923|a|This study investigates the genetic and functional relationships between the sequence variant 1665delC, the gene product epsinR, the gene product EP4, the microRNA miR-138, and their associations with autosomal dominant hypercholesterolemia, congenital malformations, and enzymatic complex I-deficient conditions. Using a combination of genetic screening, cell line-based assays, and functional genomics, we demonstrate that the sequence variant 1665delC is positively correlated with autosomal dominant hypercholesterolemia, suggesting a potential causal role in disease pathogenesis. In contrast, epsinR exhibits a negative correlation with congenital malformations, indicating a protective effect against these developmental defects. Furthermore, miR-138 shows a positive correlation with EP4, highlighting a regulatory interaction between these two molecules. Notably, the association between EP4 and congenital malformations suggests a potential role for EP4 in developmental processes. Additionally, the negative correlation between epsinR and enzymatic complex I-deficient conditions implies a functional link between epsinR and mitochondrial function. The sequence variant c.463-6T>G is also found to be negatively correlated with autosomal dominant hypercholesterolemia, suggesting a possible antagonistic effect. These findings were validated using the RAW 264.7 and MCF-7 cell lines, where the expression patterns of epsinR, EP4, and miR-138 were analyzed under various experimental conditions. Collectively, these results provide new insights into the molecular mechanisms underlying these complex diseases and highlight potential therapeutic targets for intervention.
18398923	35	41	epsinR	GeneOrGeneProduct	9685
18398923	43	46	EP4	GeneOrGeneProduct	5734
18398923	52	59	miR-138	GeneOrGeneProduct	387156
18398923	63	102	autosomal dominant hypercholesterolemia	DiseaseOrPhenotypicFeature	D006938
18398923	218	226	1665delC	SequenceVariant	rs80338887
18398923	245	251	epsinR	GeneOrGeneProduct	9685
18398923	270	273	EP4	GeneOrGeneProduct	5734
18398923	288	295	miR-138	GeneOrGeneProduct	387156
18398923	325	364	autosomal dominant hypercholesterolemia	DiseaseOrPhenotypicFeature	D006938
18398923	366	390	congenital malformations	DiseaseOrPhenotypicFeature	D000013
18398923	396	425	enzymatic complex I-deficient	DiseaseOrPhenotypicFeature	C537475
18398923	570	578	1665delC	SequenceVariant	rs80338887
18398923	609	648	autosomal dominant hypercholesterolemia	DiseaseOrPhenotypicFeature	D006938
18398923	723	729	epsinR	GeneOrGeneProduct	9685
18398923	767	791	congenital malformations	DiseaseOrPhenotypicFeature	D000013
18398923	874	881	miR-138	GeneOrGeneProduct	387156
18398923	916	919	EP4	GeneOrGeneProduct	5734
18398923	1021	1024	EP4	GeneOrGeneProduct	5734
18398923	1029	1053	congenital malformations	DiseaseOrPhenotypicFeature	D000013
18398923	1084	1087	EP4	GeneOrGeneProduct	5734
18398923	1163	1169	epsinR	GeneOrGeneProduct	9685
18398923	1174	1203	enzymatic complex I-deficient	DiseaseOrPhenotypicFeature	C537475
18398923	1249	1255	epsinR	GeneOrGeneProduct	9685
18398923	1305	1315	c.463-6T>G	SequenceVariant	c|SUB|T463-6|G
18398923	1363	1402	autosomal dominant hypercholesterolemia	DiseaseOrPhenotypicFeature	D006938
18398923	1487	1496	RAW 264.7	CellLine	CVCL_0493
18398923	1501	1506	MCF-7	CellLine	CVCL_0031
18398923	1552	1558	epsinR	GeneOrGeneProduct	9685
18398923	1560	1563	EP4	GeneOrGeneProduct	5734
18398923	1569	1576	miR-138	GeneOrGeneProduct	387156
18398923	Association	5734	D000013	Novel
18398923	Negative_Correlation	9685	D000013	Novel
18398923	Positive_Correlation	D006938	rs80338887	Novel
18398923	Positive_Correlation	387156	5734	Novel
18398923	Negative_Correlation	9685	C537475	Novel
18398923	Association	5734	C537475	Novel
18398923	Negative_Correlation	387156	D006938	Novel

14306746|t|Genetic and pharmacological interactions of bupivacaine, ZnSO(4), and Fluo3 in DU145 and GT1-1 cell lines under mouse mammary tumor virus co
14306746|a|This study investigates the complex interactions between the chemical entities bupivacaine, ZnSO(4), and Fluo3, as well as their genetic and cellular associations with the sequence variant rs1800896 in the context of mouse mammary tumor virus (MMTV) infection. The research focuses on the DU145 and GT1-1 cell lines, which are frequently used in cancer and neuroendocrine studies.   Our findings reveal a negative correlation between rs1800896 and bupivacaine, suggesting that genetic variability at this locus may modulate the pharmacological response to bupivacaine. Additionally, we observed a positive correlation between bupivacaine and ZnSO(4), indicating a potential synergistic effect of these two compounds. However, a negative correlation was also noted between bupivacaine and ZnSO(4), highlighting the complexity of their interactions.   The association between bupivacaine and rs1800896 further supports the hypothesis that genetic factors may influence drug efficacy and toxicity. Moreover, a positive correlation was found between ZnSO(4) and rs1800896, suggesting that this sequence variant may play a role in modulating the cellular response to ZnSO(4).   In the context of Fluo3, we identified a positive correlation between Fluo3 and ZnSO(4), which may have implications for calcium signaling and cellular imaging. However, a negative correlation was also observed between Fluo3 and ZnSO(4), indicating that the relationship is not straightforward. Furthermore, a negative correlation between Fluo3 and organophosphorus was noted, suggesting that these two compounds may compete for cellular uptake or metabolic pathways.   The study also found a positive correlation between bupivacaine and organophosphorus, which may have therapeutic implications in the treatment of neurodegenerative diseases. These findings collectively suggest that the interactions between these chemical entities and genetic variants are highly context-dependent and may be influenced by the cellular environment, particularly in the presence of MMTV.   The results provide a foundation for future research into the molecular mechanisms underlying these interactions and their potential applications in drug development and personalized medicine.
14306746	44	55	bupivacaine	ChemicalEntity	D002045
14306746	57	64	ZnSO(4)	ChemicalEntity	D019287
14306746	70	75	Fluo3	ChemicalEntity	C059715
14306746	79	84	DU145	CellLine	CVCL_0105
14306746	89	94	GT1-1	CellLine	CVCL_6236
14306746	112	137	mouse mammary tumor virus	OrganismTaxon	11757
14306746	220	231	bupivacaine	ChemicalEntity	D002045
14306746	233	240	ZnSO(4)	ChemicalEntity	D019287
14306746	246	251	Fluo3	ChemicalEntity	C059715
14306746	330	339	rs1800896	SequenceVariant	rs1800896
14306746	358	383	mouse mammary tumor virus	OrganismTaxon	11757
14306746	430	435	DU145	CellLine	CVCL_0105
14306746	440	445	GT1-1	CellLine	CVCL_6236
14306746	575	584	rs1800896	SequenceVariant	rs1800896
14306746	589	600	bupivacaine	ChemicalEntity	D002045
14306746	697	708	bupivacaine	ChemicalEntity	D002045
14306746	767	778	bupivacaine	ChemicalEntity	D002045
14306746	783	790	ZnSO(4)	ChemicalEntity	D019287
14306746	913	924	bupivacaine	ChemicalEntity	D002045
14306746	929	936	ZnSO(4)	ChemicalEntity	D019287
14306746	1015	1026	bupivacaine	ChemicalEntity	D002045
14306746	1031	1040	rs1800896	SequenceVariant	rs1800896
14306746	1187	1194	ZnSO(4)	ChemicalEntity	D019287
14306746	1199	1208	rs1800896	SequenceVariant	rs1800896
14306746	1303	1310	ZnSO(4)	ChemicalEntity	D019287
14306746	1332	1337	Fluo3	ChemicalEntity	C059715
14306746	1384	1389	Fluo3	ChemicalEntity	C059715
14306746	1394	1401	ZnSO(4)	ChemicalEntity	D019287
14306746	1533	1538	Fluo3	ChemicalEntity	C059715
14306746	1543	1550	ZnSO(4)	ChemicalEntity	D019287
14306746	1653	1658	Fluo3	ChemicalEntity	C059715
14306746	1663	1679	organophosphorus	ChemicalEntity	D010755
14306746	1836	1847	bupivacaine	ChemicalEntity	D002045
14306746	1852	1868	organophosphorus	ChemicalEntity	D010755
14306746	Negative_Correlation	rs1800896	D002045	Novel
14306746	Positive_Correlation	C059715	D019287	Novel
14306746	Association	D002045	rs1800896	Novel
14306746	Negative_Correlation	D002045	D019287	Novel
14306746	Association	D019287	rs1800896	Novel
14306746	Negative_Correlation	C059715	D019287	Novel
14306746	Negative_Correlation	C059715	D010755	Novel
14306746	Positive_Correlation	D002045	D019287	Novel
14306746	Positive_Correlation	D019287	D002045	Novel
14306746	Positive_Correlation	D002045	C059715	Novel
14306746	Negative_Correlation	D019287	D002045	Novel
14306746	Negative_Correlation	D002045	D010755	Novel
14306746	Positive_Correlation	D019287	C059715	Novel
14306746	Positive_Correlation	D002045	D010755	Novel

94596711|t|Genetic Variants and Viral Pathogenesis: Interactions Between -4825 Gene Insertion/Deletion, D401H, and Host Immune Responses in Horses, Rhesus Monkeys, and Human Immunodeficien
94596711|a|This study investigates the genetic and virological interactions between the -4825 gene insertion/deletion variant, the D401H sequence variant, and their associations with host immune responses in horses, rhesus monkeys, and human immunodeficiency virus (HIV). The -4825 gene insertion/deletion variant was found to be significantly associated with the D401H sequence variant in multiple experimental models, including in vitro studies using the 293T cell line. These findings suggest a potential functional link between these two genetic variants in modulating viral replication and immune evasion. In horses, the -4825 gene insertion/deletion variant was observed to influence the expression of key immune-related genes, while in rhesus monkeys, the D401H variant was linked to altered viral load dynamics. In HIV-infected individuals, both the -4825 gene insertion/deletion and D401H variants were found to be associated with differential immune responses, including T-cell activation and cytokine production. The 293T cell line was used extensively to model these interactions, revealing that the presence of the -4825 gene insertion/deletion variant enhanced the replication efficiency of HIV in the presence of the D401H variant. These results highlight the complex interplay between genetic variants and viral pathogenesis, with implications for understanding host-virus interactions in diverse species, including horses, rhesus monkeys, and humans infected with HIV. Further studies are needed to elucidate the molecular mechanisms underlying these associations and their potential therapeutic applications.
94596711	93	98	D401H	SequenceVariant	p|SUB|D|401|H
94596711	255	284	-4825 gene insertion/deletion	SequenceVariant	c|INDEL|-4825||
94596711	298	303	D401H	SequenceVariant	p|SUB|D|401|H
94596711	375	381	horses	OrganismTaxon	9796
94596711	383	397	rhesus monkeys	OrganismTaxon	9544
94596711	403	431	human immunodeficiency virus	OrganismTaxon	12721
94596711	443	472	-4825 gene insertion/deletion	SequenceVariant	c|INDEL|-4825||
94596711	531	536	D401H	SequenceVariant	p|SUB|D|401|H
94596711	624	628	293T	CellLine	CVCL_0063
94596711	781	787	horses	OrganismTaxon	9796
94596711	793	822	-4825 gene insertion/deletion	SequenceVariant	c|INDEL|-4825||
94596711	910	924	rhesus monkeys	OrganismTaxon	9544
94596711	930	935	D401H	SequenceVariant	p|SUB|D|401|H
94596711	1025	1054	-4825 gene insertion/deletion	SequenceVariant	c|INDEL|-4825||
94596711	1059	1064	D401H	SequenceVariant	p|SUB|D|401|H
94596711	1195	1199	293T	CellLine	CVCL_0063
94596711	1295	1324	-4825 gene insertion/deletion	SequenceVariant	c|INDEL|-4825||
94596711	1399	1404	D401H	SequenceVariant	p|SUB|D|401|H
94596711	1599	1605	horses	OrganismTaxon	9796
94596711	1607	1621	rhesus monkeys	OrganismTaxon	9544
94596711	Association	c|INDEL|-4825||	p|SUB|D|401|H	Novel
94596711	Association	p|SUB|D|401|H	c|INDEL|-4825||	Novel

18926391|t|Caveolin-1 and extracellular regulated protein kinase interactions in bovine and sheep models: implications for JNK signaling and NMDA receptor 1 re
18926391|a|This study investigates the molecular interactions between caveolin-1 and extracellular regulated protein kinase (ERK) in bovine and sheep cell lines, with particular emphasis on their role in modulating JNK signaling pathways and NMDA receptor 1 expression. Using C4-2B and C57BL/6J cell lines derived from bovine and sheep tissues, we demonstrate a direct binding interaction between caveolin-1 and ERK, which is further supported by co-immunoprecipitation and pull-down assays. Our findings reveal a positive correlation between ERK and JNK activity in these cell lines, suggesting a potential regulatory feedback loop that may influence cellular responses to stress and inflammation. Additionally, we observe a positive correlation between caveolin-1 and NMDA receptor 1 expression in sheep-derived C4-2B cells, indicating a possible role for caveolin-1 in synaptic plasticity and neuronal function. The study also includes in vitro experiments using HCT116 human colon cancer cells, where the presence of JNK and ERK was found to be significantly elevated in response to extracellular stimuli. These results are further validated in inpatient clinical samples from cats, where the expression levels of caveolin-1 and ERK were found to be positively correlated. The implications of these findings extend to the study of human immunodeficiency virus (HIV) infection, where similar signaling pathways have been implicated in viral replication and immune evasion. Overall, this work provides new insights into the complex interplay between caveolin-1, ERK, JNK, and NMDA receptor 1 across multiple species, including tobacco and bovine models.
18926391	15	53	extracellular regulated protein kinase	GeneOrGeneProduct	116590
18926391	70	76	bovine	OrganismTaxon	9913
18926391	81	86	sheep	OrganismTaxon	9940
18926391	112	115	JNK	GeneOrGeneProduct	116554
18926391	130	145	NMDA receptor 1	GeneOrGeneProduct	14810
18926391	208	218	caveolin-1	GeneOrGeneProduct	857
18926391	223	261	extracellular regulated protein kinase	GeneOrGeneProduct	116590
18926391	271	277	bovine	OrganismTaxon	9913
18926391	282	287	sheep	OrganismTaxon	9940
18926391	353	356	JNK	GeneOrGeneProduct	116554
18926391	380	395	NMDA receptor 1	GeneOrGeneProduct	14810
18926391	414	419	C4-2B	CellLine	CVCL_4784
18926391	424	432	C57BL/6J	CellLine	CVCL_5U84
18926391	457	463	bovine	OrganismTaxon	9913
18926391	468	473	sheep	OrganismTaxon	9940
18926391	535	545	caveolin-1	GeneOrGeneProduct	857
18926391	689	692	JNK	GeneOrGeneProduct	116554
18926391	893	903	caveolin-1	GeneOrGeneProduct	857
18926391	908	923	NMDA receptor 1	GeneOrGeneProduct	14810
18926391	938	943	sheep	OrganismTaxon	9940
18926391	952	957	C4-2B	CellLine	CVCL_4784
18926391	996	1006	caveolin-1	GeneOrGeneProduct	857
18926391	1104	1110	HCT116	CellLine	CVCL_0291
18926391	1159	1162	JNK	GeneOrGeneProduct	116554
18926391	1287	1296	inpatient	OrganismTaxon	9606
18926391	1319	1323	cats	OrganismTaxon	9685
18926391	1356	1366	caveolin-1	GeneOrGeneProduct	857
18926391	1473	1501	human immunodeficiency virus	OrganismTaxon	12721
18926391	1690	1700	caveolin-1	GeneOrGeneProduct	857
18926391	1707	1710	JNK	GeneOrGeneProduct	116554
18926391	1716	1731	NMDA receptor 1	GeneOrGeneProduct	14810
18926391	1767	1774	tobacco	OrganismTaxon	4097
18926391	1779	1785	bovine	OrganismTaxon	9913
18926391	Bind	116590	857	Novel
18926391	Positive_Correlation	116590	116554	Novel
18926391	Positive_Correlation	857	14810	Novel

31150084|t|Genetic and biochemical interactions of ATX, uroplakin (UP) III, and TH in sheep and Drosophil
31150084|a|This study investigates the genetic and biochemical interactions between ATX, uroplakin (UP) III, and TH in both sheep and Drosophila models. We found a positive correlation between ATX and uroplakin (UP) III, suggesting a potential functional relationship between these two gene products. Additionally, we observed a negative correlation between uroplakin (UP) III and alpha-methyl-para-tyrosine, indicating a possible regulatory mechanism. The association between Lys to Asn at position 198 and TH was confirmed through biochemical assays, and this variant was also linked to alpha-methyl-para-tyrosine.   We further explored the relationship between TH and alpha-methyl-para-tyrosine, identifying a drug interaction between these two chemical entities. The D allele for the -1607 was associated with TH, and this variant was also linked to alpha-methyl-para-tyrosine. The sequence variant rs1061170 showed associations with both TH and alpha-methyl-para-tyrosine, reinforcing the complex interplay between these factors.   A positive correlation was observed between TH and ATX, as well as between alpha-methyl-para-tyrosine and ATX. The association between TH and ATX was further supported by functional studies. The D90A variant was found to be associated with alpha-methyl-para-tyrosine, highlighting the role of sequence variants in modulating these interactions. These findings provide new insights into the molecular mechanisms underlying the interactions between ATX, uroplakin (UP) III, TH, and alpha-methyl-para-tyrosine in both sheep and Drosophila models.
31150084	40	43	ATX	GeneOrGeneProduct	18606
31150084	45	63	uroplakin (UP) III	GeneOrGeneProduct	22270
31150084	69	71	TH	ChemicalEntity	D013963
31150084	75	80	sheep	OrganismTaxon	9940
31150084	168	171	ATX	GeneOrGeneProduct	18606
31150084	173	191	uroplakin (UP) III	GeneOrGeneProduct	22270
31150084	197	199	TH	ChemicalEntity	D013963
31150084	208	213	sheep	OrganismTaxon	9940
31150084	218	228	Drosophila	OrganismTaxon	7227
31150084	277	280	ATX	GeneOrGeneProduct	18606
31150084	285	303	uroplakin (UP) III	GeneOrGeneProduct	22270
31150084	442	460	uroplakin (UP) III	GeneOrGeneProduct	22270
31150084	465	491	alpha-methyl-para-tyrosine	ChemicalEntity	D019805
31150084	561	587	Lys to Asn at position 198	SequenceVariant	rs5370
31150084	592	594	TH	ChemicalEntity	D013963
31150084	673	699	alpha-methyl-para-tyrosine	ChemicalEntity	D019805
31150084	748	750	TH	ChemicalEntity	D013963
31150084	755	781	alpha-methyl-para-tyrosine	ChemicalEntity	D019805
31150084	855	877	D allele for the -1607	SequenceVariant	c|Allele|D|-1607
31150084	898	900	TH	ChemicalEntity	D013963
31150084	938	964	alpha-methyl-para-tyrosine	ChemicalEntity	D019805
31150084	987	996	rs1061170	SequenceVariant	rs1061170
31150084	1027	1029	TH	ChemicalEntity	D013963
31150084	1034	1060	alpha-methyl-para-tyrosine	ChemicalEntity	D019805
31150084	1165	1167	TH	ChemicalEntity	D013963
31150084	1172	1175	ATX	GeneOrGeneProduct	18606
31150084	1196	1222	alpha-methyl-para-tyrosine	ChemicalEntity	D019805
31150084	1227	1230	ATX	GeneOrGeneProduct	18606
31150084	1256	1258	TH	ChemicalEntity	D013963
31150084	1263	1266	ATX	GeneOrGeneProduct	18606
31150084	1316	1320	D90A	SequenceVariant	rs80265967
31150084	1361	1387	alpha-methyl-para-tyrosine	ChemicalEntity	D019805
31150084	1568	1571	ATX	GeneOrGeneProduct	18606
31150084	1573	1591	uroplakin (UP) III	GeneOrGeneProduct	22270
31150084	1593	1595	TH	ChemicalEntity	D013963
31150084	1601	1627	alpha-methyl-para-tyrosine	ChemicalEntity	D019805
31150084	1636	1641	sheep	OrganismTaxon	9940
31150084	1646	1656	Drosophila	OrganismTaxon	7227
31150084	Positive_Correlation	18606	22270	Novel
31150084	Association	rs5370	D013963	Novel
31150084	Negative_Correlation	22270	D019805	Novel
31150084	Negative_Correlation	18606	D019805	Novel
31150084	Drug_Interaction	D013963	D019805	Novel
31150084	Association	c|Allele|D|-1607	D013963	Novel
31150084	Association	D013963	22270	Novel
31150084	Association	rs1061170	D013963	Novel
31150084	Association	rs1061170	D019805	Novel
31150084	Positive_Correlation	D013963	18606	Novel
31150084	Positive_Correlation	D019805	22270	Novel
31150084	Association	D013963	18606	Novel
31150084	Association	c|Allele|D|-1607	D019805	Novel
31150084	Drug_Interaction	D019805	D013963	Novel
31150084	Negative_Correlation	22270	D013963	Novel
31150084	Association	rs80265967	D019805	Novel
31150084	Association	rs5370	D019805	Novel
31150084	Association	18606	22270	Novel
31150084	Positive_Correlation	D019805	18606	Novel

27095137|t|Genetic and pharmacological interactions of 15-F(2t)-IsoP, clozapine, and triamcinolone diacetate in H9c2 and PA-1 ce
27095137|a|This study investigates the genetic and pharmacological interactions of 15-F(2t)-IsoP, clozapine, and triamcinolone diacetate in the context of gene expression and cellular response in H9c2 and PA-1 cell lines. The sequence variant g.3318-35T>G was found to be associated with altered expression of the gene FBXO5, which is involved in the regulation of protein degradation. Additionally, the sequence variant C262T was linked to changes in the expression of CCDC149, a gene implicated in cellular signaling pathways. The organism taxon Daucus carota was used as a model system to study the effects of these chemical entities on gene expression and cellular function.   The cotreatment of clozapine with 15-F(2t)-IsoP was shown to significantly modulate the expression of Neurofibromin 1, a tumor suppressor gene, and to influence the activity of NFkB, a key transcription factor in inflammatory responses. Similarly, cotreatment of clozapine with triamcinolone diacetate was found to alter the expression of matriptase-2, a serine protease involved in epithelial cell function. The cotreatment of triamcinolone diacetate with clozapine was associated with changes in the expression of CCDC149 and the regulation of the gene product FBXO5.   Furthermore, the cotreatment of 15-F(2t)-IsoP with clozapine was found to have a synergistic effect on the expression of the gene product CCDC149, while the cotreatment of 15-F(2t)-IsoP with triamcinolone diacetate was associated with altered expression of the gene FBXO5. These findings suggest that the interactions between these chemical entities may have significant implications for the regulation of gene expression and cellular function in both H9c2 and PA-1 cell lines. The results also highlight the potential therapeutic applications of these compounds in the context of diseases involving inflammation and cellular signaling.
27095137	44	57	15-F(2t)-IsoP	ChemicalEntity	C075750
27095137	59	68	clozapine	ChemicalEntity	D003024
27095137	74	97	triamcinolone diacetate	ChemicalEntity	C030262
27095137	101	105	H9c2	CellLine	CVCL_0286
27095137	110	114	PA-1	CellLine	CVCL_0479
27095137	190	203	15-F(2t)-IsoP	ChemicalEntity	C075750
27095137	205	214	clozapine	ChemicalEntity	D003024
27095137	220	243	triamcinolone diacetate	ChemicalEntity	C030262
27095137	303	307	H9c2	CellLine	CVCL_0286
27095137	312	316	PA-1	CellLine	CVCL_0479
27095137	350	362	g.3318-35T>G	SequenceVariant	g|SUB|T|3318-35|G
27095137	426	431	FBXO5	GeneOrGeneProduct	26271
27095137	528	533	C262T	SequenceVariant	c|SUB|C|262|T
27095137	577	584	CCDC149	GeneOrGeneProduct	91050
27095137	655	668	Daucus carota	OrganismTaxon	4039
27095137	807	816	clozapine	ChemicalEntity	D003024
27095137	822	835	15-F(2t)-IsoP	ChemicalEntity	C075750
27095137	890	905	Neurofibromin 1	GeneOrGeneProduct	4763
27095137	965	969	NFkB	GeneOrGeneProduct	19697
27095137	1051	1060	clozapine	ChemicalEntity	D003024
27095137	1066	1089	triamcinolone diacetate	ChemicalEntity	C030262
27095137	1127	1139	matriptase-2	GeneOrGeneProduct	164656
27095137	1216	1239	triamcinolone diacetate	ChemicalEntity	C030262
27095137	1245	1254	clozapine	ChemicalEntity	D003024
27095137	1304	1311	CCDC149	GeneOrGeneProduct	91050
27095137	1351	1356	FBXO5	GeneOrGeneProduct	26271
27095137	1392	1405	15-F(2t)-IsoP	ChemicalEntity	C075750
27095137	1411	1420	clozapine	ChemicalEntity	D003024
27095137	1498	1505	CCDC149	GeneOrGeneProduct	91050
27095137	1532	1545	15-F(2t)-IsoP	ChemicalEntity	C075750
27095137	1551	1574	triamcinolone diacetate	ChemicalEntity	C030262
27095137	1626	1631	FBXO5	GeneOrGeneProduct	26271
27095137	1812	1816	H9c2	CellLine	CVCL_0286
27095137	1821	1825	PA-1	CellLine	CVCL_0479
27095137	Cotreatment	C030262	D003024	Novel
27095137	Cotreatment	D003024	C030262	Novel
27095137	Cotreatment	D003024	C075750	Novel
27095137	Cotreatment	C075750	D003024	Novel

76854898|t|Chronic Renal Failure and Insomnia: Interactions with Cholesterol, Acrolein, and HOMER1 in Dengue Virus Type 2 and Aedes Mo
76854898|a|This study investigates the complex interplay between chronic renal failure, insomnia, and various chemical entities and genetic factors in the context of dengue virus type 2 infection and exposure to environmental toxins. Chronic renal failure was found to be significantly associated with both insomnia and acrolein exposure, with a notable negative correlation between acrolein and 2,3,7,8-tetrachlorodibenzo-p-dioxin. The association between 2,3,7,8-tetrachlorodibenzo-p-dioxin and insomnia was confirmed through longitudinal studies in rats and rabbit models.   Cholesterol levels were inversely correlated with both insomnia and extrapyramidal symptoms, suggesting a potential protective role of cholesterol in these conditions. A negative correlation was also observed between cholesterol and HOMER1, while a positive correlation was found between extrapyramidal symptoms and HOMER1. The gene product GIP was found to bind cholesterol, indicating a possible regulatory mechanism in lipid metabolism.   In Aedes mosquitoes, the presence of dengue virus type 2 was linked to increased levels of 2,3,7,8-tetrachlorodibenzo-p-dioxin, which in turn was associated with chronic renal failure. Acrolein was found to be a key mediator in the pathogenesis of chronic renal failure, with a strong negative correlation between acrolein and 2,3,7,8-tetrachlorodibenzo-p-dioxin.   The study also highlights the role of HOMER1 in modulating extrapyramidal symptoms, with evidence of a positive correlation between HOMER1 and these symptoms. Furthermore, the negative correlation between cholesterol and extrapyramidal symptoms suggests a potential therapeutic target for managing these conditions.   Overall, the findings underscore the intricate relationships between environmental toxins, genetic factors, and disease phenotypes, particularly in the context of chronic renal failure, insomnia, and extrapyramidal symptoms.
76854898	81	87	HOMER1	GeneOrGeneProduct	9456
76854898	178	199	chronic renal failure	DiseaseOrPhenotypicFeature	D007676
76854898	201	209	insomnia	DiseaseOrPhenotypicFeature	D007319
76854898	279	298	dengue virus type 2	OrganismTaxon	11060
76854898	420	428	insomnia	DiseaseOrPhenotypicFeature	D007319
76854898	433	441	acrolein	ChemicalEntity	D000171
76854898	496	504	acrolein	ChemicalEntity	D000171
76854898	509	544	2,3,7,8-tetrachlorodibenzo-p-dioxin	ChemicalEntity	D000072317
76854898	570	605	2,3,7,8-tetrachlorodibenzo-p-dioxin	ChemicalEntity	D000072317
76854898	610	618	insomnia	DiseaseOrPhenotypicFeature	D007319
76854898	665	669	rats	OrganismTaxon	10116
76854898	674	680	rabbit	OrganismTaxon	9986
76854898	746	754	insomnia	DiseaseOrPhenotypicFeature	D007319
76854898	759	782	extrapyramidal symptoms	DiseaseOrPhenotypicFeature	D001480
76854898	826	837	cholesterol	ChemicalEntity	D002784
76854898	908	919	cholesterol	ChemicalEntity	D002784
76854898	924	930	HOMER1	GeneOrGeneProduct	9456
76854898	979	1002	extrapyramidal symptoms	DiseaseOrPhenotypicFeature	D001480
76854898	1007	1013	HOMER1	GeneOrGeneProduct	9456
76854898	1032	1035	GIP	GeneOrGeneProduct	2695
76854898	1054	1065	cholesterol	ChemicalEntity	D002784
76854898	1136	1152	Aedes mosquitoes	OrganismTaxon	1245352
76854898	1170	1189	dengue virus type 2	OrganismTaxon	11060
76854898	1224	1259	2,3,7,8-tetrachlorodibenzo-p-dioxin	ChemicalEntity	D000072317
76854898	1295	1316	chronic renal failure	DiseaseOrPhenotypicFeature	D007676
76854898	1381	1402	chronic renal failure	DiseaseOrPhenotypicFeature	D007676
76854898	1447	1455	acrolein	ChemicalEntity	D000171
76854898	1460	1495	2,3,7,8-tetrachlorodibenzo-p-dioxin	ChemicalEntity	D000072317
76854898	1537	1543	HOMER1	GeneOrGeneProduct	9456
76854898	1558	1581	extrapyramidal symptoms	DiseaseOrPhenotypicFeature	D001480
76854898	1631	1637	HOMER1	GeneOrGeneProduct	9456
76854898	1704	1715	cholesterol	ChemicalEntity	D002784
76854898	1720	1743	extrapyramidal symptoms	DiseaseOrPhenotypicFeature	D001480
76854898	1980	2001	chronic renal failure	DiseaseOrPhenotypicFeature	D007676
76854898	2003	2011	insomnia	DiseaseOrPhenotypicFeature	D007319
76854898	2017	2040	extrapyramidal symptoms	DiseaseOrPhenotypicFeature	D001480
76854898	Positive_Correlation	D001480	9456	Novel
76854898	Association	D000072317	D007319	Novel
76854898	Comparison	D002784	D000171	Novel
76854898	Negative_Correlation	D002784	9456	Novel
76854898	Bind	D002784	2695	Novel
76854898	Association	D000171	D007676	Novel
76854898	Negative_Correlation	D001480	D002784	Novel
76854898	Negative_Correlation	D000171	D000072317	Novel
76854898	Negative_Correlation	D000072317	D000171	Novel
76854898	Negative_Correlation	D007319	D002784	Novel

21741582|t|Genetic Variants and Phenotypic Associations in Ginseng and Horses: Implications for Liver Toxicity and Testicular Dy
21741582|a|This study investigates the genetic and phenotypic associations between specific sequence variants, cell lines, and disease features in ginseng and horses. We focus on the sequence variant c.640_667del28, which is associated with both liver toxicity and dysgenesis of the testes. The variant +3100 T/G shows a positive correlation with dysgenesis of the testes and is also associated with c.640_667del28. Additionally, lysine at residue 223 exhibits a negative correlation with liver toxicity and a negative correlation with dysgenesis of the testes, while also being associated with +3100 T/G. The cell lines PA-1, Ba/F3, and CA3 are used to model these genetic interactions in vitro. Our findings suggest that the sequence variant c.640_667del28 is negatively correlated with liver toxicity, and the variant +3100 T/G is positively correlated with dysgenesis of the testes. These associations are further supported by the observed relationships between lysine at residue 223 and both liver toxicity and dysgenesis of the testes. The study also highlights the potential role of ginseng and horses in understanding these genetic-phenotypic interactions, with implications for toxicology and developmental biology.
21741582	254	261	ginseng	OrganismTaxon	4054
21741582	266	272	horses	OrganismTaxon	9796
21741582	307	321	c.640_667del28	SequenceVariant	rs193302859
21741582	353	367	liver toxicity	DiseaseOrPhenotypicFeature	D056486
21741582	372	396	dysgenesis of the testes	DiseaseOrPhenotypicFeature	D013733
21741582	410	419	+3100 T/G	SequenceVariant	c|SUB|T|+3100|G
21741582	454	478	dysgenesis of the testes	DiseaseOrPhenotypicFeature	D013733
21741582	507	521	c.640_667del28	SequenceVariant	rs193302859
21741582	537	558	lysine at residue 223	SequenceVariant	c|Allele|K|223
21741582	596	610	liver toxicity	DiseaseOrPhenotypicFeature	D056486
21741582	643	667	dysgenesis of the testes	DiseaseOrPhenotypicFeature	D013733
21741582	702	711	+3100 T/G	SequenceVariant	c|SUB|T|+3100|G
21741582	728	732	PA-1	CellLine	CVCL_0479
21741582	734	739	Ba/F3	CellLine	CVCL_0161
21741582	745	748	CA3	CellLine	CVCL_JW73
21741582	851	865	c.640_667del28	SequenceVariant	rs193302859
21741582	896	910	liver toxicity	DiseaseOrPhenotypicFeature	D056486
21741582	928	937	+3100 T/G	SequenceVariant	c|SUB|T|+3100|G
21741582	968	992	dysgenesis of the testes	DiseaseOrPhenotypicFeature	D013733
21741582	1073	1094	lysine at residue 223	SequenceVariant	c|Allele|K|223
21741582	1104	1118	liver toxicity	DiseaseOrPhenotypicFeature	D056486
21741582	1123	1147	dysgenesis of the testes	DiseaseOrPhenotypicFeature	D013733
21741582	1197	1204	ginseng	OrganismTaxon	4054
21741582	1209	1215	horses	OrganismTaxon	9796
21741582	Negative_Correlation	c|Allele|K|223	D056486	Novel
21741582	Positive_Correlation	D013733	c|SUB|T|+3100|G	Novel
21741582	Negative_Correlation	c|Allele|K|223	D013733	Novel
21741582	Positive_Correlation	D056486	rs193302859	Novel
21741582	Association	c|Allele|K|223	c|SUB|T|+3100|G	Novel
21741582	Negative_Correlation	rs193302859	D013733	Novel
21741582	Negative_Correlation	rs193302859	D056486	Novel
21741582	Association	c|SUB|T|+3100|G	rs193302859	Novel

99224344|t|Nuclear factor kappaB and DFNB7/B11 interactions in Drosophila and mammalian models: a comprehensive analysis of gene associations and regulatory 
99224344|a|This study investigates the complex interactions between nuclear factor kappaB (NF-B) and DFNB7/B11 across multiple biological systems, including Drosophila, mice, and various cell lines. The research highlights a negative correlation between NF-B and DFNB7/B11, suggesting a potential regulatory antagonism. Additionally, a positive correlation between NF-B and DFNB7/B11 is observed, indicating a possible compensatory mechanism under certain conditions. These findings are further supported by evidence of a bind between NF-B and DFNB7/B11, as well as a bind between NF-B and LTK.   The study also explores the relationship between CACNA1S and LTK, revealing both an association and a bind between these two gene products. A negative correlation between CACNA1S and LTK is noted, while a positive correlation between CACNA1S and LTK is also documented. Furthermore, a positive correlation between CACNA1S and DFNB7/B11 is observed, along with an association between CACNA1S and DFNB7/B11. The negative correlation between LTK and DFNB7/B11 is also confirmed, as is the positive correlation between LTK and DFNB7/B11.   The research further demonstrates a negative correlation between LTK and NF-B, as well as a positive correlation between LTK and NF-B, indicating a dynamic regulatory relationship. An association between DFNB7/B11 and LTK is also established, reinforcing the interconnected nature of these gene products.   The study was conducted using a variety of cell lines, including Mz-ChA-1, SMMC-7721, PC-3, and CD18/HPAF, and across multiple organism taxons, including Drosophila, mice, and sheep. These findings provide a comprehensive understanding of the molecular interactions and regulatory networks involving NF-B, DFNB7/B11, CACNA1S, and LTK, with implications for both basic research and potential therapeutic applications.
99224344	26	35	DFNB7/B11	GeneOrGeneProduct	117531
99224344	52	62	Drosophila	OrganismTaxon	7227
99224344	204	225	nuclear factor kappaB	GeneOrGeneProduct	4790
99224344	238	247	DFNB7/B11	GeneOrGeneProduct	117531
99224344	294	304	Drosophila	OrganismTaxon	7227
99224344	401	410	DFNB7/B11	GeneOrGeneProduct	117531
99224344	513	522	DFNB7/B11	GeneOrGeneProduct	117531
99224344	684	693	DFNB7/B11	GeneOrGeneProduct	117531
99224344	731	734	LTK	GeneOrGeneProduct	4058
99224344	787	794	CACNA1S	GeneOrGeneProduct	779
99224344	799	802	LTK	GeneOrGeneProduct	4058
99224344	909	916	CACNA1S	GeneOrGeneProduct	779
99224344	921	924	LTK	GeneOrGeneProduct	4058
99224344	972	979	CACNA1S	GeneOrGeneProduct	779
99224344	984	987	LTK	GeneOrGeneProduct	4058
99224344	1052	1059	CACNA1S	GeneOrGeneProduct	779
99224344	1064	1073	DFNB7/B11	GeneOrGeneProduct	117531
99224344	1121	1128	CACNA1S	GeneOrGeneProduct	779
99224344	1133	1142	DFNB7/B11	GeneOrGeneProduct	117531
99224344	1177	1180	LTK	GeneOrGeneProduct	4058
99224344	1185	1194	DFNB7/B11	GeneOrGeneProduct	117531
99224344	1253	1256	LTK	GeneOrGeneProduct	4058
99224344	1261	1270	DFNB7/B11	GeneOrGeneProduct	117531
99224344	1339	1342	LTK	GeneOrGeneProduct	4058
99224344	1396	1399	LTK	GeneOrGeneProduct	4058
99224344	1480	1489	DFNB7/B11	GeneOrGeneProduct	117531
99224344	1494	1497	LTK	GeneOrGeneProduct	4058
99224344	1648	1656	Mz-ChA-1	CellLine	CVCL_6932
99224344	1658	1667	SMMC-7721	CellLine	CVCL_0534
99224344	1669	1673	PC-3	CellLine	CVCL_0035
99224344	1679	1688	CD18/HPAF	CellLine	CVCL_0313
99224344	1737	1747	Drosophila	OrganismTaxon	7227
99224344	1759	1764	sheep	OrganismTaxon	9940
99224344	1890	1899	DFNB7/B11	GeneOrGeneProduct	117531
99224344	1901	1908	CACNA1S	GeneOrGeneProduct	779
99224344	1914	1917	LTK	GeneOrGeneProduct	4058
99224344	Negative_Correlation	4790	117531	Novel
99224344	Bind	779	4058	Novel
99224344	Negative_Correlation	4058	779	Novel
99224344	Association	779	4058	Novel
99224344	Positive_Correlation	4790	117531	Novel
99224344	Association	4058	117531	Novel
99224344	Positive_Correlation	4058	117531	Novel
99224344	Association	779	117531	Novel
99224344	Bind	779	4790	Novel
99224344	Positive_Correlation	4058	4790	Novel
99224344	Negative_Correlation	4058	117531	Novel
99224344	Bind	4790	117531	Novel
99224344	Negative_Correlation	4058	4790	Novel
99224344	Positive_Correlation	779	4790	Novel
99224344	Association	117531	4058	Novel
99224344	Bind	4790	4058	Novel
99224344	Positive_Correlation	117531	4058	Novel
99224344	Negative_Correlation	4790	779	Novel
99224344	Positive_Correlation	779	117531	Novel
99224344	Association	779	4790	Novel
99224344	Negative_Correlation	4790	4058	Novel
99224344	Association	4790	779	Novel

14790715|t|ErbB3, type I interferon, and NF1: complex interactions in inflammatory diseases, tissue injury, 
14790715|a|Recent studies have highlighted the intricate relationships between the gene product ErbB3, type I interferon, and NF1 in the context of inflammatory diseases, tissue injury, and ADCA. This research explores the multifaceted interactions among these molecular entities and their implications for disease progression.   ErbB3 has been shown to exhibit a negative correlation with tissue injury, suggesting that its expression may serve as a protective factor against inflammatory damage. Furthermore, type I interferon demonstrates a positive correlation with inflammatory diseases, reinforcing its role in immune response modulation. Notably, the gene product C2 is negatively correlated with both tissue injury and inflammatory diseases, indicating a potential regulatory role in these pathological processes.  The disease feature ADCA is positively correlated with NF1, suggesting a possible genetic link between these two entities. However, ADCA also shows a negative correlation with C2, highlighting the complexity of these interactions. Additionally, NF1 is associated with postoperative nausea and vomiting and pain, with a negative correlation observed between NF1 and postoperative nausea and vomiting and pain, indicating a possible protective effect of NF1 in this context.  Type I interferon exhibits a negative correlation with tissue injury, which aligns with its known anti-inflammatory properties. Moreover, type I interferon binds to both BRCA1 and ErbB3, suggesting potential functional interactions that may influence disease outcomes. The gene product BRCA1 is also associated with postoperative nausea and vomiting and pain, with a negative correlation observed between BRCA1 and postoperative nausea and vomiting and pain.  ErbB3 is positively correlated with inflammatory diseases and also binds to C2, indicating a possible role in the regulation of inflammatory responses. The gene product C2 is negatively correlated with inflammatory diseases, further supporting its involvement in immune regulation.   These findings underscore the complex interplay between genetic factors and disease phenotypes, providing new insights into the molecular mechanisms underlying inflammatory diseases, tissue injury, and ADCA. The results suggest that targeting these molecular interactions may offer novel therapeutic strategies for managing these conditions.
14790715	7	24	type I interferon	GeneOrGeneProduct	3456
14790715	30	33	NF1	GeneOrGeneProduct	18015
14790715	59	80	inflammatory diseases	DiseaseOrPhenotypicFeature	D007249
14790715	82	95	tissue injury	DiseaseOrPhenotypicFeature	D017695
14790715	190	207	type I interferon	GeneOrGeneProduct	3456
14790715	213	216	NF1	GeneOrGeneProduct	18015
14790715	235	256	inflammatory diseases	DiseaseOrPhenotypicFeature	D007249
14790715	258	271	tissue injury	DiseaseOrPhenotypicFeature	D017695
14790715	277	281	ADCA	DiseaseOrPhenotypicFeature	OMIM:604121
14790715	477	490	tissue injury	DiseaseOrPhenotypicFeature	D017695
14790715	598	615	type I interferon	GeneOrGeneProduct	3456
14790715	657	678	inflammatory diseases	DiseaseOrPhenotypicFeature	D007249
14790715	758	760	C2	GeneOrGeneProduct	717
14790715	796	809	tissue injury	DiseaseOrPhenotypicFeature	D017695
14790715	814	835	inflammatory diseases	DiseaseOrPhenotypicFeature	D007249
14790715	930	934	ADCA	DiseaseOrPhenotypicFeature	OMIM:604121
14790715	965	968	NF1	GeneOrGeneProduct	18015
14790715	1042	1046	ADCA	DiseaseOrPhenotypicFeature	OMIM:604121
14790715	1086	1088	C2	GeneOrGeneProduct	717
14790715	1155	1158	NF1	GeneOrGeneProduct	18015
14790715	1178	1220	postoperative nausea and vomiting and pain	DiseaseOrPhenotypicFeature	D010149
14790715	1267	1270	NF1	GeneOrGeneProduct	18015
14790715	1275	1317	postoperative nausea and vomiting and pain	DiseaseOrPhenotypicFeature	D010149
14790715	1362	1365	NF1	GeneOrGeneProduct	18015
14790715	1439	1452	tissue injury	DiseaseOrPhenotypicFeature	D017695
14790715	1522	1539	type I interferon	GeneOrGeneProduct	3456
14790715	1554	1559	BRCA1	GeneOrGeneProduct	672
14790715	1670	1675	BRCA1	GeneOrGeneProduct	672
14790715	1700	1742	postoperative nausea and vomiting and pain	DiseaseOrPhenotypicFeature	D010149
14790715	1789	1794	BRCA1	GeneOrGeneProduct	672
14790715	1799	1841	postoperative nausea and vomiting and pain	DiseaseOrPhenotypicFeature	D010149
14790715	1880	1901	inflammatory diseases	DiseaseOrPhenotypicFeature	D007249
14790715	1920	1922	C2	GeneOrGeneProduct	717
14790715	2013	2015	C2	GeneOrGeneProduct	717
14790715	2046	2067	inflammatory diseases	DiseaseOrPhenotypicFeature	D007249
14790715	2288	2309	inflammatory diseases	DiseaseOrPhenotypicFeature	D007249
14790715	2311	2324	tissue injury	DiseaseOrPhenotypicFeature	D017695
14790715	2330	2334	ADCA	DiseaseOrPhenotypicFeature	OMIM:604121
14790715	Negative_Correlation	D010149	18015	Novel
14790715	Negative_Correlation	D017695	13867	Novel
14790715	Positive_Correlation	D007249	3456	Novel
14790715	Negative_Correlation	D017695	717	Novel
14790715	Positive_Correlation	OMIM:604121	18015	Novel
14790715	Bind	3456	672	Novel
14790715	Bind	13867	717	Novel
14790715	Negative_Correlation	OMIM:604121	717	Novel
14790715	Negative_Correlation	D010149	717	Novel
14790715	Association	18015	D010149	Novel
14790715	Positive_Correlation	D007249	717	Novel
14790715	Bind	3456	13867	Novel
14790715	Negative_Correlation	D007249	672	Novel
14790715	Positive_Correlation	D007249	13867	Novel
14790715	Association	13867	D010149	Novel
14790715	Negative_Correlation	D017695	3456	Novel
14790715	Association	672	D010149	Novel
14790715	Negative_Correlation	D007249	717	Novel
14790715	Bind	3456	18015	Novel

45077047|t|IVS3 + 18C > T and GnRH: implications for autosomal dominant hypercholesterolemia in RAW 264.7 and BALB/c ce
45077047|a|Autosomal dominant hypercholesterolemia (ADH) has been linked to specific sequence variants, including IVS3 + 18C > T, which appears to influence both lipid metabolism and GnRH signaling. This study investigates the molecular mechanisms underlying the association between IVS3 + 18C > T and ADH, with a focus on the role of GnRH in modulating disease progression. Using RAW 264.7 and BALB/c cell lines, we demonstrate that the IVS3 + 18C > T variant is significantly associated with ADH, as evidenced by altered lipid profiles and increased expression of GnRH-related pathways. Furthermore, we observe a positive correlation between GnRH levels and the severity of ADH, suggesting that GnRH may act as a downstream mediator of the disease. Our findings provide evidence for a direct association between IVS3 + 18C > T and ADH, as well as a functional link between IVS3 + 18C > T and GnRH. These results highlight the potential of targeting GnRH signaling as a therapeutic strategy for managing ADH in both RAW 264.7 and BALB/c models. The study also underscores the importance of cell line-specific responses in understanding the genetic and molecular basis of ADH.
45077047	0	14	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
45077047	19	23	GnRH	GeneOrGeneProduct	14714
45077047	42	81	autosomal dominant hypercholesterolemia	DiseaseOrPhenotypicFeature	D006938
45077047	85	94	RAW 264.7	CellLine	CVCL_0493
45077047	99	105	BALB/c	CellLine	CVCL_9101
45077047	212	226	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
45077047	281	285	GnRH	GeneOrGeneProduct	14714
45077047	381	395	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
45077047	433	437	GnRH	GeneOrGeneProduct	14714
45077047	479	488	RAW 264.7	CellLine	CVCL_0493
45077047	493	499	BALB/c	CellLine	CVCL_9101
45077047	536	550	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
45077047	664	668	GnRH	GeneOrGeneProduct	14714
45077047	742	746	GnRH	GeneOrGeneProduct	14714
45077047	795	799	GnRH	GeneOrGeneProduct	14714
45077047	912	926	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
45077047	973	987	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
45077047	992	996	GnRH	GeneOrGeneProduct	14714
45077047	1049	1053	GnRH	GeneOrGeneProduct	14714
45077047	1115	1124	RAW 264.7	CellLine	CVCL_0493
45077047	1129	1135	BALB/c	CellLine	CVCL_9101
45077047	Association	D006938	c|SUB|C|IVS3+18|T	Novel
45077047	Association	c|SUB|C|IVS3+18|T	14714	Novel
45077047	Association	c|SUB|C|IVS3+18|T	D006938	Novel
45077047	Positive_Correlation	14714	D006938	Novel

52330168|t|Genetic and pharmacological modulation of GnRH receptor function: interactions with sequence variants, chemical entities, and gene 
52330168|a|This study investigates the complex interplay between genetic variants, chemical entities, and gene products in modulating the function of the GnRH receptor and its downstream signaling pathways. We focus on the sequence variant '144 G>A' and its association with the GnRH receptor, as well as the sequence variants 'P29S' and 'S75X', which show significant associations with the GnRH receptor. Additionally, the sequence variant 'alanine for proline at amino acid 286' is found to be highly prevalent in our cohort, suggesting a potential role in receptor function.   The chemical entity 'reserpine' is shown to bind to the gene product TXN2, and this interaction is further supported by an association between reserpine and the gene product BMPRIB. The gene product TXN2 also binds to ABCG2, and there is a negative correlation between ABCG2 and ROCK-I/II. The gene product AMT is found to bind to both ROCK-I/II and the GnRH receptor, with a negative correlation between AMT and ROCK-I/II, as well as between AMT and TXN2.   The chemical entity 'L-365,260' is cotreated with 'epipodophyllotoxin', and both are associated with the gene product BMPRIB. Furthermore, 'L-365,260' is also associated with 'Garcinielliptone FC', which itself is associated with the GnRH receptor. The chemical entity 'Garcinielliptone FC' is found to have a strong association with the GnRH receptor, suggesting a potential therapeutic role in modulating its activity.   The chemical entity 'buprenorphine' is used as a control in our pharmacological studies, and it is found to have no significant interaction with the GnRH receptor or its associated gene products. The chemical entity 'reserpine' is also found to have a significant association with the gene product BMPRIB, reinforcing its role in modulating receptor function.   Our findings highlight the intricate relationships between genetic variants, chemical entities, and gene products in the regulation of GnRH receptor function, providing a foundation for future therapeutic strategies targeting these interactions.
52330168	42	55	GnRH receptor	GeneOrGeneProduct	14715
52330168	275	288	GnRH receptor	GeneOrGeneProduct	14715
52330168	362	369	144 G>A	SequenceVariant	rs74315339
52330168	400	413	GnRH receptor	GeneOrGeneProduct	14715
52330168	449	453	P29S	SequenceVariant	rs2075789
52330168	460	464	S75X	SequenceVariant	p|SUB|S|75|X
52330168	512	525	GnRH receptor	GeneOrGeneProduct	14715
52330168	563	600	alanine for proline at amino acid 286	SequenceVariant	p|SUB|A|286|P
52330168	722	731	reserpine	ChemicalEntity	D012110
52330168	770	774	TXN2	GeneOrGeneProduct	25828
52330168	844	853	reserpine	ChemicalEntity	D012110
52330168	875	881	BMPRIB	GeneOrGeneProduct	12167
52330168	900	904	TXN2	GeneOrGeneProduct	25828
52330168	919	924	ABCG2	GeneOrGeneProduct	9429
52330168	970	975	ABCG2	GeneOrGeneProduct	9429
52330168	980	989	ROCK-I/II	GeneOrGeneProduct	19877
52330168	1008	1011	AMT	GeneOrGeneProduct	275
52330168	1037	1046	ROCK-I/II	GeneOrGeneProduct	19877
52330168	1055	1068	GnRH receptor	GeneOrGeneProduct	14715
52330168	1106	1109	AMT	GeneOrGeneProduct	275
52330168	1114	1123	ROCK-I/II	GeneOrGeneProduct	19877
52330168	1144	1147	AMT	GeneOrGeneProduct	275
52330168	1152	1156	TXN2	GeneOrGeneProduct	25828
52330168	1181	1190	L-365,260	ChemicalEntity	C058121
52330168	1211	1229	epipodophyllotoxin	ChemicalEntity	D011034
52330168	1278	1284	BMPRIB	GeneOrGeneProduct	12167
52330168	1300	1309	L-365,260	ChemicalEntity	C058121
52330168	1336	1355	Garcinielliptone FC	ChemicalEntity	C573355
52330168	1394	1407	GnRH receptor	GeneOrGeneProduct	14715
52330168	1430	1449	Garcinielliptone FC	ChemicalEntity	C573355
52330168	1498	1511	GnRH receptor	GeneOrGeneProduct	14715
52330168	1604	1617	buprenorphine	ChemicalEntity	D002047
52330168	1732	1745	GnRH receptor	GeneOrGeneProduct	14715
52330168	1800	1809	reserpine	ChemicalEntity	D012110
52330168	1881	1887	BMPRIB	GeneOrGeneProduct	12167
52330168	2080	2093	GnRH receptor	GeneOrGeneProduct	14715
52330168	Bind	25828	9429	Novel
52330168	Bind	275	19877	Novel
52330168	Association	rs74315339	14715	Novel
52330168	Bind	275	14715	Novel
52330168	Association	rs2075789	14715	Novel
52330168	Association	D012110	25828	Novel
52330168	Cotreatment	C058121	D011034	Novel
52330168	Negative_Correlation	19877	275	Novel
52330168	Negative_Correlation	19877	25828	Novel
52330168	Association	D012110	12167	Novel
52330168	Association	C573355	14715	Novel
52330168	Negative_Correlation	9429	19877	Novel
52330168	Association	C058121	12167	Novel
52330168	Association	C573355	C058121	Novel

93515313|t|Ba/F3 cell line responses to galactose and lamivudine in the context of IVS3+1G>A sequence variant and rDEN2 
93515313|a|This study investigates the interactions between the Ba/F3 cell line, the sequence variant IVS3+1G>A, and the chemical entities galactose and lamivudine in the context of the rDEN2 organism. The Ba/F3 cell line was exposed to varying concentrations of galactose and lamivudine, and the effects on cellular metabolism and gene expression were analyzed. The results revealed a complex interplay between these factors. A negative correlation was observed between lamivudine and galactose, suggesting that their presence may inhibit each other's metabolic pathways. Conversely, a positive correlation was found between galactose and lamivudine, indicating that they may share common metabolic routes or regulatory mechanisms. The sequence variant IVS3+1G>A showed a positive correlation with both galactose and lamivudine, suggesting that this variant may influence the expression or activity of genes involved in their metabolism. Additionally, a negative correlation was noted between IVS3+1G>A and galactose, indicating potential regulatory interactions. The conversion between lamivudine and galactose was also observed, highlighting the dynamic nature of their metabolic interconversion. The rDEN2 organism was found to be a key player in these interactions, with its taxonomic classification influencing the observed correlations. The Ba/F3 cell line served as a critical model for understanding these relationships, with multiple instances of the cell line being used to ensure reproducibility and robustness of the findings. The study underscores the importance of considering both genetic and metabolic factors in the context of the rDEN2 organism when analyzing the interactions between galactose, lamivudine, and the IVS3+1G>A sequence variant.
93515313	0	5	Ba/F3	CellLine	CVCL_0161
93515313	29	38	galactose	ChemicalEntity	D005690
93515313	43	53	lamivudine	ChemicalEntity	D019259
93515313	72	81	IVS3+1G>A	SequenceVariant	c|SUB|G|IVS3+1|A
93515313	103	108	rDEN2	OrganismTaxon	11060
93515313	163	168	Ba/F3	CellLine	CVCL_0161
93515313	201	210	IVS3+1G>A	SequenceVariant	c|SUB|G|IVS3+1|A
93515313	238	247	galactose	ChemicalEntity	D005690
93515313	252	262	lamivudine	ChemicalEntity	D019259
93515313	285	290	rDEN2	OrganismTaxon	11060
93515313	305	310	Ba/F3	CellLine	CVCL_0161
93515313	362	371	galactose	ChemicalEntity	D005690
93515313	376	386	lamivudine	ChemicalEntity	D019259
93515313	570	580	lamivudine	ChemicalEntity	D019259
93515313	585	594	galactose	ChemicalEntity	D005690
93515313	725	734	galactose	ChemicalEntity	D005690
93515313	739	749	lamivudine	ChemicalEntity	D019259
93515313	853	862	IVS3+1G>A	SequenceVariant	c|SUB|G|IVS3+1|A
93515313	903	912	galactose	ChemicalEntity	D005690
93515313	917	927	lamivudine	ChemicalEntity	D019259
93515313	1093	1102	IVS3+1G>A	SequenceVariant	c|SUB|G|IVS3+1|A
93515313	1107	1116	galactose	ChemicalEntity	D005690
93515313	1187	1197	lamivudine	ChemicalEntity	D019259
93515313	1202	1211	galactose	ChemicalEntity	D005690
93515313	1303	1308	rDEN2	OrganismTaxon	11060
93515313	1447	1452	Ba/F3	CellLine	CVCL_0161
93515313	1748	1753	rDEN2	OrganismTaxon	11060
93515313	1803	1812	galactose	ChemicalEntity	D005690
93515313	1814	1824	lamivudine	ChemicalEntity	D019259
93515313	1834	1843	IVS3+1G>A	SequenceVariant	c|SUB|G|IVS3+1|A
93515313	Negative_Correlation	D019259	D005690	Novel
93515313	Association	D005690	c|SUB|G|IVS3+1|A	Novel
93515313	Conversion	D019259	D005690	Novel
93515313	Positive_Correlation	D005690	D019259	Novel
93515313	Negative_Correlation	c|SUB|G|IVS3+1|A	D005690	Novel
93515313	Association	D019259	D005690	Novel
93515313	Positive_Correlation	c|SUB|G|IVS3+1|A	D019259	Novel
93515313	Association	D005690	D019259	Novel
93515313	Negative_Correlation	c|SUB|G|IVS3+1|A	D019259	Novel
93515313	Conversion	D005690	D019259	Novel
93515313	Association	D019259	c|SUB|G|IVS3+1|A	Novel
93515313	Positive_Correlation	D019259	D005690	Novel
93515313	Positive_Correlation	c|SUB|G|IVS3+1|A	D005690	Novel
93515313	Negative_Correlation	D005690	D019259	Novel
93515313	Positive_Correlation	D005690	c|SUB|G|IVS3+1|A	Novel
93515313	Positive_Correlation	D019259	c|SUB|G|IVS3+1|A	Novel

46348914|t|Genetic variants in IFN and their associations with NAFLD, dibucaine response, and sequence variants in MES-SA/D
46348914|a|This study investigates the complex interplay between genetic variants, disease states, and cellular responses in the context of NAFLD and dibucaine treatment. Using the MES-SA/Dx5 cell line, we examined the effects of sequence variants 192RR and V274I on the expression and function of the IFN gene product. Our findings reveal a significant association between the 192RR variant and IFN expression, as well as a strong positive correlation between NAFLD and the 192RR variant. Additionally, we observed a direct association between V274I and 192RR, suggesting a potential functional link between these sequence variants. The V274I variant was also found to be associated with IFN, further supporting the role of these genetic changes in modulating immune responses. Notably, dibucaine showed a positive correlation with IFN levels, indicating a possible therapeutic role in NAFLD management. These results were consistently observed across multiple experiments using the MES-SA/Dx5 cell line, with all findings replicated in at least three independent trials. The data suggest that the interplay between these genetic variants and the IFN pathway may represent a novel target for the treatment of NAFLD and related conditions.
46348914	20	23	IFN	GeneOrGeneProduct	3439
46348914	52	57	NAFLD	DiseaseOrPhenotypicFeature	D065626
46348914	59	68	dibucaine	ChemicalEntity	D003992
46348914	242	247	NAFLD	DiseaseOrPhenotypicFeature	D065626
46348914	252	261	dibucaine	ChemicalEntity	D003992
46348914	283	293	MES-SA/Dx5	CellLine	CVCL_2598
46348914	350	355	192RR	SequenceVariant	p|Allele|R|192
46348914	360	365	V274I	SequenceVariant	rs2235371
46348914	404	407	IFN	GeneOrGeneProduct	3439
46348914	480	485	192RR	SequenceVariant	p|Allele|R|192
46348914	498	501	IFN	GeneOrGeneProduct	3439
46348914	563	568	NAFLD	DiseaseOrPhenotypicFeature	D065626
46348914	577	582	192RR	SequenceVariant	p|Allele|R|192
46348914	647	652	V274I	SequenceVariant	rs2235371
46348914	657	662	192RR	SequenceVariant	p|Allele|R|192
46348914	740	745	V274I	SequenceVariant	rs2235371
46348914	791	794	IFN	GeneOrGeneProduct	3439
46348914	890	899	dibucaine	ChemicalEntity	D003992
46348914	935	938	IFN	GeneOrGeneProduct	3439
46348914	989	994	NAFLD	DiseaseOrPhenotypicFeature	D065626
46348914	1086	1096	MES-SA/Dx5	CellLine	CVCL_2598
46348914	1250	1253	IFN	GeneOrGeneProduct	3439
46348914	1312	1317	NAFLD	DiseaseOrPhenotypicFeature	D065626
46348914	Association	p|Allele|R|192	3439	Novel
46348914	Association	p|Allele|R|192	rs2235371	Novel
46348914	Positive_Correlation	D065626	p|Allele|R|192	Novel
46348914	Association	rs2235371	p|Allele|R|192	Novel
46348914	Positive_Correlation	D003992	3439	Novel
46348914	Positive_Correlation	D065626	rs2235371	Novel
46348914	Association	rs2235371	3439	Novel

58327505|t|Genetic variants in hRPTEC cells and their associations with Autosomal dominant cerebellar ataxia, A-T, and sequence 
58327505|a|This study investigates the functional and genetic associations between sequence variants in hRPTEC cells and the neurodegenerative diseases Autosomal dominant cerebellar ataxia and A-T. We analyzed multiple sequence variants, including arginine 555-to-tryptophan, P407Q, and p.A384D, in hRPTEC cell lines to determine their potential roles in disease pathogenesis. Our findings reveal a complex interplay between these variants and the two diseases.   The association between Autosomal dominant cerebellar ataxia and arginine 555-to-tryptophan is supported by multiple lines of evidence, including functional assays and genetic linkage studies. However, a negative correlation between arginine 555-to-tryptophan and Autosomal dominant cerebellar ataxia was also observed, suggesting a dual role for this variant. Similarly, a positive correlation between arginine 555-to-tryptophan and A-T was noted, while a negative correlation was found between arginine 555-to-tryptophan and A-T, indicating that the variant may have context-dependent effects.  The sequence variant P407Q showed a strong association with both Autosomal dominant cerebellar ataxia and A-T. However, the relationship between P407Q and Autosomal dominant cerebellar ataxia was both positive and negative, depending on the genetic background and cellular context. This variant also exhibited a positive correlation with A-T, but a negative correlation with Autosomal dominant cerebellar ataxia, highlighting the complexity of its role in disease.  The variant p.A384D was found to be associated with both Autosomal dominant cerebellar ataxia and A-T. A positive correlation between p.A384D and Autosomal dominant cerebellar ataxia was observed, while a negative correlation was noted between p.A384D and A-T. Additionally, a negative correlation between p.A384D and Autosomal dominant cerebellar ataxia was also detected, suggesting that this variant may have opposing effects in different disease contexts.  Overall, our results demonstrate that the hRPTEC cell line serves as a valuable model for studying the genetic and functional relationships between sequence variants and neurodegenerative diseases. The findings underscore the importance of considering both positive and negative correlations when interpreting the role of genetic variants in disease pathogenesis.
58327505	20	26	hRPTEC	CellLine	CVCL_K278
58327505	61	97	Autosomal dominant cerebellar ataxia	DiseaseOrPhenotypicFeature	OMIM:604121
58327505	99	102	A-T	DiseaseOrPhenotypicFeature	D001260
58327505	211	217	hRPTEC	CellLine	CVCL_K278
58327505	259	295	Autosomal dominant cerebellar ataxia	DiseaseOrPhenotypicFeature	OMIM:604121
58327505	300	303	A-T	DiseaseOrPhenotypicFeature	D001260
58327505	355	381	arginine 555-to-tryptophan	SequenceVariant	rs121909208
58327505	383	388	P407Q	SequenceVariant	rs115099192
58327505	394	401	p.A384D	SequenceVariant	p|SUB|A|384|D
58327505	406	412	hRPTEC	CellLine	CVCL_K278
58327505	595	631	Autosomal dominant cerebellar ataxia	DiseaseOrPhenotypicFeature	OMIM:604121
58327505	636	662	arginine 555-to-tryptophan	SequenceVariant	rs121909208
58327505	804	830	arginine 555-to-tryptophan	SequenceVariant	rs121909208
58327505	835	871	Autosomal dominant cerebellar ataxia	DiseaseOrPhenotypicFeature	OMIM:604121
58327505	974	1000	arginine 555-to-tryptophan	SequenceVariant	rs121909208
58327505	1005	1008	A-T	DiseaseOrPhenotypicFeature	D001260
58327505	1067	1093	arginine 555-to-tryptophan	SequenceVariant	rs121909208
58327505	1098	1101	A-T	DiseaseOrPhenotypicFeature	D001260
58327505	1189	1194	P407Q	SequenceVariant	rs115099192
58327505	1233	1269	Autosomal dominant cerebellar ataxia	DiseaseOrPhenotypicFeature	OMIM:604121
58327505	1274	1277	A-T	DiseaseOrPhenotypicFeature	D001260
58327505	1313	1318	P407Q	SequenceVariant	rs115099192
58327505	1323	1359	Autosomal dominant cerebellar ataxia	DiseaseOrPhenotypicFeature	OMIM:604121
58327505	1506	1509	A-T	DiseaseOrPhenotypicFeature	D001260
58327505	1543	1579	Autosomal dominant cerebellar ataxia	DiseaseOrPhenotypicFeature	OMIM:604121
58327505	1646	1653	p.A384D	SequenceVariant	p|SUB|A|384|D
58327505	1691	1727	Autosomal dominant cerebellar ataxia	DiseaseOrPhenotypicFeature	OMIM:604121
58327505	1732	1735	A-T	DiseaseOrPhenotypicFeature	D001260
58327505	1768	1775	p.A384D	SequenceVariant	p|SUB|A|384|D
58327505	1780	1816	Autosomal dominant cerebellar ataxia	DiseaseOrPhenotypicFeature	OMIM:604121
58327505	1878	1885	p.A384D	SequenceVariant	p|SUB|A|384|D
58327505	1890	1893	A-T	DiseaseOrPhenotypicFeature	D001260
58327505	1940	1947	p.A384D	SequenceVariant	p|SUB|A|384|D
58327505	1952	1988	Autosomal dominant cerebellar ataxia	DiseaseOrPhenotypicFeature	OMIM:604121
58327505	2137	2143	hRPTEC	CellLine	CVCL_K278
58327505	Association	D001260	rs115099192	Novel
58327505	Association	OMIM:604121	rs121909208	Novel
58327505	Association	D001260	p|SUB|A|384|D	Novel
58327505	Association	OMIM:604121	rs115099192	Novel
58327505	Positive_Correlation	rs115099192	D001260	Novel
58327505	Negative_Correlation	rs115099192	D001260	Novel
58327505	Negative_Correlation	p|SUB|A|384|D	OMIM:604121	Novel
58327505	Negative_Correlation	p|SUB|A|384|D	D001260	Novel
58327505	Positive_Correlation	p|SUB|A|384|D	OMIM:604121	Novel
58327505	Negative_Correlation	rs121909208	OMIM:604121	Novel
58327505	Positive_Correlation	rs121909208	D001260	Novel
58327505	Association	D001260	rs121909208	Novel
58327505	Negative_Correlation	rs121909208	D001260	Novel
58327505	Positive_Correlation	p|SUB|A|384|D	D001260	Novel
58327505	Positive_Correlation	rs115099192	OMIM:604121	Novel
58327505	Negative_Correlation	rs115099192	OMIM:604121	Novel
58327505	Association	OMIM:604121	p|SUB|A|384|D	Novel
58327505	Positive_Correlation	rs121909208	OMIM:604121	Novel

36306752|t|L-asparaginase, prostanoids, and MPTP: molecular interactions and their implications in lumbar disc disease, chronic allograft nephropathy, and visual halluc
36306752|a|Recent studies have uncovered complex molecular interactions involving L-asparaginase, prostanoids, and MPTP, with significant implications for the pathogenesis of lumbar disc disease, chronic allograft nephropathy, and visual hallucinations. L-asparaginase has been shown to bind to HGD and annexin V, and its association with FoxP3 and Keratin 12 suggests a role in immune regulation and structural integrity. Additionally, L-asparaginase cotreatments with prostanoids and MPTP have been explored in experimental models, revealing potential therapeutic applications. Prostanoids, in turn, bind to Keratin 12 and associate with annexin V, further linking them to cellular processes involved in tissue repair and inflammation. MPTP exhibits binding interactions with annexin V and Keratin 12, and its cotreatment with prostanoids and L-asparaginase has been associated with altered disease progression in models of chronic allograft nephropathy and visual hallucinations. These findings highlight the intricate network of molecular relationships that may contribute to the development and progression of lumbar disc disease and other phenotypic features such as infertility and IS. Further research is needed to fully elucidate the mechanisms underlying these interactions and their clinical relevance.
36306752	0	14	L-asparaginase	ChemicalEntity	D001215
36306752	16	26	prostanoid	ChemicalEntity	D011453
36306752	33	37	MPTP	ChemicalEntity	D015632
36306752	88	107	lumbar disc disease	DiseaseOrPhenotypicFeature	C535531
36306752	109	138	chronic allograft nephropathy	DiseaseOrPhenotypicFeature	D051436
36306752	229	243	L-asparaginase	ChemicalEntity	D001215
36306752	245	255	prostanoid	ChemicalEntity	D011453
36306752	262	266	MPTP	ChemicalEntity	D015632
36306752	322	341	lumbar disc disease	DiseaseOrPhenotypicFeature	C535531
36306752	343	372	chronic allograft nephropathy	DiseaseOrPhenotypicFeature	D051436
36306752	378	399	visual hallucinations	DiseaseOrPhenotypicFeature	D006212
36306752	401	415	L-asparaginase	ChemicalEntity	D001215
36306752	442	445	HGD	GeneOrGeneProduct	3081
36306752	450	459	annexin V	GeneOrGeneProduct	308
36306752	486	491	FoxP3	GeneOrGeneProduct	50943
36306752	496	506	Keratin 12	GeneOrGeneProduct	268482
36306752	584	598	L-asparaginase	ChemicalEntity	D001215
36306752	617	627	prostanoid	ChemicalEntity	D011453
36306752	633	637	MPTP	ChemicalEntity	D015632
36306752	757	767	Keratin 12	GeneOrGeneProduct	268482
36306752	787	796	annexin V	GeneOrGeneProduct	308
36306752	885	889	MPTP	ChemicalEntity	D015632
36306752	925	934	annexin V	GeneOrGeneProduct	308
36306752	939	949	Keratin 12	GeneOrGeneProduct	268482
36306752	976	986	prostanoid	ChemicalEntity	D011453
36306752	992	1006	L-asparaginase	ChemicalEntity	D001215
36306752	1073	1102	chronic allograft nephropathy	DiseaseOrPhenotypicFeature	D051436
36306752	1107	1128	visual hallucinations	DiseaseOrPhenotypicFeature	D006212
36306752	1262	1281	lumbar disc disease	DiseaseOrPhenotypicFeature	C535531
36306752	1320	1331	infertility	DiseaseOrPhenotypicFeature	D007247
36306752	1336	1338	IS	DiseaseOrPhenotypicFeature	D002544
36306752	Association	D015632	308	Novel
36306752	Bind	D001215	3081	Novel
36306752	Cotreatment	D011453	D001215	Novel
36306752	Cotreatment	D001215	D015632	Novel
36306752	Bind	D015632	268482	Novel
36306752	Bind	D001215	268482	Novel
36306752	Bind	D001215	308	Novel
36306752	Association	D001215	3081	Novel
36306752	Bind	D011453	268482	Novel
36306752	Association	D011453	308	Novel
36306752	Cotreatment	D015632	D011453	Novel
36306752	Cotreatment	D001215	D011453	Novel
36306752	Bind	D015632	308	Novel
36306752	Association	D001215	50943	Novel
36306752	Association	D011453	268482	Novel
36306752	Association	D001215	268482	Novel

14086103|t|DUCaP cell line and sequence variants in the context of ALD, IL-1beta, Wnt, Spred1, and TRK signaling 
14086103|a|Recent studies have highlighted the complex interplay between genetic variants, cellular signaling pathways, and disease phenotypes in the DUCaP cell line. This research investigates the role of sequence variants such as 521T>C, 111G, and rs5966709 in modulating the expression and function of key genes like nAchR, IL-1beta, Wnt, Spred1, and TRK. The DUCaP cell line, known for its relevance in neurodegenerative disease models, was used to assess the impact of these genetic variations on cellular responses.   A significant positive correlation was observed between IL-1beta and attention-deficit/hyperactivity disorder (ADHD), suggesting a potential role for this cytokine in the pathophysiology of ADHD. Furthermore, the association between AQP4 and autosomal recessive disorder of galactose metabolism was confirmed through functional assays, indicating a possible involvement of AQP4 in the transport mechanisms affected by this disorder.   The study also demonstrated that nAchR is associated with death in the DUCaP cell line, possibly through its role in apoptosis or neurodegeneration. Additionally, AQP4 was found to bind to TRK, and Wnt was shown to bind to TRK, suggesting that these interactions may be critical in regulating cell survival and differentiation.   Notably, TRK was also associated with ADHD, reinforcing the idea that TRK signaling pathways are implicated in the development of this neurodevelopmental disorder. The DUCaP cell line was also used to examine the effects of the sequence variant Cys 23-Ser 23, which was found to influence the expression of multiple genes, including Wnt and Spred1.   These findings provide new insights into the molecular mechanisms underlying various diseases and highlight the importance of genetic variability in shaping cellular responses. The SMMC-7721 cell line was also included as a control to ensure the specificity of the observed effects. Overall, this study underscores the value of integrating genetic, cellular, and functional data to better understand the complex relationships between genes, proteins, and disease phenotypes.
14086103	0	5	DUCaP	CellLine	CVCL_2025
14086103	56	59	ALD	DiseaseOrPhenotypicFeature	D000326
14086103	61	69	IL-1beta	GeneOrGeneProduct	16176
14086103	71	74	Wnt	GeneOrGeneProduct	7474
14086103	76	82	Spred1	GeneOrGeneProduct	114715
14086103	88	91	TRK	GeneOrGeneProduct	4914
14086103	242	247	DUCaP	CellLine	CVCL_2025
14086103	324	330	521T>C	SequenceVariant	c|SUB|T|521|C
14086103	332	336	111G	SequenceVariant	c|Allele|G|111
14086103	342	351	rs5966709	SequenceVariant	rs5966709
14086103	412	417	nAchR	GeneOrGeneProduct	11441
14086103	419	427	IL-1beta	GeneOrGeneProduct	16176
14086103	429	432	Wnt	GeneOrGeneProduct	7474
14086103	434	440	Spred1	GeneOrGeneProduct	114715
14086103	446	449	TRK	GeneOrGeneProduct	4914
14086103	455	460	DUCaP	CellLine	CVCL_2025
14086103	672	680	IL-1beta	GeneOrGeneProduct	16176
14086103	685	725	attention-deficit/hyperactivity disorder	DiseaseOrPhenotypicFeature	D001289
14086103	849	853	AQP4	GeneOrGeneProduct	361
14086103	858	910	autosomal recessive disorder of galactose metabolism	DiseaseOrPhenotypicFeature	D005693
14086103	989	993	AQP4	GeneOrGeneProduct	361
14086103	1084	1089	nAchR	GeneOrGeneProduct	11441
14086103	1109	1114	death	DiseaseOrPhenotypicFeature	D003643
14086103	1122	1127	DUCaP	CellLine	CVCL_2025
14086103	1214	1218	AQP4	GeneOrGeneProduct	361
14086103	1240	1243	TRK	GeneOrGeneProduct	4914
14086103	1249	1252	Wnt	GeneOrGeneProduct	7474
14086103	1274	1277	TRK	GeneOrGeneProduct	4914
14086103	1390	1393	TRK	GeneOrGeneProduct	4914
14086103	1451	1454	TRK	GeneOrGeneProduct	4914
14086103	1549	1554	DUCaP	CellLine	CVCL_2025
14086103	1626	1639	Cys 23-Ser 23	SequenceVariant	rs6318
14086103	1714	1717	Wnt	GeneOrGeneProduct	7474
14086103	1722	1728	Spred1	GeneOrGeneProduct	114715
14086103	1913	1922	SMMC-7721	CellLine	CVCL_0534
14086103	Positive_Correlation	16176	D001289	Novel
14086103	Association	361	D005693	Novel
14086103	Association	11441	D003643	Novel
14086103	Bind	361	4914	Novel
14086103	Bind	7474	4914	Novel
14086103	Association	4914	D001289	Novel

98435471|t|Dengue virus type 2 and Ishikawa cell line interactions: effects of sequence variants, anisomycin, anti-inflammatory drugs, and T allele at -31 on T-cell leukaemia or lymphoma and jo
98435471|a|This study investigates the complex interactions between dengue virus type 2, Ishikawa cell lines, and various genetic and pharmacological factors in the context of T-cell leukaemia or lymphoma and joint pain. The research focuses on the role of the sequence variant 2172_2173insCCCC and its positive correlation with Apamin, as well as the association between the T allele at -31 and joint pain. Additionally, the study explores the positive correlation between anti-inflammatory drugs and Apamin, and the cotreatment of anisomycin with anti-inflammatory drugs.   The findings reveal a significant positive correlation between anti-inflammatory drugs and Apamin, as well as between anti-inflammatory drugs and anisomycin. These results are further supported by the cotreatment of anisomycin and anti-inflammatory drugs, which was observed in multiple experimental conditions. The positive correlation between Apamin and anisomycin was also confirmed through in vitro assays using Ishikawa cell lines.   The T allele at -31 was found to be strongly associated with joint pain, particularly in the context of dengue virus type 2 infection. This association was further reinforced by the positive correlation between the T allele at -31 and anti-inflammatory drugs, suggesting a potential therapeutic target for managing joint pain in affected individuals.   The study also examined the impact of the sequence variant 2172_2173insCCCC on the expression of Apamin in Ishikawa cells, demonstrating a clear positive correlation. Furthermore, the role of yeast in modulating these interactions was explored, with seven instances of yeast being identified as a key factor in the experimental setup.   The results highlight the intricate relationships between genetic variants, pharmacological agents, and cellular responses in the context of dengue virus type 2 and T-cell leukaemia or lymphoma. The repeated use of Ishikawa and HL-7702 cell lines, along with the multiple instances of dengue virus type 2 and yeast, underscores the comprehensive nature of this investigation into the molecular mechanisms underlying these conditions.
98435471	24	32	Ishikawa	CellLine	CVCL_2529
98435471	87	97	anisomycin	ChemicalEntity	D000841
98435471	99	122	anti-inflammatory drugs	ChemicalEntity	D000893
98435471	128	143	T allele at -31	SequenceVariant	rs1143627
98435471	147	175	T-cell leukaemia or lymphoma	DiseaseOrPhenotypicFeature	D015458|D016399
98435471	240	259	dengue virus type 2	OrganismTaxon	11060
98435471	261	269	Ishikawa	CellLine	CVCL_2529
98435471	348	376	T-cell leukaemia or lymphoma	DiseaseOrPhenotypicFeature	D015458|D016399
98435471	381	391	joint pain	DiseaseOrPhenotypicFeature	D018771
98435471	450	466	2172_2173insCCCC	SequenceVariant	c|INS|2172_2173|CCCC
98435471	501	507	Apamin	ChemicalEntity	D001030
98435471	548	563	T allele at -31	SequenceVariant	rs1143627
98435471	568	578	joint pain	DiseaseOrPhenotypicFeature	D018771
98435471	646	669	anti-inflammatory drugs	ChemicalEntity	D000893
98435471	674	680	Apamin	ChemicalEntity	D001030
98435471	705	715	anisomycin	ChemicalEntity	D000841
98435471	721	744	anti-inflammatory drugs	ChemicalEntity	D000893
98435471	811	834	anti-inflammatory drugs	ChemicalEntity	D000893
98435471	839	845	Apamin	ChemicalEntity	D001030
98435471	866	889	anti-inflammatory drugs	ChemicalEntity	D000893
98435471	894	904	anisomycin	ChemicalEntity	D000841
98435471	964	974	anisomycin	ChemicalEntity	D000841
98435471	979	1002	anti-inflammatory drugs	ChemicalEntity	D000893
98435471	1093	1099	Apamin	ChemicalEntity	D001030
98435471	1104	1114	anisomycin	ChemicalEntity	D000841
98435471	1164	1172	Ishikawa	CellLine	CVCL_2529
98435471	1191	1206	T allele at -31	SequenceVariant	rs1143627
98435471	1248	1258	joint pain	DiseaseOrPhenotypicFeature	D018771
98435471	1291	1310	dengue virus type 2	OrganismTaxon	11060
98435471	1402	1417	T allele at -31	SequenceVariant	rs1143627
98435471	1422	1445	anti-inflammatory drugs	ChemicalEntity	D000893
98435471	1502	1512	joint pain	DiseaseOrPhenotypicFeature	D018771
98435471	1599	1615	2172_2173insCCCC	SequenceVariant	c|INS|2172_2173|CCCC
98435471	1637	1643	Apamin	ChemicalEntity	D001030
98435471	1647	1655	Ishikawa	CellLine	CVCL_2529
98435471	1732	1737	yeast	OrganismTaxon	4932
98435471	1809	1814	yeast	OrganismTaxon	4932
98435471	2018	2037	dengue virus type 2	OrganismTaxon	11060
98435471	2042	2070	T-cell leukaemia or lymphoma	DiseaseOrPhenotypicFeature	D015458|D016399
98435471	2092	2100	Ishikawa	CellLine	CVCL_2529
98435471	2105	2112	HL-7702	CellLine	CVCL_6926
98435471	2162	2181	dengue virus type 2	OrganismTaxon	11060
98435471	2186	2191	yeast	OrganismTaxon	4932
98435471	Positive_Correlation	D000893	D001030	Novel
98435471	Association	rs1143627	D018771	Novel
98435471	Cotreatment	D000841	D000893	Novel
98435471	Positive_Correlation	D001030	D000841	Novel
98435471	Positive_Correlation	rs1143627	D000893	Novel
98435471	Cotreatment	D000893	D000841	Novel
98435471	Cotreatment	D001030	D000893	Novel
98435471	Positive_Correlation	D000893	D000841	Novel
98435471	Positive_Correlation	c|INS|2172_2173|CCCC	D001030	Novel

64123153|t|CXCL5 dynamics in chick models: interactions with organochloride, EGTA, and Hs578T ce
64123153|a|This study investigates the complex interactions between the chemokine CXCL5 and various environmental and cellular factors in chick and Hs578T cell line models. We observed a positive correlation between CXCL5 expression and organochloride levels in chick tissues, suggesting a potential role for organochloride in modulating CXCL5 activity. Conversely, a negative correlation was found between CXCL5 and EGTA in chick-derived cell cultures, indicating that EGTA may inhibit CXCL5 signaling. However, in Hs578T cell lines, a positive correlation between CXCL5 and EGTA was noted, highlighting the context-dependent nature of these interactions. The presence of multiple EGTA molecules in the experimental setup further supported the dual role of EGTA in modulating CXCL5 expression. Additionally, the high frequency of organochloride exposure in chick environments was associated with increased CXCL5 levels, reinforcing the negative correlation between these two entities. The study also revealed that Hs578T cells, when exposed to varying concentrations of EGTA and organochloride, exhibited distinct patterns of CXCL5 expression, underscoring the importance of these chemical entities in cellular responses. These findings provide critical insights into the regulatory mechanisms governing CXCL5 in both chick and human cell line models, with implications for understanding inflammatory and immune responses in the presence of environmental toxins.
64123153	0	5	CXCL5	GeneOrGeneProduct	6374
64123153	18	23	chick	OrganismTaxon	9031
64123153	50	64	organochloride	ChemicalEntity	D006843
64123153	66	70	EGTA	ChemicalEntity	D004533
64123153	76	82	Hs578T	CellLine	CVCL_0332
64123153	157	162	CXCL5	GeneOrGeneProduct	6374
64123153	213	218	chick	OrganismTaxon	9031
64123153	223	229	Hs578T	CellLine	CVCL_0332
64123153	291	296	CXCL5	GeneOrGeneProduct	6374
64123153	312	326	organochloride	ChemicalEntity	D006843
64123153	337	342	chick	OrganismTaxon	9031
64123153	384	398	organochloride	ChemicalEntity	D006843
64123153	413	418	CXCL5	GeneOrGeneProduct	6374
64123153	482	487	CXCL5	GeneOrGeneProduct	6374
64123153	492	496	EGTA	ChemicalEntity	D004533
64123153	500	505	chick	OrganismTaxon	9031
64123153	545	549	EGTA	ChemicalEntity	D004533
64123153	562	567	CXCL5	GeneOrGeneProduct	6374
64123153	591	597	Hs578T	CellLine	CVCL_0332
64123153	641	646	CXCL5	GeneOrGeneProduct	6374
64123153	651	655	EGTA	ChemicalEntity	D004533
64123153	757	761	EGTA	ChemicalEntity	D004533
64123153	833	837	EGTA	ChemicalEntity	D004533
64123153	852	857	CXCL5	GeneOrGeneProduct	6374
64123153	906	920	organochloride	ChemicalEntity	D006843
64123153	933	938	chick	OrganismTaxon	9031
64123153	982	987	CXCL5	GeneOrGeneProduct	6374
64123153	1090	1096	Hs578T	CellLine	CVCL_0332
64123153	1146	1150	EGTA	ChemicalEntity	D004533
64123153	1155	1169	organochloride	ChemicalEntity	D006843
64123153	1202	1207	CXCL5	GeneOrGeneProduct	6374
64123153	1380	1385	CXCL5	GeneOrGeneProduct	6374
64123153	1394	1399	chick	OrganismTaxon	9031
64123153	Negative_Correlation	6374	D006843	Novel
64123153	Negative_Correlation	6374	D004533	Novel
64123153	Positive_Correlation	6374	D004533	Novel
64123153	Positive_Correlation	6374	D006843	Novel

37273265|t|Genetic Variants and Phenotypic Associations in Neurological Disorders and Radiation 
37273265|a|This study investigates the genetic and phenotypic associations of specific sequence variants and their implications in neurological disorders and radiation injury. We focus on the sequence variant T2734C, which shows a positive correlation with glioblastoma and a negative correlation with X-linked intellectual disability. Additionally, T2734C is associated with arginine 714 and p.G204VfsX28, highlighting its role in multiple biological pathways. The sequence variant -134delA is negatively correlated with glioblastoma and radiation injury, suggesting a protective effect against these conditions. Furthermore, there is a positive correlation between X-linked intellectual disability and arginine 714, reinforcing the complex interplay between genetic variants and phenotypic outcomes. The study also examines the cell lines MCF-7, PA-1, CA3, MEF, and MC3T3-E1, which are used to model the effects of these genetic variants in different cellular contexts. The organism taxa rhesus monkeys, Drosophila, Spirulina, Mangifera indica Linn, DEN-2, Toxorynchites mosquitoes, and cats are included to provide a broader understanding of the biological relevance of these associations across species. The findings underscore the importance of genetic variability in disease susceptibility and response to environmental stressors such as radiation.
37273265	233	249	radiation injury	DiseaseOrPhenotypicFeature	D011832
37273265	284	290	T2734C	SequenceVariant	c|SYB|T2734|C
37273265	332	344	glioblastoma	DiseaseOrPhenotypicFeature	D005909
37273265	377	409	X-linked intellectual disability	DiseaseOrPhenotypicFeature	D038901
37273265	425	431	T2734C	SequenceVariant	c|SYB|T2734|C
37273265	451	463	arginine 714	SequenceVariant	c|Allele|R|714
37273265	468	480	p.G204VfsX28	SequenceVariant	p|FS|G|204|V|28
37273265	558	566	-134delA	SequenceVariant	rs1800997
37273265	597	609	glioblastoma	DiseaseOrPhenotypicFeature	D005909
37273265	614	630	radiation injury	DiseaseOrPhenotypicFeature	D011832
37273265	742	774	X-linked intellectual disability	DiseaseOrPhenotypicFeature	D038901
37273265	779	791	arginine 714	SequenceVariant	c|Allele|R|714
37273265	916	921	MCF-7	CellLine	CVCL_0031
37273265	923	927	PA-1	CellLine	CVCL_0479
37273265	929	932	CA3	CellLine	CVCL_JW73
37273265	934	937	MEF	CellLine	CVCL_9115
37273265	943	951	MC3T3-E1	CellLine	CVCL_0409
37273265	1065	1079	rhesus monkeys	OrganismTaxon	9544
37273265	1081	1091	Drosophila	OrganismTaxon	7227
37273265	1093	1102	Spirulina	OrganismTaxon	551299
37273265	1104	1125	Mangifera indica Linn	OrganismTaxon	29780
37273265	1127	1132	DEN-2	OrganismTaxon	11060
37273265	1134	1158	Toxorynchites mosquitoes	OrganismTaxon	2498889
37273265	1164	1168	cats	OrganismTaxon	9685
37273265	Positive_Correlation	D038901	c|SYB|T2734|C	Novel
37273265	Negative_Correlation	rs1800997	D005909	Novel
37273265	Negative_Correlation	c|SYB|T2734|C	D038901	Novel
37273265	Association	c|SYB|T2734|C	c|Allele|R|714	Novel
37273265	Positive_Correlation	D005909	rs1800997	Novel
37273265	Association	c|SYB|T2734|C	p|FS|G|204|V|28	Novel
37273265	Association	c|Allele|R|714	p|FS|G|204|V|28	Novel
37273265	Positive_Correlation	D005909	c|SYB|T2734|C	Novel
37273265	Association	p|FS|G|204|V|28	c|SYB|T2734|C	Novel
37273265	Negative_Correlation	rs1800997	D011832	Novel
37273265	Positive_Correlation	D038901	c|Allele|R|714	Novel
37273265	Association	p|FS|G|204|V|28	c|Allele|R|714	Novel

22967458|t|Capan1 cell line and synaptotagmin interactions in the context of HPVs and sequence variants G12D and g
22967458|a|The Capan1 cell line, a well-characterized model for pancreatic cancer, was used to investigate the functional interactions between synaptotagmin, Wnt signaling, and the sequence variants G12D and g.2839T>G. Our study revealed a significant association between synaptotagmin and Wnt, with Wnt acting as a key mediator in the regulation of synaptotagmin expression. Additionally, we observed a strong correlation between the sequence variants G12D and g.2839T>G, suggesting a potential genetic linkage between these two variants. The Capan1 cell line was also found to exhibit a notable association between PAK2 and Wnt, as well as between PAK2 and synaptotagmin, indicating a complex regulatory network involving these proteins. Furthermore, the interaction between synaptotagmin and PAK2 was confirmed through multiple experimental approaches, including co-immunoprecipitation and Western blot analysis. The presence of HPVs in the Capan1 cell line was associated with altered expression levels of both synaptotagmin and Wnt, highlighting the role of viral infection in modulating these pathways. Our findings provide new insights into the molecular mechanisms underlying the interactions between synaptotagmin, Wnt, PAK2, and the sequence variants G12D and g.2839T>G in the context of HPVs and the Capan1 cell line.
22967458	0	6	Capan1	CellLine	CVCL_0237
22967458	21	34	synaptotagmin	GeneOrGeneProduct	255928
22967458	66	70	HPVs	OrganismTaxon	10566
22967458	93	97	G12D	SequenceVariant	p|SUB|G|12|D
22967458	108	114	Capan1	CellLine	CVCL_0237
22967458	236	249	synaptotagmin	GeneOrGeneProduct	255928
22967458	251	254	Wnt	GeneOrGeneProduct	22408
22967458	292	296	G12D	SequenceVariant	p|SUB|G|12|D
22967458	301	310	g.2839T>G	SequenceVariant	g|SUB|T|2839|G
22967458	365	378	synaptotagmin	GeneOrGeneProduct	255928
22967458	383	386	Wnt	GeneOrGeneProduct	22408
22967458	393	396	Wnt	GeneOrGeneProduct	22408
22967458	443	456	synaptotagmin	GeneOrGeneProduct	255928
22967458	546	550	G12D	SequenceVariant	p|SUB|G|12|D
22967458	555	564	g.2839T>G	SequenceVariant	g|SUB|T|2839|G
22967458	637	643	Capan1	CellLine	CVCL_0237
22967458	710	714	PAK2	GeneOrGeneProduct	29432
22967458	719	722	Wnt	GeneOrGeneProduct	22408
22967458	743	747	PAK2	GeneOrGeneProduct	29432
22967458	752	765	synaptotagmin	GeneOrGeneProduct	255928
22967458	870	883	synaptotagmin	GeneOrGeneProduct	255928
22967458	888	892	PAK2	GeneOrGeneProduct	29432
22967458	1025	1029	HPVs	OrganismTaxon	10566
22967458	1037	1043	Capan1	CellLine	CVCL_0237
22967458	1108	1121	synaptotagmin	GeneOrGeneProduct	255928
22967458	1126	1129	Wnt	GeneOrGeneProduct	22408
22967458	1302	1315	synaptotagmin	GeneOrGeneProduct	255928
22967458	1317	1320	Wnt	GeneOrGeneProduct	22408
22967458	1322	1326	PAK2	GeneOrGeneProduct	29432
22967458	1354	1358	G12D	SequenceVariant	p|SUB|G|12|D
22967458	1363	1372	g.2839T>G	SequenceVariant	g|SUB|T|2839|G
22967458	1391	1395	HPVs	OrganismTaxon	10566
22967458	1404	1410	Capan1	CellLine	CVCL_0237
22967458	Association	29432	22408	Novel
22967458	Association	22408	255928	Novel
22967458	Association	22408	29432	Novel
22967458	Association	p|SUB|G|12|D	g|SUB|T|2839|G	Novel
22967458	Association	29432	255928	Novel
22967458	Association	255928	22408	Novel
22967458	Association	g|SUB|T|2839|G	p|SUB|G|12|D	Novel
22967458	Association	255928	29432	Novel

77910890|t|DEPTOR and c-Jun N-terminal kinase interactions in diverse cell lines and organisms: implications for gene regulation and immune r
77910890|a|This study investigates the molecular interactions between DEPTOR and c-Jun N-terminal kinase (JNK) across multiple cell lines and organisms, with a focus on their regulatory roles in cellular signaling and immune responses. Using a combination of biochemical assays and transcriptomic profiling, we observed a positive correlation between JNK and Mad2, suggesting a potential role for JNK in mitotic regulation. Additionally, we found a negative correlation between C2 and Mad2, indicating a possible antagonistic relationship between these two proteins.   The association between C2 and JNK was further supported by co-immunoprecipitation experiments, highlighting a potential functional link between these two gene products. Notably, we also identified a negative correlation between PEMT and CD4, which was corroborated by gene expression analysis in multiple cell lines, including DUCaP and SJ-GBM2. This finding suggests a regulatory relationship between PEMT and the CD4 receptor, possibly influencing immune cell function.  In parallel, we observed a negative correlation between C2 and PEMT, which was further validated by binding assays showing direct interaction between nuclear factor kappa B (NF-B) and PEMT. This interaction may play a role in the regulation of PEMT activity in response to inflammatory signals. Furthermore, we found a positive correlation between FoxP3 and CD4, consistent with the known role of FoxP3 in the regulation of regulatory T cells.   The study also included a detailed analysis of the relationship between FoxP3 and C2, revealing a binding interaction that may contribute to the modulation of immune responses. Our findings were validated across multiple organisms, including horses, tobacco, and zebrafish, as well as in cell lines such as hRPTEC, 293T, and Ishikawa.   In addition to these findings, we examined the expression of the gene product Ubiquitin carboxyl-terminal esterase L1 in various cell lines, including LNCaP and SMMC-7721, and found no significant correlation with the other gene products studied. The study also included an analysis of the gene product MAP9 in the context of the organism Rhodiola rosea, suggesting potential applications in plant-based therapeutic strategies.  Overall, this work provides a comprehensive understanding of the molecular interactions between DEPTOR, JNK, C2, PEMT, and FoxP3, with implications for both cellular signaling and immune regulation across diverse biological systems.
77910890	0	6	DEPTOR	GeneOrGeneProduct	97998
77910890	11	34	c-Jun N-terminal kinase	GeneOrGeneProduct	116554
77910890	190	196	DEPTOR	GeneOrGeneProduct	97998
77910890	201	224	c-Jun N-terminal kinase	GeneOrGeneProduct	116554
77910890	479	483	Mad2	GeneOrGeneProduct	56150
77910890	598	600	C2	GeneOrGeneProduct	717
77910890	605	609	Mad2	GeneOrGeneProduct	56150
77910890	713	715	C2	GeneOrGeneProduct	717
77910890	918	922	PEMT	GeneOrGeneProduct	10400
77910890	927	930	CD4	GeneOrGeneProduct	920
77910890	949	952	rat	OrganismTaxon	10116
77910890	1017	1022	DUCaP	CellLine	CVCL_2025
77910890	1027	1034	SJ-GBM2	CellLine	CVCL_M141
77910890	1092	1096	PEMT	GeneOrGeneProduct	10400
77910890	1105	1108	CD4	GeneOrGeneProduct	920
77910890	1219	1221	C2	GeneOrGeneProduct	717
77910890	1226	1230	PEMT	GeneOrGeneProduct	10400
77910890	1313	1335	nuclear factor kappa B	GeneOrGeneProduct	81736
77910890	1348	1352	PEMT	GeneOrGeneProduct	10400
77910890	1408	1412	PEMT	GeneOrGeneProduct	10400
77910890	1512	1517	FoxP3	GeneOrGeneProduct	50943
77910890	1522	1525	CD4	GeneOrGeneProduct	920
77910890	1561	1566	FoxP3	GeneOrGeneProduct	50943
77910890	1682	1687	FoxP3	GeneOrGeneProduct	50943
77910890	1692	1694	C2	GeneOrGeneProduct	717
77910890	1852	1858	horses	OrganismTaxon	9796
77910890	1860	1867	tobacco	OrganismTaxon	4097
77910890	1917	1923	hRPTEC	CellLine	CVCL_K278
77910890	1925	1929	293T	CellLine	CVCL_0063
77910890	1935	1943	Ishikawa	CellLine	CVCL_2529
77910890	2025	2064	Ubiquitin carboxyl-terminal esterase L1	GeneOrGeneProduct	7345
77910890	2098	2103	LNCaP	CellLine	CVCL_0395
77910890	2108	2117	SMMC-7721	CellLine	CVCL_0534
77910890	2250	2254	MAP9	GeneOrGeneProduct	79884
77910890	2286	2300	Rhodiola rosea	OrganismTaxon	203015
77910890	2365	2368	rat	OrganismTaxon	10116
77910890	2472	2478	DEPTOR	GeneOrGeneProduct	97998
77910890	2485	2487	C2	GeneOrGeneProduct	717
77910890	2489	2493	PEMT	GeneOrGeneProduct	10400
77910890	2499	2504	FoxP3	GeneOrGeneProduct	50943
77910890	Negative_Correlation	717	56150	Novel
77910890	Association	717	116554	Novel
77910890	Negative_Correlation	10400	920	Novel
77910890	Negative_Correlation	116554	10400	Novel
77910890	Positive_Correlation	50943	920	Novel
77910890	Negative_Correlation	717	10400	Novel
77910890	Bind	81736	10400	Novel
77910890	Association	10400	50943	Novel
77910890	Positive_Correlation	116554	56150	Novel
77910890	Bind	50943	717	Novel

60921793|t|Genetic and pharmacological interactions in nephrotic syndrome: a comparative study in rabbits an
60921793|a|This study investigates the complex interactions between genetic variants, pharmacological agents, and disease phenotypes in the context of nephrotic syndrome. The research focuses on rabbits and horses, with particular attention to the sequence variant changes asparagine 86 for alanine and eliminates amino acids 87, 88, and 89 (arginine, threonine, and proline), which is associated with the E359K mutation. The study also examines the effects of sorafenib, AAS, clonidine, and Re, Rg1, and Rb1 ginsenosides on nephrotic syndrome and their interrelationships.  In rabbits, the sequence variant changes asparagine 86 for alanine and eliminates amino acids 87, 88, and 89 (arginine, threonine, and proline) is strongly associated with the E359K mutation, suggesting a potential functional link. This variant is also linked to nephrotic syndrome, with a positive correlation observed in both rabbits and horses. The study reveals that nephrotic syndrome is positively correlated with sorafenib, AAS, and clonidine, but negatively correlated with Re, Rg1, and Rb1 ginsenosides.  Sorafenib exhibits a negative correlation with AAS, clonidine, and Re, Rg1, and Rb1 ginsenosides, while it shows a positive correlation with nephrotic syndrome. The negative correlation between sorafenib and AAS is further supported by the comparison between these two chemical entities, which highlights their opposing effects on disease progression. Similarly, clonidine is negatively correlated with AAS and sorafenib, and its relationship with Re, Rg1, and Rb1 ginsenosides is explored through comparative analysis.  The study also compares AAS with Re, Rg1, and Rb1 ginsenosides, revealing a negative correlation between AAS and Re, Rg1, and Rb1 ginsenosides. This finding is consistent with the negative correlation between AAS and nephrotic syndrome, which is further reinforced by the positive correlation between nephrotic syndrome and AAS. The comparison between clonidine and Re, Rg1, and Rb1 ginsenosides suggests a complex interplay, with clonidine showing a negative correlation with these ginsenosides.  In horses, the sequence variant changes asparagine 86 for alanine and eliminates amino acids 87, 88, and 89 (arginine, threonine, and proline) is associated with nephrotic syndrome, reinforcing the positive correlation between this variant and the disease. The study also highlights the negative correlation between nephrotic syndrome and Re, Rg1, and Rb1 ginsenosides, suggesting that these ginsenosides may have protective effects against the disease.  Overall, the findings underscore the intricate relationships between genetic variants, pharmacological agents, and disease phenotypes in nephrotic syndrome, with implications for therapeutic strategies in rabbits and horses.
60921793	44	62	nephrotic syndrome	DiseaseOrPhenotypicFeature	D009404
60921793	87	93	rabbit	OrganismTaxon	9986
60921793	238	256	nephrotic syndrome	DiseaseOrPhenotypicFeature	D009404
60921793	282	288	rabbit	OrganismTaxon	9986
60921793	294	300	horses	OrganismTaxon	9796
60921793	352	462	changes asparagine 86 for alanine and eliminates amino acids 87, 88, and 89 (arginine, threonine, and proline)	SequenceVariant	p|SUB|NRTP|86_89|A
60921793	493	498	E359K	SequenceVariant	rs368489876
60921793	548	557	sorafenib	ChemicalEntity	D000077157
60921793	559	562	AAS	ChemicalEntity	D045165
60921793	564	573	clonidine	ChemicalEntity	D003000
60921793	579	608	Re, Rg1, and Rb1 ginsenosides	ChemicalEntity	C035054
60921793	612	630	nephrotic syndrome	DiseaseOrPhenotypicFeature	D009404
60921793	665	671	rabbit	OrganismTaxon	9986
60921793	695	805	changes asparagine 86 for alanine and eliminates amino acids 87, 88, and 89 (arginine, threonine, and proline)	SequenceVariant	p|SUB|NRTP|86_89|A
60921793	838	843	E359K	SequenceVariant	rs368489876
60921793	925	943	nephrotic syndrome	DiseaseOrPhenotypicFeature	D009404
60921793	990	996	rabbit	OrganismTaxon	9986
60921793	1002	1008	horses	OrganismTaxon	9796
60921793	1033	1051	nephrotic syndrome	DiseaseOrPhenotypicFeature	D009404
60921793	1082	1091	sorafenib	ChemicalEntity	D000077157
60921793	1093	1096	AAS	ChemicalEntity	D045165
60921793	1102	1111	clonidine	ChemicalEntity	D003000
60921793	1144	1173	Re, Rg1, and Rb1 ginsenosides	ChemicalEntity	C035054
60921793	1223	1226	AAS	ChemicalEntity	D045165
60921793	1228	1237	clonidine	ChemicalEntity	D003000
60921793	1243	1272	Re, Rg1, and Rb1 ginsenosides	ChemicalEntity	C035054
60921793	1317	1335	nephrotic syndrome	DiseaseOrPhenotypicFeature	D009404
60921793	1370	1379	sorafenib	ChemicalEntity	D000077157
60921793	1384	1387	AAS	ChemicalEntity	D045165
60921793	1539	1548	clonidine	ChemicalEntity	D003000
60921793	1579	1582	AAS	ChemicalEntity	D045165
60921793	1587	1596	sorafenib	ChemicalEntity	D000077157
60921793	1624	1653	Re, Rg1, and Rb1 ginsenosides	ChemicalEntity	C035054
60921793	1721	1724	AAS	ChemicalEntity	D045165
60921793	1730	1759	Re, Rg1, and Rb1 ginsenosides	ChemicalEntity	C035054
60921793	1802	1805	AAS	ChemicalEntity	D045165
60921793	1810	1839	Re, Rg1, and Rb1 ginsenosides	ChemicalEntity	C035054
60921793	1906	1909	AAS	ChemicalEntity	D045165
60921793	1914	1932	nephrotic syndrome	DiseaseOrPhenotypicFeature	D009404
60921793	1998	2016	nephrotic syndrome	DiseaseOrPhenotypicFeature	D009404
60921793	2021	2024	AAS	ChemicalEntity	D045165
60921793	2049	2058	clonidine	ChemicalEntity	D003000
60921793	2063	2092	Re, Rg1, and Rb1 ginsenosides	ChemicalEntity	C035054
60921793	2128	2137	clonidine	ChemicalEntity	D003000
60921793	2198	2204	horses	OrganismTaxon	9796
60921793	2227	2337	changes asparagine 86 for alanine and eliminates amino acids 87, 88, and 89 (arginine, threonine, and proline)	SequenceVariant	p|SUB|NRTP|86_89|A
60921793	2357	2375	nephrotic syndrome	DiseaseOrPhenotypicFeature	D009404
60921793	2511	2529	nephrotic syndrome	DiseaseOrPhenotypicFeature	D009404
60921793	2534	2563	Re, Rg1, and Rb1 ginsenosides	ChemicalEntity	C035054
60921793	2787	2805	nephrotic syndrome	DiseaseOrPhenotypicFeature	D009404
60921793	2855	2861	rabbit	OrganismTaxon	9986
60921793	2867	2873	horses	OrganismTaxon	9796
60921793	Negative_Correlation	D009404	D000077157	Novel
60921793	Negative_Correlation	D000077157	D003000	Novel
60921793	Negative_Correlation	D000077157	D045165	Novel
60921793	Comparison	C035054	D045165	Novel
60921793	Positive_Correlation	D000077157	D009404	Novel
60921793	Negative_Correlation	D045165	D003000	Novel
60921793	Association	p|SUB|NRTP|86_89|A	rs368489876	Novel
60921793	Comparison	D045165	C035054	Novel
60921793	Negative_Correlation	D009404	C035054	Novel
60921793	Comparison	D003000	C035054	Novel
60921793	Positive_Correlation	D009404	D000077157	Novel
60921793	Comparison	D045165	D000077157	Novel
60921793	Comparison	D003000	D045165	Novel
60921793	Negative_Correlation	D000077157	C035054	Novel
60921793	Negative_Correlation	D003000	D045165	Novel
60921793	Positive_Correlation	D009404	D003000	Novel
60921793	Positive_Correlation	D009404	D045165	Novel
60921793	Positive_Correlation	D009404	rs368489876	Novel
60921793	Negative_Correlation	C035054	D045165	Novel
60921793	Comparison	D000077157	D045165	Novel
60921793	Comparison	C035054	D003000	Novel
60921793	Positive_Correlation	D045165	D009404	Novel
60921793	Positive_Correlation	C035054	D009404	Novel
60921793	Negative_Correlation	D003000	D000077157	Novel
60921793	Negative_Correlation	D045165	D000077157	Novel
60921793	Association	D009404	p|SUB|NRTP|86_89|A	Novel
60921793	Negative_Correlation	D009404	D045165	Novel

00526270|t|Factor B and TNMD: interactions with 17-DMAG, collagenase, and atazanavir in Drosophila, bacteria, and mouse mammary tumor viru
00526270|a|This study investigates the complex interactions between the gene product factor B, the sequence variant D401H, and the chemical entities 17-DMAG, collagenase, atazanavir, midazolam, and the organism taxons Drosophila, bacteria, and mouse mammary tumor virus. The research focuses on the comparative and correlational relationships among these entities, particularly in the context of their biological and pharmacological effects.   A key finding is the positive correlation between 17-DMAG and TNMD, suggesting a potential synergistic effect in modulating cellular processes. Additionally, the positive correlation between 17-DMAG and factor B indicates a possible regulatory relationship, which was further supported by the drug interaction between 17-DMAG and factor B. The study also reveals a drug interaction between 17-DMAG and collagenase, as well as between 17-DMAG and midazolam, highlighting the multifaceted role of 17-DMAG in pharmacological contexts.   The comparison between 17-DMAG and collagenase underscores their distinct yet overlapping biological functions, particularly in the context of bacterial and Drosophila models. Furthermore, the comparison between atazanavir and 17-DMAG provides insights into their differential effects on factor B, with a positive correlation observed between atazanavir and factor B. The drug interaction between atazanavir and midazolam adds another layer of complexity to the pharmacological landscape, suggesting potential interactions that warrant further investigation.   The study also explores the role of the sequence variant D401H in the context of these interactions, particularly in Drosophila and bacteria, where it appears to influence the expression and function of factor B. The presence of multiple instances of the organism taxons Drosophila, bacteria, and mouse mammary tumor virus underscores the broad applicability of these findings across different biological systems.   Overall, this research provides a comprehensive analysis of the interactions between factor B, TNMD, 17-DMAG, collagenase, atazanavir, and midazolam, offering new insights into their roles in biological and pharmacological processes.
00526270	13	17	TNMD	GeneOrGeneProduct	64102
00526270	37	44	17-DMAG	ChemicalEntity	C448659
00526270	46	57	collagenase	ChemicalEntity	D017364
00526270	63	73	atazanavir	ChemicalEntity	C413408
00526270	77	87	Drosophila	OrganismTaxon	7227
00526270	89	97	bacteria	OrganismTaxon	2
00526270	202	210	factor B	GeneOrGeneProduct	629
00526270	233	238	D401H	SequenceVariant	p|SUB|D|401|H
00526270	266	273	17-DMAG	ChemicalEntity	C448659
00526270	275	286	collagenase	ChemicalEntity	D017364
00526270	288	298	atazanavir	ChemicalEntity	C413408
00526270	300	309	midazolam	ChemicalEntity	D008874
00526270	335	345	Drosophila	OrganismTaxon	7227
00526270	347	355	bacteria	OrganismTaxon	2
00526270	361	386	mouse mammary tumor virus	OrganismTaxon	11757
00526270	611	618	17-DMAG	ChemicalEntity	C448659
00526270	623	627	TNMD	GeneOrGeneProduct	64102
00526270	752	759	17-DMAG	ChemicalEntity	C448659
00526270	764	772	factor B	GeneOrGeneProduct	629
00526270	879	886	17-DMAG	ChemicalEntity	C448659
00526270	891	899	factor B	GeneOrGeneProduct	629
00526270	951	958	17-DMAG	ChemicalEntity	C448659
00526270	963	974	collagenase	ChemicalEntity	D017364
00526270	995	1002	17-DMAG	ChemicalEntity	C448659
00526270	1007	1016	midazolam	ChemicalEntity	D008874
00526270	1056	1063	17-DMAG	ChemicalEntity	C448659
00526270	1118	1125	17-DMAG	ChemicalEntity	C448659
00526270	1130	1141	collagenase	ChemicalEntity	D017364
00526270	1238	1246	bacteria	OrganismTaxon	2
00526270	1252	1262	Drosophila	OrganismTaxon	7227
00526270	1307	1317	atazanavir	ChemicalEntity	C413408
00526270	1322	1329	17-DMAG	ChemicalEntity	C448659
00526270	1383	1391	factor B	GeneOrGeneProduct	629
00526270	1438	1448	atazanavir	ChemicalEntity	C413408
00526270	1453	1461	factor B	GeneOrGeneProduct	629
00526270	1492	1502	atazanavir	ChemicalEntity	C413408
00526270	1507	1516	midazolam	ChemicalEntity	D008874
00526270	1713	1718	D401H	SequenceVariant	p|SUB|D|401|H
00526270	1773	1783	Drosophila	OrganismTaxon	7227
00526270	1788	1796	bacteria	OrganismTaxon	2
00526270	1859	1867	factor B	GeneOrGeneProduct	629
00526270	1927	1937	Drosophila	OrganismTaxon	7227
00526270	1939	1947	bacteria	OrganismTaxon	2
00526270	1953	1978	mouse mammary tumor virus	OrganismTaxon	11757
00526270	2157	2165	factor B	GeneOrGeneProduct	629
00526270	2167	2171	TNMD	GeneOrGeneProduct	64102
00526270	2173	2180	17-DMAG	ChemicalEntity	C448659
00526270	2182	2193	collagenase	ChemicalEntity	D017364
00526270	2195	2205	atazanavir	ChemicalEntity	C413408
00526270	2211	2220	midazolam	ChemicalEntity	D008874
00526270	Comparison	C448659	D017364	Novel
00526270	Positive_Correlation	C448659	64102	Novel
00526270	Positive_Correlation	C413408	629	Novel
00526270	Drug_Interaction	D008874	C448659	Novel
00526270	Positive_Correlation	C448659	629	Novel
00526270	Drug_Interaction	C413408	D008874	Novel
00526270	Drug_Interaction	C448659	D017364	Novel
00526270	Drug_Interaction	C448659	D008874	Novel
00526270	Drug_Interaction	D017364	C448659	Novel
00526270	Comparison	C413408	C448659	Novel

68875767|t|Genetic variant glycine-594-valine and its associations with Senior-Loken syndrome, drusen, cutaneous reactions, and enchondromatosis disorders Ollier disease in the context of cerivastatin and MDMA-EGTA inte
68875767|a|This study investigates the genetic and pharmacological interactions involving the sequence variant glycine-594-valine and its associations with several disease phenotypes, including Senior-Loken syndrome, drusen, cutaneous reactions, and enchondromatosis disorders Ollier disease. The research also explores the pharmacological effects of cerivastatin in relation to these conditions, revealing a consistent negative correlation between cerivastatin and all four phenotypes. Specifically, cerivastatin was found to be negatively correlated with Senior-Loken syndrome, drusen, cutaneous reactions, and enchondromatosis disorders Ollier disease, suggesting potential therapeutic or toxicological implications.   In parallel, the study examines the cotreatment of MDMA and EGTA, demonstrating an association between these two chemical entities. The findings indicate that MDMA and EGTA may interact in a manner that could influence cellular calcium dynamics, potentially affecting various physiological processes. Additionally, the study highlights the importance of understanding the interplay between genetic variants and pharmacological agents in the context of disease pathogenesis. These results provide critical insights into the complex relationships between genetic factors, chemical entities, and disease phenotypes, offering a foundation for future research into targeted therapeutic strategies.
68875767	16	34	glycine-594-valine	SequenceVariant	p|SUB|G|594|V
68875767	61	82	Senior-Loken syndrome	DiseaseOrPhenotypicFeature	C537580
68875767	84	90	drusen	DiseaseOrPhenotypicFeature	D005128
68875767	92	111	cutaneous reactions	DiseaseOrPhenotypicFeature	D003875
68875767	117	158	enchondromatosis disorders Ollier disease	DiseaseOrPhenotypicFeature	D004687
68875767	177	189	cerivastatin	ChemicalEntity	C086276
68875767	194	198	MDMA	ChemicalEntity	D018817
68875767	199	203	EGTA	ChemicalEntity	D004533
68875767	309	327	glycine-594-valine	SequenceVariant	p|SUB|G|594|V
68875767	392	413	Senior-Loken syndrome	DiseaseOrPhenotypicFeature	C537580
68875767	415	421	drusen	DiseaseOrPhenotypicFeature	D005128
68875767	423	442	cutaneous reactions	DiseaseOrPhenotypicFeature	D003875
68875767	448	489	enchondromatosis disorders Ollier disease	DiseaseOrPhenotypicFeature	D004687
68875767	549	561	cerivastatin	ChemicalEntity	C086276
68875767	647	659	cerivastatin	ChemicalEntity	C086276
68875767	699	711	cerivastatin	ChemicalEntity	C086276
68875767	755	776	Senior-Loken syndrome	DiseaseOrPhenotypicFeature	C537580
68875767	778	784	drusen	DiseaseOrPhenotypicFeature	D005128
68875767	786	805	cutaneous reactions	DiseaseOrPhenotypicFeature	D003875
68875767	811	852	enchondromatosis disorders Ollier disease	DiseaseOrPhenotypicFeature	D004687
68875767	971	975	MDMA	ChemicalEntity	D018817
68875767	980	984	EGTA	ChemicalEntity	D004533
68875767	1079	1083	MDMA	ChemicalEntity	D018817
68875767	1088	1092	EGTA	ChemicalEntity	D004533
68875767	Negative_Correlation	C537580	C086276	Novel
68875767	Negative_Correlation	D003875	C086276	Novel
68875767	Negative_Correlation	D005128	C086276	Novel
68875767	Cotreatment	D018817	D004533	Novel
68875767	Negative_Correlation	D004687	C086276	Novel
68875767	Association	D018817	D004533	Novel

16562973|t|Bmp7, modafinil, and L-364,718 interactions in HS-RDEB: a study in cats with sequence variants in NMDA receptor 2A and G
16562973|a|This study investigates the complex interactions between the gene Bmp7, the chemical entity modafinil, and the chemical entity L-364,718 in the context of HS-RDEB (Hemorrhagic Septicemia-Related Dermatomyositis in cats). We analyzed a cohort of 40 cats diagnosed with HS-RDEB, all of which exhibited multiple sequence variants, including C111G, Val624-Val625del, c.643T>C, 714C, and G12D. The presence of these variants was associated with varying degrees of disease severity and response to treatment.   Our findings reveal a positive correlation between Bmp7 and modafinil, suggesting that modafinil may modulate Bmp7 expression or activity in HS-RDEB. Additionally, we observed a positive correlation between modafinil and HS-RDEB, indicating that modafinil may have a therapeutic role in managing the disease. Furthermore, a strong positive correlation was found between L-364,718 and HS-RDEB, suggesting that L-364,718 may be a potential biomarker or therapeutic agent for this condition.   The study also highlights a positive correlation between Bmp7 and L-364,718, indicating a possible synergistic relationship between these two entities in the pathophysiology of HS-RDEB. Moreover, we found positive correlations between NMDA receptor 2A and both L-364,718 and modafinil, suggesting that these three entities may be part of a shared signaling pathway. Similarly, Gg-globin was found to have positive correlations with both L-364,718 and modafinil, further supporting the idea of a complex network of interactions among these molecules in HS-RDEB.   These results provide new insights into the molecular mechanisms underlying HS-RDEB and suggest potential therapeutic strategies involving modafinil, L-364,718, and Bmp7. The study also underscores the importance of sequence variants in modulating these interactions, as multiple variants were found to be associated with the disease phenotype in cats.
16562973	0	4	Bmp7	GeneOrGeneProduct	12162
16562973	6	15	modafinil	ChemicalEntity	C048833
16562973	21	30	L-364,718	ChemicalEntity	D020109
16562973	47	54	HS-RDEB	DiseaseOrPhenotypicFeature	D016108
16562973	67	71	cats	OrganismTaxon	9685
16562973	98	114	NMDA receptor 2A	GeneOrGeneProduct	14811
16562973	187	191	Bmp7	GeneOrGeneProduct	12162
16562973	213	222	modafinil	ChemicalEntity	C048833
16562973	248	257	L-364,718	ChemicalEntity	D020109
16562973	276	283	HS-RDEB	DiseaseOrPhenotypicFeature	D016108
16562973	335	339	cats	OrganismTaxon	9685
16562973	369	373	cats	OrganismTaxon	9685
16562973	389	396	HS-RDEB	DiseaseOrPhenotypicFeature	D016108
16562973	459	464	C111G	SequenceVariant	c|SUB|C|111|G
16562973	466	482	Val624-Val625del	SequenceVariant	p|DEL|624_625|VV
16562973	484	492	c.643T>C	SequenceVariant	c|SUB|T|643|C
16562973	494	498	714C	SequenceVariant	rs34242818
16562973	504	508	G12D	SequenceVariant	rs121913529
16562973	677	681	Bmp7	GeneOrGeneProduct	12162
16562973	686	695	modafinil	ChemicalEntity	C048833
16562973	713	722	modafinil	ChemicalEntity	C048833
16562973	736	740	Bmp7	GeneOrGeneProduct	12162
16562973	767	774	HS-RDEB	DiseaseOrPhenotypicFeature	D016108
16562973	833	842	modafinil	ChemicalEntity	C048833
16562973	847	854	HS-RDEB	DiseaseOrPhenotypicFeature	D016108
16562973	872	881	modafinil	ChemicalEntity	C048833
16562973	996	1005	L-364,718	ChemicalEntity	D020109
16562973	1010	1017	HS-RDEB	DiseaseOrPhenotypicFeature	D016108
16562973	1035	1044	L-364,718	ChemicalEntity	D020109
16562973	1174	1178	Bmp7	GeneOrGeneProduct	12162
16562973	1183	1192	L-364,718	ChemicalEntity	D020109
16562973	1294	1301	HS-RDEB	DiseaseOrPhenotypicFeature	D016108
16562973	1352	1368	NMDA receptor 2A	GeneOrGeneProduct	14811
16562973	1378	1387	L-364,718	ChemicalEntity	D020109
16562973	1392	1401	modafinil	ChemicalEntity	C048833
16562973	1494	1503	Gg-globin	GeneOrGeneProduct	3048
16562973	1554	1563	L-364,718	ChemicalEntity	D020109
16562973	1568	1577	modafinil	ChemicalEntity	C048833
16562973	1669	1676	HS-RDEB	DiseaseOrPhenotypicFeature	D016108
16562973	1756	1763	HS-RDEB	DiseaseOrPhenotypicFeature	D016108
16562973	1819	1828	modafinil	ChemicalEntity	C048833
16562973	1830	1839	L-364,718	ChemicalEntity	D020109
16562973	1845	1849	Bmp7	GeneOrGeneProduct	12162
16562973	2027	2031	cats	OrganismTaxon	9685
16562973	Positive_Correlation	12162	D020109	Novel
16562973	Positive_Correlation	C048833	D016108	Novel
16562973	Positive_Correlation	D020109	D016108	Novel
16562973	Positive_Correlation	14811	D020109	Novel
16562973	Positive_Correlation	12162	C048833	Novel
16562973	Positive_Correlation	3048	D020109	Novel
16562973	Positive_Correlation	14811	C048833	Novel
16562973	Positive_Correlation	3048	C048833	Novel

09465634|t|D90A sequence variant and its complex interactions with hyperopia, lamellate thrombi, gynecologic malignancy, and glial-cell-line-derived neurotrophic factor in HPVs and multiple ce
09465634|a|This study investigates the multifaceted interactions between the D90A sequence variant and various biological entities, including hyperopia, lamellate thrombi, gynecologic malignancy, and glial-cell-line-derived neurotrophic factor (GDNF), across multiple cell lines and HPVs. The research focuses on the role of the D90A variant in modulating disease phenotypes and cellular responses in the context of guinea pig and human-derived cell lines such as H9c2, GT1-1, HK2, and SW480.   The findings reveal a positive correlation between the D90A variant and hyperopia, lamellate thrombi, and gynecologic malignancy, while simultaneously showing a negative correlation between D90A and hyperopia. These results suggest that the D90A variant may act as a modulator in the pathogenesis of these conditions. Additionally, the study demonstrates a negative correlation between GDNF and both gynecologic malignancy and lamellate thrombi, indicating that GDNF may have a protective role against these diseases.   Interestingly, the relationship between GDNF and hyperopia is complex, with both negative correlations observed between GDNF and hyperopia, as well as between hyperopia and GDNF. These findings highlight the intricate interplay between genetic variants and disease phenotypes. The study also emphasizes the importance of HPVs in these interactions, with multiple instances of HPVs being associated with the observed phenotypes.   The results underscore the need for further research into the molecular mechanisms underlying these associations, particularly in the context of different cell lines and organismal models. The data provide a foundation for understanding how genetic variants like D90A and factors such as GDNF influence disease outcomes in diverse biological systems.
09465634	0	4	D90A	SequenceVariant	rs80265967
09465634	56	65	hyperopia	DiseaseOrPhenotypicFeature	D006956
09465634	67	84	lamellate thrombi	DiseaseOrPhenotypicFeature	D013927
09465634	86	108	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
09465634	114	157	glial-cell-line-derived neurotrophic factor	GeneOrGeneProduct	25453
09465634	161	165	HPVs	OrganismTaxon	10566
09465634	248	252	D90A	SequenceVariant	rs80265967
09465634	313	322	hyperopia	DiseaseOrPhenotypicFeature	D006956
09465634	324	341	lamellate thrombi	DiseaseOrPhenotypicFeature	D013927
09465634	343	365	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
09465634	371	414	glial-cell-line-derived neurotrophic factor	GeneOrGeneProduct	25453
09465634	454	458	HPVs	OrganismTaxon	10566
09465634	500	504	D90A	SequenceVariant	rs80265967
09465634	587	597	guinea pig	OrganismTaxon	10141
09465634	635	639	H9c2	CellLine	CVCL_0286
09465634	641	646	GT1-1	CellLine	CVCL_6236
09465634	648	651	HK2	CellLine	CVCL_0302
09465634	657	662	SW480	CellLine	CVCL_0546
09465634	721	725	D90A	SequenceVariant	rs80265967
09465634	738	747	hyperopia	DiseaseOrPhenotypicFeature	D006956
09465634	749	766	lamellate thrombi	DiseaseOrPhenotypicFeature	D013927
09465634	772	794	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
09465634	856	860	D90A	SequenceVariant	rs80265967
09465634	865	874	hyperopia	DiseaseOrPhenotypicFeature	D006956
09465634	907	911	D90A	SequenceVariant	rs80265967
09465634	1066	1088	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
09465634	1093	1110	lamellate thrombi	DiseaseOrPhenotypicFeature	D013927
09465634	1235	1244	hyperopia	DiseaseOrPhenotypicFeature	D006956
09465634	1315	1324	hyperopia	DiseaseOrPhenotypicFeature	D006956
09465634	1345	1354	hyperopia	DiseaseOrPhenotypicFeature	D006956
09465634	1507	1511	HPVs	OrganismTaxon	10566
09465634	1562	1566	HPVs	OrganismTaxon	10566
09465634	1879	1883	D90A	SequenceVariant	rs80265967
09465634	Positive_Correlation	rs80265967	D005833	Novel
09465634	Negative_Correlation	25453	D005833	Novel
09465634	Positive_Correlation	rs80265967	D013927	Novel
09465634	Negative_Correlation	25453	D013927	Novel
09465634	Positive_Correlation	rs80265967	D006956	Novel
09465634	Negative_Correlation	D006956	25453	Novel
09465634	Negative_Correlation	25453	D006956	Novel
09465634	Negative_Correlation	rs80265967	D006956	Novel
09465634	Negative_Correlation	D005833	25453	Novel
09465634	Negative_Correlation	D013927	25453	Novel
09465634	Negative_Correlation	rs80265967	D005833	Novel
09465634	Negative_Correlation	rs80265967	D013927	Novel

32044266|t|Genetic variants in PARK2 and their associations with migraines, myelosuppression, and Meningococcal disease in the context of hepatitis B virus and HIV 1/2 in
32044266|a|Recent studies have highlighted the complex interplay between genetic variants, neurological disorders, and viral infections. This research investigates the associations between specific sequence variants in the PARK2 gene and several disease phenotypes, including migraines, myelosuppression, and Meningococcal disease, in the context of hepatitis B virus (HBV) and HIV 1/2 infections. The study focuses on the sequence variants c.611delG, c.2444A>C, and p.A384D, which were found to be significantly linked to migraines, myelosuppression, and Meningococcal disease.   The findings reveal a strong association between the sequence variant c.2444A>C and migraines, suggesting a potential role for this variant in the pathogenesis of migraine disorders. Additionally, the variant c.611delG was found to be significantly associated with myelosuppression, indicating its possible involvement in the suppression of hematopoietic function. The variant p.A384D was also linked to myelosuppression, further supporting the hypothesis that multiple sequence variants in PARK2 may contribute to the development of this condition.   Interestingly, the study also identified a negative correlation between PARK2 and Meningococcal disease, suggesting that variations in PARK2 may influence susceptibility to this bacterial infection. Similarly, a negative correlation was observed between PARK2 and migraines, indicating that certain genetic variants in PARK2 may protect against the development of migraines.   The research further explored the role of HBV and HIV 1/2 in modulating these associations. The presence of HBV was found to exacerbate the effects of c.611delG on myelosuppression, while HIV 1/2 infections were associated with increased migraines in individuals carrying the c.2444A>C variant. The study also included the use of HEK cell lines to model the interactions between these genetic variants and viral proteins, providing insights into the molecular mechanisms underlying these associations.   Overall, this study underscores the importance of genetic variants in PARK2 in the context of neurological and immunological disorders, and highlights the potential for personalized medicine approaches in managing these conditions. The results also emphasize the need for further research into the interactions between genetic factors and viral infections in the development of complex diseases.
32044266	20	25	PARK2	GeneOrGeneProduct	5071
32044266	54	63	migraines	DiseaseOrPhenotypicFeature	D008881
32044266	65	81	myelosuppression	DiseaseOrPhenotypicFeature	D001855
32044266	87	108	Meningococcal disease	DiseaseOrPhenotypicFeature	D008589
32044266	127	144	hepatitis B virus	OrganismTaxon	10407
32044266	149	156	HIV 1/2	OrganismTaxon	11676
32044266	372	377	PARK2	GeneOrGeneProduct	5071
32044266	425	434	migraines	DiseaseOrPhenotypicFeature	D008881
32044266	436	452	myelosuppression	DiseaseOrPhenotypicFeature	D001855
32044266	458	479	Meningococcal disease	DiseaseOrPhenotypicFeature	D008589
32044266	499	516	hepatitis B virus	OrganismTaxon	10407
32044266	518	521	HBV	OrganismTaxon	10407
32044266	527	534	HIV 1/2	OrganismTaxon	11676
32044266	590	599	c.611delG	SequenceVariant	rs193302856
32044266	601	610	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
32044266	616	623	p.A384D	SequenceVariant	p|SUB|A|384|D
32044266	672	681	migraines	DiseaseOrPhenotypicFeature	D008881
32044266	683	699	myelosuppression	DiseaseOrPhenotypicFeature	D001855
32044266	705	726	Meningococcal disease	DiseaseOrPhenotypicFeature	D008589
32044266	800	809	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
32044266	814	823	migraines	DiseaseOrPhenotypicFeature	D008881
32044266	939	948	c.611delG	SequenceVariant	rs193302856
32044266	995	1011	myelosuppression	DiseaseOrPhenotypicFeature	D001855
32044266	1107	1114	p.A384D	SequenceVariant	p|SUB|A|384|D
32044266	1134	1150	myelosuppression	DiseaseOrPhenotypicFeature	D001855
32044266	1221	1226	PARK2	GeneOrGeneProduct	5071
32044266	1354	1359	PARK2	GeneOrGeneProduct	5071
32044266	1364	1385	Meningococcal disease	DiseaseOrPhenotypicFeature	D008589
32044266	1417	1422	PARK2	GeneOrGeneProduct	5071
32044266	1536	1541	PARK2	GeneOrGeneProduct	5071
32044266	1546	1555	migraines	DiseaseOrPhenotypicFeature	D008881
32044266	1601	1606	PARK2	GeneOrGeneProduct	5071
32044266	1646	1655	migraines	DiseaseOrPhenotypicFeature	D008881
32044266	1701	1704	HBV	OrganismTaxon	10407
32044266	1709	1716	HIV 1/2	OrganismTaxon	11676
32044266	1767	1770	HBV	OrganismTaxon	10407
32044266	1810	1819	c.611delG	SequenceVariant	rs193302856
32044266	1823	1839	myelosuppression	DiseaseOrPhenotypicFeature	D001855
32044266	1847	1854	HIV 1/2	OrganismTaxon	11676
32044266	1897	1906	migraines	DiseaseOrPhenotypicFeature	D008881
32044266	1935	1944	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
32044266	1989	1992	HEK	CellLine	CVCL_M624
32044266	2233	2238	PARK2	GeneOrGeneProduct	5071
32044266	Association	D008881	c|SUB|A|2444|C	Novel
32044266	Association	D001855	rs193302856	Novel
32044266	Association	D001855	p|SUB|A|384|D	Novel
32044266	Negative_Correlation	5071	D008589	Novel
32044266	Negative_Correlation	5071	D008881	Novel
32044266	Association	D008589	rs193302856	Novel
32044266	Association	D008881	p|SUB|A|384|D	Novel

16665966|t|Polyadenylate Binding-Protein Nuclear 1 and IKKalpha/beta: Interactions with Sequence Variants and Chemical Entities in Metabolic Re
16665966|a|This study investigates the complex interactions between the gene product polyadenylate binding-protein nuclear 1 (PABPN1), the kinase IKKalpha/beta, and various sequence variants and chemical entities in the context of metabolic regulation. The research highlights the association between the nine nucleotide insertion and free fatty acids, suggesting a potential role in lipid metabolism. Additionally, the cotreatment of free fatty acids with 5 fluorouracil and emodin was explored, revealing synergistic effects in modulating metabolic pathways.   A positive correlation was observed between PABPN1 and free fatty acids, indicating a possible regulatory role of PABPN1 in lipid homeostasis. Furthermore, a positive correlation was found between PABPN1 and emodin, suggesting that emodin may influence PABPN1 expression or activity. The association between G51S and 5 fluorouracil was confirmed, although a negative correlation between G51S and emodin was also noted, indicating potential antagonistic interactions.   The Gln/Gln variant showed an association with both free fatty acids and emodin, suggesting a dual role in metabolic processes. A negative correlation between the nine nucleotide insertion and emodin was identified, while the nine nucleotide insertion was also associated with 5 fluorouracil. The 8-bp nucleotide (TTAAATGG) deletion was found to be negatively correlated with free fatty acids and associated with 5 fluorouracil, highlighting its potential impact on metabolic pathways.   The cotreatment of 5 fluorouracil and emodin was examined, revealing a synergistic effect in modulating metabolic responses. The study also confirmed the association between G51S and free fatty acids, reinforcing the complex interplay between genetic variants and metabolic regulators. These findings provide a comprehensive understanding of the molecular mechanisms underlying metabolic regulation and the potential therapeutic implications of these interactions.
16665966	44	57	IKKalpha/beta	GeneOrGeneProduct	309361
16665966	207	246	polyadenylate binding-protein nuclear 1	GeneOrGeneProduct	8106
16665966	268	281	IKKalpha/beta	GeneOrGeneProduct	309361
16665966	427	452	nine nucleotide insertion	SequenceVariant	c|INS||9
16665966	457	473	free fatty acids	ChemicalEntity	D005230
16665966	557	573	free fatty acids	ChemicalEntity	D005230
16665966	579	593	5 fluorouracil	ChemicalEntity	D005472
16665966	598	604	emodin	ChemicalEntity	D004642
16665966	740	756	free fatty acids	ChemicalEntity	D005230
16665966	893	899	emodin	ChemicalEntity	D004642
16665966	917	923	emodin	ChemicalEntity	D004642
16665966	993	997	G51S	SequenceVariant	rs1049564
16665966	1002	1016	5 fluorouracil	ChemicalEntity	D005472
16665966	1072	1076	G51S	SequenceVariant	rs1049564
16665966	1081	1087	emodin	ChemicalEntity	D004642
16665966	1158	1165	Gln/Gln	SequenceVariant	p|SUB|Q||Q
16665966	1206	1222	free fatty acids	ChemicalEntity	D005230
16665966	1227	1233	emodin	ChemicalEntity	D004642
16665966	1317	1342	nine nucleotide insertion	SequenceVariant	c|INS||9
16665966	1347	1353	emodin	ChemicalEntity	D004642
16665966	1380	1405	nine nucleotide insertion	SequenceVariant	c|INS||9
16665966	1431	1445	5 fluorouracil	ChemicalEntity	D005472
16665966	1451	1486	8-bp nucleotide (TTAAATGG) deletion	SequenceVariant	c|DEL||TTAAATGG
16665966	1530	1546	free fatty acids	ChemicalEntity	D005230
16665966	1567	1581	5 fluorouracil	ChemicalEntity	D005472
16665966	1661	1675	5 fluorouracil	ChemicalEntity	D005472
16665966	1680	1686	emodin	ChemicalEntity	D004642
16665966	1816	1820	G51S	SequenceVariant	rs1049564
16665966	1825	1841	free fatty acids	ChemicalEntity	D005230
16665966	Association	c|INS||9	D005230	Novel
16665966	Cotreatment	D005230	D005472	Novel
16665966	Positive_Correlation	8106	D005230	Novel
16665966	Cotreatment	D005230	D004642	Novel
16665966	Association	rs1049564	D005472	Novel
16665966	Negative_Correlation	rs1049564	D005472	Novel
16665966	Association	p|SUB|Q||Q	D005230	Novel
16665966	Association	p|SUB|Q||Q	D004642	Novel
16665966	Negative_Correlation	c|INS||9	D004642	Novel
16665966	Negative_Correlation	c|DEL||TTAAATGG	D005472	Novel
16665966	Negative_Correlation	rs1049564	D004642	Novel
16665966	Association	c|INS||9	D005472	Novel
16665966	Positive_Correlation	309361	D005230	Novel
16665966	Cotreatment	D005472	D004642	Novel
16665966	Positive_Correlation	8106	D004642	Novel
16665966	Negative_Correlation	c|DEL||TTAAATGG	D005230	Novel
16665966	Association	c|DEL||TTAAATGG	D005472	Novel
16665966	Association	rs1049564	D005230	Novel
16665966	Association	rs1049564	D004642	Novel

91000712|t|Genetic Variants and Gene Expression in Zebrafish, Guinea Pigs, and Mangifera indica Linn: A Multispecies Analysis of Cidec, InsR, and Sequence 
91000712|a|This study investigates the genetic and functional relationships between sequence variants and gene expression in multiple species, including zebrafish, guinea pigs, and Mangifera indica Linn. We focus on the associations between the sequence variants del(1)(p31.2p32.3), C-1228T, 1359 G/A, and c.695T>A, and their interactions with the gene products Cidec and InsR. The study also explores the role of these genetic elements in the context of human immunodeficiency virus (HIV) and E. coli infections, as well as in C. elegans and sheep models.   Our findings reveal a complex network of associations among the sequence variants. Specifically, C-1228T is positively correlated with 1359 G/A and c.695T>A, while 1359 G/A is associated with both C-1228T and c.695T>A. Additionally, del(1)(p31.2p32.3) is linked to C-1228T, 1359 G/A, and c.695T>A, with mutual associations between del(1)(p31.2p32.3) and c.695T>A. These associations suggest a potential regulatory or functional interplay among these variants.   In terms of gene expression, we observe a positive correlation between Cidec and InsR, indicating a possible functional relationship between these gene products. This correlation is further supported by the presence of multiple instances of Cidec and InsR in the study, highlighting their importance in the genetic architecture of the organisms examined.   The study also includes data from E. coli and C. elegans, which provide insights into the broader implications of these genetic variants across different biological systems. The inclusion of human immunodeficiency virus (HIV) and Mangifera indica Linn adds a layer of complexity, as these organisms may serve as models for understanding the functional consequences of genetic variation in diverse contexts.   Overall, this research underscores the intricate relationships between genetic variants and gene expression, offering a foundation for further studies on the molecular mechanisms underlying these associations in both model and non-model organisms.
91000712	68	89	Mangifera indica Linn	OrganismTaxon	29780
91000712	118	123	Cidec	GeneOrGeneProduct	63924
91000712	125	129	InsR	GeneOrGeneProduct	3643
91000712	287	296	zebrafish	OrganismTaxon	7955
91000712	298	309	guinea pigs	OrganismTaxon	10141
91000712	315	336	Mangifera indica Linn	OrganismTaxon	29780
91000712	397	415	del(1)(p31.2p32.3)	SequenceVariant	c|DEL|p31.2_p32.3|
91000712	417	424	C-1228T	SequenceVariant	c|SUB|C|-1228|T
91000712	426	434	1359 G/A	SequenceVariant	rs1049353
91000712	440	448	c.695T>A	SequenceVariant	c|SUB|T|695|A
91000712	496	501	Cidec	GeneOrGeneProduct	63924
91000712	506	510	InsR	GeneOrGeneProduct	3643
91000712	589	617	human immunodeficiency virus	OrganismTaxon	12721
91000712	628	635	E. coli	OrganismTaxon	562
91000712	662	672	C. elegans	OrganismTaxon	6239
91000712	677	682	sheep	OrganismTaxon	9940
91000712	790	797	C-1228T	SequenceVariant	c|SUB|C|-1228|T
91000712	828	836	1359 G/A	SequenceVariant	rs1049353
91000712	841	849	c.695T>A	SequenceVariant	c|SUB|T|695|A
91000712	857	865	1359 G/A	SequenceVariant	rs1049353
91000712	890	897	C-1228T	SequenceVariant	c|SUB|C|-1228|T
91000712	902	910	c.695T>A	SequenceVariant	c|SUB|T|695|A
91000712	926	944	del(1)(p31.2p32.3)	SequenceVariant	c|DEL|p31.2_p32.3|
91000712	958	965	C-1228T	SequenceVariant	c|SUB|C|-1228|T
91000712	967	975	1359 G/A	SequenceVariant	rs1049353
91000712	981	989	c.695T>A	SequenceVariant	c|SUB|T|695|A
91000712	1024	1042	del(1)(p31.2p32.3)	SequenceVariant	c|DEL|p31.2_p32.3|
91000712	1047	1055	c.695T>A	SequenceVariant	c|SUB|T|695|A
91000712	1226	1231	Cidec	GeneOrGeneProduct	63924
91000712	1236	1240	InsR	GeneOrGeneProduct	3643
91000712	1396	1401	Cidec	GeneOrGeneProduct	63924
91000712	1406	1410	InsR	GeneOrGeneProduct	3643
91000712	1546	1553	E. coli	OrganismTaxon	562
91000712	1558	1568	C. elegans	OrganismTaxon	6239
91000712	1703	1731	human immunodeficiency virus	OrganismTaxon	12721
91000712	1742	1763	Mangifera indica Linn	OrganismTaxon	29780
91000712	Association	c|SUB|C|-1228|T	rs1049353	Novel
91000712	Association	c|SUB|C|-1228|T	c|SUB|T|695|A	Novel
91000712	Association	rs1049353	c|SUB|T|695|A	Novel
91000712	Positive_Correlation	63924	3643	Novel
91000712	Association	c|DEL|p31.2_p32.3|	c|SUB|T|695|A	Novel
91000712	Association	c|SUB|T|695|A	c|DEL|p31.2_p32.3|	Novel
91000712	Association	c|SUB|T|695|A	rs1049353	Novel
91000712	Association	c|SUB|T|695|A	c|SUB|C|-1228|T	Novel
91000712	Association	c|DEL|p31.2_p32.3|	rs1049353	Novel
91000712	Association	c|DEL|p31.2_p32.3|	c|SUB|C|-1228|T	Novel
91000712	Association	rs1049353	c|SUB|C|-1228|T	Novel
91000712	Association	rs1049353	c|DEL|p31.2_p32.3|	Novel
91000712	Positive_Correlation	3643	63924	Novel
91000712	Association	c|SUB|C|-1228|T	c|DEL|p31.2_p32.3|	Novel

44486906|t|Genetic Variants and Functional Associations in Daucus carota, Patients, and Horses: Implications for Copper/Zinc Superoxide Dismutase, WFS1, and IL-21 
44486906|a|This study investigates the functional and genetic associations between various sequence variants, gene products, and cell lines in Daucus carota, patients, and horses. We focus on the roles of copper/zinc superoxide dismutase, WFS1, and IL-21 in modulating cellular responses to chemical entities such as picrotoxin and ifosfamide. The study includes multiple cell lines, including CA3, MH134, and IEC-6, to assess the impact of genetic variability on biological processes.   Key findings include the association between p.Val204Asp and the PGA2 receptor, as well as between p.Val204Asp and IL-21. These associations are further supported by the interaction between IL-21 and the PGA2 receptor. The D allele for the -1607 variant is also linked to the PGA2 receptor, highlighting its potential role in modulating receptor function. Additionally, the C61G variant is associated with IL-21, and the WFS1 gene product is functionally connected to IL-21.   The cytosine insertion is found to be associated with both copper/zinc superoxide dismutase and IL-21, suggesting a broader regulatory role in these pathways. The nine nucleotide insertion is linked to the PGA2 receptor, while the deletion of 6 bp at position 1494 is associated with copper/zinc superoxide dismutase. The sequence variant rs4828037 is also found to be associated with the PGA2 receptor, reinforcing the complex interplay between genetic variants and gene products.   The study further explores the role of the p.Val204Asp variant in modulating the activity of copper/zinc superoxide dismutase, and the C61G variant is shown to influence IL-21 expression. These findings provide new insights into the molecular mechanisms underlying the interactions between genetic variants, gene products, and cellular responses in diverse organisms, including Daucus carota, patients, and horses.
44486906	48	61	Daucus carota	OrganismTaxon	4039
44486906	136	140	WFS1	GeneOrGeneProduct	7466
44486906	146	151	IL-21	GeneOrGeneProduct	59067
44486906	285	298	Daucus carota	OrganismTaxon	4039
44486906	300	308	patients	OrganismTaxon	9606
44486906	314	320	horses	OrganismTaxon	9796
44486906	347	379	copper/zinc superoxide dismutase	GeneOrGeneProduct	6647
44486906	381	385	WFS1	GeneOrGeneProduct	7466
44486906	391	396	IL-21	GeneOrGeneProduct	59067
44486906	459	469	picrotoxin	ChemicalEntity	D010852
44486906	474	484	ifosfamide	ChemicalEntity	D007069
44486906	536	539	CA3	CellLine	CVCL_JW73
44486906	541	546	MH134	CellLine	CVCL_8111
44486906	552	557	IEC-6	CellLine	CVCL_0343
44486906	675	686	p.Val204Asp	SequenceVariant	p|SUB|V|204|D
44486906	695	708	PGA2 receptor	GeneOrGeneProduct	5734
44486906	729	740	p.Val204Asp	SequenceVariant	p|SUB|V|204|D
44486906	745	750	IL-21	GeneOrGeneProduct	59067
44486906	820	825	IL-21	GeneOrGeneProduct	59067
44486906	834	847	PGA2 receptor	GeneOrGeneProduct	5734
44486906	853	875	D allele for the -1607	SequenceVariant	c|Allele|D|-1607
44486906	906	919	PGA2 receptor	GeneOrGeneProduct	5734
44486906	1004	1008	C61G	SequenceVariant	rs28897672
44486906	1036	1041	IL-21	GeneOrGeneProduct	59067
44486906	1051	1055	WFS1	GeneOrGeneProduct	7466
44486906	1098	1103	IL-21	GeneOrGeneProduct	59067
44486906	1111	1129	cytosine insertion	SequenceVariant	c|INS||C
44486906	1166	1198	copper/zinc superoxide dismutase	GeneOrGeneProduct	6647
44486906	1203	1208	IL-21	GeneOrGeneProduct	59067
44486906	1270	1295	nine nucleotide insertion	SequenceVariant	c|INS||9
44486906	1313	1326	PGA2 receptor	GeneOrGeneProduct	5734
44486906	1338	1371	deletion of 6 bp at position 1494	SequenceVariant	c|DEL|194|6
44486906	1391	1423	copper/zinc superoxide dismutase	GeneOrGeneProduct	6647
44486906	1446	1455	rs4828037	SequenceVariant	rs4828037
44486906	1496	1509	PGA2 receptor	GeneOrGeneProduct	5734
44486906	1634	1645	p.Val204Asp	SequenceVariant	p|SUB|V|204|D
44486906	1684	1716	copper/zinc superoxide dismutase	GeneOrGeneProduct	6647
44486906	1726	1730	C61G	SequenceVariant	rs28897672
44486906	1761	1766	IL-21	GeneOrGeneProduct	59067
44486906	1969	1982	Daucus carota	OrganismTaxon	4039
44486906	1984	1992	patients	OrganismTaxon	9606
44486906	1998	2004	horses	OrganismTaxon	9796
44486906	Association	p|SUB|V|204|D	5734	Novel
44486906	Association	p|SUB|V|204|D	59067	Novel
44486906	Association	59067	5734	Novel
44486906	Association	c|Allele|D|-1607	5734	Novel
44486906	Association	59067	7466	Novel
44486906	Association	5734	59067	Novel
44486906	Association	c|INS||C	6647	Novel
44486906	Association	p|SUB|V|204|D	6647	Novel
44486906	Association	c|INS||9	5734	Novel
44486906	Association	p|SUB|V|204|D	7466	Novel
44486906	Association	rs28897672	59067	Novel
44486906	Association	c|INS||C	59067	Novel
44486906	Association	c|INS||9	6647	Novel
44486906	Association	rs4828037	5734	Novel
44486906	Association	7466	59067	Novel

20325285|t|Genetic variants in Lyl1 and MCT1 modulate hyperalgesia and IL-17 expression in women 
20325285|a|This study investigates the genetic and functional relationships between the sequence variant p.V239del, the genes Lyl1 and MCT1, and the phenotypic feature hyperalgesia in both women and dogs. We focus on the association between p.V239del and Lyl1, which was found to be significantly correlated in both species. Additionally, we observed a strong association between Lyl1 and MCT1, with a negative correlation between Lyl1 and IL-17 in women. The sequence variant p.V239del showed a positive correlation with hyperalgesia in both women and dogs, and a negative correlation with MCT1 in women. Furthermore, hyperalgesia was found to be negatively correlated with Lyl1 in women, but positively correlated with MCT1 in dogs. The gene IL-17 was found to be associated with Lyl1, with a negative correlation between IL-17 and MCT1 in women. The study also revealed that the sequence variant p.V239del is associated with hyperalgesia in both species, and that MCT1 is associated with hyperalgesia in dogs. These findings suggest a complex interplay between genetic variants and phenotypic features in the context of pain perception and immune response. The results were validated using hRPTEC cell lines derived from both women and dogs, and the data were consistent across multiple experimental conditions. The study highlights the importance of understanding the molecular mechanisms underlying hyperalgesia and immune-related gene expression in different species.
20325285	20	24	Lyl1	GeneOrGeneProduct	17095
20325285	29	33	MCT1	GeneOrGeneProduct	20501
20325285	43	55	hyperalgesia	DiseaseOrPhenotypicFeature	D006930
20325285	60	65	IL-17	GeneOrGeneProduct	3605
20325285	80	85	women	OrganismTaxon	9606
20325285	181	190	p.V239del	SequenceVariant	p|DEL|239|V
20325285	202	206	Lyl1	GeneOrGeneProduct	17095
20325285	211	215	MCT1	GeneOrGeneProduct	20501
20325285	244	256	hyperalgesia	DiseaseOrPhenotypicFeature	D006930
20325285	265	270	women	OrganismTaxon	9606
20325285	275	279	dogs	OrganismTaxon	9615
20325285	317	326	p.V239del	SequenceVariant	p|DEL|239|V
20325285	331	335	Lyl1	GeneOrGeneProduct	17095
20325285	456	460	Lyl1	GeneOrGeneProduct	17095
20325285	465	469	MCT1	GeneOrGeneProduct	20501
20325285	507	511	Lyl1	GeneOrGeneProduct	17095
20325285	516	521	IL-17	GeneOrGeneProduct	3605
20325285	525	530	women	OrganismTaxon	9606
20325285	553	562	p.V239del	SequenceVariant	p|DEL|239|V
20325285	598	610	hyperalgesia	DiseaseOrPhenotypicFeature	D006930
20325285	619	624	women	OrganismTaxon	9606
20325285	629	633	dogs	OrganismTaxon	9615
20325285	667	671	MCT1	GeneOrGeneProduct	20501
20325285	675	680	women	OrganismTaxon	9606
20325285	695	707	hyperalgesia	DiseaseOrPhenotypicFeature	D006930
20325285	751	755	Lyl1	GeneOrGeneProduct	17095
20325285	759	764	women	OrganismTaxon	9606
20325285	797	801	MCT1	GeneOrGeneProduct	20501
20325285	805	809	dogs	OrganismTaxon	9615
20325285	820	825	IL-17	GeneOrGeneProduct	3605
20325285	858	862	Lyl1	GeneOrGeneProduct	17095
20325285	900	905	IL-17	GeneOrGeneProduct	3605
20325285	910	914	MCT1	GeneOrGeneProduct	20501
20325285	918	923	women	OrganismTaxon	9606
20325285	975	984	p.V239del	SequenceVariant	p|DEL|239|V
20325285	1004	1016	hyperalgesia	DiseaseOrPhenotypicFeature	D006930
20325285	1043	1047	MCT1	GeneOrGeneProduct	20501
20325285	1067	1079	hyperalgesia	DiseaseOrPhenotypicFeature	D006930
20325285	1083	1087	dogs	OrganismTaxon	9615
20325285	1269	1275	hRPTEC	CellLine	CVCL_K278
20325285	1305	1310	women	OrganismTaxon	9606
20325285	1315	1319	dogs	OrganismTaxon	9615
20325285	1480	1492	hyperalgesia	DiseaseOrPhenotypicFeature	D006930
20325285	Association	p|DEL|239|V	17095	Novel
20325285	Association	17095	20501	Novel
20325285	Negative_Correlation	D006930	3605	Novel
20325285	Positive_Correlation	p|DEL|239|V	D006930	Novel
20325285	Association	17095	3605	Novel
20325285	Association	D006930	p|DEL|239|V	Novel
20325285	Negative_Correlation	D006930	17095	Novel
20325285	Association	D006930	17095	Novel
20325285	Association	D006930	20501	Novel
20325285	Negative_Correlation	D006930	20501	Novel
20325285	Association	20501	17095	Novel
20325285	Negative_Correlation	17095	20501	Novel
20325285	Negative_Correlation	17095	3605	Novel
20325285	Association	p|DEL|239|V	20501	Novel
20325285	Negative_Correlation	20501	3605	Novel
20325285	Association	20501	3605	Novel
20325285	Association	p|DEL|239|V	D006930	Novel
20325285	Negative_Correlation	20501	17095	Novel
20325285	Association	3605	17095	Novel

20250171|t|Spirulina and its interactions with Metallothionein, glucose, and calcineurin inhibitors in immune ce
20250171|a|This study investigates the complex interactions between Spirulina, Metallothionein, glucose, and calcineurin inhibitors in the context of immune cell function. Using the Ba/F3 and RAW 264.7 cell lines, we explored how these factors influence each other and their biological outcomes. Our findings reveal a negative correlation between bombesin and Metallothionein, suggesting that increased levels of bombesin may suppress Metallothionein expression. Conversely, a positive correlation was observed between calcineurin inhibitors and bombesin, indicating that calcineurin inhibitors may enhance bombesin activity.   A negative correlation was also found between glucose and calcineurin inhibitors, implying that glucose may inhibit the effects of calcineurin inhibitors. In contrast, a positive correlation was noted between glucose and Histamine, as well as between Histamine and glucose, highlighting a potential regulatory role of glucose in Histamine metabolism. Additionally, an association was found between Metallothionein and glucose, suggesting that glucose may modulate Metallothionein expression.   The study also compared glucose and Metallothionein, revealing a positive correlation that supports their potential interdependence. A negative correlation was observed between Histamine and Metallothionein, indicating that these two molecules may act in opposition under certain conditions. Furthermore, a positive correlation was found between calcineurin inhibitors and Histamine, which contrasts with the earlier negative correlation between calcineurin inhibitors and Histamine, suggesting a complex regulatory network.   The association between calcineurin inhibitors and Metallothionein was also confirmed, indicating a potential functional link between these two molecules. A comparison between calcineurin inhibitors and glucose revealed an association, reinforcing the idea that glucose may influence calcineurin inhibitor activity. Finally, a positive correlation was observed between glucose and calcineurin inhibitors, which aligns with the negative correlation between calcineurin inhibitors and bombesin, suggesting a dynamic interplay among these factors.   These results provide new insights into the molecular mechanisms underlying the interactions between Spirulina, Metallothionein, glucose, and calcineurin inhibitors in immune cell lines, with implications for understanding their roles in cellular signaling and immune responses.
20250171	0	9	Spirulina	OrganismTaxon	551299
20250171	36	51	Metallothionein	ChemicalEntity	D008668
20250171	53	60	glucose	ChemicalEntity	D005947
20250171	66	88	calcineurin inhibitors	ChemicalEntity	D065095
20250171	159	168	Spirulina	OrganismTaxon	551299
20250171	170	185	Metallothionein	ChemicalEntity	D008668
20250171	187	194	glucose	ChemicalEntity	D005947
20250171	200	222	calcineurin inhibitors	ChemicalEntity	D065095
20250171	273	278	Ba/F3	CellLine	CVCL_0161
20250171	283	292	RAW 264.7	CellLine	CVCL_0493
20250171	438	446	bombesin	ChemicalEntity	D001839
20250171	451	466	Metallothionein	ChemicalEntity	D008668
20250171	504	512	bombesin	ChemicalEntity	D001839
20250171	526	541	Metallothionein	ChemicalEntity	D008668
20250171	610	632	calcineurin inhibitors	ChemicalEntity	D065095
20250171	637	645	bombesin	ChemicalEntity	D001839
20250171	663	685	calcineurin inhibitors	ChemicalEntity	D065095
20250171	698	706	bombesin	ChemicalEntity	D001839
20250171	765	772	glucose	ChemicalEntity	D005947
20250171	777	799	calcineurin inhibitors	ChemicalEntity	D065095
20250171	815	822	glucose	ChemicalEntity	D005947
20250171	850	872	calcineurin inhibitors	ChemicalEntity	D065095
20250171	928	935	glucose	ChemicalEntity	D005947
20250171	940	949	Histamine	ChemicalEntity	D006632
20250171	970	979	Histamine	ChemicalEntity	D006632
20250171	984	991	glucose	ChemicalEntity	D005947
20250171	1037	1044	glucose	ChemicalEntity	D005947
20250171	1048	1057	Histamine	ChemicalEntity	D006632
20250171	1117	1132	Metallothionein	ChemicalEntity	D008668
20250171	1137	1144	glucose	ChemicalEntity	D005947
20250171	1162	1169	glucose	ChemicalEntity	D005947
20250171	1183	1198	Metallothionein	ChemicalEntity	D008668
20250171	1237	1244	glucose	ChemicalEntity	D005947
20250171	1249	1264	Metallothionein	ChemicalEntity	D008668
20250171	1390	1399	Histamine	ChemicalEntity	D006632
20250171	1404	1419	Metallothionein	ChemicalEntity	D008668
20250171	1559	1581	calcineurin inhibitors	ChemicalEntity	D065095
20250171	1586	1595	Histamine	ChemicalEntity	D006632
20250171	1659	1681	calcineurin inhibitors	ChemicalEntity	D065095
20250171	1686	1695	Histamine	ChemicalEntity	D006632
20250171	1764	1786	calcineurin inhibitors	ChemicalEntity	D065095
20250171	1791	1806	Metallothionein	ChemicalEntity	D008668
20250171	1916	1938	calcineurin inhibitors	ChemicalEntity	D065095
20250171	1943	1950	glucose	ChemicalEntity	D005947
20250171	2002	2009	glucose	ChemicalEntity	D005947
20250171	2109	2116	glucose	ChemicalEntity	D005947
20250171	2121	2143	calcineurin inhibitors	ChemicalEntity	D065095
20250171	2196	2218	calcineurin inhibitors	ChemicalEntity	D065095
20250171	2223	2231	bombesin	ChemicalEntity	D001839
20250171	2388	2397	Spirulina	OrganismTaxon	551299
20250171	2399	2414	Metallothionein	ChemicalEntity	D008668
20250171	2416	2423	glucose	ChemicalEntity	D005947
20250171	2429	2451	calcineurin inhibitors	ChemicalEntity	D065095
20250171	Negative_Correlation	D001839	D008668	Novel
20250171	Positive_Correlation	D065095	D001839	Novel
20250171	Negative_Correlation	D005947	D065095	Novel
20250171	Comparison	D005947	D008668	Novel
20250171	Comparison	D001839	D005947	Novel
20250171	Positive_Correlation	D006632	D005947	Novel
20250171	Positive_Correlation	D005947	D006632	Novel
20250171	Association	D008668	D005947	Novel
20250171	Negative_Correlation	D065095	D006632	Novel
20250171	Positive_Correlation	D005947	D008668	Novel
20250171	Positive_Correlation	D065095	D006632	Novel
20250171	Association	D065095	D008668	Novel
20250171	Negative_Correlation	D006632	D008668	Novel
20250171	Comparison	D065095	D005947	Novel
20250171	Association	D005947	D065095	Novel
20250171	Negative_Correlation	D065095	D001839	Novel
20250171	Positive_Correlation	D005947	D065095	Novel
20250171	Association	D008668	D065095	Novel
20250171	Association	D006632	D001839	Novel
20250171	Positive_Correlation	D006632	D001839	Novel

31054275|t|Buprenorphine, Antibiotic Interactions, and Genetic Variants in Polyuria and Related Ph
31054275|a|This study investigates the complex interactions between buprenorphine, antibiotic use, and genetic sequence variants in the context of polyuria and related phenotypes. Buprenorphine, a chemical entity widely used in opioid therapy, was found to have a positive correlation with the sequence variant D299G and a strong association with polyuria. Additionally, buprenorphine showed a positive correlation with the 105-bp deletion encompassing bases 1078-1182, which was itself associated with polyuria. The conversion between buprenorphine and antibiotic was observed, with antibiotic use showing a positive correlation with both D299G and polyuria.   The sequence variant Cys 23-Ser 23 was found to be associated with polyuria and also with antibiotic use. Furthermore, Cys 23-Ser 23 exhibited a positive correlation with antibiotic and a direct association with D299G. The 105-bp deletion encompassing bases 1078-1182 was associated with both buprenorphine and Cys 23-Ser 23, and it also showed a positive correlation with antibiotic. The cotreatment of buprenorphine and antibiotic was linked to increased polyuria, and the association between antibiotic and the 105-bp deletion was further reinforced by its positive correlation with polyuria.   The study also revealed that the sequence variant D299G was associated with buprenorphine and had a positive correlation with both antibiotic and buprenorphine. The 105-bp deletion encompassing bases 1078-1182 was found to have a direct association with D299G, and the sequence variant Cys 23-Ser 23 was associated with both buprenorphine and D299G. These findings highlight the intricate relationships between chemical entities, genetic variants, and phenotypic features such as polyuria, underscoring the need for further research into their clinical implications.
31054275	145	158	buprenorphine	ChemicalEntity	D002047
31054275	160	170	antibiotic	ChemicalEntity	D000900
31054275	224	232	polyuria	DiseaseOrPhenotypicFeature	D011141
31054275	388	393	D299G	SequenceVariant	rs4986790
31054275	424	432	polyuria	DiseaseOrPhenotypicFeature	D011141
31054275	448	461	buprenorphine	ChemicalEntity	D002047
31054275	501	545	105-bp deletion encompassing bases 1078-1182	SequenceVariant	c|DEL|1078-1182|
31054275	580	588	polyuria	DiseaseOrPhenotypicFeature	D011141
31054275	613	626	buprenorphine	ChemicalEntity	D002047
31054275	631	641	antibiotic	ChemicalEntity	D000900
31054275	661	671	antibiotic	ChemicalEntity	D000900
31054275	717	722	D299G	SequenceVariant	rs4986790
31054275	727	735	polyuria	DiseaseOrPhenotypicFeature	D011141
31054275	760	773	Cys 23-Ser 23	SequenceVariant	rs6318
31054275	806	814	polyuria	DiseaseOrPhenotypicFeature	D011141
31054275	829	839	antibiotic	ChemicalEntity	D000900
31054275	858	871	Cys 23-Ser 23	SequenceVariant	rs6318
31054275	910	920	antibiotic	ChemicalEntity	D000900
31054275	951	956	D299G	SequenceVariant	rs4986790
31054275	962	1006	105-bp deletion encompassing bases 1078-1182	SequenceVariant	c|DEL|1078-1182|
31054275	1032	1045	buprenorphine	ChemicalEntity	D002047
31054275	1050	1063	Cys 23-Ser 23	SequenceVariant	rs6318
31054275	1112	1122	antibiotic	ChemicalEntity	D000900
31054275	1143	1156	buprenorphine	ChemicalEntity	D002047
31054275	1161	1171	antibiotic	ChemicalEntity	D000900
31054275	1196	1204	polyuria	DiseaseOrPhenotypicFeature	D011141
31054275	1234	1244	antibiotic	ChemicalEntity	D000900
31054275	1325	1333	polyuria	DiseaseOrPhenotypicFeature	D011141
31054275	1387	1392	D299G	SequenceVariant	rs4986790
31054275	1413	1426	buprenorphine	ChemicalEntity	D002047
31054275	1468	1478	antibiotic	ChemicalEntity	D000900
31054275	1483	1496	buprenorphine	ChemicalEntity	D002047
31054275	1502	1546	105-bp deletion encompassing bases 1078-1182	SequenceVariant	c|DEL|1078-1182|
31054275	1591	1596	D299G	SequenceVariant	rs4986790
31054275	1623	1636	Cys 23-Ser 23	SequenceVariant	rs6318
31054275	1662	1675	buprenorphine	ChemicalEntity	D002047
31054275	1680	1685	D299G	SequenceVariant	rs4986790
31054275	1817	1825	polyuria	DiseaseOrPhenotypicFeature	D011141
31054275	Association	rs6318	D011141	Novel
31054275	Positive_Correlation	D002047	rs4986790	Novel
31054275	Association	D000900	c|DEL|1078-1182|	Novel
31054275	Association	rs6318	D000900	Novel
31054275	Conversion	D000900	D002047	Novel
31054275	Positive_Correlation	D000900	rs4986790	Novel
31054275	Association	rs4986790	D002047	Novel
31054275	Association	c|DEL|1078-1182|	D011141	Novel
31054275	Positive_Correlation	D000900	c|DEL|1078-1182|	Novel
31054275	Association	c|DEL|1078-1182|	D002047	Novel
31054275	Association	D011141	D002047	Novel
31054275	Cotreatment	D002047	D000900	Novel
31054275	Association	D002047	c|DEL|1078-1182|	Novel
31054275	Positive_Correlation	D000900	D011141	Novel
31054275	Association	rs6318	D002047	Novel
31054275	Association	c|DEL|1078-1182|	rs6318	Novel
31054275	Conversion	D002047	D000900	Novel
31054275	Association	c|DEL|1078-1182|	rs4986790	Novel
31054275	Positive_Correlation	D002047	c|DEL|1078-1182|	Novel
31054275	Association	rs6318	rs4986790	Novel
31054275	Association	D011141	D000900	Novel
31054275	Positive_Correlation	D000900	rs6318	Novel

89424504|t|Genetic and functional analysis of Bmi1, DBH, and IL-2 in 253JB-V cells derived from Mangifera ind
89424504|a|In this study, we investigated the genetic and functional relationships between the gene products Bmi1, DBH, and IL-2 in the context of the 253JB-V cell line, which was isolated from Mangifera indica Linn. Our findings reveal a complex network of interactions among these genes and their sequence variants.   We observed a negative correlation between Bmi1 and IL-2, as well as between Bmi1 and DBH, while a positive correlation was noted between DBH and IL-2. These correlations were further supported by the association of the sequence variant c.689C>G with DBH, and the variant G246X with both c.689C>G and DBH. Additionally, the variant P163S was found to be associated with IL-2, DBH, and c.689C>G, and also linked to G246X.   The sequence variant G246X was found to be associated with multiple other variants, including c.689C>G and P163S, highlighting its central role in the genetic network. Furthermore, the variant P163S was associated with IL-2, reinforcing the interplay between these genes.   Our results suggest that the 253JB-V cell line from Mangifera indica Linn serves as a valuable model for studying the functional and genetic interactions of Bmi1, DBH, and IL-2, as well as their sequence variants. These findings provide new insights into the molecular mechanisms underlying these gene interactions in this unique cell line.
89424504	35	39	Bmi1	GeneOrGeneProduct	12151
89424504	41	44	DBH	GeneOrGeneProduct	13166
89424504	50	54	IL-2	GeneOrGeneProduct	3558
89424504	58	65	253JB-V	CellLine	CVCL_7937
89424504	197	201	Bmi1	GeneOrGeneProduct	12151
89424504	203	206	DBH	GeneOrGeneProduct	13166
89424504	212	216	IL-2	GeneOrGeneProduct	3558
89424504	239	246	253JB-V	CellLine	CVCL_7937
89424504	282	303	Mangifera indica Linn	OrganismTaxon	29780
89424504	451	455	Bmi1	GeneOrGeneProduct	12151
89424504	460	464	IL-2	GeneOrGeneProduct	3558
89424504	485	489	Bmi1	GeneOrGeneProduct	12151
89424504	494	497	DBH	GeneOrGeneProduct	13166
89424504	546	549	DBH	GeneOrGeneProduct	13166
89424504	554	558	IL-2	GeneOrGeneProduct	3558
89424504	645	653	c.689C>G	SequenceVariant	c|SUB|C|689|G
89424504	659	662	DBH	GeneOrGeneProduct	13166
89424504	680	685	G246X	SequenceVariant	p|SUB|G|246|X
89424504	696	704	c.689C>G	SequenceVariant	c|SUB|C|689|G
89424504	709	712	DBH	GeneOrGeneProduct	13166
89424504	740	745	P163S	SequenceVariant	rs387906769
89424504	778	782	IL-2	GeneOrGeneProduct	3558
89424504	784	787	DBH	GeneOrGeneProduct	13166
89424504	793	801	c.689C>G	SequenceVariant	c|SUB|C|689|G
89424504	822	827	G246X	SequenceVariant	p|SUB|G|246|X
89424504	852	857	G246X	SequenceVariant	p|SUB|G|246|X
89424504	925	933	c.689C>G	SequenceVariant	c|SUB|C|689|G
89424504	938	943	P163S	SequenceVariant	rs387906769
89424504	1024	1029	P163S	SequenceVariant	rs387906769
89424504	1050	1054	IL-2	GeneOrGeneProduct	3558
89424504	1134	1141	253JB-V	CellLine	CVCL_7937
89424504	1157	1178	Mangifera indica Linn	OrganismTaxon	29780
89424504	1262	1266	Bmi1	GeneOrGeneProduct	12151
89424504	1268	1271	DBH	GeneOrGeneProduct	13166
89424504	1277	1281	IL-2	GeneOrGeneProduct	3558
89424504	Negative_Correlation	13166	3558	Novel
89424504	Positive_Correlation	12151	3558	Novel
89424504	Positive_Correlation	3558	12151	Novel
89424504	Association	c|SUB|C|689|G	13166	Novel
89424504	Association	p|SUB|G|246|X	c|SUB|C|689|G	Novel
89424504	Negative_Correlation	3558	12151	Novel
89424504	Association	p|SUB|G|246|X	13166	Novel
89424504	Association	rs387906769	3558	Novel
89424504	Association	p|SUB|G|246|X	rs387906769	Novel
89424504	Association	rs387906769	p|SUB|G|246|X	Novel
89424504	Association	rs387906769	c|SUB|C|689|G	Novel
89424504	Association	p|SUB|G|246|X	3558	Novel
89424504	Association	c|SUB|C|689|G	p|SUB|G|246|X	Novel
89424504	Negative_Correlation	12151	3558	Novel
89424504	Negative_Correlation	12151	13166	Novel
89424504	Association	rs387906769	13166	Novel
89424504	Association	c|SUB|C|689|G	rs387906769	Novel
89424504	Negative_Correlation	13166	12151	Novel
89424504	Positive_Correlation	13166	3558	Novel

77071186|t|SJ-GBM2 cell line and the role of Ca(2+) channel blockers in hepatocellular carcinomas: a bacterial per
77071186|a|The SJ-GBM2 cell line, a well-characterized model for studying tumor biology, was used to investigate the relationship between Ca(2+) channel blockers and hepatocellular carcinomas. Our findings suggest a negative correlation between the presence of Ca(2+) channel blockers and the progression of hepatocellular carcinomas in this cell line. This effect was further supported by in vitro experiments where the addition of Ca(2+) channel blockers led to a significant reduction in the proliferation of SJ-GBM2 cells.   To explore the underlying mechanisms, we examined the interaction between Ca(2+) channel blockers and the bacterial microbiome, as bacteria are known to influence tumor development. The study included multiple bacterial strains, and the results indicated that certain bacteria may modulate the efficacy of Ca(2+) channel blockers in suppressing hepatocellular carcinomas.   Further analysis revealed that the presence of specific bacterial taxa correlated with a diminished response to Ca(2+) channel blockers in the SJ-GBM2 cell line. This suggests that the interplay between bacteria, Ca(2+) channel blockers, and hepatocellular carcinomas is complex and may involve microbial modulation of cellular signaling pathways. These findings highlight the importance of considering bacterial influences when evaluating the therapeutic potential of Ca(2+) channel blockers in hepatocellular carcinomas.
77071186	0	7	SJ-GBM2	CellLine	CVCL_M141
77071186	34	57	Ca(2+) channel blockers	ChemicalEntity	D002121
77071186	61	86	hepatocellular carcinomas	DiseaseOrPhenotypicFeature	D006528
77071186	90	98	bacteria	OrganismTaxon	2
77071186	108	115	SJ-GBM2	CellLine	CVCL_M141
77071186	231	254	Ca(2+) channel blockers	ChemicalEntity	D002121
77071186	259	284	hepatocellular carcinomas	DiseaseOrPhenotypicFeature	D006528
77071186	354	377	Ca(2+) channel blockers	ChemicalEntity	D002121
77071186	401	426	hepatocellular carcinomas	DiseaseOrPhenotypicFeature	D006528
77071186	526	549	Ca(2+) channel blockers	ChemicalEntity	D002121
77071186	605	612	SJ-GBM2	CellLine	CVCL_M141
77071186	696	719	Ca(2+) channel blockers	ChemicalEntity	D002121
77071186	728	736	bacteria	OrganismTaxon	2
77071186	753	761	bacteria	OrganismTaxon	2
77071186	832	840	bacteria	OrganismTaxon	2
77071186	890	898	bacteria	OrganismTaxon	2
77071186	928	951	Ca(2+) channel blockers	ChemicalEntity	D002121
77071186	967	992	hepatocellular carcinomas	DiseaseOrPhenotypicFeature	D006528
77071186	1052	1060	bacteria	OrganismTaxon	2
77071186	1108	1131	Ca(2+) channel blockers	ChemicalEntity	D002121
77071186	1139	1146	SJ-GBM2	CellLine	CVCL_M141
77071186	1199	1207	bacteria	OrganismTaxon	2
77071186	1209	1232	Ca(2+) channel blockers	ChemicalEntity	D002121
77071186	1238	1263	hepatocellular carcinomas	DiseaseOrPhenotypicFeature	D006528
77071186	1399	1407	bacteria	OrganismTaxon	2
77071186	1465	1488	Ca(2+) channel blockers	ChemicalEntity	D002121
77071186	1492	1517	hepatocellular carcinomas	DiseaseOrPhenotypicFeature	D006528
77071186	Negative_Correlation	D006528	D002121	Novel

49366684|t|FAM161A and Aniridia: genetic and functional links with memory impairment and thiamine metabolism in LbetaT2 and H446 ce
49366684|a|Recent studies have highlighted the potential role of FAM161A in the pathogenesis of Aniridia, a rare congenital disorder characterized by the absence of the iris. This study investigates the molecular mechanisms underlying the association between FAM161A and Aniridia, as well as its potential involvement in memory impairment. Using a combination of genetic and functional assays, we demonstrate a positive correlation between FAM161A expression and Aniridia, as well as between FAM161A and memory impairment. These findings are supported by the presence of multiple sequence variants, including c.263C>T and c.609+28_610-16del, which are associated with altered FAM161A function.   To further explore the functional implications, we examined the effects of thiamine and 2,3,5-triphenyltetrazolium on FAM161A expression in LbetaT2 and H446 cell lines. Our results show that thiamine treatment significantly modulates FAM161A activity, suggesting a potential role for thiamine in the regulation of this gene. Additionally, the presence of 8 nucleotide deletion variants in these cell lines correlates with changes in FAM161A expression levels. These findings provide new insights into the genetic and metabolic pathways linking FAM161A to Aniridia and memory impairment, and suggest that thiamine may serve as a therapeutic target in the management of these conditions.
49366684	0	7	FAM161A	GeneOrGeneProduct	84140
49366684	12	20	Aniridia	DiseaseOrPhenotypicFeature	D015783
49366684	56	73	memory impairment	DiseaseOrPhenotypicFeature	D008569
49366684	78	86	thiamine	ChemicalEntity	D013831
49366684	101	108	LbetaT2	CellLine	CVCL_0398
49366684	113	117	H446	CellLine	CVCL_1562
49366684	175	182	FAM161A	GeneOrGeneProduct	84140
49366684	206	214	Aniridia	DiseaseOrPhenotypicFeature	D015783
49366684	369	376	FAM161A	GeneOrGeneProduct	84140
49366684	381	389	Aniridia	DiseaseOrPhenotypicFeature	D015783
49366684	431	448	memory impairment	DiseaseOrPhenotypicFeature	D008569
49366684	550	557	FAM161A	GeneOrGeneProduct	84140
49366684	573	581	Aniridia	DiseaseOrPhenotypicFeature	D015783
49366684	602	609	FAM161A	GeneOrGeneProduct	84140
49366684	614	631	memory impairment	DiseaseOrPhenotypicFeature	D008569
49366684	719	727	c.263C>T	SequenceVariant	c|SUB|C|263|T
49366684	732	750	c.609+28_610-16del	SequenceVariant	c|DEL|609+28_610-16|
49366684	786	793	FAM161A	GeneOrGeneProduct	84140
49366684	881	889	thiamine	ChemicalEntity	D013831
49366684	894	920	2,3,5-triphenyltetrazolium	ChemicalEntity	C009591
49366684	924	931	FAM161A	GeneOrGeneProduct	84140
49366684	946	953	LbetaT2	CellLine	CVCL_0398
49366684	958	962	H446	CellLine	CVCL_1562
49366684	997	1005	thiamine	ChemicalEntity	D013831
49366684	1040	1047	FAM161A	GeneOrGeneProduct	84140
49366684	1090	1098	thiamine	ChemicalEntity	D013831
49366684	1161	1182	8 nucleotide deletion	SequenceVariant	c|DEL||8
49366684	1239	1246	FAM161A	GeneOrGeneProduct	84140
49366684	1350	1357	FAM161A	GeneOrGeneProduct	84140
49366684	1361	1369	Aniridia	DiseaseOrPhenotypicFeature	D015783
49366684	1374	1391	memory impairment	DiseaseOrPhenotypicFeature	D008569
49366684	1410	1418	thiamine	ChemicalEntity	D013831
49366684	Positive_Correlation	D015783	84140	Novel
49366684	Positive_Correlation	D008569	84140	Novel

32602126|t|LNCaP and HCT116 cell lines: interactions between sequence variants, gene products, and chemical entities in the context of dexamphetamine and reactive oxygen
32602126|a|This study investigates the complex interplay between sequence variants, gene products, and chemical entities in the LNCaP and HCT116 cell lines, with a focus on the effects of dexamphetamine and reactive oxygen species. The (GCG)6(GCA)3GCG sequence was replaced by (GCG)6(GCA)(GCG)4(GCA)3GCG variant was found to be significantly associated with altered expression of the High Mobility Group-Box 1 gene, which in turn binds to reactive oxygen species and Cyclooxygenase inhibitors. The 192RR sequence variant showed a positive correlation with both aminotransferase and reactive oxygen species, suggesting a potential regulatory role in cellular stress responses.   The gene product desmin was found to associate with aminotransferase and also bind to reactive oxygen species, highlighting its role in oxidative stress pathways. Additionally, the gene product PLAU was observed to bind to reactive oxygen species, further emphasizing the involvement of these pathways in cellular function. The gene product BMP was associated with dexamphetamine and also bound to reactive oxygen species, indicating a potential role in modulating the effects of this stimulant.   A positive correlation was observed between aminotransferase and Cyclooxygenase inhibitors, as well as between Cyclooxygenase inhibitors and reactive oxygen species. These findings suggest a coordinated response to oxidative stress and metabolic changes. The association between High Mobility Group-Box 1 and dexamphetamine was further supported by its binding to both reactive oxygen species and Cyclooxygenase inhibitors, reinforcing its role in mediating the effects of these chemical entities.   The LNCaP and HCT116 cell lines were used as models to study these interactions, with multiple instances of the cell line being included to ensure robustness of the findings. The results provide new insights into the molecular mechanisms underlying the effects of dexamphetamine and reactive oxygen species in these cell types, with implications for understanding the pathophysiology of related diseases.
32602126	0	5	LNCaP	CellLine	CVCL_0395
32602126	10	16	HCT116	CellLine	CVCL_0291
32602126	124	138	dexamphetamine	ChemicalEntity	D003913
32602126	276	281	LNCaP	CellLine	CVCL_0395
32602126	286	292	HCT116	CellLine	CVCL_0291
32602126	336	350	dexamphetamine	ChemicalEntity	D003913
32602126	384	451	(GCG)6(GCA)3GCG sequence was replaced by (GCG)6(GCA)(GCG)4(GCA)3GCG	SequenceVariant	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG
32602126	532	557	High Mobility Group-Box 1	GeneOrGeneProduct	3146
32602126	615	640	Cyclooxygenase inhibitors	ChemicalEntity	D016861
32602126	646	651	192RR	SequenceVariant	p|Allele|R|192
32602126	709	725	aminotransferase	ChemicalEntity	D000637
32602126	843	849	desmin	GeneOrGeneProduct	64362
32602126	878	894	aminotransferase	ChemicalEntity	D000637
32602126	1020	1024	PLAU	GeneOrGeneProduct	5328
32602126	1167	1170	BMP	GeneOrGeneProduct	12159
32602126	1191	1205	dexamphetamine	ChemicalEntity	D003913
32602126	1368	1384	aminotransferase	ChemicalEntity	D000637
32602126	1389	1414	Cyclooxygenase inhibitors	ChemicalEntity	D016861
32602126	1435	1460	Cyclooxygenase inhibitors	ChemicalEntity	D016861
32602126	1603	1628	High Mobility Group-Box 1	GeneOrGeneProduct	3146
32602126	1633	1647	dexamphetamine	ChemicalEntity	D003913
32602126	1721	1746	Cyclooxygenase inhibitors	ChemicalEntity	D016861
32602126	1828	1833	LNCaP	CellLine	CVCL_0395
32602126	1838	1844	HCT116	CellLine	CVCL_0291
32602126	2088	2102	dexamphetamine	ChemicalEntity	D003913
32602126	Positive_Correlation	D000637	D016861	Novel
32602126	Association	12159	D003913	Novel
32602126	Bind	12159	D017382	Novel
32602126	Positive_Correlation	D000637	p|Allele|R|192	Novel
32602126	Positive_Correlation	D016861	D017382	Novel
32602126	Positive_Correlation	D017382	p|Allele|R|192	Novel
32602126	Association	3146	D017382	Novel
32602126	Bind	3146	D016861	Novel
32602126	Positive_Correlation	D000637	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	Novel
32602126	Association	64362	D000637	Novel
32602126	Bind	3146	D003913	Novel
32602126	Association	3146	D003913	Novel
32602126	Bind	3146	D017382	Novel
32602126	Bind	64362	D017382	Novel
32602126	Bind	5328	D017382	Novel

26829993|t|miR-494 and GFC: interactions with antiarrhythmic drugs, precancerous conditions, and their associations with EH and rectal
26829993|a|Recent studies have highlighted the complex interplay between microRNAs, chemical entities, and disease phenotypes in the context of cancer progression and metabolic disorders. This study investigates the regulatory roles of miR-494 and the chemical entity GFC in the context of precancerous conditions, EH, and rectal cancers. Our findings reveal a negative correlation between miR-494 and precancerous states, suggesting that miR-494 may act as a tumor suppressor in early stages of carcinogenesis. Additionally, miR-494 exhibits a negative correlation with rectal cancers, reinforcing its potential as a biomarker for colorectal malignancies.   The chemical entity GFC is found to bind to miR-494, indicating a direct regulatory interaction that may influence gene expression patterns in cancer-related pathways. Furthermore, the antiarrhythmic drug is shown to bind to miR-494, suggesting a possible pharmacological modulation of miR-494 activity in cardiovascular and oncological contexts.   In parallel, the gene product very-long-chain acyl-coenzyme A dehydrogenase is found to have a negative correlation with both EH and rectal cancers, implying a protective role against these conditions. Notably, this gene product also shows a negative correlation with alendronate, a bisphosphonate used in the treatment of osteoporosis, suggesting potential interactions between metabolic and oncological pathways.   The study also demonstrates that miR-494 is significantly associated with multiple disease states, including breast cancer and rectal cancers, with a strong negative correlation observed in both cases. These findings underscore the importance of miR-494 in the regulation of disease progression and highlight the need for further research into its therapeutic potential in cancer and metabolic disorders.
26829993	0	7	miR-494	GeneOrGeneProduct	723878
26829993	12	15	GFC	ChemicalEntity	C573355
26829993	35	54	antiarrhythmic drug	ChemicalEntity	D000889
26829993	57	69	precancerous	DiseaseOrPhenotypicFeature	D011230
26829993	110	112	EH	DiseaseOrPhenotypicFeature	D000075222
26829993	349	356	miR-494	GeneOrGeneProduct	723878
26829993	381	384	GFC	ChemicalEntity	C573355
26829993	403	415	precancerous	DiseaseOrPhenotypicFeature	D011230
26829993	428	430	EH	DiseaseOrPhenotypicFeature	D000075222
26829993	436	450	rectal cancers	DiseaseOrPhenotypicFeature	D012004
26829993	503	510	miR-494	GeneOrGeneProduct	723878
26829993	515	527	precancerous	DiseaseOrPhenotypicFeature	D011230
26829993	552	559	miR-494	GeneOrGeneProduct	723878
26829993	639	646	miR-494	GeneOrGeneProduct	723878
26829993	684	698	rectal cancers	DiseaseOrPhenotypicFeature	D012004
26829993	792	795	GFC	ChemicalEntity	C573355
26829993	816	823	miR-494	GeneOrGeneProduct	723878
26829993	957	976	antiarrhythmic drug	ChemicalEntity	D000889
26829993	997	1004	miR-494	GeneOrGeneProduct	723878
26829993	1058	1065	miR-494	GeneOrGeneProduct	723878
26829993	1151	1196	very-long-chain acyl-coenzyme A dehydrogenase	GeneOrGeneProduct	37
26829993	1247	1249	EH	DiseaseOrPhenotypicFeature	D000075222
26829993	1254	1268	rectal cancers	DiseaseOrPhenotypicFeature	D012004
26829993	1389	1400	alendronate	ChemicalEntity	D019386
26829993	1571	1578	miR-494	GeneOrGeneProduct	723878
26829993	1665	1679	rectal cancers	DiseaseOrPhenotypicFeature	D012004
26829993	1784	1791	miR-494	GeneOrGeneProduct	723878
26829993	Negative_Correlation	37	D000075222	Novel
26829993	Bind	D000889	723878	Novel
26829993	Bind	C573355	723878	Novel
26829993	Negative_Correlation	723878	D012004	Novel
26829993	Negative_Correlation	37	D012004	Novel
26829993	Negative_Correlation	37	D019386	Novel
26829993	Negative_Correlation	723878	D011230	Novel

31121900|t|Phloridzin's multifaceted interactions with P2RX7, Delta695-725, and N-Acetylglucosamine (O-GlcNAc) transferase in Escherichia coli, PA-1, and Capan1 cell lines: implications for coronary artery disease and viral i
31121900|a|Phloridzin exhibits a complex interplay with multiple molecular targets, including the P2RX7 receptor, the sequence variant Delta695-725, and the enzyme N-Acetylglucosamine (O-GlcNAc) transferase, across diverse biological contexts. In PA-1 and Capan1 cell lines, phloridzin shows a positive correlation with P2RX7 expression and activity, suggesting a potential role in modulating purinergic signaling pathways. Additionally, phloridzin is associated with the sequence variant Delta695-725, which may influence protein structure and function in Escherichia coli and other bacterial systems.   A notable positive correlation between phloridzin and N-Acetylglucosamine (O-GlcNAc) transferase was observed in both PA-1 and Capan1 cell lines, indicating a possible regulatory relationship between the compound and glycosylation processes. This interaction is further supported by the negative correlation between phloridzin and coronary artery disease, as well as the negative correlation between phloridzin and viral infection, suggesting that phloridzin may have protective effects against these conditions.   In the context of HIV-1 and tobacco-related pathologies, phloridzin's interactions with P2RX7 and N-Acetylglucosamine (O-GlcNAc) transferase may contribute to its anti-inflammatory and antiviral properties. The consistent presence of phloridzin across multiple cell lines and organisms highlights its broad biological relevance. These findings underscore the potential of phloridzin as a therapeutic agent in the management of coronary artery disease and viral infections, with further research needed to elucidate the precise molecular mechanisms underlying its effects.
31121900	44	49	P2RX7	GeneOrGeneProduct	5027
31121900	51	63	Delta695-725	SequenceVariant	p|DEL|695-725|
31121900	69	111	N-Acetylglucosamine (O-GlcNAc) transferase	GeneOrGeneProduct	8473
31121900	115	131	Escherichia coli	OrganismTaxon	562
31121900	133	137	PA-1	CellLine	CVCL_0479
31121900	143	149	Capan1	CellLine	CVCL_0237
31121900	179	202	coronary artery disease	DiseaseOrPhenotypicFeature	D003324
31121900	302	307	P2RX7	GeneOrGeneProduct	5027
31121900	339	351	Delta695-725	SequenceVariant	p|DEL|695-725|
31121900	368	410	N-Acetylglucosamine (O-GlcNAc) transferase	GeneOrGeneProduct	8473
31121900	451	455	PA-1	CellLine	CVCL_0479
31121900	460	466	Capan1	CellLine	CVCL_0237
31121900	479	489	phloridzin	ChemicalEntity	D010695
31121900	524	529	P2RX7	GeneOrGeneProduct	5027
31121900	642	652	phloridzin	ChemicalEntity	D010695
31121900	693	705	Delta695-725	SequenceVariant	p|DEL|695-725|
31121900	761	777	Escherichia coli	OrganismTaxon	562
31121900	848	858	phloridzin	ChemicalEntity	D010695
31121900	863	905	N-Acetylglucosamine (O-GlcNAc) transferase	GeneOrGeneProduct	8473
31121900	927	931	PA-1	CellLine	CVCL_0479
31121900	936	942	Capan1	CellLine	CVCL_0237
31121900	1125	1135	phloridzin	ChemicalEntity	D010695
31121900	1140	1163	coronary artery disease	DiseaseOrPhenotypicFeature	D003324
31121900	1209	1219	phloridzin	ChemicalEntity	D010695
31121900	1224	1239	viral infection	DiseaseOrPhenotypicFeature	D014777
31121900	1257	1267	phloridzin	ChemicalEntity	D010695
31121900	1342	1347	HIV-1	OrganismTaxon	11676
31121900	1352	1359	tobacco	OrganismTaxon	4097
31121900	1381	1391	phloridzin	ChemicalEntity	D010695
31121900	1412	1417	P2RX7	GeneOrGeneProduct	5027
31121900	1422	1464	N-Acetylglucosamine (O-GlcNAc) transferase	GeneOrGeneProduct	8473
31121900	1558	1568	phloridzin	ChemicalEntity	D010695
31121900	1696	1706	phloridzin	ChemicalEntity	D010695
31121900	1751	1774	coronary artery disease	DiseaseOrPhenotypicFeature	D003324
31121900	1779	1794	viral infection	DiseaseOrPhenotypicFeature	D014777
31121900	Positive_Correlation	D010695	8473	Novel
31121900	Negative_Correlation	D010695	D003324	Novel
31121900	Negative_Correlation	D010695	D014777	Novel
31121900	Association	D010695	p|DEL|695-725|	Novel
31121900	Association	D010695	8473	Novel
31121900	Association	D010695	5027	Novel
31121900	Positive_Correlation	D010695	5027	Novel

01856672|t|Investigating the role of FBXL7, NADPH oxidases, and sequence variants in congenital panocular disorder and their interactions with tritium, neopterin, and NH3 in rabbit ce
01856672|a|This study explores the complex interactions between the gene FBXL7, the enzyme NADPH oxidases, and various sequence variants in the context of congenital panocular disorder and urolithiasis. Using rabbit cell lines 253JB-V and SNU-C2A, we investigate how these genetic and molecular elements interact with tritium, neopterin, and NH3. The findings reveal a significant association between congenital panocular disorder and neopterin, as well as between JBTS and NH3. Additionally, the sequence variant Arg124Cys is found to be associated with neopterin, while the AG-dinucleotide variant shows a strong association with neopterin as well.   The study also demonstrates a direct bind between neopterin and FBXL7, and between tritium and FBXL7, suggesting a potential role for these interactions in the pathogenesis of congenital panocular disorder. Furthermore, the enzyme NADPH oxidases is associated with both FBXL7 and tritium, indicating a possible regulatory or functional link. The drug interaction between neopterin and tritium is also observed, as is the drug interaction between NH3 and tritium.   Notably, the association between JBTS and tritium, as well as between JBTS and neopterin, highlights the potential involvement of these elements in the development of urolithiasis. The study also identifies a significant association between Arg124Cys and NH3, further emphasizing the complex interplay between genetic variants and environmental factors. These findings provide new insights into the molecular mechanisms underlying congenital panocular disorder and related phenotypic features in rabbit models.
01856672	26	31	FBXL7	GeneOrGeneProduct	23194
01856672	33	47	NADPH oxidases	GeneOrGeneProduct	1666
01856672	74	103	congenital panocular disorder	DiseaseOrPhenotypicFeature	D000013
01856672	132	139	tritium	ChemicalEntity	D014316
01856672	141	150	neopterin	ChemicalEntity	D019798
01856672	156	159	NH3	ChemicalEntity	D000641
01856672	163	169	rabbit	OrganismTaxon	9986
01856672	235	240	FBXL7	GeneOrGeneProduct	23194
01856672	253	267	NADPH oxidases	GeneOrGeneProduct	1666
01856672	317	346	congenital panocular disorder	DiseaseOrPhenotypicFeature	D000013
01856672	351	363	urolithiasis	DiseaseOrPhenotypicFeature	D052878
01856672	371	377	rabbit	OrganismTaxon	9986
01856672	389	396	253JB-V	CellLine	CVCL_7937
01856672	401	408	SNU-C2A	CellLine	CVCL_1709
01856672	480	487	tritium	ChemicalEntity	D014316
01856672	489	498	neopterin	ChemicalEntity	D019798
01856672	504	507	NH3	ChemicalEntity	D000641
01856672	563	592	congenital panocular disorder	DiseaseOrPhenotypicFeature	D000013
01856672	597	606	neopterin	ChemicalEntity	D019798
01856672	627	631	JBTS	DiseaseOrPhenotypicFeature	C536293
01856672	636	639	NH3	ChemicalEntity	D000641
01856672	676	685	Arg124Cys	SequenceVariant	rs121909210
01856672	717	726	neopterin	ChemicalEntity	D019798
01856672	738	753	AG-dinucleotide	SequenceVariant	rs193302855
01856672	794	803	neopterin	ChemicalEntity	D019798
01856672	865	874	neopterin	ChemicalEntity	D019798
01856672	879	884	FBXL7	GeneOrGeneProduct	23194
01856672	898	905	tritium	ChemicalEntity	D014316
01856672	910	915	FBXL7	GeneOrGeneProduct	23194
01856672	991	1020	congenital panocular disorder	DiseaseOrPhenotypicFeature	D000013
01856672	1046	1060	NADPH oxidases	GeneOrGeneProduct	1666
01856672	1085	1090	FBXL7	GeneOrGeneProduct	23194
01856672	1095	1102	tritium	ChemicalEntity	D014316
01856672	1186	1195	neopterin	ChemicalEntity	D019798
01856672	1200	1207	tritium	ChemicalEntity	D014316
01856672	1261	1264	NH3	ChemicalEntity	D000641
01856672	1269	1276	tritium	ChemicalEntity	D014316
01856672	1313	1317	JBTS	DiseaseOrPhenotypicFeature	C536293
01856672	1322	1329	tritium	ChemicalEntity	D014316
01856672	1350	1354	JBTS	DiseaseOrPhenotypicFeature	C536293
01856672	1359	1368	neopterin	ChemicalEntity	D019798
01856672	1447	1459	urolithiasis	DiseaseOrPhenotypicFeature	D052878
01856672	1521	1530	Arg124Cys	SequenceVariant	rs121909210
01856672	1535	1538	NH3	ChemicalEntity	D000641
01856672	1711	1740	congenital panocular disorder	DiseaseOrPhenotypicFeature	D000013
01856672	1776	1782	rabbit	OrganismTaxon	9986
01856672	Association	D014316	1666	Novel
01856672	Drug_Interaction	D019798	D014316	Novel
01856672	Association	C536293	D000641	Novel
01856672	Association	D000641	23194	Novel
01856672	Bind	D019798	23194	Novel
01856672	Association	D000013	D019798	Novel
01856672	Association	rs121909210	D019798	Novel
01856672	Association	1666	23194	Novel
01856672	Association	rs193302855	D019798	Novel
01856672	Bind	D014316	23194	Novel
01856672	Bind	D019798	1666	Novel
01856672	Drug_Interaction	D000641	D014316	Novel
01856672	Association	C536293	D014316	Novel
01856672	Drug_Interaction	D019798	D000641	Novel
01856672	Association	23194	1666	Novel
01856672	Association	C536293	D019798	Novel
01856672	Association	rs121909210	D000641	Novel

52922192|t|Genetic Variants in Platonia insignis Mart and DEN-4: Associations with Liver Failure, GI AEs, and Retino
52922192|a|This study investigates the genetic and phenotypic associations between specific sequence variants and disease outcomes in Platonia insignis Mart and DEN-4. We analyzed the impact of multiple sequence variants, including histidine 626-to-arginine, Lys198Asn, and c.1092 +1G>A, on the occurrence of liver failure, GI AEs, alopecia, and Retinoblastoma. Our findings reveal a negative correlation between histidine 626-to-arginine and GI AEs, as well as between histidine 626-to-arginine and Retinoblastoma. Additionally, we observed a negative correlation between histidine 626-to-arginine and alopecia. The sequence variant del(1)(p31.2p32.3) showed a negative correlation with liver failure, and it was also associated with c.1092 +1G>A. Furthermore, Lys198Asn was found to be associated with del(1)(p31.2p32.3). The study also included multiple instances of liver failure, alopecia, and GI AEs, with the latter being particularly prevalent in DEN-4. The organism Platonia insignis Mart was found to be associated with several of these genetic variants, suggesting a potential role in the pathogenesis of these conditions. These results highlight the complex interplay between genetic variants and disease phenotypes in both Platonia insignis Mart and DEN-4, with implications for future research into the molecular mechanisms underlying these associations.
52922192	20	42	Platonia insignis Mart	OrganismTaxon	198787
52922192	47	52	DEN-4	OrganismTaxon	11070
52922192	87	93	GI AEs	DiseaseOrPhenotypicFeature	D005767
52922192	229	251	Platonia insignis Mart	OrganismTaxon	198787
52922192	256	261	DEN-4	OrganismTaxon	11070
52922192	327	352	histidine 626-to-arginine	SequenceVariant	p|SUB|H|626|R
52922192	354	363	Lys198Asn	SequenceVariant	rs5370
52922192	369	381	c.1092 +1G>A	SequenceVariant	c|SUB|G|1092+1|A
52922192	404	417	liver failure	DiseaseOrPhenotypicFeature	D017093
52922192	419	425	GI AEs	DiseaseOrPhenotypicFeature	D005767
52922192	427	435	alopecia	DiseaseOrPhenotypicFeature	D000505
52922192	441	455	Retinoblastoma	DiseaseOrPhenotypicFeature	D012175
52922192	508	533	histidine 626-to-arginine	SequenceVariant	p|SUB|H|626|R
52922192	538	544	GI AEs	DiseaseOrPhenotypicFeature	D005767
52922192	565	590	histidine 626-to-arginine	SequenceVariant	p|SUB|H|626|R
52922192	595	609	Retinoblastoma	DiseaseOrPhenotypicFeature	D012175
52922192	668	693	histidine 626-to-arginine	SequenceVariant	p|SUB|H|626|R
52922192	698	706	alopecia	DiseaseOrPhenotypicFeature	D000505
52922192	729	747	del(1)(p31.2p32.3)	SequenceVariant	c|DEL|p31.2_p32.3|
52922192	783	796	liver failure	DiseaseOrPhenotypicFeature	D017093
52922192	830	842	c.1092 +1G>A	SequenceVariant	c|SUB|G|1092+1|A
52922192	857	866	Lys198Asn	SequenceVariant	rs5370
52922192	899	917	del(1)(p31.2p32.3)	SequenceVariant	c|DEL|p31.2_p32.3|
52922192	965	978	liver failure	DiseaseOrPhenotypicFeature	D017093
52922192	980	988	alopecia	DiseaseOrPhenotypicFeature	D000505
52922192	994	1000	GI AEs	DiseaseOrPhenotypicFeature	D005767
52922192	1050	1055	DEN-4	OrganismTaxon	11070
52922192	1070	1092	Platonia insignis Mart	OrganismTaxon	198787
52922192	1331	1353	Platonia insignis Mart	OrganismTaxon	198787
52922192	1358	1363	DEN-4	OrganismTaxon	11070
52922192	Negative_Correlation	p|SUB|H|626|R	D005767	Novel
52922192	Negative_Correlation	p|SUB|H|626|R	D012175	Novel
52922192	Negative_Correlation	c|DEL|p31.2_p32.3|	D017093	Novel
52922192	Association	rs5370	c|DEL|p31.2_p32.3|	Novel
52922192	Negative_Correlation	p|SUB|H|626|R	D000505	Novel
52922192	Negative_Correlation	c|SUB|G|1092+1|A	D000505	Novel
52922192	Association	c|DEL|p31.2_p32.3|	c|SUB|G|1092+1|A	Novel

34132125|t|Toxorynchites mosquitoes and hyperventilation: genetic and pharmacological insights into the role of -511C/T and ba
34132125|a|Toxorynchites mosquitoes have been implicated in the transmission of various diseases, and recent studies have highlighted the complex interplay between their physiological responses and environmental factors. This study investigates the relationship between hyperventilation, a phenotypic feature observed in Toxorynchites mosquitoes under stress conditions, and two key genetic and pharmacological factors: the sequence variant -511C/T and the chemical entity batimastat.   Our findings reveal a positive correlation between hyperventilation and the -511C/T sequence variant in Toxorynchites mosquitoes, suggesting that this genetic polymorphism may influence respiratory behavior under hypoxic conditions. Additionally, we demonstrate an association between hyperventilation and batimastat, a matrix metalloproteinase inhibitor, indicating that batimastat may modulate respiratory responses in these mosquitoes.   The study involved a controlled experimental setup where Toxorynchites mosquitoes were exposed to varying levels of hypoxia and treated with batimastat. The results showed that mosquitoes carrying the -511C/T variant exhibited increased hyperventilation rates compared to those with the wild-type allele. Furthermore, the administration of batimastat was associated with a significant reduction in hyperventilation, suggesting a potential pharmacological intervention for managing respiratory responses in these mosquitoes.   These findings provide new insights into the genetic and pharmacological mechanisms underlying hyperventilation in Toxorynchites mosquitoes and may have implications for understanding the physiological adaptations of mosquitoes to environmental stressors. The study also underscores the importance of considering both genetic and chemical factors in the study of mosquito behavior and disease transmission.
34132125	0	24	Toxorynchites mosquitoes	OrganismTaxon	2498889
34132125	29	45	hyperventilation	DiseaseOrPhenotypicFeature	D006985
34132125	101	108	-511C/T	SequenceVariant	rs1143634
34132125	116	140	Toxorynchites mosquitoes	OrganismTaxon	2498889
34132125	375	391	hyperventilation	DiseaseOrPhenotypicFeature	D006985
34132125	426	450	Toxorynchites mosquitoes	OrganismTaxon	2498889
34132125	546	553	-511C/T	SequenceVariant	rs1143634
34132125	578	588	batimastat	ChemicalEntity	C080985
34132125	643	659	hyperventilation	DiseaseOrPhenotypicFeature	D006985
34132125	668	675	-511C/T	SequenceVariant	rs1143634
34132125	696	720	Toxorynchites mosquitoes	OrganismTaxon	2498889
34132125	877	893	hyperventilation	DiseaseOrPhenotypicFeature	D006985
34132125	898	908	batimastat	ChemicalEntity	C080985
34132125	964	974	batimastat	ChemicalEntity	C080985
34132125	1090	1114	Toxorynchites mosquitoes	OrganismTaxon	2498889
34132125	1174	1184	batimastat	ChemicalEntity	C080985
34132125	1234	1241	-511C/T	SequenceVariant	rs1143634
34132125	1270	1286	hyperventilation	DiseaseOrPhenotypicFeature	D006985
34132125	1373	1383	batimastat	ChemicalEntity	C080985
34132125	1431	1447	hyperventilation	DiseaseOrPhenotypicFeature	D006985
34132125	1654	1670	hyperventilation	DiseaseOrPhenotypicFeature	D006985
34132125	1674	1698	Toxorynchites mosquitoes	OrganismTaxon	2498889
34132125	Positive_Correlation	D006985	rs1143634	Novel
34132125	Association	D006985	C080985	Novel

30182805|t|Genetic variants in MPO and miR-31 modulate hepatic fibrogenesis and developmental anomalies in HeLa ce
30182805|a|This study investigates the molecular mechanisms underlying the association between genetic variants and the development of cardiovascular, craniofacial, and thymic malformations, as well as hepatic fibrogenesis. Using HeLa cell lines, we explored the functional impact of several sequence variants and their interactions with key genes and microRNAs. The variant 735-6 TG>AT was found to be significantly associated with cardiovascular, craniofacial, and thymic malformations, suggesting a role in developmental pathways. Additionally, this variant was shown to influence the expression of miR-31, a microRNA known to regulate multiple cellular processes.   The sequence variant c.2380 +1G>A was strongly associated with the gene MPO, which encodes myeloperoxidase, a critical enzyme in immune response and inflammation. Functional assays in HeLa cells demonstrated that this variant alters splicing patterns and protein expression, potentially contributing to disease susceptibility.   Hepatic fibrogenesis was linked to both rs5966709 and 735-6 TG>AT. The variant rs5966709 was found to modulate the expression of genes involved in fibrotic pathways, while 735-6 TG>AT was shown to interact with miR-31, which in turn affects the regulation of fibrogenic processes. Furthermore, the insertion of (GCG)4GCA was observed to co-occur with multiple variants, suggesting a potential synergistic effect on disease progression.   The gene product RagA-D was also implicated in the pathogenesis of these conditions, with its expression levels being influenced by the studied variants. These findings highlight the complex interplay between genetic variants, gene expression, and disease phenotypes, providing new insights into the molecular basis of cardiovascular, craniofacial, and thymic malformations, as well as hepatic fibrogenesis.
30182805	20	23	MPO	GeneOrGeneProduct	4353
30182805	28	34	miR-31	GeneOrGeneProduct	723895
30182805	44	64	hepatic fibrogenesis	DiseaseOrPhenotypicFeature	D008107
30182805	96	100	HeLa	CellLine	CVCL_0030
30182805	228	282	cardiovascular, craniofacial, and thymic malformations	DiseaseOrPhenotypicFeature	D018376
30182805	295	315	hepatic fibrogenesis	DiseaseOrPhenotypicFeature	D008107
30182805	323	327	HeLa	CellLine	CVCL_0030
30182805	468	479	735-6 TG>AT	SequenceVariant	c|SUB|TG|735_736|AT
30182805	526	580	cardiovascular, craniofacial, and thymic malformations	DiseaseOrPhenotypicFeature	D018376
30182805	695	701	miR-31	GeneOrGeneProduct	723895
30182805	784	796	c.2380 +1G>A	SequenceVariant	c|SUB|G|2380+1|A
30182805	835	838	MPO	GeneOrGeneProduct	4353
30182805	947	951	HeLa	CellLine	CVCL_0030
30182805	1132	1141	rs5966709	SequenceVariant	rs5966709
30182805	1146	1157	735-6 TG>AT	SequenceVariant	c|SUB|TG|735_736|AT
30182805	1171	1180	rs5966709	SequenceVariant	rs5966709
30182805	1264	1275	735-6 TG>AT	SequenceVariant	c|SUB|TG|735_736|AT
30182805	1303	1309	miR-31	GeneOrGeneProduct	723895
30182805	1390	1412	insertion of (GCG)4GCA	SequenceVariant	c|INS|(GCG)4GCA
30182805	1547	1553	RagA-D	GeneOrGeneProduct	117043
30182805	1849	1903	cardiovascular, craniofacial, and thymic malformations	DiseaseOrPhenotypicFeature	D018376
30182805	1916	1936	hepatic fibrogenesis	DiseaseOrPhenotypicFeature	D008107
30182805	Association	c|SUB|G|2380+1|A	4353	Novel
30182805	Association	D018376	c|SUB|TG|735_736|AT	Novel
30182805	Association	c|SUB|TG|735_736|AT	723895	Novel
30182805	Association	D008107	rs5966709	Novel
30182805	Association	D008107	c|SUB|TG|735_736|AT	Novel

64374120|t|ATM/ATR kinases and E-cadherin: interactions with tarsal fusion, HIV infection, and bipolar and unipolar disorder in rDEN-2 and Toxorynchites mo
64374120|a|This study investigates the complex interactions between ATM/ATR kinases, E-cadherin, tarsal fusion, and bipolar and unipolar disorder in the context of rDEN-2 and Toxorynchites mosquitoes. Our findings reveal a positive correlation between ATM/ATR kinases and HIV infection, suggesting a potential role for these kinases in the pathogenesis of HIV. Additionally, we observe a positive correlation between ATM/ATR kinases and bipolar and unipolar disorder, indicating a possible involvement in the neurobiological mechanisms underlying these conditions.   The association between E-cadherin and bipolar and unipolar disorder is further supported by our data, highlighting the importance of cell adhesion molecules in psychiatric disorders. We also find a positive correlation between tarsal fusion and ATM/ATR kinases, which may have implications for developmental biology in rDEN-2.   Notably, there is a positive correlation between tarsal fusion and Bad, suggesting a potential regulatory relationship between these two factors. Our results also demonstrate an association between Bad and ATM/ATR kinases, as well as a positive correlation between HIV infection and Bad. Furthermore, we observe a positive correlation between RA and Bad, and a positive correlation between RA and E-cadherin, indicating overlapping pathways in inflammatory and psychiatric conditions.  A negative correlation between ATM/ATR kinases and Bad is also reported, suggesting a complex regulatory network. Additionally, we find a bind between Bad and heme oxygenase-1, which may have implications for oxidative stress and disease progression. Finally, a positive correlation between E-cadherin and HIV infection is noted, reinforcing the role of cell adhesion molecules in immune responses. These findings provide new insights into the molecular mechanisms underlying these conditions and their interrelationships in both human and mosquito models.
64374120	0	15	ATM/ATR kinases	GeneOrGeneProduct	300711
64374120	20	30	E-cadherin	GeneOrGeneProduct	12550
64374120	50	63	tarsal fusion	DiseaseOrPhenotypicFeature	D000070604
64374120	65	78	HIV infection	DiseaseOrPhenotypicFeature	D015658
64374120	84	113	bipolar and unipolar disorder	DiseaseOrPhenotypicFeature	D001714
64374120	117	123	rDEN-2	OrganismTaxon	11060
64374120	202	217	ATM/ATR kinases	GeneOrGeneProduct	300711
64374120	219	229	E-cadherin	GeneOrGeneProduct	12550
64374120	231	244	tarsal fusion	DiseaseOrPhenotypicFeature	D000070604
64374120	250	279	bipolar and unipolar disorder	DiseaseOrPhenotypicFeature	D001714
64374120	298	304	rDEN-2	OrganismTaxon	11060
64374120	309	333	Toxorynchites mosquitoes	OrganismTaxon	2498889
64374120	386	401	ATM/ATR kinases	GeneOrGeneProduct	300711
64374120	406	419	HIV infection	DiseaseOrPhenotypicFeature	D015658
64374120	551	566	ATM/ATR kinases	GeneOrGeneProduct	300711
64374120	571	600	bipolar and unipolar disorder	DiseaseOrPhenotypicFeature	D001714
64374120	725	735	E-cadherin	GeneOrGeneProduct	12550
64374120	740	769	bipolar and unipolar disorder	DiseaseOrPhenotypicFeature	D001714
64374120	929	942	tarsal fusion	DiseaseOrPhenotypicFeature	D000070604
64374120	947	962	ATM/ATR kinases	GeneOrGeneProduct	300711
64374120	1021	1027	rDEN-2	OrganismTaxon	11060
64374120	1080	1093	tarsal fusion	DiseaseOrPhenotypicFeature	D000070604
64374120	1098	1101	Bad	GeneOrGeneProduct	64639
64374120	1229	1232	Bad	GeneOrGeneProduct	64639
64374120	1237	1252	ATM/ATR kinases	GeneOrGeneProduct	300711
64374120	1296	1309	HIV infection	DiseaseOrPhenotypicFeature	D015658
64374120	1314	1317	Bad	GeneOrGeneProduct	64639
64374120	1374	1376	RA	DiseaseOrPhenotypicFeature	D005911
64374120	1381	1384	Bad	GeneOrGeneProduct	64639
64374120	1421	1423	RA	DiseaseOrPhenotypicFeature	D005911
64374120	1428	1438	E-cadherin	GeneOrGeneProduct	12550
64374120	1548	1563	ATM/ATR kinases	GeneOrGeneProduct	300711
64374120	1568	1571	Bad	GeneOrGeneProduct	64639
64374120	1668	1671	Bad	GeneOrGeneProduct	64639
64374120	1676	1692	heme oxygenase-1	GeneOrGeneProduct	15368
64374120	1808	1818	E-cadherin	GeneOrGeneProduct	12550
64374120	1823	1836	HIV infection	DiseaseOrPhenotypicFeature	D015658
64374120	Positive_Correlation	300711	D015658	Novel
64374120	Association	12550	D001714	Novel
64374120	Positive_Correlation	300711	D001714	Novel
64374120	Positive_Correlation	D000070604	64639	Novel
64374120	Association	64639	300711	Novel
64374120	Positive_Correlation	D015658	64639	Novel
64374120	Positive_Correlation	D005911	64639	Novel
64374120	Positive_Correlation	D015658	300711	Novel
64374120	Negative_Correlation	300711	64639	Novel
64374120	Positive_Correlation	D005911	12550	Novel
64374120	Bind	64639	15368	Novel
64374120	Positive_Correlation	12550	D015658	Novel
64374120	Positive_Correlation	D000070604	300711	Novel

97454426|t|Genetic and pharmacological interactions of rs7535263, morphine, and thyroxine in the context of Diffuse mesangial s
97454426|a|This study investigates the complex interplay between the genetic variant rs7535263, the opioid morphine, and the thyroid hormone thyroxine in the context of Diffuse mesangial sclerosis (DMS). Our findings reveal a positive correlation between morphine and DMS, suggesting that morphine exposure may exacerbate the progression of this renal disease. Additionally, we observed a negative correlation between thyroxine and morphine, indicating that thyroxine may mitigate the effects of morphine in this context.   The genetic variant rs7535263 was found to be positively correlated with morphine, implying a potential role in modulating morphine's pharmacological effects. However, rs7535263 also exhibited a negative correlation with thyroxine, suggesting a possible antagonistic relationship between these two chemical entities. Furthermore, rs7535263 was associated with morphine, reinforcing its potential as a genetic marker for morphine response.   Interestingly, the relationship between DMS and morphine was both positive and negative, highlighting the complexity of the disease-morphine interaction. Similarly, the relationship between DMS and thyroxine was negative, suggesting that thyroxine may have a protective effect against the development of DMS.   These findings underscore the importance of considering genetic and pharmacological interactions in the management of DMS and related conditions. The multiple correlations observed between rs7535263, morphine, and thyroxine provide a foundation for future research into personalized treatment strategies for patients with DMS.
97454426	44	53	rs7535263	SequenceVariant	rs7535263
97454426	55	63	morphine	ChemicalEntity	D009020
97454426	69	78	thyroxine	ChemicalEntity	D013974
97454426	191	200	rs7535263	SequenceVariant	rs7535263
97454426	213	221	morphine	ChemicalEntity	D009020
97454426	247	256	thyroxine	ChemicalEntity	D013974
97454426	275	302	Diffuse mesangial sclerosis	DiseaseOrPhenotypicFeature	C537346
97454426	361	369	morphine	ChemicalEntity	D009020
97454426	395	403	morphine	ChemicalEntity	D009020
97454426	524	533	thyroxine	ChemicalEntity	D013974
97454426	538	546	morphine	ChemicalEntity	D009020
97454426	564	573	thyroxine	ChemicalEntity	D013974
97454426	602	610	morphine	ChemicalEntity	D009020
97454426	650	659	rs7535263	SequenceVariant	rs7535263
97454426	703	711	morphine	ChemicalEntity	D009020
97454426	753	761	morphine	ChemicalEntity	D009020
97454426	798	807	rs7535263	SequenceVariant	rs7535263
97454426	851	860	thyroxine	ChemicalEntity	D013974
97454426	960	969	rs7535263	SequenceVariant	rs7535263
97454426	990	998	morphine	ChemicalEntity	D009020
97454426	1050	1058	morphine	ChemicalEntity	D009020
97454426	1119	1127	morphine	ChemicalEntity	D009020
97454426	1203	1211	morphine	ChemicalEntity	D009020
97454426	1269	1278	thyroxine	ChemicalEntity	D013974
97454426	1309	1318	thyroxine	ChemicalEntity	D013974
97454426	1571	1580	rs7535263	SequenceVariant	rs7535263
97454426	1582	1590	morphine	ChemicalEntity	D009020
97454426	1596	1605	thyroxine	ChemicalEntity	D013974
97454426	Positive_Correlation	D009020	C537346	Novel
97454426	Negative_Correlation	D013974	D009020	Novel
97454426	Positive_Correlation	D009020	rs7535263	Novel
97454426	Negative_Correlation	rs7535263	D013974	Novel
97454426	Association	rs7535263	D009020	Novel
97454426	Negative_Correlation	rs7535263	D009020	Novel
97454426	Negative_Correlation	C537346	D009020	Novel
97454426	Negative_Correlation	C537346	D013974	Novel
97454426	Positive_Correlation	C537346	D009020	Novel

04344717|t|Msx1, Bicaudal D2, and MAP9: Interactions with sequence variants and lovastatin in the context of catechol neurotransmitter re
04344717|a|Recent studies have revealed complex interactions between the gene products Msx1, Bicaudal D2, and MAP9, and various sequence variants, including the 5 nucleotide deletion, rs1441817, guanine (CGA) by adenine (CAA), M 235, and p.G821S. These interactions are further modulated by the chemical entity lovastatin and the biological activity of catechol neurotransmitters. A positive correlation was observed between lovastatin and M 235, as well as between lovastatin and rs1441817, suggesting a potential pharmacological synergy. Similarly, a positive correlation was found between lovastatin and p.G821S, reinforcing the role of lovastatin in modulating genetic variants.   The association between MAP9 and lovastatin, along with the positive correlation between MAP9 and catechol neurotransmitters, highlights the role of MAP9 in mediating the effects of both pharmacological and neurochemical agents. Additionally, the positive correlation between catechol neurotransmitters and guanine (CGA) by adenine (CAA) suggests a potential mechanism by which sequence variants influence neurotransmitter activity. The cotreatment of lovastatin and catechol neurotransmitters was found to enhance their individual effects, indicating a possible therapeutic strategy for neurodegenerative conditions.  Msx1 was found to bind to both Bicaudal D2 and MAP9, forming a functional network that may regulate gene expression and cellular signaling. The association between Msx1 and lovastatin, as well as between Msx1 and catechol neurotransmitters, further supports the role of Msx1 in integrating genetic and pharmacological signals. The positive correlation between catechol neurotransmitters and 5 nucleotide deletion, along with the positive correlation between catechol neurotransmitters and M 235, underscores the importance of these sequence variants in modulating neurotransmitter function.  The bind between Bicaudal D2 and Msx1, as well as between Bicaudal D2 and MAP9, suggests a coordinated regulatory mechanism involving these gene products. The positive correlation between rs1441817 and catechol neurotransmitters, and between p.G821S and catechol neurotransmitters, further supports the idea that sequence variants can influence neurotransmitter activity. Overall, these findings provide a comprehensive framework for understanding the interplay between genetic variants, pharmacological agents, and neurochemical signals in the context of disease pathogenesis.
04344717	0	4	Msx1	GeneOrGeneProduct	17701
04344717	6	17	Bicaudal D2	GeneOrGeneProduct	23299
04344717	23	27	MAP9	GeneOrGeneProduct	79884
04344717	69	79	lovastatin	ChemicalEntity	D008148
04344717	203	207	Msx1	GeneOrGeneProduct	17701
04344717	209	220	Bicaudal D2	GeneOrGeneProduct	23299
04344717	226	230	MAP9	GeneOrGeneProduct	79884
04344717	277	298	5 nucleotide deletion	SequenceVariant	c|DEL||5
04344717	300	309	rs1441817	SequenceVariant	rs1441817
04344717	311	341	guanine (CGA) by adenine (CAA)	SequenceVariant	rs9332964
04344717	343	348	M 235	SequenceVariant	p|Allele|M|235
04344717	354	361	p.G821S	SequenceVariant	rs267607116
04344717	427	437	lovastatin	ChemicalEntity	D008148
04344717	469	495	catechol neurotransmitters	ChemicalEntity	D002395
04344717	541	551	lovastatin	ChemicalEntity	D008148
04344717	556	561	M 235	SequenceVariant	p|Allele|M|235
04344717	582	592	lovastatin	ChemicalEntity	D008148
04344717	597	606	rs1441817	SequenceVariant	rs1441817
04344717	708	718	lovastatin	ChemicalEntity	D008148
04344717	723	730	p.G821S	SequenceVariant	rs267607116
04344717	756	766	lovastatin	ChemicalEntity	D008148
04344717	825	829	MAP9	GeneOrGeneProduct	79884
04344717	834	844	lovastatin	ChemicalEntity	D008148
04344717	890	894	MAP9	GeneOrGeneProduct	79884
04344717	899	925	catechol neurotransmitters	ChemicalEntity	D002395
04344717	950	954	MAP9	GeneOrGeneProduct	79884
04344717	1077	1103	catechol neurotransmitters	ChemicalEntity	D002395
04344717	1108	1138	guanine (CGA) by adenine (CAA)	SequenceVariant	rs9332964
04344717	1253	1263	lovastatin	ChemicalEntity	D008148
04344717	1268	1294	catechol neurotransmitters	ChemicalEntity	D002395
04344717	1420	1424	Msx1	GeneOrGeneProduct	17701
04344717	1451	1462	Bicaudal D2	GeneOrGeneProduct	23299
04344717	1467	1471	MAP9	GeneOrGeneProduct	79884
04344717	1584	1588	Msx1	GeneOrGeneProduct	17701
04344717	1593	1603	lovastatin	ChemicalEntity	D008148
04344717	1624	1628	Msx1	GeneOrGeneProduct	17701
04344717	1633	1659	catechol neurotransmitters	ChemicalEntity	D002395
04344717	1690	1694	Msx1	GeneOrGeneProduct	17701
04344717	1780	1806	catechol neurotransmitters	ChemicalEntity	D002395
04344717	1811	1832	5 nucleotide deletion	SequenceVariant	c|DEL||5
04344717	1878	1904	catechol neurotransmitters	ChemicalEntity	D002395
04344717	1909	1914	M 235	SequenceVariant	p|Allele|M|235
04344717	2029	2040	Bicaudal D2	GeneOrGeneProduct	23299
04344717	2045	2049	Msx1	GeneOrGeneProduct	17701
04344717	2070	2081	Bicaudal D2	GeneOrGeneProduct	23299
04344717	2086	2090	MAP9	GeneOrGeneProduct	79884
04344717	2200	2209	rs1441817	SequenceVariant	rs1441817
04344717	2214	2240	catechol neurotransmitters	ChemicalEntity	D002395
04344717	2254	2261	p.G821S	SequenceVariant	rs267607116
04344717	2266	2292	catechol neurotransmitters	ChemicalEntity	D002395
04344717	Positive_Correlation	D008148	p|Allele|M|235	Novel
04344717	Association	79884	D008148	Novel
04344717	Positive_Correlation	c|DEL||5	D008148	Novel
04344717	Positive_Correlation	c|DEL||5	D002395	Novel
04344717	Association	23299	D008148	Novel
04344717	Association	79884	D002395	Novel
04344717	Bind	17701	23299	Novel
04344717	Cotreatment	D008148	D002395	Novel
04344717	Bind	79884	17701	Novel
04344717	Positive_Correlation	p|Allele|M|235	D008148	Novel
04344717	Positive_Correlation	rs1441817	D002395	Novel
04344717	Bind	23299	17701	Novel
04344717	Bind	79884	23299	Novel
04344717	Positive_Correlation	D002395	rs9332964	Novel
04344717	Bind	23299	79884	Novel
04344717	Positive_Correlation	D002395	p|Allele|M|235	Novel
04344717	Association	17701	D008148	Novel
04344717	Positive_Correlation	D002395	rs267607116	Novel
04344717	Association	17701	D002395	Novel
04344717	Positive_Correlation	D002395	c|DEL||5	Novel
04344717	Cotreatment	D002395	D008148	Novel
04344717	Positive_Correlation	rs267607116	D008148	Novel
04344717	Positive_Correlation	D008148	rs9332964	Novel
04344717	Positive_Correlation	rs9332964	D002395	Novel
04344717	Positive_Correlation	D008148	rs1441817	Novel
04344717	Positive_Correlation	D008148	rs267607116	Novel
04344717	Positive_Correlation	rs267607116	D002395	Novel

30878785|t|Genetic Variants in THRA and Their Associations with Sequence Variants and Cell Line Models in Dogs, Rabbits, and Rhesus
30878785|a|This study investigates the functional and genetic associations between several sequence variants and the gene THRA across multiple species, including dogs, rabbits, and rhesus monkeys. The sequence variants Val624-Val625del, AFF344-345ins, and rs1329428 were analyzed in relation to the gene THRA and to each other, with particular emphasis on their roles in cellular processes. The findings reveal a complex network of interactions, including the association between rs1329428 and THRA, and between AFF344-345ins and THRA. Additionally, Val624-Val625del is found to be associated with both AFF344-345ins and rs1329428, highlighting potential genetic linkage between these variants. These associations were further validated using cell lines such as C57BL/6 and Ishikawa, which are commonly used in genetic and molecular studies. The study also includes data from guinea pigs and rhesus monkeys, demonstrating the broad relevance of these genetic variants across different species. The results suggest that these sequence variants may play a significant role in the regulation of THRA and could be important in understanding the genetic basis of certain phenotypes in these organisms. The findings provide a foundation for further research into the functional implications of these genetic variants in both basic and translational biomedical contexts.
30878785	20	24	THRA	GeneOrGeneProduct	7067
30878785	232	236	THRA	GeneOrGeneProduct	7067
30878785	272	276	dogs	OrganismTaxon	9615
30878785	278	284	rabbit	OrganismTaxon	9986
30878785	291	305	rhesus monkeys	OrganismTaxon	9544
30878785	329	345	Val624-Val625del	SequenceVariant	p|DEL|624_625|VV
30878785	347	360	AFF344-345ins	SequenceVariant	p|INS|344_345|AFF
30878785	366	375	rs1329428	SequenceVariant	rs1329428
30878785	414	418	THRA	GeneOrGeneProduct	7067
30878785	590	599	rs1329428	SequenceVariant	rs1329428
30878785	604	608	THRA	GeneOrGeneProduct	7067
30878785	622	635	AFF344-345ins	SequenceVariant	p|INS|344_345|AFF
30878785	640	644	THRA	GeneOrGeneProduct	7067
30878785	660	676	Val624-Val625del	SequenceVariant	p|DEL|624_625|VV
30878785	713	726	AFF344-345ins	SequenceVariant	p|INS|344_345|AFF
30878785	731	740	rs1329428	SequenceVariant	rs1329428
30878785	872	879	C57BL/6	CellLine	CVCL_5746
30878785	884	892	Ishikawa	CellLine	CVCL_2529
30878785	986	997	guinea pigs	OrganismTaxon	10141
30878785	1002	1016	rhesus monkeys	OrganismTaxon	9544
30878785	1202	1206	THRA	GeneOrGeneProduct	7067
30878785	Association	rs1329428	7067	Novel
30878785	Association	p|INS|344_345|AFF	7067	Novel
30878785	Association	p|DEL|624_625|VV	p|INS|344_345|AFF	Novel
30878785	Association	p|DEL|624_625|VV	7067	Novel
30878785	Association	rs1329428	p|INS|344_345|AFF	Novel
30878785	Association	p|INS|344_345|AFF	p|DEL|624_625|VV	Novel
30878785	Association	p|DEL|624_625|VV	rs1329428	Novel
30878785	Association	rs1329428	p|DEL|624_625|VV	Novel
30878785	Association	p|INS|344_345|AFF	rs1329428	Novel

26918857|t|The mToR Pathway and Its Interactions with Genetic Variants in Neurodevelopmental Disorders an
26918857|a|This study investigates the complex interactions between the mToR pathway and genetic variants in the context of neurodevelopmental disorders and cancer. The mToR gene product was found to be significantly associated with androgen and estrogen levels, suggesting a potential role in hormonal regulation. However, mToR was also negatively correlated with hypothermia and B-cell non-Hodgkin's lymphoma, indicating possible inhibitory effects on these conditions.   The sequence variant D299G showed a negative correlation with antibiotic and androgen levels, as well as with Dopamine and estrogen, suggesting that this variant may interfere with the normal function of mToR and other related pathways. Additionally, D299G was negatively correlated with paroxetine, which may have implications for the treatment of psychiatric disorders.   The sequence variant +8365 C/T was found to be negatively correlated with paroxetine and Dopamine, and also with androgen, indicating a potential role in modulating drug response and neurochemical balance. The rs5393 variant was also negatively correlated with paroxetine, further supporting the idea that genetic variability in these regions may influence drug metabolism and efficacy.  In the context of neurodevelopmental disorders, the study found that mToR was negatively correlated with Senior-Loken syndrome and cleft palate, suggesting a possible involvement in developmental processes. The presence of hypothermia was also negatively correlated with mToR, which may point to a regulatory role in thermoregulation.   The chemical entity vinblastine was associated with mToR, highlighting potential therapeutic applications in cancer treatment. Dopamine and estrogen were found to have complex interactions with mToR, with both showing negative correlations, which may have implications for neurodegenerative and endocrine disorders.   Overall, the study provides evidence for the multifaceted role of mToR in both physiological and pathological processes, as well as the importance of genetic variants in modulating these interactions. These findings may have significant implications for personalized medicine and the development of targeted therapies.
26918857	4	8	mToR	GeneOrGeneProduct	2475
26918857	156	160	mToR	GeneOrGeneProduct	2475
26918857	253	257	mToR	GeneOrGeneProduct	2475
26918857	317	325	androgen	ChemicalEntity	D000728
26918857	330	338	estrogen	ChemicalEntity	D004967
26918857	408	412	mToR	GeneOrGeneProduct	2475
26918857	449	460	hypothermia	DiseaseOrPhenotypicFeature	D007036
26918857	465	494	B-cell non-Hodgkin's lymphoma	DiseaseOrPhenotypicFeature	D008228
26918857	579	584	D299G	SequenceVariant	rs4986790
26918857	620	630	antibiotic	ChemicalEntity	D000900
26918857	635	643	androgen	ChemicalEntity	D000728
26918857	668	676	Dopamine	ChemicalEntity	D004298
26918857	681	689	estrogen	ChemicalEntity	D004967
26918857	762	766	mToR	GeneOrGeneProduct	2475
26918857	809	814	D299G	SequenceVariant	rs4986790
26918857	846	856	paroxetine	ChemicalEntity	D017374
26918857	953	962	+8365 C/T	SequenceVariant	c|SUB|C|+8365|T
26918857	1006	1016	paroxetine	ChemicalEntity	D017374
26918857	1021	1029	Dopamine	ChemicalEntity	D004298
26918857	1045	1053	androgen	ChemicalEntity	D000728
26918857	1142	1148	rs5393	SequenceVariant	rs5393
26918857	1193	1203	paroxetine	ChemicalEntity	D017374
26918857	1389	1393	mToR	GeneOrGeneProduct	2475
26918857	1425	1446	Senior-Loken syndrome	DiseaseOrPhenotypicFeature	C537580
26918857	1451	1463	cleft palate	DiseaseOrPhenotypicFeature	D002972
26918857	1543	1554	hypothermia	DiseaseOrPhenotypicFeature	D007036
26918857	1591	1595	mToR	GeneOrGeneProduct	2475
26918857	1677	1688	vinblastine	ChemicalEntity	D014747
26918857	1709	1713	mToR	GeneOrGeneProduct	2475
26918857	1784	1792	Dopamine	ChemicalEntity	D004298
26918857	1797	1805	estrogen	ChemicalEntity	D004967
26918857	1851	1855	mToR	GeneOrGeneProduct	2475
26918857	2041	2045	mToR	GeneOrGeneProduct	2475
26918857	Negative_Correlation	rs4986790	D000900	Novel
26918857	Negative_Correlation	c|SUB|C|+8365|T	D017374	Novel
26918857	Negative_Correlation	c|SUB|C|+8365|T	D004298	Novel
26918857	Association	2475	D000900	Novel
26918857	Negative_Correlation	rs4986790	D000728	Novel
26918857	Association	2475	D004967	Novel
26918857	Negative_Correlation	2475	D007036	Novel
26918857	Negative_Correlation	2475	D008228	Novel
26918857	Negative_Correlation	rs4986790	D004298	Novel
26918857	Negative_Correlation	rs4986790	D004967	Novel
26918857	Negative_Correlation	D008228	2475	Novel
26918857	Negative_Correlation	D007036	2475	Novel
26918857	Negative_Correlation	c|SUB|C|+8365|T	D000728	Novel
26918857	Negative_Correlation	rs4986790	D017374	Novel
26918857	Negative_Correlation	rs5393	D017374	Novel
26918857	Association	2475	D000728	Novel
26918857	Negative_Correlation	2475	C537580	Novel

05070404|t|KCl and diltiazem interactions in the context of b-Catenin and resting tremor: a comparative and mechanist
05070404|a|This study investigates the complex interactions between KCl, diltiazem, and b-Catenin in the context of resting tremor and their potential implications for therapeutic strategies. We demonstrate that KCl binds to insulin, suggesting a possible role in modulating insulin signaling pathways. Additionally, we find that diltiazem exhibits a significant association with b-Catenin, indicating a potential mechanism by which diltiazem may influence cellular adhesion and signaling.   Our findings also reveal that diltiazem interacts with dihydrofolate, highlighting a possible pharmacological synergy or antagonism in the treatment of certain neurological conditions. Furthermore, we compare the effects of bort and dihydrofolate, noting that bort exhibits a distinct pharmacological profile compared to dihydrofolate. Notably, bort shows a drug interaction with Arsenic, which may have implications for its use in combination therapies.   We also compare bort and diltiazem, finding that their mechanisms of action differ significantly, with bort showing a unique interaction with KCl. Additionally, we observe that KCl and diltiazem exhibit a comparative relationship, with diltiazem showing a stronger association with b-Catenin. These findings suggest that the interplay between these chemical entities and their interactions with genetic and phenotypic factors may play a critical role in the pathophysiology of resting tremor and related conditions. The results provide a foundation for further research into the therapeutic potential of these compounds in neurological disorders.
05070404	0	3	KCl	ChemicalEntity	D011189
05070404	8	17	diltiazem	ChemicalEntity	D004110
05070404	49	58	b-Catenin	GeneOrGeneProduct	12387
05070404	63	77	resting tremor	DiseaseOrPhenotypicFeature	D014202
05070404	164	167	KCl	ChemicalEntity	D011189
05070404	169	178	diltiazem	ChemicalEntity	D004110
05070404	184	193	b-Catenin	GeneOrGeneProduct	12387
05070404	212	226	resting tremor	DiseaseOrPhenotypicFeature	D014202
05070404	308	311	KCl	ChemicalEntity	D011189
05070404	321	328	insulin	GeneOrGeneProduct	3630
05070404	371	378	insulin	GeneOrGeneProduct	3630
05070404	426	435	diltiazem	ChemicalEntity	D004110
05070404	476	485	b-Catenin	GeneOrGeneProduct	12387
05070404	529	538	diltiazem	ChemicalEntity	D004110
05070404	618	627	diltiazem	ChemicalEntity	D004110
05070404	643	656	dihydrofolate	ChemicalEntity	C010920
05070404	812	816	bort	ChemicalEntity	D000069286
05070404	821	834	dihydrofolate	ChemicalEntity	C010920
05070404	848	852	bort	ChemicalEntity	D000069286
05070404	909	922	dihydrofolate	ChemicalEntity	C010920
05070404	933	937	bort	ChemicalEntity	D000069286
05070404	968	975	Arsenic	ChemicalEntity	D001151
05070404	1061	1065	bort	ChemicalEntity	D000069286
05070404	1070	1079	diltiazem	ChemicalEntity	D004110
05070404	1148	1152	bort	ChemicalEntity	D000069286
05070404	1187	1190	KCl	ChemicalEntity	D011189
05070404	1222	1225	KCl	ChemicalEntity	D011189
05070404	1230	1239	diltiazem	ChemicalEntity	D004110
05070404	1281	1290	diltiazem	ChemicalEntity	D004110
05070404	1327	1336	b-Catenin	GeneOrGeneProduct	12387
05070404	1522	1536	resting tremor	DiseaseOrPhenotypicFeature	D014202
05070404	Bind	3630	D011189	Novel
05070404	Comparison	D000069286	C010920	Novel
05070404	Drug_Interaction	C010920	D004110	Novel
05070404	Bind	12387	D004110	Novel
05070404	Drug_Interaction	D000069286	D001151	Novel
05070404	Association	D004110	12387	Novel
05070404	Drug_Interaction	C010920	D000069286	Novel
05070404	Comparison	D000069286	D004110	Novel
05070404	Comparison	D011189	D004110	Novel
05070404	Comparison	D011189	D000069286	Novel

72427701|t|CSF-1R and TBX1 interactions in Aedes mosquitoes: genetic and pharmacological implications of c.689C>G and Na+/K
72427701|a|This study investigates the molecular and pharmacological interactions between the CSF-1R gene, TBX1 gene, and the sequence variant c.689C>G in Aedes mosquitoes, with a focus on their associations with Na+/K+ ATPase and clozapine. We demonstrate a positive correlation between c.689C>G and Na+/K+ ATPase, as well as between c.689C>G and clozapine, suggesting a potential genetic and pharmacological link. Additionally, we observe a positive correlation between clozapine and Na+/K+ ATPase, indicating a drug interaction that may influence cellular function. The association between Cidec and CSF-1R is further supported by our findings, highlighting a potential regulatory pathway. In parallel, we find a positive correlation between CSF-1R and Na+/K+ ATPase, reinforcing the role of CSF-1R in modulating this critical ion pump. The association between TBX1 and Cidec is also established, suggesting a coordinated genetic network. Our results are further validated in Mouse models, where the sequence variant c.689C>G is consistently linked to clozapine and Na+/K+ ATPase. Notably, the cell line KU7 exhibits altered expression patterns of Na+/K+ ATPase in response to clozapine, providing in vitro evidence for the drug interaction. Spirulina is used as a model organism to explore the broader implications of these interactions in non-mammalian systems. These findings provide a comprehensive framework for understanding the genetic and pharmacological relationships among these key molecular entities in Aedes mosquitoes and other organisms.
72427701	0	6	CSF-1R	GeneOrGeneProduct	12978
72427701	11	15	TBX1	GeneOrGeneProduct	6899
72427701	32	48	Aedes mosquitoes	OrganismTaxon	1245352
72427701	94	102	c.689C>G	SequenceVariant	c|SUB|C|689|G
72427701	196	202	CSF-1R	GeneOrGeneProduct	12978
72427701	209	213	TBX1	GeneOrGeneProduct	6899
72427701	245	253	c.689C>G	SequenceVariant	c|SUB|C|689|G
72427701	257	273	Aedes mosquitoes	OrganismTaxon	1245352
72427701	315	328	Na+/K+ ATPase	ChemicalEntity	D000254
72427701	333	342	clozapine	ChemicalEntity	D003024
72427701	390	398	c.689C>G	SequenceVariant	c|SUB|C|689|G
72427701	403	416	Na+/K+ ATPase	ChemicalEntity	D000254
72427701	437	445	c.689C>G	SequenceVariant	c|SUB|C|689|G
72427701	450	459	clozapine	ChemicalEntity	D003024
72427701	574	583	clozapine	ChemicalEntity	D003024
72427701	588	601	Na+/K+ ATPase	ChemicalEntity	D000254
72427701	695	700	Cidec	GeneOrGeneProduct	63924
72427701	705	711	CSF-1R	GeneOrGeneProduct	12978
72427701	847	853	CSF-1R	GeneOrGeneProduct	12978
72427701	858	871	Na+/K+ ATPase	ChemicalEntity	D000254
72427701	897	903	CSF-1R	GeneOrGeneProduct	12978
72427701	966	970	TBX1	GeneOrGeneProduct	6899
72427701	975	980	Cidec	GeneOrGeneProduct	63924
72427701	1081	1086	Mouse	OrganismTaxon	10090
72427701	1122	1130	c.689C>G	SequenceVariant	c|SUB|C|689|G
72427701	1157	1166	clozapine	ChemicalEntity	D003024
72427701	1171	1184	Na+/K+ ATPase	ChemicalEntity	D000254
72427701	1209	1212	KU7	CellLine	CVCL_4714
72427701	1253	1266	Na+/K+ ATPase	ChemicalEntity	D000254
72427701	1282	1291	clozapine	ChemicalEntity	D003024
72427701	1347	1356	Spirulina	OrganismTaxon	551299
72427701	1620	1636	Aedes mosquitoes	OrganismTaxon	1245352
72427701	Positive_Correlation	D000254	D003024	Novel
72427701	Positive_Correlation	D003024	D000254	Novel
72427701	Association	63924	12978	Novel
72427701	Association	c|SUB|C|689|G	D003024	Novel
72427701	Drug_Interaction	D003024	D000254	Novel
72427701	Positive_Correlation	c|SUB|C|689|G	D000254	Novel
72427701	Positive_Correlation	12978	D000254	Novel
72427701	Association	6899	63924	Novel
72427701	Positive_Correlation	c|SUB|C|689|G	D003024	Novel
72427701	Association	c|SUB|C|689|G	D000254	Novel

22994622|t|Genetic Variants and Their Associations with Breast-Ovarian Cancer: A Comprehensive Analysis of G/C, rs6235, and H
22994622|a|Recent studies have highlighted the complex interplay between genetic variants and the risk of breast-ovarian cancer. This research investigates the associations between the sequence variants G/C, rs6235, and His626Arg with the disease phenotype of breast-ovarian cancer. The findings reveal a positive correlation between breast-ovarian cancer and the G/C sequence variant, as well as between breast-ovarian cancer and rs6235. Additionally, a significant association is observed between breast-ovarian cancer and the His626Arg variant, with a positive correlation noted.   The study also demonstrates a negative correlation between breast-ovarian cancer and the gene products TGF-beta1 and -beta2, suggesting a potential protective role of these proteins in the context of this disease. Multiple instances of the G/C sequence variant are found to be associated with breast-ovarian cancer, reinforcing its role as a risk factor. The rs6235 variant is consistently linked to the disease, with evidence supporting its involvement in the pathogenesis of breast-ovarian cancer.   Furthermore, the His626Arg variant is shown to have a positive correlation with breast-ovarian cancer, indicating its potential as a biomarker for disease susceptibility. The data suggest that the interplay between these genetic variants and the TGF-beta1 and -beta2 signaling pathways may contribute to the development of breast-ovarian cancer. These findings provide a foundation for future research into the molecular mechanisms underlying this complex disease and may inform the development of targeted therapeutic strategies.
22994622	96	99	G/C	SequenceVariant	g|SUB|G||C
22994622	101	107	rs6235	SequenceVariant	rs6235
22994622	210	231	breast-ovarian cancer	DiseaseOrPhenotypicFeature	D061325
22994622	307	310	G/C	SequenceVariant	g|SUB|G||C
22994622	312	318	rs6235	SequenceVariant	rs6235
22994622	324	333	His626Arg	SequenceVariant	p|SUB|H|626|R
22994622	364	385	breast-ovarian cancer	DiseaseOrPhenotypicFeature	D061325
22994622	438	459	breast-ovarian cancer	DiseaseOrPhenotypicFeature	D061325
22994622	468	471	G/C	SequenceVariant	g|SUB|G||C
22994622	509	530	breast-ovarian cancer	DiseaseOrPhenotypicFeature	D061325
22994622	535	541	rs6235	SequenceVariant	rs6235
22994622	603	624	breast-ovarian cancer	DiseaseOrPhenotypicFeature	D061325
22994622	633	642	His626Arg	SequenceVariant	p|SUB|H|626|R
22994622	748	769	breast-ovarian cancer	DiseaseOrPhenotypicFeature	D061325
22994622	792	812	TGF-beta1 and -beta2	GeneOrGeneProduct	4052
22994622	929	932	G/C	SequenceVariant	g|SUB|G||C
22994622	982	1003	breast-ovarian cancer	DiseaseOrPhenotypicFeature	D061325
22994622	1048	1054	rs6235	SequenceVariant	rs6235
22994622	1166	1187	breast-ovarian cancer	DiseaseOrPhenotypicFeature	D061325
22994622	1208	1217	His626Arg	SequenceVariant	p|SUB|H|626|R
22994622	1271	1292	breast-ovarian cancer	DiseaseOrPhenotypicFeature	D061325
22994622	1437	1457	TGF-beta1 and -beta2	GeneOrGeneProduct	4052
22994622	1514	1535	breast-ovarian cancer	DiseaseOrPhenotypicFeature	D061325
22994622	Association	D061325	g|SUB|G||C	Novel
22994622	Negative_Correlation	D061325	4052	Novel
22994622	Association	rs6235	D061325	Novel
22994622	Positive_Correlation	D061325	g|SUB|G||C	Novel
22994622	Association	g|SUB|G||C	D061325	Novel
22994622	Positive_Correlation	D061325	rs6235	Novel
22994622	Positive_Correlation	D061325	p|SUB|H|626|R	Novel
22994622	Association	p|SUB|H|626|R	D061325	Novel
22994622	Association	D061325	rs6235	Novel
22994622	Association	D061325	p|SUB|H|626|R	Novel

98889133|t|Actinic keratosis and chronic periodontitis: interactions with DEN-4, E. coli, mouse mammary tumor virus, West Nile virus, and HIV-1 in IEC-6 and CA3 ce
98889133|a|Actinic keratosis and chronic periodontitis are increasingly recognized as complex conditions influenced by multiple environmental and genetic factors. This study investigates the interplay between these two phenotypic features and several pathogens, including DEN-4, E. coli, mouse mammary tumor virus, West Nile virus, and HIV-1, in the context of cellular responses in IEC-6 and CA3 cell lines. The research highlights the role of actinic keratosis in modulating immune responses to DEN-4 and E. coli, while chronic periodontitis is shown to exacerbate the effects of mouse mammary tumor virus and West Nile virus. Additionally, the study explores the impact of HIV-1 on the progression of hypotonia and blindness in patients with actinic keratosis. The findings suggest that the CA3 cell line may serve as a valuable model for understanding the molecular mechanisms underlying the association between actinic keratosis and chronic periodontitis. Furthermore, the IEC-6 cell line is found to be particularly responsive to the effects of E. coli and HIV-1, with implications for the development of targeted therapies. The results also emphasize the importance of considering the interplay between these diseases and pathogens in the context of gastric lymphoma and other related conditions. This work provides a comprehensive framework for future studies on the complex relationships between actinic keratosis, chronic periodontitis, and their interactions with various organisms and cell lines.
98889133	22	43	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
98889133	63	68	DEN-4	OrganismTaxon	11070
98889133	70	77	E. coli	OrganismTaxon	562
98889133	79	104	mouse mammary tumor virus	OrganismTaxon	11757
98889133	106	121	West Nile virus	OrganismTaxon	11082
98889133	127	132	HIV-1	OrganismTaxon	11676
98889133	136	141	IEC-6	CellLine	CVCL_0343
98889133	146	149	CA3	CellLine	CVCL_JW73
98889133	175	196	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
98889133	414	419	DEN-4	OrganismTaxon	11070
98889133	421	428	E. coli	OrganismTaxon	562
98889133	430	455	mouse mammary tumor virus	OrganismTaxon	11757
98889133	457	472	West Nile virus	OrganismTaxon	11082
98889133	478	483	HIV-1	OrganismTaxon	11676
98889133	525	530	IEC-6	CellLine	CVCL_0343
98889133	535	538	CA3	CellLine	CVCL_JW73
98889133	587	604	actinic keratosis	DiseaseOrPhenotypicFeature	D055623
98889133	639	644	DEN-4	OrganismTaxon	11070
98889133	649	656	E. coli	OrganismTaxon	562
98889133	664	685	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
98889133	724	749	mouse mammary tumor virus	OrganismTaxon	11757
98889133	754	769	West Nile virus	OrganismTaxon	11082
98889133	818	823	HIV-1	OrganismTaxon	11676
98889133	846	855	hypotonia	DiseaseOrPhenotypicFeature	D009123
98889133	860	869	blindness	DiseaseOrPhenotypicFeature	D001766
98889133	887	904	actinic keratosis	DiseaseOrPhenotypicFeature	D055623
98889133	936	939	CA3	CellLine	CVCL_JW73
98889133	1058	1075	actinic keratosis	DiseaseOrPhenotypicFeature	D055623
98889133	1080	1101	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
98889133	1120	1125	IEC-6	CellLine	CVCL_0343
98889133	1193	1200	E. coli	OrganismTaxon	562
98889133	1205	1210	HIV-1	OrganismTaxon	11676
98889133	1399	1415	gastric lymphoma	DiseaseOrPhenotypicFeature	C535648
98889133	1547	1564	actinic keratosis	DiseaseOrPhenotypicFeature	D055623
98889133	1566	1587	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113

37828299|t|Sequence variant p.G204_K247del and -120-bp duplication in gliomas: interactions with histamine, Eslicarbazepine acetate, and enhanced green fluorescent protein in SNU-C2A and LbetaT2 ce
37828299|a|This study investigates the molecular and functional interactions between the sequence variant p.G204_K247del, the -120-bp duplication, histamine, Eslicarbazepine acetate, and enhanced green fluorescent protein in the context of gliomas. The research focuses on the SNU-C2A and LbetaT2 cell lines, which are frequently used to model glioma biology.   The findings reveal a negative correlation between histamine and gliomas, suggesting that histamine may act as a suppressor of glioma progression. Conversely, a positive correlation is observed between histamine and the sequence variant p.G204_K247del, indicating that this variant may enhance histamine signaling. Additionally, histamine is associated with the -120-bp duplication, which is further linked to gliomas, suggesting a potential pathway through which histamine influences glioma development.  The study also demonstrates a positive correlation between enhanced green fluorescent protein and the -120-bp duplication, implying that the duplication may promote the expression or activity of enhanced green fluorescent protein. Furthermore, Eslicarbazepine acetate shows a positive correlation with enhanced green fluorescent protein, suggesting a possible synergistic effect in cellular processes.   Drug interaction analyses reveal that histamine interacts with both enhanced green fluorescent protein and Eslicarbazepine acetate, indicating potential pharmacological implications. Notably, the sequence variant p.G204_K247del exhibits a negative correlation with both histamine and enhanced green fluorescent protein, suggesting that this variant may disrupt the signaling pathways involving these molecules.   These results provide new insights into the molecular mechanisms underlying glioma progression and highlight the complex interplay between genetic variants, chemical entities, and cellular processes in cancer biology. The use of SNU-C2A and LbetaT2 cell lines allows for a more detailed understanding of these interactions in a controlled experimental setting.
37828299	17	31	p.G204_K247del	SequenceVariant	p|DEL|204_247|
37828299	36	55	-120-bp duplication	SequenceVariant	c|DUP|-120||
37828299	59	66	gliomas	DiseaseOrPhenotypicFeature	D005910
37828299	86	95	histamine	ChemicalEntity	D006632
37828299	97	120	Eslicarbazepine acetate	ChemicalEntity	C416835
37828299	126	160	enhanced green fluorescent protein	ChemicalEntity	C485184
37828299	164	171	SNU-C2A	CellLine	CVCL_1709
37828299	176	183	LbetaT2	CellLine	CVCL_0398
37828299	282	296	p.G204_K247del	SequenceVariant	p|DEL|204_247|
37828299	302	321	-120-bp duplication	SequenceVariant	c|DUP|-120||
37828299	323	332	histamine	ChemicalEntity	D006632
37828299	334	357	Eslicarbazepine acetate	ChemicalEntity	C416835
37828299	363	397	enhanced green fluorescent protein	ChemicalEntity	C485184
37828299	416	423	gliomas	DiseaseOrPhenotypicFeature	D005910
37828299	453	460	SNU-C2A	CellLine	CVCL_1709
37828299	465	472	LbetaT2	CellLine	CVCL_0398
37828299	589	598	histamine	ChemicalEntity	D006632
37828299	603	610	gliomas	DiseaseOrPhenotypicFeature	D005910
37828299	628	637	histamine	ChemicalEntity	D006632
37828299	740	749	histamine	ChemicalEntity	D006632
37828299	775	789	p.G204_K247del	SequenceVariant	p|DEL|204_247|
37828299	832	841	histamine	ChemicalEntity	D006632
37828299	867	876	histamine	ChemicalEntity	D006632
37828299	900	919	-120-bp duplication	SequenceVariant	c|DUP|-120||
37828299	948	955	gliomas	DiseaseOrPhenotypicFeature	D005910
37828299	1002	1011	histamine	ChemicalEntity	D006632
37828299	1103	1137	enhanced green fluorescent protein	ChemicalEntity	C485184
37828299	1146	1165	-120-bp duplication	SequenceVariant	c|DUP|-120||
37828299	1239	1273	enhanced green fluorescent protein	ChemicalEntity	C485184
37828299	1288	1311	Eslicarbazepine acetate	ChemicalEntity	C416835
37828299	1346	1380	enhanced green fluorescent protein	ChemicalEntity	C485184
37828299	1486	1495	histamine	ChemicalEntity	D006632
37828299	1516	1550	enhanced green fluorescent protein	ChemicalEntity	C485184
37828299	1555	1578	Eslicarbazepine acetate	ChemicalEntity	C416835
37828299	1661	1675	p.G204_K247del	SequenceVariant	p|DEL|204_247|
37828299	1718	1727	histamine	ChemicalEntity	D006632
37828299	1732	1766	enhanced green fluorescent protein	ChemicalEntity	C485184
37828299	2090	2097	SNU-C2A	CellLine	CVCL_1709
37828299	2102	2109	LbetaT2	CellLine	CVCL_0398
37828299	Negative_Correlation	D006632	D005910	Novel
37828299	Positive_Correlation	C485184	c|DUP|-120||	Novel
37828299	Positive_Correlation	D006632	p|DEL|204_247|	Novel
37828299	Association	D006632	c|DUP|-120||	Novel
37828299	Association	c|DUP|-120||	D005910	Novel
37828299	Positive_Correlation	C416835	C485184	Novel
37828299	Drug_Interaction	D006632	C485184	Novel
37828299	Drug_Interaction	D006632	C416835	Novel
37828299	Negative_Correlation	p|DEL|204_247|	D006632	Novel
37828299	Negative_Correlation	p|DEL|204_247|	C485184	Novel

06436237|t|Genetic and pharmacological interactions of iopamidol with sequence variants in cell lines and o
06436237|a|This study investigates the complex interactions between the contrast agent iopamidol and various genetic sequence variants across multiple cell lines and organisms. The research focuses on the PC-3, SUM159PT, and HEK cell lines, which were used to model the effects of iopamidol on cellular responses. The study also includes the organism taxons of chick, Human, HPV, and horses, with a particular emphasis on the genetic variability associated with these species.   A key finding is the positive correlation between the sequence variant p.G196S and iopamidol, which was observed in both PC-3 and SUM159PT cell lines. This correlation was further supported by the positive association between p.G196S and steroid, indicating a potential pathway through which iopamidol may influence steroid metabolism. Additionally, the sequence variant rs2234671 showed a positive correlation with steroid, suggesting a possible genetic link between steroid regulation and the presence of this variant.   The sequence variant rs2073416 was found to have a positive correlation with iopamidol, reinforcing the idea that multiple genetic factors may modulate the pharmacological effects of iopamidol. Furthermore, the study demonstrated a conversion between iopamidol and steroid, highlighting the potential for iopamidol to act as a precursor or modulator of steroid pathways.   The sequence variants Q126R and rs2234671 were also found to have positive correlations with both iopamidol and steroid, suggesting a broader network of genetic interactions that influence the pharmacological and metabolic effects of these compounds. The study also included the sequence variants G7958A, 35 delG, and rs2073416, with the latter appearing 10 times, indicating its significant role in the observed interactions.   Overall, the findings suggest that the interplay between genetic sequence variants and the chemical entity iopamidol is complex and may vary across different cell lines and organisms. These results provide a foundation for further research into the molecular mechanisms underlying these interactions and their implications for drug development and personalized medicine.
06436237	44	53	iopamidol	ChemicalEntity	D007479
06436237	173	182	iopamidol	ChemicalEntity	D007479
06436237	291	295	PC-3	CellLine	CVCL_0035
06436237	297	305	SUM159PT	CellLine	CVCL_5423
06436237	311	314	HEK	CellLine	CVCL_M624
06436237	367	376	iopamidol	ChemicalEntity	D007479
06436237	447	452	chick	OrganismTaxon	9031
06436237	454	459	Human	OrganismTaxon	9606
06436237	461	464	HPV	OrganismTaxon	10566
06436237	470	476	horses	OrganismTaxon	9796
06436237	636	643	p.G196S	SequenceVariant	rs121434250
06436237	648	657	iopamidol	ChemicalEntity	D007479
06436237	686	690	PC-3	CellLine	CVCL_0035
06436237	695	703	SUM159PT	CellLine	CVCL_5423
06436237	791	798	p.G196S	SequenceVariant	rs121434250
06436237	803	810	steroid	ChemicalEntity	D013256
06436237	857	866	iopamidol	ChemicalEntity	D007479
06436237	881	888	steroid	ChemicalEntity	D013256
06436237	936	945	rs2234671	SequenceVariant	rs2234671
06436237	981	988	steroid	ChemicalEntity	D013256
06436237	1033	1040	steroid	ChemicalEntity	D013256
06436237	1109	1118	rs2073416	SequenceVariant	rs2073416
06436237	1165	1174	iopamidol	ChemicalEntity	D007479
06436237	1271	1280	iopamidol	ChemicalEntity	D007479
06436237	1339	1348	iopamidol	ChemicalEntity	D007479
06436237	1353	1360	steroid	ChemicalEntity	D013256
06436237	1393	1402	iopamidol	ChemicalEntity	D007479
06436237	1441	1448	steroid	ChemicalEntity	D013256
06436237	1483	1488	Q126R	SequenceVariant	rs368386747
06436237	1493	1502	rs2234671	SequenceVariant	rs2234671
06436237	1559	1568	iopamidol	ChemicalEntity	D007479
06436237	1573	1580	steroid	ChemicalEntity	D013256
06436237	1758	1764	G7958A	SequenceVariant	rs4998557
06436237	1766	1773	35 delG	SequenceVariant	c|DEL|35|G
06436237	1779	1788	rs2073416	SequenceVariant	rs2073416
06436237	1997	2006	iopamidol	ChemicalEntity	D007479
06436237	Positive_Correlation	rs121434250	D007479	Novel
06436237	Positive_Correlation	rs2234671	D013256	Novel
06436237	Positive_Correlation	rs121434250	D013256	Novel
06436237	Positive_Correlation	rs2073416	D007479	Novel
06436237	Conversion	D007479	D013256	Novel
06436237	Positive_Correlation	rs368386747	D007479	Novel
06436237	Positive_Correlation	rs368386747	D013256	Novel

76330830|t|Exploring drug interactions and cellular responses in diverse models: a study on COS-7, 293T, and HeLa cell lines with implications for sudden death and enzymatic complex I-deficient co
76330830|a|This study investigates the complex interactions between various chemical entities and their effects on cellular models, with a focus on drug interactions and their potential implications in disease states. Using COS-7, 293T, and HeLa cell lines, we examined the interactions between taxol and acitretin, acitretin and daunorubicin, daunorubicin and acitretin, mangiferin and Zolmitriptan, 6-OHDA and bromocriptine, bromocriptine and Zolmitriptan, 6-OHDA and morphine, Zolmitriptan and daunorubicin, daunorubicin and Zolmitriptan, and daunorubicin and taxol. These interactions were assessed in the context of cellular responses and their potential relevance to sudden death and enzymatic complex I-deficient conditions.   The study also included experiments using rat and rabbit models to evaluate the physiological effects of these drug interactions. Additionally, we explored the impact of 6-OHDA and morphine on rat models of sudden death, while examining the role of bromocriptine in modulating Zolmitriptan's effects. The interactions between daunorubicin and taxol were further analyzed in the context of their potential to induce cellular stress and apoptosis in COS-7 and 293T cell lines.   To provide a broader perspective, we also included studies on Toxorynchites mosquitoes, Aedes mosquitoes, and DEN-4 virus to assess the potential cross-species effects of these chemical entities. The findings suggest that certain drug combinations may have significant implications for both cellular function and disease progression, particularly in conditions such as sudden death and enzymatic complex I deficiency. These results highlight the importance of understanding drug interactions at the molecular and cellular levels to develop more effective therapeutic strategies.
76330830	81	86	COS-7	CellLine	CVCL_0224
76330830	88	92	293T	CellLine	CVCL_0063
76330830	98	102	HeLa	CellLine	CVCL_0030
76330830	136	148	sudden death	DiseaseOrPhenotypicFeature	D003645
76330830	153	182	enzymatic complex I-deficient	DiseaseOrPhenotypicFeature	C537475
76330830	399	404	COS-7	CellLine	CVCL_0224
76330830	406	410	293T	CellLine	CVCL_0063
76330830	416	420	HeLa	CellLine	CVCL_0030
76330830	470	475	taxol	ChemicalEntity	D017239
76330830	480	489	acitretin	ChemicalEntity	D017255
76330830	491	500	acitretin	ChemicalEntity	D017255
76330830	505	517	daunorubicin	ChemicalEntity	D003630
76330830	519	531	daunorubicin	ChemicalEntity	D003630
76330830	536	545	acitretin	ChemicalEntity	D017255
76330830	547	557	mangiferin	ChemicalEntity	C013592
76330830	562	574	Zolmitriptan	ChemicalEntity	C089750
76330830	576	582	6-OHDA	ChemicalEntity	D016627
76330830	587	600	bromocriptine	ChemicalEntity	D001971
76330830	602	615	bromocriptine	ChemicalEntity	D001971
76330830	620	632	Zolmitriptan	ChemicalEntity	C089750
76330830	634	640	6-OHDA	ChemicalEntity	D016627
76330830	645	653	morphine	ChemicalEntity	D009020
76330830	655	667	Zolmitriptan	ChemicalEntity	C089750
76330830	672	684	daunorubicin	ChemicalEntity	D003630
76330830	686	698	daunorubicin	ChemicalEntity	D003630
76330830	703	715	Zolmitriptan	ChemicalEntity	C089750
76330830	721	733	daunorubicin	ChemicalEntity	D003630
76330830	738	743	taxol	ChemicalEntity	D017239
76330830	848	860	sudden death	DiseaseOrPhenotypicFeature	D003645
76330830	865	894	enzymatic complex I-deficient	DiseaseOrPhenotypicFeature	C537475
76330830	951	954	rat	OrganismTaxon	10116
76330830	959	965	rabbit	OrganismTaxon	9986
76330830	1079	1085	6-OHDA	ChemicalEntity	D016627
76330830	1090	1098	morphine	ChemicalEntity	D009020
76330830	1102	1105	rat	OrganismTaxon	10116
76330830	1116	1128	sudden death	DiseaseOrPhenotypicFeature	D003645
76330830	1158	1171	bromocriptine	ChemicalEntity	D001971
76330830	1186	1198	Zolmitriptan	ChemicalEntity	C089750
76330830	1235	1247	daunorubicin	ChemicalEntity	D003630
76330830	1252	1257	taxol	ChemicalEntity	D017239
76330830	1357	1362	COS-7	CellLine	CVCL_0224
76330830	1367	1371	293T	CellLine	CVCL_0063
76330830	1448	1472	Toxorynchites mosquitoes	OrganismTaxon	2498889
76330830	1474	1490	Aedes mosquitoes	OrganismTaxon	1245352
76330830	1496	1501	DEN-4	OrganismTaxon	11070
76330830	1755	1767	sudden death	DiseaseOrPhenotypicFeature	D003645
76330830	1955	1958	rat	OrganismTaxon	10116
76330830	Drug_Interaction	D017239	D017255	Novel
76330830	Drug_Interaction	D017255	D003630	Novel
76330830	Drug_Interaction	D003630	D017255	Novel
76330830	Drug_Interaction	C013592	C089750	Novel
76330830	Drug_Interaction	D016627	D001971	Novel
76330830	Drug_Interaction	D001971	C089750	Novel
76330830	Drug_Interaction	D016627	D009020	Novel
76330830	Drug_Interaction	C089750	D003630	Novel
76330830	Drug_Interaction	D003630	C089750	Novel
76330830	Drug_Interaction	D003630	D017239	Novel

51546165|t|Genetic and pharmacological interactions of D90A and c.429_452dup in Rhodiola rosea and their implications in cell line responses to Amphetamine and Methamp
51546165|a|This study investigates the genetic and pharmacological interactions of the sequence variants D90A and c.429_452dup in the context of Rhodiola rosea and their effects on cell line responses to Amphetamine and Methamphetamine. The research focuses on the association between D90A and Methamphetamine, as well as the positive correlation between D90A and Amphetamine. Additionally, the study explores the relationship between c.429_452dup and Methamphetamine, and the association between keratan sulfate and c.429_452dup.   Using hRPTEC and SNU-C2A cell lines, we observed that the presence of D90A significantly enhances the cellular response to Methamphetamine, consistent with a positive correlation between these two entities. Similarly, the positive correlation between D90A and Amphetamine was confirmed through functional assays in Ba/F3 cells. The sequence variant rs17250932 was found to be positively correlated with Amphetamine, and its association with L-365,260 was further validated through pharmacological experiments.   The c.429_452dup variant was linked to keratan sulfate, suggesting a potential role in modulating the extracellular matrix in response to pharmacological agents. Furthermore, the study included experiments with E. coli and Saccharomyces cerevisiae to assess the broader implications of these genetic variants in microbial systems.   The findings highlight the complex interplay between genetic variants and pharmacological agents, particularly in the context of Rhodiola rosea and its potential therapeutic applications. The results also underscore the importance of understanding these interactions in diverse biological systems, including rabbit models and Toxorynchites mosquitoes, to better predict and manage drug responses in different organisms.
51546165	44	48	D90A	SequenceVariant	rs80265967
51546165	53	65	c.429_452dup	SequenceVariant	c|DUP|429_452||
51546165	69	83	Rhodiola rosea	OrganismTaxon	203015
51546165	133	144	Amphetamine	ChemicalEntity	D000661
51546165	251	255	D90A	SequenceVariant	rs80265967
51546165	260	272	c.429_452dup	SequenceVariant	c|DUP|429_452||
51546165	291	305	Rhodiola rosea	OrganismTaxon	203015
51546165	350	361	Amphetamine	ChemicalEntity	D000661
51546165	366	381	Methamphetamine	ChemicalEntity	D008694
51546165	431	435	D90A	SequenceVariant	rs80265967
51546165	440	455	Methamphetamine	ChemicalEntity	D008694
51546165	501	505	D90A	SequenceVariant	rs80265967
51546165	510	521	Amphetamine	ChemicalEntity	D000661
51546165	581	593	c.429_452dup	SequenceVariant	c|DUP|429_452||
51546165	598	613	Methamphetamine	ChemicalEntity	D008694
51546165	643	658	keratan sulfate	ChemicalEntity	D007632
51546165	663	675	c.429_452dup	SequenceVariant	c|DUP|429_452||
51546165	685	691	hRPTEC	CellLine	CVCL_K278
51546165	696	703	SNU-C2A	CellLine	CVCL_1709
51546165	749	753	D90A	SequenceVariant	rs80265967
51546165	802	817	Methamphetamine	ChemicalEntity	D008694
51546165	930	934	D90A	SequenceVariant	rs80265967
51546165	939	950	Amphetamine	ChemicalEntity	D000661
51546165	994	999	Ba/F3	CellLine	CVCL_0161
51546165	1028	1038	rs17250932	SequenceVariant	rs17250932
51546165	1082	1093	Amphetamine	ChemicalEntity	D000661
51546165	1120	1129	L-365,260	ChemicalEntity	C058121
51546165	1195	1207	c.429_452dup	SequenceVariant	c|DUP|429_452||
51546165	1230	1245	keratan sulfate	ChemicalEntity	D007632
51546165	1402	1409	E. coli	OrganismTaxon	562
51546165	1414	1438	Saccharomyces cerevisiae	OrganismTaxon	4932
51546165	1653	1667	Rhodiola rosea	OrganismTaxon	203015
51546165	1832	1838	rabbit	OrganismTaxon	9986
51546165	1850	1874	Toxorynchites mosquitoes	OrganismTaxon	2498889
51546165	Association	D008694	rs80265967	Novel
51546165	Association	D007632	c|DUP|429_452||	Novel
51546165	Positive_Correlation	rs17250932	D000661	Novel
51546165	Positive_Correlation	rs80265967	D008694	Novel
51546165	Association	C058121	rs17250932	Novel
51546165	Positive_Correlation	rs80265967	D000661	Novel
51546165	Positive_Correlation	c|DUP|429_452||	D008694	Novel

14045130|t|Genetic and functional analysis of Na(+)/H(+) exchanger type 3, type I TGFb receptors, and raptor in Daucus carota and Mangifera indica Linn ce
14045130|a|This study investigates the genetic and functional interactions between Na(+)/H(+) exchanger type 3, type I TGFb receptors, and raptor in the context of Daucus carota and Mangifera indica Linn. Using HeLa cell lines, we examined the association between rs25531 and type I TGFb receptors, as well as the association between rs25531 and raptor. The sequence variant p.F366L was found to be associated with type I TGFb receptors and raptor, suggesting a potential functional role in modulating these pathways.   We observed a negative correlation between type I TGFb receptors and raptor, as well as a negative correlation between Na(+)/H(+) exchanger type 3 and type I TGFb receptors. Additionally, a negative correlation was noted between Na(+)/H(+) exchanger type 3 and raptor. Functional assays confirmed a bind between Na(+)/H(+) exchanger type 3 and raptor, as well as a bind between raptor and Na(+)/H(+) exchanger type 3. These findings suggest a complex regulatory network involving these proteins in both Daucus carota and Mangifera indica Linn.   The presence of rs25531 in multiple instances across the study highlights its potential role in modulating the interactions between these proteins. Furthermore, the association between p.F366L and raptor supports the hypothesis that sequence variants may influence the functional dynamics of these molecular pathways. Our results provide new insights into the genetic and functional relationships among Na(+)/H(+) exchanger type 3, type I TGFb receptors, and raptor in plant systems, with implications for understanding their roles in cellular signaling and stress responses.
14045130	35	62	Na(+)/H(+) exchanger type 3	GeneOrGeneProduct	24784
14045130	64	85	type I TGFb receptors	GeneOrGeneProduct	657
14045130	91	97	raptor	GeneOrGeneProduct	287871
14045130	101	114	Daucus carota	OrganismTaxon	4039
14045130	119	140	Mangifera indica Linn	OrganismTaxon	29780
14045130	216	243	Na(+)/H(+) exchanger type 3	GeneOrGeneProduct	24784
14045130	245	266	type I TGFb receptors	GeneOrGeneProduct	657
14045130	272	278	raptor	GeneOrGeneProduct	287871
14045130	297	310	Daucus carota	OrganismTaxon	4039
14045130	315	336	Mangifera indica Linn	OrganismTaxon	29780
14045130	344	348	HeLa	CellLine	CVCL_0030
14045130	397	404	rs25531	SequenceVariant	rs25531
14045130	409	430	type I TGFb receptors	GeneOrGeneProduct	657
14045130	467	474	rs25531	SequenceVariant	rs25531
14045130	479	485	raptor	GeneOrGeneProduct	287871
14045130	508	515	p.F366L	SequenceVariant	rs140756663
14045130	548	569	type I TGFb receptors	GeneOrGeneProduct	657
14045130	574	580	raptor	GeneOrGeneProduct	287871
14045130	696	717	type I TGFb receptors	GeneOrGeneProduct	657
14045130	722	728	raptor	GeneOrGeneProduct	287871
14045130	772	799	Na(+)/H(+) exchanger type 3	GeneOrGeneProduct	24784
14045130	804	825	type I TGFb receptors	GeneOrGeneProduct	657
14045130	882	909	Na(+)/H(+) exchanger type 3	GeneOrGeneProduct	24784
14045130	914	920	raptor	GeneOrGeneProduct	287871
14045130	965	992	Na(+)/H(+) exchanger type 3	GeneOrGeneProduct	24784
14045130	997	1003	raptor	GeneOrGeneProduct	287871
14045130	1031	1037	raptor	GeneOrGeneProduct	287871
14045130	1042	1069	Na(+)/H(+) exchanger type 3	GeneOrGeneProduct	24784
14045130	1156	1169	Daucus carota	OrganismTaxon	4039
14045130	1174	1195	Mangifera indica Linn	OrganismTaxon	29780
14045130	1215	1222	rs25531	SequenceVariant	rs25531
14045130	1384	1391	p.F366L	SequenceVariant	rs140756663
14045130	1396	1402	raptor	GeneOrGeneProduct	287871
14045130	1602	1629	Na(+)/H(+) exchanger type 3	GeneOrGeneProduct	24784
14045130	1631	1652	type I TGFb receptors	GeneOrGeneProduct	657
14045130	1658	1664	raptor	GeneOrGeneProduct	287871
14045130	Association	24784	287871	Novel
14045130	Association	657	287871	Novel
14045130	Negative_Correlation	287871	657	Novel
14045130	Association	rs140756663	657	Novel
14045130	Negative_Correlation	657	287871	Novel
14045130	Bind	24784	287871	Novel
14045130	Negative_Correlation	287871	24784	Novel
14045130	Negative_Correlation	24784	657	Novel
14045130	Bind	287871	24784	Novel
14045130	Association	rs140756663	287871	Novel

61511405|t|DEN-4, weight loss, and cell line interactions in the context of Platonia insignis Mart, cholangiocarcinoma, and Zebrafis
61511405|a|This study investigates the complex interplay between the DEN-4 virus, weight loss, and various cell lines in the context of Platonia insignis Mart, cholangiocarcinoma, and Zebrafish models. The research focuses on the effects of DEN-4 on weight loss in both in vitro and in vivo settings, utilizing multiple cell lines including RAW 264.7, MEF, SMMC-7721, MES-SA/Dx5, Mz-ChA-1, and others. The study reveals that DEN-4 significantly influences weight loss in RAW 264.7 and MEF cell lines, with notable differences observed in SMMC-7721 and MES-SA/Dx5. Additionally, the impact of DEN-4 on weight loss is further explored in the context of Platonia insignis Mart, a plant species known for its potential therapeutic properties. The findings suggest that DEN-4 may play a role in the progression of cholangiocarcinoma, as evidenced by its effects on Mz-ChA-1 and SMMC-7721 cell lines. Furthermore, the study examines the role of Zebrafish as a model organism for understanding the relationship between DEN-4, weight loss, and cholangiocarcinoma. The results highlight the importance of cell line-specific responses to DEN-4 and provide insights into the mechanisms underlying weight loss and cholangiocarcinoma development. The study includes 4 instances of DEN-4, 4 instances of weight loss, 12 instances of RAW 264.7, 6 instances of MEF, 6 instances of SMMC-7721, 6 instances of Platonia insignis Mart, 4 instances of MES-SA/Dx5, 8 instances of Mz-ChA-1, 6 instances of cholangiocarcinoma, and 4 instances of Zebrafish.
61511405	0	5	DEN-4	OrganismTaxon	11070
61511405	7	18	weight loss	DiseaseOrPhenotypicFeature	D015431
61511405	65	87	Platonia insignis Mart	OrganismTaxon	198787
61511405	89	107	cholangiocarcinoma	DiseaseOrPhenotypicFeature	D018281
61511405	180	185	DEN-4	OrganismTaxon	11070
61511405	193	204	weight loss	DiseaseOrPhenotypicFeature	D015431
61511405	247	269	Platonia insignis Mart	OrganismTaxon	198787
61511405	271	289	cholangiocarcinoma	DiseaseOrPhenotypicFeature	D018281
61511405	295	304	Zebrafish	OrganismTaxon	7955
61511405	352	357	DEN-4	OrganismTaxon	11070
61511405	361	372	weight loss	DiseaseOrPhenotypicFeature	D015431
61511405	452	461	RAW 264.7	CellLine	CVCL_0493
61511405	463	466	MEF	CellLine	CVCL_9115
61511405	468	477	SMMC-7721	CellLine	CVCL_0534
61511405	479	489	MES-SA/Dx5	CellLine	CVCL_2598
61511405	491	499	Mz-ChA-1	CellLine	CVCL_6932
61511405	536	541	DEN-4	OrganismTaxon	11070
61511405	567	578	weight loss	DiseaseOrPhenotypicFeature	D015431
61511405	582	591	RAW 264.7	CellLine	CVCL_0493
61511405	596	599	MEF	CellLine	CVCL_9115
61511405	649	658	SMMC-7721	CellLine	CVCL_0534
61511405	663	673	MES-SA/Dx5	CellLine	CVCL_2598
61511405	703	708	DEN-4	OrganismTaxon	11070
61511405	712	723	weight loss	DiseaseOrPhenotypicFeature	D015431
61511405	762	784	Platonia insignis Mart	OrganismTaxon	198787
61511405	876	881	DEN-4	OrganismTaxon	11070
61511405	920	938	cholangiocarcinoma	DiseaseOrPhenotypicFeature	D018281
61511405	971	979	Mz-ChA-1	CellLine	CVCL_6932
61511405	984	993	SMMC-7721	CellLine	CVCL_0534
61511405	1050	1059	Zebrafish	OrganismTaxon	7955
61511405	1123	1128	DEN-4	OrganismTaxon	11070
61511405	1130	1141	weight loss	DiseaseOrPhenotypicFeature	D015431
61511405	1147	1165	cholangiocarcinoma	DiseaseOrPhenotypicFeature	D018281
61511405	1239	1244	DEN-4	OrganismTaxon	11070
61511405	1297	1308	weight loss	DiseaseOrPhenotypicFeature	D015431
61511405	1313	1331	cholangiocarcinoma	DiseaseOrPhenotypicFeature	D018281
61511405	1379	1384	DEN-4	OrganismTaxon	11070
61511405	1401	1412	weight loss	DiseaseOrPhenotypicFeature	D015431
61511405	1430	1439	RAW 264.7	CellLine	CVCL_0493
61511405	1456	1459	MEF	CellLine	CVCL_9115
61511405	1476	1485	SMMC-7721	CellLine	CVCL_0534
61511405	1502	1524	Platonia insignis Mart	OrganismTaxon	198787
61511405	1541	1551	MES-SA/Dx5	CellLine	CVCL_2598
61511405	1568	1576	Mz-ChA-1	CellLine	CVCL_6932
61511405	1593	1611	cholangiocarcinoma	DiseaseOrPhenotypicFeature	D018281
61511405	1632	1641	Zebrafish	OrganismTaxon	7955

64015799|t|Vinblastine, gynecologic malignancy, and LPG: insights from Kilham rat virus and Drosophil
64015799|a|Recent studies have highlighted the complex interplay between vinblastine, gynecologic malignancy, and LPG, with emerging evidence suggesting a significant association between vinblastine and both LPG and gynecologic malignancy. This research explores these relationships through the lens of Kilham rat virus and Drosophila models, which provide valuable insights into the molecular mechanisms underlying these associations.   Vinblastine, a well-known microtubule inhibitor, has been shown to exhibit a strong association with gynecologic malignancy, particularly in the context of its effects on cell cycle regulation and apoptosis. This association is further supported by its impact on the expression of key genes involved in tumor progression. Additionally, vinblastine has been found to interact with LPG, a phenotypic feature associated with various metabolic and developmental disorders, suggesting a potential role in modulating cellular responses to environmental stressors.  The study also incorporates the use of RAW 264.7 and LNCaP cell lines to investigate the effects of vinblastine on cellular behavior, with particular attention to the influence of sequence variants such as p.Arg104, -616C/G, and rs861019. These variants, which are prevalent in both human and model organisms, may contribute to the differential response to vinblastine observed in various cell types.   Furthermore, the role of Kilham rat virus and Drosophila as model systems is explored, with a focus on how these organisms can be used to study the broader implications of vinblastine exposure on disease progression and phenotypic outcomes. The findings underscore the importance of considering both genetic and environmental factors in understanding the complex relationships between vinblastine, gynecologic malignancy, and LPG.
64015799	13	35	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
64015799	41	44	LPG	DiseaseOrPhenotypicFeature	C567089
64015799	60	76	Kilham rat virus	OrganismTaxon	12441
64015799	153	164	vinblastine	ChemicalEntity	D014747
64015799	166	188	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
64015799	194	197	LPG	DiseaseOrPhenotypicFeature	C567089
64015799	267	278	vinblastine	ChemicalEntity	D014747
64015799	288	291	LPG	DiseaseOrPhenotypicFeature	C567089
64015799	296	318	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
64015799	383	399	Kilham rat virus	OrganismTaxon	12441
64015799	404	414	Drosophila	OrganismTaxon	7227
64015799	619	641	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
64015799	854	865	vinblastine	ChemicalEntity	D014747
64015799	898	901	LPG	DiseaseOrPhenotypicFeature	C567089
64015799	1116	1125	RAW 264.7	CellLine	CVCL_0493
64015799	1130	1135	LNCaP	CellLine	CVCL_0395
64015799	1177	1188	vinblastine	ChemicalEntity	D014747
64015799	1283	1291	p.Arg104	SequenceVariant	p|Allele|R|104
64015799	1293	1300	-616C/G	SequenceVariant	rs747302
64015799	1306	1314	rs861019	SequenceVariant	rs861019
64015799	1434	1445	vinblastine	ChemicalEntity	D014747
64015799	1505	1521	Kilham rat virus	OrganismTaxon	12441
64015799	1526	1536	Drosophila	OrganismTaxon	7227
64015799	1652	1663	vinblastine	ChemicalEntity	D014747
64015799	1865	1876	vinblastine	ChemicalEntity	D014747
64015799	1878	1900	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
64015799	1906	1909	LPG	DiseaseOrPhenotypicFeature	C567089
64015799	Association	D014747	C567089	Novel
64015799	Association	D014747	D005833	Novel

22740756|t|Zinc, cyclin D1, and des-gamma-carboxy prothrombin interactions in bradycardia and Malaria Infection: a multi-speci
22740756|a|This study investigates the complex interplay between zinc, cyclin D1, des-gamma-carboxy prothrombin, and bradycardia across multiple species, including rabbits, Escherichia coli, and chick. Our findings reveal a negative correlation between zinc and bradycardia, suggesting that zinc may have a protective role against this cardiac condition. Similarly, we observed a negative correlation between des-gamma-carboxy prothrombin and bradycardia, indicating that elevated levels of this protein may be associated with reduced cardiac rhythm disturbances. Additionally, a negative correlation was found between a-smooth muscle actin and bradycardia, highlighting the potential involvement of smooth muscle dynamics in cardiac function.   The study also explores the relationship between Malaria Infection and cyclin D1, revealing a negative correlation that suggests cyclin D1 may play a role in modulating the host's response to the parasite. Furthermore, a negative correlation was identified between zinc and Malaria Infection, implying that zinc deficiency may exacerbate the severity of the disease. These findings were corroborated across multiple organisms, including rabbits, Escherichia coli, and chick, indicating that the observed relationships may have broader biological relevance.  In addition to these findings, the study also examines the role of other genes and proteins, such as CASP8, TBX1, and des-gamma-carboxy prothrombin, in the context of malonic aciduria and HBV infection. The results contribute to a growing body of evidence supporting the importance of zinc in maintaining cardiovascular health and its potential as a therapeutic target in conditions such as bradycardia and Malaria Infection. The use of chick and Escherichia coli models further underscores the utility of these organisms in studying complex biological interactions at the molecular level.
22740756	6	15	cyclin D1	GeneOrGeneProduct	595
22740756	21	50	des-gamma-carboxy prothrombin	GeneOrGeneProduct	2147
22740756	67	78	bradycardia	DiseaseOrPhenotypicFeature	D001919
22740756	83	100	Malaria Infection	DiseaseOrPhenotypicFeature	D008288
22740756	170	174	zinc	ChemicalEntity	D015032
22740756	176	185	cyclin D1	GeneOrGeneProduct	595
22740756	187	216	des-gamma-carboxy prothrombin	GeneOrGeneProduct	2147
22740756	222	233	bradycardia	DiseaseOrPhenotypicFeature	D001919
22740756	269	275	rabbit	OrganismTaxon	9986
22740756	278	294	Escherichia coli	OrganismTaxon	562
22740756	300	305	chick	OrganismTaxon	9031
22740756	358	362	zinc	ChemicalEntity	D015032
22740756	367	378	bradycardia	DiseaseOrPhenotypicFeature	D001919
22740756	396	400	zinc	ChemicalEntity	D015032
22740756	514	543	des-gamma-carboxy prothrombin	GeneOrGeneProduct	2147
22740756	548	559	bradycardia	DiseaseOrPhenotypicFeature	D001919
22740756	724	745	a-smooth muscle actin	GeneOrGeneProduct	11475
22740756	750	761	bradycardia	DiseaseOrPhenotypicFeature	D001919
22740756	900	917	Malaria Infection	DiseaseOrPhenotypicFeature	D008288
22740756	922	931	cyclin D1	GeneOrGeneProduct	595
22740756	980	989	cyclin D1	GeneOrGeneProduct	595
22740756	1116	1120	zinc	ChemicalEntity	D015032
22740756	1125	1142	Malaria Infection	DiseaseOrPhenotypicFeature	D008288
22740756	1158	1162	zinc	ChemicalEntity	D015032
22740756	1288	1294	rabbit	OrganismTaxon	9986
22740756	1297	1313	Escherichia coli	OrganismTaxon	562
22740756	1319	1324	chick	OrganismTaxon	9031
22740756	1510	1515	CASP8	GeneOrGeneProduct	841
22740756	1517	1521	TBX1	GeneOrGeneProduct	6899
22740756	1527	1556	des-gamma-carboxy prothrombin	GeneOrGeneProduct	2147
22740756	1576	1592	malonic aciduria	DiseaseOrPhenotypicFeature	C535702
22740756	1597	1600	HBV	OrganismTaxon	10407
22740756	1694	1698	zinc	ChemicalEntity	D015032
22740756	1800	1811	bradycardia	DiseaseOrPhenotypicFeature	D001919
22740756	1816	1833	Malaria Infection	DiseaseOrPhenotypicFeature	D008288
22740756	1846	1851	chick	OrganismTaxon	9031
22740756	1856	1872	Escherichia coli	OrganismTaxon	562
22740756	Negative_Correlation	D001919	2147	Novel
22740756	Negative_Correlation	D001919	11475	Novel
22740756	Negative_Correlation	D015032	D001919	Novel
22740756	Negative_Correlation	D008288	595	Novel
22740756	Negative_Correlation	D015032	D008288	Novel

31338420|t|Hippocalcin and MCT4 in Daucus carota: genetic variants, colitis associations, and functional impl
31338420|a|Hippocalcin, a calcium-binding protein, has been implicated in various physiological processes, including inflammation and immune response regulation. In this study, we investigate the role of hippocalcin in the context of colitis, a chronic inflammatory disease of the gastrointestinal tract. Our findings reveal a positive correlation between hippocalcin expression and the development of colitis in Daucus carota, a plant species used as a model for studying gene-environment interactions. This correlation is further supported by the presence of the sequence variant p.Tyr65X, which is associated with altered hippocalcin function and increased susceptibility to colitis.   The sequence variant rs11891426, which is linked to p.Tyr65X, shows a significant association with colitis in Daucus carota. Additionally, the sequence variant G/C, which is prevalent in this species, is found to be associated with colitis, suggesting a potential role in disease pathogenesis. The gene MCT4, which encodes a monocarboxylate transporter, is also examined in this study. MCT4 is found to be upregulated in colitic tissues, and its expression is positively correlated with the severity of colitis.   Our results highlight the complex interplay between genetic variants, gene expression, and disease phenotypes in Daucus carota. The presence of multiple instances of p.Tyr65X, rs11891426, and G/C in this study underscores the importance of these sequence variants in modulating the risk of colitis. Furthermore, the association between MCT4 and colitis suggests that this gene may be a potential therapeutic target for the treatment of inflammatory bowel diseases. These findings provide new insights into the molecular mechanisms underlying colitis and the role of genetic variation in disease susceptibility.
31338420	16	20	MCT4	GeneOrGeneProduct	80879
31338420	24	37	Daucus carota	OrganismTaxon	4039
31338420	57	64	colitis	DiseaseOrPhenotypicFeature	D003092
31338420	292	303	hippocalcin	GeneOrGeneProduct	3208
31338420	322	329	colitis	DiseaseOrPhenotypicFeature	D003092
31338420	444	455	hippocalcin	GeneOrGeneProduct	3208
31338420	490	497	colitis	DiseaseOrPhenotypicFeature	D003092
31338420	501	514	Daucus carota	OrganismTaxon	4039
31338420	670	678	p.Tyr65X	SequenceVariant	rs763572195
31338420	713	724	hippocalcin	GeneOrGeneProduct	3208
31338420	766	773	colitis	DiseaseOrPhenotypicFeature	D003092
31338420	798	808	rs11891426	SequenceVariant	rs11891426
31338420	829	837	p.Tyr65X	SequenceVariant	rs763572195
31338420	876	883	colitis	DiseaseOrPhenotypicFeature	D003092
31338420	887	900	Daucus carota	OrganismTaxon	4039
31338420	937	940	G/C	SequenceVariant	g|SUB|G||C
31338420	1009	1016	colitis	DiseaseOrPhenotypicFeature	D003092
31338420	1080	1084	MCT4	GeneOrGeneProduct	80879
31338420	1163	1167	MCT4	GeneOrGeneProduct	80879
31338420	1280	1287	colitis	DiseaseOrPhenotypicFeature	D003092
31338420	1404	1417	Daucus carota	OrganismTaxon	4039
31338420	1457	1465	p.Tyr65X	SequenceVariant	rs763572195
31338420	1467	1477	rs11891426	SequenceVariant	rs11891426
31338420	1483	1486	G/C	SequenceVariant	g|SUB|G||C
31338420	1581	1588	colitis	DiseaseOrPhenotypicFeature	D003092
31338420	1627	1631	MCT4	GeneOrGeneProduct	80879
31338420	1636	1643	colitis	DiseaseOrPhenotypicFeature	D003092
31338420	1833	1840	colitis	DiseaseOrPhenotypicFeature	D003092
31338420	Positive_Correlation	D003092	3208	Novel
31338420	Association	D003092	g|SUB|G||C	Novel
31338420	Association	rs11891426	rs763572195	Novel

44443228|t|Vps2 Expression Dynamics in DEN-4-Infected Cells: Correlations with Small-Cell Carcinoma and Bladder Tumor Progression in hRPTEC and RAW 264.7 Ce
44443228|a|This study investigates the expression dynamics of the Vps2 gene in DEN-4-infected hRPTEC and RAW 264.7 cell lines, with a focus on its correlation with small-cell carcinoma and bladder tumor progression. Using quantitative real-time PCR and immunofluorescence assays, we observed a significant negative correlation between Vps2 expression and the development of small-cell carcinoma in hRPTEC cells, as well as a positive correlation between Vps2 and bladder tumor formation in RAW 264.7 cells. These findings suggest that Vps2 may act as a tumor suppressor in bladder tumor progression but may have a dual role in small-cell carcinoma, where it exhibits both positive and negative correlations depending on the cellular context. The study also highlights the role of DEN-4 in modulating Vps2 expression, with consistent downregulation observed in both hRPTEC and RAW 264.7 cell lines under DEN-4 infection. Further, the data indicate that the relationship between Vps2 and bladder tumor is more complex than previously thought, with evidence of both positive and negative correlations across different experimental conditions. These results provide new insights into the molecular mechanisms underlying the interplay between Vps2, DEN-4, and the development of small-cell carcinoma and bladder tumor in various cell line models.
44443228	0	4	Vps2	GeneOrGeneProduct	27243
44443228	28	33	DEN-4	OrganismTaxon	11070
44443228	122	128	hRPTEC	CellLine	CVCL_K278
44443228	133	142	RAW 264.7	CellLine	CVCL_0493
44443228	201	205	Vps2	GeneOrGeneProduct	27243
44443228	214	219	DEN-4	OrganismTaxon	11070
44443228	229	235	hRPTEC	CellLine	CVCL_K278
44443228	240	249	RAW 264.7	CellLine	CVCL_0493
44443228	299	319	small-cell carcinoma	DiseaseOrPhenotypicFeature	D018288
44443228	324	337	bladder tumor	DiseaseOrPhenotypicFeature	D001749
44443228	470	474	Vps2	GeneOrGeneProduct	27243
44443228	509	529	small-cell carcinoma	DiseaseOrPhenotypicFeature	D018288
44443228	533	539	hRPTEC	CellLine	CVCL_K278
44443228	589	593	Vps2	GeneOrGeneProduct	27243
44443228	598	611	bladder tumor	DiseaseOrPhenotypicFeature	D001749
44443228	625	634	RAW 264.7	CellLine	CVCL_0493
44443228	670	674	Vps2	GeneOrGeneProduct	27243
44443228	708	721	bladder tumor	DiseaseOrPhenotypicFeature	D001749
44443228	762	782	small-cell carcinoma	DiseaseOrPhenotypicFeature	D018288
44443228	915	920	DEN-4	OrganismTaxon	11070
44443228	935	939	Vps2	GeneOrGeneProduct	27243
44443228	1000	1006	hRPTEC	CellLine	CVCL_K278
44443228	1011	1020	RAW 264.7	CellLine	CVCL_0493
44443228	1038	1043	DEN-4	OrganismTaxon	11070
44443228	1112	1116	Vps2	GeneOrGeneProduct	27243
44443228	1121	1134	bladder tumor	DiseaseOrPhenotypicFeature	D001749
44443228	1373	1377	Vps2	GeneOrGeneProduct	27243
44443228	1379	1384	DEN-4	OrganismTaxon	11070
44443228	1409	1429	small-cell carcinoma	DiseaseOrPhenotypicFeature	D018288
44443228	1434	1447	bladder tumor	DiseaseOrPhenotypicFeature	D001749
44443228	Negative_Correlation	27243	D001749	Novel
44443228	Association	27243	D018288	Novel
44443228	Negative_Correlation	27243	D018288	Novel
44443228	Negative_Correlation	D018288	27243	Novel
44443228	Positive_Correlation	27243	D001749	Novel
44443228	Association	27243	D001749	Novel
44443228	Negative_Correlation	D001749	27243	Novel
44443228	Positive_Correlation	27243	D018288	Novel

20722342|t|Genetic Variants and Molecular Interactions in UCHL1, Vg4, and VEGF Receptor 2 in H
20722342|a|This study investigates the molecular interactions and functional associations between genetic variants and gene products in the context of HK2 cells. We focus on the sequence variant IVS3+1G>A, which is associated with UCHL1 and protein disulfide isomerase family A member 3, and also linked to Vg4 and VEGF receptor 2. The sequence variant methionine (ATG) by threonine (ACG) at codon 453 is found to be associated with UCHL1, Vg4, and VEGF receptor 2, highlighting its potential role in modulating these gene products. Additionally, the sequence variant G135C is associated with Sox13, VEGF receptor 2, and protein disulfide isomerase family A member 3, suggesting a complex regulatory network.   In HK2 cells, we observed a positive correlation between Vg4 and VEGF receptor 2, as well as between Vg4 and UCHL1. The positive correlation between UCHL1 and Vg4 further supports the functional interplay between these gene products. Moreover, the positive correlation between UCHL1 and Sox13, along with the positive correlation between Sox13 and UCHL1, indicates a potential regulatory relationship. The positive correlation between protein disulfide isomerase family A member 3 and Sox13, as well as between protein disulfide isomerase family A member 3 and VEGF receptor 2, suggests that these gene products may be part of a shared regulatory pathway.   The association between IVS3+1G>A and UCHL1, along with its link to protein disulfide isomerase family A member 3 and Vg4, underscores the importance of this variant in modulating gene expression. The association between IVS3+1G>A and VEGF receptor 2 further supports its role in the regulation of this receptor. The positive correlation between VEGF receptor 2 and Vg4, as well as between VEGF receptor 2 and protein disulfide isomerase family A member 3, reinforces the interconnectedness of these gene products.   Our findings provide evidence for the complex genetic and molecular interactions involving UCHL1, Vg4, VEGF receptor 2, and their associated variants in HK2 cells, offering new insights into the regulatory mechanisms underlying these gene products.
20722342	47	52	UCHL1	GeneOrGeneProduct	7345
20722342	54	57	Vg4	GeneOrGeneProduct	21638
20722342	224	227	HK2	CellLine	CVCL_0302
20722342	268	277	IVS3+1G>A	SequenceVariant	c|SUB|G|IVS3+1|A
20722342	304	309	UCHL1	GeneOrGeneProduct	7345
20722342	314	359	protein disulfide isomerase family A member 3	GeneOrGeneProduct	14827
20722342	380	383	Vg4	GeneOrGeneProduct	21638
20722342	388	403	VEGF receptor 2	GeneOrGeneProduct	16542
20722342	426	474	methionine (ATG) by threonine (ACG) at codon 453	SequenceVariant	rs121908864
20722342	506	511	UCHL1	GeneOrGeneProduct	7345
20722342	513	516	Vg4	GeneOrGeneProduct	21638
20722342	522	537	VEGF receptor 2	GeneOrGeneProduct	16542
20722342	641	646	G135C	SequenceVariant	g|SUB|G|135|C
20722342	666	671	Sox13	GeneOrGeneProduct	20668
20722342	673	688	VEGF receptor 2	GeneOrGeneProduct	16542
20722342	694	739	protein disulfide isomerase family A member 3	GeneOrGeneProduct	14827
20722342	787	790	HK2	CellLine	CVCL_0302
20722342	841	844	Vg4	GeneOrGeneProduct	21638
20722342	849	864	VEGF receptor 2	GeneOrGeneProduct	16542
20722342	885	888	Vg4	GeneOrGeneProduct	21638
20722342	893	898	UCHL1	GeneOrGeneProduct	7345
20722342	933	938	UCHL1	GeneOrGeneProduct	7345
20722342	943	946	Vg4	GeneOrGeneProduct	21638
20722342	1061	1066	UCHL1	GeneOrGeneProduct	7345
20722342	1071	1076	Sox13	GeneOrGeneProduct	20668
20722342	1122	1127	Sox13	GeneOrGeneProduct	20668
20722342	1132	1137	UCHL1	GeneOrGeneProduct	7345
20722342	1219	1264	protein disulfide isomerase family A member 3	GeneOrGeneProduct	14827
20722342	1269	1274	Sox13	GeneOrGeneProduct	20668
20722342	1295	1340	protein disulfide isomerase family A member 3	GeneOrGeneProduct	14827
20722342	1345	1360	VEGF receptor 2	GeneOrGeneProduct	16542
20722342	1466	1475	IVS3+1G>A	SequenceVariant	c|SUB|G|IVS3+1|A
20722342	1480	1485	UCHL1	GeneOrGeneProduct	7345
20722342	1510	1555	protein disulfide isomerase family A member 3	GeneOrGeneProduct	14827
20722342	1560	1563	Vg4	GeneOrGeneProduct	21638
20722342	1663	1672	IVS3+1G>A	SequenceVariant	c|SUB|G|IVS3+1|A
20722342	1677	1692	VEGF receptor 2	GeneOrGeneProduct	16542
20722342	1788	1803	VEGF receptor 2	GeneOrGeneProduct	16542
20722342	1808	1811	Vg4	GeneOrGeneProduct	21638
20722342	1832	1847	VEGF receptor 2	GeneOrGeneProduct	16542
20722342	1852	1897	protein disulfide isomerase family A member 3	GeneOrGeneProduct	14827
20722342	2050	2055	UCHL1	GeneOrGeneProduct	7345
20722342	2057	2060	Vg4	GeneOrGeneProduct	21638
20722342	2062	2077	VEGF receptor 2	GeneOrGeneProduct	16542
20722342	2112	2115	HK2	CellLine	CVCL_0302
20722342	Association	rs121908864	7345	Novel
20722342	Positive_Correlation	21638	16542	Novel
20722342	Positive_Correlation	20668	7345	Novel
20722342	Positive_Correlation	7345	21638	Novel
20722342	Association	rs121908864	21638	Novel
20722342	Association	g|SUB|G|135|C	20668	Novel
20722342	Positive_Correlation	14827	20668	Novel
20722342	Positive_Correlation	16542	7345	Novel
20722342	Association	c|SUB|G|IVS3+1|A	7345	Novel
20722342	Association	c|SUB|G|IVS3+1|A	14827	Novel
20722342	Positive_Correlation	16542	14827	Novel
20722342	Association	g|SUB|G|135|C	16542	Novel
20722342	Association	c|SUB|G|IVS3+1|A	21638	Novel
20722342	Positive_Correlation	21638	7345	Novel
20722342	Association	c|SUB|G|IVS3+1|A	16542	Novel
20722342	Positive_Correlation	21638	14827	Novel
20722342	Positive_Correlation	7345	20668	Novel
20722342	Association	g|SUB|G|135|C	14827	Novel
20722342	Association	rs121908864	16542	Novel
20722342	Positive_Correlation	7345	14827	Novel
20722342	Association	g|SUB|G|135|C	7345	Novel
20722342	Positive_Correlation	16542	21638	Novel
20722342	Positive_Correlation	14827	16542	Novel

27960827|t|Genetic and pharmacological interactions in gynecologic malignancy: roles of 2,4-diene-VPA, anthracycline, and CAA in modulating CAG repeat and sequence 
27960827|a|Recent studies have highlighted the complex interplay between genetic variants, pharmacological agents, and disease progression in gynecologic malignancy. This research investigates the associations between 2,4-diene-VPA and the CAG repeat, as well as the sequence variant rs2844580, in the context of cancer biology. Additionally, the drug interactions between anthracycline and lactate, anthracycline and CAA, and lactate and CAA are explored to understand their potential therapeutic implications.   The study also examines the association between CAA and the sequence variant c.304ins(GCG)(7), which is linked to altered protein function in cellular processes. Furthermore, the drug interaction between 2,4-diene-VPA and lactate is analyzed, revealing potential metabolic pathways that may influence tumor response to treatment.   In vitro experiments using the cell line SCID-HuH-7 and the cell line C4-2B demonstrate that anthracycline significantly modulates the activity of lactate and CAA, suggesting a role in metabolic reprogramming of cancer cells. The association between 2,4-diene-VPA and rs1800587 is further supported by functional assays, which show altered gene expression patterns in response to the compound.   The study also explores the interaction between 2,4-diene-VPA and the sequence variant (proline) with a polar amino acid (serine) at position 29, indicating a potential mechanism for altered protein stability. The role of the organism taxon Toxorynchites mosquitoes in the transmission of pathogens associated with gynecologic malignancy is discussed, along with the impact of Rhodiola rosea and Aedes mosquitoes on immune responses in guinea pigs.   The drug interaction between Serum aminotransferase and anthracycline is further validated through biochemical assays, highlighting the importance of monitoring liver function during anthracycline therapy. Overall, these findings provide a comprehensive framework for understanding the genetic and pharmacological factors that influence the progression and treatment of gynecologic malignancy.
27960827	44	66	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
27960827	77	90	2,4-diene-VPA	ChemicalEntity	C556631
27960827	92	105	anthracycline	ChemicalEntity	D018943
27960827	111	114	CAA	ChemicalEntity	C004656
27960827	129	139	CAG repeat	SequenceVariant	c|DUP||CAG|
27960827	285	307	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
27960827	361	374	2,4-diene-VPA	ChemicalEntity	C556631
27960827	383	393	CAG repeat	SequenceVariant	c|DUP||CAG|
27960827	427	436	rs2844580	SequenceVariant	rs2844580
27960827	516	529	anthracycline	ChemicalEntity	D018943
27960827	534	541	lactate	ChemicalEntity	D019344
27960827	543	556	anthracycline	ChemicalEntity	D018943
27960827	561	564	CAA	ChemicalEntity	C004656
27960827	570	577	lactate	ChemicalEntity	D019344
27960827	582	585	CAA	ChemicalEntity	C004656
27960827	705	708	CAA	ChemicalEntity	C004656
27960827	734	750	c.304ins(GCG)(7)	SequenceVariant	c|INS|304|GCG(7)
27960827	861	874	2,4-diene-VPA	ChemicalEntity	C556631
27960827	879	886	lactate	ChemicalEntity	D019344
27960827	1030	1040	SCID-HuH-7	CellLine	CVCL_0336
27960827	1059	1064	C4-2B	CellLine	CVCL_4784
27960827	1082	1095	anthracycline	ChemicalEntity	D018943
27960827	1136	1143	lactate	ChemicalEntity	D019344
27960827	1148	1151	CAA	ChemicalEntity	C004656
27960827	1239	1252	2,4-diene-VPA	ChemicalEntity	C556631
27960827	1257	1266	rs1800587	SequenceVariant	rs1800587
27960827	1433	1446	2,4-diene-VPA	ChemicalEntity	C556631
27960827	1472	1529	(proline) with a polar amino acid (serine) at position 29	SequenceVariant	rs2075789
27960827	1626	1650	Toxorynchites mosquitoes	OrganismTaxon	2498889
27960827	1700	1722	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
27960827	1762	1776	Rhodiola rosea	OrganismTaxon	203015
27960827	1781	1797	Aedes mosquitoes	OrganismTaxon	1245352
27960827	1821	1832	guinea pigs	OrganismTaxon	10141
27960827	1865	1887	Serum aminotransferase	ChemicalEntity	D001219
27960827	1892	1905	anthracycline	ChemicalEntity	D018943
27960827	2019	2032	anthracycline	ChemicalEntity	D018943
27960827	2206	2228	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
27960827	Association	C556631	c|DUP||CAG|	Novel
27960827	Drug_Interaction	D019344	D018943	Novel
27960827	Drug_Interaction	D018943	D019344	Novel
27960827	Association	C556631	rs2844580	Novel
27960827	Drug_Interaction	D018943	C004656	Novel
27960827	Drug_Interaction	C004656	C556631	Novel
27960827	Association	C004656	c|INS|304|GCG(7)	Novel
27960827	Drug_Interaction	D019344	C004656	Novel
27960827	Drug_Interaction	C556631	D019344	Novel
27960827	Drug_Interaction	D001219	D018943	Novel

49867837|t|Genetic and molecular interactions of DISC1, GLDC, and extracellular signal-regulated kinase (ERK)-1/2 in bladder dysfunction and keloid disease: insights from Daucus carota and Dan
49867837|a|This study investigates the molecular and genetic interactions between the gene products DISC1, GLDC, and extracellular signal-regulated kinase (ERK)-1/2 in the context of bladder dysfunction and keloid disease. Using a combination of in vitro and in vivo models, we explored the functional relationships between these proteins and their potential roles in disease pathogenesis. Our findings reveal a negative correlation between DISC1 and GLDC, as well as between GLDC and ERK-1/2, suggesting a regulatory network that may be disrupted in bladder dysfunction. Additionally, a negative correlation was observed between GLDC and mTOR, and between ERK-1/2 and GLDC, further supporting the involvement of these pathways in disease progression.   The study also identified a negative correlation between DISC1 and mTOR, and a binding interaction between DISC1 and both gamma-H2AX and ERK-1/2. These interactions were further supported by the binding of gamma-H2AX to mTOR and the binding of mTOR to ERK-1/2. Notably, a negative correlation was found between follistatin and both gamma-H2AX and ERK-1/2, with a binding interaction between follistatin and mTOR. These results suggest a complex regulatory network involving these proteins in the pathogenesis of bladder dysfunction and keloid disease.  In addition to these findings, the study examined the association between the sequence variant p.T286M and DISC1, as well as between A6V and both GLDC and follistatin. These associations highlight the potential role of specific genetic variants in modulating the expression and function of these proteins. The study also included the organism taxon Daucus carota and Danio rerio as model systems to explore the broader implications of these interactions in different biological contexts. Overall, this research provides new insights into the molecular mechanisms underlying bladder dysfunction and keloid disease, with potential applications in the development of targeted therapies.
49867837	38	43	DISC1	GeneOrGeneProduct	27185
49867837	45	49	GLDC	GeneOrGeneProduct	2731
49867837	55	102	extracellular signal-regulated kinase (ERK)-1/2	GeneOrGeneProduct	5595
49867837	106	125	bladder dysfunction	DiseaseOrPhenotypicFeature	D001745
49867837	130	144	keloid disease	DiseaseOrPhenotypicFeature	D007627
49867837	160	173	Daucus carota	OrganismTaxon	4039
49867837	271	276	DISC1	GeneOrGeneProduct	27185
49867837	278	282	GLDC	GeneOrGeneProduct	2731
49867837	288	335	extracellular signal-regulated kinase (ERK)-1/2	GeneOrGeneProduct	5595
49867837	354	373	bladder dysfunction	DiseaseOrPhenotypicFeature	D001745
49867837	378	392	keloid disease	DiseaseOrPhenotypicFeature	D007627
49867837	612	617	DISC1	GeneOrGeneProduct	27185
49867837	622	626	GLDC	GeneOrGeneProduct	2731
49867837	647	651	GLDC	GeneOrGeneProduct	2731
49867837	722	741	bladder dysfunction	DiseaseOrPhenotypicFeature	D001745
49867837	801	805	GLDC	GeneOrGeneProduct	2731
49867837	810	814	mTOR	GeneOrGeneProduct	56718
49867837	840	844	GLDC	GeneOrGeneProduct	2731
49867837	982	987	DISC1	GeneOrGeneProduct	27185
49867837	992	996	mTOR	GeneOrGeneProduct	56718
49867837	1032	1037	DISC1	GeneOrGeneProduct	27185
49867837	1047	1057	gamma-H2AX	GeneOrGeneProduct	500987
49867837	1131	1141	gamma-H2AX	GeneOrGeneProduct	500987
49867837	1145	1149	mTOR	GeneOrGeneProduct	56718
49867837	1169	1173	mTOR	GeneOrGeneProduct	56718
49867837	1236	1247	follistatin	GeneOrGeneProduct	14313
49867837	1257	1267	gamma-H2AX	GeneOrGeneProduct	500987
49867837	1316	1327	follistatin	GeneOrGeneProduct	14313
49867837	1332	1336	mTOR	GeneOrGeneProduct	56718
49867837	1437	1456	bladder dysfunction	DiseaseOrPhenotypicFeature	D001745
49867837	1461	1475	keloid disease	DiseaseOrPhenotypicFeature	D007627
49867837	1573	1580	p.T286M	SequenceVariant	rs193302860
49867837	1585	1590	DISC1	GeneOrGeneProduct	27185
49867837	1611	1614	A6V	SequenceVariant	rs199922907
49867837	1624	1628	GLDC	GeneOrGeneProduct	2731
49867837	1633	1644	follistatin	GeneOrGeneProduct	14313
49867837	1827	1840	Daucus carota	OrganismTaxon	4039
49867837	1845	1856	Danio rerio	OrganismTaxon	7955
49867837	2052	2071	bladder dysfunction	DiseaseOrPhenotypicFeature	D001745
49867837	2076	2090	keloid disease	DiseaseOrPhenotypicFeature	D007627
49867837	Negative_Correlation	27185	2731	Novel
49867837	Negative_Correlation	27185	56718	Novel
49867837	Bind	500987	27185	Novel
49867837	Association	rs199922907	14313	Novel
49867837	Negative_Correlation	2731	5595	Novel
49867837	Bind	500987	56718	Novel
49867837	Negative_Correlation	14313	500987	Novel
49867837	Bind	27185	500987	Novel
49867837	Bind	56718	5595	Novel
49867837	Association	rs193302860	27185	Novel
49867837	Negative_Correlation	2731	56718	Novel
49867837	Association	rs199922907	2731	Novel
49867837	Bind	2731	56718	Novel
49867837	Bind	27185	5595	Novel
49867837	Bind	14313	56718	Novel
49867837	Negative_Correlation	5595	2731	Novel
49867837	Negative_Correlation	14313	5595	Novel

77150787|t|C4A, TGF-induced protein, and nitric oxide synthase interactions in human immunodeficiency virus and Kilham rat virus in
77150787|a|This study investigates the molecular interactions between C4A, TGF-induced protein, and nitric oxide synthase in the context of human immunodeficiency virus (HIV) and Kilham rat virus (KRV) infections. Using a combination of biochemical assays and cell line models, we demonstrate that C4A binds to nitric oxide synthase in both HIV-infected and uninfected C4-2B cells. Additionally, TGF-induced protein also binds to nitric oxide synthase, suggesting a potential role for this interaction in modulating immune responses.   Our findings reveal a complex network of negative correlations between these proteins. Specifically, nitric oxide synthase exhibits a negative correlation with both C4A and TGF-induced protein, as well as with itself in SMMC-7721 and CA3 cell lines. Furthermore, C4A shows a negative correlation with TGF-induced protein, indicating a possible regulatory relationship among these molecules. These interactions are further explored in the context of Escherichia coli and ginseng, which are known to influence immune signaling pathways.   The results suggest that the interplay between C4A, TGF-induced protein, and nitric oxide synthase may play a critical role in the pathogenesis of viral infections, including HIV and KRV. These findings provide a foundation for future studies aimed at understanding the molecular mechanisms underlying these interactions and their implications in disease progression.
77150787	0	3	C4A	GeneOrGeneProduct	720
77150787	5	24	TGF-induced protein	GeneOrGeneProduct	7045
77150787	30	51	nitric oxide synthase	GeneOrGeneProduct	4843
77150787	68	96	human immunodeficiency virus	OrganismTaxon	12721
77150787	101	117	Kilham rat virus	OrganismTaxon	12441
77150787	180	183	C4A	GeneOrGeneProduct	720
77150787	185	204	TGF-induced protein	GeneOrGeneProduct	7045
77150787	210	231	nitric oxide synthase	GeneOrGeneProduct	4843
77150787	250	278	human immunodeficiency virus	OrganismTaxon	12721
77150787	289	305	Kilham rat virus	OrganismTaxon	12441
77150787	408	411	C4A	GeneOrGeneProduct	720
77150787	421	442	nitric oxide synthase	GeneOrGeneProduct	4843
77150787	479	484	C4-2B	CellLine	CVCL_4784
77150787	506	525	TGF-induced protein	GeneOrGeneProduct	7045
77150787	540	561	nitric oxide synthase	GeneOrGeneProduct	4843
77150787	747	768	nitric oxide synthase	GeneOrGeneProduct	4843
77150787	811	814	C4A	GeneOrGeneProduct	720
77150787	819	838	TGF-induced protein	GeneOrGeneProduct	7045
77150787	866	875	SMMC-7721	CellLine	CVCL_0534
77150787	880	883	CA3	CellLine	CVCL_JW73
77150787	909	912	C4A	GeneOrGeneProduct	720
77150787	947	966	TGF-induced protein	GeneOrGeneProduct	7045
77150787	1095	1111	Escherichia coli	OrganismTaxon	562
77150787	1116	1123	ginseng	OrganismTaxon	4054
77150787	1230	1233	C4A	GeneOrGeneProduct	720
77150787	1235	1254	TGF-induced protein	GeneOrGeneProduct	7045
77150787	1260	1281	nitric oxide synthase	GeneOrGeneProduct	4843
77150787	Bind	4843	720	Novel
77150787	Negative_Correlation	7045	4843	Novel
77150787	Bind	7045	4843	Novel
77150787	Negative_Correlation	4843	720	Novel
77150787	Negative_Correlation	4843	7045	Novel
77150787	Negative_Correlation	720	4843	Novel
77150787	Bind	720	4843	Novel
77150787	Negative_Correlation	720	7045	Novel

70436049|t|Genetic and pharmacological interactions in cellular models: associations between sequence variants, chemical entities, and gene 
70436049|a|This study investigates the complex interactions between genetic variants, chemical entities, and gene products in various cell lines to elucidate their functional and regulatory relationships. We focused on the effects of sequence variants such as 'insertion of the four nucleotides CCCC', 'c. 1093-1G>T', '4153delA', 'A to G', 'Leu269Phe', 'p.G705RfsX16', and 'G1103R' on gene expression and cellular responses. Additionally, we examined the impact of chemical entities including 'Clopidogrel', 'verapamil', 'eGFP', 'noradrenaline', 'CE', and 'anisomycin' on these interactions.   Our findings reveal a significant association between the insertion of the four nucleotides CCCC and both CD3 and Vps24, suggesting a potential role in immune signaling and vesicle trafficking. The sequence variant 'c. 1093-1G>T' shows a positive correlation with eGFP, indicating a possible regulatory effect on gene expression. The variant '4153delA' is associated with Vps24 and positively correlates with CE, highlighting its involvement in cellular processes related to endosomal function.   The chemical entity 'Clopidogrel' exhibits a positive correlation with both noradrenaline and CE, suggesting a synergistic effect in modulating cellular responses. 'Verapamil' is positively correlated with CE and eGFP, indicating its role in modulating gene expression and cellular signaling. The variant 'G1103R' is positively correlated with verapamil, suggesting a potential pharmacogenetic interaction.   The variant 'p.G705RfsX16' is associated with CD3 and positively correlates with eGFP, pointing to its involvement in immune-related pathways. The 'A to G' variant shows a positive correlation with both Clopidogrel and anisomycin, indicating a possible role in drug response.   These results were obtained using cell lines such as HEK293, Ishikawa, SJ-GBM2, MCF7/AdrR, C57BL/6J, and PC-3, which provided a diverse cellular context for studying these interactions. Our findings contribute to a better understanding of the molecular mechanisms underlying genetic and pharmacological interactions in cellular systems.
70436049	380	418	insertion of the four nucleotides CCCC	SequenceVariant	c|INS||CCCC
70436049	422	434	c. 1093-1G>T	SequenceVariant	c|SUB|G|1093-1|T
70436049	438	446	4153delA	SequenceVariant	c|DEL|4153|A
70436049	450	456	A to G	SequenceVariant	rs1048943
70436049	460	469	Leu269Phe	SequenceVariant	rs199852470
70436049	473	485	p.G705RfsX16	SequenceVariant	p|FS|G|705|R|16
70436049	493	499	G1103R	SequenceVariant	rs62636275
70436049	613	624	Clopidogrel	ChemicalEntity	D000077144
70436049	628	637	verapamil	ChemicalEntity	D014700
70436049	641	645	eGFP	ChemicalEntity	C485184
70436049	649	662	noradrenaline	ChemicalEntity	D009638
70436049	666	668	CE	ChemicalEntity	C105934
70436049	676	686	anisomycin	ChemicalEntity	D000841
70436049	771	809	insertion of the four nucleotides CCCC	SequenceVariant	c|INS||CCCC
70436049	819	822	CD3	GeneOrGeneProduct	915
70436049	827	832	Vps24	GeneOrGeneProduct	51652
70436049	929	941	c. 1093-1G>T	SequenceVariant	c|SUB|G|1093-1|T
70436049	977	981	eGFP	ChemicalEntity	C485184
70436049	1056	1064	4153delA	SequenceVariant	c|DEL|4153|A
70436049	1085	1090	Vps24	GeneOrGeneProduct	51652
70436049	1122	1124	CE	ChemicalEntity	C105934
70436049	1231	1242	Clopidogrel	ChemicalEntity	D000077144
70436049	1286	1299	noradrenaline	ChemicalEntity	D009638
70436049	1304	1306	CE	ChemicalEntity	C105934
70436049	1416	1418	CE	ChemicalEntity	C105934
70436049	1423	1427	eGFP	ChemicalEntity	C485184
70436049	1516	1522	G1103R	SequenceVariant	rs62636275
70436049	1554	1563	verapamil	ChemicalEntity	D014700
70436049	1632	1644	p.G705RfsX16	SequenceVariant	p|FS|G|705|R|16
70436049	1665	1668	CD3	GeneOrGeneProduct	915
70436049	1700	1704	eGFP	ChemicalEntity	C485184
70436049	1767	1773	A to G	SequenceVariant	rs1048943
70436049	1822	1833	Clopidogrel	ChemicalEntity	D000077144
70436049	1838	1848	anisomycin	ChemicalEntity	D000841
70436049	1950	1956	HEK293	CellLine	CVCL_0045
70436049	1958	1966	Ishikawa	CellLine	CVCL_2529
70436049	1968	1975	SJ-GBM2	CellLine	CVCL_M141
70436049	1977	1986	MCF7/AdrR	CellLine	 CVCL_1452
70436049	1988	1996	C57BL/6J	CellLine	CVCL_5U84
70436049	2002	2006	PC-3	CellLine	CVCL_0035
70436049	Association	c|INS||CCCC	915	Novel
70436049	Positive_Correlation	D009638	D000077144	Novel
70436049	Positive_Correlation	C485184	C105934	Novel
70436049	Positive_Correlation	c|SUB|G|1093-1|T	C485184	Novel
70436049	Positive_Correlation	c|DEL|4153|A	C105934	Novel
70436049	Association	c|DEL|4153|A	51652	Novel
70436049	Positive_Correlation	C485184	D014700	Novel
70436049	Positive_Correlation	C105934	D000077144	Novel
70436049	Positive_Correlation	D014700	C105934	Novel
70436049	Positive_Correlation	rs62636275	D014700	Novel
70436049	Positive_Correlation	p|FS|G|705|R|16	C485184	Novel
70436049	Positive_Correlation	D000077144	D009638	Novel
70436049	Association	c|INS||CCCC	51652	Novel
70436049	Positive_Correlation	rs199852470	C105934	Novel
70436049	Association	p|FS|G|705|R|16	915	Novel
70436049	Positive_Correlation	rs1048943	D000077144	Novel
70436049	Positive_Correlation	rs1048943	D000841	Novel

62828802|t|SNU-C5 cell line responses to Pilocarpine and escitalopram: associations with insulitis, muscular dystrophy, and gastrointestinal (GI) 
62828802|a|Recent studies have explored the complex interactions between chemical entities and biological systems in the context of disease progression. This study focuses on the SNU-C5 cell line, a well-characterized model for investigating cellular responses to pharmacological agents. We examined the effects of Pilocarpine and escitalopram on the SNU-C5 cell line, with particular emphasis on their associations with insulitis, muscular dystrophy, and gastrointestinal (GI) hormones.   Our findings reveal a positive correlation between Pilocarpine and insulitis, as well as between Pilocarpine and muscular dystrophy. Similarly, escitalopram shows a positive correlation with both muscular dystrophy and insulitis. These associations were further supported by the observation that gastrointestinal (GI) hormones are positively correlated with both muscular dystrophy and insulitis. Additionally, keratin 1 was found to be associated with gastrointestinal (GI) hormones, Pilocarpine, and escitalopram, highlighting its potential role in mediating these interactions.  The study also identified associations between IFN and Pilocarpine, IFN and escitalopram, and IFN and gastrointestinal (GI) hormones, suggesting a broader regulatory network involving these factors. Furthermore, SKP2 was found to be associated with propranolol, gastrointestinal (GI) hormones, and escitalopram, reinforcing its involvement in multiple pathways. Notably, propranolol was positively correlated with both muscular dystrophy and insulitis, and its association with keratin 1 was also confirmed.  These results provide new insights into the molecular mechanisms underlying the interactions between chemical entities and disease states, particularly in the context of the SNU-C5 cell line. The findings may have implications for the development of targeted therapies for conditions such as muscular dystrophy and insulitis, with potential applications in both human and rhesus monkey models.
62828802	0	6	SNU-C5	CellLine	CVCL_5112
62828802	30	41	Pilocarpine	ChemicalEntity	D010862
62828802	46	58	escitalopram	ChemicalEntity	D015283
62828802	78	87	insulitis	DiseaseOrPhenotypicFeature	D007410
62828802	89	107	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
62828802	304	310	SNU-C5	CellLine	CVCL_5112
62828802	440	451	Pilocarpine	ChemicalEntity	D010862
62828802	456	468	escitalopram	ChemicalEntity	D015283
62828802	476	482	SNU-C5	CellLine	CVCL_5112
62828802	546	555	insulitis	DiseaseOrPhenotypicFeature	D007410
62828802	557	575	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
62828802	581	611	gastrointestinal (GI) hormones	ChemicalEntity	D005768
62828802	666	677	Pilocarpine	ChemicalEntity	D010862
62828802	682	691	insulitis	DiseaseOrPhenotypicFeature	D007410
62828802	712	723	Pilocarpine	ChemicalEntity	D010862
62828802	728	746	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
62828802	759	771	escitalopram	ChemicalEntity	D015283
62828802	811	829	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
62828802	834	843	insulitis	DiseaseOrPhenotypicFeature	D007410
62828802	911	941	gastrointestinal (GI) hormones	ChemicalEntity	D005768
62828802	978	996	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
62828802	1001	1010	insulitis	DiseaseOrPhenotypicFeature	D007410
62828802	1026	1035	keratin 1	GeneOrGeneProduct	16678
62828802	1068	1098	gastrointestinal (GI) hormones	ChemicalEntity	D005768
62828802	1100	1111	Pilocarpine	ChemicalEntity	D010862
62828802	1117	1129	escitalopram	ChemicalEntity	D015283
62828802	1244	1247	IFN	GeneOrGeneProduct	25712
62828802	1252	1263	Pilocarpine	ChemicalEntity	D010862
62828802	1265	1268	IFN	GeneOrGeneProduct	25712
62828802	1273	1285	escitalopram	ChemicalEntity	D015283
62828802	1291	1294	IFN	GeneOrGeneProduct	25712
62828802	1299	1329	gastrointestinal (GI) hormones	ChemicalEntity	D005768
62828802	1409	1413	SKP2	GeneOrGeneProduct	6502
62828802	1446	1457	propranolol	ChemicalEntity	D011433
62828802	1459	1489	gastrointestinal (GI) hormones	ChemicalEntity	D005768
62828802	1495	1507	escitalopram	ChemicalEntity	D015283
62828802	1568	1579	propranolol	ChemicalEntity	D011433
62828802	1616	1634	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
62828802	1639	1648	insulitis	DiseaseOrPhenotypicFeature	D007410
62828802	1675	1684	keratin 1	GeneOrGeneProduct	16678
62828802	1880	1886	SNU-C5	CellLine	CVCL_5112
62828802	1998	2016	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
62828802	2021	2030	insulitis	DiseaseOrPhenotypicFeature	D007410
62828802	Positive_Correlation	D010862	D007410	Novel
62828802	Positive_Correlation	D015283	D009136	Novel
62828802	Association	16678	D005768	Novel
62828802	Association	16678	D010862	Novel
62828802	Positive_Correlation	D011433	D009136	Novel
62828802	Positive_Correlation	D007410	D015283	Novel
62828802	Positive_Correlation	D009136	D010862	Novel
62828802	Positive_Correlation	D005768	D009136	Novel
62828802	Association	16678	D015283	Novel
62828802	Positive_Correlation	D005768	D007410	Novel
62828802	Positive_Correlation	D010862	D009136	Novel
62828802	Positive_Correlation	D015283	D007410	Novel
62828802	Association	25712	D010862	Novel
62828802	Association	6502	D011433	Novel
62828802	Positive_Correlation	D009136	D015283	Novel
62828802	Association	25712	D015283	Novel
62828802	Association	6502	D005768	Novel
62828802	Positive_Correlation	D009136	D005768	Novel
62828802	Positive_Correlation	D007410	D010862	Novel
62828802	Positive_Correlation	D009136	D011433	Novel
62828802	Association	16678	D011433	Novel
62828802	Positive_Correlation	D011433	D007410	Novel
62828802	Association	25712	D005768	Novel
62828802	Positive_Correlation	D007410	D005768	Novel
62828802	Association	6502	D015283	Novel
62828802	Association	25712	D011433	Novel
62828802	Association	6502	D010862	Novel
62828802	Positive_Correlation	D007410	D011433	Novel

52376118|t|Genetic and molecular interactions of CYP2F1, ALDH1B1, ETV6, and miR-483-3p in the context of lipid-linked oligosaccharides and Ca2+ s
52376118|a|Recent studies have uncovered complex genetic and molecular interactions among several key genes and sequence variants in the context of lipid metabolism and Ca2+ signaling. A notable association was found between the gene products ETV6 and ALDH1B1, with further evidence supporting a bidirectional relationship between these two genes. Additionally, a negative correlation was observed between ETV6 and ALDH1B1, suggesting a regulatory interplay that may influence cellular responses to environmental stimuli.    The sequence variant His626Arg showed a positive correlation with lipid-linked oligosaccharides, indicating a potential role in modulating glycosylation pathways. This variant also exhibited a positive correlation with Ca2+ levels, while a negative correlation was noted between Ca2+ and Ecstasy, highlighting the complex interplay between neurotransmitter activity and intracellular signaling.    The gene CYP2F1 was found to be associated with GLP1R, and a negative correlation was observed between GLP1R and CYP2F1, suggesting a regulatory mechanism that may influence metabolic responses. Furthermore, miR-483-3p was associated with CYP2F1, indicating a potential role for microRNA regulation in the expression of this enzyme.    The sequence variant P163S was found to be associated with lipid-linked oligosaccharides, reinforcing the role of sequence variation in modulating metabolic pathways. The gene Cidea was associated with ETV6, and this relationship was further supported by a negative correlation between GLP1R and ETV6.    In addition, a positive correlation was observed between Ca2+ and the sequence variant -616C/G, suggesting a potential role for this polymorphism in Ca2+ homeostasis. These findings collectively highlight the intricate network of genetic and molecular interactions that may underlie various physiological and pathological processes, particularly in the context of human immunodeficiency virus infection and metabolic disorders.
52376118	38	44	CYP2F1	GeneOrGeneProduct	1572
52376118	46	53	ALDH1B1	GeneOrGeneProduct	219
52376118	55	59	ETV6	GeneOrGeneProduct	2120
52376118	65	75	miR-483-3p	GeneOrGeneProduct	723874
52376118	94	123	lipid-linked oligosaccharides	ChemicalEntity	C023023
52376118	128	132	Ca2+	ChemicalEntity	D002118
52376118	293	297	Ca2+	ChemicalEntity	D002118
52376118	367	371	ETV6	GeneOrGeneProduct	2120
52376118	376	383	ALDH1B1	GeneOrGeneProduct	219
52376118	530	534	ETV6	GeneOrGeneProduct	2120
52376118	539	546	ALDH1B1	GeneOrGeneProduct	219
52376118	670	679	His626Arg	SequenceVariant	p|SUB|H|626|R
52376118	715	744	lipid-linked oligosaccharides	ChemicalEntity	C023023
52376118	868	872	Ca2+	ChemicalEntity	D002118
52376118	928	932	Ca2+	ChemicalEntity	D002118
52376118	937	944	Ecstasy	ChemicalEntity	D018817
52376118	1056	1062	CYP2F1	GeneOrGeneProduct	1572
52376118	1095	1100	GLP1R	GeneOrGeneProduct	2740
52376118	1150	1155	GLP1R	GeneOrGeneProduct	2740
52376118	1160	1166	CYP2F1	GeneOrGeneProduct	1572
52376118	1255	1265	miR-483-3p	GeneOrGeneProduct	723874
52376118	1286	1292	CYP2F1	GeneOrGeneProduct	1572
52376118	1404	1409	P163S	SequenceVariant	rs387906769
52376118	1442	1471	lipid-linked oligosaccharides	ChemicalEntity	C023023
52376118	1559	1564	Cidea	GeneOrGeneProduct	1149
52376118	1585	1589	ETV6	GeneOrGeneProduct	2120
52376118	1669	1674	GLP1R	GeneOrGeneProduct	2740
52376118	1679	1683	ETV6	GeneOrGeneProduct	2120
52376118	1745	1749	Ca2+	ChemicalEntity	D002118
52376118	1775	1782	-616C/G	SequenceVariant	rs747302
52376118	1837	1841	Ca2+	ChemicalEntity	D002118
52376118	2052	2080	human immunodeficiency virus	OrganismTaxon	12721
52376118	Association	2120	219	Novel
52376118	Association	219	2120	Novel
52376118	Positive_Correlation	D002118	p|SUB|H|626|R	Novel
52376118	Association	1572	2740	Novel
52376118	Positive_Correlation	C023023	p|SUB|H|626|R	Novel
52376118	Association	723874	1572	Novel
52376118	Association	D002118	2740	Novel
52376118	Association	rs387906769	C023023	Novel
52376118	Negative_Correlation	2740	2120	Novel
52376118	Positive_Correlation	D002118	rs747302	Novel
52376118	Negative_Correlation	2120	219	Novel
52376118	Negative_Correlation	D002118	D018817	Novel
52376118	Association	219	723874	Novel
52376118	Association	2120	1149	Novel
52376118	Negative_Correlation	2740	1572	Novel
52376118	Association	1149	2120	Novel

16591463|t|Genetic variants in XBP1 and Na-K-2Cl cotransporter modulate Darier's disease and their interactions with vancomycin and KU7 cell line r
16591463|a|This study investigates the molecular mechanisms underlying Darier's disease, focusing on the interplay between genetic variants, protein interactions, and cellular responses in the KU7 cell line. We identified three instances of the sequence variant IVS51 + 1G-->A, which showed a positive correlation with the manifestation of Darier's disease. Similarly, six instances of the sequence variant p.W111X were found to be positively correlated with the development of Darier's disease. These findings suggest that both variants may contribute to the pathogenesis of the condition through distinct molecular pathways.   In addition, we examined the interactions between the gene products XBP1 and Na-K-2Cl cotransporter with the chemical entity vancomycin. The results demonstrated a significant bind between XBP1 and vancomycin, as well as a bind between Na-K-2Cl cotransporter and vancomycin. These interactions were further validated using the KU7 cell line, which exhibited consistent responses to vancomycin treatment in the presence of these gene products.   The study also included six instances of Darier's disease in the KU7 cell line model, highlighting the potential of this cell line as a tool for studying the disease at the molecular level. The repeated occurrence of the sequence variants and the consistent interactions observed in the KU7 cell line provide strong evidence for the role of these genetic and molecular factors in the pathophysiology of Darier's disease. Furthermore, the presence of vancomycin in the experimental setup underscores the importance of drug-protein interactions in modulating disease-related pathways.
16591463	20	24	XBP1	GeneOrGeneProduct	22433
16591463	29	51	Na-K-2Cl cotransporter	GeneOrGeneProduct	20495
16591463	61	77	Darier's disease	DiseaseOrPhenotypicFeature	D007644
16591463	106	116	vancomycin	ChemicalEntity	D014640
16591463	121	124	KU7	CellLine	CVCL_4714
16591463	197	213	Darier's disease	DiseaseOrPhenotypicFeature	D007644
16591463	319	322	KU7	CellLine	CVCL_4714
16591463	388	402	IVS51 + 1G-->A	SequenceVariant	c|SUB|G|IVS51+1|A
16591463	466	482	Darier's disease	DiseaseOrPhenotypicFeature	D007644
16591463	533	540	p.W111X	SequenceVariant	rs137852884
16591463	604	620	Darier's disease	DiseaseOrPhenotypicFeature	D007644
16591463	823	827	XBP1	GeneOrGeneProduct	22433
16591463	832	854	Na-K-2Cl cotransporter	GeneOrGeneProduct	20495
16591463	880	890	vancomycin	ChemicalEntity	D014640
16591463	944	948	XBP1	GeneOrGeneProduct	22433
16591463	953	963	vancomycin	ChemicalEntity	D014640
16591463	991	1013	Na-K-2Cl cotransporter	GeneOrGeneProduct	20495
16591463	1018	1028	vancomycin	ChemicalEntity	D014640
16591463	1082	1085	KU7	CellLine	CVCL_4714
16591463	1137	1147	vancomycin	ChemicalEntity	D014640
16591463	1241	1257	Darier's disease	DiseaseOrPhenotypicFeature	D007644
16591463	1265	1268	KU7	CellLine	CVCL_4714
16591463	1487	1490	KU7	CellLine	CVCL_4714
16591463	1603	1619	Darier's disease	DiseaseOrPhenotypicFeature	D007644
16591463	1650	1660	vancomycin	ChemicalEntity	D014640
16591463	Positive_Correlation	rs137852884	D007644	Novel
16591463	Positive_Correlation	c|SUB|G|IVS51+1|A	D007644	Novel
16591463	Bind	20495	D014640	Novel
16591463	Bind	22433	D014640	Novel

52709947|t|CGK-733 and telaprevir interactions with TP53, anemia, and genetic variants in diverse disease 
52709947|a|Recent studies have explored the complex interplay between the chemical entity CGK-733, the cell line SNU-C2A, and the gene TP53 in the context of anemia and various sequence variants. CGK-733 has been shown to exhibit a positive correlation with alpha-methyl-para-tyrosine, while simultaneously displaying a negative correlation with telaprevir. This dual relationship is further supported by the negative correlation between telaprevir and alpha-methyl-para-tyrosine, and the positive correlation between telaprevir and alpha-methyl-para-tyrosine, highlighting the intricate pharmacological interactions among these compounds.   The cell line SNU-C2A has been associated with multiple genetic variants, including A1359, p.C615R, and +3100 T/G. Notably, anemia has been found to have a positive correlation with both A1359 and p.C615R, as well as with +3100 T/G. These findings suggest that anemia may be influenced by multiple genetic factors, including the sequence variants A1359, p.C615R, and +3100 T/G. Additionally, the association between anemia and p.C615R has been reinforced by multiple studies, further supporting the role of this variant in disease progression.  The gene TP53 has been linked to several disease phenotypes, including anemia, dystonia, and oligodontia phenotype. TP53 has also been associated with the cell lines SNU-C2A, C4-2B, and PC-3, and with the sequence variants A1359 and +3100 T/G. The positive correlation between TP53 and oligodontia phenotype, as well as the positive correlation between TP53 and p.C615R, suggests a potential role for TP53 in the pathogenesis of these conditions. Furthermore, the association between TP53 and angioedema indicates a broader involvement of this gene in diverse disease states.  The sequence variant A1359 has been associated with multiple disease phenotypes, including anemia, angioedema, and non-syndromic autosomal recessive deafness. The positive correlation between A1359 and non-syndromic autosomal recessive deafness, as well as the positive correlation between A1359 and alkaptonuria, underscores the importance of this variant in genetic disease. Similarly, the positive correlation between +3100 T/G and non-syndromic autosomal recessive deafness, as well as the positive correlation between +3100 T/G and alkaptonuria, further supports the role of this variant in disease mechanisms.  These findings collectively suggest that the interplay between chemical entities, genetic variants, and disease phenotypes is complex and multifaceted, with implications for both basic research and clinical applications.
52709947	0	7	CGK-733	ChemicalEntity	C512273
52709947	12	22	telaprevir	ChemicalEntity	C486464
52709947	41	45	TP53	GeneOrGeneProduct	24842
52709947	47	53	anemia	DiseaseOrPhenotypicFeature	D000740
52709947	175	182	CGK-733	ChemicalEntity	C512273
52709947	198	205	SNU-C2A	CellLine	CVCL_1709
52709947	220	224	TP53	GeneOrGeneProduct	24842
52709947	243	249	anemia	DiseaseOrPhenotypicFeature	D000740
52709947	281	288	CGK-733	ChemicalEntity	C512273
52709947	343	369	alpha-methyl-para-tyrosine	ChemicalEntity	D019805
52709947	431	441	telaprevir	ChemicalEntity	C486464
52709947	523	533	telaprevir	ChemicalEntity	C486464
52709947	538	564	alpha-methyl-para-tyrosine	ChemicalEntity	D019805
52709947	603	613	telaprevir	ChemicalEntity	C486464
52709947	618	644	alpha-methyl-para-tyrosine	ChemicalEntity	D019805
52709947	741	748	SNU-C2A	CellLine	CVCL_1709
52709947	811	816	A1359	SequenceVariant	rs1049353
52709947	818	825	p.C615R	SequenceVariant	rs201893408
52709947	831	840	+3100 T/G	SequenceVariant	c|SUB|T|+3100|G
52709947	851	857	anemia	DiseaseOrPhenotypicFeature	D000740
52709947	914	919	A1359	SequenceVariant	rs1049353
52709947	924	931	p.C615R	SequenceVariant	rs201893408
52709947	949	958	+3100 T/G	SequenceVariant	c|SUB|T|+3100|G
52709947	988	994	anemia	DiseaseOrPhenotypicFeature	D000740
52709947	1074	1079	A1359	SequenceVariant	rs1049353
52709947	1081	1088	p.C615R	SequenceVariant	rs201893408
52709947	1094	1103	+3100 T/G	SequenceVariant	c|SUB|T|+3100|G
52709947	1143	1149	anemia	DiseaseOrPhenotypicFeature	D000740
52709947	1154	1161	p.C615R	SequenceVariant	rs201893408
52709947	1281	1285	TP53	GeneOrGeneProduct	24842
52709947	1343	1349	anemia	DiseaseOrPhenotypicFeature	D000740
52709947	1351	1359	dystonia	DiseaseOrPhenotypicFeature	D004421
52709947	1365	1386	oligodontia phenotype	DiseaseOrPhenotypicFeature	C538049
52709947	1388	1392	TP53	GeneOrGeneProduct	24842
52709947	1438	1445	SNU-C2A	CellLine	CVCL_1709
52709947	1447	1452	C4-2B	CellLine	CVCL_4784
52709947	1458	1462	PC-3	CellLine	CVCL_0035
52709947	1495	1500	A1359	SequenceVariant	rs1049353
52709947	1505	1514	+3100 T/G	SequenceVariant	c|SUB|T|+3100|G
52709947	1549	1553	TP53	GeneOrGeneProduct	24842
52709947	1558	1579	oligodontia phenotype	DiseaseOrPhenotypicFeature	C538049
52709947	1625	1629	TP53	GeneOrGeneProduct	24842
52709947	1634	1641	p.C615R	SequenceVariant	rs201893408
52709947	1673	1677	TP53	GeneOrGeneProduct	24842
52709947	1756	1760	TP53	GeneOrGeneProduct	24842
52709947	1765	1775	angioedema	DiseaseOrPhenotypicFeature	D000799
52709947	1870	1875	A1359	SequenceVariant	rs1049353
52709947	1940	1946	anemia	DiseaseOrPhenotypicFeature	D000740
52709947	1948	1958	angioedema	DiseaseOrPhenotypicFeature	D000799
52709947	1964	2006	non-syndromic autosomal recessive deafness	DiseaseOrPhenotypicFeature	C567134
52709947	2041	2046	A1359	SequenceVariant	rs1049353
52709947	2051	2093	non-syndromic autosomal recessive deafness	DiseaseOrPhenotypicFeature	C567134
52709947	2139	2144	A1359	SequenceVariant	rs1049353
52709947	2149	2161	alkaptonuria	DiseaseOrPhenotypicFeature	D000474
52709947	2270	2279	+3100 T/G	SequenceVariant	c|SUB|T|+3100|G
52709947	2284	2326	non-syndromic autosomal recessive deafness	DiseaseOrPhenotypicFeature	C567134
52709947	2372	2381	+3100 T/G	SequenceVariant	c|SUB|T|+3100|G
52709947	2386	2398	alkaptonuria	DiseaseOrPhenotypicFeature	D000474
52709947	Positive_Correlation	D000740	rs1049353	Novel
52709947	Association	D000799	rs1049353	Novel
52709947	Positive_Correlation	D000740	rs201893408	Novel
52709947	Positive_Correlation	C538049	c|SUB|T|+3100|G	Novel
52709947	Positive_Correlation	D000740	c|SUB|T|+3100|G	Novel
52709947	Positive_Correlation	C512273	D019805	Novel
52709947	Negative_Correlation	C486464	D019805	Novel
52709947	Negative_Correlation	D019805	C486464	Novel
52709947	Association	D000740	rs201893408	Novel
52709947	Positive_Correlation	D000474	rs1049353	Novel
52709947	Association	24842	C486464	Novel
52709947	Negative_Correlation	C512273	C486464	Novel
52709947	Negative_Correlation	24842	C486464	Novel
52709947	Association	D000474	rs1049353	Novel
52709947	Association	C567134	rs1049353	Novel
52709947	Association	D004421	rs201893408	Novel
52709947	Association	24842	D000740	Novel
52709947	Positive_Correlation	C567134	c|SUB|T|+3100|G	Novel
52709947	Association	C567134	c|SUB|T|+3100|G	Novel
52709947	Positive_Correlation	C486464	D019805	Novel
52709947	Positive_Correlation	D000474	c|SUB|T|+3100|G	Novel
52709947	Association	24842	C538049	Novel
52709947	Positive_Correlation	C538049	rs201893408	Novel
52709947	Association	24842	C512273	Novel
52709947	Association	24842	D000799	Novel

75368012|t|Pirenzepine and IPA-3 Modulate Dopamine Signaling in Diverse Models: A Comparative Study of Leu, Valproate, and Methylmalo
75368012|a|This study investigates the complex interactions between pirenzepine, IPA-3, and Dopamine across multiple biological systems, including mammalian and model organisms. We demonstrate a significant association between IPA-3 and pirenzepine, suggesting a potential synergistic effect in modulating dopaminergic pathways. Additionally, we observe a positive correlation between Leu and Dopamine, which is further supported by a positive correlation between IPA-3 and Dopamine. These findings are consistent across both in vitro and in vivo models, including the cell lines MES-SA/Dx5 and CD18/HPAF, as well as the organism taxon Danio rerio.   The cotreatment of Dopamine and valproate reveals a unique pharmacological profile, with valproate showing a significant association with Leu. Furthermore, we report a negative correlation between methylmalonic acid and valproate, indicating a possible antagonistic relationship. This relationship is further explored in the context of bovine and S. cerevisiae models, where valproate's effects on methylmalonic acid levels are consistently observed.   In addition, we examine the effects of valproate in the context of Spirulina and Mangifera indica Linn, where its interactions with other chemical entities and biological systems are further characterized. The study also includes the cell line SNU-C2A, where valproate's impact on methylmalonic acid levels is further validated. These findings highlight the multifaceted role of valproate in modulating various biochemical pathways and underscore the importance of understanding its interactions with other compounds in diverse biological contexts.
75368012	16	21	IPA-3	ChemicalEntity	C541795
75368012	31	39	Dopamine	ChemicalEntity	D004298
75368012	92	95	Leu	ChemicalEntity	D007930
75368012	180	191	pirenzepine	ChemicalEntity	D010890
75368012	193	198	IPA-3	ChemicalEntity	C541795
75368012	204	212	Dopamine	ChemicalEntity	D004298
75368012	339	344	IPA-3	ChemicalEntity	C541795
75368012	349	360	pirenzepine	ChemicalEntity	D010890
75368012	497	500	Leu	ChemicalEntity	D007930
75368012	505	513	Dopamine	ChemicalEntity	D004298
75368012	576	581	IPA-3	ChemicalEntity	C541795
75368012	586	594	Dopamine	ChemicalEntity	D004298
75368012	692	702	MES-SA/Dx5	CellLine	CVCL_2598
75368012	707	716	CD18/HPAF	CellLine	CVCL_0313
75368012	748	759	Danio rerio	OrganismTaxon	7955
75368012	782	790	Dopamine	ChemicalEntity	D004298
75368012	795	804	valproate	ChemicalEntity	D014635
75368012	852	861	valproate	ChemicalEntity	D014635
75368012	901	904	Leu	ChemicalEntity	D007930
75368012	960	978	methylmalonic acid	ChemicalEntity	D008764
75368012	983	992	valproate	ChemicalEntity	D014635
75368012	1099	1105	bovine	OrganismTaxon	9913
75368012	1110	1123	S. cerevisiae	OrganismTaxon	4932
75368012	1138	1147	valproate	ChemicalEntity	D014635
75368012	1161	1179	methylmalonic acid	ChemicalEntity	D008764
75368012	1255	1264	valproate	ChemicalEntity	D014635
75368012	1283	1292	Spirulina	OrganismTaxon	551299
75368012	1297	1318	Mangifera indica Linn	OrganismTaxon	29780
75368012	1460	1467	SNU-C2A	CellLine	CVCL_1709
75368012	1475	1484	valproate	ChemicalEntity	D014635
75368012	1497	1515	methylmalonic acid	ChemicalEntity	D008764
75368012	1595	1604	valproate	ChemicalEntity	D014635
75368012	Association	D007930	D014635	Novel
75368012	Cotreatment	D004298	D014635	Novel
75368012	Comparison	D014635	D008764	Novel
75368012	Association	C541795	D010890	Novel
75368012	Negative_Correlation	D008764	D014635	Novel
75368012	Positive_Correlation	D007930	D004298	Novel
75368012	Positive_Correlation	C541795	D004298	Novel

96240813|t|Functional characterization of sequence variants in 293T and Huh7 cells: interactions with alcohol, pirenzepine, and 4
96240813|a|This study investigates the functional consequences of sequence variants in 293T and Huh7 cell lines, with a focus on their interactions with alcohol, pirenzepine, and 4-ene-VPA. The sequence variant (CCTTT)13 was found to significantly alter the response of 293T cells to alcohol exposure, suggesting a potential association between (CCTTT)13 and alcohol metabolism. In contrast, the variant D299G showed a strong association with alcohol-induced changes in Huh7 cell viability, further supporting the link between D299G and alcohol.   A comparative analysis between pirenzepine and alcohol revealed that pirenzepine modulates the cellular response to alcohol in both 293T and Huh7 cells, indicating a potential therapeutic role for pirenzepine in mitigating alcohol-related toxicity. Additionally, the conversion of 4-ene-VPA to alcohol was observed in RAW 264.7 cells, suggesting a metabolic pathway that may be relevant in the context of alcohol metabolism.   The comparison between alcohol and 4-ene-VPA highlighted distinct effects on cell proliferation and apoptosis in 293T and Huh7 cells, with 4-ene-VPA showing a more pronounced protective effect against alcohol-induced damage. Furthermore, the association between D299G and 4-ene-VPA was confirmed through multiple experiments, demonstrating that D299G enhances the efficacy of 4-ene-VPA in reducing alcohol toxicity.   These findings provide critical insights into the molecular mechanisms underlying the interactions between sequence variants, alcohol, pirenzepine, and 4-ene-VPA, with implications for the development of targeted therapies in alcohol-related disorders.
96240813	52	56	293T	CellLine	CVCL_0063
96240813	61	65	Huh7	CellLine	CVCL_0336
96240813	91	98	alcohol	ChemicalEntity	D000438
96240813	100	111	pirenzepine	ChemicalEntity	D010890
96240813	195	199	293T	CellLine	CVCL_0063
96240813	204	208	Huh7	CellLine	CVCL_0336
96240813	261	268	alcohol	ChemicalEntity	D000438
96240813	270	281	pirenzepine	ChemicalEntity	D010890
96240813	287	296	4-ene-VPA	ChemicalEntity	C045022
96240813	319	328	(CCTTT)13	SequenceVariant	c|DUP||CCTTT|13
96240813	378	382	293T	CellLine	CVCL_0063
96240813	392	399	alcohol	ChemicalEntity	D000438
96240813	453	462	(CCTTT)13	SequenceVariant	c|DUP||CCTTT|13
96240813	467	474	alcohol	ChemicalEntity	D000438
96240813	512	517	D299G	SequenceVariant	rs4986790
96240813	551	558	alcohol	ChemicalEntity	D000438
96240813	578	582	Huh7	CellLine	CVCL_0336
96240813	635	640	D299G	SequenceVariant	rs4986790
96240813	645	652	alcohol	ChemicalEntity	D000438
96240813	687	698	pirenzepine	ChemicalEntity	D010890
96240813	703	710	alcohol	ChemicalEntity	D000438
96240813	725	736	pirenzepine	ChemicalEntity	D010890
96240813	772	779	alcohol	ChemicalEntity	D000438
96240813	788	792	293T	CellLine	CVCL_0063
96240813	797	801	Huh7	CellLine	CVCL_0336
96240813	853	864	pirenzepine	ChemicalEntity	D010890
96240813	879	886	alcohol	ChemicalEntity	D000438
96240813	937	946	4-ene-VPA	ChemicalEntity	C045022
96240813	950	957	alcohol	ChemicalEntity	D000438
96240813	974	983	RAW 264.7	CellLine	CVCL_0493
96240813	1061	1068	alcohol	ChemicalEntity	D000438
96240813	1106	1113	alcohol	ChemicalEntity	D000438
96240813	1118	1127	4-ene-VPA	ChemicalEntity	C045022
96240813	1196	1200	293T	CellLine	CVCL_0063
96240813	1205	1209	Huh7	CellLine	CVCL_0336
96240813	1222	1231	4-ene-VPA	ChemicalEntity	C045022
96240813	1284	1291	alcohol	ChemicalEntity	D000438
96240813	1345	1350	D299G	SequenceVariant	rs4986790
96240813	1355	1364	4-ene-VPA	ChemicalEntity	C045022
96240813	1428	1433	D299G	SequenceVariant	rs4986790
96240813	1459	1468	4-ene-VPA	ChemicalEntity	C045022
96240813	1481	1488	alcohol	ChemicalEntity	D000438
96240813	1627	1634	alcohol	ChemicalEntity	D000438
96240813	1636	1647	pirenzepine	ChemicalEntity	D010890
96240813	1653	1662	4-ene-VPA	ChemicalEntity	C045022
96240813	1727	1734	alcohol	ChemicalEntity	D000438
96240813	Association	rs4986790	D000438	Novel
96240813	Comparison	D010890	D000438	Novel
96240813	Conversion	C045022	D000438	Novel
96240813	Comparison	D000438	C045022	Novel
96240813	Association	rs4986790	C045022	Novel

89881840|t|Genetic and molecular interactions of Rab6c, CD28, and NBS1 in asthma, stroke, and hepatic failure: implications for disease mechanisms and therapeutic st
89881840|a|Recent studies have highlighted the complex interplay between genetic factors and disease phenotypes in the context of asthma, stroke, and hepatic failure. This research explores the molecular and genetic relationships among Rab6c, CD28, and NBS1, with a focus on their roles in asthma, stroke, and hepatic failure. The findings reveal a positive correlation between asthma and CD28, suggesting that CD28 may play a protective role in asthma pathogenesis. Conversely, a negative correlation was observed between asthma and Myotonic dystrophy protein kinase, indicating a potential antagonistic relationship.   In the context of stroke, a negative correlation was found between stroke and NBS1, which contrasts with a previously reported positive correlation. This discrepancy suggests that NBS1 may have context-dependent effects on stroke outcomes. Additionally, the study identified a negative correlation between hepatic failure and aryl hydrocarbon receptor interacting protein, implying that this protein may contribute to the progression of hepatic failure.   The research also examined the role of Rab6c in these conditions, with two instances of Rab6c mentioned, suggesting its involvement in multiple disease pathways. The chemical entities dUTP and GTP were found to be associated with these genetic interactions, potentially modulating the activity of Rab6c and other proteins. Triamcinolone diacetate, a corticosteroid, was also implicated in the regulation of asthma-related pathways, further emphasizing the role of chemical entities in disease modulation.  The study included a diverse range of organisms, including humans, HPV, and Zebrafish, to assess the conservation of these genetic and molecular interactions. The findings from rhesus monkeys and guinea pigs provided additional support for the observed correlations. Furthermore, the presence of rDEN2 and Aedes mosquitoes in the study highlights the potential role of viral and vector-borne factors in disease progression.   Overall, this research provides a comprehensive framework for understanding the genetic and molecular underpinnings of asthma, stroke, and hepatic failure, with implications for the development of targeted therapeutic strategies.
89881840	38	43	Rab6c	GeneOrGeneProduct	84084
89881840	45	49	CD28	GeneOrGeneProduct	940
89881840	55	59	NBS1	GeneOrGeneProduct	4683
89881840	63	69	asthma	DiseaseOrPhenotypicFeature	D001249
89881840	71	77	stroke	DiseaseOrPhenotypicFeature	D020521
89881840	83	98	hepatic failure	DiseaseOrPhenotypicFeature	D017093
89881840	274	280	asthma	DiseaseOrPhenotypicFeature	D001249
89881840	282	288	stroke	DiseaseOrPhenotypicFeature	D020521
89881840	294	309	hepatic failure	DiseaseOrPhenotypicFeature	D017093
89881840	380	385	Rab6c	GeneOrGeneProduct	84084
89881840	387	391	CD28	GeneOrGeneProduct	940
89881840	397	401	NBS1	GeneOrGeneProduct	4683
89881840	434	440	asthma	DiseaseOrPhenotypicFeature	D001249
89881840	442	448	stroke	DiseaseOrPhenotypicFeature	D020521
89881840	454	469	hepatic failure	DiseaseOrPhenotypicFeature	D017093
89881840	522	528	asthma	DiseaseOrPhenotypicFeature	D001249
89881840	533	537	CD28	GeneOrGeneProduct	940
89881840	555	559	CD28	GeneOrGeneProduct	940
89881840	590	596	asthma	DiseaseOrPhenotypicFeature	D001249
89881840	667	673	asthma	DiseaseOrPhenotypicFeature	D001249
89881840	678	711	Myotonic dystrophy protein kinase	GeneOrGeneProduct	13400
89881840	783	789	stroke	DiseaseOrPhenotypicFeature	D020521
89881840	832	838	stroke	DiseaseOrPhenotypicFeature	D020521
89881840	843	847	NBS1	GeneOrGeneProduct	4683
89881840	945	949	NBS1	GeneOrGeneProduct	4683
89881840	988	994	stroke	DiseaseOrPhenotypicFeature	D020521
89881840	1071	1086	hepatic failure	DiseaseOrPhenotypicFeature	D017093
89881840	1091	1136	aryl hydrocarbon receptor interacting protein	GeneOrGeneProduct	9049
89881840	1202	1217	hepatic failure	DiseaseOrPhenotypicFeature	D017093
89881840	1260	1265	Rab6c	GeneOrGeneProduct	84084
89881840	1309	1314	Rab6c	GeneOrGeneProduct	84084
89881840	1405	1409	dUTP	ChemicalEntity	C027078
89881840	1414	1417	GTP	ChemicalEntity	D006160
89881840	1518	1523	Rab6c	GeneOrGeneProduct	84084
89881840	1628	1634	asthma	DiseaseOrPhenotypicFeature	D001249
89881840	1786	1792	humans	OrganismTaxon	9606
89881840	1794	1797	HPV	OrganismTaxon	10566
89881840	1803	1812	Zebrafish	OrganismTaxon	7955
89881840	1904	1918	rhesus monkeys	OrganismTaxon	9544
89881840	1923	1934	guinea pigs	OrganismTaxon	10141
89881840	2023	2028	rDEN2	OrganismTaxon	11060
89881840	2033	2049	Aedes mosquitoes	OrganismTaxon	1245352
89881840	2272	2278	asthma	DiseaseOrPhenotypicFeature	D001249
89881840	2280	2286	stroke	DiseaseOrPhenotypicFeature	D020521
89881840	2292	2307	hepatic failure	DiseaseOrPhenotypicFeature	D017093
89881840	Positive_Correlation	D020521	4683	Novel
89881840	Positive_Correlation	D001249	940	Novel
89881840	Negative_Correlation	D017093	9049	Novel
89881840	Negative_Correlation	D001249	13400	Novel
89881840	Negative_Correlation	D020521	4683	Novel

67180956|t|Thromboxane, dUTP, and genetic variants in myopia and focal segmental glomerulosclerosis: a multi-cellular and multi-variant 
67180956|a|This study investigates the complex interplay between Thromboxane, dUTP, and genetic variants in the context of myopia and focal segmental glomerulosclerosis. Using a combination of in vitro and in vivo models, we examined the effects of these factors on cellular function and disease progression. The IEC-6 and Mz-ChA-1 cell lines were employed to assess the role of dUTP in modulating Thromboxane signaling, while the DUCaP and hRPTEC cell lines were used to evaluate the impact of genetic variants on disease-related pathways.   Our findings reveal a significant association between dUTP and adrenergic antagonists, suggesting a potential regulatory mechanism in cellular responses to stress. Furthermore, we observed a strong link between dUTP and myopia, with the sequence variant p.W290L showing a notable correlation with the development of myopia. The disease focal segmental glomerulosclerosis was found to be associated with multiple genetic variants, including the 1123T-->G, 137-bp insertion, and rs2070197 variants, indicating a complex genetic architecture underlying this condition.   Additionally, the association between focal segmental glomerulosclerosis and adrenergic antagonists was confirmed, highlighting the potential therapeutic implications of targeting these pathways. The sequence variant A49T was also found to be linked to focal segmental glomerulosclerosis, further supporting the role of genetic variability in disease susceptibility. The study also included the HeLa cell line to explore the broader implications of these associations across different cellular contexts.   These results provide new insights into the molecular mechanisms underlying myopia and focal segmental glomerulosclerosis, and suggest that the interplay between Thromboxane, dUTP, and genetic variants may represent a key area for future therapeutic development.
67180956	0	11	Thromboxane	ChemicalEntity	D013931
67180956	13	17	dUTP	ChemicalEntity	C027078
67180956	43	49	myopia	DiseaseOrPhenotypicFeature	D009216
67180956	54	88	focal segmental glomerulosclerosis	DiseaseOrPhenotypicFeature	D005923
67180956	180	191	Thromboxane	ChemicalEntity	D013931
67180956	193	197	dUTP	ChemicalEntity	C027078
67180956	238	244	myopia	DiseaseOrPhenotypicFeature	D009216
67180956	249	283	focal segmental glomerulosclerosis	DiseaseOrPhenotypicFeature	D005923
67180956	428	433	IEC-6	CellLine	CVCL_0343
67180956	438	446	Mz-ChA-1	CellLine	CVCL_6932
67180956	494	498	dUTP	ChemicalEntity	C027078
67180956	513	524	Thromboxane	ChemicalEntity	D013931
67180956	546	551	DUCaP	CellLine	CVCL_2025
67180956	556	562	hRPTEC	CellLine	CVCL_K278
67180956	712	716	dUTP	ChemicalEntity	C027078
67180956	721	743	adrenergic antagonists	ChemicalEntity	D018674
67180956	869	873	dUTP	ChemicalEntity	C027078
67180956	878	884	myopia	DiseaseOrPhenotypicFeature	D009216
67180956	912	919	p.W290L	SequenceVariant	rs267607117
67180956	974	980	myopia	DiseaseOrPhenotypicFeature	D009216
67180956	994	1028	focal segmental glomerulosclerosis	DiseaseOrPhenotypicFeature	D005923
67180956	1102	1111	1123T-->G	SequenceVariant	g|SUB|T|1123|G
67180956	1113	1129	137-bp insertion	SequenceVariant	c|INS||137
67180956	1135	1144	rs2070197	SequenceVariant	rs2070197
67180956	1264	1298	focal segmental glomerulosclerosis	DiseaseOrPhenotypicFeature	D005923
67180956	1303	1325	adrenergic antagonists	ChemicalEntity	D018674
67180956	1443	1447	A49T	SequenceVariant	rs9282858
67180956	1479	1513	focal segmental glomerulosclerosis	DiseaseOrPhenotypicFeature	D005923
67180956	1621	1625	HeLa	CellLine	CVCL_0030
67180956	1808	1814	myopia	DiseaseOrPhenotypicFeature	D009216
67180956	1819	1853	focal segmental glomerulosclerosis	DiseaseOrPhenotypicFeature	D005923
67180956	1894	1905	Thromboxane	ChemicalEntity	D013931
67180956	1907	1911	dUTP	ChemicalEntity	C027078
67180956	Association	C027078	D018674	Novel
67180956	Association	D009216	C027078	Novel
67180956	Association	D005923	D018674	Novel
67180956	Association	D005923	g|SUB|T|1123|G	Novel
67180956	Association	D005923	c|INS||137	Novel
67180956	Association	D013931	C027078	Novel
67180956	Association	D009216	rs267607117	Novel

91646468|t|JNK and insulin-receptor interactions in BALB/c cells treated with methylp
91646468|a|This study investigates the molecular interactions between the JNK signaling pathway and the insulin-receptor in BALB/c cells exposed to methylphenidate. Using a combination of biochemical assays and gene expression profiling, we demonstrate a significant association between JNK and insulin-receptor in BALB/c cell lines. The interaction was further validated through co-immunoprecipitation experiments, which showed a direct physical association between JNK and insulin-receptor in BALB/c cells. Additionally, treatment with methylphenidate was found to modulate the expression levels of both JNK and insulin-receptor in BALB/c cells, suggesting a potential regulatory role of methylphenidate in this signaling network. Functional assays revealed that the JNK-insulin-receptor complex plays a critical role in mediating cellular responses to methylphenidate in BALB/c cells. These findings provide new insights into the molecular mechanisms underlying the effects of methylphenidate on JNK and insulin-receptor signaling in BALB/c cell lines.
91646468	0	3	JNK	GeneOrGeneProduct	5599
91646468	8	24	insulin-receptor	GeneOrGeneProduct	24954
91646468	41	47	BALB/c	CellLine	CVCL_9101
91646468	138	141	JNK	GeneOrGeneProduct	5599
91646468	168	184	insulin-receptor	GeneOrGeneProduct	24954
91646468	188	194	BALB/c	CellLine	CVCL_9101
91646468	212	227	methylphenidate	ChemicalEntity	D008774
91646468	351	354	JNK	GeneOrGeneProduct	5599
91646468	359	375	insulin-receptor	GeneOrGeneProduct	24954
91646468	379	385	BALB/c	CellLine	CVCL_9101
91646468	531	534	JNK	GeneOrGeneProduct	5599
91646468	539	555	insulin-receptor	GeneOrGeneProduct	24954
91646468	559	565	BALB/c	CellLine	CVCL_9101
91646468	602	617	methylphenidate	ChemicalEntity	D008774
91646468	670	673	JNK	GeneOrGeneProduct	5599
91646468	678	694	insulin-receptor	GeneOrGeneProduct	24954
91646468	698	704	BALB/c	CellLine	CVCL_9101
91646468	754	769	methylphenidate	ChemicalEntity	D008774
91646468	833	836	JNK	GeneOrGeneProduct	5599
91646468	837	853	insulin-receptor	GeneOrGeneProduct	24954
91646468	919	934	methylphenidate	ChemicalEntity	D008774
91646468	938	944	BALB/c	CellLine	CVCL_9101
91646468	1044	1059	methylphenidate	ChemicalEntity	D008774
91646468	1063	1066	JNK	GeneOrGeneProduct	5599
91646468	1071	1087	insulin-receptor	GeneOrGeneProduct	24954
91646468	1101	1107	BALB/c	CellLine	CVCL_9101
91646468	Association	5599	24954	Novel
91646468	Association	24954	5599	Novel

78447847|t|Tobacco, hepatitis B virus, and ginseng: interactions between asparagine, Telaprevir, and Fibroblast growth factor receptor 4 in the context of NF1 and serine/threonine protein kinase re
78447847|a|This study investigates the complex interactions between asparagine, Telaprevir, and Fibroblast growth factor receptor 4 (FGFR4) in the context of tobacco, hepatitis B virus (HBV), and ginseng. We focus on the regulatory roles of NF1 and serine/threonine protein kinase (STK) in these interactions. Our findings reveal a positive correlation between FGFR4 and both activin and NF1, suggesting that FGFR4 may act as a key mediator in these pathways. Additionally, we observe a negative correlation between Telaprevir and STK, as well as between Telaprevir and activin, indicating potential inhibitory effects of Telaprevir on these pathways. The conversion between asparagine and Telaprevir is also demonstrated, highlighting a dynamic interplay between these chemical entities. Notably, asparagine shows a negative correlation with both NF1 and activin, suggesting a regulatory role in these processes. The study further explores the impact of tobacco and ginseng on these interactions, with tobacco being found to modulate the expression of STK in S. cerevisiae. These results provide new insights into the molecular mechanisms underlying the interactions between these biological entities and their potential therapeutic implications.
78447847	9	26	hepatitis B virus	OrganismTaxon	10407
78447847	32	39	ginseng	OrganismTaxon	4054
78447847	62	72	asparagine	ChemicalEntity	D001216
78447847	74	84	Telaprevir	ChemicalEntity	C486464
78447847	90	125	Fibroblast growth factor receptor 4	GeneOrGeneProduct	2264
78447847	144	147	NF1	GeneOrGeneProduct	18015
78447847	152	183	serine/threonine protein kinase	GeneOrGeneProduct	20869
78447847	244	254	asparagine	ChemicalEntity	D001216
78447847	256	266	Telaprevir	ChemicalEntity	C486464
78447847	272	307	Fibroblast growth factor receptor 4	GeneOrGeneProduct	2264
78447847	334	341	tobacco	OrganismTaxon	4097
78447847	343	360	hepatitis B virus	OrganismTaxon	10407
78447847	362	365	HBV	OrganismTaxon	10407
78447847	372	379	ginseng	OrganismTaxon	4054
78447847	417	420	NF1	GeneOrGeneProduct	18015
78447847	425	456	serine/threonine protein kinase	GeneOrGeneProduct	20869
78447847	552	559	activin	GeneOrGeneProduct	16323
78447847	564	567	NF1	GeneOrGeneProduct	18015
78447847	692	702	Telaprevir	ChemicalEntity	C486464
78447847	731	741	Telaprevir	ChemicalEntity	C486464
78447847	746	753	activin	GeneOrGeneProduct	16323
78447847	798	808	Telaprevir	ChemicalEntity	C486464
78447847	851	861	asparagine	ChemicalEntity	D001216
78447847	866	876	Telaprevir	ChemicalEntity	C486464
78447847	974	984	asparagine	ChemicalEntity	D001216
78447847	1024	1027	NF1	GeneOrGeneProduct	18015
78447847	1032	1039	activin	GeneOrGeneProduct	16323
78447847	1131	1138	tobacco	OrganismTaxon	4097
78447847	1143	1150	ginseng	OrganismTaxon	4054
78447847	1179	1186	tobacco	OrganismTaxon	4097
78447847	1236	1249	S. cerevisiae	OrganismTaxon	4932
78447847	Positive_Correlation	16323	20869	Novel
78447847	Negative_Correlation	D001216	18015	Novel
78447847	Negative_Correlation	C486464	20869	Novel
78447847	Conversion	D001216	C486464	Novel
78447847	Positive_Correlation	2264	16323	Novel
78447847	Positive_Correlation	2264	18015	Novel
78447847	Negative_Correlation	C486464	16323	Novel
78447847	Negative_Correlation	D001216	16323	Novel

31536453|t|Bovine fluoroquinolone exposure and its impact on renal tract abnormalities, cortical dysplasia, and metabolic interactions in multiple ce
31536453|a|This study investigates the effects of fluoroquinolone exposure on bovine renal tract abnormalities and cortical dysplasia, with a focus on metabolic interactions involving aminotransferase, phloridzin, and nicotinamide adenine dinucleotide phosphate. Using multiple cell lines including MEF, 253JB-V, and H9c2, we observed a significant association between fluoroquinolones and renal tract abnormalities, as well as a positive correlation between fluoroquinolones and cortical dysplasia. The association between renal tract abnormalities and aminotransferase was confirmed through biochemical assays, and a positive correlation between renal tract abnormalities and aminotransferase was further supported by transcriptomic analysis. Additionally, a positive correlation between cortical dysplasia and phloridzin was identified, suggesting a potential therapeutic role for phloridzin in mitigating cortical dysplasia. The drug interaction between nicotinamide adenine dinucleotide phosphate and aminotransferase was validated through enzyme kinetics, and a positive correlation between cortical dysplasia and nicotinamide adenine dinucleotide phosphate was observed. Furthermore, a drug interaction between nicotinamide adenine dinucleotide phosphate and phloridzin was demonstrated, highlighting the complex interplay between these metabolic compounds. The study also included bovine and Platonia insignis Mart as model organisms, with findings relevant to both species. The results provide critical insights into the molecular mechanisms underlying the effects of fluoroquinolones and their interactions with key metabolic pathways in bovine and other cell lines, including SMMC-7721, LNCaP, 293T, Ishikawa, KU7, and MC3T3-E1.
31536453	50	75	renal tract abnormalities	DiseaseOrPhenotypicFeature	D007674
31536453	77	95	cortical dysplasia	DiseaseOrPhenotypicFeature	D054220
31536453	206	212	bovine	OrganismTaxon	9913
31536453	213	238	renal tract abnormalities	DiseaseOrPhenotypicFeature	D007674
31536453	243	261	cortical dysplasia	DiseaseOrPhenotypicFeature	D054220
31536453	312	328	aminotransferase	ChemicalEntity	D000637
31536453	330	340	phloridzin	ChemicalEntity	D010695
31536453	346	389	nicotinamide adenine dinucleotide phosphate	ChemicalEntity	D009249
31536453	427	430	MEF	CellLine	CVCL_9115
31536453	432	439	253JB-V	CellLine	CVCL_7937
31536453	445	449	H9c2	CellLine	CVCL_0286
31536453	497	513	fluoroquinolones	ChemicalEntity	D024841
31536453	518	543	renal tract abnormalities	DiseaseOrPhenotypicFeature	D007674
31536453	587	603	fluoroquinolones	ChemicalEntity	D024841
31536453	608	626	cortical dysplasia	DiseaseOrPhenotypicFeature	D054220
31536453	652	677	renal tract abnormalities	DiseaseOrPhenotypicFeature	D007674
31536453	682	698	aminotransferase	ChemicalEntity	D000637
31536453	776	801	renal tract abnormalities	DiseaseOrPhenotypicFeature	D007674
31536453	806	822	aminotransferase	ChemicalEntity	D000637
31536453	918	936	cortical dysplasia	DiseaseOrPhenotypicFeature	D054220
31536453	941	951	phloridzin	ChemicalEntity	D010695
31536453	1012	1022	phloridzin	ChemicalEntity	D010695
31536453	1037	1055	cortical dysplasia	DiseaseOrPhenotypicFeature	D054220
31536453	1086	1129	nicotinamide adenine dinucleotide phosphate	ChemicalEntity	D009249
31536453	1134	1150	aminotransferase	ChemicalEntity	D000637
31536453	1225	1243	cortical dysplasia	DiseaseOrPhenotypicFeature	D054220
31536453	1248	1291	nicotinamide adenine dinucleotide phosphate	ChemicalEntity	D009249
31536453	1346	1389	nicotinamide adenine dinucleotide phosphate	ChemicalEntity	D009249
31536453	1394	1404	phloridzin	ChemicalEntity	D010695
31536453	1517	1523	bovine	OrganismTaxon	9913
31536453	1528	1550	Platonia insignis Mart	OrganismTaxon	198787
31536453	1705	1721	fluoroquinolones	ChemicalEntity	D024841
31536453	1776	1782	bovine	OrganismTaxon	9913
31536453	1815	1824	SMMC-7721	CellLine	CVCL_0534
31536453	1826	1831	LNCaP	CellLine	CVCL_0395
31536453	1833	1837	293T	CellLine	CVCL_0063
31536453	1839	1847	Ishikawa	CellLine	CVCL_2529
31536453	1849	1852	KU7	CellLine	CVCL_4714
31536453	1858	1866	MC3T3-E1	CellLine	CVCL_0409
31536453	Association	D007674	D000637	Novel
31536453	Positive_Correlation	D054220	D010695	Novel
31536453	Positive_Correlation	D000637	D054220	Novel
31536453	Drug_Interaction	D009249	D000637	Novel
31536453	Association	D024841	D007674	Novel
31536453	Positive_Correlation	D007674	D000637	Novel
31536453	Association	D007674	D009249	Novel
31536453	Positive_Correlation	D054220	D009249	Novel
31536453	Drug_Interaction	D009249	D010695	Novel
31536453	Positive_Correlation	D010695	D007674	Novel
31536453	Positive_Correlation	D024841	D054220	Novel

61807888|t|TIPE2 and p38 MAPK: Interactions and associations with febrile neutropenia, arrhythmia, and mucolipidosis I
61807888|a|Recent studies have highlighted the critical role of TIPE2 in modulating inflammatory responses and its interactions with key signaling pathways such as p38 MAPK and TAK1. This research explores the molecular mechanisms underlying the association between TIPE2 and p38 MAPK, as well as the functional interplay between TIPE2 and TAK1. The findings reveal a direct binding interaction between p38 MAPK and TIPE2, which is further supported by the observed association between febrile neutropenia and p38 MAPK. Additionally, the study demonstrates that TAK1 is significantly linked to arrhythmia, and this association is reinforced by the binding of TIPE2 to TAK1. Notably, both TAK1 and TIPE2 are found to be associated with mucolipidosis III gamma, suggesting a potential role in the pathogenesis of this lysosomal storage disorder. Furthermore, the study identifies a novel association between p38 MAPK and arrhythmia, expanding the understanding of how these signaling molecules contribute to cardiac dysfunction. These results provide a comprehensive framework for understanding the complex interplay between TIPE2, p38 MAPK, and TAK1 in the context of febrile neutropenia, arrhythmia, and mucolipidosis III gamma.
61807888	0	5	TIPE2	GeneOrGeneProduct	79626
61807888	10	18	p38 MAPK	GeneOrGeneProduct	26416
61807888	55	74	febrile neutropenia	DiseaseOrPhenotypicFeature	D009503
61807888	76	86	arrhythmia	DiseaseOrPhenotypicFeature	D001145
61807888	161	166	TIPE2	GeneOrGeneProduct	79626
61807888	261	269	p38 MAPK	GeneOrGeneProduct	26416
61807888	274	278	TAK1	GeneOrGeneProduct	313121
61807888	363	368	TIPE2	GeneOrGeneProduct	79626
61807888	373	381	p38 MAPK	GeneOrGeneProduct	26416
61807888	427	432	TIPE2	GeneOrGeneProduct	79626
61807888	437	441	TAK1	GeneOrGeneProduct	313121
61807888	500	508	p38 MAPK	GeneOrGeneProduct	26416
61807888	513	518	TIPE2	GeneOrGeneProduct	79626
61807888	583	602	febrile neutropenia	DiseaseOrPhenotypicFeature	D009503
61807888	607	615	p38 MAPK	GeneOrGeneProduct	26416
61807888	659	663	TAK1	GeneOrGeneProduct	313121
61807888	691	701	arrhythmia	DiseaseOrPhenotypicFeature	D001145
61807888	756	761	TIPE2	GeneOrGeneProduct	79626
61807888	765	769	TAK1	GeneOrGeneProduct	313121
61807888	785	789	TAK1	GeneOrGeneProduct	313121
61807888	794	799	TIPE2	GeneOrGeneProduct	79626
61807888	832	855	mucolipidosis III gamma	DiseaseOrPhenotypicFeature	C565367
61807888	1003	1011	p38 MAPK	GeneOrGeneProduct	26416
61807888	1016	1026	arrhythmia	DiseaseOrPhenotypicFeature	D001145
61807888	1220	1225	TIPE2	GeneOrGeneProduct	79626
61807888	1227	1235	p38 MAPK	GeneOrGeneProduct	26416
61807888	1241	1245	TAK1	GeneOrGeneProduct	313121
61807888	1264	1283	febrile neutropenia	DiseaseOrPhenotypicFeature	D009503
61807888	1285	1295	arrhythmia	DiseaseOrPhenotypicFeature	D001145
61807888	1301	1324	mucolipidosis III gamma	DiseaseOrPhenotypicFeature	C565367
61807888	Bind	26416	79626	Novel
61807888	Association	D009503	26416	Novel
61807888	Association	D001145	313121	Novel
61807888	Bind	79626	313121	Novel
61807888	Association	313121	D009503	Novel
61807888	Association	79626	C565367	Novel
61807888	Association	313121	C565367	Novel
61807888	Association	26416	D001145	Novel

48352878|t|Estrogen receptor interactions with D2 DA receptors and sequence variants in Huh7 and C57BL/6J ce
48352878|a|This study investigates the molecular interactions between the estrogen receptor and D2 DA receptors in the context of genetic variability. Using Huh7 and C57BL/6J cell lines, we demonstrate a significant association between the estrogen receptor and D2 DA receptors, suggesting a potential functional link in signal transduction pathways. Additionally, we identify a sequence variant, deletion of C at nucleotide 888, that is associated with the estrogen receptor, indicating a possible regulatory role in gene expression. The sequence variant L490R is also found to be associated with the estrogen receptor, further supporting the hypothesis of functional interactions. Our findings highlight the importance of genetic variability in modulating receptor function and provide a foundation for future studies on the role of these variants in disease mechanisms. The presence of other sequence variants, including p.R198W, G7958, G1103R, and G196S, suggests a complex genetic landscape that may influence receptor activity and downstream signaling. These results contribute to a better understanding of the molecular basis of estrogen receptor function and its interactions with other signaling pathways.
48352878	36	51	D2 DA receptors	GeneOrGeneProduct	24318
48352878	77	81	Huh7	CellLine	CVCL_0336
48352878	86	94	C57BL/6J	CellLine	CVCL_5U84
48352878	161	178	estrogen receptor	GeneOrGeneProduct	2099
48352878	183	198	D2 DA receptors	GeneOrGeneProduct	24318
48352878	244	248	Huh7	CellLine	CVCL_0336
48352878	253	261	C57BL/6J	CellLine	CVCL_5U84
48352878	327	344	estrogen receptor	GeneOrGeneProduct	2099
48352878	349	364	D2 DA receptors	GeneOrGeneProduct	24318
48352878	484	515	deletion of C at nucleotide 888	SequenceVariant	c|DEL888|C
48352878	545	562	estrogen receptor	GeneOrGeneProduct	2099
48352878	643	648	L490R	SequenceVariant	rs80338886
48352878	689	706	estrogen receptor	GeneOrGeneProduct	2099
48352878	1011	1018	p.R198W	SequenceVariant	p|SUB|R|198|W
48352878	1020	1025	G7958	SequenceVariant	c|Aelle|G|7958
48352878	1027	1033	G1103R	SequenceVariant	rs62636275
48352878	1039	1044	G196S	SequenceVariant	rs121434250
48352878	1223	1240	estrogen receptor	GeneOrGeneProduct	2099
48352878	Association	2099	24318	Novel
48352878	Association	c|DEL888|C	2099	Novel
48352878	Association	rs80338886	2099	Novel

40885526|t|Genetic variants in HIV-1 and their associations with isolated micropenis, tobacco use, and phenotypic traits in guinea pigs an
40885526|a|This study investigates the genetic associations between specific sequence variants in the human immunodeficiency virus (HIV-1) and phenotypic features such as isolated micropenis, as well as their potential impact on tobacco use and other traits in guinea pigs and horses. We identified three instances of the sequence variant g.3318-35T>G, two instances of c.1146+25insA, and one instance of C1007G in HIV-1 isolates. Additionally, we observed two instances of D374Y and three instances of C1007G, with a notable association between D374Y and C1007G. The sequence variant g.3318-35T>G was found to be in strong linkage with c.1146+25insA, and also showed a significant association with C1007G. A positive correlation was observed between isolated micropenis and c.1146+25insA, suggesting a potential genetic link between this variant and the phenotypic feature. Furthermore, the study included analyses of tobacco and Mangifera indica Linn in the context of these genetic variants, with guinea pigs and horses serving as model organisms to explore the broader implications of these associations. These findings highlight the complex interplay between genetic variability in HIV-1 and phenotypic outcomes across different species.
40885526	54	73	isolated micropenis	DiseaseOrPhenotypicFeature	C536649
40885526	75	82	tobacco	OrganismTaxon	4097
40885526	113	124	guinea pigs	OrganismTaxon	10141
40885526	219	247	human immunodeficiency virus	OrganismTaxon	12721
40885526	288	307	isolated micropenis	DiseaseOrPhenotypicFeature	C536649
40885526	346	353	tobacco	OrganismTaxon	4097
40885526	378	389	guinea pigs	OrganismTaxon	10141
40885526	394	400	horses	OrganismTaxon	9796
40885526	456	468	g.3318-35T>G	SequenceVariant	g|SUB|T|3318-35|G
40885526	487	500	c.1146+25insA	SequenceVariant	c|INS|1146+25|A
40885526	522	528	C1007G	SequenceVariant	rs72559747
40885526	591	596	D374Y	SequenceVariant	rs137852912
40885526	620	626	C1007G	SequenceVariant	rs72559747
40885526	663	668	D374Y	SequenceVariant	rs137852912
40885526	673	679	C1007G	SequenceVariant	rs72559747
40885526	702	714	g.3318-35T>G	SequenceVariant	g|SUB|T|3318-35|G
40885526	754	767	c.1146+25insA	SequenceVariant	c|INS|1146+25|A
40885526	816	822	C1007G	SequenceVariant	rs72559747
40885526	868	887	isolated micropenis	DiseaseOrPhenotypicFeature	C536649
40885526	892	905	c.1146+25insA	SequenceVariant	c|INS|1146+25|A
40885526	1036	1043	tobacco	OrganismTaxon	4097
40885526	1048	1069	Mangifera indica Linn	OrganismTaxon	29780
40885526	1117	1128	guinea pigs	OrganismTaxon	10141
40885526	1133	1139	horses	OrganismTaxon	9796
40885526	Association	g|SUB|T|3318-35|G	c|INS|1146+25|A	Novel
40885526	Association	rs72559747	c|INS|1146+25|A	Novel
40885526	Association	rs137852912	rs72559747	Novel
40885526	Association	g|SUB|T|3318-35|G	rs72559747	Novel
40885526	Positive_Correlation	C536649	c|INS|1146+25|A	Novel

93149159|t|Mesna and bacterial interactions in renal insufficiency: a study using DUCaP and 253JB-V ce
93149159|a|Mesna, a chemical entity known for its protective effects against renal insufficiency, was investigated in this study for its potential to modulate bacterial interactions in the context of renal insufficiency. The study focused on two cell lines, DUCaP and 253JB-V, which are frequently used to model renal insufficiency and bacterial infections. Mesna was found to significantly reduce the incidence of bacterial adhesion and biofilm formation in both DUCaP and 253JB-V cell lines. This effect was observed across multiple experiments, with mesna showing consistent inhibition of bacterial growth in the presence of renal insufficiency. The study also highlighted the role of mesna in altering the expression of bacterial virulence factors, which may contribute to its protective effects. The findings suggest that mesna could be a promising therapeutic agent for managing bacterial infections in patients with renal insufficiency. The results were validated using multiple cell line models, including DUCaP and 253JB-V, and were consistent across all tested bacterial strains. Mesna's ability to modulate bacterial behavior in the context of renal insufficiency was further supported by its impact on the expression of key bacterial genes involved in pathogenesis. The study underscores the importance of mesna in the treatment of bacterial infections associated with renal insufficiency and highlights the potential of DUCaP and 253JB-V cell lines as valuable tools for future research in this area.
93149159	10	18	bacteria	OrganismTaxon	2
93149159	36	55	renal insufficiency	DiseaseOrPhenotypicFeature	D051437
93149159	71	76	DUCaP	CellLine	CVCL_2025
93149159	81	88	253JB-V	CellLine	CVCL_7937
93149159	158	177	renal insufficiency	DiseaseOrPhenotypicFeature	D051437
93149159	240	248	bacteria	OrganismTaxon	2
93149159	281	300	renal insufficiency	DiseaseOrPhenotypicFeature	D051437
93149159	339	344	DUCaP	CellLine	CVCL_2025
93149159	349	356	253JB-V	CellLine	CVCL_7937
93149159	393	412	renal insufficiency	DiseaseOrPhenotypicFeature	D051437
93149159	417	425	bacteria	OrganismTaxon	2
93149159	496	504	bacteria	OrganismTaxon	2
93149159	545	550	DUCaP	CellLine	CVCL_2025
93149159	555	562	253JB-V	CellLine	CVCL_7937
93149159	634	639	mesna	ChemicalEntity	D015080
93149159	673	681	bacteria	OrganismTaxon	2
93149159	709	728	renal insufficiency	DiseaseOrPhenotypicFeature	D051437
93149159	769	774	mesna	ChemicalEntity	D015080
93149159	805	813	bacteria	OrganismTaxon	2
93149159	908	913	mesna	ChemicalEntity	D015080
93149159	966	974	bacteria	OrganismTaxon	2
93149159	1004	1023	renal insufficiency	DiseaseOrPhenotypicFeature	D051437
93149159	1095	1100	DUCaP	CellLine	CVCL_2025
93149159	1105	1112	253JB-V	CellLine	CVCL_7937
93149159	1152	1160	bacteria	OrganismTaxon	2
93149159	1199	1207	bacteria	OrganismTaxon	2
93149159	1236	1255	renal insufficiency	DiseaseOrPhenotypicFeature	D051437
93149159	1317	1325	bacteria	OrganismTaxon	2
93149159	1399	1404	mesna	ChemicalEntity	D015080
93149159	1425	1433	bacteria	OrganismTaxon	2
93149159	1462	1481	renal insufficiency	DiseaseOrPhenotypicFeature	D051437
93149159	1514	1519	DUCaP	CellLine	CVCL_2025
93149159	1524	1531	253JB-V	CellLine	CVCL_7937

18527425|t|Anthracyclines, fatty acid synthase, and bone morphogenetic protein-2: complex interactions in cystic kidney disease and pne
18527425|a|This study investigates the intricate relationships between anthracyclines, fatty acid synthase, bone morphogenetic protein-2, and their associations with cystic kidney disease, pneumonitis, and malignant hyperthermia. We demonstrate that anthracyclines can be converted into dopamine and 8-hydroxyguanine, highlighting their dual role in both metabolic and oxidative stress pathways. Furthermore, we show that dopamine can be converted into 8-hydroxyguanine and is also involved in a conversion with antibiotics, suggesting a potential link between these chemical entities in cellular signaling.   The study also reveals a negative correlation between bone morphogenetic protein-2 and both cystic kidney disease and malignant hyperthermia, indicating that the expression of this gene product may be suppressed in these conditions. Additionally, we find a negative correlation between bone morphogenetic protein-2 and Btg3, suggesting a regulatory relationship between these two gene products.   Temsirolimus is shown to be associated with Btg3, which may have implications for therapeutic strategies targeting this gene product. Moreover, fatty acid synthase exhibits a positive correlation with both anthracyclines and dopamine, and a negative correlation with bone morphogenetic protein-2, underscoring its role in metabolic regulation.   The study also reports a negative correlation between Btg3 and pneumonitis, suggesting that Btg3 may act as a protective factor against this condition. Finally, we observe a negative correlation between dopamine and cystic kidney disease, reinforcing the idea that dopamine signaling may be disrupted in this disease state. These findings provide a comprehensive framework for understanding the complex interplay between these molecular entities in disease pathogenesis.
18527425	16	35	fatty acid synthase	GeneOrGeneProduct	2194
18527425	41	69	bone morphogenetic protein-2	GeneOrGeneProduct	12156
18527425	95	116	cystic kidney disease	DiseaseOrPhenotypicFeature	D052177
18527425	185	199	anthracyclines	ChemicalEntity	D018943
18527425	201	220	fatty acid synthase	GeneOrGeneProduct	2194
18527425	222	250	bone morphogenetic protein-2	GeneOrGeneProduct	12156
18527425	280	301	cystic kidney disease	DiseaseOrPhenotypicFeature	D052177
18527425	320	342	malignant hyperthermia	DiseaseOrPhenotypicFeature	D008305
18527425	364	378	anthracyclines	ChemicalEntity	D018943
18527425	401	409	dopamine	ChemicalEntity	D004298
18527425	414	430	8-hydroxyguanine	ChemicalEntity	C024829
18527425	536	544	dopamine	ChemicalEntity	D004298
18527425	567	583	8-hydroxyguanine	ChemicalEntity	C024829
18527425	626	636	antibiotic	ChemicalEntity	D000900
18527425	778	806	bone morphogenetic protein-2	GeneOrGeneProduct	12156
18527425	816	837	cystic kidney disease	DiseaseOrPhenotypicFeature	D052177
18527425	842	864	malignant hyperthermia	DiseaseOrPhenotypicFeature	D008305
18527425	1010	1038	bone morphogenetic protein-2	GeneOrGeneProduct	12156
18527425	1043	1047	Btg3	GeneOrGeneProduct	12228
18527425	1165	1169	Btg3	GeneOrGeneProduct	12228
18527425	1265	1284	fatty acid synthase	GeneOrGeneProduct	2194
18527425	1327	1341	anthracyclines	ChemicalEntity	D018943
18527425	1346	1354	dopamine	ChemicalEntity	D004298
18527425	1388	1416	bone morphogenetic protein-2	GeneOrGeneProduct	12156
18527425	1521	1525	Btg3	GeneOrGeneProduct	12228
18527425	1559	1563	Btg3	GeneOrGeneProduct	12228
18527425	1670	1678	dopamine	ChemicalEntity	D004298
18527425	1683	1704	cystic kidney disease	DiseaseOrPhenotypicFeature	D052177
18527425	1732	1740	dopamine	ChemicalEntity	D004298
18527425	Conversion	D004298	D000900	Novel
18527425	Negative_Correlation	D008305	12156	Novel
18527425	Negative_Correlation	D052177	12156	Novel
18527425	Association	C401859	12228	Novel
18527425	Negative_Correlation	12228	12156	Novel
18527425	Negative_Correlation	D011014	12228	Novel
18527425	Conversion	D018943	D004298	Novel
18527425	Negative_Correlation	2194	12156	Novel
18527425	Conversion	C024829	D018943	Novel
18527425	Association	D004298	2194	Novel
18527425	Conversion	D018943	C024829	Novel
18527425	Conversion	D000900	D004298	Novel
18527425	Positive_Correlation	2194	D018943	Novel
18527425	Conversion	D004298	C024829	Novel
18527425	Positive_Correlation	2194	D004298	Novel
18527425	Negative_Correlation	D004298	D052177	Novel

87979038|t|Genetic and pharmacological interactions in the context of diffuse mesangial sclerosis, radiation injury, and postoperative nausea and 
87979038|a|This study investigates the complex interplay between genetic variants, chemical entities, and disease phenotypes in a multifactorial model involving diffuse mesangial sclerosis, radiation injury, and postoperative nausea and vomiting. We focus on the role of sequence variants such as T3801C and V175M, and their potential interactions with chemical entities like Fluo3, TG, leucine, tempol, and thapsigargin. The study also explores the impact of organism taxa including HBV, HIV 1/2, and Toxorynchites mosquitoes on disease progression and response to treatment.   A key finding is the conversion between TG and thapsigargin, suggesting a potential metabolic pathway that may be relevant in the context of radiation injury and proteinuria. We also observed a positive correlation between dengue and Fluo3, indicating a possible role for Fluo3 in the immune response to dengue infection. Additionally, the conversion between leucine and tempol was confirmed, highlighting the importance of metabolic pathways in cellular stress responses.   The positive correlation between proteinuria and tempol suggests that tempol may play a protective role in kidney function, particularly in conditions such as diffuse mesangial sclerosis. Furthermore, the positive correlation between radiation injury and thyroid hormones indicates a potential regulatory mechanism in the body's response to radiation exposure.   The conversion between tempol and thapsigargin was also demonstrated, reinforcing the interconnectedness of these chemical entities in cellular defense mechanisms. Lastly, the conversion between Fluo3 and urethane was identified, suggesting a possible role for Fluo3 in the metabolism of urethane, a known carcinogen.   The study also included guinea pigs as a model organism to assess the effects of these interactions in vivo, providing further evidence for the complex relationships between genetic, chemical, and environmental factors in disease pathogenesis.
87979038	88	104	radiation injury	DiseaseOrPhenotypicFeature	D011832
87979038	315	331	radiation injury	DiseaseOrPhenotypicFeature	D011832
87979038	337	370	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
87979038	422	428	T3801C	SequenceVariant	g|SUB|T|3801|C
87979038	433	438	V175M	SequenceVariant	rs7946
87979038	501	506	Fluo3	ChemicalEntity	C059715
87979038	508	510	TG	ChemicalEntity	D014280
87979038	512	519	leucine	ChemicalEntity	D007930
87979038	521	527	tempol	ChemicalEntity	C001803
87979038	533	545	thapsigargin	ChemicalEntity	D019284
87979038	609	612	HBV	OrganismTaxon	10407
87979038	614	621	HIV 1/2	OrganismTaxon	11676
87979038	627	651	Toxorynchites mosquitoes	OrganismTaxon	2498889
87979038	744	746	TG	ChemicalEntity	D014280
87979038	751	763	thapsigargin	ChemicalEntity	D019284
87979038	845	861	radiation injury	DiseaseOrPhenotypicFeature	D011832
87979038	866	877	proteinuria	DiseaseOrPhenotypicFeature	D011507
87979038	927	933	dengue	DiseaseOrPhenotypicFeature	D003715
87979038	938	943	Fluo3	ChemicalEntity	C059715
87979038	976	981	Fluo3	ChemicalEntity	C059715
87979038	1008	1014	dengue	DiseaseOrPhenotypicFeature	D003715
87979038	1063	1070	leucine	ChemicalEntity	D007930
87979038	1075	1081	tempol	ChemicalEntity	C001803
87979038	1212	1223	proteinuria	DiseaseOrPhenotypicFeature	D011507
87979038	1228	1234	tempol	ChemicalEntity	C001803
87979038	1249	1255	tempol	ChemicalEntity	C001803
87979038	1413	1429	radiation injury	DiseaseOrPhenotypicFeature	D011832
87979038	1434	1450	thyroid hormones	ChemicalEntity	D013963
87979038	1565	1571	tempol	ChemicalEntity	C001803
87979038	1576	1588	thapsigargin	ChemicalEntity	D019284
87979038	1737	1742	Fluo3	ChemicalEntity	C059715
87979038	1747	1755	urethane	ChemicalEntity	D014520
87979038	1803	1808	Fluo3	ChemicalEntity	C059715
87979038	1830	1838	urethane	ChemicalEntity	D014520
87979038	1886	1896	guinea pig	OrganismTaxon	10141
87979038	Conversion	D014280	D019284	Novel
87979038	Positive_Correlation	D003715	C059715	Novel
87979038	Conversion	D007930	C001803	Novel
87979038	Positive_Correlation	D011507	C001803	Novel
87979038	Positive_Correlation	D011832	D013963	Novel
87979038	Conversion	C001803	D019284	Novel
87979038	Conversion	C059715	D014520	Novel

15438079|t|Genetic and pharmacological interactions of sequence variants and pegylated interferon in Capan1 and hRPTEC ce
15438079|a|This study investigates the genetic and pharmacological interactions between sequence variants and pegylated interferon in the context of Capan1 and hRPTEC cell lines. We focused on the sequence variants c.429_452dup, CAG repeat, four-basepair deletion, and rs2073163, and their potential interactions with pegylated interferon. Our findings reveal a positive correlation between pegylated interferon and all four sequence variants, suggesting a possible mechanism by which pegylated interferon may modulate gene expression or cellular response in these cell lines.   In Capan1 cells, the presence of c.429_452dup was associated with increased sensitivity to pegylated interferon, as evidenced by enhanced antiviral activity and altered cytokine profiles. Similarly, in hRPTEC cells, the CAG repeat and four-basepair deletion showed a positive correlation with pegylated interferon treatment, leading to increased expression of interferon-stimulated genes. The rs2073163 variant also demonstrated a significant positive correlation with pegylated interferon, suggesting a potential role in modulating the immune response.   These results highlight the complex interplay between sequence variants and pegylated interferon, with implications for personalized medicine and therapeutic strategies in diseases involving these genetic elements. The study underscores the importance of considering genetic variability when evaluating the efficacy and safety of pegylated interferon in different cell types and patient populations.
15438079	66	86	pegylated interferon	ChemicalEntity	C417083
15438079	90	96	Capan1	CellLine	CVCL_0237
15438079	101	107	hRPTEC	CellLine	CVCL_K278
15438079	210	230	pegylated interferon	ChemicalEntity	C417083
15438079	249	255	Capan1	CellLine	CVCL_0237
15438079	260	266	hRPTEC	CellLine	CVCL_K278
15438079	315	327	c.429_452dup	SequenceVariant	c|DUP|429_452||
15438079	329	339	CAG repeat	SequenceVariant	c|DUP||CAG|
15438079	341	363	four-basepair deletion	SequenceVariant	c|DEL||4
15438079	369	378	rs2073163	SequenceVariant	rs2073163
15438079	418	438	pegylated interferon	ChemicalEntity	C417083
15438079	491	511	pegylated interferon	ChemicalEntity	C417083
15438079	585	605	pegylated interferon	ChemicalEntity	C417083
15438079	682	688	Capan1	CellLine	CVCL_0237
15438079	712	724	c.429_452dup	SequenceVariant	c|DUP|429_452||
15438079	770	790	pegylated interferon	ChemicalEntity	C417083
15438079	881	887	hRPTEC	CellLine	CVCL_K278
15438079	899	909	CAG repeat	SequenceVariant	c|DUP||CAG|
15438079	914	936	four-basepair deletion	SequenceVariant	c|DEL||4
15438079	972	992	pegylated interferon	ChemicalEntity	C417083
15438079	1072	1081	rs2073163	SequenceVariant	rs2073163
15438079	1148	1168	pegylated interferon	ChemicalEntity	C417083
15438079	1311	1331	pegylated interferon	ChemicalEntity	C417083
15438079	1565	1585	pegylated interferon	ChemicalEntity	C417083
15438079	Positive_Correlation	C417083	c|DUP||CAG|	Novel
15438079	Positive_Correlation	C417083	c|DEL||4	Novel
15438079	Positive_Correlation	C417083	c|DUP|429_452||	Novel
15438079	Positive_Correlation	C417083	rs2073163	Novel

29578586|t|Genetic Variants and Cardiac Defects: Association of AVSD with GLUT4, Tcf12, and Promoter Polymorphisms in Toxorynchites Mo
29578586|a|This study investigates the genetic underpinnings of atrioventricular septal defect (AVSD) in the context of Toxorynchites mosquitoes, with a focus on the interplay between sequence variants, gene expression, and developmental phenotypes. Using C57BL/6J cell lines, we examined the impact of the guanine insertion/deletion (G/D), the -1607 promoter polymorphism, and lysine at residue 223 on the expression of key genes such as GLUT4, apolipoprotein B-100, and Tcf12. Our findings reveal a positive correlation between AVSD and the G/D, the -1607 promoter polymorphism, suggesting that this variant may play a role in the pathogenesis of the defect. Additionally, we observed a significant association between AVSD and GLUT4, indicating that alterations in glucose transporter function may contribute to cardiac developmental anomalies. The study also highlights the potential involvement of Tcf12 in modulating the expression of genes associated with AVSD. These results provide new insights into the molecular mechanisms underlying congenital heart defects in Toxorynchites mosquitoes and underscore the importance of genetic variability in developmental biology.
29578586	53	57	AVSD	DiseaseOrPhenotypicFeature	C562831
29578586	63	68	GLUT4	GeneOrGeneProduct	20528
29578586	70	75	Tcf12	GeneOrGeneProduct	21406
29578586	209	213	AVSD	DiseaseOrPhenotypicFeature	C562831
29578586	233	257	Toxorynchites mosquitoes	OrganismTaxon	2498889
29578586	369	377	C57BL/6J	CellLine	CVCL_5U84
29578586	420	485	guanine insertion/deletion (G/D), the -1607 promoter polymorphism	SequenceVariant	c|DEL|-1607|G
29578586	491	512	lysine at residue 223	SequenceVariant	c|Allele|K|223
29578586	552	557	GLUT4	GeneOrGeneProduct	20528
29578586	559	579	apolipoprotein B-100	GeneOrGeneProduct	338
29578586	585	590	Tcf12	GeneOrGeneProduct	21406
29578586	643	647	AVSD	DiseaseOrPhenotypicFeature	C562831
29578586	834	838	AVSD	DiseaseOrPhenotypicFeature	C562831
29578586	843	848	GLUT4	GeneOrGeneProduct	20528
29578586	1016	1021	Tcf12	GeneOrGeneProduct	21406
29578586	1076	1080	AVSD	DiseaseOrPhenotypicFeature	C562831
29578586	1186	1210	Toxorynchites mosquitoes	OrganismTaxon	2498889
29578586	Positive_Correlation	C562831	c|DEL|-1607|G	Novel
29578586	Association	C562831	20528	Novel

11786861|t|LH-RH and HRH2 interactions in arrhythmic conditions: associations with XPD, caveolin-1, and vascular endothelial-cadherin in dogs, mice, and chic
11786861|a|This study investigates the molecular interactions between the luteinizing hormone-releasing hormone (LH-RH) and its receptor HRH2 in the context of arrhythmic conditions. Using a combination of in vitro and in vivo models, we demonstrate that LH-RH binds to HRH2 in both dogs and mice, with a significant association observed between HRH2 and the XPD gene in chick models. The interaction between XPD and HRH2 is further supported by the binding of bisphosphonate and Telaprevir to XPD, suggesting a potential role for these chemical entities in modulating the HRH2-XPD axis.   We also report an association between caveolin-1 and XPD, as well as between caveolin-1 and the thyrotropin receptor, in both mice and chick models. These findings are complemented by the binding of carbohydrate to XPD, which may indicate a metabolic component to the observed interactions. Additionally, the IL-13 gene is found to be associated with both XPD and caveolin-1, suggesting a broader regulatory network involving these genes.   In the context of arrhythmic conditions, the vascular endothelial-cadherin gene is associated with HRH2, highlighting potential roles in cardiac signaling. The study also includes the use of the SF188 and H446 cell lines to further explore these interactions, with the HK-2 cell line used to validate the binding of bisphosphonate to HRH2.   Notably, the study extends to the ginseng plant and the Daucus carota species, where the thyrotropin receptor is found to be associated with multiple instances of the gene, suggesting a possible evolutionary conservation of these interactions. The findings also include the association of the disease Darier's disease with the thyrotropin receptor, and the inherited bleeding disorder with the XPD gene, indicating potential clinical relevance.   The results provide a comprehensive framework for understanding the complex interplay between LH-RH, HRH2, XPD, caveolin-1, and other genes in the context of arrhythmic conditions and related phenotypes.
11786861	0	5	LH-RH	GeneOrGeneProduct	2796
11786861	10	14	HRH2	GeneOrGeneProduct	3274
11786861	31	41	arrhythmic	DiseaseOrPhenotypicFeature	D001145
11786861	72	75	XPD	GeneOrGeneProduct	2068
11786861	77	87	caveolin-1	GeneOrGeneProduct	857
11786861	93	122	vascular endothelial-cadherin	GeneOrGeneProduct	12562
11786861	126	130	dogs	OrganismTaxon	9615
11786861	249	254	LH-RH	GeneOrGeneProduct	2796
11786861	273	277	HRH2	GeneOrGeneProduct	3274
11786861	296	306	arrhythmic	DiseaseOrPhenotypicFeature	D001145
11786861	391	396	LH-RH	GeneOrGeneProduct	2796
11786861	406	410	HRH2	GeneOrGeneProduct	3274
11786861	419	423	dogs	OrganismTaxon	9615
11786861	482	486	HRH2	GeneOrGeneProduct	3274
11786861	495	498	XPD	GeneOrGeneProduct	2068
11786861	507	512	chick	OrganismTaxon	9031
11786861	545	548	XPD	GeneOrGeneProduct	2068
11786861	553	557	HRH2	GeneOrGeneProduct	3274
11786861	597	611	bisphosphonate	ChemicalEntity	D004164
11786861	616	626	Telaprevir	ChemicalEntity	C486464
11786861	630	633	XPD	GeneOrGeneProduct	2068
11786861	709	713	HRH2	GeneOrGeneProduct	3274
11786861	714	717	XPD	GeneOrGeneProduct	2068
11786861	764	774	caveolin-1	GeneOrGeneProduct	857
11786861	779	782	XPD	GeneOrGeneProduct	2068
11786861	803	813	caveolin-1	GeneOrGeneProduct	857
11786861	822	842	thyrotropin receptor	GeneOrGeneProduct	7253
11786861	861	866	chick	OrganismTaxon	9031
11786861	925	937	carbohydrate	ChemicalEntity	D002241
11786861	941	944	XPD	GeneOrGeneProduct	2068
11786861	1035	1040	IL-13	GeneOrGeneProduct	3596
11786861	1082	1085	XPD	GeneOrGeneProduct	2068
11786861	1090	1100	caveolin-1	GeneOrGeneProduct	857
11786861	1185	1195	arrhythmic	DiseaseOrPhenotypicFeature	D001145
11786861	1212	1241	vascular endothelial-cadherin	GeneOrGeneProduct	12562
11786861	1266	1270	HRH2	GeneOrGeneProduct	3274
11786861	1362	1367	SF188	CellLine	CVCL_6948
11786861	1372	1376	H446	CellLine	CVCL_1562
11786861	1436	1440	HK-2	CellLine	CVCL_0302
11786861	1483	1497	bisphosphonate	ChemicalEntity	D004164
11786861	1501	1505	HRH2	GeneOrGeneProduct	3274
11786861	1543	1550	ginseng	OrganismTaxon	4054
11786861	1565	1578	Daucus carota	OrganismTaxon	4039
11786861	1598	1618	thyrotropin receptor	GeneOrGeneProduct	7253
11786861	1810	1826	Darier's disease	DiseaseOrPhenotypicFeature	D007644
11786861	1836	1856	thyrotropin receptor	GeneOrGeneProduct	7253
11786861	1866	1893	inherited bleeding disorder	DiseaseOrPhenotypicFeature	D025861
11786861	1903	1906	XPD	GeneOrGeneProduct	2068
11786861	2050	2055	LH-RH	GeneOrGeneProduct	2796
11786861	2057	2061	HRH2	GeneOrGeneProduct	3274
11786861	2063	2066	XPD	GeneOrGeneProduct	2068
11786861	2068	2078	caveolin-1	GeneOrGeneProduct	857
11786861	2114	2124	arrhythmic	DiseaseOrPhenotypicFeature	D001145
11786861	Association	857	2068	Novel
11786861	Bind	D004164	2796	Novel
11786861	Association	857	7253	Novel
11786861	Bind	D002241	2068	Novel
11786861	Association	3274	2796	Novel
11786861	Association	2068	3274	Novel
11786861	Association	12562	3274	Novel
11786861	Association	3596	2068	Novel
11786861	Bind	D004164	3274	Novel
11786861	Bind	C486464	2068	Novel
11786861	Association	3596	857	Novel

14437841|t|Genetic Variants and Protein Interactions in HCT116 and SF188 Cell Lines: Functional Implications of CPT1, IRF6, an
14437841|a|This study investigates the functional and genetic interactions between key genes and their sequence variants in the context of HCT116 and SF188 cell lines. We focus on the associations between the sequence variants c.2444A>C and p.G196S, as well as between 125-126insAA and p.G196S, which were found to be significantly correlated. These variants were analyzed in both cell lines to assess their impact on gene expression and protein function.   The sequence variant c.2444A>C was found to be associated with both Bax and IRF6, suggesting a potential regulatory role in these pathways. Similarly, the insertion variant 125-126insAA showed a strong association with IRF6, further supporting the hypothesis that these variants may influence the expression or activity of IRF6. Additionally, the variant p.G196S was found to be associated with both IRF6 and Bax, indicating a possible functional link between these proteins.  The interaction between Bax and dynein was confirmed through biochemical assays, with a negative correlation observed between dynein and CPT1. This suggests that CPT1 may modulate dynein activity, potentially through a direct or indirect mechanism. Furthermore, a positive correlation was observed between CPT1 and IRF6, reinforcing the idea of a regulatory network involving these genes.   In HCT116 cells, the association between CPT1 and Bax was also evident, with a positive correlation observed. This finding aligns with the broader pattern of interactions involving these proteins. The study highlights the complex interplay between genetic variants and protein function, particularly in the context of cell line-specific responses. These findings provide a foundation for further research into the molecular mechanisms underlying these interactions.
14437841	45	51	HCT116	CellLine	CVCL_0291
14437841	56	61	SF188	CellLine	CVCL_6948
14437841	101	105	CPT1	GeneOrGeneProduct	1374
14437841	107	111	IRF6	GeneOrGeneProduct	3664
14437841	244	250	HCT116	CellLine	CVCL_0291
14437841	255	260	SF188	CellLine	CVCL_6948
14437841	332	341	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
14437841	346	353	p.G196S	SequenceVariant	rs121434250
14437841	374	386	125-126insAA	SequenceVariant	|INS|125_126|AA
14437841	391	398	p.G196S	SequenceVariant	rs121434250
14437841	584	593	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
14437841	631	634	Bax	GeneOrGeneProduct	12028
14437841	639	643	IRF6	GeneOrGeneProduct	3664
14437841	736	748	125-126insAA	SequenceVariant	|INS|125_126|AA
14437841	782	786	IRF6	GeneOrGeneProduct	3664
14437841	886	890	IRF6	GeneOrGeneProduct	3664
14437841	918	925	p.G196S	SequenceVariant	rs121434250
14437841	963	967	IRF6	GeneOrGeneProduct	3664
14437841	972	975	Bax	GeneOrGeneProduct	12028
14437841	1064	1067	Bax	GeneOrGeneProduct	12028
14437841	1072	1078	dynein	GeneOrGeneProduct	172041
14437841	1166	1172	dynein	GeneOrGeneProduct	172041
14437841	1177	1181	CPT1	GeneOrGeneProduct	1374
14437841	1202	1206	CPT1	GeneOrGeneProduct	1374
14437841	1220	1226	dynein	GeneOrGeneProduct	172041
14437841	1346	1350	CPT1	GeneOrGeneProduct	1374
14437841	1355	1359	IRF6	GeneOrGeneProduct	3664
14437841	1434	1440	HCT116	CellLine	CVCL_0291
14437841	1472	1476	CPT1	GeneOrGeneProduct	1374
14437841	1481	1484	Bax	GeneOrGeneProduct	12028
14437841	Association	c|SUB|A|2444|C	rs121434250	Novel
14437841	Association	|INS|125_126|AA	rs121434250	Novel
14437841	Bind	12028	172041	Novel
14437841	Association	12028	172041	Novel
14437841	Association	rs121434250	3664	Novel
14437841	Negative_Correlation	3664	12028	Novel
14437841	Positive_Correlation	1374	3664	Novel
14437841	Association	c|SUB|A|2444|C	12028	Novel
14437841	Association	|INS|125_126|AA	3664	Novel
14437841	Association	1374	12028	Novel
14437841	Positive_Correlation	1374	12028	Novel
14437841	Association	c|SUB|A|2444|C	3664	Novel
14437841	Negative_Correlation	172041	1374	Novel

00017399|t|Bovine and feline models of Senior-Loken syndrome: interactions between MYB, TLR1, VEGF receptor 3, and prazosin in glaucoma and thyrot
00017399|a|This study investigates the molecular mechanisms underlying the pathogenesis of Senior-Loken syndrome in bovine and feline models, with a focus on the interplay between key genes and chemical entities. We examined the expression patterns of MYB, TLR1, VEGF receptor 3, and their correlations with prazosin, Alpha-lipoic acid, ZnSO(4), and norfloxacin in bovine and cat tissues. The findings reveal a complex network of interactions, including a positive correlation between prazosin and VEGF receptor 3, and between VEGF receptor 3 and Alpha-lipoic acid. Additionally, norfloxacin shows a positive correlation with both TLR1 and glial fibrillary acidic protein, while ZnSO(4) is positively correlated with VEGF receptor 3, MYB, and TLR1. The study also highlights a negative correlation between MYB and TLR1, as well as between glial fibrillary acidic protein and TLR1. Notably, the gene MYB is positively correlated with prazosin, ZnSO(4), and Alpha-lipoic acid, while it is negatively correlated with glial fibrillary acidic protein. The results further demonstrate that glial fibrillary acidic protein is positively correlated with prazosin, norfloxacin, and Alpha-lipoic acid, and negatively correlated with MYB. These findings suggest that the interplay between these genes and chemical entities may play a critical role in the development of glaucoma and thyrotoxicosis in bovine and feline models. The study also includes data from Mangifera indica Linn, which shows a positive correlation between ZnSO(4) and VEGF receptor 3, and between norfloxacin and MYB. Overall, the research provides a comprehensive framework for understanding the molecular basis of Senior-Loken syndrome and its associated phenotypes in these species.
00017399	28	49	Senior-Loken syndrome	DiseaseOrPhenotypicFeature	C537580
00017399	72	75	MYB	GeneOrGeneProduct	4602
00017399	77	81	TLR1	GeneOrGeneProduct	7096
00017399	83	98	VEGF receptor 3	GeneOrGeneProduct	2324
00017399	104	112	prazosin	ChemicalEntity	D011224
00017399	116	124	glaucoma	DiseaseOrPhenotypicFeature	D005901
00017399	216	237	Senior-Loken syndrome	DiseaseOrPhenotypicFeature	C537580
00017399	241	247	bovine	OrganismTaxon	9913
00017399	377	380	MYB	GeneOrGeneProduct	4602
00017399	382	386	TLR1	GeneOrGeneProduct	7096
00017399	388	403	VEGF receptor 3	GeneOrGeneProduct	2324
00017399	433	441	prazosin	ChemicalEntity	D011224
00017399	443	460	Alpha-lipoic acid	ChemicalEntity	D008063
00017399	462	469	ZnSO(4)	ChemicalEntity	D019287
00017399	475	486	norfloxacin	ChemicalEntity	D009643
00017399	490	496	bovine	OrganismTaxon	9913
00017399	610	618	prazosin	ChemicalEntity	D011224
00017399	623	638	VEGF receptor 3	GeneOrGeneProduct	2324
00017399	652	667	VEGF receptor 3	GeneOrGeneProduct	2324
00017399	672	689	Alpha-lipoic acid	ChemicalEntity	D008063
00017399	705	716	norfloxacin	ChemicalEntity	D009643
00017399	756	760	TLR1	GeneOrGeneProduct	7096
00017399	765	796	glial fibrillary acidic protein	GeneOrGeneProduct	14580
00017399	804	811	ZnSO(4)	ChemicalEntity	D019287
00017399	842	857	VEGF receptor 3	GeneOrGeneProduct	2324
00017399	859	862	MYB	GeneOrGeneProduct	4602
00017399	868	872	TLR1	GeneOrGeneProduct	7096
00017399	931	934	MYB	GeneOrGeneProduct	4602
00017399	939	943	TLR1	GeneOrGeneProduct	7096
00017399	964	995	glial fibrillary acidic protein	GeneOrGeneProduct	14580
00017399	1000	1004	TLR1	GeneOrGeneProduct	7096
00017399	1024	1027	MYB	GeneOrGeneProduct	4602
00017399	1058	1066	prazosin	ChemicalEntity	D011224
00017399	1068	1075	ZnSO(4)	ChemicalEntity	D019287
00017399	1081	1098	Alpha-lipoic acid	ChemicalEntity	D008063
00017399	1139	1170	glial fibrillary acidic protein	GeneOrGeneProduct	14580
00017399	1209	1240	glial fibrillary acidic protein	GeneOrGeneProduct	14580
00017399	1271	1279	prazosin	ChemicalEntity	D011224
00017399	1281	1292	norfloxacin	ChemicalEntity	D009643
00017399	1298	1315	Alpha-lipoic acid	ChemicalEntity	D008063
00017399	1348	1351	MYB	GeneOrGeneProduct	4602
00017399	1484	1492	glaucoma	DiseaseOrPhenotypicFeature	D005901
00017399	1497	1511	thyrotoxicosis	DiseaseOrPhenotypicFeature	D013971
00017399	1515	1521	bovine	OrganismTaxon	9913
00017399	1575	1596	Mangifera indica Linn	OrganismTaxon	29780
00017399	1641	1648	ZnSO(4)	ChemicalEntity	D019287
00017399	1653	1668	VEGF receptor 3	GeneOrGeneProduct	2324
00017399	1682	1693	norfloxacin	ChemicalEntity	D009643
00017399	1698	1701	MYB	GeneOrGeneProduct	4602
00017399	1801	1822	Senior-Loken syndrome	DiseaseOrPhenotypicFeature	C537580
00017399	Positive_Correlation	14580	D009643	Novel
00017399	Positive_Correlation	D011224	2324	Novel
00017399	Positive_Correlation	7096	D009643	Novel
00017399	Positive_Correlation	2324	D008063	Novel
00017399	Negative_Correlation	14580	7096	Novel
00017399	Positive_Correlation	D009643	14580	Novel
00017399	Positive_Correlation	D019287	2324	Novel
00017399	Positive_Correlation	D008063	7096	Novel
00017399	Positive_Correlation	4602	D019287	Novel
00017399	Positive_Correlation	2324	D009643	Novel
00017399	Negative_Correlation	4602	14580	Novel
00017399	Positive_Correlation	4602	D011224	Novel
00017399	Negative_Correlation	4602	7096	Novel
00017399	Positive_Correlation	D019287	4602	Novel
00017399	Positive_Correlation	D008063	2324	Novel
00017399	Positive_Correlation	2324	D011224	Novel
00017399	Negative_Correlation	7096	14580	Novel
00017399	Positive_Correlation	14580	D019287	Novel
00017399	Positive_Correlation	D019287	7096	Novel
00017399	Positive_Correlation	D019287	14580	Novel
00017399	Positive_Correlation	7096	D008063	Novel
00017399	Positive_Correlation	D009643	4602	Novel
00017399	Negative_Correlation	14580	4602	Novel
00017399	Positive_Correlation	4602	D008063	Novel
00017399	Positive_Correlation	14580	D011224	Novel
00017399	Positive_Correlation	7096	D019287	Novel
00017399	Positive_Correlation	D011224	14580	Novel
00017399	Positive_Correlation	D009643	7096	Novel
00017399	Negative_Correlation	7096	4602	Novel
00017399	Positive_Correlation	2324	D019287	Novel
00017399	Negative_Correlation	2324	7096	Novel
00017399	Negative_Correlation	7096	2324	Novel
00017399	Positive_Correlation	D011224	7096	Novel
00017399	Positive_Correlation	D008063	14580	Novel
00017399	Negative_Correlation	2324	4602	Novel
00017399	Positive_Correlation	14580	D008063	Novel

78478689|t|Genetic and pharmacological interactions in neurodegenerative disorders: effects of sequence variants, chemical entities, and their asso
78478689|a|This study investigates the complex interplay between genetic sequence variants and chemical entities in the context of neurodegenerative disorders. We focus on the effects of specific sequence variants such as p.Asp50Asn, g.3318-15C>T, A49T, leucine 269 to phenylalanine, rs1800896, Arg64Trp, and p.R962T, alongside the chemical entities 17-DMAG, 5-Aza-2'-deoxy-cytidine, CNSB002, metformin, Vigabatrin, Antioxidant, hexamethonium, and prazosin.   Our findings reveal a drug interaction between Antioxidant and prazosin, suggesting potential synergistic or antagonistic effects in therapeutic applications. A positive correlation was observed between prazosin and 5-Aza-2'-deoxy-cytidine, indicating a possible mechanism of action or shared biological pathways. Similarly, metformin showed a positive correlation with 5-Aza-2'-deoxy-cytidine, highlighting potential therapeutic synergy.   The association between CNSB002 and g.3318-15C>T suggests a genetic basis for the efficacy or side effects of CNSB002. Conversion between hexamethonium and 5-Aza-2'-deoxy-cytidine was also noted, implying a possible metabolic or functional relationship. Additionally, a positive correlation between leucine 269 to phenylalanine and CNSB002 was identified, suggesting a potential role in disease progression or treatment response.   The conversion between hexamethonium and prazosin further supports the idea of shared pharmacological mechanisms. Lastly, a positive correlation between CNSB002 and 17-DMAG was observed, indicating potential therapeutic applications or interactions in neurodegenerative conditions. These results provide a foundation for future research into the molecular and pharmacological mechanisms underlying these interactions.
78478689	348	358	p.Asp50Asn	SequenceVariant	rs28931594
78478689	360	372	g.3318-15C>T	SequenceVariant	g|SUB|C|3318-15|T
78478689	374	378	A49T	SequenceVariant	rs9282858
78478689	380	408	leucine 269 to phenylalanine	SequenceVariant	rs199852470
78478689	410	419	rs1800896	SequenceVariant	rs1800896
78478689	421	429	Arg64Trp	SequenceVariant	p|SUB|R|64|W
78478689	435	442	p.R962T	SequenceVariant	p|SUB|R|962|T
78478689	476	483	17-DMAG	ChemicalEntity	C448659
78478689	485	508	5-Aza-2'-deoxy-cytidine	ChemicalEntity	D000077209
78478689	510	517	CNSB002	ChemicalEntity	C401121
78478689	519	528	metformin	ChemicalEntity	D008687
78478689	530	540	Vigabatrin	ChemicalEntity	D020888
78478689	542	553	Antioxidant	ChemicalEntity	D000975
78478689	555	568	hexamethonium	ChemicalEntity	D018738
78478689	574	582	prazosin	ChemicalEntity	D011224
78478689	633	644	Antioxidant	ChemicalEntity	D000975
78478689	649	657	prazosin	ChemicalEntity	D011224
78478689	789	797	prazosin	ChemicalEntity	D011224
78478689	802	825	5-Aza-2'-deoxy-cytidine	ChemicalEntity	D000077209
78478689	911	920	metformin	ChemicalEntity	D008687
78478689	956	979	5-Aza-2'-deoxy-cytidine	ChemicalEntity	D000077209
78478689	1051	1058	CNSB002	ChemicalEntity	C401121
78478689	1063	1075	g.3318-15C>T	SequenceVariant	g|SUB|C|3318-15|T
78478689	1137	1144	CNSB002	ChemicalEntity	C401121
78478689	1165	1178	hexamethonium	ChemicalEntity	D018738
78478689	1183	1206	5-Aza-2'-deoxy-cytidine	ChemicalEntity	D000077209
78478689	1326	1354	leucine 269 to phenylalanine	SequenceVariant	rs199852470
78478689	1359	1366	CNSB002	ChemicalEntity	C401121
78478689	1482	1495	hexamethonium	ChemicalEntity	D018738
78478689	1500	1508	prazosin	ChemicalEntity	D011224
78478689	1612	1619	CNSB002	ChemicalEntity	C401121
78478689	1624	1631	17-DMAG	ChemicalEntity	C448659
78478689	Drug_Interaction	D000975	D011224	Novel
78478689	Positive_Correlation	D011224	D000077209	Novel
78478689	Positive_Correlation	D008687	D000077209	Novel
78478689	Association	C401121	g|SUB|C|3318-15|T	Novel
78478689	Conversion	D018738	D000077209	Novel
78478689	Positive_Correlation	rs199852470	C401121	Novel
78478689	Conversion	D018738	D011224	Novel
78478689	Positive_Correlation	C401121	C448659	Novel

43651687|t|Sodium channel blockers and N-methyl-d-aspartate modulate DDB and TMPRSS2 in zebrafish models of nep
43651687|a|This study investigates the complex interactions between sodium channel blockers, N-methyl-d-aspartate, DDB, and TMPRSS2 in the context of nephropathy using zebrafish models. We demonstrate that sodium channel blockers bind to TMPRSS2, suggesting a direct molecular interaction that may influence cellular signaling pathways. Additionally, we find a negative correlation between sodium channel blockers and nephropathy, indicating that these compounds may have protective effects against renal damage. In contrast, a positive correlation is observed between nephropathy and DDB, suggesting a potential role for DDB in the progression of kidney disease.   N-methyl-d-aspartate exhibits a negative correlation with DDB, implying that these two entities may function in opposing pathways. Furthermore, N-methyl-d-aspartate shows a negative correlation with TMPRSS2, and there is an association between N-methyl-d-aspartate and TMPRSS2, highlighting a complex regulatory network. The comparison between sodium channel blockers and N-methyl-d-aspartate reveals distinct pharmacological profiles, with sodium channel blockers showing a more pronounced effect on TMPRSS2.   We also report a cotreatment between sodium channel blockers and N-methyl-d-aspartate in LbetaT2 and 253JB-V cell lines, which suggests potential synergistic or antagonistic effects in cellular responses. The study further explores the role of DDB in nephropathy, with evidence supporting its involvement in disease progression. These findings are supported by experiments conducted in zebrafish, which serve as a valuable model for understanding the molecular mechanisms underlying nephropathy and the interactions between these key biological entities.
43651687	28	48	N-methyl-d-aspartate	ChemicalEntity	D016202
43651687	58	61	DDB	GeneOrGeneProduct	1639
43651687	66	73	TMPRSS2	GeneOrGeneProduct	7113
43651687	77	86	zebrafish	OrganismTaxon	7955
43651687	158	180	sodium channel blocker	ChemicalEntity	D026941
43651687	183	203	N-methyl-d-aspartate	ChemicalEntity	D016202
43651687	205	208	DDB	GeneOrGeneProduct	1639
43651687	214	221	TMPRSS2	GeneOrGeneProduct	7113
43651687	240	251	nephropathy	DiseaseOrPhenotypicFeature	D007674
43651687	258	267	zebrafish	OrganismTaxon	7955
43651687	296	318	sodium channel blocker	ChemicalEntity	D026941
43651687	328	335	TMPRSS2	GeneOrGeneProduct	7113
43651687	480	502	sodium channel blocker	ChemicalEntity	D026941
43651687	508	519	nephropathy	DiseaseOrPhenotypicFeature	D007674
43651687	659	670	nephropathy	DiseaseOrPhenotypicFeature	D007674
43651687	675	678	DDB	GeneOrGeneProduct	1639
43651687	712	715	DDB	GeneOrGeneProduct	1639
43651687	756	776	N-methyl-d-aspartate	ChemicalEntity	D016202
43651687	814	817	DDB	GeneOrGeneProduct	1639
43651687	900	920	N-methyl-d-aspartate	ChemicalEntity	D016202
43651687	955	962	TMPRSS2	GeneOrGeneProduct	7113
43651687	1000	1020	N-methyl-d-aspartate	ChemicalEntity	D016202
43651687	1025	1032	TMPRSS2	GeneOrGeneProduct	7113
43651687	1100	1122	sodium channel blocker	ChemicalEntity	D026941
43651687	1128	1148	N-methyl-d-aspartate	ChemicalEntity	D016202
43651687	1197	1219	sodium channel blocker	ChemicalEntity	D026941
43651687	1257	1264	TMPRSS2	GeneOrGeneProduct	7113
43651687	1305	1327	sodium channel blocker	ChemicalEntity	D026941
43651687	1333	1353	N-methyl-d-aspartate	ChemicalEntity	D016202
43651687	1357	1364	LbetaT2	CellLine	CVCL_0398
43651687	1369	1376	253JB-V	CellLine	CVCL_7937
43651687	1512	1515	DDB	GeneOrGeneProduct	1639
43651687	1519	1530	nephropathy	DiseaseOrPhenotypicFeature	D007674
43651687	1654	1663	zebrafish	OrganismTaxon	7955
43651687	1751	1762	nephropathy	DiseaseOrPhenotypicFeature	D007674
43651687	Bind	D026941	7113	Novel
43651687	Positive_Correlation	D007674	1639	Novel
43651687	Negative_Correlation	7113	D016202	Novel
43651687	Negative_Correlation	D007674	D026941	Novel
43651687	Association	7113	D026941	Novel
43651687	Comparison	D026941	D016202	Novel
43651687	Negative_Correlation	D016202	1639	Novel
43651687	Comparison	D016202	D026941	Novel
43651687	Bind	D016202	1639	Novel
43651687	Cotreatment	D026941	D016202	Novel
43651687	Negative_Correlation	D026941	1639	Novel
43651687	Association	7113	D016202	Novel
43651687	Association	D016202	7113	Novel

74152825|t|Genetic Variants and Their Implications in Neurological Disorders and Retinal Pathologies: A Study on Cell Lines and Molecular Inte
74152825|a|This study investigates the molecular and genetic associations between sequence variants, gene products, and disease phenotypes in the context of neurological and retinal disorders. We focused on the sequence variant A-->G and its negative correlation with hemochromatosis, as well as its association with retinopathy of prematurity and the sequence variant G7958A. The variant G7958A was found to be associated with amnesia, while the variant A-->G showed a positive correlation with retinopathy of prematurity.   We examined the gene products chemokines, precore, and Vps2 in various cell lines, including Hs578T, HK2, and MC3T3-E1. The gene product precore was found to be associated with chemokines and Vps2, with a positive correlation between precore and retinopathy of prematurity. Additionally, precore showed a positive correlation with OIR and a negative correlation with amnesia. The gene product Vps2 was associated with OIR and showed a negative correlation with amnesia.   The gene product chemokines was found to be associated with precore and retinopathy of prematurity, with a positive correlation between chemokines and retinopathy of prematurity. Furthermore, chemokines showed a positive correlation with hemochromatosis. The disease phenotypes OIR and retinopathy of prematurity were both associated with precore, and OIR showed a positive correlation with Vps2.   The study also revealed that the sequence variant A-->G was negatively correlated with hemochromatosis and positively correlated with retinopathy of prematurity. The sequence variant G7958A was associated with amnesia. These findings suggest complex interactions between genetic variants, gene products, and disease phenotypes, particularly in the context of neurological and retinal pathologies. The results highlight the importance of understanding these molecular relationships for the development of targeted therapeutic strategies.
74152825	349	354	A-->G	SequenceVariant	rs25531
74152825	389	404	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
74152825	438	464	retinopathy of prematurity	DiseaseOrPhenotypicFeature	D012178
74152825	490	496	G7958A	SequenceVariant	rs4998557
74152825	510	516	G7958A	SequenceVariant	rs4998557
74152825	549	556	amnesia	DiseaseOrPhenotypicFeature	D000647
74152825	576	581	A-->G	SequenceVariant	rs25531
74152825	617	643	retinopathy of prematurity	DiseaseOrPhenotypicFeature	D012178
74152825	677	687	chemokines	GeneOrGeneProduct	20296
74152825	689	696	precore	GeneOrGeneProduct	944568
74152825	702	706	Vps2	GeneOrGeneProduct	27243
74152825	740	746	Hs578T	CellLine	CVCL_0332
74152825	748	751	HK2	CellLine	CVCL_0302
74152825	757	765	MC3T3-E1	CellLine	CVCL_0409
74152825	784	791	precore	GeneOrGeneProduct	944568
74152825	824	834	chemokines	GeneOrGeneProduct	20296
74152825	839	843	Vps2	GeneOrGeneProduct	27243
74152825	881	888	precore	GeneOrGeneProduct	944568
74152825	893	919	retinopathy of prematurity	DiseaseOrPhenotypicFeature	D012178
74152825	935	942	precore	GeneOrGeneProduct	944568
74152825	978	981	OIR	DiseaseOrPhenotypicFeature	D012164
74152825	1014	1021	amnesia	DiseaseOrPhenotypicFeature	D000647
74152825	1040	1044	Vps2	GeneOrGeneProduct	27243
74152825	1065	1068	OIR	DiseaseOrPhenotypicFeature	D012164
74152825	1108	1115	amnesia	DiseaseOrPhenotypicFeature	D000647
74152825	1136	1146	chemokines	GeneOrGeneProduct	20296
74152825	1179	1186	precore	GeneOrGeneProduct	944568
74152825	1191	1217	retinopathy of prematurity	DiseaseOrPhenotypicFeature	D012178
74152825	1255	1265	chemokines	GeneOrGeneProduct	20296
74152825	1270	1296	retinopathy of prematurity	DiseaseOrPhenotypicFeature	D012178
74152825	1311	1321	chemokines	GeneOrGeneProduct	20296
74152825	1357	1372	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
74152825	1397	1400	OIR	DiseaseOrPhenotypicFeature	D012164
74152825	1405	1431	retinopathy of prematurity	DiseaseOrPhenotypicFeature	D012178
74152825	1458	1465	precore	GeneOrGeneProduct	944568
74152825	1471	1474	OIR	DiseaseOrPhenotypicFeature	D012164
74152825	1510	1514	Vps2	GeneOrGeneProduct	27243
74152825	1568	1573	A-->G	SequenceVariant	rs25531
74152825	1605	1620	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
74152825	1652	1678	retinopathy of prematurity	DiseaseOrPhenotypicFeature	D012178
74152825	1701	1707	G7958A	SequenceVariant	rs4998557
74152825	1728	1735	amnesia	DiseaseOrPhenotypicFeature	D000647
74152825	Association	944568	27243	Novel
74152825	Association	27243	D012164	Novel
74152825	Association	20296	944568	Novel
74152825	Negative_Correlation	rs25531	D006432	Novel
74152825	Positive_Correlation	20296	D012178	Novel
74152825	Positive_Correlation	D012164	944568	Novel
74152825	Association	D000647	rs4998557	Novel
74152825	Association	20296	D012178	Novel
74152825	Association	D012178	944568	Novel
74152825	Association	D012178	rs25531	Novel
74152825	Positive_Correlation	944568	D012178	Novel
74152825	Association	944568	20296	Novel
74152825	Association	D006432	944568	Novel
74152825	Negative_Correlation	D000647	27243	Novel
74152825	Positive_Correlation	D012164	27243	Novel
74152825	Positive_Correlation	D006432	20296	Novel
74152825	Bind	944568	20296	Novel
74152825	Association	D012178	rs4998557	Novel

81000907|t|Sarcoplasmic reticulum Ca2 + -ATPase, 253JB-V, and Insulin: interactions in the context of actinic keratosis
81000907|a|This study investigates the complex interplay between sarcoplasmic reticulum Ca2 + -ATPase, 253JB-V cell lines, and Insulin in the context of actinic keratosis and MFA. Using a combination of biochemical assays and molecular profiling, we demonstrate a positive correlation between Insulin and thrombocytopenia, as well as a positive correlation between thrombocytopenia and Insulin. These findings suggest a potential regulatory role of Insulin in platelet function under pathological conditions. Additionally, we observe a positive correlation between Sox4 and Insulin, as well as between Sox4 and MFA, indicating a possible functional link between these molecular entities in disease progression.   Our analysis also reveals a significant association between MFA and Sox4, further supporting the hypothesis that Sox4 may serve as a key mediator in the pathogenesis of MFA. In parallel, we compare the effects of anthracyclines and 5-hydroxyindoleacetic acid on cellular responses in COS-7 and HEK293 cell lines, highlighting distinct mechanisms of action. Notably, the study includes data from rhesus monkeys and ginseng, suggesting potential translational relevance across species and plant-based compounds.   The findings underscore the importance of sarcoplasmic reticulum Ca2 + -ATPase and 253JB-V in modulating Insulin signaling, with implications for the treatment of actinic keratosis and related conditions. The repeated presence of Palmitate in our experimental models further supports its role in lipid-mediated regulation of these pathways. Overall, this work provides a comprehensive framework for understanding the molecular underpinnings of these complex interactions.
81000907	38	45	253JB-V	CellLine	CVCL_7937
81000907	51	58	Insulin	GeneOrGeneProduct	3630
81000907	91	108	actinic keratosis	DiseaseOrPhenotypicFeature	D055623
81000907	163	199	sarcoplasmic reticulum Ca2 + -ATPase	ChemicalEntity	D053498
81000907	201	208	253JB-V	CellLine	CVCL_7937
81000907	225	232	Insulin	GeneOrGeneProduct	3630
81000907	251	268	actinic keratosis	DiseaseOrPhenotypicFeature	D055623
81000907	273	276	MFA	DiseaseOrPhenotypicFeature	D018226
81000907	391	398	Insulin	GeneOrGeneProduct	3630
81000907	403	419	thrombocytopenia	DiseaseOrPhenotypicFeature	D013921
81000907	463	479	thrombocytopenia	DiseaseOrPhenotypicFeature	D013921
81000907	484	491	Insulin	GeneOrGeneProduct	3630
81000907	547	554	Insulin	GeneOrGeneProduct	3630
81000907	663	667	Sox4	GeneOrGeneProduct	20677
81000907	672	679	Insulin	GeneOrGeneProduct	3630
81000907	700	704	Sox4	GeneOrGeneProduct	20677
81000907	709	712	MFA	DiseaseOrPhenotypicFeature	D018226
81000907	871	874	MFA	DiseaseOrPhenotypicFeature	D018226
81000907	879	883	Sox4	GeneOrGeneProduct	20677
81000907	924	928	Sox4	GeneOrGeneProduct	20677
81000907	980	983	MFA	DiseaseOrPhenotypicFeature	D018226
81000907	1024	1038	anthracyclines	ChemicalEntity	D018943
81000907	1043	1069	5-hydroxyindoleacetic acid	ChemicalEntity	D006897
81000907	1095	1100	COS-7	CellLine	CVCL_0224
81000907	1105	1111	HEK293	CellLine	CVCL_0045
81000907	1206	1220	rhesus monkeys	OrganismTaxon	9544
81000907	1225	1232	ginseng	OrganismTaxon	4054
81000907	1365	1401	sarcoplasmic reticulum Ca2 + -ATPase	ChemicalEntity	D053498
81000907	1406	1413	253JB-V	CellLine	CVCL_7937
81000907	1428	1435	Insulin	GeneOrGeneProduct	3630
81000907	1486	1503	actinic keratosis	DiseaseOrPhenotypicFeature	D055623
81000907	1553	1562	Palmitate	ChemicalEntity	D010168
81000907	Positive_Correlation	3630	D013921	Novel
81000907	Positive_Correlation	D013921	3630	Novel
81000907	Positive_Correlation	20677	3630	Novel
81000907	Positive_Correlation	20677	D018226	Novel
81000907	Comparison	D018943	D006897	Novel
81000907	Association	D018226	20677	Novel

67038511|t|Epo, iron, and genetic variants in HeLa and RAW 264.7 cells: interactions with cerulenin and tobacco-derived
67038511|a|This study investigates the complex interactions between the erythropoietin (Epo) gene, iron, and the sequence variant -889TT in the context of HeLa and RAW 264.7 cell lines, with a focus on the effects of cerulenin and tobacco exposure. The research highlights the role of Epo in modulating cellular responses to iron and cerulenin, as well as the influence of genetic variants on these interactions.   In HeLa cells, Epo expression was found to positively correlate with both iron and cerulenin levels, suggesting a potential regulatory role of Epo in iron homeostasis and cerulenin toxicity. Similarly, in RAW 264.7 cells, the positive correlation between Epo and iron was further supported by cotreatment experiments, where Epo and iron together enhanced cellular uptake of cerulenin.   The sequence variant -889TT exhibited a negative correlation with both cerulenin and iron, indicating that this genetic polymorphism may alter the cellular response to these agents. In particular, the negative correlation between -889TT and cerulenin was most pronounced in tobacco-exposed cells, suggesting a possible interaction between tobacco-derived factors and the genetic variant.   Cotreatment of HeLa and RAW 264.7 cells with iron and cerulenin revealed a synergistic effect, with increased cytotoxicity observed in both cell lines. This effect was further modulated by the presence of the -889TT variant, which reduced the cytotoxic impact of cerulenin in the presence of iron.   The study also explored the impact of tobacco exposure on these interactions, finding that tobacco-derived compounds enhanced the negative correlation between -889TT and iron, while also amplifying the positive correlation between Epo and cerulenin. These findings suggest that the interplay between genetic variants, environmental factors, and chemical entities plays a critical role in determining cellular responses to Epo, iron, and cerulenin in both HeLa and RAW 264.7 cell lines.
67038511	0	3	Epo	GeneOrGeneProduct	2056
67038511	5	9	iron	ChemicalEntity	D007501
67038511	35	39	HeLa	CellLine	CVCL_0030
67038511	44	53	RAW 264.7	CellLine	CVCL_0493
67038511	79	88	cerulenin	ChemicalEntity	D002569
67038511	93	100	tobacco	OrganismTaxon	4097
67038511	186	189	Epo	GeneOrGeneProduct	2056
67038511	197	201	iron	ChemicalEntity	D007501
67038511	228	234	-889TT	SequenceVariant	rs1800587
67038511	253	257	HeLa	CellLine	CVCL_0030
67038511	262	271	RAW 264.7	CellLine	CVCL_0493
67038511	315	324	cerulenin	ChemicalEntity	D002569
67038511	329	336	tobacco	OrganismTaxon	4097
67038511	383	386	Epo	GeneOrGeneProduct	2056
67038511	423	427	iron	ChemicalEntity	D007501
67038511	432	441	cerulenin	ChemicalEntity	D002569
67038511	516	520	HeLa	CellLine	CVCL_0030
67038511	528	531	Epo	GeneOrGeneProduct	2056
67038511	587	591	iron	ChemicalEntity	D007501
67038511	596	605	cerulenin	ChemicalEntity	D002569
67038511	656	659	Epo	GeneOrGeneProduct	2056
67038511	663	667	iron	ChemicalEntity	D007501
67038511	684	693	cerulenin	ChemicalEntity	D002569
67038511	718	727	RAW 264.7	CellLine	CVCL_0493
67038511	768	771	Epo	GeneOrGeneProduct	2056
67038511	776	780	iron	ChemicalEntity	D007501
67038511	837	840	Epo	GeneOrGeneProduct	2056
67038511	845	849	iron	ChemicalEntity	D007501
67038511	887	896	cerulenin	ChemicalEntity	D002569
67038511	921	927	-889TT	SequenceVariant	rs1800587
67038511	971	980	cerulenin	ChemicalEntity	D002569
67038511	985	989	iron	ChemicalEntity	D007501
67038511	1130	1136	-889TT	SequenceVariant	rs1800587
67038511	1141	1150	cerulenin	ChemicalEntity	D002569
67038511	1174	1181	tobacco	OrganismTaxon	4097
67038511	1239	1246	tobacco	OrganismTaxon	4097
67038511	1305	1309	HeLa	CellLine	CVCL_0030
67038511	1314	1323	RAW 264.7	CellLine	CVCL_0493
67038511	1335	1339	iron	ChemicalEntity	D007501
67038511	1344	1353	cerulenin	ChemicalEntity	D002569
67038511	1499	1505	-889TT	SequenceVariant	rs1800587
67038511	1553	1562	cerulenin	ChemicalEntity	D002569
67038511	1582	1586	iron	ChemicalEntity	D007501
67038511	1628	1635	tobacco	OrganismTaxon	4097
67038511	1681	1688	tobacco	OrganismTaxon	4097
67038511	1749	1755	-889TT	SequenceVariant	rs1800587
67038511	1760	1764	iron	ChemicalEntity	D007501
67038511	1821	1824	Epo	GeneOrGeneProduct	2056
67038511	1829	1838	cerulenin	ChemicalEntity	D002569
67038511	1911	1915	iron	ChemicalEntity	D007501
67038511	2012	2015	Epo	GeneOrGeneProduct	2056
67038511	2017	2021	iron	ChemicalEntity	D007501
67038511	2027	2036	cerulenin	ChemicalEntity	D002569
67038511	2045	2049	HeLa	CellLine	CVCL_0030
67038511	2054	2063	RAW 264.7	CellLine	CVCL_0493
67038511	Negative_Correlation	rs1800587	D002569	Novel
67038511	Cotreatment	D007501	D002569	Novel
67038511	Positive_Correlation	2056	D002569	Novel
67038511	Positive_Correlation	2056	D007501	Novel
67038511	Cotreatment	D002569	D007501	Novel
67038511	Negative_Correlation	rs1800587	D007501	Novel

46460826|t|Evaluation of Spirulina supplementation in guinea pigs and its impact on left ventricular hypertrophy and GI AEs in Ba/F3 and 253JB-V ce
46460826|a|This study investigates the effects of Spirulina supplementation on cardiovascular and gastrointestinal outcomes in guinea pigs and its potential influence on the behavior of Ba/F3, 253JB-V, and MH134 cell lines. Guinea pigs were divided into groups receiving either Spirulina or a control diet, and their cardiac and gastrointestinal health was monitored over a 12-week period. The incidence of left ventricular hypertrophy was significantly higher in the control group compared to the Spirulina-treated group. Additionally, gastrointestinal adverse events (GI AEs) were observed in both groups, but the severity was reduced in the Spirulina group. To further explore the molecular mechanisms, the effects of Spirulina on Ba/F3, 253JB-V, and MH134 cell lines were evaluated in vitro. The results showed that Spirulina treatment modulated the proliferation and survival of these cell lines, suggesting potential therapeutic applications in cardiovascular and gastrointestinal disorders. The findings highlight the protective role of Spirulina in preventing left ventricular hypertrophy and reducing GI AEs, while also influencing the behavior of key cell lines involved in disease progression.
46460826	14	23	Spirulina	OrganismTaxon	551299
46460826	43	54	guinea pigs	OrganismTaxon	10141
46460826	73	101	left ventricular hypertrophy	DiseaseOrPhenotypicFeature	D017379
46460826	106	112	GI AEs	DiseaseOrPhenotypicFeature	D005767
46460826	116	121	Ba/F3	CellLine	CVCL_0161
46460826	126	133	253JB-V	CellLine	CVCL_7937
46460826	176	185	Spirulina	OrganismTaxon	551299
46460826	253	264	guinea pigs	OrganismTaxon	10141
46460826	312	317	Ba/F3	CellLine	CVCL_0161
46460826	319	326	253JB-V	CellLine	CVCL_7937
46460826	332	337	MH134	CellLine	CVCL_8111
46460826	404	413	Spirulina	OrganismTaxon	551299
46460826	533	561	left ventricular hypertrophy	DiseaseOrPhenotypicFeature	D017379
46460826	624	633	Spirulina	OrganismTaxon	551299
46460826	696	702	GI AEs	DiseaseOrPhenotypicFeature	D005767
46460826	770	779	Spirulina	OrganismTaxon	551299
46460826	847	856	Spirulina	OrganismTaxon	551299
46460826	860	865	Ba/F3	CellLine	CVCL_0161
46460826	867	874	253JB-V	CellLine	CVCL_7937
46460826	880	885	MH134	CellLine	CVCL_8111
46460826	946	955	Spirulina	OrganismTaxon	551299
46460826	1170	1179	Spirulina	OrganismTaxon	551299
46460826	1194	1222	left ventricular hypertrophy	DiseaseOrPhenotypicFeature	D017379
46460826	1236	1242	GI AEs	DiseaseOrPhenotypicFeature	D005767

41970654|t|IR and host cell factor 1 interactions modulated by Re, Rg1, Rb1 ginsenosides and malonic acid in Kilham rat virus-infected sheep and Spirulina-expose
41970654|a|This study investigates the complex interactions between the gene product IR, host cell factor 1, and the chemical entities Re, Rg1, Rb1 ginsenosides, and malonic acid in the context of Kilham rat virus infection in sheep and Spirulina exposure. The research highlights a positive correlation between Re, Rg1, and Rb1 ginsenosides and malonic acid, as well as a comparison between these two chemical entities. Additionally, the study reveals a negative correlation between Re, Rg1, and Rb1 ginsenosides and both IR and host cell factor 1, while malonic acid shows a negative correlation with both IR and host cell factor 1. These findings suggest that the metabolic and regulatory effects of these chemical entities may play a significant role in modulating the expression and function of IR and host cell factor 1 in the presence of Kilham rat virus and Spirulina. The results are further supported by in vivo experiments conducted on sheep and Spirulina-exposed models, which demonstrate the dynamic interplay between these molecular components in different biological contexts. The study underscores the potential therapeutic applications of Re, Rg1, and Rb1 ginsenosides in managing conditions associated with IR and host cell factor 1 dysregulation, particularly in viral and microbial infection models.
41970654	0	2	IR	GeneOrGeneProduct	24954
41970654	7	25	host cell factor 1	GeneOrGeneProduct	3054
41970654	82	94	malonic acid	ChemicalEntity	C030290
41970654	98	114	Kilham rat virus	OrganismTaxon	12441
41970654	124	129	sheep	OrganismTaxon	9940
41970654	134	143	Spirulina	OrganismTaxon	551299
41970654	225	227	IR	GeneOrGeneProduct	24954
41970654	229	247	host cell factor 1	GeneOrGeneProduct	3054
41970654	306	318	malonic acid	ChemicalEntity	C030290
41970654	337	353	Kilham rat virus	OrganismTaxon	12441
41970654	367	372	sheep	OrganismTaxon	9940
41970654	377	386	Spirulina	OrganismTaxon	551299
41970654	452	481	Re, Rg1, and Rb1 ginsenosides	ChemicalEntity	C035054
41970654	486	498	malonic acid	ChemicalEntity	C030290
41970654	624	653	Re, Rg1, and Rb1 ginsenosides	ChemicalEntity	C035054
41970654	663	665	IR	GeneOrGeneProduct	24954
41970654	670	688	host cell factor 1	GeneOrGeneProduct	3054
41970654	696	708	malonic acid	ChemicalEntity	C030290
41970654	748	750	IR	GeneOrGeneProduct	24954
41970654	755	773	host cell factor 1	GeneOrGeneProduct	3054
41970654	940	942	IR	GeneOrGeneProduct	24954
41970654	947	965	host cell factor 1	GeneOrGeneProduct	3054
41970654	985	1001	Kilham rat virus	OrganismTaxon	12441
41970654	1006	1015	Spirulina	OrganismTaxon	551299
41970654	1087	1092	sheep	OrganismTaxon	9940
41970654	1097	1106	Spirulina	OrganismTaxon	551299
41970654	1296	1325	Re, Rg1, and Rb1 ginsenosides	ChemicalEntity	C035054
41970654	1365	1367	IR	GeneOrGeneProduct	24954
41970654	1372	1390	host cell factor 1	GeneOrGeneProduct	3054
41970654	Positive_Correlation	C030290	C035054	Novel
41970654	Comparison	C030290	C035054	Novel
41970654	Comparison	C035054	C030290	Novel
41970654	Negative_Correlation	C035054	24954	Novel
41970654	Negative_Correlation	C035054	3054	Novel
41970654	Negative_Correlation	C030290	3054	Novel
41970654	Negative_Correlation	C030290	24954	Novel
41970654	Positive_Correlation	C035054	C030290	Novel

97972130|t|Genetic and pharmacological interactions of rs2622604 with inducible isoform of nitric oxide synthase in response to glimepiride, glipizide, Arsenic, and 
97972130|a|This study investigates the genetic and pharmacological interactions between the sequence variant rs2622604 and the inducible isoform of nitric oxide synthase in the context of cotreatment with glimepiride, glipizide, Arsenic, and contrast. The sequence variant rs2622604 was found to modulate the expression of the inducible isoform of nitric oxide synthase, which plays a critical role in vascular function and inflammation. The study further explores how the presence of rs2622604 influences the pharmacological response to glimepiride, glipizide, Arsenic, and contrast.   Cotreatment with contrast and glimepiride was associated with a significant alteration in the expression levels of the inducible isoform of nitric oxide synthase, suggesting a potential mechanism for the observed vascular effects. Similarly, cotreatment with contrast and Arsenic led to a synergistic effect on the expression of the inducible isoform of nitric oxide synthase, which may contribute to the toxicological profile of these agents. Cotreatment with contrast and glipizide also showed a notable impact on the expression of the inducible isoform of nitric oxide synthase, indicating a possible interaction between these drugs.  The cotreatment of Arsenic and glimepiride was found to significantly alter the expression of the inducible isoform of nitric oxide synthase, which may have implications for the management of diabetes and vascular complications. Additionally, cotreatment of Arsenic and glipizide was associated with a marked change in the expression of the inducible isoform of nitric oxide synthase, suggesting a potential therapeutic or toxicological interaction. Cotreatment of glimepiride and Arsenic also showed a significant effect on the expression of the inducible isoform of nitric oxide synthase, which may be relevant in the context of drug-induced toxicity.  The study also examined the role of the gene product actin and the gene EGF in these interactions. The expression of actin was found to be modulated by the presence of rs2622604, and the expression of EGF was significantly altered in response to cotreatment with glimepiride, glipizide, Arsenic, and contrast. These findings suggest that the genetic variant rs2622604 may serve as a biomarker for predicting the response to these drugs and for understanding the molecular mechanisms underlying their interactions.  In conclusion, the study provides evidence for the complex interactions between rs2622604, the inducible isoform of nitric oxide synthase, and the cotreatment of glimepiride, glipizide, Arsenic, and contrast. These findings have important implications for personalized medicine and the development of safer therapeutic strategies.
97972130	44	53	rs2622604	SequenceVariant	rs2622604
97972130	59	101	inducible isoform of nitric oxide synthase	GeneOrGeneProduct	18126
97972130	117	128	glimepiride	ChemicalEntity	C057619
97972130	130	139	glipizide	ChemicalEntity	D005913
97972130	141	148	Arsenic	ChemicalEntity	D001151
97972130	253	262	rs2622604	SequenceVariant	rs2622604
97972130	271	313	inducible isoform of nitric oxide synthase	GeneOrGeneProduct	18126
97972130	349	360	glimepiride	ChemicalEntity	C057619
97972130	362	371	glipizide	ChemicalEntity	D005913
97972130	373	380	Arsenic	ChemicalEntity	D001151
97972130	386	394	contrast	ChemicalEntity	D003287
97972130	417	426	rs2622604	SequenceVariant	rs2622604
97972130	471	513	inducible isoform of nitric oxide synthase	GeneOrGeneProduct	18126
97972130	629	638	rs2622604	SequenceVariant	rs2622604
97972130	682	693	glimepiride	ChemicalEntity	C057619
97972130	695	704	glipizide	ChemicalEntity	D005913
97972130	706	713	Arsenic	ChemicalEntity	D001151
97972130	719	727	contrast	ChemicalEntity	D003287
97972130	748	756	contrast	ChemicalEntity	D003287
97972130	761	772	glimepiride	ChemicalEntity	C057619
97972130	850	892	inducible isoform of nitric oxide synthase	GeneOrGeneProduct	18126
97972130	990	998	contrast	ChemicalEntity	D003287
97972130	1003	1010	Arsenic	ChemicalEntity	D001151
97972130	1064	1106	inducible isoform of nitric oxide synthase	GeneOrGeneProduct	18126
97972130	1192	1200	contrast	ChemicalEntity	D003287
97972130	1205	1214	glipizide	ChemicalEntity	D005913
97972130	1269	1311	inducible isoform of nitric oxide synthase	GeneOrGeneProduct	18126
97972130	1388	1395	Arsenic	ChemicalEntity	D001151
97972130	1400	1411	glimepiride	ChemicalEntity	C057619
97972130	1467	1509	inducible isoform of nitric oxide synthase	GeneOrGeneProduct	18126
97972130	1627	1634	Arsenic	ChemicalEntity	D001151
97972130	1639	1648	glipizide	ChemicalEntity	D005913
97972130	1710	1752	inducible isoform of nitric oxide synthase	GeneOrGeneProduct	18126
97972130	1834	1845	glimepiride	ChemicalEntity	C057619
97972130	1850	1857	Arsenic	ChemicalEntity	D001151
97972130	1916	1958	inducible isoform of nitric oxide synthase	GeneOrGeneProduct	18126
97972130	2077	2082	actin	GeneOrGeneProduct	60
97972130	2096	2099	EGF	GeneOrGeneProduct	25313
97972130	2141	2146	actin	GeneOrGeneProduct	60
97972130	2192	2201	rs2622604	SequenceVariant	rs2622604
97972130	2225	2228	EGF	GeneOrGeneProduct	25313
97972130	2287	2298	glimepiride	ChemicalEntity	C057619
97972130	2300	2309	glipizide	ChemicalEntity	D005913
97972130	2311	2318	Arsenic	ChemicalEntity	D001151
97972130	2324	2332	contrast	ChemicalEntity	D003287
97972130	2382	2391	rs2622604	SequenceVariant	rs2622604
97972130	2619	2628	rs2622604	SequenceVariant	rs2622604
97972130	2634	2676	inducible isoform of nitric oxide synthase	GeneOrGeneProduct	18126
97972130	2701	2712	glimepiride	ChemicalEntity	C057619
97972130	2714	2723	glipizide	ChemicalEntity	D005913
97972130	2725	2732	Arsenic	ChemicalEntity	D001151
97972130	2738	2746	contrast	ChemicalEntity	D003287
97972130	Cotreatment	D003287	C057619	Novel
97972130	Cotreatment	D003287	D001151	Novel
97972130	Cotreatment	D003287	D005913	Novel
97972130	Cotreatment	D001151	D003287	Novel
97972130	Cotreatment	D005913	C057619	Novel
97972130	Cotreatment	D005913	D001151	Novel
97972130	Cotreatment	C057619	D001151	Novel
97972130	Cotreatment	D001151	D005913	Novel
97972130	Cotreatment	C057619	D003287	Novel
97972130	Cotreatment	C057619	D005913	Novel
97972130	Cotreatment	D005913	D003287	Novel
97972130	Cotreatment	D001151	C057619	Novel

22583963|t|Clathrin and beta-dystroglycan interactions modulate the effects of sequence variants and chemical entities on gene expression and disease pro
22583963|a|This study investigates the complex interplay between clathrin, beta-dystroglycan, and various sequence variants in the context of disease mechanisms. We demonstrate that the sequence variant arginine 555-to-tryptophan exhibits a positive correlation with Antioxidant levels, suggesting a potential protective role in cellular stress responses. Additionally, the sequence variant p.V657_G726 is found to be associated with multiple gene products, including collagen SH and PI3K, highlighting its broad functional impact.   The chemical entity HGA shows a significant association with corticosteroid, indicating a possible role in inflammatory pathways. Furthermore, the sequence variant C111G is linked to Antioxidant levels, reinforcing the importance of antioxidant regulation in disease contexts. Notably, the sequence variant G12D is found to be negatively correlated with Stat5, suggesting a potential disruption in signaling pathways critical for cellular function.   Our findings also reveal a negative correlation between Stat5 and clathrin, implying a regulatory relationship that may influence cellular processes such as endocytosis. The gene product creatine kinase is negatively correlated with Antioxidant levels, suggesting a possible antagonistic relationship in metabolic regulation.   The sequence variant dup24bp is positively correlated with naproxen, indicating a potential pharmacological interaction that warrants further investigation. The chemical entity ferric is associated with multiple gene products, including gpIbalpha and acetylcholinesterase, suggesting a role in redox homeostasis and neurotransmission.   Finally, the chemical entity Antioxidant is found to be associated with multiple sequence variants, including p.A365E and C111G, underscoring its central role in modulating genetic variability and disease outcomes. These results provide a comprehensive framework for understanding the molecular mechanisms underlying these complex interactions.
22583963	13	30	beta-dystroglycan	GeneOrGeneProduct	114489
22583963	197	205	clathrin	ChemicalEntity	D002966
22583963	207	224	beta-dystroglycan	GeneOrGeneProduct	114489
22583963	335	361	arginine 555-to-tryptophan	SequenceVariant	rs121909208
22583963	399	410	Antioxidant	ChemicalEntity	D000975
22583963	523	534	p.V657_G726	SequenceVariant	p|DEL|657_726|
22583963	600	611	collagen SH	GeneOrGeneProduct	1281
22583963	616	620	PI3K	GeneOrGeneProduct	18708
22583963	686	689	HGA	ChemicalEntity	D006713
22583963	727	741	corticosteroid	ChemicalEntity	D000305
22583963	830	835	C111G	SequenceVariant	c|SUB|C|111|G
22583963	849	860	Antioxidant	ChemicalEntity	D000975
22583963	973	977	G12D	SequenceVariant	p|SUB|G|12|D
22583963	1020	1025	Stat5	GeneOrGeneProduct	20850
22583963	1173	1178	Stat5	GeneOrGeneProduct	20850
22583963	1183	1191	clathrin	ChemicalEntity	D002966
22583963	1304	1319	creatine kinase	GeneOrGeneProduct	24264
22583963	1350	1361	Antioxidant	ChemicalEntity	D000975
22583963	1466	1473	dup24bp	SequenceVariant	c|DUP||24|
22583963	1504	1512	naproxen	ChemicalEntity	D009288
22583963	1622	1628	ferric	ChemicalEntity	D007501
22583963	1682	1691	gpIbalpha	GeneOrGeneProduct	2811
22583963	1696	1716	acetylcholinesterase	GeneOrGeneProduct	83817
22583963	1811	1822	Antioxidant	ChemicalEntity	D000975
22583963	1892	1899	p.A365E	SequenceVariant	p|SUB|A|365|E
22583963	1904	1909	C111G	SequenceVariant	c|SUB|C|111|G
22583963	Positive_Correlation	c|DUP||24|	D009288	Novel
22583963	Association	D000305	D006713	Novel
22583963	Negative_Correlation	20850	D000975	Novel
22583963	Negative_Correlation	24264	D000975	Novel
22583963	Association	D000975	c|SUB|C|111|G	Novel
22583963	Negative_Correlation	20850	D002966	Novel
22583963	Association	D006713	24264	Novel
22583963	Positive_Correlation	rs121909208	D000975	Novel

53316300|t|Genetic Variants and Disease Associations in Diverse Models: Insights from Cell Lines, Organisms, and Phenotypic 
53316300|a|This study explores the complex interplay between genetic variants, disease phenotypes, and biological models across multiple species and cell lines. We investigated the associations between specific sequence variants and a range of diseases, including dementia, non-melanoma skin cancers, uterine sarcoma, inherited bleeding disorder, cleft lip, and hemochromatosis. The study also examined the relationships between these genetic variants and various organisms, including Drosophila, Platonia insignis Mart, West Nile virus, and tobacco.   Key findings include a negative correlation between the deletion (TGAG) and dementia, as well as a positive correlation between deletion (TGAG) and non-melanoma skin cancers. The sequence variant p.Ser119fsX was found to be associated with dementia, non-melanoma skin cancers, and inherited bleeding disorder, with a positive correlation between p.Ser119fsX and both dementia and inherited bleeding disorder. Additionally, p.Ser119fsX showed a negative correlation with hemochromatosis and a positive correlation with uterine sarcoma and cleft lip.   The deletion (TGAG) was also associated with hemochromatosis, uterine sarcoma, and inherited bleeding disorder, with a positive correlation between deletion (TGAG) and hemochromatosis, uterine sarcoma, and dementia. Notably, there was a negative correlation between deletion (TGAG) and non-melanoma skin cancers, and a negative correlation between p.Ser119fsX and dementia.   The study utilized a variety of cell lines, including C57BL/6J, KU7, H9c2, H446, GT1-1, and COS-7, to model these genetic associations. The results highlight the importance of genetic variants in disease pathogenesis and suggest potential therapeutic targets for conditions such as dementia, non-melanoma skin cancers, and inherited bleeding disorders. The findings also underscore the value of using diverse biological models, including Drosophila and West Nile virus, to better understand the molecular mechanisms underlying these diseases.
53316300	367	375	dementia	DiseaseOrPhenotypicFeature	D003704
53316300	377	402	non-melanoma skin cancers	DiseaseOrPhenotypicFeature	D012878
53316300	404	419	uterine sarcoma	DiseaseOrPhenotypicFeature	D014594
53316300	421	448	inherited bleeding disorder	DiseaseOrPhenotypicFeature	D025861
53316300	450	459	cleft lip	DiseaseOrPhenotypicFeature	D002971
53316300	465	480	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
53316300	588	598	Drosophila	OrganismTaxon	7227
53316300	600	622	Platonia insignis Mart	OrganismTaxon	198787
53316300	624	639	West Nile virus	OrganismTaxon	11082
53316300	645	652	tobacco	OrganismTaxon	4097
53316300	712	727	deletion (TGAG)	SequenceVariant	c|DEL||TGAG
53316300	732	740	dementia	DiseaseOrPhenotypicFeature	D003704
53316300	784	799	deletion (TGAG)	SequenceVariant	c|DEL||TGAG
53316300	804	829	non-melanoma skin cancers	DiseaseOrPhenotypicFeature	D012878
53316300	852	863	p.Ser119fsX	SequenceVariant	p|FS|S|119||
53316300	896	904	dementia	DiseaseOrPhenotypicFeature	D003704
53316300	906	931	non-melanoma skin cancers	DiseaseOrPhenotypicFeature	D012878
53316300	937	964	inherited bleeding disorder	DiseaseOrPhenotypicFeature	D025861
53316300	1002	1013	p.Ser119fsX	SequenceVariant	p|FS|S|119||
53316300	1023	1031	dementia	DiseaseOrPhenotypicFeature	D003704
53316300	1036	1063	inherited bleeding disorder	DiseaseOrPhenotypicFeature	D025861
53316300	1079	1090	p.Ser119fsX	SequenceVariant	p|FS|S|119||
53316300	1126	1141	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
53316300	1174	1189	uterine sarcoma	DiseaseOrPhenotypicFeature	D014594
53316300	1194	1203	cleft lip	DiseaseOrPhenotypicFeature	D002971
53316300	1211	1226	deletion (TGAG)	SequenceVariant	c|DEL||TGAG
53316300	1252	1267	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
53316300	1269	1284	uterine sarcoma	DiseaseOrPhenotypicFeature	D014594
53316300	1290	1317	inherited bleeding disorder	DiseaseOrPhenotypicFeature	D025861
53316300	1355	1370	deletion (TGAG)	SequenceVariant	c|DEL||TGAG
53316300	1375	1390	hemochromatosis	DiseaseOrPhenotypicFeature	D006432
53316300	1392	1407	uterine sarcoma	DiseaseOrPhenotypicFeature	D014594
53316300	1413	1421	dementia	DiseaseOrPhenotypicFeature	D003704
53316300	1473	1488	deletion (TGAG)	SequenceVariant	c|DEL||TGAG
53316300	1493	1518	non-melanoma skin cancers	DiseaseOrPhenotypicFeature	D012878
53316300	1555	1566	p.Ser119fsX	SequenceVariant	p|FS|S|119||
53316300	1571	1579	dementia	DiseaseOrPhenotypicFeature	D003704
53316300	1637	1645	C57BL/6J	CellLine	CVCL_5U84
53316300	1647	1650	KU7	CellLine	CVCL_4714
53316300	1652	1656	H9c2	CellLine	CVCL_0286
53316300	1658	1662	H446	CellLine	CVCL_1562
53316300	1664	1669	GT1-1	CellLine	CVCL_6236
53316300	1675	1680	COS-7	CellLine	CVCL_0224
53316300	1865	1873	dementia	DiseaseOrPhenotypicFeature	D003704
53316300	1875	1900	non-melanoma skin cancers	DiseaseOrPhenotypicFeature	D012878
53316300	1906	1933	inherited bleeding disorder	DiseaseOrPhenotypicFeature	D025861
53316300	2021	2031	Drosophila	OrganismTaxon	7227
53316300	2036	2051	West Nile virus	OrganismTaxon	11082
53316300	Negative_Correlation	c|DEL||TGAG	D003704	Novel
53316300	Association	p|FS|S|119||	D003704	Novel
53316300	Association	c|DEL||TGAG	D012878	Novel
53316300	Positive_Correlation	D006432	c|DEL||TGAG	Novel
53316300	Positive_Correlation	D012878	p|FS|S|119||	Novel
53316300	Negative_Correlation	c|DEL||TGAG	D012878	Novel
53316300	Positive_Correlation	D025861	p|FS|S|119||	Novel
53316300	Positive_Correlation	p|FS|S|119||	D025861	Novel
53316300	Association	c|DEL||TGAG	D002971	Novel
53316300	Association	D006432	c|DEL||TGAG	Novel
53316300	Association	c|DEL||TGAG	D006432	Novel
53316300	Association	c|DEL||TGAG	D025861	Novel
53316300	Positive_Correlation	D003704	p|FS|S|119||	Novel
53316300	Association	D025861	c|DEL||TGAG	Novel
53316300	Negative_Correlation	p|FS|S|119||	D006432	Novel
53316300	Association	D002971	p|FS|S|119||	Novel
53316300	Association	c|DEL||TGAG	p|FS|S|119||	Novel
53316300	Positive_Correlation	D014594	c|DEL||TGAG	Novel
53316300	Positive_Correlation	D006432	p|FS|S|119||	Novel
53316300	Positive_Correlation	c|DEL||TGAG	D003704	Novel
53316300	Positive_Correlation	D014594	p|FS|S|119||	Novel
53316300	Association	p|FS|S|119||	D012878	Novel
53316300	Negative_Correlation	p|FS|S|119||	D003704	Novel
53316300	Negative_Correlation	c|DEL||TGAG	D014594	Novel
53316300	Positive_Correlation	D002971	p|FS|S|119||	Novel
53316300	Positive_Correlation	p|FS|S|119||	D012878	Novel
53316300	Negative_Correlation	c|DEL||TGAG	D006432	Novel
53316300	Positive_Correlation	D003704	c|DEL||TGAG	Novel
53316300	Positive_Correlation	D012878	c|DEL||TGAG	Novel
53316300	Association	p|FS|S|119||	D002971	Novel
53316300	Positive_Correlation	p|FS|S|119||	D002971	Novel
53316300	Association	c|DEL||TGAG	D014594	Novel
53316300	Positive_Correlation	c|DEL||TGAG	D006432	Novel
53316300	Association	D012878	p|FS|S|119||	Novel
53316300	Positive_Correlation	c|DEL||TGAG	D025861	Novel
53316300	Association	p|FS|S|119||	D014594	Novel
53316300	Association	D003704	c|DEL||TGAG	Novel
53316300	Association	D006432	p|FS|S|119||	Novel

77157540|t|Genetic Variants and Cellular Responses in Neuroblastoma and Breast Cance
77157540|a|This study investigates the functional and phenotypic consequences of multiple sequence variants and their associations with specific cell lines in neuroblastoma and breast cancer models. The sequence variant del 92 nucleotide -19/+73 was found to be significantly associated with Arg16Gly, CAG and GGC repeat, rs7535263, and p.G705RfsX16 across multiple cell lines, including C57BL/6J, 253JB-V, DUCaP, and MCF7/AdrR. These associations were further validated through functional assays and transcriptomic profiling.   The sequence variant Arg16Gly was found to be linked to CAG and GGC repeat and rs7535263, with evidence of a complex regulatory network involving these elements. Additionally, the variant rs7535263 showed strong associations with p.G705RfsX16 and CAG and GGC repeat, suggesting a potential role in modulating gene expression and protein function. The variant p.G705RfsX16 was also found to be associated with Arg16Gly and CAG and GGC repeat, reinforcing the interconnectedness of these genetic elements.  In the context of cell lines, C57BL/6J and 253JB-V exhibited the most consistent responses to these variants, with del 92 nucleotide -19/+73 showing the strongest correlation with multiple sequence variants. The cell line DUCaP demonstrated unique interactions between rs7535263 and p.G705RfsX16, while MCF7/AdrR showed a distinct pattern of associations involving CAG and GGC repeat and Arg16Gly. These findings highlight the importance of cell-specific genetic interactions in understanding the molecular mechanisms underlying cancer progression and therapeutic response.  The study also revealed that the sequence variant del 92 nucleotide -19/+73 was associated with multiple other variants, including rs7535263 and p.G705RfsX16, suggesting a potential role in modulating gene expression and cellular function. These associations were further supported by in vitro experiments and computational modeling, providing a comprehensive view of the genetic landscape in these cell lines.
77157540	283	308	del 92 nucleotide -19/+73	SequenceVariant	c|DEL|-19_+73|92
77157540	355	363	Arg16Gly	SequenceVariant	p|SUB|R|16|G
77157540	365	383	CAG and GGC repeat	SequenceVariant	c|DUP||CAG_GGC|
77157540	385	394	rs7535263	SequenceVariant	rs7535263
77157540	400	412	p.G705RfsX16	SequenceVariant	p|FS|G|705|R|16
77157540	451	459	C57BL/6J	CellLine	CVCL_5U84
77157540	461	468	253JB-V	CellLine	CVCL_7937
77157540	470	475	DUCaP	CellLine	CVCL_2025
77157540	481	490	MCF7/AdrR	CellLine	 CVCL_1452
77157540	613	621	Arg16Gly	SequenceVariant	p|SUB|R|16|G
77157540	648	666	CAG and GGC repeat	SequenceVariant	c|DUP||CAG_GGC|
77157540	671	680	rs7535263	SequenceVariant	rs7535263
77157540	780	789	rs7535263	SequenceVariant	rs7535263
77157540	822	834	p.G705RfsX16	SequenceVariant	p|FS|G|705|R|16
77157540	839	857	CAG and GGC repeat	SequenceVariant	c|DUP||CAG_GGC|
77157540	951	963	p.G705RfsX16	SequenceVariant	p|FS|G|705|R|16
77157540	1001	1009	Arg16Gly	SequenceVariant	p|SUB|R|16|G
77157540	1014	1032	CAG and GGC repeat	SequenceVariant	c|DUP||CAG_GGC|
77157540	1127	1135	C57BL/6J	CellLine	CVCL_5U84
77157540	1140	1147	253JB-V	CellLine	CVCL_7937
77157540	1212	1237	del 92 nucleotide -19/+73	SequenceVariant	c|DEL|-19_+73|92
77157540	1319	1324	DUCaP	CellLine	CVCL_2025
77157540	1366	1375	rs7535263	SequenceVariant	rs7535263
77157540	1380	1392	p.G705RfsX16	SequenceVariant	p|FS|G|705|R|16
77157540	1400	1409	MCF7/AdrR	CellLine	 CVCL_1452
77157540	1462	1480	CAG and GGC repeat	SequenceVariant	c|DUP||CAG_GGC|
77157540	1485	1493	Arg16Gly	SequenceVariant	p|SUB|R|16|G
77157540	1722	1747	del 92 nucleotide -19/+73	SequenceVariant	c|DEL|-19_+73|92
77157540	1803	1812	rs7535263	SequenceVariant	rs7535263
77157540	1817	1829	p.G705RfsX16	SequenceVariant	p|FS|G|705|R|16
77157540	Association	c|DEL|-19_+73|92	p|SUB|R|16|G	Novel
77157540	Association	p|SUB|R|16|G	c|DUP||CAG_GGC|	Novel
77157540	Association	c|DEL|-19_+73|92	rs7535263	Novel
77157540	Association	c|DEL|-19_+73|92	c|DUP||CAG_GGC|	Novel
77157540	Association	rs7535263	p|FS|G|705|R|16	Novel
77157540	Association	p|FS|G|705|R|16	rs7535263	Novel
77157540	Association	c|DEL|-19_+73|92	p|FS|G|705|R|16	Novel
77157540	Association	p|FS|G|705|R|16	c|DEL|-19_+73|92	Novel
77157540	Association	p|FS|G|705|R|16	c|DUP||CAG_GGC|	Novel
77157540	Association	p|SUB|R|16|G	rs7535263	Novel
77157540	Association	c|DUP||CAG_GGC|	p|SUB|R|16|G	Novel
77157540	Association	c|DUP||CAG_GGC|	c|DEL|-19_+73|92	Novel
77157540	Association	p|SUB|R|16|G	c|DEL|-19_+73|92	Novel
77157540	Association	rs7535263	c|DUP||CAG_GGC|	Novel
77157540	Association	rs7535263	c|DEL|-19_+73|92	Novel
77157540	Association	c|DUP||CAG_GGC|	p|FS|G|705|R|16	Novel
77157540	Association	p|FS|G|705|R|16	p|SUB|R|16|G	Novel
77157540	Association	rs7535263	p|SUB|R|16|G	Novel
77157540	Association	p|SUB|R|16|G	p|FS|G|705|R|16	Novel
77157540	Association	c|DUP||CAG_GGC|	rs7535263	Novel

04927478|t|Thapsigargin and Raloxifene Hydrochloride: Multifaceted Associations with Cardiogenic Shock, NSARD, and Calcification of Ascending Aorta in Human Immunodeficiency Virus and Platonia Insig
04927478|a|This study explores the complex interactions between thapsigargin, raloxifene hydrochloride, and various disease states in the context of human immunodeficiency virus (HIV) and Platonia insignis Mart. We investigate the association between thapsigargin and MR, demonstrating a positive correlation that suggests a potential role in modulating myocardial function. Additionally, we find a positive correlation between raloxifene hydrochloride and calcification of ascending aorta, indicating a possible protective effect against aortic calcification.   The conversion between tamoxifen and thapsigargin is highlighted, with evidence suggesting that tamoxifen can be metabolized into thapsigargin, which in turn exhibits a positive correlation with MR. Furthermore, the conversion between tamoxifen and raloxifene hydrochloride is supported, indicating a potential pharmacological pathway for these two compounds.   We also report a positive correlation between thapsigargin and resting tremor, suggesting a possible involvement in neurodegenerative processes. The association between cardiogenic shock and thapsigargin is further reinforced, with thapsigargin showing a direct link to this severe cardiovascular condition. Similarly, cardiogenic shock is associated with raloxifene hydrochloride, indicating a potential therapeutic role in managing this condition.   The association between NSARD and raloxifene hydrochloride is explored, with evidence suggesting that raloxifene hydrochloride may have anti-inflammatory properties that benefit patients with NSARD. Additionally, oligodontia is found to be associated with raloxifene hydrochloride, suggesting a possible role in dental development.   The study also includes multiple instances of calcification of ascending aorta, which is associated with tamoxifen, indicating a potential link between this condition and the use of tamoxifen. Resting tremor is further associated with thapsigargin, reinforcing the complex interplay between these compounds and neurological manifestations.   The presence of human immunodeficiency virus and Platonia insignis Mart in the study population adds a unique dimension to the investigation, as these organisms are linked to various disease states and may influence the pharmacological responses observed. The findings underscore the importance of understanding the multifaceted relationships between chemical entities and disease phenotypes in both human and plant systems.
04927478	93	98	NSARD	DiseaseOrPhenotypicFeature	C567134
04927478	241	253	thapsigargin	ChemicalEntity	D019284
04927478	255	279	raloxifene hydrochloride	ChemicalEntity	D020849
04927478	326	354	human immunodeficiency virus	OrganismTaxon	12721
04927478	365	387	Platonia insignis Mart	OrganismTaxon	198787
04927478	428	440	thapsigargin	ChemicalEntity	D019284
04927478	445	447	MR	DiseaseOrPhenotypicFeature	D008607
04927478	605	629	raloxifene hydrochloride	ChemicalEntity	D020849
04927478	634	666	calcification of ascending aorta	DiseaseOrPhenotypicFeature	D001018
04927478	763	772	tamoxifen	ChemicalEntity	D013629
04927478	777	789	thapsigargin	ChemicalEntity	D019284
04927478	836	845	tamoxifen	ChemicalEntity	D013629
04927478	870	882	thapsigargin	ChemicalEntity	D019284
04927478	935	937	MR	DiseaseOrPhenotypicFeature	D008607
04927478	975	984	tamoxifen	ChemicalEntity	D013629
04927478	989	1013	raloxifene hydrochloride	ChemicalEntity	D020849
04927478	1148	1160	thapsigargin	ChemicalEntity	D019284
04927478	1165	1179	resting tremor	DiseaseOrPhenotypicFeature	D014202
04927478	1271	1288	cardiogenic shock	DiseaseOrPhenotypicFeature	D012770
04927478	1293	1305	thapsigargin	ChemicalEntity	D019284
04927478	1334	1346	thapsigargin	ChemicalEntity	D019284
04927478	1421	1438	cardiogenic shock	DiseaseOrPhenotypicFeature	D012770
04927478	1458	1482	raloxifene hydrochloride	ChemicalEntity	D020849
04927478	1578	1583	NSARD	DiseaseOrPhenotypicFeature	C567134
04927478	1588	1612	raloxifene hydrochloride	ChemicalEntity	D020849
04927478	1656	1680	raloxifene hydrochloride	ChemicalEntity	D020849
04927478	1746	1751	NSARD	DiseaseOrPhenotypicFeature	C567134
04927478	1767	1778	oligodontia	DiseaseOrPhenotypicFeature	C538049
04927478	1810	1834	raloxifene hydrochloride	ChemicalEntity	D020849
04927478	1934	1966	calcification of ascending aorta	DiseaseOrPhenotypicFeature	D001018
04927478	1993	2002	tamoxifen	ChemicalEntity	D013629
04927478	2070	2079	tamoxifen	ChemicalEntity	D013629
04927478	2123	2135	thapsigargin	ChemicalEntity	D019284
04927478	2246	2274	human immunodeficiency virus	OrganismTaxon	12721
04927478	2279	2301	Platonia insignis Mart	OrganismTaxon	198787
04927478	Association	D008607	D019284	Novel
04927478	Conversion	D013629	D019284	Novel
04927478	Positive_Correlation	D013629	D014202	Novel
04927478	Association	D012770	D019284	Novel
04927478	Association	C538049	D020849	Novel
04927478	Association	D012770	D020849	Novel
04927478	Association	C567134	D020849	Novel
04927478	Conversion	D013629	D020849	Novel
04927478	Positive_Correlation	D019284	D008607	Novel
04927478	Conversion	D019284	D020849	Novel
04927478	Positive_Correlation	D020849	D001018	Novel
04927478	Association	D001018	D013629	Novel
04927478	Association	D014202	D019284	Novel

26149509|t|Multifaceted interactions of crack cocaine, sevoflurane, and L-365,260 in modulating Jnk, Src, and other signaling pathways across diverse
26149509|a|This study investigates the complex interactions between crack cocaine, sevoflurane, and L-365,260 in modulating the activity of Jnk and Src signaling pathways across multiple species, including rats, rhesus monkeys, and Mangifera indica Linn. The research reveals a negative correlation between crack cocaine and Jnk, as well as a negative correlation between Jnk and Src. These findings are further supported by the association between Jnk and crack cocaine, and the positive correlation between sevoflurane and Jnk. Additionally, the study demonstrates a positive correlation between sevoflurane and L-365,260, as well as a positive correlation between L-365,260 and crack cocaine.   The data also show a positive correlation between sevoflurane and LY294002, and a positive correlation between LY294002 and Jnk. Notably, there is a negative correlation between Src and LY294002, and an association between Src and crack cocaine. The study further reports a conversion between LY294002 and crack cocaine, as well as a conversion between crack cocaine and sevoflurane. These interactions are examined in various cell lines, including MEF, MES-SA/Dx5, SNU-C5, and GT1-1, with the latter being the most frequently used in the experiments.   The findings suggest that these chemical entities and signaling molecules play a critical role in modulating cellular responses in both rodents and non-human primates. The study also highlights the importance of these interactions in the context of different species, including horses and Mangifera indica Linn, which were included to assess the broader biological relevance of these findings. Overall, the results provide a comprehensive understanding of the molecular mechanisms underlying the effects of these compounds on key signaling pathways.
26149509	29	42	crack cocaine	ChemicalEntity	D016578
26149509	44	55	sevoflurane	ChemicalEntity	C009250
26149509	61	70	L-365,260	ChemicalEntity	C058121
26149509	85	88	Jnk	GeneOrGeneProduct	26419
26149509	90	93	Src	GeneOrGeneProduct	6714
26149509	196	209	crack cocaine	ChemicalEntity	D016578
26149509	211	222	sevoflurane	ChemicalEntity	C009250
26149509	228	237	L-365,260	ChemicalEntity	C058121
26149509	268	271	Jnk	GeneOrGeneProduct	26419
26149509	276	279	Src	GeneOrGeneProduct	6714
26149509	340	354	rhesus monkeys	OrganismTaxon	9544
26149509	360	381	Mangifera indica Linn	OrganismTaxon	29780
26149509	435	448	crack cocaine	ChemicalEntity	D016578
26149509	453	456	Jnk	GeneOrGeneProduct	26419
26149509	500	503	Jnk	GeneOrGeneProduct	26419
26149509	508	511	Src	GeneOrGeneProduct	6714
26149509	577	580	Jnk	GeneOrGeneProduct	26419
26149509	585	598	crack cocaine	ChemicalEntity	D016578
26149509	637	648	sevoflurane	ChemicalEntity	C009250
26149509	653	656	Jnk	GeneOrGeneProduct	26419
26149509	726	737	sevoflurane	ChemicalEntity	C009250
26149509	742	751	L-365,260	ChemicalEntity	C058121
26149509	795	804	L-365,260	ChemicalEntity	C058121
26149509	809	822	crack cocaine	ChemicalEntity	D016578
26149509	876	887	sevoflurane	ChemicalEntity	C009250
26149509	892	900	LY294002	ChemicalEntity	C085911
26149509	937	945	LY294002	ChemicalEntity	C085911
26149509	950	953	Jnk	GeneOrGeneProduct	26419
26149509	1004	1007	Src	GeneOrGeneProduct	6714
26149509	1012	1020	LY294002	ChemicalEntity	C085911
26149509	1049	1052	Src	GeneOrGeneProduct	6714
26149509	1057	1070	crack cocaine	ChemicalEntity	D016578
26149509	1119	1127	LY294002	ChemicalEntity	C085911
26149509	1132	1145	crack cocaine	ChemicalEntity	D016578
26149509	1179	1192	crack cocaine	ChemicalEntity	D016578
26149509	1197	1208	sevoflurane	ChemicalEntity	C009250
26149509	1275	1278	MEF	CellLine	CVCL_9115
26149509	1280	1290	MES-SA/Dx5	CellLine	CVCL_2598
26149509	1292	1298	SNU-C5	CellLine	CVCL_5112
26149509	1304	1309	GT1-1	CellLine	CVCL_6236
26149509	1658	1664	horses	OrganismTaxon	9796
26149509	1669	1690	Mangifera indica Linn	OrganismTaxon	29780
26149509	Negative_Correlation	6714	C085911	Novel
26149509	Negative_Correlation	D016578	26419	Novel
26149509	Positive_Correlation	C058121	C009250	Novel
26149509	Negative_Correlation	26419	6714	Novel
26149509	Conversion	C085911	D016578	Novel
26149509	Positive_Correlation	C009250	26419	Novel
26149509	Association	26419	C009250	Novel
26149509	Bind	D016578	26419	Novel
26149509	Association	6714	D016578	Novel
26149509	Positive_Correlation	C009250	C085911	Novel
26149509	Positive_Correlation	C009250	C058121	Novel
26149509	Association	26419	D016578	Novel
26149509	Positive_Correlation	C085911	26419	Novel
26149509	Positive_Correlation	D016578	C058121	Novel
26149509	Association	26419	C085911	Novel
26149509	Conversion	D016578	C009250	Novel
26149509	Association	6714	C009250	Novel
26149509	Positive_Correlation	C058121	D016578	Novel

44912058|t|Postoperative Nausea and Vomiting: Genetic and Pharmacological Insights into the Role of TP53, PGE2, Epidermal Growth Factor Receptor, and Ris
44912058|a|Postoperative nausea and vomiting (PONV) remains a significant clinical challenge following surgical procedures. This study investigates the genetic and pharmacological factors influencing PONV, with a focus on the interplay between sequence variants, gene products, and chemical entities. We analyzed the association between the sequence variant (TAC-->AA) at codon 329 and PONV, finding a negative correlation between this variant and the occurrence of PONV. Similarly, the sequence variant rs12910509 showed a negative correlation with PONV, suggesting a potential protective role in reducing the incidence of this adverse event.   The gene TP53 was found to have a negative correlation with PONV, indicating that variations in TP53 expression or function may contribute to the prevention of PONV. Additionally, the gene product PGE2 exhibited a negative correlation with PONV, suggesting that reduced levels of PGE2 may be associated with a lower risk of developing PONV. The Epidermal Growth Factor Receptor (EGFR) also showed a negative correlation with PONV, implying that EGFR signaling pathways may play a role in modulating the risk of PONV.  Pharmacologically, risperidone was found to have a negative correlation with PONV, suggesting that its use may help in the management of PONV. The study further explored the interactions between these genetic and pharmacological factors, highlighting the complex regulatory networks that influence PONV. These findings provide a foundation for developing targeted interventions to reduce the incidence and severity of PONV in postoperative patients.
44912058	89	93	TP53	GeneOrGeneProduct	24842
44912058	95	99	PGE2	GeneOrGeneProduct	5732
44912058	101	133	Epidermal Growth Factor Receptor	GeneOrGeneProduct	1956
44912058	490	513	(TAC-->AA) at codon 329	SequenceVariant	c|SUB|TAC|CODON329|AA
44912058	636	646	rs12910509	SequenceVariant	rs12910509
44912058	787	791	TP53	GeneOrGeneProduct	24842
44912058	874	878	TP53	GeneOrGeneProduct	24842
44912058	975	979	PGE2	GeneOrGeneProduct	5732
44912058	1058	1062	PGE2	GeneOrGeneProduct	5732
44912058	1123	1155	Epidermal Growth Factor Receptor	GeneOrGeneProduct	1956
44912058	1315	1326	risperidone	ChemicalEntity	D018967
44912058	Negative_Correlation	5732	D020250	Novel
44912058	Negative_Correlation	1956	D020250	Novel
44912058	Negative_Correlation	24842	D020250	Novel
44912058	Negative_Correlation	D020250	D018967	Novel

50198296|t|Interleukin-6 and POSTN: dual roles in lower extremity weakness and their interactions with KU7, MEF, and HEK293 cell lines in the context of Mangifera indica Linn and mouse mammary tum
50198296|a|This study investigates the molecular mechanisms underlying lower extremity weakness and the potential roles of interleukin-6 (IL-6) and POSTN in this condition. Using a combination of in vitro and in vivo models, we examined the expression and functional interactions of IL-6 and POSTN in various cell lines, including KU7, MEF, and HEK293. Our findings reveal a positive correlation between IL-6 and POSTN, suggesting a potential regulatory relationship between these two genes. Furthermore, we observed an association between both IL-6 and POSTN with lower extremity weakness, indicating their possible involvement in the pathophysiology of this phenotypic feature. The study also explores the influence of Mangifera indica Linn and mouse mammary tumor virus on the expression of these genes in different cellular contexts. These results provide new insights into the complex interplay between cytokines, extracellular matrix proteins, and neurological phenotypes, with implications for therapeutic strategies targeting these pathways.
50198296	18	23	POSTN	GeneOrGeneProduct	10631
50198296	39	63	lower extremity weakness	DiseaseOrPhenotypicFeature	D020335
50198296	92	95	KU7	CellLine	CVCL_4714
50198296	97	100	MEF	CellLine	CVCL_9115
50198296	106	112	HEK293	CellLine	CVCL_0045
50198296	142	163	Mangifera indica Linn	OrganismTaxon	29780
50198296	246	270	lower extremity weakness	DiseaseOrPhenotypicFeature	D020335
50198296	298	311	interleukin-6	GeneOrGeneProduct	3569
50198296	323	328	POSTN	GeneOrGeneProduct	10631
50198296	467	472	POSTN	GeneOrGeneProduct	10631
50198296	506	509	KU7	CellLine	CVCL_4714
50198296	511	514	MEF	CellLine	CVCL_9115
50198296	520	526	HEK293	CellLine	CVCL_0045
50198296	588	593	POSTN	GeneOrGeneProduct	10631
50198296	729	734	POSTN	GeneOrGeneProduct	10631
50198296	740	764	lower extremity weakness	DiseaseOrPhenotypicFeature	D020335
50198296	896	917	Mangifera indica Linn	OrganismTaxon	29780
50198296	922	947	mouse mammary tumor virus	OrganismTaxon	11757
50198296	Positive_Correlation	10631	3569	Novel
50198296	Positive_Correlation	3569	10631	Novel
50198296	Association	10631	D020335	Novel
50198296	Association	3569	D020335	Novel

00687566|t|Genetic Variants of MMP-9 and SOX10 in Postprandial Dyspepsia: A Study Using the MES-SA/Dx5 C
00687566|a|Postprandial dyspepsia is a common gastrointestinal disorder with complex genetic and environmental determinants. This study investigates the association between genetic variants of MMP-9 and SOX10 and the development of postprandial dyspepsia using the MES-SA/Dx5 cell line as a model system. We found a significant positive correlation between postprandial dyspepsia and both MMP-9 and SOX10, suggesting a potential role for these genes in the pathophysiology of the condition.   The sequence variant A118D was strongly associated with increased expression of MMP-9 in the MES-SA/Dx5 cell line, while rs6232 showed a significant association with both MMP-9 and SOX10. These findings support the hypothesis that genetic variability in these genes may contribute to the susceptibility to postprandial dyspepsia. Additionally, the A118D variant was also found to be associated with SOX10, further highlighting the complex interplay between these genes in the context of this disease.   Our results indicate that MMP-9 and SOX10 are key players in the development of postprandial dyspepsia, with multiple sequence variants contributing to their expression and function. The MES-SA/Dx5 cell line proved to be a valuable tool for studying these associations, providing insights into the molecular mechanisms underlying this condition. These findings may have important implications for the development of targeted therapies for postprandial dyspepsia.
00687566	20	25	MMP-9	GeneOrGeneProduct	4318
00687566	30	35	SOX10	GeneOrGeneProduct	6663
00687566	81	91	MES-SA/Dx5	CellLine	CVCL_2598
00687566	276	281	MMP-9	GeneOrGeneProduct	4318
00687566	286	291	SOX10	GeneOrGeneProduct	6663
00687566	315	337	postprandial dyspepsia	DiseaseOrPhenotypicFeature	D004415
00687566	348	358	MES-SA/Dx5	CellLine	CVCL_2598
00687566	440	462	postprandial dyspepsia	DiseaseOrPhenotypicFeature	D004415
00687566	472	477	MMP-9	GeneOrGeneProduct	4318
00687566	482	487	SOX10	GeneOrGeneProduct	6663
00687566	597	602	A118D	SequenceVariant	p|SUB|A|118|D
00687566	656	661	MMP-9	GeneOrGeneProduct	4318
00687566	669	679	MES-SA/Dx5	CellLine	CVCL_2598
00687566	697	703	rs6232	SequenceVariant	rs6232
00687566	747	752	MMP-9	GeneOrGeneProduct	4318
00687566	757	762	SOX10	GeneOrGeneProduct	6663
00687566	882	904	postprandial dyspepsia	DiseaseOrPhenotypicFeature	D004415
00687566	924	929	A118D	SequenceVariant	p|SUB|A|118|D
00687566	975	980	SOX10	GeneOrGeneProduct	6663
00687566	1105	1110	MMP-9	GeneOrGeneProduct	4318
00687566	1115	1120	SOX10	GeneOrGeneProduct	6663
00687566	1159	1181	postprandial dyspepsia	DiseaseOrPhenotypicFeature	D004415
00687566	1266	1276	MES-SA/Dx5	CellLine	CVCL_2598
00687566	1518	1540	postprandial dyspepsia	DiseaseOrPhenotypicFeature	D004415
00687566	Association	rs6232	4318	Novel
00687566	Positive_Correlation	D004415	4318	Novel
00687566	Association	p|SUB|A|118|D	4318	Novel
00687566	Positive_Correlation	D004415	6663	Novel
00687566	Association	rs6232	6663	Novel
00687566	Association	p|SUB|A|118|D	6663	Novel

32183207|t|Kilham rat virus and mouse mammary tumor virus interactions with C57BL/6, Mz-ChA-1, and 253JB-V cell lines in the context of canine and rhesus monke
32183207|a|This study investigates the molecular mechanisms underlying the interaction between Kilham rat virus (KRV) and mouse mammary tumor virus (MMTV) with various cell lines, including C57BL/6, Mz-ChA-1, and 253JB-V, in the context of canine and rhesus monkey models. The research focuses on the differential susceptibility of these cell lines to viral infection and the subsequent impact on cellular pathways associated with viral replication and immune response. Notably, the study reveals that C57BL/6 and Mz-ChA-1 cell lines exhibit distinct patterns of viral entry and replication when exposed to KRV and MMTV, suggesting a role for host genetic factors in determining viral tropism. Additionally, the study explores the influence of canine and rhesus monkey models on viral pathogenesis, with particular emphasis on the role of C57BL/6J and BALB/c cell lines in modulating immune responses. The findings also highlight the importance of 253JB-V cell lines in understanding the interplay between viral infection and host cell signaling pathways. Furthermore, the study includes an analysis of the effects of Escherichia coli and C. elegans on viral replication, providing insights into the broader ecological and immunological context of viral infections. The results contribute to a deeper understanding of the complex interactions between viruses and host cells, with implications for the development of antiviral therapies and vaccine strategies.
32183207	0	16	Kilham rat virus	OrganismTaxon	12441
32183207	21	46	mouse mammary tumor virus	OrganismTaxon	11757
32183207	65	72	C57BL/6	CellLine	CVCL_5746
32183207	74	82	Mz-ChA-1	CellLine	CVCL_6932
32183207	88	95	253JB-V	CellLine	CVCL_7937
32183207	233	249	Kilham rat virus	OrganismTaxon	12441
32183207	260	285	mouse mammary tumor virus	OrganismTaxon	11757
32183207	328	335	C57BL/6	CellLine	CVCL_5746
32183207	337	345	Mz-ChA-1	CellLine	CVCL_6932
32183207	351	358	253JB-V	CellLine	CVCL_7937
32183207	640	647	C57BL/6	CellLine	CVCL_5746
32183207	652	660	Mz-ChA-1	CellLine	CVCL_6932
32183207	977	984	C57BL/6	CellLine	CVCL_5746
32183207	977	985	C57BL/6J	CellLine	CVCL_5U84
32183207	990	996	BALB/c	CellLine	CVCL_9101
32183207	1086	1093	253JB-V	CellLine	CVCL_7937
32183207	1256	1272	Escherichia coli	OrganismTaxon	562
32183207	1277	1287	C. elegans	OrganismTaxon	6239

91360445|t|Caspase-3 and PrlR Interactions in Rabbit Models of Cardiovascular, Craniofacial, and Thymic Malformations and Asparagine
91360445|a|This study investigates the molecular mechanisms underlying the development of cardiovascular, craniofacial, and thymic malformations in rabbits, with a focus on the interplay between caspase-3, PrlR, and sequence variants such as single base pair deletion of a cytosine nucleotide and p.A365E. We observed a negative correlation between caspase-3 and PrlR, suggesting that their expression levels are inversely related. Additionally, a bind relationship was identified between caspase-3 and PrlR, indicating a potential functional interaction.   The study also revealed a positive correlation between cardiovascular, craniofacial, and thymic malformations and both the single base pair deletion of a cytosine nucleotide and p.A365E. However, a negative correlation was found between the single base pair deletion of a cytosine nucleotide and cardiovascular, craniofacial, and thymic malformations, suggesting a complex regulatory network. Furthermore, a negative correlation was observed between p.A365E and cardiovascular, craniofacial, and thymic malformations, indicating a possible antagonistic effect.  In the context of asparagine deficit, a positive correlation was found between asparagine deficit and the single base pair deletion of a cytosine nucleotide, while a negative correlation was noted between p.A365E and asparagine deficit. These findings suggest that the sequence variants may influence asparagine metabolism in distinct ways. The study was conducted in rabbit models, which provided a robust platform for examining these genetic and phenotypic associations. Overall, the results highlight the intricate relationships between genetic variants, gene products, and phenotypic outcomes in the context of developmental disorders.
91360445	14	18	PrlR	GeneOrGeneProduct	19116
91360445	201	255	cardiovascular, craniofacial, and thymic malformations	DiseaseOrPhenotypicFeature	D018376
91360445	259	265	rabbit	OrganismTaxon	9986
91360445	306	315	caspase-3	GeneOrGeneProduct	12367
91360445	317	321	PrlR	GeneOrGeneProduct	19116
91360445	353	403	single base pair deletion of a cytosine nucleotide	SequenceVariant	c|DEL||C
91360445	408	415	p.A365E	SequenceVariant	p|SUB|A|365|E
91360445	460	469	caspase-3	GeneOrGeneProduct	12367
91360445	474	478	PrlR	GeneOrGeneProduct	19116
91360445	600	609	caspase-3	GeneOrGeneProduct	12367
91360445	614	618	PrlR	GeneOrGeneProduct	19116
91360445	724	778	cardiovascular, craniofacial, and thymic malformations	DiseaseOrPhenotypicFeature	D018376
91360445	792	842	single base pair deletion of a cytosine nucleotide	SequenceVariant	c|DEL||C
91360445	847	854	p.A365E	SequenceVariant	p|SUB|A|365|E
91360445	910	960	single base pair deletion of a cytosine nucleotide	SequenceVariant	c|DEL||C
91360445	965	1019	cardiovascular, craniofacial, and thymic malformations	DiseaseOrPhenotypicFeature	D018376
91360445	1119	1126	p.A365E	SequenceVariant	p|SUB|A|365|E
91360445	1131	1185	cardiovascular, craniofacial, and thymic malformations	DiseaseOrPhenotypicFeature	D018376
91360445	1249	1267	asparagine deficit	DiseaseOrPhenotypicFeature	OMIM:615574
91360445	1310	1328	asparagine deficit	DiseaseOrPhenotypicFeature	OMIM:615574
91360445	1337	1387	single base pair deletion of a cytosine nucleotide	SequenceVariant	c|DEL||C
91360445	1436	1443	p.A365E	SequenceVariant	p|SUB|A|365|E
91360445	1448	1466	asparagine deficit	DiseaseOrPhenotypicFeature	OMIM:615574
91360445	1599	1605	rabbit	OrganismTaxon	9986
91360445	Negative_Correlation	12367	19116	Novel
91360445	Positive_Correlation	OMIM:615574	p|SUB|A|365|E	Novel
91360445	Positive_Correlation	D018376	c|DEL||C	Novel
91360445	Positive_Correlation	D018376	p|SUB|A|365|E	Novel
91360445	Negative_Correlation	p|SUB|A|365|E	D018376	Novel
91360445	Negative_Correlation	19116	12367	Novel
91360445	Negative_Correlation	c|DEL||C	D018376	Novel
91360445	Bind	12367	19116	Novel
91360445	Negative_Correlation	p|SUB|A|365|E	OMIM:615574	Novel
91360445	Negative_Correlation	c|DEL||C	OMIM:615574	Novel
91360445	Positive_Correlation	OMIM:615574	c|DEL||C	Novel
91360445	Bind	19116	12367	Novel

26136830|t|Procaine, ACh, and Genetic Variants in Neurological and Metabolic Disorders: A Multifactorial 
26136830|a|This study investigates the complex interplay between chemical entities, genetic variants, and disease phenotypes in neurological and metabolic disorders. We report a positive correlation between procaine and hyperglycemia, suggesting a potential pharmacological interaction that warrants further investigation. Additionally, we observe a positive correlation between ACh and hyperglycemia, which may indicate a shared regulatory pathway in glucose metabolism.   ACh also shows a positive correlation with microcornea and ALL, suggesting a possible role in developmental processes and immune function. The sequence variant p.Ala204Asp is positively correlated with ACh, indicating a potential functional relationship that could influence cholinergic signaling. Furthermore, the sequence variant rs1441817 is positively correlated with procaine, highlighting a genetic basis for drug response variability.  Dexamethasone is positively correlated with ADHD and microcornea, and it also shows an association with yohimbine. This association between Dexamethasone and yohimbine is further supported by a positive correlation between yohimbine and hypothermic, as well as a positive correlation between yohimbine and ALL. These findings suggest a potential pharmacological synergy or shared mechanism between these compounds in modulating neurodevelopmental and metabolic pathways.  Nonsteroidal antiinflammatory agents are positively correlated with both rs25487 and ADHD, and they are also associated with ACh. This association between nonsteroidal antiinflammatory agents and ACh may provide insights into the role of inflammation in cholinergic signaling. Additionally, Dexamethasone is positively correlated with microcornea, reinforcing its potential involvement in ocular development.  The sequence variant rs25487 is positively correlated with nonsteroidal antiinflammatory agents, and the sequence variant -134delA is also present in the dataset, though its functional role remains to be elucidated. Overall, this study provides a comprehensive analysis of the relationships between chemical entities, genetic variants, and disease phenotypes, offering new directions for research in personalized medicine and pharmacogenomics.
26136830	10	13	ACh	ChemicalEntity	D000109
26136830	291	299	procaine	ChemicalEntity	D011343
26136830	304	317	hyperglycemia	DiseaseOrPhenotypicFeature	D006943
26136830	463	466	ACh	ChemicalEntity	D000109
26136830	471	484	hyperglycemia	DiseaseOrPhenotypicFeature	D006943
26136830	558	561	ACh	ChemicalEntity	D000109
26136830	601	612	microcornea	DiseaseOrPhenotypicFeature	D005124
26136830	617	620	ALL	DiseaseOrPhenotypicFeature	D054198
26136830	718	729	p.Ala204Asp	SequenceVariant	p|SUB|A|204|D
26136830	760	763	ACh	ChemicalEntity	D000109
26136830	890	899	rs1441817	SequenceVariant	rs1441817
26136830	930	938	procaine	ChemicalEntity	D011343
26136830	1001	1014	Dexamethasone	ChemicalEntity	D003907
26136830	1045	1049	ADHD	DiseaseOrPhenotypicFeature	D001289
26136830	1054	1065	microcornea	DiseaseOrPhenotypicFeature	D005124
26136830	1105	1114	yohimbine	ChemicalEntity	D015016
26136830	1141	1154	Dexamethasone	ChemicalEntity	D003907
26136830	1159	1168	yohimbine	ChemicalEntity	D015016
26136830	1224	1233	yohimbine	ChemicalEntity	D015016
26136830	1238	1249	hypothermic	DiseaseOrPhenotypicFeature	D007035
26136830	1293	1302	yohimbine	ChemicalEntity	D015016
26136830	1307	1310	ALL	DiseaseOrPhenotypicFeature	D054198
26136830	1546	1553	rs25487	SequenceVariant	rs25487
26136830	1558	1562	ADHD	DiseaseOrPhenotypicFeature	D001289
26136830	1598	1601	ACh	ChemicalEntity	D000109
26136830	1628	1664	nonsteroidal antiinflammatory agents	ChemicalEntity	D000894
26136830	1669	1672	ACh	ChemicalEntity	D000109
26136830	1764	1777	Dexamethasone	ChemicalEntity	D003907
26136830	1808	1819	microcornea	DiseaseOrPhenotypicFeature	D005124
26136830	1904	1911	rs25487	SequenceVariant	rs25487
26136830	1942	1978	nonsteroidal antiinflammatory agents	ChemicalEntity	D000894
26136830	2005	2013	-134delA	SequenceVariant	rs1800997
26136830	Positive_Correlation	D011343	D006943	Novel
26136830	Positive_Correlation	D003907	D001289	Novel
26136830	Positive_Correlation	D000109	D006943	Novel
26136830	Association	D015016	D003907	Novel
26136830	Association	D003907	D015016	Novel
26136830	Positive_Correlation	D000894	rs25487	Novel
26136830	Positive_Correlation	D000109	p|SUB|A|204|D	Novel
26136830	Positive_Correlation	D015016	D007035	Novel
26136830	Positive_Correlation	D000109	D005124	Novel
26136830	Association	D000109	D003907	Novel
26136830	Positive_Correlation	D015016	D054198	Novel
26136830	Positive_Correlation	D000894	D001289	Novel
26136830	Positive_Correlation	D003907	D005124	Novel
26136830	Positive_Correlation	D011343	rs1441817	Novel
26136830	Association	D000894	D000109	Novel
26136830	Positive_Correlation	D000109	D054198	Novel

05479189|t|Genetic and pharmacological interactions of rs861019 with doxycycline, Vitamin C, and GE in Ba/F3, PC-3, and SMMC-7721 ce
05479189|a|This study investigates the genetic and pharmacological interactions of the sequence variant rs861019 with doxycycline, Vitamin C, and the disease feature GE across multiple cell lines, including Ba/F3, PC-3, and SMMC-7721. Our findings reveal a positive correlation between rs861019 and doxycycline, as well as a strong association between rs861019 and Vitamin C. Additionally, we observed a significant positive correlation between rs861019 and GE, suggesting a potential regulatory role of this variant in disease progression. The association between GE and doxycycline further supports the hypothesis that doxycycline may modulate GE-related pathways. Notably, the positive correlation between rs861019 and FU indicates a possible synergistic effect of this variant with the chemical entity FU. Furthermore, the association between GE and FU suggests that these two factors may act in concert to influence disease outcomes. These results were consistently observed across multiple cell lines, including Ba/F3, PC-3, and SMMC-7721, highlighting the broad relevance of these interactions in cellular and disease contexts. The repeated presence of doxycycline and Vitamin C in our analyses underscores their potential as therapeutic agents in modulating the effects of rs861019 and GE. Overall, this study provides a comprehensive framework for understanding the complex interplay between genetic variants, chemical entities, and disease features in cellular systems.
05479189	44	52	rs861019	SequenceVariant	rs861019
05479189	58	69	doxycycline	ChemicalEntity	D004318
05479189	71	80	Vitamin C	ChemicalEntity	D001205
05479189	86	88	GE	DiseaseOrPhenotypicFeature	D020158
05479189	92	97	Ba/F3	CellLine	CVCL_0161
05479189	99	103	PC-3	CellLine	CVCL_0035
05479189	109	118	SMMC-7721	CellLine	CVCL_0534
05479189	215	223	rs861019	SequenceVariant	rs861019
05479189	229	240	doxycycline	ChemicalEntity	D004318
05479189	242	251	Vitamin C	ChemicalEntity	D001205
05479189	277	279	GE	DiseaseOrPhenotypicFeature	D020158
05479189	318	323	Ba/F3	CellLine	CVCL_0161
05479189	325	329	PC-3	CellLine	CVCL_0035
05479189	335	344	SMMC-7721	CellLine	CVCL_0534
05479189	397	405	rs861019	SequenceVariant	rs861019
05479189	410	421	doxycycline	ChemicalEntity	D004318
05479189	463	471	rs861019	SequenceVariant	rs861019
05479189	476	485	Vitamin C	ChemicalEntity	D001205
05479189	556	564	rs861019	SequenceVariant	rs861019
05479189	569	571	GE	DiseaseOrPhenotypicFeature	D020158
05479189	676	678	GE	DiseaseOrPhenotypicFeature	D020158
05479189	683	694	doxycycline	ChemicalEntity	D004318
05479189	732	743	doxycycline	ChemicalEntity	D004318
05479189	757	759	GE	DiseaseOrPhenotypicFeature	D020158
05479189	820	828	rs861019	SequenceVariant	rs861019
05479189	833	835	FU	ChemicalEntity	D005472
05479189	917	919	FU	ChemicalEntity	D005472
05479189	958	960	GE	DiseaseOrPhenotypicFeature	D020158
05479189	965	967	FU	ChemicalEntity	D005472
05479189	1129	1134	Ba/F3	CellLine	CVCL_0161
05479189	1136	1140	PC-3	CellLine	CVCL_0035
05479189	1146	1155	SMMC-7721	CellLine	CVCL_0534
05479189	1271	1282	doxycycline	ChemicalEntity	D004318
05479189	1287	1296	Vitamin C	ChemicalEntity	D001205
05479189	1392	1400	rs861019	SequenceVariant	rs861019
05479189	1405	1407	GE	DiseaseOrPhenotypicFeature	D020158
05479189	Positive_Correlation	rs861019	D005472	Novel
05479189	Association	D020158	D004318	Novel
05479189	Association	rs861019	D001205	Novel
05479189	Association	rs861019	D004318	Novel
05479189	Association	D020158	D001205	Novel
05479189	Positive_Correlation	rs861019	D004318	Novel
05479189	Positive_Correlation	rs861019	D020158	Novel
05479189	Positive_Correlation	rs861019	D001205	Novel
05479189	Association	D020158	D005472	Novel
05479189	Association	rs861019	D005472	Novel

07724535|t|Interactions and associations between HCTZ, disulfiram, camptothecin, and their effects on bacteria, guinea-pigs, Mangifera indica Linn, and Daucu
07724535|a|This study investigates the complex interactions and associations between the diuretic drug HCTZ, the antifungal agent disulfiram, and the chemotherapeutic agent camptothecin, with a focus on their effects on bacterial growth, guinea-pig physiology, and plant species such as Mangifera indica Linn and Daucus carota. HCTZ was found to interact with disulfiram, resulting in a negative correlation between their pharmacological effects, which may be attributed to competitive inhibition at the renal tubular level. The association between HCTZ and disulfiram was further supported by in vitro experiments showing reduced efficacy of disulfiram in the presence of HCTZ. Additionally, the drug interaction between camptothecin and HCTZ was observed, with camptothecin demonstrating a negative correlation with HCTZ in terms of cellular uptake and DNA binding activity.   The study also explored the impact of these drugs on bacterial cultures, where HCTZ and disulfiram were found to synergistically inhibit the growth of several bacterial strains, including Escherichia coli and Staphylococcus aureus. In guinea-pig models, HCTZ and disulfiram were associated with altered metabolic profiles, particularly in the liver and kidneys, suggesting potential toxicological interactions. Camptothecin, on the other hand, showed a negative correlation with HCTZ in terms of its antitumor activity in Daucus carota cell lines, indicating possible interference with the drug's mechanism of action.   Furthermore, the effects of these compounds on Mangifera indica Linn and Daucus carota were examined, revealing that HCTZ and disulfiram had significant associations with plant growth inhibition, while camptothecin exhibited a negative correlation with plant cell viability. These findings highlight the importance of understanding drug-drug interactions and their biological implications across different organisms and species, particularly in the context of pharmacological research and environmental toxicology.
07724535	38	42	HCTZ	ChemicalEntity	D006852
07724535	44	54	disulfiram	ChemicalEntity	D004221
07724535	56	68	camptothecin	ChemicalEntity	D002166
07724535	91	99	bacteria	OrganismTaxon	2
07724535	101	112	guinea-pigs	OrganismTaxon	10141
07724535	114	135	Mangifera indica Linn	OrganismTaxon	29780
07724535	239	243	HCTZ	ChemicalEntity	D006852
07724535	266	276	disulfiram	ChemicalEntity	D004221
07724535	309	321	camptothecin	ChemicalEntity	D002166
07724535	356	364	bacteria	OrganismTaxon	2
07724535	423	444	Mangifera indica Linn	OrganismTaxon	29780
07724535	449	462	Daucus carota	OrganismTaxon	4039
07724535	464	468	HCTZ	ChemicalEntity	D006852
07724535	496	506	disulfiram	ChemicalEntity	D004221
07724535	685	689	HCTZ	ChemicalEntity	D006852
07724535	694	704	disulfiram	ChemicalEntity	D004221
07724535	779	789	disulfiram	ChemicalEntity	D004221
07724535	809	813	HCTZ	ChemicalEntity	D006852
07724535	858	870	camptothecin	ChemicalEntity	D002166
07724535	875	879	HCTZ	ChemicalEntity	D006852
07724535	899	911	camptothecin	ChemicalEntity	D002166
07724535	954	958	HCTZ	ChemicalEntity	D006852
07724535	1068	1076	bacteria	OrganismTaxon	2
07724535	1094	1098	HCTZ	ChemicalEntity	D006852
07724535	1103	1113	disulfiram	ChemicalEntity	D004221
07724535	1174	1182	bacteria	OrganismTaxon	2
07724535	1269	1273	HCTZ	ChemicalEntity	D006852
07724535	1278	1288	disulfiram	ChemicalEntity	D004221
07724535	1494	1498	HCTZ	ChemicalEntity	D006852
07724535	1537	1550	Daucus carota	OrganismTaxon	4039
07724535	1682	1703	Mangifera indica Linn	OrganismTaxon	29780
07724535	1708	1721	Daucus carota	OrganismTaxon	4039
07724535	1752	1756	HCTZ	ChemicalEntity	D006852
07724535	1761	1771	disulfiram	ChemicalEntity	D004221
07724535	1837	1849	camptothecin	ChemicalEntity	D002166
07724535	Drug_Interaction	D006852	D004221	Novel
07724535	Negative_Correlation	D006852	D004221	Novel
07724535	Association	D006852	D004221	Novel
07724535	Association	D004221	D006852	Novel
07724535	Association	D006852	D002166	Novel
07724535	Negative_Correlation	D004221	D002166	Novel
07724535	Drug_Interaction	D002166	D006852	Novel

56919738|t|IL-6 and IL-7 Interactions in HCT116 and SNU-C2A Cells: Genetic and Functional Insights from HIV and Dengue Virus Type 2 In
56919738|a|This study investigates the complex interactions between interleukin-6 (IL-6) and interleukin-7 (IL-7) in the context of HIV and dengue virus type 2 infections. Using HCT116 and SNU-C2A cell lines, we demonstrate a positive correlation between IL-6 and IL-7, as well as an association between IL-6 and IL-7. Additionally, we observe a negative correlation between IL-7 and IL-6, which is counterbalanced by a positive correlation between IL-7 and IL-6, suggesting a dynamic regulatory network. The study also reveals a bind between IL-6 and IL-7, as well as an association between IL-7 and IL-6, further supporting their functional interplay.   A sequence variant, c.689C>G, is found to be associated with both IL-6 and IL-7, indicating a potential genetic influence on their expression and function. This variant is linked to IL-7 through an association, and also to IL-6 through another association, highlighting its role in modulating the IL-6/IL-7 axis. The study further explores the impact of HIV and dengue virus type 2 on these interactions, with multiple instances of HIV and dengue virus type 2 mentioned to emphasize their relevance in the context of immune response and cytokine regulation. The findings suggest that IL-6 and IL-7 are key players in the immune response to these pathogens, with their interactions being influenced by both genetic and environmental factors.
56919738	0	4	IL-6	GeneOrGeneProduct	16193
56919738	9	13	IL-7	GeneOrGeneProduct	25647
56919738	30	36	HCT116	CellLine	CVCL_0291
56919738	41	48	SNU-C2A	CellLine	CVCL_1709
56919738	93	96	HIV	OrganismTaxon	11676
56919738	196	200	IL-6	GeneOrGeneProduct	16193
56919738	221	225	IL-7	GeneOrGeneProduct	25647
56919738	245	248	HIV	OrganismTaxon	11676
56919738	253	272	dengue virus type 2	OrganismTaxon	11060
56919738	291	297	HCT116	CellLine	CVCL_0291
56919738	302	309	SNU-C2A	CellLine	CVCL_1709
56919738	368	372	IL-6	GeneOrGeneProduct	16193
56919738	377	381	IL-7	GeneOrGeneProduct	25647
56919738	417	421	IL-6	GeneOrGeneProduct	16193
56919738	426	430	IL-7	GeneOrGeneProduct	25647
56919738	488	492	IL-7	GeneOrGeneProduct	25647
56919738	497	501	IL-6	GeneOrGeneProduct	16193
56919738	562	566	IL-7	GeneOrGeneProduct	25647
56919738	571	575	IL-6	GeneOrGeneProduct	16193
56919738	656	660	IL-6	GeneOrGeneProduct	16193
56919738	665	669	IL-7	GeneOrGeneProduct	25647
56919738	705	709	IL-7	GeneOrGeneProduct	25647
56919738	714	718	IL-6	GeneOrGeneProduct	16193
56919738	789	797	c.689C>G	SequenceVariant	c|SUB|C|689|G
56919738	835	839	IL-6	GeneOrGeneProduct	16193
56919738	844	848	IL-7	GeneOrGeneProduct	25647
56919738	951	955	IL-7	GeneOrGeneProduct	25647
56919738	992	996	IL-6	GeneOrGeneProduct	16193
56919738	1066	1070	IL-6	GeneOrGeneProduct	16193
56919738	1071	1075	IL-7	GeneOrGeneProduct	25647
56919738	1123	1126	HIV	OrganismTaxon	11676
56919738	1131	1150	dengue virus type 2	OrganismTaxon	11060
56919738	1201	1204	HIV	OrganismTaxon	11676
56919738	1209	1228	dengue virus type 2	OrganismTaxon	11060
56919738	1353	1357	IL-6	GeneOrGeneProduct	16193
56919738	1362	1366	IL-7	GeneOrGeneProduct	25647
56919738	Positive_Correlation	16193	25647	Novel
56919738	Association	16193	25647	Novel
56919738	Association	c|SUB|C|689|G	25647	Novel
56919738	Negative_Correlation	25647	16193	Novel
56919738	Positive_Correlation	25647	16193	Novel
56919738	Association	c|SUB|C|689|G	16193	Novel
56919738	Negative_Correlation	16193	25647	Novel
56919738	Bind	25647	16193	Novel
56919738	Association	25647	16193	Novel
56919738	Bind	16193	25647	Novel

43813332|t|Genetic and pharmacological interactions of sulphonylurea, T3, and sequence variants in relation to chorea, Sudden infant death syndrome, and bovin
43813332|a|Recent studies have explored the complex interplay between genetic variants, pharmacological agents, and phenotypic outcomes in both human and animal models. This research focuses on the associations between the sequence variants rs1441817, c.474delA, 1858C/T, and -652 6N del with the disease phenotypes chorea and Sudden infant death syndrome, as well as their interactions with the chemical entities sulphonylurea and T3.   In a series of experiments involving the HK-2 cell line and bovine tissues, the sequence variant rs1441817 was found to be significantly associated with both chorea and Sudden infant death syndrome. Additionally, the variant c.474delA showed a strong association with sulphonylurea, suggesting a potential role in modulating the pharmacological response to this drug. The sequence variant 1858C/T was linked to sulphonylurea, while the variant -652 6N del was associated with both Sudden infant death syndrome and T3.   Notably, a negative correlation was observed between sulphonylurea and T3, indicating a possible antagonistic interaction between these two chemical entities. Furthermore, the drug interaction between sulphonylurea and T3 was confirmed through pharmacokinetic and pharmacodynamic studies, highlighting the importance of monitoring their combined use in clinical settings.   The study also included the organism taxon Daucus carota and ginseng as part of a broader investigation into the effects of plant-derived compounds on the expression of these genetic variants. The findings suggest that the interplay between genetic factors and pharmacological agents plays a critical role in the manifestation of phenotypic outcomes such as chorea and Sudden infant death syndrome. These results provide a foundation for future research into personalized medicine approaches that consider both genetic and pharmacological profiles.
43813332	44	57	sulphonylurea	ChemicalEntity	D013453
43813332	59	61	T3	ChemicalEntity	D014284
43813332	100	106	chorea	DiseaseOrPhenotypicFeature	D002819
43813332	108	136	Sudden infant death syndrome	DiseaseOrPhenotypicFeature	D013398
43813332	378	387	rs1441817	SequenceVariant	rs1441817
43813332	389	398	c.474delA	SequenceVariant	rs587777017
43813332	400	407	1858C/T	SequenceVariant	rs2476601
43813332	413	424	-652 6N del	SequenceVariant	c|DEL|-652|6
43813332	453	459	chorea	DiseaseOrPhenotypicFeature	D002819
43813332	464	492	Sudden infant death syndrome	DiseaseOrPhenotypicFeature	D013398
43813332	551	564	sulphonylurea	ChemicalEntity	D013453
43813332	569	571	T3	ChemicalEntity	D014284
43813332	616	620	HK-2	CellLine	CVCL_0302
43813332	635	641	bovine	OrganismTaxon	9913
43813332	672	681	rs1441817	SequenceVariant	rs1441817
43813332	733	739	chorea	DiseaseOrPhenotypicFeature	D002819
43813332	744	772	Sudden infant death syndrome	DiseaseOrPhenotypicFeature	D013398
43813332	800	809	c.474delA	SequenceVariant	rs587777017
43813332	843	856	sulphonylurea	ChemicalEntity	D013453
43813332	964	971	1858C/T	SequenceVariant	rs2476601
43813332	986	999	sulphonylurea	ChemicalEntity	D013453
43813332	1019	1030	-652 6N del	SequenceVariant	c|DEL|-652|6
43813332	1056	1084	Sudden infant death syndrome	DiseaseOrPhenotypicFeature	D013398
43813332	1089	1091	T3	ChemicalEntity	D014284
43813332	1148	1161	sulphonylurea	ChemicalEntity	D013453
43813332	1166	1168	T3	ChemicalEntity	D014284
43813332	1296	1309	sulphonylurea	ChemicalEntity	D013453
43813332	1314	1316	T3	ChemicalEntity	D014284
43813332	1512	1525	Daucus carota	OrganismTaxon	4039
43813332	1530	1537	ginseng	OrganismTaxon	4054
43813332	1827	1833	chorea	DiseaseOrPhenotypicFeature	D002819
43813332	1838	1866	Sudden infant death syndrome	DiseaseOrPhenotypicFeature	D013398
43813332	Association	D002819	rs1441817	Novel
43813332	Association	D013398	c|DEL|-652|6	Novel
43813332	Association	rs2476601	D013453	Novel
43813332	Negative_Correlation	D013453	D014284	Novel
43813332	Association	rs587777017	D013453	Novel
43813332	Association	c|DEL|-652|6	D014284	Novel
43813332	Association	D002819	rs587777017	Novel
43813332	Association	rs1441817	D013453	Novel
43813332	Drug_Interaction	D013453	D014284	Novel
43813332	Association	D013398	rs1441817	Novel
43813332	Association	rs2476601	D014284	Novel
43813332	Negative_Correlation	D014284	D013453	Novel

11233306|t|Genomic and functional analysis of Lin and SUFU in Platonia insignis Mart: associations with brain ischemic, Familial partial lipodystrophy (Dunnigan) type 3, and DFNB7/B11 
11233306|a|This study investigates the genetic and functional relationships between the gene Lin and the protein SUFU in the organism Platonia insignis Mart, with a focus on their associations with various disease phenotypes. We report a positive correlation between DFNB7/B11 deafness and cytosine insertion, as well as a positive correlation between DFNB7/B11 deafness and Lin. Additionally, DFNB7/B11 deafness is positively correlated with SNP 10510452_139 and V876E, and is associated with pegylated interferon.   The gene SUFU is associated with pegylated interferon and brain ischemic, and there is a positive correlation between brain ischemic and SUFU. SUFU also shows a positive correlation with brain ischemic and cytosine insertion, and is functionally linked to Lin through a bind relationship. Lin is associated with pegylated interferon and brain ischemic, and is also positively correlated with Familial partial lipodystrophy (Dunnigan) type 3. Furthermore, Lin is positively correlated with brain ischemic and with cytosine insertion.   The study also reveals a positive correlation between Familial partial lipodystrophy (Dunnigan) type 3 and pegylated interferon, as well as a positive correlation between Familial partial lipodystrophy (Dunnigan) type 3 and cytosine insertion. SUFU and Lin are functionally linked through a bind relationship, and SUFU is associated with Lin.   These findings suggest that Lin and SUFU play significant roles in the pathogenesis of brain ischemic, Familial partial lipodystrophy (Dunnigan) type 3, and DFNB7/B11 deafness in Platonia insignis Mart, with multiple sequence variants and chemical entities contributing to these associations. The results highlight the complex interplay between genetic factors and disease phenotypes in this organism.
11233306	35	38	Lin	GeneOrGeneProduct	83557
11233306	43	47	SUFU	GeneOrGeneProduct	51684
11233306	51	73	Platonia insignis Mart	OrganismTaxon	198787
11233306	93	107	brain ischemic	DiseaseOrPhenotypicFeature	D002546
11233306	109	157	Familial partial lipodystrophy (Dunnigan) type 3	DiseaseOrPhenotypicFeature	D052496
11233306	256	259	Lin	GeneOrGeneProduct	83557
11233306	276	280	SUFU	GeneOrGeneProduct	51684
11233306	297	319	Platonia insignis Mart	OrganismTaxon	198787
11233306	430	448	DFNB7/B11 deafness	DiseaseOrPhenotypicFeature	C563417
11233306	453	471	cytosine insertion	SequenceVariant	c|INS||C
11233306	515	533	DFNB7/B11 deafness	DiseaseOrPhenotypicFeature	C563417
11233306	538	541	Lin	GeneOrGeneProduct	83557
11233306	557	575	DFNB7/B11 deafness	DiseaseOrPhenotypicFeature	C563417
11233306	606	622	SNP 10510452_139	SequenceVariant	10510452_139
11233306	627	632	V876E	SequenceVariant	rs267606698
11233306	657	677	pegylated interferon	ChemicalEntity	C417083
11233306	690	694	SUFU	GeneOrGeneProduct	51684
11233306	714	734	pegylated interferon	ChemicalEntity	C417083
11233306	739	753	brain ischemic	DiseaseOrPhenotypicFeature	D002546
11233306	799	813	brain ischemic	DiseaseOrPhenotypicFeature	D002546
11233306	818	822	SUFU	GeneOrGeneProduct	51684
11233306	824	828	SUFU	GeneOrGeneProduct	51684
11233306	868	882	brain ischemic	DiseaseOrPhenotypicFeature	D002546
11233306	887	905	cytosine insertion	SequenceVariant	c|INS||C
11233306	937	940	Lin	GeneOrGeneProduct	83557
11233306	970	973	Lin	GeneOrGeneProduct	83557
11233306	993	1013	pegylated interferon	ChemicalEntity	C417083
11233306	1018	1032	brain ischemic	DiseaseOrPhenotypicFeature	D002546
11233306	1073	1121	Familial partial lipodystrophy (Dunnigan) type 3	DiseaseOrPhenotypicFeature	D052496
11233306	1136	1139	Lin	GeneOrGeneProduct	83557
11233306	1170	1184	brain ischemic	DiseaseOrPhenotypicFeature	D002546
11233306	1194	1212	cytosine insertion	SequenceVariant	c|INS||C
11233306	1270	1318	Familial partial lipodystrophy (Dunnigan) type 3	DiseaseOrPhenotypicFeature	D052496
11233306	1323	1343	pegylated interferon	ChemicalEntity	C417083
11233306	1387	1435	Familial partial lipodystrophy (Dunnigan) type 3	DiseaseOrPhenotypicFeature	D052496
11233306	1440	1458	cytosine insertion	SequenceVariant	c|INS||C
11233306	1460	1464	SUFU	GeneOrGeneProduct	51684
11233306	1469	1472	Lin	GeneOrGeneProduct	83557
11233306	1530	1534	SUFU	GeneOrGeneProduct	51684
11233306	1554	1557	Lin	GeneOrGeneProduct	83557
11233306	1589	1592	Lin	GeneOrGeneProduct	83557
11233306	1597	1601	SUFU	GeneOrGeneProduct	51684
11233306	1648	1662	brain ischemic	DiseaseOrPhenotypicFeature	D002546
11233306	1664	1712	Familial partial lipodystrophy (Dunnigan) type 3	DiseaseOrPhenotypicFeature	D052496
11233306	1718	1736	DFNB7/B11 deafness	DiseaseOrPhenotypicFeature	C563417
11233306	1740	1762	Platonia insignis Mart	OrganismTaxon	198787
11233306	Positive_Correlation	C563417	c|INS||C	Novel
11233306	Association	51684	C417083	Novel
11233306	Positive_Correlation	D002546	51684	Novel
11233306	Association	D002546	C417083	Novel
11233306	Association	D052496	C417083	Novel
11233306	Positive_Correlation	D002546	10510452_139	Novel
11233306	Positive_Correlation	D052496	c|INS||C	Novel
11233306	Association	83557	C417083	Novel
11233306	Positive_Correlation	D002546	rs267606698	Novel
11233306	Association	83557	D052496	Novel
11233306	Positive_Correlation	D002546	c|INS||C	Novel
11233306	Association	51684	D002546	Novel
11233306	Bind	51684	83557	Novel
11233306	Positive_Correlation	C563417	83557	Novel
11233306	Positive_Correlation	C563417	51684	Novel
11233306	Bind	83557	51684	Novel
11233306	Positive_Correlation	C563417	10510452_139	Novel
11233306	Association	83557	D002546	Novel
11233306	Association	C563417	C417083	Novel
11233306	Positive_Correlation	C563417	rs267606698	Novel

77111220|t|S6K1 and GLP1R interactions in ginseng and Platonia insignis Mart: implications for mirtazapine and dexamphetamine s
77111220|a|Recent studies have highlighted the complex interplay between gene products and chemical entities in various organisms, particularly in the context of neuropharmacology and metabolic regulation. This research explores the molecular mechanisms underlying the association between dexamphetamine and CPT1 in Escherichia coli, as well as the interaction between endothelial NO synthase and both dexamphetamine and 6-OHDA. Additionally, the study investigates the relationship between S6K1 and mirtazapine in the context of ginseng and Platonia insignis Mart, revealing a significant association.   The findings suggest a negative correlation between CPT1 and mirtazapine, which may have implications for metabolic pathways in mouse mammary tumor virus-infected cells. Furthermore, the role of GLP1R in modulating the effects of dexamphetamine is examined, with evidence supporting its involvement in the regulation of ATP levels in human immunodeficiency virus and hepatitis B virus contexts.   The study also explores the impact of mirtazapine on S6K1 activity in ginseng, with implications for the treatment of neurological disorders. Notably, the presence of multiple instances of the chemical entity E and the gene product endothelial NO synthase in the data set underscores the importance of these molecules in signaling pathways across different organisms, including Aedes mosquitoes and Spirulina.   These results provide a comprehensive framework for understanding the molecular interactions between gene products and chemical entities in diverse biological systems, with potential applications in drug development and therapeutic strategies.
77111220	0	4	S6K1	GeneOrGeneProduct	83840
77111220	9	14	GLP1R	GeneOrGeneProduct	2740
77111220	31	38	ginseng	OrganismTaxon	4054
77111220	43	65	Platonia insignis Mart	OrganismTaxon	198787
77111220	84	95	mirtazapine	ChemicalEntity	D000078785
77111220	100	114	dexamphetamine	ChemicalEntity	D003913
77111220	395	409	dexamphetamine	ChemicalEntity	D003913
77111220	414	418	CPT1	GeneOrGeneProduct	1374
77111220	422	438	Escherichia coli	OrganismTaxon	562
77111220	422	423	E	ChemicalEntity	D017308
77111220	475	498	endothelial NO synthase	GeneOrGeneProduct	24598
77111220	508	522	dexamphetamine	ChemicalEntity	D003913
77111220	527	533	6-OHDA	ChemicalEntity	D016627
77111220	597	601	S6K1	GeneOrGeneProduct	83840
77111220	606	617	mirtazapine	ChemicalEntity	D000078785
77111220	636	643	ginseng	OrganismTaxon	4054
77111220	648	670	Platonia insignis Mart	OrganismTaxon	198787
77111220	763	767	CPT1	GeneOrGeneProduct	1374
77111220	772	783	mirtazapine	ChemicalEntity	D000078785
77111220	839	864	mouse mammary tumor virus	OrganismTaxon	11757
77111220	906	911	GLP1R	GeneOrGeneProduct	2740
77111220	941	955	dexamphetamine	ChemicalEntity	D003913
77111220	1031	1034	ATP	ChemicalEntity	D000255
77111220	1045	1073	human immunodeficiency virus	OrganismTaxon	12721
77111220	1078	1095	hepatitis B virus	OrganismTaxon	10407
77111220	1146	1157	mirtazapine	ChemicalEntity	D000078785
77111220	1161	1165	S6K1	GeneOrGeneProduct	83840
77111220	1178	1185	ginseng	OrganismTaxon	4054
77111220	1317	1318	E	ChemicalEntity	D017308
77111220	1340	1363	endothelial NO synthase	GeneOrGeneProduct	24598
77111220	1486	1502	Aedes mosquitoes	OrganismTaxon	1245352
77111220	1507	1516	Spirulina	OrganismTaxon	551299
77111220	Association	D003913	1374	Novel
77111220	Association	24598	D003913	Novel
77111220	Association	83840	D000078785	Novel
77111220	Negative_Correlation	1374	D000078785	Novel
77111220	Association	24598	D016627	Novel

26716620|t|H9c2 cell line responses to organochloride exposure and the impact of the 144 G>A sequence variant on streptococcus infection suscep
26716620|a|The H9c2 cell line, a widely used model for cardiac myocyte studies, was exposed to varying concentrations of organochloride to investigate its effects on cellular function and gene expression. Results showed a positive correlation between organochloride exposure and the presence of the 144 G>A sequence variant in the H9c2 cell line, suggesting a potential genetic predisposition to altered responses to this chemical entity. Further analysis revealed an association between organochloride and the 144 G>A variant, with higher expression levels of the variant observed under organochloride stress conditions.   To explore the broader implications of the 144 G>A variant, we examined its role in streptococcus infection susceptibility using the H9c2 cell line. The 144 G>A variant was found to be significantly associated with increased susceptibility to streptococcus infection, as evidenced by higher bacterial adherence and lower phagocytic activity in H9c2 cells carrying this variant. These findings were consistent across multiple independent experiments, with 17 instances of streptococcus infection reported in H9c2 cell cultures harboring the 144 G>A variant.   The study also demonstrated that the 144 G>A variant may modulate the cellular response to organochloride, potentially through altered transcriptional regulation of immune-related pathways. Given the high frequency of the 144 G>A variant in the H9c2 cell line (13 instances) and its strong association with both organochloride exposure and streptococcus infection, this variant may represent a key genetic factor in the interplay between environmental toxins and infectious disease susceptibility. These results highlight the importance of considering genetic variability in the context of environmental exposures and infectious disease outcomes.
26716620	0	4	H9c2	CellLine	CVCL_0286
26716620	28	42	organochloride	ChemicalEntity	D006843
26716620	74	81	144 G>A	SequenceVariant	rs74315339
26716620	102	125	streptococcus infection	DiseaseOrPhenotypicFeature	D013290
26716620	137	141	H9c2	CellLine	CVCL_0286
26716620	243	257	organochloride	ChemicalEntity	D006843
26716620	373	387	organochloride	ChemicalEntity	D006843
26716620	421	428	144 G>A	SequenceVariant	rs74315339
26716620	453	457	H9c2	CellLine	CVCL_0286
26716620	610	624	organochloride	ChemicalEntity	D006843
26716620	633	640	144 G>A	SequenceVariant	rs74315339
26716620	710	724	organochloride	ChemicalEntity	D006843
26716620	789	796	144 G>A	SequenceVariant	rs74315339
26716620	830	853	streptococcus infection	DiseaseOrPhenotypicFeature	D013290
26716620	879	883	H9c2	CellLine	CVCL_0286
26716620	899	906	144 G>A	SequenceVariant	rs74315339
26716620	989	1012	streptococcus infection	DiseaseOrPhenotypicFeature	D013290
26716620	1090	1094	H9c2	CellLine	CVCL_0286
26716620	1217	1240	streptococcus infection	DiseaseOrPhenotypicFeature	D013290
26716620	1253	1257	H9c2	CellLine	CVCL_0286
26716620	1286	1293	144 G>A	SequenceVariant	rs74315339
26716620	1342	1349	144 G>A	SequenceVariant	rs74315339
26716620	1396	1410	organochloride	ChemicalEntity	D006843
26716620	1527	1534	144 G>A	SequenceVariant	rs74315339
26716620	1550	1554	H9c2	CellLine	CVCL_0286
26716620	1617	1631	organochloride	ChemicalEntity	D006843
26716620	1645	1668	streptococcus infection	DiseaseOrPhenotypicFeature	D013290
26716620	Positive_Correlation	D006843	rs74315339	Novel
26716620	Association	D006843	rs74315339	Novel
26716620	Association	rs74315339	D013290	Novel

42071956|t|Genetic and pharmacological interactions of sequence variants, reactive oxygen species, and disease in Drosophila and chic
42071956|a|This study investigates the complex interplay between genetic sequence variants, reactive oxygen species (ROS), and disease mechanisms in both Drosophila and chick models. A key focus is the association between autosomal dominant cerebellar ataxia (ADCA) and the sequence variant G/C, which was observed in multiple experimental conditions. The variant c.1151C>A was found to be genetically linked to P120T, and this relationship was further supported by the reciprocal association between P120T and c.1151C>A. These findings suggest a potential functional relationship between these sequence variants in the context of ADCA. Additionally, the variant P120T was shown to interact with the drug etoricoxib, indicating a possible pharmacological relevance in disease management. The study also explored the role of reactive oxygen species in modulating the effects of c.1151C>A and G/C, with evidence suggesting that these variants may influence ROS production in both Drosophila and chick models. Cyclosporin A and alpha-methyl-para-tyrosine were used as pharmacological tools to modulate these interactions, with cyclosporin A showing a significant effect on the expression of G/C in bacterial cultures. The presence of multiple sequence variants, including P120T and c.1151C>A, was consistently observed across different experimental conditions, reinforcing their potential role in the pathogenesis of ADCA. The study also highlights the importance of considering both genetic and environmental factors in understanding the molecular basis of ADCA and its associated phenotypes. The findings provide a foundation for further research into the therapeutic targeting of these variants in both model organisms and human disease.
42071956	63	86	reactive oxygen species	ChemicalEntity	D017382
42071956	103	113	Drosophila	OrganismTaxon	7227
42071956	204	227	reactive oxygen species	ChemicalEntity	D017382
42071956	266	276	Drosophila	OrganismTaxon	7227
42071956	281	286	chick	OrganismTaxon	9031
42071956	334	370	autosomal dominant cerebellar ataxia	DiseaseOrPhenotypicFeature	OMIM:604121
42071956	403	406	G/C	SequenceVariant	g|SUB|G||C
42071956	476	485	c.1151C>A	SequenceVariant	c|SUB|C|1151|A
42071956	524	529	P120T	SequenceVariant	c|SUB|P|120|T
42071956	613	618	P120T	SequenceVariant	c|SUB|P|120|T
42071956	623	632	c.1151C>A	SequenceVariant	c|SUB|C|1151|A
42071956	775	780	P120T	SequenceVariant	c|SUB|P|120|T
42071956	817	827	etoricoxib	ChemicalEntity	D000077613
42071956	936	959	reactive oxygen species	ChemicalEntity	D017382
42071956	989	998	c.1151C>A	SequenceVariant	c|SUB|C|1151|A
42071956	1003	1006	G/C	SequenceVariant	g|SUB|G||C
42071956	1090	1100	Drosophila	OrganismTaxon	7227
42071956	1105	1110	chick	OrganismTaxon	9031
42071956	1137	1163	alpha-methyl-para-tyrosine	ChemicalEntity	D019805
42071956	1236	1249	cyclosporin A	ChemicalEntity	D016572
42071956	1300	1303	G/C	SequenceVariant	g|SUB|G||C
42071956	1307	1315	bacteria	OrganismTaxon	2
42071956	1381	1386	P120T	SequenceVariant	c|SUB|P|120|T
42071956	1391	1400	c.1151C>A	SequenceVariant	c|SUB|C|1151|A
42071956	Association	OMIM:604121	g|SUB|G||C	Novel
42071956	Association	c|SUB|C|1151|A	c|SUB|P|120|T	Novel
42071956	Association	c|SUB|P|120|T	c|SUB|C|1151|A	Novel
42071956	Association	c|SUB|P|120|T	D000077613	Novel
42071956	Association	c|SUB|C|1151|A	g|SUB|G||C	Novel
42071956	Association	g|SUB|G||C	c|SUB|C|1151|A	Novel

14471404|t|GSH, GH-binding protein, and mivacurium interactions in sheep models of left ventricular dysfunction and tooth 
14471404|a|This study investigates the complex interactions between glutathione (GSH), GH-binding protein, and mivacurium in sheep models of left ventricular systolic and diastolic dysfunction and tooth agenesis. The research focuses on the molecular and physiological mechanisms underlying these associations, particularly in the context of cell lines such as SW480, KU7, H9c2, SMMC-7721, and 253JB-V.   Our findings reveal a negative correlation between GSH and GH-binding protein, suggesting that increased levels of GSH may inhibit the activity of GH-binding protein. Conversely, a positive correlation is observed between left ventricular systolic and diastolic dysfunction and GSH, indicating that GSH may play a protective role in cardiac function. Additionally, a negative correlation is found between left ventricular dysfunction and mivacurium, implying that mivacurium may exacerbate cardiac dysfunction.   Tooth agenesis is significantly associated with both GH-binding protein and GSH, with a positive correlation between tooth agenesis and GH-binding protein and a negative correlation between tooth agenesis and GSH. Furthermore, mivacurium shows a complex relationship with tooth agenesis, exhibiting both positive and negative correlations, which may reflect its dual role in modulating cellular processes.   The study also highlights the role of cell lines such as SW480, KU7, H9c2, SMMC-7721, and 253JB-V in mediating these interactions, providing insights into the cellular mechanisms underlying the observed associations. These results contribute to a better understanding of the interplay between GSH, GH-binding protein, and mivacurium in the context of cardiac and dental pathologies in sheep models.
14471404	0	3	GSH	ChemicalEntity	D005978
14471404	5	23	GH-binding protein	GeneOrGeneProduct	2690
14471404	29	39	mivacurium	ChemicalEntity	D000077590
14471404	56	61	sheep	OrganismTaxon	9940
14471404	182	185	GSH	ChemicalEntity	D005978
14471404	188	206	GH-binding protein	GeneOrGeneProduct	2690
14471404	212	222	mivacurium	ChemicalEntity	D000077590
14471404	226	231	sheep	OrganismTaxon	9940
14471404	242	293	left ventricular systolic and diastolic dysfunction	DiseaseOrPhenotypicFeature	D018487
14471404	298	312	tooth agenesis	DiseaseOrPhenotypicFeature	D000848
14471404	462	467	SW480	CellLine	CVCL_0546
14471404	469	472	KU7	CellLine	CVCL_4714
14471404	474	478	H9c2	CellLine	CVCL_0286
14471404	480	489	SMMC-7721	CellLine	CVCL_0534
14471404	495	502	253JB-V	CellLine	CVCL_7937
14471404	557	560	GSH	ChemicalEntity	D005978
14471404	565	583	GH-binding protein	GeneOrGeneProduct	2690
14471404	621	624	GSH	ChemicalEntity	D005978
14471404	653	671	GH-binding protein	GeneOrGeneProduct	2690
14471404	728	779	left ventricular systolic and diastolic dysfunction	DiseaseOrPhenotypicFeature	D018487
14471404	784	787	GSH	ChemicalEntity	D005978
14471404	805	808	GSH	ChemicalEntity	D005978
14471404	944	954	mivacurium	ChemicalEntity	D000077590
14471404	970	980	mivacurium	ChemicalEntity	D000077590
14471404	1072	1090	GH-binding protein	GeneOrGeneProduct	2690
14471404	1095	1098	GSH	ChemicalEntity	D005978
14471404	1136	1150	tooth agenesis	DiseaseOrPhenotypicFeature	D000848
14471404	1155	1173	GH-binding protein	GeneOrGeneProduct	2690
14471404	1209	1223	tooth agenesis	DiseaseOrPhenotypicFeature	D000848
14471404	1228	1231	GSH	ChemicalEntity	D005978
14471404	1246	1256	mivacurium	ChemicalEntity	D000077590
14471404	1291	1305	tooth agenesis	DiseaseOrPhenotypicFeature	D000848
14471404	1484	1489	SW480	CellLine	CVCL_0546
14471404	1491	1494	KU7	CellLine	CVCL_4714
14471404	1496	1500	H9c2	CellLine	CVCL_0286
14471404	1502	1511	SMMC-7721	CellLine	CVCL_0534
14471404	1517	1524	253JB-V	CellLine	CVCL_7937
14471404	1720	1723	GSH	ChemicalEntity	D005978
14471404	1725	1743	GH-binding protein	GeneOrGeneProduct	2690
14471404	1749	1759	mivacurium	ChemicalEntity	D000077590
14471404	1812	1817	sheep	OrganismTaxon	9940
14471404	Negative_Correlation	D005978	2690	Novel
14471404	Association	D018487	2690	Novel
14471404	Association	D000848	2690	Novel
14471404	Association	D000848	D005978	Novel
14471404	Negative_Correlation	D018487	D000077590	Novel
14471404	Positive_Correlation	D018487	D005978	Novel
14471404	Association	D000848	D000077590	Novel
14471404	Association	D018487	D005978	Novel
14471404	Positive_Correlation	D000848	D005978	Novel
14471404	Negative_Correlation	D000077590	2690	Novel
14471404	Negative_Correlation	D000848	D005978	Novel
14471404	Negative_Correlation	D018487	D005978	Novel
14471404	Positive_Correlation	D018487	D000077590	Novel
14471404	Positive_Correlation	2690	D000848	Novel
14471404	Positive_Correlation	2690	D018487	Novel
14471404	Positive_Correlation	D000848	D000077590	Novel
14471404	Negative_Correlation	D000848	D000077590	Novel
14471404	Association	D018487	D000077590	Novel

66380767|t|Protein disulfide isomerase family A member 3: genetic variants and their associations with IEC-6 cell line function and ex
66380767|a|Protein disulfide isomerase family A member 3 (PDIAM3) plays a critical role in maintaining the structural integrity of proteins through its isomerase activity. This study investigates the functional and expression consequences of specific sequence variants in PDIAM3, particularly in the context of the IEC-6 cell line, which is a well-characterized model for intestinal epithelial function.   We analyzed the impact of the sequence variant c.357-3C>G on PDIAM3 expression and activity in IEC-6 cells. This variant was found to significantly alter the splicing pattern of the PDIAM3 pre-mRNA, leading to a reduction in the levels of the full-length protein. Additionally, the variant was associated with a decrease in the enzymatic activity of PDIAM3, as measured by its ability to catalyze disulfide bond formation in recombinant proteins.   The sequence variant T3801C was also examined for its effect on PDIAM3 expression. This variant was shown to be linked to a subtle but consistent reduction in PDIAM3 protein levels in IEC-6 cells, which correlated with impaired cell viability under oxidative stress conditions. Furthermore, the variant p.Thr26 was found to be a key determinant of PDIAM3's redox sensitivity, with the Thr26 residue playing a central role in the protein's ability to respond to changes in the cellular redox environment.   Our findings suggest that the sequence variants c.357-3C>G, T3801C, and p.Thr26 are functionally significant in modulating the expression and activity of PDIAM3 in IEC-6 cells. These results highlight the importance of genetic variability in PDIAM3 and its potential implications for cellular function and disease susceptibility.
66380767	92	97	IEC-6	CellLine	CVCL_0343
66380767	428	433	IEC-6	CellLine	CVCL_0343
66380767	566	576	c.357-3C>G	SequenceVariant	c|SUB|C|357-3|G
66380767	614	619	IEC-6	CellLine	CVCL_0343
66380767	989	995	T3801C	SequenceVariant	g|SUB|T|3801|C
66380767	1152	1157	IEC-6	CellLine	CVCL_0343
66380767	1271	1278	p.Thr26	SequenceVariant	p|Allele|T|26
66380767	1522	1532	c.357-3C>G	SequenceVariant	c|SUB|C|357-3|G
66380767	1534	1540	T3801C	SequenceVariant	g|SUB|T|3801|C
66380767	1546	1553	p.Thr26	SequenceVariant	p|Allele|T|26
66380767	1638	1643	IEC-6	CellLine	CVCL_0343
66380767	Association	c|SUB|C|357-3|G	14827	Novel
66380767	Association	g|SUB|T|3801|C	14827	Novel
66380767	Association	p|Allele|T|26	14827	Novel

80971043|t|Glucocorticoid resistance, Cortical dysplasia, and sudden infant death with dysgenesis of the testes syndrome: genetic and pharmacological insights using IEC-6 and LbetaT2 ce
80971043|a|This study investigates the complex interplay between glucocorticoid resistance, Cortical dysplasia, and sudden infant death with dysgenesis of the testes syndrome, with a focus on the genetic and pharmacological mechanisms underlying these conditions. Using the IEC-6 and LbetaT2 cell lines, we explored the effects of sequence variants and chemical entities on disease phenotypes. Our findings reveal a significant association between Cortical dysplasia and the sequence variant S429T, as well as between Cortical dysplasia and rs713041. Similarly, sudden infant death with dysgenesis of the testes syndrome is strongly linked to the sequence variants 1284A>C and rs713041, and also to I238M.   Glucocorticoid resistance is associated with multiple sequence variants, including S429T, rs713041, and I238M, as well as with the sequence variant 1284A>C. These associations suggest a potential role for these genetic variants in the pathogenesis of glucocorticoid resistance. Additionally, insomnia is found to be linked to S429T, rs713041, and I238M, highlighting a possible genetic basis for this condition.   The chemical entity Apomorphine shows a significant association with I238M, rs713041, and 1284A>C, indicating its potential involvement in modulating the expression or function of these genetic variants. Furthermore, the gene product GDF15 is found to be highly expressed in both IEC-6 and LbetaT2 cell lines, and its expression is modulated by the sequence variant 1284A>C. The gene product MEN1 is also implicated in the regulation of glucocorticoid resistance and is associated with the sequence variant 1284A>C.   The gene product Cidec is found to be upregulated in IEC-6 cells in response to Apomorphine, and the gene product Sp3 is associated with the sequence variant rs713041. These findings provide new insights into the molecular mechanisms underlying these complex diseases and highlight the potential of using cell lines like IEC-6 and LbetaT2 to study the genetic and pharmacological basis of glucocorticoid resistance, Cortical dysplasia, and sudden infant death with dysgenesis of the testes syndrome.
80971043	27	45	Cortical dysplasia	DiseaseOrPhenotypicFeature	D054220
80971043	51	109	sudden infant death with dysgenesis of the testes syndrome	DiseaseOrPhenotypicFeature	C563856
80971043	154	159	IEC-6	CellLine	CVCL_0343
80971043	164	171	LbetaT2	CellLine	CVCL_0398
80971043	229	254	glucocorticoid resistance	DiseaseOrPhenotypicFeature	C564221
80971043	256	274	Cortical dysplasia	DiseaseOrPhenotypicFeature	D054220
80971043	280	338	sudden infant death with dysgenesis of the testes syndrome	DiseaseOrPhenotypicFeature	C563856
80971043	438	443	IEC-6	CellLine	CVCL_0343
80971043	448	455	LbetaT2	CellLine	CVCL_0398
80971043	612	630	Cortical dysplasia	DiseaseOrPhenotypicFeature	D054220
80971043	656	661	S429T	SequenceVariant	p|SUB|S|429|T
80971043	682	700	Cortical dysplasia	DiseaseOrPhenotypicFeature	D054220
80971043	705	713	rs713041	SequenceVariant	rs713041
80971043	726	784	sudden infant death with dysgenesis of the testes syndrome	DiseaseOrPhenotypicFeature	C563856
80971043	829	836	1284A>C	SequenceVariant	c|SUB|A|1284|C
80971043	841	849	rs713041	SequenceVariant	rs713041
80971043	863	868	I238M	SequenceVariant	rs34242818
80971043	955	960	S429T	SequenceVariant	p|SUB|S|429|T
80971043	962	970	rs713041	SequenceVariant	rs713041
80971043	976	981	I238M	SequenceVariant	rs34242818
80971043	1020	1027	1284A>C	SequenceVariant	c|SUB|A|1284|C
80971043	1123	1148	glucocorticoid resistance	DiseaseOrPhenotypicFeature	C564221
80971043	1164	1172	insomnia	DiseaseOrPhenotypicFeature	D007319
80971043	1198	1203	S429T	SequenceVariant	p|SUB|S|429|T
80971043	1205	1213	rs713041	SequenceVariant	rs713041
80971043	1219	1224	I238M	SequenceVariant	rs34242818
80971043	1306	1317	Apomorphine	ChemicalEntity	D001058
80971043	1355	1360	I238M	SequenceVariant	rs34242818
80971043	1362	1370	rs713041	SequenceVariant	rs713041
80971043	1376	1383	1284A>C	SequenceVariant	c|SUB|A|1284|C
80971043	1520	1525	GDF15	GeneOrGeneProduct	9518
80971043	1566	1571	IEC-6	CellLine	CVCL_0343
80971043	1576	1583	LbetaT2	CellLine	CVCL_0398
80971043	1652	1659	1284A>C	SequenceVariant	c|SUB|A|1284|C
80971043	1678	1682	MEN1	GeneOrGeneProduct	4221
80971043	1723	1748	glucocorticoid resistance	DiseaseOrPhenotypicFeature	C564221
80971043	1793	1800	1284A>C	SequenceVariant	c|SUB|A|1284|C
80971043	1821	1826	Cidec	GeneOrGeneProduct	63924
80971043	1857	1862	IEC-6	CellLine	CVCL_0343
80971043	1884	1895	Apomorphine	ChemicalEntity	D001058
80971043	1918	1921	Sp3	GeneOrGeneProduct	20687
80971043	1962	1970	rs713041	SequenceVariant	rs713041
80971043	2125	2130	IEC-6	CellLine	CVCL_0343
80971043	2135	2142	LbetaT2	CellLine	CVCL_0398
80971043	2193	2218	glucocorticoid resistance	DiseaseOrPhenotypicFeature	C564221
80971043	2220	2238	Cortical dysplasia	DiseaseOrPhenotypicFeature	D054220
80971043	2244	2302	sudden infant death with dysgenesis of the testes syndrome	DiseaseOrPhenotypicFeature	C563856
80971043	Association	D054220	p|SUB|S|429|T	Novel
80971043	Association	C563856	c|SUB|A|1284|C	Novel
80971043	Association	D054220	rs34242818	Novel
80971043	Association	C563856	rs713041	Novel
80971043	Association	C564221	p|SUB|S|429|T	Novel
80971043	Association	C564221	rs713041	Novel
80971043	Association	D007319	p|SUB|S|429|T	Novel
80971043	Association	D001058	rs34242818	Novel
80971043	Association	C563856	rs34242818	Novel
80971043	Association	D007319	rs713041	Novel
80971043	Association	C564221	c|SUB|A|1284|C	Novel
80971043	Association	D007319	rs34242818	Novel
80971043	Association	D054220	rs713041	Novel
80971043	Association	C564221	rs34242818	Novel
80971043	Association	D001058	rs713041	Novel
80971043	Association	D001058	c|SUB|A|1284|C	Novel
80971043	Association	D054220	c|SUB|A|1284|C	Novel
80971043	Association	D007319	c|SUB|A|1284|C	Novel
80971043	Association	C563856	p|SUB|S|429|T	Novel
80971043	Association	D001058	p|SUB|S|429|T	Novel

28324620|t|Genetic and pharmacological interactions in cancer cell lines and viral infections: insights from sequence variants and chemical 
28324620|a|This study investigates the complex interactions between genetic sequence variants, chemical entities, and their effects on cancer cell lines and viral infections. We focused on the C57BL/6J cell line, which was used in multiple experiments to assess the impact of sequence variants such as c.1146+25insA and 457_458insG. The C57BL/6J cell line was also cotreated with polyalanine and extract of Daucus carota seeds, revealing a synergistic effect in modulating cellular responses.   The LNCaP cell line, which was used five times in the study, was found to exhibit a negative correlation between the adenine 474 deletion and MK-801 treatment. This suggests that the presence of the adenine 474 deletion may reduce the efficacy of MK-801 in this cell line. Similarly, the SNU-C2A cell line showed a negative correlation between the sequence variant c.1146+25insA and the extract of Daucus carota seeds, indicating a potential antagonistic interaction between these two factors.  The C4-2B and LbetaT2 cell lines were also included in the study, with the latter being used to examine the effects of taxol. The MCF7/AdrR cell line was used to assess the impact of the sequence variant rs713041, while the SF188 cell line was used to evaluate the effects of the M204V variant. The C57BL/6J cell line was used in five separate experiments, highlighting its importance in the study.  In addition to cancer cell lines, the study also examined the effects of HIV-1 and mouse mammary tumor virus on the expression of various sequence variants. The Aedes mosquitoes were included as a model organism to study the transmission dynamics of these viruses. The results suggest that the interaction between genetic variants and chemical entities plays a critical role in determining the biological outcomes in both cancer and viral contexts.
28324620	312	320	C57BL/6J	CellLine	CVCL_5U84
28324620	421	434	c.1146+25insA	SequenceVariant	c|INS|1146+25|A
28324620	439	450	457_458insG	SequenceVariant	c|INS|457_458|G
28324620	456	464	C57BL/6J	CellLine	CVCL_5U84
28324620	499	510	polyalanine	ChemicalEntity	C019529
28324620	515	545	extract of Daucus carota seeds	ChemicalEntity	D010936
28324620	618	623	LNCaP	CellLine	CVCL_0395
28324620	731	751	adenine 474 deletion	SequenceVariant	rs587777017
28324620	756	762	MK-801	ChemicalEntity	D016291
28324620	813	833	adenine 474 deletion	SequenceVariant	rs587777017
28324620	861	867	MK-801	ChemicalEntity	D016291
28324620	902	909	SNU-C2A	CellLine	CVCL_1709
28324620	979	992	c.1146+25insA	SequenceVariant	c|INS|1146+25|A
28324620	1001	1031	extract of Daucus carota seeds	ChemicalEntity	D010936
28324620	1113	1118	C4-2B	CellLine	CVCL_4784
28324620	1123	1130	LbetaT2	CellLine	CVCL_0398
28324620	1228	1233	taxol	ChemicalEntity	D017239
28324620	1239	1248	MCF7/AdrR	CellLine	 CVCL_1452
28324620	1313	1321	rs713041	SequenceVariant	rs713041
28324620	1333	1338	SF188	CellLine	CVCL_6948
28324620	1389	1394	M204V	SequenceVariant	p|SUB|M|204|V
28324620	1408	1416	C57BL/6J	CellLine	CVCL_5U84
28324620	1582	1587	HIV-1	OrganismTaxon	11676
28324620	1592	1617	mouse mammary tumor virus	OrganismTaxon	11757
28324620	1670	1686	Aedes mosquitoes	OrganismTaxon	1245352
28324620	Negative_Correlation	rs587777017	D016291	Novel
28324620	Negative_Correlation	c|INS|1146+25|A	D010936	Novel
28324620	Cotreatment	C019529	D010936	Novel

99169851|t|Genetic and pharmacological interactions of CEBPbeta, VCAM1, and sequence variants in AN, SCID, and glomerulos
99169851|a|This study investigates the complex genetic and pharmacological interactions between the transcription factor CEBPbeta, the adhesion molecule VCAM1, and various sequence variants in the context of autoimmune diseases, immunodeficiencies, and renal disorders. We report that the sequence variant M204I in CEBPbeta is positively correlated with increased expression of VCAM1, suggesting a potential regulatory role in immune cell adhesion and inflammation. Additionally, we find that the sequence variant -134delA in CEBPbeta is negatively correlated with VCAM1 expression, indicating a possible antagonistic relationship between these two molecules.   Our findings also reveal a positive correlation between the sequence variant M204I and the disease AN, highlighting its potential as a genetic risk factor for this condition. Furthermore, we demonstrate that the sequence variant -134delA is associated with the development of SCID, suggesting a critical role in immune system function. The chemical entity hexamethonium is found to be positively correlated with both VCAM1 and SCID, and its cotreatment with ristocetin is shown to modulate immune responses in experimental models.   We also report that the chemical entity cytochrome P-450 3A4 inhibitors are positively correlated with hexamethonium and VCAM1, and that they are associated with increased VCAM1 expression. Notably, there is a negative correlation between CEBPbeta and cytochrome P-450 3A4 inhibitors, suggesting a potential regulatory interaction. The sequence variant M204I is also found to be positively correlated with the gene Vps2, which is associated with AN, further linking these genetic elements in the pathogenesis of autoimmune diseases.   In addition, we observe that the sequence variant -134delA is associated with glomerulosclerosis, indicating a possible role in renal disease progression. The chemical entity ristocetin is found to be associated with CEBPbeta, and its cotreatment with hexamethonium is shown to enhance the effects of both agents in modulating immune responses. These findings provide new insights into the molecular mechanisms underlying the interplay between genetic variants, chemical entities, and disease phenotypes in the context of autoimmune and immunodeficiency disorders.
99169851	44	52	CEBPbeta	GeneOrGeneProduct	1051
99169851	54	59	VCAM1	GeneOrGeneProduct	7412
99169851	86	88	AN	DiseaseOrPhenotypicFeature	D015783
99169851	90	94	SCID	DiseaseOrPhenotypicFeature	D016511
99169851	221	229	CEBPbeta	GeneOrGeneProduct	1051
99169851	253	258	VCAM1	GeneOrGeneProduct	7412
99169851	406	411	M204I	SequenceVariant	p|SUB|M|204|I
99169851	415	423	CEBPbeta	GeneOrGeneProduct	1051
99169851	478	483	VCAM1	GeneOrGeneProduct	7412
99169851	614	622	-134delA	SequenceVariant	rs1800997
99169851	626	634	CEBPbeta	GeneOrGeneProduct	1051
99169851	665	670	VCAM1	GeneOrGeneProduct	7412
99169851	839	844	M204I	SequenceVariant	p|SUB|M|204|I
99169851	861	863	AN	DiseaseOrPhenotypicFeature	D015783
99169851	991	999	-134delA	SequenceVariant	rs1800997
99169851	1038	1042	SCID	DiseaseOrPhenotypicFeature	D016511
99169851	1118	1131	hexamethonium	ChemicalEntity	D018738
99169851	1179	1184	VCAM1	GeneOrGeneProduct	7412
99169851	1189	1193	SCID	DiseaseOrPhenotypicFeature	D016511
99169851	1220	1230	ristocetin	ChemicalEntity	D012310
99169851	1335	1366	cytochrome P-450 3A4 inhibitors	ChemicalEntity	D065692
99169851	1398	1411	hexamethonium	ChemicalEntity	D018738
99169851	1416	1421	VCAM1	GeneOrGeneProduct	7412
99169851	1467	1472	VCAM1	GeneOrGeneProduct	7412
99169851	1534	1542	CEBPbeta	GeneOrGeneProduct	1051
99169851	1547	1578	cytochrome P-450 3A4 inhibitors	ChemicalEntity	D065692
99169851	1648	1653	M204I	SequenceVariant	p|SUB|M|204|I
99169851	1710	1714	Vps2	GeneOrGeneProduct	27243
99169851	1741	1743	AN	DiseaseOrPhenotypicFeature	D015783
99169851	1880	1888	-134delA	SequenceVariant	rs1800997
99169851	1908	1926	glomerulosclerosis	DiseaseOrPhenotypicFeature	D005921
99169851	2005	2015	ristocetin	ChemicalEntity	D012310
99169851	2047	2055	CEBPbeta	GeneOrGeneProduct	1051
99169851	2082	2095	hexamethonium	ChemicalEntity	D018738
99169851	Association	D065692	7412	Novel
99169851	Cotreatment	D012310	D018738	Novel
99169851	Negative_Correlation	1051	7412	Novel
99169851	Positive_Correlation	27243	7412	Novel
99169851	Association	D018738	7412	Novel
99169851	Negative_Correlation	1051	D065692	Novel
99169851	Cotreatment	D065692	D018738	Novel
99169851	Association	D012310	1051	Novel
99169851	Positive_Correlation	D018738	D016511	Novel
99169851	Positive_Correlation	D015783	27243	Novel
99169851	Positive_Correlation	D065692	D018738	Novel
99169851	Positive_Correlation	7412	1051	Novel

69028654|t|Genetic variant p.Asp46_Gln48delinsGlu and its associations with antipyretic use, leukemic progression, and skin lesions in human immunodeficiency virus and rhesus
69028654|a|This study investigates the genetic variant p.Asp46_Gln48delinsGlu and its potential associations with antipyretic use, leukemic progression, and skin lesions in both human immunodeficiency virus (HIV) and rhesus monkeys. The variant was identified in multiple studies involving human immunodeficiency virus (HIV) and was found to be significantly correlated with antipyretic use in a cohort of patients with leukemic features. In addition, the variant showed a strong positive correlation with the development of leukemic conditions in human immunodeficiency virus (HIV) patients. Furthermore, the variant was associated with the presence of skin lesions in both human immunodeficiency virus (HIV) and rhesus monkeys. The study also included multiple instances of the cell line SW480, which was used to model the effects of the variant in vitro. The results suggest that the sequence variant p.Asp46_Gln48delinsGlu may play a role in modulating the response to antipyretic drugs and in the progression of leukemic and skin-related conditions in both human immunodeficiency virus (HIV) and rhesus monkeys. These findings highlight the potential importance of this variant in understanding the molecular mechanisms underlying these diseases and their interactions with therapeutic agents.
69028654	16	38	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
69028654	65	76	antipyretic	ChemicalEntity	D058633
69028654	82	90	leukemic	DiseaseOrPhenotypicFeature	D007938
69028654	108	120	skin lesions	DiseaseOrPhenotypicFeature	D012871
69028654	124	152	human immunodeficiency virus	OrganismTaxon	12721
69028654	208	230	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
69028654	267	278	antipyretic	ChemicalEntity	D058633
69028654	284	292	leukemic	DiseaseOrPhenotypicFeature	D007938
69028654	310	322	skin lesions	DiseaseOrPhenotypicFeature	D012871
69028654	331	359	human immunodeficiency virus	OrganismTaxon	12721
69028654	370	384	rhesus monkeys	OrganismTaxon	9544
69028654	443	471	human immunodeficiency virus	OrganismTaxon	12721
69028654	528	539	antipyretic	ChemicalEntity	D058633
69028654	573	581	leukemic	DiseaseOrPhenotypicFeature	D007938
69028654	678	686	leukemic	DiseaseOrPhenotypicFeature	D007938
69028654	701	729	human immunodeficiency virus	OrganismTaxon	12721
69028654	807	819	skin lesions	DiseaseOrPhenotypicFeature	D012871
69028654	828	856	human immunodeficiency virus	OrganismTaxon	12721
69028654	867	881	rhesus monkeys	OrganismTaxon	9544
69028654	943	948	SW480	CellLine	CVCL_0546
69028654	1057	1079	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
69028654	1126	1137	antipyretic	ChemicalEntity	D058633
69028654	1170	1178	leukemic	DiseaseOrPhenotypicFeature	D007938
69028654	1215	1243	human immunodeficiency virus	OrganismTaxon	12721
69028654	1254	1268	rhesus monkeys	OrganismTaxon	9544
69028654	Positive_Correlation	p|INDEL|46_48|Glu	D058633	Novel
69028654	Positive_Correlation	p|INDEL|46_48|Glu	D007938	Novel
69028654	Positive_Correlation	p|INDEL|46_48|Glu	D012871	Novel

08310300|t|West Nile virus and the molecular interplay of crumbs, Interferon regulatory factor 5, vimentin, and sequence variants c.2607C>A and c.1970_2177del in KU7 ce
08310300|a|West Nile virus (WNV) has been implicated in a range of neurological disorders, and its interaction with host cellular components is a critical area of investigation. This study explores the molecular mechanisms by which WNV modulates the expression and function of crumbs, Interferon regulatory factor 5 (IRF5), and vimentin in the KU7 cell line, with a focus on the sequence variants c.2607C>A and c.1970_2177del.   Our findings reveal that the sequence variant c.2607C>A is associated with both crumbs and IRF5, suggesting a potential regulatory role in their expression or function. Additionally, c.2607C>A is also linked to vimentin, indicating a broader impact on the cellular response to WNV. The variant c.1970_2177del is associated with IRF5, vimentin, and crumbs, further highlighting the complex interplay between these genetic elements and the virus.   Notably, there is a negative correlation between crumbs and vimentin, as well as between crumbs and IRF5, suggesting that these proteins may function in opposing pathways or regulatory networks. Similarly, a negative correlation is observed between IRF5 and vimentin, reinforcing the idea of a dynamic balance in the host response. The variant c.1970_2177del is also associated with c.2607C>A, indicating a potential functional relationship between these two sequence variants.   Furthermore, we observe that IRF5 binds to both crumbs and vimentin, while vimentin binds to crumbs, suggesting a direct interaction network involving these proteins. The negative correlation between IRF5 and crumbs, as well as between IRF5 and vimentin, underscores the complexity of the regulatory landscape in WNV-infected KU7 cells.   These results provide new insights into the molecular mechanisms by which WNV interacts with host factors, particularly in the context of the KU7 cell line. The associations and correlations identified here may serve as a foundation for future studies aimed at understanding the pathogenesis of WNV-related diseases and developing targeted therapeutic strategies.
08310300	0	15	West Nile virus	OrganismTaxon	11082
08310300	47	53	crumbs	GeneOrGeneProduct	42896
08310300	55	85	Interferon regulatory factor 5	GeneOrGeneProduct	3663
08310300	87	95	vimentin	GeneOrGeneProduct	22352
08310300	119	128	c.2607C>A	SequenceVariant	rs386833565
08310300	133	147	c.1970_2177del	SequenceVariant	c|DEL|1970_2177|
08310300	151	154	KU7	CellLine	CVCL_4714
08310300	158	173	West Nile virus	OrganismTaxon	11082
08310300	424	430	crumbs	GeneOrGeneProduct	42896
08310300	432	462	Interferon regulatory factor 5	GeneOrGeneProduct	3663
08310300	475	483	vimentin	GeneOrGeneProduct	22352
08310300	491	494	KU7	CellLine	CVCL_4714
08310300	544	553	c.2607C>A	SequenceVariant	rs386833565
08310300	558	572	c.1970_2177del	SequenceVariant	c|DEL|1970_2177|
08310300	622	631	c.2607C>A	SequenceVariant	rs386833565
08310300	656	662	crumbs	GeneOrGeneProduct	42896
08310300	759	768	c.2607C>A	SequenceVariant	rs386833565
08310300	787	795	vimentin	GeneOrGeneProduct	22352
08310300	870	884	c.1970_2177del	SequenceVariant	c|DEL|1970_2177|
08310300	910	918	vimentin	GeneOrGeneProduct	22352
08310300	924	930	crumbs	GeneOrGeneProduct	42896
08310300	1072	1078	crumbs	GeneOrGeneProduct	42896
08310300	1083	1091	vimentin	GeneOrGeneProduct	22352
08310300	1112	1118	crumbs	GeneOrGeneProduct	42896
08310300	1281	1289	vimentin	GeneOrGeneProduct	22352
08310300	1367	1381	c.1970_2177del	SequenceVariant	c|DEL|1970_2177|
08310300	1406	1415	c.2607C>A	SequenceVariant	rs386833565
08310300	1551	1557	crumbs	GeneOrGeneProduct	42896
08310300	1562	1570	vimentin	GeneOrGeneProduct	22352
08310300	1578	1586	vimentin	GeneOrGeneProduct	22352
08310300	1596	1602	crumbs	GeneOrGeneProduct	42896
08310300	1712	1718	crumbs	GeneOrGeneProduct	42896
08310300	1748	1756	vimentin	GeneOrGeneProduct	22352
08310300	1829	1832	KU7	CellLine	CVCL_4714
08310300	1984	1987	KU7	CellLine	CVCL_4714
08310300	Bind	42896	3663	Novel
08310300	Association	rs386833565	42896	Novel
08310300	Association	rs386833565	3663	Novel
08310300	Association	rs386833565	22352	Novel
08310300	Bind	3663	22352	Novel
08310300	Association	c|DEL|1970_2177|	3663	Novel
08310300	Negative_Correlation	42896	22352	Novel
08310300	Association	c|DEL|1970_2177|	22352	Novel
08310300	Negative_Correlation	22352	42896	Novel
08310300	Bind	3663	42896	Novel
08310300	Negative_Correlation	22352	3663	Novel
08310300	Association	c|DEL|1970_2177|	rs386833565	Novel
08310300	Bind	22352	3663	Novel
08310300	Bind	42896	22352	Novel
08310300	Bind	22352	42896	Novel
08310300	Negative_Correlation	42896	3663	Novel
08310300	Negative_Correlation	3663	22352	Novel
08310300	Association	c|DEL|1970_2177|	42896	Novel
08310300	Negative_Correlation	3663	42896	Novel
08310300	Association	rs386833565	c|DEL|1970_2177|	Novel

68597273|t|Erythematous erysipelas and postoperative nausea and vomiting in 293T cell lines: effects of tobacco, rat, and Spirulina on disease pro
68597273|a|This study investigates the complex interplay between erythematous erysipelas, postoperative nausea and vomiting, and the influence of 293T cell lines, tobacco, rat models, and Spirulina in modulating disease outcomes. The 293T cell line, widely used in molecular biology, was employed to model the inflammatory response associated with erythematous erysipelas. Our findings reveal that exposure to tobacco significantly exacerbates the severity of erythematous erysipelas, as evidenced by increased cytokine production and vascular permeability in 293T cells.   In parallel, we explored the role of postoperative nausea and vomiting in patients undergoing surgical procedures, with a focus on the impact of 293T cell line-derived factors on gastrointestinal motility. The results indicate that 293T cell line-derived proteins may contribute to the pathophysiology of postoperative nausea and vomiting, particularly in individuals with a history of tobacco use.   To further understand the disease mechanisms, we utilized rat models and Spirulina as potential therapeutic agents. The rat model demonstrated that Spirulina supplementation reduced the incidence of erythematous erysipelas by modulating the immune response and decreasing oxidative stress. Additionally, Spirulina was found to mitigate the effects of postoperative nausea and vomiting in rat models, suggesting its potential as a complementary therapy.   Our study highlights the importance of 293T cell lines in elucidating the molecular pathways underlying erythematous erysipelas and postoperative nausea and vomiting. The findings also underscore the role of tobacco and Spirulina in disease progression and recovery, offering new insights into the development of targeted interventions. The repeated use of 293T cell lines, tobacco, rat models, and Spirulina in this study provides a comprehensive framework for understanding the multifactorial nature of these conditions.
68597273	28	61	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
68597273	35	38	rat	OrganismTaxon	10116
68597273	65	69	293T	CellLine	CVCL_0063
68597273	93	100	tobacco	OrganismTaxon	4097
68597273	102	105	rat	OrganismTaxon	10116
68597273	111	120	Spirulina	OrganismTaxon	551299
68597273	190	213	erythematous erysipelas	DiseaseOrPhenotypicFeature	D004886
68597273	215	248	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
68597273	222	225	rat	OrganismTaxon	10116
68597273	271	275	293T	CellLine	CVCL_0063
68597273	288	295	tobacco	OrganismTaxon	4097
68597273	297	300	rat	OrganismTaxon	10116
68597273	313	322	Spirulina	OrganismTaxon	551299
68597273	359	363	293T	CellLine	CVCL_0063
68597273	473	496	erythematous erysipelas	DiseaseOrPhenotypicFeature	D004886
68597273	535	542	tobacco	OrganismTaxon	4097
68597273	585	608	erythematous erysipelas	DiseaseOrPhenotypicFeature	D004886
68597273	685	689	293T	CellLine	CVCL_0063
68597273	736	769	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
68597273	743	746	rat	OrganismTaxon	10116
68597273	844	848	293T	CellLine	CVCL_0063
68597273	931	935	293T	CellLine	CVCL_0063
68597273	1004	1037	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
68597273	1011	1014	rat	OrganismTaxon	10116
68597273	1085	1092	tobacco	OrganismTaxon	4097
68597273	1158	1161	rat	OrganismTaxon	10116
68597273	1173	1182	Spirulina	OrganismTaxon	551299
68597273	1220	1223	rat	OrganismTaxon	10116
68597273	1237	1240	rat	OrganismTaxon	10116
68597273	1248	1257	Spirulina	OrganismTaxon	551299
68597273	1299	1322	erythematous erysipelas	DiseaseOrPhenotypicFeature	D004886
68597273	1404	1413	Spirulina	OrganismTaxon	551299
68597273	1451	1484	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
68597273	1458	1461	rat	OrganismTaxon	10116
68597273	1488	1491	rat	OrganismTaxon	10116
68597273	1594	1598	293T	CellLine	CVCL_0063
68597273	1659	1682	erythematous erysipelas	DiseaseOrPhenotypicFeature	D004886
68597273	1687	1720	postoperative nausea and vomiting	DiseaseOrPhenotypicFeature	D020250
68597273	1694	1697	rat	OrganismTaxon	10116
68597273	1763	1770	tobacco	OrganismTaxon	4097
68597273	1775	1784	Spirulina	OrganismTaxon	551299
68597273	1912	1916	293T	CellLine	CVCL_0063
68597273	1929	1936	tobacco	OrganismTaxon	4097
68597273	1938	1941	rat	OrganismTaxon	10116
68597273	1954	1963	Spirulina	OrganismTaxon	551299

76461972|t|Homogentisic Acid, T-Cell Receptor, and Sequence Variants in Murine Models of Pituitary Adenylyl Cyclase-Activating Polypeptide and CD36 Re
76461972|a|This study investigates the complex interactions between homogentisic acid, T-cell receptor, and sequence variants in Murine models, with a focus on the regulation of pituitary adenylyl cyclase-activating polypeptide and CD36. We demonstrate a positive correlation between homogentisic acid and pituitary adenylyl cyclase-activating polypeptide, suggesting a potential role for homogentisic acid in modulating the expression or activity of this gene. Additionally, we observe a significant association between TAK1 and ADRB3, which may be linked to the regulation of CD36. The study also reveals a positive correlation between SH and HeLa E-box binding protein, as well as between SH and TAK1, indicating a potential signaling pathway involving these molecules. Furthermore, we find an association between ADRB3 and HeLa E-box binding protein, and between CD36 and ADRB3, highlighting the interconnectedness of these pathways. The research was conducted in Murine models, with additional analysis in mouse mammary tumor virus and HPV systems. Sequence variants such as 1469T->G, rs2073162, and p.F366L were identified, along with the 15 kb deletion, rs2622604, and cyclic AMP. Methoctramine was used as a pharmacological tool to modulate these interactions. These findings provide new insights into the molecular mechanisms underlying the regulation of these genes and their potential roles in disease.
76461972	61	67	Murine	OrganismTaxon	10090
76461972	132	136	CD36	GeneOrGeneProduct	948
76461972	197	214	homogentisic acid	ChemicalEntity	D006713
76461972	216	231	T-cell receptor	GeneOrGeneProduct	6955
76461972	258	264	Murine	OrganismTaxon	10090
76461972	307	356	pituitary adenylyl cyclase-activating polypeptide	GeneOrGeneProduct	11516
76461972	361	365	CD36	GeneOrGeneProduct	948
76461972	413	430	homogentisic acid	ChemicalEntity	D006713
76461972	435	484	pituitary adenylyl cyclase-activating polypeptide	GeneOrGeneProduct	11516
76461972	518	535	homogentisic acid	ChemicalEntity	D006713
76461972	650	654	TAK1	GeneOrGeneProduct	313121
76461972	659	664	ADRB3	GeneOrGeneProduct	155
76461972	707	711	CD36	GeneOrGeneProduct	948
76461972	767	769	SH	ChemicalEntity	D013439
76461972	774	800	HeLa E-box binding protein	GeneOrGeneProduct	21406
76461972	821	823	SH	ChemicalEntity	D013439
76461972	828	832	TAK1	GeneOrGeneProduct	313121
76461972	946	951	ADRB3	GeneOrGeneProduct	155
76461972	956	982	HeLa E-box binding protein	GeneOrGeneProduct	21406
76461972	996	1000	CD36	GeneOrGeneProduct	948
76461972	1005	1010	ADRB3	GeneOrGeneProduct	155
76461972	1097	1103	Murine	OrganismTaxon	10090
76461972	1140	1165	mouse mammary tumor virus	OrganismTaxon	11757
76461972	1170	1173	HPV	OrganismTaxon	10566
76461972	1209	1217	1469T->G	SequenceVariant	rs80338886
76461972	1219	1228	rs2073162	SequenceVariant	rs2073162
76461972	1234	1241	p.F366L	SequenceVariant	rs140756663
76461972	1274	1288	15 kb deletion	SequenceVariant	c|DEL||15K
76461972	1290	1299	rs2622604	SequenceVariant	rs2622604
76461972	1305	1315	cyclic AMP	ChemicalEntity	D000242
76461972	Association	313121	155	Novel
76461972	Positive_Correlation	D013439	21406	Novel
76461972	Positive_Correlation	D006713	11516	Novel
76461972	Association	155	948	Novel
76461972	Positive_Correlation	D013439	313121	Novel
76461972	Association	155	21406	Novel
76461972	Association	948	155	Novel

08599787|t|Sequence variants in thrombin receptor and TGF-betaRI: associations with developmental defects, juvenile open angle glaucoma, and Kilham rat virus infection in Mice and Aedes mo
08599787|a|Recent studies have revealed complex interactions between sequence variants in the thrombin receptor and TGF-betaRI, with implications for developmental defects, juvenile open angle glaucoma, and viral pathogenesis. A key finding is the association between the sequence variant p.D815A and the thrombin receptor, which was further supported by its positive correlation with TGF-betaRI. Similarly, the sequence variant p.Ser119fsX was found to be associated with both the thrombin receptor and TGF-betaRI, highlighting a potential functional link between these two proteins.   The Ile/Val polymorphism in the thrombin receptor was also found to be associated with both the thrombin receptor and TGF-betaRI, suggesting a broader role for this variant in modulating receptor function. Notably, the thrombin receptor was associated with developmental defects and juvenile open angle glaucoma, with the latter being directly linked to TGF-betaRI. This association was further reinforced by the positive correlation between TGF-betaRI and thrombin receptor, indicating a potential regulatory relationship between these two proteins.  In addition to these associations, the TGF-betaRI was found to be linked to developmental defects, reinforcing its role in developmental pathways. The study also explored the role of Kilham rat virus in these associations, particularly in Mice, where the virus was found to influence the expression of both the thrombin receptor and TGF-betaRI. Aedes mosquitoes were also implicated in the spread of these genetic associations, suggesting a possible environmental component to the observed phenotypes. These findings underscore the importance of sequence variants in the thrombin receptor and TGF-betaRI in the pathogenesis of developmental defects and juvenile open angle glaucoma, with potential implications for viral infections in both Mice and Aedes mosquitoes.
08599787	21	38	thrombin receptor	GeneOrGeneProduct	14062
08599787	43	53	TGF-betaRI	GeneOrGeneProduct	7046
08599787	73	94	developmental defects	DiseaseOrPhenotypicFeature	D003147
08599787	96	124	juvenile open angle glaucoma	DiseaseOrPhenotypicFeature	D005902
08599787	130	146	Kilham rat virus	OrganismTaxon	12441
08599787	160	164	Mice	OrganismTaxon	10090
08599787	261	278	thrombin receptor	GeneOrGeneProduct	14062
08599787	283	293	TGF-betaRI	GeneOrGeneProduct	7046
08599787	317	338	developmental defects	DiseaseOrPhenotypicFeature	D003147
08599787	340	368	juvenile open angle glaucoma	DiseaseOrPhenotypicFeature	D005902
08599787	456	463	p.D815A	SequenceVariant	p|SUB|D|815|A
08599787	472	489	thrombin receptor	GeneOrGeneProduct	14062
08599787	552	562	TGF-betaRI	GeneOrGeneProduct	7046
08599787	596	607	p.Ser119fsX	SequenceVariant	p|FS|S|119||
08599787	649	666	thrombin receptor	GeneOrGeneProduct	14062
08599787	671	681	TGF-betaRI	GeneOrGeneProduct	7046
08599787	758	765	Ile/Val	SequenceVariant	rs1695
08599787	786	803	thrombin receptor	GeneOrGeneProduct	14062
08599787	850	867	thrombin receptor	GeneOrGeneProduct	14062
08599787	872	882	TGF-betaRI	GeneOrGeneProduct	7046
08599787	973	990	thrombin receptor	GeneOrGeneProduct	14062
08599787	1011	1032	developmental defects	DiseaseOrPhenotypicFeature	D003147
08599787	1037	1065	juvenile open angle glaucoma	DiseaseOrPhenotypicFeature	D005902
08599787	1108	1118	TGF-betaRI	GeneOrGeneProduct	7046
08599787	1196	1206	TGF-betaRI	GeneOrGeneProduct	7046
08599787	1211	1228	thrombin receptor	GeneOrGeneProduct	14062
08599787	1345	1355	TGF-betaRI	GeneOrGeneProduct	7046
08599787	1382	1403	developmental defects	DiseaseOrPhenotypicFeature	D003147
08599787	1489	1505	Kilham rat virus	OrganismTaxon	12441
08599787	1545	1549	Mice	OrganismTaxon	10090
08599787	1617	1634	thrombin receptor	GeneOrGeneProduct	14062
08599787	1639	1649	TGF-betaRI	GeneOrGeneProduct	7046
08599787	1651	1667	Aedes mosquitoes	OrganismTaxon	1245352
08599787	1877	1894	thrombin receptor	GeneOrGeneProduct	14062
08599787	1899	1909	TGF-betaRI	GeneOrGeneProduct	7046
08599787	1933	1954	developmental defects	DiseaseOrPhenotypicFeature	D003147
08599787	1959	1987	juvenile open angle glaucoma	DiseaseOrPhenotypicFeature	D005902
08599787	2046	2050	Mice	OrganismTaxon	10090
08599787	2055	2071	Aedes mosquitoes	OrganismTaxon	1245352
08599787	Association	p|SUB|D|815|A	14062	Novel
08599787	Association	7046	D005902	Novel
08599787	Association	rs1695	14062	Novel
08599787	Positive_Correlation	14062	7046	Novel
08599787	Association	14062	D005902	Novel
08599787	Association	14062	D003147	Novel
08599787	Association	p|SUB|D|815|A	7046	Novel
08599787	Positive_Correlation	7046	14062	Novel
08599787	Association	rs1695	7046	Novel
08599787	Association	p|FS|S|119||	7046	Novel
08599787	Association	7046	D003147	Novel
08599787	Association	p|FS|S|119||	14062	Novel

34220188|t|Escherichia coli and the role of O2- in modulating lactate dehydrogenase A, guanine-nucleotide exchange factor, C-peptide, and TPO inte
34220188|a|Recent studies have highlighted the complex interplay between Escherichia coli and various molecular entities, including O2-, lactate dehydrogenase A, guanine-nucleotide exchange factor, C-peptide, and TPO. This research explores the multifaceted relationships among these components in the context of bacterial physiology and host-pathogen interactions.   Escherichia coli, a common Gram-negative bacterium, has been shown to interact with O2- in multiple cellular processes, including oxidative stress response and energy metabolism. The association between lactate dehydrogenase A and TPO was observed in several experimental models, suggesting a potential regulatory role of TPO in lactate dehydrogenase A activity. Additionally, lactate dehydrogenase A was found to bind O2-, indicating a direct interaction that may influence metabolic pathways under hypoxic conditions.  The guanine-nucleotide exchange factor was also found to bind O2-, suggesting a possible role in signal transduction pathways involving reactive oxygen species. Furthermore, the association between lactate dehydrogenase A and guanine-nucleotide exchange factor was confirmed through co-immunoprecipitation and proximity ligation assays, indicating a functional link between these two proteins.  C-peptide, a byproduct of insulin processing, was shown to bind O2- in a dose-dependent manner, potentially modulating its biological activity. The presence of multiple Escherichia coli strains and the repeated observation of O2- interactions with various molecular entities underscore the importance of reactive oxygen species in bacterial adaptation and host response.   These findings provide new insights into the molecular mechanisms underlying Escherichia coli's interactions with host cells and the role of O2- in modulating key metabolic and signaling pathways. The repeated occurrence of these interactions across multiple experimental conditions supports the hypothesis that O2- serves as a critical mediator in the complex network of molecular relationships involving lactate dehydrogenase A, guanine-nucleotide exchange factor, C-peptide, and TPO.
34220188	0	16	Escherichia coli	OrganismTaxon	562
34220188	33	36	O2-	ChemicalEntity	D013481
34220188	76	110	guanine-nucleotide exchange factor	GeneOrGeneProduct	9138
34220188	112	121	C-peptide	GeneOrGeneProduct	3630
34220188	127	130	TPO	GeneOrGeneProduct	7066
34220188	198	214	Escherichia coli	OrganismTaxon	562
34220188	257	260	O2-	ChemicalEntity	D013481
34220188	287	321	guanine-nucleotide exchange factor	GeneOrGeneProduct	9138
34220188	323	332	C-peptide	GeneOrGeneProduct	3630
34220188	338	341	TPO	GeneOrGeneProduct	7066
34220188	493	509	Escherichia coli	OrganismTaxon	562
34220188	577	580	O2-	ChemicalEntity	D013481
34220188	724	727	TPO	GeneOrGeneProduct	7066
34220188	815	818	TPO	GeneOrGeneProduct	7066
34220188	912	915	O2-	ChemicalEntity	D013481
34220188	1018	1052	guanine-nucleotide exchange factor	GeneOrGeneProduct	9138
34220188	1076	1079	O2-	ChemicalEntity	D013481
34220188	1240	1274	guanine-nucleotide exchange factor	GeneOrGeneProduct	9138
34220188	1409	1418	C-peptide	GeneOrGeneProduct	3630
34220188	1473	1476	O2-	ChemicalEntity	D013481
34220188	1578	1594	Escherichia coli	OrganismTaxon	562
34220188	1635	1638	O2-	ChemicalEntity	D013481
34220188	1859	1875	Escherichia coli	OrganismTaxon	562
34220188	1923	1926	O2-	ChemicalEntity	D013481
34220188	2094	2097	O2-	ChemicalEntity	D013481
34220188	2213	2247	guanine-nucleotide exchange factor	GeneOrGeneProduct	9138
34220188	2249	2258	C-peptide	GeneOrGeneProduct	3630
34220188	2264	2267	TPO	GeneOrGeneProduct	7066
34220188	Association	3939	7066	Novel
34220188	Bind	3630	D013481	Novel
34220188	Bind	9138	D013481	Novel
34220188	Bind	3939	D013481	Novel
34220188	Association	3939	9138	Novel

81720470|t|ERK-1/2 signaling and T2734C variant in horses: implications for language delay and cellular responses in hRPT
81720470|a|Recent studies have highlighted the critical role of extracellular signal-regulated kinase (ERK)-1/2 in modulating neural development and synaptic plasticity, which are essential for language acquisition. In horses, a significant association has been observed between the T2734C sequence variant and altered ERK-1/2 activity, suggesting a potential genetic mechanism underlying language delay in equine models. This finding is further supported by the presence of the T2734C variant in multiple horses exhibiting language delay, which correlates with reduced ERK-1/2 phosphorylation levels.   The hRPTEC cell line, derived from renal epithelial tissue, has been used to investigate the molecular pathways linking ERK-1/2 signaling to language delay. In these cells, the T2734C variant was found to be associated with a decrease in ERK-1/2 activation, which may reflect a broader mechanism of impaired neural signaling. Notably, the association between language delay and ERK-1/2 activity was confirmed in multiple independent studies, with a negative correlation observed in horses carrying the T2734C variant. This negative correlation suggests that increased ERK-1/2 activity may be protective against language delay, while reduced activity is linked to its occurrence.  Further analysis of the T2734C variant in horses revealed a consistent association with ERK-1/2 signaling, with the variant being present in 5 out of 8 horses with language delay. In contrast, the variant was absent in 3 horses without language delay, reinforcing the link between the T2734C sequence variant and ERK-1/2 function. These findings provide strong evidence for the role of ERK-1/2 in the pathogenesis of language delay and highlight the importance of genetic variants like T2734C in modulating this pathway. The hRPTEC cell line has also been used to demonstrate that the T2734C variant leads to a reduction in ERK-1/2 phosphorylation, which may contribute to the observed phenotypic effects in horses. Overall, these studies underscore the complex interplay between genetic variants, signaling pathways, and phenotypic outcomes in horses.
81720470	22	28	T2734C	SequenceVariant	c|SYB|T2734|C
81720470	40	46	horses	OrganismTaxon	9796
81720470	65	79	language delay	DiseaseOrPhenotypicFeature	D007805
81720470	164	211	extracellular signal-regulated kinase (ERK)-1/2	GeneOrGeneProduct	5595
81720470	319	325	horses	OrganismTaxon	9796
81720470	383	389	T2734C	SequenceVariant	c|SYB|T2734|C
81720470	489	503	language delay	DiseaseOrPhenotypicFeature	D007805
81720470	579	585	T2734C	SequenceVariant	c|SYB|T2734|C
81720470	606	612	horses	OrganismTaxon	9796
81720470	624	638	language delay	DiseaseOrPhenotypicFeature	D007805
81720470	708	714	hRPTEC	CellLine	CVCL_K278
81720470	845	859	language delay	DiseaseOrPhenotypicFeature	D007805
81720470	881	887	T2734C	SequenceVariant	c|SYB|T2734|C
81720470	1063	1077	language delay	DiseaseOrPhenotypicFeature	D007805
81720470	1186	1192	horses	OrganismTaxon	9796
81720470	1206	1212	T2734C	SequenceVariant	c|SYB|T2734|C
81720470	1315	1329	language delay	DiseaseOrPhenotypicFeature	D007805
81720470	1408	1414	T2734C	SequenceVariant	c|SYB|T2734|C
81720470	1426	1432	horses	OrganismTaxon	9796
81720470	1536	1542	horses	OrganismTaxon	9796
81720470	1548	1562	language delay	DiseaseOrPhenotypicFeature	D007805
81720470	1605	1611	horses	OrganismTaxon	9796
81720470	1620	1634	language delay	DiseaseOrPhenotypicFeature	D007805
81720470	1669	1675	T2734C	SequenceVariant	c|SYB|T2734|C
81720470	1801	1815	language delay	DiseaseOrPhenotypicFeature	D007805
81720470	1870	1876	T2734C	SequenceVariant	c|SYB|T2734|C
81720470	1909	1915	hRPTEC	CellLine	CVCL_K278
81720470	1969	1975	T2734C	SequenceVariant	c|SYB|T2734|C
81720470	2092	2098	horses	OrganismTaxon	9796
81720470	2229	2235	horses	OrganismTaxon	9796
81720470	Association	D007805	5595	Novel
81720470	Negative_Correlation	D007805	5595	Novel
81720470	Association	c|SYB|T2734|C	5595	Novel

96340093|t|Apolipoprotein E and CHL2 Interactions in the Context of Benign Prostatic Hyperplasia, Developmental Delay, and Ventricular Tachycardia: A Multifactorial Analysis Involving Ponatinib and 5-Hydroxyindoleace
96340093|a|This study investigates the complex interactions between apolipoprotein E, CHL2, and various chemical entities in the context of multiple diseases and phenotypic features, including benign prostatic hyperplasia, developmental delay, and ventricular tachycardia. The research highlights the multifaceted roles of apolipoprotein E and CHL2 in modulating disease progression and response to therapeutic agents such as ponatinib and 5-hydroxyindoleacetic acid.   Apolipoprotein E was found to exhibit a negative correlation with both doxycycline and 5-hydroxyindoleacetic acid, suggesting a potential inhibitory effect of these compounds on apolipoprotein E activity. Conversely, a positive correlation was observed between apolipoprotein E and ponatinib, indicating that ponatinib may enhance apolipoprotein E expression or function. Additionally, a positive correlation was noted between doxycycline and apolipoprotein E, suggesting a possible synergistic relationship between these two entities.   CHL2 showed a positive correlation with ponatinib, while a negative correlation was observed between CHL2 and doxycycline, indicating that these two chemical entities may have opposing effects on CHL2 expression or activity. Furthermore, a negative correlation was found between CHL2 and 5-hydroxyindoleacetic acid, suggesting a potential antagonistic relationship. Importantly, a bind was identified between apolipoprotein E and CHL2, highlighting a direct molecular interaction that may play a critical role in disease mechanisms.   The study also revealed that apolipoprotein E and CHL2 are significantly associated with benign prostatic hyperplasia, developmental delay, and ventricular tachycardia, with apolipoprotein E showing a stronger association with developmental delay and ventricular tachycardia. These findings underscore the importance of understanding the interplay between these molecular entities in the context of complex diseases and their potential as therapeutic targets. The results provide a foundation for further research into the molecular mechanisms underlying these conditions and the development of targeted interventions.
96340093	21	25	CHL2	GeneOrGeneProduct	69121
96340093	263	279	apolipoprotein E	GeneOrGeneProduct	348
96340093	281	285	CHL2	GeneOrGeneProduct	69121
96340093	388	416	benign prostatic hyperplasia	DiseaseOrPhenotypicFeature	D011470
96340093	418	437	developmental delay	DiseaseOrPhenotypicFeature	D002658
96340093	443	466	ventricular tachycardia	DiseaseOrPhenotypicFeature	D017180
96340093	518	534	apolipoprotein E	GeneOrGeneProduct	348
96340093	539	543	CHL2	GeneOrGeneProduct	69121
96340093	621	630	ponatinib	ChemicalEntity	C545373
96340093	635	661	5-hydroxyindoleacetic acid	ChemicalEntity	D006897
96340093	736	747	doxycycline	ChemicalEntity	D004318
96340093	752	778	5-hydroxyindoleacetic acid	ChemicalEntity	D006897
96340093	843	859	apolipoprotein E	GeneOrGeneProduct	348
96340093	926	942	apolipoprotein E	GeneOrGeneProduct	348
96340093	947	956	ponatinib	ChemicalEntity	C545373
96340093	974	983	ponatinib	ChemicalEntity	C545373
96340093	996	1012	apolipoprotein E	GeneOrGeneProduct	348
96340093	1092	1103	doxycycline	ChemicalEntity	D004318
96340093	1108	1124	apolipoprotein E	GeneOrGeneProduct	348
96340093	1203	1207	CHL2	GeneOrGeneProduct	69121
96340093	1243	1252	ponatinib	ChemicalEntity	C545373
96340093	1304	1308	CHL2	GeneOrGeneProduct	69121
96340093	1313	1324	doxycycline	ChemicalEntity	D004318
96340093	1399	1403	CHL2	GeneOrGeneProduct	69121
96340093	1482	1486	CHL2	GeneOrGeneProduct	69121
96340093	1491	1517	5-hydroxyindoleacetic acid	ChemicalEntity	D006897
96340093	1612	1628	apolipoprotein E	GeneOrGeneProduct	348
96340093	1633	1637	CHL2	GeneOrGeneProduct	69121
96340093	1767	1783	apolipoprotein E	GeneOrGeneProduct	348
96340093	1788	1792	CHL2	GeneOrGeneProduct	69121
96340093	1827	1855	benign prostatic hyperplasia	DiseaseOrPhenotypicFeature	D011470
96340093	1857	1876	developmental delay	DiseaseOrPhenotypicFeature	D002658
96340093	1882	1905	ventricular tachycardia	DiseaseOrPhenotypicFeature	D017180
96340093	1912	1928	apolipoprotein E	GeneOrGeneProduct	348
96340093	1965	1984	developmental delay	DiseaseOrPhenotypicFeature	D002658
96340093	1989	2012	ventricular tachycardia	DiseaseOrPhenotypicFeature	D017180
96340093	Negative_Correlation	69121	D004318	Novel
96340093	Positive_Correlation	D004318	348	Novel
96340093	Positive_Correlation	D006897	348	Novel
96340093	Positive_Correlation	D006897	69121	Novel
96340093	Negative_Correlation	348	D006897	Novel
96340093	Negative_Correlation	348	D004318	Novel
96340093	Positive_Correlation	C545373	69121	Novel
96340093	Negative_Correlation	69121	C545373	Novel
96340093	Bind	348	69121	Novel
96340093	Negative_Correlation	348	C545373	Novel
96340093	Negative_Correlation	69121	D006897	Novel
96340093	Positive_Correlation	C545373	348	Novel
96340093	Positive_Correlation	D004318	69121	Novel
96340093	Bind	69121	348	Novel

37949192|t|Regulation of Mg+2 ATPase and C2 in LNCaP and PC-3 cells: interactions with prednisolone, ibrutinib, and MHC class 
37949192|a|Recent studies have explored the complex regulatory networks involving Mg+2 ATPase, C2, and MHC class I and II in various cell lines, including LNCaP and PC-3. In LNCaP cells, Mg+2 ATPase levels were found to be negatively correlated with prednisolone treatment, suggesting a potential inhibitory effect of prednisolone on Mg+2 ATPase activity. Similarly, ibrutinib was shown to have a negative correlation with Mg+2 ATPase, indicating that ibrutinib may interfere with the function of this enzyme. These findings were further supported by experiments in PC-3 cells, where both prednisolone and ibrutinib consistently reduced Mg+2 ATPase expression.   In contrast, C2 exhibited a positive correlation with prednisolone, suggesting that prednisolone may enhance the expression or activity of C2. This relationship was observed in both LNCaP and PC-3 cell lines, as well as in MES-SA/Dx5 cells. Additionally, epsinR was found to have a positive correlation with MHC class I and II, indicating a potential role for epsinR in the regulation of these immune-related proteins. This was further supported by the positive correlation between MHC class I and II and C2, suggesting a coordinated regulatory mechanism involving these three gene products.  The study also included experiments using Aedes mosquitoes to assess the impact of Mg+2 ATPase and prednisolone on cellular processes in non-mammalian systems. These findings highlight the importance of Mg+2 ATPase, C2, and MHC class I and II in cellular signaling and immune responses, with implications for therapeutic strategies targeting these pathways in both human and vector biology.
37949192	14	25	Mg+2 ATPase	ChemicalEntity	D017301
37949192	30	32	C2	GeneOrGeneProduct	717
37949192	36	41	LNCaP	CellLine	CVCL_0395
37949192	46	50	PC-3	CellLine	CVCL_0035
37949192	76	88	prednisolone	ChemicalEntity	D011239
37949192	90	99	ibrutinib	ChemicalEntity	C551803
37949192	187	198	Mg+2 ATPase	ChemicalEntity	D017301
37949192	200	202	C2	GeneOrGeneProduct	717
37949192	208	226	MHC class I and II	GeneOrGeneProduct	14961
37949192	260	265	LNCaP	CellLine	CVCL_0395
37949192	270	274	PC-3	CellLine	CVCL_0035
37949192	279	284	LNCaP	CellLine	CVCL_0395
37949192	292	303	Mg+2 ATPase	ChemicalEntity	D017301
37949192	355	367	prednisolone	ChemicalEntity	D011239
37949192	423	435	prednisolone	ChemicalEntity	D011239
37949192	439	450	Mg+2 ATPase	ChemicalEntity	D017301
37949192	472	481	ibrutinib	ChemicalEntity	C551803
37949192	528	539	Mg+2 ATPase	ChemicalEntity	D017301
37949192	557	566	ibrutinib	ChemicalEntity	C551803
37949192	671	675	PC-3	CellLine	CVCL_0035
37949192	694	706	prednisolone	ChemicalEntity	D011239
37949192	711	720	ibrutinib	ChemicalEntity	C551803
37949192	742	753	Mg+2 ATPase	ChemicalEntity	D017301
37949192	781	783	C2	GeneOrGeneProduct	717
37949192	822	834	prednisolone	ChemicalEntity	D011239
37949192	852	864	prednisolone	ChemicalEntity	D011239
37949192	907	909	C2	GeneOrGeneProduct	717
37949192	950	955	LNCaP	CellLine	CVCL_0395
37949192	960	964	PC-3	CellLine	CVCL_0035
37949192	991	1001	MES-SA/Dx5	CellLine	CVCL_2598
37949192	1023	1029	epsinR	GeneOrGeneProduct	9685
37949192	1076	1094	MHC class I and II	GeneOrGeneProduct	14961
37949192	1128	1134	epsinR	GeneOrGeneProduct	9685
37949192	1250	1268	MHC class I and II	GeneOrGeneProduct	14961
37949192	1273	1275	C2	GeneOrGeneProduct	717
37949192	1403	1419	Aedes mosquitoes	OrganismTaxon	1245352
37949192	1444	1455	Mg+2 ATPase	ChemicalEntity	D017301
37949192	1460	1472	prednisolone	ChemicalEntity	D011239
37949192	1564	1575	Mg+2 ATPase	ChemicalEntity	D017301
37949192	1577	1579	C2	GeneOrGeneProduct	717
37949192	1585	1603	MHC class I and II	GeneOrGeneProduct	14961
37949192	Negative_Correlation	D017301	D011239	Novel
37949192	Negative_Correlation	C551803	D017301	Novel
37949192	Negative_Correlation	D017301	C551803	Novel
37949192	Positive_Correlation	717	D011239	Novel
37949192	Positive_Correlation	9685	14961	Novel
37949192	Positive_Correlation	14961	717	Novel

21478250|t|Genetic variants and their associations with metabolic disorders and neurodevelopmental conditions in Zebrafish and Mangifera ind
21478250|a|This study investigates the genetic and biochemical interactions of specific sequence variants with metabolic and neurodevelopmental phenotypes in Zebrafish and Mangifera indica Linn. We focus on the sequence variant c.695T>A, which shows an association with glutamine levels, while also exhibiting a negative correlation with scopolamine and Resistance to thyroid hormone syndrome. The variant Gln27Glu is found to have a negative correlation with both Macular corneal dystrophy and Resistance to thyroid hormone syndrome, and a negative correlation with scopolamine. The sequence variant R47W is associated with scopolamine and shows a negative correlation with Meckel-Gruber syndrome (MKS) type 3. The variant rs1800872 is negatively correlated with both Meckel-Gruber syndrome (MKS) type 3 and Macular corneal dystrophy. The amino acid substitution glycine to glutamine is associated with glutamine and also negatively correlated with Meckel-Gruber syndrome (MKS) type 3. In Zebrafish models, the variant Gln27Glu is linked to altered metabolic profiles, while in Mangifera indica Linn, the variant rs1800872 is associated with developmental anomalies. The study highlights the complex interplay between genetic variants and their biochemical and phenotypic consequences, providing insights into the molecular mechanisms underlying these conditions.
21478250	102	111	Zebrafish	OrganismTaxon	7955
21478250	277	286	Zebrafish	OrganismTaxon	7955
21478250	291	312	Mangifera indica Linn	OrganismTaxon	29780
21478250	347	355	c.695T>A	SequenceVariant	c|SUB|T|695|A
21478250	389	398	glutamine	ChemicalEntity	D005973
21478250	457	468	scopolamine	ChemicalEntity	D012601
21478250	473	511	Resistance to thyroid hormone syndrome	DiseaseOrPhenotypicFeature	D018382
21478250	525	533	Gln27Glu	SequenceVariant	p|SUB|Q|27|E
21478250	584	609	Macular corneal dystrophy	DiseaseOrPhenotypicFeature	D003317
21478250	614	652	Resistance to thyroid hormone syndrome	DiseaseOrPhenotypicFeature	D018382
21478250	686	697	scopolamine	ChemicalEntity	D012601
21478250	720	724	R47W	SequenceVariant	rs121917720
21478250	744	755	scopolamine	ChemicalEntity	D012601
21478250	794	829	Meckel-Gruber syndrome (MKS) type 3	DiseaseOrPhenotypicFeature	C536132
21478250	843	852	rs1800872	SequenceVariant	rs1800872
21478250	888	923	Meckel-Gruber syndrome (MKS) type 3	DiseaseOrPhenotypicFeature	C536132
21478250	928	953	Macular corneal dystrophy	DiseaseOrPhenotypicFeature	D003317
21478250	983	1003	glycine to glutamine	SequenceVariant	p|SUB|G||Q
21478250	994	1003	glutamine	ChemicalEntity	D005973
21478250	1023	1032	glutamine	ChemicalEntity	D005973
21478250	1069	1104	Meckel-Gruber syndrome (MKS) type 3	DiseaseOrPhenotypicFeature	C536132
21478250	1109	1118	Zebrafish	OrganismTaxon	7955
21478250	1139	1147	Gln27Glu	SequenceVariant	p|SUB|Q|27|E
21478250	1198	1219	Mangifera indica Linn	OrganismTaxon	29780
21478250	1233	1242	rs1800872	SequenceVariant	rs1800872
21478250	Negative_Correlation	p|SUB|Q|27|E	D003317	Novel
21478250	Negative_Correlation	p|SUB|G||Q	D005973	Novel
21478250	Negative_Correlation	rs1800872	C536132	Novel
21478250	Negative_Correlation	rs121917720	C536132	Novel
21478250	Negative_Correlation	p|SUB|G||Q	C536132	Novel
21478250	Association	c|SUB|T|695|A	D005973	Novel
21478250	Negative_Correlation	p|SUB|Q|27|E	D012601	Novel
21478250	Negative_Correlation	c|SUB|T|695|A	D005973	Novel
21478250	Association	rs121917720	D012601	Novel
21478250	Association	p|SUB|G||Q	D005973	Novel
21478250	Negative_Correlation	rs1800872	D003317	Novel
21478250	Negative_Correlation	p|SUB|Q|27|E	D018382	Novel
21478250	Negative_Correlation	c|SUB|T|695|A	D012601	Novel
21478250	Negative_Correlation	c|SUB|T|695|A	D018382	Novel

79569519|t|Complex Interactions Between Aedes Mosquitoes, S. cerevisiae, and Human Pathogens: A Study on Chemical Entities and Their Biological
79569519|a|This study explores the intricate relationships between various chemical entities and their interactions with multiple organisms, including Aedes mosquitoes, S. cerevisiae, and human pathogens such as the human immunodeficiency virus (HIV) and West Nile virus (WNV). The research highlights the dynamic interplay between chemical compounds like collagenase, aconitine, adrenaline, verapamil, glimepiride, and Ca2+, and their roles in biological processes.   A key finding is the positive correlation between glimepiride and Ca2+, which suggests a potential therapeutic application in modulating intracellular calcium levels. Additionally, the cotreatment of adrenaline with both W and Ca2+ indicates a complex regulatory network involving these compounds. The association between verapamil and collagenase, as well as the positive correlation between verapamil and aconitine, underscores the importance of these drugs in enzyme activity and cellular signaling.  The study also reveals a strong association between aconitine and collagenase, with a conversion between aconitine and Ca2+ further emphasizing the role of these compounds in metabolic pathways. The cotreatment of W with glimepiride and the positive correlation between W and collagenase suggest a potential therapeutic synergy in managing viral infections.   Notably, the cotreatment of collagenase with adrenaline and the conversion between collagenase and W highlight the multifaceted roles of these entities in both enzymatic and pathogenic contexts. The comparison between W and adrenaline, as well as the positive correlation between adrenaline and collagenase, provides insights into the mechanisms underlying immune responses.   The study further demonstrates the positive correlation between Ca2+ and verapamil, and the cotreatment of glimepiride with Ca2+ and aconitine, reinforcing the need for a comprehensive understanding of these interactions. The presence of multiple instances of Aedes mosquitoes, S. cerevisiae, and bacteria in the study reflects the broad scope of the research, which spans from microbial interactions to human health implications.   Overall, this research contributes to the growing body of knowledge on the complex relationships between chemical entities and their biological effects, offering new perspectives on potential therapeutic strategies and disease mechanisms.
79569519	47	60	S. cerevisiae	OrganismTaxon	4932
79569519	273	289	Aedes mosquitoes	OrganismTaxon	1245352
79569519	291	304	S. cerevisiae	OrganismTaxon	4932
79569519	338	366	human immunodeficiency virus	OrganismTaxon	12721
79569519	377	392	West Nile virus	OrganismTaxon	11082
79569519	377	378	W	ChemicalEntity	D014859
79569519	394	395	W	ChemicalEntity	D014859
79569519	478	489	collagenase	ChemicalEntity	D017364
79569519	491	500	aconitine	ChemicalEntity	D000157
79569519	502	512	adrenaline	ChemicalEntity	D004837
79569519	514	523	verapamil	ChemicalEntity	D014700
79569519	525	536	glimepiride	ChemicalEntity	C057619
79569519	542	546	Ca2+	ChemicalEntity	D000069285
79569519	641	652	glimepiride	ChemicalEntity	C057619
79569519	657	661	Ca2+	ChemicalEntity	D000069285
79569519	791	801	adrenaline	ChemicalEntity	D004837
79569519	812	813	W	ChemicalEntity	D014859
79569519	818	822	Ca2+	ChemicalEntity	D000069285
79569519	913	922	verapamil	ChemicalEntity	D014700
79569519	927	938	collagenase	ChemicalEntity	D017364
79569519	984	993	verapamil	ChemicalEntity	D014700
79569519	998	1007	aconitine	ChemicalEntity	D000157
79569519	1147	1156	aconitine	ChemicalEntity	D000157
79569519	1161	1172	collagenase	ChemicalEntity	D017364
79569519	1200	1209	aconitine	ChemicalEntity	D000157
79569519	1214	1218	Ca2+	ChemicalEntity	D000069285
79569519	1309	1310	W	ChemicalEntity	D014859
79569519	1316	1327	glimepiride	ChemicalEntity	C057619
79569519	1365	1366	W	ChemicalEntity	D014859
79569519	1371	1382	collagenase	ChemicalEntity	D017364
79569519	1483	1494	collagenase	ChemicalEntity	D017364
79569519	1500	1510	adrenaline	ChemicalEntity	D004837
79569519	1538	1549	collagenase	ChemicalEntity	D017364
79569519	1554	1555	W	ChemicalEntity	D014859
79569519	1673	1674	W	ChemicalEntity	D014859
79569519	1679	1689	adrenaline	ChemicalEntity	D004837
79569519	1735	1745	adrenaline	ChemicalEntity	D004837
79569519	1750	1761	collagenase	ChemicalEntity	D017364
79569519	1896	1900	Ca2+	ChemicalEntity	D000069285
79569519	1905	1914	verapamil	ChemicalEntity	D014700
79569519	1939	1950	glimepiride	ChemicalEntity	C057619
79569519	1956	1960	Ca2+	ChemicalEntity	D000069285
79569519	1965	1974	aconitine	ChemicalEntity	D000157
79569519	2092	2108	Aedes mosquitoes	OrganismTaxon	1245352
79569519	2110	2123	S. cerevisiae	OrganismTaxon	4932
79569519	2129	2137	bacteria	OrganismTaxon	2
79569519	Positive_Correlation	C057619	D000069285	Novel
79569519	Cotreatment	D004837	D014859	Novel
79569519	Cotreatment	D004837	D000069285	Novel
79569519	Association	D014700	D017364	Novel
79569519	Positive_Correlation	C057619	D014859	Novel
79569519	Association	D000157	D014700	Novel
79569519	Positive_Correlation	D014700	D000157	Novel
79569519	Cotreatment	D014859	C057619	Novel
79569519	Cotreatment	D000157	D014700	Novel
79569519	Association	C057619	D014859	Novel
79569519	Association	D000157	D017364	Novel
79569519	Conversion	D000069285	D000157	Novel
79569519	Positive_Correlation	D004837	D017364	Novel
79569519	Association	D014859	D000069285	Novel
79569519	Association	D004837	D017364	Novel
79569519	Conversion	D017364	D014859	Novel
79569519	Association	D004837	C057619	Novel
79569519	Cotreatment	D017364	D004837	Novel
79569519	Cotreatment	D014859	D000069285	Novel
79569519	Cotreatment	C057619	D017364	Novel
79569519	Cotreatment	C057619	D000157	Novel
79569519	Positive_Correlation	D000069285	D014700	Novel
79569519	Cotreatment	C057619	D000069285	Novel
79569519	Conversion	C057619	D004837	Novel
79569519	Comparison	D014859	D004837	Novel
79569519	Positive_Correlation	D014859	D017364	Novel
79569519	Conversion	D000157	D000069285	Novel
79569519	Comparison	D000069285	D004837	Novel

93101697|t|Zinc, Trypan Blue, and Lovastatin: Comparative and Correlational Studies in Degenerative Disease and Osteoarthritis in Dogs and Platonia insig
93101697|a|A comprehensive study was conducted to investigate the comparative and correlational effects of zinc, trypan blue, and lovastatin in the context of degenerative disease, osteoarthritis, and their associations with dogs and Platonia insignis Mart. The research aimed to evaluate the interactions between these chemical entities and their potential roles in the progression of degenerative disease and osteoarthritis.   The study revealed a negative correlation between trypan blue and zinc, as well as a negative correlation between zinc and trypan blue, indicating that these two chemical entities may have opposing effects in the context of these diseases. Additionally, a positive correlation was observed between zinc and degenerative disease, suggesting that zinc levels may be associated with the severity of degenerative disease.   Lovastatin was found to have an association with both degenerative disease and osteoarthritis, with a positive correlation between lovastatin and osteoarthritis. Furthermore, a drug interaction was identified between lovastatin and trypan blue, highlighting the need for caution in their concurrent use.   The study also demonstrated a negative correlation between osteoarthritis and zinc, suggesting that zinc may have a protective role against the development of osteoarthritis. Additionally, an association was found between degenerative disease and trypan blue, indicating that trypan blue may play a role in the pathogenesis of degenerative disease.   Comparative analyses between trypan blue and zinc, as well as between trypan blue and lovastatin, were conducted to better understand their respective roles in the context of these diseases. The findings underscore the complex interplay between these chemical entities and their potential therapeutic or pathological implications in dogs and Platonia insignis Mart. The results provide a foundation for further research into the mechanisms underlying these associations and their clinical relevance.
93101697	239	243	zinc	ChemicalEntity	D015032
93101697	245	256	trypan blue	ChemicalEntity	D014343
93101697	262	272	lovastatin	ChemicalEntity	D008148
93101697	291	311	degenerative disease	DiseaseOrPhenotypicFeature	D019636
93101697	313	327	osteoarthritis	DiseaseOrPhenotypicFeature	D010003
93101697	357	361	dogs	OrganismTaxon	9615
93101697	366	388	Platonia insignis Mart	OrganismTaxon	198787
93101697	518	538	degenerative disease	DiseaseOrPhenotypicFeature	D019636
93101697	543	557	osteoarthritis	DiseaseOrPhenotypicFeature	D010003
93101697	611	622	trypan blue	ChemicalEntity	D014343
93101697	627	631	zinc	ChemicalEntity	D015032
93101697	675	679	zinc	ChemicalEntity	D015032
93101697	684	695	trypan blue	ChemicalEntity	D014343
93101697	859	863	zinc	ChemicalEntity	D015032
93101697	868	888	degenerative disease	DiseaseOrPhenotypicFeature	D019636
93101697	906	910	zinc	ChemicalEntity	D015032
93101697	957	977	degenerative disease	DiseaseOrPhenotypicFeature	D019636
93101697	1035	1055	degenerative disease	DiseaseOrPhenotypicFeature	D019636
93101697	1060	1074	osteoarthritis	DiseaseOrPhenotypicFeature	D010003
93101697	1112	1122	lovastatin	ChemicalEntity	D008148
93101697	1127	1141	osteoarthritis	DiseaseOrPhenotypicFeature	D010003
93101697	1198	1208	lovastatin	ChemicalEntity	D008148
93101697	1213	1224	trypan blue	ChemicalEntity	D014343
93101697	1346	1360	osteoarthritis	DiseaseOrPhenotypicFeature	D010003
93101697	1365	1369	zinc	ChemicalEntity	D015032
93101697	1387	1391	zinc	ChemicalEntity	D015032
93101697	1446	1460	osteoarthritis	DiseaseOrPhenotypicFeature	D010003
93101697	1509	1529	degenerative disease	DiseaseOrPhenotypicFeature	D019636
93101697	1534	1545	trypan blue	ChemicalEntity	D014343
93101697	1563	1574	trypan blue	ChemicalEntity	D014343
93101697	1614	1634	degenerative disease	DiseaseOrPhenotypicFeature	D019636
93101697	1667	1678	trypan blue	ChemicalEntity	D014343
93101697	1683	1687	zinc	ChemicalEntity	D015032
93101697	1708	1719	trypan blue	ChemicalEntity	D014343
93101697	1724	1734	lovastatin	ChemicalEntity	D008148
93101697	1971	1975	dogs	OrganismTaxon	9615
93101697	1980	2002	Platonia insignis Mart	OrganismTaxon	198787
93101697	Comparison	D015032	D014343	Novel
93101697	Negative_Correlation	D014343	D015032	Novel
93101697	Negative_Correlation	D010003	D015032	Novel
93101697	Drug_Interaction	D008148	D014343	Novel
93101697	Negative_Correlation	D019636	D014343	Novel
93101697	Association	D019636	D008148	Novel
93101697	Comparison	D014343	D015032	Novel
93101697	Positive_Correlation	D015032	D019636	Novel
93101697	Association	D019636	D014343	Novel
93101697	Association	D010003	D008148	Novel
93101697	Comparison	D014343	D008148	Novel
93101697	Negative_Correlation	D015032	D014343	Novel
93101697	Positive_Correlation	D008148	D010003	Novel

42819038|t|Adrenaline Modulation of HEB and YWHAZ in the Context of Mucolipidosis III Gamma and Left Ventricular Hyp
42819038|a|This study investigates the complex interplay between adrenaline signaling, genetic variants, and disease phenotypes in the context of mucolipidosis III gamma and left ventricular hypertrophy. We demonstrate a significant positive correlation between mucolipidosis III gamma and the sequence variant Arg124Leu, as well as between mucolipidosis III gamma and the insertion variant c.14_15insC. These findings suggest that these genetic alterations may contribute to the pathogenesis of mucolipidosis III gamma through altered protein function and structural stability.   Further, we observe a negative correlation between left ventricular hypertrophy and the gene product HEB, indicating that HEB may act as a protective factor against the development of this cardiac condition. Our data also highlight the involvement of YWHAZ in the regulation of cellular responses to adrenaline, with two distinct instances of YWHAZ expression observed in different experimental conditions.   Additionally, we find that the p38 Mitogen-activated protein kinase pathway is modulated by adrenaline, and this modulation is influenced by the presence of the HEB gene product. The study underscores the importance of understanding the molecular mechanisms underlying the interactions between adrenaline, genetic variants, and disease phenotypes, particularly in the context of mucolipidosis III gamma and left ventricular hypertrophy. These findings provide a foundation for future research into targeted therapeutic strategies for these conditions.
42819038	25	28	HEB	GeneOrGeneProduct	21406
42819038	33	38	YWHAZ	GeneOrGeneProduct	7534
42819038	160	170	adrenaline	ChemicalEntity	D004837
42819038	241	264	mucolipidosis III gamma	DiseaseOrPhenotypicFeature	C565367
42819038	269	297	left ventricular hypertrophy	DiseaseOrPhenotypicFeature	D017379
42819038	357	380	mucolipidosis III gamma	DiseaseOrPhenotypicFeature	C565367
42819038	406	415	Arg124Leu	SequenceVariant	rs121909211
42819038	436	459	mucolipidosis III gamma	DiseaseOrPhenotypicFeature	C565367
42819038	486	497	c.14_15insC	SequenceVariant	rs11399890
42819038	591	614	mucolipidosis III gamma	DiseaseOrPhenotypicFeature	C565367
42819038	727	755	left ventricular hypertrophy	DiseaseOrPhenotypicFeature	D017379
42819038	777	780	HEB	GeneOrGeneProduct	21406
42819038	798	801	HEB	GeneOrGeneProduct	21406
42819038	927	932	YWHAZ	GeneOrGeneProduct	7534
42819038	976	986	adrenaline	ChemicalEntity	D004837
42819038	1019	1024	YWHAZ	GeneOrGeneProduct	7534
42819038	1116	1152	p38 Mitogen-activated protein kinase	GeneOrGeneProduct	26416
42819038	1177	1187	adrenaline	ChemicalEntity	D004837
42819038	1246	1249	HEB	GeneOrGeneProduct	21406
42819038	1379	1389	adrenaline	ChemicalEntity	D004837
42819038	1464	1487	mucolipidosis III gamma	DiseaseOrPhenotypicFeature	C565367
42819038	1492	1520	left ventricular hypertrophy	DiseaseOrPhenotypicFeature	D017379
42819038	Positive_Correlation	C565367	rs121909211	Novel
42819038	Positive_Correlation	C565367	rs11399890	Novel
42819038	Negative_Correlation	D017379	21406	Novel

41429355|t|Star-PAP and GDF15 in the context of carcinogenesis: a study in guinea-pigs and the role of 
41429355|a|In this study, we investigated the molecular mechanisms underlying carcinogenesis in guinea-pigs, with a particular focus on the interplay between the gene product Star-PAP, the gene GDF15, and the hormone cortisol. The cell line MES-SA/Dx5 was used as a model system to explore the effects of cortisol on Star-PAP expression, revealing a significant association between cortisol and Star-PAP. Furthermore, we observed a negative correlation between Star-PAP and GDF15, suggesting that Star-PAP may act as a regulatory factor in the expression of GDF15. The cell line GT1-1 was also employed to examine the role of Star-PAP in the progression of carcinogenesis, with results indicating a positive correlation between carcinogenesis and cortisol levels. Additionally, the presence of cortisol was found to modulate the expression of Star-PAP in a manner that may influence the development of cancerous phenotypes. The guinea-pigs used in this study were exposed to varying concentrations of cortisol, and the effects on Star-PAP and GDF15 were monitored over time. Our findings suggest that the relationship between Star-PAP, GDF15, and cortisol is complex and may play a critical role in the pathogenesis of carcinogenesis. The results also highlight the importance of considering the interactions between these molecular entities in the context of disease progression. The cell line MES-SA/Dx5 was used in multiple experiments to validate the observed correlations, while the cell line GT1-1 provided additional insights into the cellular mechanisms involved. The data from this study provide a foundation for further research into the role of Star-PAP and GDF15 in the context of carcinogenesis and their potential as therapeutic targets.
41429355	0	8	Star-PAP	GeneOrGeneProduct	64852
41429355	13	18	GDF15	GeneOrGeneProduct	9518
41429355	37	51	carcinogenesis	DiseaseOrPhenotypicFeature	D063646
41429355	64	75	guinea-pigs	OrganismTaxon	10141
41429355	160	174	carcinogenesis	DiseaseOrPhenotypicFeature	D063646
41429355	178	189	guinea-pigs	OrganismTaxon	10141
41429355	257	265	Star-PAP	GeneOrGeneProduct	64852
41429355	276	281	GDF15	GeneOrGeneProduct	9518
41429355	299	307	cortisol	ChemicalEntity	D006854
41429355	323	333	MES-SA/Dx5	CellLine	CVCL_2598
41429355	387	395	cortisol	ChemicalEntity	D006854
41429355	399	407	Star-PAP	GeneOrGeneProduct	64852
41429355	464	472	cortisol	ChemicalEntity	D006854
41429355	477	485	Star-PAP	GeneOrGeneProduct	64852
41429355	543	551	Star-PAP	GeneOrGeneProduct	64852
41429355	556	561	GDF15	GeneOrGeneProduct	9518
41429355	579	587	Star-PAP	GeneOrGeneProduct	64852
41429355	640	645	GDF15	GeneOrGeneProduct	9518
41429355	661	666	GT1-1	CellLine	CVCL_6236
41429355	708	716	Star-PAP	GeneOrGeneProduct	64852
41429355	739	753	carcinogenesis	DiseaseOrPhenotypicFeature	D063646
41429355	810	824	carcinogenesis	DiseaseOrPhenotypicFeature	D063646
41429355	829	837	cortisol	ChemicalEntity	D006854
41429355	876	884	cortisol	ChemicalEntity	D006854
41429355	925	933	Star-PAP	GeneOrGeneProduct	64852
41429355	1010	1021	guinea-pigs	OrganismTaxon	10141
41429355	1083	1091	cortisol	ChemicalEntity	D006854
41429355	1112	1120	Star-PAP	GeneOrGeneProduct	64852
41429355	1125	1130	GDF15	GeneOrGeneProduct	9518
41429355	1208	1216	Star-PAP	GeneOrGeneProduct	64852
41429355	1218	1223	GDF15	GeneOrGeneProduct	9518
41429355	1229	1237	cortisol	ChemicalEntity	D006854
41429355	1301	1315	carcinogenesis	DiseaseOrPhenotypicFeature	D063646
41429355	1477	1487	MES-SA/Dx5	CellLine	CVCL_2598
41429355	1580	1585	GT1-1	CellLine	CVCL_6236
41429355	1738	1746	Star-PAP	GeneOrGeneProduct	64852
41429355	1751	1756	GDF15	GeneOrGeneProduct	9518
41429355	1775	1789	carcinogenesis	DiseaseOrPhenotypicFeature	D063646
41429355	Association	D006854	64852	Novel
41429355	Negative_Correlation	64852	9518	Novel
41429355	Positive_Correlation	D063646	D006854	Novel
41429355	Negative_Correlation	9518	64852	Novel

93891287|t|Genomic and pharmacological interactions of sequence variants, chemical entities, and organisms in metabolic and viral 
93891287|a|This study explores the complex interplay between sequence variants, chemical entities, and organism taxa in the context of metabolic regulation and viral infection. We investigated the associations between the sequence variant g.3426G>A and c. 1093-1G>T, which were found to be linked in a significant manner. Additionally, the sequence variant c. 1093-1G>T was associated with p.Asp46_Gln48delinsGlu, suggesting a potential functional relationship. The sequence variant G3853A was also found to be associated with A1359A, highlighting the importance of these genetic elements in regulatory pathways.   The sequence variant p.D815A was found to have a negative correlation with phosphatidylcholine, indicating a possible antagonistic relationship. Similarly, simvastatin hydroxy acid exhibited a negative correlation with phosphatidylcholine, suggesting that its metabolic effects may be counteracted by this lipid. In contrast, simvastatin hydroxy acid showed a positive correlation with p.Asp46_Gln48delinsGlu, reinforcing its role in modulating this variant. Furthermore, simvastatin hydroxy acid was positively correlated with Fentanyl, indicating a potential synergistic effect in certain biological contexts.   The comparison between cholesterol and Fentanyl revealed a complex relationship, with Fentanyl showing a distinct metabolic profile in the presence of cholesterol. The sequence variant C61G was associated with p.D815A, suggesting a possible regulatory mechanism. The sequence variant p.Asp46_Gln48delinsGlu was also found to be associated with phosphatidylcholine, further emphasizing its role in lipid metabolism.   The organism taxon Rhodiola rosea was found to interact with multiple sequence variants, including g.3426G>A and c. 1093-1G>T, suggesting a potential role in modulating genetic expression. The organism taxon Kilham rat virus was associated with several sequence variants, including G3853A and C61G, indicating a possible viral influence on genetic stability. The organism taxon tobacco was found to be linked to multiple sequence variants, including p.Asp46_Gln48delinsGlu and G3853A, suggesting a possible environmental impact on genetic expression.   The organism taxon E. coli was associated with several sequence variants, including p.D815A and C61G, indicating a potential role in bacterial-host interactions. The sequence variant G3853A was also found to be associated with c. 1093-1G>T, reinforcing the interconnected nature of these genetic elements. The sequence variant p.Asp46_Gln48delinsGlu was found to be associated with multiple chemical entities, including simvastatin hydroxy acid and phosphatidylcholine, highlighting its central role in metabolic regulation.   Overall, this study provides a comprehensive analysis of the interactions between sequence variants, chemical entities, and organism taxa, offering new insights into the molecular mechanisms underlying metabolic and viral processes.
93891287	348	357	g.3426G>A	SequenceVariant	rs72474224
93891287	362	374	c. 1093-1G>T	SequenceVariant	c|SUB|G|1093-1|T
93891287	466	478	c. 1093-1G>T	SequenceVariant	c|SUB|G|1093-1|T
93891287	499	521	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
93891287	592	598	G3853A	SequenceVariant	c|SUB|G|3853|A
93891287	636	642	A1359A	SequenceVariant	rs1049353
93891287	745	752	p.D815A	SequenceVariant	p|SUB|D|815|A
93891287	799	818	phosphatidylcholine	ChemicalEntity	D010713
93891287	880	904	simvastatin hydroxy acid	ChemicalEntity	C532833
93891287	943	962	phosphatidylcholine	ChemicalEntity	D010713
93891287	1050	1074	simvastatin hydroxy acid	ChemicalEntity	C532833
93891287	1110	1132	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
93891287	1196	1220	simvastatin hydroxy acid	ChemicalEntity	C532833
93891287	1252	1260	Fentanyl	ChemicalEntity	D005283
93891287	1361	1372	cholesterol	ChemicalEntity	D002784
93891287	1377	1385	Fentanyl	ChemicalEntity	D005283
93891287	1424	1432	Fentanyl	ChemicalEntity	D005283
93891287	1489	1500	cholesterol	ChemicalEntity	D002784
93891287	1523	1527	C61G	SequenceVariant	rs28897672
93891287	1548	1555	p.D815A	SequenceVariant	p|SUB|D|815|A
93891287	1622	1644	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
93891287	1682	1701	phosphatidylcholine	ChemicalEntity	D010713
93891287	1774	1788	Rhodiola rosea	OrganismTaxon	203015
93891287	1854	1863	g.3426G>A	SequenceVariant	rs72474224
93891287	1868	1880	c. 1093-1G>T	SequenceVariant	c|SUB|G|1093-1|T
93891287	1963	1979	Kilham rat virus	OrganismTaxon	12441
93891287	2037	2043	G3853A	SequenceVariant	c|SUB|G|3853|A
93891287	2048	2052	C61G	SequenceVariant	rs28897672
93891287	2133	2140	tobacco	OrganismTaxon	4097
93891287	2205	2227	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
93891287	2232	2238	G3853A	SequenceVariant	c|SUB|G|3853|A
93891287	2327	2334	E. coli	OrganismTaxon	562
93891287	2392	2399	p.D815A	SequenceVariant	p|SUB|D|815|A
93891287	2404	2408	C61G	SequenceVariant	rs28897672
93891287	2491	2497	G3853A	SequenceVariant	c|SUB|G|3853|A
93891287	2535	2547	c. 1093-1G>T	SequenceVariant	c|SUB|G|1093-1|T
93891287	2635	2657	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
93891287	2728	2752	simvastatin hydroxy acid	ChemicalEntity	C532833
93891287	2757	2776	phosphatidylcholine	ChemicalEntity	D010713
93891287	Negative_Correlation	p|SUB|D|815|A	D010713	Novel
93891287	Negative_Correlation	C532833	D010713	Novel
93891287	Positive_Correlation	D005283	C532833	Novel
93891287	Association	C532833	p|INDEL|46_48|Glu	Novel
93891287	Association	c|SUB|G|3853|A	rs1049353	Novel
93891287	Association	rs28897672	p|SUB|D|815|A	Novel
93891287	Comparison	D002784	D005283	Novel
93891287	Positive_Correlation	C532833	p|INDEL|46_48|Glu	Novel
93891287	Association	rs72474224	c|SUB|G|1093-1|T	Novel
93891287	Association	D010713	p|INDEL|46_48|Glu	Novel
93891287	Association	c|SUB|G|1093-1|T	p|INDEL|46_48|Glu	Novel
93891287	Association	c|SUB|G|3853|A	c|SUB|G|1093-1|T	Novel

78128956|t|Imatinib and Cerivastatin in the Management of Cauda Equina Syndrome and Tarsal Fusion: A Multifactorial Analysis of Neurological Deficits and In
78128956|a|A recent study investigated the complex interplay between imatinib, cerivastatin, norfloxacin, sodium bicarbonate, and various disease states including cauda equina syndrome, tarsal fusion, neurological deficits, Klebsiella pneumoniae infection, alkaptonuria, and carcinogenesis. The research aimed to elucidate the potential therapeutic and pathological relationships among these entities.   The study found a positive correlation between cauda equina syndrome and sodium bicarbonate, suggesting that sodium bicarbonate may play a role in the pathophysiology or management of this condition. Similarly, a positive correlation was observed between sodium bicarbonate and cauda equina syndrome, reinforcing the potential therapeutic utility of sodium bicarbonate in this context.   Norfloxacin was found to have a positive correlation with both neurological deficits and carcinogenesis, indicating its possible involvement in the development or progression of these conditions. Additionally, imatinib showed a positive correlation with neurological deficits, suggesting a potential role in the modulation of neurological outcomes.   The study also revealed a positive correlation between alkaptonuria and imatinib, which may imply a pharmacological interaction or a shared underlying mechanism. Furthermore, the presence of Klebsiella pneumoniae was associated with multiple disease states, highlighting the complexity of microbial interactions in these conditions.   The findings suggest that the management of cauda equina syndrome and tarsal fusion may require a multifaceted approach, incorporating the use of sodium bicarbonate, imatinib, and other agents such as cerivastatin and norfloxacin. The study underscores the importance of understanding the intricate relationships between chemical entities and disease states in the context of neurological and systemic disorders.
78128956	204	212	imatinib	ChemicalEntity	D000068877
78128956	214	226	cerivastatin	ChemicalEntity	C086276
78128956	228	239	norfloxacin	ChemicalEntity	D009643
78128956	241	259	sodium bicarbonate	ChemicalEntity	D017693
78128956	298	319	cauda equina syndrome	DiseaseOrPhenotypicFeature	D011128
78128956	321	334	tarsal fusion	DiseaseOrPhenotypicFeature	D000070604
78128956	336	357	neurological deficits	DiseaseOrPhenotypicFeature	D009461
78128956	359	380	Klebsiella pneumoniae	DiseaseOrPhenotypicFeature	D007710
78128956	392	404	alkaptonuria	DiseaseOrPhenotypicFeature	D000474
78128956	410	424	carcinogenesis	DiseaseOrPhenotypicFeature	D063646
78128956	586	607	cauda equina syndrome	DiseaseOrPhenotypicFeature	D011128
78128956	612	630	sodium bicarbonate	ChemicalEntity	D017693
78128956	648	666	sodium bicarbonate	ChemicalEntity	D017693
78128956	794	812	sodium bicarbonate	ChemicalEntity	D017693
78128956	817	838	cauda equina syndrome	DiseaseOrPhenotypicFeature	D011128
78128956	889	907	sodium bicarbonate	ChemicalEntity	D017693
78128956	990	1011	neurological deficits	DiseaseOrPhenotypicFeature	D009461
78128956	1016	1030	carcinogenesis	DiseaseOrPhenotypicFeature	D063646
78128956	1137	1145	imatinib	ChemicalEntity	D000068877
78128956	1181	1202	neurological deficits	DiseaseOrPhenotypicFeature	D009461
78128956	1333	1345	alkaptonuria	DiseaseOrPhenotypicFeature	D000474
78128956	1350	1358	imatinib	ChemicalEntity	D000068877
78128956	1469	1490	Klebsiella pneumoniae	DiseaseOrPhenotypicFeature	D007710
78128956	1657	1678	cauda equina syndrome	DiseaseOrPhenotypicFeature	D011128
78128956	1683	1696	tarsal fusion	DiseaseOrPhenotypicFeature	D000070604
78128956	1759	1777	sodium bicarbonate	ChemicalEntity	D017693
78128956	1779	1787	imatinib	ChemicalEntity	D000068877
78128956	1814	1826	cerivastatin	ChemicalEntity	C086276
78128956	1831	1842	norfloxacin	ChemicalEntity	D009643
78128956	Positive_Correlation	D011128	D017693	Novel
78128956	Positive_Correlation	D017693	D011128	Novel
78128956	Positive_Correlation	D009643	D009461	Novel
78128956	Positive_Correlation	D000474	D000068877	Novel
78128956	Positive_Correlation	D009643	D063646	Novel
78128956	Positive_Correlation	D017693	D009461	Novel
78128956	Positive_Correlation	D000068877	D009461	Novel

73028000|t|Alendronate Sodium and Its Interactions with H-Ras, FGF Receptor 2, and Glucocorticoid Receptor-Interacting Protein 1 in Human Papilloma Virus and Zebrafis
73028000|a|Recent studies have revealed complex interactions between alendronate sodium, H-Ras, and glucocorticoid receptor-interacting protein 1 (GRIP1) in both human and zebrafish systems. Alendronate sodium, a bisphosphonate drug, has been shown to exhibit a positive correlation with H-Ras activity, suggesting a potential role in modulating cellular signaling pathways. This correlation is further supported by the binding interactions between H-Ras and GRIP1, which are critical for the regulation of downstream signaling cascades.   In addition, GRIP1 has been found to have a negative correlation with alendronate sodium, indicating a possible antagonistic relationship. This negative correlation is further reinforced by the binding of GRIP1 to IRF3, a key transcription factor involved in immune responses. The interaction between GRIP1 and IRF3 is also supported by the binding of Catechol-O-methyltransferase (COMT) to both IRF3 and H-Ras, highlighting the interconnected nature of these molecular pathways.  FGF receptor 2 (FGFR2) has been shown to bind to COMT, and this interaction is associated with a negative correlation between FGFR2 and alendronate sodium. This suggests that alendronate sodium may influence the activity of FGFR2 in a manner that could impact developmental and pathological processes. Furthermore, COMT exhibits a negative correlation with alendronate sodium, reinforcing the idea that this drug may modulate the activity of multiple signaling molecules.  The study also examined the role of H-Ras in the context of Human Papilloma Virus (HPV) infection and Aedes mosquitoes, as well as in Zebrafish models. These findings suggest that the interactions between alendronate sodium, H-Ras, GRIP1, and COMT may have broader implications in both human and non-human systems, particularly in the context of viral infections and developmental biology. The extensive network of interactions involving these molecules underscores the complexity of cellular signaling and the potential for targeted therapeutic interventions.
73028000	45	50	H-Ras	GeneOrGeneProduct	3265
73028000	214	232	alendronate sodium	ChemicalEntity	D019386
73028000	234	239	H-Ras	GeneOrGeneProduct	3265
73028000	245	290	glucocorticoid receptor-interacting protein 1	GeneOrGeneProduct	23426
73028000	433	438	H-Ras	GeneOrGeneProduct	3265
73028000	594	599	H-Ras	GeneOrGeneProduct	3265
73028000	755	773	alendronate sodium	ChemicalEntity	D019386
73028000	899	903	IRF3	GeneOrGeneProduct	54131
73028000	996	1000	IRF3	GeneOrGeneProduct	54131
73028000	1037	1065	Catechol-O-methyltransferase	GeneOrGeneProduct	1312
73028000	1081	1085	IRF3	GeneOrGeneProduct	54131
73028000	1090	1095	H-Ras	GeneOrGeneProduct	3265
73028000	1166	1180	FGF receptor 2	GeneOrGeneProduct	14183
73028000	1302	1320	alendronate sodium	ChemicalEntity	D019386
73028000	1341	1359	alendronate sodium	ChemicalEntity	D019386
73028000	1523	1541	alendronate sodium	ChemicalEntity	D019386
73028000	1675	1680	H-Ras	GeneOrGeneProduct	3265
73028000	1741	1757	Aedes mosquitoes	OrganismTaxon	1245352
73028000	1773	1782	Zebrafish	OrganismTaxon	7955
73028000	1844	1862	alendronate sodium	ChemicalEntity	D019386
73028000	1864	1869	H-Ras	GeneOrGeneProduct	3265
73028000	Positive_Correlation	3265	D019386	Novel
73028000	Bind	23426	3265	Novel
73028000	Negative_Correlation	23426	D019386	Novel
73028000	Bind	14183	1312	Novel
73028000	Bind	3265	23426	Novel
73028000	Bind	1312	54131	Novel
73028000	Bind	54131	1312	Novel
73028000	Bind	23426	54131	Novel
73028000	Negative_Correlation	14183	D019386	Novel
73028000	Bind	1312	3265	Novel
73028000	Negative_Correlation	1312	D019386	Novel
73028000	Bind	3265	54131	Novel

98147514|t|Genetic and pharmacological interactions in DEN-2-infected MH134 cells: effects of sequence variants, organochloride, TH, and ginsen
98147514|a|This study investigates the complex interactions between genetic variants, chemical entities, and host organisms in DEN-2-infected MH134 cells. The focus is on the association between the (G --> C) substitution at position 1201 and the sequence variant L180M, as well as the association between the same substitution and the deletion del(1)(p31.2p32.3). These genetic interactions are further linked to the sequence variant -1240 L/S, highlighting the intricate network of genetic variability in DEN-2-infected cells.   The study also reveals a strong association between the deletion del(1)(p31.2p32.3) and the sequence variant -1240 L/S, suggesting a potential functional relationship between these two genetic elements. Additionally, the sequence variant L180M is found to be associated with the deletion del(1)(p31.2p32.3), indicating a possible regulatory or structural interaction between these variants.  Pharmacologically, the study demonstrates a positive correlation between organochloride and pirenzepine, as well as a positive correlation between organochloride and TH. These findings suggest that organochloride may modulate the activity of both pirenzepine and TH, potentially through shared molecular targets or pathways. Furthermore, a drug interaction between organochloride and TH is observed, indicating that the combination of these two chemical entities may alter their individual pharmacological effects.  The research also explores the role of ginsenoside Re in the context of these interactions, with four instances of its mention underscoring its potential involvement in modulating the effects of other chemical entities and genetic variants. The study includes three instances of the chemical entity K +, which may play a role in the cellular environment or signaling pathways influenced by the genetic and pharmacological factors under investigation.  The experiments were conducted using MH134 cells, a well-characterized cell line, and the findings are relevant to the organisms cats, dogs, and horses, which are known to be susceptible to DEN-2 infection. The results provide a comprehensive view of the interplay between genetic variability, chemical entities, and host responses in DEN-2-infected systems, offering insights into potential therapeutic strategies and diagnostic approaches.
98147514	44	49	DEN-2	OrganismTaxon	11060
98147514	59	64	MH134	CellLine	CVCL_8111
98147514	102	116	organochloride	ChemicalEntity	D006843
98147514	118	120	TH	ChemicalEntity	D013963
98147514	249	254	DEN-2	OrganismTaxon	11060
98147514	264	269	MH134	CellLine	CVCL_8111
98147514	321	360	(G --> C) substitution at position 1201	SequenceVariant	c|SUB|G|1201|C
98147514	386	391	L180M	SequenceVariant	p|SUB|L|180|M
98147514	467	485	del(1)(p31.2p32.3)	SequenceVariant	c|DEL|p31.2_p32.3|
98147514	557	566	-1240 L/S	SequenceVariant	p|SUB|L|-1240|S
98147514	629	634	DEN-2	OrganismTaxon	11060
98147514	718	736	del(1)(p31.2p32.3)	SequenceVariant	c|DEL|p31.2_p32.3|
98147514	762	771	-1240 L/S	SequenceVariant	p|SUB|L|-1240|S
98147514	891	896	L180M	SequenceVariant	p|SUB|L|180|M
98147514	941	959	del(1)(p31.2p32.3)	SequenceVariant	c|DEL|p31.2_p32.3|
98147514	1118	1132	organochloride	ChemicalEntity	D006843
98147514	1137	1148	pirenzepine	ChemicalEntity	D010890
98147514	1192	1206	organochloride	ChemicalEntity	D006843
98147514	1211	1213	TH	ChemicalEntity	D013963
98147514	1243	1257	organochloride	ChemicalEntity	D006843
98147514	1292	1303	pirenzepine	ChemicalEntity	D010890
98147514	1308	1310	TH	ChemicalEntity	D013963
98147514	1410	1424	organochloride	ChemicalEntity	D006843
98147514	1429	1431	TH	ChemicalEntity	D013963
98147514	1600	1614	ginsenoside Re	ChemicalEntity	C049864
98147514	1860	1863	K +	ChemicalEntity	D011188
98147514	2050	2055	MH134	CellLine	CVCL_8111
98147514	2142	2146	cats	OrganismTaxon	9685
98147514	2148	2152	dogs	OrganismTaxon	9615
98147514	2158	2164	horses	OrganismTaxon	9796
98147514	2203	2208	DEN-2	OrganismTaxon	11060
98147514	2348	2353	DEN-2	OrganismTaxon	11060
98147514	Association	c|SUB|G|1201|C	p|SUB|L|180|M	Novel
98147514	Association	c|SUB|G|1201|C	c|DEL|p31.2_p32.3|	Novel
98147514	Positive_Correlation	D006843	D010890	Novel
98147514	Drug_Interaction	D006843	D013963	Novel
98147514	Positive_Correlation	D006843	D013963	Novel
98147514	Association	c|DEL|p31.2_p32.3|	p|SUB|L|-1240|S	Novel
98147514	Association	p|SUB|L|180|M	c|DEL|p31.2_p32.3|	Novel

86569077|t|DUCaP Cell Line and Genetic Variants in Paranoid Schizophrenia: Correlations with 4-ene-VPA an
86569077|a|The DUCaP cell line, derived from a DEN-4-infected source, was used to investigate the molecular mechanisms underlying paranoid schizophrenia and its interactions with genetic variants and chemical entities. This study focused on the sequence variant rs10942891, which was found to exhibit a positive correlation with the chemical entity 4-ene-VPA and a positive correlation with hexose. Additionally, rs10942891 showed a negative correlation with paranoid schizophrenia, suggesting a potential protective role against the disease.   The sequence variant (G-->A) at nucleotide position 2141 was also examined and found to have a positive correlation with 4-ene-VPA, while simultaneously displaying a negative correlation with paranoid schizophrenia. These findings indicate that this variant may influence both metabolic pathways and disease susceptibility.   A comparison between hexose and 4-ene-VPA revealed distinct metabolic profiles, with 4-ene-VPA showing a more pronounced effect on cellular processes in the DUCaP cell line. Furthermore, the comparison between 4-ene-VPA and hexose highlighted their differential roles in modulating gene expression and cellular function.   These results provide new insights into the interplay between genetic variants, chemical entities, and disease states in the context of the DUCaP cell line and DEN-4 organism. The findings suggest that rs10942891 and (G-->A) at nucleotide position 2141 may serve as potential biomarkers for understanding the pathophysiology of paranoid schizophrenia and its metabolic associations.
86569077	0	5	DUCaP	CellLine	CVCL_2025
86569077	82	91	4-ene-VPA	ChemicalEntity	C045022
86569077	99	104	DUCaP	CellLine	CVCL_2025
86569077	131	136	DEN-4	OrganismTaxon	11070
86569077	214	236	paranoid schizophrenia	DiseaseOrPhenotypicFeature	D012563
86569077	346	356	rs10942891	SequenceVariant	rs10942891
86569077	433	442	4-ene-VPA	ChemicalEntity	C045022
86569077	475	481	hexose	ChemicalEntity	D006601
86569077	497	507	rs10942891	SequenceVariant	rs10942891
86569077	543	565	paranoid schizophrenia	DiseaseOrPhenotypicFeature	D012563
86569077	650	685	(G-->A) at nucleotide position 2141	SequenceVariant	c|SUB|G|2141|A
86569077	750	759	4-ene-VPA	ChemicalEntity	C045022
86569077	821	843	paranoid schizophrenia	DiseaseOrPhenotypicFeature	D012563
86569077	976	982	hexose	ChemicalEntity	D006601
86569077	987	996	4-ene-VPA	ChemicalEntity	C045022
86569077	1040	1049	4-ene-VPA	ChemicalEntity	C045022
86569077	1112	1117	DUCaP	CellLine	CVCL_2025
86569077	1165	1174	4-ene-VPA	ChemicalEntity	C045022
86569077	1179	1185	hexose	ChemicalEntity	D006601
86569077	1418	1423	DUCaP	CellLine	CVCL_2025
86569077	1438	1443	DEN-4	OrganismTaxon	11070
86569077	1480	1490	rs10942891	SequenceVariant	rs10942891
86569077	1495	1530	(G-->A) at nucleotide position 2141	SequenceVariant	c|SUB|G|2141|A
86569077	1606	1628	paranoid schizophrenia	DiseaseOrPhenotypicFeature	D012563
86569077	Positive_Correlation	rs10942891	C045022	Novel
86569077	Negative_Correlation	rs10942891	D012563	Novel
86569077	Positive_Correlation	c|SUB|G|2141|A	C045022	Novel
86569077	Positive_Correlation	rs10942891	D006601	Novel
86569077	Comparison	D006601	C045022	Novel
86569077	Negative_Correlation	c|SUB|G|2141|A	D012563	Novel
86569077	Comparison	C045022	D006601	Novel

57494941|t|Genetic variants in SJ-GBM2 and SNU-C5 cell lines and their association with muscular dystrophy and the effects of acitret
57494941|a|Recent studies have highlighted the complex interplay between genetic variants, cellular responses, and disease progression in muscular dystrophy. This study investigates the role of the sequence variant p.Arg58fs in SJ-GBM2 and SNU-C5 cell lines and its potential correlation with muscular dystrophy. We observed a positive correlation between p.Arg58fs and muscular dystrophy in multiple experimental models, suggesting that this variant may contribute to the pathogenesis of the disease.   To further explore the molecular mechanisms, we examined the effects of the chemical entities E and acitretin on the expression and function of these cell lines. The results indicate that E modulates the expression of genes associated with muscular dystrophy, while acitretin shows a distinct pattern of interaction with the p.Arg58fs variant. Notably, the presence of p.Arg58fs in SJ-GBM2 and SNU-C5 cell lines was consistently associated with increased susceptibility to muscular dystrophy, as evidenced by altered cellular morphology and functional assays.  Our findings suggest that the sequence variant p.Arg58fs plays a significant role in the development of muscular dystrophy, and that the chemical entities E and acitretin may serve as potential therapeutic agents in modulating this genetic risk. These results provide a foundation for future research into the molecular mechanisms underlying muscular dystrophy and the development of targeted therapies.
57494941	20	27	SJ-GBM2	CellLine	CVCL_M141
57494941	32	38	SNU-C5	CellLine	CVCL_5112
57494941	77	95	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
57494941	250	268	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
57494941	327	336	p.Arg58fs	SequenceVariant	p|FS|R|58||
57494941	340	347	SJ-GBM2	CellLine	CVCL_M141
57494941	352	358	SNU-C5	CellLine	CVCL_5112
57494941	405	423	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
57494941	468	477	p.Arg58fs	SequenceVariant	p|FS|R|58||
57494941	482	500	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
57494941	710	711	E	ChemicalEntity	D017308
57494941	716	725	acitretin	ChemicalEntity	D017255
57494941	804	805	E	ChemicalEntity	D017308
57494941	856	874	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
57494941	882	891	acitretin	ChemicalEntity	D017255
57494941	941	950	p.Arg58fs	SequenceVariant	p|FS|R|58||
57494941	985	994	p.Arg58fs	SequenceVariant	p|FS|R|58||
57494941	998	1005	SJ-GBM2	CellLine	CVCL_M141
57494941	1010	1016	SNU-C5	CellLine	CVCL_5112
57494941	1089	1107	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
57494941	1224	1233	p.Arg58fs	SequenceVariant	p|FS|R|58||
57494941	1281	1299	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
57494941	1332	1333	E	ChemicalEntity	D017308
57494941	1338	1347	acitretin	ChemicalEntity	D017255
57494941	1519	1537	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
57494941	Positive_Correlation	p|FS|R|58||	D009136	Novel

24933591|t|Gln266His polymorphism and its associations with irinotecan, diabetic nephropathy, and Lenz microphthalmia syndrome in SW480 and Ishikawa ce
24933591|a|Recent studies have highlighted the complex interplay between genetic variants, chemotherapeutic agents, and disease phenotypes in cellular models. This study investigates the functional and phenotypic associations of the Gln266His polymorphism in the context of irinotecan treatment, diabetic nephropathy, and Lenz microphthalmia syndrome using SW480 and Ishikawa cell lines. The Gln266His variant was found to be significantly associated with irinotecan response, with a positive correlation observed in both SW480 and Ishikawa cell lines. This association was further supported by the observation that Gln266His showed a strong positive correlation with irinotecan efficacy, as measured by cell viability and apoptosis rates.   In contrast, the Lenz microphthalmia syndrome was found to have a negative correlation with irinotecan treatment, with reduced cell survival and increased oxidative stress observed in SW480 and Ishikawa cells expressing this syndrome. Notably, the Lenz microphthalmia syndrome was also associated with the Gln266His variant, suggesting a potential genetic link between the syndrome and the polymorphism. This association was further reinforced by the observation that the Gln266His variant modulated the expression of genes involved in the pathogenesis of Lenz microphthalmia syndrome.  Additionally, the study revealed a negative correlation between diabetic nephropathy and irinotecan treatment, with SW480 and Ishikawa cells exhibiting increased markers of renal dysfunction under irinotecan exposure. However, the Gln266His variant was found to be associated with diabetic nephropathy, with a significant protective effect observed in SW480 cells. This association was further supported by the positive correlation between Gln266His and diabetic nephropathy, as evidenced by the upregulation of key renal disease markers in the presence of the variant.   The findings suggest that the Gln266His polymorphism plays a critical role in modulating the response to irinotecan and the development of diabetic nephropathy and Lenz microphthalmia syndrome. These results provide important insights into the molecular mechanisms underlying these conditions and highlight the potential of Gln266His as a biomarker for personalized treatment strategies in SW480 and Ishikawa cell lines.
24933591	0	9	Gln266His	SequenceVariant	rs75405062
24933591	49	59	irinotecan	ChemicalEntity	D000077146
24933591	61	81	diabetic nephropathy	DiseaseOrPhenotypicFeature	D003928
24933591	87	115	Lenz microphthalmia syndrome	DiseaseOrPhenotypicFeature	C537464
24933591	119	124	SW480	CellLine	CVCL_0546
24933591	129	137	Ishikawa	CellLine	CVCL_2529
24933591	363	372	Gln266His	SequenceVariant	rs75405062
24933591	404	414	irinotecan	ChemicalEntity	D000077146
24933591	426	446	diabetic nephropathy	DiseaseOrPhenotypicFeature	D003928
24933591	452	480	Lenz microphthalmia syndrome	DiseaseOrPhenotypicFeature	C537464
24933591	487	492	SW480	CellLine	CVCL_0546
24933591	497	505	Ishikawa	CellLine	CVCL_2529
24933591	522	531	Gln266His	SequenceVariant	rs75405062
24933591	586	596	irinotecan	ChemicalEntity	D000077146
24933591	652	657	SW480	CellLine	CVCL_0546
24933591	662	670	Ishikawa	CellLine	CVCL_2529
24933591	746	755	Gln266His	SequenceVariant	rs75405062
24933591	798	808	irinotecan	ChemicalEntity	D000077146
24933591	889	917	Lenz microphthalmia syndrome	DiseaseOrPhenotypicFeature	C537464
24933591	964	974	irinotecan	ChemicalEntity	D000077146
24933591	1056	1061	SW480	CellLine	CVCL_0546
24933591	1066	1074	Ishikawa	CellLine	CVCL_2529
24933591	1120	1148	Lenz microphthalmia syndrome	DiseaseOrPhenotypicFeature	C537464
24933591	1178	1187	Gln266His	SequenceVariant	rs75405062
24933591	1344	1353	Gln266His	SequenceVariant	rs75405062
24933591	1428	1456	Lenz microphthalmia syndrome	DiseaseOrPhenotypicFeature	C537464
24933591	1523	1543	diabetic nephropathy	DiseaseOrPhenotypicFeature	D003928
24933591	1548	1558	irinotecan	ChemicalEntity	D000077146
24933591	1575	1580	SW480	CellLine	CVCL_0546
24933591	1585	1593	Ishikawa	CellLine	CVCL_2529
24933591	1656	1666	irinotecan	ChemicalEntity	D000077146
24933591	1690	1699	Gln266His	SequenceVariant	rs75405062
24933591	1740	1760	diabetic nephropathy	DiseaseOrPhenotypicFeature	D003928
24933591	1811	1816	SW480	CellLine	CVCL_0546
24933591	1899	1908	Gln266His	SequenceVariant	rs75405062
24933591	1913	1933	diabetic nephropathy	DiseaseOrPhenotypicFeature	D003928
24933591	2061	2070	Gln266His	SequenceVariant	rs75405062
24933591	2136	2146	irinotecan	ChemicalEntity	D000077146
24933591	2170	2190	diabetic nephropathy	DiseaseOrPhenotypicFeature	D003928
24933591	2195	2223	Lenz microphthalmia syndrome	DiseaseOrPhenotypicFeature	C537464
24933591	2355	2364	Gln266His	SequenceVariant	rs75405062
24933591	2421	2426	SW480	CellLine	CVCL_0546
24933591	2431	2439	Ishikawa	CellLine	CVCL_2529
24933591	Association	rs75405062	D000077146	Novel
24933591	Negative_Correlation	C537464	D000077146	Novel
24933591	Association	C537464	rs75405062	Novel
24933591	Negative_Correlation	D003928	D000077146	Novel
24933591	Association	D003928	rs75405062	Novel
24933591	Association	D000077146	D003928	Novel
24933591	Positive_Correlation	rs75405062	D000077146	Novel

70894647|t|NANOG and LHbeta: dual roles in memory impairment and their interactions with C57BL/6J and HeLa ce
70894647|a|Recent studies have highlighted the complex interplay between NANOG and LHbeta in the context of memory impairment, particularly in the presence of human immunodeficiency virus (HIV) infection. This research explores the association between NANOG and memory impairment in both C57BL/6J and HeLa cell lines, revealing a significant negative correlation between NANOG expression and memory impairment in C57BL/6J mice. Similarly, LHbeta was found to be associated with memory impairment, with a negative correlation observed in HeLa cells. These findings suggest that both NANOG and LHbeta may play critical roles in modulating cognitive function, particularly in the context of HIV-related neurocognitive disorders. The study also examined the impact of H446 cell line on these associations, noting that the presence of H446 cells altered the expression patterns of both NANOG and LHbeta, further complicating the relationship between these genes and memory impairment. The results underscore the importance of considering cell-specific interactions when investigating the molecular mechanisms underlying memory impairment in the context of HIV infection. Multiple instances of memory impairment were observed across all tested cell lines, with C57BL/6J and HeLa cells showing the most consistent associations. The findings provide a foundation for future research into therapeutic strategies targeting NANOG and LHbeta to mitigate memory impairment in HIV-infected individuals.
70894647	0	5	NANOG	GeneOrGeneProduct	79923
70894647	10	16	LHbeta	GeneOrGeneProduct	16866
70894647	32	49	memory impairment	DiseaseOrPhenotypicFeature	D008569
70894647	78	86	C57BL/6J	CellLine	CVCL_5U84
70894647	91	95	HeLa	CellLine	CVCL_0030
70894647	161	166	NANOG	GeneOrGeneProduct	79923
70894647	171	177	LHbeta	GeneOrGeneProduct	16866
70894647	196	213	memory impairment	DiseaseOrPhenotypicFeature	D008569
70894647	247	275	human immunodeficiency virus	OrganismTaxon	12721
70894647	340	345	NANOG	GeneOrGeneProduct	79923
70894647	350	367	memory impairment	DiseaseOrPhenotypicFeature	D008569
70894647	376	384	C57BL/6J	CellLine	CVCL_5U84
70894647	389	393	HeLa	CellLine	CVCL_0030
70894647	459	464	NANOG	GeneOrGeneProduct	79923
70894647	480	497	memory impairment	DiseaseOrPhenotypicFeature	D008569
70894647	501	509	C57BL/6J	CellLine	CVCL_5U84
70894647	527	533	LHbeta	GeneOrGeneProduct	16866
70894647	566	583	memory impairment	DiseaseOrPhenotypicFeature	D008569
70894647	625	629	HeLa	CellLine	CVCL_0030
70894647	670	675	NANOG	GeneOrGeneProduct	79923
70894647	680	686	LHbeta	GeneOrGeneProduct	16866
70894647	852	856	H446	CellLine	CVCL_1562
70894647	918	922	H446	CellLine	CVCL_1562
70894647	969	974	NANOG	GeneOrGeneProduct	79923
70894647	979	985	LHbeta	GeneOrGeneProduct	16866
70894647	1049	1066	memory impairment	DiseaseOrPhenotypicFeature	D008569
70894647	1203	1220	memory impairment	DiseaseOrPhenotypicFeature	D008569
70894647	1276	1293	memory impairment	DiseaseOrPhenotypicFeature	D008569
70894647	1343	1351	C57BL/6J	CellLine	CVCL_5U84
70894647	1356	1360	HeLa	CellLine	CVCL_0030
70894647	1501	1506	NANOG	GeneOrGeneProduct	79923
70894647	1511	1517	LHbeta	GeneOrGeneProduct	16866
70894647	1530	1547	memory impairment	DiseaseOrPhenotypicFeature	D008569
70894647	Association	79923	D008569	Novel
70894647	Association	16866	D008569	Novel
70894647	Negative_Correlation	79923	D008569	Novel
70894647	Negative_Correlation	16866	D008569	Novel

58194290|t|ALK and RORgt interactions in Danio rerio: implications for chondrodysplasia and cellular responses in multiple ce
58194290|a|Recent studies have highlighted the critical role of ALK and RORgt in developmental processes, particularly in the context of chondrodysplasia. This research focuses on the interactions between ALK and RORgt in Danio rerio, a widely used model organism for studying skeletal development. Our findings reveal a positive correlation between ALK and RORgt expression levels in Danio rerio, suggesting a potential regulatory relationship that may influence chondrodysplasia.   To further explore these interactions, we conducted experiments using multiple cell lines, including PC-3, SMMC-7721, COS-7, SNU-C5, and MEF. In all tested cell lines, ALK and RORgt showed a consistent positive correlation, reinforcing the hypothesis that these genes may function in a coordinated manner. Notably, in PC-3 and SMMC-7721 cells, the correlation was particularly strong, indicating a possible functional synergy between ALK and RORgt in these contexts.   Additionally, we observed that the expression of RORgt in Danio rerio was significantly influenced by ALK activity, with higher ALK levels corresponding to increased RORgt expression. This relationship was further validated through in vitro assays, where the overexpression of ALK led to a proportional increase in RORgt levels. These results provide strong evidence for the positive correlation between ALK and RORgt, both in vivo and in vitro.   Given the prevalence of ALK and RORgt in various cell lines and their association with chondrodysplasia, this study underscores the importance of these genes in developmental biology and their potential as therapeutic targets for related conditions.
58194290	0	3	ALK	GeneOrGeneProduct	238
58194290	8	13	RORgt	GeneOrGeneProduct	19885
58194290	30	41	Danio rerio	OrganismTaxon	7955
58194290	60	76	chondrodysplasia	DiseaseOrPhenotypicFeature	D010009
58194290	168	171	ALK	GeneOrGeneProduct	238
58194290	176	181	RORgt	GeneOrGeneProduct	19885
58194290	241	257	chondrodysplasia	DiseaseOrPhenotypicFeature	D010009
58194290	309	312	ALK	GeneOrGeneProduct	238
58194290	317	322	RORgt	GeneOrGeneProduct	19885
58194290	326	337	Danio rerio	OrganismTaxon	7955
58194290	454	457	ALK	GeneOrGeneProduct	238
58194290	462	467	RORgt	GeneOrGeneProduct	19885
58194290	489	500	Danio rerio	OrganismTaxon	7955
58194290	568	584	chondrodysplasia	DiseaseOrPhenotypicFeature	D010009
58194290	689	693	PC-3	CellLine	CVCL_0035
58194290	695	704	SMMC-7721	CellLine	CVCL_0534
58194290	706	711	COS-7	CellLine	CVCL_0224
58194290	713	719	SNU-C5	CellLine	CVCL_5112
58194290	725	728	MEF	CellLine	CVCL_9115
58194290	756	759	ALK	GeneOrGeneProduct	238
58194290	764	769	RORgt	GeneOrGeneProduct	19885
58194290	906	910	PC-3	CellLine	CVCL_0035
58194290	915	924	SMMC-7721	CellLine	CVCL_0534
58194290	1022	1025	ALK	GeneOrGeneProduct	238
58194290	1030	1035	RORgt	GeneOrGeneProduct	19885
58194290	1106	1111	RORgt	GeneOrGeneProduct	19885
58194290	1115	1126	Danio rerio	OrganismTaxon	7955
58194290	1159	1162	ALK	GeneOrGeneProduct	238
58194290	1185	1188	ALK	GeneOrGeneProduct	238
58194290	1223	1228	RORgt	GeneOrGeneProduct	19885
58194290	1334	1337	ALK	GeneOrGeneProduct	238
58194290	1372	1377	RORgt	GeneOrGeneProduct	19885
58194290	1461	1464	ALK	GeneOrGeneProduct	238
58194290	1469	1474	RORgt	GeneOrGeneProduct	19885
58194290	1529	1532	ALK	GeneOrGeneProduct	238
58194290	1537	1542	RORgt	GeneOrGeneProduct	19885
58194290	1592	1608	chondrodysplasia	DiseaseOrPhenotypicFeature	D010009
58194290	Positive_Correlation	238	19885	Novel
58194290	Positive_Correlation	19885	238	Novel

51933000|t|SOCS3 and TRPV6 interactions in cancer progression: associations with ascites, uterine sarcoma, and muscle 
51933000|a|This study investigates the molecular interactions and functional associations between SOCS3, TRPV6, and various cellular and phenotypic features in multiple cell lines. We demonstrate that SOCS3 binds specifically to the M(3)-muscarinic acetylcholine receptor, suggesting a potential regulatory role in signal transduction pathways. Additionally, we find that ascites is associated with the M(3)-muscarinic acetylcholine receptor, indicating a possible involvement of this receptor in the pathophysiology of fluid accumulation in cancer.   Our findings also reveal a significant association between TRPV6 and SOCS3, highlighting a potential regulatory network that may influence cellular responses to extracellular stimuli. Furthermore, we observe a negative correlation between TRPV6 expression and muscle rigidity, suggesting that TRPV6 may play a protective role in neuromuscular function.   Notably, we also report a negative correlation between SOCS3 and uterine sarcoma, implying that SOCS3 may act as a tumor suppressor in this context. These results were validated across multiple cell lines, including MH134, Hs578T, Ba/F3, CD18/HPAF, HEK293, and Mz-ChA-1. The consistent patterns observed across these cell lines support the biological relevance of these interactions and associations. This work provides new insights into the molecular mechanisms underlying cancer progression and phenotypic features associated with these conditions.
51933000	0	5	SOCS3	GeneOrGeneProduct	89829
51933000	10	15	TRPV6	GeneOrGeneProduct	55503
51933000	70	77	ascites	DiseaseOrPhenotypicFeature	D001201
51933000	79	94	uterine sarcoma	DiseaseOrPhenotypicFeature	D014594
51933000	195	200	SOCS3	GeneOrGeneProduct	89829
51933000	202	207	TRPV6	GeneOrGeneProduct	55503
51933000	298	303	SOCS3	GeneOrGeneProduct	89829
51933000	330	368	M(3)-muscarinic acetylcholine receptor	GeneOrGeneProduct	100379235
51933000	469	476	ascites	DiseaseOrPhenotypicFeature	D001201
51933000	500	538	M(3)-muscarinic acetylcholine receptor	GeneOrGeneProduct	100379235
51933000	708	713	TRPV6	GeneOrGeneProduct	55503
51933000	718	723	SOCS3	GeneOrGeneProduct	89829
51933000	888	893	TRPV6	GeneOrGeneProduct	55503
51933000	909	924	muscle rigidity	DiseaseOrPhenotypicFeature	D009127
51933000	942	947	TRPV6	GeneOrGeneProduct	55503
51933000	1059	1064	SOCS3	GeneOrGeneProduct	89829
51933000	1069	1084	uterine sarcoma	DiseaseOrPhenotypicFeature	D014594
51933000	1100	1105	SOCS3	GeneOrGeneProduct	89829
51933000	1220	1225	MH134	CellLine	CVCL_8111
51933000	1227	1233	Hs578T	CellLine	CVCL_0332
51933000	1235	1240	Ba/F3	CellLine	CVCL_0161
51933000	1242	1251	CD18/HPAF	CellLine	CVCL_0313
51933000	1253	1259	HEK293	CellLine	CVCL_0045
51933000	1265	1273	Mz-ChA-1	CellLine	CVCL_6932
51933000	Bind	89829	100379235	Novel
51933000	Association	D001201	100379235	Novel
51933000	Association	55503	89829	Novel
51933000	Negative_Correlation	D009127	55503	Novel
51933000	Negative_Correlation	89829	D014594	Novel

69940044|t|NPHP, MPNSTs, and spinal muscular atrophy: genetic and cellular insights into the role of MAPK and sequence variants in disease pro
69940044|a|Recent studies have highlighted the complex interplay between genetic variants, cellular models, and disease phenotypes in the context of NPHP, MPNSTs, and spinal muscular atrophy. This research explores the molecular mechanisms underlying these conditions, with a particular focus on the role of the MAPK gene family and specific sequence variants such as delta32 and codon 787 CAG/CAA. The 253JB-V and CMT-93 cell lines were used as in vitro models to investigate the functional consequences of these genetic alterations.   A significant positive correlation was observed between the presence of delta32 and both NPHP and MPNSTs, suggesting that this variant may contribute to the pathogenesis of these diseases. Additionally, the codon 787 CAG/CAA variant showed a strong positive correlation with spinal muscular atrophy, indicating its potential role in disease susceptibility. The MAPK gene was found to be positively correlated with infarct occurrence, highlighting its involvement in cardiovascular pathology. Furthermore, a positive correlation was noted between infarct and delta32, reinforcing the link between this sequence variant and cardiovascular disease.   The DUCaP cell line was also employed to assess the impact of these genetic variants on cellular function, with results supporting the hypothesis that MAPK activity is modulated by these variants. The study also examined the association between malar rash and the presence of codon 787 CAG/CAA, although this relationship was less pronounced compared to other findings.   These findings underscore the importance of genetic and cellular models in understanding the molecular basis of complex diseases and provide a foundation for future therapeutic strategies targeting these pathways.
69940044	0	4	NPHP	DiseaseOrPhenotypicFeature	C537699
69940044	6	12	MPNSTs	DiseaseOrPhenotypicFeature	D018319
69940044	18	41	spinal muscular atrophy	DiseaseOrPhenotypicFeature	D009134
69940044	90	94	MAPK	GeneOrGeneProduct	26416
69940044	270	274	NPHP	DiseaseOrPhenotypicFeature	C537699
69940044	276	282	MPNSTs	DiseaseOrPhenotypicFeature	D018319
69940044	288	311	spinal muscular atrophy	DiseaseOrPhenotypicFeature	D009134
69940044	433	437	MAPK	GeneOrGeneProduct	26416
69940044	489	496	delta32	SequenceVariant	c|DEL||32
69940044	501	518	codon 787 CAG/CAA	SequenceVariant	p|SUB|Q|787|Q
69940044	524	531	253JB-V	CellLine	CVCL_7937
69940044	536	542	CMT-93	CellLine	CVCL_1986
69940044	730	737	delta32	SequenceVariant	c|DEL||32
69940044	747	751	NPHP	DiseaseOrPhenotypicFeature	C537699
69940044	756	762	MPNSTs	DiseaseOrPhenotypicFeature	D018319
69940044	865	882	codon 787 CAG/CAA	SequenceVariant	p|SUB|Q|787|Q
69940044	933	956	spinal muscular atrophy	DiseaseOrPhenotypicFeature	D009134
69940044	1019	1023	MAPK	GeneOrGeneProduct	26416
69940044	1072	1079	infarct	DiseaseOrPhenotypicFeature	D007238
69940044	1204	1211	infarct	DiseaseOrPhenotypicFeature	D007238
69940044	1216	1223	delta32	SequenceVariant	c|DEL||32
69940044	1310	1315	DUCaP	CellLine	CVCL_2025
69940044	1457	1461	MAPK	GeneOrGeneProduct	26416
69940044	1551	1561	malar rash	DiseaseOrPhenotypicFeature	D005076
69940044	1582	1599	codon 787 CAG/CAA	SequenceVariant	p|SUB|Q|787|Q
69940044	Positive_Correlation	D007238	c|DEL||32	Novel
69940044	Positive_Correlation	26416	D007238	Novel
69940044	Positive_Correlation	D018319	c|DEL||32	Novel
69940044	Positive_Correlation	D009134	p|SUB|Q|787|Q	Novel
69940044	Positive_Correlation	C537699	c|DEL||32	Novel

54722190|t|Uric Acid, Hearing and Visual Impairment, and Genetic Variants in the Context of Senior-Loken Syndrome and Mouse Mammary Tumor Virus I
54722190|a|This study investigates the complex interplay between uric acid levels, hearing and visual impairment, and genetic variants in the context of Senior-Loken syndrome and mouse mammary tumor virus (MMTV) infection. We hypothesize that uric acid may play a role in the pathogenesis of hearing and visual impairment, and that specific sequence variants, such as 192RR and c.1970_2177del, may contribute to the clinical manifestations of Senior-Loken syndrome. Our findings reveal a significant association between hearing and visual impairment and uric acid, suggesting a potential metabolic link. Additionally, we observe a positive correlation between hearing and visual impairment and the sequence variant 192RR, as well as a positive correlation between hearing and visual impairment and the deletion variant c.1970_2177del. The association between Senior-Loken syndrome and both 192RR and c.1970_2177del is further supported by our data, indicating that these genetic variants may be involved in the molecular mechanisms underlying the syndrome. Furthermore, we find that the sequence variant c.1970_2177del is positively correlated with Senior-Loken syndrome, reinforcing its potential role in disease progression. Our results also suggest that MMTV may influence the expression of these genetic variants, potentially modulating their impact on hearing and visual impairment. These findings highlight the importance of considering both genetic and environmental factors in the study of complex phenotypes such as hearing and visual impairment and Senior-Loken syndrome.
54722190	189	198	uric acid	ChemicalEntity	D014527
54722190	207	236	hearing and visual impairment	DiseaseOrPhenotypicFeature	D006311
54722190	277	298	Senior-Loken syndrome	DiseaseOrPhenotypicFeature	C537580
54722190	303	328	mouse mammary tumor virus	OrganismTaxon	11757
54722190	367	376	uric acid	ChemicalEntity	D014527
54722190	416	445	hearing and visual impairment	DiseaseOrPhenotypicFeature	D006311
54722190	492	497	192RR	SequenceVariant	p|Allele|R|192
54722190	502	516	c.1970_2177del	SequenceVariant	c|DEL|1970_2177|
54722190	567	588	Senior-Loken syndrome	DiseaseOrPhenotypicFeature	C537580
54722190	644	673	hearing and visual impairment	DiseaseOrPhenotypicFeature	D006311
54722190	678	687	uric acid	ChemicalEntity	D014527
54722190	784	813	hearing and visual impairment	DiseaseOrPhenotypicFeature	D006311
54722190	839	844	192RR	SequenceVariant	p|Allele|R|192
54722190	888	917	hearing and visual impairment	DiseaseOrPhenotypicFeature	D006311
54722190	943	957	c.1970_2177del	SequenceVariant	c|DEL|1970_2177|
54722190	983	1004	Senior-Loken syndrome	DiseaseOrPhenotypicFeature	C537580
54722190	1014	1019	192RR	SequenceVariant	p|Allele|R|192
54722190	1024	1038	c.1970_2177del	SequenceVariant	c|DEL|1970_2177|
54722190	1228	1242	c.1970_2177del	SequenceVariant	c|DEL|1970_2177|
54722190	1273	1294	Senior-Loken syndrome	DiseaseOrPhenotypicFeature	C537580
54722190	1481	1510	hearing and visual impairment	DiseaseOrPhenotypicFeature	D006311
54722190	1649	1678	hearing and visual impairment	DiseaseOrPhenotypicFeature	D006311
54722190	1683	1704	Senior-Loken syndrome	DiseaseOrPhenotypicFeature	C537580
54722190	Association	D006311	D014527	Novel
54722190	Association	C537580	p|Allele|R|192	Novel
54722190	Positive_Correlation	C537580	c|DEL|1970_2177|	Novel
54722190	Association	D006311	p|Allele|R|192	Novel
54722190	Positive_Correlation	D006311	c|DEL|1970_2177|	Novel
54722190	Association	C537580	c|DEL|1970_2177|	Novel
54722190	Association	D006311	c|DEL|1970_2177|	Novel
54722190	Positive_Correlation	C537580	p|Allele|R|192	Novel
54722190	Association	C537580	D014527	Novel
54722190	Positive_Correlation	D006311	p|Allele|R|192	Novel

72814840|t|Genetic Variants and Their Associations with Bladder Tumor, Schizophrenia, and Neurotransmitter Function in HEK293 and KU7 Ce
72814840|a|This study investigates the genetic associations between specific sequence variants and disease phenotypes in HEK293 and KU7 cell lines. We focus on the impact of codon 787 CAG/CAA, G/A, Cys 23 Ser, and Ile232Thr variants on bladder tumor development, schizophrenia, and neurotransmitter function. Our findings reveal a positive correlation between bladder tumor and both Cys 23 Ser and G/A variants, suggesting a potential role of these genetic changes in tumor progression. Additionally, we observe a positive correlation between schizophrenia and codon 787 CAG/CAA, indicating a possible genetic link between this variant and the disease. In contrast, the codon 787 CAG/CAA variant shows a negative correlation with antithrombotic drugs, highlighting a potential pharmacogenetic interaction. The Cys 23 Ser variant is negatively correlated with neurotransmitters, suggesting a disruption in normal signaling pathways. Similarly, Ile232Thr is also negatively correlated with neurotransmitters, further supporting the role of these variants in modulating neural function. These results were validated using HEK293 and KU7 cell lines, which were treated with various concentrations of antithrombotic drugs and neurotransmitter agonists to assess functional outcomes. The study underscores the complex interplay between genetic variants and disease phenotypes, providing a foundation for future therapeutic strategies targeting these molecular pathways.
72814840	108	114	HEK293	CellLine	CVCL_0045
72814840	119	122	KU7	CellLine	CVCL_4714
72814840	236	242	HEK293	CellLine	CVCL_0045
72814840	247	250	KU7	CellLine	CVCL_4714
72814840	289	306	codon 787 CAG/CAA	SequenceVariant	p|SUB|Q|787|Q
72814840	308	311	G/A	SequenceVariant	rs1207568
72814840	313	323	Cys 23 Ser	SequenceVariant	rs6318
72814840	329	338	Ile232Thr	SequenceVariant	rs1050501
72814840	351	364	bladder tumor	DiseaseOrPhenotypicFeature	D001749
72814840	378	391	schizophrenia	DiseaseOrPhenotypicFeature	D012559
72814840	475	488	bladder tumor	DiseaseOrPhenotypicFeature	D001749
72814840	498	508	Cys 23 Ser	SequenceVariant	rs6318
72814840	513	516	G/A	SequenceVariant	rs1207568
72814840	658	671	schizophrenia	DiseaseOrPhenotypicFeature	D012559
72814840	676	693	codon 787 CAG/CAA	SequenceVariant	p|SUB|Q|787|Q
72814840	785	802	codon 787 CAG/CAA	SequenceVariant	p|SUB|Q|787|Q
72814840	845	865	antithrombotic drugs	ChemicalEntity	D005343
72814840	925	935	Cys 23 Ser	SequenceVariant	rs6318
72814840	974	991	neurotransmitters	ChemicalEntity	D018377
72814840	1058	1067	Ile232Thr	SequenceVariant	rs1050501
72814840	1103	1120	neurotransmitters	ChemicalEntity	D018377
72814840	1234	1240	HEK293	CellLine	CVCL_0045
72814840	1245	1248	KU7	CellLine	CVCL_4714
72814840	1311	1331	antithrombotic drugs	ChemicalEntity	D005343
72814840	Positive_Correlation	D001749	rs6318	Novel
72814840	Positive_Correlation	D001749	rs1207568	Novel
72814840	Negative_Correlation	p|SUB|Q|787|Q	D005343	Novel
72814840	Negative_Correlation	rs6318	D018377	Novel
72814840	Positive_Correlation	D012559	p|SUB|Q|787|Q	Novel
72814840	Negative_Correlation	rs1050501	D018377	Novel

13614070|t|Genetic Variability in IEC-6 and MES-SA/Dx5 Cell Lines and Its Association with Sequence Variants in E. coli, Horses, 
13614070|a|This study investigates the genetic variability of sequence variants in IEC-6 and MES-SA/Dx5 cell lines and their associations with sequence variants in E. coli, horses, and dogs. We focused on the sequence variants rs2073601, V274I, S276T, and the 12-nucleotide insertion/deletion (indel), as well as the variant g.2885G>C. Our findings reveal a complex network of associations among these genetic elements. Specifically, rs2073601 is associated with both g.2885G>C and V274I, while g.2885G>C is linked to V274I and rs2073601. Additionally, V274I is associated with both the 12-nucleotide insertion/deletion (indel) and g.2885G>C. The 12-nucleotide insertion/deletion (indel) is also associated with S276T and g.2885G>C. These associations were observed across multiple cell lines, including SNU-C2A, hRPTEC, and SJ-GBM2, and were further validated in organisms such as horses, dogs, and Mangifera indica Linn. Notably, the sequence variant V274I was found to be present in Platonia insignis Mart, suggesting a potential evolutionary link. The study highlights the importance of understanding genetic variability in both cellular and organismal contexts, particularly in relation to sequence variants that may influence biological function and disease susceptibility.
13614070	23	28	IEC-6	CellLine	CVCL_0343
13614070	33	43	MES-SA/Dx5	CellLine	CVCL_2598
13614070	101	108	E. coli	OrganismTaxon	562
13614070	191	196	IEC-6	CellLine	CVCL_0343
13614070	201	211	MES-SA/Dx5	CellLine	CVCL_2598
13614070	272	279	E. coli	OrganismTaxon	562
13614070	281	287	horses	OrganismTaxon	9796
13614070	293	297	dogs	OrganismTaxon	9615
13614070	335	344	rs2073601	SequenceVariant	rs2073601
13614070	346	351	V274I	SequenceVariant	rs2235371
13614070	353	358	S276T	SequenceVariant	rs2234671
13614070	368	408	12-nucleotide insertion/deletion (indel)	SequenceVariant	c|INDEL||12
13614070	433	442	g.2885G>C	SequenceVariant	g|SUB|G|2885|C
13614070	542	551	rs2073601	SequenceVariant	rs2073601
13614070	576	585	g.2885G>C	SequenceVariant	g|SUB|G|2885|C
13614070	590	595	V274I	SequenceVariant	rs2235371
13614070	603	612	g.2885G>C	SequenceVariant	g|SUB|G|2885|C
13614070	626	631	V274I	SequenceVariant	rs2235371
13614070	636	645	rs2073601	SequenceVariant	rs2073601
13614070	661	666	V274I	SequenceVariant	rs2235371
13614070	695	735	12-nucleotide insertion/deletion (indel)	SequenceVariant	c|INDEL||12
13614070	740	749	g.2885G>C	SequenceVariant	g|SUB|G|2885|C
13614070	755	795	12-nucleotide insertion/deletion (indel)	SequenceVariant	c|INDEL||12
13614070	820	825	S276T	SequenceVariant	rs2234671
13614070	830	839	g.2885G>C	SequenceVariant	g|SUB|G|2885|C
13614070	912	919	SNU-C2A	CellLine	CVCL_1709
13614070	921	927	hRPTEC	CellLine	CVCL_K278
13614070	933	940	SJ-GBM2	CellLine	CVCL_M141
13614070	990	996	horses	OrganismTaxon	9796
13614070	998	1002	dogs	OrganismTaxon	9615
13614070	1008	1029	Mangifera indica Linn	OrganismTaxon	29780
13614070	1061	1066	V274I	SequenceVariant	rs2235371
13614070	1094	1116	Platonia insignis Mart	OrganismTaxon	198787
13614070	Association	rs2073601	g|SUB|G|2885|C	Novel
13614070	Association	c|INDEL||12	rs2235371	Novel
13614070	Association	g|SUB|G|2885|C	rs2073601	Novel
13614070	Association	g|SUB|G|2885|C	rs2235371	Novel
13614070	Association	rs2235371	c|INDEL||12	Novel
13614070	Association	rs2235371	g|SUB|G|2885|C	Novel
13614070	Association	rs2073601	rs2235371	Novel
13614070	Association	rs2234671	rs2073601	Novel
13614070	Association	c|INDEL||12	rs2234671	Novel
13614070	Association	c|INDEL||12	g|SUB|G|2885|C	Novel

71963119|t|E359K and dopamine agonists in H446 cells: interactions with Cyclin-d2 and 5-HT 2A r
71963119|a|The study investigates the molecular mechanisms underlying the interaction between the sequence variant E359K and dopamine agonists in the context of the H446 cell line. E359K was found to significantly modulate the cellular response to dopamine agonists, suggesting a potential role in signal transduction pathways. This effect was observed in multiple independent experiments using the H446 cell line, with E359K consistently associated with altered sensitivity to dopamine agonists.   Further analysis revealed a complex regulatory network involving the gene product Cyclin-d2. The study demonstrated a negative correlation between Cyclin-d2 expression and the activity of 5-HT 2A receptors, with this relationship being consistently observed across multiple experimental conditions. The H446 cell line was used to validate these findings, and the results were replicated in 18 separate experiments.   In addition, the study found that the presence of E359K in the H446 cell line was associated with a reduced expression of Cyclin-d2, which in turn led to a decrease in the activation of 5-HT 2A receptors. This negative correlation between Cyclin-d2 and 5-HT 2A receptors was confirmed through multiple assays, including real-time PCR and immunoblotting. The findings suggest that E359K may act as a regulatory element that influences both Cyclin-d2 and 5-HT 2A receptor activity in the H446 cell line.   The results highlight the importance of understanding the interplay between sequence variants, gene products, and chemical entities in cellular signaling. The H446 cell line served as a critical model for these studies, with dopamine agonists and Cyclin-d2 being repeatedly linked to the observed effects. The negative correlation between Cyclin-d2 and 5-HT 2A receptors was further supported by the consistent presence of these gene products in the H446 cell line across all experimental conditions. These findings provide new insights into the molecular mechanisms underlying the interactions between sequence variants, gene products, and chemical entities in cellular signaling pathways.
71963119	0	5	E359K	SequenceVariant	rs368489876
71963119	10	27	dopamine agonists	ChemicalEntity	D018491
71963119	31	35	H446	CellLine	CVCL_1562
71963119	61	70	Cyclin-d2	GeneOrGeneProduct	12444
71963119	189	194	E359K	SequenceVariant	rs368489876
71963119	199	216	dopamine agonists	ChemicalEntity	D018491
71963119	239	243	H446	CellLine	CVCL_1562
71963119	255	260	E359K	SequenceVariant	rs368489876
71963119	322	339	dopamine agonists	ChemicalEntity	D018491
71963119	473	477	H446	CellLine	CVCL_1562
71963119	494	499	E359K	SequenceVariant	rs368489876
71963119	552	569	dopamine agonists	ChemicalEntity	D018491
71963119	655	664	Cyclin-d2	GeneOrGeneProduct	12444
71963119	720	729	Cyclin-d2	GeneOrGeneProduct	12444
71963119	761	778	5-HT 2A receptors	GeneOrGeneProduct	29595
71963119	876	880	H446	CellLine	CVCL_1562
71963119	1040	1045	E359K	SequenceVariant	rs368489876
71963119	1053	1057	H446	CellLine	CVCL_1562
71963119	1112	1121	Cyclin-d2	GeneOrGeneProduct	12444
71963119	1176	1193	5-HT 2A receptors	GeneOrGeneProduct	29595
71963119	1229	1238	Cyclin-d2	GeneOrGeneProduct	12444
71963119	1243	1260	5-HT 2A receptors	GeneOrGeneProduct	29595
71963119	1370	1375	E359K	SequenceVariant	rs368489876
71963119	1429	1438	Cyclin-d2	GeneOrGeneProduct	12444
71963119	1476	1480	H446	CellLine	CVCL_1562
71963119	1653	1657	H446	CellLine	CVCL_1562
71963119	1719	1736	dopamine agonists	ChemicalEntity	D018491
71963119	1741	1750	Cyclin-d2	GeneOrGeneProduct	12444
71963119	1833	1842	Cyclin-d2	GeneOrGeneProduct	12444
71963119	1847	1864	5-HT 2A receptors	GeneOrGeneProduct	29595
71963119	1944	1948	H446	CellLine	CVCL_1562
71963119	Association	rs368489876	D018491	Novel
71963119	Negative_Correlation	29595	12444	Novel
71963119	Negative_Correlation	12444	29595	Novel

93459272|t|Etomidate, steatosis, and the role of Ubiquitin carboxyl-terminal esterase L1 in B-NHL and DEN-4 i
93459272|a|Recent studies have highlighted the complex interplay between etomidate exposure, steatosis development, and the expression of key genes in cats and ginseng. This research explores the molecular mechanisms underlying the association between Ubiquitin carboxyl-terminal esterase L1 (UCHL1) and B-NHL, a type of non-Hodgkin lymphoma, while also examining the impact of etomidate on steatosis in DEN-4-infected cats. The findings reveal a significant association between UCHL1 and B-NHL, suggesting a potential role for this gene in the pathogenesis of the disease. Furthermore, the study demonstrates a negative correlation between UCHL1 and both CXCL9 and Tak1, indicating that UCHL1 may act as a suppressor of these inflammatory pathways. In addition, a negative correlation was observed between CXCL9 and Tak1, reinforcing the idea of a regulatory network involving these genes. The association between VII collagen and B-NHL, as well as between VII collagen and steatosis, was also confirmed, suggesting a broader role for collagen in immune-related diseases and metabolic disorders. Notably, the study also found that etomidate treatment in cats led to increased steatosis, while the presence of ginseng was associated with reduced steatosis. These results provide new insights into the molecular mechanisms linking etomidate, steatosis, and the immune system, with implications for the treatment of B-NHL and related conditions. The role of anthraquinone and desipramine in modulating these interactions was also explored, with preliminary evidence suggesting their potential as therapeutic agents in the context of DEN-4 infection and steatosis.
93459272	11	20	steatosis	DiseaseOrPhenotypicFeature	D005234
93459272	38	77	Ubiquitin carboxyl-terminal esterase L1	GeneOrGeneProduct	7345
93459272	81	86	B-NHL	DiseaseOrPhenotypicFeature	D016393
93459272	91	96	DEN-4	OrganismTaxon	11070
93459272	161	170	etomidate	ChemicalEntity	D005045
93459272	181	190	steatosis	DiseaseOrPhenotypicFeature	D005234
93459272	239	243	cats	OrganismTaxon	9685
93459272	248	255	ginseng	OrganismTaxon	4054
93459272	340	379	Ubiquitin carboxyl-terminal esterase L1	GeneOrGeneProduct	7345
93459272	392	397	B-NHL	DiseaseOrPhenotypicFeature	D016393
93459272	466	475	etomidate	ChemicalEntity	D005045
93459272	479	488	steatosis	DiseaseOrPhenotypicFeature	D005234
93459272	492	497	DEN-4	OrganismTaxon	11070
93459272	507	511	cats	OrganismTaxon	9685
93459272	577	582	B-NHL	DiseaseOrPhenotypicFeature	D016393
93459272	744	749	CXCL9	GeneOrGeneProduct	4283
93459272	754	758	Tak1	GeneOrGeneProduct	26409
93459272	895	900	CXCL9	GeneOrGeneProduct	4283
93459272	905	909	Tak1	GeneOrGeneProduct	26409
93459272	1003	1015	VII collagen	GeneOrGeneProduct	1294
93459272	1020	1025	B-NHL	DiseaseOrPhenotypicFeature	D016393
93459272	1046	1058	VII collagen	GeneOrGeneProduct	1294
93459272	1063	1072	steatosis	DiseaseOrPhenotypicFeature	D005234
93459272	1220	1229	etomidate	ChemicalEntity	D005045
93459272	1243	1247	cats	OrganismTaxon	9685
93459272	1265	1274	steatosis	DiseaseOrPhenotypicFeature	D005234
93459272	1298	1305	ginseng	OrganismTaxon	4054
93459272	1334	1343	steatosis	DiseaseOrPhenotypicFeature	D005234
93459272	1418	1427	etomidate	ChemicalEntity	D005045
93459272	1429	1438	steatosis	DiseaseOrPhenotypicFeature	D005234
93459272	1502	1507	B-NHL	DiseaseOrPhenotypicFeature	D016393
93459272	1544	1557	anthraquinone	ChemicalEntity	D000880
93459272	1562	1573	desipramine	ChemicalEntity	D003891
93459272	1719	1724	DEN-4	OrganismTaxon	11070
93459272	1739	1748	steatosis	DiseaseOrPhenotypicFeature	D005234
93459272	Association	7345	D016393	Novel
93459272	Negative_Correlation	7345	4283	Novel
93459272	Negative_Correlation	7345	26409	Novel
93459272	Negative_Correlation	4283	26409	Novel
93459272	Association	1294	D016393	Novel
93459272	Association	26409	D016393	Novel
93459272	Association	1294	D005234	Novel

42882953|t|Cidec and GCD type I: genetic and molecular interactions with Peutz-Jeghers syndrome, HS-RDEB, and glial fibrillary acidic
42882953|a|Recent studies have highlighted the complex interplay between genetic variants and disease phenotypes, particularly in the context of neurodevelopmental disorders and metabolic syndromes. This study investigates the molecular and genetic relationships between the gene Cidec, the sequence variant c.695T>A, and the disease GCD type I, with a focus on their associations with Peutz-Jeghers syndrome, HS-RDEB, and glial fibrillary acidic protein. The findings reveal a positive correlation between Cidec and Peutz-Jeghers syndrome, suggesting a potential role for Cidec in the pathogenesis of this rare genetic disorder. Additionally, the sequence variant c.695T>A is found to be associated with GCD type I, further supporting the hypothesis that genetic variability in Cidec contributes to the development of this condition. The study also demonstrates a positive correlation between GCD type I and glial fibrillary acidic protein, indicating a possible functional link between these two entities. Furthermore, the gene ABCA4 is shown to have a positive correlation with both Peutz-Jeghers syndrome and HS-RDEB, suggesting a broader role for ABCA4 in the regulation of these phenotypic features. The chemical entities Asenapine, AAS, and Fentanyl are explored for their potential modulatory effects on these genetic and phenotypic interactions, while CNSB002 is introduced as a novel therapeutic candidate. These findings provide new insights into the molecular mechanisms underlying these complex diseases and open avenues for targeted therapeutic strategies.
42882953	0	5	Cidec	GeneOrGeneProduct	63924
42882953	10	20	GCD type I	DiseaseOrPhenotypicFeature	C537304
42882953	62	84	Peutz-Jeghers syndrome	DiseaseOrPhenotypicFeature	D010580
42882953	86	93	HS-RDEB	DiseaseOrPhenotypicFeature	D016108
42882953	392	397	Cidec	GeneOrGeneProduct	63924
42882953	420	428	c.695T>A	SequenceVariant	c|SUB|T|695|A
42882953	446	456	GCD type I	DiseaseOrPhenotypicFeature	C537304
42882953	498	520	Peutz-Jeghers syndrome	DiseaseOrPhenotypicFeature	D010580
42882953	522	529	HS-RDEB	DiseaseOrPhenotypicFeature	D016108
42882953	535	566	glial fibrillary acidic protein	GeneOrGeneProduct	14580
42882953	619	624	Cidec	GeneOrGeneProduct	63924
42882953	629	651	Peutz-Jeghers syndrome	DiseaseOrPhenotypicFeature	D010580
42882953	685	690	Cidec	GeneOrGeneProduct	63924
42882953	777	785	c.695T>A	SequenceVariant	c|SUB|T|695|A
42882953	817	827	GCD type I	DiseaseOrPhenotypicFeature	C537304
42882953	891	896	Cidec	GeneOrGeneProduct	63924
42882953	1006	1016	GCD type I	DiseaseOrPhenotypicFeature	C537304
42882953	1021	1052	glial fibrillary acidic protein	GeneOrGeneProduct	14580
42882953	1142	1147	ABCA4	GeneOrGeneProduct	24
42882953	1198	1220	Peutz-Jeghers syndrome	DiseaseOrPhenotypicFeature	D010580
42882953	1225	1232	HS-RDEB	DiseaseOrPhenotypicFeature	D016108
42882953	1264	1269	ABCA4	GeneOrGeneProduct	24
42882953	1340	1349	Asenapine	ChemicalEntity	C522667
42882953	1351	1354	AAS	ChemicalEntity	D045165
42882953	1360	1368	Fentanyl	ChemicalEntity	D005283
42882953	1473	1480	CNSB002	ChemicalEntity	C401121
42882953	Positive_Correlation	24	D010580	Novel
42882953	Positive_Correlation	D010580	14580	Novel
42882953	Positive_Correlation	24	D016108	Novel
42882953	Positive_Correlation	63924	D010580	Novel
42882953	Positive_Correlation	C537304	14580	Novel
42882953	Association	C537304	63924	Novel

87883603|t|Multifaceted interactions of CD72, C2, NPM, and TIMP3 with Ca2+, benzoylcholine, and Modafinil in human immunodeficiency virus-infected SCID-HuH-7 cells and
87883603|a|This study investigates the complex interactions between CD72, C2, NPM, and TIMP3 with Ca2+, benzoylcholine, and Modafinil in the context of human immunodeficiency virus (HIV) infection and their effects on SCID-HuH-7 cells and E. coli. We demonstrate that CD72 binds to both benzoylcholine and calcium, while also showing a negative correlation with Ca2+ and a positive correlation with Modafinil. The association between CD72 and Mg+2 ATPase is further supported by its binding to alpha(2) and its positive correlation with NPM.   C2 exhibits a positive correlation with Ca2+ and benzoylcholine, and a negative correlation with Mg+2 ATPase. NPM shows a negative correlation with both Ca2+ and Mg+2 ATPase, and a positive correlation with benzoylcholine and TIMP3. TIMP3 is found to bind to Mg+2 ATPase, C2, and alpha(2), and exhibits a negative correlation with Mg+2 ATPase and benzoylcholine, while showing a positive correlation with NPM and bupivacaine.   Bupivacaine is associated with TIMP3 and Mg+2 ATPase, and shows a positive correlation with TIMP3 and NPM. The interaction between alpha(2) and Modafinil is confirmed through binding, as is the association between alpha(2) and benzoylcholine. Additionally, alpha(2) binds to CD11c and C2, and shows a positive correlation with calcium and mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2 (MAPK/ERK1/2).   MAPK/ERK1/2 is associated with alpha(2), CD72, and benzoylcholine, and shows a negative correlation with Ca2+ and bupivacaine. CD11c binds to alpha(2) and bupivacaine, and is associated with benzoylcholine. The study also reveals that Ca2+ is associated with calcium and MAPK/ERK1/2, and that calcium shows a positive correlation with MAPK/ERK1/2.   These findings highlight the intricate network of interactions between these molecules in the context of HIV infection and their potential roles in cellular signaling and immune responses. The results provide a foundation for further research into the therapeutic targeting of these interactions in disease states involving HIV, E. coli, and bovine systems.
87883603	29	33	CD72	GeneOrGeneProduct	12517
87883603	35	37	C2	GeneOrGeneProduct	717
87883603	39	42	NPM	GeneOrGeneProduct	4869
87883603	48	53	TIMP3	GeneOrGeneProduct	7078
87883603	59	63	Ca2+	ChemicalEntity	D000069285
87883603	65	79	benzoylcholine	ChemicalEntity	D001588
87883603	85	94	Modafinil	ChemicalEntity	C048833
87883603	98	126	human immunodeficiency virus	OrganismTaxon	12721
87883603	136	146	SCID-HuH-7	CellLine	CVCL_0336
87883603	214	218	CD72	GeneOrGeneProduct	12517
87883603	220	222	C2	GeneOrGeneProduct	717
87883603	224	227	NPM	GeneOrGeneProduct	4869
87883603	233	238	TIMP3	GeneOrGeneProduct	7078
87883603	244	248	Ca2+	ChemicalEntity	D000069285
87883603	250	264	benzoylcholine	ChemicalEntity	D001588
87883603	270	279	Modafinil	ChemicalEntity	C048833
87883603	298	326	human immunodeficiency virus	OrganismTaxon	12721
87883603	364	374	SCID-HuH-7	CellLine	CVCL_0336
87883603	385	392	E. coli	OrganismTaxon	562
87883603	414	418	CD72	GeneOrGeneProduct	12517
87883603	433	447	benzoylcholine	ChemicalEntity	D001588
87883603	452	459	calcium	ChemicalEntity	D002118
87883603	508	512	Ca2+	ChemicalEntity	D000069285
87883603	545	554	Modafinil	ChemicalEntity	C048833
87883603	580	584	CD72	GeneOrGeneProduct	12517
87883603	589	600	Mg+2 ATPase	ChemicalEntity	D017301
87883603	640	648	alpha(2)	GeneOrGeneProduct	11551
87883603	683	686	NPM	GeneOrGeneProduct	4869
87883603	690	692	C2	GeneOrGeneProduct	717
87883603	730	734	Ca2+	ChemicalEntity	D000069285
87883603	739	753	benzoylcholine	ChemicalEntity	D001588
87883603	787	798	Mg+2 ATPase	ChemicalEntity	D017301
87883603	800	803	NPM	GeneOrGeneProduct	4869
87883603	843	847	Ca2+	ChemicalEntity	D000069285
87883603	852	863	Mg+2 ATPase	ChemicalEntity	D017301
87883603	897	911	benzoylcholine	ChemicalEntity	D001588
87883603	916	921	TIMP3	GeneOrGeneProduct	7078
87883603	923	928	TIMP3	GeneOrGeneProduct	7078
87883603	949	960	Mg+2 ATPase	ChemicalEntity	D017301
87883603	962	964	C2	GeneOrGeneProduct	717
87883603	970	978	alpha(2)	GeneOrGeneProduct	11551
87883603	1021	1032	Mg+2 ATPase	ChemicalEntity	D017301
87883603	1037	1051	benzoylcholine	ChemicalEntity	D001588
87883603	1095	1098	NPM	GeneOrGeneProduct	4869
87883603	1103	1114	bupivacaine	ChemicalEntity	D002045
87883603	1149	1154	TIMP3	GeneOrGeneProduct	7078
87883603	1159	1170	Mg+2 ATPase	ChemicalEntity	D017301
87883603	1210	1215	TIMP3	GeneOrGeneProduct	7078
87883603	1220	1223	NPM	GeneOrGeneProduct	4869
87883603	1249	1257	alpha(2)	GeneOrGeneProduct	11551
87883603	1262	1271	Modafinil	ChemicalEntity	C048833
87883603	1332	1340	alpha(2)	GeneOrGeneProduct	11551
87883603	1345	1359	benzoylcholine	ChemicalEntity	D001588
87883603	1375	1383	alpha(2)	GeneOrGeneProduct	11551
87883603	1393	1398	CD11c	GeneOrGeneProduct	16411
87883603	1403	1405	C2	GeneOrGeneProduct	717
87883603	1445	1452	calcium	ChemicalEntity	D002118
87883603	1457	1533	mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2	GeneOrGeneProduct	5594
87883603	1582	1590	alpha(2)	GeneOrGeneProduct	11551
87883603	1592	1596	CD72	GeneOrGeneProduct	12517
87883603	1602	1616	benzoylcholine	ChemicalEntity	D001588
87883603	1656	1660	Ca2+	ChemicalEntity	D000069285
87883603	1665	1676	bupivacaine	ChemicalEntity	D002045
87883603	1678	1683	CD11c	GeneOrGeneProduct	16411
87883603	1693	1701	alpha(2)	GeneOrGeneProduct	11551
87883603	1706	1717	bupivacaine	ChemicalEntity	D002045
87883603	1742	1756	benzoylcholine	ChemicalEntity	D001588
87883603	1786	1790	Ca2+	ChemicalEntity	D000069285
87883603	1810	1817	calcium	ChemicalEntity	D002118
87883603	1844	1851	calcium	ChemicalEntity	D002118
87883603	2230	2237	E. coli	OrganismTaxon	562
87883603	2243	2249	bovine	OrganismTaxon	9913
87883603	Association	12517	D001588	Novel
87883603	Association	717	D000069285	Novel
87883603	Negative_Correlation	4869	D000069285	Novel
87883603	Association	16411	D017301	Novel
87883603	Bind	11551	C048833	Novel
87883603	Positive_Correlation	D002045	7078	Novel
87883603	Bind	12517	D001588	Novel
87883603	Negative_Correlation	12517	D000069285	Novel
87883603	Positive_Correlation	D002118	11551	Novel
87883603	Association	717	D001588	Novel
87883603	Bind	5594	11551	Novel
87883603	Bind	12517	11551	Novel
87883603	Bind	5594	D001588	Novel
87883603	Negative_Correlation	4869	D017301	Novel
87883603	Bind	16411	11551	Novel
87883603	Association	D000069285	D002045	Novel
87883603	Positive_Correlation	D001588	4869	Novel
87883603	Negative_Correlation	7078	D017301	Novel
87883603	Bind	7078	D017301	Novel
87883603	Positive_Correlation	D001588	12517	Novel
87883603	Bind	12517	D000069285	Novel
87883603	Negative_Correlation	16411	C048833	Novel
87883603	Association	11551	D001588	Novel
87883603	Bind	7078	C048833	Novel
87883603	Negative_Correlation	5594	D000069285	Novel
87883603	Negative_Correlation	5594	D002045	Novel
87883603	Bind	7078	11551	Novel
87883603	Bind	7078	D002045	Novel
87883603	Association	D002045	D017301	Novel
87883603	Bind	12517	D002118	Novel
87883603	Association	D002045	D001588	Novel
87883603	Positive_Correlation	C048833	4869	Novel
87883603	Bind	11551	D002045	Novel
87883603	Bind	5594	C048833	Novel
87883603	Positive_Correlation	D017301	4869	Novel
87883603	Association	11551	C048833	Novel
87883603	Negative_Correlation	717	D017301	Novel
87883603	Association	D001588	D017301	Novel
87883603	Bind	7078	717	Novel
87883603	Association	12517	D017301	Novel
87883603	Bind	11551	16411	Novel
87883603	Bind	4869	717	Novel
87883603	Positive_Correlation	D002118	5594	Novel
87883603	Negative_Correlation	7078	D001588	Novel
87883603	Association	7078	D002045	Novel
87883603	Association	D000069285	D002118	Novel
87883603	Bind	5594	D000069285	Novel
87883603	Association	D001588	C048833	Novel
87883603	Bind	16411	D002045	Novel
87883603	Bind	5594	12517	Novel
87883603	Bind	12517	D017301	Novel
87883603	Bind	4869	D002045	Novel
87883603	Bind	4869	D017301	Novel
87883603	Association	16411	D001588	Novel
87883603	Bind	717	D001588	Novel

25676005|t|Genetic and pharmacological interactions of sequence variants, dioxin, and free fatty acids in neurotoxic lesions and bone def
25676005|a|This study investigates the complex interactions between genetic sequence variants, environmental toxins, and metabolic factors in the context of neurotoxic lesions and bone deformities. A key focus is the sequence variant g.3774G>A, which exhibits both positive and negative correlations with Bortezomib and free fatty acids. The variant also shows a negative correlation with dioxin, suggesting a potential protective role against dioxin-induced toxicity.   The chemical entity Bortezomib is found to have a positive correlation with g.3774G>A, but a negative correlation with bone deformities, indicating that while Bortezomib may be beneficial in certain contexts, it may also contribute to adverse skeletal outcomes. Additionally, Bortezomib is cotreated with free fatty acids, highlighting a potential therapeutic synergy in managing neurotoxic lesions.   The sequence variant 735-6 TG>AT is negatively correlated with free fatty acids, suggesting a possible antagonistic relationship. However, free fatty acids are positively correlated with both 735-6 TG>AT and g.3774G>A, indicating a complex interplay between these genetic and metabolic factors.   Dioxin is negatively correlated with neurotoxic lesions, which may imply a protective effect against neurotoxicity, but it is also negatively correlated with bone deformities, suggesting a dual role in skeletal health. Dioxin is cotreated with Bortezomib, further complicating the pharmacological landscape.   The study also examines the effects of these interactions in various cell lines, including RAW 264.7, 293T, and DUCaP, to better understand the cellular mechanisms underlying these relationships. The findings underscore the importance of considering both genetic and environmental factors in the development of neurotoxic lesions and bone deformities, and suggest potential therapeutic strategies involving Bortezomib, free fatty acids, and dioxin.
25676005	63	69	dioxin	ChemicalEntity	D004147
25676005	75	91	free fatty acids	ChemicalEntity	D005230
25676005	95	113	neurotoxic lesions	DiseaseOrPhenotypicFeature	D020258
25676005	273	291	neurotoxic lesions	DiseaseOrPhenotypicFeature	D020258
25676005	296	312	bone deformities	DiseaseOrPhenotypicFeature	D001847
25676005	350	359	g.3774G>A	SequenceVariant	rs111033186
25676005	421	431	Bortezomib	ChemicalEntity	D000069286
25676005	436	452	free fatty acids	ChemicalEntity	D005230
25676005	505	511	dioxin	ChemicalEntity	D004147
25676005	560	566	dioxin	ChemicalEntity	D004147
25676005	607	617	Bortezomib	ChemicalEntity	D000069286
25676005	663	672	g.3774G>A	SequenceVariant	rs111033186
25676005	706	722	bone deformities	DiseaseOrPhenotypicFeature	D001847
25676005	746	756	Bortezomib	ChemicalEntity	D000069286
25676005	863	873	Bortezomib	ChemicalEntity	D000069286
25676005	892	908	free fatty acids	ChemicalEntity	D005230
25676005	967	985	neurotoxic lesions	DiseaseOrPhenotypicFeature	D020258
25676005	1010	1021	735-6 TG>AT	SequenceVariant	c|SUB|TG|735_736|AT
25676005	1052	1068	free fatty acids	ChemicalEntity	D005230
25676005	1128	1144	free fatty acids	ChemicalEntity	D005230
25676005	1181	1192	735-6 TG>AT	SequenceVariant	c|SUB|TG|735_736|AT
25676005	1197	1206	g.3774G>A	SequenceVariant	rs111033186
25676005	1323	1341	neurotoxic lesions	DiseaseOrPhenotypicFeature	D020258
25676005	1444	1460	bone deformities	DiseaseOrPhenotypicFeature	D001847
25676005	1530	1540	Bortezomib	ChemicalEntity	D000069286
25676005	1687	1696	RAW 264.7	CellLine	CVCL_0493
25676005	1698	1702	293T	CellLine	CVCL_0063
25676005	1708	1713	DUCaP	CellLine	CVCL_2025
25676005	1907	1925	neurotoxic lesions	DiseaseOrPhenotypicFeature	D020258
25676005	1930	1946	bone deformities	DiseaseOrPhenotypicFeature	D001847
25676005	2003	2013	Bortezomib	ChemicalEntity	D000069286
25676005	2015	2031	free fatty acids	ChemicalEntity	D005230
25676005	2037	2043	dioxin	ChemicalEntity	D004147
25676005	Positive_Correlation	rs111033186	D000069286	Novel
25676005	Negative_Correlation	D000069286	D001847	Novel
25676005	Negative_Correlation	rs111033186	D000069286	Novel
25676005	Negative_Correlation	c|SUB|TG|735_736|AT	D005230	Novel
25676005	Negative_Correlation	D004147	D020258	Novel
25676005	Positive_Correlation	rs111033186	D005230	Novel
25676005	Cotreatment	D005230	D000069286	Novel
25676005	Positive_Correlation	D005230	c|SUB|TG|735_736|AT	Novel
25676005	Negative_Correlation	rs111033186	D004147	Novel
25676005	Negative_Correlation	rs111033186	D005230	Novel
25676005	Negative_Correlation	D005230	D020258	Novel
25676005	Cotreatment	D004147	D000069286	Novel
25676005	Positive_Correlation	D005230	rs111033186	Novel
25676005	Negative_Correlation	D004147	D001847	Novel

10747273|t|Genetic Variants and Cellular Responses in Chick and Zebrafish Models of Immune Reconstitution Syndrome and
10747273|a|This study investigates the molecular and cellular mechanisms underlying the association between specific sequence variants and disease phenotypes in chick and zebrafish models. We focus on the sequence variants D374Y and c.1146+25insA, which are found in multiple cell lines including 253JB-V, PC-3, HeLa, and CMT-93. Our findings reveal a positive correlation between the G12D variant and the development of gliomas, suggesting a potential oncogenic role for this mutation. Additionally, we observe an association between c.1146+25insA and D374Y, indicating a possible functional relationship between these two variants. The negative correlation between c.1146+25insA and tarsal fusion, as well as its negative correlation with gliomas, highlights the complex regulatory networks involving these genetic elements. Furthermore, the association between immune reconstitution syndrome and G12D suggests a potential role for this variant in immune-related pathologies. Notably, the negative correlation between D374Y and immune reconstitution syndrome indicates a possible protective effect of this variant against immune-related complications. These results are supported by experiments conducted in chick and zebrafish models, which provide valuable insights into the biological relevance of these genetic variants in disease contexts. The use of multiple cell lines, including 253JB-V, PC-3, HeLa, and CMT-93, allows for a comprehensive analysis of variant expression and function across different cellular environments. The study also includes the organism taxon chick, Zebrafish, and Platonia insignis Mart, with C. elegans serving as a complementary model system. Overall, this work contributes to the understanding of how genetic variants influence disease phenotypes and cellular responses in diverse biological systems.
10747273	53	62	Zebrafish	OrganismTaxon	7955
10747273	258	263	chick	OrganismTaxon	9031
10747273	320	325	D374Y	SequenceVariant	rs137852912
10747273	330	343	c.1146+25insA	SequenceVariant	c|INS|1146+25|A
10747273	394	401	253JB-V	CellLine	CVCL_7937
10747273	403	407	PC-3	CellLine	CVCL_0035
10747273	409	413	HeLa	CellLine	CVCL_0030
10747273	419	425	CMT-93	CellLine	CVCL_1986
10747273	482	486	G12D	SequenceVariant	rs121913529
10747273	518	525	gliomas	DiseaseOrPhenotypicFeature	D005910
10747273	632	645	c.1146+25insA	SequenceVariant	c|INS|1146+25|A
10747273	650	655	D374Y	SequenceVariant	rs137852912
10747273	764	777	c.1146+25insA	SequenceVariant	c|INS|1146+25|A
10747273	782	795	tarsal fusion	DiseaseOrPhenotypicFeature	D000070604
10747273	838	845	gliomas	DiseaseOrPhenotypicFeature	D005910
10747273	961	991	immune reconstitution syndrome	DiseaseOrPhenotypicFeature	D054019
10747273	996	1000	G12D	SequenceVariant	rs121913529
10747273	1117	1122	D374Y	SequenceVariant	rs137852912
10747273	1127	1157	immune reconstitution syndrome	DiseaseOrPhenotypicFeature	D054019
10747273	1307	1312	chick	OrganismTaxon	9031
10747273	1486	1493	253JB-V	CellLine	CVCL_7937
10747273	1495	1499	PC-3	CellLine	CVCL_0035
10747273	1501	1505	HeLa	CellLine	CVCL_0030
10747273	1511	1517	CMT-93	CellLine	CVCL_1986
10747273	1673	1678	chick	OrganismTaxon	9031
10747273	1680	1689	Zebrafish	OrganismTaxon	7955
10747273	1695	1717	Platonia insignis Mart	OrganismTaxon	198787
10747273	1724	1734	C. elegans	OrganismTaxon	6239
10747273	Positive_Correlation	rs121913529	D005910	Novel
10747273	Association	c|INS|1146+25|A	rs137852912	Novel
10747273	Negative_Correlation	c|INS|1146+25|A	D000070604	Novel
10747273	Negative_Correlation	c|INS|1146+25|A	D005910	Novel
10747273	Association	rs137852912	c|INS|1146+25|A	Novel
10747273	Association	D054019	rs121913529	Novel
10747273	Negative_Correlation	rs137852912	D054019	Novel

21128395|t|Genetic and pharmacological interactions of sequence variants, cell lines, and chemical entities in diverse o
21128395|a|This study explores the complex interactions between genetic sequence variants, chemical entities, and cell lines across multiple organisms, with a focus on their functional and phenotypic implications. The research highlights the association between the sequence variant rs5393 and the chemical entity simvastatin-ezetimibe, suggesting a potential pharmacogenetic link. Additionally, the comparison between serotonergic and 2,3,7,8-tetrachlorodibenzo-p-dioxin reveals distinct biological responses, with serotonergic pathways showing greater sensitivity to environmental toxins.   The chemical entity W is compared with simvastatin-ezetimibe, and the results indicate a significant conversion between these two entities in certain cell lines, such as MCF-7 and SCID-HuH-7. The association between the sequence variant glycine to glutamine and serotonergic pathways is further supported by its interaction with simvastatin-ezetimibe, suggesting a possible role in modulating neurotransmitter activity.   The sequence variant Q126R is found to be associated with both simvastatin-ezetimibe and W, indicating a potential dual role in pharmacological responses. The comparison between W and 2,3,7,8-tetrachlorodibenzo-p-dioxin reveals a complex interplay, with W showing a higher affinity for certain metabolic pathways. The conversion between serotonergic and simvastatin-ezetimibe is also observed, highlighting the dynamic nature of these interactions.   The sequence variant p.G204VfsX28 is associated with both simvastatin-ezetimibe and W, and its interaction with 2,3,7,8-tetrachlorodibenzo-p-dioxin suggests a possible role in environmental stress responses. The association between rs1800872 and serotonergic pathways is further supported by its interaction with simvastatin-ezetimibe, indicating a potential regulatory mechanism.   The study also examines the association between the sequence variant -616C/G and both serotonergic pathways and simvastatin-ezetimibe, suggesting a role in modulating gene expression. The comparison between simvastatin-ezetimibe and 2,3,7,8-tetrachlorodibenzo-p-dioxin reveals a significant conversion, with implications for drug metabolism and toxicity.   The research includes data from various cell lines, including MCF-7, C57BL/6, MH134, and Ishikawa, as well as the organism taxon Drosophila, Women, hepatitis B virus, and human immunodeficiency virus. The findings underscore the importance of considering genetic and environmental factors in understanding the functional consequences of sequence variants and their interactions with chemical entities. The study provides a comprehensive framework for future research on the interplay between genetics, pharmacology, and environmental influences in diverse biological systems.
21128395	382	388	rs5393	SequenceVariant	rs5393
21128395	413	434	simvastatin-ezetimibe	ChemicalEntity	D000069499
21128395	518	530	serotonergic	ChemicalEntity	D018490
21128395	535	570	2,3,7,8-tetrachlorodibenzo-p-dioxin	ChemicalEntity	D000072317
21128395	615	627	serotonergic	ChemicalEntity	D018490
21128395	712	713	W	ChemicalEntity	D014859
21128395	731	752	simvastatin-ezetimibe	ChemicalEntity	D000069499
21128395	862	867	MCF-7	CellLine	CVCL_0031
21128395	872	882	SCID-HuH-7	CellLine	CVCL_0336
21128395	929	949	glycine to glutamine	SequenceVariant	p|SUB|G||Q
21128395	954	966	serotonergic	ChemicalEntity	D018490
21128395	1021	1042	simvastatin-ezetimibe	ChemicalEntity	D000069499
21128395	1135	1140	Q126R	SequenceVariant	rs368386747
21128395	1177	1198	simvastatin-ezetimibe	ChemicalEntity	D000069499
21128395	1203	1204	W	ChemicalEntity	D014859
21128395	1292	1293	W	ChemicalEntity	D014859
21128395	1298	1333	2,3,7,8-tetrachlorodibenzo-p-dioxin	ChemicalEntity	D000072317
21128395	1368	1369	W	ChemicalEntity	D014859
21128395	1451	1463	serotonergic	ChemicalEntity	D018490
21128395	1468	1489	simvastatin-ezetimibe	ChemicalEntity	D000069499
21128395	1586	1598	p.G204VfsX28	SequenceVariant	p|FS|G|204|V|28
21128395	1623	1644	simvastatin-ezetimibe	ChemicalEntity	D000069499
21128395	1649	1650	W	ChemicalEntity	D014859
21128395	1677	1712	2,3,7,8-tetrachlorodibenzo-p-dioxin	ChemicalEntity	D000072317
21128395	1797	1806	rs1800872	SequenceVariant	rs1800872
21128395	1811	1823	serotonergic	ChemicalEntity	D018490
21128395	1878	1899	simvastatin-ezetimibe	ChemicalEntity	D000069499
21128395	2017	2024	-616C/G	SequenceVariant	rs747302
21128395	2034	2046	serotonergic	ChemicalEntity	D018490
21128395	2060	2081	simvastatin-ezetimibe	ChemicalEntity	D000069499
21128395	2155	2176	simvastatin-ezetimibe	ChemicalEntity	D000069499
21128395	2181	2216	2,3,7,8-tetrachlorodibenzo-p-dioxin	ChemicalEntity	D000072317
21128395	2367	2372	MCF-7	CellLine	CVCL_0031
21128395	2374	2381	C57BL/6	CellLine	CVCL_5746
21128395	2383	2388	MH134	CellLine	CVCL_8111
21128395	2394	2402	Ishikawa	CellLine	CVCL_2529
21128395	2434	2444	Drosophila	OrganismTaxon	7227
21128395	2446	2451	Women	OrganismTaxon	9606
21128395	2446	2447	W	ChemicalEntity	D014859
21128395	2453	2470	hepatitis B virus	OrganismTaxon	10407
21128395	2476	2504	human immunodeficiency virus	OrganismTaxon	12721
21128395	Association	rs5393	D000069499	Novel
21128395	Comparison	D018490	D000072317	Novel
21128395	Comparison	D014859	D000069499	Novel
21128395	Association	p|SUB|G||Q	D018490	Novel
21128395	Comparison	D000069499	D014859	Novel
21128395	Association	rs368386747	D000069499	Novel
21128395	Association	rs368386747	D014859	Novel
21128395	Comparison	D000072317	D018490	Novel
21128395	Comparison	D014859	D000072317	Novel
21128395	Comparison	D000072317	D000069499	Novel
21128395	Conversion	D014859	D018490	Novel
21128395	Association	p|SUB|G||Q	D000069499	Novel
21128395	Association	p|FS|G|204|V|28	D000069499	Novel
21128395	Conversion	D018490	D000069499	Novel
21128395	Conversion	D000072317	D000069499	Novel
21128395	Conversion	D014859	D000072317	Novel
21128395	Association	p|FS|G|204|V|28	D014859	Novel
21128395	Conversion	D000072317	D018490	Novel
21128395	Conversion	D000072317	D014859	Novel
21128395	Comparison	D018490	D000069499	Novel
21128395	Association	rs1800872	D018490	Novel
21128395	Conversion	D014859	D000069499	Novel
21128395	Association	p|SUB|G||Q	D000072317	Novel
21128395	Association	rs368386747	D018490	Novel
21128395	Association	rs1800872	D000069499	Novel
21128395	Association	rs5393	D000072317	Novel
21128395	Conversion	D000069499	D000072317	Novel
21128395	Association	rs5393	D014859	Novel
21128395	Comparison	D000069499	D018490	Novel
21128395	Conversion	D000069499	D018490	Novel
21128395	Association	p|FS|G|204|V|28	D000072317	Novel
21128395	Comparison	D018490	D014859	Novel
21128395	Comparison	D000069499	D000072317	Novel
21128395	Association	p|FS|G|204|V|28	D018490	Novel
21128395	Comparison	D014859	D018490	Novel
21128395	Association	rs747302	D018490	Novel
21128395	Conversion	D018490	D014859	Novel
21128395	Association	rs747302	D000069499	Novel

68037295|t|Garcinielliptone FC and its effects on CK-18 expression in MEF cells: interactions with ABL, thrombin receptor, and low-density lipoprotein receptor in 
68037295|a|Garcinielliptone FC, a natural compound derived from Mangifera indica Linn, has been shown to modulate the expression of CK-18 in MEF cells. This study investigates the molecular mechanisms underlying these effects, focusing on the interactions between Garcinielliptone FC and key gene products such as ABL, thrombin receptor, and low-density lipoprotein receptor. The findings suggest that Garcinielliptone FC may influence bacterial populations by altering the expression of these genes in both MEF cells and bacteria. Further experiments revealed that the compound significantly affects the activity of ABL and thrombin receptor, which are known to play critical roles in cellular signaling pathways. Additionally, the low-density lipoprotein receptor was found to be upregulated in response to Garcinielliptone FC treatment, indicating a potential role in lipid metabolism. These results highlight the complex interplay between Garcinielliptone FC and various molecular targets, offering new insights into its therapeutic potential. The study also emphasizes the importance of Mangifera indica Linn as a source of bioactive compounds with broad biological activities.
68037295	39	44	CK-18	GeneOrGeneProduct	3875
68037295	59	62	MEF	CellLine	CVCL_9115
68037295	88	91	ABL	GeneOrGeneProduct	25
68037295	93	110	thrombin receptor	GeneOrGeneProduct	14062
68037295	116	148	low-density lipoprotein receptor	GeneOrGeneProduct	3949
68037295	206	227	Mangifera indica Linn	OrganismTaxon	29780
68037295	274	279	CK-18	GeneOrGeneProduct	3875
68037295	283	286	MEF	CellLine	CVCL_9115
68037295	456	459	ABL	GeneOrGeneProduct	25
68037295	461	478	thrombin receptor	GeneOrGeneProduct	14062
68037295	484	516	low-density lipoprotein receptor	GeneOrGeneProduct	3949
68037295	578	586	bacteria	OrganismTaxon	2
68037295	650	653	MEF	CellLine	CVCL_9115
68037295	664	672	bacteria	OrganismTaxon	2
68037295	759	762	ABL	GeneOrGeneProduct	25
68037295	767	784	thrombin receptor	GeneOrGeneProduct	14062
68037295	875	907	low-density lipoprotein receptor	GeneOrGeneProduct	3949
68037295	1234	1255	Mangifera indica Linn	OrganismTaxon	29780

81810748|t|YC1 and phospholipase C epsilon 1: dual roles in modulating visual hallucinations and interactions with bup
81810748|a|Recent studies have highlighted the complex interplay between genetic factors and neurochemical agents in the pathogenesis of visual hallucinations. This research investigates the role of YC1 and phospholipase C epsilon 1 in modulating the occurrence of visual hallucinations, with a focus on their interactions with the local anesthetic bupivacaine. YC1, a gene product implicated in neuronal signaling, was found to exhibit a negative correlation with the frequency of visual hallucinations in a cohort of patients undergoing neuroimaging and behavioral assessments. Similarly, phospholipase C epsilon 1, a key enzyme in intracellular signaling pathways, showed a negative correlation with the presence of visual hallucinations, suggesting a potential inhibitory role in their development.   The study further explored the impact of bupivacaine, a commonly used local anesthetic, on these genetic factors. Bupivacaine was administered in controlled doses to a group of patients, and its effects on YC1 and phospholipase C epsilon 1 expression were monitored. The results indicated that bupivacaine may modulate the activity of both YC1 and phospholipase C epsilon 1, potentially influencing the manifestation of visual hallucinations. These findings suggest that the interplay between genetic factors and pharmacological agents may play a critical role in the pathophysiology of visual hallucinations. Further research is warranted to elucidate the precise mechanisms underlying these relationships and to explore potential therapeutic strategies targeting these pathways.
81810748	0	3	YC1	GeneOrGeneProduct	56878
81810748	8	33	phospholipase C epsilon 1	GeneOrGeneProduct	51196
81810748	60	81	visual hallucinations	DiseaseOrPhenotypicFeature	D006212
81810748	234	255	visual hallucinations	DiseaseOrPhenotypicFeature	D006212
81810748	296	299	YC1	GeneOrGeneProduct	56878
81810748	304	329	phospholipase C epsilon 1	GeneOrGeneProduct	51196
81810748	362	383	visual hallucinations	DiseaseOrPhenotypicFeature	D006212
81810748	446	457	bupivacaine	ChemicalEntity	D002045
81810748	459	462	YC1	GeneOrGeneProduct	56878
81810748	579	600	visual hallucinations	DiseaseOrPhenotypicFeature	D006212
81810748	688	713	phospholipase C epsilon 1	GeneOrGeneProduct	51196
81810748	816	837	visual hallucinations	DiseaseOrPhenotypicFeature	D006212
81810748	943	954	bupivacaine	ChemicalEntity	D002045
81810748	1108	1111	YC1	GeneOrGeneProduct	56878
81810748	1116	1141	phospholipase C epsilon 1	GeneOrGeneProduct	51196
81810748	1196	1207	bupivacaine	ChemicalEntity	D002045
81810748	1242	1245	YC1	GeneOrGeneProduct	56878
81810748	1250	1275	phospholipase C epsilon 1	GeneOrGeneProduct	51196
81810748	1322	1343	visual hallucinations	DiseaseOrPhenotypicFeature	D006212
81810748	1489	1510	visual hallucinations	DiseaseOrPhenotypicFeature	D006212
81810748	Negative_Correlation	56878	D006212	Novel
81810748	Negative_Correlation	51196	D006212	Novel

89074264|t|GC and bone fractures: a novel association in SNU-C5 and SW480 cell lines across PATIENTS and mouse mammary tumor viru
89074264|a|Recent studies have highlighted a potential link between the chemical entity GC and the occurrence of bone fractures, particularly in the context of cancer biology. This study investigates the relationship between GC and bone fractures in multiple cell lines, including SNU-C5 and SW480, and explores its implications in both human PATIENTS and mouse mammary tumor virus (MMTV) models. Using in vitro assays, we observed a positive correlation between GC exposure and the incidence of bone fractures in SNU-C5 cells, which was further validated in SW480 cell lines. These findings were corroborated by in vivo experiments in PATIENTS, where elevated GC levels were associated with increased bone fracture risk. Additionally, the role of MMTV in modulating this relationship was examined, revealing a significant positive correlation between GC and bone fractures in MMTV-infected mouse models. The results suggest that GC may play a critical role in the pathogenesis of bone fractures, particularly in the context of cancer-related bone metabolism. Further research is warranted to explore the molecular mechanisms underlying this association and its potential therapeutic implications.
89074264	0	2	GC	ChemicalEntity	D005938
89074264	7	21	bone fractures	DiseaseOrPhenotypicFeature	D050723
89074264	46	52	SNU-C5	CellLine	CVCL_5112
89074264	57	62	SW480	CellLine	CVCL_0546
89074264	81	89	PATIENTS	OrganismTaxon	9606
89074264	196	198	GC	ChemicalEntity	D005938
89074264	221	235	bone fractures	DiseaseOrPhenotypicFeature	D050723
89074264	333	335	GC	ChemicalEntity	D005938
89074264	340	354	bone fractures	DiseaseOrPhenotypicFeature	D050723
89074264	389	395	SNU-C5	CellLine	CVCL_5112
89074264	400	405	SW480	CellLine	CVCL_0546
89074264	451	459	PATIENTS	OrganismTaxon	9606
89074264	464	489	mouse mammary tumor virus	OrganismTaxon	11757
89074264	571	573	GC	ChemicalEntity	D005938
89074264	604	618	bone fractures	DiseaseOrPhenotypicFeature	D050723
89074264	622	628	SNU-C5	CellLine	CVCL_5112
89074264	667	672	SW480	CellLine	CVCL_0546
89074264	744	752	PATIENTS	OrganismTaxon	9606
89074264	769	771	GC	ChemicalEntity	D005938
89074264	960	962	GC	ChemicalEntity	D005938
89074264	967	981	bone fractures	DiseaseOrPhenotypicFeature	D050723
89074264	1038	1040	GC	ChemicalEntity	D005938
89074264	1089	1103	bone fractures	DiseaseOrPhenotypicFeature	D050723
89074264	Positive_Correlation	D050723	D005938	Novel
89074264	Positive_Correlation	D005938	D050723	Novel

35482258|t|Genetic variants and cell line responses in cats: associations between M 235, G51S, and g.80_87delT
35482258|a|This study investigates the functional and phenotypic associations between specific genetic variants and cell line responses in cats. We focused on three sequence variants: M 235, G51S, and g.80_87delT CGCGAAG, and their interactions with multiple cell lines including HEK, RAW 264.7, SF188, Ba/F3, and SNU-C2A. Our findings reveal a complex network of associations, with M 235 showing significant interactions with both G51S and g.80_87delT CGCGAAG. Specifically, M 235 is associated with G51S, and both M 235 and G51S are linked to g.80_87delT CGCGAAG. These associations were observed across multiple cell lines, including HEK, SF188, and Ba/F3. Additionally, the variant g.80_87delT CGCGAAG was found to be associated with both M 235 and G51S, suggesting a potential functional overlap or regulatory interaction between these variants. The study also highlights the importance of cell line-specific responses in understanding the biological implications of these genetic variants in cats. These results provide a foundation for further research into the molecular mechanisms underlying these associations and their potential impact on disease susceptibility and cellular function in feline models.
35482258	44	48	cats	OrganismTaxon	9685
35482258	71	76	M 235	SequenceVariant	p|Allele|M|235
35482258	78	82	G51S	SequenceVariant	rs1049564
35482258	228	232	cats	OrganismTaxon	9685
35482258	273	278	M 235	SequenceVariant	p|Allele|M|235
35482258	280	284	G51S	SequenceVariant	rs1049564
35482258	290	309	g.80_87delT CGCGAAG	SequenceVariant	g|DEL|80_87|TCGCGAAG
35482258	369	372	HEK	CellLine	CVCL_M624
35482258	374	383	RAW 264.7	CellLine	CVCL_0493
35482258	385	390	SF188	CellLine	CVCL_6948
35482258	392	397	Ba/F3	CellLine	CVCL_0161
35482258	403	410	SNU-C2A	CellLine	CVCL_1709
35482258	472	477	M 235	SequenceVariant	p|Allele|M|235
35482258	521	525	G51S	SequenceVariant	rs1049564
35482258	530	549	g.80_87delT CGCGAAG	SequenceVariant	g|DEL|80_87|TCGCGAAG
35482258	565	570	M 235	SequenceVariant	p|Allele|M|235
35482258	590	594	G51S	SequenceVariant	rs1049564
35482258	605	610	M 235	SequenceVariant	p|Allele|M|235
35482258	615	619	G51S	SequenceVariant	rs1049564
35482258	634	653	g.80_87delT CGCGAAG	SequenceVariant	g|DEL|80_87|TCGCGAAG
35482258	726	729	HEK	CellLine	CVCL_M624
35482258	731	736	SF188	CellLine	CVCL_6948
35482258	742	747	Ba/F3	CellLine	CVCL_0161
35482258	775	794	g.80_87delT CGCGAAG	SequenceVariant	g|DEL|80_87|TCGCGAAG
35482258	832	837	M 235	SequenceVariant	p|Allele|M|235
35482258	842	846	G51S	SequenceVariant	rs1049564
35482258	1087	1091	cats	OrganismTaxon	9685
35482258	Association	rs1049564	p|Allele|M|235	Novel
35482258	Association	p|Allele|M|235	g|DEL|80_87|TCGCGAAG	Novel
35482258	Association	p|Allele|M|235	rs1049564	Novel
35482258	Association	rs1049564	g|DEL|80_87|TCGCGAAG	Novel
35482258	Association	g|DEL|80_87|TCGCGAAG	p|Allele|M|235	Novel
35482258	Association	g|DEL|80_87|TCGCGAAG	rs1049564	Novel

13303411|t|Genetic Variants and Their Functional Implications in Prostate and Colorectal Cancer Ce
13303411|a|This study investigates the functional and genetic interactions among multiple sequence variants and their associations with specific cell lines in the context of prostate and colorectal cancer. The sequence variants examined include the 19-base pair deletion, -930A>G, P120T, and the arginine residue for the proline residue at position 158, while the cell lines used are C4-2B, HCT116, MEF, and HEK293. Our findings reveal a complex network of genetic interactions, with the 19-base pair deletion showing significant associations with the -930A>G variant, the P120T variant, and the arginine residue for the proline residue at position 158. The -930A>G variant is also linked to the P120T variant, the rs2476601 variant, and the arginine residue for the proline residue at position 158. The rs2476601 variant is found to be associated with the 19-base pair deletion, the -930A>G variant, and the arginine residue for the proline residue at position 158. The arginine residue for the proline residue at position 158 is functionally connected to multiple variants, including the 19-base pair deletion, the -930A>G variant, the P120T variant, and the rs2476601 variant. These associations were validated across multiple cell lines, including C4-2B, HCT116, MEF, and HEK293, with the MEF cell line showing the highest frequency of variant expression. The results suggest that these genetic variants may play a role in the pathogenesis and progression of cancer, and further studies are warranted to explore their functional mechanisms in different cellular contexts.
13303411	326	347	19-base pair deletion	SequenceVariant	c|DEL||19
13303411	349	356	-930A>G	SequenceVariant	rs9932581
13303411	358	363	P120T	SequenceVariant	c|SUB|P|120|T
13303411	373	429	arginine residue for the proline residue at position 158	SequenceVariant	p|SUB|R|158|P
13303411	461	466	C4-2B	CellLine	CVCL_4784
13303411	468	474	HCT116	CellLine	CVCL_0291
13303411	476	479	MEF	CellLine	CVCL_9115
13303411	485	491	HEK293	CellLine	CVCL_0045
13303411	565	586	19-base pair deletion	SequenceVariant	c|DEL||19
13303411	629	636	-930A>G	SequenceVariant	rs9932581
13303411	650	655	P120T	SequenceVariant	c|SUB|P|120|T
13303411	673	729	arginine residue for the proline residue at position 158	SequenceVariant	p|SUB|R|158|P
13303411	735	742	-930A>G	SequenceVariant	rs9932581
13303411	773	778	P120T	SequenceVariant	c|SUB|P|120|T
13303411	792	801	rs2476601	SequenceVariant	rs2476601
13303411	819	875	arginine residue for the proline residue at position 158	SequenceVariant	p|SUB|R|158|P
13303411	881	890	rs2476601	SequenceVariant	rs2476601
13303411	934	955	19-base pair deletion	SequenceVariant	c|DEL||19
13303411	961	968	-930A>G	SequenceVariant	rs9932581
13303411	986	1042	arginine residue for the proline residue at position 158	SequenceVariant	p|SUB|R|158|P
13303411	1048	1104	arginine residue for the proline residue at position 158	SequenceVariant	p|SUB|R|158|P
13303411	1167	1188	19-base pair deletion	SequenceVariant	c|DEL||19
13303411	1194	1201	-930A>G	SequenceVariant	rs9932581
13303411	1215	1220	P120T	SequenceVariant	c|SUB|P|120|T
13303411	1238	1247	rs2476601	SequenceVariant	rs2476601
13303411	1329	1334	C4-2B	CellLine	CVCL_4784
13303411	1336	1342	HCT116	CellLine	CVCL_0291
13303411	1344	1347	MEF	CellLine	CVCL_9115
13303411	1353	1359	HEK293	CellLine	CVCL_0045
13303411	1370	1373	MEF	CellLine	CVCL_9115
13303411	Association	c|SUB|P|120|T	rs2476601	Novel
13303411	Association	c|SUB|P|120|T	c|DEL||19	Novel
13303411	Association	c|DEL||19	rs2476601	Novel
13303411	Association	rs9932581	c|DEL||19	Novel
13303411	Association	rs9932581	rs2476601	Novel
13303411	Association	rs9932581	c|SUB|P|120|T	Novel
13303411	Association	p|SUB|R|158|P	rs9932581	Novel
13303411	Association	rs2476601	rs9932581	Novel
13303411	Association	rs2476601	c|DEL||19	Novel
13303411	Association	rs2476601	p|SUB|R|158|P	Novel
13303411	Association	c|DEL||19	p|SUB|R|158|P	Novel
13303411	Association	c|DEL||19	rs9932581	Novel
13303411	Association	p|SUB|R|158|P	c|SUB|P|120|T	Novel
13303411	Association	rs9932581	p|SUB|R|158|P	Novel
13303411	Association	c|DEL||19	c|SUB|P|120|T	Novel
13303411	Association	c|SUB|P|120|T	p|SUB|R|158|P	Novel
13303411	Association	p|SUB|R|158|P	rs2476601	Novel
13303411	Association	p|SUB|R|158|P	c|DEL||19	Novel
13303411	Association	c|SUB|P|120|T	rs9932581	Novel
13303411	Association	rs2476601	c|SUB|P|120|T	Novel

28864359|t|Genetic and pharmacological interactions of sequence variants and chemical entities in CD18/HPAF and C4-2B cell lines with implications for impairments in learning an
28864359|a|This study investigates the complex interactions between genetic sequence variants and chemical entities in the context of impairments in learning and memory. We focused on the CD18/HPAF and C4-2B cell lines, which were used to model the effects of the sequence variants G1103R and 3472delC. The chemical entities malonic acid and Contrast were evaluated for their potential to modulate these genetic effects.   Our findings reveal a positive correlation between the sequence variant 3472delC and the chemical entity Contrast, suggesting that Contrast may enhance or stabilize the expression or function of this variant. Additionally, there is an association between 3472delC and G1103R, indicating a potential functional or structural link between these two variants. The cotreatment of malonic acid and Contrast was found to have a significant impact on cellular responses, and this cotreatment was also associated with impairments in learning and memory.   The positive correlation between G1103R and Contrast further supports the idea that Contrast may influence the expression or activity of G1103R. Moreover, G1103R was found to be associated with malonic acid, and this association was reinforced by a positive correlation between G1103R and malonic acid. The association between malonic acid and impairments in learning and memory was also observed, suggesting that malonic acid may contribute to or exacerbate these cognitive impairments.   Contrast was found to be associated with impairments in learning and memory, and this association was further supported by a positive correlation between impairments in learning and memory and Contrast. The comparison between Contrast and malonic acid revealed distinct but overlapping effects on cellular and behavioral outcomes.   The association between G1103R and 3472delC, along with the positive correlation between 3472delC and malonic acid, highlights the interconnected nature of these genetic and chemical factors. Furthermore, the association between Contrast and malonic acid, as well as the cotreatment between these two chemical entities, underscores the importance of considering their combined effects in the context of impairments in learning and memory.   These results provide a comprehensive framework for understanding the interplay between genetic variants and chemical entities in the development and progression of impairments in learning and memory, with potential implications for therapeutic strategies targeting these conditions.
28864359	87	96	CD18/HPAF	CellLine	CVCL_0313
28864359	101	106	C4-2B	CellLine	CVCL_4784
28864359	290	324	impairments in learning and memory	DiseaseOrPhenotypicFeature	D007859
28864359	344	353	CD18/HPAF	CellLine	CVCL_0313
28864359	358	363	C4-2B	CellLine	CVCL_4784
28864359	438	444	G1103R	SequenceVariant	rs62636275
28864359	449	457	3472delC	SequenceVariant	c|DEL|3472|C
28864359	481	493	malonic acid	ChemicalEntity	C030290
28864359	498	506	Contrast	ChemicalEntity	D003287
28864359	651	659	3472delC	SequenceVariant	c|DEL|3472|C
28864359	684	692	Contrast	ChemicalEntity	D003287
28864359	710	718	Contrast	ChemicalEntity	D003287
28864359	834	842	3472delC	SequenceVariant	c|DEL|3472|C
28864359	847	853	G1103R	SequenceVariant	rs62636275
28864359	955	967	malonic acid	ChemicalEntity	C030290
28864359	972	980	Contrast	ChemicalEntity	D003287
28864359	1089	1123	impairments in learning and memory	DiseaseOrPhenotypicFeature	D007859
28864359	1160	1166	G1103R	SequenceVariant	rs62636275
28864359	1171	1179	Contrast	ChemicalEntity	D003287
28864359	1211	1219	Contrast	ChemicalEntity	D003287
28864359	1264	1270	G1103R	SequenceVariant	rs62636275
28864359	1282	1288	G1103R	SequenceVariant	rs62636275
28864359	1321	1333	malonic acid	ChemicalEntity	C030290
28864359	1405	1411	G1103R	SequenceVariant	rs62636275
28864359	1416	1428	malonic acid	ChemicalEntity	C030290
28864359	1454	1466	malonic acid	ChemicalEntity	C030290
28864359	1471	1505	impairments in learning and memory	DiseaseOrPhenotypicFeature	D007859
28864359	1541	1553	malonic acid	ChemicalEntity	C030290
28864359	1617	1625	Contrast	ChemicalEntity	D003287
28864359	1658	1692	impairments in learning and memory	DiseaseOrPhenotypicFeature	D007859
28864359	1771	1805	impairments in learning and memory	DiseaseOrPhenotypicFeature	D007859
28864359	1810	1818	Contrast	ChemicalEntity	D003287
28864359	1843	1851	Contrast	ChemicalEntity	D003287
28864359	1856	1868	malonic acid	ChemicalEntity	C030290
28864359	1974	1980	G1103R	SequenceVariant	rs62636275
28864359	1985	1993	3472delC	SequenceVariant	c|DEL|3472|C
28864359	2039	2047	3472delC	SequenceVariant	c|DEL|3472|C
28864359	2052	2064	malonic acid	ChemicalEntity	C030290
28864359	2179	2187	Contrast	ChemicalEntity	D003287
28864359	2192	2204	malonic acid	ChemicalEntity	C030290
28864359	2353	2387	impairments in learning and memory	DiseaseOrPhenotypicFeature	D007859
28864359	2556	2590	impairments in learning and memory	DiseaseOrPhenotypicFeature	D007859
28864359	Positive_Correlation	c|DEL|3472|C	D003287	Novel
28864359	Association	c|DEL|3472|C	rs62636275	Novel
28864359	Cotreatment	D003287	C030290	Novel
28864359	Positive_Correlation	rs62636275	D003287	Novel
28864359	Association	rs62636275	C030290	Novel
28864359	Positive_Correlation	rs62636275	C030290	Novel
28864359	Association	D007859	D003287	Novel
28864359	Association	C030290	D007859	Novel
28864359	Association	C030290	D003287	Novel
28864359	Positive_Correlation	D007859	rs62636275	Novel
28864359	Comparison	C030290	D003287	Novel
28864359	Association	rs62636275	D003287	Novel
28864359	Association	c|DEL|3472|C	C030290	Novel
28864359	Association	c|DEL|3472|C	D003287	Novel
28864359	Cotreatment	C030290	D003287	Novel
28864359	Comparison	D003287	C030290	Novel
28864359	Association	rs62636275	c|DEL|3472|C	Novel
28864359	Positive_Correlation	c|DEL|3472|C	C030290	Novel
28864359	Association	D003287	C030290	Novel
28864359	Association	D003287	D007859	Novel
28864359	Association	D007859	C030290	Novel
28864359	Positive_Correlation	D007859	c|DEL|3472|C	Novel

95017505|t|Genomic and functional interactions of TNFa, JNK, RABL4, and sequence variants in Drosophila, mouse mammary tumor virus, and shee
95017505|a|This study explores the complex genomic and functional interactions between the cytokine TNFa, the signaling molecule JNK, the GTPase RABL4, and multiple sequence variants in diverse biological systems. Using a combination of genetic, molecular, and computational approaches, we investigate the relationships between these elements in Drosophila, mouse mammary tumor virus, and sheep models. Our findings reveal a positive correlation between TNFa and JNK, as well as a negative correlation between TNFa and JNK, suggesting a dynamic regulatory network. The bind between TNFa and JNK is further supported by direct molecular interactions, while the negative correlation between JNK and TNFa indicates potential feedback mechanisms. Additionally, we observe a positive correlation between RABL4 and TNFa, and a positive correlation between RABL4 and JNK, highlighting the role of RABL4 as a mediator in these pathways. The sequence variant rs25487 is associated with JNK, TNFa, and rs8041922, while rs12141189 is linked to JNK and TNFa. The variant rs8041922 is associated with RABL4 and TNFa, and also shows an association with rs25487. These associations are further reinforced by the mutual relationship between rs25487 and rs8041922, as well as between rs12141189 and rs8041922. The cell line DU145 is used as a model system to study these interactions, and the cell line MCF7/AdrR is employed to examine the effects of these genetic and molecular factors in drug-resistant contexts. The organism taxon Drosophila, mouse mammary tumor virus, and sheep are used to validate the cross-species relevance of these findings. Overall, this study provides a comprehensive framework for understanding the interplay between TNFa, JNK, RABL4, and sequence variants across multiple biological systems.
95017505	39	43	TNFa	GeneOrGeneProduct	21926
95017505	45	48	JNK	GeneOrGeneProduct	26419
95017505	50	55	RABL4	GeneOrGeneProduct	11020
95017505	82	92	Drosophila	OrganismTaxon	7227
95017505	94	119	mouse mammary tumor virus	OrganismTaxon	11757
95017505	219	223	TNFa	GeneOrGeneProduct	21926
95017505	248	251	JNK	GeneOrGeneProduct	26419
95017505	264	269	RABL4	GeneOrGeneProduct	11020
95017505	465	475	Drosophila	OrganismTaxon	7227
95017505	477	502	mouse mammary tumor virus	OrganismTaxon	11757
95017505	508	513	sheep	OrganismTaxon	9940
95017505	573	577	TNFa	GeneOrGeneProduct	21926
95017505	582	585	JNK	GeneOrGeneProduct	26419
95017505	629	633	TNFa	GeneOrGeneProduct	21926
95017505	638	641	JNK	GeneOrGeneProduct	26419
95017505	701	705	TNFa	GeneOrGeneProduct	21926
95017505	710	713	JNK	GeneOrGeneProduct	26419
95017505	808	811	JNK	GeneOrGeneProduct	26419
95017505	816	820	TNFa	GeneOrGeneProduct	21926
95017505	918	923	RABL4	GeneOrGeneProduct	11020
95017505	928	932	TNFa	GeneOrGeneProduct	21926
95017505	969	974	RABL4	GeneOrGeneProduct	11020
95017505	979	982	JNK	GeneOrGeneProduct	26419
95017505	1009	1014	RABL4	GeneOrGeneProduct	11020
95017505	1069	1076	rs25487	SequenceVariant	rs25487
95017505	1096	1099	JNK	GeneOrGeneProduct	26419
95017505	1101	1105	TNFa	GeneOrGeneProduct	21926
95017505	1111	1120	rs8041922	SequenceVariant	rs8041922
95017505	1128	1138	rs12141189	SequenceVariant	rs12141189
95017505	1152	1155	JNK	GeneOrGeneProduct	26419
95017505	1160	1164	TNFa	GeneOrGeneProduct	21926
95017505	1178	1187	rs8041922	SequenceVariant	rs8041922
95017505	1207	1212	RABL4	GeneOrGeneProduct	11020
95017505	1217	1221	TNFa	GeneOrGeneProduct	21926
95017505	1258	1265	rs25487	SequenceVariant	rs25487
95017505	1344	1351	rs25487	SequenceVariant	rs25487
95017505	1356	1365	rs8041922	SequenceVariant	rs8041922
95017505	1386	1396	rs12141189	SequenceVariant	rs12141189
95017505	1401	1410	rs8041922	SequenceVariant	rs8041922
95017505	1426	1431	DU145	CellLine	CVCL_0105
95017505	1505	1514	MCF7/AdrR	CellLine	 CVCL_1452
95017505	1636	1646	Drosophila	OrganismTaxon	7227
95017505	1648	1673	mouse mammary tumor virus	OrganismTaxon	11757
95017505	1679	1684	sheep	OrganismTaxon	9940
95017505	1848	1852	TNFa	GeneOrGeneProduct	21926
95017505	1854	1857	JNK	GeneOrGeneProduct	26419
95017505	1859	1864	RABL4	GeneOrGeneProduct	11020
95017505	Positive_Correlation	21926	26419	Novel
95017505	Association	rs8041922	rs12141189	Novel
95017505	Bind	21926	26419	Novel
95017505	Negative_Correlation	21926	26419	Novel
95017505	Association	rs25487	26419	Novel
95017505	Association	rs12141189	21926	Novel
95017505	Association	rs8041922	11020	Novel
95017505	Bind	26419	21926	Novel
95017505	Positive_Correlation	11020	21926	Novel
95017505	Association	rs8041922	rs25487	Novel
95017505	Association	rs25487	rs8041922	Novel
95017505	Association	rs12141189	26419	Novel
95017505	Bind	21926	11020	Novel
95017505	Positive_Correlation	11020	26419	Novel
95017505	Association	rs25487	21926	Novel
95017505	Association	21926	11020	Novel
95017505	Negative_Correlation	26419	21926	Novel
95017505	Association	11020	21926	Novel
95017505	Bind	11020	21926	Novel
95017505	Negative_Correlation	26419	11020	Novel
95017505	Association	rs25487	rs12141189	Novel
95017505	Association	rs8041922	21926	Novel
95017505	Association	11020	26419	Novel
95017505	Bind	11020	26419	Novel
95017505	Association	rs12141189	rs8041922	Novel

33726435|t|N: A multifaceted modulator of joint abnormalities, dopaminergic deficits, and sensorineural hearing impairment in DUCaP, GT1-1, Ishikawa, and HCT116 ce
33726435|a|N has emerged as a critical modulator in the pathophysiology of multiple disease states, including joint abnormalities, dopaminergic deficits, and sensorineural hearing impairment. This study systematically investigates the interactions between N and these phenotypic features across a panel of cell lines, including DUCaP, GT1-1, Ishikawa, and HCT116. Our findings reveal a complex network of associations, with N showing both positive and negative correlations with different disease states. Notably, N is associated with hepatic fibrogenesis and dopaminergic deficits, while it exhibits a negative correlation with joint abnormalities, sensorineural hearing impairment, and hepatic fibrogenesis. These results suggest that N may act as a dual-edged mediator, promoting some pathologies while inhibiting others. The negative correlation between N and sensorineural hearing impairment, along with the association between N and dopaminergic deficits, highlights the need for further mechanistic studies to elucidate the underlying pathways. Our data also underscore the importance of cell line-specific responses, as the effects of N vary across DUCaP, GT1-1, Ishikawa, and HCT116. These findings provide a foundation for future research into the therapeutic potential of modulating N in the context of these diseases.
33726435	0	1	N	ChemicalEntity	C012655
33726435	31	50	joint abnormalities	DiseaseOrPhenotypicFeature	D007592
33726435	52	73	dopaminergic deficits	DiseaseOrPhenotypicFeature	D009461
33726435	79	111	sensorineural hearing impairment	DiseaseOrPhenotypicFeature	D034381
33726435	115	120	DUCaP	CellLine	CVCL_2025
33726435	122	127	GT1-1	CellLine	CVCL_6236
33726435	129	137	Ishikawa	CellLine	CVCL_2529
33726435	143	149	HCT116	CellLine	CVCL_0291
33726435	153	154	N	ChemicalEntity	C012655
33726435	252	271	joint abnormalities	DiseaseOrPhenotypicFeature	D007592
33726435	273	294	dopaminergic deficits	DiseaseOrPhenotypicFeature	D009461
33726435	300	332	sensorineural hearing impairment	DiseaseOrPhenotypicFeature	D034381
33726435	398	399	N	ChemicalEntity	C012655
33726435	470	475	DUCaP	CellLine	CVCL_2025
33726435	477	482	GT1-1	CellLine	CVCL_6236
33726435	484	492	Ishikawa	CellLine	CVCL_2529
33726435	498	504	HCT116	CellLine	CVCL_0291
33726435	566	567	N	ChemicalEntity	C012655
33726435	647	648	N	ChemicalEntity	C012655
33726435	656	657	N	ChemicalEntity	C012655
33726435	677	697	hepatic fibrogenesis	DiseaseOrPhenotypicFeature	D008107
33726435	702	723	dopaminergic deficits	DiseaseOrPhenotypicFeature	D009461
33726435	771	790	joint abnormalities	DiseaseOrPhenotypicFeature	D007592
33726435	792	824	sensorineural hearing impairment	DiseaseOrPhenotypicFeature	D034381
33726435	830	850	hepatic fibrogenesis	DiseaseOrPhenotypicFeature	D008107
33726435	879	880	N	ChemicalEntity	C012655
33726435	1000	1001	N	ChemicalEntity	C012655
33726435	1006	1038	sensorineural hearing impairment	DiseaseOrPhenotypicFeature	D034381
33726435	1075	1076	N	ChemicalEntity	C012655
33726435	1081	1102	dopaminergic deficits	DiseaseOrPhenotypicFeature	D009461
33726435	1285	1286	N	ChemicalEntity	C012655
33726435	1299	1304	DUCaP	CellLine	CVCL_2025
33726435	1306	1311	GT1-1	CellLine	CVCL_6236
33726435	1313	1321	Ishikawa	CellLine	CVCL_2529
33726435	1327	1333	HCT116	CellLine	CVCL_0291
33726435	1436	1437	N	ChemicalEntity	C012655
33726435	Negative_Correlation	D034381	C012655	Novel
33726435	Association	C012655	D008107	Novel
33726435	Association	C012655	D009461	Novel
33726435	Negative_Correlation	D009461	C012655	Novel
33726435	Negative_Correlation	D007592	C012655	Novel
33726435	Negative_Correlation	D008107	C012655	Novel
33726435	Association	C012655	D034381	Novel

31227766|t|Hydrophobic protein variants and their associations with breast cancer, fat metabolism, and hypoth
31227766|a|Recent studies have highlighted the complex interplay between genetic variants, metabolic processes, and disease susceptibility. This research investigates the role of hydrophobic protein variants, particularly p.D815A and p.W111X, in the context of breast cancer, fat metabolism, and hypothyroidism. The findings reveal a negative correlation between hydrophobic protein and fat, as well as a positive correlation between hydrophobic protein and fat, suggesting a dual regulatory mechanism. Additionally, a negative correlation between insulin and fat was observed, while a positive correlation between insulin and fat was also noted, indicating a dynamic relationship between these factors. The study further explores the association between hydrophobic protein variants and breast cancer, with evidence suggesting that these variants may contribute to the development of the disease. Hypothyroidism was found to be significantly linked to the presence of these variants, highlighting the potential for a broader impact on metabolic health. The results underscore the importance of understanding the molecular mechanisms underlying these associations and their implications for disease prevention and treatment strategies.
31227766	57	70	breast cancer	DiseaseOrPhenotypicFeature	D001943
31227766	72	75	fat	ChemicalEntity	D004041
31227766	267	286	hydrophobic protein	GeneOrGeneProduct	-
31227766	310	317	p.D815A	SequenceVariant	p|SUB|D|815|A
31227766	322	329	p.W111X	SequenceVariant	rs137852884
31227766	349	362	breast cancer	DiseaseOrPhenotypicFeature	D001943
31227766	364	367	fat	ChemicalEntity	D004041
31227766	384	398	hypothyroidism	DiseaseOrPhenotypicFeature	D007037
31227766	451	470	hydrophobic protein	GeneOrGeneProduct	-
31227766	475	478	fat	ChemicalEntity	D004041
31227766	522	541	hydrophobic protein	GeneOrGeneProduct	-
31227766	546	549	fat	ChemicalEntity	D004041
31227766	636	643	insulin	GeneOrGeneProduct	3630
31227766	648	651	fat	ChemicalEntity	D004041
31227766	703	710	insulin	GeneOrGeneProduct	3630
31227766	715	718	fat	ChemicalEntity	D004041
31227766	843	862	hydrophobic protein	GeneOrGeneProduct	-
31227766	876	889	breast cancer	DiseaseOrPhenotypicFeature	D001943
31227766	Positive_Correlation	3630	D004041	Novel
31227766	Negative_Correlation	-	D004041	Novel
31227766	Positive_Correlation	-	D004041	Novel
31227766	Negative_Correlation	3630	D004041	Novel

68763187|t|PC-3 cell line responses to agarose, cyclin D1, and tooth agenesis: interactions with glimepiride, lovastatin, and long-chain fa
68763187|a|The PC-3 cell line, a well-characterized prostate cancer model, was investigated for its response to various chemical entities and genetic factors. The study focused on the interactions between agarose, cyclin D1, and tooth agenesis, with particular attention to the correlations between these elements and other compounds. A significant positive correlation was observed between tooth agenesis and agarose, suggesting a potential role for agarose in modulating developmental pathways associated with tooth formation. Similarly, a positive correlation was found between tooth agenesis and lovastatin, indicating that lovastatin may influence the expression or activity of genes involved in tooth development.   Further, the study explored the relationship between glimepiride and dexrazoxane, revealing a positive correlation that suggests a possible synergistic or additive effect in their biological activities. Additionally, a positive correlation was identified between long-chain fatty acid and glimepiride, implying that these two compounds may interact in metabolic or signaling pathways.   The PC-3 cell line was also exposed to multiple instances of agarose, cyclin D1, and other chemical entities, including glimepiride, lovastatin, and dexrazoxane, to assess their combined effects. The results highlight the complex interplay between genetic factors and chemical entities in cellular processes. The findings provide new insights into the molecular mechanisms underlying tooth agenesis and the potential therapeutic applications of compounds like agarose, lovastatin, and glimepiride in related conditions.
68763187	0	4	PC-3	CellLine	CVCL_0035
68763187	28	35	agarose	ChemicalEntity	D012685
68763187	37	46	cyclin D1	GeneOrGeneProduct	595
68763187	52	66	tooth agenesis	DiseaseOrPhenotypicFeature	D000848
68763187	86	97	glimepiride	ChemicalEntity	C057619
68763187	99	109	lovastatin	ChemicalEntity	D008148
68763187	133	137	PC-3	CellLine	CVCL_0035
68763187	323	330	agarose	ChemicalEntity	D012685
68763187	332	341	cyclin D1	GeneOrGeneProduct	595
68763187	347	361	tooth agenesis	DiseaseOrPhenotypicFeature	D000848
68763187	509	523	tooth agenesis	DiseaseOrPhenotypicFeature	D000848
68763187	528	535	agarose	ChemicalEntity	D012685
68763187	569	576	agarose	ChemicalEntity	D012685
68763187	699	713	tooth agenesis	DiseaseOrPhenotypicFeature	D000848
68763187	718	728	lovastatin	ChemicalEntity	D008148
68763187	746	756	lovastatin	ChemicalEntity	D008148
68763187	893	904	glimepiride	ChemicalEntity	C057619
68763187	909	920	dexrazoxane	ChemicalEntity	D064730
68763187	1103	1124	long-chain fatty acid	ChemicalEntity	D005227
68763187	1129	1140	glimepiride	ChemicalEntity	C057619
68763187	1231	1235	PC-3	CellLine	CVCL_0035
68763187	1288	1295	agarose	ChemicalEntity	D012685
68763187	1297	1306	cyclin D1	GeneOrGeneProduct	595
68763187	1347	1358	glimepiride	ChemicalEntity	C057619
68763187	1360	1370	lovastatin	ChemicalEntity	D008148
68763187	1376	1387	dexrazoxane	ChemicalEntity	D064730
68763187	1611	1625	tooth agenesis	DiseaseOrPhenotypicFeature	D000848
68763187	1687	1694	agarose	ChemicalEntity	D012685
68763187	1696	1706	lovastatin	ChemicalEntity	D008148
68763187	1712	1723	glimepiride	ChemicalEntity	C057619
68763187	Positive_Correlation	C057619	D064730	Novel
68763187	Positive_Correlation	D000848	D012685	Novel
68763187	Positive_Correlation	D000848	D008148	Novel
68763187	Positive_Correlation	D005227	C057619	Novel

13645794|t|Ppg, crea, and genetic variants: a comprehensive analysis of metabolic interactions and sequence variant asso
13645794|a|This study investigates the complex interplay between the chemical entity Ppg, the biomarker crea, and a series of sequence variants in a cohort of 1,200 individuals. The research highlights the dynamic relationship between Ppg and crea, demonstrating a bidirectional conversion between the two entities. The findings reveal that Ppg levels are positively correlated with crea, suggesting a potential metabolic pathway linking these two compounds.   The study also explores the associations between various sequence variants and both Ppg and crea. Notably, the sequence variant p.G821R shows a dual relationship, being both positively correlated with Ppg and associated with crea. In contrast, the variant p.A365E exhibits a negative correlation with Ppg and a negative correlation with crea, indicating a possible inhibitory effect on metabolic processes.   The sequence variant Val624-Val625del demonstrates a positive correlation with Ppg and a positive correlation with crea, suggesting a potential role in enhancing metabolic activity. However, the same variant also shows a negative correlation with crea, highlighting the complexity of its functional impact.   The sequence variant K294E is positively correlated with Ppg, while the variant Ile/Val is positively correlated with crea. The variant 7488CC is associated with Ppg and shows a negative correlation with crea, indicating a possible regulatory role in metabolic pathways.   The variant c.1475G>A is associated with crea and Ppg, with a positive correlation with crea and a negative correlation with Ppg, suggesting a dual effect on metabolic processes. Additionally, the variant C to T is found to be present in multiple individuals, though its functional role remains to be elucidated.   The study also identifies the variant 7488CC as having a negative correlation with crea, reinforcing the complex interplay between genetic variants and metabolic markers. These findings provide a comprehensive framework for understanding the genetic and metabolic underpinnings of Ppg and crea interactions, offering new insights into potential therapeutic targets and diagnostic markers.
13645794	0	3	Ppg	ChemicalEntity	D010457
13645794	5	9	crea	ChemicalEntity	D003404
13645794	184	187	Ppg	ChemicalEntity	D010457
13645794	203	207	crea	ChemicalEntity	D003404
13645794	334	337	Ppg	ChemicalEntity	D010457
13645794	342	346	crea	ChemicalEntity	D003404
13645794	440	443	Ppg	ChemicalEntity	D010457
13645794	482	486	crea	ChemicalEntity	D003404
13645794	644	647	Ppg	ChemicalEntity	D010457
13645794	652	656	crea	ChemicalEntity	D003404
13645794	688	695	p.G821R	SequenceVariant	rs267607116
13645794	761	764	Ppg	ChemicalEntity	D010457
13645794	785	789	crea	ChemicalEntity	D003404
13645794	816	823	p.A365E	SequenceVariant	p|SUB|A|365|E
13645794	861	864	Ppg	ChemicalEntity	D010457
13645794	897	901	crea	ChemicalEntity	D003404
13645794	990	1006	Val624-Val625del	SequenceVariant	p|DEL|624_625|VV
13645794	1048	1051	Ppg	ChemicalEntity	D010457
13645794	1084	1088	crea	ChemicalEntity	D003404
13645794	1216	1220	crea	ChemicalEntity	D003404
13645794	1299	1304	K294E	SequenceVariant	rs143544690
13645794	1335	1338	Ppg	ChemicalEntity	D010457
13645794	1358	1365	Ile/Val	SequenceVariant	rs1695
13645794	1396	1400	crea	ChemicalEntity	D003404
13645794	1414	1420	7488CC	SequenceVariant	rs763780
13645794	1440	1443	Ppg	ChemicalEntity	D010457
13645794	1482	1486	crea	ChemicalEntity	D003404
13645794	1563	1572	c.1475G>A	SequenceVariant	c|SUB|G|1475|A
13645794	1592	1596	crea	ChemicalEntity	D003404
13645794	1601	1604	Ppg	ChemicalEntity	D010457
13645794	1639	1643	crea	ChemicalEntity	D003404
13645794	1676	1679	Ppg	ChemicalEntity	D010457
13645794	1756	1762	C to T	SequenceVariant	c|SUB|C||T
13645794	1904	1910	7488CC	SequenceVariant	rs763780
13645794	1949	1953	crea	ChemicalEntity	D003404
13645794	2147	2150	Ppg	ChemicalEntity	D010457
13645794	2155	2159	crea	ChemicalEntity	D003404
13645794	Negative_Correlation	rs763780	D003404	Novel
13645794	Association	D010457	D003404	Novel
13645794	Conversion	D003404	D010457	Novel
13645794	Association	rs267607116	D010457	Novel
13645794	Positive_Correlation	p|DEL|624_625|VV	D010457	Novel
13645794	Association	rs763780	D010457	Novel
13645794	Positive_Correlation	rs763780	D010457	Novel
13645794	Negative_Correlation	p|SUB|A|365|E	D010457	Novel
13645794	Positive_Correlation	rs143544690	D010457	Novel
13645794	Association	p|DEL|624_625|VV	D010457	Novel
13645794	Negative_Correlation	rs267607116	D010457	Novel
13645794	Association	rs267607116	D003404	Novel
13645794	Conversion	D010457	D003404	Novel
13645794	Positive_Correlation	p|DEL|624_625|VV	D003404	Novel
13645794	Association	c|SUB|G|1475|A	D003404	Novel
13645794	Association	p|DEL|624_625|VV	D003404	Novel
13645794	Negative_Correlation	c|SUB|G|1475|A	D010457	Novel
13645794	Negative_Correlation	p|SUB|A|365|E	D003404	Novel
13645794	Positive_Correlation	rs1695	D003404	Novel
13645794	Association	c|SUB|G|1475|A	D010457	Novel
13645794	Negative_Correlation	p|DEL|624_625|VV	D003404	Novel
13645794	Positive_Correlation	p|SUB|A|365|E	D010457	Novel
13645794	Positive_Correlation	c|SUB|G|1475|A	D003404	Novel
13645794	Negative_Correlation	rs267607116	D003404	Novel

57505640|t|Estrone-3-sulfate and its associations with genetic variants, cell lines, and disease phenotypes in mous
57505640|a|Estrone-3-sulfate has been implicated in multiple biological processes, including its association with genetic variants and disease phenotypes. In this study, we investigated the relationship between estrone-3-sulfate and the sequence variant G12D in the LbetaT2 cell line, finding a significant association. Additionally, we observed that estrone-3-sulfate binds to the gene product ARID1B in the BALB/c cell line, suggesting a potential functional interaction. The positive correlation between estrone-3-sulfate and coronary artery vasospasm was further supported by our analysis in the SNU-C5 cell line, where estrone-3-sulfate levels were consistently elevated in models exhibiting this condition. Similarly, a positive correlation was found between estrone-3-sulfate and weight gain when depressed, as evidenced by experiments in the LbetaT2 cell line and in mice. Furthermore, we identified an association between estrone-3-sulfate and the sequence variant AFF344-345ins in the BALB/c cell line, which may indicate a regulatory role for estrone-3-sulfate in gene expression. These findings were corroborated across multiple cell lines, including LbetaT2, BALB/c, and SNU-C5, and in both mice and mouse mammary tumor virus models. The results highlight the complex interplay between estrone-3-sulfate and various genetic and phenotypic factors, providing new insights into its biological significance.
57505640	305	322	estrone-3-sulfate	ChemicalEntity	C017296
57505640	348	352	G12D	SequenceVariant	p|SUB|G|12|D
57505640	360	367	LbetaT2	CellLine	CVCL_0398
57505640	445	462	estrone-3-sulfate	ChemicalEntity	C017296
57505640	489	495	ARID1B	GeneOrGeneProduct	57492
57505640	503	509	BALB/c	CellLine	CVCL_9101
57505640	601	618	estrone-3-sulfate	ChemicalEntity	C017296
57505640	623	648	coronary artery vasospasm	DiseaseOrPhenotypicFeature	D003329
57505640	694	700	SNU-C5	CellLine	CVCL_5112
57505640	718	735	estrone-3-sulfate	ChemicalEntity	C017296
57505640	859	876	estrone-3-sulfate	ChemicalEntity	C017296
57505640	881	907	weight gain when depressed	DiseaseOrPhenotypicFeature	D015430
57505640	944	951	LbetaT2	CellLine	CVCL_0398
57505640	969	973	mice	OrganismTaxon	10090
57505640	1025	1042	estrone-3-sulfate	ChemicalEntity	C017296
57505640	1068	1081	AFF344-345ins	SequenceVariant	p|INS|344_345|AFF
57505640	1089	1095	BALB/c	CellLine	CVCL_9101
57505640	1148	1165	estrone-3-sulfate	ChemicalEntity	C017296
57505640	1257	1264	LbetaT2	CellLine	CVCL_0398
57505640	1266	1272	BALB/c	CellLine	CVCL_9101
57505640	1278	1284	SNU-C5	CellLine	CVCL_5112
57505640	1298	1302	mice	OrganismTaxon	10090
57505640	1307	1332	mouse mammary tumor virus	OrganismTaxon	11757
57505640	1393	1410	estrone-3-sulfate	ChemicalEntity	C017296
57505640	Association	C017296	p|SUB|G|12|D	Novel
57505640	Bind	57492	C017296	Novel
57505640	Positive_Correlation	D003329	C017296	Novel
57505640	Positive_Correlation	D015430	C017296	Novel
57505640	Association	C017296	p|INS|344_345|AFF	Novel

72273646|t|Genetic variants and their associations with enzymatic complex I-deficient, muscular dystrophy, and other phenotypic features: a comprehensive analysis of sequence variants and chemical 
72273646|a|This study investigates the complex interplay between genetic sequence variants and various phenotypic features, including enzymatic complex I-deficient, muscular dystrophy, and skin reactions, as well as their interactions with chemical entities such as [(3)H]-2-deoxy-d-glucose, ouabain, and LPS. We examined a panel of sequence variants, including four-basepair deletion, Ile105Val, G12D, p.Asp46_Gln48delinsGlu, 1494del6, and g.3352delG, in relation to multiple disease states and chemical entities.   Our findings reveal a negative correlation between [(3)H]-2-deoxy-d-glucose and benzoylcholine, suggesting a potential antagonistic interaction between these two chemical entities. Additionally, we observed a positive correlation between skin reactions and p.Asp46_Gln48delinsGlu, indicating that this sequence variant may contribute to the development of skin reactions. The sequence variant g.3352delG was found to be negatively correlated with muscular dystrophy, while it was positively correlated with [(3)H]-2-deoxy-d-glucose and benzoylcholine.   The sequence variant four-basepair deletion showed a positive correlation with Mantle cell lymphoma and a negative correlation with arrhythmia. Furthermore, the sequence variant Ile105Val was positively correlated with both arrhythmia and Dystonia, and was also associated with tricarboxylic acid. The sequence variant G12D was negatively correlated with infections and enzymatic complex I-deficient, while it was also negatively correlated with Dystonia.   The chemical entity ouabain exhibited a negative correlation with both aspirin and L-365,260, and was associated with g.3352delG. The chemical entity LPS showed a negative correlation with anesthetics, and the chemical entity aspirin was negatively correlated with both tricarboxylic acid and L-365,260.   Overall, this study provides a comprehensive analysis of the relationships between genetic sequence variants and phenotypic features, as well as their interactions with chemical entities, offering new insights into the molecular mechanisms underlying these conditions.
72273646	45	74	enzymatic complex I-deficient	DiseaseOrPhenotypicFeature	C537475
72273646	76	94	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
72273646	310	339	enzymatic complex I-deficient	DiseaseOrPhenotypicFeature	C537475
72273646	341	359	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
72273646	365	379	skin reactions	DiseaseOrPhenotypicFeature	D003875
72273646	442	466	[(3)H]-2-deoxy-d-glucose	ChemicalEntity	D003847
72273646	468	475	ouabain	ChemicalEntity	D010042
72273646	481	484	LPS	ChemicalEntity	D008070
72273646	538	560	four-basepair deletion	SequenceVariant	c|DEL||4
72273646	562	571	Ile105Val	SequenceVariant	rs1695
72273646	573	577	G12D	SequenceVariant	rs121913529
72273646	579	601	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
72273646	603	611	1494del6	SequenceVariant	c|DEL|1494|6
72273646	617	627	g.3352delG	SequenceVariant	g|DEL|3352|G
72273646	744	768	[(3)H]-2-deoxy-d-glucose	ChemicalEntity	D003847
72273646	773	787	benzoylcholine	ChemicalEntity	D001588
72273646	931	945	skin reactions	DiseaseOrPhenotypicFeature	D003875
72273646	950	972	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
72273646	1049	1063	skin reactions	DiseaseOrPhenotypicFeature	D003875
72273646	1086	1096	g.3352delG	SequenceVariant	g|DEL|3352|G
72273646	1140	1158	muscular dystrophy	DiseaseOrPhenotypicFeature	D009136
72273646	1200	1224	[(3)H]-2-deoxy-d-glucose	ChemicalEntity	D003847
72273646	1229	1243	benzoylcholine	ChemicalEntity	D001588
72273646	1268	1290	four-basepair deletion	SequenceVariant	c|DEL||4
72273646	1326	1346	Mantle cell lymphoma	DiseaseOrPhenotypicFeature	D020522
72273646	1379	1389	arrhythmia	DiseaseOrPhenotypicFeature	D001145
72273646	1425	1434	Ile105Val	SequenceVariant	rs1695
72273646	1471	1481	arrhythmia	DiseaseOrPhenotypicFeature	D001145
72273646	1486	1494	Dystonia	DiseaseOrPhenotypicFeature	D004421
72273646	1525	1543	tricarboxylic acid	ChemicalEntity	D014233
72273646	1566	1570	G12D	SequenceVariant	rs121913529
72273646	1602	1612	infections	DiseaseOrPhenotypicFeature	D007239
72273646	1617	1646	enzymatic complex I-deficient	DiseaseOrPhenotypicFeature	C537475
72273646	1693	1701	Dystonia	DiseaseOrPhenotypicFeature	D004421
72273646	1725	1732	ouabain	ChemicalEntity	D010042
72273646	1776	1783	aspirin	ChemicalEntity	D001241
72273646	1788	1797	L-365,260	ChemicalEntity	C058121
72273646	1823	1833	g.3352delG	SequenceVariant	g|DEL|3352|G
72273646	1855	1858	LPS	ChemicalEntity	D008070
72273646	1894	1905	anesthetics	ChemicalEntity	D000777
72273646	1931	1938	aspirin	ChemicalEntity	D001241
72273646	1975	1993	tricarboxylic acid	ChemicalEntity	D014233
72273646	1998	2007	L-365,260	ChemicalEntity	C058121
72273646	Negative_Correlation	D003847	D001588	Novel
72273646	Positive_Correlation	D003875	p|INDEL|46_48|Glu	Novel
72273646	Negative_Correlation	g|DEL|3352|G	D009136	Novel
72273646	Negative_Correlation	C058121	D010042	Novel
72273646	Positive_Correlation	D001145	rs1695	Novel
72273646	Association	g|DEL|3352|G	D003847	Novel
72273646	Negative_Correlation	rs121913529	D007239	Novel
72273646	Positive_Correlation	D003875	c|DEL||4	Novel
72273646	Negative_Correlation	D010042	D001241	Novel
72273646	Negative_Correlation	D000777	D008070	Novel
72273646	Negative_Correlation	D014233	C058121	Novel
72273646	Negative_Correlation	c|DEL||4	D001145	Novel
72273646	Negative_Correlation	D001241	D014233	Novel
72273646	Positive_Correlation	D009136	g|DEL|3352|G	Novel
72273646	Positive_Correlation	D004421	rs1695	Novel
72273646	Negative_Correlation	D000777	D001241	Novel
72273646	Positive_Correlation	D020522	c|DEL||4	Novel
72273646	Negative_Correlation	rs121913529	C537475	Novel
72273646	Positive_Correlation	D007239	rs1695	Novel
72273646	Negative_Correlation	p|INDEL|46_48|Glu	D009136	Novel
72273646	Positive_Correlation	D009136	c|DEL||4	Novel
72273646	Negative_Correlation	D010042	C058121	Novel
72273646	Association	p|INDEL|46_48|Glu	D001241	Novel
72273646	Positive_Correlation	D020522	c|DEL|1494|6	Novel
72273646	Association	rs1695	D014233	Novel
72273646	Negative_Correlation	D000777	D001588	Novel
72273646	Association	g|DEL|3352|G	D001588	Novel
72273646	Association	rs1695	D001588	Novel
72273646	Negative_Correlation	D014233	D001588	Novel
72273646	Association	p|INDEL|46_48|Glu	D001588	Novel
72273646	Negative_Correlation	rs121913529	D004421	Novel
72273646	Negative_Correlation	D001588	D014233	Novel
72273646	Association	g|DEL|3352|G	D010042	Novel
72273646	Positive_Correlation	D007239	p|INDEL|46_48|Glu	Novel

59500169|t|Genetic and functional analysis of SUFU, GNPTG, TIMP4, and melanophilin in alopecia, weight loss, and arterios
59500169|a|Recent studies have highlighted the complex interplay between genetic variants and phenotypic features in the pathogenesis of alopecia, weight loss, and arteriosclerosis. This study investigates the molecular mechanisms underlying these conditions by examining the associations between the sequence variant p.S216P, the gene products SUFU, GNPTG, TIMP4, and melanophilin, and the phenotypic features alopecia, loss of appetite, weight loss, and arteriosclerosis.   The findings reveal a significant association between the sequence variant rs5393 and the gene product SUFU, which is further linked to the phenotypic features of alopecia, weight loss, and arteriosclerosis. Additionally, the gene product GNPTG is found to be associated with both SUFU and TIMP4, with a strong binding interaction between GNPTG and melanophilin. The gene product TIMP4 is also associated with melanophilin and SUFU, and exhibits a binding relationship with both GNPTG and SUFU.   Notably, the gene product melanophilin is associated with multiple phenotypic features, including loss of appetite, weight loss, and arteriosclerosis, and is functionally linked to both GNPTG and TIMP4. The sequence variant p.S216P is found to be associated with the gene product TIMP4, which in turn is linked to the phenotypic features of alopecia and weight loss.   These results provide new insights into the molecular pathways involved in the development of alopecia, weight loss, and arteriosclerosis, and suggest that the interplay between SUFU, GNPTG, TIMP4, and melanophilin plays a critical role in these conditions. Further research is needed to fully elucidate the functional mechanisms and potential therapeutic targets for these diseases.
59500169	35	39	SUFU	GeneOrGeneProduct	51684
59500169	41	46	GNPTG	GeneOrGeneProduct	84572
59500169	48	53	TIMP4	GeneOrGeneProduct	7079
59500169	59	71	melanophilin	GeneOrGeneProduct	79083
59500169	75	83	alopecia	DiseaseOrPhenotypicFeature	D000505
59500169	85	96	weight loss	DiseaseOrPhenotypicFeature	D015431
59500169	237	245	alopecia	DiseaseOrPhenotypicFeature	D000505
59500169	247	258	weight loss	DiseaseOrPhenotypicFeature	D015431
59500169	264	280	arteriosclerosis	DiseaseOrPhenotypicFeature	D001161
59500169	418	425	p.S216P	SequenceVariant	p|SUB|S|216|P
59500169	445	449	SUFU	GeneOrGeneProduct	51684
59500169	451	456	GNPTG	GeneOrGeneProduct	84572
59500169	458	463	TIMP4	GeneOrGeneProduct	7079
59500169	469	481	melanophilin	GeneOrGeneProduct	79083
59500169	511	519	alopecia	DiseaseOrPhenotypicFeature	D000505
59500169	521	537	loss of appetite	DiseaseOrPhenotypicFeature	D001068
59500169	539	550	weight loss	DiseaseOrPhenotypicFeature	D015431
59500169	556	572	arteriosclerosis	DiseaseOrPhenotypicFeature	D001161
59500169	651	657	rs5393	SequenceVariant	rs5393
59500169	679	683	SUFU	GeneOrGeneProduct	51684
59500169	739	747	alopecia	DiseaseOrPhenotypicFeature	D000505
59500169	749	760	weight loss	DiseaseOrPhenotypicFeature	D015431
59500169	766	782	arteriosclerosis	DiseaseOrPhenotypicFeature	D001161
59500169	815	820	GNPTG	GeneOrGeneProduct	84572
59500169	857	861	SUFU	GeneOrGeneProduct	51684
59500169	866	871	TIMP4	GeneOrGeneProduct	7079
59500169	915	920	GNPTG	GeneOrGeneProduct	84572
59500169	925	937	melanophilin	GeneOrGeneProduct	79083
59500169	956	961	TIMP4	GeneOrGeneProduct	7079
59500169	986	998	melanophilin	GeneOrGeneProduct	79083
59500169	1003	1007	SUFU	GeneOrGeneProduct	51684
59500169	1055	1060	GNPTG	GeneOrGeneProduct	84572
59500169	1065	1069	SUFU	GeneOrGeneProduct	51684
59500169	1099	1111	melanophilin	GeneOrGeneProduct	79083
59500169	1171	1187	loss of appetite	DiseaseOrPhenotypicFeature	D001068
59500169	1189	1200	weight loss	DiseaseOrPhenotypicFeature	D015431
59500169	1206	1222	arteriosclerosis	DiseaseOrPhenotypicFeature	D001161
59500169	1259	1264	GNPTG	GeneOrGeneProduct	84572
59500169	1269	1274	TIMP4	GeneOrGeneProduct	7079
59500169	1297	1304	p.S216P	SequenceVariant	p|SUB|S|216|P
59500169	1353	1358	TIMP4	GeneOrGeneProduct	7079
59500169	1414	1422	alopecia	DiseaseOrPhenotypicFeature	D000505
59500169	1427	1438	weight loss	DiseaseOrPhenotypicFeature	D015431
59500169	1536	1544	alopecia	DiseaseOrPhenotypicFeature	D000505
59500169	1546	1557	weight loss	DiseaseOrPhenotypicFeature	D015431
59500169	1563	1579	arteriosclerosis	DiseaseOrPhenotypicFeature	D001161
59500169	1620	1624	SUFU	GeneOrGeneProduct	51684
59500169	1626	1631	GNPTG	GeneOrGeneProduct	84572
59500169	1633	1638	TIMP4	GeneOrGeneProduct	7079
59500169	1644	1656	melanophilin	GeneOrGeneProduct	79083
59500169	Association	51684	84572	Novel
59500169	Bind	84572	79083	Novel
59500169	Association	D000505	51684	Novel
59500169	Association	7079	84572	Novel
59500169	Association	84572	7079	Novel
59500169	Association	D001068	51684	Novel
59500169	Association	79083	84572	Novel
59500169	Association	D000505	7079	Novel
59500169	Association	79083	51684	Novel
59500169	Bind	7079	51684	Novel
59500169	Association	D015431	7079	Novel
59500169	Bind	79083	51684	Novel
59500169	Association	7079	79083	Novel
59500169	Association	84572	79083	Novel
59500169	Association	79083	7079	Novel
59500169	Association	51684	79083	Novel
59500169	Bind	84572	7079	Novel
59500169	Association	51684	7079	Novel
59500169	Association	D015431	79083	Novel
59500169	Association	84572	51684	Novel
59500169	Association	D015431	51684	Novel
59500169	Association	D001161	51684	Novel
59500169	Bind	51684	7079	Novel
59500169	Bind	79083	84572	Novel
59500169	Association	D001161	84572	Novel
59500169	Association	D001068	79083	Novel

51746499|t|TARBP2 and HEY2: Genetic associations with primary Hodgkin lymphoma, spinal muscular atrophy, and other phenotypic features in sheep and bacteria
51746499|a|Recent studies have highlighted the role of TARBP2 and HEY2 in modulating immune responses and developmental pathways, with implications for a range of diseases. This study investigates the genetic associations between TARBP2 and HEY2 and several phenotypic features, including primary Hodgkin lymphoma, spinal muscular atrophy, and restless legs syndrome, in both human and model systems.   In sheep, a sequence variant (W) allele at codon 620 was found to be significantly associated with primary Hodgkin lymphoma, suggesting a potential role in immune dysregulation. This variant was also linked to the R3500Q polymorphism, indicating a possible functional relationship. Additionally, the rs763780 variant was found to be in linkage disequilibrium with the (W) allele at codon 620, further supporting a genetic connection.   The gene Lactoferrin showed a positive correlation with HEY2 expression, which may be relevant in the context of immune modulation and tumor suppression. Furthermore, Lactoferrin was associated with restless legs syndrome, suggesting a broader role in neurodevelopmental processes.   Spinal muscular atrophy was found to be associated with both rs10954213 and rs7535263, with the latter also showing a correlation with the 1284A>C variant. These findings suggest that multiple sequence variants may contribute to the pathogenesis of this neurodegenerative disorder.   In bacterial models, including Escherichia coli and S. cerevisiae, the gene ornithine decarboxylase was found to interact with the sequence variant arginine84, which was also associated with p.A365E. These interactions may have implications for metabolic pathways and disease susceptibility.   The study also examined the role of GM-CSF in primary Hodgkin lymphoma, finding a significant positive correlation between GM-CSF levels and the disease. Additionally, the sequence variant rs10954213 was found to be associated with GH insensitivity syndrome, while the variant (W) allele at codon 620 was linked to sudden infant death with dysgenesis of the testes syndrome.   These findings underscore the complex interplay between genetic variants and phenotypic outcomes, with implications for both human and microbial systems. Further research is needed to elucidate the molecular mechanisms underlying these associations.
51746499	0	6	TARBP2	GeneOrGeneProduct	21357
51746499	11	15	HEY2	GeneOrGeneProduct	23493
51746499	43	67	primary Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
51746499	69	92	spinal muscular atrophy	DiseaseOrPhenotypicFeature	D009134
51746499	127	132	sheep	OrganismTaxon	9940
51746499	137	145	bacteria	OrganismTaxon	2
51746499	190	196	TARBP2	GeneOrGeneProduct	21357
51746499	201	205	HEY2	GeneOrGeneProduct	23493
51746499	365	371	TARBP2	GeneOrGeneProduct	21357
51746499	376	380	HEY2	GeneOrGeneProduct	23493
51746499	424	448	primary Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
51746499	450	473	spinal muscular atrophy	DiseaseOrPhenotypicFeature	D009134
51746499	479	501	restless legs syndrome	DiseaseOrPhenotypicFeature	D012148
51746499	541	546	sheep	OrganismTaxon	9940
51746499	567	590	(W) allele at codon 620	SequenceVariant	rs2476601
51746499	637	661	primary Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
51746499	752	758	R3500Q	SequenceVariant	rs5742904
51746499	838	846	rs763780	SequenceVariant	rs763780
51746499	906	929	(W) allele at codon 620	SequenceVariant	rs2476601
51746499	983	994	Lactoferrin	GeneOrGeneProduct	301034
51746499	1030	1034	HEY2	GeneOrGeneProduct	23493
51746499	1141	1152	Lactoferrin	GeneOrGeneProduct	301034
51746499	1173	1195	restless legs syndrome	DiseaseOrPhenotypicFeature	D012148
51746499	1319	1329	rs10954213	SequenceVariant	rs10954213
51746499	1334	1343	rs7535263	SequenceVariant	rs7535263
51746499	1397	1404	1284A>C	SequenceVariant	c|SUB|A|1284|C
51746499	1545	1553	bacteria	OrganismTaxon	2
51746499	1573	1589	Escherichia coli	OrganismTaxon	562
51746499	1594	1607	S. cerevisiae	OrganismTaxon	4932
51746499	1618	1641	ornithine decarboxylase	GeneOrGeneProduct	4953
51746499	1690	1700	arginine84	SequenceVariant	rs74315458
51746499	1733	1740	p.A365E	SequenceVariant	p|SUB|A|365|E
51746499	1872	1878	GM-CSF	GeneOrGeneProduct	1437
51746499	1882	1906	primary Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
51746499	1959	1965	GM-CSF	GeneOrGeneProduct	1437
51746499	2025	2035	rs10954213	SequenceVariant	rs10954213
51746499	2068	2093	GH insensitivity syndrome	DiseaseOrPhenotypicFeature	D046150
51746499	2113	2136	(W) allele at codon 620	SequenceVariant	rs2476601
51746499	2151	2209	sudden infant death with dysgenesis of the testes syndrome	DiseaseOrPhenotypicFeature	C563856
51746499	Association	D006689	rs2476601	Novel
51746499	Positive_Correlation	301034	23493	Novel
51746499	Association	D009134	rs10954213	Novel
51746499	Association	301034	D012148	Novel
51746499	Association	rs74315458	p|SUB|A|365|E	Novel
51746499	Association	rs2476601	rs5742904	Novel
51746499	Association	rs763780	rs2476601	Novel
51746499	Association	1437	D006689	Novel
51746499	Association	rs7535263	c|SUB|A|1284|C	Novel
51746499	Association	D009134	rs7535263	Novel

93608841|t|BMPRIB, c-Fos, and protein kinase ribonucleic acid (RNA)-like ER kinase: complex interactions with diarrheas, hepatoencephalopathy, and FSH in HK2, SUM159PT, and SNU-C5 ce
93608841|a|This study investigates the molecular mechanisms underlying the interplay between BMPRIB, c-Fos, and protein kinase ribonucleic acid (RNA)-like ER kinase in the context of diarrheas, hepatoencephalopathy, and FSH signaling across multiple cell lines, including HK2, SUM159PT, and SNU-C5. Our findings reveal a positive correlation between protein kinase ribonucleic acid (RNA)-like ER kinase and hepatoencephalopathy, suggesting a potential role for this kinase in the pathogenesis of this neurological disorder. Additionally, we observe a negative correlation between c-Fos and BMPRIB, indicating a regulatory relationship that may influence cellular responses to stress.   The association between protein kinase ribonucleic acid (RNA)-like ER kinase and diarrheas further supports its involvement in gastrointestinal pathophysiology. Notably, there is a negative correlation between c-Fos and protein kinase ribonucleic acid (RNA)-like ER kinase, as well as between BMPRIB and protein kinase ribonucleic acid (RNA)-like ER kinase, highlighting a complex network of interactions.   We also find that diarrheas are negatively correlated with FSH, and this relationship is further reinforced by the negative correlation between FSH and BMPRIB. In contrast, FSH exhibits a positive correlation with diarrheas, suggesting a dual role in modulating intestinal function. The association between ARHGAP29 and diarrheas, along with the negative correlation between ARHGAP29 and FSH, underscores the involvement of this gene in both gastrointestinal and endocrine pathways.   Our results demonstrate that the interplay between these genes and proteins is critical in understanding the molecular basis of diarrheas, hepatoencephalopathy, and FSH-related disorders. These findings provide a foundation for future studies aimed at developing targeted therapeutic strategies for these conditions.
93608841	0	6	BMPRIB	GeneOrGeneProduct	12167
93608841	8	13	c-Fos	GeneOrGeneProduct	14281
93608841	19	71	protein kinase ribonucleic acid (RNA)-like ER kinase	GeneOrGeneProduct	13666
93608841	99	108	diarrheas	DiseaseOrPhenotypicFeature	D003967
93608841	110	130	hepatoencephalopathy	DiseaseOrPhenotypicFeature	C563797
93608841	136	139	FSH	GeneOrGeneProduct	443387
93608841	143	146	HK2	CellLine	CVCL_0302
93608841	148	156	SUM159PT	CellLine	CVCL_5423
93608841	162	168	SNU-C5	CellLine	CVCL_5112
93608841	254	260	BMPRIB	GeneOrGeneProduct	12167
93608841	262	267	c-Fos	GeneOrGeneProduct	14281
93608841	273	325	protein kinase ribonucleic acid (RNA)-like ER kinase	GeneOrGeneProduct	13666
93608841	344	353	diarrheas	DiseaseOrPhenotypicFeature	D003967
93608841	355	375	hepatoencephalopathy	DiseaseOrPhenotypicFeature	C563797
93608841	381	384	FSH	GeneOrGeneProduct	443387
93608841	433	436	HK2	CellLine	CVCL_0302
93608841	438	446	SUM159PT	CellLine	CVCL_5423
93608841	452	458	SNU-C5	CellLine	CVCL_5112
93608841	511	563	protein kinase ribonucleic acid (RNA)-like ER kinase	GeneOrGeneProduct	13666
93608841	568	588	hepatoencephalopathy	DiseaseOrPhenotypicFeature	C563797
93608841	741	746	c-Fos	GeneOrGeneProduct	14281
93608841	751	757	BMPRIB	GeneOrGeneProduct	12167
93608841	871	923	protein kinase ribonucleic acid (RNA)-like ER kinase	GeneOrGeneProduct	13666
93608841	928	937	diarrheas	DiseaseOrPhenotypicFeature	D003967
93608841	1057	1062	c-Fos	GeneOrGeneProduct	14281
93608841	1067	1119	protein kinase ribonucleic acid (RNA)-like ER kinase	GeneOrGeneProduct	13666
93608841	1140	1146	BMPRIB	GeneOrGeneProduct	12167
93608841	1151	1203	protein kinase ribonucleic acid (RNA)-like ER kinase	GeneOrGeneProduct	13666
93608841	1273	1282	diarrheas	DiseaseOrPhenotypicFeature	D003967
93608841	1314	1317	FSH	GeneOrGeneProduct	443387
93608841	1399	1402	FSH	GeneOrGeneProduct	443387
93608841	1407	1413	BMPRIB	GeneOrGeneProduct	12167
93608841	1428	1431	FSH	GeneOrGeneProduct	443387
93608841	1469	1478	diarrheas	DiseaseOrPhenotypicFeature	D003967
93608841	1562	1570	ARHGAP29	GeneOrGeneProduct	9411
93608841	1575	1584	diarrheas	DiseaseOrPhenotypicFeature	D003967
93608841	1630	1638	ARHGAP29	GeneOrGeneProduct	9411
93608841	1643	1646	FSH	GeneOrGeneProduct	443387
93608841	1868	1877	diarrheas	DiseaseOrPhenotypicFeature	D003967
93608841	1879	1899	hepatoencephalopathy	DiseaseOrPhenotypicFeature	C563797
93608841	1905	1908	FSH	GeneOrGeneProduct	443387
93608841	Positive_Correlation	13666	C563797	Novel
93608841	Negative_Correlation	14281	12167	Novel
93608841	Association	13666	D003967	Novel
93608841	Negative_Correlation	14281	13666	Novel
93608841	Negative_Correlation	12167	14281	Novel
93608841	Negative_Correlation	D003967	443387	Novel
93608841	Negative_Correlation	443387	12167	Novel
93608841	Association	9411	D003967	Novel
93608841	Positive_Correlation	443387	D003967	Novel
93608841	Association	12167	D003967	Novel
93608841	Negative_Correlation	9411	443387	Novel
93608841	Negative_Correlation	443387	13666	Novel
93608841	Negative_Correlation	13666	443387	Novel
93608841	Positive_Correlation	9411	D003967	Novel
93608841	Negative_Correlation	12167	13666	Novel
93608841	Negative_Correlation	C563797	443387	Novel
93608841	Negative_Correlation	12167	443387	Novel
93608841	Positive_Correlation	12167	D003967	Novel
93608841	Association	13666	C563797	Novel
93608841	Negative_Correlation	C563797	14281	Novel

32589760|t|Sp3 and LDLr Interactions in Leiomyoma and Focal Segmental Glomerulosclerosis: Insights from C. elegans, Chick, and Mangifera indica Lin
32589760|a|This study investigates the complex interactions between the transcription factor Sp3, the gene product lymphoid-specific phosphatase (LSP), and the LDL receptor (LDLr) in the context of Leiomyoma and focal segmental glomerulosclerosis (FSGS). Using a multi-species approach, we examined these interactions in C. elegans, chick, and Mangifera indica Linn, with a focus on the biochemical and genetic mechanisms underlying disease progression.   Our findings reveal a negative correlation between LSP and Sp3, suggesting that LSP may act as a repressor of Sp3 activity. This relationship is further supported by the observation of a positive correlation between Sp3 and succinylcholine, indicating a potential regulatory role of succinylcholine in modulating Sp3 expression. Additionally, we observed a positive correlation between LSP and NH3, which may imply a metabolic or signaling pathway involving these two entities.   The study also demonstrates a binding interaction between LSP and LDLr, as well as between Sp3 and LDLr, highlighting the potential for these proteins to form functional complexes that influence disease outcomes. Notably, a negative correlation was found between LDLr and Sp3, suggesting a competitive or antagonistic relationship between these two proteins in the context of disease.   In the context of Leiomyoma, our data suggest that the interplay between Sp3, LSP, and LDLr may contribute to the pathogenesis of the disease. Similarly, in FSGS, the observed interactions provide a potential molecular basis for the development of glomerular injury. These findings are further supported by the presence of retinopathy of prematurity in some of the experimental models, which may be linked to the broader regulatory network involving these proteins.   The use of C. elegans, chick, and Mangifera indica Linn as model organisms allowed us to explore the evolutionary conservation of these interactions, providing insights into the functional relevance of Sp3, LSP, and LDLr across different species. Overall, this study underscores the importance of understanding the molecular mechanisms underlying these interactions in the context of disease and highlights potential therapeutic targets for the treatment of Leiomyoma and related conditions.
32589760	0	3	Sp3	GeneOrGeneProduct	20687
32589760	8	12	LDLr	GeneOrGeneProduct	300438
32589760	29	38	Leiomyoma	DiseaseOrPhenotypicFeature	D007889
32589760	93	103	C. elegans	OrganismTaxon	6239
32589760	219	222	Sp3	GeneOrGeneProduct	20687
32589760	241	270	lymphoid-specific phosphatase	GeneOrGeneProduct	26191
32589760	300	304	LDLr	GeneOrGeneProduct	300438
32589760	324	333	Leiomyoma	DiseaseOrPhenotypicFeature	D007889
32589760	338	372	focal segmental glomerulosclerosis	DiseaseOrPhenotypicFeature	D005923
32589760	447	457	C. elegans	OrganismTaxon	6239
32589760	459	464	chick	OrganismTaxon	9031
32589760	470	491	Mangifera indica Linn	OrganismTaxon	29780
32589760	641	644	Sp3	GeneOrGeneProduct	20687
32589760	692	695	Sp3	GeneOrGeneProduct	20687
32589760	798	801	Sp3	GeneOrGeneProduct	20687
32589760	806	821	succinylcholine	ChemicalEntity	D013390
32589760	865	880	succinylcholine	ChemicalEntity	D013390
32589760	895	898	Sp3	GeneOrGeneProduct	20687
32589760	976	979	NH3	ChemicalEntity	D000641
32589760	1128	1132	LDLr	GeneOrGeneProduct	300438
32589760	1153	1156	Sp3	GeneOrGeneProduct	20687
32589760	1161	1165	LDLr	GeneOrGeneProduct	300438
32589760	1325	1329	LDLr	GeneOrGeneProduct	300438
32589760	1334	1337	Sp3	GeneOrGeneProduct	20687
32589760	1467	1476	Leiomyoma	DiseaseOrPhenotypicFeature	D007889
32589760	1522	1525	Sp3	GeneOrGeneProduct	20687
32589760	1536	1540	LDLr	GeneOrGeneProduct	300438
32589760	1772	1798	retinopathy of prematurity	DiseaseOrPhenotypicFeature	D012178
32589760	1928	1938	C. elegans	OrganismTaxon	6239
32589760	1940	1945	chick	OrganismTaxon	9031
32589760	1951	1972	Mangifera indica Linn	OrganismTaxon	29780
32589760	2119	2122	Sp3	GeneOrGeneProduct	20687
32589760	2133	2137	LDLr	GeneOrGeneProduct	300438
32589760	2375	2384	Leiomyoma	DiseaseOrPhenotypicFeature	D007889
32589760	Negative_Correlation	26191	20687	Novel
32589760	Positive_Correlation	20687	D013390	Novel
32589760	Bind	26191	300438	Novel
32589760	Bind	20687	300438	Novel
32589760	Positive_Correlation	26191	D000641	Novel
32589760	Negative_Correlation	300438	20687	Novel

23251164|t|Lys198Asn variant of mitogen-activated protein kinase in horses: associations with Type 2 Diabetes and its negative cor
23251164|a|A recent study investigated the role of the Lys198Asn variant of mitogen-activated protein kinase in horses and its potential association with Type 2 Diabetes. The Lys198Asn variant was found to be present in 19 instances across the study population, with 17 instances of the gene or gene product 'mitogen-activated protein kinase' being analyzed. The study focused on horses, with 15 instances of the organism taxon 'horses' included in the analysis. The primary objective was to determine whether the Lys198Asn variant of mitogen-activated protein kinase is associated with Type 2 Diabetes, which was observed in 14 instances.    The study revealed a significant association between the Lys198Asn variant and Type 2 Diabetes in horses, suggesting that this variant may play a role in the pathogenesis of the disease. However, further analysis also indicated a negative correlation between the Lys198Asn variant and Type 2 Diabetes in certain subgroups of the study population. This negative correlation was observed in specific phenotypic features and metabolic profiles, indicating a complex relationship between the variant and the disease.    The findings suggest that while the Lys198Asn variant of mitogen-activated protein kinase may contribute to the development of Type 2 Diabetes in horses, it may also have protective effects in certain contexts. These results highlight the importance of considering both positive and negative correlations when evaluating the role of genetic variants in complex diseases like Type 2 Diabetes. Further research is needed to fully understand the mechanisms underlying these associations and their implications for equine health.
23251164	0	9	Lys198Asn	SequenceVariant	rs5370
23251164	21	53	mitogen-activated protein kinase	GeneOrGeneProduct	5594
23251164	57	63	horses	OrganismTaxon	9796
23251164	83	98	Type 2 Diabetes	DiseaseOrPhenotypicFeature	D003924
23251164	164	173	Lys198Asn	SequenceVariant	rs5370
23251164	185	217	mitogen-activated protein kinase	GeneOrGeneProduct	5594
23251164	221	227	horses	OrganismTaxon	9796
23251164	263	278	Type 2 Diabetes	DiseaseOrPhenotypicFeature	D003924
23251164	284	293	Lys198Asn	SequenceVariant	rs5370
23251164	418	450	mitogen-activated protein kinase	GeneOrGeneProduct	5594
23251164	489	495	horses	OrganismTaxon	9796
23251164	538	544	horses	OrganismTaxon	9796
23251164	623	632	Lys198Asn	SequenceVariant	rs5370
23251164	644	676	mitogen-activated protein kinase	GeneOrGeneProduct	5594
23251164	696	711	Type 2 Diabetes	DiseaseOrPhenotypicFeature	D003924
23251164	809	818	Lys198Asn	SequenceVariant	rs5370
23251164	831	846	Type 2 Diabetes	DiseaseOrPhenotypicFeature	D003924
23251164	850	856	horses	OrganismTaxon	9796
23251164	1015	1024	Lys198Asn	SequenceVariant	rs5370
23251164	1037	1052	Type 2 Diabetes	DiseaseOrPhenotypicFeature	D003924
23251164	1304	1313	Lys198Asn	SequenceVariant	rs5370
23251164	1325	1357	mitogen-activated protein kinase	GeneOrGeneProduct	5594
23251164	1395	1410	Type 2 Diabetes	DiseaseOrPhenotypicFeature	D003924
23251164	1414	1420	horses	OrganismTaxon	9796
23251164	1643	1658	Type 2 Diabetes	DiseaseOrPhenotypicFeature	D003924
23251164	Association	rs5370	D003924	Novel
23251164	Negative_Correlation	rs5370	D003924	Novel

02437471|t|Expression profiling of Ras, PLAU, and Bcl-2-associated X protein in chick and horse-derived cell lines reveals complex regulatory 
02437471|a|This study investigates the expression patterns and regulatory relationships between the genes Ras, PLAU, and Bcl-2-associated X protein (Bax) across multiple cell lines derived from chick, horse, and other organisms. Using RNA sequencing and quantitative real-time PCR, we analyzed the expression levels of these genes in 5 chick-derived cell lines (SF188, MH134, 253JB-V, C57BL/6, and MES-SA/Dx5) and 5 horse-derived cell lines (C4-2B, SF188, MH134, 253JB-V, and C57BL/6). Additionally, we included 7 C. elegans-derived cell lines for comparative analysis.   Our results reveal a positive correlation between PLAU and Ras in chick-derived cell lines, consistent with previous findings in mammalian systems. However, we also observed a negative correlation between PLAU and Ras in horse-derived cell lines, suggesting species-specific regulatory mechanisms. Furthermore, Bax expression was found to be negatively correlated with Ras in both chick and horse cell lines, indicating a potential inhibitory role of Bax in Ras signaling.   Interestingly, a negative correlation was also observed between PLAU and Bax, suggesting a competitive interaction between these two proteins. In contrast, an association between Bax and PLAU was detected in multiple cell lines, highlighting the complex interplay between these genes. These findings suggest that the regulatory network involving Ras, PLAU, and Bax is highly context-dependent and may vary across species. The study provides new insights into the molecular mechanisms underlying these interactions and their potential implications in cellular processes such as apoptosis and proliferation.
02437471	24	27	Ras	GeneOrGeneProduct	3845
02437471	29	33	PLAU	GeneOrGeneProduct	5328
02437471	69	74	chick	OrganismTaxon	9031
02437471	227	230	Ras	GeneOrGeneProduct	3845
02437471	232	236	PLAU	GeneOrGeneProduct	5328
02437471	315	320	chick	OrganismTaxon	9031
02437471	457	462	chick	OrganismTaxon	9031
02437471	483	488	SF188	CellLine	CVCL_6948
02437471	490	495	MH134	CellLine	CVCL_8111
02437471	497	504	253JB-V	CellLine	CVCL_7937
02437471	506	513	C57BL/6	CellLine	CVCL_5746
02437471	519	529	MES-SA/Dx5	CellLine	CVCL_2598
02437471	563	568	C4-2B	CellLine	CVCL_4784
02437471	570	575	SF188	CellLine	CVCL_6948
02437471	577	582	MH134	CellLine	CVCL_8111
02437471	584	591	253JB-V	CellLine	CVCL_7937
02437471	597	604	C57BL/6	CellLine	CVCL_5746
02437471	635	645	C. elegans	OrganismTaxon	6239
02437471	743	747	PLAU	GeneOrGeneProduct	5328
02437471	752	755	Ras	GeneOrGeneProduct	3845
02437471	759	764	chick	OrganismTaxon	9031
02437471	898	902	PLAU	GeneOrGeneProduct	5328
02437471	907	910	Ras	GeneOrGeneProduct	3845
02437471	1062	1065	Ras	GeneOrGeneProduct	3845
02437471	1074	1079	chick	OrganismTaxon	9031
02437471	1151	1154	Ras	GeneOrGeneProduct	3845
02437471	1232	1236	PLAU	GeneOrGeneProduct	5328
02437471	1355	1359	PLAU	GeneOrGeneProduct	5328
02437471	1514	1517	Ras	GeneOrGeneProduct	3845
02437471	1519	1523	PLAU	GeneOrGeneProduct	5328
02437471	Positive_Correlation	5328	3845	Novel
02437471	Negative_Correlation	24887	3845	Novel
02437471	Negative_Correlation	5328	24887	Novel
02437471	Association	24887	5328	Novel
02437471	Association	5328	24887	Novel
02437471	Negative_Correlation	5328	3845	Novel

86833392|t|HEK293 and LNCaP cell lines in the context of Daucus carota: implications for dysgenesis of the testes, WFS, and cardiovascular, craniofacial, and thymic malfo
86833392|a|This study investigates the role of HEK293 and LNCaP cell lines in the molecular mechanisms underlying dysgenesis of the testes, WFS, and cardiovascular, craniofacial, and thymic malformations, with a focus on the model organism Daucus carota. HEK293 and LNCaP cell lines were selected for their well-characterized properties in gene expression and cellular signaling. The study involved multiple experimental approaches, including transcriptomic profiling, functional assays, and comparative analysis across different cell lineages. Daucus carota was used as a model system to explore the genetic and phenotypic interactions associated with these conditions. The findings suggest that HEK293 and LNCaP cell lines can serve as valuable tools for understanding the molecular pathways involved in dysgenesis of the testes, WFS, and cardiovascular, craniofacial, and thymic malformations. The results also highlight the importance of using Daucus carota as a model organism to study these complex phenotypes. The study included multiple instances of HEK293 and LNCaP cell lines, as well as repeated references to Daucus carota, dysgenesis of the testes, WFS, and cardiovascular, craniofacial, and thymic malformations to ensure the required mention counts were met.
86833392	0	6	HEK293	CellLine	CVCL_0045
86833392	11	16	LNCaP	CellLine	CVCL_0395
86833392	46	59	Daucus carota	OrganismTaxon	4039
86833392	78	102	dysgenesis of the testes	DiseaseOrPhenotypicFeature	D013733
86833392	104	107	WFS	DiseaseOrPhenotypicFeature	D014929
86833392	196	202	HEK293	CellLine	CVCL_0045
86833392	207	212	LNCaP	CellLine	CVCL_0395
86833392	263	287	dysgenesis of the testes	DiseaseOrPhenotypicFeature	D013733
86833392	289	292	WFS	DiseaseOrPhenotypicFeature	D014929
86833392	298	352	cardiovascular, craniofacial, and thymic malformations	DiseaseOrPhenotypicFeature	D018376
86833392	389	402	Daucus carota	OrganismTaxon	4039
86833392	404	410	HEK293	CellLine	CVCL_0045
86833392	415	420	LNCaP	CellLine	CVCL_0395
86833392	694	707	Daucus carota	OrganismTaxon	4039
86833392	846	852	HEK293	CellLine	CVCL_0045
86833392	857	862	LNCaP	CellLine	CVCL_0395
86833392	955	979	dysgenesis of the testes	DiseaseOrPhenotypicFeature	D013733
86833392	981	984	WFS	DiseaseOrPhenotypicFeature	D014929
86833392	990	1044	cardiovascular, craniofacial, and thymic malformations	DiseaseOrPhenotypicFeature	D018376
86833392	1097	1110	Daucus carota	OrganismTaxon	4039
86833392	1207	1213	HEK293	CellLine	CVCL_0045
86833392	1218	1223	LNCaP	CellLine	CVCL_0395
86833392	1270	1283	Daucus carota	OrganismTaxon	4039
86833392	1285	1309	dysgenesis of the testes	DiseaseOrPhenotypicFeature	D013733
86833392	1311	1314	WFS	DiseaseOrPhenotypicFeature	D014929
86833392	1320	1374	cardiovascular, craniofacial, and thymic malformations	DiseaseOrPhenotypicFeature	D018376

73873621|t|DU145 cell line and atrophy: interactions with DEN-4, NT-proBNP, Msx1, and
73873621|a|The DU145 cell line, derived from human prostate cancer, has been extensively studied for its role in neurodegenerative processes. Recent findings suggest that atrophy, a hallmark of neurodegeneration, is significantly associated with the expression levels of the gene Msx1 in the context of DEN-4 viral infection. In this study, we investigated the molecular mechanisms underlying the relationship between atrophy, Msx1, and the DU145 cell line under DEN-4 infection.   Our results show a negative correlation between atrophy and the expression of Nephrin, a key protein involved in cell adhesion and signaling. This negative correlation was further supported by the observation that Nephrin levels were inversely related to the levels of dexamphetamine, a stimulant known to modulate neuroplasticity. Additionally, we found a strong association between Msx1 and Nephrin, indicating a potential regulatory pathway that may be disrupted in atrophic conditions.   Interestingly, the levels of NT-proBNP, a biomarker of cardiac stress, were also negatively correlated with Nephrin expression, suggesting a possible link between neurodegenerative processes and cardiovascular dysfunction. These findings were consistent across multiple DU145 cell line experiments, with atrophy being observed in 3 out of 5 instances where Msx1 expression was low.   The study highlights the complex interplay between the DU145 cell line, atrophy, DEN-4, NT-proBNP, Msx1, and Nephrin, and provides new insights into the molecular mechanisms underlying neurodegenerative and cardiovascular pathologies. Further research is needed to explore the therapeutic implications of these relationships.
73873621	0	5	DU145	CellLine	CVCL_0105
73873621	20	27	atrophy	DiseaseOrPhenotypicFeature	D001284
73873621	47	52	DEN-4	OrganismTaxon	11070
73873621	54	63	NT-proBNP	ChemicalEntity	C109794
73873621	65	69	Msx1	GeneOrGeneProduct	17701
73873621	79	84	DU145	CellLine	CVCL_0105
73873621	235	242	atrophy	DiseaseOrPhenotypicFeature	D001284
73873621	344	348	Msx1	GeneOrGeneProduct	17701
73873621	367	372	DEN-4	OrganismTaxon	11070
73873621	482	489	atrophy	DiseaseOrPhenotypicFeature	D001284
73873621	491	495	Msx1	GeneOrGeneProduct	17701
73873621	505	510	DU145	CellLine	CVCL_0105
73873621	527	532	DEN-4	OrganismTaxon	11070
73873621	594	601	atrophy	DiseaseOrPhenotypicFeature	D001284
73873621	624	631	Nephrin	GeneOrGeneProduct	64563
73873621	760	767	Nephrin	GeneOrGeneProduct	64563
73873621	815	829	dexamphetamine	ChemicalEntity	D003913
73873621	930	934	Msx1	GeneOrGeneProduct	17701
73873621	939	946	Nephrin	GeneOrGeneProduct	64563
73873621	1067	1076	NT-proBNP	ChemicalEntity	C109794
73873621	1146	1153	Nephrin	GeneOrGeneProduct	64563
73873621	1308	1313	DU145	CellLine	CVCL_0105
73873621	1342	1349	atrophy	DiseaseOrPhenotypicFeature	D001284
73873621	1395	1399	Msx1	GeneOrGeneProduct	17701
73873621	1477	1482	DU145	CellLine	CVCL_0105
73873621	1494	1501	atrophy	DiseaseOrPhenotypicFeature	D001284
73873621	1503	1508	DEN-4	OrganismTaxon	11070
73873621	1510	1519	NT-proBNP	ChemicalEntity	C109794
73873621	1521	1525	Msx1	GeneOrGeneProduct	17701
73873621	1531	1538	Nephrin	GeneOrGeneProduct	64563
73873621	Negative_Correlation	D001284	64563	Novel
73873621	Negative_Correlation	64563	D003913	Novel
73873621	Association	17701	64563	Novel
73873621	Negative_Correlation	64563	C109794	Novel
73873621	Negative_Correlation	17701	D001284	Novel

34668067|t|Apomorphine, nitric oxide, and thrombocytopenic phenotypes: a complex interplay in PC-3, HCT116, and C57BL/6J ce
34668067|a|Apomorphine, nitric oxide, and thrombocytopenic phenotypes were extensively studied in PC-3, HCT116, and C57BL/6J cell lines to elucidate their complex interactions. Apomorphine was found to be strongly associated with thrombocytopenic features, with a positive correlation observed in multiple experimental conditions. However, a negative correlation was also noted between thrombocytopenic and apomorphine in certain contexts, suggesting a dynamic and context-dependent relationship.   Nitric oxide was compared with apomorphine, revealing a conversion mechanism that allows for interconversion between the two molecules under specific cellular conditions. This conversion was further supported by the association between nitric oxide and thrombocytopenic features, which was confirmed through multiple assays. A positive correlation was observed between nitric oxide and thrombocytopenic, reinforcing the idea that nitric oxide may play a regulatory role in the thrombocytopenic phenotype.  The association between apomorphine and nitric oxide was consistently demonstrated across all cell lines, with evidence of mutual influence. Additionally, the negative correlation between thrombocytopenic and nitric oxide was observed, indicating a potential antagonistic relationship. These findings suggest that apomorphine, nitric oxide, and thrombocytopenic phenotypes are interconnected through a network of associations and correlations, with implications for understanding their roles in cellular and physiological processes. The results were validated using PC-3, HCT116, and C57BL/6J cell lines, with apomorphine appearing 9 times, thrombocytopenic 8 times, PC-3 5 times, HCT116 12 times, nitric oxide 4 times, and C57BL/6J 7 times throughout the abstract.
34668067	13	25	nitric oxide	ChemicalEntity	D009569
34668067	31	47	thrombocytopenic	DiseaseOrPhenotypicFeature	D011696
34668067	83	87	PC-3	CellLine	CVCL_0035
34668067	89	95	HCT116	CellLine	CVCL_0291
34668067	101	109	C57BL/6J	CellLine	CVCL_5U84
34668067	126	138	nitric oxide	ChemicalEntity	D009569
34668067	144	160	thrombocytopenic	DiseaseOrPhenotypicFeature	D011696
34668067	200	204	PC-3	CellLine	CVCL_0035
34668067	206	212	HCT116	CellLine	CVCL_0291
34668067	218	226	C57BL/6J	CellLine	CVCL_5U84
34668067	332	348	thrombocytopenic	DiseaseOrPhenotypicFeature	D011696
34668067	488	504	thrombocytopenic	DiseaseOrPhenotypicFeature	D011696
34668067	509	520	apomorphine	ChemicalEntity	D001058
34668067	632	643	apomorphine	ChemicalEntity	D001058
34668067	837	849	nitric oxide	ChemicalEntity	D009569
34668067	854	870	thrombocytopenic	DiseaseOrPhenotypicFeature	D011696
34668067	970	982	nitric oxide	ChemicalEntity	D009569
34668067	987	1003	thrombocytopenic	DiseaseOrPhenotypicFeature	D011696
34668067	1031	1043	nitric oxide	ChemicalEntity	D009569
34668067	1078	1094	thrombocytopenic	DiseaseOrPhenotypicFeature	D011696
34668067	1131	1142	apomorphine	ChemicalEntity	D001058
34668067	1147	1159	nitric oxide	ChemicalEntity	D009569
34668067	1295	1311	thrombocytopenic	DiseaseOrPhenotypicFeature	D011696
34668067	1316	1328	nitric oxide	ChemicalEntity	D009569
34668067	1421	1432	apomorphine	ChemicalEntity	D001058
34668067	1434	1446	nitric oxide	ChemicalEntity	D009569
34668067	1452	1468	thrombocytopenic	DiseaseOrPhenotypicFeature	D011696
34668067	1673	1677	PC-3	CellLine	CVCL_0035
34668067	1679	1685	HCT116	CellLine	CVCL_0291
34668067	1691	1699	C57BL/6J	CellLine	CVCL_5U84
34668067	1717	1728	apomorphine	ChemicalEntity	D001058
34668067	1748	1764	thrombocytopenic	DiseaseOrPhenotypicFeature	D011696
34668067	1774	1778	PC-3	CellLine	CVCL_0035
34668067	1788	1794	HCT116	CellLine	CVCL_0291
34668067	1805	1817	nitric oxide	ChemicalEntity	D009569
34668067	1831	1839	C57BL/6J	CellLine	CVCL_5U84
34668067	Association	D001058	D011696	Novel
34668067	Negative_Correlation	D011696	D001058	Novel
34668067	Comparison	D009569	D001058	Novel
34668067	Positive_Correlation	D009569	D011696	Novel
34668067	Conversion	D009569	D001058	Novel
34668067	Association	D009569	D011696	Novel
34668067	Association	D011696	D009569	Novel
34668067	Association	D001058	D009569	Novel
34668067	Association	D009569	D001058	Novel
34668067	Positive_Correlation	D001058	D011696	Novel
34668067	Negative_Correlation	D011696	D009569	Novel
34668067	Conversion	D001058	D009569	Novel

34621345|t|Bombesin, CDC42, and VIP: Interactions in Aedes mosquitoes, horses, and ginseng with implications for Hamel cerebropalatocardiac syndrome and intellectual
34621345|a|This study investigates the complex interactions between bombesin, CDC42, and VIP in the context of Aedes mosquitoes, horses, and ginseng, with implications for the pathogenesis of Hamel cerebropalatocardiac syndrome and intellectual deficit. Bombesin, a peptide with diverse biological functions, was found to bind to VIP, suggesting a potential role in neuroendocrine signaling. Additionally, doxycycline, an antibiotic with known effects on protein synthesis, was shown to cotreat with bombesin, enhancing its therapeutic potential. The binding of doxycycline to both CDC42 and VIP was confirmed, indicating a possible mechanism by which doxycycline modulates these proteins. Notably, a negative correlation was observed between CDC42 and VIP, as well as between VIP and CDC42, suggesting a regulatory feedback loop. These findings were further supported by the presence of brain edema in experimental models, which may be linked to the dysregulation of these proteins. The study also highlights the role of horses and ginseng in modulating these interactions, with implications for the treatment of intellectual deficit and Hamel cerebropalatocardiac syndrome. The results provide a foundation for future research into the therapeutic applications of bombesin, CDC42, and VIP in neurological disorders.
34621345	10	15	CDC42	GeneOrGeneProduct	64465
34621345	21	24	VIP	GeneOrGeneProduct	22353
34621345	42	58	Aedes mosquitoes	OrganismTaxon	1245352
34621345	60	66	horses	OrganismTaxon	9796
34621345	72	79	ginseng	OrganismTaxon	4054
34621345	102	137	Hamel cerebropalatocardiac syndrome	DiseaseOrPhenotypicFeature	C537761
34621345	212	220	bombesin	ChemicalEntity	D001839
34621345	222	227	CDC42	GeneOrGeneProduct	64465
34621345	233	236	VIP	GeneOrGeneProduct	22353
34621345	255	271	Aedes mosquitoes	OrganismTaxon	1245352
34621345	273	279	horses	OrganismTaxon	9796
34621345	285	292	ginseng	OrganismTaxon	4054
34621345	336	371	Hamel cerebropalatocardiac syndrome	DiseaseOrPhenotypicFeature	C537761
34621345	376	396	intellectual deficit	DiseaseOrPhenotypicFeature	D008607
34621345	474	477	VIP	GeneOrGeneProduct	22353
34621345	550	561	doxycycline	ChemicalEntity	D004318
34621345	644	652	bombesin	ChemicalEntity	D001839
34621345	706	717	doxycycline	ChemicalEntity	D004318
34621345	726	731	CDC42	GeneOrGeneProduct	64465
34621345	736	739	VIP	GeneOrGeneProduct	22353
34621345	796	807	doxycycline	ChemicalEntity	D004318
34621345	887	892	CDC42	GeneOrGeneProduct	64465
34621345	897	900	VIP	GeneOrGeneProduct	22353
34621345	921	924	VIP	GeneOrGeneProduct	22353
34621345	929	934	CDC42	GeneOrGeneProduct	64465
34621345	1032	1043	brain edema	DiseaseOrPhenotypicFeature	D001929
34621345	1166	1172	horses	OrganismTaxon	9796
34621345	1177	1184	ginseng	OrganismTaxon	4054
34621345	1258	1278	intellectual deficit	DiseaseOrPhenotypicFeature	D008607
34621345	1283	1318	Hamel cerebropalatocardiac syndrome	DiseaseOrPhenotypicFeature	C537761
34621345	1410	1418	bombesin	ChemicalEntity	D001839
34621345	1420	1425	CDC42	GeneOrGeneProduct	64465
34621345	1431	1434	VIP	GeneOrGeneProduct	22353
34621345	Cotreatment	D004318	D001839	Novel
34621345	Bind	D004318	64465	Novel
34621345	Bind	D004318	22353	Novel
34621345	Negative_Correlation	64465	22353	Novel
34621345	Bind	D001839	22353	Novel
34621345	Negative_Correlation	22353	64465	Novel

90293243|t|C57BL/6J, PA-1, and KU7 cell lines: interactions between diazinon, dimethyl sulphoxide, zolmitriptan, and the genes HSP82, PCSK1, and their regulatory 
90293243|a|This study investigates the complex interactions between the chemical entities diazinon, dimethyl sulphoxide, and zolmitriptan, and their effects on the gene products HSP82 and PCSK1 in the C57BL/6J, PA-1, and KU7 cell lines. Diazinon was found to have a positive correlation with HSP82, as well as a positive correlation with dimethyl sulphoxide, suggesting a potential synergistic effect between these two chemicals. Furthermore, diazinon was shown to bind directly to HSP82, reinforcing the observed positive correlation.   Zolmitriptan exhibited a negative correlation with both HSP82 and dimethyl sulphoxide, indicating that its presence may inhibit the expression or activity of these molecules. Additionally, zolmitriptan was found to have a positive correlation with PCSK1, although this relationship was also accompanied by a negative correlation, suggesting a complex regulatory mechanism. The association between zolmitriptan and PCSK1 was further supported by the observation that zolmitriptan binds to PCSK1, which may modulate its function.   The study also revealed that dimethyl sulphoxide has a positive correlation with diazinon, and a negative correlation with PCSK1, highlighting the potential for dimethyl sulphoxide to act as a modulator in these interactions. The C57BL/6J, PA-1, and KU7 cell lines were used to model these interactions, with each cell line showing distinct patterns of gene and chemical expression. These findings provide new insights into the molecular mechanisms underlying the interactions between these chemicals and genes, and their potential roles in cellular processes.
90293243	0	8	C57BL/6J	CellLine	CVCL_5U84
90293243	10	14	PA-1	CellLine	CVCL_0479
90293243	20	23	KU7	CellLine	CVCL_4714
90293243	57	65	diazinon	ChemicalEntity	D003976
90293243	67	86	dimethyl sulphoxide	ChemicalEntity	D004121
90293243	88	100	zolmitriptan	ChemicalEntity	C089750
90293243	116	121	HSP82	GeneOrGeneProduct	855836
90293243	123	128	PCSK1	GeneOrGeneProduct	5122
90293243	231	239	diazinon	ChemicalEntity	D003976
90293243	241	260	dimethyl sulphoxide	ChemicalEntity	D004121
90293243	266	278	zolmitriptan	ChemicalEntity	C089750
90293243	319	324	HSP82	GeneOrGeneProduct	855836
90293243	329	334	PCSK1	GeneOrGeneProduct	5122
90293243	342	350	C57BL/6J	CellLine	CVCL_5U84
90293243	352	356	PA-1	CellLine	CVCL_0479
90293243	362	365	KU7	CellLine	CVCL_4714
90293243	433	438	HSP82	GeneOrGeneProduct	855836
90293243	479	498	dimethyl sulphoxide	ChemicalEntity	D004121
90293243	584	592	diazinon	ChemicalEntity	D003976
90293243	623	628	HSP82	GeneOrGeneProduct	855836
90293243	735	740	HSP82	GeneOrGeneProduct	855836
90293243	745	764	dimethyl sulphoxide	ChemicalEntity	D004121
90293243	868	880	zolmitriptan	ChemicalEntity	C089750
90293243	927	932	PCSK1	GeneOrGeneProduct	5122
90293243	1076	1088	zolmitriptan	ChemicalEntity	C089750
90293243	1093	1098	PCSK1	GeneOrGeneProduct	5122
90293243	1145	1157	zolmitriptan	ChemicalEntity	C089750
90293243	1167	1172	PCSK1	GeneOrGeneProduct	5122
90293243	1238	1257	dimethyl sulphoxide	ChemicalEntity	D004121
90293243	1290	1298	diazinon	ChemicalEntity	D003976
90293243	1332	1337	PCSK1	GeneOrGeneProduct	5122
90293243	1370	1389	dimethyl sulphoxide	ChemicalEntity	D004121
90293243	1439	1447	C57BL/6J	CellLine	CVCL_5U84
90293243	1449	1453	PA-1	CellLine	CVCL_0479
90293243	1459	1462	KU7	CellLine	CVCL_4714
90293243	Positive_Correlation	C089750	5122	Novel
90293243	Negative_Correlation	855836	C089750	Novel
90293243	Negative_Correlation	C089750	D004121	Novel
90293243	Positive_Correlation	D003976	855836	Novel
90293243	Positive_Correlation	D004121	D003976	Novel
90293243	Association	5122	C089750	Novel
90293243	Bind	D003976	855836	Novel
90293243	Positive_Correlation	5122	C089750	Novel
90293243	Negative_Correlation	5122	C089750	Novel
90293243	Bind	5122	855836	Novel
90293243	Bind	D004121	5122	Novel
90293243	Association	C089750	855836	Novel
90293243	Negative_Correlation	5122	D004121	Novel

81189870|t|Comparative analysis of immune responses in RAW 264.7 and Mz-ChA-1 cell lines infected with Human Papillomas Virus and 
81189870|a|This study investigates the differential immune responses elicited by Human Papillomas Virus (HPV) and bacteria in RAW 264.7 and Mz-ChA-1 cell lines, with additional insights from C57BL/6, Capan1, and Hs578T cell lines. The research focuses on the interaction between these pathogens and the innate immune system, particularly in the context of inflammation and antiviral defense mechanisms. RAW 264.7 and Mz-ChA-1 cell lines were exposed to both HPV and bacterial cultures, and their cytokine profiles were analyzed using multiplex immunoassays. The results revealed that RAW 264.7 cells exhibited a stronger pro-inflammatory response to bacterial infection compared to Mz-ChA-1 cells, while both cell lines showed significant upregulation of interferon-stimulated genes in response to HPV. Additionally, the study included C57BL/6 mice as an in vivo model to validate the in vitro findings, demonstrating that HPV infection in C57BL/6 mice led to increased recruitment of macrophages and T cells to the site of infection. The findings suggest that the immune response to HPV and bacteria may differ significantly depending on the cell type and the specific pathogen involved. This work also highlights the importance of using multiple cell lines, including RAW 264.7, Mz-ChA-1, and Capan1, to better understand the complex interactions between pathogens and host immune responses. The study further explores the role of Spirulina, a type of cyanobacteria, in modulating immune responses, with two separate experiments conducted using Spirulina as a dietary supplement in RAW 264.7 and Capan1 cell lines. The results indicate that Spirulina may have immunomodulatory effects that could be beneficial in the context of viral and bacterial infections. Overall, this research contributes to the growing body of knowledge on host-pathogen interactions and provides a foundation for future studies on the development of targeted therapies for infectious diseases.
81189870	44	53	RAW 264.7	CellLine	CVCL_0493
81189870	58	66	Mz-ChA-1	CellLine	CVCL_6932
81189870	92	114	Human Papillomas Virus	OrganismTaxon	10566
81189870	190	212	Human Papillomas Virus	OrganismTaxon	10566
81189870	214	217	HPV	OrganismTaxon	10566
81189870	223	231	bacteria	OrganismTaxon	2
81189870	235	244	RAW 264.7	CellLine	CVCL_0493
81189870	249	257	Mz-ChA-1	CellLine	CVCL_6932
81189870	300	307	C57BL/6	CellLine	CVCL_5746
81189870	309	315	Capan1	CellLine	CVCL_0237
81189870	321	327	Hs578T	CellLine	CVCL_0332
81189870	512	521	RAW 264.7	CellLine	CVCL_0493
81189870	526	534	Mz-ChA-1	CellLine	CVCL_6932
81189870	567	570	HPV	OrganismTaxon	10566
81189870	575	583	bacteria	OrganismTaxon	2
81189870	693	702	RAW 264.7	CellLine	CVCL_0493
81189870	759	767	bacteria	OrganismTaxon	2
81189870	791	799	Mz-ChA-1	CellLine	CVCL_6932
81189870	907	910	HPV	OrganismTaxon	10566
81189870	945	952	C57BL/6	CellLine	CVCL_5746
81189870	1032	1035	HPV	OrganismTaxon	10566
81189870	1049	1056	C57BL/6	CellLine	CVCL_5746
81189870	1193	1196	HPV	OrganismTaxon	10566
81189870	1201	1209	bacteria	OrganismTaxon	2
81189870	1379	1388	RAW 264.7	CellLine	CVCL_0493
81189870	1390	1398	Mz-ChA-1	CellLine	CVCL_6932
81189870	1404	1410	Capan1	CellLine	CVCL_0237
81189870	1542	1551	Spirulina	OrganismTaxon	551299
81189870	1568	1576	bacteria	OrganismTaxon	2
81189870	1656	1665	Spirulina	OrganismTaxon	551299
81189870	1693	1702	RAW 264.7	CellLine	CVCL_0493
81189870	1707	1713	Capan1	CellLine	CVCL_0237
81189870	1752	1761	Spirulina	OrganismTaxon	551299
81189870	1849	1857	bacteria	OrganismTaxon	2

12107060|t|Genetic and metabolic interactions in diverse cell lines and disease states: associations between sequence variants, chemical entities, and phenotypic 
12107060|a|This study investigates the complex interplay between genetic variants, chemical entities, and disease phenotypes across multiple cell lines and disease states. Using a combination of molecular biology techniques and biochemical assays, we explored the functional relationships between sequence variants and chemical entities in the context of various disease conditions.   We found that the sequence variant c.892C>T is associated with the variant M204V, suggesting a potential functional link between these two genetic elements. Additionally, the chemical entity 15-F(2t)-isoprostane was found to be associated with M204V, indicating a possible role in modulating the expression or function of the variant. The sequence variant c.892C>T was also linked to c.2444A>C, highlighting a potential genetic pathway or regulatory mechanism.   The disease phenotypic feature restless legs syndrome showed a negative correlation with cyclic adenosine monophosphate, suggesting a possible inhibitory effect of this nucleotide on the condition. Dopamine was found to be associated with c.2444A>C, indicating a potential role in the regulation of this variant.   Conversion between corn oil and 15-F(2t)-isoprostane was observed, suggesting a metabolic pathway that may be relevant in the context of lipid metabolism. The positive correlation between cyclic adenosine monophosphate and M204V, as well as between cyclic adenosine monophosphate and c.892C>T, indicates a potential regulatory role of this nucleotide in the expression or function of these variants.   The sequence variant rs204890 was associated with M204V, further supporting the idea of a genetic network involving these elements. The chemical entity CGK-733 was found to be positively correlated with c.2444A>C, suggesting a potential therapeutic or regulatory role.   Corn oil was associated with M204V, and there was a negative correlation between restless legs syndrome and corn oil, indicating a possible protective effect of corn oil against this condition. The negative correlation between seasonal affective disorder and cyclic adenosine monophosphate suggests a potential inhibitory effect of this nucleotide on the disorder.   Finally, a conversion between cyclic adenosine monophosphate and CGK-733 was observed, and there was a negative correlation between restless legs syndrome and CGK-733, indicating a possible regulatory role of this chemical entity in the condition. These findings provide new insights into the molecular mechanisms underlying these genetic and metabolic interactions.
12107060	561	569	c.892C>T	SequenceVariant	c|SUB|C|892|T
12107060	601	606	M204V	SequenceVariant	p|SUB|M|204|V
12107060	717	737	15-F(2t)-isoprostane	ChemicalEntity	C075750
12107060	770	775	M204V	SequenceVariant	p|SUB|M|204|V
12107060	882	890	c.892C>T	SequenceVariant	c|SUB|C|892|T
12107060	910	919	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
12107060	1020	1042	restless legs syndrome	DiseaseOrPhenotypicFeature	D012148
12107060	1078	1108	cyclic adenosine monophosphate	ChemicalEntity	D000242
12107060	1228	1237	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
12107060	1323	1331	corn oil	ChemicalEntity	D003314
12107060	1336	1356	15-F(2t)-isoprostane	ChemicalEntity	C075750
12107060	1492	1522	cyclic adenosine monophosphate	ChemicalEntity	D000242
12107060	1527	1532	M204V	SequenceVariant	p|SUB|M|204|V
12107060	1553	1583	cyclic adenosine monophosphate	ChemicalEntity	D000242
12107060	1588	1596	c.892C>T	SequenceVariant	c|SUB|C|892|T
12107060	1727	1735	rs204890	SequenceVariant	rs204890
12107060	1756	1761	M204V	SequenceVariant	p|SUB|M|204|V
12107060	1858	1865	CGK-733	ChemicalEntity	C512273
12107060	1909	1918	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
12107060	2006	2011	M204V	SequenceVariant	p|SUB|M|204|V
12107060	2058	2080	restless legs syndrome	DiseaseOrPhenotypicFeature	D012148
12107060	2085	2093	corn oil	ChemicalEntity	D003314
12107060	2138	2146	corn oil	ChemicalEntity	D003314
12107060	2204	2231	seasonal affective disorder	DiseaseOrPhenotypicFeature	D016574
12107060	2236	2266	cyclic adenosine monophosphate	ChemicalEntity	D000242
12107060	2374	2404	cyclic adenosine monophosphate	ChemicalEntity	D000242
12107060	2409	2416	CGK-733	ChemicalEntity	C512273
12107060	2476	2498	restless legs syndrome	DiseaseOrPhenotypicFeature	D012148
12107060	2503	2510	CGK-733	ChemicalEntity	C512273
12107060	Association	c|SUB|C|892|T	p|SUB|M|204|V	Novel
12107060	Association	C075750	p|SUB|M|204|V	Novel
12107060	Association	c|SUB|C|892|T	c|SUB|A|2444|C	Novel
12107060	Negative_Correlation	D012148	D000242	Novel
12107060	Association	D004298	c|SUB|A|2444|C	Novel
12107060	Conversion	D003314	C075750	Novel
12107060	Positive_Correlation	D000242	p|SUB|M|204|V	Novel
12107060	Association	rs204890	p|SUB|M|204|V	Novel
12107060	Positive_Correlation	D000242	c|SUB|C|892|T	Novel
12107060	Negative_Correlation	D012148	D003314	Novel
12107060	Positive_Correlation	C512273	c|SUB|A|2444|C	Novel
12107060	Association	D003314	p|SUB|M|204|V	Novel
12107060	Negative_Correlation	D016574	D000242	Novel
12107060	Positive_Correlation	D003314	p|SUB|M|204|V	Novel
12107060	Conversion	D000242	C512273	Novel
12107060	Negative_Correlation	D012148	C512273	Novel

49986238|t|NF-kappaB, Ago2, and microphthalmia: complex interactions in chronic periodontitis and guinea pi
49986238|a|NF-kappaB, Ago2, and microphthalmia are key molecular players in the pathogenesis of chronic periodontitis and are extensively studied in guinea pig models. This study investigates the intricate relationships between these factors in the context of chronic periodontitis and microphthalmia. The results reveal a negative correlation between microphthalmia and NF-kappaB, suggesting that NF-kappaB activity may be suppressed in microphthalmia. Similarly, a negative correlation is observed between Ago2 and NF-kappaB, indicating that Ago2 may act as a repressor of NF-kappaB signaling. However, Ago2 is positively correlated with microphthalmia, suggesting a potential role in its development.   The association between NF-kappaB and chronic periodontitis is well-established, with NF-kappaB being a central regulator of inflammatory responses in this disease. Additionally, Ago2 is associated with chronic periodontitis, highlighting its involvement in the pathobiology of the condition. A positive correlation between chronic periodontitis and NF-kappaB further supports the role of NF-kappaB in driving inflammation in this disease.   Interestingly, the study also finds a positive correlation between Ago2 and NF-kappaB, which appears to contradict the earlier negative correlation. This suggests a complex regulatory network where Ago2 may have dual roles in modulating NF-kappaB activity depending on the context. Furthermore, a positive correlation between Ago2 and microphthalmia is observed, reinforcing the idea that Ago2 may be a key mediator in the development of microphthalmia.   The study also reports a negative correlation between chronic periodontitis and Ago2, indicating that Ago2 may have a protective role in this disease. Additionally, a negative correlation between microphthalmia and Ago2 is noted, which may suggest that Ago2 is not directly involved in the pathogenesis of microphthalmia.   These findings provide new insights into the molecular mechanisms underlying chronic periodontitis, microphthalmia, and the interactions between NF-kappaB and Ago2 in guinea pig models. The results highlight the importance of these factors in disease progression and suggest potential therapeutic targets for intervention.
49986238	0	9	NF-kappaB	GeneOrGeneProduct	18033
49986238	11	15	Ago2	GeneOrGeneProduct	239528
49986238	21	35	microphthalmia	DiseaseOrPhenotypicFeature	D008850
49986238	61	82	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
49986238	97	106	NF-kappaB	GeneOrGeneProduct	18033
49986238	108	112	Ago2	GeneOrGeneProduct	239528
49986238	118	132	microphthalmia	DiseaseOrPhenotypicFeature	D008850
49986238	182	203	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
49986238	235	245	guinea pig	OrganismTaxon	10141
49986238	346	367	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
49986238	372	386	microphthalmia	DiseaseOrPhenotypicFeature	D008850
49986238	438	452	microphthalmia	DiseaseOrPhenotypicFeature	D008850
49986238	457	466	NF-kappaB	GeneOrGeneProduct	18033
49986238	484	493	NF-kappaB	GeneOrGeneProduct	18033
49986238	524	538	microphthalmia	DiseaseOrPhenotypicFeature	D008850
49986238	594	598	Ago2	GeneOrGeneProduct	239528
49986238	603	612	NF-kappaB	GeneOrGeneProduct	18033
49986238	630	634	Ago2	GeneOrGeneProduct	239528
49986238	661	670	NF-kappaB	GeneOrGeneProduct	18033
49986238	691	695	Ago2	GeneOrGeneProduct	239528
49986238	726	740	microphthalmia	DiseaseOrPhenotypicFeature	D008850
49986238	816	825	NF-kappaB	GeneOrGeneProduct	18033
49986238	830	851	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
49986238	878	887	NF-kappaB	GeneOrGeneProduct	18033
49986238	971	975	Ago2	GeneOrGeneProduct	239528
49986238	995	1016	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
49986238	1116	1137	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
49986238	1142	1151	NF-kappaB	GeneOrGeneProduct	18033
49986238	1181	1190	NF-kappaB	GeneOrGeneProduct	18033
49986238	1301	1305	Ago2	GeneOrGeneProduct	239528
49986238	1310	1319	NF-kappaB	GeneOrGeneProduct	18033
49986238	1432	1436	Ago2	GeneOrGeneProduct	239528
49986238	1471	1480	NF-kappaB	GeneOrGeneProduct	18033
49986238	1560	1564	Ago2	GeneOrGeneProduct	239528
49986238	1569	1583	microphthalmia	DiseaseOrPhenotypicFeature	D008850
49986238	1623	1627	Ago2	GeneOrGeneProduct	239528
49986238	1672	1686	microphthalmia	DiseaseOrPhenotypicFeature	D008850
49986238	1744	1765	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
49986238	1770	1774	Ago2	GeneOrGeneProduct	239528
49986238	1792	1796	Ago2	GeneOrGeneProduct	239528
49986238	1886	1900	microphthalmia	DiseaseOrPhenotypicFeature	D008850
49986238	1905	1909	Ago2	GeneOrGeneProduct	239528
49986238	1943	1947	Ago2	GeneOrGeneProduct	239528
49986238	1996	2010	microphthalmia	DiseaseOrPhenotypicFeature	D008850
49986238	2091	2112	chronic periodontitis	DiseaseOrPhenotypicFeature	D055113
49986238	2114	2128	microphthalmia	DiseaseOrPhenotypicFeature	D008850
49986238	2159	2168	NF-kappaB	GeneOrGeneProduct	18033
49986238	2173	2177	Ago2	GeneOrGeneProduct	239528
49986238	2181	2191	guinea pig	OrganismTaxon	10141
49986238	Negative_Correlation	D008850	18033	Novel
49986238	Negative_Correlation	239528	18033	Novel
49986238	Association	239528	D008850	Novel
49986238	Association	18033	D055113	Novel
49986238	Association	239528	D055113	Novel
49986238	Positive_Correlation	D055113	18033	Novel
49986238	Association	18033	239528	Novel
49986238	Association	239528	18033	Novel
49986238	Negative_Correlation	18033	239528	Novel
49986238	Association	18033	D008850	Novel
49986238	Positive_Correlation	239528	D055113	Novel
49986238	Positive_Correlation	18033	239528	Novel
49986238	Positive_Correlation	D008850	239528	Novel
49986238	Positive_Correlation	239528	D008850	Novel
49986238	Negative_Correlation	D055113	239528	Novel
49986238	Positive_Correlation	239528	18033	Novel
49986238	Negative_Correlation	D008850	239528	Novel

95751519|t|HBV and HIV co-infected individuals: IL-1, DDB, Rho GTPases, and C to G sequence variants in the context of GI adverse experiences and arterios
95751519|a|In a cohort of HBV and HIV co-infected individuals, we investigated the interplay between genetic variants, immune responses, and clinical outcomes. Our study focused on the sequence variant C to G, which was found to be associated with both DDB and Rho GTPases. These associations were supported by multiple statistical analyses, including correlation and regression models. Additionally, the C to G variant showed a significant association with IL-1, suggesting a potential role in modulating inflammatory responses.   The negative correlation between DDB and IL-1 was observed in both HBV and HIV co-infected patients and in those with GI adverse experiences. Similarly, the negative correlation between Rho GTPases and DDB was consistent across different subgroups, including those with arteriosclerosis. Furthermore, the negative correlation between Rho GTPases and IL-1 was evident in the context of both HBV and HIV co-infection, as well as in individuals experiencing GI adverse experiences.   Our findings also revealed a negative correlation between IL-1 and DDB, which was particularly pronounced in patients with arteriosclerosis. These results suggest that the C to G sequence variant may act as a regulatory element influencing the expression or function of DDB, Rho GTPases, and IL-1. The complex network of interactions among these genes and variants may contribute to the pathogenesis of GI adverse experiences and arteriosclerosis in HBV and HIV co-infected individuals. Further studies are needed to elucidate the precise mechanisms underlying these associations.
95751519	0	23	HBV and HIV co-infected	DiseaseOrPhenotypicFeature	D006509
95751519	37	41	IL-1	GeneOrGeneProduct	111343
95751519	43	46	DDB	GeneOrGeneProduct	1639
95751519	48	59	Rho GTPases	GeneOrGeneProduct	387
95751519	65	71	C to G	SequenceVariant	c|SUB|C||G
95751519	108	130	GI adverse experiences	DiseaseOrPhenotypicFeature	D005767
95751519	159	182	HBV and HIV co-infected	DiseaseOrPhenotypicFeature	D006509
95751519	335	341	C to G	SequenceVariant	c|SUB|C||G
95751519	386	389	DDB	GeneOrGeneProduct	1639
95751519	394	405	Rho GTPases	GeneOrGeneProduct	387
95751519	538	544	C to G	SequenceVariant	c|SUB|C||G
95751519	591	595	IL-1	GeneOrGeneProduct	111343
95751519	698	701	DDB	GeneOrGeneProduct	1639
95751519	706	710	IL-1	GeneOrGeneProduct	111343
95751519	732	755	HBV and HIV co-infected	DiseaseOrPhenotypicFeature	D006509
95751519	783	805	GI adverse experiences	DiseaseOrPhenotypicFeature	D005767
95751519	851	862	Rho GTPases	GeneOrGeneProduct	387
95751519	867	870	DDB	GeneOrGeneProduct	1639
95751519	935	951	arteriosclerosis	DiseaseOrPhenotypicFeature	D001161
95751519	999	1010	Rho GTPases	GeneOrGeneProduct	387
95751519	1015	1019	IL-1	GeneOrGeneProduct	111343
95751519	1120	1142	GI adverse experiences	DiseaseOrPhenotypicFeature	D005767
95751519	1204	1208	IL-1	GeneOrGeneProduct	111343
95751519	1213	1216	DDB	GeneOrGeneProduct	1639
95751519	1269	1285	arteriosclerosis	DiseaseOrPhenotypicFeature	D001161
95751519	1318	1324	C to G	SequenceVariant	c|SUB|C||G
95751519	1416	1419	DDB	GeneOrGeneProduct	1639
95751519	1421	1432	Rho GTPases	GeneOrGeneProduct	387
95751519	1438	1442	IL-1	GeneOrGeneProduct	111343
95751519	1549	1571	GI adverse experiences	DiseaseOrPhenotypicFeature	D005767
95751519	1576	1592	arteriosclerosis	DiseaseOrPhenotypicFeature	D001161
95751519	1596	1619	HBV and HIV co-infected	DiseaseOrPhenotypicFeature	D006509
95751519	Association	c|SUB|C||G	1639	Novel
95751519	Association	c|SUB|C||G	387	Novel
95751519	Negative_Correlation	1639	111343	Novel
95751519	Association	c|SUB|C||G	111343	Novel
95751519	Negative_Correlation	387	1639	Novel
95751519	Negative_Correlation	111343	387	Novel
95751519	Negative_Correlation	387	111343	Novel
95751519	Negative_Correlation	111343	1639	Novel
95751519	Negative_Correlation	1639	387	Novel

55032326|t|Genetic and functional analysis of sequence variants in guinea-pigs and their impact on gene expression in LbetaT2, SNU-C2A, DU145, and KU7 ce
55032326|a|This study investigates the functional and genetic implications of sequence variants in guinea-pigs, focusing on their effects on gene expression in various cell lines. We analyzed the impact of the sequence variants 7488T/C, p.S216P, and g.3395C>T on the expression of genes such as dopamine beta-hydroxylase, CD72, and KCa3.1 in LbetaT2, SNU-C2A, DU145, and KU7 cell lines. The presence of these variants was associated with altered expression patterns, particularly in the context of interactions with other genes and chemical entities.   We observed a significant bind between IGFBP-3 and PKC, suggesting a potential regulatory role of IGFBP-3 in PKC signaling pathways. Additionally, a negative correlation was found between HSP82 and IGFBP-3, indicating a possible antagonistic relationship. The bind between KCa3.1 and endonuclease III was confirmed, highlighting a novel interaction that may influence cellular processes. A negative correlation between endonuclease III and dopamine beta-hydroxylase was also identified, suggesting a regulatory mechanism in metabolic pathways.   Furthermore, HSP82 was found to bind with endonuclease III, reinforcing the role of HSP82 in DNA repair and maintenance. The bind between dopamine beta-hydroxylase and CD72 was confirmed, and CD72 was shown to interact with KCa3.1, forming a potential signaling cascade. These findings were supported by experiments conducted in guinea-pigs and cell lines, with the chemical entities 5-hydroxyindoleacetic acid, sevoflurane, and VAL used to modulate gene expression and cellular responses. The study provides new insights into the genetic and functional relationships among these genes and their variants in guinea-pigs and cell lines.
55032326	56	67	guinea-pigs	OrganismTaxon	10141
55032326	107	114	LbetaT2	CellLine	CVCL_0398
55032326	116	123	SNU-C2A	CellLine	CVCL_1709
55032326	125	130	DU145	CellLine	CVCL_0105
55032326	136	139	KU7	CellLine	CVCL_4714
55032326	231	242	guinea-pigs	OrganismTaxon	10141
55032326	360	367	7488T/C	SequenceVariant	rs763780
55032326	369	376	p.S216P	SequenceVariant	p|SUB|S|216|P
55032326	382	391	g.3395C>T	SequenceVariant	g|SUB|C|3395|T
55032326	427	452	dopamine beta-hydroxylase	GeneOrGeneProduct	13166
55032326	454	458	CD72	GeneOrGeneProduct	12517
55032326	464	470	KCa3.1	GeneOrGeneProduct	16534
55032326	474	481	LbetaT2	CellLine	CVCL_0398
55032326	483	490	SNU-C2A	CellLine	CVCL_1709
55032326	492	497	DU145	CellLine	CVCL_0105
55032326	503	506	KU7	CellLine	CVCL_4714
55032326	724	731	IGFBP-3	GeneOrGeneProduct	3486
55032326	736	739	PKC	GeneOrGeneProduct	24681
55032326	783	790	IGFBP-3	GeneOrGeneProduct	3486
55032326	794	797	PKC	GeneOrGeneProduct	24681
55032326	873	878	HSP82	GeneOrGeneProduct	855836
55032326	883	890	IGFBP-3	GeneOrGeneProduct	3486
55032326	958	964	KCa3.1	GeneOrGeneProduct	16534
55032326	969	985	endonuclease III	GeneOrGeneProduct	4913
55032326	1104	1120	endonuclease III	GeneOrGeneProduct	4913
55032326	1125	1150	dopamine beta-hydroxylase	GeneOrGeneProduct	13166
55032326	1244	1249	HSP82	GeneOrGeneProduct	855836
55032326	1273	1289	endonuclease III	GeneOrGeneProduct	4913
55032326	1315	1320	HSP82	GeneOrGeneProduct	855836
55032326	1369	1394	dopamine beta-hydroxylase	GeneOrGeneProduct	13166
55032326	1399	1403	CD72	GeneOrGeneProduct	12517
55032326	1423	1427	CD72	GeneOrGeneProduct	12517
55032326	1455	1461	KCa3.1	GeneOrGeneProduct	16534
55032326	1560	1571	guinea-pigs	OrganismTaxon	10141
55032326	1615	1641	5-hydroxyindoleacetic acid	ChemicalEntity	D006897
55032326	1643	1654	sevoflurane	ChemicalEntity	C009250
55032326	1660	1663	VAL	ChemicalEntity	C081489
55032326	1839	1850	guinea-pigs	OrganismTaxon	10141
55032326	Bind	3486	24681	Novel
55032326	Negative_Correlation	855836	3486	Novel
55032326	Bind	16534	4913	Novel
55032326	Negative_Correlation	4913	13166	Novel
55032326	Bind	855836	4913	Novel
55032326	Bind	13166	12517	Novel
55032326	Bind	12517	16534	Novel

59984515|t|Genetic and metabolic interactions in prostate carcinogenesis: roles of g.2839T>G, ADP, CDG, and antiviral drugs in SCID-HuH-7 and HK2 ce
59984515|a|Prostate carcinogenesis is a complex process influenced by genetic, metabolic, and environmental factors. This study investigates the interplay between genetic variants, metabolic entities, and disease phenotypes in the context of prostate carcinogenesis. The sequence variant g.2839T>G was found to be positively correlated with prostate carcinogenesis in both SCID-HuH-7 and HK2 cell lines, suggesting a potential role in disease progression. Additionally, the association between g.2839T>G and CDG was observed, indicating a possible genetic link between these two conditions. ADP was shown to be associated with prostate carcinogenesis, and further analysis revealed a positive correlation between ADP and CDG, suggesting a shared metabolic pathway. Antiviral drugs were also found to be associated with prostate carcinogenesis, and their relationship with CDG was confirmed through multiple experimental approaches. The study utilized SCID-HuH-7 and HK2 cell lines to model these interactions, providing evidence for the complex network of relationships between genetic variants, metabolic entities, and disease phenotypes in prostate carcinogenesis. These findings highlight the importance of considering both genetic and metabolic factors in the development and progression of prostate cancer.
59984515	38	61	prostate carcinogenesis	DiseaseOrPhenotypicFeature	D011471
59984515	72	81	g.2839T>G	SequenceVariant	g|SUB|T|2839|G
59984515	83	86	ADP	ChemicalEntity	D000244
59984515	88	91	CDG	DiseaseOrPhenotypicFeature	D018981
59984515	97	112	antiviral drugs	ChemicalEntity	D000998
59984515	116	126	SCID-HuH-7	CellLine	CVCL_0336
59984515	131	134	HK2	CellLine	CVCL_0302
59984515	369	392	prostate carcinogenesis	DiseaseOrPhenotypicFeature	D011471
59984515	415	424	g.2839T>G	SequenceVariant	g|SUB|T|2839|G
59984515	468	491	prostate carcinogenesis	DiseaseOrPhenotypicFeature	D011471
59984515	500	510	SCID-HuH-7	CellLine	CVCL_0336
59984515	515	518	HK2	CellLine	CVCL_0302
59984515	621	630	g.2839T>G	SequenceVariant	g|SUB|T|2839|G
59984515	635	638	CDG	DiseaseOrPhenotypicFeature	D018981
59984515	718	721	ADP	ChemicalEntity	D000244
59984515	754	777	prostate carcinogenesis	DiseaseOrPhenotypicFeature	D011471
59984515	840	843	ADP	ChemicalEntity	D000244
59984515	848	851	CDG	DiseaseOrPhenotypicFeature	D018981
59984515	946	969	prostate carcinogenesis	DiseaseOrPhenotypicFeature	D011471
59984515	999	1002	CDG	DiseaseOrPhenotypicFeature	D018981
59984515	1078	1088	SCID-HuH-7	CellLine	CVCL_0336
59984515	1093	1096	HK2	CellLine	CVCL_0302
59984515	1269	1292	prostate carcinogenesis	DiseaseOrPhenotypicFeature	D011471
59984515	Association	D000244	D011471	Novel
59984515	Positive_Correlation	D011471	g|SUB|T|2839|G	Novel
59984515	Association	D018981	g|SUB|T|2839|G	Novel
59984515	Association	D000998	D011471	Novel
59984515	Association	D011471	g|SUB|T|2839|G	Novel
59984515	Association	D000244	D018981	Novel
59984515	Association	D000998	D018981	Novel
59984515	Positive_Correlation	D018981	g|SUB|T|2839|G	Novel

66601400|t|Genetic and pharmacological insights into the role of 5-HT(6) receptor antagonists, sequence variants, and metabolic syndrome in disease path
66601400|a|This study investigates the complex interplay between genetic variants, pharmacological agents, and metabolic disorders in the context of disease mechanisms. We focus on the association between the sequence variant +8365 C/T and metabolic syndrome, which was found to significantly increase the risk of developing metabolic syndrome in a cohort of patients with a family history of metabolic disorders. Additionally, the sequence variant +8365 C/T was also linked to meningitis and joint pain, suggesting a broader role in inflammatory and metabolic pathways.   The chemical entity Nimesulide was shown to modulate the expression of the +8365 C/T variant, potentially influencing its pathogenic effects. Furthermore, the association between 5-HT(6) receptor antagonists and the sequence variant I238M was explored, revealing that these drugs may alter the functional consequences of I238M in cellular models. Using the Ba/F3 cell line, we demonstrated that 5-HT(6) receptor antagonists can modulate the activity of the I238M variant, which is associated with altered signaling in metabolic pathways.  In addition, the study examined the role of the sequence variant 'aspartic acid to histidine substitution at amino acid position 401' in the context of cystic fibrosis, where it was found to contribute to disease severity. The cell line H9c2 was used to model the effects of this variant on cellular function, while the cell line Hs578T was employed to study the interaction between the sequence variant +8365 C/T and the disease OMIM 605839.   The chemical entity Re was also evaluated for its potential to influence the expression of the sequence variant +8365 C/T, with preliminary results suggesting a possible regulatory role. Finally, the study highlights the importance of understanding the genetic and pharmacological factors that contribute to the development of metabolic syndrome, joint pain, and radiculopathy, with implications for personalized medicine and therapeutic strategies.
66601400	54	82	5-HT(6) receptor antagonists	ChemicalEntity	D012702
66601400	107	125	metabolic syndrome	DiseaseOrPhenotypicFeature	D008659
66601400	357	366	+8365 C/T	SequenceVariant	c|SUB|C|+8365|T
66601400	371	389	metabolic syndrome	DiseaseOrPhenotypicFeature	D008659
66601400	456	474	metabolic syndrome	DiseaseOrPhenotypicFeature	D008659
66601400	580	589	+8365 C/T	SequenceVariant	c|SUB|C|+8365|T
66601400	609	619	meningitis	DiseaseOrPhenotypicFeature	D008581
66601400	624	634	joint pain	DiseaseOrPhenotypicFeature	D018771
66601400	724	734	Nimesulide	ChemicalEntity	C012655
66601400	779	788	+8365 C/T	SequenceVariant	c|SUB|C|+8365|T
66601400	883	911	5-HT(6) receptor antagonists	ChemicalEntity	D012702
66601400	937	942	I238M	SequenceVariant	rs34242818
66601400	1025	1030	I238M	SequenceVariant	rs34242818
66601400	1061	1066	Ba/F3	CellLine	CVCL_0161
66601400	1099	1127	5-HT(6) receptor antagonists	ChemicalEntity	D012702
66601400	1161	1166	I238M	SequenceVariant	rs34242818
66601400	1309	1375	aspartic acid to histidine substitution at amino acid position 401	SequenceVariant	p|SUB|D|401|H
66601400	1395	1410	cystic fibrosis	DiseaseOrPhenotypicFeature	D003550
66601400	1480	1484	H9c2	CellLine	CVCL_0286
66601400	1573	1579	Hs578T	CellLine	CVCL_0332
66601400	1647	1656	+8365 C/T	SequenceVariant	c|SUB|C|+8365|T
66601400	1673	1684	OMIM 605839	DiseaseOrPhenotypicFeature	C535516
66601400	1708	1710	Re	ChemicalEntity	C049864
66601400	1800	1809	+8365 C/T	SequenceVariant	c|SUB|C|+8365|T
66601400	2015	2033	metabolic syndrome	DiseaseOrPhenotypicFeature	D008659
66601400	2035	2045	joint pain	DiseaseOrPhenotypicFeature	D018771
66601400	2051	2064	radiculopathy	DiseaseOrPhenotypicFeature	D011843
66601400	Association	c|SUB|C|+8365|T	D008659	Novel
66601400	Association	C012655	c|SUB|C|+8365|T	Novel
66601400	Association	D012702	rs34242818	Novel
66601400	Association	c|SUB|C|+8365|T	D008581	Novel
66601400	Association	c|SUB|C|+8365|T	D018771	Novel

98841868|t|Curcumin and anabolic androgenic steroid interactions in B-cell non-Hodgkin lymphoma, breast-ovarian cancer, and growth failure: a multi-cell li
98841868|a|This study investigates the complex interactions between the chemical entity Curcumin and the anabolic androgenic steroid in the context of B-cell non-Hodgkin lymphoma, breast-ovarian cancer, and growth failure across multiple cell lines, including yeast, hRPTEC, Capan1, SNU-C2A, C4-2B, and SJ-GBM2. Our findings reveal a significant association between Curcumin and B-cell non-Hodgkin lymphoma, with a positive correlation observed between Curcumin and the disease. Additionally, we demonstrate a positive correlation between B-cell non-Hodgkin lymphoma and the anabolic androgenic steroid, suggesting a potential synergistic or antagonistic relationship.   The study also identifies a drug interaction between Curcumin and the anabolic androgenic steroid, which may have implications for therapeutic strategies. Furthermore, we observe an association between the anabolic androgenic steroid and growth failure, as well as a positive correlation between Curcumin and growth failure. These results are supported by experimental data from yeast and human cell lines, including hRPTEC, Capan1, SNU-C2A, C4-2B, and SJ-GBM2.   Notably, Curcumin also shows a significant association with breast-ovarian cancer, and the disease is positively correlated with Curcumin. The findings highlight the potential of Curcumin as a therapeutic agent in the treatment of B-cell non-Hodgkin lymphoma and breast-ovarian cancer, while also emphasizing the need for further research into its interactions with anabolic androgenic steroids in the context of growth failure. The results provide a foundation for future studies exploring the molecular mechanisms underlying these associations.
98841868	0	8	Curcumin	ChemicalEntity	D003474
98841868	13	40	anabolic androgenic steroid	ChemicalEntity	D045165
98841868	57	84	B-cell non-Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D016393
98841868	86	107	breast-ovarian cancer	DiseaseOrPhenotypicFeature	D061325
98841868	113	127	growth failure	DiseaseOrPhenotypicFeature	D006130
98841868	222	230	Curcumin	ChemicalEntity	D003474
98841868	239	266	anabolic androgenic steroid	ChemicalEntity	D045165
98841868	285	312	B-cell non-Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D016393
98841868	314	335	breast-ovarian cancer	DiseaseOrPhenotypicFeature	D061325
98841868	341	355	growth failure	DiseaseOrPhenotypicFeature	D006130
98841868	394	399	yeast	OrganismTaxon	4932
98841868	401	407	hRPTEC	CellLine	CVCL_K278
98841868	409	415	Capan1	CellLine	CVCL_0237
98841868	417	424	SNU-C2A	CellLine	CVCL_1709
98841868	426	431	C4-2B	CellLine	CVCL_4784
98841868	437	444	SJ-GBM2	CellLine	CVCL_M141
98841868	500	508	Curcumin	ChemicalEntity	D003474
98841868	513	540	B-cell non-Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D016393
98841868	587	595	Curcumin	ChemicalEntity	D003474
98841868	673	700	B-cell non-Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D016393
98841868	709	736	anabolic androgenic steroid	ChemicalEntity	D045165
98841868	858	866	Curcumin	ChemicalEntity	D003474
98841868	875	902	anabolic androgenic steroid	ChemicalEntity	D045165
98841868	1011	1038	anabolic androgenic steroid	ChemicalEntity	D045165
98841868	1043	1057	growth failure	DiseaseOrPhenotypicFeature	D006130
98841868	1101	1109	Curcumin	ChemicalEntity	D003474
98841868	1114	1128	growth failure	DiseaseOrPhenotypicFeature	D006130
98841868	1184	1189	yeast	OrganismTaxon	4932
98841868	1222	1228	hRPTEC	CellLine	CVCL_K278
98841868	1230	1236	Capan1	CellLine	CVCL_0237
98841868	1238	1245	SNU-C2A	CellLine	CVCL_1709
98841868	1247	1252	C4-2B	CellLine	CVCL_4784
98841868	1258	1265	SJ-GBM2	CellLine	CVCL_M141
98841868	1278	1286	Curcumin	ChemicalEntity	D003474
98841868	1329	1350	breast-ovarian cancer	DiseaseOrPhenotypicFeature	D061325
98841868	1398	1406	Curcumin	ChemicalEntity	D003474
98841868	1448	1456	Curcumin	ChemicalEntity	D003474
98841868	1500	1527	B-cell non-Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D016393
98841868	1532	1553	breast-ovarian cancer	DiseaseOrPhenotypicFeature	D061325
98841868	1635	1662	anabolic androgenic steroid	ChemicalEntity	D045165
98841868	1682	1696	growth failure	DiseaseOrPhenotypicFeature	D006130
98841868	Association	D003474	D016393	Novel
98841868	Positive_Correlation	D016393	D045165	Novel
98841868	Positive_Correlation	D016393	D003474	Novel
98841868	Association	D003474	D061325	Novel
98841868	Positive_Correlation	D006130	D003474	Novel
98841868	Drug_Interaction	D045165	D003474	Novel
98841868	Association	D045165	D006130	Novel
98841868	Association	D003474	D006130	Novel
98841868	Association	D045165	D016393	Novel
98841868	Drug_Interaction	D003474	D045165	Novel

74952162|t|LDH and BLM interactions in cell lines: a comparative study of drug effects and cellular r
74952162|a|This study investigates the interactions between lactate dehydrogenase (LDH) and bleomycin (BLM) across multiple cell lines, with a focus on their association and potential drug interactions. The research highlights the role of LDH in mediating cellular responses to BLM treatment, particularly in COS-7, IEC-6, and C57BL/6J cells. The findings suggest a significant association between LDH activity and BLM-induced cytotoxicity, supporting the hypothesis that LDH may serve as a biomarker for BLM sensitivity.   In addition, the study compares the effects of buprenorphine and iron on cellular function, with particular emphasis on their impact on HeLa and H9c2 cells. The results indicate that buprenorphine exhibits a distinct pharmacological profile compared to iron, with implications for their use in therapeutic settings. Furthermore, the research explores the drug interaction between BLM and LDH, revealing that their combined presence alters metabolic pathways in Capan1 and H446 cells, potentially enhancing or mitigating the cytotoxic effects of BLM.  The study also includes a comparative analysis of BLM and buprenorphine in C57BL/6J and COS-7 cells, demonstrating that while both compounds affect cellular metabolism, their mechanisms of action differ significantly. The data suggest that BLM primarily targets DNA integrity, whereas buprenorphine influences intracellular signaling pathways.   Overall, the findings provide a comprehensive understanding of the interactions between LDH, BLM, buprenorphine, and iron, with implications for drug development and therapeutic strategies in cellular and clinical contexts. The results are supported by multiple experimental validations across the cell lines COS-7, IEC-6, C57BL/6J, and H446, with additional data from H9c2, HeLa, and Capan1 cells.
74952162	0	3	LDH	ChemicalEntity	D007770
74952162	8	11	BLM	ChemicalEntity	D001761
74952162	163	166	LDH	ChemicalEntity	D007770
74952162	183	186	BLM	ChemicalEntity	D001761
74952162	319	322	LDH	ChemicalEntity	D007770
74952162	358	361	BLM	ChemicalEntity	D001761
74952162	389	394	COS-7	CellLine	CVCL_0224
74952162	396	401	IEC-6	CellLine	CVCL_0343
74952162	407	415	C57BL/6J	CellLine	CVCL_5U84
74952162	478	481	LDH	ChemicalEntity	D007770
74952162	495	498	BLM	ChemicalEntity	D001761
74952162	552	555	LDH	ChemicalEntity	D007770
74952162	585	588	BLM	ChemicalEntity	D001761
74952162	651	664	buprenorphine	ChemicalEntity	D002047
74952162	669	673	iron	ChemicalEntity	D007501
74952162	740	744	HeLa	CellLine	CVCL_0030
74952162	749	753	H9c2	CellLine	CVCL_0286
74952162	787	800	buprenorphine	ChemicalEntity	D002047
74952162	857	861	iron	ChemicalEntity	D007501
74952162	984	987	BLM	ChemicalEntity	D001761
74952162	992	995	LDH	ChemicalEntity	D007770
74952162	1065	1071	Capan1	CellLine	CVCL_0237
74952162	1076	1080	H446	CellLine	CVCL_1562
74952162	1149	1152	BLM	ChemicalEntity	D001761
74952162	1205	1208	BLM	ChemicalEntity	D001761
74952162	1213	1226	buprenorphine	ChemicalEntity	D002047
74952162	1230	1238	C57BL/6J	CellLine	CVCL_5U84
74952162	1243	1248	COS-7	CellLine	CVCL_0224
74952162	1395	1398	BLM	ChemicalEntity	D001761
74952162	1440	1453	buprenorphine	ChemicalEntity	D002047
74952162	1589	1592	LDH	ChemicalEntity	D007770
74952162	1594	1597	BLM	ChemicalEntity	D001761
74952162	1599	1612	buprenorphine	ChemicalEntity	D002047
74952162	1618	1622	iron	ChemicalEntity	D007501
74952162	1810	1815	COS-7	CellLine	CVCL_0224
74952162	1817	1822	IEC-6	CellLine	CVCL_0343
74952162	1824	1832	C57BL/6J	CellLine	CVCL_5U84
74952162	1838	1842	H446	CellLine	CVCL_1562
74952162	1870	1874	H9c2	CellLine	CVCL_0286
74952162	1876	1880	HeLa	CellLine	CVCL_0030
74952162	1886	1892	Capan1	CellLine	CVCL_0237
74952162	Association	D007770	D001761	Novel
74952162	Comparison	D002047	D007501	Novel
74952162	Drug_Interaction	D001761	D007770	Novel
74952162	Comparison	D001761	D002047	Novel

29829874|t|Genetic variants S140G and c.474delA in HIV-1 and horses: associations with cholangiocarcinoma, calcification of ascending aorta, and achondroplasia in cell lines hRPTEC, Capan1, H446, an
29829874|a|This study investigates the genetic and phenotypic associations of two sequence variants, S140G and c.474delA, in the context of HIV-1 and horses, and their potential roles in the development of cholangiocarcinoma, calcification of ascending aorta, and achondroplasia. Using a combination of molecular and cellular approaches, we examined the effects of these variants in multiple cell lines, including hRPTEC, Capan1, H446, and HCT116. Our findings reveal a significant positive correlation between S140G and cholangiocarcinoma, with multiple instances of this association observed across different cell lines. Additionally, we found a strong association between S140G and calcification of ascending aorta, as well as a positive correlation between calcification of ascending aorta and S140G.   The variant c.474delA was also found to be associated with achondroplasia, and there is a positive correlation between c.474delA and both cholangiocarcinoma and calcification of ascending aorta. Furthermore, we observed a positive correlation between c.474delA and calcification of ascending aorta, reinforcing the potential role of this variant in the pathogenesis of these conditions. The study also highlights the presence of these variants in HIV-1 and horses, suggesting possible cross-species interactions or shared genetic mechanisms. These results provide important insights into the molecular basis of these diseases and may have implications for future therapeutic strategies targeting these genetic variants in both human and animal models.
29829874	17	22	S140G	SequenceVariant	p|SUB|S|140|G
29829874	27	36	c.474delA	SequenceVariant	rs587777017
29829874	40	45	HIV-1	OrganismTaxon	11676
29829874	50	56	horses	OrganismTaxon	9796
29829874	76	94	cholangiocarcinoma	DiseaseOrPhenotypicFeature	D018281
29829874	96	128	calcification of ascending aorta	DiseaseOrPhenotypicFeature	D001018
29829874	134	148	achondroplasia	DiseaseOrPhenotypicFeature	D000130
29829874	163	169	hRPTEC	CellLine	CVCL_K278
29829874	171	177	Capan1	CellLine	CVCL_0237
29829874	179	183	H446	CellLine	CVCL_1562
29829874	278	283	S140G	SequenceVariant	p|SUB|S|140|G
29829874	288	297	c.474delA	SequenceVariant	rs587777017
29829874	317	322	HIV-1	OrganismTaxon	11676
29829874	327	333	horses	OrganismTaxon	9796
29829874	383	401	cholangiocarcinoma	DiseaseOrPhenotypicFeature	D018281
29829874	403	435	calcification of ascending aorta	DiseaseOrPhenotypicFeature	D001018
29829874	441	455	achondroplasia	DiseaseOrPhenotypicFeature	D000130
29829874	591	597	hRPTEC	CellLine	CVCL_K278
29829874	599	605	Capan1	CellLine	CVCL_0237
29829874	607	611	H446	CellLine	CVCL_1562
29829874	617	623	HCT116	CellLine	CVCL_0291
29829874	688	693	S140G	SequenceVariant	p|SUB|S|140|G
29829874	698	716	cholangiocarcinoma	DiseaseOrPhenotypicFeature	D018281
29829874	852	857	S140G	SequenceVariant	p|SUB|S|140|G
29829874	862	894	calcification of ascending aorta	DiseaseOrPhenotypicFeature	D001018
29829874	938	970	calcification of ascending aorta	DiseaseOrPhenotypicFeature	D001018
29829874	975	980	S140G	SequenceVariant	p|SUB|S|140|G
29829874	996	1005	c.474delA	SequenceVariant	rs587777017
29829874	1043	1057	achondroplasia	DiseaseOrPhenotypicFeature	D000130
29829874	1103	1112	c.474delA	SequenceVariant	rs587777017
29829874	1122	1140	cholangiocarcinoma	DiseaseOrPhenotypicFeature	D018281
29829874	1145	1177	calcification of ascending aorta	DiseaseOrPhenotypicFeature	D001018
29829874	1235	1244	c.474delA	SequenceVariant	rs587777017
29829874	1249	1281	calcification of ascending aorta	DiseaseOrPhenotypicFeature	D001018
29829874	1431	1436	HIV-1	OrganismTaxon	11676
29829874	1441	1447	horses	OrganismTaxon	9796
29829874	Association	D000130	p|SUB|S|140|G	Novel
29829874	Positive_Correlation	p|SUB|S|140|G	D018281	Novel
29829874	Association	p|SUB|S|140|G	D001018	Novel
29829874	Association	D001018	p|SUB|S|140|G	Novel
29829874	Positive_Correlation	D000130	p|SUB|S|140|G	Novel
29829874	Positive_Correlation	D001018	rs587777017	Novel
29829874	Association	rs587777017	D000130	Novel
29829874	Association	rs587777017	D018281	Novel
29829874	Positive_Correlation	rs587777017	D018281	Novel
29829874	Positive_Correlation	rs587777017	D001018	Novel
29829874	Positive_Correlation	D001018	p|SUB|S|140|G	Novel
29829874	Association	rs587777017	D001018	Novel
29829874	Association	p|SUB|S|140|G	D018281	Novel

25405696|t|Chick-derived PA-1 cells and the impact of palmitic acid on 19-base pair deletion variants in chick dev
25405696|a|This study investigates the effects of palmitic acid on chick-derived PA-1 cells, with a focus on the role of 19-base pair deletion variants in modulating cellular responses. Chick-derived PA-1 cells were exposed to varying concentrations of palmitic acid, and the expression of genes associated with the 19-base pair deletion variant was monitored. The results indicate that palmitic acid significantly alters the expression patterns of genes linked to the 19-base pair deletion in chick cells. Furthermore, the presence of the 19-base pair deletion in chick-derived PA-1 cells was found to influence the metabolic response to palmitic acid. These findings suggest that the 19-base pair deletion may play a critical role in the cellular adaptation of chick-derived PA-1 cells to palmitic acid exposure. The study also highlights the importance of understanding the interplay between palmitic acid and genetic variants in chick models for elucidating the molecular mechanisms underlying lipid metabolism and cellular function.
25405696	14	18	PA-1	CellLine	CVCL_0479
25405696	43	56	palmitic acid	ChemicalEntity	D019308
25405696	60	81	19-base pair deletion	SequenceVariant	c|DEL||19
25405696	94	99	chick	OrganismTaxon	9031
25405696	143	156	palmitic acid	ChemicalEntity	D019308
25405696	160	165	chick	OrganismTaxon	9031
25405696	174	178	PA-1	CellLine	CVCL_0479
25405696	214	235	19-base pair deletion	SequenceVariant	c|DEL||19
25405696	293	297	PA-1	CellLine	CVCL_0479
25405696	346	359	palmitic acid	ChemicalEntity	D019308
25405696	409	430	19-base pair deletion	SequenceVariant	c|DEL||19
25405696	480	493	palmitic acid	ChemicalEntity	D019308
25405696	562	583	19-base pair deletion	SequenceVariant	c|DEL||19
25405696	587	592	chick	OrganismTaxon	9031
25405696	633	654	19-base pair deletion	SequenceVariant	c|DEL||19
25405696	658	663	chick	OrganismTaxon	9031
25405696	672	676	PA-1	CellLine	CVCL_0479
25405696	732	745	palmitic acid	ChemicalEntity	D019308
25405696	779	800	19-base pair deletion	SequenceVariant	c|DEL||19
25405696	856	861	chick	OrganismTaxon	9031
25405696	870	874	PA-1	CellLine	CVCL_0479
25405696	884	897	palmitic acid	ChemicalEntity	D019308
25405696	988	1001	palmitic acid	ChemicalEntity	D019308
25405696	1026	1031	chick	OrganismTaxon	9031

25380016|t|Genetic and molecular associations between sequence variants, gene products, and multiple disease phenotypes in Rats and
25380016|a|This study investigates the complex genetic and molecular relationships between sequence variants, gene products, and a range of disease phenotypes in both Rats and HIV 1/2. A key focus is the sequence variant rs12910509, which is associated with erythema, suggesting a potential role in inflammatory responses. The gene product GPCR is found to be associated with congenital disorder of glycosylation-Ic and polyuria, highlighting its involvement in metabolic and developmental pathways. Additionally, GPCR shows a positive correlation with congenital disorder of glycosylation-Ic, reinforcing its functional relevance in this condition.   The gene product laminin exhibits multiple positive correlations, including with GPCR, erythema, polyuria, Leiomyoma, and Alzheimer's disease. These findings suggest that laminin may play a central role in tissue remodeling and disease progression. Furthermore, laminin is positively correlated with Leiomyoma, indicating a potential link between extracellular matrix components and tumor development.   The sequence variant V876E is associated with both thrombocytopenia and cystic fibrosis, suggesting a possible mechanism by which this variant influences platelet function and epithelial integrity. CD44 is positively correlated with thrombocytopenia and is also associated with cystic fibrosis, indicating a potential role in immune and epithelial responses.   In Rats, the associations between these genetic and molecular elements provide insights into the pathophysiology of multiple diseases, including congenital disorders, inflammatory conditions, and neurodegenerative diseases. The study also highlights the importance of considering both genetic and environmental factors in understanding the complex interplay between gene products and disease phenotypes in HIV 1/2. These findings contribute to the growing body of evidence supporting the use of genetic and molecular approaches in the diagnosis and treatment of complex diseases.
25380016	112	116	Rats	OrganismTaxon	10116
25380016	277	281	Rats	OrganismTaxon	10116
25380016	286	293	HIV 1/2	OrganismTaxon	11676
25380016	331	341	rs12910509	SequenceVariant	rs12910509
25380016	368	376	erythema	DiseaseOrPhenotypicFeature	D004890
25380016	450	454	GPCR	GeneOrGeneProduct	295589
25380016	486	525	congenital disorder of glycosylation-Ic	DiseaseOrPhenotypicFeature	C535741
25380016	530	538	polyuria	DiseaseOrPhenotypicFeature	D011141
25380016	624	628	GPCR	GeneOrGeneProduct	295589
25380016	663	702	congenital disorder of glycosylation-Ic	DiseaseOrPhenotypicFeature	C535741
25380016	779	786	laminin	GeneOrGeneProduct	16777
25380016	843	847	GPCR	GeneOrGeneProduct	295589
25380016	849	857	erythema	DiseaseOrPhenotypicFeature	D004890
25380016	859	867	polyuria	DiseaseOrPhenotypicFeature	D011141
25380016	869	878	Leiomyoma	DiseaseOrPhenotypicFeature	D007889
25380016	884	903	Alzheimer's disease	DiseaseOrPhenotypicFeature	D000544
25380016	933	940	laminin	GeneOrGeneProduct	16777
25380016	1024	1031	laminin	GeneOrGeneProduct	16777
25380016	1062	1071	Leiomyoma	DiseaseOrPhenotypicFeature	D007889
25380016	1187	1192	V876E	SequenceVariant	rs267606698
25380016	1217	1233	thrombocytopenia	DiseaseOrPhenotypicFeature	D013921
25380016	1238	1253	cystic fibrosis	DiseaseOrPhenotypicFeature	D003550
25380016	1364	1368	CD44	GeneOrGeneProduct	960
25380016	1399	1415	thrombocytopenia	DiseaseOrPhenotypicFeature	D013921
25380016	1444	1459	cystic fibrosis	DiseaseOrPhenotypicFeature	D003550
25380016	1530	1534	Rats	OrganismTaxon	10116
25380016	1933	1940	HIV 1/2	OrganismTaxon	11676
25380016	Positive_Correlation	960	D013921	Novel
25380016	Association	295589	C535741	Novel
25380016	Positive_Correlation	16777	295589	Novel
25380016	Association	960	D013921	Novel
25380016	Positive_Correlation	16777	C535741	Novel
25380016	Association	295589	D011141	Novel
25380016	Positive_Correlation	16777	D004890	Novel
25380016	Association	D013921	rs267606698	Novel
25380016	Positive_Correlation	295589	C535741	Novel
25380016	Association	D003550	rs267606698	Novel
25380016	Positive_Correlation	16777	D011141	Novel
25380016	Association	16777	D000544	Novel
25380016	Positive_Correlation	16777	D007889	Novel
25380016	Association	960	D003550	Novel
25380016	Association	D004890	rs12910509	Novel

04513772|t|miR-141 regulation in LbetaT2 and MCF7/AdrR cells: implications for ginseng-derived sequence 
04513772|a|Recent studies have highlighted the critical role of miR-141 in modulating gene expression in various cell types, including the LbetaT2 and MCF7/AdrR cell lines. This study investigates the functional impact of miR-141 on cellular processes in these cell lines, with a particular focus on its interaction with ginseng-derived sequence variants. The sequence variant p.G204VfsX28, which has been previously associated with altered protein function, was found to significantly influence miR-141 expression levels in both LbetaT2 and MCF7/AdrR cells.   Using a combination of RNA sequencing and quantitative PCR, we observed that miR-141 expression was consistently upregulated in the presence of the p.G204VfsX28 variant in both cell lines. This effect was further validated through luciferase reporter assays, which demonstrated that the variant enhances the binding affinity of miR-141 to its target sites. Additionally, the study revealed that miR-141 plays a key role in regulating the expression of genes involved in cell proliferation and differentiation, particularly in the context of ginseng-derived compounds.  The findings suggest that the interplay between miR-141 and the p.G204VfsX28 variant may have significant implications for the therapeutic potential of ginseng in modulating cellular responses. Given the high frequency of miR-141 and the sequence variant in both LbetaT2 and MCF7/AdrR cells, further research is warranted to explore the broader biological and clinical relevance of these interactions in the context of ginseng-based treatments.
04513772	0	7	miR-141	GeneOrGeneProduct	387159
04513772	22	29	LbetaT2	CellLine	CVCL_0398
04513772	34	43	MCF7/AdrR	CellLine	 CVCL_1452
04513772	68	75	ginseng	OrganismTaxon	4054
04513772	147	154	miR-141	GeneOrGeneProduct	387159
04513772	222	229	LbetaT2	CellLine	CVCL_0398
04513772	234	243	MCF7/AdrR	CellLine	 CVCL_1452
04513772	305	312	miR-141	GeneOrGeneProduct	387159
04513772	404	411	ginseng	OrganismTaxon	4054
04513772	460	472	p.G204VfsX28	SequenceVariant	p|FS|G|204|V|28
04513772	579	586	miR-141	GeneOrGeneProduct	387159
04513772	613	620	LbetaT2	CellLine	CVCL_0398
04513772	625	634	MCF7/AdrR	CellLine	 CVCL_1452
04513772	721	728	miR-141	GeneOrGeneProduct	387159
04513772	792	804	p.G204VfsX28	SequenceVariant	p|FS|G|204|V|28
04513772	972	979	miR-141	GeneOrGeneProduct	387159
04513772	1039	1046	miR-141	GeneOrGeneProduct	387159
04513772	1185	1192	ginseng	OrganismTaxon	4054
04513772	1261	1268	miR-141	GeneOrGeneProduct	387159
04513772	1277	1289	p.G204VfsX28	SequenceVariant	p|FS|G|204|V|28
04513772	1365	1372	ginseng	OrganismTaxon	4054
04513772	1435	1442	miR-141	GeneOrGeneProduct	387159
04513772	1476	1483	LbetaT2	CellLine	CVCL_0398
04513772	1488	1497	MCF7/AdrR	CellLine	 CVCL_1452
04513772	1632	1639	ginseng	OrganismTaxon	4054

90702758|t|Genetic and metabolic interactions of rs7802, Bmp7, and HMGB1 in Keloid disease: a study in women, chicks, a
90702758|a|This study investigates the complex genetic and metabolic interactions between the sequence variant rs7802, the gene Bmp7, the gene HMGB1, and the chemical entities insulin, urethane, mannose, and Ro4368554 in the context of Keloid disease. The research was conducted in women, chicks, and rDEN2, with a focus on understanding how these factors influence disease progression and metabolic responses.   The findings reveal a negative correlation between Ro4368554 and urethane, as well as between urethane and mannose. Urethane and insulin were found to be cotreated, and there is a negative correlation between mannose and Ro4368554. Conversely, a positive correlation was observed between urethane and Ro4368554. The cotreatment of urethane and mannose, along with the cotreatment of mannose and insulin, suggests a complex interplay between these chemical entities.   A negative correlation was also noted between insulin and urethane, while a positive correlation was found between insulin and urethane. The cotreatment of insulin and mannose further supports the metabolic interactions among these compounds. Additionally, the association between rs7802 and urethane, as well as between rs7802 and mannose, highlights the genetic underpinnings of these interactions.   The study also found a positive correlation between Ro4368554 and mannose, and a negative correlation between Ro4368554 and insulin. These results suggest that the sequence variant rs7802 may play a role in modulating the expression of Bmp7 and HMGB1, which are implicated in Keloid disease. The cotreatment of Ro4368554 and mannose, along with the positive correlation between Ro4368554 and insulin, further underscores the intricate network of interactions among these factors.   Overall, the study provides evidence for the involvement of rs7802, Bmp7, HMGB1, and the chemical entities insulin, urethane, mannose, and Ro4368554 in the pathogenesis of Keloid disease, particularly in women, chicks, and rDEN2. These findings may have implications for the development of targeted therapeutic strategies in the management of this condition.
90702758	38	44	rs7802	SequenceVariant	rs7802
90702758	46	50	Bmp7	GeneOrGeneProduct	12162
90702758	56	61	HMGB1	GeneOrGeneProduct	3146
90702758	65	79	Keloid disease	DiseaseOrPhenotypicFeature	D007627
90702758	92	97	women	OrganismTaxon	9606
90702758	99	104	chick	OrganismTaxon	9031
90702758	209	215	rs7802	SequenceVariant	rs7802
90702758	226	230	Bmp7	GeneOrGeneProduct	12162
90702758	241	246	HMGB1	GeneOrGeneProduct	3146
90702758	274	281	insulin	ChemicalEntity	D007328
90702758	283	291	urethane	ChemicalEntity	D014520
90702758	293	300	mannose	ChemicalEntity	D008358
90702758	306	315	Ro4368554	ChemicalEntity	C507242
90702758	334	348	Keloid disease	DiseaseOrPhenotypicFeature	D007627
90702758	380	385	women	OrganismTaxon	9606
90702758	387	392	chick	OrganismTaxon	9031
90702758	399	404	rDEN2	OrganismTaxon	11060
90702758	562	571	Ro4368554	ChemicalEntity	C507242
90702758	576	584	urethane	ChemicalEntity	D014520
90702758	605	613	urethane	ChemicalEntity	D014520
90702758	618	625	mannose	ChemicalEntity	D008358
90702758	640	647	insulin	ChemicalEntity	D007328
90702758	720	727	mannose	ChemicalEntity	D008358
90702758	732	741	Ro4368554	ChemicalEntity	C507242
90702758	799	807	urethane	ChemicalEntity	D014520
90702758	812	821	Ro4368554	ChemicalEntity	C507242
90702758	842	850	urethane	ChemicalEntity	D014520
90702758	855	862	mannose	ChemicalEntity	D008358
90702758	894	901	mannose	ChemicalEntity	D008358
90702758	906	913	insulin	ChemicalEntity	D007328
90702758	1025	1032	insulin	ChemicalEntity	D007328
90702758	1037	1045	urethane	ChemicalEntity	D014520
90702758	1094	1101	insulin	ChemicalEntity	D007328
90702758	1106	1114	urethane	ChemicalEntity	D014520
90702758	1135	1142	insulin	ChemicalEntity	D007328
90702758	1147	1154	mannose	ChemicalEntity	D008358
90702758	1260	1266	rs7802	SequenceVariant	rs7802
90702758	1271	1279	urethane	ChemicalEntity	D014520
90702758	1300	1306	rs7802	SequenceVariant	rs7802
90702758	1311	1318	mannose	ChemicalEntity	D008358
90702758	1434	1443	Ro4368554	ChemicalEntity	C507242
90702758	1448	1455	mannose	ChemicalEntity	D008358
90702758	1492	1501	Ro4368554	ChemicalEntity	C507242
90702758	1506	1513	insulin	ChemicalEntity	D007328
90702758	1563	1569	rs7802	SequenceVariant	rs7802
90702758	1618	1622	Bmp7	GeneOrGeneProduct	12162
90702758	1627	1632	HMGB1	GeneOrGeneProduct	3146
90702758	1658	1672	Keloid disease	DiseaseOrPhenotypicFeature	D007627
90702758	1693	1702	Ro4368554	ChemicalEntity	C507242
90702758	1707	1714	mannose	ChemicalEntity	D008358
90702758	1760	1769	Ro4368554	ChemicalEntity	C507242
90702758	1774	1781	insulin	ChemicalEntity	D007328
90702758	1924	1930	rs7802	SequenceVariant	rs7802
90702758	1932	1936	Bmp7	GeneOrGeneProduct	12162
90702758	1938	1943	HMGB1	GeneOrGeneProduct	3146
90702758	1971	1978	insulin	ChemicalEntity	D007328
90702758	1980	1988	urethane	ChemicalEntity	D014520
90702758	1990	1997	mannose	ChemicalEntity	D008358
90702758	2003	2012	Ro4368554	ChemicalEntity	C507242
90702758	2036	2050	Keloid disease	DiseaseOrPhenotypicFeature	D007627
90702758	2068	2073	women	OrganismTaxon	9606
90702758	2075	2080	chick	OrganismTaxon	9031
90702758	2087	2092	rDEN2	OrganismTaxon	11060
90702758	Negative_Correlation	C507242	D014520	Novel
90702758	Negative_Correlation	D014520	D008358	Novel
90702758	Cotreatment	D014520	D007328	Novel
90702758	Negative_Correlation	D008358	C507242	Novel
90702758	Positive_Correlation	D014520	C507242	Novel
90702758	Cotreatment	D008358	D007328	Novel
90702758	Negative_Correlation	D008358	D014520	Novel
90702758	Negative_Correlation	D007328	D014520	Novel
90702758	Positive_Correlation	D007328	D014520	Novel
90702758	Cotreatment	D007328	D008358	Novel
90702758	Association	rs7802	D014520	Novel
90702758	Cotreatment	D008358	D014520	Novel
90702758	Positive_Correlation	C507242	D008358	Novel
90702758	Negative_Correlation	C507242	D008358	Novel
90702758	Negative_Correlation	D014520	C507242	Novel
90702758	Association	rs7802	C507242	Novel
90702758	Association	rs7802	D008358	Novel
90702758	Positive_Correlation	C507242	D007328	Novel
90702758	Negative_Correlation	D014520	D007328	Novel
90702758	Cotreatment	D014520	D008358	Novel
90702758	Cotreatment	D008358	C507242	Novel
90702758	Negative_Correlation	D007328	C507242	Novel
90702758	Positive_Correlation	D014520	D007328	Novel
90702758	Negative_Correlation	C507242	D007328	Novel
90702758	Cotreatment	C507242	D008358	Novel
90702758	Positive_Correlation	D008358	D007328	Novel
90702758	Positive_Correlation	D008358	C507242	Novel
90702758	Positive_Correlation	D014520	D008358	Novel
90702758	Negative_Correlation	D008358	D007328	Novel
90702758	Positive_Correlation	D008358	D014520	Novel

06352967|t|Alpha-lipoic acid and DMSO modulate TNFRSF6 and STAT3 expression in rDEN2-infected HEK cells: implications for thrombotic microangiopathy and ApoE re
06352967|a|Recent studies have highlighted the potential therapeutic role of Alpha-lipoic acid and DMSO in modulating cellular responses to viral infections and inflammatory conditions. In this study, we investigated the effects of Alpha-lipoic acid and DMSO on the expression of key genes involved in immune signaling and apoptosis, including TNFRSF6 and STAT3, in rDEN2-infected HEK cells. Our findings reveal a positive correlation between Alpha-lipoic acid and TNFRSF6 expression, suggesting a potential mechanism by which this compound may enhance immune responses against viral pathogens. Additionally, we observed a positive correlation between DMSO and STAT3 activation, indicating that DMSO may serve as a modulator of inflammatory pathways. These results were further validated using thrombotic microangiopathy as a model disease, where both Alpha-lipoic acid and DMSO showed protective effects. Notably, the expression of ApoE, a critical regulator of lipid metabolism and vascular function, was significantly altered in response to these compounds, suggesting a potential link between ApoE dysregulation and the pathogenesis of thrombotic microangiopathy. Our findings provide new insights into the molecular mechanisms underlying the therapeutic potential of Alpha-lipoic acid and DMSO in the context of viral infections and inflammatory diseases.
06352967	0	17	Alpha-lipoic acid	ChemicalEntity	D008063
06352967	22	26	DMSO	ChemicalEntity	D004121
06352967	36	43	TNFRSF6	GeneOrGeneProduct	355
06352967	48	53	STAT3	GeneOrGeneProduct	6774
06352967	68	73	rDEN2	OrganismTaxon	11060
06352967	83	86	HEK	CellLine	CVCL_M624
06352967	111	137	thrombotic microangiopathy	DiseaseOrPhenotypicFeature	D057049
06352967	142	146	ApoE	GeneOrGeneProduct	348
06352967	216	233	Alpha-lipoic acid	ChemicalEntity	D008063
06352967	238	242	DMSO	ChemicalEntity	D004121
06352967	371	388	Alpha-lipoic acid	ChemicalEntity	D008063
06352967	393	397	DMSO	ChemicalEntity	D004121
06352967	483	490	TNFRSF6	GeneOrGeneProduct	355
06352967	495	500	STAT3	GeneOrGeneProduct	6774
06352967	505	510	rDEN2	OrganismTaxon	11060
06352967	520	523	HEK	CellLine	CVCL_M624
06352967	582	599	Alpha-lipoic acid	ChemicalEntity	D008063
06352967	604	611	TNFRSF6	GeneOrGeneProduct	355
06352967	791	795	DMSO	ChemicalEntity	D004121
06352967	800	805	STAT3	GeneOrGeneProduct	6774
06352967	834	838	DMSO	ChemicalEntity	D004121
06352967	933	959	thrombotic microangiopathy	DiseaseOrPhenotypicFeature	D057049
06352967	991	1008	Alpha-lipoic acid	ChemicalEntity	D008063
06352967	1013	1017	DMSO	ChemicalEntity	D004121
06352967	1072	1076	ApoE	GeneOrGeneProduct	348
06352967	1236	1240	ApoE	GeneOrGeneProduct	348
06352967	1279	1305	thrombotic microangiopathy	DiseaseOrPhenotypicFeature	D057049
06352967	1411	1428	Alpha-lipoic acid	ChemicalEntity	D008063
06352967	1433	1437	DMSO	ChemicalEntity	D004121
06352967	Positive_Correlation	D008063	355	Novel
06352967	Positive_Correlation	D004121	6774	Novel

86777844|t|Estradiol-17beta-D-glucuronide and paroxetine interactions in dogs: genetic and metabolic correlations with rs1155794, rs2622604, an
86777844|a|This study investigates the complex interactions between estradiol-17beta-D-glucuronide and paroxetine in dogs, with a focus on their genetic and metabolic correlations. We observed a positive correlation between estradiol-17beta-D-glucuronide and paroxetine, suggesting a potential pharmacodynamic synergy. Additionally, we found a positive correlation between rs1155794 and estradiol-17beta-D-glucuronide, as well as between rs1155794 and paroxetine, indicating that this sequence variant may influence the metabolism or expression of genes involved in these compounds.   Further, a positive correlation was noted between rs2622604 and alpha-methyl-para-tyrosine, and between rs2622604 and estradiol-17beta-D-glucuronide, suggesting that this variant may play a role in modulating the metabolic pathways of these compounds. The 30delG variant showed a positive correlation with DFG and with estradiol-17beta-D-glucuronide, highlighting its potential involvement in the regulation of these molecules.   Moreover, we found a positive correlation between paroxetine and DFG, as well as between DFG and estradiol-17beta-D-glucuronide, indicating a possible network of interactions among these compounds. The alpha-methyl-para-tyrosine and DFG also showed a positive correlation, reinforcing the interconnectedness of these metabolic pathways.   Our findings were validated in a population of dogs, with additional analysis involving the organism taxon 'Mangifera indica Linn' to explore cross-species metabolic similarities. The study also included the organism taxon 'West Nile virus' to assess potential interactions with these compounds in viral contexts. The results provide a comprehensive understanding of the genetic and metabolic relationships among estradiol-17beta-D-glucuronide, paroxetine, and other related compounds in dogs, with implications for drug development and metabolic research.
86777844	35	45	paroxetine	ChemicalEntity	D017374
86777844	62	66	dogs	OrganismTaxon	9615
86777844	108	117	rs1155794	SequenceVariant	rs1155794
86777844	119	128	rs2622604	SequenceVariant	rs2622604
86777844	190	220	estradiol-17beta-D-glucuronide	ChemicalEntity	C025483
86777844	225	235	paroxetine	ChemicalEntity	D017374
86777844	239	243	dogs	OrganismTaxon	9615
86777844	346	376	estradiol-17beta-D-glucuronide	ChemicalEntity	C025483
86777844	381	391	paroxetine	ChemicalEntity	D017374
86777844	495	504	rs1155794	SequenceVariant	rs1155794
86777844	509	539	estradiol-17beta-D-glucuronide	ChemicalEntity	C025483
86777844	560	569	rs1155794	SequenceVariant	rs1155794
86777844	574	584	paroxetine	ChemicalEntity	D017374
86777844	757	766	rs2622604	SequenceVariant	rs2622604
86777844	771	797	alpha-methyl-para-tyrosine	ChemicalEntity	D019805
86777844	811	820	rs2622604	SequenceVariant	rs2622604
86777844	825	855	estradiol-17beta-D-glucuronide	ChemicalEntity	C025483
86777844	963	969	30delG	SequenceVariant	c|DEL|30|G
86777844	1013	1016	DFG	ChemicalEntity	C553185
86777844	1026	1056	estradiol-17beta-D-glucuronide	ChemicalEntity	C025483
86777844	1092	1095	men	OrganismTaxon	9606
86777844	1187	1197	paroxetine	ChemicalEntity	D017374
86777844	1202	1205	DFG	ChemicalEntity	C553185
86777844	1226	1229	DFG	ChemicalEntity	C553185
86777844	1234	1264	estradiol-17beta-D-glucuronide	ChemicalEntity	C025483
86777844	1339	1365	alpha-methyl-para-tyrosine	ChemicalEntity	D019805
86777844	1370	1373	DFG	ChemicalEntity	C553185
86777844	1523	1527	dogs	OrganismTaxon	9615
86777844	1584	1605	Mangifera indica Linn	OrganismTaxon	29780
86777844	1700	1715	West Nile virus	OrganismTaxon	11082
86777844	1889	1919	estradiol-17beta-D-glucuronide	ChemicalEntity	C025483
86777844	1921	1931	paroxetine	ChemicalEntity	D017374
86777844	1964	1968	dogs	OrganismTaxon	9615
86777844	2004	2007	men	OrganismTaxon	9606
86777844	Positive_Correlation	C025483	D017374	Novel
86777844	Positive_Correlation	rs2622604	D019805	Novel
86777844	Positive_Correlation	c|DEL|30|G	C553185	Novel
86777844	Positive_Correlation	rs1155794	C025483	Novel
86777844	Positive_Correlation	D017374	C025483	Novel
86777844	Positive_Correlation	D017374	C553185	Novel
86777844	Positive_Correlation	rs1155794	D017374	Novel
86777844	Positive_Correlation	C025483	D019805	Novel
86777844	Positive_Correlation	rs2622604	C553185	Novel
86777844	Positive_Correlation	c|DEL|30|G	C025483	Novel
86777844	Positive_Correlation	C025483	C553185	Novel
86777844	Positive_Correlation	C553185	C025483	Novel
86777844	Positive_Correlation	D019805	C553185	Novel
86777844	Positive_Correlation	rs2622604	C025483	Novel
86777844	Positive_Correlation	C553185	D017374	Novel

41346357|t|Genetic Variants and Phenotypic Associations in KU7 Cells and Multiple O
41346357|a|This study investigates the genetic and phenotypic associations between specific sequence variants and disease features across multiple organisms, including the cell line KU7 and the organism taxon rDEN2. The research focuses on the sequence variant Gln/Gln and its correlations with several disease phenotypes, including renal cell cancer, left ventricular hypertrophy, and nail dystrophy. Additionally, the sequence variant rs4704559 is examined for its associations with nail dystrophy, edema, and left ventricular hypertrophy.   The findings reveal a positive correlation between Gln/Gln and renal cell cancer, as well as a positive correlation between Gln/Gln and left ventricular hypertrophy. Furthermore, Gln/Gln is associated with nail dystrophy, and there is a positive correlation between rs4704559 and nail dystrophy. The study also identifies a negative correlation between rs4704559 and edema, and a positive correlation between rs4704559 and left ventricular hypertrophy.   In addition, the sequence variant Gln/Gln is associated with depressive symptoms, and there is a negative correlation between Gln/Gln and depressive features. The study also reports a positive correlation between Gln/Gln and edema. Notably, the sequence variant rs4704559 is negatively correlated with renal cell cancer, highlighting the complex interplay between genetic variants and disease phenotypes.   The research includes data from multiple organisms, including Platonia insignis Mart, horses, and chick, to explore the broader implications of these genetic associations. The results suggest that genetic variability may play a significant role in the development of various phenotypic features across different species, providing a foundation for further studies in genetic epidemiology and comparative genomics.
41346357	48	51	KU7	CellLine	CVCL_4714
41346357	244	247	KU7	CellLine	CVCL_4714
41346357	271	276	rDEN2	OrganismTaxon	11060
41346357	323	330	Gln/Gln	SequenceVariant	p|SUB|Q||Q
41346357	395	412	renal cell cancer	DiseaseOrPhenotypicFeature	D002292
41346357	414	442	left ventricular hypertrophy	DiseaseOrPhenotypicFeature	D017379
41346357	448	462	nail dystrophy	DiseaseOrPhenotypicFeature	D009260
41346357	499	508	rs4704559	SequenceVariant	rs4704559
41346357	547	561	nail dystrophy	DiseaseOrPhenotypicFeature	D009260
41346357	563	568	edema	DiseaseOrPhenotypicFeature	D004487
41346357	574	602	left ventricular hypertrophy	DiseaseOrPhenotypicFeature	D017379
41346357	657	664	Gln/Gln	SequenceVariant	p|SUB|Q||Q
41346357	669	686	renal cell cancer	DiseaseOrPhenotypicFeature	D002292
41346357	730	737	Gln/Gln	SequenceVariant	p|SUB|Q||Q
41346357	742	770	left ventricular hypertrophy	DiseaseOrPhenotypicFeature	D017379
41346357	785	792	Gln/Gln	SequenceVariant	p|SUB|Q||Q
41346357	812	826	nail dystrophy	DiseaseOrPhenotypicFeature	D009260
41346357	872	881	rs4704559	SequenceVariant	rs4704559
41346357	886	900	nail dystrophy	DiseaseOrPhenotypicFeature	D009260
41346357	959	968	rs4704559	SequenceVariant	rs4704559
41346357	973	978	edema	DiseaseOrPhenotypicFeature	D004487
41346357	1015	1024	rs4704559	SequenceVariant	rs4704559
41346357	1029	1057	left ventricular hypertrophy	DiseaseOrPhenotypicFeature	D017379
41346357	1095	1102	Gln/Gln	SequenceVariant	p|SUB|Q||Q
41346357	1122	1132	depressive	DiseaseOrPhenotypicFeature	D000275
41346357	1187	1194	Gln/Gln	SequenceVariant	p|SUB|Q||Q
41346357	1199	1209	depressive	DiseaseOrPhenotypicFeature	D000275
41346357	1274	1281	Gln/Gln	SequenceVariant	p|SUB|Q||Q
41346357	1286	1291	edema	DiseaseOrPhenotypicFeature	D004487
41346357	1323	1332	rs4704559	SequenceVariant	rs4704559
41346357	1363	1380	renal cell cancer	DiseaseOrPhenotypicFeature	D002292
41346357	1530	1552	Platonia insignis Mart	OrganismTaxon	198787
41346357	1554	1560	horses	OrganismTaxon	9796
41346357	1566	1571	chick	OrganismTaxon	9031
41346357	Positive_Correlation	rs4704559	D009260	Novel
41346357	Positive_Correlation	p|SUB|Q||Q	D002292	Novel
41346357	Association	D000275	p|SUB|Q||Q	Novel
41346357	Positive_Correlation	p|SUB|Q||Q	D017379	Novel
41346357	Negative_Correlation	p|SUB|Q||Q	D000275	Novel
41346357	Positive_Correlation	D004487	p|SUB|Q||Q	Novel
41346357	Negative_Correlation	rs4704559	D004487	Novel
41346357	Positive_Correlation	D017379	p|SUB|Q||Q	Novel
41346357	Association	p|SUB|Q||Q	D004487	Novel
41346357	Negative_Correlation	rs4704559	D002292	Novel
41346357	Association	p|SUB|Q||Q	D017379	Novel
41346357	Positive_Correlation	rs4704559	D017379	Novel
41346357	Association	D000275	rs4704559	Novel
41346357	Positive_Correlation	D002292	rs4704559	Novel

11039417|t|Gamma-H2AX expression dynamics in Zebrafish, chick, and West Nile virus-infected horses: implications for DNA damage response in SJ-GBM2, MC3T3-E1, and H446 ce
11039417|a|Gamma-H2AX, a critical marker of DNA double-strand breaks, was investigated in Zebrafish, chick, and West Nile virus-infected horses to understand its role in the DNA damage response. In Zebrafish embryos, gamma-H2AX phosphorylation was rapidly induced following ionizing radiation, indicating a conserved mechanism across vertebrates. Similar patterns were observed in chick embryos, where gamma-H2AX levels correlated with the extent of DNA damage. In West Nile virus-infected horses, gamma-H2AX expression was significantly elevated, suggesting a potential role in viral-induced genomic instability.    To further explore the cellular context of gamma-H2AX, we examined its expression in three distinct cell lines: SJ-GBM2, MC3T3-E1, and H446. In SJ-GBM2 glioblastoma cells, gamma-H2AX levels increased in response to oxidative stress, highlighting its involvement in cellular stress responses. MC3T3-E1 osteoblast-like cells showed a transient gamma-H2AX response to DNA damaging agents, which was followed by efficient DNA repair. In contrast, H446 neuroblastoma cells exhibited prolonged gamma-H2AX accumulation, suggesting a defect in DNA repair mechanisms.    These findings underscore the importance of gamma-H2AX in monitoring and responding to DNA damage across diverse organisms and cell types. The study provides insights into the molecular mechanisms underlying DNA damage response in Zebrafish, chick, and West Nile virus-infected horses, with implications for understanding cellular resilience and disease progression in these systems.
11039417	34	43	Zebrafish	OrganismTaxon	7955
11039417	45	50	chick	OrganismTaxon	9031
11039417	56	71	West Nile virus	OrganismTaxon	11082
11039417	81	87	horses	OrganismTaxon	9796
11039417	129	136	SJ-GBM2	CellLine	CVCL_M141
11039417	138	146	MC3T3-E1	CellLine	CVCL_0409
11039417	152	156	H446	CellLine	CVCL_1562
11039417	239	248	Zebrafish	OrganismTaxon	7955
11039417	250	255	chick	OrganismTaxon	9031
11039417	261	276	West Nile virus	OrganismTaxon	11082
11039417	286	292	horses	OrganismTaxon	9796
11039417	347	356	Zebrafish	OrganismTaxon	7955
11039417	366	376	gamma-H2AX	GeneOrGeneProduct	15270
11039417	530	535	chick	OrganismTaxon	9031
11039417	551	561	gamma-H2AX	GeneOrGeneProduct	15270
11039417	614	629	West Nile virus	OrganismTaxon	11082
11039417	639	645	horses	OrganismTaxon	9796
11039417	647	657	gamma-H2AX	GeneOrGeneProduct	15270
11039417	809	819	gamma-H2AX	GeneOrGeneProduct	15270
11039417	878	885	SJ-GBM2	CellLine	CVCL_M141
11039417	887	895	MC3T3-E1	CellLine	CVCL_0409
11039417	901	905	H446	CellLine	CVCL_1562
11039417	910	917	SJ-GBM2	CellLine	CVCL_M141
11039417	938	948	gamma-H2AX	GeneOrGeneProduct	15270
11039417	1058	1066	MC3T3-E1	CellLine	CVCL_0409
11039417	1108	1118	gamma-H2AX	GeneOrGeneProduct	15270
11039417	1209	1213	H446	CellLine	CVCL_1562
11039417	1254	1264	gamma-H2AX	GeneOrGeneProduct	15270
11039417	1372	1382	gamma-H2AX	GeneOrGeneProduct	15270
11039417	1559	1568	Zebrafish	OrganismTaxon	7955
11039417	1570	1575	chick	OrganismTaxon	9031
11039417	1581	1596	West Nile virus	OrganismTaxon	11082
11039417	1606	1612	horses	OrganismTaxon	9796

49056490|t|STAT3 and angiotensin II receptor type 1a in POAG: a novel pathway in glaucoma progression and its implications for B-cell non-Hodgkin 
49056490|a|Recent studies have highlighted the critical role of STAT3 in the pathogenesis of POAG, with a positive correlation observed between STAT3 expression and disease progression in the CA3 cell line. This correlation was further supported by in vitro experiments using the MC3T3-E1 cell line, where STAT3 activation was found to enhance the expression of angiotensin II receptor type 1a, a key mediator in the development of POAG. The positive correlation between angiotensin II receptor type 1a and POAG was confirmed through transcriptomic analysis of the COS-7 cell line, where increased levels of angiotensin II receptor type 1a were associated with elevated intraocular pressure and optic nerve damage.    In addition to its role in POAG, STAT3 has been implicated in the progression of B-cell non-Hodgkin lymphoma, with multiple studies showing that STAT3 overexpression in the CA3 cell line correlates with tumor aggressiveness and poor patient outcomes. The interaction between STAT3 and angiotensin II receptor type 1a was further explored in the context of congestive heart failure, where cholinesterase activity was found to be positively correlated with disease severity. This relationship was validated in the CA3 cell line, where increased cholinesterase levels were associated with impaired cardiac function and elevated markers of heart failure.    The study also examined the role of glycoproteins in the pathophysiology of ataxia, with four distinct subtypes of ataxia showing altered glycoprotein expression in the CA3 cell line. These findings suggest that glycoproteins may serve as potential biomarkers for ataxia subtypes. Furthermore, the presence of AIDS was noted in a subset of patients with POAG, where the disease was associated with increased STAT3 activity and altered cholinesterase levels.    Overall, these findings underscore the complex interplay between STAT3, angiotensin II receptor type 1a, and other molecular players in the development of POAG, B-cell non-Hodgkin lymphoma, and related conditions, providing new insights into potential therapeutic targets for these diseases.
49056490	0	5	STAT3	GeneOrGeneProduct	25125
49056490	10	41	angiotensin II receptor type 1a	GeneOrGeneProduct	24180
49056490	45	49	POAG	DiseaseOrPhenotypicFeature	D005902
49056490	189	194	STAT3	GeneOrGeneProduct	25125
49056490	218	222	POAG	DiseaseOrPhenotypicFeature	D005902
49056490	269	274	STAT3	GeneOrGeneProduct	25125
49056490	317	320	CA3	CellLine	CVCL_JW73
49056490	405	413	MC3T3-E1	CellLine	CVCL_0409
49056490	431	436	STAT3	GeneOrGeneProduct	25125
49056490	487	518	angiotensin II receptor type 1a	GeneOrGeneProduct	24180
49056490	557	561	POAG	DiseaseOrPhenotypicFeature	D005902
49056490	596	627	angiotensin II receptor type 1a	GeneOrGeneProduct	24180
49056490	632	636	POAG	DiseaseOrPhenotypicFeature	D005902
49056490	690	695	COS-7	CellLine	CVCL_0224
49056490	733	764	angiotensin II receptor type 1a	GeneOrGeneProduct	24180
49056490	870	874	POAG	DiseaseOrPhenotypicFeature	D005902
49056490	876	881	STAT3	GeneOrGeneProduct	25125
49056490	924	951	B-cell non-Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D016393
49056490	988	993	STAT3	GeneOrGeneProduct	25125
49056490	1016	1019	CA3	CellLine	CVCL_JW73
49056490	1118	1123	STAT3	GeneOrGeneProduct	25125
49056490	1128	1159	angiotensin II receptor type 1a	GeneOrGeneProduct	24180
49056490	1199	1223	congestive heart failure	DiseaseOrPhenotypicFeature	D006333
49056490	1231	1245	cholinesterase	GeneOrGeneProduct	12038
49056490	1355	1358	CA3	CellLine	CVCL_JW73
49056490	1386	1400	cholinesterase	GeneOrGeneProduct	12038
49056490	1533	1546	glycoproteins	GeneOrGeneProduct	2811
49056490	1573	1579	ataxia	DiseaseOrPhenotypicFeature	D001259
49056490	1612	1618	ataxia	DiseaseOrPhenotypicFeature	D001259
49056490	1666	1669	CA3	CellLine	CVCL_JW73
49056490	1709	1722	glycoproteins	GeneOrGeneProduct	2811
49056490	1761	1767	ataxia	DiseaseOrPhenotypicFeature	D001259
49056490	1807	1811	AIDS	DiseaseOrPhenotypicFeature	D000163
49056490	1851	1855	POAG	DiseaseOrPhenotypicFeature	D005902
49056490	1905	1910	STAT3	GeneOrGeneProduct	25125
49056490	1932	1946	cholinesterase	GeneOrGeneProduct	12038
49056490	2023	2028	STAT3	GeneOrGeneProduct	25125
49056490	2030	2061	angiotensin II receptor type 1a	GeneOrGeneProduct	24180
49056490	2113	2117	POAG	DiseaseOrPhenotypicFeature	D005902
49056490	2119	2146	B-cell non-Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D016393
49056490	Positive_Correlation	24180	D005902	Novel
49056490	Positive_Correlation	12038	D006333	Novel

10680271|t|Genetic and pharmacological interactions of VE-cadherin, TXN2, and levamisole in mouse mammary tumor virus-infected GT1
10680271|a|This study investigates the complex interactions between genetic variants, pharmacological agents, and cellular responses in GT1-1 cells infected with mouse mammary tumor virus. We focus on the sequence variant g.3512C>A and its association with the gene product VE-cadherin, as well as the impact of the variant R211H on the expression of TXN2. The role of levamisole in modulating these genetic and cellular processes is explored, with evidence of a positive correlation between VE-cadherin and levamisole, as well as between TXN2 and levamisole.    Our findings reveal that the sequence variant g.3512C>A is significantly associated with altered expression levels of VE-cadherin, which in turn influences the cellular response to levamisole. Additionally, the variant R211H is found to be linked to changes in the expression of TXN2, further supporting the positive correlation between TXN2 and levamisole. The study also demonstrates a negative correlation between 2,3,5-triphenyltetrazolium and NOS, suggesting that the presence of 2,3,5-triphenyltetrazolium may inhibit NOS activity.    Furthermore, we observe an association between NOS and p70s6k, indicating a potential regulatory pathway involving these two gene products. The effects of sugars on these interactions are also examined, with evidence suggesting that sugar metabolism may modulate the observed relationships. The results highlight the importance of genetic and pharmacological factors in the pathophysiology of mouse mammary tumor virus-infected GT1-1 cells, providing a foundation for future studies on the therapeutic potential of levamisole in modulating these interactions.
10680271	44	55	VE-cadherin	GeneOrGeneProduct	1003
10680271	57	61	TXN2	GeneOrGeneProduct	25828
10680271	67	77	levamisole	ChemicalEntity	D007978
10680271	81	106	mouse mammary tumor virus	OrganismTaxon	11757
10680271	245	250	GT1-1	CellLine	CVCL_6236
10680271	271	296	mouse mammary tumor virus	OrganismTaxon	11757
10680271	331	340	g.3512C>A	SequenceVariant	rs763572195
10680271	383	394	VE-cadherin	GeneOrGeneProduct	1003
10680271	433	438	R211H	SequenceVariant	p|SUB|R|211|H
10680271	460	464	TXN2	GeneOrGeneProduct	25828
10680271	478	488	levamisole	ChemicalEntity	D007978
10680271	601	612	VE-cadherin	GeneOrGeneProduct	1003
10680271	617	627	levamisole	ChemicalEntity	D007978
10680271	648	652	TXN2	GeneOrGeneProduct	25828
10680271	657	667	levamisole	ChemicalEntity	D007978
10680271	718	727	g.3512C>A	SequenceVariant	rs763572195
10680271	790	801	VE-cadherin	GeneOrGeneProduct	1003
10680271	853	863	levamisole	ChemicalEntity	D007978
10680271	891	896	R211H	SequenceVariant	p|SUB|R|211|H
10680271	951	955	TXN2	GeneOrGeneProduct	25828
10680271	1009	1013	TXN2	GeneOrGeneProduct	25828
10680271	1018	1028	levamisole	ChemicalEntity	D007978
10680271	1089	1115	2,3,5-triphenyltetrazolium	ChemicalEntity	C009591
10680271	1120	1123	NOS	GeneOrGeneProduct	24598
10680271	1157	1183	2,3,5-triphenyltetrazolium	ChemicalEntity	C009591
10680271	1196	1199	NOS	GeneOrGeneProduct	24598
10680271	1260	1263	NOS	GeneOrGeneProduct	24598
10680271	1268	1274	p70s6k	GeneOrGeneProduct	6198
10680271	1368	1374	sugars	ChemicalEntity	D000073893
10680271	1606	1631	mouse mammary tumor virus	OrganismTaxon	11757
10680271	1641	1646	GT1-1	CellLine	CVCL_6236
10680271	1728	1738	levamisole	ChemicalEntity	D007978
10680271	Positive_Correlation	25828	D007978	Novel
10680271	Negative_Correlation	C009591	24598	Novel
10680271	Positive_Correlation	1003	D007978	Novel
10680271	Association	p|SUB|R|211|H	D007978	Novel
10680271	Association	24598	6198	Novel

41663702|t|Pravastatin, Rofecoxib, and Genetic Variants: Interactions with Filamin A, B and C, Desmin, and EXT1 in Prostate Cancer Ce
41663702|a|This study investigates the molecular interactions and genetic associations involving the cholesterol-lowering drug pravastatin, the COX-2 inhibitor rofecoxib, and several genetic variants in prostate cancer cell lines. The focus is on the binding interactions between pravastatin and filamin A, B and C, as well as between pravastatin and desmin, which are critical structural proteins in the cytoskeleton. Rofecoxib is shown to bind to desmin and to exhibit a positive correlation with both desmin and filamin A, B and C. Additionally, rofecoxib demonstrates a positive correlation with EXT1, a gene involved in extracellular matrix organization.   The sequence variant N157K is found to be associated with filamin A, B and C, suggesting a potential functional role in protein structure or function. The variant rs1800734 is associated with both filamin A, B and C and EXT1, indicating a possible regulatory or structural interaction. Pravastatin is also associated with rs1800734, and there is a negative correlation between pravastatin and rofecoxib, which may reflect competitive binding or opposing biological effects.   Furthermore, pravastatin exhibits a positive correlation with EXT1, while rofecoxib shows a positive correlation with EXT1 as well. The negative correlation between pravastatin and rofecoxib is further supported by the binding interactions observed in the DU145 cell line, which is used as a model for prostate cancer. These findings suggest that pravastatin and rofecoxib may have distinct but overlapping roles in modulating the expression and function of filamin A, B and C, desmin, and EXT1, with potential implications for therapeutic strategies in prostate cancer and related diseases.
41663702	96	100	EXT1	GeneOrGeneProduct	2131
41663702	239	250	pravastatin	ChemicalEntity	D017035
41663702	272	281	rofecoxib	ChemicalEntity	C116926
41663702	392	403	pravastatin	ChemicalEntity	D017035
41663702	408	426	filamin A, B and C	GeneOrGeneProduct	2316
41663702	447	458	pravastatin	ChemicalEntity	D017035
41663702	463	469	desmin	GeneOrGeneProduct	64362
41663702	561	567	desmin	GeneOrGeneProduct	64362
41663702	616	622	desmin	GeneOrGeneProduct	64362
41663702	627	645	filamin A, B and C	GeneOrGeneProduct	2316
41663702	661	670	rofecoxib	ChemicalEntity	C116926
41663702	712	716	EXT1	GeneOrGeneProduct	2131
41663702	795	800	N157K	SequenceVariant	rs143117125
41663702	832	850	filamin A, B and C	GeneOrGeneProduct	2316
41663702	937	946	rs1800734	SequenceVariant	rs1800734
41663702	971	989	filamin A, B and C	GeneOrGeneProduct	2316
41663702	994	998	EXT1	GeneOrGeneProduct	2131
41663702	1096	1105	rs1800734	SequenceVariant	rs1800734
41663702	1151	1162	pravastatin	ChemicalEntity	D017035
41663702	1167	1176	rofecoxib	ChemicalEntity	C116926
41663702	1263	1274	pravastatin	ChemicalEntity	D017035
41663702	1312	1316	EXT1	GeneOrGeneProduct	2131
41663702	1324	1333	rofecoxib	ChemicalEntity	C116926
41663702	1368	1372	EXT1	GeneOrGeneProduct	2131
41663702	1415	1426	pravastatin	ChemicalEntity	D017035
41663702	1431	1440	rofecoxib	ChemicalEntity	C116926
41663702	1506	1511	DU145	CellLine	CVCL_0105
41663702	1597	1608	pravastatin	ChemicalEntity	D017035
41663702	1613	1622	rofecoxib	ChemicalEntity	C116926
41663702	1708	1726	filamin A, B and C	GeneOrGeneProduct	2316
41663702	1728	1734	desmin	GeneOrGeneProduct	64362
41663702	1740	1744	EXT1	GeneOrGeneProduct	2131
41663702	Bind	D017035	64362	Novel
41663702	Positive_Correlation	C116926	64362	Novel
41663702	Positive_Correlation	C116926	2316	Novel
41663702	Negative_Correlation	2316	2131	Novel
41663702	Association	rs1800734	2316	Novel
41663702	Association	rs1800734	2131	Novel
41663702	Association	D017035	rs1800734	Novel
41663702	Positive_Correlation	D017035	64362	Novel
41663702	Association	rs143117125	2316	Novel
41663702	Association	C116926	rs143117125	Novel
41663702	Negative_Correlation	D017035	C116926	Novel
41663702	Positive_Correlation	D017035	2131	Novel
41663702	Positive_Correlation	C116926	2131	Novel
41663702	Bind	C116926	64362	Novel
41663702	Bind	D017035	2316	Novel
41663702	Negative_Correlation	C116926	D017035	Novel

21647498|t|Genetic and cellular analysis of MEK 1/2 activity in chick, sheep, and tobacco models with focus on the 888delC variant and its association with loss of 
21647498|a|This study investigates the molecular mechanisms underlying the association between the sequence variant 888delC and the phenotypic feature loss of appetite in multiple model organisms, including chick, sheep, and tobacco. Using a combination of genetic, transcriptomic, and functional assays, we demonstrate that the 888delC variant is significantly associated with loss of appetite in all three species. Furthermore, we show that the expression levels of MEK 1/2 are inversely correlated with the severity of loss of appetite in chick and sheep models, while a positive correlation is observed in tobacco. These findings suggest that MEK 1/2 activity may play a dual role in modulating appetite, depending on the biological context. The study also reveals that the 888delC variant is strongly associated with MEK 1/2 expression in chick and sheep, but not in tobacco, indicating species-specific regulatory mechanisms. To further validate these findings, we conducted experiments using the cell lines 253JB-V, SUM159PT, and IEC-6, which were derived from chick, human, and bovine sources, respectively. The results from these cell lines support the observed associations between MEK 1/2, 888delC, and loss of appetite, providing a comprehensive framework for understanding the genetic and cellular basis of appetite regulation across different species.
21647498	33	40	MEK 1/2	GeneOrGeneProduct	26395
21647498	53	58	chick	OrganismTaxon	9031
21647498	60	65	sheep	OrganismTaxon	9940
21647498	71	78	tobacco	OrganismTaxon	4097
21647498	104	111	888delC	SequenceVariant	c|DEL888|C
21647498	259	266	888delC	SequenceVariant	c|DEL888|C
21647498	294	310	loss of appetite	DiseaseOrPhenotypicFeature	D001068
21647498	350	355	chick	OrganismTaxon	9031
21647498	357	362	sheep	OrganismTaxon	9940
21647498	368	375	tobacco	OrganismTaxon	4097
21647498	472	479	888delC	SequenceVariant	c|DEL888|C
21647498	521	537	loss of appetite	DiseaseOrPhenotypicFeature	D001068
21647498	611	618	MEK 1/2	GeneOrGeneProduct	26395
21647498	665	681	loss of appetite	DiseaseOrPhenotypicFeature	D001068
21647498	685	690	chick	OrganismTaxon	9031
21647498	695	700	sheep	OrganismTaxon	9940
21647498	753	760	tobacco	OrganismTaxon	4097
21647498	790	797	MEK 1/2	GeneOrGeneProduct	26395
21647498	921	928	888delC	SequenceVariant	c|DEL888|C
21647498	965	972	MEK 1/2	GeneOrGeneProduct	26395
21647498	987	992	chick	OrganismTaxon	9031
21647498	997	1002	sheep	OrganismTaxon	9940
21647498	1015	1022	tobacco	OrganismTaxon	4097
21647498	1157	1164	253JB-V	CellLine	CVCL_7937
21647498	1166	1174	SUM159PT	CellLine	CVCL_5423
21647498	1180	1185	IEC-6	CellLine	CVCL_0343
21647498	1211	1216	chick	OrganismTaxon	9031
21647498	1335	1342	MEK 1/2	GeneOrGeneProduct	26395
21647498	1344	1351	888delC	SequenceVariant	c|DEL888|C
21647498	1357	1373	loss of appetite	DiseaseOrPhenotypicFeature	D001068
21647498	Association	D001068	c|DEL888|C	Novel
21647498	Negative_Correlation	26395	D001068	Novel
21647498	Positive_Correlation	D001068	26395	Novel
21647498	Association	D001068	26395	Novel
21647498	Association	26395	D001068	Novel
21647498	Association	c|DEL888|C	26395	Novel

86316467|t|Cerebellar ataxia and hydronephrosis: genetic and metabolic interactions involving D2 DA receptors, ET-1, and oxidative metabolism re
86316467|a|Cerebellar ataxia and hydronephrosis are complex phenotypes that may arise from genetic and metabolic interactions. This study investigates the role of D2 DA receptors, ET-1, and master regulators of oxidative metabolism transcription factor A mitochondrial in these conditions. A sequence variant, c.2444A>C, was found to be associated with cerebellar ataxia, while another variant, p.Val153Ile, was linked to both cerebellar ataxia and hydronephrosis. The sequence variant p.W111X was observed in patients with cerebellar ataxia and was correlated with altered expression of ET-1.   The chemical entity NE was found to modulate the activity of D2 DA receptors, which in turn influenced the progression of cerebellar ataxia. Oxygen levels were positively correlated with the severity of cerebellar ataxia, suggesting a potential mechanism involving oxidative stress. The master regulators of oxidative metabolism transcription factor A mitochondrial were found to be upregulated in cerebellar ataxia, and their expression was influenced by the presence of the sequence variant c.2444A>C.   Furthermore, the chemical entity oxygen was shown to have an association with cerebellar ataxia, with higher oxygen levels correlating with increased disease severity. This study highlights the intricate interplay between genetic variants, chemical entities, and metabolic pathways in the pathogenesis of cerebellar ataxia and hydronephrosis. The findings suggest that targeting oxidative metabolism and D2 DA receptor signaling may offer therapeutic strategies for these conditions.
86316467	22	36	hydronephrosis	DiseaseOrPhenotypicFeature	D006869
86316467	83	98	D2 DA receptors	GeneOrGeneProduct	24318
86316467	100	104	ET-1	GeneOrGeneProduct	24323
86316467	156	170	hydronephrosis	DiseaseOrPhenotypicFeature	D006869
86316467	286	301	D2 DA receptors	GeneOrGeneProduct	24318
86316467	303	307	ET-1	GeneOrGeneProduct	24323
86316467	313	391	master regulators of oxidative metabolism transcription factor A mitochondrial	GeneOrGeneProduct	10891
86316467	433	442	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
86316467	476	493	cerebellar ataxia	DiseaseOrPhenotypicFeature	D002524
86316467	518	529	p.Val153Ile	SequenceVariant	rs111033186
86316467	550	567	cerebellar ataxia	DiseaseOrPhenotypicFeature	D002524
86316467	572	586	hydronephrosis	DiseaseOrPhenotypicFeature	D006869
86316467	609	616	p.W111X	SequenceVariant	rs137852884
86316467	647	664	cerebellar ataxia	DiseaseOrPhenotypicFeature	D002524
86316467	711	715	ET-1	GeneOrGeneProduct	24323
86316467	739	741	NE	ChemicalEntity	D009638
86316467	780	795	D2 DA receptors	GeneOrGeneProduct	24318
86316467	841	858	cerebellar ataxia	DiseaseOrPhenotypicFeature	D002524
86316467	922	939	cerebellar ataxia	DiseaseOrPhenotypicFeature	D002524
86316467	1006	1084	master regulators of oxidative metabolism transcription factor A mitochondrial	GeneOrGeneProduct	10891
86316467	1117	1134	cerebellar ataxia	DiseaseOrPhenotypicFeature	D002524
86316467	1212	1221	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
86316467	1258	1264	oxygen	ChemicalEntity	D010100
86316467	1303	1320	cerebellar ataxia	DiseaseOrPhenotypicFeature	D002524
86316467	1334	1340	oxygen	ChemicalEntity	D010100
86316467	1530	1547	cerebellar ataxia	DiseaseOrPhenotypicFeature	D002524
86316467	1552	1566	hydronephrosis	DiseaseOrPhenotypicFeature	D006869
86316467	Association	D010100	D002524	Novel
86316467	Positive_Correlation	D010100	D002524	Novel

13843237|t|Genetic and pharmacological interactions in cancer and immune response: a multi-cell line and multi-varia
13843237|a|This study investigates the complex interactions between genetic variants, pharmacological agents, and cellular responses in both cancer and immune systems. We focused on the effects of sequence variants in *Mangifera indica Linn* and human immunodeficiency virus on cellular behavior, particularly in the context of drug interactions and cotreatments. The role of sequence variants such as p.R198W, p.Asp46_Gln48delinsGlu, 15 kb deletion, glycine to glutamine, 2172_2173insCCCC, 111G, rs1611115, and c.695T>A was examined in various cell lines including LNCaP, HeLa, Ishikawa, RAW 264.7, CMT-93, and KU7.   We observed that the drug interaction between Ato and anthracycline significantly altered the metabolic profile of HeLa cells, suggesting potential therapeutic synergy. Additionally, the cotreatment of ritanserin with LPS in RAW 264.7 cells led to a marked reduction in inflammatory cytokine production, indicating a possible anti-inflammatory effect. The cotreatment between LPS and ritanserin in CMT-93 cells further supported this finding, highlighting the dual role of ritanserin in modulating immune responses.  The drug interaction between ribavirin and ritanserin was found to enhance antiviral activity in Ishikawa cells, while the cotreatment between ribavirin and daunorubicin in LNCaP cells showed increased cytotoxicity. Furthermore, the cotreatment of daunorubicin and morphine in HeLa cells resulted in a synergistic effect on cell death, suggesting potential applications in cancer therapy.   Our findings underscore the importance of understanding both genetic and pharmacological interactions in the context of multi-cell line and multi-variant studies, providing a foundation for future research into personalized medicine and targeted therapies.
13843237	314	335	Mangifera indica Linn	OrganismTaxon	29780
13843237	341	369	human immunodeficiency virus	OrganismTaxon	12721
13843237	497	504	p.R198W	SequenceVariant	p|SUB|R|198|W
13843237	506	528	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
13843237	530	544	15 kb deletion	SequenceVariant	c|DEL||15K
13843237	546	566	glycine to glutamine	SequenceVariant	p|SUB|G||Q
13843237	568	584	2172_2173insCCCC	SequenceVariant	c|INS|2172_2173|CCCC
13843237	586	590	111G	SequenceVariant	c|Allele|G|111
13843237	592	601	rs1611115	SequenceVariant	rs1611115
13843237	607	615	c.695T>A	SequenceVariant	c|SUB|T|695|A
13843237	661	666	LNCaP	CellLine	CVCL_0395
13843237	668	672	HeLa	CellLine	CVCL_0030
13843237	674	682	Ishikawa	CellLine	CVCL_2529
13843237	684	693	RAW 264.7	CellLine	CVCL_0493
13843237	695	701	CMT-93	CellLine	CVCL_1986
13843237	707	710	KU7	CellLine	CVCL_4714
13843237	760	763	Ato	ChemicalEntity	C065179
13843237	768	781	anthracycline	ChemicalEntity	D018943
13843237	829	833	HeLa	CellLine	CVCL_0030
13843237	916	926	ritanserin	ChemicalEntity	D016713
13843237	932	935	LPS	ChemicalEntity	D008070
13843237	939	948	RAW 264.7	CellLine	CVCL_0493
13843237	1090	1093	LPS	ChemicalEntity	D008070
13843237	1098	1108	ritanserin	ChemicalEntity	D016713
13843237	1112	1118	CMT-93	CellLine	CVCL_1986
13843237	1187	1197	ritanserin	ChemicalEntity	D016713
13843237	1260	1269	ribavirin	ChemicalEntity	D012254
13843237	1274	1284	ritanserin	ChemicalEntity	D016713
13843237	1328	1336	Ishikawa	CellLine	CVCL_2529
13843237	1374	1383	ribavirin	ChemicalEntity	D012254
13843237	1388	1400	daunorubicin	ChemicalEntity	D003630
13843237	1404	1409	LNCaP	CellLine	CVCL_0395
13843237	1479	1491	daunorubicin	ChemicalEntity	D003630
13843237	1496	1504	morphine	ChemicalEntity	D009020
13843237	1508	1512	HeLa	CellLine	CVCL_0030
13843237	Drug_Interaction	C065179	D018943	Novel
13843237	Cotreatment	D016713	D008070	Novel
13843237	Cotreatment	D008070	D016713	Novel
13843237	Drug_Interaction	D012254	D016713	Novel
13843237	Cotreatment	D003630	D009020	Novel
13843237	Cotreatment	D012254	D003630	Novel

19513895|t|Genetic Variants in Ras and Insulin Resistance: Implications for Sudden Infant Death Syndrome and Escherichia coli In
19513895|a|Recent studies have highlighted the complex interplay between genetic variants in the Ras gene and metabolic disorders such as insulin resistance. This research explores the association between Ras and insulin resistance, revealing a significant negative correlation in Escherichia coli-infected individuals. The study also identifies a strong positive association between Ras and sudden infant death syndrome (SIDS), suggesting a potential role for Ras in the pathophysiology of SIDS. Furthermore, the presence of the sequence variant 'arginine to tryptophan at codon 198' is found to be closely linked to the variant 'Ile326Ile', with a bidirectional association observed. These findings are particularly relevant in the context of Toxorynchites mosquitoes, which are known to transmit pathogens that may exacerbate underlying genetic predispositions. The study also notes that the variant 'Ile326Ile' is frequently observed in individuals with insulin resistance, reinforcing the link between Ras and metabolic dysfunction. Additionally, the negative correlation between Ras and insulin resistance is further supported by longitudinal data from a cohort of Escherichia coli-infected patients. These results underscore the importance of understanding the genetic architecture of Ras and its interactions with both metabolic and infectious disease states.
19513895	20	23	Ras	GeneOrGeneProduct	3845
19513895	98	114	Escherichia coli	OrganismTaxon	562
19513895	204	207	Ras	GeneOrGeneProduct	3845
19513895	312	315	Ras	GeneOrGeneProduct	3845
19513895	388	404	Escherichia coli	OrganismTaxon	562
19513895	491	494	Ras	GeneOrGeneProduct	3845
19513895	568	571	Ras	GeneOrGeneProduct	3845
19513895	655	690	arginine to tryptophan at codon 198	SequenceVariant	p|SUB|R|198|W
19513895	738	747	Ile326Ile	SequenceVariant	rs3730089
19513895	852	876	Toxorynchites mosquitoes	OrganismTaxon	2498889
19513895	1011	1020	Ile326Ile	SequenceVariant	rs3730089
19513895	1114	1117	Ras	GeneOrGeneProduct	3845
19513895	1192	1195	Ras	GeneOrGeneProduct	3845
19513895	1278	1294	Escherichia coli	OrganismTaxon	562
19513895	1399	1402	Ras	GeneOrGeneProduct	3845
19513895	Negative_Correlation	3845	D013398	Novel
19513895	Association	3845	D013398	Novel
19513895	Association	3845	D007333	Novel
19513895	Association	p|SUB|R|198|W	rs3730089	Novel
19513895	Association	rs3730089	p|SUB|R|198|W	Novel
19513895	Negative_Correlation	3845	D007333	Novel

65929614|t|Genetic Variants and Cellular Responses in Mangifera indica Linn: A Study on 8 Nucleotide Deletion and Its Associations with R462Q an
65929614|a|This study investigates the functional and phenotypic consequences of genetic variants in Mangifera indica Linn, with a focus on the 8 nucleotide deletion and its associations with the sequence variants R462Q and 521T>C. Using a combination of molecular and cellular approaches, we examined the effects of these variants in multiple cell lines, including 293T, MH134, and LNCaP. The 8 nucleotide deletion was found to be significantly associated with both R462Q and 521T>C, suggesting a potential functional interplay between these genetic elements. In particular, the 8 nucleotide deletion was shown to co-occur with R462Q and 521T>C in multiple independent experiments, indicating a possible regulatory or structural relationship. Furthermore, the association between R462Q and 521T>C was confirmed through sequence analysis and functional assays, highlighting the complex genetic architecture underlying these variants. These findings provide new insights into the molecular mechanisms governing genetic diversity in Mangifera indica Linn and underscore the importance of considering multiple sequence variants in functional studies. The results were consistent across all tested cell lines, including 293T, MH134, and LNCaP, reinforcing the robustness of the observed associations. This work lays the foundation for further studies on the functional implications of these genetic variants in both plant and human systems.
65929614	43	64	Mangifera indica Linn	OrganismTaxon	29780
65929614	125	130	R462Q	SequenceVariant	rs486907
65929614	224	245	Mangifera indica Linn	OrganismTaxon	29780
65929614	267	288	8 nucleotide deletion	SequenceVariant	c|DEL||8
65929614	337	342	R462Q	SequenceVariant	rs486907
65929614	347	353	521T>C	SequenceVariant	c|SUB|T|521|C
65929614	489	493	293T	CellLine	CVCL_0063
65929614	495	500	MH134	CellLine	CVCL_8111
65929614	506	511	LNCaP	CellLine	CVCL_0395
65929614	517	538	8 nucleotide deletion	SequenceVariant	c|DEL||8
65929614	590	595	R462Q	SequenceVariant	rs486907
65929614	600	606	521T>C	SequenceVariant	c|SUB|T|521|C
65929614	703	724	8 nucleotide deletion	SequenceVariant	c|DEL||8
65929614	752	757	R462Q	SequenceVariant	rs486907
65929614	762	768	521T>C	SequenceVariant	c|SUB|T|521|C
65929614	904	909	R462Q	SequenceVariant	rs486907
65929614	914	920	521T>C	SequenceVariant	c|SUB|T|521|C
65929614	1154	1175	Mangifera indica Linn	OrganismTaxon	29780
65929614	1339	1343	293T	CellLine	CVCL_0063
65929614	1345	1350	MH134	CellLine	CVCL_8111
65929614	1356	1361	LNCaP	CellLine	CVCL_0395
65929614	Association	c|SUB|T|521|C	rs486907	Novel
65929614	Association	rs486907	c|DEL||8	Novel
65929614	Association	c|DEL||8	c|SUB|T|521|C	Novel
65929614	Association	c|DEL||8	rs486907	Novel
65929614	Association	c|SUB|T|521|C	c|DEL||8	Novel
65929614	Association	rs486907	c|SUB|T|521|C	Novel

15343636|t|Glutathione, Peptidoglycan, and VAL: Interactions with Mitochondrial Dysfunction, Cardiac Toxicity, and Neurodegenerative Disorders in Yeast, Mouse, and Human Ce
15343636|a|Recent studies have explored the complex interactions between glutathione, Peptidoglycan, and VAL in the context of mitochondrial dysfunction, cardiac toxicity, and neurodegenerative disorders. In yeast, glutathione levels were found to be negatively correlated with VAL concentrations, suggesting a potential regulatory mechanism in cellular redox homeostasis. However, glutathione exhibited a positive correlation with Peptidoglycan, indicating a possible role in maintaining bacterial cell wall integrity. This relationship was further supported by findings in mouse models, where increased glutathione levels were associated with reduced Peptidoglycan accumulation, which in turn correlated with lower cardiac toxicity.   VAL was found to have a positive correlation with both neurodegenerative disorders and mitochondrial dysfunction, highlighting its potential involvement in oxidative stress pathways. In Huh7 cells, VAL treatment led to increased mitochondrial dysfunction, which was accompanied by elevated levels of glutathione, suggesting a complex interplay between these molecules. Additionally, in SJ-GBM2 cells, the positive correlation between VAL and glutathione was further validated, reinforcing the idea of a regulatory feedback loop.  Peptidoglycan was also positively correlated with cardiac toxicity, particularly in Mouse models, where elevated Peptidoglycan levels were associated with increased myocardial damage. This finding was consistent across multiple studies, including those involving Rhodiola rosea extracts, which were shown to modulate Peptidoglycan levels and reduce cardiac toxicity.   Iron overload and viral infection were also observed in these models, with iron overload being linked to increased mitochondrial dysfunction and neurodegenerative disorders. Notably, VWD (von Willebrand disease) was found to be associated with altered glutathione metabolism, further emphasizing the role of these molecules in disease pathogenesis. These findings collectively suggest that glutathione, Peptidoglycan, and VAL are key players in the development and progression of various diseases, including mitochondrial dysfunction, cardiac toxicity, and neurodegenerative disorders.
15343636	13	26	Peptidoglycan	ChemicalEntity	D010457
15343636	32	35	VAL	ChemicalEntity	C081489
15343636	55	80	Mitochondrial Dysfunction	DiseaseOrPhenotypicFeature	D028361
15343636	142	147	Mouse	OrganismTaxon	10090
15343636	224	235	glutathione	ChemicalEntity	D005978
15343636	237	250	Peptidoglycan	ChemicalEntity	D010457
15343636	256	259	VAL	ChemicalEntity	C081489
15343636	305	321	cardiac toxicity	DiseaseOrPhenotypicFeature	D066126
15343636	327	354	neurodegenerative disorders	DiseaseOrPhenotypicFeature	D019636
15343636	359	364	yeast	OrganismTaxon	4932
15343636	366	377	glutathione	ChemicalEntity	D005978
15343636	429	432	VAL	ChemicalEntity	C081489
15343636	533	544	glutathione	ChemicalEntity	D005978
15343636	583	596	Peptidoglycan	ChemicalEntity	D010457
15343636	756	767	glutathione	ChemicalEntity	D005978
15343636	804	817	Peptidoglycan	ChemicalEntity	D010457
15343636	868	884	cardiac toxicity	DiseaseOrPhenotypicFeature	D066126
15343636	888	891	VAL	ChemicalEntity	C081489
15343636	943	970	neurodegenerative disorders	DiseaseOrPhenotypicFeature	D019636
15343636	1074	1078	Huh7	CellLine	CVCL_0336
15343636	1086	1089	VAL	ChemicalEntity	C081489
15343636	1188	1199	glutathione	ChemicalEntity	D005978
15343636	1274	1281	SJ-GBM2	CellLine	CVCL_M141
15343636	1322	1325	VAL	ChemicalEntity	C081489
15343636	1330	1341	glutathione	ChemicalEntity	D005978
15343636	1418	1431	Peptidoglycan	ChemicalEntity	D010457
15343636	1468	1484	cardiac toxicity	DiseaseOrPhenotypicFeature	D066126
15343636	1502	1507	Mouse	OrganismTaxon	10090
15343636	1531	1544	Peptidoglycan	ChemicalEntity	D010457
15343636	1681	1695	Rhodiola rosea	OrganismTaxon	203015
15343636	1735	1748	Peptidoglycan	ChemicalEntity	D010457
15343636	1767	1783	cardiac toxicity	DiseaseOrPhenotypicFeature	D066126
15343636	1805	1820	viral infection	DiseaseOrPhenotypicFeature	D014777
15343636	1862	1875	iron overload	DiseaseOrPhenotypicFeature	D019190
15343636	1932	1959	neurodegenerative disorders	DiseaseOrPhenotypicFeature	D019636
15343636	1970	1973	VWD	DiseaseOrPhenotypicFeature	D014842
15343636	2039	2050	glutathione	ChemicalEntity	D005978
15343636	2177	2188	glutathione	ChemicalEntity	D005978
15343636	2190	2203	Peptidoglycan	ChemicalEntity	D010457
15343636	2209	2212	VAL	ChemicalEntity	C081489
15343636	2322	2338	cardiac toxicity	DiseaseOrPhenotypicFeature	D066126
15343636	2344	2371	neurodegenerative disorders	DiseaseOrPhenotypicFeature	D019636
15343636	Negative_Correlation	C081489	D005978	Novel
15343636	Positive_Correlation	D005978	D010457	Novel
15343636	Positive_Correlation	C081489	D019636	Novel
15343636	Positive_Correlation	D010457	D066126	Novel
15343636	Positive_Correlation	C081489	D028361	Novel
15343636	Positive_Correlation	D005978	C081489	Novel

07361938|t|Genetic Variants and Phenotypic Associations in Mouse and Yeast Models of Sepsis, Brain Edema, and Autoimmune
07361938|a|This study investigates the genetic and phenotypic associations between specific sequence variants and disease features in both mouse and yeast models. We focus on the impact of variants such as p.W111X, cytosine insertion, c.643T>C, c.1072T>C, 111G, glycine to glutamine, rs2844580, A207D, and others on the development of conditions like Sepsis, brain edema, and RA.   In mouse models, we observed a positive correlation between glycine to glutamine and Sepsis, as well as between A207D and RA. The association between glycine to glutamine and c.1072T>C was also evident, with c.1072T>C showing a positive correlation with brain edema. Additionally, the association between rash and c.643T>C was noted, and brain edema was found to be associated with glycine to glutamine.   The rs2844580 variant was linked to 111G, and c.1072T>C was associated with 111G. Furthermore, glycine to glutamine was found to be associated with p.W111X, and rs2844580 was associated with RA. The glycine to glutamine variant also showed a positive correlation with A207D.   In yeast models, we examined the effects of these variants on phenotypic outcomes, including the association between Sepsis and c.643T>C. The study also included cell lines such as SUM159PT, SF188, and SNU-C5, which were used to further explore the functional implications of these genetic variants.   These findings highlight the complex interplay between genetic variants and disease phenotypes, providing a foundation for future research into the molecular mechanisms underlying these conditions.
07361938	48	53	Mouse	OrganismTaxon	10090
07361938	74	80	Sepsis	DiseaseOrPhenotypicFeature	D018805
07361938	248	253	yeast	OrganismTaxon	4932
07361938	305	312	p.W111X	SequenceVariant	rs137852884
07361938	314	332	cytosine insertion	SequenceVariant	c|INS||C
07361938	334	342	c.643T>C	SequenceVariant	c|SUB|T|643|C
07361938	344	353	c.1072T>C	SequenceVariant	c|SUB|T|1072|C
07361938	355	359	111G	SequenceVariant	c|Allele|G|111
07361938	361	381	glycine to glutamine	SequenceVariant	p|SUB|G||Q
07361938	383	392	rs2844580	SequenceVariant	rs2844580
07361938	394	399	A207D	SequenceVariant	rs767564684
07361938	450	456	Sepsis	DiseaseOrPhenotypicFeature	D018805
07361938	458	469	brain edema	DiseaseOrPhenotypicFeature	D001929
07361938	475	477	RA	DiseaseOrPhenotypicFeature	D001172
07361938	541	561	glycine to glutamine	SequenceVariant	p|SUB|G||Q
07361938	566	572	Sepsis	DiseaseOrPhenotypicFeature	D018805
07361938	593	598	A207D	SequenceVariant	rs767564684
07361938	603	605	RA	DiseaseOrPhenotypicFeature	D001172
07361938	631	651	glycine to glutamine	SequenceVariant	p|SUB|G||Q
07361938	656	665	c.1072T>C	SequenceVariant	c|SUB|T|1072|C
07361938	689	698	c.1072T>C	SequenceVariant	c|SUB|T|1072|C
07361938	735	746	brain edema	DiseaseOrPhenotypicFeature	D001929
07361938	786	790	rash	DiseaseOrPhenotypicFeature	D005076
07361938	795	803	c.643T>C	SequenceVariant	c|SUB|T|643|C
07361938	819	830	brain edema	DiseaseOrPhenotypicFeature	D001929
07361938	863	883	glycine to glutamine	SequenceVariant	p|SUB|G||Q
07361938	891	900	rs2844580	SequenceVariant	rs2844580
07361938	923	927	111G	SequenceVariant	c|Allele|G|111
07361938	933	942	c.1072T>C	SequenceVariant	c|SUB|T|1072|C
07361938	963	967	111G	SequenceVariant	c|Allele|G|111
07361938	982	1002	glycine to glutamine	SequenceVariant	p|SUB|G||Q
07361938	1035	1042	p.W111X	SequenceVariant	rs137852884
07361938	1048	1057	rs2844580	SequenceVariant	rs2844580
07361938	1078	1080	RA	DiseaseOrPhenotypicFeature	D001172
07361938	1086	1106	glycine to glutamine	SequenceVariant	p|SUB|G||Q
07361938	1155	1160	A207D	SequenceVariant	rs767564684
07361938	1167	1172	yeast	OrganismTaxon	4932
07361938	1281	1287	Sepsis	DiseaseOrPhenotypicFeature	D018805
07361938	1292	1300	c.643T>C	SequenceVariant	c|SUB|T|643|C
07361938	1345	1353	SUM159PT	CellLine	CVCL_5423
07361938	1355	1360	SF188	CellLine	CVCL_6948
07361938	1366	1372	SNU-C5	CellLine	CVCL_5112
07361938	Positive_Correlation	p|SUB|G||Q	D018805	Novel
07361938	Positive_Correlation	rs767564684	D001172	Novel
07361938	Association	p|SUB|G||Q	c|SUB|T|1072|C	Novel
07361938	Positive_Correlation	c|SUB|T|1072|C	D001929	Novel
07361938	Association	D005076	c|SUB|T|643|C	Novel
07361938	Association	D001929	p|SUB|G||Q	Novel
07361938	Association	rs2844580	c|Allele|G|111	Novel
07361938	Association	c|SUB|T|1072|C	c|Allele|G|111	Novel
07361938	Association	p|SUB|G||Q	rs137852884	Novel
07361938	Association	rs2844580	D001172	Novel
07361938	Association	p|SUB|G||Q	rs2844580	Novel
07361938	Association	p|SUB|G||Q	rs767564684	Novel
07361938	Association	c|SUB|T|1072|C	D005076	Novel
07361938	Association	rs137852884	c|SUB|T|1072|C	Novel
07361938	Association	rs767564684	c|SUB|T|643|C	Novel
07361938	Association	D018805	c|SUB|T|643|C	Novel

93852910|t|Exploring molecular interactions and cotreatments in diverse organisms: insights from E. coli, mouse, S. cerevisiae, Aedes mosquitoes, Rhodiola rosea, an
93852910|a|This study investigates the molecular interactions and cotreatment effects of various compounds and genes across multiple organisms, including E. coli, mouse, S. cerevisiae, Aedes mosquitoes, Rhodiola rosea, and rDEN-2. A key focus is the binding interactions between PKC and Apomorphine, as well as between PKC and lamotrigine, which were observed through biochemical assays. These findings suggest a potential role for PKC in modulating the effects of Apomorphine and lamotrigine in neurological contexts. Additionally, the binding of ACC to both lamotrigine and cannabis was confirmed, indicating a possible regulatory role of ACC in response to these compounds. The cotreatment of contrast and cannabis was examined in mouse models, revealing synergistic effects that may be relevant in neuropharmacological applications. Furthermore, the interaction between GLUT1 and Leu was validated, highlighting the role of GLUT1 in amino acid transport. The binding of ACE to cannabis was also demonstrated, suggesting a potential involvement of ACE in cannabis-related physiological responses. In S. cerevisiae, the expression of ACC was found to be modulated by cannabis, while in Aedes mosquitoes, the gene B65 was associated with the response to contrast. These findings collectively provide a comprehensive understanding of molecular interactions and cotreatment effects across diverse biological systems, offering new avenues for therapeutic development and mechanistic studies.
93852910	86	93	E. coli	OrganismTaxon	562
93852910	95	100	mouse	OrganismTaxon	10090
93852910	102	115	S. cerevisiae	OrganismTaxon	4932
93852910	117	133	Aedes mosquitoes	OrganismTaxon	1245352
93852910	135	149	Rhodiola rosea	OrganismTaxon	203015
93852910	297	304	E. coli	OrganismTaxon	562
93852910	306	311	mouse	OrganismTaxon	10090
93852910	313	326	S. cerevisiae	OrganismTaxon	4932
93852910	328	344	Aedes mosquitoes	OrganismTaxon	1245352
93852910	346	360	Rhodiola rosea	OrganismTaxon	203015
93852910	366	372	rDEN-2	OrganismTaxon	11060
93852910	422	425	PKC	GeneOrGeneProduct	24681
93852910	430	441	Apomorphine	ChemicalEntity	D001058
93852910	462	465	PKC	GeneOrGeneProduct	24681
93852910	470	481	lamotrigine	ChemicalEntity	D000077213
93852910	575	578	PKC	GeneOrGeneProduct	24681
93852910	608	619	Apomorphine	ChemicalEntity	D001058
93852910	624	635	lamotrigine	ChemicalEntity	D000077213
93852910	691	694	ACC	GeneOrGeneProduct	31
93852910	703	714	lamotrigine	ChemicalEntity	D000077213
93852910	719	727	cannabis	ChemicalEntity	D002188
93852910	784	787	ACC	GeneOrGeneProduct	31
93852910	839	847	contrast	ChemicalEntity	D003287
93852910	852	860	cannabis	ChemicalEntity	D002188
93852910	877	882	mouse	OrganismTaxon	10090
93852910	1017	1022	GLUT1	GeneOrGeneProduct	20525
93852910	1027	1030	Leu	ChemicalEntity	D007930
93852910	1071	1076	GLUT1	GeneOrGeneProduct	20525
93852910	1117	1120	ACE	GeneOrGeneProduct	24310
93852910	1124	1132	cannabis	ChemicalEntity	D002188
93852910	1194	1197	ACE	GeneOrGeneProduct	24310
93852910	1201	1209	cannabis	ChemicalEntity	D002188
93852910	1246	1259	S. cerevisiae	OrganismTaxon	4932
93852910	1279	1282	ACC	GeneOrGeneProduct	31
93852910	1312	1320	cannabis	ChemicalEntity	D002188
93852910	1331	1347	Aedes mosquitoes	OrganismTaxon	1245352
93852910	1358	1361	B65	GeneOrGeneProduct	-
93852910	1398	1406	contrast	ChemicalEntity	D003287
93852910	Bind	24681	D001058	Novel
93852910	Cotreatment	D000077213	D003287	Novel
93852910	Bind	31	D000077213	Novel
93852910	Cotreatment	D003287	D002188	Novel
93852910	Bind	24681	D000077213	Novel
93852910	Bind	31	D002188	Novel
93852910	Bind	20525	D007930	Novel
93852910	Bind	24310	D002188	Novel

90424319|t|LPL and FA interactions in HEK, COS-7, MH134, and Ishikawa cells: a study on the role of S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-car
90424319|a|This study investigates the interactions between the gene LPL, the chemical entity FA, and the compound S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide in various cell lines, including HEK, COS-7, MH134, and Ishikawa. The research focuses on the molecular mechanisms underlying the association between FA and S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide, as well as the role of LPL in modulating these interactions.   Using HEK cells, we observed that FA significantly alters the expression levels of LPL, suggesting a direct regulatory relationship. In COS-7 cells, the presence of S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide was found to enhance the binding affinity of FA to LPL, indicating a potential synergistic effect. MH134 cells were used to examine the impact of FA on the enzymatic activity of LPL, revealing a dose-dependent increase in activity in the presence of S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide.   Ishikawa cells provided further evidence of the association between FA and S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide, as both compounds were found to co-localize in lipid rafts, suggesting a structural and functional interplay. The results from all cell lines support the hypothesis that FA and S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide are functionally linked through their interaction with LPL. These findings highlight the importance of understanding the molecular pathways involving these entities in cellular metabolism and disease.
90424319	0	3	LPL	GeneOrGeneProduct	4023
90424319	8	10	FA	ChemicalEntity	D005492
90424319	27	30	HEK	CellLine	CVCL_M624
90424319	32	37	COS-7	CellLine	CVCL_0224
90424319	39	44	MH134	CellLine	CVCL_8111
90424319	50	58	Ishikawa	CellLine	CVCL_2529
90424319	207	210	LPL	GeneOrGeneProduct	4023
90424319	232	234	FA	ChemicalEntity	D005492
90424319	253	320	S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide	ChemicalEntity	C416835
90424319	354	357	HEK	CellLine	CVCL_M624
90424319	359	364	COS-7	CellLine	CVCL_0224
90424319	366	371	MH134	CellLine	CVCL_8111
90424319	377	385	Ishikawa	CellLine	CVCL_2529
90424319	471	473	FA	ChemicalEntity	D005492
90424319	478	545	S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide	ChemicalEntity	C416835
90424319	570	573	LPL	GeneOrGeneProduct	4023
90424319	616	619	HEK	CellLine	CVCL_M624
90424319	644	646	FA	ChemicalEntity	D005492
90424319	693	696	LPL	GeneOrGeneProduct	4023
90424319	746	751	COS-7	CellLine	CVCL_0224
90424319	775	842	S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide	ChemicalEntity	C416835
90424319	888	890	FA	ChemicalEntity	D005492
90424319	894	897	LPL	GeneOrGeneProduct	4023
90424319	942	947	MH134	CellLine	CVCL_8111
90424319	989	991	FA	ChemicalEntity	D005492
90424319	1021	1024	LPL	GeneOrGeneProduct	4023
90424319	1093	1160	S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide	ChemicalEntity	C416835
90424319	1164	1172	Ishikawa	CellLine	CVCL_2529
90424319	1232	1234	FA	ChemicalEntity	D005492
90424319	1239	1306	S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide	ChemicalEntity	C416835
90424319	1478	1480	FA	ChemicalEntity	D005492
90424319	1485	1552	S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide	ChemicalEntity	C416835
90424319	1608	1611	LPL	GeneOrGeneProduct	4023
90424319	Association	C416835	D005492	Novel
90424319	Association	D005492	C416835	Novel

88394163|t|Androgen receptor and vascular endothelial growth factor interactions in GCD type I: implications of p.R246Q and 1123T-->G sequence variants in BALB/c, LNCaP, and MC3T3-E1 ce
88394163|a|This study investigates the molecular mechanisms underlying the pathogenesis of GCD type I, with a focus on the functional interactions between the androgen receptor (AR) and vascular endothelial growth factor (VEGF) in the context of specific sequence variants. We examined the effects of the p.R246Q and 1123T-->G variants on AR and VEGF expression and activity in BALB/c, LNCaP, and MC3T3-E1 cell lines. Our findings reveal a significant association between p.R246Q and 1123T-->G, suggesting a potential functional link between these variants. Furthermore, we demonstrate that the p.R246Q variant is strongly correlated with the androgen receptor, and this association is further reinforced by its interaction with VEGF. The vascular endothelial growth factor is also found to be associated with GCD type I, with a positive correlation observed between VEGF levels and the disease phenotype. Additionally, the 1123T-->G variant shows a direct association with the androgen receptor, highlighting its potential role in modulating AR function. These results provide new insights into the molecular pathways involved in GCD type I and suggest that the interplay between AR and VEGF, influenced by specific sequence variants, may be a critical factor in disease progression. The study underscores the importance of these genetic and molecular interactions in understanding the pathophysiology of GCD type I and opens new avenues for targeted therapeutic interventions.
88394163	22	56	vascular endothelial growth factor	GeneOrGeneProduct	7422
88394163	73	83	GCD type I	DiseaseOrPhenotypicFeature	C537304
88394163	101	108	p.R246Q	SequenceVariant	rs9332967
88394163	113	122	1123T-->G	SequenceVariant	g|SUB|T|1123|G
88394163	144	150	BALB/c	CellLine	CVCL_9101
88394163	152	157	LNCaP	CellLine	CVCL_0395
88394163	163	171	MC3T3-E1	CellLine	CVCL_0409
88394163	255	265	GCD type I	DiseaseOrPhenotypicFeature	C537304
88394163	323	340	androgen receptor	GeneOrGeneProduct	367
88394163	350	384	vascular endothelial growth factor	GeneOrGeneProduct	7422
88394163	469	476	p.R246Q	SequenceVariant	rs9332967
88394163	481	490	1123T-->G	SequenceVariant	g|SUB|T|1123|G
88394163	542	548	BALB/c	CellLine	CVCL_9101
88394163	550	555	LNCaP	CellLine	CVCL_0395
88394163	561	569	MC3T3-E1	CellLine	CVCL_0409
88394163	636	643	p.R246Q	SequenceVariant	rs9332967
88394163	648	657	1123T-->G	SequenceVariant	g|SUB|T|1123|G
88394163	759	766	p.R246Q	SequenceVariant	rs9332967
88394163	807	824	androgen receptor	GeneOrGeneProduct	367
88394163	903	937	vascular endothelial growth factor	GeneOrGeneProduct	7422
88394163	974	984	GCD type I	DiseaseOrPhenotypicFeature	C537304
88394163	1088	1097	1123T-->G	SequenceVariant	g|SUB|T|1123|G
88394163	1142	1159	androgen receptor	GeneOrGeneProduct	367
88394163	1295	1305	GCD type I	DiseaseOrPhenotypicFeature	C537304
88394163	1570	1580	GCD type I	DiseaseOrPhenotypicFeature	C537304
88394163	Association	rs9332967	g|SUB|T|1123|G	Novel
88394163	Association	7422	C537304	Novel
88394163	Association	367	7422	Novel
88394163	Association	g|SUB|T|1123|G	367	Novel
88394163	Association	367	C537304	Novel
88394163	Association	rs9332967	367	Novel
88394163	Association	rs9332967	7422	Novel
88394163	Association	7422	367	Novel
88394163	Positive_Correlation	7422	C537304	Novel

09261612|t|Eslicarbazepine Acetate and Myocardial Stunning: Interactions with ALDH, TGF-betaRII, and High Mobility Group-Box 1 in Dogs Infected with Hepatitis
09261612|a|This study investigates the complex interactions between Eslicarbazepine acetate, myocardial stunning, and various molecular entities in dogs infected with hepatitis B virus. We demonstrate that Eslicarbazepine acetate exhibits a negative correlation with myocardial stunning, suggesting a potential protective role against cardiac dysfunction. Additionally, we find that the sequence variant C311A is negatively correlated with both myocardial stunning and Eslicarbazepine acetate, indicating a possible mechanism by which this variant may modulate drug response and cardiac outcomes.   Our findings also reveal a strong association between TGF-betaRII and myocardial stunning, as well as between TGF-betaRII and Eslicarbazepine acetate, suggesting that TGF-betaRII may serve as a key mediator in the pathophysiology of myocardial stunning and its response to treatment. Furthermore, we observe a significant association between ALDH and myocardial stunning, as well as between ALDH and Eslicarbazepine acetate, highlighting the role of ALDH in both the disease process and drug metabolism.   Notably, High Mobility Group-Box 1 is also associated with myocardial stunning and with Eslicarbazepine acetate, pointing to its involvement in the inflammatory and metabolic pathways underlying cardiac dysfunction. These results provide critical insights into the molecular mechanisms linking Eslicarbazepine acetate, myocardial stunning, and the genetic and molecular factors involved in this complex interplay. The study was conducted in a cohort of dogs infected with hepatitis B virus, offering a unique model for understanding these interactions in a clinical context.
09261612	67	71	ALDH	GeneOrGeneProduct	217
09261612	73	84	TGF-betaRII	GeneOrGeneProduct	7048
09261612	90	115	High Mobility Group-Box 1	GeneOrGeneProduct	3146
09261612	205	228	Eslicarbazepine acetate	ChemicalEntity	C416835
09261612	230	249	myocardial stunning	DiseaseOrPhenotypicFeature	D017682
09261612	285	289	dogs	OrganismTaxon	9615
09261612	304	321	hepatitis B virus	OrganismTaxon	10407
09261612	343	366	Eslicarbazepine acetate	ChemicalEntity	C416835
09261612	404	423	myocardial stunning	DiseaseOrPhenotypicFeature	D017682
09261612	541	546	C311A	SequenceVariant	p|SUB|C|311|A
09261612	582	601	myocardial stunning	DiseaseOrPhenotypicFeature	D017682
09261612	606	629	Eslicarbazepine acetate	ChemicalEntity	C416835
09261612	790	801	TGF-betaRII	GeneOrGeneProduct	7048
09261612	806	825	myocardial stunning	DiseaseOrPhenotypicFeature	D017682
09261612	846	857	TGF-betaRII	GeneOrGeneProduct	7048
09261612	862	885	Eslicarbazepine acetate	ChemicalEntity	C416835
09261612	903	914	TGF-betaRII	GeneOrGeneProduct	7048
09261612	969	988	myocardial stunning	DiseaseOrPhenotypicFeature	D017682
09261612	1078	1082	ALDH	GeneOrGeneProduct	217
09261612	1087	1106	myocardial stunning	DiseaseOrPhenotypicFeature	D017682
09261612	1127	1131	ALDH	GeneOrGeneProduct	217
09261612	1136	1159	Eslicarbazepine acetate	ChemicalEntity	C416835
09261612	1186	1190	ALDH	GeneOrGeneProduct	217
09261612	1251	1276	High Mobility Group-Box 1	GeneOrGeneProduct	3146
09261612	1301	1320	myocardial stunning	DiseaseOrPhenotypicFeature	D017682
09261612	1330	1353	Eslicarbazepine acetate	ChemicalEntity	C416835
09261612	1536	1559	Eslicarbazepine acetate	ChemicalEntity	C416835
09261612	1561	1580	myocardial stunning	DiseaseOrPhenotypicFeature	D017682
09261612	1695	1699	dogs	OrganismTaxon	9615
09261612	1714	1731	hepatitis B virus	OrganismTaxon	10407
09261612	Negative_Correlation	p|SUB|C|311|A	D017682	Novel
09261612	Negative_Correlation	p|SUB|C|311|A	C416835	Novel
09261612	Association	7048	D017682	Novel
09261612	Association	D017682	7048	Novel
09261612	Association	D017682	217	Novel
09261612	Association	7048	C416835	Novel
09261612	Association	217	C416835	Novel
09261612	Association	D017682	3146	Novel
09261612	Association	217	D017682	Novel
09261612	Association	3146	C416835	Novel

90553673|t|Bromocriptine and neurotoxic lesions in dogs: effects on Ba/F3 cell lines and implications for ovarian epithelial malignancy and skeletal d
90553673|a|This study investigates the effects of bromocriptine on neurotoxic lesions in dogs, with a focus on its impact on the Ba/F3 cell line. Bromocriptine, a dopamine receptor agonist, was administered to dogs with pre-existing neurotoxic lesions to assess its therapeutic potential. The Ba/F3 cell line, a murine pro-B cell line, was used as a model to evaluate the molecular mechanisms underlying bromocriptine's effects on cellular signaling and proliferation. Results showed that bromocriptine significantly reduced the severity of neurotoxic lesions in dogs, suggesting a potential neuroprotective role. Additionally, bromocriptine was found to modulate the expression of genes associated with the Ba/F3 cell line, indicating a possible mechanism for its neuroprotective effects. The study also explored the association between bromocriptine treatment and the development of ovarian epithelial malignancy in dogs, with findings suggesting a possible protective effect against this disease. Furthermore, bromocriptine was linked to a reduction in the incidence of skeletal dysplasia in dogs, which may be related to its effects on bone remodeling and growth factors. These findings highlight the potential of bromocriptine as a therapeutic agent for neurotoxic lesions and related conditions in dogs, with implications for the management of ovarian epithelial malignancy and skeletal dysplasia. The study also identified a novel association between bromocriptine and Mal de Meleda, a rare genetic disorder, suggesting further research is needed to explore this connection.
90553673	18	36	neurotoxic lesions	DiseaseOrPhenotypicFeature	D020258
90553673	40	44	dogs	OrganismTaxon	9615
90553673	57	62	Ba/F3	CellLine	CVCL_0161
90553673	95	124	ovarian epithelial malignancy	DiseaseOrPhenotypicFeature	D002277
90553673	179	192	bromocriptine	ChemicalEntity	D001971
90553673	196	214	neurotoxic lesions	DiseaseOrPhenotypicFeature	D020258
90553673	218	222	dogs	OrganismTaxon	9615
90553673	258	263	Ba/F3	CellLine	CVCL_0161
90553673	339	343	dogs	OrganismTaxon	9615
90553673	362	380	neurotoxic lesions	DiseaseOrPhenotypicFeature	D020258
90553673	422	427	Ba/F3	CellLine	CVCL_0161
90553673	533	546	bromocriptine	ChemicalEntity	D001971
90553673	618	631	bromocriptine	ChemicalEntity	D001971
90553673	670	688	neurotoxic lesions	DiseaseOrPhenotypicFeature	D020258
90553673	692	696	dogs	OrganismTaxon	9615
90553673	757	770	bromocriptine	ChemicalEntity	D001971
90553673	837	842	Ba/F3	CellLine	CVCL_0161
90553673	967	980	bromocriptine	ChemicalEntity	D001971
90553673	1014	1043	ovarian epithelial malignancy	DiseaseOrPhenotypicFeature	D002277
90553673	1047	1051	dogs	OrganismTaxon	9615
90553673	1142	1155	bromocriptine	ChemicalEntity	D001971
90553673	1202	1220	skeletal dysplasia	DiseaseOrPhenotypicFeature	D001848
90553673	1224	1228	dogs	OrganismTaxon	9615
90553673	1347	1360	bromocriptine	ChemicalEntity	D001971
90553673	1388	1406	neurotoxic lesions	DiseaseOrPhenotypicFeature	D020258
90553673	1433	1437	dogs	OrganismTaxon	9615
90553673	1479	1508	ovarian epithelial malignancy	DiseaseOrPhenotypicFeature	D002277
90553673	1513	1531	skeletal dysplasia	DiseaseOrPhenotypicFeature	D001848
90553673	1587	1600	bromocriptine	ChemicalEntity	D001971
90553673	1605	1618	Mal de Meleda	DiseaseOrPhenotypicFeature	D007645

22887558|t|Bax and glucocorticoid receptor-interacting protein 1 in multiple cutaneous and uterine leiomyomas: interactions with sequence variants and cardiac and neurological ph
22887558|a|Recent studies have highlighted the complex interplay between genetic variants and the development of multiple cutaneous and uterine leiomyomas (MCUL), a condition characterized by benign smooth muscle tumors. This study investigates the role of the Bax gene and its interactions with sequence variants such as C311A and -616C/G in the pathogenesis of MCUL. We also explore the association between Bax and Cortical dysplasia, a neurological disorder, and the potential influence of genetic variants on cardiac phenotypes like right bundle branch block (RBBB).   Our findings reveal a negative correlation between Bax expression and the occurrence of MCUL, suggesting that Bax may act as a tumor suppressor in this context. Conversely, the sequence variant C311A shows a positive correlation with MCUL, indicating a possible role in promoting tumor formation. Additionally, we observed a positive correlation between Bax and Cortical dysplasia, implying a shared genetic pathway between these two conditions.   The sequence variant c.855 +1G>C was found to be associated with RBBB, a cardiac conduction disorder, while the variant -652 6N del was linked to TS, a genetic syndrome. The variant 1359 G/A was also associated with TS, further supporting the genetic heterogeneity of this condition.   Notably, the gene Adrenoleukodystrophy gene was found to interact with the sequence variant -616C/G, suggesting a potential regulatory role in disease expression. These results underscore the importance of genetic variants in modulating the expression of key genes like Bax and glucocorticoid receptor-interacting protein 1, and their impact on both cutaneous and neurological phenotypes. Further research is needed to fully elucidate the molecular mechanisms underlying these associations.
22887558	0	3	Bax	GeneOrGeneProduct	581
22887558	8	53	glucocorticoid receptor-interacting protein 1	GeneOrGeneProduct	23426
22887558	57	98	multiple cutaneous and uterine leiomyomas	DiseaseOrPhenotypicFeature	C535516
22887558	270	311	multiple cutaneous and uterine leiomyomas	DiseaseOrPhenotypicFeature	C535516
22887558	418	421	Bax	GeneOrGeneProduct	581
22887558	479	484	C311A	SequenceVariant	p|SUB|C|311|A
22887558	489	496	-616C/G	SequenceVariant	rs747302
22887558	566	569	Bax	GeneOrGeneProduct	581
22887558	574	592	Cortical dysplasia	DiseaseOrPhenotypicFeature	D054220
22887558	694	719	right bundle branch block	DiseaseOrPhenotypicFeature	D002037
22887558	781	784	Bax	GeneOrGeneProduct	581
22887558	840	843	Bax	GeneOrGeneProduct	581
22887558	924	929	C311A	SequenceVariant	p|SUB|C|311|A
22887558	1084	1087	Bax	GeneOrGeneProduct	581
22887558	1092	1110	Cortical dysplasia	DiseaseOrPhenotypicFeature	D054220
22887558	1199	1210	c.855 +1G>C	SequenceVariant	c|SUB|C|855+1|C
22887558	1298	1309	-652 6N del	SequenceVariant	c|DEL|-652|6
22887558	1324	1326	TS	DiseaseOrPhenotypicFeature	D054549
22887558	1360	1368	1359 G/A	SequenceVariant	rs1049353
22887558	1394	1396	TS	DiseaseOrPhenotypicFeature	D054549
22887558	1482	1507	Adrenoleukodystrophy gene	GeneOrGeneProduct	215
22887558	1556	1563	-616C/G	SequenceVariant	rs747302
22887558	1734	1737	Bax	GeneOrGeneProduct	581
22887558	1742	1787	glucocorticoid receptor-interacting protein 1	GeneOrGeneProduct	23426
22887558	Negative_Correlation	C535516	581	Novel
22887558	Positive_Correlation	p|SUB|C|311|A	C535516	Novel
22887558	Positive_Correlation	581	D054220	Novel
22887558	Positive_Correlation	p|SUB|C|311|A	D002037	Novel

26621825|t|Genetic Variants and Phenotypic Associations in Sheep and Human Cell Lines: A Study on Hypoplastic Disorders, Skin Pigmentation,
26621825|a|This study investigates the genetic and phenotypic associations between specific sequence variants and disease features in both sheep and human cell lines. We focused on the sheep organism taxon and the human cell lines SMMC-7721 and DU145. Our findings reveal significant associations between the sequence variant rs2071349 and D299G, as well as between rs2071349 and del642T. These associations suggest a potential functional link between these genetic variants.   We also observed a positive correlation between hypoplastic and K294E, indicating that the presence of the K294E variant may be associated with the hypoplastic phenotype. Additionally, the sequence variant del642T was found to be associated with L351A, and there was a positive correlation between del642T and hypoplastic, further supporting the role of del642T in the development of hypoplastic conditions.   The sequence variant A30P was associated with LCA, and there was a positive correlation between LCA and D299G, suggesting that D299G may contribute to the pathogenesis of LCA. Furthermore, we found a positive correlation between LCA and K294E, reinforcing the potential role of K294E in LCA. The sequence variant rs2071349 was also associated with LCA, indicating its possible involvement in the disease.   In addition, we identified a positive correlation between skin pigmentation and K294E, suggesting that K294E may influence skin pigmentation. The sequence variant Gly49Ser was found to occur three times in our dataset, and it was associated with multiple phenotypic features, including hypoplastic and LCA.   Our results highlight the complex interplay between genetic variants and phenotypic outcomes in both sheep and human cell lines, providing valuable insights into the molecular mechanisms underlying these conditions.
26621825	257	262	sheep	OrganismTaxon	9940
26621825	303	308	sheep	OrganismTaxon	9940
26621825	349	358	SMMC-7721	CellLine	CVCL_0534
26621825	363	368	DU145	CellLine	CVCL_0105
26621825	444	453	rs2071349	SequenceVariant	rs2071349
26621825	458	463	D299G	SequenceVariant	rs4986790
26621825	484	493	rs2071349	SequenceVariant	rs2071349
26621825	498	505	del642T	SequenceVariant	c|DEL|642|T
26621825	644	655	hypoplastic	DiseaseOrPhenotypicFeature	D029502
26621825	660	665	K294E	SequenceVariant	rs143544690
26621825	703	708	K294E	SequenceVariant	rs143544690
26621825	744	755	hypoplastic	DiseaseOrPhenotypicFeature	D029502
26621825	802	809	del642T	SequenceVariant	c|DEL|642|T
26621825	842	847	L351A	SequenceVariant	p|SUB|L|351|A
26621825	894	901	del642T	SequenceVariant	c|DEL|642|T
26621825	906	917	hypoplastic	DiseaseOrPhenotypicFeature	D029502
26621825	950	957	del642T	SequenceVariant	c|DEL|642|T
26621825	980	991	hypoplastic	DiseaseOrPhenotypicFeature	D029502
26621825	1027	1031	A30P	SequenceVariant	p|SUB|A|30|P
26621825	1052	1055	LCA	DiseaseOrPhenotypicFeature	D057130
26621825	1102	1105	LCA	DiseaseOrPhenotypicFeature	D057130
26621825	1110	1115	D299G	SequenceVariant	rs4986790
26621825	1133	1138	D299G	SequenceVariant	rs4986790
26621825	1177	1180	LCA	DiseaseOrPhenotypicFeature	D057130
26621825	1235	1238	LCA	DiseaseOrPhenotypicFeature	D057130
26621825	1243	1248	K294E	SequenceVariant	rs143544690
26621825	1284	1289	K294E	SequenceVariant	rs143544690
26621825	1293	1296	LCA	DiseaseOrPhenotypicFeature	D057130
26621825	1319	1328	rs2071349	SequenceVariant	rs2071349
26621825	1354	1357	LCA	DiseaseOrPhenotypicFeature	D057130
26621825	1471	1488	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
26621825	1493	1498	K294E	SequenceVariant	rs143544690
26621825	1516	1521	K294E	SequenceVariant	rs143544690
26621825	1536	1553	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
26621825	1576	1584	Gly49Ser	SequenceVariant	p|SUB|G|49|S
26621825	1699	1710	hypoplastic	DiseaseOrPhenotypicFeature	D029502
26621825	1715	1718	LCA	DiseaseOrPhenotypicFeature	D057130
26621825	1823	1828	sheep	OrganismTaxon	9940
26621825	Association	rs2071349	rs4986790	Novel
26621825	Positive_Correlation	D029502	rs143544690	Novel
26621825	Association	c|DEL|642|T	p|SUB|L|351|A	Novel
26621825	Association	D029502	rs4986790	Novel
26621825	Association	D010859	rs143544690	Novel
26621825	Positive_Correlation	D057130	rs4986790	Novel
26621825	Association	c|DEL|642|T	D029502	Novel
26621825	Positive_Correlation	D057130	rs143544690	Novel
26621825	Association	D057130	rs2071349	Novel
26621825	Association	rs2071349	c|DEL|642|T	Novel
26621825	Association	p|SUB|A|30|P	D057130	Novel

58833799|t|Genetic Variants and Disease Associations in Primary Hodgkin Lymphoma, Diffuse Mesangial Sclerosis, and Hepatoenceph
58833799|a|This study investigates the complex genetic interactions between sequence variants and disease phenotypes, focusing on primary Hodgkin lymphoma, diffuse mesangial sclerosis, and hepatoencephalopathy. We identified multiple sequence variants, including rs17015215, g.3627A>C, and V175M, and their associations with various disease states. The variant rs17015215 was found to be associated with both g.3627A>C and diffuse mesangial sclerosis, suggesting a potential genetic link between these two sequence variants and the disease. Additionally, rs17015215 showed a positive correlation with Reis-Bucklers dystrophy, indicating a broader genetic influence. The variant g.3627A>C was strongly associated with diffuse mesangial sclerosis and exhibited a positive correlation with this disease, while also showing a negative correlation with hepatoencephalopathy. The deletion (10-12Mb) was found to be negatively correlated with diffuse mesangial sclerosis and was associated with both primary Hodgkin lymphoma and Reis-Bucklers dystrophy. The variant V175M was associated with primary Hodgkin lymphoma and showed a positive correlation with diffuse mesangial sclerosis. These findings highlight the intricate relationships between genetic variants and disease phenotypes, providing new insights into the molecular mechanisms underlying these conditions.
58833799	236	260	primary Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
58833799	262	289	diffuse mesangial sclerosis	DiseaseOrPhenotypicFeature	C537346
58833799	295	315	hepatoencephalopathy	DiseaseOrPhenotypicFeature	C563797
58833799	369	379	rs17015215	SequenceVariant	rs17015215
58833799	381	390	g.3627A>C	SequenceVariant	g|SUB|A|3627|C
58833799	396	401	V175M	SequenceVariant	rs7946
58833799	467	477	rs17015215	SequenceVariant	rs17015215
58833799	515	524	g.3627A>C	SequenceVariant	g|SUB|A|3627|C
58833799	529	556	diffuse mesangial sclerosis	DiseaseOrPhenotypicFeature	C537346
58833799	661	671	rs17015215	SequenceVariant	rs17015215
58833799	707	730	Reis-Bucklers dystrophy	DiseaseOrPhenotypicFeature	C535476
58833799	784	793	g.3627A>C	SequenceVariant	g|SUB|A|3627|C
58833799	823	850	diffuse mesangial sclerosis	DiseaseOrPhenotypicFeature	C537346
58833799	954	974	hepatoencephalopathy	DiseaseOrPhenotypicFeature	C563797
58833799	980	998	deletion (10-12Mb)	SequenceVariant	c|DEL||10-12MB
58833799	1042	1069	diffuse mesangial sclerosis	DiseaseOrPhenotypicFeature	C537346
58833799	1099	1123	primary Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
58833799	1128	1151	Reis-Bucklers dystrophy	DiseaseOrPhenotypicFeature	C535476
58833799	1165	1170	V175M	SequenceVariant	rs7946
58833799	1191	1215	primary Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
58833799	1255	1282	diffuse mesangial sclerosis	DiseaseOrPhenotypicFeature	C537346
58833799	Association	rs17015215	g|SUB|A|3627|C	Novel
58833799	Association	D006689	rs7946	Novel
58833799	Negative_Correlation	c|DEL||10-12MB	C537346	Novel
58833799	Association	g|SUB|A|3627|C	C537346	Novel
58833799	Association	C537346	g|SUB|A|3627|C	Novel
58833799	Positive_Correlation	rs7946	C537346	Novel
58833799	Association	rs17015215	C537346	Novel
58833799	Positive_Correlation	C563797	g|SUB|A|3627|C	Novel
58833799	Positive_Correlation	g|SUB|A|3627|C	C537346	Novel
58833799	Association	rs17015215	c|DEL||10-12MB	Novel
58833799	Association	c|DEL||10-12MB	C535476	Novel
58833799	Positive_Correlation	C537346	rs17015215	Novel
58833799	Negative_Correlation	g|SUB|A|3627|C	C563797	Novel
58833799	Association	c|DEL||10-12MB	D006689	Novel
58833799	Association	C535476	g|SUB|A|3627|C	Novel
58833799	Positive_Correlation	rs17015215	C535476	Novel

68354105|t|Dopamine, clathrin, and their interactions with CCL2, TNFa, and acetylcholinesterase in the context of multiple diseases and genetic
68354105|a|This study explores the complex interplay between dopamine, clathrin, and key inflammatory mediators such as CCL2, TNFa, and acetylcholinesterase in the context of various diseases and genetic factors. Dopamine exhibits a positive correlation with clathrin, suggesting a potential functional relationship in cellular processes. However, dopamine also shows a negative correlation with maternal diabetes, small-cell carcinoma, streptococcus infection, and arthritis, indicating its role in modulating disease progression. The negative correlation between clathrin and maternal diabetes, as well as between clathrin and streptococcus infection, highlights the involvement of clathrin in immune and metabolic pathways.   Clathrin is further associated with acetylcholinesterase, and this relationship is reinforced by the binding interaction between acetylcholinesterase and TNFa. TNFa, in turn, binds to CCL2, and this interaction is supported by the association between TNFa and CCL2. The negative correlation between clathrin and the deficiency of the normal VLCAD protein suggests a potential role for clathrin in lipid metabolism. Additionally, clathrin shows a negative correlation with small-cell carcinoma, reinforcing its involvement in tumor biology.  The study also reveals a negative correlation between dopamine and malar rash, indicating a possible link between dopamine signaling and autoimmune responses. Dopamine's negative correlation with streptococcus infection and small-cell carcinoma further underscores its role in immune regulation and cancer biology. The negative correlation between clathrin and dopamine, despite the positive correlation between dopamine and clathrin, suggests a complex regulatory network involving these molecules. These findings provide new insights into the molecular mechanisms underlying the interactions between dopamine, clathrin, and inflammatory mediators in the context of multiple diseases.
68354105	10	18	clathrin	ChemicalEntity	D002966
68354105	48	52	CCL2	GeneOrGeneProduct	24770
68354105	54	58	TNFa	GeneOrGeneProduct	21926
68354105	64	84	acetylcholinesterase	GeneOrGeneProduct	83817
68354105	183	191	dopamine	ChemicalEntity	D004298
68354105	193	201	clathrin	ChemicalEntity	D002966
68354105	242	246	CCL2	GeneOrGeneProduct	24770
68354105	248	252	TNFa	GeneOrGeneProduct	21926
68354105	258	278	acetylcholinesterase	GeneOrGeneProduct	83817
68354105	381	389	clathrin	ChemicalEntity	D002966
68354105	470	478	dopamine	ChemicalEntity	D004298
68354105	518	535	maternal diabetes	DiseaseOrPhenotypicFeature	D016640
68354105	537	557	small-cell carcinoma	DiseaseOrPhenotypicFeature	D018288
68354105	559	582	streptococcus infection	DiseaseOrPhenotypicFeature	D013290
68354105	588	597	arthritis	DiseaseOrPhenotypicFeature	D001168
68354105	687	695	clathrin	ChemicalEntity	D002966
68354105	700	717	maternal diabetes	DiseaseOrPhenotypicFeature	D016640
68354105	738	746	clathrin	ChemicalEntity	D002966
68354105	751	774	streptococcus infection	DiseaseOrPhenotypicFeature	D013290
68354105	806	814	clathrin	ChemicalEntity	D002966
68354105	887	907	acetylcholinesterase	GeneOrGeneProduct	83817
68354105	980	1000	acetylcholinesterase	GeneOrGeneProduct	83817
68354105	1005	1009	TNFa	GeneOrGeneProduct	21926
68354105	1011	1015	TNFa	GeneOrGeneProduct	21926
68354105	1035	1039	CCL2	GeneOrGeneProduct	24770
68354105	1102	1106	TNFa	GeneOrGeneProduct	21926
68354105	1111	1115	CCL2	GeneOrGeneProduct	24770
68354105	1150	1158	clathrin	ChemicalEntity	D002966
68354105	1167	1205	deficiency of the normal VLCAD protein	DiseaseOrPhenotypicFeature	C536353
68354105	1236	1244	clathrin	ChemicalEntity	D002966
68354105	1280	1288	clathrin	ChemicalEntity	D002966
68354105	1323	1343	small-cell carcinoma	DiseaseOrPhenotypicFeature	D018288
68354105	1446	1454	dopamine	ChemicalEntity	D004298
68354105	1459	1469	malar rash	DiseaseOrPhenotypicFeature	D005076
68354105	1506	1514	dopamine	ChemicalEntity	D004298
68354105	1588	1611	streptococcus infection	DiseaseOrPhenotypicFeature	D013290
68354105	1616	1636	small-cell carcinoma	DiseaseOrPhenotypicFeature	D018288
68354105	1740	1748	clathrin	ChemicalEntity	D002966
68354105	1753	1761	dopamine	ChemicalEntity	D004298
68354105	1804	1812	dopamine	ChemicalEntity	D004298
68354105	1817	1825	clathrin	ChemicalEntity	D002966
68354105	1994	2002	dopamine	ChemicalEntity	D004298
68354105	2004	2012	clathrin	ChemicalEntity	D002966
68354105	Positive_Correlation	D004298	D002966	Novel
68354105	Negative_Correlation	D002966	D016640	Novel
68354105	Negative_Correlation	D005076	D004298	Novel
68354105	Association	D004298	21926	Novel
68354105	Negative_Correlation	D004298	D016640	Novel
68354105	Negative_Correlation	D004298	D013290	Novel
68354105	Bind	21926	24770	Novel
68354105	Association	D002966	83817	Novel
68354105	Negative_Correlation	D002966	C536353	Novel
68354105	Negative_Correlation	D001168	D002966	Novel
68354105	Negative_Correlation	D013290	D002966	Novel
68354105	Bind	83817	21926	Novel
68354105	Negative_Correlation	D016640	D004298	Novel
68354105	Negative_Correlation	D004298	D018288	Novel
68354105	Negative_Correlation	D002966	D004298	Novel
68354105	Positive_Correlation	D002966	D004298	Novel
68354105	Bind	24770	21926	Novel
68354105	Negative_Correlation	C536353	D002966	Novel
68354105	Negative_Correlation	D002966	D013290	Novel
68354105	Negative_Correlation	D002966	D018288	Novel

33629712|t|Genetic and pharmacological interactions of MT, estrogen, and penicillin in modulating N-type voltage-gated calcium channels and their associations with UP, Smac, and cell line responses in women and
33629712|a|This study investigates the complex interactions between the chemical entity MT, the hormone estrogen, and the antibiotic penicillin in their effects on N-type voltage-gated calcium channels and their downstream associations with the gene products UP and Smac. Using the cell lines IEC-6, MEF, and Hs578T, we examined the functional and molecular responses of these entities in both human and animal models, including women and rabbits. Our findings reveal a significant association between penicillin and UP, as well as between MT and Smac, suggesting potential therapeutic and regulatory roles in cellular signaling. Additionally, we observed that estrogen and penicillin exhibit a synergistic relationship, with estrogen enhancing the effects of penicillin on N-type voltage-gated calcium channels. The sequence variant rs2274700 and p.F366L were found to modulate these interactions, particularly in the context of the gene product Bicaudal D2. Furthermore, the chemical entity MT was shown to interact with N-type voltage-gated calcium channels, and this interaction was further reinforced by the presence of the sequence variant C111G. The study also included the organism taxon Platonia insignis Mart, which exhibited unique responses to these compounds, particularly in the context of the cell line SNU-C2A. These results highlight the importance of genetic variability and pharmacological interactions in understanding the biological mechanisms underlying these associations, with implications for both human and animal health, particularly in the context of women and rabbits.
33629712	44	46	MT	ChemicalEntity	D008668
33629712	48	56	estrogen	ChemicalEntity	D004967
33629712	62	72	penicillin	ChemicalEntity	D010406
33629712	87	124	N-type voltage-gated calcium channels	GeneOrGeneProduct	774
33629712	153	155	UP	GeneOrGeneProduct	11045
33629712	157	161	Smac	GeneOrGeneProduct	56616
33629712	277	279	MT	ChemicalEntity	D008668
33629712	293	301	estrogen	ChemicalEntity	D004967
33629712	322	332	penicillin	ChemicalEntity	D010406
33629712	353	390	N-type voltage-gated calcium channels	GeneOrGeneProduct	774
33629712	448	450	UP	GeneOrGeneProduct	11045
33629712	455	459	Smac	GeneOrGeneProduct	56616
33629712	482	487	IEC-6	CellLine	CVCL_0343
33629712	489	492	MEF	CellLine	CVCL_9115
33629712	498	504	Hs578T	CellLine	CVCL_0332
33629712	628	634	rabbit	OrganismTaxon	9986
33629712	691	701	penicillin	ChemicalEntity	D010406
33629712	706	708	UP	GeneOrGeneProduct	11045
33629712	729	731	MT	ChemicalEntity	D008668
33629712	736	740	Smac	GeneOrGeneProduct	56616
33629712	850	858	estrogen	ChemicalEntity	D004967
33629712	863	873	penicillin	ChemicalEntity	D010406
33629712	915	923	estrogen	ChemicalEntity	D004967
33629712	949	959	penicillin	ChemicalEntity	D010406
33629712	963	1000	N-type voltage-gated calcium channels	GeneOrGeneProduct	774
33629712	1023	1032	rs2274700	SequenceVariant	rs2274700
33629712	1037	1044	p.F366L	SequenceVariant	rs140756663
33629712	1136	1147	Bicaudal D2	GeneOrGeneProduct	23299
33629712	1182	1184	MT	ChemicalEntity	D008668
33629712	1212	1249	N-type voltage-gated calcium channels	GeneOrGeneProduct	774
33629712	1335	1340	C111G	SequenceVariant	c|SUB|C|111|G
33629712	1385	1407	Platonia insignis Mart	OrganismTaxon	198787
33629712	1507	1514	SNU-C2A	CellLine	CVCL_1709
33629712	1778	1784	rabbit	OrganismTaxon	9986
33629712	Association	D010406	11045	Novel
33629712	Association	D008668	56616	Novel
33629712	Association	D004967	D010406	Novel
33629712	Association	D010406	D008668	Novel
33629712	Association	D010406	774	Novel
33629712	Association	D008668	774	Novel

16717075|t|Role of ubiquitin carboxyl-terminal esterase L1 in cerebellar anomalies and SCID: a study in MES-SA/Dx5 cells and Escheric
16717075|a|This study investigates the molecular mechanisms underlying the association between ubiquitin carboxyl-terminal esterase L1 (UCHL1) and cerebellar anomalies, as well as its relationship with severe combined immunodeficiency (SCID), using the MES-SA/Dx5 cell line and Escherichia coli as model systems. The MES-SA/Dx5 cell line, a well-characterized human mesenchymal stem cell line, was used to assess the expression and functional role of UCHL1 in the context of cerebellar anomalies. Our findings reveal a negative correlation between UCHL1 expression and the occurrence of cerebellar anomalies, suggesting that UCHL1 may act as a protective factor against these developmental defects.   To further explore the relationship between UCHL1 and SCID, we conducted experiments using Escherichia coli as a model organism. The results indicate a negative correlation between UCHL1 activity and the manifestation of SCID-like phenotypes, implying that UCHL1 may play a critical role in immune system development. These findings are supported by multiple independent experiments, including gene expression profiling and functional assays in both MES-SA/Dx5 cells and Escherichia coli.   The study also highlights the importance of UCHL1 in maintaining cellular homeostasis and its potential as a therapeutic target for conditions associated with cerebellar anomalies and SCID. The consistent negative correlation observed across different experimental models reinforces the biological relevance of these findings. Further research is warranted to elucidate the precise molecular pathways through which UCHL1 exerts its protective effects in these contexts.
16717075	8	47	ubiquitin carboxyl-terminal esterase L1	GeneOrGeneProduct	7345
16717075	51	71	cerebellar anomalies	DiseaseOrPhenotypicFeature	D002526
16717075	76	80	SCID	DiseaseOrPhenotypicFeature	D016511
16717075	93	103	MES-SA/Dx5	CellLine	CVCL_2598
16717075	207	246	ubiquitin carboxyl-terminal esterase L1	GeneOrGeneProduct	7345
16717075	259	279	cerebellar anomalies	DiseaseOrPhenotypicFeature	D002526
16717075	348	352	SCID	DiseaseOrPhenotypicFeature	D016511
16717075	365	375	MES-SA/Dx5	CellLine	CVCL_2598
16717075	390	406	Escherichia coli	OrganismTaxon	562
16717075	429	439	MES-SA/Dx5	CellLine	CVCL_2598
16717075	587	607	cerebellar anomalies	DiseaseOrPhenotypicFeature	D002526
16717075	699	719	cerebellar anomalies	DiseaseOrPhenotypicFeature	D002526
16717075	867	871	SCID	DiseaseOrPhenotypicFeature	D016511
16717075	904	920	Escherichia coli	OrganismTaxon	562
16717075	1034	1038	SCID	DiseaseOrPhenotypicFeature	D016511
16717075	1263	1273	MES-SA/Dx5	CellLine	CVCL_2598
16717075	1284	1300	Escherichia coli	OrganismTaxon	562
16717075	1463	1483	cerebellar anomalies	DiseaseOrPhenotypicFeature	D002526
16717075	1488	1492	SCID	DiseaseOrPhenotypicFeature	D016511
16717075	Negative_Correlation	D002526	7345	Novel
16717075	Negative_Correlation	D016511	7345	Novel

01777352|t|Multiminicore disease and its associations with PAC1, TIMP3, GPX4, and genetic variants in RAW 264.7 and Ishikawa ce
01777352|a|Multiminicore disease is a rare neuromuscular disorder characterized by the presence of multiple core-like structures in muscle fibers. This study investigates the molecular mechanisms underlying multiminicore disease by examining the interactions between the genes PAC1, TIMP3, and GPX4, as well as their associations with genetic variants in RAW 264.7, Ishikawa, and MES-SA/Dx5 cell lines. The study reveals a positive correlation between PAC1 and TIMP3, as well as between TIMP3 and GPX4, suggesting a potential regulatory network involving these genes. Additionally, a positive correlation is observed between GPX4 and PAC1, further supporting the interconnectedness of these pathways. The association between TIMP3 and multiminicore disease is highlighted, with TIMP3 also showing a positive correlation with GPX4. Furthermore, GPX4 is found to be associated with multiminicore disease, reinforcing its role in the pathogenesis of the condition. The study also identifies several sequence variants, including rs1217412, A53T, and p.E947stop, which are present in multiple cell lines, including RAW 264.7, Ishikawa, and C. elegans. The presence of glycine (Gly) with arginine (Arg) as a sequence variant is also noted in various cell lines, suggesting a potential role in modulating gene expression. These findings provide new insights into the genetic and molecular basis of multiminicore disease and its potential therapeutic targets.
01777352	48	52	PAC1	GeneOrGeneProduct	11517
01777352	54	59	TIMP3	GeneOrGeneProduct	7078
01777352	61	65	GPX4	GeneOrGeneProduct	2879
01777352	91	100	RAW 264.7	CellLine	CVCL_0493
01777352	105	113	Ishikawa	CellLine	CVCL_2529
01777352	313	334	multiminicore disease	DiseaseOrPhenotypicFeature	C564969
01777352	383	387	PAC1	GeneOrGeneProduct	11517
01777352	389	394	TIMP3	GeneOrGeneProduct	7078
01777352	400	404	GPX4	GeneOrGeneProduct	2879
01777352	461	470	RAW 264.7	CellLine	CVCL_0493
01777352	472	480	Ishikawa	CellLine	CVCL_2529
01777352	486	496	MES-SA/Dx5	CellLine	CVCL_2598
01777352	558	562	PAC1	GeneOrGeneProduct	11517
01777352	567	572	TIMP3	GeneOrGeneProduct	7078
01777352	593	598	TIMP3	GeneOrGeneProduct	7078
01777352	603	607	GPX4	GeneOrGeneProduct	2879
01777352	731	735	GPX4	GeneOrGeneProduct	2879
01777352	740	744	PAC1	GeneOrGeneProduct	11517
01777352	831	836	TIMP3	GeneOrGeneProduct	7078
01777352	841	862	multiminicore disease	DiseaseOrPhenotypicFeature	C564969
01777352	884	889	TIMP3	GeneOrGeneProduct	7078
01777352	931	935	GPX4	GeneOrGeneProduct	2879
01777352	950	954	GPX4	GeneOrGeneProduct	2879
01777352	986	1007	multiminicore disease	DiseaseOrPhenotypicFeature	C564969
01777352	1131	1140	rs1217412	SequenceVariant	rs1217412
01777352	1142	1146	A53T	SequenceVariant	p|SUB|A|53|T
01777352	1152	1162	p.E947stop	SequenceVariant	p|SUB|E|947|X
01777352	1216	1225	RAW 264.7	CellLine	CVCL_0493
01777352	1227	1235	Ishikawa	CellLine	CVCL_2529
01777352	1241	1251	C. elegans	OrganismTaxon	6239
01777352	1269	1302	glycine (Gly) with arginine (Arg)	SequenceVariant	rs351855
01777352	1497	1518	multiminicore disease	DiseaseOrPhenotypicFeature	C564969
01777352	Positive_Correlation	11517	7078	Novel
01777352	Positive_Correlation	7078	2879	Novel
01777352	Positive_Correlation	2879	7078	Novel
01777352	Association	7078	C564969	Novel
01777352	Positive_Correlation	2879	11517	Novel
01777352	Positive_Correlation	11517	2879	Novel
01777352	Association	2879	C564969	Novel
01777352	Positive_Correlation	7078	11517	Novel
01777352	Association	11517	C564969	Novel

75425185|t|Chick, rat, and yeast models reveal complex interactions between clathrin, fluoroquinolone, and sequence variants in bacterial and rabbit
75425185|a|This study explores the intricate relationships between clathrin, fluoroquinolone, and various sequence variants across multiple organisms, including chick, rat, yeast, and rabbit. We demonstrate a positive correlation between clathrin and fluoroquinolone, as well as a positive correlation between clathrin and agar. The association between clathrin and the sequence variant '+3100 T/G' is further supported by experimental data. Additionally, we find that fluoroquinolone is associated with the sequence variant 'rs2622604', and there is a conversion between fluoroquinolone and clathrin, as well as between clathrin and fluoroquinolone.   The sequence variant 'changes asparagine 86 for alanine and eliminates amino acids 87, 88, and 89 (arginine, threonine, and proline)' is associated with both fluoroquinolone and agar. This variant is also linked to the chemical entity agar, highlighting its potential role in bacterial and rabbit systems. The presence of this variant in chick, rat, and yeast models suggests a conserved mechanism across these organisms.   Our findings also reveal that agar is associated with the same sequence variant, and there is a conversion between agar and clathrin. These results provide new insights into the molecular mechanisms underlying the interactions between clathrin, fluoroquinolone, and sequence variants in diverse biological contexts. The study further emphasizes the importance of these interactions in bacterial and rabbit systems, with implications for understanding the broader role of clathrin in cellular processes.
75425185	7	10	rat	OrganismTaxon	10116
75425185	16	21	yeast	OrganismTaxon	4932
75425185	65	73	clathrin	ChemicalEntity	D002966
75425185	75	90	fluoroquinolone	ChemicalEntity	D024841
75425185	117	125	bacteria	OrganismTaxon	2
75425185	131	137	rabbit	OrganismTaxon	9986
75425185	194	202	clathrin	ChemicalEntity	D002966
75425185	204	219	fluoroquinolone	ChemicalEntity	D024841
75425185	288	293	chick	OrganismTaxon	9031
75425185	295	298	rat	OrganismTaxon	10116
75425185	300	305	yeast	OrganismTaxon	4932
75425185	311	317	rabbit	OrganismTaxon	9986
75425185	329	332	rat	OrganismTaxon	10116
75425185	365	373	clathrin	ChemicalEntity	D002966
75425185	378	393	fluoroquinolone	ChemicalEntity	D024841
75425185	437	445	clathrin	ChemicalEntity	D002966
75425185	450	454	agar	ChemicalEntity	D000362
75425185	480	488	clathrin	ChemicalEntity	D002966
75425185	515	524	+3100 T/G	SequenceVariant	c|SUB|T|+3100|G
75425185	596	611	fluoroquinolone	ChemicalEntity	D024841
75425185	653	662	rs2622604	SequenceVariant	rs2622604
75425185	699	714	fluoroquinolone	ChemicalEntity	D024841
75425185	719	727	clathrin	ChemicalEntity	D002966
75425185	748	756	clathrin	ChemicalEntity	D002966
75425185	761	776	fluoroquinolone	ChemicalEntity	D024841
75425185	802	912	changes asparagine 86 for alanine and eliminates amino acids 87, 88, and 89 (arginine, threonine, and proline)	SequenceVariant	p|SUB|NRTP|86_89|A
75425185	938	953	fluoroquinolone	ChemicalEntity	D024841
75425185	958	962	agar	ChemicalEntity	D000362
75425185	1015	1019	agar	ChemicalEntity	D000362
75425185	1056	1064	bacteria	OrganismTaxon	2
75425185	1070	1076	rabbit	OrganismTaxon	9986
75425185	1118	1123	chick	OrganismTaxon	9031
75425185	1125	1128	rat	OrganismTaxon	10116
75425185	1134	1139	yeast	OrganismTaxon	4932
75425185	1234	1238	agar	ChemicalEntity	D000362
75425185	1319	1323	agar	ChemicalEntity	D000362
75425185	1328	1336	clathrin	ChemicalEntity	D002966
75425185	1439	1447	clathrin	ChemicalEntity	D002966
75425185	1449	1464	fluoroquinolone	ChemicalEntity	D024841
75425185	1589	1597	bacteria	OrganismTaxon	2
75425185	1603	1609	rabbit	OrganismTaxon	9986
75425185	1675	1683	clathrin	ChemicalEntity	D002966
75425185	Association	D024841	rs2622604	Novel
75425185	Positive_Correlation	D002966	D024841	Novel
75425185	Association	D002966	c|SUB|T|+3100|G	Novel
75425185	Association	D024841	p|SUB|NRTP|86_89|A	Novel
75425185	Conversion	D024841	D002966	Novel
75425185	Conversion	D002966	D024841	Novel
75425185	Association	D000362	p|SUB|NRTP|86_89|A	Novel
75425185	Conversion	D000362	D002966	Novel
75425185	Positive_Correlation	D000362	D024841	Novel
75425185	Association	D002966	rs2622604	Novel
75425185	Association	D024841	D002966	Novel
75425185	Positive_Correlation	D002966	D000362	Novel
75425185	Association	D002966	D000362	Novel

05992462|t|C57BL/6J mice and the role of GCSH in microcornea: effects of D542A sequence variant and naproxen t
05992462|a|The C57BL/6J mouse model has been widely used to study the genetic and environmental factors contributing to microcornea, a phenotypic feature characterized by abnormally small corneas. In this study, we investigated the impact of the D542A sequence variant in the GCSH gene on the development of microcornea in C57BL/6J mice. The GCSH gene, which encodes the enzyme gamma-glutamylcysteine synthetase heavy subunit, plays a critical role in glutathione synthesis, a key antioxidant pathway. We found that the D542A variant significantly increased the susceptibility of C57BL/6J mice to microcornea, with 7 out of 10 instances of the variant correlating with the disease phenotype.   To further explore the interaction between genetic and environmental factors, we administered naproxen, a nonsteroidal anti-inflammatory drug, to C57BL/6J mice carrying the D542A variant. Naproxen treatment was associated with a reduction in the severity of microcornea, as evidenced by improved corneal dimensions in 7 out of 10 instances. The study also revealed that the presence of the D542A variant in GCSH was linked to altered expression levels of the gene in C57BL/6J mice, with 5 out of 10 instances showing a significant downregulation.   Our findings suggest that the D542A sequence variant in GCSH contributes to the pathogenesis of microcornea in C57BL/6J mice, and that naproxen may have a protective effect in this context. These results highlight the importance of both genetic and pharmacological interventions in managing microcornea in this model system. The C57BL/6J mice remain a valuable tool for studying the molecular mechanisms underlying microcornea and for testing potential therapeutic strategies.
05992462	0	8	C57BL/6J	CellLine	CVCL_5U84
05992462	30	34	GCSH	GeneOrGeneProduct	2653
05992462	38	49	microcornea	DiseaseOrPhenotypicFeature	D005124
05992462	62	67	D542A	SequenceVariant	p|SUB|D|542|A
05992462	89	97	naproxen	ChemicalEntity	D009288
05992462	104	112	C57BL/6J	CellLine	CVCL_5U84
05992462	209	220	microcornea	DiseaseOrPhenotypicFeature	D005124
05992462	335	340	D542A	SequenceVariant	p|SUB|D|542|A
05992462	365	369	GCSH	GeneOrGeneProduct	2653
05992462	397	408	microcornea	DiseaseOrPhenotypicFeature	D005124
05992462	412	420	C57BL/6J	CellLine	CVCL_5U84
05992462	431	435	GCSH	GeneOrGeneProduct	2653
05992462	609	614	D542A	SequenceVariant	p|SUB|D|542|A
05992462	669	677	C57BL/6J	CellLine	CVCL_5U84
05992462	686	697	microcornea	DiseaseOrPhenotypicFeature	D005124
05992462	877	885	naproxen	ChemicalEntity	D009288
05992462	929	937	C57BL/6J	CellLine	CVCL_5U84
05992462	956	961	D542A	SequenceVariant	p|SUB|D|542|A
05992462	1041	1052	microcornea	DiseaseOrPhenotypicFeature	D005124
05992462	1173	1178	D542A	SequenceVariant	p|SUB|D|542|A
05992462	1190	1194	GCSH	GeneOrGeneProduct	2653
05992462	1250	1258	C57BL/6J	CellLine	CVCL_5U84
05992462	1362	1367	D542A	SequenceVariant	p|SUB|D|542|A
05992462	1388	1392	GCSH	GeneOrGeneProduct	2653
05992462	1428	1439	microcornea	DiseaseOrPhenotypicFeature	D005124
05992462	1443	1451	C57BL/6J	CellLine	CVCL_5U84
05992462	1467	1475	naproxen	ChemicalEntity	D009288
05992462	1623	1634	microcornea	DiseaseOrPhenotypicFeature	D005124
05992462	1661	1669	C57BL/6J	CellLine	CVCL_5U84
05992462	1747	1758	microcornea	DiseaseOrPhenotypicFeature	D005124

79836211|t|Genetic Variants in EPOR and Group-I-PAKs: Implications for HIV, West Nile Virus, and Bovine Path
79836211|a|This study investigates the genetic landscape of the erythropoietin receptor (EPOR) and its interactions with Group-I-PAKs in the context of viral infections and host responses. We identified multiple sequence variants in the EPOR gene, including p.Q298X, c.742_744delTAC, p.Asp46_Gln48delinsGlu, (G --> C) substitution at position 1201, c.1094C>T, and arginine 555-to-tryptophan, across various organisms. These variants were observed in HIV, West Nile virus, and bovine populations, suggesting a potential role in viral pathogenesis and host immune responses.   The study also examined the relationship between EPOR and Group-I-PAKs, revealing a positive correlation between these two gene products. This correlation was further supported by the association of Group-I-PAKs with glycoprotein IX, indicating a potential signaling pathway involved in immune responses. Additionally, the adrenocorticotrophic hormone (ACTH) was found to have a positive correlation with EPOR, suggesting a possible regulatory mechanism in stress responses and immune modulation.  The presence of these genetic variants in Toxorynchites mosquitoes and tobacco further highlights the broad relevance of these molecular interactions across different biological systems. Our findings provide new insights into the genetic basis of host-virus interactions and the potential therapeutic targets for managing viral infections in both human and animal models.
79836211	20	24	EPOR	GeneOrGeneProduct	13857
79836211	29	41	Group-I-PAKs	GeneOrGeneProduct	29431
79836211	60	63	HIV	OrganismTaxon	11676
79836211	176	180	EPOR	GeneOrGeneProduct	13857
79836211	208	220	Group-I-PAKs	GeneOrGeneProduct	29431
79836211	324	328	EPOR	GeneOrGeneProduct	13857
79836211	345	352	p.Q298X	SequenceVariant	p|SUB|Q|298|X
79836211	354	369	c.742_744delTAC	SequenceVariant	rs267606574
79836211	371	393	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu
79836211	395	434	(G --> C) substitution at position 1201	SequenceVariant	c|SUB|G|1201|C
79836211	436	445	c.1094C>T	SequenceVariant	c|SUB|C|1094|T
79836211	451	477	arginine 555-to-tryptophan	SequenceVariant	rs121909208
79836211	537	540	HIV	OrganismTaxon	11676
79836211	542	557	West Nile virus	OrganismTaxon	11082
79836211	563	569	bovine	OrganismTaxon	9913
79836211	711	715	EPOR	GeneOrGeneProduct	13857
79836211	720	732	Group-I-PAKs	GeneOrGeneProduct	29431
79836211	861	873	Group-I-PAKs	GeneOrGeneProduct	29431
79836211	879	894	glycoprotein IX	GeneOrGeneProduct	2815
79836211	985	1013	adrenocorticotrophic hormone	GeneOrGeneProduct	5443
79836211	1067	1071	EPOR	GeneOrGeneProduct	13857
79836211	1202	1226	Toxorynchites mosquitoes	OrganismTaxon	2498889
79836211	1231	1238	tobacco	OrganismTaxon	4097
79836211	Positive_Correlation	29431	13857	Novel
79836211	Positive_Correlation	13857	29431	Novel
79836211	Positive_Correlation	5443	13857	Novel
79836211	Positive_Correlation	29431	2815	Novel

06975765|t|Catalase and TP53 expression in hRPTEC cells under the influence of methylmalonic acid, Sal, and Kilham rat virus i
06975765|a|This study investigates the complex interactions between catalase, TP53, and C-reactive protein in hRPTEC cells exposed to methylmalonic acid, Sal, and Kilham rat virus. The research highlights the conversion between Sal and methylmalonic acid, as well as the negative correlation between these two chemical entities. Cotreatment with Sal and methylmalonic acid was found to significantly alter the expression levels of catalase and TP53, suggesting a potential regulatory mechanism. Furthermore, the study demonstrates that the conversion between methylmalonic acid and Sal is not only bidirectional but also influenced by the presence of Kilham rat virus. The negative correlation between methylmalonic acid and Sal was confirmed through multiple experimental approaches, including gene expression profiling and metabolic flux analysis. The cotreatment of methylmalonic acid and Sal was shown to modulate the expression of C-reactive protein, which is known to be a key mediator of inflammation. The findings suggest that the interplay between these chemical entities and the hRPTEC cell line may have important implications for understanding the pathophysiology of renal diseases. Additionally, the study reveals that the presence of Kilham rat virus exacerbates the effects of methylmalonic acid and Sal on catalase and TP53 expression, indicating a potential role for viral infection in the regulation of these genes. The results provide new insights into the molecular mechanisms underlying the interactions between methylmalonic acid, Sal, and the hRPTEC cell line, with potential applications in the development of therapeutic strategies for renal disorders.
06975765	13	17	TP53	GeneOrGeneProduct	24842
06975765	32	38	hRPTEC	CellLine	CVCL_K278
06975765	68	86	methylmalonic acid	ChemicalEntity	D008764
06975765	88	91	Sal	ChemicalEntity	C009172
06975765	97	113	Kilham rat virus	OrganismTaxon	12441
06975765	173	181	catalase	GeneOrGeneProduct	24248
06975765	183	187	TP53	GeneOrGeneProduct	24842
06975765	193	211	C-reactive protein	GeneOrGeneProduct	1401
06975765	215	221	hRPTEC	CellLine	CVCL_K278
06975765	239	257	methylmalonic acid	ChemicalEntity	D008764
06975765	259	262	Sal	ChemicalEntity	C009172
06975765	268	284	Kilham rat virus	OrganismTaxon	12441
06975765	333	336	Sal	ChemicalEntity	C009172
06975765	341	359	methylmalonic acid	ChemicalEntity	D008764
06975765	451	454	Sal	ChemicalEntity	C009172
06975765	459	477	methylmalonic acid	ChemicalEntity	D008764
06975765	536	544	catalase	GeneOrGeneProduct	24248
06975765	549	553	TP53	GeneOrGeneProduct	24842
06975765	664	682	methylmalonic acid	ChemicalEntity	D008764
06975765	687	690	Sal	ChemicalEntity	C009172
06975765	756	772	Kilham rat virus	OrganismTaxon	12441
06975765	807	825	methylmalonic acid	ChemicalEntity	D008764
06975765	830	833	Sal	ChemicalEntity	C009172
06975765	974	992	methylmalonic acid	ChemicalEntity	D008764
06975765	997	1000	Sal	ChemicalEntity	C009172
06975765	1041	1059	C-reactive protein	GeneOrGeneProduct	1401
06975765	1194	1200	hRPTEC	CellLine	CVCL_K278
06975765	1353	1369	Kilham rat virus	OrganismTaxon	12441
06975765	1397	1415	methylmalonic acid	ChemicalEntity	D008764
06975765	1420	1423	Sal	ChemicalEntity	C009172
06975765	1427	1435	catalase	GeneOrGeneProduct	24248
06975765	1440	1444	TP53	GeneOrGeneProduct	24842
06975765	1638	1656	methylmalonic acid	ChemicalEntity	D008764
06975765	1658	1661	Sal	ChemicalEntity	C009172
06975765	1671	1677	hRPTEC	CellLine	CVCL_K278
06975765	Conversion	C009172	D008764	Novel
06975765	Negative_Correlation	C009172	D008764	Novel
06975765	Cotreatment	C009172	D008764	Novel
06975765	Conversion	D008764	C009172	Novel
06975765	Negative_Correlation	D008764	C009172	Novel
06975765	Cotreatment	D008764	C009172	Novel

94441525|t|Genetic Variants and Their Associations with Disease Phenotypes in Human Immunodeficiency Virus and Mangifera ind
94441525|a|This study investigates the genetic associations between specific sequence variants and disease phenotypes in both human immunodeficiency virus (HIV) and Mangifera indica Linn. We focused on the impact of sequence variants such as C282Y, Ex2+860G>C, c.2477G>C, and p.Leu307Arg on gene expression and disease outcomes. The gene products ATGL, resistin, IDO, and InsR were analyzed in relation to these variants.   In the HIV cohort, we observed a negative correlation between bradycardia and IDO expression, suggesting that IDO may play a protective role in cardiovascular function under HIV infection. Additionally, the sequence variant p.Leu307Arg was found to be significantly associated with InsR, indicating a potential role in insulin signaling pathways. A negative correlation was also noted between AMD and InsR, suggesting that InsR dysfunction may contribute to the pathogenesis of age-related macular degeneration.   In the Mangifera indica Linn plant model, we identified three instances of the organism taxon and explored the genetic basis of disease phenotypes such as rash. The sequence variant p.Leu307Arg was again associated with InsR, while a negative correlation was observed between rash and both resistin and alpha(1). Furthermore, a negative correlation was found between AMD and alpha(1), implying that alpha(1) may be involved in the progression of AMD.   The gene product alpha(1) was also found to be highly expressed in multiple contexts, with four instances of the gene or gene product noted in the study. The presence of multiple sequence variants and their associations with disease phenotypes highlights the complex interplay between genetic factors and disease outcomes in both human and plant systems.
94441525	229	257	human immunodeficiency virus	OrganismTaxon	12721
94441525	268	289	Mangifera indica Linn	OrganismTaxon	29780
94441525	345	350	C282Y	SequenceVariant	rs1800562
94441525	352	362	Ex2+860G>C	SequenceVariant	rs2234671
94441525	364	373	c.2477G>C	SequenceVariant	c|SUB|G|2477|C
94441525	379	390	p.Leu307Arg	SequenceVariant	p|SUB|L|307|R
94441525	450	454	ATGL	GeneOrGeneProduct	57104
94441525	456	464	resistin	GeneOrGeneProduct	56729
94441525	466	469	IDO	GeneOrGeneProduct	3620
94441525	475	479	InsR	GeneOrGeneProduct	3643
94441525	589	600	bradycardia	DiseaseOrPhenotypicFeature	D001919
94441525	605	608	IDO	GeneOrGeneProduct	3620
94441525	637	640	IDO	GeneOrGeneProduct	3620
94441525	751	762	p.Leu307Arg	SequenceVariant	p|SUB|L|307|R
94441525	809	813	InsR	GeneOrGeneProduct	3643
94441525	920	923	AMD	DiseaseOrPhenotypicFeature	D008268
94441525	928	932	InsR	GeneOrGeneProduct	3643
94441525	950	954	InsR	GeneOrGeneProduct	3643
94441525	1048	1069	Mangifera indica Linn	OrganismTaxon	29780
94441525	1196	1200	rash	DiseaseOrPhenotypicFeature	D005076
94441525	1223	1234	p.Leu307Arg	SequenceVariant	p|SUB|L|307|R
94441525	1261	1265	InsR	GeneOrGeneProduct	3643
94441525	1317	1321	rash	DiseaseOrPhenotypicFeature	D005076
94441525	1331	1339	resistin	GeneOrGeneProduct	56729
94441525	1344	1352	alpha(1)	GeneOrGeneProduct	11549
94441525	1408	1411	AMD	DiseaseOrPhenotypicFeature	D008268
94441525	1416	1424	alpha(1)	GeneOrGeneProduct	11549
94441525	1440	1448	alpha(1)	GeneOrGeneProduct	11549
94441525	1487	1490	AMD	DiseaseOrPhenotypicFeature	D008268
94441525	1511	1519	alpha(1)	GeneOrGeneProduct	11549
94441525	Negative_Correlation	D001919	3620	Novel
94441525	Association	p|SUB|L|307|R	3643	Novel
94441525	Negative_Correlation	D008268	3643	Novel
94441525	Negative_Correlation	D005076	56729	Novel
94441525	Negative_Correlation	D005076	11549	Novel
94441525	Negative_Correlation	D008268	11549	Novel

68750122|t|CCR2 and sequence variants in relation to antiretroviral therapy and chemical entities in diverse o
68750122|a|Recent studies have explored the role of the chemokine receptor CCR2 in immune responses and its potential interactions with sequence variants and chemical entities in various organisms. This research focuses on the associations between the sequence variants p.G204VfsX28 and 5382insC, and their correlations with the chemical entities ciprofloxacin, SH, and d4T. The findings suggest a positive correlation between p.G204VfsX28 and ciprofloxacin, as well as between p.G204VfsX28 and SH. Similarly, 5382insC shows a positive correlation with both ciprofloxacin and SH. Additionally, the sequence variant 5382insC is positively correlated with d4T, and p.G204VfsX28 is also positively correlated with d4T. These associations were observed across multiple organisms, including hepatitis B virus, tobacco, Mangifera indica Linn, and chick. The study highlights the potential role of CCR2 in modulating the effects of these sequence variants and chemical entities in different biological contexts. Further research is needed to elucidate the molecular mechanisms underlying these interactions and their implications for therapeutic strategies in diverse species.
68750122	0	4	CCR2	GeneOrGeneProduct	60463
68750122	164	168	CCR2	GeneOrGeneProduct	60463
68750122	359	371	p.G204VfsX28	SequenceVariant	p|FS|G|204|V|28
68750122	376	384	5382insC	SequenceVariant	c|INS|5382|C
68750122	436	449	ciprofloxacin	ChemicalEntity	D002939
68750122	451	453	SH	ChemicalEntity	D013439
68750122	459	462	d4T	ChemicalEntity	D018119
68750122	516	528	p.G204VfsX28	SequenceVariant	p|FS|G|204|V|28
68750122	533	546	ciprofloxacin	ChemicalEntity	D002939
68750122	567	579	p.G204VfsX28	SequenceVariant	p|FS|G|204|V|28
68750122	584	586	SH	ChemicalEntity	D013439
68750122	599	607	5382insC	SequenceVariant	c|INS|5382|C
68750122	647	660	ciprofloxacin	ChemicalEntity	D002939
68750122	665	667	SH	ChemicalEntity	D013439
68750122	704	712	5382insC	SequenceVariant	c|INS|5382|C
68750122	743	746	d4T	ChemicalEntity	D018119
68750122	752	764	p.G204VfsX28	SequenceVariant	p|FS|G|204|V|28
68750122	800	803	d4T	ChemicalEntity	D018119
68750122	875	892	hepatitis B virus	OrganismTaxon	10407
68750122	894	901	tobacco	OrganismTaxon	4097
68750122	903	924	Mangifera indica Linn	OrganismTaxon	29780
68750122	930	935	chick	OrganismTaxon	9031
68750122	980	984	CCR2	GeneOrGeneProduct	60463
68750122	Positive_Correlation	p|FS|G|204|V|28	D002939	Novel
68750122	Positive_Correlation	p|FS|G|204|V|28	D013439	Novel
68750122	Positive_Correlation	c|INS|5382|C	D002939	Novel
68750122	Positive_Correlation	c|INS|5382|C	D013439	Novel
68750122	Positive_Correlation	p|FS|G|204|V|28	D018119	Novel
68750122	Positive_Correlation	c|INS|5382|C	D018119	Novel

40848066|t|Dengue virus type 2, DEN-4, and Toxorynchites mosquitoes: interactions with Daucus carota, West Nile virus, and human immunodeficiency virus in diverse host
40848066|a|This study investigates the complex interactions between dengue virus type 2, DEN-4, Toxorynchites mosquitoes, Daucus carota, West Nile virus, and human immunodeficiency virus across multiple host systems. The research focuses on the role of Toxorynchites mosquitoes as potential vectors for dengue virus type 2 and DEN-4, with particular attention to their ecological interactions with Daucus carota. The study also explores the cross-species transmission dynamics between dengue virus type 2 and West Nile virus, highlighting the shared environmental reservoirs and vector systems. Additionally, the impact of human immunodeficiency virus on immune responses to dengue virus type 2 and DEN-4 is examined, with a focus on the implications for viral persistence and pathogenesis. The findings suggest that the interplay between these organisms is critical in shaping disease outcomes in both human and animal populations. The study further emphasizes the importance of understanding these interactions for the development of targeted public health interventions and vaccine strategies. The results provide new insights into the ecological and immunological factors that influence the spread and severity of these pathogens, particularly in regions where multiple viral threats coexist.
40848066	21	26	DEN-4	OrganismTaxon	11070
40848066	32	56	Toxorynchites mosquitoes	OrganismTaxon	2498889
40848066	76	89	Daucus carota	OrganismTaxon	4039
40848066	91	106	West Nile virus	OrganismTaxon	11082
40848066	112	140	human immunodeficiency virus	OrganismTaxon	12721
40848066	214	233	dengue virus type 2	OrganismTaxon	11060
40848066	235	240	DEN-4	OrganismTaxon	11070
40848066	242	266	Toxorynchites mosquitoes	OrganismTaxon	2498889
40848066	268	281	Daucus carota	OrganismTaxon	4039
40848066	283	298	West Nile virus	OrganismTaxon	11082
40848066	304	332	human immunodeficiency virus	OrganismTaxon	12721
40848066	399	423	Toxorynchites mosquitoes	OrganismTaxon	2498889
40848066	449	468	dengue virus type 2	OrganismTaxon	11060
40848066	473	478	DEN-4	OrganismTaxon	11070
40848066	544	557	Daucus carota	OrganismTaxon	4039
40848066	631	650	dengue virus type 2	OrganismTaxon	11060
40848066	655	670	West Nile virus	OrganismTaxon	11082
40848066	769	797	human immunodeficiency virus	OrganismTaxon	12721
40848066	821	840	dengue virus type 2	OrganismTaxon	11060
40848066	845	850	DEN-4	OrganismTaxon	11070

31291798|t|AP7 and its interactions with norfloxacin, 4-diphenylacetoxy-N-methylpiperidine-methiodide, and YC1 in the context of hepatitis B virus and primary Hodgkin 
31291798|a|Recent studies have highlighted the complex interactions between the chemical entity AP7 and various therapeutic agents, including norfloxacin and 4-diphenylacetoxy-N-methylpiperidine-methiodide, in the context of viral and neoplastic diseases. This study investigates the molecular and pharmacological relationships between AP7 and these compounds, as well as their associations with specific genes and disease states.   AP7 was found to bind specifically to the gene product GALT, suggesting a potential role in modulating immune responses. Furthermore, cotreatment with norfloxacin and AP7 was observed to enhance therapeutic efficacy, although this was accompanied by a negative correlation between norfloxacin and the gene YC1. Similarly, cotreatment with AP7 and 4-diphenylacetoxy-N-methylpiperidine-methiodide was associated with improved outcomes, and this relationship was further supported by a negative correlation between 4-diphenylacetoxy-N-methylpiperidine-methiodide and YC1.   The gene YC1 was also found to exhibit a negative correlation with both norfloxacin and 4-diphenylacetoxy-N-methylpiperidine-methiodide, indicating a potential regulatory role in the response to these compounds. Additionally, the gene CD36 was identified as a key player in the interaction network, particularly in the context of bovine models and the disease Hyperprolactinemia.   In the context of primary Hodgkin lymphoma, the presence of hepatitis B virus was associated with altered expression patterns of GALT and CD36, suggesting a possible link between viral infection and the progression of this disease. The study also noted that sudden death was more frequently observed in patients with Hyperprolactinemia, further emphasizing the complex interplay between genetic, chemical, and phenotypic factors in disease pathogenesis.
31291798	0	3	AP7	ChemicalEntity	C031231
31291798	30	41	norfloxacin	ChemicalEntity	D009643
31291798	43	90	4-diphenylacetoxy-N-methylpiperidine-methiodide	ChemicalEntity	C042375
31291798	96	99	YC1	GeneOrGeneProduct	56878
31291798	118	135	hepatitis B virus	OrganismTaxon	10407
31291798	242	245	AP7	ChemicalEntity	C031231
31291798	288	299	norfloxacin	ChemicalEntity	D009643
31291798	304	351	4-diphenylacetoxy-N-methylpiperidine-methiodide	ChemicalEntity	C042375
31291798	482	485	AP7	ChemicalEntity	C031231
31291798	579	582	AP7	ChemicalEntity	C031231
31291798	634	638	GALT	GeneOrGeneProduct	2592
31291798	730	741	norfloxacin	ChemicalEntity	D009643
31291798	746	749	AP7	ChemicalEntity	C031231
31291798	860	871	norfloxacin	ChemicalEntity	D009643
31291798	885	888	YC1	GeneOrGeneProduct	56878
31291798	918	921	AP7	ChemicalEntity	C031231
31291798	926	973	4-diphenylacetoxy-N-methylpiperidine-methiodide	ChemicalEntity	C042375
31291798	1091	1138	4-diphenylacetoxy-N-methylpiperidine-methiodide	ChemicalEntity	C042375
31291798	1143	1146	YC1	GeneOrGeneProduct	56878
31291798	1159	1162	YC1	GeneOrGeneProduct	56878
31291798	1222	1233	norfloxacin	ChemicalEntity	D009643
31291798	1238	1285	4-diphenylacetoxy-N-methylpiperidine-methiodide	ChemicalEntity	C042375
31291798	1385	1389	CD36	GeneOrGeneProduct	948
31291798	1480	1486	bovine	OrganismTaxon	9913
31291798	1510	1528	Hyperprolactinemia	DiseaseOrPhenotypicFeature	D006966
31291798	1550	1574	primary Hodgkin lymphoma	DiseaseOrPhenotypicFeature	D006689
31291798	1592	1609	hepatitis B virus	OrganismTaxon	10407
31291798	1661	1665	GALT	GeneOrGeneProduct	2592
31291798	1670	1674	CD36	GeneOrGeneProduct	948
31291798	1790	1802	sudden death	DiseaseOrPhenotypicFeature	D003645
31291798	1849	1867	Hyperprolactinemia	DiseaseOrPhenotypicFeature	D006966
31291798	Bind	2592	C031231	Novel
31291798	Cotreatment	C031231	D009643	Novel
31291798	Negative_Correlation	C031231	56878	Novel
31291798	Cotreatment	C031231	C042375	Novel
31291798	Negative_Correlation	D009643	56878	Novel
31291798	Cotreatment	C042375	C031231	Novel
31291798	Negative_Correlation	C042375	56878	Novel

20593696|t|TGFB1 and DEPTOR Interactions in Rabbit and Guinea Pig Models: Correlations with Midazolam, 8-Hydroxyguanine, and G
20593696|a|This study investigates the molecular interactions and regulatory relationships between the gene products TGFB1 and DEPTOR in rabbit and guinea pig models, with a focus on their interactions with the chemical entities midazolam and 8-hydroxyguanine, as well as the cell lines GT1-1 and MH134. We demonstrate that TGFB1 binds directly to DEPTOR, and this interaction is further reinforced by the binding of DEPTOR to GSK-3beta and TGFB1. Additionally, GSK-3beta binds to both DEPTOR and TGFB1, forming a complex regulatory network.   Our findings reveal a positive correlation between midazolam and both TGFB1 and DEPTOR, while midazolam also shows a negative correlation with 8-hydroxyguanine. Conversely, 8-hydroxyguanine exhibits a positive correlation with both TGFB1 and DEPTOR, and a strong positive correlation with GSK-3beta. Notably, there is a conversion relationship between midazolam and 8-hydroxyguanine, suggesting a dynamic interplay between these chemical entities.   The comparison between midazolam and 8-hydroxyguanine highlights their opposing effects on the regulatory pathways involving TGFB1 and DEPTOR. Furthermore, the study demonstrates that the cell line MH134 is particularly responsive to these interactions, while the GT1-1 cell line shows a distinct pattern of gene expression. The organism taxon Spirulina is also included as a model system to explore the broader implications of these molecular interactions in different biological contexts.   These results provide a comprehensive framework for understanding the complex regulatory networks involving TGFB1, DEPTOR, GSK-3beta, midazolam, and 8-hydroxyguanine, with potential applications in pharmacology and molecular biology.
20593696	0	5	TGFB1	GeneOrGeneProduct	7040
20593696	10	16	DEPTOR	GeneOrGeneProduct	97998
20593696	222	227	TGFB1	GeneOrGeneProduct	7040
20593696	232	238	DEPTOR	GeneOrGeneProduct	97998
20593696	242	248	rabbit	OrganismTaxon	9986
20593696	253	263	guinea pig	OrganismTaxon	10141
20593696	334	343	midazolam	ChemicalEntity	D008874
20593696	348	364	8-hydroxyguanine	ChemicalEntity	C024829
20593696	392	397	GT1-1	CellLine	CVCL_6236
20593696	402	407	MH134	CellLine	CVCL_8111
20593696	429	434	TGFB1	GeneOrGeneProduct	7040
20593696	453	459	DEPTOR	GeneOrGeneProduct	97998
20593696	522	528	DEPTOR	GeneOrGeneProduct	97998
20593696	532	541	GSK-3beta	GeneOrGeneProduct	2932
20593696	546	551	TGFB1	GeneOrGeneProduct	7040
20593696	567	576	GSK-3beta	GeneOrGeneProduct	2932
20593696	591	597	DEPTOR	GeneOrGeneProduct	97998
20593696	602	607	TGFB1	GeneOrGeneProduct	7040
20593696	700	709	midazolam	ChemicalEntity	D008874
20593696	719	724	TGFB1	GeneOrGeneProduct	7040
20593696	729	735	DEPTOR	GeneOrGeneProduct	97998
20593696	743	752	midazolam	ChemicalEntity	D008874
20593696	792	808	8-hydroxyguanine	ChemicalEntity	C024829
20593696	822	838	8-hydroxyguanine	ChemicalEntity	C024829
20593696	881	886	TGFB1	GeneOrGeneProduct	7040
20593696	891	897	DEPTOR	GeneOrGeneProduct	97998
20593696	938	947	GSK-3beta	GeneOrGeneProduct	2932
20593696	1001	1010	midazolam	ChemicalEntity	D008874
20593696	1015	1031	8-hydroxyguanine	ChemicalEntity	C024829
20593696	1122	1131	midazolam	ChemicalEntity	D008874
20593696	1136	1152	8-hydroxyguanine	ChemicalEntity	C024829
20593696	1224	1229	TGFB1	GeneOrGeneProduct	7040
20593696	1234	1240	DEPTOR	GeneOrGeneProduct	97998
20593696	1297	1302	MH134	CellLine	CVCL_8111
20593696	1363	1368	GT1-1	CellLine	CVCL_6236
20593696	1443	1452	Spirulina	OrganismTaxon	551299
20593696	1700	1705	TGFB1	GeneOrGeneProduct	7040
20593696	1707	1713	DEPTOR	GeneOrGeneProduct	97998
20593696	1715	1724	GSK-3beta	GeneOrGeneProduct	2932
20593696	1726	1735	midazolam	ChemicalEntity	D008874
20593696	1741	1757	8-hydroxyguanine	ChemicalEntity	C024829
20593696	Bind	7040	97998	Novel
20593696	Negative_Correlation	D008874	C024829	Novel
20593696	Positive_Correlation	D008874	97998	Novel
20593696	Negative_Correlation	C024829	D008874	Novel
20593696	Conversion	C024829	D008874	Novel
20593696	Positive_Correlation	C024829	2932	Novel
20593696	Positive_Correlation	D008874	2932	Novel
20593696	Comparison	C024829	D008874	Novel
20593696	Bind	97998	2932	Novel
20593696	Positive_Correlation	D008874	7040	Novel
20593696	Positive_Correlation	C024829	7040	Novel
20593696	Positive_Correlation	C024829	97998	Novel
20593696	Bind	2932	97998	Novel
20593696	Bind	97998	7040	Novel
20593696	Bind	7040	2932	Novel
20593696	Comparison	D008874	C024829	Novel
20593696	Bind	2932	7040	Novel
20593696	Conversion	D008874	C024829	Novel

03929514|t|Genetic analysis of p.A27fsX132 in Mangifera indica Linn and its associations with multiple phenotypic features in human immunodeficiency virus and SJ-GBM2 ce
03929514|a|This study investigates the genetic variant p.A27fsX132 and its associations with various phenotypic features in the context of Mangifera indica Linn and human immunodeficiency virus (HIV). The variant p.A27fsX132 was identified in multiple instances across different experimental models, including the SJ-GBM2 cell line and BALB/c mice. The research highlights a significant association between p.A27fsX132 and several disease phenotypes, including Fanconi syndrome, anemia, myoglobinuria, T-cell leukaemia or lymphoma, and motion abnormalities. These associations were observed through a combination of in vitro and in vivo experiments, with particular emphasis on the role of p.A27fsX132 in modulating cellular responses in the SJ-GBM2 cell line. The findings suggest that p.A27fsX132 may play a critical role in the pathogenesis of these conditions, particularly in the context of HIV infection. Additionally, the study explores the potential of Mangifera indica Linn as a therapeutic agent in mitigating the effects of p.A27fsX132-related phenotypes. The results provide a foundation for further research into the molecular mechanisms underlying these associations and their implications for clinical management.
03929514	20	31	p.A27fsX132	SequenceVariant	p|FS|A|27||132
03929514	35	56	Mangifera indica Linn	OrganismTaxon	29780
03929514	115	143	human immunodeficiency virus	OrganismTaxon	12721
03929514	148	155	SJ-GBM2	CellLine	CVCL_M141
03929514	203	214	p.A27fsX132	SequenceVariant	p|FS|A|27||132
03929514	287	308	Mangifera indica Linn	OrganismTaxon	29780
03929514	313	341	human immunodeficiency virus	OrganismTaxon	12721
03929514	361	372	p.A27fsX132	SequenceVariant	p|FS|A|27||132
03929514	462	469	SJ-GBM2	CellLine	CVCL_M141
03929514	484	490	BALB/c	CellLine	CVCL_9101
03929514	555	566	p.A27fsX132	SequenceVariant	p|FS|A|27||132
03929514	609	625	Fanconi syndrome	DiseaseOrPhenotypicFeature	D005198
03929514	627	633	anemia	DiseaseOrPhenotypicFeature	D000740
03929514	635	648	myoglobinuria	DiseaseOrPhenotypicFeature	D009212
03929514	650	678	T-cell leukaemia or lymphoma	DiseaseOrPhenotypicFeature	D015458|D016399
03929514	684	704	motion abnormalities	DiseaseOrPhenotypicFeature	D009041
03929514	838	849	p.A27fsX132	SequenceVariant	p|FS|A|27||132
03929514	890	897	SJ-GBM2	CellLine	CVCL_M141
03929514	935	946	p.A27fsX132	SequenceVariant	p|FS|A|27||132
03929514	1109	1130	Mangifera indica Linn	OrganismTaxon	29780
03929514	1183	1194	p.A27fsX132	SequenceVariant	p|FS|A|27||132
03929514	Association	D005198	p|FS|A|27||132	Novel
03929514	Association	D000740	p|FS|A|27||132	Novel
03929514	Association	D009212	p|FS|A|27||132	Novel
03929514	Association	D015458|D016399	p|FS|A|27||132	Novel
03929514	Association	D009041	p|FS|A|27||132	Novel

45497703|t|Curcumin and Selective Serotonin Reuptake Inhibitors: Interactions with Pulmonary Arterial Hypertension, Autoimmune Diseases, and miR-217 in Cats a
45497703|a|Recent studies have explored the complex interactions between curcumin, selective serotonin reuptake inhibitors (SSRIs), pulmonary arterial hypertension (PAH), autoimmune diseases, and miR-217 in both cats and sheep. A negative correlation was observed between curcumin and SSRIs, suggesting that these two chemical entities may have opposing effects on certain biological pathways. This negative correlation was further supported by findings of a conversion between curcumin and SSRIs, indicating a dynamic interplay between these compounds in modulating cellular responses.    The association between PAH and curcumin was highlighted through experimental models in cats, where curcumin showed potential therapeutic benefits in reducing vascular remodeling and pulmonary pressure. Additionally, a strong association was found between PAH and miR-217, with miR-217 acting as a regulatory factor in the pathogenesis of PAH. This relationship was further reinforced by the association between miR-217 and autoimmune diseases, suggesting that miR-217 may play a dual role in both PAH and autoimmune conditions.    In sheep, the association between autoimmune diseases and SSRIs was demonstrated through immunological profiling, where SSRIs were found to modulate immune responses and reduce inflammation. This was further supported by the conversion between SSRIs and curcumin, indicating that these compounds may influence each other's bioavailability and efficacy.    Moreover, the association between autoimmune diseases and curcumin was observed in both species, with curcumin showing anti-inflammatory and immunomodulatory properties. Finally, the association between PAH and SSRIs was confirmed through longitudinal studies, where SSRIs were found to have a dual effect on vascular tone and immune function, potentially influencing the progression of PAH. These findings underscore the intricate relationships between these biological entities and their potential therapeutic applications in veterinary medicine.
45497703	130	137	miR-217	GeneOrGeneProduct	387213
45497703	210	218	curcumin	ChemicalEntity	D003474
45497703	220	259	selective serotonin reuptake inhibitors	ChemicalEntity	D017367
45497703	269	300	pulmonary arterial hypertension	DiseaseOrPhenotypicFeature	D000081029
45497703	308	327	autoimmune diseases	DiseaseOrPhenotypicFeature	D001327
45497703	333	340	miR-217	GeneOrGeneProduct	387213
45497703	349	353	cats	OrganismTaxon	9685
45497703	358	363	sheep	OrganismTaxon	9940
45497703	409	417	curcumin	ChemicalEntity	D003474
45497703	615	623	curcumin	ChemicalEntity	D003474
45497703	759	767	curcumin	ChemicalEntity	D003474
45497703	815	819	cats	OrganismTaxon	9685
45497703	827	835	curcumin	ChemicalEntity	D003474
45497703	991	998	miR-217	GeneOrGeneProduct	387213
45497703	1005	1012	miR-217	GeneOrGeneProduct	387213
45497703	1139	1146	miR-217	GeneOrGeneProduct	387213
45497703	1151	1170	autoimmune diseases	DiseaseOrPhenotypicFeature	D001327
45497703	1188	1195	miR-217	GeneOrGeneProduct	387213
45497703	1262	1267	sheep	OrganismTaxon	9940
45497703	1293	1312	autoimmune diseases	DiseaseOrPhenotypicFeature	D001327
45497703	1513	1521	curcumin	ChemicalEntity	D003474
45497703	1649	1668	autoimmune diseases	DiseaseOrPhenotypicFeature	D001327
45497703	1673	1681	curcumin	ChemicalEntity	D003474
45497703	1717	1725	curcumin	ChemicalEntity	D003474
45497703	Negative_Correlation	D003474	D017367	Novel
45497703	Association	D000081029	D003474	Novel
45497703	Conversion	D017367	D003474	Novel
45497703	Association	D001327	D017367	Novel
45497703	Association	D000081029	387213	Novel
45497703	Association	387213	D001327	Novel
45497703	Conversion	D003474	D017367	Novel
45497703	Association	D000081029	D017367	Novel
45497703	Association	D001327	387213	Novel
45497703	Negative_Correlation	D017367	D003474	Novel

18812184|t|NMDA receptor modulation in Mz-ChA-1 cells: effects of del642T on NDUFS3 expression and 
18812184|a|The NMDA receptor, a key player in synaptic plasticity and neuronal communication, has been extensively studied for its role in various neurological disorders. In this study, we investigate the impact of the sequence variant del642T on the expression and function of the NDUFS3 gene in the Mz-ChA-1 cell line, a well-characterized model for neuroblastoma research. NDUFS3, a subunit of the mitochondrial complex I, is critical for cellular energy production and has been implicated in several neurodegenerative diseases. Our findings reveal that the del642T variant significantly alters the stability and localization of NDUFS3 protein in Mz-ChA-1 cells. This effect was observed across multiple experimental conditions, including baseline expression, stress-induced changes, and in response to NMDA receptor activation. Furthermore, the presence of del642T was associated with reduced mitochondrial respiration and increased oxidative stress in Mz-ChA-1 cells. These results suggest that the del642T variant may contribute to the pathophysiology of neurodegenerative conditions by disrupting NDUFS3 function through its interaction with NMDA receptor signaling pathways. Given the high prevalence of NDUFS3 mutations in the Mz-ChA-1 cell line and the significant impact of del642T on NMDA receptor-mediated processes, further studies are warranted to explore the therapeutic potential of targeting this variant in neurodegenerative diseases.
18812184	0	4	NMDA	ChemicalEntity	D016202
18812184	28	36	Mz-ChA-1	CellLine	CVCL_6932
18812184	55	62	del642T	SequenceVariant	c|DEL|642|T
18812184	66	72	NDUFS3	GeneOrGeneProduct	4722
18812184	93	97	NMDA	ChemicalEntity	D016202
18812184	314	321	del642T	SequenceVariant	c|DEL|642|T
18812184	360	366	NDUFS3	GeneOrGeneProduct	4722
18812184	379	387	Mz-ChA-1	CellLine	CVCL_6932
18812184	454	460	NDUFS3	GeneOrGeneProduct	4722
18812184	639	646	del642T	SequenceVariant	c|DEL|642|T
18812184	710	716	NDUFS3	GeneOrGeneProduct	4722
18812184	728	736	Mz-ChA-1	CellLine	CVCL_6932
18812184	884	888	NMDA	ChemicalEntity	D016202
18812184	939	946	del642T	SequenceVariant	c|DEL|642|T
18812184	1035	1043	Mz-ChA-1	CellLine	CVCL_6932
18812184	1082	1089	del642T	SequenceVariant	c|DEL|642|T
18812184	1182	1188	NDUFS3	GeneOrGeneProduct	4722
18812184	1227	1231	NMDA	ChemicalEntity	D016202
18812184	1290	1296	NDUFS3	GeneOrGeneProduct	4722
18812184	1314	1322	Mz-ChA-1	CellLine	CVCL_6932
18812184	1363	1370	del642T	SequenceVariant	c|DEL|642|T
18812184	1374	1378	NMDA	ChemicalEntity	D016202

17024799|t|Genetic and pharmacological interactions in neurodevelopmental disorders: a multi-cellular and multi-varia
17024799|a|This study investigates the complex interplay between genetic variants, pharmacological agents, and cellular responses in neurodevelopmental disorders. Using a combination of in vitro and in vivo models, we examined the effects of various sequence variants and chemical entities on cell line behavior and drug interactions.   Our findings reveal a positive correlation between procaine and domperidone, suggesting a synergistic effect in modulating neuronal activity. Conversely, a negative correlation was observed between p.F366L and domperidone, indicating a potential antagonistic relationship. The positive correlation between p.F366L and 5-fluorouracil suggests that this variant may enhance the efficacy of 5-fluorouracil in certain cellular contexts.   We also found a positive correlation between G183S and AraG, which may have implications for the metabolism of nucleoside analogs in cancer therapy. The negative correlation between R3500Q and 5-fluorouracil highlights a potential mechanism of resistance to this chemotherapeutic agent.   In the context of neuropharmacology, a positive correlation was observed between fluoroquinolone and vigabatrin, suggesting a possible interaction in the modulation of cholinergic pathways. Additionally, a negative correlation between leucine to methionine and AraG was noted, which may influence the metabolic processing of nucleoside analogs.   The positive correlation between procaine and organophosphorus indicates a potential mechanism for the enhancement of cholinergic signaling, while the negative correlation between A2718G and organophosphorus suggests a regulatory role in this pathway. A positive correlation between organophosphorus and vigabatrin further supports the involvement of these compounds in cholinergic modulation.   The negative correlation between g.3318-15C>T and domperidone suggests a potential genetic basis for differential drug response. Furthermore, the negative correlation between dup24bp and 5-fluorouracil indicates a possible mechanism of resistance to this drug.   Our study also examined the effects of these genetic and pharmacological factors in multiple cell lines, including MEF, 293T, C57BL/6J, Mz-ChA-1, LbetaT2, HEK, KU7, Ba/F3, SNU-C2A, and DU145. These findings provide a comprehensive framework for understanding the molecular and pharmacological interactions that underlie neurodevelopmental disorders and their treatment.
17024799	484	492	procaine	ChemicalEntity	D011343
17024799	497	508	domperidone	ChemicalEntity	D004294
17024799	631	638	p.F366L	SequenceVariant	rs140756663
17024799	643	654	domperidone	ChemicalEntity	D004294
17024799	739	746	p.F366L	SequenceVariant	rs140756663
17024799	751	765	5-fluorouracil	ChemicalEntity	D005472
17024799	821	835	5-fluorouracil	ChemicalEntity	D005472
17024799	913	918	G183S	SequenceVariant	rs121434247
17024799	923	927	AraG	ChemicalEntity	C104457
17024799	1050	1056	R3500Q	SequenceVariant	rs5742904
17024799	1061	1075	5-fluorouracil	ChemicalEntity	D005472
17024799	1238	1253	fluoroquinolone	ChemicalEntity	D024841
17024799	1258	1268	vigabatrin	ChemicalEntity	D020888
17024799	1325	1336	cholinergic	ChemicalEntity	D018678
17024799	1392	1413	leucine to methionine	SequenceVariant	rs2073601
17024799	1418	1422	AraG	ChemicalEntity	C104457
17024799	1537	1545	procaine	ChemicalEntity	D011343
17024799	1550	1566	organophosphorus	ChemicalEntity	D010755
17024799	1622	1633	cholinergic	ChemicalEntity	D018678
17024799	1684	1690	A2718G	SequenceVariant	rs4539
17024799	1695	1711	organophosphorus	ChemicalEntity	D010755
17024799	1787	1803	organophosphorus	ChemicalEntity	D010755
17024799	1808	1818	vigabatrin	ChemicalEntity	D020888
17024799	1874	1885	cholinergic	ChemicalEntity	D018678
17024799	1933	1945	g.3318-15C>T	SequenceVariant	g|SUB|C|3318-15|T
17024799	1950	1961	domperidone	ChemicalEntity	D004294
17024799	2075	2082	dup24bp	SequenceVariant	c|DUP||24|
17024799	2087	2101	5-fluorouracil	ChemicalEntity	D005472
17024799	2278	2281	MEF	CellLine	CVCL_9115
17024799	2283	2287	293T	CellLine	CVCL_0063
17024799	2289	2297	C57BL/6J	CellLine	CVCL_5U84
17024799	2299	2307	Mz-ChA-1	CellLine	CVCL_6932
17024799	2309	2316	LbetaT2	CellLine	CVCL_0398
17024799	2318	2321	HEK	CellLine	CVCL_M624
17024799	2323	2326	KU7	CellLine	CVCL_4714
17024799	2328	2333	Ba/F3	CellLine	CVCL_0161
17024799	2335	2342	SNU-C2A	CellLine	CVCL_1709
17024799	2348	2353	DU145	CellLine	CVCL_0105
17024799	Positive_Correlation	D011343	D004294	Novel
17024799	Negative_Correlation	rs140756663	D004294	Novel
17024799	Positive_Correlation	rs140756663	D005472	Novel
17024799	Positive_Correlation	rs121434247	C104457	Novel
17024799	Negative_Correlation	rs5742904	D005472	Novel
17024799	Positive_Correlation	D024841	D020888	Novel
17024799	Negative_Correlation	rs2073601	C104457	Novel
17024799	Positive_Correlation	D011343	D010755	Novel
17024799	Negative_Correlation	rs4539	D010755	Novel
17024799	Positive_Correlation	D010755	D020888	Novel
17024799	Positive_Correlation	D018678	D011343	Novel
17024799	Negative_Correlation	g|SUB|C|3318-15|T	D004294	Novel
17024799	Negative_Correlation	c|DUP||24|	D005472	Novel
17024799	Positive_Correlation	D024841	D004294	Novel

71972081|t|Ouabain, AP7, and Thiamine Modulate MYB and GJA8 Expression in Guinea-Pigs and Human Immunodeficiency Virus In
71972081|a|Recent studies have highlighted the complex interactions between chemical entities, sequence variants, and gene products in modulating cellular responses in various organisms. This study investigates the molecular mechanisms underlying the effects of ouabain, AP7, and Thiamine on the expression of MYB and GJA8 in guinea-pigs and their potential role in human immunodeficiency virus (HIV) infections.   Our findings reveal a positive correlation between MYB expression and ouabain treatment in guinea-pigs, suggesting a potential regulatory role of ouabain in MYB activity. Additionally, we observed a significant bind between AP7 and Msx2, indicating a direct interaction that may influence downstream signaling pathways. Cotreatment experiments demonstrated that ouabain and ibuprofen, when administered together, elicit a synergistic effect, while ibuprofen and Thiamine also show a cotreatment response, suggesting possible pharmacological interactions.   Further, we found that ouabain and AP7 exhibit a cotreatment effect, which may be relevant in the context of therapeutic strategies involving these compounds. The bind between Thiamine and MYB was confirmed through molecular docking studies, reinforcing the role of Thiamine in modulating MYB function.   Interestingly, the study also identified the presence of the sequence variant p.A384D in multiple guinea-pigs, along with the 15 kb deletion in human immunodeficiency virus (HIV) isolates. These variants were associated with altered gene expression patterns, particularly in the context of GJA8 and MYB. The sequence variant g.2885G>C was also found in several HIV strains, suggesting its potential role in viral pathogenesis.   In addition, the sequence variant C1007G was detected in guinea-pigs, while Ile(146)-->Leu was observed in human immunodeficiency virus isolates. The presence of these variants, along with the chemical entities AP7 and Thiamine, highlights the complexity of molecular interactions in both host and pathogen systems.   This study provides new insights into the molecular mechanisms underlying the interactions between chemical entities, sequence variants, and gene products in guinea-pigs and HIV infections, with implications for therapeutic strategies and disease management.
71972081	9	12	AP7	ChemicalEntity	C031231
71972081	18	26	Thiamine	ChemicalEntity	D013831
71972081	36	39	MYB	GeneOrGeneProduct	4602
71972081	44	48	GJA8	GeneOrGeneProduct	2703
71972081	362	369	ouabain	ChemicalEntity	D010042
71972081	371	374	AP7	ChemicalEntity	C031231
71972081	380	388	Thiamine	ChemicalEntity	D013831
71972081	410	413	MYB	GeneOrGeneProduct	4602
71972081	418	422	GJA8	GeneOrGeneProduct	2703
71972081	426	437	guinea-pigs	OrganismTaxon	10141
71972081	466	494	human immunodeficiency virus	OrganismTaxon	12721
71972081	566	569	MYB	GeneOrGeneProduct	4602
71972081	585	592	ouabain	ChemicalEntity	D010042
71972081	606	617	guinea-pigs	OrganismTaxon	10141
71972081	661	668	ouabain	ChemicalEntity	D010042
71972081	672	675	MYB	GeneOrGeneProduct	4602
71972081	739	742	AP7	ChemicalEntity	C031231
71972081	747	751	Msx2	GeneOrGeneProduct	17702
71972081	877	884	ouabain	ChemicalEntity	D010042
71972081	889	898	ibuprofen	ChemicalEntity	D007052
71972081	963	972	ibuprofen	ChemicalEntity	D007052
71972081	977	985	Thiamine	ChemicalEntity	D013831
71972081	1095	1102	ouabain	ChemicalEntity	D010042
71972081	1107	1110	AP7	ChemicalEntity	C031231
71972081	1248	1256	Thiamine	ChemicalEntity	D013831
71972081	1261	1264	MYB	GeneOrGeneProduct	4602
71972081	1338	1346	Thiamine	ChemicalEntity	D013831
71972081	1361	1364	MYB	GeneOrGeneProduct	4602
71972081	1455	1462	p.A384D	SequenceVariant	p|SUB|A|384|D
71972081	1475	1486	guinea-pigs	OrganismTaxon	10141
71972081	1503	1517	15 kb deletion	SequenceVariant	c|DEL||15K
71972081	1521	1549	human immunodeficiency virus	OrganismTaxon	12721
71972081	1667	1671	GJA8	GeneOrGeneProduct	2703
71972081	1676	1679	MYB	GeneOrGeneProduct	4602
71972081	1702	1711	g.2885G>C	SequenceVariant	g|SUB|G|2885|C
71972081	1840	1846	C1007G	SequenceVariant	rs72559747
71972081	1863	1874	guinea-pigs	OrganismTaxon	10141
71972081	1882	1896	Ile(146)-->Leu	SequenceVariant	rs72478580
71972081	1913	1941	human immunodeficiency virus	OrganismTaxon	12721
71972081	2017	2020	AP7	ChemicalEntity	C031231
71972081	2025	2033	Thiamine	ChemicalEntity	D013831
71972081	2282	2293	guinea-pigs	OrganismTaxon	10141
71972081	Positive_Correlation	4602	D010042	Novel
71972081	Bind	C031231	17702	Novel
71972081	Cotreatment	D010042	D007052	Novel
71972081	Cotreatment	D007052	D013831	Novel
71972081	Cotreatment	D010042	C031231	Novel
71972081	Bind	D013831	4602	Novel

50147812|t|Cortical malformations in horses: genetic associations with MODY3, Mx1, CD4, and frataxin 
50147812|a|Cortical malformations in horses have been linked to multiple genetic factors, including the MODY3 gene, Mx1 gene, CD4 protein, and frataxin. This study investigates the molecular mechanisms underlying these associations and their implications for neurological and metabolic disorders in equine populations. A total of 7 instances of cortical malformations were observed in horses with mutations in the MODY3 gene, which is also associated with hyperglycemia in 8 cases. The Mx1 gene was found to be significantly associated with both cortical malformations and hyperglycemia, with 6 instances of the gene product showing a direct correlation with these phenotypes. Additionally, the CD4 protein was found to be associated with both cortical malformations and chorea, with 9 instances of the protein and 5 instances of chorea showing a strong relationship. The G22 5A sequence variant was found to be linked to the 33-bp genomic deletion, with 6 instances of each variant co-occurring in the same genomic context. Frataxin was associated with both chorea and hyperglycemia, with 4 instances of the gene product and 5 instances of chorea, as well as 8 instances of hyperglycemia. The 33-bp genomic deletion was also found to be associated with the G22 5A variant, with 4 instances of the deletion and 6 instances of the variant co-occurring. These findings suggest a complex interplay between genetic variants and phenotypic features in horses, with implications for understanding the genetic basis of neurological and metabolic disorders in equine species.
50147812	26	32	horses	OrganismTaxon	9796
50147812	60	65	MODY3	GeneOrGeneProduct	6927
50147812	67	70	Mx1	GeneOrGeneProduct	17857
50147812	72	75	CD4	GeneOrGeneProduct	12504
50147812	81	89	frataxin	GeneOrGeneProduct	2395
50147812	117	123	horses	OrganismTaxon	9796
50147812	184	189	MODY3	GeneOrGeneProduct	6927
50147812	196	199	Mx1	GeneOrGeneProduct	17857
50147812	206	209	CD4	GeneOrGeneProduct	12504
50147812	223	231	frataxin	GeneOrGeneProduct	2395
50147812	425	447	cortical malformations	DiseaseOrPhenotypicFeature	D054220
50147812	465	471	horses	OrganismTaxon	9796
50147812	494	499	MODY3	GeneOrGeneProduct	6927
50147812	536	549	hyperglycemia	DiseaseOrPhenotypicFeature	D006943
50147812	566	569	Mx1	GeneOrGeneProduct	17857
50147812	626	648	cortical malformations	DiseaseOrPhenotypicFeature	D054220
50147812	653	666	hyperglycemia	DiseaseOrPhenotypicFeature	D006943
50147812	775	778	CD4	GeneOrGeneProduct	12504
50147812	824	846	cortical malformations	DiseaseOrPhenotypicFeature	D054220
50147812	851	857	chorea	DiseaseOrPhenotypicFeature	D002819
50147812	910	916	chorea	DiseaseOrPhenotypicFeature	D002819
50147812	952	958	G22 5A	SequenceVariant	rs6410
50147812	1006	1028	33-bp genomic deletion	SequenceVariant	g|DEL||33
50147812	1139	1145	chorea	DiseaseOrPhenotypicFeature	D002819
50147812	1150	1163	hyperglycemia	DiseaseOrPhenotypicFeature	D006943
50147812	1221	1227	chorea	DiseaseOrPhenotypicFeature	D002819
50147812	1255	1268	hyperglycemia	DiseaseOrPhenotypicFeature	D006943
50147812	1274	1296	33-bp genomic deletion	SequenceVariant	g|DEL||33
50147812	1338	1344	G22 5A	SequenceVariant	rs6410
50147812	1527	1533	horses	OrganismTaxon	9796
50147812	Association	12504	D002819	Novel
50147812	Association	6927	D054220	Novel
50147812	Association	17857	D054220	Novel
50147812	Association	rs6410	g|DEL||33	Novel
50147812	Association	17857	D006943	Novel
50147812	Association	17857	D002819	Novel
50147812	Association	6927	D002819	Novel
50147812	Association	2395	D002819	Novel
50147812	Association	2395	D006943	Novel
50147812	Association	g|DEL||33	rs6410	Novel
50147812	Association	12504	D054220	Novel
50147812	Association	12504	D006943	Novel
50147812	Association	6927	D006943	Novel
50147812	Association	2395	D054220	Novel

78266526|t|Ciliopathies, fatty acid synthase, and TCRg: complex interactions in prostate tumors an
78266526|a|Ciliopathies, a group of genetic disorders affecting cilia function, have been implicated in a variety of phenotypic features, including developmental abnormalities and metabolic dysregulation. This study explores the intricate relationships between ciliopathies, fatty acid synthase (FAS), TCRg, and Noggin, with a focus on their roles in prostate tumors and in the context of the organism Spirulina and the cell line MES-SA/Dx5.   Our findings reveal a significant association between ciliopathies and TCRg, with both positive and negative correlations observed in different experimental models. Notably, the relationship between ciliopathies and TCRg is further modulated by the presence of Noggin, which itself is associated with ciliopathies. The study also demonstrates a strong association between ciliopathies and fatty acid synthase, suggesting a potential metabolic pathway involved in ciliary dysfunction.   In the context of prostate tumors, we observed a significant association between prostate tumors and TCRg, as well as between prostate tumors and fatty acid synthase. Additionally, prostate tumors showed a correlation with Noggin, highlighting the potential involvement of these genes in tumor progression.   The organism Spirulina was used as a model system to investigate the interactions between ciliopathies and the gene products TCRg and Noggin, with the cell line MES-SA/Dx5 serving as a representative model for human cancer. The results suggest that the interplay between ciliopathies, TCRg, Noggin, and fatty acid synthase may have broader implications in both developmental and pathological contexts, including in horses, where ciliopathies have been previously reported.   These findings underscore the complexity of gene-disease interactions and provide a foundation for further research into the molecular mechanisms underlying ciliopathies and their associations with other phenotypic features.
78266526	14	33	fatty acid synthase	GeneOrGeneProduct	2194
78266526	39	43	TCRg	GeneOrGeneProduct	110067
78266526	69	84	prostate tumors	DiseaseOrPhenotypicFeature	D011471
78266526	338	350	ciliopathies	DiseaseOrPhenotypicFeature	D000072661
78266526	352	371	fatty acid synthase	GeneOrGeneProduct	2194
78266526	379	383	TCRg	GeneOrGeneProduct	110067
78266526	389	395	Noggin	GeneOrGeneProduct	9241
78266526	428	443	prostate tumors	DiseaseOrPhenotypicFeature	D011471
78266526	479	488	Spirulina	OrganismTaxon	551299
78266526	507	517	MES-SA/Dx5	CellLine	CVCL_2598
78266526	575	587	ciliopathies	DiseaseOrPhenotypicFeature	D000072661
78266526	592	596	TCRg	GeneOrGeneProduct	110067
78266526	720	732	ciliopathies	DiseaseOrPhenotypicFeature	D000072661
78266526	737	741	TCRg	GeneOrGeneProduct	110067
78266526	782	788	Noggin	GeneOrGeneProduct	9241
78266526	822	834	ciliopathies	DiseaseOrPhenotypicFeature	D000072661
78266526	893	905	ciliopathies	DiseaseOrPhenotypicFeature	D000072661
78266526	910	929	fatty acid synthase	GeneOrGeneProduct	2194
78266526	1025	1040	prostate tumors	DiseaseOrPhenotypicFeature	D011471
78266526	1088	1103	prostate tumors	DiseaseOrPhenotypicFeature	D011471
78266526	1108	1112	TCRg	GeneOrGeneProduct	110067
78266526	1133	1148	prostate tumors	DiseaseOrPhenotypicFeature	D011471
78266526	1153	1172	fatty acid synthase	GeneOrGeneProduct	2194
78266526	1188	1203	prostate tumors	DiseaseOrPhenotypicFeature	D011471
78266526	1230	1236	Noggin	GeneOrGeneProduct	9241
78266526	1329	1338	Spirulina	OrganismTaxon	551299
78266526	1406	1418	ciliopathies	DiseaseOrPhenotypicFeature	D000072661
78266526	1441	1445	TCRg	GeneOrGeneProduct	110067
78266526	1450	1456	Noggin	GeneOrGeneProduct	9241
78266526	1477	1487	MES-SA/Dx5	CellLine	CVCL_2598
78266526	1587	1599	ciliopathies	DiseaseOrPhenotypicFeature	D000072661
78266526	1601	1605	TCRg	GeneOrGeneProduct	110067
78266526	1607	1613	Noggin	GeneOrGeneProduct	9241
78266526	1619	1638	fatty acid synthase	GeneOrGeneProduct	2194
78266526	1731	1737	horses	OrganismTaxon	9796
78266526	1745	1757	ciliopathies	DiseaseOrPhenotypicFeature	D000072661
78266526	1948	1960	ciliopathies	DiseaseOrPhenotypicFeature	D000072661
78266526	Association	D011471	110067	Novel
78266526	Association	D000072661	110067	Novel
78266526	Association	110067	9241	Novel
78266526	Association	D000072661	2194	Novel
78266526	Association	D000072661	9241	Novel
78266526	Positive_Correlation	D000072661	9241	Novel
78266526	Negative_Correlation	D000072661	9241	Novel
78266526	Association	D011471	2194	Novel
78266526	Negative_Correlation	D000072661	110067	Novel
78266526	Association	2194	110067	Novel
78266526	Association	D011471	9241	Novel
78266526	Association	110067	2194	Novel

08927156|t|Fluo3 and receptor activator of NF-kappaB ligand interactions in mood disorder and jaw of steel: a study of genetic and chemical corr
08927156|a|This study investigates the complex interplay between the chemical entity Fluo3, the gene product receptor activator of NF-kappaB ligand, and the sequence variant c.461_462delAG in the context of mood disorder and jaw of steel. We also explore the relationships between Fluo3 and other key molecular entities such as LAT2, E-cadherin, and 2,3,5-triphenyltetrazolium, as well as the disease phenotypes familial hypercholesterolemia and jaw of steel.   Our findings reveal a positive correlation between c.461_462delAG and both Fluo3 and ester, suggesting a potential biochemical pathway linking these entities. Additionally, we observe a strong positive correlation between receptor activator of NF-kappaB ligand and Fluo3, as well as between receptor activator of NF-kappaB ligand and ester. These results are further supported by the positive correlation between receptor activator of NF-kappaB ligand and 2,3,5-triphenyltetrazolium, indicating a possible role for this gene product in cellular responses to chemical stimuli.  The study also demonstrates a positive correlation between E-cadherin and both 2,3,5-triphenyltetrazolium and Fluo3, as well as between E-cadherin and ester. These findings suggest that E-cadherin may serve as a key mediator in the interaction between chemical entities and cellular processes. Furthermore, the positive correlation between LAT2 and Fluo3 highlights the potential involvement of LAT2 in modulating the effects of Fluo3 in the context of mood disorder and jaw of steel.  The data presented here provide a comprehensive framework for understanding the molecular and biochemical relationships between these entities and their implications in disease phenotypes such as mood disorder and jaw of steel. These findings may have important implications for the development of targeted therapies and diagnostic tools in the treatment of these conditions.
08927156	0	5	Fluo3	ChemicalEntity	C059715
08927156	10	48	receptor activator of NF-kappaB ligand	GeneOrGeneProduct	21943
08927156	65	78	mood disorder	DiseaseOrPhenotypicFeature	D019964
08927156	83	95	jaw of steel	DiseaseOrPhenotypicFeature	D014313
08927156	208	213	Fluo3	ChemicalEntity	C059715
08927156	232	270	receptor activator of NF-kappaB ligand	GeneOrGeneProduct	21943
08927156	297	311	c.461_462delAG	SequenceVariant	rs606231195
08927156	330	343	mood disorder	DiseaseOrPhenotypicFeature	D019964
08927156	348	360	jaw of steel	DiseaseOrPhenotypicFeature	D014313
08927156	404	409	Fluo3	ChemicalEntity	C059715
08927156	451	455	LAT2	GeneOrGeneProduct	84551
08927156	457	467	E-cadherin	GeneOrGeneProduct	12550
08927156	473	499	2,3,5-triphenyltetrazolium	ChemicalEntity	C009591
08927156	535	564	familial hypercholesterolemia	DiseaseOrPhenotypicFeature	D006937
08927156	553	558	ester	ChemicalEntity	D004952
08927156	569	581	jaw of steel	DiseaseOrPhenotypicFeature	D014313
08927156	636	650	c.461_462delAG	SequenceVariant	rs606231195
08927156	660	665	Fluo3	ChemicalEntity	C059715
08927156	670	675	ester	ChemicalEntity	D004952
08927156	807	845	receptor activator of NF-kappaB ligand	GeneOrGeneProduct	21943
08927156	850	855	Fluo3	ChemicalEntity	C059715
08927156	876	914	receptor activator of NF-kappaB ligand	GeneOrGeneProduct	21943
08927156	919	924	ester	ChemicalEntity	D004952
08927156	998	1036	receptor activator of NF-kappaB ligand	GeneOrGeneProduct	21943
08927156	1041	1067	2,3,5-triphenyltetrazolium	ChemicalEntity	C009591
08927156	1221	1231	E-cadherin	GeneOrGeneProduct	12550
08927156	1241	1267	2,3,5-triphenyltetrazolium	ChemicalEntity	C009591
08927156	1272	1277	Fluo3	ChemicalEntity	C059715
08927156	1298	1308	E-cadherin	GeneOrGeneProduct	12550
08927156	1313	1318	ester	ChemicalEntity	D004952
08927156	1348	1358	E-cadherin	GeneOrGeneProduct	12550
08927156	1502	1506	LAT2	GeneOrGeneProduct	84551
08927156	1511	1516	Fluo3	ChemicalEntity	C059715
08927156	1557	1561	LAT2	GeneOrGeneProduct	84551
08927156	1591	1596	Fluo3	ChemicalEntity	C059715
08927156	1615	1628	mood disorder	DiseaseOrPhenotypicFeature	D019964
08927156	1633	1645	jaw of steel	DiseaseOrPhenotypicFeature	D014313
08927156	1844	1857	mood disorder	DiseaseOrPhenotypicFeature	D019964
08927156	1862	1874	jaw of steel	DiseaseOrPhenotypicFeature	D014313
08927156	Positive_Correlation	rs606231195	D004952	Novel
08927156	Positive_Correlation	rs606231195	C059715	Novel
08927156	Positive_Correlation	84551	C059715	Novel
08927156	Positive_Correlation	12550	C009591	Novel
08927156	Positive_Correlation	21943	C059715	Novel
08927156	Positive_Correlation	12550	C059715	Novel
08927156	Positive_Correlation	21943	D004952	Novel
08927156	Positive_Correlation	rs606231195	C009591	Novel
08927156	Positive_Correlation	21943	C009591	Novel
08927156	Positive_Correlation	12550	D004952	Novel

77205283|t|VDAC and neuropathic pain: a complex interplay with the Capan1 cell line and the G196S sequence
77205283|a|Neuropathic pain is a debilitating condition that has been increasingly linked to various molecular mechanisms, including alterations in mitochondrial function and gene expression. This study investigates the relationship between neuropathic pain and the voltage-dependent anion channel (VDAC), a key protein involved in mitochondrial permeability and cellular metabolism. Our findings reveal a positive correlation between neuropathic pain and VDAC expression, as well as a positive correlation between VDAC and neuropathic pain, suggesting that VDAC may play a critical role in the pathophysiology of this condition.    To further explore these associations, we utilized the Capan1 cell line, a well-characterized human pancreatic cancer cell line, to model the effects of VDAC on pain signaling pathways. The Capan1 cell line was exposed to varying concentrations of the sequence variant G196S, a missense mutation in the VDAC gene, and its impact on neuropathic pain-related markers was assessed. The results indicate a negative correlation between the G196S variant and neuropathic pain, as well as an association between G196S and neuropathic pain, suggesting that this sequence variant may modulate the expression or function of VDAC in a manner that influences pain perception.    Additionally, the study found an association between neuropathic pain and G196S, reinforcing the hypothesis that genetic variations in VDAC may contribute to the development or severity of neuropathic pain. These findings highlight the complex interplay between VDAC, the G196S variant, and neuropathic pain, and provide a foundation for future research into targeted therapeutic strategies for pain management.
77205283	0	4	VDAC	GeneOrGeneProduct	7416
77205283	9	25	neuropathic pain	DiseaseOrPhenotypicFeature	D009437
77205283	56	62	Capan1	CellLine	CVCL_0237
77205283	81	86	G196S	SequenceVariant	rs121434250
77205283	326	342	neuropathic pain	DiseaseOrPhenotypicFeature	D009437
77205283	384	388	VDAC	GeneOrGeneProduct	7416
77205283	520	536	neuropathic pain	DiseaseOrPhenotypicFeature	D009437
77205283	541	545	VDAC	GeneOrGeneProduct	7416
77205283	600	604	VDAC	GeneOrGeneProduct	7416
77205283	609	625	neuropathic pain	DiseaseOrPhenotypicFeature	D009437
77205283	643	647	VDAC	GeneOrGeneProduct	7416
77205283	773	779	Capan1	CellLine	CVCL_0237
77205283	871	875	VDAC	GeneOrGeneProduct	7416
77205283	908	914	Capan1	CellLine	CVCL_0237
77205283	987	992	G196S	SequenceVariant	rs121434250
77205283	1021	1025	VDAC	GeneOrGeneProduct	7416
77205283	1050	1066	neuropathic pain	DiseaseOrPhenotypicFeature	D009437
77205283	1153	1158	G196S	SequenceVariant	rs121434250
77205283	1171	1187	neuropathic pain	DiseaseOrPhenotypicFeature	D009437
77205283	1223	1228	G196S	SequenceVariant	rs121434250
77205283	1233	1249	neuropathic pain	DiseaseOrPhenotypicFeature	D009437
77205283	1332	1336	VDAC	GeneOrGeneProduct	7416
77205283	1438	1454	neuropathic pain	DiseaseOrPhenotypicFeature	D009437
77205283	1459	1464	G196S	SequenceVariant	rs121434250
77205283	1520	1524	VDAC	GeneOrGeneProduct	7416
77205283	1574	1590	neuropathic pain	DiseaseOrPhenotypicFeature	D009437
77205283	1647	1651	VDAC	GeneOrGeneProduct	7416
77205283	1657	1662	G196S	SequenceVariant	rs121434250
77205283	1676	1692	neuropathic pain	DiseaseOrPhenotypicFeature	D009437
77205283	Positive_Correlation	D009437	7416	Novel
77205283	Positive_Correlation	7416	D009437	Novel
77205283	Negative_Correlation	rs121434250	D009437	Novel
77205283	Association	rs121434250	D009437	Novel
77205283	Association	D009437	rs121434250	Novel

21783273|t|Investigating the interplay between genetic variants, metabolic substrates, and erythematous erysipelas in 293T ce
21783273|a|A recent study explored the complex interactions between genetic sequence variants, metabolic substrates, and the inflammatory disease erythematous erysipelas using the 293T cell line. The research focused on the effects of the sequence variants p.G705RfsX16 and c.2444A>C on the development of erythematous erysipelas, revealing a negative correlation between p.G705RfsX16 and the disease. Similarly, the variant c.2444A>C was also found to have a negative correlation with erythematous erysipelas. In contrast, the sequence variant rs10954213 showed a negative correlation with the disease, suggesting a potential protective role.   The study also examined the association between the gene bcl-2 and erythematous erysipelas, finding a significant positive correlation. This suggests that bcl-2 may play a role in the pathogenesis of the disease.   In addition to genetic factors, the research compared the effects of trypan blue and d-fructose on cellular processes. The results indicated a positive correlation between trypan blue and d-fructose, as well as a comparison between the two compounds. These findings suggest that d-fructose may influence the behavior of trypan blue in cellular environments.   The study utilized the 293T cell line to model these interactions, providing a platform for further investigation into the molecular mechanisms underlying erythematous erysipelas. The findings highlight the importance of both genetic and metabolic factors in the development of this inflammatory condition, with implications for future therapeutic strategies.
21783273	80	103	erythematous erysipelas	DiseaseOrPhenotypicFeature	D004886
21783273	107	111	293T	CellLine	CVCL_0063
21783273	250	273	erythematous erysipelas	DiseaseOrPhenotypicFeature	D004886
21783273	284	288	293T	CellLine	CVCL_0063
21783273	361	373	p.G705RfsX16	SequenceVariant	p|FS|G|705|R|16
21783273	378	387	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
21783273	410	433	erythematous erysipelas	DiseaseOrPhenotypicFeature	D004886
21783273	476	488	p.G705RfsX16	SequenceVariant	p|FS|G|705|R|16
21783273	529	538	c.2444A>C	SequenceVariant	c|SUB|A|2444|C
21783273	590	613	erythematous erysipelas	DiseaseOrPhenotypicFeature	D004886
21783273	649	659	rs10954213	SequenceVariant	rs10954213
21783273	807	812	bcl-2	GeneOrGeneProduct	24224
21783273	817	840	erythematous erysipelas	DiseaseOrPhenotypicFeature	D004886
21783273	905	910	bcl-2	GeneOrGeneProduct	24224
21783273	1034	1045	trypan blue	ChemicalEntity	D014343
21783273	1050	1060	d-fructose	ChemicalEntity	D005632
21783273	1137	1148	trypan blue	ChemicalEntity	D014343
21783273	1153	1163	d-fructose	ChemicalEntity	D005632
21783273	1244	1254	d-fructose	ChemicalEntity	D005632
21783273	1285	1296	trypan blue	ChemicalEntity	D014343
21783273	1348	1352	293T	CellLine	CVCL_0063
21783273	1480	1503	erythematous erysipelas	DiseaseOrPhenotypicFeature	D004886
21783273	Negative_Correlation	p|FS|G|705|R|16	D004886	Novel
21783273	Comparison	D014343	D005632	Novel
21783273	Positive_Correlation	D005632	D014343	Novel
21783273	Comparison	D005632	D014343	Novel
21783273	Negative_Correlation	c|SUB|A|2444|C	D004886	Novel
21783273	Association	24224	D004886	Novel
21783273	Negative_Correlation	rs10954213	D004886	Novel
21783273	Positive_Correlation	D014343	D005632	Novel

01166406|t|CGI-58 and rs8041922: functional and evolutionary insights from Daucus carota, ginseng, and Escheric
01166406|a|CGI-58, a key regulator of lipid metabolism, has been extensively studied in various organisms, including Daucus carota, ginseng, and Escherichia coli. This study explores the functional and evolutionary implications of the sequence variant rs8041922 in the CGI-58 gene across these species. The presence of CGI-58 in Daucus carota suggests a conserved role in lipid homeostasis, while its interaction with rs8041922 indicates potential regulatory effects on gene expression. In ginseng, CGI-58 is associated with the modulation of secondary metabolite pathways, and the variant rs8041922 may influence the plant's response to environmental stressors. In Escherichia coli, CGI-58 homologs are involved in membrane dynamics, and the sequence variant rs8041922 may affect protein stability and function. The study highlights the importance of CGI-58 and rs8041922 in diverse biological contexts, emphasizing their potential as targets for therapeutic and agricultural applications. Further research is needed to fully understand the molecular mechanisms underlying these interactions in different organisms.
01166406	0	6	CGI-58	GeneOrGeneProduct	51099
01166406	11	20	rs8041922	SequenceVariant	rs8041922
01166406	64	77	Daucus carota	OrganismTaxon	4039
01166406	79	86	ginseng	OrganismTaxon	4054
01166406	101	107	CGI-58	GeneOrGeneProduct	51099
01166406	207	220	Daucus carota	OrganismTaxon	4039
01166406	222	229	ginseng	OrganismTaxon	4054
01166406	235	251	Escherichia coli	OrganismTaxon	562
01166406	342	351	rs8041922	SequenceVariant	rs8041922
01166406	359	365	CGI-58	GeneOrGeneProduct	51099
01166406	409	415	CGI-58	GeneOrGeneProduct	51099
01166406	419	432	Daucus carota	OrganismTaxon	4039
01166406	508	517	rs8041922	SequenceVariant	rs8041922
01166406	580	587	ginseng	OrganismTaxon	4054
01166406	589	595	CGI-58	GeneOrGeneProduct	51099
01166406	680	689	rs8041922	SequenceVariant	rs8041922
01166406	756	772	Escherichia coli	OrganismTaxon	562
01166406	774	780	CGI-58	GeneOrGeneProduct	51099
01166406	850	859	rs8041922	SequenceVariant	rs8041922
01166406	942	948	CGI-58	GeneOrGeneProduct	51099
01166406	953	962	rs8041922	SequenceVariant	rs8041922

81336201|t|Genetic and pharmacological interactions of sequence variants, cell lines, and chemical entities in the context of Toxorynchites mosquitoes, human immunodeficiency virus, and
81336201|a|This study investigates the complex interactions between genetic variants, cell lines, and chemical entities in the context of Toxorynchites mosquitoes, human immunodeficiency virus, and ginseng. The focus is on the sequence variant rs1329428, which was found to be associated with altered expression patterns in C57BL/6J and SMMC-7721 cell lines. Additionally, the sequence variant rs2073601 was observed to influence the response of CMT-93 and SUM159PT cell lines to various chemical entities.   The chemical entity Dox was found to interact with ESA in a cotreatment setting, which was further supported by its interaction with atorvastatin. Similarly, sarcoplasmic reticulum Ca2 + -ATPase was shown to cotreat with both atorvastatin and ESA, highlighting its potential role in modulating the pharmacological effects of these agents. These interactions were studied in multiple cell lines, including C57BL/6J, SMMC-7721, and CMT-93, which were exposed to varying concentrations of the chemical entities under controlled conditions.  The organism taxon human immunodeficiency virus was used as a model system to study the effects of these interactions on viral replication and host cell response. The presence of ginseng was also explored for its potential to modulate the interactions between the sequence variants and chemical entities. The study also included the organism taxon Spirulina and rabbit as controls to ensure the specificity of the observed effects.  The results suggest that the sequence variant rs1329428 and rs2073601, along with the chemical entities Dox, ESA, atorvastatin, and sarcoplasmic reticulum Ca2 + -ATPase, play a significant role in the biological processes under investigation. The cotreatment effects observed in this study provide a foundation for further research into the therapeutic potential of these agents in various contexts, including the treatment of viral infections and the modulation of cellular responses.
81336201	115	139	Toxorynchites mosquitoes	OrganismTaxon	2498889
81336201	141	169	human immunodeficiency virus	OrganismTaxon	12721
81336201	302	326	Toxorynchites mosquitoes	OrganismTaxon	2498889
81336201	328	356	human immunodeficiency virus	OrganismTaxon	12721
81336201	362	369	ginseng	OrganismTaxon	4054
81336201	408	417	rs1329428	SequenceVariant	rs1329428
81336201	488	496	C57BL/6J	CellLine	CVCL_5U84
81336201	501	510	SMMC-7721	CellLine	CVCL_0534
81336201	558	567	rs2073601	SequenceVariant	rs2073601
81336201	610	616	CMT-93	CellLine	CVCL_1986
81336201	621	629	SUM159PT	CellLine	CVCL_5423
81336201	693	696	Dox	ChemicalEntity	D004317
81336201	724	727	ESA	ChemicalEntity	D006397
81336201	806	818	atorvastatin	ChemicalEntity	D000069059
81336201	831	867	sarcoplasmic reticulum Ca2 + -ATPase	ChemicalEntity	D053498
81336201	899	911	atorvastatin	ChemicalEntity	D000069059
81336201	916	919	ESA	ChemicalEntity	D006397
81336201	1078	1086	C57BL/6J	CellLine	CVCL_5U84
81336201	1088	1097	SMMC-7721	CellLine	CVCL_0534
81336201	1103	1109	CMT-93	CellLine	CVCL_1986
81336201	1230	1258	human immunodeficiency virus	OrganismTaxon	12721
81336201	1390	1397	ginseng	OrganismTaxon	4054
81336201	1559	1568	Spirulina	OrganismTaxon	551299
81336201	1573	1579	rabbit	OrganismTaxon	9986
81336201	1690	1699	rs1329428	SequenceVariant	rs1329428
81336201	1704	1713	rs2073601	SequenceVariant	rs2073601
81336201	1748	1751	Dox	ChemicalEntity	D004317
81336201	1753	1756	ESA	ChemicalEntity	D006397
81336201	1758	1770	atorvastatin	ChemicalEntity	D000069059
81336201	1776	1812	sarcoplasmic reticulum Ca2 + -ATPase	ChemicalEntity	D053498
81336201	Cotreatment	D006397	D004317	Novel
81336201	Cotreatment	D006397	D000069059	Novel
81336201	Cotreatment	D053498	D000069059	Novel
81336201	Cotreatment	D000069059	D053498	Novel
81336201	Cotreatment	D006397	D053498	Novel

21875036|t|Genetic and pharmacological interactions in cancer cell lines and their implications for therapeutic st
21875036|a|Recent studies have explored the complex interplay between genetic variants, chemical entities, and disease phenotypes in various cancer cell lines. This research focuses on the MCF7/AdrR and IEC-6 cell lines, where multiple sequence variants and chemical treatments were evaluated for their impact on disease outcomes. A key finding was the negative correlation between Irinotecan and brain and genital malformations, suggesting potential off-target effects of this chemotherapeutic agent. Additionally, the sequence variant S276T was found to be negatively correlated with lymphomagenesis, highlighting its protective role in cancer prevention.   The association between D374Y and Autosomal dominant cerebellar ataxia was confirmed through functional assays, as was the link between rs17250932 and the same disease. Notably, the sequence variant S276T was also associated with Autosomal dominant cerebellar ataxia, reinforcing the role of this region in neurodegenerative processes. In the SUM159PT cell line, the sequence variant G12D was linked to mitochondrial DNA depletion, indicating a potential role in mitochondrial dysfunction.  Pharmacological interactions were also investigated. Lamotrigine was found to have a negative correlation with hypertriglyceridemia, while it was positively associated with lipid levels. This dual effect suggests a complex metabolic profile of lamotrigine. Furthermore, lipid levels were positively correlated with both lamotrigine and levamisole, but negatively correlated with lymphomagenesis, indicating a possible protective role of lipid metabolism in cancer suppression.   The chemical entity 2,4-diene-VPA was found to have a negative correlation with lymphomagenesis, suggesting its potential as a chemopreventive agent. However, levamisole was negatively correlated with Lynch Syndrome, raising concerns about its use in patients with a genetic predisposition to this condition.   These findings underscore the importance of understanding both genetic and pharmacological interactions in the context of disease and treatment response, particularly in cancer cell lines such as MCF7/AdrR, IEC-6, and SUM159PT. The results provide a foundation for developing more targeted and effective therapeutic strategies.
21875036	282	291	MCF7/AdrR	CellLine	 CVCL_1452
21875036	296	301	IEC-6	CellLine	CVCL_0343
21875036	475	485	Irinotecan	ChemicalEntity	D000077146
21875036	490	521	brain and genital malformations	DiseaseOrPhenotypicFeature	D000013
21875036	630	635	S276T	SequenceVariant	rs2234671
21875036	679	694	lymphomagenesis	DiseaseOrPhenotypicFeature	D008223
21875036	777	782	D374Y	SequenceVariant	rs137852912
21875036	787	823	Autosomal dominant cerebellar ataxia	DiseaseOrPhenotypicFeature	OMIM:604121
21875036	889	899	rs17250932	SequenceVariant	rs17250932
21875036	952	957	S276T	SequenceVariant	rs2234671
21875036	983	1019	Autosomal dominant cerebellar ataxia	DiseaseOrPhenotypicFeature	OMIM:604121
21875036	1096	1104	SUM159PT	CellLine	CVCL_5423
21875036	1137	1141	G12D	SequenceVariant	rs121913529
21875036	1156	1183	mitochondrial DNA depletion	DiseaseOrPhenotypicFeature	D028361
21875036	1355	1375	hypertriglyceridemia	DiseaseOrPhenotypicFeature	D015228
21875036	1417	1422	lipid	ChemicalEntity	D008055
21875036	1488	1499	lamotrigine	ChemicalEntity	D000077213
21875036	1514	1519	lipid	ChemicalEntity	D008055
21875036	1564	1575	lamotrigine	ChemicalEntity	D000077213
21875036	1580	1590	levamisole	ChemicalEntity	D007978
21875036	1623	1638	lymphomagenesis	DiseaseOrPhenotypicFeature	D008223
21875036	1681	1686	lipid	ChemicalEntity	D008055
21875036	1743	1756	2,4-diene-VPA	ChemicalEntity	C556631
21875036	1803	1818	lymphomagenesis	DiseaseOrPhenotypicFeature	D008223
21875036	1882	1892	levamisole	ChemicalEntity	D007978
21875036	1924	1938	Lynch Syndrome	DiseaseOrPhenotypicFeature	D003123
21875036	2230	2239	MCF7/AdrR	CellLine	 CVCL_1452
21875036	2241	2246	IEC-6	CellLine	CVCL_0343
21875036	2252	2260	SUM159PT	CellLine	CVCL_5423
21875036	Negative_Correlation	D000077213	D015228	Novel
21875036	Negative_Correlation	C556631	D008223	Novel
21875036	Negative_Correlation	rs2234671	D008223	Novel
21875036	Negative_Correlation	D000077146	D000013	Novel
21875036	Association	D000077213	D008055	Novel
21875036	Association	rs137852912	OMIM:604121	Novel
21875036	Association	rs17250932	OMIM:604121	Novel
21875036	Association	rs137852912	D015228	Novel
21875036	Association	D008055	D007978	Novel
21875036	Association	D008055	D000077213	Novel
21875036	Association	rs2234671	OMIM:604121	Novel
21875036	Negative_Correlation	D000077213	D028361	Novel
21875036	Negative_Correlation	D007978	D003123	Novel
21875036	Negative_Correlation	D008055	D008223	Novel

04623410|t|Thromboxane B2 and 32-bp deletion associations in asthma: a study on Platonia insignis Mart and
04623410|a|This study investigates the potential relationship between thromboxane B2 levels and the presence of the 32-bp deletion in individuals with asthma, with a focus on the effects of Platonia insignis Mart and ginseng. Asthma is a complex disease influenced by both genetic and environmental factors, and recent research has highlighted the role of inflammatory mediators such as thromboxane B2 in its pathophysiology. The 32-bp deletion, a known genetic variant, has been implicated in various inflammatory processes, including those associated with respiratory conditions.   In this study, we examined 32-bp deletion frequency in 100 asthma patients and found a significant positive correlation with thromboxane B2 levels. This correlation was further supported by in vitro experiments using Platonia insignis Mart and ginseng extracts, which demonstrated modulatory effects on thromboxane B2 production. The results suggest that the 32-bp deletion may enhance the production of thromboxane B2, thereby contributing to the inflammatory response in asthma.   Our findings were consistent across multiple cohorts, with 32-bp deletion instances observed in 70% of asthma cases and thromboxane B2 levels showing a positive trend in those with the deletion. The study also included 50 healthy controls, where the 32-bp deletion was less prevalent, and thromboxane B2 levels were lower. The use of Platonia insignis Mart and ginseng in the study provided additional insights into the potential therapeutic applications of these natural products in managing asthma-related inflammation.   These results highlight the importance of understanding the interplay between genetic variants like the 32-bp deletion and inflammatory mediators such as thromboxane B2 in the context of asthma. The study underscores the need for further research into the role of these factors in respiratory diseases and the potential of natural compounds in modulating their effects.
04623410	19	33	32-bp deletion	SequenceVariant	c|DEL||32
04623410	50	56	asthma	DiseaseOrPhenotypicFeature	D001249
04623410	69	91	Platonia insignis Mart	OrganismTaxon	198787
04623410	155	169	thromboxane B2	ChemicalEntity	D013929
04623410	201	215	32-bp deletion	SequenceVariant	c|DEL||32
04623410	236	242	asthma	DiseaseOrPhenotypicFeature	D001249
04623410	275	297	Platonia insignis Mart	OrganismTaxon	198787
04623410	302	309	ginseng	OrganismTaxon	4054
04623410	472	486	thromboxane B2	ChemicalEntity	D013929
04623410	515	529	32-bp deletion	SequenceVariant	c|DEL||32
04623410	696	710	32-bp deletion	SequenceVariant	c|DEL||32
04623410	728	734	asthma	DiseaseOrPhenotypicFeature	D001249
04623410	794	808	thromboxane B2	ChemicalEntity	D013929
04623410	886	908	Platonia insignis Mart	OrganismTaxon	198787
04623410	913	920	ginseng	OrganismTaxon	4054
04623410	972	986	thromboxane B2	ChemicalEntity	D013929
04623410	1028	1042	32-bp deletion	SequenceVariant	c|DEL||32
04623410	1073	1087	thromboxane B2	ChemicalEntity	D013929
04623410	1142	1148	asthma	DiseaseOrPhenotypicFeature	D001249
04623410	1211	1225	32-bp deletion	SequenceVariant	c|DEL||32
04623410	1255	1261	asthma	DiseaseOrPhenotypicFeature	D001249
04623410	1272	1286	thromboxane B2	ChemicalEntity	D013929
04623410	1402	1416	32-bp deletion	SequenceVariant	c|DEL||32
04623410	1441	1455	thromboxane B2	ChemicalEntity	D013929
04623410	1486	1508	Platonia insignis Mart	OrganismTaxon	198787
04623410	1513	1520	ginseng	OrganismTaxon	4054
04623410	1645	1651	asthma	DiseaseOrPhenotypicFeature	D001249
04623410	1780	1794	32-bp deletion	SequenceVariant	c|DEL||32
04623410	1830	1844	thromboxane B2	ChemicalEntity	D013929
04623410	1863	1869	asthma	DiseaseOrPhenotypicFeature	D001249
04623410	Positive_Correlation	D013929	c|DEL||32	Novel

90928073|t|Genetic variants rs204890 and G1103R: associations with CIN, Gorlin syndrome, and glomerulosclerosis in Human and Danio reri
90928073|a|This study investigates the genetic and phenotypic associations of sequence variants rs204890 and G1103R in the context of human and model organism systems. The focus is on their roles in disease processes such as CIN, Gorlin syndrome, and glomerulosclerosis. In human populations, rs204890 was found to exhibit a positive correlation with glomerulosclerosis and a positive correlation with uraemia. Additionally, the variant G1103R showed a strong positive correlation with CIN and with Gorlin syndrome, while also being associated with glomerulosclerosis. Notably, there was a negative correlation between G1103R and uraemia, suggesting a complex interplay between these genetic variants and disease states. The study also included analyses in Danio rerio, where the effects of these variants were examined in relation to similar phenotypic outcomes. Furthermore, the role of rs204890, which includes the G/C polymorphism, was explored in the context of synovial inflammation and its potential impact on disease progression. The findings highlight the importance of these genetic variants in understanding the molecular mechanisms underlying various human diseases, including those related to Human Papilloma Virus (HPV) infection and other conditions such as axonal damage. The results provide a foundation for further research into the functional roles of these variants in both human and model systems.
90928073	17	25	rs204890	SequenceVariant	rs204890
90928073	30	36	G1103R	SequenceVariant	rs62636275
90928073	56	59	CIN	DiseaseOrPhenotypicFeature	D043171
90928073	61	76	Gorlin syndrome	DiseaseOrPhenotypicFeature	D001478
90928073	82	100	glomerulosclerosis	DiseaseOrPhenotypicFeature	D005921
90928073	104	109	Human	OrganismTaxon	9606
90928073	210	218	rs204890	SequenceVariant	rs204890
90928073	223	229	G1103R	SequenceVariant	rs62636275
90928073	339	342	CIN	DiseaseOrPhenotypicFeature	D043171
90928073	344	359	Gorlin syndrome	DiseaseOrPhenotypicFeature	D001478
90928073	365	383	glomerulosclerosis	DiseaseOrPhenotypicFeature	D005921
90928073	407	415	rs204890	SequenceVariant	rs204890
90928073	465	483	glomerulosclerosis	DiseaseOrPhenotypicFeature	D005921
90928073	516	523	uraemia	DiseaseOrPhenotypicFeature	D014511
90928073	551	557	G1103R	SequenceVariant	rs62636275
90928073	600	603	CIN	DiseaseOrPhenotypicFeature	D043171
90928073	613	628	Gorlin syndrome	DiseaseOrPhenotypicFeature	D001478
90928073	663	681	glomerulosclerosis	DiseaseOrPhenotypicFeature	D005921
90928073	733	739	G1103R	SequenceVariant	rs62636275
90928073	744	751	uraemia	DiseaseOrPhenotypicFeature	D014511
90928073	871	882	Danio rerio	OrganismTaxon	7955
90928073	1003	1011	rs204890	SequenceVariant	rs204890
90928073	1032	1035	G/C	SequenceVariant	g|SUB|G||C
90928073	1081	1102	synovial inflammation	DiseaseOrPhenotypicFeature	D013585
90928073	1320	1325	Human	OrganismTaxon	9606
90928073	1387	1400	axonal damage	DiseaseOrPhenotypicFeature	D020833
90928073	Positive_Correlation	g|SUB|G||C	D005921	Novel
90928073	Positive_Correlation	D014511	g|SUB|G||C	Novel
90928073	Positive_Correlation	rs62636275	D043171	Novel
90928073	Positive_Correlation	rs62636275	D001478	Novel
90928073	Association	D005921	rs62636275	Novel
90928073	Association	rs62636275	D001478	Novel
90928073	Negative_Correlation	rs62636275	D014511	Novel

24819216|t|G0S2 and miR-148a: interactions, correlations, and associations with 35 delG in 293T ce
24819216|a|Recent studies have highlighted the complex regulatory interactions between the gene G0S2 and the microRNA miR-148a, particularly in the context of the 293T cell line. This research explores the molecular mechanisms underlying the binding and negative correlation between G0S2 and miR-148a, as well as the association of the sequence variant 35 delG with both genes.   In 293T cells, G0S2 was found to bind directly to miR-148a, suggesting a potential regulatory role of miR-148a in modulating G0S2 expression. Furthermore, a strong negative correlation was observed between the levels of G0S2 and miR-148a, indicating that miR-148a may act as a repressor of G0S2. This negative correlation was consistently observed across multiple 293T cell line experiments, with 12 instances of G0S2 and 12 instances of miR-148a showing inverse expression patterns.  The sequence variant 35 delG was found to be significantly associated with both G0S2 and miR-148a. In 293T cells, the presence of 35 delG correlated with altered expression levels of G0S2 and miR-148a, with 16 instances of 293T cell lines showing this association. Additionally, the variant 35 delG was found to influence the binding affinity between G0S2 and miR-148a, further supporting the hypothesis that this sequence variant plays a critical role in the regulatory network involving these two molecules.  These findings provide new insights into the molecular interactions between G0S2 and miR-148a, as well as the impact of the 35 delG variant on their expression and function in 293T cells. The results suggest that the interplay between G0S2, miR-148a, and 35 delG may be a key factor in the regulation of cellular processes in these cell lines.
24819216	0	4	G0S2	GeneOrGeneProduct	50486
24819216	9	17	miR-148a	GeneOrGeneProduct	387166
24819216	69	76	35 delG	SequenceVariant	c|DEL|35|G
24819216	80	84	293T	CellLine	CVCL_0063
24819216	173	177	G0S2	GeneOrGeneProduct	50486
24819216	195	203	miR-148a	GeneOrGeneProduct	387166
24819216	240	244	293T	CellLine	CVCL_0063
24819216	360	364	G0S2	GeneOrGeneProduct	50486
24819216	369	377	miR-148a	GeneOrGeneProduct	387166
24819216	430	437	35 delG	SequenceVariant	c|DEL|35|G
24819216	460	464	293T	CellLine	CVCL_0063
24819216	472	476	G0S2	GeneOrGeneProduct	50486
24819216	507	515	miR-148a	GeneOrGeneProduct	387166
24819216	559	567	miR-148a	GeneOrGeneProduct	387166
24819216	582	586	G0S2	GeneOrGeneProduct	50486
24819216	677	681	G0S2	GeneOrGeneProduct	50486
24819216	686	694	miR-148a	GeneOrGeneProduct	387166
24819216	712	720	miR-148a	GeneOrGeneProduct	387166
24819216	747	751	G0S2	GeneOrGeneProduct	50486
24819216	821	825	293T	CellLine	CVCL_0063
24819216	870	874	G0S2	GeneOrGeneProduct	50486
24819216	895	903	miR-148a	GeneOrGeneProduct	387166
24819216	963	970	35 delG	SequenceVariant	c|DEL|35|G
24819216	1022	1026	G0S2	GeneOrGeneProduct	50486
24819216	1031	1039	miR-148a	GeneOrGeneProduct	387166
24819216	1044	1048	293T	CellLine	CVCL_0063
24819216	1072	1079	35 delG	SequenceVariant	c|DEL|35|G
24819216	1125	1129	G0S2	GeneOrGeneProduct	50486
24819216	1134	1142	miR-148a	GeneOrGeneProduct	387166
24819216	1165	1169	293T	CellLine	CVCL_0063
24819216	1233	1240	35 delG	SequenceVariant	c|DEL|35|G
24819216	1293	1297	G0S2	GeneOrGeneProduct	50486
24819216	1302	1310	miR-148a	GeneOrGeneProduct	387166
24819216	1529	1533	G0S2	GeneOrGeneProduct	50486
24819216	1538	1546	miR-148a	GeneOrGeneProduct	387166
24819216	1577	1584	35 delG	SequenceVariant	c|DEL|35|G
24819216	1629	1633	293T	CellLine	CVCL_0063
24819216	1688	1692	G0S2	GeneOrGeneProduct	50486
24819216	1694	1702	miR-148a	GeneOrGeneProduct	387166
24819216	1708	1715	35 delG	SequenceVariant	c|DEL|35|G
24819216	Bind	50486	387166	Novel
24819216	Negative_Correlation	387166	50486	Novel
24819216	Bind	387166	50486	Novel
24819216	Negative_Correlation	50486	387166	Novel
24819216	Association	c|DEL|35|G	50486	Novel
24819216	Association	c|DEL|35|G	387166	Novel

34867681|t|LTK expression and ristocetin activity in Aedes mosquitoes: implications for osteopenia and SNU-C5 cell line r
34867681|a|Recent studies have highlighted the complex interplay between the LTK gene and ristocetin in modulating cellular responses in Aedes mosquitoes. This research investigates the positive correlation between LTK expression and ristocetin activity, revealing a novel regulatory mechanism that may influence the pathophysiology of osteopenia. Using the SNU-C5 cell line, we observed that ristocetin significantly modulates LTK signaling pathways, suggesting a potential therapeutic target for osteopenia. Furthermore, our findings demonstrate an association between ristocetin and osteopenia in both in vitro and in vivo models, with Aedes mosquitoes serving as a unique model system to study these interactions. The results provide new insights into the molecular mechanisms underlying osteopenia and highlight the importance of LTK and ristocetin in cellular homeostasis. These findings may have significant implications for the development of targeted therapies for osteopenia and related conditions.
34867681	0	3	LTK	GeneOrGeneProduct	4058
34867681	19	29	ristocetin	ChemicalEntity	D012310
34867681	42	58	Aedes mosquitoes	OrganismTaxon	1245352
34867681	77	87	osteopenia	DiseaseOrPhenotypicFeature	D001851
34867681	92	98	SNU-C5	CellLine	CVCL_5112
34867681	177	180	LTK	GeneOrGeneProduct	4058
34867681	190	200	ristocetin	ChemicalEntity	D012310
34867681	237	253	Aedes mosquitoes	OrganismTaxon	1245352
34867681	315	318	LTK	GeneOrGeneProduct	4058
34867681	334	344	ristocetin	ChemicalEntity	D012310
34867681	436	446	osteopenia	DiseaseOrPhenotypicFeature	D001851
34867681	458	464	SNU-C5	CellLine	CVCL_5112
34867681	493	503	ristocetin	ChemicalEntity	D012310
34867681	528	531	LTK	GeneOrGeneProduct	4058
34867681	598	608	osteopenia	DiseaseOrPhenotypicFeature	D001851
34867681	671	681	ristocetin	ChemicalEntity	D012310
34867681	686	696	osteopenia	DiseaseOrPhenotypicFeature	D001851
34867681	739	755	Aedes mosquitoes	OrganismTaxon	1245352
34867681	892	902	osteopenia	DiseaseOrPhenotypicFeature	D001851
34867681	935	938	LTK	GeneOrGeneProduct	4058
34867681	943	953	ristocetin	ChemicalEntity	D012310
34867681	1074	1084	osteopenia	DiseaseOrPhenotypicFeature	D001851
34867681	Positive_Correlation	4058	D012310	Novel
34867681	Association	D001851	D012310	Novel

46866375|t|Genetic variants in MHC class II and CXCL1 genes associated with CHD in rats and West Nile virus i
46866375|a|This study investigates the genetic and molecular mechanisms underlying the association between cardiovascular disease (CHD) and specific sequence variants in rats infected with West Nile virus. We focused on the impact of two key sequence variants, 1123T-->G and Val175Met, on the expression and function of MHC class II and CXCL1 genes. The study involved a cohort of 50 rats, which were genetically modified to carry these variants and then exposed to West Nile virus.   The results showed a significant association between the presence of the 1123T-->G variant and an increased susceptibility to CHD, as evidenced by elevated levels of inflammatory markers and reduced cardiac function. Similarly, the Val175Met variant was found to be strongly correlated with the development of CHD, particularly in rats with pre-existing cardiovascular conditions. These findings were further supported by the observation that the expression of MHC class II and CXCL1 genes was significantly altered in the presence of these variants, suggesting a potential role in immune response modulation.  Additionally, the study revealed that the 1123T-->G variant was associated with a higher viral load in West Nile virus-infected rats, indicating a possible link between genetic variability and viral pathogenesis. The Val175Met variant, on the other hand, was linked to a more severe clinical outcome in infected animals, including increased mortality and tissue damage. These results highlight the importance of genetic factors in determining the progression of CHD and the severity of viral infections in rats. The findings provide a foundation for further research into the molecular mechanisms underlying these associations and their implications for human health.
46866375	20	32	MHC class II	GeneOrGeneProduct	3108
46866375	37	42	CXCL1	GeneOrGeneProduct	14825
46866375	65	68	CHD	DiseaseOrPhenotypicFeature	D006331
46866375	72	76	rats	OrganismTaxon	10116
46866375	81	96	West Nile virus	OrganismTaxon	11082
46866375	219	222	CHD	DiseaseOrPhenotypicFeature	D006331
46866375	258	262	rats	OrganismTaxon	10116
46866375	277	292	West Nile virus	OrganismTaxon	11082
46866375	349	358	1123T-->G	SequenceVariant	g|SUB|T|1123|G
46866375	363	372	Val175Met	SequenceVariant	rs7946
46866375	408	420	MHC class II	GeneOrGeneProduct	3108
46866375	425	430	CXCL1	GeneOrGeneProduct	14825
46866375	472	476	rats	OrganismTaxon	10116
46866375	554	569	West Nile virus	OrganismTaxon	11082
46866375	646	655	1123T-->G	SequenceVariant	g|SUB|T|1123|G
46866375	699	702	CHD	DiseaseOrPhenotypicFeature	D006331
46866375	805	814	Val175Met	SequenceVariant	rs7946
46866375	883	886	CHD	DiseaseOrPhenotypicFeature	D006331
46866375	904	908	rats	OrganismTaxon	10116
46866375	1034	1046	MHC class II	GeneOrGeneProduct	3108
46866375	1051	1056	CXCL1	GeneOrGeneProduct	14825
46866375	1226	1235	1123T-->G	SequenceVariant	g|SUB|T|1123|G
46866375	1287	1302	West Nile virus	OrganismTaxon	11082
46866375	1312	1316	rats	OrganismTaxon	10116
46866375	1401	1410	Val175Met	SequenceVariant	rs7946
46866375	1646	1649	CHD	DiseaseOrPhenotypicFeature	D006331
46866375	1690	1694	rats	OrganismTaxon	10116
46866375	Association	D006331	rs7946	Novel
46866375	Association	D006331	g|SUB|T|1123|G	Novel

81876582|t|DGCR8 and RIP3 interactions in cellular stress responses: associations with anxiety, benign prostate hyperplasia, and metabolic d
81876582|a|Recent studies have highlighted the critical role of DGCR8 and RIP3 in cellular stress responses, particularly in the context of anxiety and benign prostate hyperplasia. This study investigates the molecular interactions between DGCR8 and RIP3, revealing a direct bind between these two proteins, which may contribute to the pathogenesis of stress-related disorders. The findings suggest that the 15 kb deletion in DGCR8 may disrupt its normal function, leading to altered signaling pathways that are implicated in anxiety.   In parallel, the association between anxiety and sodium bicarbonate was explored, with evidence suggesting that sodium bicarbonate may modulate neuronal activity in anxiety-related conditions. Similarly, the relationship between anxiety and fat was examined, showing that fat accumulation may exacerbate anxiety symptoms. Additionally, the association between anxiety and cortisol was confirmed, indicating a potential feedback loop between stress and metabolic regulation.  The study also investigated the link between benign prostate hyperplasia and [(3)H]-2-deoxy-d-glucose, finding that [(3)H]-2-deoxy-d-glucose may serve as a biomarker for metabolic dysregulation in this condition. Furthermore, the association between benign prostate hyperplasia and sodium bicarbonate was supported, suggesting a possible role for sodium bicarbonate in modulating prostate cell function. The relationship between benign prostate hyperplasia and alendronate was also established, with alendronate showing potential therapeutic benefits in managing this condition.   Moreover, the association between benign prostate hyperplasia and cortisol was confirmed, highlighting the role of the hypothalamic-pituitary-adrenal axis in prostate health. The study also found a significant association between benign prostate hyperplasia and fat, indicating that metabolic factors may contribute to the development of this disease.   The cell lines COS-7, C57BL/6J, and HK-2 were used to validate these findings, with all three cell lines showing consistent results across multiple experimental conditions. The chemical entities [(3)H]-2-deoxy-d-glucose, sodium bicarbonate, cortisol, and alendronate were consistently associated with the disease states and phenotypic features under investigation. The repeated use of these entities in the study underscores their importance in understanding the complex interplay between genetic, metabolic, and environmental factors in disease pathogenesis.
81876582	0	5	DGCR8	GeneOrGeneProduct	94223
81876582	10	14	RIP3	GeneOrGeneProduct	11035
81876582	76	83	anxiety	DiseaseOrPhenotypicFeature	D001008
81876582	85	112	benign prostate hyperplasia	DiseaseOrPhenotypicFeature	D011470
81876582	183	188	DGCR8	GeneOrGeneProduct	94223
81876582	193	197	RIP3	GeneOrGeneProduct	11035
81876582	259	266	anxiety	DiseaseOrPhenotypicFeature	D001008
81876582	271	298	benign prostate hyperplasia	DiseaseOrPhenotypicFeature	D011470
81876582	359	364	DGCR8	GeneOrGeneProduct	94223
81876582	369	373	RIP3	GeneOrGeneProduct	11035
81876582	527	541	15 kb deletion	SequenceVariant	c|DEL||15K
81876582	545	550	DGCR8	GeneOrGeneProduct	94223
81876582	645	652	anxiety	DiseaseOrPhenotypicFeature	D001008
81876582	693	700	anxiety	DiseaseOrPhenotypicFeature	D001008
81876582	705	723	sodium bicarbonate	ChemicalEntity	D017693
81876582	768	786	sodium bicarbonate	ChemicalEntity	D017693
81876582	821	828	anxiety	DiseaseOrPhenotypicFeature	D001008
81876582	885	892	anxiety	DiseaseOrPhenotypicFeature	D001008
81876582	897	900	fat	ChemicalEntity	D004041
81876582	928	931	fat	ChemicalEntity	D004041
81876582	960	967	anxiety	DiseaseOrPhenotypicFeature	D001008
81876582	1016	1023	anxiety	DiseaseOrPhenotypicFeature	D001008
81876582	1028	1036	cortisol	ChemicalEntity	D006854
81876582	1176	1203	benign prostate hyperplasia	DiseaseOrPhenotypicFeature	D011470
81876582	1208	1232	[(3)H]-2-deoxy-d-glucose	ChemicalEntity	D003847
81876582	1247	1271	[(3)H]-2-deoxy-d-glucose	ChemicalEntity	D003847
81876582	1381	1408	benign prostate hyperplasia	DiseaseOrPhenotypicFeature	D011470
81876582	1413	1431	sodium bicarbonate	ChemicalEntity	D017693
81876582	1478	1496	sodium bicarbonate	ChemicalEntity	D017693
81876582	1560	1587	benign prostate hyperplasia	DiseaseOrPhenotypicFeature	D011470
81876582	1592	1603	alendronate	ChemicalEntity	D019386
81876582	1631	1642	alendronate	ChemicalEntity	D019386
81876582	1746	1773	benign prostate hyperplasia	DiseaseOrPhenotypicFeature	D011470
81876582	1778	1786	cortisol	ChemicalEntity	D006854
81876582	1942	1969	benign prostate hyperplasia	DiseaseOrPhenotypicFeature	D011470
81876582	1974	1977	fat	ChemicalEntity	D004041
81876582	2081	2086	COS-7	CellLine	CVCL_0224
81876582	2088	2096	C57BL/6J	CellLine	CVCL_5U84
81876582	2102	2106	HK-2	CellLine	CVCL_0302
81876582	2261	2285	[(3)H]-2-deoxy-d-glucose	ChemicalEntity	D003847
81876582	2287	2305	sodium bicarbonate	ChemicalEntity	D017693
81876582	2307	2315	cortisol	ChemicalEntity	D006854
81876582	2321	2332	alendronate	ChemicalEntity	D019386
81876582	Association	D001008	D017693	Novel
81876582	Bind	11035	94223	Novel
81876582	Association	D011470	D003847	Novel
81876582	Association	D011470	D017693	Novel
81876582	Association	D001008	D004041	Novel
81876582	Association	D011470	D019386	Novel
81876582	Association	D001008	D019386	Novel
81876582	Association	D001008	D003847	Novel
81876582	Association	D001008	D006854	Novel
81876582	Association	D011470	D004041	Novel
81876582	Bind	94223	11035	Novel
81876582	Association	D011470	D006854	Novel

46584343|t|CE and CCDC-104 interactions in MH134 cells: a study on bcl-xl and IkappaBalpha binding and functional corr
46584343|a|In this study, we investigated the interactions between the chemical entity CE and the gene product CCDC-104 in the context of MH134 cell lines. Our findings revealed a positive correlation between CE and CCDC-104 expression levels in MH134 cells, suggesting a potential regulatory role of CE in modulating CCDC-104 activity. Furthermore, we demonstrated that CCDC-104 binds directly to IkappaBalpha, a key regulator of NF-B signaling, in MH134 cells. This interaction was confirmed through co-immunoprecipitation and pull-down assays. Additionally, we observed that bcl-xl, an anti-apoptotic gene product, binds to both IkappaBalpha and CCDC-104 in MH134 cells, indicating a potential functional link between these proteins. The binding of bcl-xl to IkappaBalpha was further supported by biochemical assays, and the interaction between bcl-xl and CCDC-104 was validated using proximity ligation assays. These results suggest that the interplay between CE, CCDC-104, IkappaBalpha, and bcl-xl may play a significant role in cellular survival and inflammatory responses in MH134 cells. The repeated mentions of MH134, bcl-xl, CE, IkappaBalpha, and CCDC-104 in our experiments underscore the importance of these entities in the observed biological processes.
46584343	0	2	CE	ChemicalEntity	C105934
46584343	7	15	CCDC-104	GeneOrGeneProduct	112942
46584343	32	37	MH134	CellLine	CVCL_8111
46584343	56	62	bcl-xl	GeneOrGeneProduct	24888
46584343	67	79	IkappaBalpha	GeneOrGeneProduct	18035
46584343	184	186	CE	ChemicalEntity	C105934
46584343	208	216	CCDC-104	GeneOrGeneProduct	112942
46584343	235	240	MH134	CellLine	CVCL_8111
46584343	306	308	CE	ChemicalEntity	C105934
46584343	313	321	CCDC-104	GeneOrGeneProduct	112942
46584343	343	348	MH134	CellLine	CVCL_8111
46584343	398	400	CE	ChemicalEntity	C105934
46584343	415	423	CCDC-104	GeneOrGeneProduct	112942
46584343	468	476	CCDC-104	GeneOrGeneProduct	112942
46584343	495	507	IkappaBalpha	GeneOrGeneProduct	18035
46584343	548	553	MH134	CellLine	CVCL_8111
46584343	676	682	bcl-xl	GeneOrGeneProduct	24888
46584343	730	742	IkappaBalpha	GeneOrGeneProduct	18035
46584343	747	755	CCDC-104	GeneOrGeneProduct	112942
46584343	759	764	MH134	CellLine	CVCL_8111
46584343	850	856	bcl-xl	GeneOrGeneProduct	24888
46584343	860	872	IkappaBalpha	GeneOrGeneProduct	18035
46584343	946	952	bcl-xl	GeneOrGeneProduct	24888
46584343	957	965	CCDC-104	GeneOrGeneProduct	112942
46584343	1062	1064	CE	ChemicalEntity	C105934
46584343	1066	1074	CCDC-104	GeneOrGeneProduct	112942
46584343	1076	1088	IkappaBalpha	GeneOrGeneProduct	18035
46584343	1094	1100	bcl-xl	GeneOrGeneProduct	24888
46584343	1180	1185	MH134	CellLine	CVCL_8111
46584343	1218	1223	MH134	CellLine	CVCL_8111
46584343	1225	1231	bcl-xl	GeneOrGeneProduct	24888
46584343	1233	1235	CE	ChemicalEntity	C105934
46584343	1237	1249	IkappaBalpha	GeneOrGeneProduct	18035
46584343	1255	1263	CCDC-104	GeneOrGeneProduct	112942
46584343	Positive_Correlation	C105934	112942	Novel
46584343	Bind	112942	18035	Novel
46584343	Bind	24888	18035	Novel
46584343	Bind	24888	112942	Novel
46584343	Bind	18035	112942	Novel

66062880|t|CD4 and glucagon interactions in familial hypertrophic cardiomyopathy and cerebral ischemia: implications for HPVs, rDEN-2, an
66062880|a|This study investigates the complex interactions between CD4 and glucagon in the context of familial hypertrophic cardiomyopathy and cerebral ischemia, with particular emphasis on their roles in modulating immune responses and metabolic pathways. We demonstrate a positive correlation between CD4 and glucagon, as well as between CD4 and ERK1/2, and between ERK1/2 and glucagon. These findings are supported by experimental evidence showing a direct bind between CD4 and glucagon, as well as between ERK1/2 and glucagon, and between CD4 and ERK1/2. The positive correlation between ERK1/2 and CD4 further reinforces the interconnectedness of these molecular pathways.   Our analysis also reveals that the sequence variant p.F366L in CD4 is associated with altered binding affinities to both glucagon and ERK1/2, suggesting a potential mechanism by which this variant may contribute to disease susceptibility. The study further explores the role of HPVs, rDEN-2, and horses in modulating these interactions, particularly in the context of EH and other phenotypic features.   In horses, the expression of CD4 and glucagon is significantly elevated in response to cerebral ischemia, and this is accompanied by increased ERK1/2 activity. These findings suggest that the CD4-glucagon-ERK1/2 axis may play a critical role in the pathophysiology of both familial hypertrophic cardiomyopathy and cerebral ischemia. The presence of multiple instances of these molecular entities across different organisms and disease states underscores the importance of cross-species comparisons in understanding the functional significance of these interactions.
66062880	0	3	CD4	GeneOrGeneProduct	920
66062880	8	16	glucagon	GeneOrGeneProduct	14526
66062880	33	69	familial hypertrophic cardiomyopathy	DiseaseOrPhenotypicFeature	D024741
66062880	74	91	cerebral ischemia	DiseaseOrPhenotypicFeature	D002545
66062880	110	114	HPVs	OrganismTaxon	10566
66062880	116	122	rDEN-2	OrganismTaxon	11060
66062880	184	187	CD4	GeneOrGeneProduct	920
66062880	192	200	glucagon	GeneOrGeneProduct	14526
66062880	219	255	familial hypertrophic cardiomyopathy	DiseaseOrPhenotypicFeature	D024741
66062880	260	277	cerebral ischemia	DiseaseOrPhenotypicFeature	D002545
66062880	420	423	CD4	GeneOrGeneProduct	920
66062880	428	436	glucagon	GeneOrGeneProduct	14526
66062880	457	460	CD4	GeneOrGeneProduct	920
66062880	465	471	ERK1/2	GeneOrGeneProduct	5595
66062880	485	491	ERK1/2	GeneOrGeneProduct	5595
66062880	496	504	glucagon	GeneOrGeneProduct	14526
66062880	590	593	CD4	GeneOrGeneProduct	920
66062880	598	606	glucagon	GeneOrGeneProduct	14526
66062880	627	633	ERK1/2	GeneOrGeneProduct	5595
66062880	638	646	glucagon	GeneOrGeneProduct	14526
66062880	660	663	CD4	GeneOrGeneProduct	920
66062880	668	674	ERK1/2	GeneOrGeneProduct	5595
66062880	709	715	ERK1/2	GeneOrGeneProduct	5595
66062880	720	723	CD4	GeneOrGeneProduct	920
66062880	849	856	p.F366L	SequenceVariant	rs140756663
66062880	860	863	CD4	GeneOrGeneProduct	920
66062880	918	926	glucagon	GeneOrGeneProduct	14526
66062880	931	937	ERK1/2	GeneOrGeneProduct	5595
66062880	1075	1079	HPVs	OrganismTaxon	10566
66062880	1081	1087	rDEN-2	OrganismTaxon	11060
66062880	1093	1099	horses	OrganismTaxon	9796
66062880	1165	1167	EH	DiseaseOrPhenotypicFeature	D000075222
66062880	1204	1210	horses	OrganismTaxon	9796
66062880	1230	1233	CD4	GeneOrGeneProduct	920
66062880	1238	1246	glucagon	GeneOrGeneProduct	14526
66062880	1288	1305	cerebral ischemia	DiseaseOrPhenotypicFeature	D002545
66062880	1344	1350	ERK1/2	GeneOrGeneProduct	5595
66062880	1393	1396	CD4	GeneOrGeneProduct	920
66062880	1397	1405	glucagon	GeneOrGeneProduct	14526
66062880	1406	1412	ERK1/2	GeneOrGeneProduct	5595
66062880	1474	1510	familial hypertrophic cardiomyopathy	DiseaseOrPhenotypicFeature	D024741
66062880	1515	1532	cerebral ischemia	DiseaseOrPhenotypicFeature	D002545
66062880	Positive_Correlation	920	14526	Novel
66062880	Bind	5595	14526	Novel
66062880	Bind	920	5595	Novel
66062880	Bind	14526	920	Novel
66062880	Positive_Correlation	5595	920	Novel
66062880	Positive_Correlation	14526	5595	Novel
66062880	Bind	5595	920	Novel
66062880	Bind	14526	5595	Novel
66062880	Positive_Correlation	920	5595	Novel
66062880	Positive_Correlation	5595	14526	Novel
66062880	Positive_Correlation	14526	920	Novel
66062880	Bind	920	14526	Novel

54275436|t|Genetic Variants in SOD3 and Their Associations with Jaundice and Other Phenotypes in Saccharomyces cerevisiae and PA-1 Ce
54275436|a|Recent studies have explored the genetic architecture of jaundice and its associations with various sequence variants and gene products in both Saccharomyces cerevisiae and PA-1 cell lines. This research highlights the complex interplay between SOD3, a key antioxidant enzyme, and multiple sequence variants, including IVS3 + 18C > T, +8365 C/T, and p.V239del, in the context of jaundice.   In Saccharomyces cerevisiae, SOD3 has been shown to have a negative correlation with jaundice, suggesting that its expression may be modulated by the presence of jaundice-related phenotypes. Similarly, in PA-1 cell lines, SOD3 exhibits a positive correlation with jaundice, indicating a potential dual role in different biological contexts. The association between SOD3 and jaundice is further supported by the observation that the sequence variant +8365 C/T is positively correlated with jaundice and is also associated with SOD3.   The sequence variant p.V239del is found to be associated with both +8365 C/T and IVS3 + 18C > T, suggesting a potential genetic network involving these variants. Additionally, p.V239del shows a positive correlation with jaundice, while also being negatively correlated with SOD3. This dual relationship underscores the complexity of genetic interactions in the context of jaundice.   The sequence variant IVS3 + 18C > T is associated with both p.V239del and +8365 C/T, and it exhibits a positive correlation with jaundice. However, it also shows a negative correlation with jaundice, indicating a possible context-dependent effect. Furthermore, IVS3 + 18C > T is associated with SOD3, reinforcing the interconnected nature of these genetic elements.   In rhesus monkeys, the presence of these sequence variants and their associations with jaundice and SOD3 provide additional evidence for the broader relevance of these genetic interactions across species. These findings suggest that the genetic landscape of jaundice is highly complex and involves multiple sequence variants and gene products, with both positive and negative correlations observed in different biological systems.
54275436	20	24	SOD3	GeneOrGeneProduct	6649
54275436	86	110	Saccharomyces cerevisiae	OrganismTaxon	4932
54275436	115	119	PA-1	CellLine	CVCL_0479
54275436	180	188	jaundice	DiseaseOrPhenotypicFeature	D007565
54275436	267	291	Saccharomyces cerevisiae	OrganismTaxon	4932
54275436	296	300	PA-1	CellLine	CVCL_0479
54275436	368	372	SOD3	GeneOrGeneProduct	6649
54275436	442	456	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
54275436	458	467	+8365 C/T	SequenceVariant	c|SUB|C|+8365|T
54275436	473	482	p.V239del	SequenceVariant	p|DEL|239|V
54275436	502	510	jaundice	DiseaseOrPhenotypicFeature	D007565
54275436	517	541	Saccharomyces cerevisiae	OrganismTaxon	4932
54275436	543	547	SOD3	GeneOrGeneProduct	6649
54275436	599	607	jaundice	DiseaseOrPhenotypicFeature	D007565
54275436	676	684	jaundice	DiseaseOrPhenotypicFeature	D007565
54275436	719	723	PA-1	CellLine	CVCL_0479
54275436	736	740	SOD3	GeneOrGeneProduct	6649
54275436	778	786	jaundice	DiseaseOrPhenotypicFeature	D007565
54275436	879	883	SOD3	GeneOrGeneProduct	6649
54275436	888	896	jaundice	DiseaseOrPhenotypicFeature	D007565
54275436	963	972	+8365 C/T	SequenceVariant	c|SUB|C|+8365|T
54275436	1003	1011	jaundice	DiseaseOrPhenotypicFeature	D007565
54275436	1040	1044	SOD3	GeneOrGeneProduct	6649
54275436	1069	1078	p.V239del	SequenceVariant	p|DEL|239|V
54275436	1115	1124	+8365 C/T	SequenceVariant	c|SUB|C|+8365|T
54275436	1129	1143	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
54275436	1224	1233	p.V239del	SequenceVariant	p|DEL|239|V
54275436	1268	1276	jaundice	DiseaseOrPhenotypicFeature	D007565
54275436	1322	1326	SOD3	GeneOrGeneProduct	6649
54275436	1420	1428	jaundice	DiseaseOrPhenotypicFeature	D007565
54275436	1453	1467	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
54275436	1492	1501	p.V239del	SequenceVariant	p|DEL|239|V
54275436	1506	1515	+8365 C/T	SequenceVariant	c|SUB|C|+8365|T
54275436	1561	1569	jaundice	DiseaseOrPhenotypicFeature	D007565
54275436	1622	1630	jaundice	DiseaseOrPhenotypicFeature	D007565
54275436	1693	1707	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T
54275436	1727	1731	SOD3	GeneOrGeneProduct	6649
54275436	1803	1817	rhesus monkeys	OrganismTaxon	9544
54275436	1887	1895	jaundice	DiseaseOrPhenotypicFeature	D007565
54275436	1900	1904	SOD3	GeneOrGeneProduct	6649
54275436	2058	2066	jaundice	DiseaseOrPhenotypicFeature	D007565
54275436	Association	6649	D007565	Novel
54275436	Association	p|DEL|239|V	c|SUB|C|+8365|T	Novel
54275436	Association	c|SUB|C|+8365|T	c|SUB|C|IVS3+18|T	Novel
54275436	Negative_Correlation	p|DEL|239|V	D007565	Novel
54275436	Negative_Correlation	c|SUB|C|+8365|T	D007565	Novel
54275436	Association	p|DEL|239|V	c|SUB|C|IVS3+18|T	Novel
54275436	Association	c|SUB|C|+8365|T	6649	Novel
54275436	Negative_Correlation	D007565	6649	Novel
54275436	Negative_Correlation	6649	D007565	Novel
54275436	Positive_Correlation	D007565	c|SUB|C|IVS3+18|T	Novel
54275436	Negative_Correlation	c|SUB|C|IVS3+18|T	D007565	Novel
54275436	Association	c|SUB|C|IVS3+18|T	p|DEL|239|V	Novel
54275436	Association	c|SUB|C|IVS3+18|T	c|SUB|C|+8365|T	Novel
54275436	Positive_Correlation	D007565	c|SUB|C|+8365|T	Novel
54275436	Positive_Correlation	D007565	6649	Novel
54275436	Association	c|SUB|C|+8365|T	p|DEL|239|V	Novel
54275436	Positive_Correlation	D007565	p|DEL|239|V	Novel
54275436	Association	p|DEL|239|V	6649	Novel
54275436	Association	c|SUB|C|IVS3+18|T	6649	Novel

39691847|t|Spirulina and Amikacin interactions with FGF2, TNFalpha, CD36, and sequence variants C282Y and
39691847|a|Spirulina, a widely studied cyanobacterium, has been implicated in various physiological and immunological processes. Recent studies have highlighted its potential role in modulating inflammatory responses and gene expression profiles. In this study, we investigate the interactions between Spirulina and Amikacin, a broad-spectrum aminoglycoside antibiotic, with respect to their effects on the expression of FGF2, TNFalpha, CD36, and the sequence variants C282Y and p.R428C.   Our findings reveal a significant association between FGF2 and TNFalpha, suggesting a potential regulatory relationship in the context of Spirulina exposure. Similarly, a reciprocal association is observed between TNFalpha and FGF2, indicating a complex interplay between these two gene products. The sequence variants C282Y and p.R428C are found to be associated, suggesting a possible genetic linkage or functional interaction.   Interestingly, a negative correlation is observed between FGF2 and Amikacin, implying that Amikacin may inhibit FGF2 expression or activity. This effect is further supported by the negative correlation between CD36 and Amikacin, which suggests that Amikacin may also modulate CD36 expression. However, an association is found between Amikacin and CD36, indicating a more nuanced relationship that may involve both direct and indirect mechanisms.   Additionally, CD36 is found to be associated with FGF2, reinforcing the idea of a network of interactions involving these gene products. The presence of multiple Spirulina instances in the study underscores its role as a key variable in these interactions. The repeated mentions of Amikacin, FGF2, TNFalpha, CD36, C282Y, and p.R428C highlight the complexity of the biological systems under investigation. These results provide new insights into the molecular mechanisms underlying the effects of Spirulina and Amikacin on gene expression and sequence variant interactions.
39691847	0	9	Spirulina	OrganismTaxon	551299
39691847	14	22	Amikacin	ChemicalEntity	D000583
39691847	41	45	FGF2	GeneOrGeneProduct	2247
39691847	47	55	TNFalpha	GeneOrGeneProduct	21926
39691847	57	61	CD36	GeneOrGeneProduct	948
39691847	85	90	C282Y	SequenceVariant	rs1800562
39691847	95	104	Spirulina	OrganismTaxon	551299
39691847	386	395	Spirulina	OrganismTaxon	551299
39691847	400	408	Amikacin	ChemicalEntity	D000583
39691847	505	509	FGF2	GeneOrGeneProduct	2247
39691847	511	519	TNFalpha	GeneOrGeneProduct	21926
39691847	521	525	CD36	GeneOrGeneProduct	948
39691847	553	558	C282Y	SequenceVariant	rs1800562
39691847	563	570	p.R428C	SequenceVariant	rs750700202
39691847	628	632	FGF2	GeneOrGeneProduct	2247
39691847	637	645	TNFalpha	GeneOrGeneProduct	21926
39691847	712	721	Spirulina	OrganismTaxon	551299
39691847	788	796	TNFalpha	GeneOrGeneProduct	21926
39691847	801	805	FGF2	GeneOrGeneProduct	2247
39691847	893	898	C282Y	SequenceVariant	rs1800562
39691847	903	910	p.R428C	SequenceVariant	rs750700202
39691847	1064	1068	FGF2	GeneOrGeneProduct	2247
39691847	1073	1081	Amikacin	ChemicalEntity	D000583
39691847	1097	1105	Amikacin	ChemicalEntity	D000583
39691847	1118	1122	FGF2	GeneOrGeneProduct	2247
39691847	1216	1220	CD36	GeneOrGeneProduct	948
39691847	1225	1233	Amikacin	ChemicalEntity	D000583
39691847	1255	1263	Amikacin	ChemicalEntity	D000583
39691847	1282	1286	CD36	GeneOrGeneProduct	948
39691847	1340	1348	Amikacin	ChemicalEntity	D000583
39691847	1353	1357	CD36	GeneOrGeneProduct	948
39691847	1468	1472	CD36	GeneOrGeneProduct	948
39691847	1504	1508	FGF2	GeneOrGeneProduct	2247
39691847	1616	1625	Spirulina	OrganismTaxon	551299
39691847	1736	1744	Amikacin	ChemicalEntity	D000583
39691847	1746	1750	FGF2	GeneOrGeneProduct	2247
39691847	1752	1760	TNFalpha	GeneOrGeneProduct	21926
39691847	1762	1766	CD36	GeneOrGeneProduct	948
39691847	1768	1773	C282Y	SequenceVariant	rs1800562
39691847	1779	1786	p.R428C	SequenceVariant	rs750700202
39691847	1950	1959	Spirulina	OrganismTaxon	551299
39691847	1964	1972	Amikacin	ChemicalEntity	D000583
39691847	Association	2247	21926	Novel
39691847	Association	21926	2247	Novel
39691847	Association	rs1800562	rs750700202	Novel
39691847	Negative_Correlation	2247	D000583	Novel
39691847	Association	948	2247	Novel
39691847	Negative_Correlation	948	D000583	Novel
39691847	Association	D000583	948	Novel
39691847	Association	rs750700202	rs1800562	Novel

59585457|t|Levamisole, ester, and breast diseases: a multi-faceted investigation into their associations with neurotoxic lesions and the Ishikawa c
59585457|a|Recent studies have explored the complex interplay between breast diseases, neurotoxic lesions, and the chemical entities levamisole and ester, with a particular focus on their interactions and associations. This research highlights a positive correlation between breast diseases and both levamisole and ester, suggesting a potential therapeutic or pathological link. Additionally, a strong positive correlation was observed between neurotoxic lesions and both levamisole and ester, indicating a possible mechanism by which these chemical entities may contribute to neurodegenerative processes.   The drug interaction between levamisole and ester was found to be significant, with evidence of both a direct drug interaction and an association between the two compounds. These findings were further supported by in vitro studies using the Ishikawa cell line, which demonstrated altered gene expression patterns in response to levamisole and ester exposure. Specifically, the gene RIP1 showed increased expression levels in the presence of both compounds, suggesting a potential role for RIP1 in mediating the effects of these chemicals on cellular pathways.  Moreover, the study revealed that ester and levamisole may act synergistically in the context of breast diseases, with their combined effects potentially exacerbating or mitigating disease progression. The Ishikawa cell line was used as a model to investigate these interactions, providing insights into the molecular mechanisms underlying the observed correlations. These findings underscore the importance of understanding the complex relationships between chemical entities, disease states, and cellular responses in the development of targeted therapeutic strategies.
59585457	12	17	ester	ChemicalEntity	D004952
59585457	23	38	breast diseases	DiseaseOrPhenotypicFeature	D001941
59585457	99	117	neurotoxic lesions	DiseaseOrPhenotypicFeature	D020258
59585457	126	134	Ishikawa	CellLine	CVCL_2529
59585457	196	211	breast diseases	DiseaseOrPhenotypicFeature	D001941
59585457	213	231	neurotoxic lesions	DiseaseOrPhenotypicFeature	D020258
59585457	259	269	levamisole	ChemicalEntity	D007978
59585457	274	279	ester	ChemicalEntity	D004952
59585457	401	416	breast diseases	DiseaseOrPhenotypicFeature	D001941
59585457	426	436	levamisole	ChemicalEntity	D007978
59585457	441	446	ester	ChemicalEntity	D004952
59585457	570	588	neurotoxic lesions	DiseaseOrPhenotypicFeature	D020258
59585457	598	608	levamisole	ChemicalEntity	D007978
59585457	613	618	ester	ChemicalEntity	D004952
59585457	763	773	levamisole	ChemicalEntity	D007978
59585457	778	783	ester	ChemicalEntity	D004952
59585457	975	983	Ishikawa	CellLine	CVCL_2529
59585457	1062	1072	levamisole	ChemicalEntity	D007978
59585457	1077	1082	ester	ChemicalEntity	D004952
59585457	1116	1120	RIP1	GeneOrGeneProduct	8737
59585457	1223	1227	RIP1	GeneOrGeneProduct	8737
59585457	1329	1334	ester	ChemicalEntity	D004952
59585457	1339	1349	levamisole	ChemicalEntity	D007978
59585457	1392	1407	breast diseases	DiseaseOrPhenotypicFeature	D001941
59585457	1501	1509	Ishikawa	CellLine	CVCL_2529
59585457	Positive_Correlation	D020258	D004952	Novel
59585457	Drug_Interaction	D004952	D007978	Novel
59585457	Positive_Correlation	D001941	D007978	Novel
59585457	Association	D007978	D004952	Novel
59585457	Positive_Correlation	D001941	D004952	Novel
59585457	Drug_Interaction	D007978	D004952	Novel
59585457	Association	D004952	D007978	Novel
59585457	Positive_Correlation	D020258	D007978	Novel

03721229|t|H446 cell line responses to carbohydrate and triglyceride metabolism influenced by sequence variants A49T, rs3753394, and del 92 nucleotide -19/+73 in type I and type II TGF-beta r
03721229|a|The H446 cell line, a well-characterized human lung cancer cell line, was used to investigate the interplay between carbohydrate metabolism, triglyceride accumulation, and genetic variants in the context of type I and type II TGF-beta receptors. Our study revealed a significant positive correlation between carbohydrate levels and the expression of type I and type II TGF-beta receptors, suggesting a regulatory role for these receptors in glucose metabolism. Additionally, we observed a strong association between carbohydrate levels and the sequence variant rs3753394, as well as between carbohydrate and A49T, indicating that these genetic markers may modulate metabolic responses in the H446 cell line.   Triglyceride accumulation was found to be significantly associated with the del 92 nucleotide -19/+73 variant, and this association was further supported by a positive correlation between triglyceride levels and type I and type II TGF-beta receptors. Moreover, triglyceride levels were positively correlated with the A49T variant, highlighting a potential role for this sequence variant in lipid metabolism. The rs3753394 variant also showed a significant association with triglyceride levels, reinforcing the idea that multiple genetic factors contribute to the regulation of lipid and carbohydrate metabolism in the H446 cell line. These findings provide new insights into the molecular mechanisms underlying metabolic dysregulation in cancer cells and suggest potential therapeutic targets for metabolic intervention.
03721229	0	4	H446	CellLine	CVCL_1562
03721229	28	40	carbohydrate	ChemicalEntity	D002241
03721229	45	57	triglyceride	ChemicalEntity	D014280
03721229	101	105	A49T	SequenceVariant	rs9282858
03721229	107	116	rs3753394	SequenceVariant	rs3753394
03721229	122	147	del 92 nucleotide -19/+73	SequenceVariant	c|DEL|-19_+73|92
03721229	185	189	H446	CellLine	CVCL_1562
03721229	297	309	carbohydrate	ChemicalEntity	D002241
03721229	322	334	triglyceride	ChemicalEntity	D014280
03721229	388	425	type I and type II TGF-beta receptors	GeneOrGeneProduct	7046
03721229	489	501	carbohydrate	ChemicalEntity	D002241
03721229	531	568	type I and type II TGF-beta receptors	GeneOrGeneProduct	7046
03721229	697	709	carbohydrate	ChemicalEntity	D002241
03721229	742	751	rs3753394	SequenceVariant	rs3753394
03721229	772	784	carbohydrate	ChemicalEntity	D002241
03721229	789	793	A49T	SequenceVariant	rs9282858
03721229	873	877	H446	CellLine	CVCL_1562
03721229	967	992	del 92 nucleotide -19/+73	SequenceVariant	c|DEL|-19_+73|92
03721229	1079	1091	triglyceride	ChemicalEntity	D014280
03721229	1103	1140	type I and type II TGF-beta receptors	GeneOrGeneProduct	7046
03721229	1152	1164	triglyceride	ChemicalEntity	D014280
03721229	1208	1212	A49T	SequenceVariant	rs9282858
03721229	1303	1312	rs3753394	SequenceVariant	rs3753394
03721229	1364	1376	triglyceride	ChemicalEntity	D014280
03721229	1478	1490	carbohydrate	ChemicalEntity	D002241
03721229	1509	1513	H446	CellLine	CVCL_1562
03721229	Association	D014280	c|DEL|-19_+73|92	Novel
03721229	Positive_Correlation	D002241	7046	Novel
03721229	Association	D002241	rs3753394	Novel
03721229	Association	D002241	rs9282858	Novel
03721229	Association	D014280	rs9282858	Novel
03721229	Association	D002241	c|DEL|-19_+73|92	Novel
03721229	Positive_Correlation	D014280	7046	Novel
03721229	Association	D014280	rs3753394	Novel

04563975|t|Heme oxygenase-1 and p53 interactions in response to ROS and sequence variants: implications for anthraquinone and propofol phar
04563975|a|This study investigates the molecular mechanisms underlying the interactions between heme oxygenase-1, p53, and reactive oxygen species (ROS) in the context of sequence variants such as (CCTTT)10 and p.Val204Asp. We demonstrate that the sequence variant (CCTTT)10 exhibits a negative correlation with anthraquinone levels, suggesting a potential regulatory role in cellular redox homeostasis. Additionally, the p.Val204Asp variant shows a negative correlation with ROS accumulation, indicating a possible protective effect against oxidative stress.   Our findings also reveal that anthraquinone interacts with both ROS and propofol, highlighting its dual role as a chemical entity that modulates oxidative stress and pharmacological responses. Furthermore, we report a drug interaction between propofol and anthraquinone, which may influence their combined therapeutic efficacy or toxicity. The K(+) channel and Ca(2+) channel blocker was found to interact with ROS, suggesting a potential mechanism by which these compounds modulate cellular signaling pathways.   Notably, the gene product THRA was found to be co-expressed with p53 in response to ROS, indicating a possible regulatory network involving these proteins. The presence of multiple sequence variants, including rs3806325, further underscores the genetic complexity of these interactions. These results provide new insights into the interplay between genetic factors, chemical entities, and cellular responses, with implications for the development of targeted therapies involving anthraquinone, propofol, and other pharmacological agents.
04563975	21	24	p53	GeneOrGeneProduct	22060
04563975	53	56	ROS	ChemicalEntity	D017382
04563975	97	110	anthraquinone	ChemicalEntity	D000880
04563975	115	123	propofol	ChemicalEntity	D015742
04563975	214	230	heme oxygenase-1	GeneOrGeneProduct	15368
04563975	232	235	p53	GeneOrGeneProduct	22060
04563975	266	269	ROS	ChemicalEntity	D017382
04563975	315	324	(CCTTT)10	SequenceVariant	c|DUP||CCTTT|10
04563975	329	340	p.Val204Asp	SequenceVariant	p|SUB|V|204|D
04563975	383	392	(CCTTT)10	SequenceVariant	c|DUP||CCTTT|10
04563975	430	443	anthraquinone	ChemicalEntity	D000880
04563975	540	551	p.Val204Asp	SequenceVariant	p|SUB|V|204|D
04563975	594	597	ROS	ChemicalEntity	D017382
04563975	710	723	anthraquinone	ChemicalEntity	D000880
04563975	744	747	ROS	ChemicalEntity	D017382
04563975	752	760	propofol	ChemicalEntity	D015742
04563975	923	931	propofol	ChemicalEntity	D015742
04563975	936	949	anthraquinone	ChemicalEntity	D000880
04563975	1024	1063	K(+) channel and Ca(2+) channel blocker	ChemicalEntity	D002121
04563975	1091	1094	ROS	ChemicalEntity	D017382
04563975	1220	1224	THRA	GeneOrGeneProduct	7067
04563975	1259	1262	p53	GeneOrGeneProduct	22060
04563975	1278	1281	ROS	ChemicalEntity	D017382
04563975	1404	1413	rs3806325	SequenceVariant	rs3806325
04563975	1673	1686	anthraquinone	ChemicalEntity	D000880
04563975	1688	1696	propofol	ChemicalEntity	D015742
04563975	Drug_Interaction	D015742	D000880	Novel
04563975	Drug_Interaction	D002121	D017382	Novel
04563975	Drug_Interaction	D000880	D015742	Novel
04563975	Negative_Correlation	p|SUB|V|204|D	D017382	Novel
04563975	Drug_Interaction	D000880	D017382	Novel
04563975	Negative_Correlation	c|DUP||CCTTT|10	D000880	Novel

89985955|t|Alpha-methyldopa and SB 202190 interactions in Aedes mosquitoes, C4-2B, SMMC-7721, and LNCaP cell lines: implications for outpatient and Danio reri
89985955|a|This study investigates the interactions between alpha-methyldopa and SB 202190 in various biological systems, including Aedes mosquitoes, C4-2B, SMMC-7721, and LNCaP cell lines. The research focuses on the potential therapeutic and toxicological implications of these chemical entities in both in vitro and in vivo models.   Alpha-methyldopa, a well-known antihypertensive drug, was found to exhibit a positive correlation with SB 202190, a p38 MAP kinase inhibitor, in multiple experimental conditions. This correlation was observed in Aedes mosquitoes, where both compounds were tested for their effects on viral replication and immune response. In C4-2B and SMMC-7721 cell lines, the combined treatment of alpha-methyldopa and SB 202190 led to a significant reduction in cell proliferation, suggesting a synergistic effect.   Further analysis in LNCaP cell lines, which are derived from human prostate cancer, revealed that the co-administration of alpha-methyldopa and SB 202190 resulted in enhanced apoptosis and reduced metastatic potential. These findings were corroborated in mouse mammary tumor virus-infected models, where the combination treatment showed a positive correlation with reduced viral load and improved host survival.   The study also explored the effects of these compounds in outpatient settings, where patients with chronic hypertension and inflammatory conditions were monitored. The results indicated that the combination of alpha-methyldopa and SB 202190 was well-tolerated and showed promising therapeutic outcomes.   In addition, the study utilized Danio rerio (zebrafish) as an in vivo model to assess the developmental toxicity of these compounds. The positive correlation between alpha-methyldopa and SB 202190 was further supported by the observed effects on embryonic development and organogenesis.   Overall, the findings suggest that the interaction between alpha-methyldopa and SB 202190 is not only significant in cellular and animal models but also has potential clinical relevance in outpatient care. The results provide a foundation for further research into the therapeutic applications of these compounds in various disease states.
89985955	21	30	SB 202190	ChemicalEntity	C090942
89985955	47	63	Aedes mosquitoes	OrganismTaxon	1245352
89985955	65	70	C4-2B	CellLine	CVCL_4784
89985955	72	81	SMMC-7721	CellLine	CVCL_0534
89985955	87	92	LNCaP	CellLine	CVCL_0395
89985955	122	132	outpatient	OrganismTaxon	9606
89985955	197	213	alpha-methyldopa	ChemicalEntity	D008750
89985955	218	227	SB 202190	ChemicalEntity	C090942
89985955	269	285	Aedes mosquitoes	OrganismTaxon	1245352
89985955	287	292	C4-2B	CellLine	CVCL_4784
89985955	294	303	SMMC-7721	CellLine	CVCL_0534
89985955	309	314	LNCaP	CellLine	CVCL_0395
89985955	577	586	SB 202190	ChemicalEntity	C090942
89985955	686	702	Aedes mosquitoes	OrganismTaxon	1245352
89985955	800	805	C4-2B	CellLine	CVCL_4784
89985955	810	819	SMMC-7721	CellLine	CVCL_0534
89985955	858	874	alpha-methyldopa	ChemicalEntity	D008750
89985955	879	888	SB 202190	ChemicalEntity	C090942
89985955	998	1003	LNCaP	CellLine	CVCL_0395
89985955	1101	1117	alpha-methyldopa	ChemicalEntity	D008750
89985955	1122	1131	SB 202190	ChemicalEntity	C090942
89985955	1233	1258	mouse mammary tumor virus	OrganismTaxon	11757
89985955	1450	1460	outpatient	OrganismTaxon	9606
89985955	1602	1618	alpha-methyldopa	ChemicalEntity	D008750
89985955	1623	1632	SB 202190	ChemicalEntity	C090942
89985955	1729	1740	Danio rerio	OrganismTaxon	7955
89985955	1863	1879	alpha-methyldopa	ChemicalEntity	D008750
89985955	1884	1893	SB 202190	ChemicalEntity	C090942
89985955	2045	2061	alpha-methyldopa	ChemicalEntity	D008750
89985955	2066	2075	SB 202190	ChemicalEntity	C090942
89985955	2175	2185	outpatient	OrganismTaxon	9606
89985955	Positive_Correlation	D008750	C090942	Novel
89985955	Positive_Correlation	C090942	D008750	Novel

54913052|t|Comparative analysis of tumor growth and immune response in multiple cell lines: implications for cancer therapy and immunomo
54913052|a|This study investigates the differential responses of various cell lines to immunomodulatory treatments and their implications for cancer therapy. The cell lines SJ-GBM2, H446, MCF-7, CMT-93, LbetaT2, MH134, DU145, C57BL/6, H9c2, RAW 264.7, SMMC-7721, GT1-1, and SW480 were selected for their relevance in cancer research and immune system studies.   The primary objective was to evaluate the effects of immunomodulatory agents on tumor growth and immune cell activation. SJ-GBM2 and H446 were used as models for glioblastoma and small cell lung cancer, respectively, while MCF-7 and CMT-93 represented breast and melanoma cell lines. LbetaT2 and MH134 were included for their roles in endocrine and hepatic functions, and DU145 served as a prostate cancer model.   C57BL/6 mice were used as a control for in vivo experiments, while H9c2 and RAW 264.7 were employed to study cardiac and macrophage responses. SMMC-7721 and GT1-1 were selected for their relevance in hepatocellular carcinoma and neuroendocrine tumors, respectively. SW480 was included as a colorectal cancer model.   The results showed that SJ-GBM2 and H446 exhibited significant resistance to immunomodulatory treatments, whereas MCF-7 and CMT-93 showed variable responses. LbetaT2 and MH134 demonstrated enhanced immune cell activation, and DU145 showed a unique pattern of cytokine secretion. C57BL/6 mice provided a consistent baseline for immune response measurements, while H9c2 and RAW 264.7 revealed distinct mechanisms of immune modulation.   These findings suggest that the choice of cell line significantly impacts the outcomes of immunomodulatory therapies, highlighting the need for tailored approaches in cancer treatment. The study underscores the importance of using diverse cell lines to better understand the complex interactions between tumors and the immune system.
54913052	288	295	SJ-GBM2	CellLine	CVCL_M141
54913052	297	301	H446	CellLine	CVCL_1562
54913052	303	308	MCF-7	CellLine	CVCL_0031
54913052	310	316	CMT-93	CellLine	CVCL_1986
54913052	318	325	LbetaT2	CellLine	CVCL_0398
54913052	327	332	MH134	CellLine	CVCL_8111
54913052	334	339	DU145	CellLine	CVCL_0105
54913052	341	348	C57BL/6	CellLine	CVCL_5746
54913052	350	354	H9c2	CellLine	CVCL_0286
54913052	356	365	RAW 264.7	CellLine	CVCL_0493
54913052	367	376	SMMC-7721	CellLine	CVCL_0534
54913052	378	383	GT1-1	CellLine	CVCL_6236
54913052	389	394	SW480	CellLine	CVCL_0546
54913052	598	605	SJ-GBM2	CellLine	CVCL_M141
54913052	610	614	H446	CellLine	CVCL_1562
54913052	700	705	MCF-7	CellLine	CVCL_0031
54913052	710	716	CMT-93	CellLine	CVCL_1986
54913052	761	768	LbetaT2	CellLine	CVCL_0398
54913052	773	778	MH134	CellLine	CVCL_8111
54913052	849	854	DU145	CellLine	CVCL_0105
54913052	892	899	C57BL/6	CellLine	CVCL_5746
54913052	959	963	H9c2	CellLine	CVCL_0286
54913052	968	977	RAW 264.7	CellLine	CVCL_0493
54913052	1035	1044	SMMC-7721	CellLine	CVCL_0534
54913052	1049	1054	GT1-1	CellLine	CVCL_6236
54913052	1158	1163	SW480	CellLine	CVCL_0546
54913052	1233	1240	SJ-GBM2	CellLine	CVCL_M141
54913052	1245	1249	H446	CellLine	CVCL_1562
54913052	1323	1328	MCF-7	CellLine	CVCL_0031
54913052	1333	1339	CMT-93	CellLine	CVCL_1986
54913052	1367	1374	LbetaT2	CellLine	CVCL_0398
54913052	1379	1384	MH134	CellLine	CVCL_8111
54913052	1435	1440	DU145	CellLine	CVCL_0105
54913052	1488	1495	C57BL/6	CellLine	CVCL_5746
54913052	1572	1576	H9c2	CellLine	CVCL_0286
54913052	1581	1590	RAW 264.7	CellLine	CVCL_0493

11422571|t|Acanthosis Nigricans and Vitamin E: Interactions with Pancreatic Growth-Factors, TP53, and Cellular Models in Mouse and Human Immunodeficiency Virus In
11422571|a|Acanthosis nigricans (acanthosis) is a phenotypic feature associated with metabolic disorders and has been linked to various cellular and molecular mechanisms. This study investigates the relationship between vitamin E and acanthosis in the context of pancreatic growth-factors and TP53 expression in both human immunodeficiency virus (HIV) and non-HIV models. Using SUM159PT and Mz-ChA-1 cell lines, we observed a negative correlation between vitamin E levels and the expression of pancreatic growth-factors, as well as a negative correlation between vitamin E and TP53 activity. These findings were consistent across multiple experimental conditions, including in vitro models involving Mouse-derived cell lines. The study also explored the impact of acanthosis on these molecular pathways in both HIV-infected and uninfected human subjects. Notably, the presence of acanthosis was associated with altered vitamin E metabolism and reduced TP53 function, suggesting a potential role for vitamin E in modulating these pathways. Further research is needed to determine the clinical implications of these interactions in human immunodeficiency virus and other disease states.
11422571	81	85	TP53	GeneOrGeneProduct	7157
11422571	110	115	Mouse	OrganismTaxon	10090
11422571	174	184	acanthosis	DiseaseOrPhenotypicFeature	D000052
11422571	361	370	vitamin E	ChemicalEntity	D014810
11422571	375	385	acanthosis	DiseaseOrPhenotypicFeature	D000052
11422571	404	429	pancreatic growth-factors	GeneOrGeneProduct	25266
11422571	434	438	TP53	GeneOrGeneProduct	7157
11422571	458	486	human immunodeficiency virus	OrganismTaxon	12721
11422571	519	527	SUM159PT	CellLine	CVCL_5423
11422571	532	540	Mz-ChA-1	CellLine	CVCL_6932
11422571	596	605	vitamin E	ChemicalEntity	D014810
11422571	635	660	pancreatic growth-factors	GeneOrGeneProduct	25266
11422571	704	713	vitamin E	ChemicalEntity	D014810
11422571	718	722	TP53	GeneOrGeneProduct	7157
11422571	841	846	Mouse	OrganismTaxon	10090
11422571	905	915	acanthosis	DiseaseOrPhenotypicFeature	D000052
11422571	1021	1031	acanthosis	DiseaseOrPhenotypicFeature	D000052
11422571	1060	1069	vitamin E	ChemicalEntity	D014810
11422571	1093	1097	TP53	GeneOrGeneProduct	7157
11422571	1140	1149	vitamin E	ChemicalEntity	D014810
11422571	1271	1299	human immunodeficiency virus	OrganismTaxon	12721
11422571	Negative_Correlation	D014810	25266	Novel
11422571	Negative_Correlation	D014810	7157	Novel

09113062|t|Genetic Variants and Cellular Models in Neurological and Oncological Disorders: A Multifaceted Analysis of Disease Asso
09113062|a|This study explores the complex interplay between genetic variants and cellular models in the context of neurological and oncological disorders. We investigated the associations between specific sequence variants and disease phenotypes using a combination of in vitro models, including the HeLa, 293T, SNU-C5, HCT116, SNU-C2A, H9c2, MEF, HEK, and BALB/c cell lines, as well as the KU7 cell line. The analysis focused on the relationships between sequence variants such as p.N102DfsX4, +8365 C/T, Glu873Stop, g.3455_3460del, E831X, 1858T, and alanine for proline at amino acid 286, and disease phenotypes including head and neck cancer, cerebral ischemia, hepatorenal syndrome, interstitial nephritis, astrogliosis, retinal degeneration, and memory deterioration.    Our findings reveal a significant positive correlation between Glu873Stop and hepatorenal syndrome, as well as between g.3455_3460del and memory deterioration. The sequence variant p.N102DfsX4 was found to be positively correlated with retinal degeneration, head and neck cancer, and memory deterioration. Additionally, the +8365 C/T variant showed a strong association with head and neck cancer and interstitial nephritis. The 1858T variant was linked to hepatorenal syndrome and astrogliosis, while the g.3455_3460del variant was associated with memory deterioration, head and neck cancer, and cerebral ischemia.    The alanine for proline at amino acid 286 variant demonstrated a positive correlation with memory deterioration, hepatorenal syndrome, interstitial nephritis, and astrogliosis. The E831X variant was found to be associated with astrogliosis and cerebral ischemia. Furthermore, the sequence variant Glu873Stop was also linked to interstitial nephritis. These associations were validated using multiple cell lines, including HeLa, 293T, SNU-C5, HCT116, SNU-C2A, H9c2, MEF, HEK, and BALB/c, which were used to model the disease phenotypes in vitro.    The results highlight the importance of genetic variants in the pathogenesis of neurological and oncological disorders and underscore the value of using diverse cellular models to study these complex relationships. This study provides a comprehensive framework for understanding the molecular mechanisms underlying these diseases and may inform future therapeutic strategies.
09113062	410	414	HeLa	CellLine	CVCL_0030
09113062	416	420	293T	CellLine	CVCL_0063
09113062	422	428	SNU-C5	CellLine	CVCL_5112
09113062	430	436	HCT116	CellLine	CVCL_0291
09113062	438	445	SNU-C2A	CellLine	CVCL_1709
09113062	447	451	H9c2	CellLine	CVCL_0286
09113062	453	456	MEF	CellLine	CVCL_9115
09113062	458	461	HEK	CellLine	CVCL_M624
09113062	467	473	BALB/c	CellLine	CVCL_9101
09113062	501	504	KU7	CellLine	CVCL_4714
09113062	592	603	p.N102DfsX4	SequenceVariant	p|FS|N|102|D|4
09113062	605	614	+8365 C/T	SequenceVariant	c|SUB|C|+8365|T
09113062	616	626	Glu873Stop	SequenceVariant	rs121918047
09113062	628	642	g.3455_3460del	SequenceVariant	g|DEL|3455_3460|
09113062	644	649	E831X	SequenceVariant	rs397508387
09113062	651	656	1858T	SequenceVariant	rs2476601
09113062	662	699	alanine for proline at amino acid 286	SequenceVariant	p|SUB|A|286|P
09113062	734	754	head and neck cancer	DiseaseOrPhenotypicFeature	D006258
09113062	756	773	cerebral ischemia	DiseaseOrPhenotypicFeature	D002545
09113062	775	795	hepatorenal syndrome	DiseaseOrPhenotypicFeature	D006530
09113062	797	819	interstitial nephritis	DiseaseOrPhenotypicFeature	D009395
09113062	821	833	astrogliosis	DiseaseOrPhenotypicFeature	D005911
09113062	835	855	retinal degeneration	DiseaseOrPhenotypicFeature	D012162
09113062	861	881	memory deterioration	DiseaseOrPhenotypicFeature	D008569
09113062	949	959	Glu873Stop	SequenceVariant	rs121918047
09113062	964	984	hepatorenal syndrome	DiseaseOrPhenotypicFeature	D006530
09113062	1005	1019	g.3455_3460del	SequenceVariant	g|DEL|3455_3460|
09113062	1024	1044	memory deterioration	DiseaseOrPhenotypicFeature	D008569
09113062	1067	1078	p.N102DfsX4	SequenceVariant	p|FS|N|102|D|4
09113062	1122	1142	retinal degeneration	DiseaseOrPhenotypicFeature	D012162
09113062	1144	1164	head and neck cancer	DiseaseOrPhenotypicFeature	D006258
09113062	1170	1190	memory deterioration	DiseaseOrPhenotypicFeature	D008569
09113062	1210	1219	+8365 C/T	SequenceVariant	c|SUB|C|+8365|T
09113062	1261	1281	head and neck cancer	DiseaseOrPhenotypicFeature	D006258
09113062	1286	1308	interstitial nephritis	DiseaseOrPhenotypicFeature	D009395
09113062	1314	1319	1858T	SequenceVariant	rs2476601
09113062	1342	1362	hepatorenal syndrome	DiseaseOrPhenotypicFeature	D006530
09113062	1367	1379	astrogliosis	DiseaseOrPhenotypicFeature	D005911
09113062	1391	1405	g.3455_3460del	SequenceVariant	g|DEL|3455_3460|
09113062	1434	1454	memory deterioration	DiseaseOrPhenotypicFeature	D008569
09113062	1456	1476	head and neck cancer	DiseaseOrPhenotypicFeature	D006258
09113062	1482	1499	cerebral ischemia	DiseaseOrPhenotypicFeature	D002545
09113062	1508	1545	alanine for proline at amino acid 286	SequenceVariant	p|SUB|A|286|P
09113062	1595	1615	memory deterioration	DiseaseOrPhenotypicFeature	D008569
09113062	1617	1637	hepatorenal syndrome	DiseaseOrPhenotypicFeature	D006530
09113062	1639	1661	interstitial nephritis	DiseaseOrPhenotypicFeature	D009395
09113062	1667	1679	astrogliosis	DiseaseOrPhenotypicFeature	D005911
09113062	1685	1690	E831X	SequenceVariant	rs397508387
09113062	1731	1743	astrogliosis	DiseaseOrPhenotypicFeature	D005911
09113062	1748	1765	cerebral ischemia	DiseaseOrPhenotypicFeature	D002545
09113062	1801	1811	Glu873Stop	SequenceVariant	rs121918047
09113062	1831	1853	interstitial nephritis	DiseaseOrPhenotypicFeature	D009395
09113062	1926	1930	HeLa	CellLine	CVCL_0030
09113062	1932	1936	293T	CellLine	CVCL_0063
09113062	1938	1944	SNU-C5	CellLine	CVCL_5112
09113062	1946	1952	HCT116	CellLine	CVCL_0291
09113062	1954	1961	SNU-C2A	CellLine	CVCL_1709
09113062	1963	1967	H9c2	CellLine	CVCL_0286
09113062	1969	1972	MEF	CellLine	CVCL_9115
09113062	1974	1977	HEK	CellLine	CVCL_M624
09113062	1983	1989	BALB/c	CellLine	CVCL_9101
09113062	Positive_Correlation	rs121918047	D006530	Novel
09113062	Positive_Correlation	g|DEL|3455_3460|	D008569	Novel
09113062	Positive_Correlation	D008569	p|FS|N|102|D|4	Novel
09113062	Positive_Correlation	D006530	rs2476601	Novel
09113062	Positive_Correlation	D012162	c|SUB|C|+8365|T	Novel
09113062	Positive_Correlation	D006258	g|DEL|3455_3460|	Novel
09113062	Positive_Correlation	p|SUB|A|286|P	D008569	Novel
09113062	Positive_Correlation	p|SUB|A|286|P	D006530	Novel
09113062	Positive_Correlation	p|SUB|A|286|P	D005911	Novel
09113062	Positive_Correlation	p|FS|N|102|D|4	D012162	Novel
09113062	Positive_Correlation	D009395	p|SUB|A|286|P	Novel
09113062	Positive_Correlation	c|SUB|C|+8365|T	D006258	Novel
09113062	Positive_Correlation	rs2476601	D006530	Novel
09113062	Positive_Correlation	D012162	g|DEL|3455_3460|	Novel
09113062	Positive_Correlation	D005911	rs397508387	Novel
09113062	Positive_Correlation	p|FS|N|102|D|4	D006258	Novel
09113062	Positive_Correlation	D006530	rs121918047	Novel
09113062	Positive_Correlation	p|FS|N|102|D|4	D008569	Novel
09113062	Positive_Correlation	D009395	rs397508387	Novel
09113062	Positive_Correlation	c|SUB|C|+8365|T	D009395	Novel
09113062	Positive_Correlation	D005911	p|FS|N|102|D|4	Novel
09113062	Positive_Correlation	D002545	rs397508387	Novel
09113062	Positive_Correlation	p|SUB|A|286|P	D009395	Novel
09113062	Positive_Correlation	rs2476601	D005911	Novel
09113062	Positive_Correlation	g|DEL|3455_3460|	D006258	Novel
09113062	Positive_Correlation	rs2476601	D012162	Novel
09113062	Positive_Correlation	D008569	p|SUB|A|286|P	Novel
09113062	Positive_Correlation	g|DEL|3455_3460|	D002545	Novel
09113062	Positive_Correlation	p|FS|N|102|D|4	D002545	Novel
09113062	Positive_Correlation	D005911	p|SUB|A|286|P	Novel
09113062	Positive_Correlation	c|SUB|C|+8365|T	D006530	Novel
09113062	Positive_Correlation	rs2476601	D009395	Novel
09113062	Positive_Correlation	g|DEL|3455_3460|	D012162	Novel
09113062	Positive_Correlation	rs121918047	D009395	Novel
09113062	Positive_Correlation	D006258	p|FS|N|102|D|4	Novel
09113062	Positive_Correlation	D006258	rs121918047	Novel
09113062	Positive_Correlation	g|DEL|3455_3460|	D005911	Novel

49840030|t|DOX and Amiodarone: complex interactions with FasL, TUBA1A, major histocompatibility complex, and u
49840030|a|This study investigates the multifaceted interactions between the chemotherapeutic agent DOX and the antiarrhythmic drug Amiodarone, with a focus on their associations with key biological entities such as FasL, TUBA1A, major histocompatibility complex (MHC), and ubiquitin. The research reveals a significant association between DOX and FasL, suggesting a potential role for FasL in mediating DOX-induced cellular responses. Additionally, DOX is found to be strongly associated with TUBA1A, indicating a possible involvement of TUBA1A in DOX toxicity or cellular remodeling.   Amiodarone exhibits a complex relationship with FasL, where it is associated with both the gene and its protein product, suggesting a potential regulatory or functional interaction. Furthermore, Amiodarone is significantly associated with the major histocompatibility complex, highlighting its potential role in immune modulation. The study also identifies a negative correlation between Amiodarone and DOX, implying that these two drugs may have opposing effects on certain biological pathways.   The association between DOX and the major histocompatibility complex is further supported by the presence of the sequence variant (CCTTT)13, which is found to be linked to DOX treatment outcomes. Additionally, the D allele for the -1607 variant is associated with DOX, suggesting a genetic predisposition to its effects. The glycine-594-valine sequence variant is also found to be linked to DOX, reinforcing the genetic complexity of its interactions.   Amiodarone is also associated with ubiquitin, indicating a potential role in protein degradation or cellular stress responses. The study further notes that the sequence variant -616C/G is associated with Amiodarone, suggesting a genetic basis for its pharmacological effects.   These findings underscore the intricate interplay between DOX and Amiodarone with various biological entities, providing a foundation for future research into their therapeutic and toxicological profiles.
49840030	0	3	DOX	ChemicalEntity	D004317
49840030	8	18	Amiodarone	ChemicalEntity	D000638
49840030	46	50	FasL	GeneOrGeneProduct	14103
49840030	52	58	TUBA1A	GeneOrGeneProduct	7846
49840030	60	92	major histocompatibility complex	GeneOrGeneProduct	3123
49840030	189	192	DOX	ChemicalEntity	D004317
49840030	221	231	Amiodarone	ChemicalEntity	D000638
49840030	305	309	FasL	GeneOrGeneProduct	14103
49840030	311	317	TUBA1A	GeneOrGeneProduct	7846
49840030	319	351	major histocompatibility complex	GeneOrGeneProduct	3123
49840030	363	372	ubiquitin	GeneOrGeneProduct	850620
49840030	429	432	DOX	ChemicalEntity	D004317
49840030	437	441	FasL	GeneOrGeneProduct	14103
49840030	475	479	FasL	GeneOrGeneProduct	14103
49840030	493	496	DOX	ChemicalEntity	D004317
49840030	539	542	DOX	ChemicalEntity	D004317
49840030	583	589	TUBA1A	GeneOrGeneProduct	7846
49840030	628	634	TUBA1A	GeneOrGeneProduct	7846
49840030	638	641	DOX	ChemicalEntity	D004317
49840030	677	687	Amiodarone	ChemicalEntity	D000638
49840030	725	729	FasL	GeneOrGeneProduct	14103
49840030	872	882	Amiodarone	ChemicalEntity	D000638
49840030	920	952	major histocompatibility complex	GeneOrGeneProduct	3123
49840030	1065	1075	Amiodarone	ChemicalEntity	D000638
49840030	1080	1083	DOX	ChemicalEntity	D004317
49840030	1199	1202	DOX	ChemicalEntity	D004317
49840030	1211	1243	major histocompatibility complex	GeneOrGeneProduct	3123
49840030	1305	1314	(CCTTT)13	SequenceVariant	c|DUP||CCTTT|13
49840030	1347	1350	DOX	ChemicalEntity	D004317
49840030	1389	1411	D allele for the -1607	SequenceVariant	c|Allele|D|-1607
49840030	1439	1442	DOX	ChemicalEntity	D004317
49840030	1500	1518	glycine-594-valine	SequenceVariant	p|SUB|G|594|V
49840030	1566	1569	DOX	ChemicalEntity	D004317
49840030	1629	1639	Amiodarone	ChemicalEntity	D000638
49840030	1664	1673	ubiquitin	GeneOrGeneProduct	850620
49840030	1806	1813	-616C/G	SequenceVariant	rs747302
49840030	1833	1843	Amiodarone	ChemicalEntity	D000638
49840030	1965	1968	DOX	ChemicalEntity	D004317
49840030	1973	1983	Amiodarone	ChemicalEntity	D000638
49840030	Association	D000638	14103	Novel
49840030	Association	D004317	7846	Novel
49840030	Association	D000638	3123	Novel
49840030	Association	D004317	3123	Novel
49840030	Association	D000638	7846	Novel
49840030	Negative_Correlation	D000638	D004317	Novel
49840030	Association	D004317	850620	Novel
49840030	Association	D004317	14103	Novel
49840030	Negative_Correlation	D004317	D000638	Novel
49840030	Association	D000638	850620	Novel

20044565|t|LNCaP cell line and MYF5 gene expression: effects of selenium and sequence variants in guinea pi
20044565|a|The LNCaP cell line, a well-characterized prostate cancer model, was used to investigate the effects of selenium on MYF5 gene expression in guinea pig-derived cell cultures. Selenium was introduced at varying concentrations, and its impact on MYF5 expression was assessed using quantitative real-time PCR. The results showed a negative correlation between selenium levels and MYF5 expression, consistent with previous findings in other cell lines. This negative correlation was further supported by the observation that higher selenium concentrations led to reduced MYF5 mRNA levels in LNCaP cells.   To explore the genetic basis of this interaction, we examined the influence of sequence variants on MYF5 expression. The -4825 gene insertion/deletion variant and rs2073416 were found to modulate the response of MYF5 to selenium treatment. Specifically, the -4825 insertion variant was associated with a more pronounced decrease in MYF5 expression in the presence of selenium, while the rs2073416 variant showed a moderate effect. Additionally, the Delta30 sequence variant was found to influence the stability of the MYF5 transcript, further complicating the relationship between selenium and MYF5 expression.  In guinea pig models, the negative correlation between selenium and MYF5 was consistently observed across multiple experimental conditions. The LNCaP cell line, when co-cultured with guinea pig-derived fibroblasts, exhibited a stronger response to selenium treatment, suggesting a potential cross-species interaction. These findings highlight the complex interplay between selenium, MYF5, and genetic variants in regulating gene expression, particularly in the context of the LNCaP cell line and guinea pig models. The results provide new insights into the molecular mechanisms underlying selenium's effects on MYF5 and its potential therapeutic applications in prostate-related diseases.
20044565	0	5	LNCaP	CellLine	CVCL_0395
20044565	20	24	MYF5	GeneOrGeneProduct	4617
20044565	53	61	selenium	ChemicalEntity	D012643
20044565	101	106	LNCaP	CellLine	CVCL_0395
20044565	201	209	selenium	ChemicalEntity	D012643
20044565	213	217	MYF5	GeneOrGeneProduct	4617
20044565	237	247	guinea pig	OrganismTaxon	10141
20044565	340	344	MYF5	GeneOrGeneProduct	4617
20044565	453	461	selenium	ChemicalEntity	D012643
20044565	473	477	MYF5	GeneOrGeneProduct	4617
20044565	624	632	selenium	ChemicalEntity	D012643
20044565	663	667	MYF5	GeneOrGeneProduct	4617
20044565	683	688	LNCaP	CellLine	CVCL_0395
20044565	798	802	MYF5	GeneOrGeneProduct	4617
20044565	819	848	-4825 gene insertion/deletion	SequenceVariant	c|INDEL|-4825||
20044565	861	870	rs2073416	SequenceVariant	rs2073416
20044565	910	914	MYF5	GeneOrGeneProduct	4617
20044565	918	926	selenium	ChemicalEntity	D012643
20044565	1030	1034	MYF5	GeneOrGeneProduct	4617
20044565	1065	1073	selenium	ChemicalEntity	D012643
20044565	1085	1094	rs2073416	SequenceVariant	rs2073416
20044565	1147	1154	Delta30	SequenceVariant	c|DEL||30
20044565	1216	1220	MYF5	GeneOrGeneProduct	4617
20044565	1279	1287	selenium	ChemicalEntity	D012643
20044565	1292	1296	MYF5	GeneOrGeneProduct	4617
20044565	1313	1323	guinea pig	OrganismTaxon	10141
20044565	1365	1373	selenium	ChemicalEntity	D012643
20044565	1378	1382	MYF5	GeneOrGeneProduct	4617
20044565	1454	1459	LNCaP	CellLine	CVCL_0395
20044565	1493	1503	guinea pig	OrganismTaxon	10141
20044565	1558	1566	selenium	ChemicalEntity	D012643
20044565	1683	1691	selenium	ChemicalEntity	D012643
20044565	1693	1697	MYF5	GeneOrGeneProduct	4617
20044565	1786	1791	LNCaP	CellLine	CVCL_0395
20044565	1806	1816	guinea pig	OrganismTaxon	10141
20044565	1899	1907	selenium	ChemicalEntity	D012643
20044565	1921	1925	MYF5	GeneOrGeneProduct	4617
20044565	Negative_Correlation	D012643	4617	Novel
20044565	Negative_Correlation	4617	D012643	Novel

54204279|t|Salidroside and Ritanserin: complex interactions with retinopathy, genetic variants, and disease phenotypes in HIV 1/2, Kilham rat virus, and HP
54204279|a|Recent studies have explored the multifaceted interactions between Salidroside, Ritanserin, and various disease phenotypes, including retinopathy, microtia, and cystic kidney disease, in the context of multiple organisms such as HIV 1/2, Kilham rat virus, and HPV. Salidroside has been shown to exhibit a positive correlation with cystic kidney disease and a negative correlation with retinopathy and microtia. These findings suggest that Salidroside may have protective or detrimental effects depending on the disease context. In contrast, Ritanserin has been associated with retinopathy, HS-RDEB, and A-T, with both positive and negative correlations observed. Notably, Ritanserin shows a negative correlation with Salidroside, indicating a potential antagonistic relationship between the two compounds. The deletion of 6 bp at position 1494 has been found to be associated with both Ritanserin and Salidroside, suggesting a possible genetic mechanism underlying their interactions. In HIV 1/2 models, the effects of these compounds on retinopathy and other phenotypes have been extensively studied, with some evidence pointing to a role in modulating disease progression. Additionally, the Kilham rat virus and HPV models have provided insights into the broader implications of these chemical entities in disease pathogenesis. These findings highlight the complex interplay between Salidroside, Ritanserin, and various genetic and phenotypic factors, underscoring the need for further research to fully understand their therapeutic potential and mechanisms of action.
54204279	0	11	Salidroside	ChemicalEntity	C009172
54204279	16	26	Ritanserin	ChemicalEntity	D016713
54204279	54	65	retinopathy	DiseaseOrPhenotypicFeature	D012164
54204279	111	118	HIV 1/2	OrganismTaxon	11676
54204279	120	136	Kilham rat virus	OrganismTaxon	12441
54204279	212	223	Salidroside	ChemicalEntity	C009172
54204279	225	235	Ritanserin	ChemicalEntity	D016713
54204279	279	290	retinopathy	DiseaseOrPhenotypicFeature	D012164
54204279	292	300	microtia	DiseaseOrPhenotypicFeature	D065817
54204279	306	327	cystic kidney disease	DiseaseOrPhenotypicFeature	D052177
54204279	374	381	HIV 1/2	OrganismTaxon	11676
54204279	383	399	Kilham rat virus	OrganismTaxon	12441
54204279	405	408	HPV	OrganismTaxon	10566
54204279	410	421	Salidroside	ChemicalEntity	C009172
54204279	476	497	cystic kidney disease	DiseaseOrPhenotypicFeature	D052177
54204279	530	541	retinopathy	DiseaseOrPhenotypicFeature	D012164
54204279	546	554	microtia	DiseaseOrPhenotypicFeature	D065817
54204279	584	595	Salidroside	ChemicalEntity	C009172
54204279	686	696	Ritanserin	ChemicalEntity	D016713
54204279	722	733	retinopathy	DiseaseOrPhenotypicFeature	D012164
54204279	735	742	HS-RDEB	DiseaseOrPhenotypicFeature	D016108
54204279	748	751	A-T	DiseaseOrPhenotypicFeature	D001260
54204279	817	827	Ritanserin	ChemicalEntity	D016713
54204279	862	873	Salidroside	ChemicalEntity	C009172
54204279	955	988	deletion of 6 bp at position 1494	SequenceVariant	c|DEL|194|6
54204279	1031	1041	Ritanserin	ChemicalEntity	D016713
54204279	1046	1057	Salidroside	ChemicalEntity	C009172
54204279	1133	1140	HIV 1/2	OrganismTaxon	11676
54204279	1183	1194	retinopathy	DiseaseOrPhenotypicFeature	D012164
54204279	1338	1354	Kilham rat virus	OrganismTaxon	12441
54204279	1359	1362	HPV	OrganismTaxon	10566
54204279	1530	1541	Salidroside	ChemicalEntity	C009172
54204279	1543	1553	Ritanserin	ChemicalEntity	D016713
54204279	Positive_Correlation	D016713	D012164	Novel
54204279	Association	D016713	c|DEL|194|6	Novel
54204279	Negative_Correlation	C009172	D012164	Novel
54204279	Positive_Correlation	D016713	D016108	Novel
54204279	Positive_Correlation	C009172	D052177	Novel
54204279	Association	C009172	c|DEL|194|6	Novel
54204279	Negative_Correlation	D016713	D016108	Novel
54204279	Negative_Correlation	D016713	C009172	Novel
54204279	Association	c|DEL|194|6	D016713	Novel
54204279	Negative_Correlation	C009172	D065817	Novel
54204279	Negative_Correlation	C009172	D016713	Novel
54204279	Positive_Correlation	C009172	D065817	Novel
54204279	Negative_Correlation	D016713	D065817	Novel
54204279	Positive_Correlation	D016713	D065817	Novel
54204279	Negative_Correlation	D016713	D001260	Novel
54204279	Negative_Correlation	D016713	D052177	Novel

48419256|t|ACC, doxorubicinol, and sequence variants in the context of diabetic neuropathy, MCD, and cell line r
48419256|a|Recent studies have highlighted the complex interplay between ACC, doxorubicinol, and sequence variants in the context of diabetic neuropathy and MCD. In this study, we investigated the effects of doxorubicinol on ACC expression and activity in the HL-7702 and KU7 cell lines, as well as its association with sequence variants such as +3100 T/G and A>G. Our findings reveal a positive correlation between ACC and doxorubicinol, suggesting that doxorubicinol may modulate ACC function in these cell lines. Additionally, we observed a positive correlation between the proapoptotic protein and doxorubicinol, indicating a potential role for doxorubicinol in promoting apoptosis through this pathway.   Further analysis showed a strong association between doxorubicinol and diabetic neuropathy, with increased levels of doxorubicinol correlating with the severity of the condition. Similarly, doxorubicinol was found to be significantly associated with MCD, suggesting a possible role in the pathogenesis of this disease. The study also demonstrated a positive correlation between uncoupling proteins 2 and 3 and doxorubicinol, which may have implications for mitochondrial function and energy metabolism.   GLUT4 expression was found to be positively correlated with doxorubicinol levels, suggesting a potential regulatory role of doxorubicinol in glucose transport. These findings were consistent across multiple cell lines, including HL-7702 and KU7, and were supported by repeated measurements of the sequence variants +3100 T/G and A>G. Overall, this study provides new insights into the molecular mechanisms underlying the interactions between ACC, doxorubicinol, and various disease states, with potential applications in the development of targeted therapies for diabetic neuropathy and MCD.
48419256	0	3	ACC	GeneOrGeneProduct	31
48419256	5	18	doxorubicinol	ChemicalEntity	C010013
48419256	60	79	diabetic neuropathy	DiseaseOrPhenotypicFeature	D003929
48419256	81	84	MCD	DiseaseOrPhenotypicFeature	D003317
48419256	164	167	ACC	GeneOrGeneProduct	31
48419256	169	182	doxorubicinol	ChemicalEntity	C010013
48419256	224	243	diabetic neuropathy	DiseaseOrPhenotypicFeature	D003929
48419256	248	251	MCD	DiseaseOrPhenotypicFeature	D003317
48419256	299	312	doxorubicinol	ChemicalEntity	C010013
48419256	316	319	ACC	GeneOrGeneProduct	31
48419256	351	358	HL-7702	CellLine	CVCL_6926
48419256	363	366	KU7	CellLine	CVCL_4714
48419256	437	446	+3100 T/G	SequenceVariant	c|SUB|T|+3100|G
48419256	451	454	A>G	SequenceVariant	rs9932581
48419256	507	510	ACC	GeneOrGeneProduct	31
48419256	515	528	doxorubicinol	ChemicalEntity	C010013
48419256	546	559	doxorubicinol	ChemicalEntity	C010013
48419256	573	576	ACC	GeneOrGeneProduct	31
48419256	668	688	proapoptotic protein	GeneOrGeneProduct	332
48419256	693	706	doxorubicinol	ChemicalEntity	C010013
48419256	740	753	doxorubicinol	ChemicalEntity	C010013
48419256	854	867	doxorubicinol	ChemicalEntity	C010013
48419256	872	891	diabetic neuropathy	DiseaseOrPhenotypicFeature	D003929
48419256	918	931	doxorubicinol	ChemicalEntity	C010013
48419256	991	1004	doxorubicinol	ChemicalEntity	C010013
48419256	1051	1054	MCD	DiseaseOrPhenotypicFeature	D003317
48419256	1179	1206	uncoupling proteins 2 and 3	GeneOrGeneProduct	25708
48419256	1211	1224	doxorubicinol	ChemicalEntity	C010013
48419256	1306	1311	GLUT4	GeneOrGeneProduct	25139
48419256	1366	1379	doxorubicinol	ChemicalEntity	C010013
48419256	1430	1443	doxorubicinol	ChemicalEntity	C010013
48419256	1535	1542	HL-7702	CellLine	CVCL_6926
48419256	1547	1550	KU7	CellLine	CVCL_4714
48419256	1621	1630	+3100 T/G	SequenceVariant	c|SUB|T|+3100|G
48419256	1635	1638	A>G	SequenceVariant	rs9932581
48419256	1748	1751	ACC	GeneOrGeneProduct	31
48419256	1753	1766	doxorubicinol	ChemicalEntity	C010013
48419256	1869	1888	diabetic neuropathy	DiseaseOrPhenotypicFeature	D003929
48419256	1893	1896	MCD	DiseaseOrPhenotypicFeature	D003317
48419256	Positive_Correlation	332	C010013	Novel
48419256	Positive_Correlation	31	C010013	Novel
48419256	Association	C010013	D003929	Novel
48419256	Association	C010013	D003317	Novel
48419256	Positive_Correlation	25708	C010013	Novel
48419256	Positive_Correlation	25139	C010013	Novel

34718436|t|FSHbeta and angiotensin I-converting enzyme interactions in the context of HBV and HPV infections: genetic variants and cell line
34718436|a|This study investigates the molecular interactions between FSHbeta and angiotensin I-converting enzyme (ACE) in the context of HBV and HPV infections, with a focus on genetic variants and their functional implications in multiple cell lines. We demonstrate a significant association between FSHbeta and ACE, suggesting a potential regulatory or functional link between these two proteins. Additionally, we report a novel interaction between FSHbeta and IL-7, highlighting the role of FSHbeta in modulating cytokine signaling pathways.   Our findings also reveal a complex relationship between the sequence variant g.2885G>C and both Delta695-725 and FSHbeta, indicating that this variant may influence the expression or function of FSHbeta. Furthermore, the sequence variant c.2113_2114delGG is found to be associated with Delta695-725, suggesting a possible genetic pathway involving these two variants.   To validate these associations, we conducted experiments in multiple cell lines, including HEK293, HCT116, and SNU-C5. The results from these cell lines support the observed genetic and functional relationships. Notably, the presence of the sequence variant S429T was also detected in these cell lines, further emphasizing the role of genetic variability in modulating protein function.   The study underscores the importance of understanding the interplay between genetic variants and protein interactions in the context of HBV and HPV infections, with potential implications for therapeutic strategies targeting these pathways.
34718436	0	7	FSHbeta	GeneOrGeneProduct	14308
34718436	12	43	angiotensin I-converting enzyme	GeneOrGeneProduct	1636
34718436	75	78	HBV	OrganismTaxon	10407
34718436	83	86	HPV	OrganismTaxon	10566
34718436	189	196	FSHbeta	GeneOrGeneProduct	14308
34718436	201	232	angiotensin I-converting enzyme	GeneOrGeneProduct	1636
34718436	257	260	HBV	OrganismTaxon	10407
34718436	265	268	HPV	OrganismTaxon	10566
34718436	421	428	FSHbeta	GeneOrGeneProduct	14308
34718436	571	578	FSHbeta	GeneOrGeneProduct	14308
34718436	583	587	IL-7	GeneOrGeneProduct	25647
34718436	614	621	FSHbeta	GeneOrGeneProduct	14308
34718436	744	753	g.2885G>C	SequenceVariant	g|SUB|G|2885|C
34718436	763	775	Delta695-725	SequenceVariant	p|DEL|695-725|
34718436	780	787	FSHbeta	GeneOrGeneProduct	14308
34718436	862	869	FSHbeta	GeneOrGeneProduct	14308
34718436	905	921	c.2113_2114delGG	SequenceVariant	c|DEL|2113_2114|GG
34718436	953	965	Delta695-725	SequenceVariant	p|DEL|695-725|
34718436	1128	1134	HEK293	CellLine	CVCL_0045
34718436	1136	1142	HCT116	CellLine	CVCL_0291
34718436	1148	1154	SNU-C5	CellLine	CVCL_5112
34718436	1295	1300	S429T	SequenceVariant	p|SUB|S|429|T
34718436	1562	1565	HBV	OrganismTaxon	10407
34718436	1570	1573	HPV	OrganismTaxon	10566
34718436	Association	1636	25647	Novel
34718436	Association	14308	1636	Novel
34718436	Association	g|SUB|G|2885|C	p|DEL|695-725|	Novel
34718436	Association	14308	25647	Novel
34718436	Association	g|SUB|G|2885|C	14308	Novel

92671239|t|Drosophila and human immunodeficiency virus interactions with MCF-7, HCT116, and PC-3 cell lines: effects of opiates, Chloroacetaldehyde, and genetic variants on optic atrophy and muscle 
92671239|a|This study investigates the complex interactions between Drosophila and human immunodeficiency virus (HIV) with various cell lines, including MCF-7, HCT116, and PC-3, in the context of chemical exposure and genetic variation. The research focuses on the effects of opiates and Chloroacetaldehyde on cellular responses, particularly in relation to optic atrophy and muscle rigidity.   We conducted a comparative analysis of opiate and Chloroacetaldehyde exposure on Drosophila and HIV-infected cell lines, revealing distinct patterns of cellular response. The study also explores the association between the sequence variant G7958 and optic atrophy, finding a significant link that supports its role in the pathogenesis of this condition. Furthermore, we observed a positive correlation between G7958 and muscle rigidity, suggesting a potential genetic basis for the co-occurrence of these phenotypic features.  In addition, the study demonstrates a positive correlation between optic atrophy and both G7958 and the sequence variant C311A, indicating that these genetic factors may contribute to the development of optic atrophy. The findings also highlight the importance of considering genetic variability, such as the C311A variant, in understanding the molecular mechanisms underlying optic atrophy.   The results provide new insights into the interplay between chemical exposure, genetic variation, and phenotypic outcomes in both Drosophila and human cell lines, with implications for the development of targeted therapeutic strategies for conditions such as optic atrophy and muscle rigidity.
92671239	0	10	Drosophila	OrganismTaxon	7227
92671239	15	43	human immunodeficiency virus	OrganismTaxon	12721
92671239	62	67	MCF-7	CellLine	CVCL_0031
92671239	69	75	HCT116	CellLine	CVCL_0291
92671239	81	85	PC-3	CellLine	CVCL_0035
92671239	109	115	opiate	ChemicalEntity	D053610
92671239	118	136	Chloroacetaldehyde	ChemicalEntity	C004656
92671239	162	175	optic atrophy	DiseaseOrPhenotypicFeature	D009896
92671239	245	255	Drosophila	OrganismTaxon	7227
92671239	260	288	human immunodeficiency virus	OrganismTaxon	12721
92671239	330	335	MCF-7	CellLine	CVCL_0031
92671239	337	343	HCT116	CellLine	CVCL_0291
92671239	349	353	PC-3	CellLine	CVCL_0035
92671239	453	459	opiate	ChemicalEntity	D053610
92671239	465	483	Chloroacetaldehyde	ChemicalEntity	C004656
92671239	535	548	optic atrophy	DiseaseOrPhenotypicFeature	D009896
92671239	553	568	muscle rigidity	DiseaseOrPhenotypicFeature	D009127
92671239	611	617	opiate	ChemicalEntity	D053610
92671239	622	640	Chloroacetaldehyde	ChemicalEntity	C004656
92671239	653	663	Drosophila	OrganismTaxon	7227
92671239	812	817	G7958	SequenceVariant	c|Aelle|G|7958
92671239	822	835	optic atrophy	DiseaseOrPhenotypicFeature	D009896
92671239	982	987	G7958	SequenceVariant	c|Aelle|G|7958
92671239	992	1007	muscle rigidity	DiseaseOrPhenotypicFeature	D009127
92671239	1166	1179	optic atrophy	DiseaseOrPhenotypicFeature	D009896
92671239	1189	1194	G7958	SequenceVariant	c|Aelle|G|7958
92671239	1220	1225	C311A	SequenceVariant	p|SUB|C|311|A
92671239	1302	1315	optic atrophy	DiseaseOrPhenotypicFeature	D009896
92671239	1408	1413	C311A	SequenceVariant	p|SUB|C|311|A
92671239	1476	1489	optic atrophy	DiseaseOrPhenotypicFeature	D009896
92671239	1623	1633	Drosophila	OrganismTaxon	7227
92671239	1752	1765	optic atrophy	DiseaseOrPhenotypicFeature	D009896
92671239	1770	1785	muscle rigidity	DiseaseOrPhenotypicFeature	D009127
92671239	Comparison	D053610	C004656	Novel
92671239	Association	c|Aelle|G|7958	D009896	Novel
92671239	Positive_Correlation	D009127	c|Aelle|G|7958	Novel
92671239	Positive_Correlation	D009896	c|Aelle|G|7958	Novel
92671239	Positive_Correlation	D009896	p|SUB|C|311|A	Novel
92671239	Association	c|Aelle|G|7958	D009127	Novel

47920098|t|Kilham rat virus and Platonia insignis Mart: interactions with Vg4, sequence variants, and chemical entities in a complex biological
47920098|a|This study investigates the intricate interactions between Kilham rat virus, Platonia insignis Mart, the gene Vg4, and various chemical entities and sequence variants. The research highlights the multifaceted relationships among these elements, including the conversion between olanzapine and domperione, the conversion between lovastatin and domperione, and the conversion between domperione and olanzapine. Additionally, the study reveals the conversion between lovastatin and olanzapine, as well as the conversion between olanzapine and lovastatin, underscoring the dynamic interplay between these chemical entities.   The association between del 92 nucleotide -19/+73 and Vg4 is demonstrated through functional assays, while the negative correlation between del 92 nucleotide -19/+73 and domperione is supported by statistical analysis. Similarly, the negative correlation between del 92 nucleotide -19/+73 and olanzapine is further validated. The association between rs1800872 and Vg4 is also established, along with the negative correlation between rs1800872 and domperione, and the negative correlation between rs1800872 and olanzapine. Furthermore, the negative correlation between rs1800872 and lovastatin is confirmed, highlighting the complex regulatory network involving these sequence variants and gene products.  The association between lovastatin and Vg4 is supported by molecular docking studies, and the association between domperione and Vg4 is reinforced through gene expression profiling. The study also explores the interactions between Kilham rat virus and Platonia insignis Mart, revealing that these organisms may influence the expression of Vg4 and the activity of the chemical entities under investigation. The findings suggest that the interplay between these biological and chemical components plays a critical role in modulating cellular processes and disease mechanisms.
47920098	0	16	Kilham rat virus	OrganismTaxon	12441
47920098	21	43	Platonia insignis Mart	OrganismTaxon	198787
47920098	63	66	Vg4	GeneOrGeneProduct	21638
47920098	192	208	Kilham rat virus	OrganismTaxon	12441
47920098	210	232	Platonia insignis Mart	OrganismTaxon	198787
47920098	243	246	Vg4	GeneOrGeneProduct	21638
47920098	411	421	olanzapine	ChemicalEntity	C076029
47920098	426	436	domperione	ChemicalEntity	D004294
47920098	461	471	lovastatin	ChemicalEntity	D008148
47920098	476	486	domperione	ChemicalEntity	D004294
47920098	515	525	domperione	ChemicalEntity	D004294
47920098	530	540	olanzapine	ChemicalEntity	C076029
47920098	597	607	lovastatin	ChemicalEntity	D008148
47920098	612	622	olanzapine	ChemicalEntity	C076029
47920098	658	668	olanzapine	ChemicalEntity	C076029
47920098	673	683	lovastatin	ChemicalEntity	D008148
47920098	779	804	del 92 nucleotide -19/+73	SequenceVariant	c|DEL|-19_+73|92
47920098	809	812	Vg4	GeneOrGeneProduct	21638
47920098	895	920	del 92 nucleotide -19/+73	SequenceVariant	c|DEL|-19_+73|92
47920098	925	935	domperione	ChemicalEntity	D004294
47920098	1018	1043	del 92 nucleotide -19/+73	SequenceVariant	c|DEL|-19_+73|92
47920098	1048	1058	olanzapine	ChemicalEntity	C076029
47920098	1105	1114	rs1800872	SequenceVariant	rs1800872
47920098	1119	1122	Vg4	GeneOrGeneProduct	21638
47920098	1188	1197	rs1800872	SequenceVariant	rs1800872
47920098	1202	1212	domperione	ChemicalEntity	D004294
47920098	1251	1260	rs1800872	SequenceVariant	rs1800872
47920098	1265	1275	olanzapine	ChemicalEntity	C076029
47920098	1323	1332	rs1800872	SequenceVariant	rs1800872
47920098	1337	1347	lovastatin	ChemicalEntity	D008148
47920098	1484	1494	lovastatin	ChemicalEntity	D008148
47920098	1499	1502	Vg4	GeneOrGeneProduct	21638
47920098	1574	1584	domperione	ChemicalEntity	D004294
47920098	1589	1592	Vg4	GeneOrGeneProduct	21638
47920098	1691	1707	Kilham rat virus	OrganismTaxon	12441
47920098	1712	1734	Platonia insignis Mart	OrganismTaxon	198787
47920098	1799	1802	Vg4	GeneOrGeneProduct	21638
47920098	Conversion	C076029	D004294	Novel
47920098	Association	c|DEL|-19_+73|92	21638	Novel
47920098	Conversion	D008148	D004294	Novel
47920098	Association	C076029	21638	Novel
47920098	Negative_Correlation	rs1800872	D004294	Novel
47920098	Conversion	D004294	D008148	Novel
47920098	Negative_Correlation	c|DEL|-19_+73|92	D004294	Novel
47920098	Conversion	D008148	C076029	Novel
47920098	Negative_Correlation	c|DEL|-19_+73|92	C076029	Novel
47920098	Conversion	D004294	C076029	Novel
47920098	Association	rs1800872	21638	Novel
47920098	Negative_Correlation	rs1800872	C076029	Novel
47920098	Negative_Correlation	c|DEL|-19_+73|92	D008148	Novel
47920098	Association	D008148	21638	Novel
47920098	Negative_Correlation	rs1800872	D008148	Novel
47920098	Association	D004294	21638	Novel
47920098	Conversion	C076029	D008148	Novel

89013477|t|Selenium, lipidemia, and Bernard-Soulier syndrome: genetic and cellular insights from C4-2B, C57BL/6, and hRPTEC cell lines in Mangifera indica Linn and bovin
89013477|a|This study investigates the complex interplay between selenium, lipidemia, and Bernard-Soulier syndrome across multiple biological systems. Using a combination of in vitro and in vivo models, we explore the molecular and genetic mechanisms underlying these associations. Selenium was found to exhibit a positive correlation with Bernard-Soulier syndrome, as well as a positive correlation with lipidemia, suggesting a potential role in modulating both conditions. The association between selenium and Bernard-Soulier syndrome was further supported by its link to the 8 nucleotide deletion and the sequence variant p.G821S.   In addition, lipidemia was associated with the p.G821S variant and the 8 nucleotide deletion, indicating a shared genetic basis. The C4-2B cell line, known for its relevance in prostate cancer research, was used to model the effects of selenium on lipid metabolism and platelet function, both of which are impaired in Bernard-Soulier syndrome. The C57BL/6 and hRPTEC cell lines were employed to study the impact of selenium on lipid profiles and cellular responses in different tissue contexts.   The organism taxon Mangifera indica Linn was included to examine the role of selenium in plant-based models of lipid metabolism, while bovine models were used to validate findings in a mammalian system. Our results highlight the importance of selenium in the pathophysiology of Bernard-Soulier syndrome and lipidemia, with implications for therapeutic strategies targeting these conditions. The repeated use of the C4-2B cell line underscores its utility in studying the molecular mechanisms of these diseases, while the multiple instances of the organism taxon 'bovine' reflect the broad applicability of our findings across species.
89013477	10	19	lipidemia	DiseaseOrPhenotypicFeature	D006949
89013477	25	49	Bernard-Soulier syndrome	DiseaseOrPhenotypicFeature	D001606
89013477	86	91	C4-2B	CellLine	CVCL_4784
89013477	93	100	C57BL/6	CellLine	CVCL_5746
89013477	106	112	hRPTEC	CellLine	CVCL_K278
89013477	127	148	Mangifera indica Linn	OrganismTaxon	29780
89013477	213	221	selenium	ChemicalEntity	D012643
89013477	223	232	lipidemia	DiseaseOrPhenotypicFeature	D006949
89013477	238	262	Bernard-Soulier syndrome	DiseaseOrPhenotypicFeature	D001606
89013477	488	512	Bernard-Soulier syndrome	DiseaseOrPhenotypicFeature	D001606
89013477	553	562	lipidemia	DiseaseOrPhenotypicFeature	D006949
89013477	647	655	selenium	ChemicalEntity	D012643
89013477	660	684	Bernard-Soulier syndrome	DiseaseOrPhenotypicFeature	D001606
89013477	726	747	8 nucleotide deletion	SequenceVariant	c|DEL||8
89013477	773	780	p.G821S	SequenceVariant	rs267607116
89013477	797	806	lipidemia	DiseaseOrPhenotypicFeature	D006949
89013477	831	838	p.G821S	SequenceVariant	rs267607116
89013477	855	876	8 nucleotide deletion	SequenceVariant	c|DEL||8
89013477	917	922	C4-2B	CellLine	CVCL_4784
89013477	1020	1028	selenium	ChemicalEntity	D012643
89013477	1102	1126	Bernard-Soulier syndrome	DiseaseOrPhenotypicFeature	D001606
89013477	1132	1139	C57BL/6	CellLine	CVCL_5746
89013477	1144	1150	hRPTEC	CellLine	CVCL_K278
89013477	1199	1207	selenium	ChemicalEntity	D012643
89013477	1300	1321	Mangifera indica Linn	OrganismTaxon	29780
89013477	1358	1366	selenium	ChemicalEntity	D012643
89013477	1416	1422	bovine	OrganismTaxon	9913
89013477	1524	1532	selenium	ChemicalEntity	D012643
89013477	1559	1583	Bernard-Soulier syndrome	DiseaseOrPhenotypicFeature	D001606
89013477	1588	1597	lipidemia	DiseaseOrPhenotypicFeature	D006949
89013477	1696	1701	C4-2B	CellLine	CVCL_4784
89013477	1844	1850	bovine	OrganismTaxon	9913
89013477	Positive_Correlation	D012643	D001606	Novel
89013477	Association	D012643	D001606	Novel
89013477	Association	D001606	c|DEL||8	Novel
89013477	Association	D006949	rs267607116	Novel
89013477	Association	D012643	D006949	Novel
89013477	Association	D006949	c|DEL||8	Novel
89013477	Association	D001606	rs267607116	Novel
89013477	Positive_Correlation	D012643	D006949	Novel

36318350|t|Genetic and molecular mechanisms linking liver disease, perforin, and sequence variants in the context of ATP
36318350|a|Recent studies have highlighted the complex interplay between genetic variants, molecular pathways, and disease progression in liver disease. This research investigates the association between liver disease and two specific sequence variants: c.G1714C and methionine to threonine substitution at codon 235. Both variants show a positive correlation with the development and severity of liver disease, suggesting a potential role in disease pathogenesis.   The study also explores the functional relationship between perforin and the gene products LAMTOR-1 and -2. Using in vitro and in vivo models, we demonstrate a significant association between perforin and LAMTOR-1 and -2, indicating a potential regulatory or cooperative role in cellular processes. These findings are further supported by the presence of ATP, which appears to modulate the activity of perforin and its interaction with LAMTOR-1 and -2.  In addition, the chemical entity TPA is shown to influence the expression levels of perforin and the stability of the sequence variant c.G1714C. The presence of picrotoxin, a known modulator of ion channels, is also linked to altered expression patterns of perforin and the sequence variants, suggesting a broader network of interactions.   Collectively, these results provide new insights into the molecular mechanisms underlying liver disease and highlight the importance of genetic and chemical factors in disease progression. The findings may have implications for the development of targeted therapies and personalized treatment strategies.
36318350	41	54	liver disease	DiseaseOrPhenotypicFeature	D008107
36318350	56	64	perforin	GeneOrGeneProduct	18646
36318350	106	109	ATP	ChemicalEntity	D000255
36318350	237	250	liver disease	DiseaseOrPhenotypicFeature	D008107
36318350	303	316	liver disease	DiseaseOrPhenotypicFeature	D008107
36318350	353	361	c.G1714C	SequenceVariant	rs121908072
36318350	366	415	methionine to threonine substitution at codon 235	SequenceVariant	rs699
36318350	496	509	liver disease	DiseaseOrPhenotypicFeature	D008107
36318350	626	634	perforin	GeneOrGeneProduct	18646
36318350	657	672	LAMTOR-1 and -2	GeneOrGeneProduct	295234
36318350	758	766	perforin	GeneOrGeneProduct	18646
36318350	771	786	LAMTOR-1 and -2	GeneOrGeneProduct	295234
36318350	921	924	ATP	ChemicalEntity	D000255
36318350	968	976	perforin	GeneOrGeneProduct	18646
36318350	1002	1017	LAMTOR-1 and -2	GeneOrGeneProduct	295234
36318350	1053	1056	TPA	ChemicalEntity	D013755
36318350	1104	1112	perforin	GeneOrGeneProduct	18646
36318350	1155	1163	c.G1714C	SequenceVariant	rs121908072
36318350	1181	1191	picrotoxin	ChemicalEntity	D010852
36318350	1277	1285	perforin	GeneOrGeneProduct	18646
36318350	1451	1464	liver disease	DiseaseOrPhenotypicFeature	D008107
36318350	Association	295234	18646	Novel
36318350	Positive_Correlation	D008107	rs121908072	Novel
36318350	Positive_Correlation	D008107	rs699	Novel
36318350	Association	18646	295234	Novel

46693084|t|Cyclooxygenase inhibitors, antipyretic, and tacrolimus: interactions and correlations in MCF-7, 293T, and MEF cell lines with sequence variants rs2073162, c.429_452dup, a
46693084|a|This study investigates the pharmacological interactions and genetic correlations between Cyclooxygenase inhibitors, antipyretic agents, and tacrolimus in various cell lines, including MCF-7, 293T, and MEF. The research focuses on the effects of sequence variants rs2073162, c.429_452dup, and A-->G on these interactions. We observed a significant drug interaction between antipyretic and Cyclooxygenase inhibitors, which was further supported by a positive correlation between these two chemical entities. Additionally, a drug interaction was found between Cyclooxygenase inhibitors and Contrast, highlighting potential clinical implications for drug combinations. The study also revealed a drug interaction between tacrolimus and antipyretic, suggesting possible pharmacokinetic and pharmacodynamic effects. These findings were validated across multiple cell lines, including two instances of MCF-7, one instance of 293T, and one instance of MEF. The sequence variant rs2073162 was found to be associated with the observed interactions, while c.429_452dup and A-->G were also implicated in modulating the effects of these drugs. The results provide a foundation for understanding the complex interplay between chemical entities and genetic variability in cellular responses.
46693084	0	25	Cyclooxygenase inhibitors	ChemicalEntity	D016861
46693084	27	38	antipyretic	ChemicalEntity	D058633
46693084	44	54	tacrolimus	ChemicalEntity	D016559
46693084	89	94	MCF-7	CellLine	CVCL_0031
46693084	96	100	293T	CellLine	CVCL_0063
46693084	106	109	MEF	CellLine	CVCL_9115
46693084	144	153	rs2073162	SequenceVariant	rs2073162
46693084	155	167	c.429_452dup	SequenceVariant	c|DUP|429_452||
46693084	261	286	Cyclooxygenase inhibitors	ChemicalEntity	D016861
46693084	288	299	antipyretic	ChemicalEntity	D058633
46693084	312	322	tacrolimus	ChemicalEntity	D016559
46693084	356	361	MCF-7	CellLine	CVCL_0031
46693084	363	367	293T	CellLine	CVCL_0063
46693084	373	376	MEF	CellLine	CVCL_9115
46693084	435	444	rs2073162	SequenceVariant	rs2073162
46693084	446	458	c.429_452dup	SequenceVariant	c|DUP|429_452||
46693084	464	469	A-->G	SequenceVariant	rs25531
46693084	544	555	antipyretic	ChemicalEntity	D058633
46693084	560	585	Cyclooxygenase inhibitors	ChemicalEntity	D016861
46693084	729	754	Cyclooxygenase inhibitors	ChemicalEntity	D016861
46693084	759	767	Contrast	ChemicalEntity	D003287
46693084	888	898	tacrolimus	ChemicalEntity	D016559
46693084	903	914	antipyretic	ChemicalEntity	D058633
46693084	1066	1071	MCF-7	CellLine	CVCL_0031
46693084	1089	1093	293T	CellLine	CVCL_0063
46693084	1115	1118	MEF	CellLine	CVCL_9115
46693084	1141	1150	rs2073162	SequenceVariant	rs2073162
46693084	1216	1228	c.429_452dup	SequenceVariant	c|DUP|429_452||
46693084	1233	1238	A-->G	SequenceVariant	rs25531
46693084	Drug_Interaction	D058633	D016861	Novel
46693084	Drug_Interaction	D016861	D003287	Novel
46693084	Drug_Interaction	D016559	D058633	Novel
46693084	Positive_Correlation	D058633	D016861	Novel

30899549|t|Genetic and molecular interactions of rs12910509, SYT14, and FXIIIB in skin pigmentation and their associations with ginseng, bacteria, and ra
30899549|a|Recent studies have revealed complex genetic and molecular interactions involving the sequence variant rs12910509, the gene SYT14, and the gene product FXIIIB in the regulation of skin pigmentation. These interactions have been explored in both human and animal models, including ginseng, bacteria, and rat systems. The sequence variant rs12910509 has been found to be associated with skin pigmentation, with a positive correlation observed between rs12910509 and skin pigmentation. Additionally, a positive correlation was noted between skin pigmentation and rs12910509, reinforcing the genetic link between these two entities.   The gene SYT14 has been shown to have a positive correlation with skin pigmentation, while a negative correlation was found between skin pigmentation and SYT14. This suggests a complex regulatory mechanism involving SYT14 in the context of skin pigmentation. Furthermore, FXIIIB has been found to have a positive correlation with skin pigmentation, but a negative correlation was also observed between FXIIIB and skin pigmentation, indicating a dual role for FXIIIB in this biological process.   Notably, FXIIIB and SYT14 have been found to be associated with each other, with both an association and a binding interaction reported between these two gene products. These findings suggest that FXIIIB and SYT14 may function in a coordinated manner to influence skin pigmentation. The interactions between these genetic elements have been studied in various organisms, including ginseng, bacteria, and rat models, highlighting the broad relevance of these findings across different biological systems.   The study also underscores the importance of considering the interplay between genetic variants and gene products in understanding the molecular basis of skin pigmentation. These findings provide a foundation for further research into the genetic and molecular mechanisms underlying skin pigmentation and their potential applications in biotechnology and medicine.
30899549	38	48	rs12910509	SequenceVariant	rs12910509
30899549	50	55	SYT14	GeneOrGeneProduct	255928
30899549	61	67	FXIIIB	GeneOrGeneProduct	2165
30899549	71	88	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
30899549	117	124	ginseng	OrganismTaxon	4054
30899549	126	134	bacteria	OrganismTaxon	2
30899549	246	256	rs12910509	SequenceVariant	rs12910509
30899549	267	272	SYT14	GeneOrGeneProduct	255928
30899549	295	301	FXIIIB	GeneOrGeneProduct	2165
30899549	323	340	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
30899549	423	430	ginseng	OrganismTaxon	4054
30899549	432	440	bacteria	OrganismTaxon	2
30899549	446	449	rat	OrganismTaxon	10116
30899549	480	490	rs12910509	SequenceVariant	rs12910509
30899549	528	545	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
30899549	592	602	rs12910509	SequenceVariant	rs12910509
30899549	607	624	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
30899549	681	698	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
30899549	703	713	rs12910509	SequenceVariant	rs12910509
30899549	783	788	SYT14	GeneOrGeneProduct	255928
30899549	840	857	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
30899549	906	923	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
30899549	928	933	SYT14	GeneOrGeneProduct	255928
30899549	990	995	SYT14	GeneOrGeneProduct	255928
30899549	1014	1031	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
30899549	1046	1052	FXIIIB	GeneOrGeneProduct	2165
30899549	1104	1121	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
30899549	1176	1182	FXIIIB	GeneOrGeneProduct	2165
30899549	1187	1204	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
30899549	1233	1239	FXIIIB	GeneOrGeneProduct	2165
30899549	1279	1285	FXIIIB	GeneOrGeneProduct	2165
30899549	1290	1295	SYT14	GeneOrGeneProduct	255928
30899549	1467	1473	FXIIIB	GeneOrGeneProduct	2165
30899549	1478	1483	SYT14	GeneOrGeneProduct	255928
30899549	1534	1551	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
30899549	1651	1658	ginseng	OrganismTaxon	4054
30899549	1660	1668	bacteria	OrganismTaxon	2
30899549	1674	1677	rat	OrganismTaxon	10116
30899549	1930	1947	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
30899549	2059	2076	skin pigmentation	DiseaseOrPhenotypicFeature	D010859
30899549	Positive_Correlation	2165	D010859	Novel
30899549	Association	rs12910509	D010859	Novel
30899549	Positive_Correlation	D010859	rs12910509	Novel
30899549	Positive_Correlation	255928	D010859	Novel
30899549	Negative_Correlation	D010859	2165	Novel
30899549	Association	2165	255928	Novel
30899549	Association	255928	2165	Novel
30899549	Bind	2165	255928	Novel
30899549	Negative_Correlation	D010859	255928	Novel
30899549	Bind	255928	2165	Novel

87335895|t|AP7 and PS modulate type I and type II TGF-beta receptors in C. elegans and 253JB-V cells: implications for Urotensin-II signaling and C314A variant asso
87335895|a|This study investigates the molecular interactions and regulatory relationships between AP7, PS, and Urotensin-II in the context of type I and type II TGF-beta receptors in C. elegans and the 253JB-V cell line. We demonstrate a positive correlation between PS and type I and type II TGF-beta receptors, as well as a positive correlation between Urotensin-II and these receptors. Additionally, we show that PS binds directly to both type I and type II TGF-beta receptors, while Urotensin-II also binds to these receptors, suggesting a potential functional synergy between these molecules.   Our findings further reveal a negative correlation between type I and type II TGF-beta receptors and PS, which may indicate a regulatory feedback mechanism. Notably, we observe a positive correlation between PS and Urotensin-II, suggesting that these two chemical entities may act in concert to modulate receptor activity.   In addition to these interactions, we identify an association between AP7 and the sequence variant C314A, which may provide insights into the functional consequences of this variant in the context of TGF-beta signaling. These results highlight the complex interplay between AP7, PS, Urotensin-II, and the TGF-beta receptor system in C. elegans and 253JB-V cells, with potential implications for understanding the molecular basis of receptor-mediated signaling in these organisms. The study also underscores the importance of C314A in modulating the activity of these pathways.
87335895	0	3	AP7	ChemicalEntity	C031231
87335895	8	10	PS	ChemicalEntity	D010718
87335895	20	57	type I and type II TGF-beta receptors	GeneOrGeneProduct	7046
87335895	61	71	C. elegans	OrganismTaxon	6239
87335895	76	83	253JB-V	CellLine	CVCL_7937
87335895	108	120	Urotensin-II	GeneOrGeneProduct	24111
87335895	135	140	C314A	SequenceVariant	p|SUB|C|314|A
87335895	242	245	AP7	ChemicalEntity	C031231
87335895	247	249	PS	ChemicalEntity	D010718
87335895	255	267	Urotensin-II	GeneOrGeneProduct	24111
87335895	286	323	type I and type II TGF-beta receptors	GeneOrGeneProduct	7046
87335895	327	337	C. elegans	OrganismTaxon	6239
87335895	346	353	253JB-V	CellLine	CVCL_7937
87335895	411	413	PS	ChemicalEntity	D010718
87335895	418	455	type I and type II TGF-beta receptors	GeneOrGeneProduct	7046
87335895	499	511	Urotensin-II	GeneOrGeneProduct	24111
87335895	560	562	PS	ChemicalEntity	D010718
87335895	586	623	type I and type II TGF-beta receptors	GeneOrGeneProduct	7046
87335895	631	643	Urotensin-II	GeneOrGeneProduct	24111
87335895	803	840	type I and type II TGF-beta receptors	GeneOrGeneProduct	7046
87335895	845	847	PS	ChemicalEntity	D010718
87335895	952	954	PS	ChemicalEntity	D010718
87335895	959	971	Urotensin-II	GeneOrGeneProduct	24111
87335895	1139	1142	AP7	ChemicalEntity	C031231
87335895	1168	1173	C314A	SequenceVariant	p|SUB|C|314|A
87335895	1343	1346	AP7	ChemicalEntity	C031231
87335895	1348	1350	PS	ChemicalEntity	D010718
87335895	1352	1364	Urotensin-II	GeneOrGeneProduct	24111
87335895	1402	1412	C. elegans	OrganismTaxon	6239
87335895	1417	1424	253JB-V	CellLine	CVCL_7937
87335895	1594	1599	C314A	SequenceVariant	p|SUB|C|314|A
87335895	Positive_Correlation	D010718	7046	Novel
87335895	Bind	C031231	7046	Novel
87335895	Positive_Correlation	24111	7046	Novel
87335895	Bind	D010718	24111	Novel
87335895	Association	C031231	p|SUB|C|314|A	Novel
87335895	Negative_Correlation	7046	D010718	Novel
87335895	Positive_Correlation	D010718	24111	Novel

09325980|t|DRD4 c.304delA and cholinergic activity in horses: implications for acute renal failure and genetic var
09325980|a|A recent study in horses has revealed a significant association between the sequence variant c.304delA in the DRD4 gene and altered cholinergic activity, which may contribute to the development of acute renal failure. This research, conducted across a large cohort of horses, found that the presence of c.304delA was consistently linked to changes in cholinergic signaling, suggesting a potential mechanism by which this genetic variant influences renal function. Furthermore, the study demonstrated a negative correlation between DRD4 expression levels and cholinergic activity, indicating that higher DRD4 activity may suppress cholinergic pathways. These findings were corroborated through multiple experimental approaches, including gene expression analysis, behavioral assays, and physiological measurements. The results highlight the complex interplay between genetic variants, neurotransmitter systems, and disease outcomes in horses. Notably, the association between c.304delA and cholinergic activity was observed in all 14 instances of the sequence variant, while the negative correlation between DRD4 and cholinergic activity was consistently present across all 8 instances of DRD4. The study also found that acute renal failure was more prevalent in horses carrying the c.304delA variant, with 14 instances of the disease reported in this group. These findings provide new insights into the genetic and physiological mechanisms underlying acute renal failure in horses and underscore the importance of considering genetic variability in the management of this condition.
09325980	0	4	DRD4	GeneOrGeneProduct	1815
09325980	5	14	c.304delA	SequenceVariant	c|DEL|304|A
09325980	19	30	cholinergic	ChemicalEntity	D018678
09325980	43	49	horses	OrganismTaxon	9796
09325980	122	128	horses	OrganismTaxon	9796
09325980	197	206	c.304delA	SequenceVariant	c|DEL|304|A
09325980	214	218	DRD4	GeneOrGeneProduct	1815
09325980	236	247	cholinergic	ChemicalEntity	D018678
09325980	372	378	horses	OrganismTaxon	9796
09325980	407	416	c.304delA	SequenceVariant	c|DEL|304|A
09325980	455	466	cholinergic	ChemicalEntity	D018678
09325980	635	639	DRD4	GeneOrGeneProduct	1815
09325980	662	673	cholinergic	ChemicalEntity	D018678
09325980	707	711	DRD4	GeneOrGeneProduct	1815
09325980	734	745	cholinergic	ChemicalEntity	D018678
09325980	1038	1044	horses	OrganismTaxon	9796
09325980	1079	1088	c.304delA	SequenceVariant	c|DEL|304|A
09325980	1093	1104	cholinergic	ChemicalEntity	D018678
09325980	1211	1215	DRD4	GeneOrGeneProduct	1815
09325980	1220	1231	cholinergic	ChemicalEntity	D018678
09325980	1292	1296	DRD4	GeneOrGeneProduct	1815
09325980	1366	1372	horses	OrganismTaxon	9796
09325980	1386	1395	c.304delA	SequenceVariant	c|DEL|304|A
09325980	1578	1584	horses	OrganismTaxon	9796
09325980	Negative_Correlation	1815	D018678	Novel
09325980	Association	c|DEL|304|A	D018678	Novel

44578029|t|ROCK and HSP82 interactions in Multiple fibroadenomas: role of p.G159R variant in C57BL/6J, MEF, and Ishikawa ce
44578029|a|This study investigates the molecular mechanisms underlying the development of Multiple fibroadenomas, with a focus on the interplay between the ROCK and HSP82 proteins and the impact of the p.G159R sequence variant. Using a combination of biochemical assays and functional genomics, we demonstrate a positive correlation between ROCK and HSP82 expression in C57BL/6J, MEF, and Ishikawa cell lines. The p.G159R variant was found to be significantly associated with Multiple fibroadenomas, particularly in C57BL/6J and Ishikawa cell models. Our findings suggest that the p.G159R variant may disrupt the normal regulatory interactions between ROCK and HSP82, leading to the pathogenesis of Multiple fibroadenomas. Furthermore, we observed that the presence of the p.G159R variant correlates with increased ROCK activity and altered HSP82 expression levels in MEF and Ishikawa cell lines. These results highlight the potential of targeting the ROCK-HSP82 axis as a therapeutic strategy for Multiple fibroadenomas. The study also underscores the importance of cell line-specific responses to genetic variants, as the effects of p.G159R were most pronounced in C57BL/6J and Ishikawa cells. Overall, our data provide new insights into the molecular basis of Multiple fibroadenomas and the role of the p.G159R variant in modulating ROCK and HSP82 interactions.
44578029	0	4	ROCK	GeneOrGeneProduct	6093
44578029	9	14	HSP82	GeneOrGeneProduct	855836
44578029	31	53	Multiple fibroadenomas	DiseaseOrPhenotypicFeature	D018226
44578029	63	70	p.G159R	SequenceVariant	rs760654579
44578029	82	90	C57BL/6J	CellLine	CVCL_5U84
44578029	92	95	MEF	CellLine	CVCL_9115
44578029	101	109	Ishikawa	CellLine	CVCL_2529
44578029	192	214	Multiple fibroadenomas	DiseaseOrPhenotypicFeature	D018226
44578029	258	262	ROCK	GeneOrGeneProduct	6093
44578029	267	272	HSP82	GeneOrGeneProduct	855836
44578029	304	311	p.G159R	SequenceVariant	rs760654579
44578029	443	447	ROCK	GeneOrGeneProduct	6093
44578029	452	457	HSP82	GeneOrGeneProduct	855836
44578029	472	480	C57BL/6J	CellLine	CVCL_5U84
44578029	482	485	MEF	CellLine	CVCL_9115
44578029	491	499	Ishikawa	CellLine	CVCL_2529
44578029	516	523	p.G159R	SequenceVariant	rs760654579
44578029	578	600	Multiple fibroadenomas	DiseaseOrPhenotypicFeature	D018226
44578029	618	626	C57BL/6J	CellLine	CVCL_5U84
44578029	631	639	Ishikawa	CellLine	CVCL_2529
44578029	683	690	p.G159R	SequenceVariant	rs760654579
44578029	754	758	ROCK	GeneOrGeneProduct	6093
44578029	763	768	HSP82	GeneOrGeneProduct	855836
44578029	801	823	Multiple fibroadenomas	DiseaseOrPhenotypicFeature	D018226
44578029	875	882	p.G159R	SequenceVariant	rs760654579
44578029	917	921	ROCK	GeneOrGeneProduct	6093
44578029	943	948	HSP82	GeneOrGeneProduct	855836
44578029	970	973	MEF	CellLine	CVCL_9115
44578029	978	986	Ishikawa	CellLine	CVCL_2529
44578029	1054	1058	ROCK	GeneOrGeneProduct	6093
44578029	1059	1064	HSP82	GeneOrGeneProduct	855836
44578029	1100	1122	Multiple fibroadenomas	DiseaseOrPhenotypicFeature	D018226
44578029	1237	1244	p.G159R	SequenceVariant	rs760654579
44578029	1269	1277	C57BL/6J	CellLine	CVCL_5U84
44578029	1282	1290	Ishikawa	CellLine	CVCL_2529
44578029	1365	1387	Multiple fibroadenomas	DiseaseOrPhenotypicFeature	D018226
44578029	1408	1415	p.G159R	SequenceVariant	rs760654579
44578029	1438	1442	ROCK	GeneOrGeneProduct	6093
44578029	1447	1452	HSP82	GeneOrGeneProduct	855836
44578029	Positive_Correlation	855836	6093	Novel
44578029	Association	D018226	rs760654579	Novel
44578029	Positive_Correlation	6093	855836	Novel

75960817|t|Bovine cocaine addiction and metabolic alterations: genetic variants, norepinephrine dynamics, and interactions with rilmenidine and car
75960817|a|This study investigates the complex interplay between genetic variants, neurotransmitter dynamics, and metabolic changes in bovine models of cocaine addiction and associated phenotypes. We focus on the role of the sequence variant c.715_717delGTC in modulating norepinephrine levels, which show a positive correlation with this variant. Additionally, we explore the conversion between norepinephrine and terbutaline, as well as the conversion between norepinephrine and rilmenidine. Rilmenidine is found to be in a negative correlation with diarrhea, a common phenotypic feature in bovine cocaine addiction.    The sequence variant del418T is associated with triglyceride levels, and there is a conversion between triglyceride and rilmenidine. Furthermore, the 137-bp insertion is linked to both carotenoids and triglyceride, highlighting its potential role in metabolic regulation. Carotenoids are also negatively correlated with cocaine addiction, suggesting a protective effect against the disease.    In bovine models, the conversion between carotenoids and norepinephrine is observed, indicating a possible regulatory mechanism. The sequence variant 137-bp insertion is further associated with carotenoids, reinforcing its role in metabolic pathways. These findings provide new insights into the genetic and biochemical mechanisms underlying cocaine addiction and its associated metabolic disturbances in bovines.
75960817	7	24	cocaine addiction	DiseaseOrPhenotypicFeature	D019970
75960817	70	84	norepinephrine	ChemicalEntity	D009638
75960817	117	128	rilmenidine	ChemicalEntity	C032302
75960817	261	267	bovine	OrganismTaxon	9913
75960817	278	295	cocaine addiction	DiseaseOrPhenotypicFeature	D019970
75960817	368	383	c.715_717delGTC	SequenceVariant	c|DEL|715_717|GTC
75960817	398	412	norepinephrine	ChemicalEntity	D009638
75960817	522	536	norepinephrine	ChemicalEntity	D009638
75960817	541	552	terbutaline	ChemicalEntity	D013726
75960817	588	602	norepinephrine	ChemicalEntity	D009638
75960817	607	618	rilmenidine	ChemicalEntity	C032302
75960817	678	686	diarrhea	DiseaseOrPhenotypicFeature	D003967
75960817	719	725	bovine	OrganismTaxon	9913
75960817	726	743	cocaine addiction	DiseaseOrPhenotypicFeature	D019970
75960817	769	776	del418T	SequenceVariant	c|DEL|418|T
75960817	796	808	triglyceride	ChemicalEntity	D014280
75960817	851	863	triglyceride	ChemicalEntity	D014280
75960817	868	879	rilmenidine	ChemicalEntity	C032302
75960817	898	914	137-bp insertion	SequenceVariant	c|INS||137
75960817	933	944	carotenoids	ChemicalEntity	D002338
75960817	949	961	triglyceride	ChemicalEntity	D014280
75960817	1068	1085	cocaine addiction	DiseaseOrPhenotypicFeature	D019970
75960817	1145	1151	bovine	OrganismTaxon	9913
75960817	1183	1194	carotenoids	ChemicalEntity	D002338
75960817	1199	1213	norepinephrine	ChemicalEntity	D009638
75960817	1292	1308	137-bp insertion	SequenceVariant	c|INS||137
75960817	1336	1347	carotenoids	ChemicalEntity	D002338
75960817	1484	1501	cocaine addiction	DiseaseOrPhenotypicFeature	D019970
75960817	1547	1553	bovine	OrganismTaxon	9913
75960817	Conversion	D014280	C032302	Novel
75960817	Association	c|INS||137	D002338	Novel
75960817	Positive_Correlation	D009638	c|DEL|715_717|GTC	Novel
75960817	Conversion	D009638	D013726	Novel
75960817	Conversion	D002338	D009638	Novel
75960817	Association	c|DEL|418|T	D014280	Novel
75960817	Conversion	D013726	C032302	Novel
75960817	Negative_Correlation	C032302	D003967	Novel
75960817	Association	c|INS||137	D014280	Novel
75960817	Association	c|DEL|715_717|GTC	D009638	Novel
75960817	Negative_Correlation	D002338	D019970	Novel

24811491|t|Genetic and molecular interactions in glomerulosclerosis, VSD, and skin reactions: roles of antioxidant factors, thrombin, and bone morphogenetic proteins (BMP)-4 in Danio rerio and C. elegan
24811491|a|Recent studies have highlighted the complex interplay between genetic factors and disease phenotypes in the context of glomerulosclerosis, VSD, and skin reactions. This research explores the molecular mechanisms underlying these conditions, with a focus on the roles of antioxidant factors, thrombin, and bone morphogenetic proteins (BMP)-4 in both Danio rerio and C. elegans models. The findings reveal a positive correlation between VSD and BMP-4, suggesting a potential therapeutic target for this condition. Additionally, a positive correlation was observed between glomerulosclerosis and Purkinje cell atrophy associated protein-1, indicating a possible shared pathway in the pathogenesis of these diseases. The association between BMP-4 and Purkinje cell atrophy associated protein-1 further supports the involvement of these molecules in cellular stress responses. In parallel, the positive correlation between UP Ia and VCAM1 underscores the importance of these proteins in immune-mediated processes. The study also demonstrates the utility of MCF-7, SNU-C5, and Capan1 cell lines in modeling these interactions, with particular emphasis on the role of antioxidant factors in modulating disease progression. These results provide a foundation for future investigations into the molecular basis of glomerulosclerosis, VSD, and skin reactions, with implications for the development of targeted therapies.
24811491	38	56	glomerulosclerosis	DiseaseOrPhenotypicFeature	D005921
24811491	58	61	VSD	DiseaseOrPhenotypicFeature	D006345
24811491	67	81	skin reactions	DiseaseOrPhenotypicFeature	D003875
24811491	92	111	antioxidant factors	GeneOrGeneProduct	14775
24811491	113	121	thrombin	GeneOrGeneProduct	29251
24811491	127	162	bone morphogenetic proteins (BMP)-4	GeneOrGeneProduct	443502
24811491	166	177	Danio rerio	OrganismTaxon	7955
24811491	311	329	glomerulosclerosis	DiseaseOrPhenotypicFeature	D005921
24811491	331	334	VSD	DiseaseOrPhenotypicFeature	D006345
24811491	340	354	skin reactions	DiseaseOrPhenotypicFeature	D003875
24811491	462	481	antioxidant factors	GeneOrGeneProduct	14775
24811491	483	491	thrombin	GeneOrGeneProduct	29251
24811491	497	532	bone morphogenetic proteins (BMP)-4	GeneOrGeneProduct	443502
24811491	541	552	Danio rerio	OrganismTaxon	7955
24811491	557	567	C. elegans	OrganismTaxon	6239
24811491	627	630	VSD	DiseaseOrPhenotypicFeature	D006345
24811491	762	780	glomerulosclerosis	DiseaseOrPhenotypicFeature	D005921
24811491	785	827	Purkinje cell atrophy associated protein-1	GeneOrGeneProduct	25894
24811491	939	981	Purkinje cell atrophy associated protein-1	GeneOrGeneProduct	25894
24811491	1110	1115	UP Ia	GeneOrGeneProduct	11045
24811491	1120	1125	VCAM1	GeneOrGeneProduct	7412
24811491	1244	1249	MCF-7	CellLine	CVCL_0031
24811491	1251	1257	SNU-C5	CellLine	CVCL_5112
24811491	1263	1269	Capan1	CellLine	CVCL_0237
24811491	1353	1372	antioxidant factors	GeneOrGeneProduct	14775
24811491	1497	1515	glomerulosclerosis	DiseaseOrPhenotypicFeature	D005921
24811491	1517	1520	VSD	DiseaseOrPhenotypicFeature	D006345
24811491	1526	1540	skin reactions	DiseaseOrPhenotypicFeature	D003875
24811491	Positive_Correlation	11045	7412	Novel
24811491	Association	443502	25894	Novel
24811491	Positive_Correlation	D006345	443502	Novel
24811491	Positive_Correlation	D005921	25894	Novel

93043690|t|Genetic variants in ACC and PKC: associations with lymphoma, palmoplantar erythrokeratoderma, and neuro
93043690|a|This study investigates the genetic and functional relationships between sequence variants in the ACC gene, the PKC gene, and the ARG2 gene, and their associations with lymphoma, palmoplantar erythrokeratoderma, and neurodeficits. We identified three instances of the sequence variant c.1970_2177del in patients with palmoplantar erythrokeratoderma, suggesting a strong association between this deletion and the disease. Additionally, we found that the valine (Val) to alanine (Ala) substitution at amino acid 16 is negatively correlated with the development of lymphoma, indicating a protective effect against this malignancy.   The gene product ACC was found to be associated with both PKC and ARG2, with a significant positive correlation between ACC and PKC, and a positive correlation between ACC and ARG2. However, palmoplantar erythrokeratoderma was negatively correlated with both PKC and ARG2, suggesting that these genes may play a role in the pathogenesis of this skin condition. Furthermore, we observed that the sequence variant Asp218Asn was present in multiple individuals with lymphoma, although its functional role remains to be determined.   Our findings highlight the complex interplay between genetic variants in ACC, PKC, and ARG2 and their associations with various diseases, including lymphoma and palmoplantar erythrokeratoderma. The negative correlation between palmoplantar erythrokeratoderma and PKC, as well as the negative correlation between palmoplantar erythrokeratoderma and ARG2, suggests that these genes may act as negative regulators in the development of this condition. The study also underscores the importance of further research into the molecular mechanisms underlying these associations.
93043690	20	23	ACC	GeneOrGeneProduct	31
93043690	28	31	PKC	GeneOrGeneProduct	24681
93043690	51	59	lymphoma	DiseaseOrPhenotypicFeature	D008223
93043690	61	92	palmoplantar erythrokeratoderma	DiseaseOrPhenotypicFeature	C563781
93043690	202	205	ACC	GeneOrGeneProduct	31
93043690	216	219	PKC	GeneOrGeneProduct	24681
93043690	234	238	ARG2	GeneOrGeneProduct	853374
93043690	273	281	lymphoma	DiseaseOrPhenotypicFeature	D008223
93043690	283	314	palmoplantar erythrokeratoderma	DiseaseOrPhenotypicFeature	C563781
93043690	320	333	neurodeficits	DiseaseOrPhenotypicFeature	D001927
93043690	389	403	c.1970_2177del	SequenceVariant	c|DEL|1970_2177|
93043690	421	452	palmoplantar erythrokeratoderma	DiseaseOrPhenotypicFeature	C563781
93043690	557	616	valine (Val) to alanine (Ala) substitution at amino acid 16	SequenceVariant	p|SUB|V|16|A
93043690	666	674	lymphoma	DiseaseOrPhenotypicFeature	D008223
93043690	751	754	ACC	GeneOrGeneProduct	31
93043690	792	795	PKC	GeneOrGeneProduct	24681
93043690	800	804	ARG2	GeneOrGeneProduct	853374
93043690	854	857	ACC	GeneOrGeneProduct	31
93043690	862	865	PKC	GeneOrGeneProduct	24681
93043690	902	905	ACC	GeneOrGeneProduct	31
93043690	910	914	ARG2	GeneOrGeneProduct	853374
93043690	925	956	palmoplantar erythrokeratoderma	DiseaseOrPhenotypicFeature	C563781
93043690	993	996	PKC	GeneOrGeneProduct	24681
93043690	1001	1005	ARG2	GeneOrGeneProduct	853374
93043690	1146	1155	Asp218Asn	SequenceVariant	rs305974
93043690	1197	1205	lymphoma	DiseaseOrPhenotypicFeature	D008223
93043690	1337	1340	ACC	GeneOrGeneProduct	31
93043690	1342	1345	PKC	GeneOrGeneProduct	24681
93043690	1351	1355	ARG2	GeneOrGeneProduct	853374
93043690	1412	1420	lymphoma	DiseaseOrPhenotypicFeature	D008223
93043690	1425	1456	palmoplantar erythrokeratoderma	DiseaseOrPhenotypicFeature	C563781
93043690	1491	1522	palmoplantar erythrokeratoderma	DiseaseOrPhenotypicFeature	C563781
93043690	1527	1530	PKC	GeneOrGeneProduct	24681
93043690	1576	1607	palmoplantar erythrokeratoderma	DiseaseOrPhenotypicFeature	C563781
93043690	1612	1616	ARG2	GeneOrGeneProduct	853374
93043690	Negative_Correlation	p|SUB|V|16|A	D008223	Novel
93043690	Association	24681	31	Novel
93043690	Association	C563781	c|DEL|1970_2177|	Novel
93043690	Negative_Correlation	C563781	24681	Novel
93043690	Association	31	853374	Novel
93043690	Negative_Correlation	C563781	853374	Novel
93043690	Association	24681	853374	Novel

75895879|t|S-1, Syncope, and c.610-2A>G: complex interactions in CD18/HPAF cells and Rhodiola rosea-derived gene ex
75895879|a|This study investigates the intricate relationships between the chemotherapeutic agent S-1, the clinical condition Syncope, and the sequence variant c.610-2A>G in the context of CD18/HPAF cell lines and Rhodiola rosea. Our findings reveal a positive correlation between S-1 and Syncope, suggesting that S-1 may play a role in the pathophysiology of Syncope. Additionally, we observed a positive correlation between p85alpha and Syncope, indicating that p85alpha may be a contributing factor to the occurrence of Syncope. However, a negative correlation was found between p85alpha and S-1, suggesting a potential antagonistic relationship between these two entities.   The sequence variant c.610-2A>G was found to be associated with both p85alpha and the M(3)-muscarinic acetylcholine receptor, highlighting its potential role in modulating the expression or function of these gene products. Furthermore, a positive correlation was observed between the M(3)-muscarinic acetylcholine receptor and Syncope, reinforcing the idea that this receptor may be involved in the mechanisms underlying Syncope.   Our results also demonstrate that CD18/HPAF cells, when exposed to Rhodiola rosea, exhibit altered expression patterns of p85alpha and the M(3)-muscarinic acetylcholine receptor, which may contribute to the observed correlations with Syncope. These findings provide a foundation for further research into the molecular mechanisms linking these entities and their potential therapeutic implications in the management of Syncope.
75895879	0	3	S-1	ChemicalEntity	C079198
75895879	5	12	Syncope	DiseaseOrPhenotypicFeature	D013575
75895879	18	28	c.610-2A>G	SequenceVariant	rs193302855
75895879	54	63	CD18/HPAF	CellLine	CVCL_0313
75895879	74	88	Rhodiola rosea	OrganismTaxon	203015
75895879	192	195	S-1	ChemicalEntity	C079198
75895879	220	227	Syncope	DiseaseOrPhenotypicFeature	D013575
75895879	254	264	c.610-2A>G	SequenceVariant	rs193302855
75895879	283	292	CD18/HPAF	CellLine	CVCL_0313
75895879	308	322	Rhodiola rosea	OrganismTaxon	203015
75895879	375	378	S-1	ChemicalEntity	C079198
75895879	383	390	Syncope	DiseaseOrPhenotypicFeature	D013575
75895879	408	411	S-1	ChemicalEntity	C079198
75895879	454	461	Syncope	DiseaseOrPhenotypicFeature	D013575
75895879	520	528	p85alpha	GeneOrGeneProduct	5295
75895879	533	540	Syncope	DiseaseOrPhenotypicFeature	D013575
75895879	558	566	p85alpha	GeneOrGeneProduct	5295
75895879	617	624	Syncope	DiseaseOrPhenotypicFeature	D013575
75895879	676	684	p85alpha	GeneOrGeneProduct	5295
75895879	689	692	S-1	ChemicalEntity	C079198
75895879	794	804	c.610-2A>G	SequenceVariant	rs193302855
75895879	842	850	p85alpha	GeneOrGeneProduct	5295
75895879	859	897	M(3)-muscarinic acetylcholine receptor	GeneOrGeneProduct	100379235
75895879	1057	1095	M(3)-muscarinic acetylcholine receptor	GeneOrGeneProduct	100379235
75895879	1100	1107	Syncope	DiseaseOrPhenotypicFeature	D013575
75895879	1194	1201	Syncope	DiseaseOrPhenotypicFeature	D013575
75895879	1239	1248	CD18/HPAF	CellLine	CVCL_0313
75895879	1272	1286	Rhodiola rosea	OrganismTaxon	203015
75895879	1327	1335	p85alpha	GeneOrGeneProduct	5295
75895879	1344	1382	M(3)-muscarinic acetylcholine receptor	GeneOrGeneProduct	100379235
75895879	1439	1446	Syncope	DiseaseOrPhenotypicFeature	D013575
75895879	1624	1631	Syncope	DiseaseOrPhenotypicFeature	D013575
75895879	Positive_Correlation	5295	D013575	Novel
75895879	Positive_Correlation	C079198	D013575	Novel
75895879	Positive_Correlation	100379235	D013575	Novel
75895879	Positive_Correlation	D013575	C079198	Novel
75895879	Negative_Correlation	5295	C079198	Novel
75895879	Association	rs193302855	5295	Novel
75895879	Association	rs193302855	100379235	Novel

30345783|t|Paroxetine, Sodium Bicarbonate, and Renal Impairment: Interactions with Spirulina, Bovine, Glutathione-S-Transferase P1, DDR2, Tenascin-C, and Cytochrome P450 (
30345783|a|Recent studies have explored the complex interactions between paroxetine, sodium bicarbonate, and renal impairment in the context of Spirulina and bovine models. Paroxetine, a selective serotonin reuptake inhibitor, has been shown to bind to cytochrome P450 (CYP) 1A2, which exhibits a positive correlation with both paroxetine and sodium bicarbonate. This binding interaction is further supported by the positive correlation between cytochrome P450 (CYP) 1A2 and sodium bicarbonate, suggesting a potential role for this enzyme in the metabolism of both compounds.   Sodium bicarbonate has been found to bind to tenascin-C, a gene product that is positively correlated with both sodium bicarbonate and renal impairment. This association is further reinforced by the positive correlation between tenascin-C and renal impairment, as well as the negative correlation between renal impairment and tenascin-C. Notably, the negative correlation between renal impairment and DDR2 suggests a potential protective role for DDR2 in the context of renal dysfunction.   Glutathione-S-transferase P1, a key enzyme in detoxification processes, has been found to have a positive correlation with paroxetine, indicating a possible interaction between these two entities. However, sodium bicarbonate exhibits a negative correlation with paroxetine, suggesting a competitive or inhibitory relationship.   The study also highlights the role of Spirulina and bovine models in understanding these interactions. These organisms have been used to investigate the effects of paroxetine, sodium bicarbonate, and their associated gene products, including tenascin-C and DDR2, on renal function and metabolic pathways. The findings suggest that the interplay between these chemical entities, gene products, and biological systems is complex and requires further investigation to fully understand their implications in health and disease.
30345783	72	81	Spirulina	OrganismTaxon	551299
30345783	121	125	DDR2	GeneOrGeneProduct	4921
30345783	223	233	paroxetine	ChemicalEntity	D017374
30345783	235	253	sodium bicarbonate	ChemicalEntity	D017693
30345783	259	275	renal impairment	DiseaseOrPhenotypicFeature	D007674
30345783	294	303	Spirulina	OrganismTaxon	551299
30345783	308	314	bovine	OrganismTaxon	9913
30345783	403	428	cytochrome P450 (CYP) 1A2	GeneOrGeneProduct	1544
30345783	478	488	paroxetine	ChemicalEntity	D017374
30345783	493	511	sodium bicarbonate	ChemicalEntity	D017693
30345783	595	620	cytochrome P450 (CYP) 1A2	GeneOrGeneProduct	1544
30345783	625	643	sodium bicarbonate	ChemicalEntity	D017693
30345783	773	783	tenascin-C	GeneOrGeneProduct	3371
30345783	840	858	sodium bicarbonate	ChemicalEntity	D017693
30345783	863	879	renal impairment	DiseaseOrPhenotypicFeature	D007674
30345783	956	966	tenascin-C	GeneOrGeneProduct	3371
30345783	971	987	renal impairment	DiseaseOrPhenotypicFeature	D007674
30345783	1033	1049	renal impairment	DiseaseOrPhenotypicFeature	D007674
30345783	1054	1064	tenascin-C	GeneOrGeneProduct	3371
30345783	1108	1124	renal impairment	DiseaseOrPhenotypicFeature	D007674
30345783	1129	1133	DDR2	GeneOrGeneProduct	4921
30345783	1175	1179	DDR2	GeneOrGeneProduct	4921
30345783	1342	1352	paroxetine	ChemicalEntity	D017374
30345783	1425	1443	sodium bicarbonate	ChemicalEntity	D017693
30345783	1481	1491	paroxetine	ChemicalEntity	D017374
30345783	1586	1595	Spirulina	OrganismTaxon	551299
30345783	1600	1606	bovine	OrganismTaxon	9913
30345783	1712	1722	paroxetine	ChemicalEntity	D017374
30345783	1724	1742	sodium bicarbonate	ChemicalEntity	D017693
30345783	1790	1800	tenascin-C	GeneOrGeneProduct	3371
30345783	1805	1809	DDR2	GeneOrGeneProduct	4921
30345783	Bind	D017693	3371	Novel
30345783	Positive_Correlation	1544	D017693	Novel
30345783	Positive_Correlation	3371	D007674	Novel
30345783	Association	D017693	D007674	Novel
30345783	Positive_Correlation	2950	D017374	Novel
30345783	Negative_Correlation	D017693	D017374	Novel
30345783	Bind	D017374	1544	Novel
30345783	Positive_Correlation	3371	D017693	Novel
30345783	Positive_Correlation	1544	D017374	Novel
30345783	Negative_Correlation	D007674	3371	Novel
30345783	Negative_Correlation	D007674	4921	Novel
30345783	Positive_Correlation	3371	D017374	Novel

93279609|t|CD72, CD45RO, and Shh Interactions with Matrix Metalloproteinases, p38, and Genetic Variants in Daucus carota, Mangifera indica Linn, an
93279609|a|This study explores the complex interactions between CD72, CD45RO, and Shh with Matrix metalloproteinases, p38, and various genetic variants in Daucus carota, Mangifera indica Linn, and horses. We investigated the binding interactions between CD45RO and CD72, as well as between Shh and CD45RO, revealing a significant bind between these molecules. Additionally, we found a positive correlation between CD45RO and CD72, while a negative correlation was observed between CD45RO and p38. The association between Shh and p38 was also confirmed, along with a positive correlation between Shh and CD72.   The study further examined the relationship between Matrix metalloproteinases and CD72, finding a negative correlation between these two entities. A negative correlation was also observed between Matrix metalloproteinases and Shh, and a positive correlation was noted between Matrix metalloproteinases and p38. The interaction between CD72 and Matrix metalloproteinases was confirmed through binding assays, and a negative correlation between CD72 and p38 was also identified.   Genetic variants were analyzed in detail, including the association between rs5393 and L351A, as well as between rs5393 and rs6235. The variant L180M was found to be associated with rs6235 and with the 12-nucleotide insertion/deletion (indel), while N221D was linked to L180M, rs5393, and (CCTTT)13. The variant (CCTTT)13 was also associated with L351A and CD72. The variant c.342delA was found to be associated with p38, CD72, and N221D, and it was also linked to the 12-nucleotide insertion/deletion (indel).   The 12-nucleotide insertion/deletion (indel) was associated with CD45RO, p38, and L180M, while L351A was associated with N221D and CD72. The variant L180M was also found to be associated with CD72 and (CCTTT)13. The study also revealed a negative correlation between CD72 and CD45RO, and a negative correlation between p38 and CD45RO.   These findings provide new insights into the molecular mechanisms underlying the interactions between these proteins and genetic variants in Daucus carota, Mangifera indica Linn, and horses, highlighting the potential for further research into their roles in biological processes and disease.
93279609	0	4	CD72	GeneOrGeneProduct	971
93279609	6	12	CD45RO	GeneOrGeneProduct	5788
93279609	18	21	Shh	GeneOrGeneProduct	20423
93279609	67	70	p38	GeneOrGeneProduct	26416
93279609	96	109	Daucus carota	OrganismTaxon	4039
93279609	111	132	Mangifera indica Linn	OrganismTaxon	29780
93279609	190	194	CD72	GeneOrGeneProduct	971
93279609	196	202	CD45RO	GeneOrGeneProduct	5788
93279609	208	211	Shh	GeneOrGeneProduct	20423
93279609	217	242	Matrix metalloproteinases	GeneOrGeneProduct	4312
93279609	244	247	p38	GeneOrGeneProduct	26416
93279609	281	294	Daucus carota	OrganismTaxon	4039
93279609	296	317	Mangifera indica Linn	OrganismTaxon	29780
93279609	323	329	horses	OrganismTaxon	9796
93279609	380	386	CD45RO	GeneOrGeneProduct	5788
93279609	391	395	CD72	GeneOrGeneProduct	971
93279609	416	419	Shh	GeneOrGeneProduct	20423
93279609	424	430	CD45RO	GeneOrGeneProduct	5788
93279609	540	546	CD45RO	GeneOrGeneProduct	5788
93279609	551	555	CD72	GeneOrGeneProduct	971
93279609	607	613	CD45RO	GeneOrGeneProduct	5788
93279609	618	621	p38	GeneOrGeneProduct	26416
93279609	647	650	Shh	GeneOrGeneProduct	20423
93279609	655	658	p38	GeneOrGeneProduct	26416
93279609	721	724	Shh	GeneOrGeneProduct	20423
93279609	729	733	CD72	GeneOrGeneProduct	971
93279609	789	814	Matrix metalloproteinases	GeneOrGeneProduct	4312
93279609	819	823	CD72	GeneOrGeneProduct	971
93279609	933	958	Matrix metalloproteinases	GeneOrGeneProduct	4312
93279609	963	966	Shh	GeneOrGeneProduct	20423
93279609	1013	1038	Matrix metalloproteinases	GeneOrGeneProduct	4312
93279609	1043	1046	p38	GeneOrGeneProduct	26416
93279609	1072	1076	CD72	GeneOrGeneProduct	971
93279609	1081	1106	Matrix metalloproteinases	GeneOrGeneProduct	4312
93279609	1180	1184	CD72	GeneOrGeneProduct	971
93279609	1189	1192	p38	GeneOrGeneProduct	26416
93279609	1292	1298	rs5393	SequenceVariant	rs5393
93279609	1303	1308	L351A	SequenceVariant	p|SUB|L|351|A
93279609	1329	1335	rs5393	SequenceVariant	rs5393
93279609	1340	1346	rs6235	SequenceVariant	rs6235
93279609	1360	1365	L180M	SequenceVariant	p|SUB|L|180|M
93279609	1398	1404	rs6235	SequenceVariant	rs6235
93279609	1418	1458	12-nucleotide insertion/deletion (indel)	SequenceVariant	c|INDEL||12
93279609	1466	1471	N221D	SequenceVariant	rs6232
93279609	1486	1491	L180M	SequenceVariant	p|SUB|L|180|M
93279609	1493	1499	rs5393	SequenceVariant	rs5393
93279609	1505	1514	(CCTTT)13	SequenceVariant	c|DUP||CCTTT|13
93279609	1528	1537	(CCTTT)13	SequenceVariant	c|DUP||CCTTT|13
93279609	1563	1568	L351A	SequenceVariant	p|SUB|L|351|A
93279609	1573	1577	CD72	GeneOrGeneProduct	971
93279609	1591	1600	c.342delA	SequenceVariant	c|DEL|342|A
93279609	1633	1636	p38	GeneOrGeneProduct	26416
93279609	1638	1642	CD72	GeneOrGeneProduct	971
93279609	1648	1653	N221D	SequenceVariant	rs6232
93279609	1685	1725	12-nucleotide insertion/deletion (indel)	SequenceVariant	c|INDEL||12
93279609	1733	1773	12-nucleotide insertion/deletion (indel)	SequenceVariant	c|INDEL||12
93279609	1794	1800	CD45RO	GeneOrGeneProduct	5788
93279609	1802	1805	p38	GeneOrGeneProduct	26416
93279609	1811	1816	L180M	SequenceVariant	p|SUB|L|180|M
93279609	1824	1829	L351A	SequenceVariant	p|SUB|L|351|A
93279609	1850	1855	N221D	SequenceVariant	rs6232
93279609	1860	1864	CD72	GeneOrGeneProduct	971
93279609	1878	1883	L180M	SequenceVariant	p|SUB|L|180|M
93279609	1921	1925	CD72	GeneOrGeneProduct	971
93279609	1930	1939	(CCTTT)13	SequenceVariant	c|DUP||CCTTT|13
93279609	1996	2000	CD72	GeneOrGeneProduct	971
93279609	2005	2011	CD45RO	GeneOrGeneProduct	5788
93279609	2048	2051	p38	GeneOrGeneProduct	26416
93279609	2056	2062	CD45RO	GeneOrGeneProduct	5788
93279609	2207	2220	Daucus carota	OrganismTaxon	4039
93279609	2222	2243	Mangifera indica Linn	OrganismTaxon	29780
93279609	2249	2255	horses	OrganismTaxon	9796
93279609	Bind	5788	971	Novel
93279609	Bind	20423	5788	Novel
93279609	Association	p|SUB|L|180|M	rs6235	Novel
93279609	Association	rs6232	p|SUB|L|180|M	Novel
93279609	Negative_Correlation	4312	971	Novel
93279609	Association	c|DUP||CCTTT|13	p|SUB|L|351|A	Novel
93279609	Positive_Correlation	5788	26416	Novel
93279609	Association	c|DEL|342|A	26416	Novel
93279609	Association	rs6232	rs5393	Novel
93279609	Negative_Correlation	5788	26416	Novel
93279609	Association	c|INDEL||12	5788	Novel
93279609	Association	4312	26416	Novel
93279609	Negative_Correlation	4312	20423	Novel
93279609	Association	c|DUP||CCTTT|13	971	Novel
93279609	Association	rs6232	5788	Novel
93279609	Negative_Correlation	971	26416	Novel
93279609	Association	5788	971	Novel
93279609	Bind	971	4312	Novel
93279609	Negative_Correlation	5788	4312	Novel
93279609	Association	c|INDEL||12	c|DUP||CCTTT|13	Novel
93279609	Association	rs6232	20423	Novel
93279609	Negative_Correlation	26416	4312	Novel
93279609	Association	rs5393	p|SUB|L|351|A	Novel
93279609	Association	c|DEL|342|A	c|INDEL||12	Novel
93279609	Association	p|SUB|L|180|M	c|INDEL||12	Novel
93279609	Positive_Correlation	5788	971	Novel
93279609	Association	c|INDEL||12	26416	Novel
93279609	Association	20423	26416	Novel
93279609	Association	c|INDEL||12	4312	Novel
93279609	Association	p|SUB|L|180|M	971	Novel
93279609	Association	p|SUB|L|351|A	rs6232	Novel
93279609	Association	p|SUB|L|180|M	c|DUP||CCTTT|13	Novel
93279609	Negative_Correlation	971	5788	Novel
93279609	Association	c|DEL|342|A	rs6232	Novel
93279609	Bind	26416	20423	Novel
93279609	Association	c|DEL|342|A	4312	Novel
93279609	Association	c|DUP||CCTTT|13	c|DEL|342|A	Novel
93279609	Association	c|INDEL||12	p|SUB|L|180|M	Novel
93279609	Association	c|DEL|342|A	971	Novel
93279609	Negative_Correlation	5788	20423	Novel
93279609	Positive_Correlation	5788	20423	Novel
93279609	Association	20423	4312	Novel
93279609	Association	c|DUP||CCTTT|13	p|SUB|L|180|M	Novel
93279609	Association	p|SUB|L|351|A	971	Novel
93279609	Association	rs5393	rs6235	Novel
93279609	Association	p|SUB|L|180|M	rs5393	Novel
93279609	Association	rs6232	c|DUP||CCTTT|13	Novel
93279609	Association	p|SUB|L|351|A	20423	Novel
93279609	Bind	971	20423	Novel
93279609	Positive_Correlation	26416	971	Novel
93279609	Association	p|SUB|L|180|M	p|SUB|L|351|A	Novel
93279609	Association	4312	971	Novel
93279609	Bind	20423	4312	Novel
93279609	Negative_Correlation	26416	5788	Novel
93279609	Bind	971	26416	Novel
93279609	Association	rs6232	c|DEL|342|A	Novel
93279609	Bind	5788	4312	Novel
93279609	Positive_Correlation	20423	971	Novel
93279609	Positive_Correlation	4312	20423	Novel
93279609	Positive_Correlation	20423	26416	Novel

63002495|t|THRA and Lipid A interactions in murine models: implications for meningococcal disease and the role of 5-alpha-reductase type 2 and mela
63002495|a|This study investigates the molecular interactions between the thyroid hormone receptor alpha (THRA) and Lipid A in murine models, with a focus on their potential roles in meningococcal disease. Using HEK and HL-7702 cell lines, we demonstrate that THRA binds to Lipid A, suggesting a regulatory mechanism that may influence immune responses. Additionally, we show that 5-alpha-reductase type 2 binds to both Lipid A and melanotan II, indicating a possible cross-talk between lipid signaling and hormone pathways. The association between melanotan II and THRA further supports the hypothesis that these molecules may modulate inflammatory processes. Fluo-4AM, a calcium-sensitive fluorescent dye, was used to monitor intracellular calcium dynamics in response to melanotan II, revealing a direct association between the two. Furthermore, melanotan II was found to associate with Fluo-4AM, suggesting a functional link between the peptide and calcium signaling. These findings highlight the complex interplay between Lipid A, THRA, 5-alpha-reductase type 2, and melanotan II in murine systems, with potential implications for the pathogenesis of meningococcal disease. The use of murine models and multiple cell lines provides a robust framework for understanding these interactions at the molecular level.
63002495	0	4	THRA	GeneOrGeneProduct	7067
63002495	9	16	Lipid A	ChemicalEntity	D008050
63002495	33	39	murine	OrganismTaxon	10090
63002495	103	127	5-alpha-reductase type 2	GeneOrGeneProduct	6716
63002495	232	236	THRA	GeneOrGeneProduct	7067
63002495	242	249	Lipid A	ChemicalEntity	D008050
63002495	253	259	murine	OrganismTaxon	10090
63002495	338	341	HEK	CellLine	CVCL_M624
63002495	346	353	HL-7702	CellLine	CVCL_6926
63002495	386	390	THRA	GeneOrGeneProduct	7067
63002495	400	407	Lipid A	ChemicalEntity	D008050
63002495	507	531	5-alpha-reductase type 2	GeneOrGeneProduct	6716
63002495	546	553	Lipid A	ChemicalEntity	D008050
63002495	558	570	melanotan II	ChemicalEntity	C079282
63002495	675	687	melanotan II	ChemicalEntity	C079282
63002495	692	696	THRA	GeneOrGeneProduct	7067
63002495	787	795	Fluo-4AM	ChemicalEntity	C409648
63002495	900	912	melanotan II	ChemicalEntity	C079282
63002495	975	987	melanotan II	ChemicalEntity	C079282
63002495	1016	1024	Fluo-4AM	ChemicalEntity	C409648
63002495	1153	1160	Lipid A	ChemicalEntity	D008050
63002495	1162	1166	THRA	GeneOrGeneProduct	7067
63002495	1168	1192	5-alpha-reductase type 2	GeneOrGeneProduct	6716
63002495	1198	1210	melanotan II	ChemicalEntity	C079282
63002495	1214	1220	murine	OrganismTaxon	10090
63002495	1316	1322	murine	OrganismTaxon	10090
63002495	Bind	6716	C079282	Novel
63002495	Bind	6716	D008050	Novel
63002495	Bind	7067	D008050	Novel
63002495	Association	C079282	7067	Novel
63002495	Association	C409648	C079282	Novel
63002495	Association	C079282	C409648	Novel

88352003|t|Kilham rat virus, RB1, and ZnSO(4): interactions with glycine, MEN1, and Toxorynchites mosquitoes in tobacco
88352003|a|Recent studies have revealed complex interactions between Kilham rat virus, RB1, and ZnSO(4) in the context of glycine metabolism. The conversion between K + and glycine was observed in both in vitro and in vivo models, suggesting a potential regulatory role of K + in glycine homeostasis. Additionally, the binding of ZnSO(4) to RB1 was confirmed through biochemical assays, indicating a direct interaction that may influence cellular signaling pathways. The conversion between ZnSO(4) and glycine further supports the hypothesis that these chemical entities play a synergistic role in modulating gene expression.   Toxorynchites mosquitoes were found to be a significant vector in the transmission of Kilham rat virus, particularly in environments where tobacco is cultivated. Tobacco plants were shown to accumulate high levels of glycine and ZnSO(4), which may contribute to the persistence of the virus in these ecosystems. The presence of MEN1 in tobacco tissues was correlated with the expression levels of RB1, suggesting a potential regulatory network involving these gene products.   These findings highlight the intricate relationships between Kilham rat virus, RB1, ZnSO(4), glycine, Toxorynchites mosquitoes, and tobacco, providing new insights into the molecular mechanisms underlying these interactions.
88352003	0	16	Kilham rat virus	OrganismTaxon	12441
88352003	18	21	RB1	GeneOrGeneProduct	5925
88352003	27	34	ZnSO(4)	ChemicalEntity	D019287
88352003	54	61	glycine	ChemicalEntity	D005998
88352003	63	67	MEN1	GeneOrGeneProduct	4221
88352003	73	97	Toxorynchites mosquitoes	OrganismTaxon	2498889
88352003	101	108	tobacco	OrganismTaxon	4097
88352003	167	183	Kilham rat virus	OrganismTaxon	12441
88352003	185	188	RB1	GeneOrGeneProduct	5925
88352003	194	201	ZnSO(4)	ChemicalEntity	D019287
88352003	220	227	glycine	ChemicalEntity	D005998
88352003	263	266	K +	ChemicalEntity	D011188
88352003	271	278	glycine	ChemicalEntity	D005998
88352003	371	374	K +	ChemicalEntity	D011188
88352003	378	385	glycine	ChemicalEntity	D005998
88352003	428	435	ZnSO(4)	ChemicalEntity	D019287
88352003	439	442	RB1	GeneOrGeneProduct	5925
88352003	588	595	ZnSO(4)	ChemicalEntity	D019287
88352003	600	607	glycine	ChemicalEntity	D005998
88352003	726	750	Toxorynchites mosquitoes	OrganismTaxon	2498889
88352003	812	828	Kilham rat virus	OrganismTaxon	12441
88352003	865	872	tobacco	OrganismTaxon	4097
88352003	943	950	glycine	ChemicalEntity	D005998
88352003	955	962	ZnSO(4)	ChemicalEntity	D019287
88352003	1054	1058	MEN1	GeneOrGeneProduct	4221
88352003	1062	1069	tobacco	OrganismTaxon	4097
88352003	1123	1126	RB1	GeneOrGeneProduct	5925
88352003	1264	1280	Kilham rat virus	OrganismTaxon	12441
88352003	1282	1285	RB1	GeneOrGeneProduct	5925
88352003	1287	1294	ZnSO(4)	ChemicalEntity	D019287
88352003	1296	1303	glycine	ChemicalEntity	D005998
88352003	1305	1329	Toxorynchites mosquitoes	OrganismTaxon	2498889
88352003	1335	1342	tobacco	OrganismTaxon	4097
88352003	Conversion	D011188	D005998	Novel
88352003	Bind	D019287	5925	Novel
88352003	Conversion	D019287	D005998	Novel

12148722|t|Vitamin C, alcohol, and their interactions with AR, fibronectin, and glutathione peroxidase in the context of CDG-Ic a
12148722|a|This study investigates the complex interactions between Vitamin C, alcohol, and key molecular entities such as AR, fibronectin, and glutathione peroxidase in the context of CDG-Ic and DEN-4. The research focuses on the cotreatment of Vitamin C and alcohol, revealing significant biological implications. Using IEC-6 and MCF7/AdrR cell lines, we observed that Vitamin C and alcohol are cotreated in multiple experimental conditions, suggesting a potential synergistic or antagonistic effect.   Our findings indicate a negative correlation between Vitamin C and CDG-Ic, as well as between Vitamin C and fibronectin, which may suggest a regulatory role of Vitamin C in fibronectin expression. Similarly, a negative correlation was found between Vitamin C and AR, indicating that Vitamin C may modulate AR activity. Additionally, the negative correlation between AR and alcohol suggests that alcohol may influence AR expression or function.   The study also highlights a negative correlation between fibronectin and alcohol, which could imply that alcohol affects fibronectin levels in cellular models. Furthermore, glutathione peroxidase shows a negative correlation with both Vitamin C and alcohol, suggesting that these compounds may interfere with the antioxidant activity of glutathione peroxidase.   These results were consistently observed across multiple experiments involving DEN-4 and HBV organisms, emphasizing the broad relevance of these interactions. The findings provide a foundation for understanding the molecular mechanisms underlying the effects of Vitamin C and alcohol on cellular processes and disease states such as CDG-Ic.
12148722	0	9	Vitamin C	ChemicalEntity	D001205
12148722	11	18	alcohol	ChemicalEntity	D000431
12148722	48	50	AR	GeneOrGeneProduct	367
12148722	52	63	fibronectin	GeneOrGeneProduct	2335
12148722	69	91	glutathione peroxidase	GeneOrGeneProduct	24404
12148722	110	116	CDG-Ic	DiseaseOrPhenotypicFeature	C535741
12148722	176	185	Vitamin C	ChemicalEntity	D001205
12148722	187	194	alcohol	ChemicalEntity	D000431
12148722	231	233	AR	GeneOrGeneProduct	367
12148722	235	246	fibronectin	GeneOrGeneProduct	2335
12148722	252	274	glutathione peroxidase	GeneOrGeneProduct	24404
12148722	293	299	CDG-Ic	DiseaseOrPhenotypicFeature	C535741
12148722	304	309	DEN-4	OrganismTaxon	11070
12148722	354	363	Vitamin C	ChemicalEntity	D001205
12148722	368	375	alcohol	ChemicalEntity	D000431
12148722	430	435	IEC-6	CellLine	CVCL_0343
12148722	440	449	MCF7/AdrR	CellLine	 CVCL_1452
12148722	479	488	Vitamin C	ChemicalEntity	D001205
12148722	493	500	alcohol	ChemicalEntity	D000431
12148722	666	675	Vitamin C	ChemicalEntity	D001205
12148722	680	686	CDG-Ic	DiseaseOrPhenotypicFeature	C535741
12148722	707	716	Vitamin C	ChemicalEntity	D001205
12148722	721	732	fibronectin	GeneOrGeneProduct	2335
12148722	773	782	Vitamin C	ChemicalEntity	D001205
12148722	786	797	fibronectin	GeneOrGeneProduct	2335
12148722	862	871	Vitamin C	ChemicalEntity	D001205
12148722	876	878	AR	GeneOrGeneProduct	367
12148722	896	905	Vitamin C	ChemicalEntity	D001205
12148722	919	921	AR	GeneOrGeneProduct	367
12148722	979	981	AR	GeneOrGeneProduct	367
12148722	986	993	alcohol	ChemicalEntity	D000431
12148722	1008	1015	alcohol	ChemicalEntity	D000431
12148722	1030	1032	AR	GeneOrGeneProduct	367
12148722	1116	1127	fibronectin	GeneOrGeneProduct	2335
12148722	1132	1139	alcohol	ChemicalEntity	D000431
12148722	1164	1171	alcohol	ChemicalEntity	D000431
12148722	1180	1191	fibronectin	GeneOrGeneProduct	2335
12148722	1232	1254	glutathione peroxidase	GeneOrGeneProduct	24404
12148722	1294	1303	Vitamin C	ChemicalEntity	D001205
12148722	1308	1315	alcohol	ChemicalEntity	D000431
12148722	1396	1418	glutathione peroxidase	GeneOrGeneProduct	24404
12148722	1501	1506	DEN-4	OrganismTaxon	11070
12148722	1511	1514	HBV	OrganismTaxon	10407
12148722	1684	1693	Vitamin C	ChemicalEntity	D001205
12148722	1698	1705	alcohol	ChemicalEntity	D000431
12148722	1755	1761	CDG-Ic	DiseaseOrPhenotypicFeature	C535741
12148722	Cotreatment	D001205	D000431	Novel
12148722	Negative_Correlation	2335	D001205	Novel
12148722	Negative_Correlation	367	D001205	Novel
12148722	Negative_Correlation	367	D000431	Novel
12148722	Negative_Correlation	D001205	C535741	Novel
12148722	Negative_Correlation	24404	D001205	Novel
12148722	Negative_Correlation	2335	D000431	Novel
12148722	Cotreatment	D000431	D001205	Novel
12148722	Negative_Correlation	24404	D000431	Novel
12148722	Negative_Correlation	D000431	C535741	Novel

29830209|t|Genetic and molecular interactions of bone morphogenetic proteins (BMP)-4, caspase-8, and p70s6k in juvenile polyposis and other phenotypic 
29830209|a|This study investigates the molecular and genetic interactions between bone morphogenetic proteins (BMP)-4, caspase-8, and p70s6k in the context of juvenile polyposis and other phenotypic features. We report that the sequence variant rs1800872 is associated with altered expression of BMP-4 in human tissues, which may contribute to the pathogenesis of juvenile polyposis. Additionally, we find that the sequence variant del418T is linked to increased levels of BMP-4 in Spirulina-fed mice, suggesting a potential role for Spirulina in modulating BMP-4 activity.   Our findings also reveal a significant association between juvenile polyposis and p70s6k, with the gene product p70s6k showing a direct binding interaction with caspase-8. This binding is further supported by the observation that the sequence variant I146L in caspase-8 enhances its interaction with p70s6k. Moreover, we demonstrate that the gene product glucocorticoid receptor-interacting protein 1 modulates the binding of p70s6k to caspase-8, suggesting a complex regulatory network involving these proteins.  We also report that the gene product angiotensin II type-1 receptor binds to p70s6k, and this interaction is associated with infertility. Furthermore, we find that infertility is significantly associated with both the angiotensin II type-1 receptor and caspase-8, indicating a potential role for these proteins in reproductive health.   In addition, we observe that the sequence variant 'alanine for proline at amino acid 286' in the gene product p70s6k is linked to premature pubarche, while the sequence variant 'I146L' in caspase-8 is associated with nausea. The study also includes data from Toxorynchites mosquitoes and Daucus carota, which show differential expression of BMP-4 in response to environmental factors, suggesting a broader ecological and evolutionary context for these molecular interactions.  Overall, this research provides new insights into the genetic and molecular mechanisms underlying juvenile polyposis and other phenotypic features, highlighting the importance of BMP-4, caspase-8, and p70s6k in disease pathogenesis and physiological regulation.
29830209	38	73	bone morphogenetic proteins (BMP)-4	GeneOrGeneProduct	443502
29830209	75	84	caspase-8	GeneOrGeneProduct	841
29830209	90	96	p70s6k	GeneOrGeneProduct	6198
29830209	100	118	juvenile polyposis	DiseaseOrPhenotypicFeature	C537702
29830209	212	247	bone morphogenetic proteins (BMP)-4	GeneOrGeneProduct	443502
29830209	249	258	caspase-8	GeneOrGeneProduct	841
29830209	264	270	p70s6k	GeneOrGeneProduct	6198
29830209	289	307	juvenile polyposis	DiseaseOrPhenotypicFeature	C537702
29830209	375	384	rs1800872	SequenceVariant	rs1800872
29830209	435	440	human	OrganismTaxon	9606
29830209	494	512	juvenile polyposis	DiseaseOrPhenotypicFeature	C537702
29830209	562	569	del418T	SequenceVariant	c|DEL|418|T
29830209	612	621	Spirulina	OrganismTaxon	551299
29830209	664	673	Spirulina	OrganismTaxon	551299
29830209	765	783	juvenile polyposis	DiseaseOrPhenotypicFeature	C537702
29830209	788	794	p70s6k	GeneOrGeneProduct	6198
29830209	818	824	p70s6k	GeneOrGeneProduct	6198
29830209	867	876	caspase-8	GeneOrGeneProduct	841
29830209	957	962	I146L	SequenceVariant	rs72478580
29830209	966	975	caspase-8	GeneOrGeneProduct	841
29830209	1006	1012	p70s6k	GeneOrGeneProduct	6198
29830209	1061	1106	glucocorticoid receptor-interacting protein 1	GeneOrGeneProduct	23426
29830209	1132	1138	p70s6k	GeneOrGeneProduct	6198
29830209	1142	1151	caspase-8	GeneOrGeneProduct	841
29830209	1257	1287	angiotensin II type-1 receptor	GeneOrGeneProduct	24180
29830209	1297	1303	p70s6k	GeneOrGeneProduct	6198
29830209	1345	1356	infertility	DiseaseOrPhenotypicFeature	D007247
29830209	1384	1395	infertility	DiseaseOrPhenotypicFeature	D007247
29830209	1438	1468	angiotensin II type-1 receptor	GeneOrGeneProduct	24180
29830209	1473	1482	caspase-8	GeneOrGeneProduct	841
29830209	1608	1645	alanine for proline at amino acid 286	SequenceVariant	p|SUB|A|286|P
29830209	1667	1673	p70s6k	GeneOrGeneProduct	6198
29830209	1687	1705	premature pubarche	DiseaseOrPhenotypicFeature	C567552
29830209	1735	1740	I146L	SequenceVariant	rs72478580
29830209	1745	1754	caspase-8	GeneOrGeneProduct	841
29830209	1774	1780	nausea	DiseaseOrPhenotypicFeature	D009325
29830209	1816	1840	Toxorynchites mosquitoes	OrganismTaxon	2498889
29830209	1845	1858	Daucus carota	OrganismTaxon	4039
29830209	2132	2150	juvenile polyposis	DiseaseOrPhenotypicFeature	C537702
29830209	2220	2229	caspase-8	GeneOrGeneProduct	841
29830209	2235	2241	p70s6k	GeneOrGeneProduct	6198
29830209	Bind	6198	841	Novel
29830209	Association	D007247	841	Novel
29830209	Bind	841	6198	Novel
29830209	Association	D007247	24180	Novel
29830209	Bind	24180	6198	Novel
29830209	Association	C537702	6198	Novel

31054284|t|Genetic Variants and Pharmacological Responses in Zebrafish Models: A Comprehensive Analysis of Sequence Variants, Cell Lines, and Chemical 
31054284|a|This study investigates the complex interplay between genetic variants, cell lines, and chemical entities in Zebrafish models to elucidate their roles in pharmacological responses and disease mechanisms. We focused on the sequence variants 'guanine (CGA) by adenine (CAA)', 'del 92 nucleotide -19/+73', 'R3500Q', 'rs2004640', and 'arginine by glutamine at position 714', as well as the cell lines 'Huh7' and 'H446', and the chemical entities 'terbutaline' and '4-ene-VPA'.   Our findings reveal a negative correlation between 'R3500Q' and '4-ene-VPA', suggesting that these variants may modulate the efficacy of 4-ene-VPA in Zebrafish models. Additionally, we observed a negative correlation between 'rs2004640' and 'terbutaline', indicating that rs2004640 may influence the pharmacological response to terbutaline. The association between 'guanine (CGA) by adenine (CAA)' and 'terbutaline' highlights a potential role for this sequence variant in modulating terbutaline's effects.   A comparison between '4-ene-VPA' and 'terbutaline' revealed distinct pharmacological profiles, with '4-ene-VPA' showing a positive correlation with 'guanine (CGA) by adenine (CAA)'. Furthermore, '4-ene-VPA' was found to be negatively correlated with 'del 92 nucleotide -19/+73' and 'arginine by glutamine at position 714', while also being positively correlated with 'R3500Q' and 'rs2004640'. The negative correlation between 'del 92 nucleotide -19/+73' and 'terbutaline' suggests that this variant may act as a modulator of terbutaline's effects.   Notably, 'arginine by glutamine at position 714' was found to be associated with both '4-ene-VPA' and 'terbutaline', indicating a potential regulatory role in pharmacological responses. The positive correlation between 'terbutaline' and 'rs2004640' further supports the involvement of rs2004640 in modulating terbutaline's activity.   These results were validated using the Huh7 and H446 cell lines, which were used to model the effects of these genetic and chemical factors in Zebrafish. The study underscores the importance of understanding the interactions between genetic variants, cell lines, and chemical entities in the context of pharmacological responses and disease mechanisms.
31054284	50	59	Zebrafish	OrganismTaxon	7955
31054284	250	259	Zebrafish	OrganismTaxon	7955
31054284	382	412	guanine (CGA) by adenine (CAA)	SequenceVariant	rs9332964
31054284	416	441	del 92 nucleotide -19/+73	SequenceVariant	c|DEL|-19_+73|92
31054284	445	451	R3500Q	SequenceVariant	rs5742904
31054284	455	464	rs2004640	SequenceVariant	rs2004640
31054284	472	509	arginine by glutamine at position 714	SequenceVariant	c|SUB|R|714|Q
31054284	539	543	Huh7	CellLine	CVCL_0336
31054284	550	554	H446	CellLine	CVCL_1562
31054284	584	595	terbutaline	ChemicalEntity	D013726
31054284	602	611	4-ene-VPA	ChemicalEntity	C045022
31054284	668	674	R3500Q	SequenceVariant	rs5742904
31054284	681	690	4-ene-VPA	ChemicalEntity	C045022
31054284	753	762	4-ene-VPA	ChemicalEntity	C045022
31054284	766	775	Zebrafish	OrganismTaxon	7955
31054284	842	851	rs2004640	SequenceVariant	rs2004640
31054284	858	869	terbutaline	ChemicalEntity	D013726
31054284	888	897	rs2004640	SequenceVariant	rs2004640
31054284	944	955	terbutaline	ChemicalEntity	D013726
31054284	982	1012	guanine (CGA) by adenine (CAA)	SequenceVariant	rs9332964
31054284	1019	1030	terbutaline	ChemicalEntity	D013726
31054284	1100	1111	terbutaline	ChemicalEntity	D013726
31054284	1147	1156	4-ene-VPA	ChemicalEntity	C045022
31054284	1163	1174	terbutaline	ChemicalEntity	D013726
31054284	1226	1235	4-ene-VPA	ChemicalEntity	C045022
31054284	1274	1304	guanine (CGA) by adenine (CAA)	SequenceVariant	rs9332964
31054284	1321	1330	4-ene-VPA	ChemicalEntity	C045022
31054284	1376	1401	del 92 nucleotide -19/+73	SequenceVariant	c|DEL|-19_+73|92
31054284	1408	1445	arginine by glutamine at position 714	SequenceVariant	c|SUB|R|714|Q
31054284	1493	1499	R3500Q	SequenceVariant	rs5742904
31054284	1506	1515	rs2004640	SequenceVariant	rs2004640
31054284	1552	1577	del 92 nucleotide -19/+73	SequenceVariant	c|DEL|-19_+73|92
31054284	1584	1595	terbutaline	ChemicalEntity	D013726
31054284	1650	1661	terbutaline	ChemicalEntity	D013726
31054284	1685	1722	arginine by glutamine at position 714	SequenceVariant	c|SUB|R|714|Q
31054284	1762	1771	4-ene-VPA	ChemicalEntity	C045022
31054284	1778	1789	terbutaline	ChemicalEntity	D013726
31054284	1895	1906	terbutaline	ChemicalEntity	D013726
31054284	1913	1922	rs2004640	SequenceVariant	rs2004640
31054284	1960	1969	rs2004640	SequenceVariant	rs2004640
31054284	1984	1995	terbutaline	ChemicalEntity	D013726
31054284	2049	2053	Huh7	CellLine	CVCL_0336
31054284	2058	2062	H446	CellLine	CVCL_1562
31054284	2153	2162	Zebrafish	OrganismTaxon	7955
31054284	Negative_Correlation	rs5742904	C045022	Novel
31054284	Negative_Correlation	rs2004640	D013726	Novel
31054284	Association	rs9332964	D013726	Novel
31054284	Comparison	C045022	D013726	Novel
31054284	Negative_Correlation	c|SUB|R|714|Q	D013726	Novel
31054284	Association	C045022	c|SUB|R|714|Q	Novel
31054284	Association	c|SUB|R|714|Q	D013726	Novel
31054284	Negative_Correlation	c|DEL|-19_+73|92	C045022	Novel
31054284	Association	C045022	rs5742904	Novel
31054284	Positive_Correlation	C045022	rs9332964	Novel
31054284	Negative_Correlation	c|DEL|-19_+73|92	D013726	Novel
31054284	Association	C045022	rs2004640	Novel
31054284	Positive_Correlation	C045022	rs2004640	Novel
31054284	Negative_Correlation	rs9332964	D013726	Novel
31054284	Positive_Correlation	D013726	c|DEL|-19_+73|92	Novel
31054284	Association	c|DEL|-19_+73|92	D013726	Novel
31054284	Positive_Correlation	D013726	rs2004640	Novel

58455444|t|Smad1 and Erk1 signaling in Ba/F3 cells: interactions with GCK and the role of mirtazapine in bra
58455444|a|This study investigates the molecular mechanisms underlying the interaction between Smad1 and Erk1 signaling pathways in Ba/F3 cells, with a focus on the regulatory role of GCK. We demonstrate that Smad1 and Erk1 exhibit distinct but overlapping functions in modulating cellular responses to various stimuli, including growth factors and cytokines. The expression of GCK is significantly upregulated in Ba/F3 cells under conditions of stress, suggesting a potential role for this gene in cellular adaptation.   Our findings reveal a negative correlation between mirtazapine and bradycardia, as evidenced by the observed reduction in heart rate in experimental models treated with mirtazapine. This effect is further supported by the association between mirtazapine and bradycardia, which is consistent with clinical reports linking the drug to cardiac side effects. Notably, the presence of GCK appears to modulate the extent of this effect, with higher GCK expression correlating with a diminished bradycardic response.  In addition to its effects on cardiac function, mirtazapine also influences the expression of Smad1 and Erk1 in Ba/F3 cells. These changes are particularly pronounced in the SMMC-7721 cell line, where mirtazapine treatment leads to a significant downregulation of Smad1 and a concomitant upregulation of Erk1. This suggests a complex interplay between these signaling pathways in response to pharmacological agents.   The study also highlights the importance of GCK in mediating the effects of mirtazapine on cardiac function, as GCK knockout models exhibit a more severe bradycardic response to the drug. These results provide new insights into the molecular basis of mirtazapine-induced bradycardia and underscore the need for further research into the therapeutic implications of these interactions.
58455444	0	5	Smad1	GeneOrGeneProduct	17125
58455444	10	14	Erk1	GeneOrGeneProduct	26417
58455444	28	33	Ba/F3	CellLine	CVCL_0161
58455444	59	62	GCK	GeneOrGeneProduct	2645
58455444	79	90	mirtazapine	ChemicalEntity	D000078785
58455444	182	187	Smad1	GeneOrGeneProduct	17125
58455444	192	196	Erk1	GeneOrGeneProduct	26417
58455444	219	224	Ba/F3	CellLine	CVCL_0161
58455444	271	274	GCK	GeneOrGeneProduct	2645
58455444	296	301	Smad1	GeneOrGeneProduct	17125
58455444	306	310	Erk1	GeneOrGeneProduct	26417
58455444	465	468	GCK	GeneOrGeneProduct	2645
58455444	501	506	Ba/F3	CellLine	CVCL_0161
58455444	660	671	mirtazapine	ChemicalEntity	D000078785
58455444	676	687	bradycardia	DiseaseOrPhenotypicFeature	D001919
58455444	778	789	mirtazapine	ChemicalEntity	D000078785
58455444	851	862	mirtazapine	ChemicalEntity	D000078785
58455444	867	878	bradycardia	DiseaseOrPhenotypicFeature	D001919
58455444	989	992	GCK	GeneOrGeneProduct	2645
58455444	1052	1055	GCK	GeneOrGeneProduct	2645
58455444	1168	1179	mirtazapine	ChemicalEntity	D000078785
58455444	1214	1219	Smad1	GeneOrGeneProduct	17125
58455444	1224	1228	Erk1	GeneOrGeneProduct	26417
58455444	1232	1237	Ba/F3	CellLine	CVCL_0161
58455444	1294	1303	SMMC-7721	CellLine	CVCL_0534
58455444	1321	1332	mirtazapine	ChemicalEntity	D000078785
58455444	1384	1389	Smad1	GeneOrGeneProduct	17125
58455444	1424	1428	Erk1	GeneOrGeneProduct	26417
58455444	1582	1585	GCK	GeneOrGeneProduct	2645
58455444	1614	1625	mirtazapine	ChemicalEntity	D000078785
58455444	1650	1653	GCK	GeneOrGeneProduct	2645
58455444	1789	1800	mirtazapine	ChemicalEntity	D000078785
58455444	1809	1820	bradycardia	DiseaseOrPhenotypicFeature	D001919
58455444	Negative_Correlation	D000078785	D001919	Novel
58455444	Association	D001919	D000078785	Novel

96913820|t|Drosophila bcl-xl and clathrin interactions in cellular trafficking: implications for human immunodeficiency virus type 1 and calbindin-D28k re
96913820|a|Recent studies have revealed a critical role for the anti-apoptotic protein bcl-xl in modulating clathrin-mediated endocytosis, a process essential for cellular trafficking. This association between bcl-xl and clathrin was demonstrated in Drosophila melanogaster models, where disruption of clathrin function led to impaired bcl-xl localization and increased apoptosis. These findings were corroborated in human immunodeficiency virus type 1 (HIV-1) infected SMMC-7721 cells, where clathrin-dependent pathways were found to be dysregulated, potentially contributing to viral entry and replication.   In parallel, research on calbindin-D28k, a calcium-binding protein, has shown a positive correlation with clathrin expression in chick and mouse models. This correlation was further supported by in vitro experiments using Atorvastatin, a cholesterol-lowering drug, which was found to enhance calbindin-D28k levels in a clathrin-dependent manner. Notably, this effect was observed in both chick and human immunodeficiency virus type 1 (HIV-1) cell lines, suggesting a potential therapeutic target for modulating calcium homeostasis in disease states.  Additionally, the interaction between dystrophin and clathrin was investigated in tobacco and mouse models, revealing a novel mechanism by which dystrophin stabilizes clathrin-coated pits during endocytosis. This interaction was further validated in SMMC-7721 cells, where dystrophin overexpression led to increased clathrin recruitment and enhanced endocytic activity. These findings highlight the complex interplay between clathrin and various proteins, including bcl-xl, calbindin-D28k, and dystrophin, across multiple species and disease contexts.
96913820	0	10	Drosophila	OrganismTaxon	7227
96913820	11	17	bcl-xl	GeneOrGeneProduct	24888
96913820	22	30	clathrin	ChemicalEntity	D002966
96913820	86	121	human immunodeficiency virus type 1	OrganismTaxon	11676
96913820	126	140	calbindin-D28k	GeneOrGeneProduct	12307
96913820	220	226	bcl-xl	GeneOrGeneProduct	24888
96913820	241	249	clathrin	ChemicalEntity	D002966
96913820	343	349	bcl-xl	GeneOrGeneProduct	24888
96913820	354	362	clathrin	ChemicalEntity	D002966
96913820	383	393	Drosophila	OrganismTaxon	7227
96913820	435	443	clathrin	ChemicalEntity	D002966
96913820	469	475	bcl-xl	GeneOrGeneProduct	24888
96913820	550	585	human immunodeficiency virus type 1	OrganismTaxon	11676
96913820	603	612	SMMC-7721	CellLine	CVCL_0534
96913820	626	634	clathrin	ChemicalEntity	D002966
96913820	769	783	calbindin-D28k	GeneOrGeneProduct	12307
96913820	850	858	clathrin	ChemicalEntity	D002966
96913820	873	878	chick	OrganismTaxon	9031
96913820	883	888	mouse	OrganismTaxon	10090
96913820	966	978	Atorvastatin	ChemicalEntity	D000069059
96913820	1036	1050	calbindin-D28k	GeneOrGeneProduct	12307
96913820	1063	1071	clathrin	ChemicalEntity	D002966
96913820	1132	1137	chick	OrganismTaxon	9031
96913820	1142	1177	human immunodeficiency virus type 1	OrganismTaxon	11676
96913820	1333	1343	dystrophin	GeneOrGeneProduct	24907
96913820	1348	1356	clathrin	ChemicalEntity	D002966
96913820	1377	1384	tobacco	OrganismTaxon	4097
96913820	1389	1394	mouse	OrganismTaxon	10090
96913820	1440	1450	dystrophin	GeneOrGeneProduct	24907
96913820	1462	1470	clathrin	ChemicalEntity	D002966
96913820	1545	1554	SMMC-7721	CellLine	CVCL_0534
96913820	1568	1578	dystrophin	GeneOrGeneProduct	24907
96913820	1611	1619	clathrin	ChemicalEntity	D002966
96913820	1720	1728	clathrin	ChemicalEntity	D002966
96913820	1761	1767	bcl-xl	GeneOrGeneProduct	24888
96913820	1769	1783	calbindin-D28k	GeneOrGeneProduct	12307
96913820	1789	1799	dystrophin	GeneOrGeneProduct	24907
96913820	Association	24888	D002966	Novel
96913820	Association	12307	D000069059	Novel
96913820	Association	24907	D002966	Novel
96913820	Positive_Correlation	12307	D002966	Novel

90606158|t|HNF-6 and bcl-xl interactions in ginseng and bovine cell lines: a comprehensive analysis of binding and regulatory relat
90606158|a|This study investigates the complex interactions between hepatocyte nuclear factor (HNF)-6 and bcl-xl in the context of ginseng and bovine cell lines. Using a combination of molecular biology techniques, we demonstrate both negative and positive correlations between HNF-6 and bcl-xl, as well as direct binding interactions between the two proteins. The findings suggest that HNF-6 may act as a transcriptional regulator of bcl-xl, with implications for cell survival and apoptosis in both ginseng and bovine systems.   We examined the expression levels of HNF-6 and bcl-xl in the CMT-93, CD18/HPAF, and SF188 cell lines, which were derived from ginseng and bovine sources. In CMT-93 cells, a negative correlation was observed between HNF-6 and bcl-xl, while in CD18/HPAF cells, an association was noted. In SF188 cells, both a negative correlation and an association were detected, indicating cell-type-specific regulatory mechanisms.   Further, electrophoretic mobility shift assays (EMSAs) confirmed that HNF-6 binds directly to bcl-xl in both ginseng and bovine cell lines. This binding was further validated through chromatin immunoprecipitation (ChIP) experiments, which showed that HNF-6 occupies the promoter region of the bcl-xl gene in these cell lines.   Our results highlight the dynamic relationship between HNF-6 and bcl-xl, with evidence of both negative and positive regulatory interactions. These findings provide a foundation for understanding the molecular mechanisms underlying cell survival and death in ginseng and bovine systems, with potential applications in biotechnology and regenerative medicine.
90606158	10	16	bcl-xl	GeneOrGeneProduct	24888
90606158	33	40	ginseng	OrganismTaxon	4054
90606158	45	51	bovine	OrganismTaxon	9913
90606158	178	211	hepatocyte nuclear factor (HNF)-6	GeneOrGeneProduct	3175
90606158	216	222	bcl-xl	GeneOrGeneProduct	24888
90606158	241	248	ginseng	OrganismTaxon	4054
90606158	253	259	bovine	OrganismTaxon	9913
90606158	398	404	bcl-xl	GeneOrGeneProduct	24888
90606158	545	551	bcl-xl	GeneOrGeneProduct	24888
90606158	611	618	ginseng	OrganismTaxon	4054
90606158	623	629	bovine	OrganismTaxon	9913
90606158	688	694	bcl-xl	GeneOrGeneProduct	24888
90606158	702	708	CMT-93	CellLine	CVCL_1986
90606158	710	719	CD18/HPAF	CellLine	CVCL_0313
90606158	725	730	SF188	CellLine	CVCL_6948
90606158	767	774	ginseng	OrganismTaxon	4054
90606158	779	785	bovine	OrganismTaxon	9913
90606158	798	804	CMT-93	CellLine	CVCL_1986
90606158	866	872	bcl-xl	GeneOrGeneProduct	24888
90606158	883	892	CD18/HPAF	CellLine	CVCL_0313
90606158	929	934	SF188	CellLine	CVCL_6948
90606158	1153	1159	bcl-xl	GeneOrGeneProduct	24888
90606158	1168	1175	ginseng	OrganismTaxon	4054
90606158	1180	1186	bovine	OrganismTaxon	9913
90606158	1352	1358	bcl-xl	GeneOrGeneProduct	24888
90606158	1452	1458	bcl-xl	GeneOrGeneProduct	24888
90606158	1646	1653	ginseng	OrganismTaxon	4054
90606158	1658	1664	bovine	OrganismTaxon	9913
90606158	Negative_Correlation	24888	3175	Novel
90606158	Association	24888	3175	Novel
90606158	Negative_Correlation	3175	24888	Novel
90606158	Association	3175	24888	Novel
90606158	Bind	3175	24888	Novel
90606158	Bind	24888	3175	Novel

10254160|t|KU7 cell line and c.855 +1G>C sequence variant interactions in tobacco and viral infections: a study on Drosophila and Human Papillo
10254160|a|This study investigates the interactions between the KU7 cell line and the sequence variant c.855 +1G>C in the context of tobacco exposure and viral infections. The research focuses on the effects of this sequence variant on cellular responses in the KU7 cell line, which is frequently used in studies involving tobacco-related diseases. The c.855 +1G>C variant was found to significantly alter gene expression patterns in the KU7 cell line when exposed to tobacco extracts.   In addition, the study explores the role of the c.855 +1G>C variant in the susceptibility of the KU7 cell line to infections by Kilham rat virus and dengue virus type 2. The results indicate that the presence of this variant may enhance viral replication in the KU7 cell line, particularly under conditions of tobacco exposure.   The research also examines the impact of the c.855 +1G>C variant on the Drosophila model system, where it was observed to influence the expression of genes related to viral defense mechanisms. Furthermore, the study investigates the association between the variant and Human Papilloma Virus (HPV) infection in the MH134 cell line, which is known to be susceptible to HPV.   The findings suggest that the c.855 +1G>C sequence variant may play a critical role in modulating the host response to both viral and environmental factors, such as tobacco. The study also highlights the importance of the KU7 cell line in understanding the molecular mechanisms underlying these interactions. The results have implications for the development of targeted therapies for viral infections and tobacco-related diseases.
10254160	0	3	KU7	CellLine	CVCL_4714
10254160	18	29	c.855 +1G>C	SequenceVariant	c|SUB|C|855+1|C
10254160	63	70	tobacco	OrganismTaxon	4097
10254160	104	114	Drosophila	OrganismTaxon	7227
10254160	186	189	KU7	CellLine	CVCL_4714
10254160	225	236	c.855 +1G>C	SequenceVariant	c|SUB|C|855+1|C
10254160	255	262	tobacco	OrganismTaxon	4097
10254160	384	387	KU7	CellLine	CVCL_4714
10254160	445	452	tobacco	OrganismTaxon	4097
10254160	475	486	c.855 +1G>C	SequenceVariant	c|SUB|C|855+1|C
10254160	560	563	KU7	CellLine	CVCL_4714
10254160	590	597	tobacco	OrganismTaxon	4097
10254160	658	669	c.855 +1G>C	SequenceVariant	c|SUB|C|855+1|C
10254160	707	710	KU7	CellLine	CVCL_4714
10254160	738	754	Kilham rat virus	OrganismTaxon	12441
10254160	759	778	dengue virus type 2	OrganismTaxon	11060
10254160	872	875	KU7	CellLine	CVCL_4714
10254160	920	927	tobacco	OrganismTaxon	4097
10254160	985	996	c.855 +1G>C	SequenceVariant	c|SUB|C|855+1|C
10254160	1012	1022	Drosophila	OrganismTaxon	7227
10254160	1254	1259	MH134	CellLine	CVCL_8111
10254160	1344	1355	c.855 +1G>C	SequenceVariant	c|SUB|C|855+1|C
10254160	1479	1486	tobacco	OrganismTaxon	4097
10254160	1536	1539	KU7	CellLine	CVCL_4714
10254160	1720	1727	tobacco	OrganismTaxon	4097

86985581|t|Efavirenz and its associations with infertility, radiculopathy, and obesity in DEN-4-infected PA-1 cells and Aedes mo
86985581|a|Recent studies have explored the multifaceted interactions between the antiretroviral drug efavirenz and various biological outcomes in both in vitro and in vivo models. This research focuses on the effects of efavirenz on DEN-4-infected PA-1 cells and its potential role in the development of infertility, radiculopathy, and obesity. The findings reveal a significant association between efavirenz and infertility, suggesting that efavirenz may contribute to reproductive dysfunction in DEN-4-infected PA-1 cells. Additionally, a positive correlation was observed between efavirenz and radiculopathy, indicating that efavirenz may exacerbate or contribute to the development of radiculopathy in certain contexts.   Further analysis showed a strong positive correlation between efavirenz and obesity, with multiple instances of association between efavirenz and obese phenotypes. These results suggest that efavirenz may influence metabolic pathways that lead to weight gain and obesity. The study also examined the role of Aedes mosquitoes in the transmission of DEN-4 and its interaction with efavirenz. Notably, the presence of efavirenz in the environment was found to influence the expression of certain genes in Aedes mosquitoes, potentially affecting their ability to transmit DEN-4.   Moreover, the study explored the relationship between efavirenz and colon cancer, finding that efavirenz may have a protective effect against the development of colon cancer in certain cell lines. However, the association between efavirenz and radiculopathy was consistently observed across multiple models, reinforcing the need for further investigation into its potential neurotoxic effects. The findings highlight the complex interplay between efavirenz, DEN-4, and various disease states, including infertility, radiculopathy, and obesity, and underscore the importance of understanding these relationships in both clinical and ecological contexts.
86985581	36	47	infertility	DiseaseOrPhenotypicFeature	D007247
86985581	49	62	radiculopathy	DiseaseOrPhenotypicFeature	D011843
86985581	79	84	DEN-4	OrganismTaxon	11070
86985581	94	98	PA-1	CellLine	CVCL_0479
86985581	209	218	efavirenz	ChemicalEntity	C098320
86985581	328	337	efavirenz	ChemicalEntity	C098320
86985581	341	346	DEN-4	OrganismTaxon	11070
86985581	356	360	PA-1	CellLine	CVCL_0479
86985581	412	423	infertility	DiseaseOrPhenotypicFeature	D007247
86985581	425	438	radiculopathy	DiseaseOrPhenotypicFeature	D011843
86985581	507	516	efavirenz	ChemicalEntity	C098320
86985581	521	532	infertility	DiseaseOrPhenotypicFeature	D007247
86985581	550	559	efavirenz	ChemicalEntity	C098320
86985581	606	611	DEN-4	OrganismTaxon	11070
86985581	621	625	PA-1	CellLine	CVCL_0479
86985581	691	700	efavirenz	ChemicalEntity	C098320
86985581	705	718	radiculopathy	DiseaseOrPhenotypicFeature	D011843
86985581	736	745	efavirenz	ChemicalEntity	C098320
86985581	797	810	radiculopathy	DiseaseOrPhenotypicFeature	D011843
86985581	896	905	efavirenz	ChemicalEntity	C098320
86985581	966	975	efavirenz	ChemicalEntity	C098320
86985581	980	985	obese	DiseaseOrPhenotypicFeature	D009765
86985581	1025	1034	efavirenz	ChemicalEntity	C098320
86985581	1142	1158	Aedes mosquitoes	OrganismTaxon	1245352
86985581	1182	1187	DEN-4	OrganismTaxon	11070
86985581	1213	1222	efavirenz	ChemicalEntity	C098320
86985581	1249	1258	efavirenz	ChemicalEntity	C098320
86985581	1336	1352	Aedes mosquitoes	OrganismTaxon	1245352
86985581	1402	1407	DEN-4	OrganismTaxon	11070
86985581	1465	1474	efavirenz	ChemicalEntity	C098320
86985581	1479	1491	colon cancer	DiseaseOrPhenotypicFeature	D003110
86985581	1506	1515	efavirenz	ChemicalEntity	C098320
86985581	1572	1584	colon cancer	DiseaseOrPhenotypicFeature	D003110
86985581	1641	1650	efavirenz	ChemicalEntity	C098320
86985581	1655	1668	radiculopathy	DiseaseOrPhenotypicFeature	D011843
86985581	1858	1867	efavirenz	ChemicalEntity	C098320
86985581	1869	1874	DEN-4	OrganismTaxon	11070
86985581	1914	1925	infertility	DiseaseOrPhenotypicFeature	D007247
86985581	1927	1940	radiculopathy	DiseaseOrPhenotypicFeature	D011843
86985581	Association	D007247	C098320	Novel
86985581	Positive_Correlation	D011843	C098320	Novel
86985581	Association	C098320	D011843	Novel
86985581	Positive_Correlation	D009765	C098320	Novel
86985581	Association	C098320	D009765	Novel
86985581	Positive_Correlation	C098320	D009765	Novel
86985581	Positive_Correlation	C098320	D011843	Novel
86985581	Association	D009765	C098320	Novel
86985581	Association	D011843	C098320	Novel

77738027|t|CFHR1, LYAR, and SDHx: Interactions with iNOS, low-density lipoprotein receptor, and opioid peptides in congenital or infantile nephrotic syndrome and langua
77738027|a|This study investigates the molecular interactions and functional relationships between CFHR1, LYAR, SDHx, iNOS, low-density lipoprotein receptor, opioid peptides, and their associations with congenital or infantile nephrotic syndrome and language delay. Using a combination of biochemical assays and bioinformatics approaches, we demonstrate that CFHR1 binds to both iNOS and low-density lipoprotein receptor, while LYAR interacts with CFHR1. SDHx is found to bind to both low-density lipoprotein receptor and iNOS, suggesting a potential role in modulating these interactions. Opioid peptides are shown to bind to iNOS, and this interaction is further linked to the association between opioid peptides and language delay. Additionally, we observe a negative correlation between opioid peptides and language delay, indicating a possible inhibitory effect. The study also reveals a negative correlation between STZ and low-density lipoprotein receptor, as well as between STZ and congenital or infantile nephrotic syndrome. Fluoxetine is associated with congenital or infantile nephrotic syndrome, but it exhibits a negative correlation with the same condition, suggesting complex regulatory mechanisms. Furthermore, bcl-xl is found to bind to LYAR, highlighting potential roles in cellular signaling pathways. These findings provide new insights into the molecular mechanisms underlying congenital or infantile nephrotic syndrome and language delay, and they underscore the importance of these interactions in disease pathogenesis. The results also suggest that the interactions between CFHR1, LYAR, SDHx, iNOS, and low-density lipoprotein receptor may be critical in modulating the effects of opioid peptides and other chemical entities on cellular function.
77738027	0	5	CFHR1	GeneOrGeneProduct	3078
77738027	7	11	LYAR	GeneOrGeneProduct	55646
77738027	17	21	SDHx	GeneOrGeneProduct	6390
77738027	41	45	iNOS	GeneOrGeneProduct	4843
77738027	47	79	low-density lipoprotein receptor	GeneOrGeneProduct	3949
77738027	85	100	opioid peptides	ChemicalEntity	D018847
77738027	104	146	congenital or infantile nephrotic syndrome	DiseaseOrPhenotypicFeature	C535761
77738027	246	251	CFHR1	GeneOrGeneProduct	3078
77738027	253	257	LYAR	GeneOrGeneProduct	55646
77738027	259	263	SDHx	GeneOrGeneProduct	6390
77738027	265	269	iNOS	GeneOrGeneProduct	4843
77738027	271	303	low-density lipoprotein receptor	GeneOrGeneProduct	3949
77738027	305	320	opioid peptides	ChemicalEntity	D018847
77738027	350	392	congenital or infantile nephrotic syndrome	DiseaseOrPhenotypicFeature	C535761
77738027	397	411	language delay	DiseaseOrPhenotypicFeature	D007805
77738027	506	511	CFHR1	GeneOrGeneProduct	3078
77738027	526	530	iNOS	GeneOrGeneProduct	4843
77738027	535	567	low-density lipoprotein receptor	GeneOrGeneProduct	3949
77738027	575	579	LYAR	GeneOrGeneProduct	55646
77738027	595	600	CFHR1	GeneOrGeneProduct	3078
77738027	602	606	SDHx	GeneOrGeneProduct	6390
77738027	632	664	low-density lipoprotein receptor	GeneOrGeneProduct	3949
77738027	669	673	iNOS	GeneOrGeneProduct	4843
77738027	774	778	iNOS	GeneOrGeneProduct	4843
77738027	846	861	opioid peptides	ChemicalEntity	D018847
77738027	866	880	language delay	DiseaseOrPhenotypicFeature	D007805
77738027	938	953	opioid peptides	ChemicalEntity	D018847
77738027	958	972	language delay	DiseaseOrPhenotypicFeature	D007805
77738027	1069	1072	STZ	ChemicalEntity	D013311
77738027	1077	1109	low-density lipoprotein receptor	GeneOrGeneProduct	3949
77738027	1130	1133	STZ	ChemicalEntity	D013311
77738027	1138	1180	congenital or infantile nephrotic syndrome	DiseaseOrPhenotypicFeature	C535761
77738027	1212	1254	congenital or infantile nephrotic syndrome	DiseaseOrPhenotypicFeature	C535761
77738027	1375	1381	bcl-xl	GeneOrGeneProduct	24888
77738027	1402	1406	LYAR	GeneOrGeneProduct	55646
77738027	1546	1588	congenital or infantile nephrotic syndrome	DiseaseOrPhenotypicFeature	C535761
77738027	1593	1607	language delay	DiseaseOrPhenotypicFeature	D007805
77738027	1746	1751	CFHR1	GeneOrGeneProduct	3078
77738027	1753	1757	LYAR	GeneOrGeneProduct	55646
77738027	1759	1763	SDHx	GeneOrGeneProduct	6390
77738027	1765	1769	iNOS	GeneOrGeneProduct	4843
77738027	1775	1807	low-density lipoprotein receptor	GeneOrGeneProduct	3949
77738027	1853	1868	opioid peptides	ChemicalEntity	D018847
77738027	Negative_Correlation	D013311	3949	Novel
77738027	Association	C535761	D005473	Novel
77738027	Bind	D018847	4843	Novel
77738027	Bind	3949	4843	Novel
77738027	Association	D007805	D018847	Novel
77738027	Association	C535761	D013311	Novel
77738027	Bind	6390	3949	Novel
77738027	Bind	3078	3949	Novel
77738027	Bind	4843	3078	Novel
77738027	Bind	6390	4843	Novel
77738027	Negative_Correlation	D013311	C535761	Novel
77738027	Bind	3078	4843	Novel
77738027	Bind	55646	3078	Novel
77738027	Negative_Correlation	C535761	D005473	Novel
77738027	Negative_Correlation	D007805	D018847	Novel
77738027	Bind	24888	55646	Novel

71975042|t|N-Acetylglucosamine (O-GlcNAc) transferase interactions with curcumin, antipyretic, and Sch in the context of gynecologic malignancy and to
71975042|a|Recent studies have explored the complex interplay between N-Acetylglucosamine (O-GlcNAc) transferase and various chemical entities, including curcumin and antipyretic, in the context of disease progression and therapeutic response. A positive correlation was observed between N-Acetylglucosamine (O-GlcNAc) transferase and curcumin, suggesting a potential synergistic effect in modulating cellular pathways involved in inflammation and tumor suppression. Similarly, a positive correlation was found between N-Acetylglucosamine (O-GlcNAc) transferase and antipyretic, indicating a possible role in mitigating fever-related symptoms and inflammatory responses. However, a negative correlation was noted between antipyretic and toxicities, highlighting the need for careful dosing to avoid adverse effects. Additionally, a negative correlation was identified between Sch and experimental autoimmune encephalomyelitis, suggesting that Sch may have a protective role in autoimmune conditions.   The study also examined the impact of Allopurinol on angioedema and gynecologic malignancy, revealing a negative correlation between Allopurinol and both conditions, which may have implications for its use in patients with these disorders. Furthermore, the role of antipyretic in relation to angioedema was found to be negative, reinforcing the importance of monitoring for allergic reactions in patients receiving antipyretic therapy.   In the context of viral infections, the study included analyses of West Nile virus, Kilham rat virus, and tobacco, with particular attention to the interactions between these organisms and the chemical entities under investigation. The presence of ginseng and Spirulina was also noted, as these organisms may influence the metabolic pathways affected by the studied compounds.   Overall, the findings underscore the intricate relationships between N-Acetylglucosamine (O-GlcNAc) transferase, various chemical entities, and disease states, providing a foundation for future research into targeted therapeutic strategies for gynecologic malignancy and other conditions associated with toxicities.
71975042	0	42	N-Acetylglucosamine (O-GlcNAc) transferase	GeneOrGeneProduct	8473
71975042	61	69	curcumin	ChemicalEntity	D003474
71975042	71	82	antipyretic	ChemicalEntity	D058633
71975042	88	91	Sch	ChemicalEntity	D013390
71975042	110	132	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
71975042	199	241	N-Acetylglucosamine (O-GlcNAc) transferase	GeneOrGeneProduct	8473
71975042	283	291	curcumin	ChemicalEntity	D003474
71975042	296	307	antipyretic	ChemicalEntity	D058633
71975042	417	459	N-Acetylglucosamine (O-GlcNAc) transferase	GeneOrGeneProduct	8473
71975042	464	472	curcumin	ChemicalEntity	D003474
71975042	648	690	N-Acetylglucosamine (O-GlcNAc) transferase	GeneOrGeneProduct	8473
71975042	695	706	antipyretic	ChemicalEntity	D058633
71975042	850	861	antipyretic	ChemicalEntity	D058633
71975042	866	876	toxicities	DiseaseOrPhenotypicFeature	D064420
71975042	1005	1008	Sch	ChemicalEntity	D013390
71975042	1013	1054	experimental autoimmune encephalomyelitis	DiseaseOrPhenotypicFeature	D004681
71975042	1072	1075	Sch	ChemicalEntity	D013390
71975042	1169	1180	Allopurinol	ChemicalEntity	D000493
71975042	1184	1194	angioedema	DiseaseOrPhenotypicFeature	D000799
71975042	1199	1221	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
71975042	1264	1275	Allopurinol	ChemicalEntity	D000493
71975042	1396	1407	antipyretic	ChemicalEntity	D058633
71975042	1423	1433	angioedema	DiseaseOrPhenotypicFeature	D000799
71975042	1546	1557	antipyretic	ChemicalEntity	D058633
71975042	1636	1651	West Nile virus	OrganismTaxon	11082
71975042	1653	1669	Kilham rat virus	OrganismTaxon	12441
71975042	1675	1682	tobacco	OrganismTaxon	4097
71975042	1817	1824	ginseng	OrganismTaxon	4054
71975042	1829	1838	Spirulina	OrganismTaxon	551299
71975042	2017	2059	N-Acetylglucosamine (O-GlcNAc) transferase	GeneOrGeneProduct	8473
71975042	2192	2214	gynecologic malignancy	DiseaseOrPhenotypicFeature	D005833
71975042	2252	2262	toxicities	DiseaseOrPhenotypicFeature	D064420
71975042	Negative_Correlation	D013390	D004681	Novel
71975042	Positive_Correlation	8473	D003474	Novel
71975042	Positive_Correlation	8473	D058633	Novel
71975042	Negative_Correlation	D058633	D064420	Novel
71975042	Negative_Correlation	D000493	D000799	Novel
71975042	Negative_Correlation	D058633	D000799	Novel
71975042	Negative_Correlation	D000493	D005833	Novel

90918610|t|Paracetamol, Derp1, and Serpina 3g: Interactions in MH134 cells and their association with low-density lipoprotein me
90918610|a|This study investigates the complex interactions between paracetamol, Derp1, Serpina 3g, and low-density lipoprotein in the context of MH134 cell biology. Paracetamol, a widely used analgesic and antipyretic, was found to modulate the expression of Derp1 and Serpina 3g in MH134 cells. The negative correlation between Derp1 and Serpina 3g was consistently observed across multiple experimental conditions, suggesting a regulatory relationship where increased Derp1 expression is associated with decreased Serpina 3g levels.   Further analysis revealed that low-density lipoprotein exhibits a significant association with Serpina 3g, indicating a potential role for lipoprotein metabolism in the regulation of this gene. The association between Derp1 and Serpina 3g was also confirmed through co-expression studies, reinforcing the bidirectional relationship between these two gene products. Additionally, the association between Serpina 3g and Derp1 was further supported by functional assays, where changes in Serpina 3g expression influenced the activity of Derp1 in MH134 cells.  These findings highlight the intricate interplay between paracetamol, Derp1, Serpina 3g, and low-density lipoprotein in cellular processes. The study underscores the importance of understanding these molecular interactions for developing targeted therapeutic strategies in metabolic and inflammatory diseases.
90918610	13	18	Derp1	GeneOrGeneProduct	113791973
90918610	24	34	Serpina 3g	GeneOrGeneProduct	20715
90918610	52	57	MH134	CellLine	CVCL_8111
90918610	91	114	low-density lipoprotein	ChemicalEntity	D008077
90918610	175	186	paracetamol	ChemicalEntity	D000082
90918610	188	193	Derp1	GeneOrGeneProduct	113791973
90918610	195	205	Serpina 3g	GeneOrGeneProduct	20715
90918610	211	234	low-density lipoprotein	ChemicalEntity	D008077
90918610	253	258	MH134	CellLine	CVCL_8111
90918610	367	372	Derp1	GeneOrGeneProduct	113791973
90918610	377	387	Serpina 3g	GeneOrGeneProduct	20715
90918610	391	396	MH134	CellLine	CVCL_8111
90918610	437	442	Derp1	GeneOrGeneProduct	113791973
90918610	447	457	Serpina 3g	GeneOrGeneProduct	20715
90918610	578	583	Derp1	GeneOrGeneProduct	113791973
90918610	624	634	Serpina 3g	GeneOrGeneProduct	20715
90918610	676	699	low-density lipoprotein	ChemicalEntity	D008077
90918610	740	750	Serpina 3g	GeneOrGeneProduct	20715
90918610	863	868	Derp1	GeneOrGeneProduct	113791973
90918610	873	883	Serpina 3g	GeneOrGeneProduct	20715
90918610	1048	1058	Serpina 3g	GeneOrGeneProduct	20715
90918610	1063	1068	Derp1	GeneOrGeneProduct	113791973
90918610	1130	1140	Serpina 3g	GeneOrGeneProduct	20715
90918610	1179	1184	Derp1	GeneOrGeneProduct	113791973
90918610	1188	1193	MH134	CellLine	CVCL_8111
90918610	1259	1270	paracetamol	ChemicalEntity	D000082
90918610	1272	1277	Derp1	GeneOrGeneProduct	113791973
90918610	1279	1289	Serpina 3g	GeneOrGeneProduct	20715
90918610	1295	1318	low-density lipoprotein	ChemicalEntity	D008077
90918610	Negative_Correlation	113791973	20715	Novel
90918610	Association	D008077	20715	Novel
90918610	Association	113791973	20715	Novel
90918610	Association	20715	113791973	Novel

51424595|t|Genomic and cellular analyses of dup27bp, CAG repeat, and their associations with adenoid cystic carcinoma and ventriculomegaly in rhesus monkeys, chick, and Toxorynchites mo
51424595|a|This study investigates the molecular and cellular mechanisms underlying the associations between specific sequence variants, including dup27bp and CAG repeat, and disease phenotypes such as adenoid cystic carcinoma and ventriculomegaly. Using a combination of genomic, transcriptomic, and cellular approaches, we examined these associations in multiple model systems, including rhesus monkeys, chick, and Toxorynchites mosquitoes. The DUCaP cell line was used as a primary model for studying the effects of dup27bp and CAG repeat on cellular behavior, while the SNU-C5, LbetaT2, and Ba/F3 cell lines were employed to assess the functional consequences of these sequence variants in different cellular contexts. Our findings reveal a positive correlation between dup27bp and adenoid cystic carcinoma, as well as between dup27bp and ventriculomegaly. Additionally, we observed a strong association between adenoid cystic carcinoma and CAG repeat, with a positive correlation between CAG repeat and adenoid cystic carcinoma. The association between ventriculomegaly and CAG repeat, as well as between ventriculomegaly and dup27bp, was further supported by our data. These results suggest that dup27bp and CAG repeat may play critical roles in the pathogenesis of these diseases. The study also highlights the importance of using diverse model organisms, including rhesus monkeys, chick, and Toxorynchites mosquitoes, to better understand the genetic and cellular basis of these conditions. The DUCaP, SNU-C5, LbetaT2, and Ba/F3 cell lines were consistently used across multiple experiments to ensure reproducibility and robustness of the findings.
51424595	33	40	dup27bp	SequenceVariant	c|DUP||27|
51424595	42	52	CAG repeat	SequenceVariant	c|DUP||CAG|
51424595	82	106	adenoid cystic carcinoma	DiseaseOrPhenotypicFeature	D003528
51424595	111	127	ventriculomegaly	DiseaseOrPhenotypicFeature	D006849
51424595	131	145	rhesus monkeys	OrganismTaxon	9544
51424595	147	152	chick	OrganismTaxon	9031
51424595	311	318	dup27bp	SequenceVariant	c|DUP||27|
51424595	323	333	CAG repeat	SequenceVariant	c|DUP||CAG|
51424595	366	390	adenoid cystic carcinoma	DiseaseOrPhenotypicFeature	D003528
51424595	395	411	ventriculomegaly	DiseaseOrPhenotypicFeature	D006849
51424595	554	568	rhesus monkeys	OrganismTaxon	9544
51424595	570	575	chick	OrganismTaxon	9031
51424595	581	605	Toxorynchites mosquitoes	OrganismTaxon	2498889
51424595	611	616	DUCaP	CellLine	CVCL_2025
51424595	683	690	dup27bp	SequenceVariant	c|DUP||27|
51424595	695	705	CAG repeat	SequenceVariant	c|DUP||CAG|
51424595	738	744	SNU-C5	CellLine	CVCL_5112
51424595	746	753	LbetaT2	CellLine	CVCL_0398
51424595	759	764	Ba/F3	CellLine	CVCL_0161
51424595	938	945	dup27bp	SequenceVariant	c|DUP||27|
51424595	950	974	adenoid cystic carcinoma	DiseaseOrPhenotypicFeature	D003528
51424595	995	1002	dup27bp	SequenceVariant	c|DUP||27|
51424595	1007	1023	ventriculomegaly	DiseaseOrPhenotypicFeature	D006849
51424595	1080	1104	adenoid cystic carcinoma	DiseaseOrPhenotypicFeature	D003528
51424595	1109	1119	CAG repeat	SequenceVariant	c|DUP||CAG|
51424595	1157	1167	CAG repeat	SequenceVariant	c|DUP||CAG|
51424595	1172	1196	adenoid cystic carcinoma	DiseaseOrPhenotypicFeature	D003528
51424595	1222	1238	ventriculomegaly	DiseaseOrPhenotypicFeature	D006849
51424595	1243	1253	CAG repeat	SequenceVariant	c|DUP||CAG|
51424595	1274	1290	ventriculomegaly	DiseaseOrPhenotypicFeature	D006849
51424595	1295	1302	dup27bp	SequenceVariant	c|DUP||27|
51424595	1366	1373	dup27bp	SequenceVariant	c|DUP||27|
51424595	1378	1388	CAG repeat	SequenceVariant	c|DUP||CAG|
51424595	1537	1551	rhesus monkeys	OrganismTaxon	9544
51424595	1553	1558	chick	OrganismTaxon	9031
51424595	1564	1588	Toxorynchites mosquitoes	OrganismTaxon	2498889
51424595	1667	1672	DUCaP	CellLine	CVCL_2025
51424595	1674	1680	SNU-C5	CellLine	CVCL_5112
51424595	1682	1689	LbetaT2	CellLine	CVCL_0398
51424595	1695	1700	Ba/F3	CellLine	CVCL_0161
51424595	Positive_Correlation	c|DUP||27|	D003528	Novel
51424595	Positive_Correlation	c|DUP||27|	D006849	Novel
51424595	Association	D003528	c|DUP||CAG|	Novel
51424595	Association	D003528	c|DUP||27|	Novel
51424595	Positive_Correlation	c|DUP||CAG|	D003528	Novel
51424595	Association	D006849	c|DUP||CAG|	Novel
51424595	Association	D006849	c|DUP||27|	Novel
51424595	Positive_Correlation	c|DUP||CAG|	D006849	Novel

74168673|t|CXCL1, Purkinje cell atrophy associated protein-1, and MSH2: Interactions with sequence variants, cell lines, and chemical entities in Spirulina, Daucus carota, and Mangifera ind
74168673|a|This study investigates the molecular interactions and functional relationships between the gene CXCL1, the protein Purkinje cell atrophy associated protein-1, and the gene MSH2, in the context of various sequence variants, cell lines, and chemical entities. The research focuses on the interactions between these molecular entities in different biological systems, including Spirulina, Daucus carota, and Mangifera indica Linn.   The study reveals a positive correlation between the sequence variant Glu873Stop and caffeine, suggesting a potential pharmacological or physiological link. Additionally, corticosteroid and letrozole show a positive correlation, indicating possible synergistic or antagonistic effects in cellular processes. The protein Purkinje cell atrophy associated protein-1 binds to MSH2, and this interaction is further supported by an association between MSH2 and MSX1.   The gene MSH2 is also associated with the X-ray repair cross-complementing protein, and this association is reinforced by a direct binding interaction between MSH2 and MSX1. The sequence variant M 235 is found in association with MSH2, highlighting its potential role in gene function.   The drug interaction between 5,7-DHT and LAM is observed, and this is further supported by a positive correlation between LAM and Glu873Stop. The protein X-ray repair cross-complementing is found to bind with the Ragulator complex, and this complex is also associated with LAM.   The study also demonstrates a positive correlation between caffeine and 5,7-DHT, as well as a drug interaction between caffeine and 5,7-DHT. The chemical entity letrozole is found to interact with LAM, and corticosteroid shows a positive correlation with the sequence variant 30delG.   The gene CXCL1 is associated with Purkinje cell atrophy associated protein-1, and this association is further supported by the binding interaction between Purkinje cell atrophy associated protein-1 and MSX1. The study also includes the cell lines GT1-1, H9c2, and SNU-C5, which are used to model the interactions in different cellular contexts.   Overall, the findings provide a comprehensive view of the molecular interactions and functional relationships between these genes, proteins, sequence variants, cell lines, and chemical entities, offering insights into their potential roles in biological processes and disease mechanisms.
74168673	0	5	CXCL1	GeneOrGeneProduct	14825
74168673	7	49	Purkinje cell atrophy associated protein-1	GeneOrGeneProduct	25894
74168673	55	59	MSH2	GeneOrGeneProduct	4436
74168673	135	144	Spirulina	OrganismTaxon	551299
74168673	146	159	Daucus carota	OrganismTaxon	4039
74168673	276	281	CXCL1	GeneOrGeneProduct	14825
74168673	295	337	Purkinje cell atrophy associated protein-1	GeneOrGeneProduct	25894
74168673	352	356	MSH2	GeneOrGeneProduct	4436
74168673	555	564	Spirulina	OrganismTaxon	551299
74168673	566	579	Daucus carota	OrganismTaxon	4039
74168673	585	606	Mangifera indica Linn	OrganismTaxon	29780
74168673	680	690	Glu873Stop	SequenceVariant	rs121918047
74168673	695	703	caffeine	ChemicalEntity	D002110
74168673	781	795	corticosteroid	ChemicalEntity	D000305
74168673	800	809	letrozole	ChemicalEntity	C067431
74168673	930	972	Purkinje cell atrophy associated protein-1	GeneOrGeneProduct	25894
74168673	982	986	MSH2	GeneOrGeneProduct	4436
74168673	1056	1060	MSH2	GeneOrGeneProduct	4436
74168673	1065	1069	MSX1	GeneOrGeneProduct	4487
74168673	1082	1086	MSH2	GeneOrGeneProduct	4436
74168673	1115	1147	X-ray repair cross-complementing	GeneOrGeneProduct	7515
74168673	1232	1236	MSH2	GeneOrGeneProduct	4436
74168673	1241	1245	MSX1	GeneOrGeneProduct	4487
74168673	1268	1273	M 235	SequenceVariant	p|Allele|M|235
74168673	1303	1307	MSH2	GeneOrGeneProduct	4436
74168673	1390	1397	5,7-DHT	ChemicalEntity	D015116
74168673	1402	1405	LAM	ChemicalEntity	D019259
74168673	1483	1486	LAM	ChemicalEntity	D019259
74168673	1491	1501	Glu873Stop	SequenceVariant	rs121918047
74168673	1515	1547	X-ray repair cross-complementing	GeneOrGeneProduct	7515
74168673	1574	1591	Ragulator complex	GeneOrGeneProduct	295234
74168673	1634	1637	LAM	ChemicalEntity	D019259
74168673	1700	1708	caffeine	ChemicalEntity	D002110
74168673	1713	1720	5,7-DHT	ChemicalEntity	D015116
74168673	1760	1768	caffeine	ChemicalEntity	D002110
74168673	1773	1780	5,7-DHT	ChemicalEntity	D015116
74168673	1802	1811	letrozole	ChemicalEntity	C067431
74168673	1838	1841	LAM	ChemicalEntity	D019259
74168673	1847	1861	corticosteroid	ChemicalEntity	D000305
74168673	1917	1923	30delG	SequenceVariant	c|DEL|30|G
74168673	1936	1941	CXCL1	GeneOrGeneProduct	14825
74168673	1961	2003	Purkinje cell atrophy associated protein-1	GeneOrGeneProduct	25894
74168673	2082	2124	Purkinje cell atrophy associated protein-1	GeneOrGeneProduct	25894
74168673	2129	2133	MSX1	GeneOrGeneProduct	4487
74168673	2174	2179	GT1-1	CellLine	CVCL_6236
74168673	2181	2185	H9c2	CellLine	CVCL_0286
74168673	2191	2197	SNU-C5	CellLine	CVCL_5112
74168673	Positive_Correlation	rs121918047	D002110	Novel
74168673	Positive_Correlation	D000305	C067431	Novel
74168673	Bind	25894	4436	Novel
74168673	Association	4436	7515	Novel
74168673	Drug_Interaction	D015116	D019259	Novel
74168673	Bind	7515	295234	Novel
74168673	Bind	25894	4487	Novel
74168673	Positive_Correlation	D019259	rs121918047	Novel
74168673	Association	14825	25894	Novel
74168673	Bind	4436	4487	Novel
74168673	Positive_Correlation	D000305	c|DEL|30|G	Novel
74168673	Positive_Correlation	D015116	C067431	Novel
74168673	Association	295234	D019259	Novel
74168673	Association	4436	D015116	Novel
74168673	Association	4487	4436	Novel
74168673	Drug_Interaction	C067431	D019259	Novel
74168673	Positive_Correlation	D002110	D015116	Novel
74168673	Association	25894	4436	Novel
74168673	Association	25894	4487	Novel
74168673	Drug_Interaction	D002110	D015116	Novel

97758589|t|CD133, AMP-alpha2 protein kinase, and snail: complex interactions in NSCLC and their implications for immunodeficiency in ginseng and Mangifera ind
97758589|a|Recent studies have highlighted the intricate relationships between CD133, AMP-alpha2 protein kinase, and snail in the context of NSCLC and immunodeficiency. This research explores the molecular mechanisms underlying these interactions, particularly focusing on the negative correlation between CD133 and both AMP-alpha2 protein kinase and snail, as well as the positive correlation between CD133 and NSCLC and immunodeficiency. Additionally, the negative correlation between AMP-alpha2 protein kinase and snail, along with the positive correlation between AMP-alpha2 protein kinase and NSCLC and immunodeficiency, suggests a complex regulatory network. The study also investigates the role of A6V sequence variants in these interactions, particularly in the context of ginseng and Mangifera indica Linn. Using Mz-ChA-1 cell lines, the research demonstrates that A6V variants in CD133 and AMP-alpha2 protein kinase significantly influence their expression levels and functional outcomes. These findings provide new insights into the molecular basis of NSCLC and immunodeficiency, with potential applications in the development of targeted therapies. The results emphasize the importance of understanding the interplay between these genes and their variants in both human and plant models, such as ginseng and Mangifera indica Linn, to uncover novel therapeutic strategies.
97758589	0	5	CD133	GeneOrGeneProduct	8842
97758589	7	32	AMP-alpha2 protein kinase	GeneOrGeneProduct	65248
97758589	38	43	snail	GeneOrGeneProduct	20613
97758589	69	74	NSCLC	DiseaseOrPhenotypicFeature	D002289
97758589	102	118	immunodeficiency	DiseaseOrPhenotypicFeature	D007153
97758589	122	129	ginseng	OrganismTaxon	4054
97758589	216	221	CD133	GeneOrGeneProduct	8842
97758589	223	248	AMP-alpha2 protein kinase	GeneOrGeneProduct	65248
97758589	254	259	snail	GeneOrGeneProduct	20613
97758589	278	283	NSCLC	DiseaseOrPhenotypicFeature	D002289
97758589	288	304	immunodeficiency	DiseaseOrPhenotypicFeature	D007153
97758589	443	448	CD133	GeneOrGeneProduct	8842
97758589	458	483	AMP-alpha2 protein kinase	GeneOrGeneProduct	65248
97758589	488	493	snail	GeneOrGeneProduct	20613
97758589	539	544	CD133	GeneOrGeneProduct	8842
97758589	549	554	NSCLC	DiseaseOrPhenotypicFeature	D002289
97758589	559	575	immunodeficiency	DiseaseOrPhenotypicFeature	D007153
97758589	624	649	AMP-alpha2 protein kinase	GeneOrGeneProduct	65248
97758589	654	659	snail	GeneOrGeneProduct	20613
97758589	705	730	AMP-alpha2 protein kinase	GeneOrGeneProduct	65248
97758589	735	740	NSCLC	DiseaseOrPhenotypicFeature	D002289
97758589	745	761	immunodeficiency	DiseaseOrPhenotypicFeature	D007153
97758589	842	845	A6V	SequenceVariant	rs199922907
97758589	918	925	ginseng	OrganismTaxon	4054
97758589	930	951	Mangifera indica Linn	OrganismTaxon	29780
97758589	959	967	Mz-ChA-1	CellLine	CVCL_6932
97758589	1011	1014	A6V	SequenceVariant	rs199922907
97758589	1027	1032	CD133	GeneOrGeneProduct	8842
97758589	1037	1062	AMP-alpha2 protein kinase	GeneOrGeneProduct	65248
97758589	1200	1205	NSCLC	DiseaseOrPhenotypicFeature	D002289
97758589	1210	1226	immunodeficiency	DiseaseOrPhenotypicFeature	D007153
97758589	1445	1452	ginseng	OrganismTaxon	4054
97758589	1457	1478	Mangifera indica Linn	OrganismTaxon	29780
97758589	Negative_Correlation	20613	8842	Novel
97758589	Negative_Correlation	65248	8842	Novel
97758589	Positive_Correlation	8842	D007153	Novel
97758589	Positive_Correlation	65248	D002289	Novel
97758589	Negative_Correlation	8842	65248	Novel
97758589	Negative_Correlation	65248	20613	Novel
97758589	Negative_Correlation	8842	20613	Novel
97758589	Positive_Correlation	8842	D002289	Novel
97758589	Positive_Correlation	20613	D002289	Novel
97758589	Positive_Correlation	65248	D007153	Novel

99607325|t|Genetic variants in the R246W and c.1627A>T regions: associations with sequence variants and cell line responses in rabbit and murin
99607325|a|This study investigates the functional and genetic associations between the sequence variants R246W, c.1627A>T, and 217_218insC in the context of rabbit and murine models. The research focuses on the interactions between these variants and their implications in cellular responses across multiple cell lines, including MC3T3-E1, HCT116, and Ba/F3.   The findings reveal a significant association between R246W and both c.1627A>T and 217_218insC, suggesting a potential functional link between these variants. Additionally, c.1627A>T is found to be associated with 217_218insC, reinforcing the interconnected nature of these genetic elements. The study also demonstrates that 217_218insC is associated with both R246W and c.1627A>T, highlighting the complex genetic network involving these variants.   The research further explores the impact of these variants in different organisms, including the rabbit and Murine species, as well as the Kilham rat virus. The results indicate that the presence of these sequence variants may influence cellular behavior in various contexts, particularly in the MC3T3-E1, HCT116, and Ba/F3 cell lines. The study underscores the importance of understanding the interplay between these genetic elements in both human and animal models, with implications for disease mechanisms and therapeutic strategies.
99607325	24	29	R246W	SequenceVariant	rs121434244
99607325	34	43	c.1627A>T	SequenceVariant	c|SUB|A|1627|T
99607325	116	122	rabbit	OrganismTaxon	9986
99607325	227	232	R246W	SequenceVariant	rs121434244
99607325	234	243	c.1627A>T	SequenceVariant	c|SUB|A|1627|T
99607325	249	260	217_218insC	SequenceVariant	c|INS|217_218|C
99607325	279	285	rabbit	OrganismTaxon	9986
99607325	452	460	MC3T3-E1	CellLine	CVCL_0409
99607325	462	468	HCT116	CellLine	CVCL_0291
99607325	474	479	Ba/F3	CellLine	CVCL_0161
99607325	537	542	R246W	SequenceVariant	rs121434244
99607325	552	561	c.1627A>T	SequenceVariant	c|SUB|A|1627|T
99607325	566	577	217_218insC	SequenceVariant	c|INS|217_218|C
99607325	656	665	c.1627A>T	SequenceVariant	c|SUB|A|1627|T
99607325	697	708	217_218insC	SequenceVariant	c|INS|217_218|C
99607325	808	819	217_218insC	SequenceVariant	c|INS|217_218|C
99607325	844	849	R246W	SequenceVariant	rs121434244
99607325	854	863	c.1627A>T	SequenceVariant	c|SUB|A|1627|T
99607325	1031	1037	rabbit	OrganismTaxon	9986
99607325	1042	1048	Murine	OrganismTaxon	10090
99607325	1073	1089	Kilham rat virus	OrganismTaxon	12441
99607325	1230	1238	MC3T3-E1	CellLine	CVCL_0409
99607325	1240	1246	HCT116	CellLine	CVCL_0291
99607325	1252	1257	Ba/F3	CellLine	CVCL_0161
99607325	Association	rs121434244	c|INS|217_218|C	Novel
99607325	Association	rs121434244	c|SUB|A|1627|T	Novel
99607325	Association	c|SUB|A|1627|T	c|INS|217_218|C	Novel
99607325	Association	c|INS|217_218|C	c|SUB|A|1627|T	Novel
99607325	Association	c|INS|217_218|C	rs121434244	Novel
99607325	Association	c|SUB|A|1627|T	rs121434244	Novel

71965536|t|Genetic and pharmacological insights into inherited bleeding disorder, bladder dysfunction, and cardiovascular phenotypes in multiple
71965536|a|This study investigates the genetic and pharmacological underpinnings of inherited bleeding disorder, bladder dysfunction, and cardiovascular phenotypes across multiple species, including humans, rats, dogs, and rhesus monkeys. A comprehensive analysis of sequence variants and their associations with disease phenotypes was conducted. The nine nucleotide insertion was found to be associated with fluoxetine treatment, suggesting a potential pharmacogenetic interaction. Additionally, the sequence variant c.1151C>A was associated with rilmenidine, highlighting a possible therapeutic target for managing inherited bleeding disorder.   The sequence variant G12D exhibited a negative correlation with bladder dysfunction, indicating a protective effect against this phenotype. Estrone-3-sulfate was found to be associated with G12D, suggesting a potential metabolic or signaling pathway link. The sequence variant p.P230R showed a negative correlation with tachycardia, implying a possible role in cardiac regulation.   In humans, the gene DBH was found to have a negative correlation with inherited bleeding disorder, suggesting a functional relationship between DBH and the pathophysiology of this condition. Furthermore, the gene Epo was associated with the sequence variant c.1092 +1G>A, and the gene crumbs was linked to the sequence variant c.695T>A. These findings underscore the complex interplay between genetic variants, gene products, and phenotypic outcomes across different species. The study also highlights the importance of cross-species comparisons in understanding the molecular mechanisms underlying these conditions.
71965536	42	69	inherited bleeding disorder	DiseaseOrPhenotypicFeature	D025861
71965536	71	90	bladder dysfunction	DiseaseOrPhenotypicFeature	D001745
71965536	207	234	inherited bleeding disorder	DiseaseOrPhenotypicFeature	D025861
71965536	236	255	bladder dysfunction	DiseaseOrPhenotypicFeature	D001745
71965536	322	327	human	OrganismTaxon	9606
71965536	330	333	rat	OrganismTaxon	10116
71965536	336	340	dogs	OrganismTaxon	9615
71965536	346	360	rhesus monkeys	OrganismTaxon	9544
71965536	474	499	nine nucleotide insertion	SequenceVariant	c|INS||9
71965536	532	542	fluoxetine	ChemicalEntity	D005473
71965536	641	650	c.1151C>A	SequenceVariant	c|SUB|C|1151|A
71965536	671	682	rilmenidine	ChemicalEntity	C032302
71965536	740	767	inherited bleeding disorder	DiseaseOrPhenotypicFeature	D025861
71965536	792	796	G12D	SequenceVariant	rs121913529
71965536	835	854	bladder dysfunction	DiseaseOrPhenotypicFeature	D001745
71965536	961	965	G12D	SequenceVariant	rs121913529
71965536	1048	1055	p.P230R	SequenceVariant	p|SUB|P|230|R
71965536	1091	1102	tachycardia	DiseaseOrPhenotypicFeature	D013610
71965536	1157	1162	human	OrganismTaxon	9606
71965536	1174	1177	DBH	GeneOrGeneProduct	13166
71965536	1224	1251	inherited bleeding disorder	DiseaseOrPhenotypicFeature	D025861
71965536	1298	1301	DBH	GeneOrGeneProduct	13166
71965536	1367	1370	Epo	GeneOrGeneProduct	13856
71965536	1412	1424	c.1092 +1G>A	SequenceVariant	c|SUB|G|1092+1|A
71965536	1439	1445	crumbs	GeneOrGeneProduct	42896
71965536	1481	1489	c.695T>A	SequenceVariant	c|SUB|T|695|A
71965536	Negative_Correlation	rs121913529	D001745	Novel
71965536	Association	C032302	c|SUB|C|1151|A	Novel
71965536	Association	C017296	rs121913529	Novel
71965536	Association	D005473	c|INS||9	Novel
71965536	Negative_Correlation	p|SUB|P|230|R	D013610	Novel
71965536	Association	D025861	D005473	Novel
71965536	Negative_Correlation	13166	D025861	Novel

22748915|t|Genetic variants, gene expression, and disease associations in Aedes mosquitoes and human ce
22748915|a|This study investigates the complex interplay between genetic variants, gene expression, and disease phenotypes in both Aedes mosquitoes and human cell lines. A key focus is on the sequence variant rs1800734, which is associated with multiple genes and disease features. rs1800734 shows a significant association with the gene SPO11, as well as with collagen, suggesting a potential role in structural and functional pathways. Additionally, rs1800734 is linked to the gene PrlR, which is further associated with hyperthyroidism. These findings highlight the importance of rs1800734 in modulating gene expression and disease susceptibility.   Collagen is also directly associated with hyperthyroidism, indicating a possible role in the pathophysiology of this condition. The gene NDE1 is found to be associated with hyperthyroidism, reinforcing the genetic complexity of this disease. Furthermore, the gene SPO11 is linked to hyperthyroidism, suggesting a broader network of genetic interactions.   The study also examines the expression of these genes in various cell lines, including Hs578T and Ishikawa. The Ishikawa cell line, in particular, is used to model the effects of these genetic variants on cellular processes. The Hs578T cell line is employed to study the interactions between collagen and other genes in the context of disease.   The research further explores the role of bacteria in modulating these genetic associations, with four instances of the organism taxon 'bacteria' indicating their potential influence on gene expression and disease outcomes. The findings suggest that the interplay between genetic variants, gene products, and environmental factors such as bacteria may contribute to the development and progression of hyperthyroidism.   Overall, this study provides a comprehensive analysis of the genetic and molecular mechanisms underlying hyperthyroidism, with implications for both basic research and clinical applications.
22748915	63	79	Aedes mosquitoes	OrganismTaxon	1245352
22748915	213	229	Aedes mosquitoes	OrganismTaxon	1245352
22748915	291	300	rs1800734	SequenceVariant	rs1800734
22748915	364	373	rs1800734	SequenceVariant	rs1800734
22748915	420	425	SPO11	GeneOrGeneProduct	856364
22748915	443	451	collagen	GeneOrGeneProduct	12842
22748915	534	543	rs1800734	SequenceVariant	rs1800734
22748915	566	570	PrlR	GeneOrGeneProduct	19116
22748915	605	620	hyperthyroidism	DiseaseOrPhenotypicFeature	D006980
22748915	665	674	rs1800734	SequenceVariant	rs1800734
22748915	777	792	hyperthyroidism	DiseaseOrPhenotypicFeature	D006980
22748915	872	876	NDE1	GeneOrGeneProduct	54820
22748915	908	923	hyperthyroidism	DiseaseOrPhenotypicFeature	D006980
22748915	999	1004	SPO11	GeneOrGeneProduct	856364
22748915	1018	1033	hyperthyroidism	DiseaseOrPhenotypicFeature	D006980
22748915	1178	1184	Hs578T	CellLine	CVCL_0332
22748915	1189	1197	Ishikawa	CellLine	CVCL_2529
22748915	1203	1211	Ishikawa	CellLine	CVCL_2529
22748915	1320	1326	Hs578T	CellLine	CVCL_0332
22748915	1383	1391	collagen	GeneOrGeneProduct	12842
22748915	1479	1487	bacteria	OrganismTaxon	2
22748915	1573	1581	bacteria	OrganismTaxon	2
22748915	1776	1784	bacteria	OrganismTaxon	2
22748915	1838	1853	hyperthyroidism	DiseaseOrPhenotypicFeature	D006980
22748915	1962	1977	hyperthyroidism	DiseaseOrPhenotypicFeature	D006980
22748915	Association	rs1800734	856364	Novel
22748915	Association	rs1800734	12842	Novel
22748915	Association	19116	D006980	Novel
22748915	Association	54820	D006980	Novel
22748915	Association	rs1800734	19116	Novel
22748915	Association	12842	D006980	Novel
22748915	Association	856364	D006980	Novel

42174782|t|Letrozole and losartan interactions with RAD51, GALT, and other molecular targets in metabolic and neurological 
42174782|a|This study investigates the molecular interactions between letrozole and losartan, two pharmacological agents with diverse therapeutic applications, and their associations with key molecular targets such as RAD51, GALT, and the serotonin transporter. The research highlights the conversion between letrozole and losartan, suggesting potential pharmacodynamic cross-talk in metabolic pathways. Additionally, the study identifies an association between RAD51 and VAL, indicating a possible role for VAL in DNA repair mechanisms. The conversion between VAL and Cyclooxygenase inhibitors is further explored, suggesting a regulatory link between these compounds in inflammatory responses.   GALT is found to be associated with VAL, potentially implicating this gene in metabolic processes involving amino acid metabolism. The conversion between norepinephrine and sarcoplasmic reticulum Ca2+ -ATPase is demonstrated, highlighting a potential role for norepinephrine in calcium homeostasis. The sarcoplasmic reticulum Ca2+ -ATPase is also shown to convert to malonic acid, suggesting a metabolic pathway involving mitochondrial function. Malonic acid, in turn, is converted to GSH, indicating a role in redox regulation and cellular protection.  The association between the low-density lipoprotein receptor and Mg+2 ATPase is examined, providing insights into lipid metabolism and cellular energy dynamics. The muscarinic cholinergic system is found to be associated with malonic acid, suggesting a potential link between cholinergic signaling and metabolic regulation.   The study also includes a comprehensive analysis of sequence variants, including 111G, 2172_2173insCCCC, rs11798018, V876E, rs17250932, dup24bp, C111G (twice), IVS3+1G>A (twice), and R246W (twice), which are associated with various gene products such as GALT, serotonin transporter, nephrin, transferrin receptor 2, c-Jun N-terminal kinase, and RAD51. These variants are linked to functional changes, including the substitution of asparagine 86 for alanine and the elimination of amino acids 87, 88, and 89 (arginine, threonine, and proline).   Finally, the conversion between Cyclooxygenase inhibitors and opioid peptides is demonstrated, suggesting a potential role for these compounds in pain modulation and inflammatory responses. The findings provide a framework for understanding the complex interplay between chemical entities, gene products, and sequence variants in metabolic and neurological pathways.
42174782	14	22	losartan	ChemicalEntity	D019808
42174782	41	46	RAD51	GeneOrGeneProduct	5888
42174782	48	52	GALT	GeneOrGeneProduct	2592
42174782	172	181	letrozole	ChemicalEntity	C067431
42174782	186	194	losartan	ChemicalEntity	D019808
42174782	320	325	RAD51	GeneOrGeneProduct	5888
42174782	327	331	GALT	GeneOrGeneProduct	2592
42174782	341	362	serotonin transporter	GeneOrGeneProduct	15567
42174782	411	420	letrozole	ChemicalEntity	C067431
42174782	425	433	losartan	ChemicalEntity	D019808
42174782	564	569	RAD51	GeneOrGeneProduct	5888
42174782	574	577	VAL	ChemicalEntity	C081489
42174782	610	613	VAL	ChemicalEntity	C081489
42174782	663	666	VAL	ChemicalEntity	C081489
42174782	671	696	Cyclooxygenase inhibitors	ChemicalEntity	D016861
42174782	800	804	GALT	GeneOrGeneProduct	2592
42174782	836	839	VAL	ChemicalEntity	C081489
42174782	954	968	norepinephrine	ChemicalEntity	D009638
42174782	960	967	nephrin	GeneOrGeneProduct	64563
42174782	1060	1074	norepinephrine	ChemicalEntity	D009638
42174782	1066	1073	nephrin	GeneOrGeneProduct	64563
42174782	1167	1179	malonic acid	ChemicalEntity	C030290
42174782	1285	1288	GSH	ChemicalEntity	D005978
42174782	1382	1414	low-density lipoprotein receptor	GeneOrGeneProduct	3949
42174782	1419	1430	Mg+2 ATPase	ChemicalEntity	D017301
42174782	1519	1541	muscarinic cholinergic	GeneOrGeneProduct	25229
42174782	1580	1592	malonic acid	ChemicalEntity	C030290
42174782	1761	1765	111G	SequenceVariant	c|Allele|G|111
42174782	1767	1783	2172_2173insCCCC	SequenceVariant	c|INS|2172_2173|CCCC
42174782	1785	1795	rs11798018	SequenceVariant	rs11798018
42174782	1797	1802	V876E	SequenceVariant	rs267606698
42174782	1804	1814	rs17250932	SequenceVariant	rs17250932
42174782	1816	1823	dup24bp	SequenceVariant	c|DUP||24|
42174782	1825	1830	C111G	SequenceVariant	c|SUB|C|111|G
42174782	1826	1830	111G	SequenceVariant	c|Allele|G|111
42174782	1840	1849	IVS3+1G>A	SequenceVariant	c|SUB|G|IVS3+1|A
42174782	1863	1868	R246W	SequenceVariant	rs121434244
42174782	1934	1938	GALT	GeneOrGeneProduct	2592
42174782	1940	1961	serotonin transporter	GeneOrGeneProduct	15567
42174782	1963	1970	nephrin	GeneOrGeneProduct	64563
42174782	1972	1994	transferrin receptor 2	GeneOrGeneProduct	7036
42174782	1996	2019	c-Jun N-terminal kinase	GeneOrGeneProduct	116554
42174782	2025	2030	RAD51	GeneOrGeneProduct	5888
42174782	2257	2282	Cyclooxygenase inhibitors	ChemicalEntity	D016861
42174782	2287	2302	opioid peptides	ChemicalEntity	D018847
42174782	Association	5888	C081489	Novel
42174782	Conversion	C081489	D016861	Novel
42174782	Conversion	C067431	D019808	Novel
42174782	Association	2592	C081489	Novel
42174782	Conversion	D009638	D053498	Novel
42174782	Conversion	D053498	C030290	Novel
42174782	Conversion	D016861	D018847	Novel
42174782	Conversion	C030290	D005978	Novel
42174782	Association	3949	D017301	Novel
42174782	Association	25229	C030290	Novel

48721118|t|Genetic and pharmacological interactions of rilmenidine, alendronate, and aminoglycosides in iron deficiency and hypoxia-related pat
48721118|a|Recent studies have explored the complex interplay between genetic variants, pharmacological agents, and disease states in the context of iron deficiency and hypoxia. This research focuses on the associations between the sequence variant P163S and the drug rilmenidine, which was found to exhibit a positive correlation with iron deficiency. Additionally, the chemical entity alendronate showed a positive correlation with both iron deficiency and STS, as well as a positive correlation with hypoxia. The aminoglycoside class of drugs was also found to have a positive correlation with iron deficiency and hypoxia, suggesting a potential synergistic effect in these conditions. The sequence variant 338G>A was associated with rilmenidine, further highlighting the genetic underpinnings of drug response. The cell line HK2 was used to model the effects of these compounds on iron homeostasis, while MC3T3-E1, PA-1, and hRPTEC were employed to study their impact on cellular responses under hypoxic conditions. Bisphosphonates, including alendronate, were found to have a positive correlation with hypoxia, reinforcing their role in modulating cellular metabolism in low-oxygen environments. The sequence variant C262 was also linked to the pharmacological response to bisphosphonates, indicating a potential genetic basis for variability in drug efficacy. These findings underscore the importance of understanding the molecular mechanisms underlying the interactions between genetic factors, pharmacological agents, and disease states in the context of iron deficiency and hypoxia-related disorders.
48721118	44	55	rilmenidine	ChemicalEntity	C032302
48721118	57	68	alendronate	ChemicalEntity	D019386
48721118	74	88	aminoglycoside	ChemicalEntity	D000617
48721118	93	108	iron deficiency	DiseaseOrPhenotypicFeature	D018798
48721118	113	120	hypoxia	DiseaseOrPhenotypicFeature	D000860
48721118	271	286	iron deficiency	DiseaseOrPhenotypicFeature	D018798
48721118	291	298	hypoxia	DiseaseOrPhenotypicFeature	D000860
48721118	371	376	P163S	SequenceVariant	rs387906769
48721118	390	401	rilmenidine	ChemicalEntity	C032302
48721118	458	473	iron deficiency	DiseaseOrPhenotypicFeature	D018798
48721118	509	520	alendronate	ChemicalEntity	D019386
48721118	561	576	iron deficiency	DiseaseOrPhenotypicFeature	D018798
48721118	581	584	STS	DiseaseOrPhenotypicFeature	D012509
48721118	625	632	hypoxia	DiseaseOrPhenotypicFeature	D000860
48721118	638	652	aminoglycoside	ChemicalEntity	D000617
48721118	719	734	iron deficiency	DiseaseOrPhenotypicFeature	D018798
48721118	739	746	hypoxia	DiseaseOrPhenotypicFeature	D000860
48721118	832	838	338G>A	SequenceVariant	rs768372697
48721118	859	870	rilmenidine	ChemicalEntity	C032302
48721118	951	954	HK2	CellLine	CVCL_0302
48721118	1031	1039	MC3T3-E1	CellLine	CVCL_0409
48721118	1041	1045	PA-1	CellLine	CVCL_0479
48721118	1051	1057	hRPTEC	CellLine	CVCL_K278
48721118	1169	1180	alendronate	ChemicalEntity	D019386
48721118	1229	1236	hypoxia	DiseaseOrPhenotypicFeature	D000860
48721118	1344	1348	C262	SequenceVariant	c|Aelle|C|262
48721118	1400	1415	bisphosphonates	ChemicalEntity	D004164
48721118	1685	1700	iron deficiency	DiseaseOrPhenotypicFeature	D018798
48721118	1705	1712	hypoxia	DiseaseOrPhenotypicFeature	D000860
48721118	Positive_Correlation	C032302	D018798	Novel
48721118	Positive_Correlation	D018798	D019386	Novel
48721118	Positive_Correlation	D000617	D018798	Novel
48721118	Positive_Correlation	D004164	D000860	Novel
48721118	Positive_Correlation	D000860	D000617	Novel
48721118	Positive_Correlation	D018798	D004164	Novel
48721118	Positive_Correlation	D018798	D000617	Novel
48721118	Positive_Correlation	D019386	D012509	Novel
48721118	Association	rs768372697	C032302	Novel
48721118	Positive_Correlation	D019386	D000860	Novel

16115465|t|X-ray repair cross-complementing gene variants and their associations with sequence alterations in dogs and mouse mammary tum
16115465|a|The X-ray repair cross-complementing (XRCC) gene plays a critical role in DNA repair mechanisms, particularly in the context of double-strand break repair. This study investigates the functional and phenotypic consequences of specific sequence variants in the XRCC gene across multiple species, including dogs and mouse mammary tumor virus (MMTV). We identified three instances of the sequence variant c.1546_1547insC, which was found to be associated with both the frameshift variant P686fs and the missense variant A190T. These associations were confirmed through in silico modeling and experimental validation using cell lines derived from dogs. Additionally, the sequence variant 5.5 kb deletion was found to co-occur with A190T, suggesting a potential functional link between these two variants. The A190T variant was also observed in conjunction with c.1546_1547insC, reinforcing the hypothesis that these sequence alterations may act synergistically in modulating the expression and function of the XRCC gene. In horses, we observed two instances of the A190T variant, which was not associated with the 5.5 kb deletion. The study also included five instances of the sequence variant p.T286M, which was found to be present in both dogs and MMTV, but not in horses. These findings highlight the complex interplay between different sequence variants in the XRCC gene and their potential impact on DNA repair efficiency across species. Further research is needed to elucidate the precise molecular mechanisms underlying these associations.
16115465	0	32	X-ray repair cross-complementing	GeneOrGeneProduct	7515
16115465	99	103	dogs	OrganismTaxon	9615
16115465	130	162	X-ray repair cross-complementing	GeneOrGeneProduct	7515
16115465	431	435	dogs	OrganismTaxon	9615
16115465	440	465	mouse mammary tumor virus	OrganismTaxon	11757
16115465	528	543	c.1546_1547insC	SequenceVariant	c|INS|1546_1547|C
16115465	611	617	P686fs	SequenceVariant	p|FS|P|686||
16115465	643	648	A190T	SequenceVariant	rs550921485
16115465	769	773	dogs	OrganismTaxon	9615
16115465	810	825	5.5 kb deletion	SequenceVariant	c|DEL||5.5K
16115465	853	858	A190T	SequenceVariant	rs550921485
16115465	931	936	A190T	SequenceVariant	rs550921485
16115465	983	998	c.1546_1547insC	SequenceVariant	c|INS|1546_1547|C
16115465	1146	1152	horses	OrganismTaxon	9796
16115465	1187	1192	A190T	SequenceVariant	rs550921485
16115465	1236	1251	5.5 kb deletion	SequenceVariant	c|DEL||5.5K
16115465	1316	1323	p.T286M	SequenceVariant	rs193302860
16115465	1363	1367	dogs	OrganismTaxon	9615
16115465	1389	1395	horses	OrganismTaxon	9796
16115465	Association	c|INS|1546_1547|C	p|FS|P|686||	Novel
16115465	Association	c|INS|1546_1547|C	rs550921485	Novel
16115465	Association	c|DEL||5.5K	rs550921485	Novel
16115465	Association	rs550921485	c|DEL||5.5K	Novel
16115465	Association	rs550921485	c|INS|1546_1547|C	Novel

64272231|t|Dopaminergic drug effects on Hypoxia in Toxorynchites mosquitoes: interactions with NF-kappaB and the role of cell lines in hereditary 
64272231|a|Recent studies have explored the complex interplay between dopaminergic drugs, Hypoxia, and genetic factors in Toxorynchites mosquitoes. Researchers have demonstrated that exposure to dopaminergic drugs significantly modulates Hypoxia-related pathways, with a notable negative correlation observed between bupivacaine and Hypoxia levels in experimental models. This finding suggests that bupivacaine may act as a protective agent against Hypoxia-induced cellular stress in these organisms.   The role of NF-kappaB in mediating these effects has been extensively investigated, with multiple studies showing that NF-kappaB activation is both necessary and sufficient for the transcriptional response to Hypoxia. This pathway appears to be conserved across various species, including Drosophila, which has been used as a model system to study the molecular mechanisms underlying Hypoxia tolerance.   In parallel, the impact of hereditary diseases on cellular responses to Hypoxia has been examined using a range of cell lines, including DUCaP, BALB/c, and Capan1. These cell lines have been shown to exhibit distinct patterns of gene expression and signaling activation under Hypoxia conditions, highlighting the importance of genetic background in determining cellular resilience.   Interestingly, the presence of dibucaine and d-myo-inositol 1,4,5-trisphosphate has been found to modulate the activity of NF-kappaB in a dose-dependent manner, further complicating the relationship between Hypoxia and genetic factors. Additionally, the study of Hamel cerebropalatocardiac syndrome in Drosophila has provided insights into the broader implications of Hypoxia-related pathways in neurodevelopmental disorders.   These findings underscore the intricate relationship between chemical entities, genetic factors, and environmental stressors in shaping cellular responses to Hypoxia, with significant implications for both basic research and clinical applications.
64272231	29	36	Hypoxia	DiseaseOrPhenotypicFeature	D000860
64272231	40	64	Toxorynchites mosquitoes	OrganismTaxon	2498889
64272231	84	93	NF-kappaB	GeneOrGeneProduct	81736
64272231	195	212	dopaminergic drug	ChemicalEntity	D004298
64272231	215	222	Hypoxia	DiseaseOrPhenotypicFeature	D000860
64272231	247	271	Toxorynchites mosquitoes	OrganismTaxon	2498889
64272231	320	337	dopaminergic drug	ChemicalEntity	D004298
64272231	363	370	Hypoxia	DiseaseOrPhenotypicFeature	D000860
64272231	442	453	bupivacaine	ChemicalEntity	D002045
64272231	458	465	Hypoxia	DiseaseOrPhenotypicFeature	D000860
64272231	524	535	bupivacaine	ChemicalEntity	D002045
64272231	574	581	Hypoxia	DiseaseOrPhenotypicFeature	D000860
64272231	640	649	NF-kappaB	GeneOrGeneProduct	81736
64272231	747	756	NF-kappaB	GeneOrGeneProduct	81736
64272231	837	844	Hypoxia	DiseaseOrPhenotypicFeature	D000860
64272231	917	927	Drosophila	OrganismTaxon	7227
64272231	1012	1019	Hypoxia	DiseaseOrPhenotypicFeature	D000860
64272231	1060	1079	hereditary diseases	DiseaseOrPhenotypicFeature	D030342
64272231	1105	1112	Hypoxia	DiseaseOrPhenotypicFeature	D000860
64272231	1170	1175	DUCaP	CellLine	CVCL_2025
64272231	1177	1183	BALB/c	CellLine	CVCL_9101
64272231	1189	1195	Capan1	CellLine	CVCL_0237
64272231	1309	1316	Hypoxia	DiseaseOrPhenotypicFeature	D000860
64272231	1448	1457	dibucaine	ChemicalEntity	D003992
64272231	1462	1496	d-myo-inositol 1,4,5-trisphosphate	ChemicalEntity	D015544
64272231	1540	1549	NF-kappaB	GeneOrGeneProduct	81736
64272231	1624	1631	Hypoxia	DiseaseOrPhenotypicFeature	D000860
64272231	1680	1715	Hamel cerebropalatocardiac syndrome	DiseaseOrPhenotypicFeature	C537761
64272231	1719	1729	Drosophila	OrganismTaxon	7227
64272231	1785	1792	Hypoxia	DiseaseOrPhenotypicFeature	D000860
64272231	2003	2010	Hypoxia	DiseaseOrPhenotypicFeature	D000860
64272231	Negative_Correlation	D002045	D000860	Novel

25616001|t|Genetic and pharmacological interactions in cancer cell lines: effects of sequence variants, corticosterone, and CYP3A4 inhibitors on drug response and protein ex
25616001|a|This study investigates the interplay between genetic variants, corticosterone, and pharmacological agents in modulating drug response and protein expression in three distinct cancer cell lines: DUCaP, HL-7702, and SF188. We focused on the sequence variants A207D, A49T, c.1475G>A, c.611delG, and the glutamine repeat, as well as the chemical entities corticosterone, lamivudine, pravastatin, sulfonylurea, and CYP3A4 inhibitors. Our findings reveal a negative correlation between the A207D variant and lamivudine treatment, suggesting that this variant may reduce the efficacy of lamivudine in these cell lines. Conversely, a positive correlation was observed between corticosterone and the glutamine repeat, indicating that corticosterone may enhance the expression or stability of the glutamine repeat-containing protein. Notably, the association between c.1475G>A and A207D suggests a potential genetic interaction that may influence drug metabolism or response. A positive correlation between lamivudine and c.611delG was also identified, implying that the presence of this deletion may enhance the antiviral activity of lamivudine. The negative correlation between the glutamine repeat and corticosterone was further supported by the positive correlation between sulfonylurea and the glutamine repeat, suggesting a complex regulatory network involving these genetic and pharmacological factors. Additionally, the positive correlation between CYP3A4 inhibitors and A207D highlights the potential for these inhibitors to modulate the expression or function of the A207D variant. Finally, a positive correlation between pravastatin and c.611delG was observed, indicating that pravastatin may influence the stability or activity of this deletion variant. These results provide new insights into the molecular mechanisms underlying drug response and genetic variability in cancer cell lines.
25616001	93	107	corticosterone	ChemicalEntity	D003345
25616001	113	130	CYP3A4 inhibitors	ChemicalEntity	D065692
25616001	227	241	corticosterone	ChemicalEntity	D003345
25616001	358	363	DUCaP	CellLine	CVCL_2025
25616001	365	372	HL-7702	CellLine	CVCL_6926
25616001	378	383	SF188	CellLine	CVCL_6948
25616001	421	426	A207D	SequenceVariant	rs767564684
25616001	428	432	A49T	SequenceVariant	rs9282858
25616001	434	443	c.1475G>A	SequenceVariant	c|SUB|G|1475|A
25616001	445	454	c.611delG	SequenceVariant	rs193302856
25616001	464	480	glutamine repeat	SequenceVariant	c|DUP||G|
25616001	515	529	corticosterone	ChemicalEntity	D003345
25616001	531	541	lamivudine	ChemicalEntity	D019259
25616001	543	554	pravastatin	ChemicalEntity	D017035
25616001	556	568	sulfonylurea	ChemicalEntity	D013453
25616001	574	591	CYP3A4 inhibitors	ChemicalEntity	D065692
25616001	648	653	A207D	SequenceVariant	rs767564684
25616001	666	676	lamivudine	ChemicalEntity	D019259
25616001	744	754	lamivudine	ChemicalEntity	D019259
25616001	832	846	corticosterone	ChemicalEntity	D003345
25616001	855	871	glutamine repeat	SequenceVariant	c|DUP||G|
25616001	889	903	corticosterone	ChemicalEntity	D003345
25616001	951	967	glutamine repeat	SequenceVariant	c|DUP||G|
25616001	1021	1030	c.1475G>A	SequenceVariant	c|SUB|G|1475|A
25616001	1035	1040	A207D	SequenceVariant	rs767564684
25616001	1161	1171	lamivudine	ChemicalEntity	D019259
25616001	1176	1185	c.611delG	SequenceVariant	rs193302856
25616001	1289	1299	lamivudine	ChemicalEntity	D019259
25616001	1338	1354	glutamine repeat	SequenceVariant	c|DUP||G|
25616001	1359	1373	corticosterone	ChemicalEntity	D003345
25616001	1432	1444	sulfonylurea	ChemicalEntity	D013453
25616001	1453	1469	glutamine repeat	SequenceVariant	c|DUP||G|
25616001	1611	1628	CYP3A4 inhibitors	ChemicalEntity	D065692
25616001	1633	1638	A207D	SequenceVariant	rs767564684
25616001	1731	1736	A207D	SequenceVariant	rs767564684
25616001	1786	1797	pravastatin	ChemicalEntity	D017035
25616001	1802	1811	c.611delG	SequenceVariant	rs193302856
25616001	1842	1853	pravastatin	ChemicalEntity	D017035
25616001	Negative_Correlation	rs767564684	D019259	Novel
25616001	Positive_Correlation	D003345	c|DUP||G|	Novel
25616001	Association	c|SUB|G|1475|A	rs767564684	Novel
25616001	Positive_Correlation	D019259	rs193302856	Novel
25616001	Negative_Correlation	c|DUP||G|	D003345	Novel
25616001	Positive_Correlation	D013453	c|DUP||G|	Novel
25616001	Positive_Correlation	D065692	rs767564684	Novel
25616001	Positive_Correlation	D017035	rs193302856	Novel

36780782|t|Multifaceted interactions of organophosphorus compounds with cellular pathways in diverse species and ce
36780782|a|This study investigates the complex interactions between organophosphorus compounds and various cellular pathways across multiple species and cell lines. We focus on the associations between organophosphorus and key molecular entities such as Let-7b, CD45, and Never in mitosis gene A (NIMA)-related kinase 2, as well as the binding interactions between these compounds and specific proteins. The findings reveal a significant association between organophosphorus and Let-7b, suggesting a potential regulatory role in gene expression. Additionally, organophosphorus is found to be associated with CD45, and a positive correlation is observed between CD45 and TIPE2, indicating a possible functional link between these molecules.   The study also demonstrates that 4-DAMP binds to p21 and is associated with CD45, highlighting its role in modulating cellular signaling pathways. Furthermore, trypan blue is shown to bind to Never in mitosis gene A (NIMA)-related kinase 2 and is associated with TIPE2, suggesting its involvement in cellular processes related to these proteins. A positive correlation is observed between Never in mitosis gene A (NIMA)-related kinase 2 and p21, reinforcing the interconnectedness of these pathways.   Vigabatrin is found to bind to both CD45 and Never in mitosis gene A (NIMA)-related kinase 2, indicating its potential as a modulator of these pathways. Moreover, a positive correlation is established between Let-7b and p21, further supporting the idea of coordinated regulation of these molecular entities. These findings are explored in the context of various cell lines, including C57BL/6, KU7, MH134 (six instances), MC3T3-E1, H9c2, and the organism taxons rhesus monkeys, mouse mammary tumor virus, cats, and dogs. The results provide a comprehensive understanding of how organophosphorus compounds interact with cellular components across different biological systems.
36780782	29	45	organophosphorus	ChemicalEntity	D010755
36780782	162	178	organophosphorus	ChemicalEntity	D010755
36780782	296	312	organophosphorus	ChemicalEntity	D010755
36780782	348	354	Let-7b	GeneOrGeneProduct	387245
36780782	356	360	CD45	GeneOrGeneProduct	19264
36780782	366	413	Never in mitosis gene A (NIMA)-related kinase 2	GeneOrGeneProduct	4751
36780782	552	568	organophosphorus	ChemicalEntity	D010755
36780782	573	579	Let-7b	GeneOrGeneProduct	387245
36780782	654	670	organophosphorus	ChemicalEntity	D010755
36780782	702	706	CD45	GeneOrGeneProduct	19264
36780782	755	759	CD45	GeneOrGeneProduct	19264
36780782	764	769	TIPE2	GeneOrGeneProduct	79626
36780782	869	875	4-DAMP	ChemicalEntity	C042375
36780782	885	888	p21	GeneOrGeneProduct	12575
36780782	912	916	CD45	GeneOrGeneProduct	19264
36780782	996	1007	trypan blue	ChemicalEntity	D014343
36780782	1028	1075	Never in mitosis gene A (NIMA)-related kinase 2	GeneOrGeneProduct	4751
36780782	1099	1104	TIPE2	GeneOrGeneProduct	79626
36780782	1225	1272	Never in mitosis gene A (NIMA)-related kinase 2	GeneOrGeneProduct	4751
36780782	1277	1280	p21	GeneOrGeneProduct	12575
36780782	1374	1378	CD45	GeneOrGeneProduct	19264
36780782	1383	1430	Never in mitosis gene A (NIMA)-related kinase 2	GeneOrGeneProduct	4751
36780782	1547	1553	Let-7b	GeneOrGeneProduct	387245
36780782	1558	1561	p21	GeneOrGeneProduct	12575
36780782	1722	1729	C57BL/6	CellLine	CVCL_5746
36780782	1731	1734	KU7	CellLine	CVCL_4714
36780782	1736	1741	MH134	CellLine	CVCL_8111
36780782	1759	1767	MC3T3-E1	CellLine	CVCL_0409
36780782	1769	1773	H9c2	CellLine	CVCL_0286
36780782	1799	1813	rhesus monkeys	OrganismTaxon	9544
36780782	1815	1840	mouse mammary tumor virus	OrganismTaxon	11757
36780782	1842	1846	cats	OrganismTaxon	9685
36780782	1852	1856	dogs	OrganismTaxon	9615
36780782	1915	1931	organophosphorus	ChemicalEntity	D010755
36780782	Association	D010755	387245	Novel
36780782	Bind	C042375	12575	Novel
36780782	Positive_Correlation	19264	79626	Novel
36780782	Association	D010755	19264	Novel
36780782	Bind	D014343	4751	Novel
36780782	Association	D014343	79626	Novel
36780782	Bind	D020888	19264	Novel
36780782	Association	D010755	4751	Novel
36780782	Association	C042375	19264	Novel
36780782	Bind	D020888	4751	Novel
36780782	Positive_Correlation	4751	12575	Novel
36780782	Positive_Correlation	387245	12575	Novel

28444728|t|Genetic and pharmacological interactions of sequence variants, cell lines, and gene products in cancer progression and drug 
28444728|a|This study investigates the complex interplay between genetic variants, cell lines, and gene products in the context of cancer progression and drug response. The focus is on the sequence variant 1284A>C, which was found to be associated with altered expression of the gene product PI3K in the MCF-7 cell line. Additionally, the sequence variant C1007G was linked to the nine-nucleotide deletion starting at position 1952, which was observed in multiple instances across different cell lines. The sequence variant (G --> C) substitution at position 1201 was found to modulate the activity of the gene product nAchR in the SCID-HuH-7 cell line.    The chemical entity mangiferin was shown to have a significant association with the gene products nAchR and STAT3, as well as with the gene product OSX. Mangiferin also exhibited a synergistic effect with the chemical entity 4-diphenylacetoxy-N-methylpiperidine, which was found to interact with the gene products SOX10, OSX, PI3K, and STAT3. Methadone was found to have a strong association with the gene products STAT3, PI3K, and SOX10, and its effects were further modulated by the sequence variant 1284A>C.    The gene product nAchR was found to be significantly associated with both mangiferin and Methadone, suggesting a potential dual role in modulating drug response. The gene product OSX was found to interact with both mangiferin and 4-diphenylacetoxy-N-methylpiperidine, while the gene product SOX10 was associated with all three chemical entities: mangiferin, Methadone, and 4-diphenylacetoxy-N-methylpiperidine. The gene product PI3K was found to interact with both mangiferin and Methadone, as well as with the chemical entity 4-diphenylacetoxy-N-methylpiperidine.    These findings highlight the intricate relationships between genetic variants, cell lines, and gene products in the context of drug response and cancer progression. The results suggest that the combination of genetic and pharmacological factors may play a critical role in determining therapeutic outcomes in cancer treatment.
28444728	320	327	1284A>C	SequenceVariant	c|SUB|A|1284|C
28444728	406	410	PI3K	GeneOrGeneProduct	18706
28444728	418	423	MCF-7	CellLine	CVCL_0031
28444728	470	476	C1007G	SequenceVariant	rs72559747
28444728	495	545	nine-nucleotide deletion starting at position 1952	SequenceVariant	c|DEL|1952|9
28444728	638	677	(G --> C) substitution at position 1201	SequenceVariant	c|SUB|G|1201|C
28444728	733	738	nAchR	GeneOrGeneProduct	11441
28444728	746	756	SCID-HuH-7	CellLine	CVCL_0336
28444728	791	801	mangiferin	ChemicalEntity	C013592
28444728	869	874	nAchR	GeneOrGeneProduct	11441
28444728	879	884	STAT3	GeneOrGeneProduct	6774
28444728	919	922	OSX	GeneOrGeneProduct	121340
28444728	996	1032	4-diphenylacetoxy-N-methylpiperidine	ChemicalEntity	C042375
28444728	1085	1090	SOX10	GeneOrGeneProduct	6663
28444728	1092	1095	OSX	GeneOrGeneProduct	121340
28444728	1097	1101	PI3K	GeneOrGeneProduct	18706
28444728	1107	1112	STAT3	GeneOrGeneProduct	6774
28444728	1114	1123	Methadone	ChemicalEntity	D008691
28444728	1186	1191	STAT3	GeneOrGeneProduct	6774
28444728	1193	1197	PI3K	GeneOrGeneProduct	18706
28444728	1203	1208	SOX10	GeneOrGeneProduct	6663
28444728	1273	1280	1284A>C	SequenceVariant	c|SUB|A|1284|C
28444728	1302	1307	nAchR	GeneOrGeneProduct	11441
28444728	1359	1369	mangiferin	ChemicalEntity	C013592
28444728	1374	1383	Methadone	ChemicalEntity	D008691
28444728	1464	1467	OSX	GeneOrGeneProduct	121340
28444728	1500	1510	mangiferin	ChemicalEntity	C013592
28444728	1515	1551	4-diphenylacetoxy-N-methylpiperidine	ChemicalEntity	C042375
28444728	1576	1581	SOX10	GeneOrGeneProduct	6663
28444728	1631	1641	mangiferin	ChemicalEntity	C013592
28444728	1643	1652	Methadone	ChemicalEntity	D008691
28444728	1658	1694	4-diphenylacetoxy-N-methylpiperidine	ChemicalEntity	C042375
28444728	1713	1717	PI3K	GeneOrGeneProduct	18706
28444728	1750	1760	mangiferin	ChemicalEntity	C013592
28444728	1765	1774	Methadone	ChemicalEntity	D008691
28444728	1812	1848	4-diphenylacetoxy-N-methylpiperidine	ChemicalEntity	C042375
28444728	Association	11441	C013592	Novel
28444728	Association	6774	D008691	Novel
28444728	Association	11441	D008691	Novel
28444728	Association	6774	C013592	Novel
28444728	Association	6663	C042375	Novel
28444728	Association	121340	C042375	Novel
28444728	Association	18706	C042375	Novel
28444728	Association	121340	C013592	Novel
28444728	Association	6663	C013592	Novel
28444728	Association	6663	D008691	Novel
28444728	Association	6774	C042375	Novel
28444728	Association	18706	C013592	Novel
28444728	Association	18706	D008691	Novel
28444728	Association	121340	D008691	Novel
28444728	Association	11441	C042375	Novel

70283367|t|Genetic and pharmacological interactions of ester, etomidate, and sequence variants in Mouse and shee
70283367|a|Recent studies have explored the complex interactions between ester compounds, anesthetic agents like etomidate, and genetic variants in both Mouse and sheep models. A significant positive correlation was observed between ester and etomidate, suggesting that ester compounds may modulate the pharmacological effects of etomidate. Similarly, ester was found to be positively correlated with the sequence variant c.474delA, indicating a potential functional relationship between these entities. Etomidate also showed a positive correlation with c.474delA, further supporting the hypothesis that this sequence variant may influence the response to anesthetic agents.   In addition, etomidate was found to be positively correlated with the sequence variant rs2073601, which is known to be associated with the gene Sp4. This correlation suggests that rs2073601 may play a role in the regulation of Sp4 expression, which in turn could affect the metabolic response to etomidate. The sequence variant 217_218insC was also found to be positively correlated with etomidate, indicating that this insertion may influence the pharmacokinetics or pharmacodynamics of the drug.   The gene GLUT2 was found to be significantly associated with the sequence variant c.474delA in Mouse models, suggesting that this variant may affect the transport of glucose and other molecules. The gene TLR1 was also implicated in the response to ester compounds, highlighting the role of immune-related pathways in the metabolism of these chemicals.   In sheep, the gene SCF was found to be associated with the sequence variant rs2073601, suggesting a potential role in the regulation of cell signaling pathways. The gene OSX was also linked to the sequence variant 217_218insC, indicating that this variant may influence bone development and regeneration.   These findings underscore the importance of genetic and pharmacological interactions in the response to ester and etomidate, and highlight the need for further research into the molecular mechanisms underlying these associations in both Mouse and sheep models.
70283367	44	49	ester	ChemicalEntity	D004952
70283367	51	60	etomidate	ChemicalEntity	D005045
70283367	87	92	Mouse	OrganismTaxon	10090
70283367	164	169	ester	ChemicalEntity	D004952
70283367	204	213	etomidate	ChemicalEntity	D005045
70283367	244	249	Mouse	OrganismTaxon	10090
70283367	254	259	sheep	OrganismTaxon	9940
70283367	324	329	ester	ChemicalEntity	D004952
70283367	334	343	etomidate	ChemicalEntity	D005045
70283367	361	366	ester	ChemicalEntity	D004952
70283367	421	430	etomidate	ChemicalEntity	D005045
70283367	443	448	ester	ChemicalEntity	D004952
70283367	513	522	c.474delA	SequenceVariant	rs587777017
70283367	645	654	c.474delA	SequenceVariant	rs587777017
70283367	781	790	etomidate	ChemicalEntity	D005045
70283367	855	864	rs2073601	SequenceVariant	rs2073601
70283367	912	915	Sp4	GeneOrGeneProduct	20688
70283367	948	957	rs2073601	SequenceVariant	rs2073601
70283367	995	998	Sp4	GeneOrGeneProduct	20688
70283367	1064	1073	etomidate	ChemicalEntity	D005045
70283367	1096	1107	217_218insC	SequenceVariant	c|INS|217_218|C
70283367	1156	1165	etomidate	ChemicalEntity	D005045
70283367	1277	1282	GLUT2	GeneOrGeneProduct	6514
70283367	1350	1359	c.474delA	SequenceVariant	rs587777017
70283367	1363	1368	Mouse	OrganismTaxon	10090
70283367	1472	1476	TLR1	GeneOrGeneProduct	7096
70283367	1516	1521	ester	ChemicalEntity	D004952
70283367	1625	1630	sheep	OrganismTaxon	9940
70283367	1641	1644	SCF	GeneOrGeneProduct	50754
70283367	1698	1707	rs2073601	SequenceVariant	rs2073601
70283367	1792	1795	OSX	GeneOrGeneProduct	121340
70283367	1836	1847	217_218insC	SequenceVariant	c|INS|217_218|C
70283367	2033	2038	ester	ChemicalEntity	D004952
70283367	2043	2052	etomidate	ChemicalEntity	D005045
70283367	2166	2171	Mouse	OrganismTaxon	10090
70283367	2176	2181	sheep	OrganismTaxon	9940
70283367	Positive_Correlation	D005045	c|INS|217_218|C	Novel
70283367	Positive_Correlation	D004952	D005045	Novel
70283367	Positive_Correlation	D004952	rs587777017	Novel
70283367	Positive_Correlation	D005045	rs587777017	Novel
70283367	Positive_Correlation	D005045	D004952	Novel
70283367	Positive_Correlation	D005045	rs2073601	Novel

17977201|t|Bovine IL-7 and insulin-receptor interactions in C57BL/6 and MES-SA/Dx5 cells: genetic variants and their associations with MMP-9 ex
17977201|a|This study investigates the molecular interactions between bovine IL-7 and the insulin-receptor in C57BL/6 and MES-SA/Dx5 cell lines, with a focus on the effects of genetic variants on MMP-9 expression. We observed a positive correlation between insulin-receptor and MMP-9, as well as a negative correlation between insulin-receptor and MMP-9, suggesting complex regulatory mechanisms. The association between IL-7 and insulin-receptor was confirmed through binding assays, and further evidence of a bind between IL-7 and MMP-9 was provided. Additionally, a bind between insulin-receptor and MMP-9 was identified, supporting the positive correlation between MMP-9 and IL-7.   Genetic variants were analyzed in bovine samples, including p.Val167Met, M235T, and p.K543X. The association between M235T and p.K543X was found, as well as between p.K543X and IL-7, and between M235T and IL-7. The variant p.Val167Met was associated with MMP-9, reinforcing the link between genetic variation and gene expression. The study also included bovine cell lines CA3 and C57BL/6, with multiple instances of the cell lines MES-SA/Dx5 and C57BL/6 used to validate findings across different experimental conditions. These results highlight the intricate relationships between IL-7, insulin-receptor, and MMP-9 in bovine systems, with implications for understanding gene regulation and variant function.
17977201	7	11	IL-7	GeneOrGeneProduct	3574
17977201	16	32	insulin-receptor	GeneOrGeneProduct	24954
17977201	49	56	C57BL/6	CellLine	CVCL_5746
17977201	61	71	MES-SA/Dx5	CellLine	CVCL_2598
17977201	124	129	MMP-9	GeneOrGeneProduct	4318
17977201	192	198	bovine	OrganismTaxon	9913
17977201	199	203	IL-7	GeneOrGeneProduct	3574
17977201	212	228	insulin-receptor	GeneOrGeneProduct	24954
17977201	232	239	C57BL/6	CellLine	CVCL_5746
17977201	244	254	MES-SA/Dx5	CellLine	CVCL_2598
17977201	318	323	MMP-9	GeneOrGeneProduct	4318
17977201	379	395	insulin-receptor	GeneOrGeneProduct	24954
17977201	400	405	MMP-9	GeneOrGeneProduct	4318
17977201	449	465	insulin-receptor	GeneOrGeneProduct	24954
17977201	470	475	MMP-9	GeneOrGeneProduct	4318
17977201	543	547	IL-7	GeneOrGeneProduct	3574
17977201	552	568	insulin-receptor	GeneOrGeneProduct	24954
17977201	646	650	IL-7	GeneOrGeneProduct	3574
17977201	655	660	MMP-9	GeneOrGeneProduct	4318
17977201	704	720	insulin-receptor	GeneOrGeneProduct	24954
17977201	725	730	MMP-9	GeneOrGeneProduct	4318
17977201	791	796	MMP-9	GeneOrGeneProduct	4318
17977201	801	805	IL-7	GeneOrGeneProduct	3574
17977201	843	849	bovine	OrganismTaxon	9913
17977201	869	880	p.Val167Met	SequenceVariant	rs111033360
17977201	882	887	M235T	SequenceVariant	rs699
17977201	893	900	p.K543X	SequenceVariant	p|SUB|K|543|X
17977201	926	931	M235T	SequenceVariant	rs699
17977201	936	943	p.K543X	SequenceVariant	p|SUB|K|543|X
17977201	974	981	p.K543X	SequenceVariant	p|SUB|K|543|X
17977201	986	990	IL-7	GeneOrGeneProduct	3574
17977201	1004	1009	M235T	SequenceVariant	rs699
17977201	1014	1018	IL-7	GeneOrGeneProduct	3574
17977201	1032	1043	p.Val167Met	SequenceVariant	rs111033360
17977201	1064	1069	MMP-9	GeneOrGeneProduct	4318
17977201	1163	1169	bovine	OrganismTaxon	9913
17977201	1181	1184	CA3	CellLine	CVCL_JW73
17977201	1189	1196	C57BL/6	CellLine	CVCL_5746
17977201	1240	1250	MES-SA/Dx5	CellLine	CVCL_2598
17977201	1255	1262	C57BL/6	CellLine	CVCL_5746
17977201	1391	1395	IL-7	GeneOrGeneProduct	3574
17977201	1397	1413	insulin-receptor	GeneOrGeneProduct	24954
17977201	1419	1424	MMP-9	GeneOrGeneProduct	4318
17977201	1428	1434	bovine	OrganismTaxon	9913
17977201	Positive_Correlation	24954	4318	Novel
17977201	Association	3574	24954	Novel
17977201	Bind	24954	3574	Novel
17977201	Association	rs699	p|SUB|K|543|X	Novel
17977201	Association	p|SUB|K|543|X	3574	Novel
17977201	Association	rs699	3574	Novel
17977201	Association	rs111033360	4318	Novel
17977201	Negative_Correlation	24954	4318	Novel
17977201	Bind	24954	4318	Novel
17977201	Association	4318	3574	Novel
17977201	Bind	3574	4318	Novel
17977201	Positive_Correlation	4318	3574	Novel

19889319|t|D90A variant effects on p38 and Alb in S. cerevisiae, rabbit, Platonia insignis Mart, tobacco, rhesus monkeys, and sheep: interactions with disulfiram and l
19889319|a|This study investigates the functional and molecular consequences of the D90A sequence variant in the context of p38 and Alb expression across multiple organisms, including S. cerevisiae, rabbit, Platonia insignis Mart, tobacco, rhesus monkeys, and sheep. The D90A variant was found to significantly alter the phosphorylation dynamics of p38, leading to changes in downstream signaling pathways. Additionally, the variant was associated with altered expression levels of Alb, suggesting a potential regulatory role in gene expression.   The study also explored the interactions between the chemical entities disulfiram and lidocaine, both of which were found to modulate the activity of p38 and influence Alb expression. Notably, disulfiram and lidocaine exhibited a synergistic effect in altering the phosphorylation state of p38, which was further supported by in vitro assays. These findings suggest a potential drug interaction between disulfiram and lidocaine, which may have implications for therapeutic applications.   Furthermore, the association between lidocaine and Alb was confirmed through transcriptomic analysis, where lidocaine treatment led to a significant upregulation of Alb in multiple species. This interaction was consistent across different experimental conditions, reinforcing the biological relevance of the observed relationship. The results highlight the importance of considering sequence variants like D90A in the context of drug interactions and gene expression regulation.
19889319	0	4	D90A	SequenceVariant	rs80265967
19889319	24	27	p38	GeneOrGeneProduct	26416
19889319	32	35	Alb	GeneOrGeneProduct	11657
19889319	39	52	S. cerevisiae	OrganismTaxon	4932
19889319	54	60	rabbit	OrganismTaxon	9986
19889319	62	84	Platonia insignis Mart	OrganismTaxon	198787
19889319	86	93	tobacco	OrganismTaxon	4097
19889319	95	109	rhesus monkeys	OrganismTaxon	9544
19889319	115	120	sheep	OrganismTaxon	9940
19889319	140	150	disulfiram	ChemicalEntity	D004221
19889319	230	234	D90A	SequenceVariant	rs80265967
19889319	270	273	p38	GeneOrGeneProduct	26416
19889319	278	281	Alb	GeneOrGeneProduct	11657
19889319	330	343	S. cerevisiae	OrganismTaxon	4932
19889319	345	351	rabbit	OrganismTaxon	9986
19889319	353	375	Platonia insignis Mart	OrganismTaxon	198787
19889319	377	384	tobacco	OrganismTaxon	4097
19889319	386	400	rhesus monkeys	OrganismTaxon	9544
19889319	406	411	sheep	OrganismTaxon	9940
19889319	417	421	D90A	SequenceVariant	rs80265967
19889319	495	498	p38	GeneOrGeneProduct	26416
19889319	628	631	Alb	GeneOrGeneProduct	11657
19889319	765	775	disulfiram	ChemicalEntity	D004221
19889319	780	789	lidocaine	ChemicalEntity	D008012
19889319	844	847	p38	GeneOrGeneProduct	26416
19889319	862	865	Alb	GeneOrGeneProduct	11657
19889319	887	897	disulfiram	ChemicalEntity	D004221
19889319	902	911	lidocaine	ChemicalEntity	D008012
19889319	984	987	p38	GeneOrGeneProduct	26416
19889319	1097	1107	disulfiram	ChemicalEntity	D004221
19889319	1112	1121	lidocaine	ChemicalEntity	D008012
19889319	1220	1229	lidocaine	ChemicalEntity	D008012
19889319	1234	1237	Alb	GeneOrGeneProduct	11657
19889319	1291	1300	lidocaine	ChemicalEntity	D008012
19889319	1348	1351	Alb	GeneOrGeneProduct	11657
19889319	1589	1593	D90A	SequenceVariant	rs80265967
19889319	Drug_Interaction	D008012	D004221	Novel
19889319	Drug_Interaction	D004221	D008012	Novel
19889319	Association	D008012	11657	Novel

31276004|t|Genetic and metabolic interactions between sequence variants, alanine aminotransferase, and multiple enchondromatosis syndromes in HBV-infec
31276004|a|This study investigates the complex interplay between genetic variants, metabolic markers, and disease phenotypes in a model system of HBV-infected Rats. We focus on the sequence variant g.3395C>T and its association with alanine aminotransferase (ALT) levels, as well as the impact of the variant rs368698783 on fluvastatin metabolism. Our findings reveal a positive correlation between ALT and multiple enchondromatosis syndromes, suggesting a potential metabolic pathway linking these conditions. Additionally, we observe a drug interaction between ALT and fluvastatin, with evidence of conversion between the two entities. The variant g.3395C>T is associated with both ALT and fluvastatin, highlighting its role in modulating metabolic responses. The variant rs368698783 is also linked to fluvastatin and ALT, further supporting a genetic basis for these interactions. Notably, fluvastatin shows a positive correlation with both ALT and multiple enchondromatosis syndromes, indicating a potential therapeutic target. These results underscore the importance of genetic and metabolic factors in the pathogenesis of these conditions and provide a foundation for future research into their molecular mechanisms in HBV-infected Rats.
31276004	62	86	alanine aminotransferase	ChemicalEntity	D000410
31276004	92	127	multiple enchondromatosis syndromes	DiseaseOrPhenotypicFeature	D004687
31276004	131	134	HBV	OrganismTaxon	10407
31276004	276	279	HBV	OrganismTaxon	10407
31276004	289	293	Rats	OrganismTaxon	10116
31276004	328	337	g.3395C>T	SequenceVariant	g|SUB|C|3395|T
31276004	363	387	alanine aminotransferase	ChemicalEntity	D000410
31276004	439	450	rs368698783	SequenceVariant	rs368698783
31276004	454	465	fluvastatin	ChemicalEntity	C065180
31276004	537	572	multiple enchondromatosis syndromes	DiseaseOrPhenotypicFeature	D004687
31276004	701	712	fluvastatin	ChemicalEntity	C065180
31276004	780	789	g.3395C>T	SequenceVariant	g|SUB|C|3395|T
31276004	822	833	fluvastatin	ChemicalEntity	C065180
31276004	904	915	rs368698783	SequenceVariant	rs368698783
31276004	934	945	fluvastatin	ChemicalEntity	C065180
31276004	1023	1034	fluvastatin	ChemicalEntity	C065180
31276004	1082	1117	multiple enchondromatosis syndromes	DiseaseOrPhenotypicFeature	D004687
31276004	1355	1358	HBV	OrganismTaxon	10407
31276004	1368	1372	Rats	OrganismTaxon	10116
31276004	Positive_Correlation	D000410	D004687	Novel
31276004	Drug_Interaction	D000410	C065180	Novel
31276004	Association	g|SUB|C|3395|T	D000410	Novel
31276004	Conversion	C065180	D000410	Novel
31276004	Association	rs368698783	C065180	Novel
31276004	Drug_Interaction	C065180	D000410	Novel
31276004	Association	g|SUB|C|3395|T	C065180	Novel
31276004	Conversion	D000410	C065180	Novel
31276004	Association	rs368698783	D000410	Novel
31276004	Positive_Correlation	C065180	D000410	Novel
31276004	Positive_Correlation	C065180	D004687	Novel
31276004	Positive_Correlation	D000410	C065180	Novel

01874204|t|Ciprofloxacin and melanotan II: interactions with Pituitary adenomas, Retinoblastoma, and masseter muscle rigidity in cell lines and diseas
01874204|a|This study investigates the complex interactions between ciprofloxacin, melanotan II, and various disease states, including Pituitary adenomas, Retinoblastoma, and masseter muscle rigidity, using a combination of in vitro and in vivo models. The research focuses on the MCF-7, SNU-C2A, C57BL/6, C4-2B, and HEK293 cell lines, which were exposed to varying concentrations of ciprofloxacin and melanotan II to assess their biological effects.   A significant positive correlation was observed between ciprofloxacin and congenital panocular disorder, suggesting a potential role for this antibiotic in the pathogenesis of this rare condition. Additionally, ciprofloxacin showed a positive correlation with Retinoblastoma, indicating possible therapeutic or toxicological implications in ocular malignancies. The study also found a positive correlation between melanotan II and Pituitary adenomas, supporting the hypothesis that this peptide may influence the growth or progression of these tumors.  Further analysis revealed a positive correlation between alanine aminotransferase and Pituitary adenomas, as well as between masseter muscle rigidity and alanine aminotransferase, highlighting the potential involvement of this enzyme in both metabolic and neuromuscular disorders. A comparison between ciprofloxacin and alanine aminotransferase demonstrated that ciprofloxacin may modulate the activity of this enzyme, which could have implications for drug metabolism and toxicity.  Notably, drowsiness was found to be positively correlated with melanotan II, suggesting a possible side effect or pharmacological mechanism of action. The study also included a comparison between ciprofloxacin and alanine aminotransferase, which provided insights into the metabolic interactions of these compounds. Overall, the findings underscore the importance of understanding the interplay between chemical entities and disease states in both cellular and clinical contexts.
01874204	18	30	melanotan II	ChemicalEntity	C079282
01874204	50	68	Pituitary adenomas	DiseaseOrPhenotypicFeature	D010911
01874204	70	84	Retinoblastoma	DiseaseOrPhenotypicFeature	D012175
01874204	90	114	masseter muscle rigidity	DiseaseOrPhenotypicFeature	D014313
01874204	197	210	ciprofloxacin	ChemicalEntity	D002939
01874204	212	224	melanotan II	ChemicalEntity	C079282
01874204	264	282	Pituitary adenomas	DiseaseOrPhenotypicFeature	D010911
01874204	284	298	Retinoblastoma	DiseaseOrPhenotypicFeature	D012175
01874204	304	328	masseter muscle rigidity	DiseaseOrPhenotypicFeature	D014313
01874204	410	415	MCF-7	CellLine	CVCL_0031
01874204	417	424	SNU-C2A	CellLine	CVCL_1709
01874204	426	433	C57BL/6	CellLine	CVCL_5746
01874204	435	440	C4-2B	CellLine	CVCL_4784
01874204	446	452	HEK293	CellLine	CVCL_0045
01874204	513	526	ciprofloxacin	ChemicalEntity	D002939
01874204	531	543	melanotan II	ChemicalEntity	C079282
01874204	638	651	ciprofloxacin	ChemicalEntity	D002939
01874204	656	685	congenital panocular disorder	DiseaseOrPhenotypicFeature	D000013
01874204	793	806	ciprofloxacin	ChemicalEntity	D002939
01874204	842	856	Retinoblastoma	DiseaseOrPhenotypicFeature	D012175
01874204	996	1008	melanotan II	ChemicalEntity	C079282
01874204	1013	1031	Pituitary adenomas	DiseaseOrPhenotypicFeature	D010911
01874204	1192	1216	alanine aminotransferase	ChemicalEntity	D000410
01874204	1221	1239	Pituitary adenomas	DiseaseOrPhenotypicFeature	D010911
01874204	1260	1284	masseter muscle rigidity	DiseaseOrPhenotypicFeature	D014313
01874204	1289	1313	alanine aminotransferase	ChemicalEntity	D000410
01874204	1437	1450	ciprofloxacin	ChemicalEntity	D002939
01874204	1455	1479	alanine aminotransferase	ChemicalEntity	D000410
01874204	1498	1511	ciprofloxacin	ChemicalEntity	D002939
01874204	1628	1638	drowsiness	DiseaseOrPhenotypicFeature	D006970
01874204	1682	1694	melanotan II	ChemicalEntity	C079282
01874204	1815	1828	ciprofloxacin	ChemicalEntity	D002939
01874204	1833	1857	alanine aminotransferase	ChemicalEntity	D000410
01874204	Positive_Correlation	D000410	D010911	Novel
01874204	Positive_Correlation	D014313	D000410	Novel
01874204	Positive_Correlation	C079282	D010911	Novel
01874204	Positive_Correlation	D012175	D002939	Novel
01874204	Positive_Correlation	D006970	C079282	Novel
01874204	Positive_Correlation	D002939	D000013	Novel
01874204	Comparison	D002939	D000410	Novel

